Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific nTPM" "RNA single cell type specificity" "RNA single cell type distribution" "RNA single cell type specificity score" "RNA single cell type specific nTPM" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific nTPM" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific nTPM" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific nTPM" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific nTPM" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific nTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific nTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "CCD Protein" "CCD Transcript" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Blood expression cluster" "Tissue expression cluster" "Cell line expression cluster" "Single cell expression cluster" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [nTPM]" "Tissue RNA - adrenal gland [nTPM]" "Tissue RNA - amygdala [nTPM]" "Tissue RNA - appendix [nTPM]" "Tissue RNA - basal ganglia [nTPM]" "Tissue RNA - bone marrow [nTPM]" "Tissue RNA - breast [nTPM]" "Tissue RNA - cerebellum [nTPM]" "Tissue RNA - cerebral cortex [nTPM]" "Tissue RNA - cervix [nTPM]" "Tissue RNA - choroid plexus [nTPM]" "Tissue RNA - colon [nTPM]" "Tissue RNA - duodenum [nTPM]" "Tissue RNA - endometrium 1 [nTPM]" "Tissue RNA - epididymis [nTPM]" "Tissue RNA - esophagus [nTPM]" "Tissue RNA - fallopian tube [nTPM]" "Tissue RNA - gallbladder [nTPM]" "Tissue RNA - heart muscle [nTPM]" "Tissue RNA - hippocampal formation [nTPM]" "Tissue RNA - hypothalamus [nTPM]" "Tissue RNA - kidney [nTPM]" "Tissue RNA - liver [nTPM]" "Tissue RNA - lung [nTPM]" "Tissue RNA - lymph node [nTPM]" "Tissue RNA - medulla oblongata [nTPM]" "Tissue RNA - midbrain [nTPM]" "Tissue RNA - ovary [nTPM]" "Tissue RNA - pancreas [nTPM]" "Tissue RNA - parathyroid gland [nTPM]" "Tissue RNA - pituitary gland [nTPM]" "Tissue RNA - placenta [nTPM]" "Tissue RNA - pons [nTPM]" "Tissue RNA - prostate [nTPM]" "Tissue RNA - rectum [nTPM]" "Tissue RNA - retina [nTPM]" "Tissue RNA - salivary gland [nTPM]" "Tissue RNA - seminal vesicle [nTPM]" "Tissue RNA - skeletal muscle [nTPM]" "Tissue RNA - skin 1 [nTPM]" "Tissue RNA - small intestine [nTPM]" "Tissue RNA - smooth muscle [nTPM]" "Tissue RNA - spinal cord [nTPM]" "Tissue RNA - spleen [nTPM]" "Tissue RNA - stomach 1 [nTPM]" "Tissue RNA - testis [nTPM]" "Tissue RNA - thalamus [nTPM]" "Tissue RNA - thymus [nTPM]" "Tissue RNA - thyroid gland [nTPM]" "Tissue RNA - tongue [nTPM]" "Tissue RNA - tonsil [nTPM]" "Tissue RNA - urinary bladder [nTPM]" "Tissue RNA - vagina [nTPM]" "Tissue RNA - white matter [nTPM]" "Cell RNA - A-431 [nTPM]" "Cell RNA - A549 [nTPM]" "Cell RNA - AF22 [nTPM]" "Cell RNA - AN3-CA [nTPM]" "Cell RNA - ASC diff [nTPM]" "Cell RNA - ASC TERT1 [nTPM]" "Cell RNA - BEWO [nTPM]" "Cell RNA - BJ [nTPM]" "Cell RNA - BJ hTERT+ [nTPM]" "Cell RNA - BJ hTERT+ SV40 Large T+ [nTPM]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [nTPM]" "Cell RNA - CACO-2 [nTPM]" "Cell RNA - CAPAN-2 [nTPM]" "Cell RNA - Daudi [nTPM]" "Cell RNA - EFO-21 [nTPM]" "Cell RNA - fHDF/TERT166 [nTPM]" "Cell RNA - GAMG [nTPM]" "Cell RNA - HaCaT [nTPM]" "Cell RNA - HAP1 [nTPM]" "Cell RNA - HBEC3-KT [nTPM]" "Cell RNA - HBF TERT88 [nTPM]" "Cell RNA - HDLM-2 [nTPM]" "Cell RNA - HEK 293 [nTPM]" "Cell RNA - HEL [nTPM]" "Cell RNA - HeLa [nTPM]" "Cell RNA - Hep G2 [nTPM]" "Cell RNA - HHSteC [nTPM]" "Cell RNA - HL-60 [nTPM]" "Cell RNA - HMC-1 [nTPM]" "Cell RNA - HSkMC [nTPM]" "Cell RNA - hTCEpi [nTPM]" "Cell RNA - hTEC/SVTERT24-B [nTPM]" "Cell RNA - hTERT-HME1 [nTPM]" "Cell RNA - hTERT-RPE1 [nTPM]" "Cell RNA - HUVEC TERT2 [nTPM]" "Cell RNA - JURKAT [nTPM]" "Cell RNA - K-562 [nTPM]" "Cell RNA - Karpas-707 [nTPM]" "Cell RNA - LHCN-M2 [nTPM]" "Cell RNA - MCF7 [nTPM]" "Cell RNA - MOLT-4 [nTPM]" "Cell RNA - NB-4 [nTPM]" "Cell RNA - NTERA-2 [nTPM]" "Cell RNA - OE19 [nTPM]" "Cell RNA - PC-3 [nTPM]" "Cell RNA - REH [nTPM]" "Cell RNA - RH-30 [nTPM]" "Cell RNA - RPMI-8226 [nTPM]" "Cell RNA - RPTEC TERT1 [nTPM]" "Cell RNA - RT4 [nTPM]" "Cell RNA - SCLC-21H [nTPM]" "Cell RNA - SH-SY5Y [nTPM]" "Cell RNA - SiHa [nTPM]" "Cell RNA - SK-BR-3 [nTPM]" "Cell RNA - SK-MEL-30 [nTPM]" "Cell RNA - SuSa [nTPM]" "Cell RNA - T-47d [nTPM]" "Cell RNA - THP-1 [nTPM]" "Cell RNA - TIME [nTPM]" "Cell RNA - U-138 MG [nTPM]" "Cell RNA - U-2 OS [nTPM]" "Cell RNA - U-2197 [nTPM]" "Cell RNA - U-251 MG [nTPM]" "Cell RNA - U-266/70 [nTPM]" "Cell RNA - U-266/84 [nTPM]" "Cell RNA - U-698 [nTPM]" "Cell RNA - U-87 MG [nTPM]" "Cell RNA - U-937 [nTPM]" "Cell RNA - WM-115 [nTPM]" "Blood RNA - basophil [nTPM]" "Blood RNA - classical monocyte [nTPM]" "Blood RNA - eosinophil [nTPM]" "Blood RNA - gdT-cell [nTPM]" "Blood RNA - intermediate monocyte [nTPM]" "Blood RNA - MAIT T-cell [nTPM]" "Blood RNA - memory B-cell [nTPM]" "Blood RNA - memory CD4 T-cell [nTPM]" "Blood RNA - memory CD8 T-cell [nTPM]" "Blood RNA - myeloid DC [nTPM]" "Blood RNA - naive B-cell [nTPM]" "Blood RNA - naive CD4 T-cell [nTPM]" "Blood RNA - naive CD8 T-cell [nTPM]" "Blood RNA - neutrophil [nTPM]" "Blood RNA - NK-cell [nTPM]" "Blood RNA - non-classical monocyte [nTPM]" "Blood RNA - plasmacytoid DC [nTPM]" "Blood RNA - T-reg [nTPM]" "Blood RNA - total PBMC [nTPM]" "Brain RNA - amygdala [nTPM]" "Brain RNA - basal ganglia [nTPM]" "Brain RNA - cerebellum [nTPM]" "Brain RNA - cerebral cortex [nTPM]" "Brain RNA - hippocampal formation [nTPM]" "Brain RNA - hypothalamus [nTPM]" "Brain RNA - medulla oblongata [nTPM]" "Brain RNA - midbrain [nTPM]" "Brain RNA - pons [nTPM]" "Brain RNA - spinal cord [nTPM]" "Brain RNA - thalamus [nTPM]" "Brain RNA - white matter [nTPM]" "Single Cell Type RNA - Adipocytes [nTPM]" "Single Cell Type RNA - Alveolar cells type 1 [nTPM]" "Single Cell Type RNA - Alveolar cells type 2 [nTPM]" "Single Cell Type RNA - Astrocytes [nTPM]" "Single Cell Type RNA - B-cells [nTPM]" "Single Cell Type RNA - Basal keratinocytes [nTPM]" "Single Cell Type RNA - Basal prostatic cells [nTPM]" "Single Cell Type RNA - Basal respiratory cells [nTPM]" "Single Cell Type RNA - Basal squamous epithelial cells [nTPM]" "Single Cell Type RNA - Bipolar cells [nTPM]" "Single Cell Type RNA - Breast glandular cells [nTPM]" "Single Cell Type RNA - Breast myoepithelial cells [nTPM]" "Single Cell Type RNA - Cardiomyocytes [nTPM]" "Single Cell Type RNA - Cholangiocytes [nTPM]" "Single Cell Type RNA - Club cells [nTPM]" "Single Cell Type RNA - Collecting duct cells [nTPM]" "Single Cell Type RNA - Cone photoreceptor cells [nTPM]" "Single Cell Type RNA - Cytotrophoblasts [nTPM]" "Single Cell Type RNA - dendritic cells [nTPM]" "Single Cell Type RNA - Distal enterocytes [nTPM]" "Single Cell Type RNA - Distal tubular cells [nTPM]" "Single Cell Type RNA - Ductal cells [nTPM]" "Single Cell Type RNA - Early spermatids [nTPM]" "Single Cell Type RNA - Endometrial ciliated cells [nTPM]" "Single Cell Type RNA - Endometrial stromal cells [nTPM]" "Single Cell Type RNA - Endothelial cells [nTPM]" "Single Cell Type RNA - Enteroendocrine cells [nTPM]" "Single Cell Type RNA - Erythroid cells [nTPM]" "Single Cell Type RNA - Excitatory neurons [nTPM]" "Single Cell Type RNA - Exocrine glandular cells [nTPM]" "Single Cell Type RNA - Extravillous trophoblasts [nTPM]" "Single Cell Type RNA - Fibroblasts [nTPM]" "Single Cell Type RNA - Gastric mucus-secreting cells [nTPM]" "Single Cell Type RNA - Glandular and luminal cells [nTPM]" "Single Cell Type RNA - granulocytes [nTPM]" "Single Cell Type RNA - Granulosa cells [nTPM]" "Single Cell Type RNA - Hepatic stellate cells [nTPM]" "Single Cell Type RNA - Hepatocytes [nTPM]" "Single Cell Type RNA - Hofbauer cells [nTPM]" "Single Cell Type RNA - Horizontal cells [nTPM]" "Single Cell Type RNA - Inhibitory neurons [nTPM]" "Single Cell Type RNA - Intestinal goblet cells [nTPM]" "Single Cell Type RNA - Ionocytes [nTPM]" "Single Cell Type RNA - Kupffer cells [nTPM]" "Single Cell Type RNA - Langerhans cells [nTPM]" "Single Cell Type RNA - Late spermatids [nTPM]" "Single Cell Type RNA - Leydig cells [nTPM]" "Single Cell Type RNA - Macrophages [nTPM]" "Single Cell Type RNA - Melanocytes [nTPM]" "Single Cell Type RNA - Microglial cells [nTPM]" "Single Cell Type RNA - monocytes [nTPM]" "Single Cell Type RNA - Muller glia cells [nTPM]" "Single Cell Type RNA - NK-cells [nTPM]" "Single Cell Type RNA - Oligodendrocyte precursor cells [nTPM]" "Single Cell Type RNA - Oligodendrocytes [nTPM]" "Single Cell Type RNA - Pancreatic endocrine cells [nTPM]" "Single Cell Type RNA - Paneth cells [nTPM]" "Single Cell Type RNA - Peritubular cells [nTPM]" "Single Cell Type RNA - Plasma cells [nTPM]" "Single Cell Type RNA - Prostatic glandular cells [nTPM]" "Single Cell Type RNA - Proximal enterocytes [nTPM]" "Single Cell Type RNA - Proximal tubular cells [nTPM]" "Single Cell Type RNA - Respiratory ciliated cells [nTPM]" "Single Cell Type RNA - Rod photoreceptor cells [nTPM]" "Single Cell Type RNA - Sertoli cells [nTPM]" "Single Cell Type RNA - Skeletal myocytes [nTPM]" "Single Cell Type RNA - Smooth muscle cells [nTPM]" "Single Cell Type RNA - Spermatocytes [nTPM]" "Single Cell Type RNA - Spermatogonia [nTPM]" "Single Cell Type RNA - Squamous epithelial cells [nTPM]" "Single Cell Type RNA - Suprabasal keratinocytes [nTPM]" "Single Cell Type RNA - Syncytiotrophoblasts [nTPM]" "Single Cell Type RNA - T-cells [nTPM]" "Single Cell Type RNA - Theca cells [nTPM]" "Single Cell Type RNA - Undifferentiated cells [nTPM]" "Single Cell Type RNA - Urothelial cells [nTPM]" ABAT "GABA-T, GABAT" ENSG00000183044 "4-aminobutyrate aminotransferase" P80404 16 8674596-8784575 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Neurotransmitter degradation" "Aminotransferase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 137.9;kidney: 133.3;liver: 345.6;pancreas: 138.3" "Cell type enhanced" "Detected in many" "Hepatocytes: 268.2;Inhibitory neurons: 95.0;Oligodendrocyte precursor cells: 76.9;Proximal tubular cells: 94.9" "Cancer enhanced" "Detected in all" "glioma: 27.3;liver cancer: 26.8" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Hep G2: 127.5;MCF7: 81.9;RH-30: 67.4;T-47d: 42.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041528, HPA041690" Enhanced Supported Supported Mitochondria No No 2100000 "Cluster 14: Monocytes - Unknown function" "Cluster 22: Non-specific - Unknown function" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 67: Proximal tubular cells - Tubular reabsorption" Mitochondria "HPA041528: AB_10795690, HPA041690: AB_10794674" "unprognostic (1.77e-2)" "unprognostic (3.27e-1)" "unprognostic (1.00e-1)" "unprognostic (2.71e-1)" "unprognostic (2.90e-1)" "unprognostic (2.05e-1)" "prognostic favorable (5.36e-5)" "prognostic favorable (5.93e-4)" "unprognostic (1.71e-1)" "unprognostic (1.30e-1)" "unprognostic (1.56e-2)" "unprognostic (1.04e-1)" "prognostic favorable (5.44e-8)" "unprognostic (2.10e-1)" "unprognostic (2.48e-2)" "unprognostic (3.80e-1)" "unprognostic (1.50e-2)" 3.3 27.7 94.6 4.7 105.4 2.2 5.1 85.2 103.4 3.8 70.7 7.6 43.6 3.8 9.6 7.7 6.2 4.4 14.1 90.2 120.7 133.3 345.6 4.5 5.0 90.8 107.4 10.5 138.3 8.2 55.8 3.4 137.6 21.7 7.8 29.6 6.5 3.5 1.6 2.7 20.1 2.7 88.1 4.1 7.4 13.4 137.9 4.2 29.3 1.4 5.9 9.9 4.1 70.9 0.7 0.2 32.1 18.7 5.0 1.7 2.0 4.2 2.2 1.8 0.7 12.7 0.9 4.0 1.4 2.3 1.2 8.3 2.1 7.7 2.4 2.3 2.1 5.5 0.1 127.5 8.1 1.3 8.3 6.5 3.4 3.2 1.4 0.9 0.6 10.7 1.1 2.6 0.6 81.9 2.1 0.6 2.8 23.2 0.3 9.7 67.4 1.8 1.2 20.9 5.1 15.7 1.9 1.0 0.2 6.2 42.6 3.4 0.6 0.8 5.7 2.7 0.1 3.0 0.3 0.8 0.8 5.7 4.2 0.7 1.9 2.7 1.5 2.2 0.7 0.6 1.0 1.1 1.2 1.2 0.7 1.1 6.1 1.2 4.2 0.2 1.1 1.2 94.6 105.4 85.2 103.4 90.2 120.7 90.8 107.4 137.6 88.1 137.9 70.9 1.7 0.0 6.9 39.5 6.1 1.5 4.0 3.3 2.2 27.3 9.1 5.0 10.8 20.0 5.8 1.8 4.2 1.4 5.3 8.9 23.5 1.6 13.0 12.9 6.2 2.4 15.6 13.9 41.8 6.2 1.5 3.2 5.6 12.9 1.3 59.5 7.1 268.2 5.2 35.3 95.0 3.9 2.0 15.7 7.4 8.7 3.7 8.2 1.8 19.7 6.5 48.6 9.2 76.9 17.7 6.8 6.1 4.5 1.0 7.4 15.7 94.9 3.6 5.8 0.0 4.3 3.8 3.7 0.9 9.5 0.6 1.4 6.3 2.3 6.9 5.0 ABCA1 "ABC1, HDLDT1, TGD" ENSG00000165029 "ATP binding cassette subfamily A member 1" O95477 9 104781006-104928155 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism, Transport" Translocase "Atherosclerosis, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 105.8;Hepatocytes: 175.5;Kupffer cells: 169.1;Langerhans cells: 109.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "eosinophil: 13.1;neutrophil: 10.6" "Lineage enriched" "Detected in many" 8 "granulocytes: 13.1" "Cell line enhanced" "Detected in many" "HSkMC: 34.1;U-87 MG: 79.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA057283, CAB069889" Approved Approved Nucleoplasm,Vesicles NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 15: Liver - Metabolism" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 36: Stromal cells - Cell proliferation" "Nucleoplasm, Vesicles" "CAB069889: AB_10002789, HPA057283: AB_2683396" "unprognostic (1.58e-2)" "unprognostic (2.54e-1)" "unprognostic (1.46e-1)" "unprognostic (2.80e-1)" "unprognostic (7.47e-3)" "unprognostic (1.85e-1)" "unprognostic (9.22e-2)" "unprognostic (9.80e-2)" "unprognostic (2.04e-1)" "unprognostic (7.28e-3)" "unprognostic (2.14e-1)" "unprognostic (4.78e-2)" "unprognostic (1.04e-2)" "unprognostic (2.00e-3)" "unprognostic (2.51e-2)" "unprognostic (6.71e-2)" "unprognostic (2.57e-1)" 24.7 36.5 12.0 11.0 29.1 20.7 13.3 14.4 12.5 7.4 4.1 16.3 4.5 5.6 8.2 4.9 8.0 15.0 4.6 10.4 13.7 7.2 38.7 12.3 8.9 19.5 26.2 8.9 4.0 1.8 2.5 22.7 19.0 4.1 9.9 3.7 5.7 5.0 10.9 13.4 8.1 7.6 16.4 7.1 6.7 3.6 27.3 11.0 5.1 3.4 5.4 19.7 7.6 20.7 0.0 5.6 4.6 0.0 13.1 4.9 4.1 5.9 22.6 1.9 2.1 0.8 0.8 8.2 6.4 5.9 21.7 0.0 2.5 0.3 1.7 0.0 0.0 0.9 1.9 20.3 23.5 0.0 13.8 34.1 1.5 22.7 0.4 21.6 2.2 0.7 0.0 20.2 0.5 0.8 5.2 11.1 6.5 1.2 1.7 0.1 0.0 0.4 3.7 3.9 0.7 0.2 6.2 1.0 1.2 8.7 0.1 4.1 2.1 6.0 0.4 8.0 6.5 7.9 4.0 4.8 79.0 0.0 0.1 2.4 0.8 13.1 0.1 1.0 0.2 1.2 0.3 0.0 0.2 1.5 0.6 0.0 10.6 0.1 1.7 0.1 0.1 0.2 12.0 29.1 14.4 12.5 10.4 13.7 19.5 26.2 19.0 16.4 27.3 20.7 35.8 105.8 9.3 71.5 21.1 29.7 5.9 6.3 61.5 18.4 4.6 7.0 8.9 22.8 11.7 11.0 47.9 31.1 2.4 8.4 0.0 4.5 1.9 17.1 76.0 18.7 9.1 1.3 8.1 1.5 6.9 44.0 14.3 29.4 46.9 3.6 31.4 175.5 75.0 0.0 22.5 2.2 8.2 169.1 109.5 2.5 31.1 74.8 26.6 38.4 6.4 0.5 0.0 57.8 7.7 4.9 5.0 28.2 2.2 2.6 0.1 18.0 8.4 6.7 46.0 24.3 23.4 1.0 1.8 17.1 19.5 8.9 6.5 39.5 3.2 13.3 ABCC1 "GS-X, MRP, MRP1" ENSG00000103222 "ATP binding cassette subfamily C member 1" P33527 16 15949138-16143257 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" Transport "Hydrolase, Translocase" "Cancer-related genes, Deafness, FDA approved drug targets, Non-syndromic deafness" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Gastric mucus-secreting cells: 49.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "EFO-21: 79.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002380, HPA076011" Uncertain Supported "Plasma membrane,Cell Junctions" NA NA "Cluster 72: Non-specific - Transcription" "Cluster 38: EFO-21 - Unknown function" "Cluster 44: Endometrium - Transcription" "Plasma membrane" "Cell Junctions" "HPA002380: AB_1844432, HPA076011: " "unprognostic (9.97e-2)" "unprognostic (2.06e-1)" "unprognostic (2.05e-2)" "unprognostic (2.94e-1)" "unprognostic (4.89e-2)" "unprognostic (1.15e-1)" "prognostic unfavorable (5.42e-5)" "unprognostic (3.42e-1)" "unprognostic (3.31e-1)" "unprognostic (4.07e-2)" "unprognostic (9.78e-3)" "unprognostic (7.19e-2)" "prognostic unfavorable (1.55e-6)" "unprognostic (1.84e-1)" "unprognostic (1.15e-1)" "unprognostic (1.43e-2)" "unprognostic (1.80e-2)" 10.4 11.6 0.3 4.0 0.2 3.6 8.6 0.3 0.7 10.4 4.1 16.1 1.1 11.0 0.1 22.8 7.0 3.1 11.2 0.3 0.5 8.0 2.3 15.5 4.4 1.1 0.8 8.9 8.9 3.6 7.2 2.0 0.7 15.2 0.7 0.4 9.2 0.9 21.2 9.7 12.4 6.3 0.5 15.7 15.0 13.1 0.6 4.3 21.0 0.1 1.1 15.4 12.8 0.9 4.3 43.7 0.3 11.7 3.2 4.5 0.5 15.4 19.0 13.1 13.8 6.7 34.8 7.0 79.6 29.6 11.0 12.1 3.4 12.4 4.6 22.2 4.4 16.4 22.0 16.3 25.1 5.9 39.5 15.0 9.0 1.1 2.3 3.8 10.2 28.6 17.8 6.8 0.5 5.4 12.0 0.9 3.5 1.8 8.2 41.9 7.8 5.3 0.7 15.2 6.4 11.8 18.9 17.8 3.6 11.9 6.2 0.8 3.5 0.4 2.0 11.4 11.9 13.5 7.4 3.3 6.6 0.6 0.7 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.3 0.7 0.3 0.5 1.1 0.8 0.7 0.5 0.6 0.9 8.6 25.6 5.6 10.7 13.1 8.8 8.5 18.2 9.6 3.1 4.4 3.7 6.0 4.3 14.4 5.5 22.9 0.9 9.8 2.7 3.9 9.1 11.0 15.7 12.9 8.6 18.6 16.0 26.6 6.2 3.2 12.3 49.5 17.8 22.1 16.8 8.6 0.4 8.5 5.0 38.5 6.6 14.2 21.4 9.1 14.3 7.5 12.2 3.6 11.2 10.5 1.2 5.2 12.1 15.9 11.2 4.5 6.8 15.7 18.7 0.5 1.1 9.9 8.8 0.0 6.4 5.1 4.9 6.6 18.1 5.1 0.5 17.4 37.1 3.7 11.6 ABCC2 "CMOAT, cMRP, DJS, MRP2" ENSG00000023839 "ATP binding cassette subfamily C member 2" Q92887 10 99782640-99852594 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" Transport Translocase "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 40.2;liver: 121.7" "Cell type enriched" "Detected in some" 4 "Hepatocytes: 70.7" "Cancer enriched" "Detected in many" 5 "liver cancer: 24.0" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "A549: 204.4;Hep G2: 208.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA071145 Enhanced NA NA "Cluster 41: Intestine & Liver - Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 2: Hepatocytes - Metabolism" "HPA071145: " "unprognostic (1.49e-3)" "unprognostic (5.92e-2)" "unprognostic (1.59e-1)" "unprognostic (3.67e-1)" "unprognostic (1.93e-2)" "unprognostic (2.33e-1)" "unprognostic (2.51e-1)" "unprognostic (7.15e-3)" "unprognostic (5.68e-2)" "unprognostic (2.01e-1)" "unprognostic (4.30e-1)" "unprognostic (1.40e-3)" "prognostic unfavorable (1.93e-5)" "unprognostic (1.31e-1)" "unprognostic (3.22e-2)" "unprognostic (2.95e-1)" "unprognostic (1.26e-2)" 1.6 0.4 0.2 0.7 0.4 0.8 3.0 0.5 0.3 0.5 0.1 0.6 39.1 0.4 0.2 0.3 0.7 24.4 0.2 0.3 0.2 18.5 121.7 0.5 0.7 0.4 0.3 0.3 1.1 0.1 0.1 0.5 0.4 0.4 0.4 3.9 0.5 0.2 1.1 1.7 40.2 0.2 0.2 1.4 0.7 0.7 0.3 0.8 0.4 0.7 0.5 1.3 0.5 0.6 0.3 204.4 3.5 10.2 15.3 12.0 3.4 0.5 1.3 0.5 0.6 44.6 0.3 0.4 0.3 0.7 0.5 1.3 0.3 0.4 0.6 0.5 0.3 0.0 1.0 208.7 0.5 0.3 0.7 1.9 13.9 1.5 1.4 0.2 0.4 0.6 0.0 0.3 0.2 1.0 0.2 1.4 0.3 39.8 0.3 0.3 0.2 0.4 1.4 0.3 0.1 0.2 0.5 3.4 25.9 0.4 0.1 0.4 0.7 0.6 0.6 0.9 0.6 0.8 0.1 0.2 16.1 1.8 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.5 0.3 0.3 0.2 0.4 0.3 0.4 0.2 0.3 0.6 0.7 0.0 0.0 2.3 0.4 0.0 0.2 0.2 0.0 0.3 0.1 0.0 0.5 1.5 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.2 2.6 2.9 0.2 0.3 0.0 0.4 1.0 0.4 0.0 1.7 0.0 0.6 1.3 0.1 1.4 70.7 0.2 0.0 1.3 0.6 0.0 1.0 0.0 1.1 0.3 0.4 5.4 1.9 0.3 0.1 0.0 1.0 2.2 0.1 0.0 0.0 0.1 0.2 15.5 10.7 2.8 1.5 0.0 0.4 0.5 1.2 0.7 0.1 0.0 1.6 0.4 0.1 0.4 0.0 ABCC8 "ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2" ENSG00000006071 "ATP binding cassette subfamily C member 8" Q09428 11 17392498-17476879 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" Transport Receptor "Diabetes mellitus, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "pancreas: 20.1;pituitary gland: 34.4" "Group enriched" "Detected in some" 4 "Astrocytes: 19.6;Bipolar cells: 39.0;Endometrial stromal cells: 17.9;Enteroendocrine cells: 22.0;Excitatory neurons: 48.2;Inhibitory neurons: 39.3;Oligodendrocyte precursor cells: 39.2" "Cancer enriched" "Detected in some" 9 "pancreatic cancer: 16.5" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "A549: 1.8;AN3-CA: 1.4;SCLC-21H: 2.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011451, HPA042318" Approved Approved "Nucleoli,Golgi apparatus,Cytosol" No NA "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 56: Bipolar cells - Visual perception" Nucleoli "Golgi apparatus, Cytosol" "CAB011451: , HPA042318: AB_2677947" "unprognostic (4.30e-2)" "unprognostic (1.02e-1)" "unprognostic (5.09e-2)" "unprognostic (4.73e-2)" "unprognostic (9.48e-3)" "unprognostic (2.23e-1)" "unprognostic (4.46e-3)" "unprognostic (2.53e-3)" "unprognostic (6.04e-2)" "unprognostic (2.34e-2)" "unprognostic (8.72e-3)" "unprognostic (1.13e-1)" "unprognostic (2.22e-2)" "unprognostic (1.96e-2)" "unprognostic (6.88e-5)" "unprognostic (2.72e-2)" "unprognostic (1.85e-1)" 0.4 2.8 2.6 0.0 3.7 0.0 1.8 3.9 5.2 3.5 0.0 0.7 0.5 2.6 1.4 0.1 0.6 0.0 1.6 3.1 1.4 0.5 0.1 5.0 0.0 3.3 2.7 0.4 20.1 0.2 34.4 0.4 3.3 2.1 0.3 2.2 0.0 1.5 1.5 0.2 1.0 0.2 0.6 0.1 6.1 0.4 1.2 0.0 3.4 0.6 0.0 0.4 1.3 3.5 0.0 1.8 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 3.7 3.9 5.2 3.1 1.4 3.3 2.7 3.3 0.6 1.2 3.5 0.3 0.0 0.0 19.6 0.3 0.0 0.1 0.0 0.0 39.0 5.3 3.7 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.2 0.5 17.9 0.3 22.0 0.0 48.2 0.0 0.0 0.6 0.0 0.7 0.0 0.0 0.0 0.3 0.1 0.0 39.3 0.7 0.0 0.3 0.5 0.0 0.0 0.1 0.0 3.7 0.0 1.9 0.0 39.2 7.6 0.4 0.0 0.0 0.0 1.1 0.0 0.0 0.0 1.3 0.0 0.7 2.0 0.1 0.8 0.0 0.1 0.0 0.1 2.6 0.1 0.2 ABCC9 "CMD1O, SUR2" ENSG00000069431 "ATP binding cassette subfamily C member 9" O60706 12 21797389-21942529 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" Transport Receptor "Atrial fibrillation, Cardiomyopathy, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 45.2" "Cell type enhanced" "Detected in many" "Alveolar cells type 2: 60.3;Astrocytes: 72.1;Hepatocytes: 99.4;Sertoli cells: 131.5;Smooth muscle cells: 140.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC diff: 24.9;BJ hTERT+: 14.0;CACO-2: 20.8;HSkMC: 27.1;U-138 MG: 27.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007279 Uncertain Approved Nucleoplasm,Cytosol NA NA "Cluster 55: Non-specific - Mitochondria & Proteasome" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 48: Smooth muscle cells - ECM organization" "Nucleoplasm, Cytosol" "HPA007279: AB_1844435" "unprognostic (4.82e-2)" "unprognostic (3.62e-2)" "unprognostic (5.51e-4)" "unprognostic (1.09e-1)" "unprognostic (1.09e-1)" "unprognostic (8.30e-2)" "unprognostic (3.17e-2)" "unprognostic (1.50e-2)" "unprognostic (2.47e-2)" "unprognostic (8.72e-2)" "unprognostic (2.51e-2)" "unprognostic (3.57e-1)" "prognostic unfavorable (1.85e-5)" "unprognostic (2.66e-2)" "unprognostic (1.21e-2)" "unprognostic (3.10e-3)" "unprognostic (8.22e-5)" 27.4 5.9 4.5 3.4 5.4 1.7 9.2 3.1 9.2 8.2 11.6 7.4 4.0 19.1 8.3 6.2 12.3 11.7 28.3 5.4 3.6 6.6 45.2 7.7 3.5 4.8 7.4 10.9 3.5 1.9 2.2 3.6 3.7 7.9 1.8 3.2 4.5 9.9 41.9 4.2 3.1 21.0 3.4 4.4 8.1 1.2 5.1 1.8 6.3 30.3 1.5 5.3 5.1 7.2 0.9 0.2 11.9 0.3 24.9 11.0 0.3 6.1 14.0 7.0 3.5 20.8 1.0 0.5 1.2 0.6 0.8 0.3 0.0 0.0 7.2 0.3 0.2 0.5 0.8 0.3 0.1 0.5 0.6 27.1 0.0 6.7 2.5 0.4 0.0 0.4 0.3 1.2 0.3 1.4 0.2 0.4 1.4 1.2 0.6 0.5 0.3 0.3 0.0 1.2 0.4 1.7 0.4 0.5 0.2 1.7 1.2 0.3 0.3 27.0 1.9 2.2 8.7 1.1 1.3 0.4 6.7 0.3 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 4.5 5.4 3.1 9.2 5.4 3.6 4.8 7.4 3.7 3.4 5.1 7.2 33.8 35.3 60.3 72.1 0.2 3.4 1.5 5.0 0.6 0.8 0.5 0.8 38.2 0.0 25.6 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.6 0.8 20.6 19.7 0.0 0.0 17.2 0.2 0.1 26.2 1.1 0.6 24.0 0.0 7.1 99.4 0.1 1.7 1.0 0.0 0.0 2.4 5.9 0.1 0.3 2.5 10.6 2.8 0.0 15.9 0.0 1.5 1.4 0.1 0.0 0.4 0.0 0.5 0.0 0.1 20.4 1.2 131.5 11.1 140.7 0.4 1.6 1.1 2.3 0.3 2.5 0.2 0.0 2.2 ABL1 "ABL, c-ABL, JTK7, p150" ENSG00000097007 "ABL proto-oncogene 1, non-receptor tyrosine kinase" P00519 9 130713016-130887675 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Autophagy, Cell adhesion, DNA damage, DNA repair, Endocytosis" "DNA-binding, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Microglial cells: 71.2;Oligodendrocytes: 116.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002686, HPA027251, HPA027280, HPA028409" Supported Enhanced "Nucleoplasm,Nuclear bodies" Yes No "Cluster 37: B-cells - Transcription" "Cluster 12: Smooth muscle tissue - Mixed function" "Cluster 1: K-562 - Erythropoiesis" "Cluster 50: Fibroblasts - ECM organization" Nucleoplasm "Nuclear bodies" "CAB002686: , HPA027251: AB_1844453, HPA027280: AB_1844454, HPA028409: AB_10601011" "unprognostic (4.82e-2)" "unprognostic (3.99e-2)" "unprognostic (5.55e-2)" "unprognostic (4.72e-2)" "unprognostic (1.16e-1)" "unprognostic (1.46e-1)" "unprognostic (3.75e-3)" "unprognostic (1.89e-3)" "unprognostic (2.34e-1)" "unprognostic (2.54e-2)" "unprognostic (1.09e-2)" "unprognostic (1.48e-1)" "unprognostic (3.96e-3)" "unprognostic (1.10e-2)" "unprognostic (1.47e-1)" "unprognostic (1.22e-1)" "unprognostic (1.06e-1)" 50.9 30.7 27.4 25.3 38.9 23.4 45.8 33.6 31.4 60.5 40.4 96.4 23.1 63.0 11.6 33.8 55.6 35.7 36.1 26.6 28.3 23.1 17.5 37.3 16.3 39.3 38.5 56.0 24.9 32.5 34.9 26.5 35.8 43.5 26.7 14.2 32.4 33.6 29.4 36.3 45.2 41.2 31.3 23.3 51.6 20.1 34.9 22.4 46.7 30.8 15.4 79.3 42.7 41.3 22.5 48.3 53.6 62.9 76.5 93.3 18.8 38.8 60.4 44.8 38.1 36.4 28.3 32.3 22.3 52.0 47.6 42.5 23.5 36.0 30.7 20.6 16.3 23.7 84.1 33.4 51.8 36.5 32.3 68.8 37.2 80.6 50.0 64.1 61.0 47.9 135.8 26.5 54.9 42.0 49.2 30.5 57.9 34.3 33.8 55.9 67.9 35.9 45.0 25.7 47.9 60.1 66.1 23.5 29.2 31.0 46.2 33.1 71.1 170.7 44.1 66.3 62.6 8.4 20.3 47.9 72.1 27.6 55.1 0.0 0.7 0.3 0.6 0.4 0.8 1.3 0.6 0.6 0.7 0.4 0.6 0.5 0.0 0.8 1.9 1.0 0.3 0.6 27.4 38.9 33.6 31.4 26.6 28.3 39.3 38.5 35.8 31.3 34.9 41.3 16.2 9.6 13.6 54.9 4.7 9.2 7.3 9.8 5.2 8.2 11.6 10.2 6.2 7.2 7.2 14.7 12.5 13.6 12.1 21.2 1.9 14.4 5.9 8.6 29.7 18.1 22.1 4.6 52.5 11.1 4.3 36.7 5.6 12.4 2.5 22.1 20.3 15.9 16.6 10.1 63.7 17.5 6.1 16.4 11.7 8.8 28.0 10.2 5.4 71.2 6.6 19.2 6.2 66.9 116.0 17.9 18.3 25.6 5.6 8.6 11.6 10.3 7.8 9.1 19.7 29.5 19.8 16.9 16.5 6.6 6.8 15.2 7.9 20.1 21.4 7.2 ACAA1 ENSG00000060971 "Acetyl-CoA acyltransferase 1" P09110 3 38103129-38137242 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism" "Acyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "kidney: 212.6;liver: 659.3" "Cell type enhanced" "Detected in all" "Distal enterocytes: 356.8;Hepatocytes: 686.0;Proximal enterocytes: 441.1;Proximal tubular cells: 721.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "OE19: 224.0;SK-BR-3: 342.9" "Low region specificity" "Detected in all" "HPA006764, HPA007244" Enhanced Supported Peroxisomes NA NA 4700000 "Cluster 31: Non-specific - Inflammatory response" "Cluster 85: Liver - Metabolism" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 67: Proximal tubular cells - Tubular reabsorption" Peroxisomes "HPA006764: AB_1078085, HPA007244: AB_1078084" "prognostic favorable (3.00e-4)" "unprognostic (5.57e-2)" "unprognostic (4.54e-2)" "prognostic favorable (7.53e-4)" "unprognostic (2.63e-1)" "prognostic favorable (1.23e-4)" "unprognostic (9.35e-3)" "unprognostic (2.91e-2)" "unprognostic (8.11e-2)" "unprognostic (2.22e-1)" "unprognostic (2.24e-1)" "unprognostic (4.90e-1)" "prognostic favorable (6.99e-9)" "unprognostic (1.72e-1)" "unprognostic (1.99e-1)" "unprognostic (2.50e-2)" "unprognostic (1.65e-2)" 42.8 54.1 47.5 24.0 54.4 44.7 41.2 54.3 49.5 28.3 42.3 56.9 101.0 20.8 44.6 56.7 19.4 29.8 84.8 44.6 48.7 212.6 659.3 34.9 26.1 54.2 50.4 20.9 59.3 47.9 24.8 17.2 53.0 55.1 51.2 4.9 38.9 25.3 48.2 30.7 89.5 18.7 50.9 41.3 42.1 15.5 53.6 28.0 32.1 53.8 30.0 43.7 33.5 54.9 35.5 39.8 13.0 40.7 55.6 32.2 44.6 32.2 47.0 36.3 34.5 52.8 38.8 21.1 22.6 52.0 17.4 24.5 34.9 54.0 20.0 31.0 37.2 27.0 35.4 155.5 35.3 63.3 59.8 59.0 39.3 31.2 22.5 23.9 49.9 49.7 26.2 24.2 41.3 49.2 60.3 45.3 13.3 224.0 47.0 13.9 25.0 34.3 103.4 110.4 10.9 16.5 31.7 342.9 23.7 18.0 35.1 48.9 36.8 21.9 21.1 43.2 44.2 31.9 21.7 16.1 34.8 54.4 34.7 79.9 114.4 130.4 48.8 159.1 41.2 33.9 45.7 47.4 178.1 36.0 45.2 42.5 76.3 71.9 187.7 104.5 77.2 82.1 47.5 54.4 54.3 49.5 44.6 48.7 54.2 50.4 53.0 50.9 53.6 54.9 30.7 41.7 38.7 50.6 45.6 33.3 56.5 57.6 40.9 36.9 48.7 37.1 3.2 98.7 44.3 66.2 14.6 91.6 61.7 356.8 166.3 98.0 4.5 40.7 38.6 25.4 55.1 40.4 25.6 78.4 64.5 34.4 76.5 39.1 19.0 32.5 37.1 686.0 81.7 8.4 24.7 73.1 48.8 93.5 86.8 9.6 35.8 83.2 58.7 14.0 89.5 43.1 53.5 12.5 30.9 100.9 270.6 33.1 44.5 60.6 441.1 721.8 26.3 16.7 32.9 28.5 27.4 19.8 11.7 48.1 35.5 99.3 44.4 186.7 84.3 87.0 ACE "ACE1, CD143, DCP1" ENSG00000159640 "Angiotensin I converting enzyme" P12821 17 63477061-63498380 "Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Carboxypeptidase, Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 265.1;testis: 101.9" "Group enriched" "Detected in many" 20 "Early spermatids: 543.6;Late spermatids: 1322.9;Proximal enterocytes: 1172.8" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in many" "basal ganglia: 8.1" "Immune cell enhanced" "Detected in single" "memory B-cell: 1.0" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in many" 4 "ASC TERT1: 63.3;HUVEC TERT2: 33.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002426, CAB002921, HPA029298, HPA069790" Enhanced Approved Vesicles "Secreted to blood" NA NA 104000000 170000000 "Cluster 43: B-cells - Humoral immune response" "Cluster 56: Intestine - Transmembrane transport" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 45: Enterocytes - Digestion" Vesicles "CAB002426: AB_442052, CAB002921: , HPA029298: AB_10960255, HPA069790: AB_2686197" "unprognostic (4.72e-2)" "unprognostic (4.16e-1)" "unprognostic (1.93e-3)" "unprognostic (6.06e-2)" "unprognostic (2.78e-1)" "unprognostic (1.35e-2)" "unprognostic (4.37e-1)" "unprognostic (1.54e-1)" "unprognostic (1.56e-1)" "unprognostic (1.25e-2)" "unprognostic (3.13e-2)" "unprognostic (2.38e-1)" "unprognostic (7.66e-2)" "unprognostic (9.07e-2)" "unprognostic (1.66e-1)" "unprognostic (1.08e-1)" "unprognostic (2.76e-2)" 13.4 4.9 1.7 4.8 8.1 0.1 8.1 0.2 2.5 18.1 0.5 11.2 176.4 8.1 3.5 4.1 6.3 8.2 10.4 1.3 1.0 10.8 1.9 49.0 4.9 1.3 0.9 1.9 6.2 18.7 9.2 11.6 1.3 8.9 6.1 0.4 7.6 23.8 16.1 3.8 265.1 9.6 0.8 2.8 8.3 101.9 2.0 0.8 19.2 10.0 2.1 5.5 3.8 1.1 0.0 0.0 0.0 0.0 2.6 63.3 0.6 2.4 4.7 0.0 0.0 0.9 5.1 1.3 1.8 11.4 0.1 0.0 3.1 0.0 0.0 0.0 1.4 6.6 0.0 0.0 1.4 0.0 0.0 4.2 0.0 0.1 0.0 1.2 33.8 0.0 5.8 0.0 0.1 1.1 0.0 1.4 0.4 11.7 0.7 0.1 0.5 0.9 0.0 0.0 8.2 5.6 0.0 0.0 0.0 1.3 2.9 0.4 0.0 0.1 0.2 0.5 0.1 0.0 0.0 0.0 1.0 0.0 0.5 0.0 0.0 0.0 0.1 0.1 0.2 1.0 0.5 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 1.7 8.1 0.2 2.5 1.3 1.0 1.3 0.9 1.3 0.8 2.0 1.1 50.0 0.0 3.3 0.0 0.5 1.5 2.6 0.1 1.2 4.0 3.6 1.9 2.1 1.5 0.7 0.0 0.0 0.1 0.3 11.9 0.0 5.9 543.6 10.8 8.0 34.7 18.0 0.0 4.7 0.4 0.1 11.5 2.0 36.3 7.0 24.1 3.6 0.8 4.2 0.0 1.8 39.8 0.0 33.7 3.5 1322.9 4.4 13.6 3.6 4.7 0.0 1.8 0.0 1.0 0.2 0.7 40.9 2.6 0.1 4.2 1172.8 21.7 0.0 1.1 0.0 2.0 4.2 13.5 6.4 0.2 0.1 0.1 2.2 0.3 26.2 2.1 ACHE YT ENSG00000087085 "Acetylcholinesterase (Cartwright blood group)" P22303 7 100889994-100896974 "Blood group antigen proteins, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Neurotransmitter degradation" "Blood group antigen, Hydrolase, Serine esterase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "brain: 98.2;skeletal muscle: 163.2;tongue: 48.0" "Cell type enhanced" "Detected in many" "Distal enterocytes: 86.2;Erythroid cells: 37.7;Exocrine glandular cells: 39.7;Horizontal cells: 55.5;Paneth cells: 118.3;Proximal enterocytes: 45.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 7.9;CACO-2: 13.0;K-562: 13.9;Karpas-707: 19.7;U-2 OS: 6.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA027098 Approved "Golgi apparatus,Vesicles" "Intracellular and membrane" NA NA 990000 "Cluster 80: Striated muscle - Unknown function" "Cluster 2: Karpas-707 - Immune response" "Cluster 53: Intestinal epithelial cells - Unknown function" "Golgi apparatus" Vesicles "HPA027098: AB_2672111" "unprognostic (2.23e-1)" "unprognostic (9.44e-2)" "unprognostic (2.71e-2)" "unprognostic (5.80e-3)" "prognostic unfavorable (5.27e-4)" "unprognostic (2.49e-1)" "unprognostic (2.54e-1)" "unprognostic (1.36e-2)" "unprognostic (2.48e-2)" "unprognostic (8.92e-2)" "unprognostic (2.65e-2)" "unprognostic (1.78e-1)" "prognostic unfavorable (3.88e-5)" "unprognostic (2.95e-1)" "unprognostic (2.59e-2)" "unprognostic (9.28e-2)" "unprognostic (8.38e-2)" 1.4 4.7 20.9 2.2 16.8 7.9 2.0 37.1 32.5 5.0 0.0 7.6 4.9 2.6 0.2 2.3 3.2 1.3 12.5 8.0 98.2 8.8 4.1 4.4 3.5 66.1 54.2 4.6 4.3 4.7 8.3 0.7 72.7 8.1 1.8 5.7 7.1 1.6 163.2 1.3 9.1 0.5 26.2 3.5 2.4 3.9 58.1 3.6 2.3 48.0 1.5 1.4 3.7 10.5 0.0 0.2 0.2 0.2 0.3 0.0 7.9 0.3 0.0 0.1 0.2 13.0 0.1 0.0 0.6 0.0 1.2 0.6 2.0 0.1 0.0 4.6 0.5 0.2 0.1 0.2 0.1 0.0 0.4 0.5 0.1 0.1 0.0 0.0 0.0 0.1 13.9 19.7 0.1 4.3 0.0 0.2 1.1 0.3 0.3 0.0 0.1 0.0 0.1 0.0 0.8 1.5 0.1 0.8 0.0 2.9 0.0 0.0 0.2 0.5 6.0 0.2 0.1 0.0 0.2 0.0 0.1 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.9 16.8 37.1 32.5 8.0 98.2 66.1 54.2 72.7 26.2 58.1 10.5 0.5 0.0 0.0 3.3 0.5 0.8 20.9 0.9 6.2 13.5 2.9 1.1 6.4 5.7 0.4 0.0 0.0 8.2 0.9 86.2 0.0 10.5 0.0 0.5 1.5 2.1 3.5 37.7 4.7 39.7 2.6 3.0 1.5 2.4 0.0 7.4 2.2 0.4 0.8 55.5 9.7 12.0 0.0 0.3 6.6 0.4 0.6 1.7 1.8 1.0 4.6 11.4 0.0 8.5 0.8 20.1 118.3 0.7 1.8 20.4 45.6 1.1 0.1 6.8 0.0 13.5 4.9 4.1 8.0 1.7 1.0 7.1 0.6 1.4 4.6 15.2 ACLY "ACL, ATPCL, CLATP" ENSG00000131473 "ATP citrate lyase" P53396 17 41866917-41930542 "Cancer-related genes, Citric acid cycle related proteins, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Lipid biosynthesis, Lipid metabolism" Transferase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB007783, HPA022434, HPA022953, HPA022959, HPA028758" Enhanced Supported Nucleoplasm,Cytosol No No 3100000 "Cluster 44: Non-specific - Transcription" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 29: Early spermatids - Spermatogenesis" Cytosol Nucleoplasm "CAB007783: AB_562242, HPA022434: AB_1844513, HPA022953: AB_1844514, HPA022959: AB_1844515, HPA028758: AB_10603575" "unprognostic (2.21e-2)" "prognostic unfavorable (1.79e-4)" "unprognostic (1.41e-1)" "unprognostic (1.21e-2)" "unprognostic (2.83e-1)" "unprognostic (8.94e-3)" "prognostic unfavorable (3.66e-4)" "unprognostic (3.38e-3)" "unprognostic (4.11e-2)" "unprognostic (5.94e-3)" "unprognostic (2.13e-2)" "unprognostic (3.01e-2)" "unprognostic (3.88e-3)" "unprognostic (1.66e-1)" "unprognostic (9.36e-2)" "unprognostic (3.90e-2)" "unprognostic (4.67e-3)" 64.9 30.2 24.0 43.9 27.2 34.7 46.7 33.6 55.5 33.2 22.5 35.4 49.3 34.4 34.7 30.5 36.0 31.1 27.1 24.7 66.5 47.5 27.5 35.3 42.7 80.3 48.6 21.3 46.3 37.4 22.4 42.4 76.5 62.6 35.7 23.2 39.1 28.5 15.3 28.9 43.7 42.5 34.2 39.1 38.9 32.2 43.1 48.4 30.8 14.9 40.3 36.7 29.2 43.7 127.1 423.2 194.8 168.8 296.1 274.4 178.3 174.0 188.0 213.7 266.3 217.9 141.8 204.7 108.8 245.2 200.6 197.2 253.9 298.0 177.8 184.9 243.0 117.3 228.3 227.5 136.9 191.9 147.1 219.8 88.3 376.9 75.6 140.0 228.7 155.0 147.4 158.5 180.4 130.0 317.8 107.6 127.6 84.8 75.7 205.2 236.2 262.2 221.0 222.4 364.7 200.2 124.5 382.8 133.7 167.6 229.4 181.0 248.4 165.7 135.5 169.0 291.0 91.9 127.0 193.0 280.3 145.7 137.5 32.2 29.2 36.5 30.9 30.9 29.1 21.6 24.4 27.7 33.0 18.3 18.1 20.3 14.6 24.0 39.8 19.1 34.3 33.8 24.0 27.2 33.6 55.5 24.7 66.5 80.3 48.6 76.5 34.2 43.1 43.7 28.2 28.9 26.2 12.4 20.5 25.0 10.0 25.4 12.5 12.1 38.6 21.6 12.6 31.5 21.0 23.9 4.2 22.6 25.9 26.7 11.7 33.8 73.3 31.6 35.3 33.4 65.9 34.3 10.9 33.6 46.5 28.9 23.4 29.2 15.2 28.7 41.4 53.0 31.0 18.5 14.7 54.0 20.3 39.0 25.9 17.5 61.8 27.6 32.0 16.9 42.9 7.6 25.7 11.6 13.6 42.9 16.2 51.1 17.4 35.9 40.4 87.0 31.1 9.4 13.1 17.6 25.7 17.9 36.0 21.6 33.0 22.2 25.1 49.0 22.2 15.5 ADA ADA1 ENSG00000196839 "Adenosine deaminase" P00813 20 44619522-44652233 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Cell adhesion, Nucleotide metabolism" Hydrolase "Disease variant, FDA approved drug targets, Hereditary hemolytic anemia, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "intestine: 507.2;lymphoid tissue: 259.0" "Cell type enhanced" "Detected in many" "dendritic cells: 76.4;Extravillous trophoblasts: 128.2;NK-cells: 56.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "intermediate monocyte: 168.5;NK-cell: 94.5;non-classical monocyte: 362.8;plasmacytoid DC: 218.6" "Group enriched" "Detected in all" 4 "dendritic cells: 218.6;monocytes: 362.8;NK-cells: 94.5" "Group enriched" "Detected in many" 5 "JURKAT: 570.9;MOLT-4: 1915.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA001399, CAB004307, HPA023884" Enhanced Supported "Plasma membrane,Cytosol" No No 470000 "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 9: Intestine - Unknown function" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 38: Extravillous trophoblasts - Unknown function" "Plasma membrane" Cytosol "CAB004307: AB_626634, HPA001399: AB_1078099, HPA023884: AB_1844573" "unprognostic (4.30e-2)" "unprognostic (6.89e-2)" "unprognostic (3.96e-2)" "prognostic unfavorable (1.23e-7)" "unprognostic (9.33e-2)" "unprognostic (9.07e-3)" "prognostic unfavorable (6.77e-5)" "prognostic unfavorable (2.20e-4)" "unprognostic (1.59e-1)" "unprognostic (2.16e-1)" "unprognostic (3.66e-2)" "unprognostic (3.48e-1)" "prognostic unfavorable (2.94e-14)" "unprognostic (2.29e-1)" "unprognostic (1.04e-2)" "unprognostic (1.53e-1)" "unprognostic (1.82e-1)" 16.6 6.3 6.9 18.5 8.2 20.2 10.9 6.8 9.4 7.3 5.6 5.7 507.2 3.8 1.7 9.0 5.6 9.2 17.8 6.9 7.0 3.3 4.4 6.2 33.4 7.2 8.2 2.1 5.3 1.5 1.3 4.6 7.2 4.3 3.6 0.3 4.7 2.8 5.3 6.0 17.9 5.7 6.1 17.5 46.0 2.4 8.7 259.0 5.8 6.4 26.4 9.3 5.4 8.8 14.0 37.7 19.2 13.2 35.6 48.7 30.5 13.7 7.8 13.2 9.3 17.5 14.8 38.4 15.8 17.9 24.7 2.2 13.2 55.1 7.3 2.9 17.2 7.8 6.6 13.5 15.0 6.3 20.3 234.3 23.2 5.1 9.0 12.6 50.3 570.9 20.4 30.7 6.0 33.1 1915.5 28.9 5.2 17.2 13.5 102.3 25.8 95.0 2.3 0.0 0.7 9.3 20.2 4.4 24.2 24.0 4.5 19.1 16.9 10.1 18.6 20.5 2.8 40.1 27.3 82.3 3.5 32.5 9.0 0.5 9.8 1.2 43.3 168.5 27.8 7.5 35.5 51.0 35.2 7.6 27.3 38.6 2.5 94.5 362.8 218.6 29.8 57.4 6.9 8.2 6.8 9.4 6.9 7.0 7.2 8.2 7.2 6.1 8.7 8.8 18.2 0.0 1.9 2.9 13.5 12.9 3.4 10.0 13.6 0.0 2.7 3.2 2.1 0.0 4.8 1.8 0.0 2.9 76.4 0.8 0.0 3.7 0.4 0.7 9.1 17.0 0.0 10.7 0.2 19.7 128.2 19.7 14.8 0.8 0.0 3.5 7.1 3.6 28.5 0.0 0.2 1.5 10.2 20.8 25.5 1.8 42.3 27.6 8.8 3.7 37.4 3.8 56.7 0.5 9.4 10.7 0.3 2.6 31.4 6.0 0.7 3.0 2.4 0.0 13.1 1.9 14.1 0.3 6.2 12.9 13.9 3.7 30.9 6.8 4.9 2.7 ADH1A ADH1 ENSG00000187758 "Alcohol dehydrogenase 1A (class I), alpha polypeptide" P07327 4 99276369-99291003 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 306 "liver: 2739.1" "Cell type enriched" "Detected in some" 12 "Hepatocytes: 200.9" "Cancer enriched" "Detected in some" 251 "liver cancer: 165.9" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 7 "ASC diff: 8.2" "CAB009562, HPA047814, HPA060902" Enhanced Approved "Plasma membrane,Cytosol" NA NA 38000000 "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 2: Hepatocytes - Metabolism" "Plasma membrane, Cytosol" "CAB009562: AB_2257984, HPA047814: AB_2680163, HPA060902: AB_2684384" "unprognostic (5.89e-2)" "unprognostic (6.16e-2)" "unprognostic (1.20e-1)" "unprognostic (2.07e-1)" "unprognostic (4.40e-1)" "prognostic favorable (2.38e-4)" "unprognostic (2.78e-3)" "unprognostic (4.25e-1)" "unprognostic (4.79e-3)" "unprognostic (6.21e-2)" "unprognostic (9.36e-2)" "unprognostic (3.25e-2)" "unprognostic (1.40e-1)" "unprognostic (2.86e-2)" 7.2 1.6 0.0 0.4 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.3 8.9 0.3 0.5 0.1 0.5 6.6 0.3 0.0 0.0 0.7 2739.1 0.8 0.0 0.1 0.1 0.1 1.1 0.0 0.3 0.1 0.0 0.0 0.3 0.0 0.2 0.0 0.1 0.1 1.8 0.0 0.1 0.3 0.4 0.3 0.0 0.0 0.1 1.0 0.1 0.3 0.1 0.1 0.0 0.0 0.0 0.0 8.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 15.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.5 0.1 0.1 0.3 0.0 10.7 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 8.6 200.9 0.0 0.0 0.0 0.0 0.0 9.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.3 0.2 0.1 0.0 0.0 0.5 0.0 0.0 0.0 ADH1B ADH2 ENSG00000196616 "Alcohol dehydrogenase 1B (class I), beta polypeptide" P00325 4 99304971-99352760 "Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 1501.5;liver: 5858.7" "Cell type enriched" "Detected in many" 6 "Hepatocytes: 4153.7" "Cancer enriched" "Detected in many" 31 "liver cancer: 223.1" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 7 "ASC diff: 6574.3" "HPA047814, HPA060902" Supported Approved "Plasma membrane,Cytosol" NA NA 39000000 "Cluster 85: Liver - Metabolism" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 2: Hepatocytes - Metabolism" "Plasma membrane, Cytosol" "HPA047814: AB_2680163, HPA060902: AB_2684384" "unprognostic (5.13e-2)" "unprognostic (9.80e-3)" "unprognostic (6.59e-2)" "unprognostic (5.56e-2)" "unprognostic (9.49e-2)" "unprognostic (5.53e-2)" "unprognostic (1.54e-3)" "unprognostic (1.04e-2)" "unprognostic (6.51e-2)" "unprognostic (2.73e-2)" "unprognostic (7.47e-3)" "unprognostic (7.79e-2)" "prognostic unfavorable (7.87e-4)" "unprognostic (4.60e-3)" "unprognostic (2.33e-1)" "unprognostic (2.58e-1)" "unprognostic (1.60e-2)" 1501.5 140.2 2.2 36.4 3.4 0.1 924.6 1.9 9.0 41.0 13.5 202.2 38.5 161.4 74.8 105.8 385.0 145.1 215.3 2.0 1.9 66.7 5858.7 373.2 25.8 4.7 2.2 117.7 49.1 7.8 24.2 6.8 3.2 26.7 114.7 0.1 67.9 26.7 66.6 159.2 237.1 73.4 4.4 72.7 141.1 2.8 2.2 19.8 94.5 228.2 16.0 287.9 118.7 2.4 0.0 0.0 0.0 0.0 6574.3 956.7 0.2 0.0 2.0 0.0 0.0 0.0 0.0 0.7 0.1 1.1 0.0 0.0 0.5 1.4 0.0 0.1 0.0 1.1 0.1 0.0 26.9 3.0 0.0 216.8 0.1 0.0 0.8 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.1 0.5 0.1 0.0 0.0 0.1 3.2 0.1 0.0 0.0 0.1 0.2 1.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.5 0.2 0.2 0.3 1.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 3.4 1.9 9.0 2.0 1.9 4.7 2.2 3.2 4.4 2.2 2.4 29.0 0.0 3.4 0.0 8.1 22.3 0.5 0.1 6.8 0.1 1.1 2.5 12.2 110.1 2.3 0.0 0.0 0.1 1.5 0.0 0.0 0.0 0.6 0.1 0.9 14.7 0.0 115.0 0.0 0.0 0.1 633.1 11.2 0.0 1.3 0.0 96.8 4153.7 0.1 0.0 0.0 0.0 0.0 98.8 25.4 0.6 55.3 3.5 28.4 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 7.1 0.7 0.0 0.1 0.2 0.1 6.6 15.0 47.9 0.0 0.1 10.4 13.1 0.1 8.9 0.1 0.0 0.2 ADH1C ADH3 ENSG00000248144 "Alcohol dehydrogenase 1C (class I), gamma polypeptide" P00326 4 99336497-99352746 "Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 21 "intestine: 598.1;liver: 2062.2;stomach 1: 570.6" "Cell type enhanced" "Detected in many" "Exocrine glandular cells: 699.4;Gastric mucus-secreting cells: 611.2;Hepatocytes: 440.6;Undifferentiated cells: 420.5" "Cancer enriched" "Detected in many" 7 "liver cancer: 238.2" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 2.1;ASC TERT1: 3.6;HSkMC: 11.9;RPMI-8226: 2.1" "HPA047814, HPA060902" Supported Supported "Plasma membrane,Cytosol" NA NA 31000000 "Cluster 85: Liver - Metabolism" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 1: Pancreatic cells - Digestion" "Plasma membrane, Cytosol" "HPA047814: AB_2680163, HPA060902: AB_2684384" "unprognostic (3.98e-2)" "unprognostic (9.88e-3)" "unprognostic (7.04e-2)" "unprognostic (1.90e-1)" "unprognostic (5.14e-1)" "unprognostic (1.57e-1)" "prognostic favorable (4.55e-4)" "prognostic favorable (2.99e-4)" "unprognostic (8.25e-2)" "unprognostic (8.89e-3)" "unprognostic (7.95e-2)" "unprognostic (2.04e-1)" "unprognostic (1.12e-1)" "unprognostic (1.21e-1)" "unprognostic (1.53e-1)" "unprognostic (1.70e-1)" "unprognostic (9.37e-2)" 22.9 0.8 0.1 29.8 0.1 0.0 19.2 0.1 0.1 4.7 0.0 329.5 598.1 5.1 7.2 5.1 5.8 51.6 5.9 0.1 0.0 19.6 2062.2 2.9 0.6 0.1 0.1 4.0 16.7 0.1 1.6 0.1 0.1 9.4 191.9 0.0 19.3 6.2 23.9 0.7 190.7 16.3 0.1 0.7 570.6 0.8 0.1 0.5 2.9 31.1 0.5 5.9 3.6 0.2 0.0 2.1 0.0 0.0 1.4 3.6 0.9 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.4 0.3 0.0 0.2 1.1 0.3 11.9 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.3 0.8 0.2 0.0 0.1 0.1 0.8 2.1 0.8 0.0 0.3 1.1 0.5 0.7 0.0 0.0 0.2 0.0 0.1 0.0 0.4 0.3 0.1 0.1 0.0 0.3 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 2.1 3.2 7.3 0.7 1.3 0.0 4.0 0.0 25.0 0.0 0.1 0.3 1.0 64.3 24.8 29.5 0.0 0.0 0.1 108.4 0.0 159.5 2.3 1.3 0.8 1.2 21.6 29.5 0.3 699.4 0.0 21.1 611.2 1.3 0.0 0.0 13.2 440.6 0.0 0.0 0.2 86.3 0.0 13.2 0.0 1.0 10.5 0.8 0.0 0.0 2.0 0.0 0.0 0.5 0.1 66.3 120.8 0.0 0.6 3.1 59.4 1.4 43.7 0.0 0.0 1.3 2.0 0.0 0.7 10.6 0.0 0.0 1.8 1.6 420.5 3.6 ADORA1 RDC7 ENSG00000163485 "Adenosine A1 receptor" P30542 1 203090654-203167405 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 54.8;testis: 21.4" "Cell type enhanced" "Detected in some" "Excitatory neurons: 18.1;granulocytes: 22.3;Muller glia cells: 44.4;Oligodendrocyte precursor cells: 35.2;Oligodendrocytes: 31.5" "Cancer enhanced" "Detected in many" "glioma: 24.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "CACO-2: 40.3;MCF7: 24.4;RH-30: 65.4;RPTEC TERT1: 31.7;SK-BR-3: 35.2;U-138 MG: 20.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044383 Supported "Plasma membrane" NA NA "Cluster 76: Brain & Bone marrow - Chromatin organization" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 5: Muller glia cells - Visual perception" "Plasma membrane" "HPA044383: AB_2678921" "unprognostic (3.93e-3)" "unprognostic (8.16e-2)" "unprognostic (6.16e-2)" "unprognostic (2.38e-3)" "unprognostic (2.25e-2)" "unprognostic (2.34e-1)" "unprognostic (4.64e-2)" "unprognostic (4.17e-2)" "unprognostic (3.04e-1)" "unprognostic (4.80e-3)" "unprognostic (1.42e-1)" "unprognostic (2.98e-1)" "unprognostic (2.96e-3)" "unprognostic (1.54e-1)" "unprognostic (1.27e-1)" "unprognostic (4.13e-2)" "unprognostic (5.76e-4)" 3.7 0.2 31.9 1.6 34.6 0.0 4.6 28.6 33.8 1.0 0.0 1.0 1.0 1.2 0.6 1.1 1.2 0.9 11.4 29.6 23.0 9.3 0.4 1.7 0.6 35.7 35.0 0.3 13.2 8.0 1.9 6.8 41.8 1.0 0.6 4.8 6.4 0.4 1.7 4.6 1.2 0.4 23.6 6.3 1.0 21.4 54.8 0.4 2.2 2.5 0.5 1.6 0.7 41.5 0.3 3.0 0.6 0.2 0.2 1.6 0.2 2.0 3.0 0.7 0.4 40.3 0.7 0.0 8.9 7.3 4.8 0.1 0.7 0.0 0.2 0.0 1.1 0.0 0.4 0.0 0.6 0.0 0.1 0.9 0.0 0.9 0.0 6.4 0.0 6.4 0.0 0.1 6.2 24.4 0.1 0.0 10.2 0.0 0.0 0.0 65.4 2.3 31.7 0.0 0.8 0.7 4.4 35.2 0.5 3.6 2.0 1.0 0.0 20.9 10.6 0.0 11.7 0.0 0.2 0.0 10.5 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 31.9 34.6 28.6 33.8 29.6 23.0 35.7 35.0 41.8 23.6 54.8 41.5 0.0 0.0 0.0 11.1 0.0 0.0 0.0 0.0 0.0 1.1 9.4 6.9 3.1 7.2 0.0 3.7 0.0 0.1 0.1 0.1 0.0 11.7 0.1 0.0 0.4 0.3 0.0 0.0 18.1 3.3 1.3 1.1 0.0 0.1 22.3 0.8 0.0 0.0 0.9 0.0 2.9 0.0 0.0 1.0 1.0 0.5 0.0 0.6 1.8 1.9 0.2 44.4 0.0 35.2 31.5 0.5 0.0 0.7 0.0 0.0 0.0 3.0 0.0 1.6 0.0 0.0 0.6 0.1 0.3 0.0 0.0 0.1 0.1 0.0 0.0 0.1 ADORA2A "ADORA2, RDC8" ENSG00000128271 "Adenosine A2a receptor" P29274 22 24417879-24442357 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 40.6;brain: 101.4;lymphoid tissue: 54.1" "Group enriched" "Detected in some" 6 "B-cells: 5.8;monocytes: 10.9;Plasma cells: 11.8;T-cells: 3.0" "Not detected" "Not detected" "Region enriched" "Detected in all" 5 "basal ganglia: 101.4" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 39.3;Karpas-707: 52.8;RPMI-8226: 41.1;SK-BR-3: 74.0;U-266/70: 52.8;U-266/84: 74.4;U-698: 55.0" "Region enriched" "Detected in many" 9 "basal ganglia: 399.8" "Region enriched" "Detected in many" 50 "basal ganglia: 142.2" "CAB001943, HPA065566, HPA075997" Enhanced Supported NA NA "Cluster 13: T-cells - Unknown function" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 58: T-cells - T-cell receptor" "CAB001943: , HPA065566: , HPA075997: AB_2732298" "unprognostic (7.30e-2)" "unprognostic (2.42e-2)" "unprognostic (3.30e-2)" "unprognostic (2.04e-1)" "unprognostic (7.44e-2)" "unprognostic (1.88e-3)" "unprognostic (9.85e-2)" "unprognostic (3.63e-1)" "unprognostic (2.88e-2)" "unprognostic (4.57e-3)" "unprognostic (2.15e-3)" "unprognostic (1.87e-3)" "unprognostic (6.81e-4)" "unprognostic (1.50e-1)" "unprognostic (9.78e-3)" "unprognostic (1.30e-1)" "unprognostic (7.10e-3)" 3.4 5.4 12.3 13.5 101.4 40.6 2.5 10.8 19.2 4.0 8.0 4.1 6.6 2.9 1.6 2.0 3.7 3.0 13.5 11.6 10.0 17.5 14.5 14.6 20.5 10.2 10.4 3.9 2.3 0.2 6.7 1.8 10.4 5.5 1.0 2.1 3.2 1.7 2.5 1.6 7.0 0.9 9.9 15.2 4.0 3.1 19.9 54.1 4.3 1.4 10.4 5.3 3.4 9.7 0.5 0.9 1.0 0.3 0.4 0.3 1.0 0.7 23.2 1.3 2.4 4.5 0.3 39.3 2.6 0.7 2.4 1.0 2.4 0.0 0.0 4.7 6.6 0.7 0.2 5.6 0.4 0.8 18.7 0.2 0.2 7.2 0.0 0.5 8.2 5.8 0.3 52.8 0.0 0.7 14.0 4.2 1.6 5.0 0.1 0.6 1.7 41.1 0.1 0.3 3.9 21.6 1.1 74.0 0.3 1.1 0.8 3.7 0.5 2.2 3.7 0.5 0.4 52.8 74.4 55.0 11.5 13.6 0.3 9.6 2.1 11.6 20.0 6.5 46.9 21.9 37.4 39.2 2.6 38.3 51.5 42.4 32.6 6.3 23.1 2.9 54.0 27.1 12.3 101.4 10.8 19.2 11.6 10.0 10.2 10.4 10.4 9.9 19.9 9.7 0.0 0.0 0.5 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.6 0.0 0.2 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.2 0.0 0.0 0.5 0.0 0.0 10.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.1 ADORA2B ENSG00000170425 "Adenosine A2b receptor" P29275 17 15944917-15975746 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 11.7;urinary bladder: 14.2" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 73.5;Basal respiratory cells: 75.6;Langerhans cells: 31.9;Suprabasal keratinocytes: 64.4;Urothelial cells: 32.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "basophil: 14.9;myeloid DC: 9.0" "Group enriched" "Detected in many" 97 "dendritic cells: 9.0;granulocytes: 14.9;monocytes: 5.0" "Cell line enhanced" "Detected in many" "GAMG: 160.8;HMC-1: 162.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA073747 Uncertain Cytosol NA Yes "Cluster 10: Basophils - Unknown function" "Cluster 27: Brain & Skin - Unknown function" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 26: Respiratory epithelial cells - Mucosal defense" Cytosol "HPA073747: " "unprognostic (6.04e-3)" "unprognostic (1.22e-1)" "unprognostic (8.14e-2)" "unprognostic (1.32e-2)" "unprognostic (4.68e-1)" "unprognostic (7.88e-3)" "unprognostic (2.64e-4)" "unprognostic (1.44e-1)" "unprognostic (1.84e-1)" "unprognostic (1.50e-2)" "unprognostic (2.18e-3)" "unprognostic (1.38e-1)" "unprognostic (1.66e-9)" "unprognostic (2.07e-1)" "unprognostic (3.49e-1)" "unprognostic (1.50e-2)" "unprognostic (2.84e-1)" 0.5 1.1 7.5 1.7 9.4 0.8 0.7 7.0 11.7 2.4 9.0 8.6 0.2 0.7 0.5 9.1 0.9 1.1 1.6 9.1 7.3 0.3 0.1 1.9 0.3 7.7 7.7 0.0 1.3 0.0 1.4 5.0 7.1 1.3 6.6 2.8 1.4 0.1 0.1 8.5 1.3 1.3 6.4 0.2 1.2 0.3 8.3 0.4 0.1 0.5 1.3 14.2 5.2 8.2 34.1 18.3 0.6 0.7 5.8 11.1 0.7 6.4 28.4 18.3 22.6 8.8 34.6 4.4 7.8 5.7 160.8 51.9 7.9 47.8 24.2 9.7 18.0 32.7 5.8 13.0 22.3 0.0 162.6 6.5 20.1 26.0 60.4 31.3 9.3 5.1 1.6 0.1 18.2 8.9 2.2 6.6 1.9 72.0 25.5 0.1 0.4 0.0 19.1 9.1 0.8 1.2 14.3 3.4 9.0 13.4 0.1 5.1 7.7 6.5 17.1 18.3 30.3 2.8 0.0 0.0 25.8 0.0 9.2 14.9 4.2 2.8 0.0 5.0 0.0 0.0 0.0 0.0 9.0 0.0 0.0 0.0 0.4 0.0 2.6 0.1 0.0 1.7 7.5 9.4 7.0 11.7 9.1 7.3 7.7 7.7 7.1 6.4 8.3 8.2 0.1 3.2 4.2 18.9 0.2 73.5 21.0 75.6 27.3 0.2 1.3 1.9 0.9 1.5 20.2 0.0 0.0 10.9 0.1 10.8 0.0 6.6 0.9 0.9 0.6 1.7 2.4 3.4 0.9 0.9 3.2 4.9 2.0 1.2 0.0 0.1 2.2 0.0 4.5 0.0 1.1 1.7 2.0 1.4 31.9 0.4 0.0 6.7 7.2 3.7 1.3 7.9 0.0 1.0 1.0 1.0 7.2 0.0 0.0 15.6 0.2 0.0 8.3 0.5 0.0 0.7 2.1 0.5 1.4 23.0 64.4 6.2 0.3 0.3 5.7 32.4 ADORA3 AD026 ENSG00000282608 "Adenosine A3 receptor" P0DMS8 1 111499429-111503633 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 21.8" "Cell type enhanced" "Detected in some" "Hofbauer cells: 17.9;Kupffer cells: 79.2;Late spermatids: 18.2;Macrophages: 26.3" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 40 "eosinophil: 601.6" "Lineage enriched" "Detected in many" 40 "granulocytes: 601.6" "Cell line enriched" "Detected in some" 9 "HMC-1: 108.1" "Low region specificity" "Detected in many" NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 3: HMC-1 - Innate immune response" "Cluster 4: Macrophages - Innate immune response" 4.5 15.0 8.9 4.3 9.2 0.2 5.5 10.6 14.6 4.4 8.8 6.6 4.5 1.9 0.2 2.5 3.6 5.8 3.4 8.8 12.3 1.6 3.3 3.5 6.4 16.1 11.1 1.8 1.8 3.1 2.6 2.8 14.9 2.4 5.1 1.0 2.8 2.4 0.5 0.9 9.4 4.8 13.5 4.3 3.0 1.2 16.9 3.5 1.4 1.0 2.7 4.3 1.7 21.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.8 0.0 0.0 0.0 0.0 108.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 12.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 10.0 8.1 601.6 0.0 5.6 0.1 0.2 0.0 0.0 15.0 0.1 0.1 0.1 2.0 0.1 2.1 3.0 0.0 2.5 8.9 9.2 10.6 14.6 8.8 12.3 16.1 11.1 14.9 13.5 16.9 21.8 0.2 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.1 0.1 0.6 0.4 0.0 0.0 0.0 0.0 0.1 1.4 0.1 0.0 0.0 7.3 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 7.0 0.0 1.8 0.2 17.9 0.0 0.0 0.0 0.0 79.2 4.4 18.2 0.3 26.3 0.0 0.0 2.2 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.0 0.7 0.0 0.2 0.0 0.2 0.2 0.4 0.3 0.1 0.4 0.0 1.6 0.0 0.0 0.1 ADRA1A "ADRA1C, ADRA1L1" ENSG00000120907 "Adrenoceptor alpha 1A" P35348 8 26748150-26867278 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 42.6;liver: 60.1" "Cell type enhanced" "Detected in some" "Astrocytes: 105.4;Early spermatids: 51.3;Inhibitory neurons: 123.2;Late spermatids: 28.3;Oligodendrocyte precursor cells: 114.1" "Cancer enhanced" "Detected in some" "liver cancer: 0.9;prostate cancer: 0.6" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA029678, HPA029679, HPA076693" Approved Supported Supported Nucleoplasm,Vesicles,Cytosol NA NA "Cluster 15: Liver - Metabolism" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Cytosol "Nucleoplasm, Vesicles" "HPA029678: AB_10602108, HPA029679: AB_2673143, HPA076693: " "unprognostic (1.27e-1)" "unprognostic (1.68e-2)" "unprognostic (1.99e-1)" "unprognostic (3.57e-1)" "unprognostic (5.04e-4)" "unprognostic (1.97e-1)" "unprognostic (9.55e-2)" "unprognostic (3.08e-1)" "unprognostic (1.58e-2)" "unprognostic (7.47e-2)" "unprognostic (1.71e-2)" "unprognostic (6.06e-3)" "unprognostic (7.41e-2)" "unprognostic (1.52e-2)" "unprognostic (1.30e-1)" 21.8 0.5 13.3 1.1 11.1 0.0 3.6 3.0 22.6 0.7 0.0 1.4 0.9 1.4 0.6 0.8 0.2 0.3 7.6 42.6 20.8 0.7 60.1 3.9 1.7 9.3 4.9 0.9 0.0 0.0 0.1 0.0 9.5 12.4 0.5 0.3 6.2 13.5 0.2 0.6 1.1 2.9 1.5 9.2 0.9 0.1 4.2 0.1 0.1 1.4 0.4 0.4 0.3 6.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.3 11.1 3.0 22.6 42.6 20.8 9.3 4.9 9.5 1.5 4.2 6.9 0.0 0.0 0.0 105.4 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 51.3 0.0 0.0 0.1 0.0 0.0 15.5 0.0 0.0 0.5 0.0 0.0 0.0 0.1 0.7 16.2 0.0 0.0 123.2 0.0 0.0 0.0 0.5 28.3 0.6 0.0 0.0 9.4 0.0 0.0 0.0 114.1 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 1.4 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 ADRA1B ENSG00000170214 "Adrenoceptor alpha 1B" P35368 5 159865080-159973012 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 36.9;liver: 11.4;lymphoid tissue: 11.6" "Group enriched" "Detected in some" 7 "Excitatory neurons: 41.5;Inhibitory neurons: 32.6" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "midbrain: 36.9" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "EFO-21: 11.9;HaCaT: 5.8;TIME: 9.8;U-2 OS: 7.9;U-251 MG: 6.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA074416 Supported "Plasma membrane" NA NA "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 38: EFO-21 - Unknown function" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" "HPA074416: AB_2686688" "unprognostic (4.93e-3)" "unprognostic (2.94e-2)" "unprognostic (1.79e-1)" "prognostic unfavorable (6.00e-5)" "prognostic unfavorable (6.98e-4)" "unprognostic (4.08e-3)" "unprognostic (1.67e-3)" "unprognostic (1.68e-1)" "unprognostic (6.12e-2)" "prognostic favorable (2.67e-4)" "unprognostic (2.28e-1)" "unprognostic (1.37e-1)" "prognostic unfavorable (1.40e-6)" "unprognostic (5.24e-4)" "unprognostic (2.54e-1)" "prognostic favorable (3.19e-5)" "unprognostic (1.59e-2)" 4.2 1.8 3.4 0.3 16.1 0.0 1.9 0.0 7.9 0.4 0.0 0.7 0.4 0.9 1.4 0.3 3.0 0.5 2.0 6.0 3.4 3.9 11.4 4.0 1.2 0.0 36.9 2.9 0.4 0.5 0.6 0.3 6.3 0.6 0.3 0.5 0.3 0.7 0.7 0.9 1.4 0.4 0.0 11.6 0.7 0.2 4.5 0.1 1.5 0.7 0.3 0.4 0.6 5.2 0.4 4.5 0.3 0.0 1.9 0.8 0.1 0.5 0.1 0.5 0.2 0.0 3.8 0.0 11.9 3.4 4.4 5.8 0.0 0.5 0.3 0.0 0.2 0.0 1.7 0.0 4.1 0.0 0.0 2.2 0.0 0.0 0.1 1.5 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.7 0.0 3.8 0.0 0.4 0.0 0.0 0.3 0.3 1.7 0.1 0.0 9.8 0.1 7.9 0.0 6.6 0.0 0.0 0.0 2.9 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 16.1 0.0 7.9 6.0 3.4 0.0 36.9 6.3 0.0 4.5 5.2 0.1 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 41.5 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 32.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.0 0.0 0.0 0.0 1.5 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ADRA1D "ADRA1, ADRA1A, ADRA1R" ENSG00000171873 "Adrenoceptor alpha 1D" P25100 20 4220630-4249287 "FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 9.6;cervix: 7.2" "Cell type enhanced" "Detected in some" "Endothelial cells: 1.2;Excitatory neurons: 2.1;Inhibitory neurons: 2.4;Oligodendrocyte precursor cells: 1.0;Smooth muscle cells: 2.4" "Cancer enhanced" "Detected in some" "glioma: 1.6" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 1.7;BJ: 7.5;CAPAN-2: 3.3;fHDF/TERT166: 4.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA038789 Uncertain NA NA "Cluster 57: Non-specific - Angiogenesis" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 48: Smooth muscle cells - ECM organization" "HPA038789: AB_10673475" "unprognostic (5.37e-2)" "unprognostic (4.65e-1)" "unprognostic (8.73e-2)" "unprognostic (7.75e-11)" "unprognostic (7.83e-3)" "unprognostic (1.54e-2)" "unprognostic (7.62e-2)" "unprognostic (7.82e-4)" "unprognostic (4.41e-3)" "unprognostic (8.37e-2)" "unprognostic (6.09e-2)" "unprognostic (7.24e-3)" "unprognostic (7.71e-7)" "unprognostic (5.21e-3)" "unprognostic (2.76e-1)" "unprognostic (6.01e-3)" "unprognostic (3.32e-5)" 1.2 0.4 5.0 0.0 0.6 0.0 0.8 0.3 4.8 7.2 0.0 2.0 0.0 3.5 0.3 0.2 2.0 0.2 0.3 7.5 4.2 0.3 0.1 2.3 0.0 2.7 4.9 0.6 0.3 0.2 0.0 0.1 2.4 3.4 0.1 0.0 0.2 1.7 0.5 0.4 0.2 0.3 1.3 1.4 1.6 0.7 9.6 0.0 0.8 0.4 0.0 2.4 2.9 1.1 0.0 1.7 0.1 0.0 0.0 0.0 0.0 7.5 1.3 0.4 0.1 0.3 3.3 0.0 0.0 4.4 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.8 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.6 0.3 4.8 7.5 4.2 2.7 4.9 2.4 1.3 9.6 1.1 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.2 0.0 0.0 2.1 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.1 0.9 0.0 0.0 0.0 0.0 0.1 0.1 0.1 ADRA2A "ADRA2, ADRA2R, ADRAR" ENSG00000150594 "Adrenoceptor alpha 2A" P08913 10 111077029-111080907 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 50.5;cervix: 46.6" "Cell type enhanced" "Detected in many" "Cholangiocytes: 52.9;Paneth cells: 105.9;Smooth muscle cells: 118.7" "Cancer enhanced" "Detected in all" "pancreatic cancer: 17.7" "Region enhanced" "Detected in all" "pons: 26.8" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 10.5;ASC TERT1: 12.9;HEL: 20.3;HeLa: 10.7;HSkMC: 30.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 82: Adipose tissue - ECM organization" "Cluster 36: HEL - Hemostasis" "Cluster 48: Smooth muscle cells - ECM organization" "unprognostic (3.87e-2)" "unprognostic (1.63e-2)" "unprognostic (1.38e-1)" "prognostic favorable (8.06e-4)" "unprognostic (1.36e-2)" "unprognostic (1.04e-1)" "unprognostic (4.78e-2)" "unprognostic (2.81e-2)" "unprognostic (1.03e-1)" "unprognostic (4.64e-3)" "unprognostic (5.86e-2)" "unprognostic (5.63e-2)" "unprognostic (3.08e-6)" "unprognostic (1.45e-1)" "unprognostic (3.70e-2)" "unprognostic (1.35e-2)" "unprognostic (1.89e-3)" 50.5 1.7 3.4 4.9 3.4 0.0 32.9 1.6 4.3 46.6 7.7 7.4 10.0 6.8 1.6 2.9 4.1 19.9 2.1 3.4 7.4 6.0 1.1 4.3 11.2 5.9 5.8 18.1 30.5 1.3 2.3 3.7 26.8 6.9 3.7 0.0 7.0 6.1 1.0 10.9 4.9 2.8 1.4 14.7 3.7 5.0 3.2 1.0 9.0 0.6 13.1 15.9 23.4 6.1 0.0 0.0 0.0 0.0 10.5 12.9 0.0 0.1 0.0 1.1 2.5 0.0 0.0 0.0 0.1 6.1 0.0 0.0 0.0 0.0 1.0 0.0 0.1 20.3 10.7 0.0 0.0 0.0 0.0 30.8 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 1.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.2 0.7 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 3.4 1.6 4.3 3.4 7.4 5.9 5.8 26.8 1.4 3.2 6.1 8.3 0.0 1.3 1.0 0.0 10.3 0.4 0.0 1.2 0.0 17.2 12.2 1.5 52.9 1.3 0.0 0.0 0.1 0.0 11.7 0.0 5.9 3.5 6.9 9.1 4.9 12.4 0.0 2.2 3.3 0.1 7.3 10.7 25.8 7.0 19.4 0.7 0.0 0.1 0.0 5.9 3.5 0.0 0.3 17.3 1.2 22.4 7.3 28.4 1.0 0.0 0.0 0.0 0.0 0.2 0.3 105.9 4.9 0.0 0.9 3.5 0.6 0.0 0.0 6.6 3.1 118.7 5.4 0.1 0.2 6.1 0.1 1.2 8.5 8.6 1.1 ADRA2B "ADRA2L1, ADRA2RL1, ADRARL1" ENSG00000274286 "Adrenoceptor alpha 2B" P18089 2 96112876-96116571 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in some" "Glandular and luminal cells: 9.0;Langerhans cells: 8.0;Sertoli cells: 32.9;Smooth muscle cells: 13.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 1.5;EFO-21: 1.0" "Group enriched" "Detected in some" 6 "basal ganglia: 2.5;cerebellum: 1.0;thalamus: 3.2" "Low region specificity" "Detected in some" "HPA066029, HPA074948" Approved Supported Vesicles,Cytosol NA NA "Cluster 18: Non-specific - Mitochondria" "Cluster 28: BEWO - Transcription regulation" "Cluster 48: Smooth muscle cells - ECM organization" Vesicles Cytosol "HPA066029: AB_2685599, HPA074948: " "unprognostic (6.16e-2)" "unprognostic (1.31e-2)" "unprognostic (1.76e-2)" "unprognostic (4.93e-4)" "unprognostic (1.84e-2)" "unprognostic (5.24e-2)" "unprognostic (6.80e-5)" "unprognostic (4.85e-2)" "unprognostic (1.69e-1)" "unprognostic (3.16e-2)" "unprognostic (8.34e-2)" "unprognostic (2.54e-1)" "unprognostic (2.21e-1)" "unprognostic (4.43e-2)" "unprognostic (3.39e-1)" "unprognostic (1.36e-1)" "unprognostic (6.55e-2)" 6.4 2.1 1.5 0.3 1.7 0.8 3.0 1.4 2.7 1.5 4.9 2.3 0.3 1.9 3.8 0.7 3.0 0.6 10.1 1.2 1.4 5.1 7.0 0.5 0.2 1.8 1.6 1.7 0.8 0.5 0.5 0.8 1.7 1.4 0.3 0.0 2.2 1.5 6.4 1.9 2.6 0.7 1.3 8.6 2.2 1.6 2.6 0.2 1.3 5.0 0.1 2.5 1.8 2.4 0.0 0.0 0.2 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.4 0.0 0.0 0.3 0.0 0.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 1.7 1.4 2.7 1.2 1.4 1.8 1.6 1.7 1.3 2.6 2.4 2.9 0.0 0.0 0.0 0.9 1.1 0.7 0.7 0.6 0.0 0.9 0.9 2.5 0.0 1.5 1.8 0.0 0.8 2.9 0.1 0.0 0.2 0.0 2.2 1.0 2.4 2.4 0.0 0.0 0.6 0.2 1.0 1.1 9.0 0.0 0.0 2.5 0.0 0.3 0.0 0.0 0.2 0.0 0.3 8.0 0.0 1.8 5.1 1.8 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.4 0.4 0.7 0.0 0.1 1.4 0.0 32.9 0.7 13.3 0.0 0.3 0.6 1.4 0.4 2.8 0.1 0.1 0.3 ADRA2C "ADRA2L2, ADRA2RL2, ADRARL2" ENSG00000184160 "Adrenoceptor alpha 2C" P18825 4 3766348-3768526 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix: 84.9;endometrium 1: 57.6" "Cell type enriched" "Detected in some" 5 "Endometrial stromal cells: 135.9" "Cancer enhanced" "Detected in many" "ovarian cancer: 22.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "Hep G2: 13.3;MCF7: 21.9;NTERA-2: 7.4;OE19: 8.6;SCLC-21H: 8.0;SH-SY5Y: 9.7" "Low region specificity" "Detected in all" "Region enriched" "Detected in all" 6 "basal ganglia: 34.3" HPA057688 Uncertain NA NA "Cluster 89: Fibroblasts - ECM organization" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 36: Stromal cells - Cell proliferation" "HPA057688: AB_2683503" "unprognostic (1.44e-2)" "unprognostic (2.21e-3)" "unprognostic (1.23e-1)" "unprognostic (2.02e-2)" "unprognostic (4.70e-2)" "unprognostic (1.11e-1)" "unprognostic (7.12e-2)" "unprognostic (6.69e-2)" "unprognostic (1.88e-1)" "unprognostic (3.71e-1)" "unprognostic (3.24e-2)" "unprognostic (9.08e-3)" "unprognostic (1.01e-2)" "unprognostic (6.00e-2)" "unprognostic (2.63e-1)" "unprognostic (1.72e-1)" "unprognostic (6.48e-2)" 17.9 3.7 7.6 0.5 22.3 0.0 8.2 3.7 8.8 84.9 3.2 3.1 0.4 57.6 2.2 2.0 22.7 0.4 7.6 6.8 5.5 32.9 0.6 4.1 0.7 5.4 5.7 8.3 3.8 0.2 4.8 3.6 7.1 22.4 0.2 0.8 1.2 18.6 3.5 7.4 3.2 2.1 3.8 22.0 2.4 3.7 8.6 0.4 1.4 1.8 0.1 4.2 14.1 6.4 0.0 4.6 0.1 0.1 0.5 0.0 0.2 0.5 0.0 0.1 0.0 2.4 1.4 0.0 2.3 0.4 0.8 0.0 0.2 0.0 0.0 0.0 6.6 0.0 0.0 13.3 0.6 0.0 0.9 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.5 0.0 3.2 21.9 0.0 0.0 7.4 8.6 0.0 0.0 6.8 0.0 0.0 0.4 8.0 9.7 3.0 0.0 0.1 1.9 7.0 0.1 0.0 0.0 5.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.6 22.3 3.7 8.8 6.8 5.5 5.4 5.7 7.1 3.8 8.6 6.4 26.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 2.2 1.7 0.8 0.9 1.0 2.8 0.0 12.9 0.0 0.9 0.1 0.1 3.9 0.4 0.0 4.7 135.9 5.4 0.0 0.0 1.2 0.0 0.2 1.4 0.0 2.4 0.0 10.7 1.1 0.0 0.3 3.3 0.6 0.2 0.0 0.0 0.7 0.4 1.5 0.6 0.0 1.0 0.0 5.8 0.0 0.0 0.2 0.1 0.0 3.8 0.0 0.3 0.0 2.4 0.0 0.1 0.0 0.9 5.8 0.1 1.6 0.0 0.0 1.6 0.6 0.0 0.1 0.2 ADRB1 ADRB1R ENSG00000043591 "Adrenoceptor beta 1" P08588 10 114043866-114046904 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 23.7;lung: 13.1;placenta: 29.1" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 85.7;Cytotrophoblasts: 84.5;Sertoli cells: 52.6;Syncytiotrophoblasts: 38.4" "Cancer enriched" "Detected in many" 10 "prostate cancer: 12.6" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HDLM-2: 7.1;PC-3: 2.6;THP-1: 4.5;TIME: 5.8;U-937: 3.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA067972 Enhanced NA NA "Cluster 57: Non-specific - Angiogenesis" "Cluster 44: HDLM-2 - Immune response" "Cluster 47: Cytotrophoblasts - Unknown function" "HPA067972: AB_2685936" "unprognostic (1.45e-3)" "unprognostic (1.18e-3)" "unprognostic (1.44e-1)" "unprognostic (4.92e-2)" "unprognostic (3.22e-1)" "unprognostic (8.88e-2)" "unprognostic (9.28e-2)" "unprognostic (3.52e-2)" "unprognostic (1.51e-1)" "unprognostic (1.96e-2)" "unprognostic (2.77e-4)" "unprognostic (1.33e-1)" "unprognostic (7.80e-3)" "unprognostic (1.53e-1)" "unprognostic (1.85e-1)" "unprognostic (1.59e-2)" "unprognostic (1.44e-1)" 4.0 0.2 5.5 0.3 10.3 0.5 2.3 0.7 12.0 0.1 0.2 3.1 0.9 0.1 0.1 0.9 0.1 0.1 23.7 6.8 3.3 1.1 1.4 13.1 0.2 1.8 3.1 0.0 1.3 0.8 0.8 29.1 2.4 4.4 0.6 2.1 5.4 0.1 2.3 0.4 1.9 0.1 0.9 1.5 0.7 0.5 5.0 0.1 0.6 0.0 0.3 0.7 0.1 7.8 1.4 0.8 0.1 0.8 0.0 0.0 0.2 0.1 0.0 0.1 0.1 0.3 1.0 0.2 0.2 0.0 0.4 0.3 0.1 0.1 0.1 7.1 0.4 0.3 0.1 0.1 0.0 0.2 0.4 0.0 0.7 0.0 1.3 0.1 0.1 1.0 0.0 0.1 0.1 0.8 1.1 0.9 0.3 0.2 2.6 0.2 0.2 0.1 0.0 1.1 0.1 0.2 0.0 0.5 0.0 0.3 0.2 4.5 5.8 0.2 0.1 0.1 0.1 0.0 0.0 0.3 0.0 3.4 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.5 10.3 0.7 12.0 6.8 3.3 1.8 3.1 2.4 0.9 5.0 7.8 1.1 19.2 7.8 15.0 0.5 1.0 3.9 0.8 1.2 21.8 1.0 0.5 85.7 2.8 9.8 0.0 0.0 84.5 3.0 0.1 1.9 0.1 0.1 0.4 0.6 11.3 0.0 0.0 12.8 0.2 5.2 5.3 0.0 0.3 0.0 0.0 0.4 0.2 4.4 13.5 2.5 3.3 2.0 2.2 1.6 0.2 0.0 2.8 1.8 7.5 0.6 0.7 3.1 1.0 0.3 0.1 1.4 0.4 1.2 6.1 0.8 0.0 12.1 1.7 52.6 0.4 8.2 0.5 0.2 0.1 0.0 38.4 4.8 0.0 0.6 3.9 ADRB2 "ADRB2R, ADRBR, B2AR, BAR" ENSG00000169252 "Adrenoceptor beta 2" P07550 5 148826611-148828623 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Adipocytes: 196.1;Basal keratinocytes: 387.5;Basal respiratory cells: 146.6;Squamous epithelial cells: 276.0;Suprabasal keratinocytes: 245.4" "Cancer enhanced" "Detected in many" "prostate cancer: 9.0" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTCEpi: 72.4;hTERT-HME1: 74.1;PC-3: 31.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003431, HPA075322" Uncertain Uncertain Cytosol NA NA "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 31: Skin - Epidermis development" "Cluster 30: Epithelial cell lines - Translation" "Cluster 61: Squamous epithelial cells - Keratinization" Cytosol "HPA003431: AB_1845333, HPA075322: " "unprognostic (2.28e-2)" "unprognostic (1.50e-1)" "unprognostic (1.21e-1)" "unprognostic (1.17e-2)" "unprognostic (1.69e-1)" "unprognostic (1.17e-1)" "unprognostic (9.35e-3)" "unprognostic (5.54e-2)" "unprognostic (2.34e-1)" "unprognostic (9.85e-2)" "unprognostic (3.17e-2)" "unprognostic (2.23e-1)" "prognostic favorable (3.15e-9)" "unprognostic (1.55e-2)" "unprognostic (1.46e-1)" "unprognostic (1.49e-1)" "unprognostic (7.65e-2)" 19.5 1.6 4.5 3.2 4.7 12.5 18.7 5.1 4.4 13.5 1.8 2.3 1.9 2.3 1.7 15.1 4.1 3.8 6.7 5.3 4.2 1.1 14.2 19.5 4.1 6.0 5.6 0.9 1.2 2.2 0.3 9.9 6.2 9.0 2.8 0.6 4.2 1.5 11.7 21.8 2.1 3.7 6.2 7.9 7.5 0.5 7.1 2.7 1.0 8.6 6.0 6.8 7.2 7.6 23.3 0.1 0.1 0.0 0.8 0.2 0.0 4.3 13.2 6.0 6.7 0.0 9.7 0.1 6.1 1.3 21.5 20.0 0.0 27.9 6.9 0.0 0.6 0.0 5.1 0.0 0.6 0.1 11.0 0.1 72.4 2.0 74.1 5.0 2.8 0.0 0.1 8.3 16.0 0.0 0.0 12.9 0.4 0.2 31.2 6.7 4.1 13.0 3.2 5.8 0.1 0.1 5.4 0.4 2.0 2.5 0.0 7.0 12.3 0.0 5.0 7.2 3.5 1.9 0.0 0.2 0.0 15.1 2.6 16.5 21.8 67.8 151.4 37.1 112.3 21.5 34.3 93.0 24.7 15.6 5.8 53.3 35.4 37.2 53.3 28.4 2.3 53.4 4.5 4.7 5.1 4.4 5.3 4.2 6.0 5.6 6.2 6.2 7.1 7.6 196.1 112.2 31.6 1.6 16.5 387.5 36.6 146.6 127.5 0.5 23.3 15.2 18.6 0.0 67.4 0.0 0.0 0.4 59.2 3.7 0.0 2.4 0.5 3.2 0.5 40.3 3.0 1.3 0.0 0.2 0.3 6.2 35.7 3.0 118.6 0.1 6.8 14.1 17.7 0.0 0.0 3.1 16.2 20.8 54.9 0.7 0.0 21.1 30.2 15.9 4.0 4.1 90.6 0.0 0.1 8.6 0.1 0.0 23.2 23.5 0.1 0.1 27.8 5.0 0.0 19.8 9.6 0.7 0.1 276.0 245.4 0.5 40.1 0.1 3.5 61.5 ADRB3 ENSG00000188778 "Adrenoceptor beta 3" P13945 8 37962990-37966599 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Diabetes mellitus, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 8.1;ovary: 11.7" "Cell type enhanced" "Detected in some" "Fibroblasts: 2.8;Hofbauer cells: 1.1;Langerhans cells: 1.2" "Not detected" "Not detected" "Region enhanced" "Detected in many" "medulla oblongata: 8.1" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Not detected" "Not detected" HPA061969 Uncertain NA NA "Cluster 57: Non-specific - Angiogenesis" "Cluster 33: Fibroblasts - ECM organization" "HPA061969: AB_2732674" "unprognostic (1.70e-1)" "unprognostic (2.24e-1)" "unprognostic (6.64e-3)" "unprognostic (5.41e-1)" "unprognostic (1.07e-2)" "unprognostic (1.07e-1)" "unprognostic (1.14e-1)" "unprognostic (9.49e-2)" "unprognostic (2.33e-1)" "unprognostic (1.06e-3)" "unprognostic (3.77e-2)" "unprognostic (2.29e-8)" "unprognostic (1.10e-3)" "unprognostic (2.81e-2)" "unprognostic (5.37e-2)" "unprognostic (6.06e-3)" 0.3 0.0 1.2 0.4 1.1 0.2 0.3 0.5 0.9 0.4 1.5 2.1 0.2 0.7 1.1 0.1 4.1 1.7 0.0 0.9 0.7 0.0 0.0 0.1 0.1 8.1 2.7 11.7 0.0 0.0 0.0 2.9 3.1 0.8 0.2 0.1 0.0 0.0 0.0 0.0 0.6 1.0 0.4 0.0 2.1 0.0 1.8 0.0 0.0 0.0 0.0 4.6 0.4 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.2 1.1 0.5 0.9 0.9 0.7 8.1 2.7 3.1 0.4 1.8 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 2.8 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.6 0.0 0.0 0.0 1.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 AGTR1 "AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R" ENSG00000144891 "Angiotensin II receptor type 1" P30556 3 148697784-148743008 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 96.6;placenta: 141.6" "Cell type enhanced" "Detected in some" "Fibroblasts: 53.1;Hepatocytes: 30.9;Leydig cells: 145.1;Sertoli cells: 144.7;Smooth muscle cells: 71.2" "Group enriched" "Detected in many" 8 "breast cancer: 9.6;liver cancer: 9.8;prostate cancer: 6.8;renal cancer: 2.8" "Region enhanced" "Detected in some" "midbrain: 8.1" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 176.8;ASC TERT1: 24.4;BJ hTERT+ SV40 Large T+: 34.8;HBF TERT88: 53.9;HSkMC: 32.2" "Low region specificity" "Detected in all" HPA003596 Enhanced Uncertain Vesicles NA NA "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 50: Fibroblasts - ECM organization" Vesicles "HPA003596: AB_1845163" "unprognostic (2.19e-1)" "unprognostic (1.17e-1)" "unprognostic (8.78e-2)" "unprognostic (2.48e-4)" "unprognostic (5.28e-3)" "unprognostic (1.55e-1)" "unprognostic (3.46e-1)" "unprognostic (1.28e-2)" "unprognostic (3.26e-2)" "unprognostic (3.08e-2)" "unprognostic (9.25e-3)" "unprognostic (4.11e-2)" "unprognostic (4.79e-2)" "unprognostic (3.21e-3)" "unprognostic (1.46e-1)" "unprognostic (2.54e-1)" "unprognostic (5.41e-3)" 65.9 38.2 0.3 1.8 0.7 0.0 39.9 0.2 0.4 3.4 0.4 21.1 0.8 3.5 2.7 2.8 9.8 6.2 10.9 0.4 1.4 18.4 96.6 10.4 0.7 2.1 8.1 3.8 3.5 2.8 3.8 141.6 0.9 5.3 4.4 0.9 4.7 4.2 11.6 15.8 4.3 4.6 0.2 9.1 6.5 2.2 0.7 3.0 14.2 13.8 0.2 14.6 6.1 0.2 0.0 1.0 0.8 0.0 176.8 24.4 0.0 0.2 3.9 34.8 20.0 0.0 0.0 0.0 0.0 2.6 0.2 0.0 0.0 0.0 53.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 32.2 0.0 3.4 1.8 1.0 0.0 0.0 0.0 0.0 8.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.4 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.7 0.2 0.4 0.4 1.4 2.1 8.1 0.9 0.2 0.7 0.2 20.5 0.0 0.6 0.0 0.0 3.4 0.2 0.0 0.0 0.0 1.3 0.9 6.3 2.8 0.0 0.0 0.0 0.5 0.3 0.1 0.0 0.1 0.8 0.0 0.3 3.8 23.5 0.0 0.1 7.6 0.3 53.1 0.5 0.0 0.0 0.0 17.5 30.9 0.7 0.0 0.0 0.2 0.0 0.3 3.5 1.7 145.1 0.5 1.8 2.8 0.0 5.7 0.0 0.0 0.1 0.5 0.0 7.5 0.4 1.1 0.0 0.1 0.0 0.1 144.7 7.6 71.2 0.0 1.8 0.3 1.7 0.3 0.5 0.3 0.0 0.1 AKR1B1 "ALDR1, AR" ENSG00000085662 "Aldo-keto reductase family 1 member B" P15121 7 134442356-134459284 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 8 "adrenal gland: 3039.1" "Cell type enhanced" "Detected in many" "Collecting duct cells: 649.2;Cytotrophoblasts: 1105.1;Extravillous trophoblasts: 1284.9;Ionocytes: 697.8;Syncytiotrophoblasts: 2022.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "A549: 1667.3;BJ hTERT+: 3096.2;RPTEC TERT1: 1447.8;U-87 MG: 1343.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026425, CAB027391, CAB047353, HPA052751" Enhanced Supported Nucleoplasm,Cytosol No No 1500000 "Cluster 44: Non-specific - Transcription" "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 38: Extravillous trophoblasts - Unknown function" Cytosol Nucleoplasm "CAB027391: , CAB047353: , HPA026425: AB_10601563, HPA052751: AB_2681935" "unprognostic (2.76e-2)" "unprognostic (2.84e-2)" "unprognostic (2.02e-2)" "unprognostic (1.37e-2)" "unprognostic (6.81e-2)" "unprognostic (2.26e-1)" "unprognostic (4.18e-2)" "unprognostic (5.09e-2)" "unprognostic (2.51e-3)" "unprognostic (2.47e-1)" "unprognostic (2.98e-2)" "unprognostic (8.78e-2)" "unprognostic (2.81e-2)" "prognostic unfavorable (2.44e-5)" "unprognostic (2.03e-1)" "unprognostic (1.39e-1)" "prognostic unfavorable (7.00e-4)" 65.1 3039.1 83.1 38.4 89.3 21.9 52.3 91.8 97.4 41.4 80.9 40.1 20.5 42.4 44.0 28.2 38.7 40.2 208.2 84.1 92.5 218.0 19.3 55.0 74.6 101.6 96.9 60.5 34.4 111.2 76.5 203.7 104.9 34.4 30.9 36.5 41.9 332.7 330.0 26.6 50.8 39.6 91.4 62.8 51.4 44.9 88.7 54.9 44.3 396.9 62.5 67.3 35.0 101.4 184.2 1667.3 186.5 261.4 785.9 212.3 494.6 177.2 3096.2 259.3 335.0 75.8 170.6 0.0 79.2 301.5 1143.3 78.6 204.0 175.3 206.6 65.2 168.2 93.4 225.0 230.1 1117.9 0.1 0.8 196.9 133.4 367.6 98.3 252.8 370.3 181.1 0.1 62.4 292.4 3.5 283.3 131.0 309.2 13.9 1.8 292.9 116.5 138.8 1447.8 915.5 137.1 301.6 1261.5 1.5 134.3 121.3 0.6 140.6 289.6 254.5 116.0 22.7 195.6 168.2 196.9 470.0 1343.5 0.7 153.0 125.7 106.4 5.6 147.6 72.3 135.2 133.0 124.7 144.5 145.3 121.7 162.9 156.7 8.5 119.7 39.2 20.4 94.9 230.2 83.1 89.3 91.8 97.4 84.1 92.5 101.6 96.9 104.9 91.4 88.7 101.4 34.1 12.8 19.4 9.1 50.3 20.6 55.3 66.1 20.5 36.2 11.7 27.9 202.4 25.8 26.4 649.2 8.4 1105.1 35.1 2.3 164.4 112.7 5.0 6.1 20.9 50.9 31.0 20.2 10.5 41.5 1284.9 100.3 20.4 5.9 53.8 59.8 82.1 2.6 394.1 72.3 18.7 15.1 697.8 172.8 53.9 14.5 79.2 127.7 30.2 14.0 76.3 49.3 66.9 5.5 12.4 51.0 4.5 77.5 72.6 25.6 0.3 60.2 24.9 24.1 59.2 98.9 54.5 22.6 100.2 10.5 11.6 2022.4 49.9 70.5 6.7 54.2 AKR1C2 "BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD" ENSG00000151632 "Aldo-keto reductase family 1 member C2" P52895 10 4987400-5018031 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Lipid metabolism, Steroid metabolism" Oxidoreductase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 341.5;liver: 481.9" "Cell type enhanced" "Detected in many" "Basal respiratory cells: 141.7;Club cells: 128.8;Gastric mucus-secreting cells: 133.5;Hepatocytes: 397.4;Urothelial cells: 271.9" "Group enriched" "Detected in many" 6 "cervical cancer: 21.7;head and neck cancer: 31.5;liver cancer: 50.2;lung cancer: 69.0;urothelial cancer: 35.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "A549: 2054.8;ASC diff: 2439.5;Hep G2: 3926.2;OE19: 2684.9;RT4: 1178.9" "CAB047304, HPA068265" Enhanced Approved "Nucleoplasm,Nucleoli fibrillar center,Endoplasmic reticulum,Cytosol" NA NA "Cluster 85: Liver - Metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 2: Hepatocytes - Metabolism" "Nucleoplasm, Cytosol" "Nucleoli fibrillar center, Endoplasmic reticulum" "CAB047304: , HPA068265: AB_2685966" "unprognostic (6.77e-2)" "unprognostic (8.88e-3)" "unprognostic (3.02e-2)" "unprognostic (2.24e-1)" "unprognostic (1.31e-1)" "unprognostic (1.72e-2)" "unprognostic (2.86e-2)" "unprognostic (8.65e-2)" "unprognostic (5.03e-2)" "unprognostic (2.58e-1)" "unprognostic (1.02e-1)" "unprognostic (6.25e-3)" "unprognostic (8.58e-2)" "unprognostic (1.09e-2)" "unprognostic (8.60e-3)" "unprognostic (1.46e-2)" "unprognostic (8.30e-2)" 341.5 20.8 9.8 10.0 11.6 1.0 205.6 10.7 12.9 17.4 8.1 37.1 29.6 5.6 3.3 202.5 8.6 98.1 83.8 7.2 16.6 43.0 481.9 23.5 2.1 18.7 13.7 10.4 11.8 1.1 8.1 0.8 17.1 11.7 13.3 15.2 116.5 12.9 286.9 42.5 33.7 9.2 11.5 2.1 137.0 11.8 16.8 4.4 38.3 36.5 9.3 253.9 47.0 9.7 0.0 2054.8 2.4 214.1 2439.5 83.4 0.1 0.7 8.6 0.9 2.0 8.1 0.2 0.4 11.5 14.2 10.0 57.8 0.2 10.7 1.2 0.6 0.2 0.7 516.4 3926.2 4.6 0.4 0.9 218.3 126.4 10.5 10.4 0.7 0.9 0.3 81.9 0.3 20.4 3.3 0.2 0.0 0.7 2684.9 0.8 0.3 0.6 34.6 19.0 1178.9 1.2 0.4 21.2 0.3 0.1 0.4 0.5 4.0 8.6 5.1 1.8 74.6 0.8 0.6 0.6 0.3 25.9 30.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 9.8 11.6 10.7 12.9 7.2 16.6 18.7 13.7 17.1 11.5 16.8 9.7 15.2 12.8 2.8 0.0 0.9 11.9 9.5 141.7 20.5 1.9 0.8 1.4 5.5 102.9 128.8 0.0 0.0 0.0 0.0 10.3 0.0 18.3 17.3 0.7 0.5 7.5 1.8 8.0 2.6 103.3 0.1 44.2 133.5 0.8 0.0 0.1 10.8 397.4 0.1 3.3 4.2 5.4 46.8 12.0 7.8 7.8 79.2 1.0 8.8 19.7 0.6 39.6 0.0 5.5 0.3 90.0 6.6 78.6 0.8 23.7 15.9 3.6 40.3 3.0 0.0 5.3 13.9 0.2 0.3 112.9 13.5 0.0 1.3 0.4 8.5 271.9 AKR1D1 SRD5B1 ENSG00000122787 "Aldo-keto reductase family 1 member D1" P51857 7 138002324-138118305 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Bile acid catabolism, Lipid degradation, Lipid metabolism, Steroid metabolism" Oxidoreductase "Disease variant, FDA approved drug targets, Intrahepatic cholestasis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 83 "liver: 426.9" "Group enriched" "Detected in some" 31 "Early spermatids: 65.4;Hepatocytes: 110.3;Late spermatids: 126.1" "Cancer enriched" "Detected in single" 77 "liver cancer: 20.1" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 21 "Hep G2: 12.6" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA057002 Enhanced Approved Nucleoplasm,Cytosol No NA 61000 "Cluster 17: Basophils - Unknown function" "Cluster 62: Liver - Hemostasis" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 2: Hepatocytes - Metabolism" Nucleoplasm Cytosol "HPA057002: AB_2683308" "unprognostic (2.38e-1)" "unprognostic (1.65e-2)" "unprognostic (1.02e-2)" "unprognostic (1.52e-2)" "prognostic favorable (9.91e-5)" "unprognostic (6.11e-2)" "unprognostic (2.31e-1)" "unprognostic (1.30e-1)" "unprognostic (6.87e-2)" "unprognostic (2.94e-1)" "unprognostic (9.68e-3)" "unprognostic (2.90e-1)" "unprognostic (5.80e-2)" "unprognostic (3.11e-1)" "unprognostic (1.67e-2)" 0.0 0.1 0.2 0.0 0.1 0.2 5.1 0.3 0.3 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.0 0.1 426.9 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 12.6 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.7 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.1 0.1 0.1 0.0 0.0 0.2 0.1 0.3 0.3 0.2 0.0 0.2 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.3 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 65.4 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.1 0.0 0.0 1.4 110.3 0.4 0.0 0.2 0.2 0.0 3.2 0.4 126.1 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.9 0.1 1.6 0.3 0.0 0.0 0.3 0.3 0.0 0.0 0.2 ALAD "ALADH, PBGS" ENSG00000148218 "Aminolevulinate dehydratase" P13716 9 113386312-113401290 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Heme biosynthesis, Porphyrin biosynthesis" "Allosteric enzyme, Lyase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 209.8" "Cell type enhanced" "Detected in all" "Erythroid cells: 147.8;Granulosa cells: 86.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA021023, HPA022124" Enhanced Approved Cytosol NA NA 44000000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 35: Non-specific - Unknown function" "Cluster 28: BEWO - Transcription regulation" "Cluster 6: Erythroid cells - Oxygen transport" Cytosol "HPA021023: AB_1844716, HPA022124: AB_1844717" "unprognostic (2.75e-1)" "unprognostic (6.26e-2)" "prognostic unfavorable (7.33e-5)" "prognostic favorable (5.64e-4)" "unprognostic (4.16e-2)" "unprognostic (9.49e-2)" "prognostic favorable (8.80e-5)" "unprognostic (2.87e-3)" "unprognostic (3.49e-1)" "unprognostic (2.95e-1)" "unprognostic (1.62e-1)" "unprognostic (3.31e-2)" "prognostic favorable (1.65e-4)" "unprognostic (1.75e-1)" "unprognostic (1.22e-1)" "unprognostic (3.40e-1)" "unprognostic (1.31e-2)" 54.7 153.9 73.5 16.8 82.7 82.2 23.2 75.2 84.7 18.4 53.6 25.7 29.5 16.3 26.6 35.0 15.6 27.4 51.9 66.0 74.5 73.2 209.8 20.6 15.6 85.4 83.5 28.9 46.5 73.2 15.9 24.9 84.5 34.1 24.5 19.0 98.6 24.2 28.8 38.9 26.6 17.6 80.1 13.6 50.4 13.1 81.1 20.3 25.9 23.9 18.7 18.4 19.3 83.7 8.1 14.8 11.0 15.7 71.2 48.4 67.8 21.9 35.4 13.7 17.2 19.2 16.7 11.7 12.7 30.3 11.0 29.1 8.1 14.6 8.3 29.5 10.2 22.0 18.2 26.2 16.4 21.2 19.0 41.2 10.8 12.7 5.5 53.9 27.1 18.6 8.9 16.5 23.7 61.8 23.8 21.2 5.4 57.9 27.4 19.5 18.7 19.8 21.4 16.6 10.2 9.4 27.2 32.5 20.1 19.2 34.1 23.7 30.7 12.5 9.3 25.1 12.4 23.8 26.0 9.8 34.1 18.9 13.6 10.2 13.7 23.6 11.3 15.5 6.0 6.8 9.3 6.0 14.6 10.2 8.7 9.9 6.2 6.9 17.4 6.0 10.8 9.7 73.5 82.7 75.2 84.7 66.0 74.5 85.4 83.5 84.5 80.1 81.1 83.7 7.2 16.0 15.6 18.6 10.4 7.0 8.9 7.1 8.0 12.9 16.7 11.6 50.3 25.8 12.0 14.7 27.1 48.2 7.4 27.7 13.7 20.3 5.4 17.7 9.2 11.5 9.1 147.8 10.0 26.3 23.2 10.2 15.3 27.7 14.5 86.5 11.0 70.0 17.0 5.0 10.7 12.5 10.2 15.1 6.4 10.8 11.8 12.4 12.4 9.4 12.4 6.4 8.2 7.1 20.0 15.0 35.3 14.7 11.0 7.6 32.6 59.0 10.6 15.7 6.6 8.9 24.6 6.8 9.5 22.6 9.1 11.4 8.8 11.7 16.7 9.2 ALB ENSG00000163631 Albumin P02768 4 73397114-73421482 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 135 "liver: 212494.0" "Cell type enriched" "Detected in many" 4 "Hepatocytes: 65190.0" "Cancer enriched" "Detected in many" 384 "liver cancer: 14213.7" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 38 "Hep G2: 4500.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB006262, HPA031024, HPA031025" Enhanced Enhanced "Endoplasmic reticulum,Golgi apparatus" "Secreted to blood" NA NA 40000000000000 "Cluster 62: Liver - Hemostasis" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 2: Hepatocytes - Metabolism" "Golgi apparatus" "Endoplasmic reticulum" "CAB006262: AB_425297, HPA031024: AB_2673703, HPA031025: AB_2673704" "unprognostic (1.38e-1)" "unprognostic (8.72e-2)" "unprognostic (1.73e-1)" "unprognostic (2.60e-1)" "unprognostic (4.44e-1)" "unprognostic (2.46e-1)" "unprognostic (9.53e-3)" "unprognostic (2.16e-2)" "unprognostic (2.40e-1)" "unprognostic (6.43e-2)" "unprognostic (3.84e-2)" "unprognostic (5.37e-2)" "unprognostic (1.25e-1)" "prognostic unfavorable (7.87e-4)" "unprognostic (7.23e-2)" "unprognostic (1.05e-3)" "unprognostic (1.02e-2)" 8.3 3.7 0.9 0.0 1.0 0.0 5.9 0.6 1.3 1.9 0.6 2.5 0.0 1.8 15.4 2.6 4.3 3.8 8.2 0.7 0.9 465.2 212494.0 6.7 1.3 0.7 0.8 2.5 1569.1 1.0 3.4 4.5 0.7 2.2 0.1 0.5 2.1 0.1 1.9 3.3 2.3 0.0 0.7 37.0 10.1 3.6 1.0 0.3 3.6 0.1 1.4 0.9 1.7 0.8 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 18.8 0.6 0.0 0.0 1.6 0.0 0.0 0.1 0.6 0.0 31.7 2.1 4500.0 0.0 117.1 3.4 0.0 0.0 0.0 0.0 0.2 0.0 0.1 17.0 0.2 0.0 0.1 2.0 0.0 4.0 0.0 0.1 2.1 95.1 0.0 0.0 3.2 0.0 0.0 52.3 0.0 0.0 0.0 0.0 0.0 13.5 0.0 1.4 0.1 0.1 7.0 0.6 32.9 0.1 33.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.0 0.6 1.3 0.7 0.9 0.7 0.8 0.7 0.7 1.0 0.8 0.1 0.0 0.0 1.0 187.5 0.0 0.0 0.0 0.0 0.0 43.4 18.9 0.1 13788.8 0.0 38.6 0.0 1.4 0.6 0.1 72.4 5.3 2.5 0.2 0.1 65.5 1.8 1133.8 0.2 273.8 11.1 0.5 4.6 0.0 0.0 0.1 1252.5 65190.0 8.5 0.0 0.2 0.0 0.0 1764.5 0.0 0.1 0.0 2.9 0.0 0.0 1.0 0.0 0.0 0.0 0.1 160.6 0.0 0.0 0.0 0.2 0.0 686.5 0.0 0.0 0.0 0.0 1.1 0.2 1.3 0.0 0.1 21.2 77.1 0.1 0.0 0.1 ALDH2 ENSG00000111275 "Aldehyde dehydrogenase 2 family member" P05091 12 111766887-111817532 "Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 857.7" "Cell type enhanced" "Detected in all" "Hepatocytes: 857.0;monocytes: 940.8;Proximal tubular cells: 882.0" "Cancer enhanced" "Detected in all" "liver cancer: 71.5" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "classical monocyte: 212.0;myeloid DC: 213.2" "Group enriched" "Detected in many" 4 "dendritic cells: 213.2;monocytes: 212.0" "Cell line enhanced" "Detected in many" "ASC diff: 86.8;HHSteC: 97.0;OE19: 152.2;SK-BR-3: 201.0;THP-1: 92.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051065 Approved NA NA 2200000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 15: Liver - Metabolism" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "HPA051065: AB_2681332" "unprognostic (9.22e-3)" "unprognostic (1.20e-2)" "unprognostic (4.14e-3)" "prognostic favorable (2.63e-4)" "unprognostic (1.16e-1)" "unprognostic (1.32e-3)" "prognostic favorable (3.95e-7)" "unprognostic (5.62e-3)" "unprognostic (3.00e-1)" "unprognostic (1.16e-1)" "unprognostic (8.22e-2)" "unprognostic (1.51e-1)" "prognostic favorable (5.24e-6)" "unprognostic (9.70e-2)" "unprognostic (3.40e-1)" "unprognostic (1.50e-2)" "prognostic unfavorable (7.71e-4)" 303.8 102.4 139.7 39.8 146.1 29.2 77.2 136.5 163.5 25.0 123.3 73.3 73.7 30.1 21.3 73.6 32.3 37.4 111.3 132.2 139.7 177.7 857.7 111.6 18.7 140.7 144.9 42.0 23.3 2.6 23.3 7.0 141.1 34.6 72.3 29.2 32.4 29.5 130.8 127.9 74.8 30.2 143.0 20.6 101.5 13.0 151.8 27.1 30.8 165.7 52.9 50.0 29.0 144.5 8.8 13.1 18.7 31.9 86.8 13.0 60.9 9.3 16.8 4.3 3.1 23.5 12.1 0.5 45.3 20.8 11.9 16.2 0.1 4.6 2.7 0.6 6.1 0.7 8.4 64.7 97.0 0.9 0.9 23.9 22.6 14.8 0.3 17.7 26.9 0.9 17.9 3.0 4.1 0.5 1.0 23.4 24.8 152.2 2.1 0.6 0.4 1.9 31.4 0.6 7.5 23.1 22.8 201.0 0.2 33.7 20.3 92.1 1.1 0.4 16.5 0.6 0.4 5.5 3.0 25.7 22.0 0.8 0.4 6.5 212.0 51.1 0.7 93.0 0.9 6.2 0.3 0.7 213.2 5.2 0.7 0.5 10.7 3.4 25.4 70.6 0.5 123.5 139.7 146.1 136.5 163.5 132.2 139.7 140.7 144.9 141.1 143.0 151.8 144.5 27.7 147.4 242.7 51.2 22.6 60.0 205.2 311.1 80.8 78.7 35.0 23.7 378.9 165.8 243.1 66.2 18.8 62.4 48.6 260.3 399.2 127.5 4.3 27.8 24.5 66.2 55.2 42.1 11.7 218.0 127.5 103.1 200.3 47.7 30.9 29.0 139.6 857.0 129.2 35.3 18.2 231.0 101.7 278.5 124.1 10.6 79.9 189.3 35.6 26.2 940.8 130.2 8.2 14.1 6.8 130.2 366.5 149.0 12.5 84.4 384.3 882.0 89.4 42.6 46.0 46.0 67.6 3.0 3.9 105.1 124.7 42.1 13.1 81.0 272.6 150.4 ALDH3B2 ALDH8 ENSG00000132746 "Aldehyde dehydrogenase 3 family member B2" P48448 11 67662160-67681224 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "breast: 73.0;esophagus: 152.2;skin 1: 123.0;vagina: 41.0" "Cell type enhanced" "Detected in some" "Breast glandular cells: 26.2;Endometrial ciliated cells: 12.6;Glandular and luminal cells: 28.1;Squamous epithelial cells: 53.3;Suprabasal keratinocytes: 14.8;Syncytiotrophoblasts: 14.6" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "MCF7: 71.9;SK-BR-3: 70.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA045132 Approved NA NA "Cluster 11: Squamous epithelial cells - Epithelial cell function" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 61: Squamous epithelial cells - Keratinization" "HPA045132: AB_10795993" "unprognostic (2.25e-1)" "unprognostic (2.41e-1)" "unprognostic (1.65e-1)" "unprognostic (8.65e-2)" "unprognostic (2.13e-1)" "unprognostic (6.09e-2)" "unprognostic (3.12e-2)" "unprognostic (6.32e-2)" "unprognostic (1.48e-1)" "unprognostic (5.56e-2)" "unprognostic (1.24e-2)" "unprognostic (1.40e-2)" "unprognostic (2.59e-2)" "unprognostic (1.61e-1)" "unprognostic (1.15e-2)" "unprognostic (5.92e-2)" 0.3 0.0 0.1 0.1 0.0 0.2 73.0 0.0 0.0 14.4 0.0 0.1 0.1 0.8 6.8 152.2 4.6 0.3 0.1 0.0 0.0 0.7 0.1 0.4 0.0 0.0 0.0 0.0 0.3 5.2 0.1 3.2 0.0 3.3 0.1 0.5 17.3 4.8 0.3 123.0 0.0 0.1 0.0 0.0 0.3 0.1 0.0 2.4 0.0 0.0 21.1 8.3 41.0 0.0 0.2 0.0 0.1 0.1 0.0 0.0 7.9 0.0 0.0 0.1 0.0 1.3 3.5 3.3 0.1 0.0 0.1 3.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.3 0.0 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 71.9 6.8 0.0 0.1 9.0 0.0 0.0 0.0 1.9 0.0 13.0 0.0 0.1 0.0 70.7 0.1 0.4 15.3 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.3 0.0 0.0 1.7 1.2 4.9 1.2 0.0 26.2 7.2 0.4 0.0 7.3 5.5 0.0 10.6 0.2 0.0 1.9 1.1 0.0 12.6 2.6 0.2 0.0 0.0 0.1 0.2 10.6 0.2 0.0 28.1 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 2.0 0.0 0.8 0.0 0.0 0.2 1.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.0 2.8 0.0 0.0 0.0 0.5 0.0 0.0 53.3 14.8 14.6 0.2 0.0 0.0 7.6 ALK CD246 ENSG00000171094 "ALK receptor tyrosine kinase" Q9UM73 2 29192774-29921586 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "brain: 10.9" "Group enriched" "Detected in some" 5 "Inhibitory neurons: 274.2;Oligodendrocyte precursor cells: 433.8" "Group enriched" "Detected in some" 5 "glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 6 "SH-SY5Y: 31.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010694 Approved Supported "Plasma membrane" NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane" "HPA010694: AB_1078133" "unprognostic (4.96e-2)" "unprognostic (1.11e-2)" "unprognostic (1.45e-1)" "unprognostic (4.56e-7)" "unprognostic (7.17e-2)" "unprognostic (1.71e-1)" "unprognostic (9.07e-3)" "unprognostic (6.29e-3)" "unprognostic (1.18e-1)" "unprognostic (1.01e-1)" "unprognostic (2.67e-4)" "unprognostic (3.70e-2)" "unprognostic (2.06e-2)" "unprognostic (7.15e-2)" "unprognostic (1.98e-1)" "unprognostic (1.38e-1)" "unprognostic (3.61e-2)" 0.3 0.6 2.2 0.2 2.4 0.0 0.1 0.7 2.8 0.1 0.8 0.6 0.1 0.0 0.0 0.0 0.0 0.2 0.0 1.5 3.9 0.0 0.0 0.1 0.0 4.4 6.8 0.0 0.0 0.0 1.3 0.0 10.9 0.0 0.2 0.7 0.1 0.1 0.0 0.1 0.3 0.1 2.9 0.0 0.1 1.2 2.7 0.0 0.3 0.0 0.0 0.0 0.0 2.1 0.1 0.0 0.5 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.0 4.3 0.0 0.0 0.1 0.4 31.7 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 3.7 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 2.4 0.7 2.8 1.5 3.9 4.4 6.8 10.9 2.9 2.7 2.1 0.0 0.0 0.0 66.6 0.0 0.0 0.0 0.0 0.0 1.9 0.2 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 42.1 0.5 0.1 0.2 0.0 0.0 12.5 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 3.4 0.0 274.2 0.0 0.0 0.0 0.0 41.2 0.0 0.5 0.0 7.5 0.0 0.6 0.0 433.8 21.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.1 0.8 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 ALOX5 5-LOX ENSG00000012779 "Arachidonate 5-lipoxygenase" P09917 10 45374176-45446119 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Leukotriene biosynthesis" "Dioxygenase, Hydrolase, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 72.8;lymphoid tissue: 93.9" "Cell type enhanced" "Detected in many" "B-cells: 63.7;granulocytes: 201.3;Hofbauer cells: 85.0;Kupffer cells: 78.5;Macrophages: 86.5;monocytes: 59.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "BEWO: 13.9;Daudi: 40.9;HMC-1: 24.0;U-266/70: 30.8;U-698: 11.0" "Region enriched" "Detected in single" 4 "white matter: 2.9" "Low region specificity" "Detected in all" HPA071285 Enhanced Supported Nucleoplasm NA NA "Cluster 14: Monocytes - Unknown function" "Cluster 64: Macrophages - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" Nucleoplasm "HPA071285: AB_2686379" "unprognostic (2.57e-2)" "unprognostic (2.81e-1)" "unprognostic (4.82e-2)" "unprognostic (1.75e-2)" "unprognostic (7.98e-3)" "unprognostic (1.26e-1)" "unprognostic (5.32e-2)" "unprognostic (8.69e-2)" "unprognostic (1.86e-2)" "unprognostic (6.91e-2)" "unprognostic (5.04e-2)" "unprognostic (3.42e-1)" "prognostic unfavorable (1.80e-5)" "unprognostic (5.59e-3)" "unprognostic (4.22e-2)" "unprognostic (1.53e-1)" "prognostic favorable (7.18e-4)" 16.8 8.4 1.4 8.4 1.1 31.1 12.7 2.8 2.9 6.1 1.0 11.0 3.0 6.9 0.3 10.7 11.1 3.4 6.7 1.2 1.8 8.3 5.5 72.8 6.7 4.1 2.5 2.6 23.2 0.9 3.2 3.6 2.7 11.8 2.3 0.1 14.1 1.5 2.1 5.6 35.8 4.9 2.5 93.9 9.3 2.1 2.2 2.6 4.7 3.7 8.9 40.0 7.9 4.2 0.0 0.0 0.0 0.0 0.0 0.0 13.9 0.0 0.0 0.0 0.0 0.0 7.4 40.9 0.7 0.0 0.0 0.3 0.3 0.0 0.0 0.3 0.1 8.6 0.0 0.0 0.0 0.0 24.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 5.0 0.0 0.0 0.0 0.3 0.0 1.0 0.0 0.1 0.0 2.7 0.0 5.2 0.7 0.0 0.0 0.2 0.0 0.1 0.1 0.6 0.0 0.0 2.2 0.0 0.0 30.8 2.8 11.0 0.0 0.1 0.0 462.5 225.6 317.6 0.3 198.4 0.6 133.9 5.3 1.7 119.7 98.5 0.7 0.5 457.8 0.2 210.5 2.4 1.2 136.1 1.4 1.1 2.8 2.9 1.2 1.8 4.1 2.5 2.7 2.5 2.2 4.2 0.7 16.0 38.4 1.3 63.7 1.1 7.3 0.2 1.2 1.3 7.3 4.3 2.2 12.8 9.5 9.2 2.1 0.7 1.7 1.7 0.0 20.9 0.5 0.7 0.5 3.0 7.1 1.7 2.8 21.6 2.0 1.7 13.7 4.4 201.3 2.2 3.6 1.1 85.0 0.0 1.1 2.0 14.2 78.5 17.8 1.1 0.3 86.5 0.0 47.8 59.5 0.7 4.1 4.0 1.4 18.4 0.6 0.0 13.8 4.0 9.4 0.2 2.6 0.3 13.1 0.3 1.1 0.3 1.1 9.2 1.4 4.1 5.9 0.7 3.2 45.3 ALPG "ALPPL2, GCAP" ENSG00000163286 "Alkaline phosphatase, germ cell" P10696 2 232406844-232410714 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at transcript level" "Evidence at protein level" "Not detected" "Not detected" "Not detected" "Not detected" "Cancer enhanced" "Detected in many" "endometrial cancer: 49.1;testis cancer: 64.8" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "CAPAN-2: 33.9;HaCaT: 24.9;SuSa: 38.3" "CAB020698, HPA038764, HPA038765, HPA051699" Approved Approved "Plasma membrane" "Intracellular and membrane" NA NA "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 44: Endometrium - Transcription" "Plasma membrane" "CAB020698: , HPA038764: AB_2676194, HPA038765: AB_2676195, HPA051699: AB_2681577" "unprognostic (1.39e-1)" "unprognostic (6.63e-3)" "unprognostic (1.27e-2)" "unprognostic (2.89e-1)" "unprognostic (1.46e-1)" "unprognostic (1.26e-1)" "unprognostic (1.69e-3)" "unprognostic (1.65e-1)" "unprognostic (2.67e-1)" "unprognostic (6.72e-3)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.1 0.0 0.3 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.7 33.9 0.0 0.0 0.0 0.0 24.9 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 3.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.5 0.3 0.0 38.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 AMY2A AMY2 ENSG00000243480 "Amylase alpha 2A" P04746 1 103616811-103625780 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted secreted proteins" "Carbohydrate metabolism" "Glycosidase, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 1983 "pancreas: 148689.6" "Cell type enriched" "Detected in some" 114 "Exocrine glandular cells: 1016.0" "Cancer enriched" "Detected in single" 2010 "pancreatic cancer: 200.3" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA045394, HPA045399, CAB045960, HPA046980" Enhanced "Secreted to digestive system" NA NA "Cluster 25: Pancreas - Digestion" "Cluster 1: Pancreatic cells - Digestion" "CAB045960: AB_2226891, HPA045394: AB_2679311, HPA045399: AB_2679313, HPA046980: AB_2679889" "unprognostic (3.27e-1)" "unprognostic (1.78e-3)" "unprognostic (3.24e-2)" "unprognostic (1.29e-1)" "unprognostic (2.13e-2)" 6.0 1.3 1.2 2.8 1.3 0.3 3.9 0.7 1.4 3.3 0.6 1.7 22.5 2.9 0.1 2.3 0.8 0.0 26.6 1.2 0.9 1.5 4.7 1.0 5.4 0.8 0.9 74.9 148689.6 0.1 1.5 8.3 0.8 2.1 0.0 0.6 30.0 0.0 1.5 1.4 10.7 0.0 0.7 1.7 2.2 1.2 0.9 0.0 1.1 0.0 0.0 0.5 1.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 1.3 0.7 1.4 1.2 0.9 0.8 0.9 0.8 0.7 0.9 1.0 0.1 0.0 0.0 2.0 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.0 1.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.1 2.1 0.0 0.0 0.2 0.0 0.0 1.3 1016.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.8 0.0 0.2 0.0 0.0 4.6 0.0 0.0 0.0 0.1 8.9 0.0 0.0 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.2 0.1 0.4 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.6 ANO1 "DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A" ENSG00000131620 "Anoctamin 1" Q5XXA6 11 70078302-70189528 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Developmental protein, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "epididymis: 181.7;salivary gland: 180.5;seminal vesicle: 209.2" "Cell type enhanced" "Detected in many" "Breast myoepithelial cells: 70.2;Early spermatids: 54.9;Hepatocytes: 141.3;Late spermatids: 75.1;Sertoli cells: 46.0;Smooth muscle cells: 52.5;Suprabasal keratinocytes: 46.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "A-431: 140.2;CAPAN-2: 207.9;HaCaT: 254.0;OE19: 182.2" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "spinal cord: 6.6" "HPA032148, HPA057356" Enhanced Supported "Nucleoplasm,Plasma membrane" NA NA "Cluster 30: Epididymis - Antimicrobial activity" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 2: Hepatocytes - Metabolism" "Plasma membrane" Nucleoplasm "HPA032148: AB_2674180, HPA057356: AB_2732610" "unprognostic (2.73e-1)" "unprognostic (7.91e-2)" "unprognostic (3.66e-2)" "prognostic favorable (4.58e-6)" "unprognostic (1.90e-1)" "prognostic unfavorable (7.28e-5)" "unprognostic (1.16e-3)" "prognostic unfavorable (2.40e-4)" "unprognostic (2.13e-2)" "unprognostic (3.51e-1)" "prognostic unfavorable (1.70e-4)" "unprognostic (1.21e-1)" "prognostic unfavorable (4.09e-6)" "unprognostic (1.56e-1)" "unprognostic (1.06e-1)" "unprognostic (8.85e-3)" "unprognostic (1.81e-1)" 16.3 2.2 0.3 3.6 1.6 0.1 86.8 0.8 1.3 46.7 0.1 14.3 3.6 40.0 181.7 12.7 59.1 54.4 21.9 0.5 0.1 6.4 108.5 16.1 3.4 1.0 0.2 2.9 9.1 48.0 4.4 5.2 1.1 17.1 11.0 0.9 180.5 209.2 12.7 97.4 4.6 30.1 0.2 1.2 48.3 10.4 0.1 1.5 35.4 33.0 4.0 6.7 12.8 0.5 140.2 5.3 0.3 4.5 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.1 207.9 0.0 2.5 0.0 0.3 254.0 0.0 0.7 0.0 0.4 0.2 0.1 0.1 0.0 0.0 0.3 0.2 0.0 0.1 0.4 0.2 0.0 0.6 0.0 0.0 0.1 0.0 1.0 0.5 0.3 1.1 182.2 19.6 0.3 0.0 0.7 0.0 0.2 7.3 0.2 0.1 43.1 0.8 1.4 16.2 0.5 0.5 0.3 1.1 0.0 3.5 0.1 0.3 0.2 0.2 0.0 14.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.6 0.8 1.3 0.5 0.1 1.0 0.2 1.1 0.2 0.1 0.5 7.2 0.0 0.0 0.7 0.4 17.7 21.5 4.2 0.0 0.0 30.5 70.2 3.5 17.2 2.0 0.0 0.0 1.3 0.2 0.4 0.0 4.1 54.9 10.0 27.5 5.6 0.0 2.7 0.7 0.0 0.6 4.2 36.7 18.5 4.5 0.0 3.3 141.3 0.2 0.0 20.4 13.3 0.0 1.6 3.0 75.1 1.8 0.7 5.4 2.8 0.0 0.8 0.0 1.5 0.7 1.0 0.5 1.5 0.3 22.6 0.0 0.7 0.3 0.4 46.0 1.1 52.5 1.4 2.3 1.4 46.7 4.1 0.7 0.1 0.4 20.9 ANXA1 "ANX1, LPC1" ENSG00000135046 "Annexin A1" P04083 9 73151865-73170393 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters" "Adaptive immunity, Immunity, Inflammatory response, Innate immunity" "Phospholipase A2 inhibitor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 7527.7" "Cell type enhanced" "Detected in many" "Squamous epithelial cells: 3632.9;Syncytiotrophoblasts: 7071.8;Urothelial cells: 4808.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "basophil: 2816.9" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011271, HPA011272, CAB013023, CAB035987, CAB058693" Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" "Secreted to blood" NA Yes 3000000000 "Cluster 2: Granulocytes - Unknown function" "Cluster 84: Esophagus - Epithelial cell function" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 22: Epithelial cell types - Mixed function" "Plasma membrane, Cytosol" Nucleoplasm "CAB013023: AB_2533983, CAB035987: , CAB058693: AB_2665585, HPA011271: AB_1844883, HPA011272: AB_1844884" "unprognostic (2.53e-2)" "unprognostic (1.31e-1)" "unprognostic (9.08e-2)" "prognostic favorable (5.71e-5)" "unprognostic (1.53e-2)" "unprognostic (4.28e-2)" "unprognostic (1.82e-2)" "unprognostic (1.30e-2)" "unprognostic (1.30e-1)" "unprognostic (1.14e-1)" "unprognostic (2.54e-3)" "unprognostic (1.47e-1)" "unprognostic (9.82e-3)" "unprognostic (1.13e-1)" "unprognostic (8.55e-2)" "prognostic favorable (4.57e-5)" "prognostic unfavorable (6.19e-6)" 719.8 60.3 27.5 268.3 35.1 2132.2 442.6 24.8 44.4 952.0 32.8 152.7 64.1 116.2 58.6 7527.7 264.6 329.4 145.3 28.4 53.4 67.9 54.7 470.4 67.9 55.5 46.4 109.4 61.8 28.2 98.1 559.4 36.5 165.3 103.2 6.5 1547.5 154.9 47.6 213.8 88.7 261.5 40.4 79.6 90.2 17.9 45.9 109.9 206.8 89.1 1485.5 386.3 1536.1 43.2 960.2 1485.7 65.8 68.4 905.8 855.6 4.2 1614.6 1008.5 656.3 441.9 43.5 841.0 2.2 520.1 1426.5 1441.9 1147.7 142.6 984.1 516.8 541.6 10.3 73.2 398.5 1.4 719.4 160.9 34.7 495.7 800.6 664.7 1294.6 604.0 947.8 85.4 309.3 39.5 822.6 4.3 287.0 87.7 82.6 379.7 597.6 0.9 369.1 3.2 1495.9 200.4 1.0 0.7 556.6 14.7 377.9 862.7 3.5 24.3 1176.2 761.8 478.9 1058.2 845.1 6.8 2.0 3.6 1757.9 147.8 1171.2 2816.9 1237.6 2227.6 744.1 328.7 757.0 13.7 662.7 664.5 1513.3 3.3 190.7 348.5 128.4 443.6 324.0 53.2 134.5 2021.5 27.5 35.1 24.8 44.4 28.4 53.4 55.5 46.4 36.5 40.4 45.9 43.2 447.4 583.3 415.2 1.6 39.0 846.7 2486.8 2417.6 1748.3 0.1 225.0 417.1 22.5 58.6 2214.7 62.5 0.0 1543.4 602.1 32.2 0.0 167.4 8.2 2037.4 241.6 362.2 5.3 81.2 3.7 23.1 1747.7 732.0 86.6 1993.5 2550.6 0.1 136.7 6.5 593.8 0.0 0.1 20.8 1330.6 545.0 1190.3 7.3 222.4 901.7 307.7 29.0 575.0 0.2 319.3 0.5 0.6 733.2 5.5 9.4 140.4 1552.2 0.1 5.7 1996.9 0.0 65.7 728.2 413.3 2.3 4.0 3632.9 597.7 7071.8 1348.3 3.0 12.6 4808.1 ANXA2 "ANX2, ANX2L4, CAL1H, LIP2, LPC2D" ENSG00000182718 "Annexin A2" P07355 15 60347134-60402883 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters" "Host-virus interaction" RNA-binding "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 2185.3" "Cell type enhanced" "Detected in many" "Basal respiratory cells: 5755.6;Pancreatic endocrine cells: 5217.8;Prostatic glandular cells: 4575.5;Urothelial cells: 4326.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 4 "basophil: 4429.7;classical monocyte: 2762.3;intermediate monocyte: 2401.9;myeloid DC: 4018.8;non-classical monocyte: 2686.5;T-reg: 1681.4" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "spinal cord: 174.7" "CAB004311, HPA046964, HPA061798" Enhanced Approved "Plasma membrane,Cytosol" "Secreted to blood" NA NA 19000000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 11: Squamous epithelial cells - Epithelial cell function" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 16: Pancreatic endocrine cells - Mixed function" "Plasma membrane" Cytosol "CAB004311: AB_626677, HPA046964: AB_2732537, HPA061798: AB_2732671" "unprognostic (1.61e-1)" "unprognostic (1.31e-3)" "unprognostic (1.84e-1)" "prognostic favorable (6.88e-5)" "unprognostic (4.06e-3)" "unprognostic (5.42e-3)" "prognostic unfavorable (2.54e-5)" "prognostic unfavorable (7.51e-4)" "unprognostic (2.94e-1)" "unprognostic (4.10e-3)" "prognostic unfavorable (8.47e-6)" "unprognostic (5.16e-2)" "prognostic unfavorable (2.11e-6)" "unprognostic (7.74e-2)" "unprognostic (2.55e-1)" "unprognostic (7.41e-2)" "prognostic unfavorable (6.59e-5)" 975.6 370.5 49.0 461.9 50.5 151.7 708.5 49.6 96.9 806.3 95.6 631.2 502.0 296.2 267.2 2185.3 388.4 453.9 393.0 47.6 79.4 358.3 185.5 878.3 200.7 90.0 83.6 187.0 324.3 344.0 163.9 650.4 84.9 399.3 606.1 30.2 933.4 386.4 304.8 1140.8 487.5 425.4 73.3 301.6 379.0 116.1 120.9 188.7 351.2 205.8 541.1 842.2 1256.7 80.1 4183.3 4421.4 223.6 105.5 2962.4 4744.2 971.0 4703.6 2968.4 2868.4 2534.9 2083.5 1903.6 10.0 3907.2 5983.6 2185.1 4304.9 992.9 8695.5 3113.5 846.8 103.9 78.2 1918.7 882.7 1782.0 4.5 59.9 2324.4 2278.6 2013.2 4335.0 3477.2 5455.0 58.4 320.9 447.9 6271.8 468.4 18.5 239.1 508.2 3444.1 3283.5 48.9 1198.8 226.6 5172.4 2410.7 295.1 171.9 1774.5 424.8 1942.8 2305.1 922.7 173.6 6336.8 2534.1 3406.8 8668.0 4807.4 172.6 616.3 83.8 2449.2 47.9 5206.0 4429.7 2762.3 355.0 603.8 2401.9 668.5 657.9 686.4 701.7 4018.8 412.1 77.0 313.9 73.6 287.1 2686.5 609.4 1681.4 3754.4 49.0 50.5 49.6 96.9 47.6 79.4 90.0 83.6 84.9 73.3 120.9 80.1 673.9 2141.0 414.8 0.3 101.3 2512.2 3396.9 5755.6 246.4 2.5 395.9 337.4 28.2 773.5 3086.6 560.9 0.0 1874.5 135.9 933.6 13.7 3941.4 93.0 855.9 457.1 772.0 103.4 38.7 0.2 2411.4 2714.4 1076.7 328.7 1376.3 105.7 97.5 474.0 64.2 1537.2 0.0 1.3 689.0 1668.2 429.6 1992.1 126.6 771.1 715.1 1417.6 15.9 1284.0 19.4 138.0 1.5 0.1 5217.8 920.9 638.7 144.5 4575.5 845.8 51.8 2446.8 8.1 184.1 437.7 831.1 13.0 29.3 789.7 2325.1 1150.1 224.1 8.6 749.9 4326.1 ANXA3 ANX3 ENSG00000138772 "Annexin A3" P12429 4 78551747-78610451 "FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Phospholipase A2 inhibitor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 337.7" "Cell type enhanced" "Detected in many" "Adipocytes: 322.7;Alveolar cells type 1: 589.7;Ductal cells: 434.5;Exocrine glandular cells: 305.3;Pancreatic endocrine cells: 754.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 320 "neutrophil: 207.7" "Lineage enriched" "Detected in single" 327 "granulocytes: 207.7" "Cell line enhanced" "Detected in many" "A-431: 419.5;CACO-2: 403.5;CAPAN-2: 563.7;EFO-21: 334.7;hTERT-HME1: 566.3;OE19: 502.1;RPTEC TERT1: 477.8" "Low region specificity" "Detected in all" "HPA013398, HPA013431" Enhanced Supported "Plasma membrane" NA NA 6400000 "Cluster 9: Neutrophils - Innate immune response" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 16: Pancreatic endocrine cells - Mixed function" "Plasma membrane" "HPA013398: AB_1844861, HPA013431: AB_1844862" "unprognostic (2.66e-1)" "unprognostic (5.65e-3)" "unprognostic (4.92e-3)" "unprognostic (8.67e-2)" "unprognostic (2.41e-1)" "unprognostic (5.02e-3)" "unprognostic (4.17e-2)" "unprognostic (1.87e-1)" "unprognostic (5.09e-2)" "unprognostic (2.10e-3)" "prognostic unfavorable (1.28e-4)" "unprognostic (4.82e-2)" "prognostic favorable (8.48e-6)" "unprognostic (2.23e-1)" "unprognostic (2.02e-2)" "unprognostic (7.20e-2)" "unprognostic (3.30e-2)" 52.9 3.1 16.5 22.7 17.3 337.7 43.8 14.5 28.2 19.6 11.7 27.7 15.8 12.5 3.7 55.2 16.8 17.3 51.2 14.2 21.6 24.9 3.9 144.4 2.4 19.9 16.1 2.5 32.7 34.0 5.9 81.5 20.8 68.0 26.7 1.6 119.5 12.9 28.3 10.0 13.3 20.1 14.6 21.6 90.5 1.9 19.9 7.1 83.7 36.7 12.7 10.2 15.6 14.7 419.5 77.7 1.3 0.9 1.0 0.9 0.6 4.9 0.4 11.0 10.9 403.5 563.7 0.1 334.7 14.4 0.4 161.6 0.1 300.0 16.0 1.4 3.3 36.4 142.0 23.9 45.9 5.9 0.2 2.4 262.6 4.1 566.3 60.1 118.9 9.0 0.7 0.3 1.9 15.9 1.7 0.2 13.0 502.1 55.4 0.0 0.8 0.0 477.8 45.2 0.3 0.3 235.5 58.2 16.6 186.1 9.9 4.3 153.2 0.6 52.6 0.2 93.0 3.1 5.1 2.2 0.0 0.4 0.1 0.6 0.2 0.0 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.4 0.1 0.0 207.7 0.1 0.6 0.1 0.0 2.9 16.5 17.3 14.5 28.2 14.2 21.6 19.9 16.1 20.8 14.6 19.9 14.7 322.7 589.7 47.3 0.0 1.1 24.9 81.8 144.9 1.8 0.2 27.6 85.9 8.6 55.8 175.2 38.6 0.0 212.6 1.0 35.4 17.6 434.5 1.1 33.7 4.4 84.6 5.4 3.2 0.9 305.3 106.2 16.9 99.9 58.1 5.1 0.1 23.2 0.6 18.9 0.0 0.3 33.4 122.1 0.3 0.3 0.3 3.1 6.9 5.4 42.2 21.0 1.2 0.0 1.0 0.6 754.2 61.6 0.4 0.6 158.6 11.5 5.5 89.6 0.4 0.0 7.6 18.7 1.1 0.6 21.9 6.7 62.8 2.3 1.3 29.7 46.7 ANXA4 ANX4 ENSG00000196975 "Annexin A4" P09525 2 69644425-69827112 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "gallbladder: 569.9;pancreas: 356.8" "Cell type enhanced" "Detected in all" "Cholangiocytes: 2344.8;Ductal cells: 1469.8;Proximal enterocytes: 657.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "EFO-21: 414.2;Hep G2: 456.9;RPTEC TERT1: 623.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005076, HPA007393, CAB017560" Enhanced Approved Cytosol NA NA 550000 "Cluster 24: B-cells - Unknown function" "Cluster 29: Non-specific - Vesicular transport" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 1: Pancreatic cells - Digestion" Cytosol "CAB005076: AB_630869, CAB017560: AB_2227370, HPA007393: AB_1078168" "prognostic unfavorable (8.55e-4)" "unprognostic (3.37e-2)" "unprognostic (4.82e-2)" "unprognostic (9.03e-2)" "unprognostic (1.62e-3)" "unprognostic (1.66e-1)" "unprognostic (3.57e-1)" "unprognostic (3.21e-1)" "unprognostic (4.52e-2)" "prognostic unfavorable (2.38e-4)" "unprognostic (7.23e-3)" "unprognostic (1.29e-1)" "prognostic unfavorable (6.05e-4)" "unprognostic (1.79e-1)" "unprognostic (8.85e-2)" "unprognostic (3.60e-2)" "unprognostic (3.97e-2)" 48.2 21.6 14.5 33.6 15.4 30.8 45.9 14.9 18.9 62.4 52.4 101.7 271.3 50.9 30.3 43.0 68.6 569.9 26.1 14.4 15.2 104.0 120.9 81.6 21.1 15.6 15.1 38.8 356.8 78.0 11.9 52.7 15.8 46.3 92.3 30.0 39.2 52.1 17.2 61.0 232.4 52.0 15.7 24.2 108.2 9.7 15.2 23.0 43.6 20.4 24.0 61.3 50.2 16.6 69.6 249.4 3.4 31.0 185.0 158.3 11.3 66.0 101.5 27.1 38.0 37.9 121.7 22.8 414.2 109.5 78.9 104.7 23.8 108.1 27.6 65.2 20.3 35.0 20.5 456.9 131.2 12.5 43.0 95.9 104.8 36.5 87.3 62.9 71.1 11.0 2.0 20.1 74.7 63.8 18.3 22.8 6.1 280.0 34.3 19.4 6.8 28.3 623.2 99.1 5.1 22.9 72.9 99.5 103.8 35.6 33.3 156.3 100.9 49.2 23.8 65.5 37.7 8.2 9.7 1.3 75.8 59.7 34.1 80.4 34.7 29.6 23.1 42.5 17.5 40.6 11.7 17.5 50.6 46.7 2.0 12.5 4.9 9.5 58.7 15.5 14.5 24.2 14.5 15.4 14.9 18.9 14.4 15.2 15.6 15.1 15.8 15.7 15.2 16.6 66.4 205.1 154.8 47.3 27.3 74.2 98.5 148.2 68.9 8.2 36.8 36.4 10.6 2344.8 139.4 84.6 6.2 86.4 27.2 315.1 221.1 1469.8 14.6 257.9 79.0 49.1 18.6 12.6 29.9 344.4 370.1 103.6 196.7 488.8 111.5 24.3 33.9 68.5 227.6 8.4 17.7 193.8 240.1 46.1 80.4 11.2 64.7 54.5 92.5 63.7 87.2 48.7 45.3 17.6 106.0 245.7 268.6 92.2 6.9 55.6 657.1 400.4 230.2 59.9 6.6 27.6 64.6 15.8 3.7 61.3 79.6 439.6 32.5 19.1 174.1 96.9 ANXA5 "ANX5, ENX2" ENSG00000164111 "Annexin A5" P08758 4 121667946-121696995 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Blood coagulation, Hemostasis" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cytotrophoblasts: 1156.8;Extravillous trophoblasts: 1125.1;Syncytiotrophoblasts: 1140.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003677, HPA035330" Approved Approved "Nuclear membrane" NA NA 5000000 "Cluster 7: Monocytes - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 16: Pancreatic endocrine cells - Mixed function" "Nuclear membrane" "CAB003677: AB_425305, HPA035330: AB_2674574" "unprognostic (1.22e-1)" "unprognostic (1.03e-2)" "unprognostic (9.70e-2)" "prognostic favorable (3.64e-4)" "unprognostic (1.80e-1)" "prognostic unfavorable (3.01e-5)" "prognostic unfavorable (1.64e-5)" "unprognostic (7.33e-3)" "unprognostic (3.09e-1)" "unprognostic (6.04e-2)" "unprognostic (6.49e-3)" "unprognostic (4.54e-1)" "prognostic unfavorable (9.29e-7)" "prognostic unfavorable (7.19e-4)" "unprognostic (1.02e-1)" "unprognostic (1.53e-2)" "prognostic unfavorable (1.26e-4)" 490.6 286.5 111.7 241.7 126.3 96.2 314.0 136.9 144.7 429.1 137.7 181.9 96.5 288.7 162.6 135.1 225.0 273.1 213.9 106.4 134.7 216.2 149.5 299.0 136.2 151.2 129.6 224.7 162.9 133.7 176.7 466.0 150.4 211.7 155.5 78.1 273.8 250.5 85.2 132.5 130.9 370.3 134.3 175.7 186.0 110.4 154.3 63.3 182.9 114.8 135.2 298.1 178.6 157.3 463.5 339.6 438.0 256.1 2094.3 1645.5 503.4 1582.7 1464.9 841.3 744.8 246.2 200.6 35.7 282.9 2224.8 581.7 165.4 287.3 727.6 762.2 335.1 171.2 105.0 281.6 647.4 1213.9 221.1 178.3 945.5 344.7 705.1 665.9 927.4 1120.9 25.2 106.0 271.8 2133.5 306.7 225.5 75.1 231.9 417.7 718.5 8.2 1014.5 72.6 1368.9 66.3 117.1 141.4 579.7 227.6 1515.2 872.3 201.5 261.2 830.6 1322.1 632.1 955.2 478.0 240.8 308.6 76.0 847.8 123.5 1586.2 122.2 725.8 359.9 104.8 830.5 136.0 127.3 158.8 131.9 745.6 89.5 51.3 74.6 157.9 48.4 798.0 91.2 289.9 773.3 111.7 126.3 136.9 144.7 106.4 134.7 151.2 129.6 150.4 134.3 154.3 157.3 286.5 243.6 233.9 13.7 85.0 199.3 266.4 395.9 76.2 6.8 101.6 107.4 88.3 265.9 257.2 132.4 25.0 1156.8 53.2 15.6 297.4 703.5 16.2 239.7 318.1 287.7 48.6 29.0 15.4 338.2 1125.1 564.7 91.3 312.6 148.7 177.5 186.4 54.8 753.2 13.5 7.1 110.9 187.2 446.5 705.1 41.4 379.9 544.0 352.2 45.0 412.5 161.4 13.4 23.1 26.8 501.1 31.2 366.3 203.1 473.8 15.3 194.3 268.9 30.0 295.9 443.1 377.2 15.9 28.6 101.1 140.8 1140.8 122.0 185.7 43.2 188.2 AOC3 "HPAO, VAP-1, VAP1" ENSG00000131471 "Amine oxidase copper containing 3" Q16853 17 42851184-42858130 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adipose tissue: 422.8" "Group enriched" "Detected in many" 4 "Adipocytes: 58.2;Peritubular cells: 74.9;Sertoli cells: 118.3;Smooth muscle cells: 93.0;Theca cells: 74.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 17 "ASC diff: 307.5" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA000980, CAB025797" Enhanced Approved "Golgi apparatus,Cytosol" "Secreted - unknown location" NA NA 240000000 "Cluster 46: Fibroblasts - ECM organization" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 48: Smooth muscle cells - ECM organization" Cytosol "Golgi apparatus" "CAB025797: , HPA000980: AB_1078170" "unprognostic (2.20e-1)" "unprognostic (4.49e-2)" "prognostic unfavorable (3.68e-4)" "unprognostic (2.97e-2)" "unprognostic (1.17e-1)" "unprognostic (2.64e-1)" "unprognostic (2.22e-1)" "unprognostic (2.15e-2)" "unprognostic (1.48e-1)" "unprognostic (4.00e-2)" "unprognostic (2.95e-1)" "unprognostic (9.02e-2)" "prognostic unfavorable (1.79e-5)" "unprognostic (5.61e-2)" "unprognostic (1.67e-1)" "unprognostic (8.39e-2)" "prognostic unfavorable (6.98e-4)" 422.8 48.4 2.6 31.9 3.2 1.4 169.2 2.5 4.2 52.8 2.7 210.8 17.3 95.1 33.5 88.0 84.8 50.7 50.2 2.9 2.5 24.1 19.1 218.6 12.4 2.5 2.5 26.5 12.0 8.4 5.4 28.0 2.6 59.1 41.0 1.7 14.7 103.6 17.8 24.6 57.6 144.8 2.3 21.4 66.6 12.8 2.4 5.9 28.2 22.9 3.9 142.1 50.9 2.5 0.1 1.5 0.2 1.0 307.5 0.3 5.0 0.3 0.1 0.2 0.8 0.9 0.0 0.7 0.7 0.1 0.2 0.5 0.8 0.2 0.8 1.5 5.7 0.4 0.5 18.4 0.8 0.3 1.0 3.3 1.0 0.3 0.8 0.0 0.2 2.2 0.3 1.7 0.6 0.2 0.2 1.4 0.7 0.1 0.4 0.7 0.8 3.0 0.1 2.2 0.3 0.4 0.0 0.2 2.0 2.2 0.1 0.1 0.0 0.3 2.7 1.2 0.4 4.8 5.9 0.6 0.4 2.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.6 3.2 2.5 4.2 2.9 2.5 2.5 2.5 2.6 2.3 2.4 2.5 58.2 3.2 6.0 0.0 0.5 2.9 0.1 0.0 2.2 0.0 1.1 2.2 9.5 0.0 1.9 0.0 0.0 0.1 0.4 0.1 0.0 0.2 4.5 0.8 2.3 12.3 0.0 0.0 0.4 0.2 0.1 11.3 0.0 1.4 1.3 2.1 20.7 0.2 1.4 0.0 0.3 0.1 0.0 1.4 2.7 2.6 3.4 0.9 3.6 3.7 0.0 0.2 0.0 0.0 0.1 0.2 0.0 74.9 0.0 0.4 0.1 1.4 1.0 0.4 118.3 2.6 93.0 1.1 1.3 0.7 1.8 0.3 0.6 74.6 0.1 0.3 APP AD1 ENSG00000142192 "Amyloid beta precursor protein" P05067 21 25880550-26171128 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Apoptosis, Cell adhesion, Endocytosis, Notch signaling pathway" "Heparin-binding, Protease inhibitor, Serine protease inhibitor" "Alzheimer disease, Amyloidosis, Disease variant, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Oligodendrocytes: 870.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 5 "plasmacytoid DC: 38.1" "Lineage enriched" "Detected in many" 5 "dendritic cells: 38.1" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000157, HPA001462" Enhanced Approved "Golgi apparatus,Vesicles" "Secreted to blood" NA NA 26000000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 7: Kidney - Transmembrane transport" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "Golgi apparatus" Vesicles "CAB000157: AB_323833, HPA001462: AB_1078185" "unprognostic (3.30e-1)" "unprognostic (1.02e-2)" "unprognostic (1.90e-1)" "unprognostic (1.24e-1)" "unprognostic (1.92e-1)" "unprognostic (3.69e-3)" "unprognostic (2.54e-1)" "unprognostic (8.22e-2)" "unprognostic (1.28e-1)" "unprognostic (9.45e-2)" "unprognostic (4.28e-2)" "unprognostic (5.35e-2)" "prognostic favorable (2.79e-6)" "unprognostic (3.77e-2)" "unprognostic (2.46e-1)" "unprognostic (5.23e-2)" "unprognostic (2.08e-3)" 249.9 498.0 413.0 157.4 457.6 134.4 447.5 413.1 572.4 264.2 396.8 357.2 226.4 281.1 293.3 178.6 308.1 350.8 389.0 456.2 405.3 532.5 298.2 279.4 78.9 425.0 481.9 306.2 323.5 278.6 155.4 451.9 448.7 260.6 328.5 209.3 270.7 343.6 107.5 218.6 200.3 379.9 419.7 154.4 213.5 165.6 426.4 159.2 469.9 176.0 78.2 304.9 151.7 523.5 388.7 489.9 538.4 448.5 707.7 869.8 559.8 757.1 1029.2 386.6 449.3 286.4 941.0 0.9 848.3 614.8 505.1 255.6 326.4 921.6 324.4 14.7 253.1 0.8 275.6 204.1 688.0 372.0 19.6 790.4 990.7 456.8 823.0 1584.3 1750.7 158.6 0.8 39.0 614.5 433.1 6.5 4.0 416.2 644.9 418.6 241.2 505.2 325.3 1283.3 270.1 267.3 385.6 824.0 549.0 393.4 720.0 482.4 400.1 1837.1 850.8 350.2 310.4 371.6 232.3 3.1 4.8 690.4 1.6 836.3 1.1 7.5 0.0 0.2 2.2 0.3 0.8 2.2 0.7 5.6 2.2 2.3 0.6 1.5 0.5 1.6 38.1 0.6 3.3 413.0 457.6 413.1 572.4 456.2 405.3 425.0 481.9 448.7 419.7 426.4 523.5 330.2 109.0 39.6 70.5 47.6 181.6 215.6 449.0 306.7 45.2 280.3 199.6 143.2 296.0 214.0 502.1 29.2 472.6 180.7 395.2 56.7 398.7 46.1 78.8 162.2 416.0 162.6 29.2 481.6 180.4 141.2 309.5 164.7 110.7 8.2 100.3 539.7 125.7 76.3 84.1 525.5 303.1 256.3 61.6 79.9 61.8 242.6 69.9 161.9 189.3 89.9 329.9 4.1 423.2 870.8 205.4 223.1 296.8 24.0 187.5 95.2 165.8 164.7 24.5 118.3 336.5 198.5 38.3 86.9 85.9 106.1 552.1 27.0 111.4 283.5 133.6 AR "AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1" ENSG00000169083 "Androgen receptor" P10275 X 67544021-67730619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease variant, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 38.2" "Cell type enhanced" "Detected in many" "Breast glandular cells: 93.7;Granulosa cells: 104.8;Hepatocytes: 269.2;Leydig cells: 77.9;Peritubular cells: 86.5;Skeletal myocytes: 75.0" "Cancer enhanced" "Detected in many" "breast cancer: 15.6;prostate cancer: 16.9" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AF22: 13.3;BJ hTERT+: 10.3;HAP1: 14.9;LHCN-M2: 16.1;RH-30: 23.6;T-47d: 10.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000001, HPA004733, CAB065764" Enhanced Supported Cytosol NA NA "Cluster 85: Liver - Metabolism" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 35: Glandular cells - Unknown function" Cytosol "CAB000001: AB_2060174, CAB065764: AB_10620739, HPA004733: " "unprognostic (1.34e-1)" "unprognostic (8.10e-3)" "unprognostic (2.49e-2)" "unprognostic (5.95e-2)" "unprognostic (1.04e-2)" "unprognostic (3.35e-2)" "prognostic favorable (8.77e-4)" "unprognostic (4.99e-2)" "unprognostic (1.72e-1)" "unprognostic (7.79e-2)" "unprognostic (2.30e-1)" "unprognostic (2.29e-1)" "prognostic favorable (1.03e-8)" "unprognostic (8.23e-3)" "unprognostic (8.90e-2)" "unprognostic (4.23e-2)" "unprognostic (7.97e-2)" 6.7 1.0 1.1 0.5 1.3 0.0 8.7 1.7 1.1 23.6 0.2 2.0 0.2 18.6 16.1 1.2 20.7 2.0 5.8 1.0 3.5 3.6 38.2 1.5 0.3 3.5 2.6 14.6 0.8 0.1 1.9 0.1 2.7 16.5 0.6 0.2 1.4 18.2 13.9 5.2 0.9 9.5 2.1 1.3 1.5 3.9 4.8 2.7 2.1 6.1 0.5 3.5 12.9 2.0 0.0 4.8 13.3 0.0 0.0 0.0 0.0 7.3 10.3 0.3 0.1 0.1 0.0 0.0 0.0 1.0 0.0 0.0 14.9 0.0 0.0 0.0 2.4 0.0 1.5 0.0 0.8 0.0 0.0 5.5 0.0 1.8 0.0 0.0 3.9 0.1 4.6 2.2 16.1 1.5 0.0 0.0 5.4 0.0 0.0 0.0 23.6 0.1 0.4 0.0 0.0 0.0 0.0 0.3 0.0 3.6 10.9 7.6 0.3 0.3 2.2 0.0 3.5 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 1.3 1.7 1.1 1.0 3.5 3.5 2.6 2.7 2.1 4.8 2.0 3.1 0.0 5.0 28.4 0.4 9.7 17.8 0.2 15.9 0.7 93.7 33.7 37.4 14.3 10.7 3.7 0.0 3.5 14.0 0.0 1.9 11.3 1.1 2.9 49.1 10.5 0.0 5.3 7.7 0.0 0.2 39.4 0.0 5.8 1.3 104.8 36.0 269.2 0.8 0.0 17.8 0.3 0.0 2.2 4.2 4.4 77.9 3.3 10.6 1.0 1.7 0.2 0.0 26.7 0.2 0.6 0.0 86.5 0.0 36.5 0.6 27.7 3.6 0.3 65.7 75.0 20.8 0.8 3.3 12.7 16.1 1.0 1.7 37.8 0.2 22.0 ATIC "AICARFT, IMPCHASE, PURH" ENSG00000138363 "5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase" P31939 2 215311956-215349773 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Purine biosynthesis" "Hydrolase, Multifunctional enzyme, Transferase" "Cancer-related genes, Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cytotrophoblasts: 171.4;Extravillous trophoblasts: 166.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013462, HPA021012" Supported Approved "Plasma membrane,Cytosol" NA NA 3900000 "Cluster 44: Non-specific - Transcription" "Cluster 3: T-cells - Adaptive immune response" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 38: Extravillous trophoblasts - Unknown function" Cytosol "Plasma membrane" "CAB013462: , HPA021012: AB_1845169" "unprognostic (1.41e-2)" "unprognostic (2.18e-1)" "unprognostic (1.13e-2)" "unprognostic (8.46e-2)" "unprognostic (2.90e-1)" "unprognostic (3.81e-2)" "prognostic unfavorable (1.99e-7)" "unprognostic (1.86e-2)" "unprognostic (5.07e-2)" "unprognostic (1.83e-1)" "unprognostic (6.31e-3)" "unprognostic (9.21e-2)" "prognostic unfavorable (8.77e-4)" "unprognostic (1.00e-1)" "unprognostic (1.30e-1)" "unprognostic (4.18e-2)" "unprognostic (4.39e-3)" 24.8 26.0 19.8 31.7 23.4 26.4 33.9 21.4 23.5 22.2 18.8 36.4 32.0 30.0 20.3 19.4 29.4 20.4 21.3 19.6 21.5 32.7 34.6 18.0 44.9 20.5 21.5 32.0 26.2 29.6 18.6 37.3 23.3 28.7 47.5 19.1 18.8 38.4 43.2 23.8 27.2 37.0 21.0 27.6 24.5 20.1 22.9 41.8 22.5 25.4 51.8 29.1 17.6 27.5 102.2 133.8 85.1 144.0 112.5 113.2 40.6 105.4 91.9 117.4 134.9 278.6 157.3 149.6 122.8 110.0 164.5 106.7 187.8 157.0 169.5 113.4 189.3 179.1 108.7 271.5 145.4 226.1 92.0 98.4 119.8 154.7 188.5 82.0 79.7 144.5 237.0 124.4 166.3 178.7 203.4 112.1 330.3 167.4 84.9 185.8 117.3 133.4 126.4 146.5 129.3 87.8 84.3 103.1 124.3 189.2 169.7 82.9 70.2 96.0 101.2 127.3 65.8 160.3 195.7 300.1 85.6 124.5 146.8 12.6 16.4 0.4 34.6 23.5 59.1 56.6 49.0 53.8 36.3 39.9 50.0 46.9 1.8 55.4 21.1 31.7 50.2 29.0 19.8 23.4 21.4 23.5 19.6 21.5 20.5 21.5 23.3 21.0 22.9 27.5 7.2 12.8 19.3 18.6 34.7 15.0 28.2 55.0 30.7 10.0 18.2 16.1 21.1 28.6 33.3 23.9 4.2 171.4 23.3 17.6 27.4 45.2 1.1 20.7 28.2 6.1 19.2 32.2 15.4 49.3 166.3 25.3 22.4 20.8 25.3 32.9 5.3 22.2 52.4 10.1 15.4 33.8 26.4 14.4 10.8 1.7 23.9 20.2 30.2 2.8 26.1 21.3 26.8 16.6 25.7 32.4 28.5 34.3 36.3 24.0 18.8 52.7 27.3 14.7 26.3 19.2 29.0 3.3 43.8 24.6 8.5 95.4 29.8 40.7 58.4 18.1 ATP1A1 ENSG00000163399 "ATPase Na+/K+ transporting subunit alpha 1" P05023 1 116372668-116410261 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" Translocase "Cancer-related genes, Charcot-Marie-Tooth disease, Epilepsy, FDA approved drug targets, Mental retardation, Neurodegeneration, Neuropathy, Primary hypomagnesemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "parathyroid gland: 1482.3" "Cell type enhanced" "Detected in all" "Proximal enterocytes: 1879.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "SK-MEL-30: 2979.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018702, CAB069993" Enhanced NA NA 420000 "Cluster 35: T-regs - Unknown function" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 45: Enterocytes - Digestion" "CAB018702: AB_626713, CAB069993: AB_2060979" "unprognostic (6.18e-2)" "unprognostic (2.18e-1)" "unprognostic (6.91e-2)" "unprognostic (1.42e-2)" "unprognostic (6.80e-2)" "unprognostic (2.15e-1)" "prognostic unfavorable (1.42e-4)" "unprognostic (1.80e-1)" "unprognostic (1.21e-2)" "unprognostic (6.32e-2)" "unprognostic (1.61e-2)" "unprognostic (1.65e-1)" "prognostic favorable (8.98e-8)" "unprognostic (4.75e-2)" "unprognostic (1.17e-1)" "unprognostic (3.11e-2)" "prognostic unfavorable (4.01e-4)" 150.9 206.6 115.5 144.1 135.7 104.3 220.2 176.4 264.7 137.6 209.2 580.5 785.5 92.3 304.6 255.9 143.6 361.3 233.1 176.0 133.9 1127.5 132.5 255.7 89.7 140.8 103.5 137.7 661.3 1482.3 160.6 120.0 196.3 176.4 542.6 301.2 721.9 294.1 147.3 316.6 813.9 146.1 117.4 78.1 201.5 140.0 104.1 92.8 744.4 117.7 132.4 149.7 187.4 142.2 399.8 144.8 147.2 74.5 288.8 277.5 750.8 232.9 462.9 281.6 396.6 583.9 278.5 314.2 321.3 279.0 284.4 505.1 293.8 493.7 406.2 116.1 324.2 183.5 249.2 498.4 220.1 465.2 246.1 311.6 808.0 328.4 429.0 395.5 350.8 187.4 306.9 294.2 253.0 793.7 189.6 167.7 346.0 630.5 285.6 179.7 343.4 278.6 1023.2 405.1 143.8 126.7 363.0 679.6 2979.2 358.2 179.1 265.9 311.9 159.4 221.4 415.4 479.5 140.7 118.1 238.0 488.2 263.1 956.1 19.2 36.6 17.2 59.7 56.6 62.8 26.4 66.9 64.2 59.6 15.2 76.5 55.5 4.5 30.8 86.0 30.4 57.6 53.6 115.5 135.7 176.4 264.7 176.0 133.9 140.8 103.5 196.3 117.4 104.1 142.2 199.2 275.7 295.3 26.8 84.6 276.8 336.8 220.5 390.9 101.0 189.2 145.2 74.1 579.0 238.4 770.6 398.2 83.7 89.1 789.9 373.7 625.6 31.2 205.4 54.3 201.6 176.4 89.2 130.5 315.6 160.6 141.6 134.6 372.1 43.8 212.6 144.2 71.2 129.8 102.6 123.9 353.4 463.9 98.8 254.2 19.3 117.8 145.5 208.1 36.5 56.9 556.8 64.9 77.9 60.9 187.6 307.8 100.8 73.2 271.6 1879.9 308.2 171.6 147.7 32.9 109.8 147.4 20.2 35.8 320.7 268.9 67.6 133.3 58.3 498.6 280.6 ATP2A1 "ATP2A, SERCA1" ENSG00000196296 "ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1" O14983 16 28878405-28904466 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Calcium transport, Ion transport, Transport" Translocase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 85 "skeletal muscle: 8241.7;tongue: 3199.6" "Cell type enriched" "Detected in some" 4 "Skeletal myocytes: 65.2" "Cancer enhanced" "Detected in many" "head and neck cancer: 4.7" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in some" "NK-cell: 1.6" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HEK 293: 30.0" "Region enriched" "Detected in some" 8 "thalamus: 13.1" "Group enriched" "Detected in some" 6 "basal ganglia: 1.3;cerebral cortex: 1.4;hippocampal formation: 1.2" "CAB002310, CAB032706" Enhanced Approved "Endoplasmic reticulum" NA NA 2800000 "Cluster 15: NK-cells - Transcription" "Cluster 33: Striated muscle - Muscle contraction" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 37: Myocytes - Muscle contraction" "Endoplasmic reticulum" "CAB002310: AB_564139, CAB032706: AB_2061286" "unprognostic (2.37e-1)" "unprognostic (6.81e-2)" "unprognostic (2.23e-5)" "unprognostic (5.35e-2)" "unprognostic (2.27e-1)" "unprognostic (2.04e-1)" "unprognostic (1.89e-1)" "unprognostic (1.19e-1)" "unprognostic (5.24e-2)" "unprognostic (1.87e-1)" "unprognostic (5.22e-2)" "unprognostic (4.94e-2)" "unprognostic (2.72e-4)" "unprognostic (1.70e-2)" "unprognostic (1.91e-1)" "unprognostic (1.49e-1)" "unprognostic (2.51e-2)" 1.5 1.1 0.7 1.6 0.8 1.9 1.8 0.9 2.6 1.0 0.1 1.4 1.6 1.5 0.4 27.7 1.4 0.5 1.2 0.6 0.8 1.3 3.1 1.2 2.9 1.1 0.7 1.6 1.0 0.5 3.2 0.7 1.5 9.5 0.4 7.9 67.2 3.5 8241.7 2.4 2.2 0.4 0.7 1.5 1.1 10.7 1.1 1.5 2.2 3199.6 0.4 1.2 1.2 1.4 7.7 8.0 14.4 8.7 0.7 2.3 13.3 3.5 2.0 0.6 0.6 4.5 6.7 11.9 4.1 0.6 4.8 7.9 3.6 0.2 1.0 5.9 30.0 4.2 19.0 14.4 0.3 1.8 3.8 5.9 1.6 0.9 0.7 7.3 0.4 21.8 8.2 9.8 0.4 15.2 17.3 9.5 14.4 2.8 11.2 26.4 10.2 9.1 0.1 0.9 9.2 7.3 5.0 6.8 5.2 5.2 5.1 4.2 3.1 4.5 9.4 8.5 4.5 14.2 9.5 12.0 8.7 23.4 4.4 0.0 0.0 0.2 0.3 0.0 0.4 0.5 0.3 0.3 0.0 0.2 0.4 0.4 0.0 1.6 0.0 1.0 0.5 0.2 0.7 0.8 0.9 2.6 0.6 0.8 1.1 0.7 1.5 0.7 1.1 1.4 0.3 0.0 0.0 0.7 0.2 0.1 0.0 0.3 0.6 2.1 0.5 0.5 0.5 0.0 0.2 0.0 14.6 0.4 0.0 0.6 0.0 0.1 1.3 0.4 0.4 0.3 0.0 0.0 2.3 0.2 0.2 0.5 1.5 0.7 0.0 0.7 0.0 0.6 0.1 0.0 2.3 0.3 0.0 0.6 0.0 3.9 0.3 0.3 0.0 1.0 0.0 0.3 0.0 0.5 2.3 0.2 1.2 0.0 0.1 0.2 0.7 0.1 0.4 4.7 0.0 65.2 0.6 5.7 3.4 0.3 0.1 0.7 0.4 0.7 0.6 0.1 ATP2A2 "ATP2B, DAR, SERCA2" ENSG00000174437 "ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2" P16615 12 110280756-110351093 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" Translocase "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 12 "heart muscle: 1005.8;skeletal muscle: 2856.8;tongue: 2768.8" "Cell type enriched" "Detected in all" 7 "Cardiomyocytes: 2119.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA062605 Enhanced NA NA 2500000 "Cluster 27: Non-specific - Gene expression" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 15: RT4 - Unknown function" "Cluster 54: Cardiomyocytes - Muscle contraction" "HPA062605: AB_2684805" "unprognostic (4.81e-2)" "unprognostic (2.16e-2)" "unprognostic (1.87e-1)" "unprognostic (3.41e-3)" "unprognostic (2.50e-1)" "unprognostic (3.98e-3)" "unprognostic (1.91e-2)" "unprognostic (6.20e-2)" "unprognostic (4.69e-2)" "unprognostic (2.42e-1)" "unprognostic (1.20e-2)" "unprognostic (1.00e-1)" "unprognostic (3.47e-2)" "unprognostic (1.36e-3)" "unprognostic (2.26e-1)" "unprognostic (5.62e-2)" "unprognostic (9.93e-2)" 60.4 49.6 26.2 57.8 34.6 46.0 34.1 36.0 28.0 43.4 23.2 64.2 47.5 46.6 39.0 181.2 67.0 60.5 1005.8 39.0 28.8 34.4 54.7 49.0 36.0 32.5 46.3 42.0 38.1 56.1 24.5 55.4 29.8 93.4 69.0 19.1 92.2 70.0 2856.8 46.5 56.4 74.4 29.8 30.5 47.2 74.1 57.6 36.2 73.3 2768.8 48.1 90.9 57.9 36.1 129.7 305.7 135.4 106.5 95.3 111.7 185.1 154.9 197.2 163.6 102.1 229.1 131.3 155.4 129.2 165.4 115.4 185.0 215.9 264.4 157.3 130.0 127.2 148.0 115.6 121.5 164.7 151.1 130.6 130.3 170.7 202.3 190.1 165.4 134.9 82.6 162.9 74.9 118.6 131.3 76.0 53.2 139.7 126.6 134.8 96.8 130.2 128.6 59.5 279.2 138.2 101.5 207.8 151.1 87.0 113.9 213.7 95.6 159.8 147.8 69.3 93.9 127.4 140.6 189.5 169.0 152.3 70.9 168.8 0.0 0.6 0.0 0.5 1.3 0.2 0.1 0.3 0.2 0.5 0.2 0.3 0.3 0.0 0.3 0.6 0.5 0.3 0.2 26.2 34.6 36.0 28.0 39.0 28.8 32.5 46.3 29.8 29.8 57.6 36.1 48.9 44.8 57.5 85.5 26.3 114.5 95.2 134.5 68.9 63.6 70.2 64.6 2119.9 41.5 103.5 51.5 64.6 33.4 37.4 155.1 1.9 43.7 14.8 291.6 90.8 59.7 137.3 14.1 161.0 71.0 37.6 104.2 49.5 258.1 45.0 47.3 40.7 122.2 64.3 84.1 146.1 109.6 65.1 54.6 64.9 13.4 30.4 65.3 67.6 63.7 33.8 27.5 15.5 119.6 96.4 98.0 89.4 83.1 56.8 117.4 78.0 25.3 176.4 42.9 52.6 88.0 110.2 80.3 47.7 142.3 109.0 30.6 32.7 40.0 97.7 126.4 ATP2B1 PMCA1 ENSG00000070961 "ATPase plasma membrane Ca2+ transporting 1" P20020 12 89588049-89709300 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calmodulin-binding, Translocase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 106.8" "Cell type enhanced" "Detected in all" "Excitatory neurons: 781.6;Langerhans cells: 435.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "hTERT-HME1: 314.6;LHCN-M2: 501.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005605, HPA011166, HPA012945" Enhanced Supported Supported "Plasma membrane" NA NA "Cluster 1: Neutrophils - Mixed function" "Cluster 76: Brain & Bone marrow - Chromatin organization" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 41: Macrophages - Immune response" "Plasma membrane" "CAB005605: AB_2061563, HPA011166: AB_1855484, HPA012945: AB_1855483" "unprognostic (6.78e-2)" "unprognostic (5.27e-2)" "unprognostic (1.57e-2)" "unprognostic (8.23e-2)" "unprognostic (1.72e-1)" "unprognostic (6.44e-2)" "prognostic unfavorable (7.74e-4)" "unprognostic (2.77e-2)" "unprognostic (2.46e-2)" "unprognostic (7.82e-2)" "unprognostic (5.98e-2)" "unprognostic (2.68e-1)" "unprognostic (4.60e-2)" "unprognostic (1.92e-2)" "unprognostic (2.31e-1)" "unprognostic (1.01e-1)" "unprognostic (1.13e-2)" 18.5 11.2 33.0 25.6 92.0 106.8 19.6 14.0 59.1 18.8 0.0 33.1 40.8 18.2 12.1 14.7 18.6 25.2 11.0 52.7 4.9 16.4 22.7 21.3 29.2 0.0 14.4 13.1 17.1 21.5 11.0 27.3 0.0 13.9 32.3 71.2 11.5 14.9 24.4 26.0 30.1 19.7 0.0 30.7 29.0 23.0 10.9 18.4 14.4 24.1 28.8 37.0 10.6 34.9 24.0 117.8 45.5 22.1 64.5 102.2 20.9 71.2 232.6 67.5 106.8 47.7 21.6 46.8 4.9 99.3 77.6 21.0 40.3 19.7 187.5 16.2 46.9 16.6 39.8 41.9 209.6 70.7 26.6 85.0 36.9 210.8 314.6 78.9 17.5 17.6 27.9 16.6 501.1 37.6 22.1 30.1 35.6 32.9 55.6 31.1 146.4 19.7 64.4 108.5 42.9 23.4 82.6 22.9 20.2 91.7 33.9 7.8 12.5 181.8 29.4 67.6 78.9 12.7 21.2 49.1 82.6 19.6 41.0 9.4 39.4 22.3 20.9 42.5 26.4 84.5 36.3 26.8 51.3 84.4 13.2 16.8 127.1 27.0 86.1 9.0 53.7 21.8 33.0 92.0 14.0 59.1 52.7 4.9 0.0 14.4 0.0 0.0 10.9 34.9 46.0 44.8 46.0 90.8 226.4 201.6 71.0 29.3 76.2 370.9 30.9 109.7 20.3 45.8 30.0 53.3 154.3 176.8 139.8 181.5 1.9 27.6 2.3 29.3 61.0 63.6 91.6 31.5 781.6 28.5 42.1 91.6 44.9 59.4 31.6 45.5 49.6 39.5 193.5 302.9 279.1 30.7 16.2 116.0 435.1 9.6 29.2 285.4 55.2 126.5 157.1 96.4 50.4 193.5 91.9 25.5 80.6 32.0 133.9 54.7 75.0 22.1 20.6 113.3 32.9 97.0 69.5 44.5 130.7 30.4 204.7 228.8 125.1 76.0 65.9 90.2 ATP2B2 PMCA2 ENSG00000157087 "ATPase plasma membrane Ca2+ transporting 2" Q01814 3 10324023-10708007 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calmodulin-binding, Translocase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 104.0;choroid plexus: 43.0;salivary gland: 33.2;skeletal muscle: 37.4" "Cell type enhanced" "Detected in some" "Astrocytes: 117.5;Bipolar cells: 87.7;Excitatory neurons: 323.2;Horizontal cells: 104.3;Inhibitory neurons: 230.5;Oligodendrocyte precursor cells: 58.3" "Cancer enhanced" "Detected in some" "liver cancer: 7.7" "Region enhanced" "Detected in many" "cerebral cortex: 104.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "EFO-21: 4.0;RPMI-8226: 11.9;SCLC-21H: 4.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB005606 Enhanced NA NA "Cluster 47: Non-specific - Unknown function" "Cluster 25: RPMI-8226 - Immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "CAB005606: AB_2243199" "unprognostic (2.04e-1)" "unprognostic (1.26e-2)" "unprognostic (6.84e-2)" "unprognostic (1.59e-2)" "unprognostic (3.59e-1)" "unprognostic (3.62e-1)" "unprognostic (4.09e-2)" "unprognostic (4.65e-1)" "unprognostic (5.61e-2)" "unprognostic (1.93e-1)" "unprognostic (2.32e-4)" "unprognostic (2.70e-1)" "unprognostic (1.46e-3)" "unprognostic (1.08e-3)" "unprognostic (1.33e-2)" "unprognostic (8.34e-2)" "unprognostic (7.95e-3)" 0.0 0.6 3.4 0.0 15.8 0.0 0.1 38.6 104.0 2.0 43.0 0.1 0.0 2.2 0.2 0.1 3.7 0.0 0.1 10.4 0.2 0.2 20.3 0.0 0.0 1.6 9.8 0.0 0.2 2.0 3.5 0.0 2.7 0.0 0.0 13.5 33.2 0.0 37.4 0.4 0.1 1.4 0.0 0.1 0.1 0.6 16.1 0.5 0.0 4.9 0.1 0.0 0.1 30.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 11.9 0.0 0.0 4.3 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 15.8 38.6 104.0 10.4 0.2 1.6 9.8 2.7 0.0 16.1 30.3 0.1 0.0 0.0 117.5 0.1 0.5 0.0 0.0 0.0 87.7 3.6 0.3 12.4 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 7.7 0.8 0.7 0.0 0.0 323.2 0.0 0.0 0.5 0.0 14.1 2.5 0.1 0.4 27.1 0.0 104.3 230.5 0.0 0.0 0.8 0.7 7.5 0.0 0.1 3.6 14.0 0.0 16.4 0.0 58.3 8.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 8.2 0.0 2.3 0.5 0.1 0.3 0.0 0.3 0.0 0.2 0.0 0.0 0.0 ATP2B3 "CFAP39, CLA2, PMCA3, SCAX1" ENSG00000067842 "ATPase plasma membrane Ca2+ transporting 3" Q16720 X 153517676-153582939 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins" "Calcium transport, Ion transport, Transport" "Calmodulin-binding, Translocase" "Cancer-related genes, Disease variant, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "choroid plexus: 187.9" "Cell type enhanced" "Detected in some" "Bipolar cells: 8.1;Endometrial ciliated cells: 6.5;Excitatory neurons: 23.7;Extravillous trophoblasts: 10.7;Inhibitory neurons: 30.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "SCLC-21H: 9.9;SH-SY5Y: 2.9;THP-1: 2.5;U-937: 2.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001583 Enhanced Supported NA NA "Cluster 88: Choroid plexus - Transmembrane transport" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 10: Non-specific - Unknown function" "HPA001583: AB_1079641" "unprognostic (1.35e-1)" "unprognostic (3.07e-2)" "unprognostic (3.28e-1)" "unprognostic (6.82e-2)" "unprognostic (1.30e-1)" "unprognostic (4.32e-2)" "unprognostic (2.67e-1)" "unprognostic (6.34e-2)" "unprognostic (2.68e-2)" "unprognostic (8.58e-2)" "unprognostic (1.38e-3)" "unprognostic (3.44e-1)" "unprognostic (2.71e-12)" "unprognostic (1.44e-3)" "unprognostic (2.04e-1)" "unprognostic (2.42e-2)" 0.0 9.7 6.0 0.0 7.5 0.0 0.0 3.4 33.7 0.0 187.9 0.3 0.0 0.0 0.9 0.0 1.2 0.0 0.0 25.7 1.3 0.2 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 1.4 0.5 4.8 0.0 0.0 2.2 0.2 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 2.7 0.0 0.0 0.0 0.0 0.0 0.0 12.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.9 2.9 0.0 0.0 0.0 0.1 0.0 2.5 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.0 7.5 3.4 33.7 25.7 1.3 5.5 0.0 4.8 0.0 2.7 12.2 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 8.1 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 6.5 1.3 0.1 0.0 0.0 23.7 0.0 10.7 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.0 30.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.9 0.0 0.4 0.0 3.5 2.1 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 2.4 0.0 0.6 4.5 0.0 0.1 0.0 0.0 0.7 0.0 0.2 0.0 0.0 ATP2B4 "ATP2B2, MXRA1, PMCA4" ENSG00000058668 "ATPase plasma membrane Ca2+ transporting 4" P23634 1 203626787-203744081 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calmodulin-binding, Translocase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "smooth muscle: 175.3" "Cell type enhanced" "Detected in many" "Adipocytes: 171.6;Oligodendrocyte precursor cells: 199.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "BJ: 200.0;BJ hTERT+: 276.4;fHDF/TERT166: 212.8;SuSa: 222.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB016118, HPA040431" Enhanced Supported "Plasma membrane" NA NA "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 46: Fibroblasts - ECM organization" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "Plasma membrane" "CAB016118: AB_2061729, HPA040431: AB_2676980" "unprognostic (7.43e-2)" "unprognostic (1.58e-1)" "unprognostic (1.60e-2)" "unprognostic (8.17e-2)" "unprognostic (2.53e-2)" "unprognostic (9.23e-3)" "unprognostic (8.68e-2)" "unprognostic (3.81e-2)" "unprognostic (9.74e-2)" "unprognostic (1.70e-1)" "unprognostic (1.64e-2)" "unprognostic (1.12e-1)" "prognostic unfavorable (1.21e-4)" "unprognostic (3.52e-3)" "unprognostic (2.61e-2)" "unprognostic (1.30e-1)" "unprognostic (2.56e-3)" 58.9 25.0 39.7 25.6 36.3 16.0 16.6 0.0 33.5 47.5 0.3 58.2 12.5 104.5 20.1 32.5 48.4 25.2 59.5 40.2 13.3 9.9 9.3 35.1 12.8 8.0 8.0 40.6 9.9 11.8 3.8 40.6 11.2 33.0 30.2 42.5 7.1 69.7 14.4 54.8 14.4 175.3 0.2 12.2 15.4 27.4 44.7 21.7 15.1 27.7 19.4 37.2 15.3 2.6 45.7 7.8 15.6 15.1 120.4 175.1 84.5 200.0 276.4 32.1 27.4 3.8 22.8 9.8 28.8 212.8 43.5 43.5 22.6 27.7 34.3 126.5 8.0 28.7 37.4 2.5 43.1 42.0 51.3 130.5 26.9 102.9 16.2 81.6 63.5 57.1 12.9 20.3 25.1 2.5 44.3 14.5 9.7 8.7 24.2 22.3 11.6 16.7 11.3 4.0 4.6 6.7 68.3 10.5 30.2 222.1 9.3 21.4 54.9 80.5 11.4 136.6 48.3 13.4 20.9 5.4 80.7 31.0 24.5 3.2 2.0 0.0 8.7 1.3 6.4 0.9 5.4 7.2 2.2 0.3 1.3 3.4 4.0 3.8 2.2 3.7 5.7 2.7 39.7 36.3 0.0 33.5 40.2 13.3 8.0 8.0 11.2 0.2 44.7 2.6 171.6 89.8 68.2 127.6 9.9 97.1 18.9 43.1 41.5 4.8 11.2 9.4 76.5 7.2 35.0 18.4 2.1 27.9 56.2 2.2 0.0 35.3 5.8 78.0 92.4 67.6 23.9 35.9 55.9 14.9 18.9 56.0 13.7 89.7 10.1 30.6 58.9 18.2 38.5 117.8 9.8 2.4 14.2 14.7 38.8 4.8 43.8 20.4 26.6 37.5 18.1 136.1 66.9 199.0 40.4 31.4 11.1 38.0 27.6 48.2 7.2 3.3 39.7 7.8 19.7 50.7 81.2 21.7 2.8 54.7 150.9 26.0 59.7 8.0 3.3 62.0 ATP2C1 "ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1" ENSG00000017260 "ATPase secretory pathway Ca2+ transporting 1" P98194 3 130850595-131016712 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" Translocase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Astrocytes: 162.6;Excitatory neurons: 172.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010207, HPA035116, HPA069684" Supported Supported "Golgi apparatus" NA NA "Cluster 46: Basophils - DNA binding" "Cluster 88: Choroid plexus - Transmembrane transport" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Golgi apparatus" "CAB010207: AB_2061744, HPA035116: AB_10673106, HPA069684: AB_2686169" "unprognostic (1.52e-1)" "unprognostic (1.37e-1)" "unprognostic (2.74e-2)" "unprognostic (1.08e-1)" "unprognostic (2.99e-1)" "unprognostic (1.32e-2)" "prognostic unfavorable (5.06e-6)" "unprognostic (7.66e-2)" "unprognostic (6.52e-2)" "unprognostic (2.45e-1)" "prognostic unfavorable (1.52e-4)" "unprognostic (8.44e-2)" "prognostic favorable (1.55e-4)" "unprognostic (2.19e-1)" "unprognostic (1.95e-1)" "unprognostic (3.73e-2)" "unprognostic (3.06e-1)" 32.2 32.7 34.0 25.3 36.6 38.6 32.9 31.8 42.8 33.4 76.9 36.5 23.9 30.9 28.0 23.6 37.2 27.2 31.9 40.7 38.6 44.7 28.5 51.4 21.9 37.0 38.9 28.8 22.6 78.0 22.7 32.7 40.3 85.8 35.9 59.4 29.2 25.2 28.1 31.9 26.9 31.0 33.6 19.5 31.5 25.2 48.8 36.2 35.0 21.1 26.2 31.6 18.1 48.6 133.1 51.1 49.9 48.5 136.7 110.0 53.9 141.2 186.8 69.4 87.0 83.5 106.3 47.6 95.6 134.4 96.4 153.6 95.1 77.9 100.8 104.4 34.2 127.2 51.5 39.0 87.2 51.2 148.4 86.8 76.6 73.2 82.2 126.3 74.6 59.3 37.3 84.1 86.7 59.0 50.6 40.9 57.0 71.7 54.8 36.3 49.9 75.6 127.5 87.7 76.7 45.9 121.4 37.8 72.8 70.8 55.7 41.7 102.6 73.3 40.8 95.5 65.8 54.6 71.1 69.9 75.8 38.0 62.6 30.6 8.9 15.9 7.4 7.6 7.0 5.6 7.3 6.6 9.5 3.6 4.9 4.9 4.3 11.5 9.6 8.2 9.3 6.5 34.0 36.6 31.8 42.8 40.7 38.6 37.0 38.9 40.3 33.6 48.8 48.6 30.2 38.5 53.0 162.6 17.4 39.4 34.5 34.8 26.7 25.9 34.4 22.4 30.2 35.8 41.1 46.0 20.9 16.3 15.5 39.0 5.9 35.3 17.5 26.9 34.1 27.8 35.6 23.3 172.5 38.0 27.6 25.9 33.1 55.8 28.5 28.2 26.7 27.4 27.7 82.4 136.5 32.4 36.7 26.2 34.8 18.9 16.1 39.5 21.4 128.4 20.5 26.4 19.6 148.3 154.3 51.1 27.5 14.7 18.5 69.0 16.3 19.8 52.7 33.4 6.6 27.7 25.9 16.2 14.1 24.7 52.8 17.6 19.5 17.3 31.2 36.9 ATP2C2 "KIAA0703, SPCA2" ENSG00000064270 "ATPase secretory pathway Ca2+ transporting 2" O75185 16 84368527-84464187 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" Translocase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 37.4;skin 1: 26.0" "Cell type enhanced" "Detected in many" "Alveolar cells type 2: 56.2;Club cells: 50.0;Intestinal goblet cells: 82.3;Oligodendrocyte precursor cells: 58.8;Respiratory ciliated cells: 78.2;Undifferentiated cells: 77.1" "Cancer enhanced" "Detected in many" "colorectal cancer: 11.4" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "MCF7: 24.5;OE19: 44.4;RT4: 19.3;SK-BR-3: 33.0;T-47d: 11.1" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "HPA052262, HPA075812" Approved Approved "Plasma membrane,Focal adhesion sites" NA NA "Cluster 1: Neutrophils - Mixed function" "Cluster 37: Intestine - Unknown function" "Cluster 21: OE19 - Mitochondria" "Cluster 53: Intestinal epithelial cells - Unknown function" "Plasma membrane, Focal adhesion sites" "HPA052262: AB_2681776, HPA075812: AB_2686765" "unprognostic (2.28e-2)" "unprognostic (6.13e-2)" "unprognostic (3.34e-2)" "prognostic favorable (6.20e-6)" "unprognostic (2.04e-1)" "unprognostic (2.41e-2)" "unprognostic (8.36e-2)" "unprognostic (1.72e-1)" "unprognostic (9.92e-2)" "unprognostic (1.89e-2)" "unprognostic (5.08e-2)" "unprognostic (2.16e-1)" "unprognostic (8.37e-3)" "unprognostic (1.17e-1)" "unprognostic (1.02e-1)" "unprognostic (4.32e-4)" "unprognostic (1.39e-1)" 0.0 0.0 1.4 2.4 1.4 11.0 2.5 0.5 1.3 6.4 0.5 30.1 27.3 1.0 0.1 4.7 6.8 4.6 0.0 1.3 1.1 1.8 0.1 10.5 0.0 1.0 0.9 0.0 0.7 3.3 1.0 0.9 1.0 12.5 37.4 0.9 19.6 0.2 0.1 26.0 20.3 0.6 0.6 0.4 5.9 0.4 1.1 0.0 8.9 0.0 0.5 4.0 4.6 0.8 6.2 0.4 0.9 0.1 0.0 0.0 6.4 0.2 0.0 0.0 0.0 5.8 5.2 0.0 0.1 0.0 0.0 9.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 2.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 24.5 0.0 0.0 0.0 44.4 0.1 0.0 0.0 0.2 0.0 19.3 4.9 0.0 0.0 33.0 0.2 0.9 11.1 0.0 0.0 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 1.4 1.4 0.5 1.3 1.3 1.1 1.0 0.9 1.0 0.6 1.1 0.8 0.0 32.1 56.2 4.2 0.0 0.6 14.3 39.9 0.6 1.3 20.8 3.2 0.8 5.7 50.0 0.0 0.0 2.0 0.1 44.4 0.0 9.0 3.2 26.8 2.5 0.7 34.2 0.0 8.3 2.5 2.4 0.5 22.4 28.0 8.9 0.0 0.0 0.1 0.3 0.0 1.8 82.3 8.2 0.0 1.2 1.9 0.0 0.6 1.8 1.0 0.0 1.9 0.0 58.8 2.4 4.7 29.2 0.0 0.0 13.8 10.2 1.8 78.2 5.2 0.0 0.1 1.8 0.8 1.0 1.5 1.1 24.1 0.9 0.2 77.1 9.9 ATP4A ATP6A ENSG00000105675 "ATPase H+/K+ transporting subunit alpha" P20648 19 35550031-35563658 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Hydrogen ion transport, Ion transport, Potassium transport, Transport" Translocase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in some" 83 "stomach 1: 841.9" "Group enriched" "Detected in some" 6 "Gastric mucus-secreting cells: 66.3;Late spermatids: 21.0" "Cancer enriched" "Detected in single" 21 "stomach cancer: 5.4" "Region enhanced" "Detected in single" "cerebellum: 1.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA039154, HPA076684" Enhanced NA NA "Cluster 4: Stomach - Digestion" "Cluster 16: Pancreatic endocrine cells - Mixed function" "HPA039154: AB_10672772, HPA076684: " "unprognostic (3.54e-2)" "unprognostic (6.98e-3)" "unprognostic (2.77e-2)" "unprognostic (1.43e-1)" "unprognostic (5.84e-3)" "unprognostic (4.96e-2)" "unprognostic (1.02e-1)" "unprognostic (1.50e-1)" "unprognostic (9.68e-2)" "unprognostic (1.47e-3)" "unprognostic (3.90e-3)" "unprognostic (3.92e-2)" "unprognostic (4.86e-2)" "unprognostic (1.23e-1)" "unprognostic (2.18e-1)" 1.1 2.5 0.0 0.0 0.0 0.0 0.0 1.0 0.3 0.1 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.2 0.2 0.0 0.0 0.0 10.1 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 841.9 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 1.2 0.4 0.0 0.0 66.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 21.0 0.6 1.2 0.0 0.0 0.6 0.1 0.0 0.0 0.1 1.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 2.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 ATP4B ATP6B ENSG00000186009 "ATPase H+/K+ transporting subunit beta" P51164 13 113648804-113658198 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Hydrogen ion transport, Ion transport, Potassium transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 305 "stomach 1: 1096.8" "Cell type enriched" "Detected in some" 76 "Gastric mucus-secreting cells: 145.8" "Cancer enriched" "Detected in some" 12 "stomach cancer: 8.9" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA045400, HPA052649" Enhanced Uncertain "Plasma membrane" NA NA "Cluster 4: Stomach - Digestion" "Cluster 16: Pancreatic endocrine cells - Mixed function" "Plasma membrane" "HPA045400: AB_2679314, HPA052649: AB_2681900" "unprognostic (9.92e-2)" "unprognostic (2.19e-1)" "unprognostic (2.66e-1)" "unprognostic (4.86e-1)" "unprognostic (6.43e-3)" "unprognostic (7.81e-3)" "unprognostic (1.95e-1)" "unprognostic (3.22e-1)" "unprognostic (6.50e-2)" "unprognostic (6.65e-4)" "unprognostic (2.25e-1)" "unprognostic (2.78e-1)" "unprognostic (3.78e-2)" 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 3.5 0.3 0.0 0.0 0.0 0.3 3.3 0.0 0.2 0.2 0.1 0.4 0.1 0.4 0.0 0.5 0.6 0.0 0.1 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 1096.8 0.1 0.2 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.5 0.6 0.2 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.6 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 145.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 ATP6V1B2 "ATP6B2, HO57, VATB, Vma2, VPP3" ENSG00000147416 "ATPase H+ transporting V1 subunit B2" P21281 8 20197381-20226819 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Transporters" "Hydrogen ion transport, Ion transport, Transport" Hydrolase "Deafness, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Proximal tubular cells: 256.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "neutrophil: 1130.7" "Group enriched" "Detected in all" 10 "dendritic cells: 336.8;granulocytes: 1130.7;monocytes: 682.0" "Cell line enhanced" "Detected in all" "SK-MEL-30: 317.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008147 Enhanced Supported Vesicles NA NA 310000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 58: Brain - Synaptic function" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 67: Proximal tubular cells - Tubular reabsorption" Vesicles "HPA008147: AB_1845195" "unprognostic (1.90e-1)" "unprognostic (7.24e-3)" "unprognostic (3.62e-2)" "unprognostic (2.57e-1)" "unprognostic (2.84e-2)" "unprognostic (5.59e-3)" "unprognostic (1.76e-2)" "unprognostic (3.78e-2)" "unprognostic (4.68e-2)" "unprognostic (4.23e-3)" "unprognostic (1.29e-2)" "unprognostic (1.34e-1)" "prognostic favorable (8.41e-4)" "unprognostic (2.41e-1)" "unprognostic (2.09e-2)" "unprognostic (2.47e-2)" "unprognostic (5.25e-2)" 46.4 76.4 112.6 71.9 111.2 45.7 35.3 72.8 126.0 30.1 72.5 38.0 43.9 29.4 31.0 51.3 32.8 39.0 38.2 124.0 135.5 145.8 49.2 72.7 54.1 103.4 120.0 27.5 34.5 71.4 74.5 50.5 138.2 28.1 43.0 205.7 40.4 27.0 66.7 62.5 57.8 40.1 74.8 66.1 32.8 67.8 100.3 50.2 33.4 64.7 48.9 44.5 36.1 99.5 44.2 71.5 87.4 29.2 117.7 72.3 79.1 96.6 61.5 121.5 125.2 81.7 25.4 77.7 38.4 93.1 123.7 36.8 70.1 64.6 129.0 32.9 47.2 54.2 29.9 63.6 137.6 39.0 108.0 65.0 57.9 76.0 69.3 134.1 77.2 101.2 82.0 72.8 132.5 25.0 114.6 46.2 65.6 64.6 31.5 46.6 113.4 40.8 112.9 68.2 68.0 97.9 46.9 62.7 317.9 72.4 81.6 70.7 82.8 61.1 46.3 101.9 78.5 29.4 42.7 90.9 84.6 91.6 158.4 183.7 682.0 485.9 52.9 618.6 57.7 50.2 54.1 56.8 336.8 44.5 54.4 53.7 1130.7 50.8 576.1 82.7 73.0 622.6 112.6 111.2 72.8 126.0 124.0 135.5 103.4 120.0 138.2 74.8 100.3 99.5 16.6 25.6 20.7 20.5 28.1 58.0 28.4 52.1 33.0 106.1 18.5 15.6 17.6 25.8 28.8 29.5 102.2 109.2 38.9 23.3 80.3 43.2 40.8 20.2 13.6 24.1 74.4 35.8 64.3 38.5 56.4 38.8 25.0 35.9 22.2 22.3 25.7 34.7 178.5 190.1 68.0 21.4 36.7 185.2 178.7 24.4 19.6 167.6 104.9 30.0 169.1 51.5 20.6 27.6 29.0 45.2 19.7 28.2 20.7 17.4 75.0 256.7 18.0 137.8 13.1 29.3 34.2 121.6 55.3 43.3 71.6 124.6 27.1 23.1 24.7 20.1 ATP6V1C1 "ATP6C, ATP6D, VATC, Vma5" ENSG00000155097 "ATPase H+ transporting V1 subunit C1" P21283 8 103021063-103073051 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Transporters" "Hydrogen ion transport, Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Early spermatids: 162.7;Late spermatids: 166.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023943, HPA057297" Approved Approved Nucleoplasm,Cytosol NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 39: Non-specific - Mitochondria" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 10: Non-specific - Unknown function" Nucleoplasm Cytosol "HPA023943: AB_1845197, HPA057297: AB_2683402" "unprognostic (5.73e-3)" "unprognostic (3.30e-1)" "unprognostic (1.09e-2)" "unprognostic (1.93e-2)" "unprognostic (1.52e-2)" "unprognostic (3.35e-2)" "prognostic unfavorable (8.82e-4)" "unprognostic (3.29e-2)" "unprognostic (3.87e-1)" "unprognostic (5.62e-2)" "unprognostic (1.19e-1)" "unprognostic (5.59e-2)" "unprognostic (3.98e-2)" "unprognostic (1.23e-1)" "unprognostic (3.85e-1)" "unprognostic (3.88e-1)" "unprognostic (2.83e-1)" 23.8 32.2 31.6 23.8 36.8 9.7 21.6 18.7 38.2 17.8 20.7 15.4 16.1 19.0 14.2 15.6 16.8 19.8 30.1 39.4 28.9 51.7 27.5 18.6 26.2 25.4 24.5 17.7 18.8 39.0 22.2 30.2 31.5 18.3 18.8 36.7 15.3 16.1 17.2 11.9 17.8 20.6 20.2 19.9 17.4 20.9 25.5 21.9 37.8 24.3 24.5 25.2 14.0 26.3 68.4 38.6 20.2 15.6 54.6 39.3 27.7 49.0 49.7 60.6 68.9 30.4 76.7 41.2 58.2 40.8 97.5 29.6 42.4 41.0 87.8 30.3 26.4 39.2 28.0 35.8 59.5 20.8 52.5 28.8 55.4 77.4 36.2 35.6 43.9 28.7 54.6 37.3 71.4 32.1 46.2 16.7 19.1 67.9 37.6 24.6 36.0 36.4 70.3 48.8 28.5 22.6 26.9 26.9 102.0 40.5 58.9 27.8 44.4 33.2 36.1 74.3 35.0 45.1 17.7 42.1 60.2 47.2 33.2 16.8 30.5 38.1 15.1 44.9 17.2 18.7 12.7 15.1 29.0 18.7 14.4 16.0 50.2 18.7 42.7 15.8 23.1 21.1 31.6 36.8 18.7 38.2 39.4 28.9 25.4 24.5 31.5 20.2 25.5 26.3 31.3 32.1 26.4 38.2 22.9 34.9 33.1 31.2 21.1 32.3 21.9 20.6 43.3 15.7 26.5 31.3 16.7 35.4 15.5 14.7 64.6 36.9 162.7 18.3 19.5 25.5 15.6 33.6 64.9 31.5 35.6 28.4 12.2 16.4 24.1 14.0 17.5 19.0 101.8 37.0 56.6 12.4 46.8 47.6 99.6 166.9 24.2 62.8 19.6 36.5 34.3 34.5 14.4 39.2 44.7 30.4 18.2 18.4 25.1 34.7 19.2 139.1 41.2 25.3 19.7 20.7 45.5 11.1 23.4 19.5 32.8 74.8 18.5 17.4 13.5 27.4 AVPR1A AVPR1 ENSG00000166148 "Arginine vasopressin receptor 1A" P37288 12 63142759-63151201 "FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 56.6" "Cell type enhanced" "Detected in some" "Endometrial stromal cells: 24.1;Hepatocytes: 62.7;Sertoli cells: 78.9;Smooth muscle cells: 100.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 12 "ASC diff: 5.6;Karpas-707: 13.1;U-266/84: 9.8" "Group enriched" "Detected in some" 5 "basal ganglia: 7.0;hypothalamus: 3.8" "Low region specificity" "Detected in all" NA NA "Cluster 85: Liver - Metabolism" "Cluster 2: Karpas-707 - Immune response" "Cluster 48: Smooth muscle cells - ECM organization" "unprognostic (1.49e-1)" "unprognostic (2.82e-1)" "unprognostic (9.90e-3)" "unprognostic (2.90e-1)" "unprognostic (1.59e-1)" "unprognostic (1.43e-3)" "unprognostic (3.79e-2)" "unprognostic (2.60e-1)" "unprognostic (3.58e-6)" "unprognostic (1.45e-1)" "unprognostic (7.29e-2)" "unprognostic (1.55e-1)" "unprognostic (1.38e-3)" "unprognostic (4.65e-3)" "unprognostic (1.25e-1)" "unprognostic (4.77e-2)" "unprognostic (4.66e-4)" 17.2 56.6 0.4 1.4 0.2 0.0 9.0 0.0 0.3 9.1 1.4 1.7 0.7 10.9 1.1 3.0 4.8 6.1 2.0 0.3 0.5 4.6 20.9 0.5 1.2 0.5 0.2 1.3 2.3 2.2 0.5 0.3 0.2 2.3 1.2 1.4 1.1 4.2 2.0 1.8 0.9 12.2 0.1 0.8 1.7 0.6 0.8 1.4 10.4 3.5 0.6 2.5 2.6 0.2 0.1 0.2 0.6 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.1 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 9.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.2 0.0 0.3 0.3 0.5 0.5 0.2 0.2 0.1 0.8 0.2 14.1 0.0 0.0 0.0 0.0 1.1 0.2 0.0 0.6 0.3 0.2 0.3 3.4 1.5 0.0 5.5 0.0 0.1 0.0 0.0 0.0 0.0 0.4 3.1 24.1 4.5 0.0 2.7 0.1 0.0 0.5 2.7 0.5 1.6 0.0 0.2 0.7 62.7 0.2 0.0 1.0 0.0 0.0 1.3 0.3 0.0 2.8 1.4 0.0 0.0 0.0 7.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 78.9 2.9 100.9 0.2 0.2 0.0 0.3 0.1 0.6 2.1 0.0 0.3 AVPR1B AVPR3 ENSG00000198049 "Arginine vasopressin receptor 1B" P47901 1 206106936-206117699 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in single" 18 "pituitary gland: 6.8" "Not detected" "Not detected" "Cancer enhanced" "Detected in some" "renal cancer: 1.3" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA075404 Enhanced NA NA "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 44: Endometrium - Transcription" "HPA075404: AB_2732291" "unprognostic (4.87e-2)" "unprognostic (1.44e-1)" "unprognostic (4.82e-1)" "unprognostic (2.82e-1)" "unprognostic (2.87e-1)" "unprognostic (1.08e-2)" "unprognostic (3.33e-1)" "unprognostic (2.96e-2)" "unprognostic (6.23e-2)" "unprognostic (7.65e-2)" "unprognostic (1.86e-1)" "unprognostic (6.66e-3)" 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.3 0.0 6.8 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 AVPR2 "DIR, DIR3, V2R" ENSG00000126895 "Arginine vasopressin receptor 2" P30518 X 153902531-153907166 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Diabetes insipidus, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 8.1" "Group enriched" "Detected in some" 4 "Adipocytes: 48.0;Collecting duct cells: 49.7;Endothelial cells: 17.4" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in single" 7 "cerebellum: 3.9" "Group enriched" "Detected in some" 28 "intermediate monocyte: 3.6;non-classical monocyte: 3.2" "Lineage enriched" "Detected in single" 29 "monocytes: 3.6" "Cell line enhanced" "Detected in some" "EFO-21: 3.2;SCLC-21H: 3.7;U-266/84: 3.7;U-698: 3.6" "Not detected" "Not detected" "Region enriched" "Detected in single" 22 "cerebellum: 6.8" NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 16: U-266 - Nucleosome" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "unprognostic (3.05e-2)" "unprognostic (5.62e-2)" "unprognostic (1.99e-4)" "unprognostic (2.50e-4)" "unprognostic (2.76e-1)" "unprognostic (7.10e-6)" "unprognostic (3.80e-3)" "unprognostic (1.17e-1)" "unprognostic (2.20e-1)" "unprognostic (2.56e-2)" "unprognostic (4.21e-2)" "unprognostic (1.91e-1)" "unprognostic (1.33e-1)" "unprognostic (1.08e-2)" "unprognostic (1.87e-1)" "unprognostic (4.38e-1)" "unprognostic (9.83e-2)" 5.2 0.2 0.1 0.2 0.0 0.8 3.1 3.9 0.1 1.0 0.5 0.8 0.6 0.9 0.1 0.6 1.6 1.0 5.1 0.1 0.0 8.1 0.0 1.3 1.0 0.3 0.5 0.2 0.6 0.7 0.1 0.2 0.4 0.7 0.2 0.0 0.7 0.6 3.1 1.5 0.8 0.8 0.1 0.3 0.7 0.2 0.1 0.4 0.9 4.0 0.3 0.8 1.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 1.6 3.2 0.0 0.5 0.0 0.0 0.0 0.0 1.1 0.1 1.2 0.6 0.0 0.0 1.6 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.5 0.0 0.0 0.8 1.0 0.1 0.0 0.0 1.4 0.6 1.4 0.0 0.0 3.7 0.7 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.1 0.6 3.7 3.6 0.0 0.9 0.0 0.0 0.1 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.1 0.1 0.0 3.9 0.1 0.1 0.0 0.3 0.5 0.4 0.1 0.1 0.2 48.0 3.2 1.3 0.0 0.1 1.0 0.0 0.0 0.0 0.0 0.5 0.4 1.5 0.0 0.0 49.7 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.1 0.0 17.4 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.1 1.3 0.0 0.7 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 8.6 0.8 0.0 0.0 0.1 1.3 0.0 0.1 0.5 0.0 0.1 AXL "ARK, JTK11, Tyro7, UFO" ENSG00000167601 "AXL receptor tyrosine kinase" P30530 19 41219223-41261766 "Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins" "Differentiation, Host-virus interaction, Immunity, Innate immunity" "Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "FDA approved drug targets, Oncogene, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Fibroblasts: 147.2;Kupffer cells: 187.5;Langerhans cells: 185.5;Prostatic glandular cells: 123.4;Sertoli cells: 210.4;Smooth muscle cells: 171.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "NK-cell: 11.1;plasmacytoid DC: 25.7" "Group enriched" "Detected in many" 12 "dendritic cells: 25.7;NK-cells: 11.1" "Cell line enhanced" "Detected in many" "fHDF/TERT166: 501.2;U-251 MG: 540.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB032501, HPA037422, HPA037423, HPA075217" Uncertain Supported "Vesicles,Plasma membrane,Actin filaments" NA Yes 12100000 72000000 "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 57: Non-specific - Angiogenesis" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 48: Smooth muscle cells - ECM organization" "Plasma membrane" "Vesicles, Actin filaments" "CAB032501: AB_2062572, HPA037422: AB_10672347, HPA037423: AB_2675470, HPA075217: " "unprognostic (2.20e-1)" "unprognostic (2.02e-1)" "unprognostic (6.79e-3)" "unprognostic (1.01e-1)" "unprognostic (1.40e-1)" "unprognostic (8.49e-3)" "unprognostic (2.42e-1)" "unprognostic (1.74e-1)" "unprognostic (3.15e-2)" "unprognostic (2.82e-2)" "unprognostic (9.57e-3)" "unprognostic (1.98e-1)" "prognostic unfavorable (2.53e-7)" "unprognostic (1.16e-3)" "unprognostic (1.52e-2)" "unprognostic (5.56e-2)" "unprognostic (4.83e-3)" 43.6 18.8 17.5 15.5 22.6 1.7 26.6 19.7 17.7 36.1 12.4 42.5 11.7 34.4 8.7 17.6 25.4 22.4 26.7 16.6 18.8 9.8 15.0 25.9 6.2 26.8 20.6 24.7 6.3 10.7 7.3 34.2 22.1 19.2 12.6 5.8 10.6 24.6 9.4 20.0 19.0 37.1 20.9 37.7 21.4 18.6 24.0 7.2 16.6 11.3 5.0 32.5 25.2 21.9 408.0 160.0 9.7 1.3 34.6 34.7 0.5 314.5 280.2 450.9 278.2 8.5 185.5 0.2 124.7 501.2 235.3 33.3 0.4 211.8 384.8 0.7 0.3 0.0 100.4 6.3 125.0 0.3 0.3 26.4 3.8 266.7 409.5 254.8 169.8 0.1 15.8 0.5 284.6 0.5 0.2 0.4 4.1 1.0 76.3 0.2 165.3 0.3 202.3 0.2 0.1 0.1 81.5 0.6 1.8 57.4 0.9 7.2 351.8 317.8 214.6 307.7 540.8 0.5 0.9 1.0 211.5 0.5 241.8 1.5 0.3 0.2 0.1 0.4 0.2 0.1 0.3 0.1 6.0 0.1 0.3 0.3 0.3 11.1 0.2 25.7 0.4 0.3 17.5 22.6 19.7 17.7 16.6 18.8 26.8 20.6 22.1 20.9 24.0 21.9 13.5 9.6 3.6 35.9 1.9 41.7 88.3 10.3 3.4 0.5 2.3 14.2 8.6 1.5 4.4 5.5 0.0 4.2 0.8 0.1 0.0 6.9 8.7 6.0 45.8 17.7 0.0 0.0 0.8 0.2 2.1 147.2 1.5 5.4 0.0 17.3 11.0 1.2 28.8 1.7 1.1 0.1 2.0 187.5 185.5 5.5 61.5 61.4 26.6 30.9 3.1 26.8 0.0 11.1 0.5 14.5 0.1 79.7 0.8 123.4 0.3 0.1 2.8 1.2 210.4 38.1 171.1 1.9 2.0 1.2 29.1 11.5 3.6 2.5 0.1 28.0 BCHE "CHE1, CHE2, E1" ENSG00000114200 Butyrylcholinesterase P06276 3 165772904-165837462 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Hydrolase, Serine esterase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 13 "liver: 525.1" "Group enriched" "Detected in many" 9 "Hepatocytes: 420.3;Oligodendrocyte precursor cells: 210.1" "Group enriched" "Detected in many" 6 "glioma: 24.0;liver cancer: 13.7;melanoma: 18.9" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in many" 9 "Karpas-707: 785.6" "Low region specificity" "Detected in all" HPA001560 Approved "Secreted to blood" NA NA 9400000000 "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 2: Karpas-707 - Immune response" "Cluster 2: Hepatocytes - Metabolism" "HPA001560: AB_1078271" "unprognostic (4.74e-2)" "unprognostic (2.00e-1)" "unprognostic (9.21e-4)" "unprognostic (8.19e-8)" "unprognostic (2.66e-2)" "prognostic unfavorable (1.06e-4)" "unprognostic (1.44e-1)" "unprognostic (5.04e-2)" "unprognostic (6.15e-2)" "unprognostic (9.59e-2)" "unprognostic (5.15e-2)" "unprognostic (3.65e-2)" "unprognostic (3.18e-3)" "unprognostic (4.46e-5)" "unprognostic (2.17e-2)" "unprognostic (5.92e-2)" "unprognostic (4.26e-4)" 30.4 11.6 9.3 2.7 7.4 0.0 4.7 7.5 12.0 22.0 5.0 36.1 4.7 41.0 24.3 25.8 36.2 6.0 9.7 7.9 7.3 4.9 525.1 10.9 0.2 7.9 9.4 3.7 2.3 0.1 1.8 0.0 7.8 12.5 16.1 8.8 1.9 32.3 2.7 8.7 10.6 29.7 7.4 5.9 3.5 1.3 12.2 2.9 1.3 5.1 0.1 11.3 5.1 9.4 0.0 2.1 82.1 0.1 0.2 0.0 0.1 0.0 1.5 0.6 7.3 0.0 0.1 0.3 30.7 0.0 0.0 0.5 5.7 0.4 5.8 0.4 0.8 0.0 0.0 0.0 6.3 0.2 0.4 23.5 1.4 0.0 8.1 25.3 3.6 30.0 0.0 785.6 0.0 0.0 0.0 0.1 2.1 0.0 0.8 0.0 28.4 67.3 0.7 0.0 0.0 0.8 0.1 0.0 46.5 0.0 34.0 0.2 0.0 19.3 0.5 0.0 8.3 3.5 0.0 1.6 8.2 0.2 84.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.3 7.4 7.5 12.0 7.9 7.3 7.9 9.4 7.8 7.4 12.2 9.4 5.8 0.0 0.0 1.0 0.7 5.5 0.9 0.0 1.8 1.4 0.0 0.1 9.0 15.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 30.6 0.0 0.7 3.4 0.0 8.0 3.0 0.0 0.0 22.0 0.5 0.0 0.0 0.2 8.9 420.3 0.1 1.7 10.5 0.4 0.0 4.7 1.5 8.7 2.1 0.3 19.6 3.7 0.0 31.7 0.0 210.1 16.1 0.0 0.0 0.0 0.0 0.2 0.0 3.7 0.0 1.2 0.0 0.8 6.5 0.3 0.3 0.6 3.4 0.0 1.1 0.1 0.0 0.1 BCL2 "Bcl-2, PPP1R50" ENSG00000171791 "BCL2 apoptosis regulator" P10415 18 63123346-63320128 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Apoptosis "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Astrocytes: 271.6;Inhibitory neurons: 102.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Group enriched" "Detected in many" 18 "B-cells: 5.4;T-cells: 8.5" "Cell line enhanced" "Detected in many" "HDLM-2: 44.2;HL-60: 43.7;Karpas-707: 72.9;U-266/70: 217.4" "Low region specificity" "Detected in all" "CAB000003, HPA055295" Enhanced Supported "Nucleoplasm,Nuclear membrane" NA NA "Cluster 13: T-cells - Unknown function" "Cluster 52: Non-specific - Ribosome" "Cluster 29: U-266 - Adaptive immune response" "Cluster 64: Astrocytes - Nervous system maintenance" "Nuclear membrane" Nucleoplasm "CAB000003: AB_2064429, HPA055295: AB_2682776" "unprognostic (1.11e-3)" "prognostic favorable (5.13e-5)" "unprognostic (5.49e-2)" "unprognostic (1.19e-1)" "unprognostic (1.89e-1)" "unprognostic (3.05e-3)" "unprognostic (2.88e-1)" "unprognostic (1.93e-3)" "unprognostic (4.78e-2)" "unprognostic (2.08e-1)" "unprognostic (2.23e-2)" "unprognostic (8.51e-2)" "prognostic favorable (1.29e-8)" "unprognostic (6.67e-2)" "unprognostic (1.19e-1)" "prognostic unfavorable (2.47e-4)" "unprognostic (2.63e-1)" 12.8 1.9 5.5 10.2 7.8 5.0 9.6 4.7 3.4 10.7 0.0 6.2 4.4 11.6 2.9 5.9 11.8 6.5 5.3 2.9 6.6 6.7 2.1 3.7 14.7 11.2 7.9 14.5 3.1 13.0 4.7 4.6 7.5 6.4 5.5 2.1 3.7 7.0 16.5 4.8 8.1 6.6 7.9 17.9 3.8 1.5 8.2 18.3 24.0 8.8 14.6 5.4 7.7 5.7 1.7 0.3 6.8 5.9 6.7 1.3 2.4 1.0 0.7 2.4 2.0 3.5 0.4 0.3 1.1 0.9 4.7 0.4 6.7 0.9 1.5 44.2 1.6 0.5 2.0 0.7 2.0 43.7 5.6 1.7 0.8 3.3 5.8 1.1 0.7 4.3 0.8 72.9 2.2 1.4 9.8 10.7 1.5 0.8 1.3 39.5 1.9 26.5 7.4 8.5 7.2 6.4 0.3 0.3 8.5 1.4 0.3 29.9 0.3 9.9 3.3 0.9 5.1 217.4 40.1 2.9 1.9 24.9 6.0 0.3 0.0 0.0 1.9 0.0 7.6 5.4 6.3 3.4 0.1 3.1 3.3 3.2 0.0 0.2 0.3 0.2 8.5 1.3 5.5 7.8 4.7 3.4 2.9 6.6 11.2 7.9 7.5 7.9 8.2 5.7 7.1 0.0 1.1 271.6 84.9 19.5 33.6 1.6 13.6 1.9 39.7 19.7 17.4 18.6 2.4 7.3 0.0 14.0 39.9 2.7 15.6 3.7 0.4 9.8 9.8 5.9 5.4 3.8 60.7 0.0 0.7 15.8 5.6 24.9 15.8 38.8 3.9 1.2 9.4 0.0 102.3 10.5 24.4 15.0 29.6 1.9 8.7 29.0 46.2 88.1 19.7 18.8 18.6 76.4 56.7 0.2 5.9 13.9 50.1 41.6 0.9 18.0 0.1 0.6 26.3 48.8 19.7 0.3 1.3 6.2 17.6 49.1 76.1 24.1 9.8 76.2 BCR "ALL, BCR1, CML, D22S11, D22S662, PHL" ENSG00000186716 "BCR activator of RhoGEF and GTPase" P11274 22 23179704-23318037 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "GTPase activation, Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 65.7" "Cell type enhanced" "Detected in many" "Hepatic stellate cells: 70.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "K-562: 112.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010421, CAB018545, HPA038337" Approved Approved "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 65: Brain - Ion transport" "Cluster 1: K-562 - Erythropoiesis" "Cluster 44: Endometrium - Transcription" "Plasma membrane, Cytosol" Nucleoplasm "CAB010421: AB_2274682, CAB018545: AB_2063918, HPA038337: AB_10675795" "unprognostic (7.46e-3)" "unprognostic (2.43e-2)" "unprognostic (2.15e-3)" "unprognostic (1.16e-1)" "unprognostic (5.35e-2)" "unprognostic (1.45e-1)" "unprognostic (5.08e-2)" "unprognostic (1.44e-1)" "unprognostic (7.55e-2)" "unprognostic (1.81e-1)" "unprognostic (9.46e-2)" "unprognostic (2.39e-2)" "prognostic favorable (9.15e-10)" "unprognostic (1.47e-1)" "unprognostic (7.10e-2)" "unprognostic (4.10e-2)" "unprognostic (7.43e-2)" 19.4 11.1 34.3 11.0 65.7 34.6 17.4 15.9 30.7 14.3 10.6 11.7 10.0 12.3 16.1 24.5 12.1 9.3 12.2 45.0 22.2 21.1 13.8 18.6 13.7 27.1 26.5 9.4 14.6 20.6 25.0 10.3 24.1 11.8 7.6 7.4 18.3 10.1 5.8 23.5 10.2 8.8 20.9 11.4 16.1 11.0 35.0 14.7 19.7 5.7 10.8 15.3 14.3 14.1 47.6 20.1 30.3 31.2 17.7 12.1 45.6 16.8 15.7 15.2 12.2 35.6 18.7 32.9 30.5 14.4 14.7 47.6 3.6 46.8 4.3 63.3 32.3 28.8 27.7 28.6 22.9 26.9 14.6 10.2 31.1 22.8 19.8 27.0 53.6 23.3 112.5 15.1 7.0 31.3 25.4 21.4 25.8 37.4 19.5 32.9 12.4 21.7 23.7 29.6 27.7 26.3 30.7 26.1 12.6 19.3 16.6 21.7 61.4 9.1 1.0 14.9 14.0 3.4 14.8 11.7 23.4 20.1 14.3 0.0 0.5 0.0 3.1 0.2 1.1 0.6 1.5 1.6 0.4 0.6 1.3 1.7 0.5 1.5 0.5 0.4 0.8 1.4 34.3 65.7 15.9 30.7 45.0 22.2 27.1 26.5 24.1 20.9 35.0 14.1 19.3 9.6 11.5 51.2 4.5 15.4 11.9 18.2 6.2 22.9 17.1 9.9 7.5 17.2 20.9 18.4 22.9 14.0 23.9 17.7 9.8 14.4 5.6 22.1 8.0 27.8 19.9 5.5 24.6 16.6 6.8 7.1 11.7 31.4 10.8 9.9 70.6 22.1 7.2 23.5 20.7 13.9 12.2 9.3 11.1 13.5 8.7 9.2 5.4 18.7 6.6 13.2 15.5 32.2 7.0 27.7 8.1 5.7 10.7 11.8 10.7 18.2 12.5 9.4 0.0 4.0 6.8 2.7 7.3 9.3 15.8 10.8 10.3 10.0 13.7 13.3 BDKRB2 BK-2 ENSG00000168398 "Bradykinin receptor B2" P30411 14 96204679-96244166 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "urinary bladder: 41.1" "Cell type enhanced" "Detected in many" "Distal enterocytes: 19.3;Endothelial cells: 18.2;Fibroblasts: 25.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC TERT1: 49.2;BJ hTERT+: 94.5;U-87 MG: 39.7" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA003551, HPA050841" Approved Supported "Golgi apparatus,Vesicles,Plasma membrane" NA NA "Cluster 12: Smooth muscle tissue - Mixed function" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 50: Fibroblasts - ECM organization" "Plasma membrane" "Golgi apparatus, Vesicles" "HPA003551: , HPA050841: AB_2681254" "unprognostic (1.03e-1)" "unprognostic (7.90e-2)" "unprognostic (1.12e-1)" "unprognostic (1.83e-1)" "unprognostic (8.79e-3)" "unprognostic (2.68e-2)" "unprognostic (1.93e-1)" "unprognostic (4.66e-2)" "unprognostic (1.94e-1)" "unprognostic (2.84e-2)" "unprognostic (3.19e-1)" "unprognostic (1.72e-1)" "unprognostic (3.32e-3)" "unprognostic (3.11e-2)" "unprognostic (9.40e-2)" "unprognostic (9.90e-2)" "unprognostic (1.49e-2)" 14.0 1.4 0.8 5.5 1.0 0.0 5.8 3.8 1.1 15.6 0.9 12.4 7.9 6.7 2.4 17.2 7.2 20.8 1.2 0.9 0.8 13.4 0.7 2.5 0.3 4.9 1.3 1.0 9.4 0.9 0.8 1.3 5.0 4.8 12.2 0.0 3.5 6.2 0.9 5.4 9.7 10.2 1.0 0.1 4.9 0.2 1.5 0.9 3.6 1.8 1.7 41.1 15.4 1.2 1.7 6.1 0.1 11.0 16.2 49.2 0.0 5.5 94.5 3.2 3.7 0.3 10.4 0.0 0.2 8.7 3.7 14.8 0.0 2.4 2.8 1.2 0.1 0.0 1.1 0.0 7.8 0.0 0.0 15.1 7.5 9.4 4.7 0.0 0.0 0.0 0.0 0.0 0.0 7.9 0.0 0.1 0.1 20.4 0.0 0.0 2.2 0.0 3.2 0.0 3.4 1.1 1.8 15.6 0.1 2.1 1.0 0.0 0.0 0.3 0.3 3.3 0.1 0.2 0.0 0.0 39.7 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.8 1.0 3.8 1.1 0.9 0.8 4.9 1.3 5.0 1.0 1.5 1.2 8.2 3.2 3.1 0.0 0.0 9.2 0.7 5.3 6.8 0.0 0.2 0.5 0.6 10.0 11.6 9.2 0.0 1.2 0.0 19.3 7.9 11.5 0.0 7.5 16.1 18.2 7.1 0.0 1.8 3.8 3.6 25.8 1.1 4.6 0.0 0.0 3.3 0.2 0.2 0.0 0.4 7.2 8.2 0.0 15.2 0.0 0.9 0.4 5.4 0.0 0.0 0.0 0.0 1.0 1.9 6.9 6.2 1.2 0.0 1.0 10.6 0.2 12.5 0.0 0.0 4.5 1.2 0.0 0.0 15.3 5.8 4.0 0.3 0.1 0.9 2.9 BGLAP OCN ENSG00000242252 "Bone gamma-carboxyglutamate protein" P02818 1 156242184-156243317 "FDA approved drug targets, Predicted secreted proteins" Biomineralization "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "brain: 19.9;choroid plexus: 10.8;intestine: 8.5" "Cell type enhanced" "Detected in some" "Ionocytes: 4.1;Melanocytes: 3.6;Plasma cells: 2.8;Sertoli cells: 6.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 17 "NK-cell: 1.8;plasmacytoid DC: 1.6" "Group enriched" "Detected in many" 17 "dendritic cells: 1.6;NK-cells: 1.8" "Cell line enhanced" "Detected in some" "hTERT-RPE1: 8.3;U-87 MG: 5.4" "Region enriched" "Detected in single" 9 "olfactory bulb: 7.8" "Low region specificity" "Detected in many" "Secreted to blood" NA NA 15500000 2200000 "Cluster 40: NK-cells - Unknown function" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 48: Smooth muscle cells - ECM organization" "unprognostic (2.50e-2)" "unprognostic (4.49e-2)" "unprognostic (3.82e-4)" "unprognostic (1.13e-1)" "unprognostic (1.57e-1)" "unprognostic (8.44e-5)" "unprognostic (2.63e-2)" "unprognostic (6.54e-2)" "unprognostic (5.64e-2)" "unprognostic (2.00e-1)" "unprognostic (1.53e-3)" "unprognostic (4.70e-2)" "unprognostic (9.67e-6)" "unprognostic (3.02e-2)" "unprognostic (1.72e-1)" "unprognostic (4.34e-2)" "unprognostic (8.64e-3)" 0.7 0.5 12.7 0.6 13.9 0.9 0.6 13.3 19.9 1.7 10.8 8.5 0.6 1.4 1.1 0.7 1.4 0.6 0.8 12.3 12.7 1.1 1.6 0.6 0.4 14.6 13.4 1.9 0.8 0.2 1.1 0.4 13.5 2.0 1.8 0.2 1.7 0.7 0.5 1.7 2.3 1.8 14.0 1.9 0.8 0.4 13.4 0.3 1.4 0.0 0.2 0.8 1.0 14.7 0.1 1.5 0.7 0.4 0.0 1.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 0.0 0.0 0.0 0.4 0.2 0.0 0.0 0.0 0.5 0.5 0.0 0.8 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.3 0.0 0.5 0.1 0.2 0.4 0.0 0.0 0.7 0.6 0.1 0.3 0.7 0.1 0.4 1.8 0.0 0.2 0.6 0.0 0.4 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.4 0.4 0.7 1.1 1.4 5.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 1.6 0.0 0.0 12.7 13.9 13.3 19.9 12.3 12.7 14.6 13.4 13.5 14.0 13.4 14.7 0.6 0.0 0.0 0.0 0.6 1.5 1.0 1.0 0.6 0.2 1.1 0.9 0.0 0.0 1.0 0.0 0.0 0.5 0.2 0.1 0.0 0.1 0.1 0.3 0.4 0.6 0.0 0.0 0.0 0.2 0.3 1.0 0.5 0.5 0.0 1.1 1.1 0.2 0.2 0.0 0.0 0.9 4.1 0.0 0.8 0.2 1.5 0.5 3.6 0.0 0.4 0.4 1.0 0.0 0.0 0.0 1.1 0.4 2.8 0.7 0.3 2.0 0.3 0.6 6.6 0.5 0.3 0.4 0.8 0.6 1.3 0.4 0.6 0.8 0.8 0.7 BLVRB "FLR, SDR43U1" ENSG00000090013 "Biliverdin reductase B" P30043 19 40447765-40465764 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 625.2" "Cell type enhanced" "Detected in all" "Erythroid cells: 3131.8;Hofbauer cells: 1099.2;Proximal enterocytes: 864.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "classical monocyte: 465.2" "Group enriched" "Detected in all" 7 "dendritic cells: 343.3;monocytes: 465.2" "Cell line enhanced" "Detected in many" "A549: 506.6;K-562: 506.8;OE19: 451.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041698, HPA041937" Enhanced Supported "Nucleoplasm,Vesicles,Plasma membrane,Cytosol" No No 370000000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 55: Non-specific - Mitochondria & Proteasome" "Cluster 1: K-562 - Erythropoiesis" "Cluster 6: Erythroid cells - Oxygen transport" Cytosol "Nucleoplasm, Vesicles, Plasma membrane" "HPA041698: AB_10796781, HPA041937: AB_10794308" "unprognostic (1.86e-1)" "unprognostic (1.14e-2)" "unprognostic (4.23e-1)" "unprognostic (1.50e-1)" "unprognostic (2.08e-1)" "unprognostic (2.46e-1)" "unprognostic (9.92e-2)" "unprognostic (1.20e-2)" "unprognostic (8.56e-2)" "unprognostic (1.35e-1)" "prognostic unfavorable (3.90e-4)" "unprognostic (2.30e-1)" "unprognostic (2.70e-1)" "unprognostic (2.02e-1)" "unprognostic (5.11e-2)" "unprognostic (1.25e-1)" "unprognostic (3.92e-2)" 115.7 76.8 46.6 48.2 46.9 625.2 93.8 49.4 61.0 86.2 52.1 78.5 75.1 59.0 20.5 188.8 69.3 50.9 125.6 44.5 48.0 103.1 266.2 102.8 58.9 56.0 48.6 66.7 73.2 46.1 25.2 52.1 58.5 74.3 30.3 5.5 89.4 42.2 210.4 83.9 72.2 31.7 49.8 166.7 138.4 10.2 52.3 27.5 64.5 94.1 25.3 81.0 96.5 53.4 227.9 506.6 7.3 77.7 73.7 70.2 57.3 28.0 88.7 39.3 75.4 103.4 203.8 74.3 212.3 56.3 126.8 73.1 30.4 64.6 10.5 123.8 20.0 114.9 73.4 62.4 169.8 1.6 32.2 69.2 119.4 52.4 34.2 40.1 41.8 27.4 506.8 137.0 51.0 359.2 6.1 7.2 1.9 451.4 133.8 54.0 23.4 120.3 50.9 146.5 0.4 10.5 84.5 224.5 84.4 13.2 221.5 17.6 39.2 99.4 103.9 156.4 15.9 71.7 92.1 28.5 259.1 46.2 39.0 45.5 465.2 18.0 29.2 220.9 27.0 58.2 24.3 24.5 343.3 37.5 24.7 19.3 58.4 27.4 117.7 75.8 37.3 259.4 46.6 46.9 49.4 61.0 44.5 48.0 56.0 48.6 58.5 49.8 52.3 53.4 74.6 221.2 164.5 9.4 34.4 129.4 348.5 337.9 103.6 11.2 93.8 143.0 130.5 164.5 184.2 97.5 6.2 84.9 39.5 343.6 266.1 234.2 10.0 56.5 46.3 51.1 44.9 3131.8 5.2 267.3 94.7 112.5 280.3 83.1 43.1 31.0 57.1 680.8 1099.2 10.1 5.1 223.5 158.7 627.7 165.4 23.6 124.2 286.7 144.1 13.1 219.8 88.0 32.0 2.0 5.6 260.4 464.0 94.0 25.7 229.7 864.3 488.3 139.1 13.5 32.9 65.4 146.0 2.6 4.0 160.3 130.4 74.7 34.5 34.7 191.0 260.5 BRAF BRAF1 ENSG00000157764 "B-Raf proto-oncogene, serine/threonine kinase" P15056 7 140719327-140924929 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease variant, Ectodermal dysplasia, FDA approved drug targets, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Excitatory neurons: 252.3;Inhibitory neurons: 242.4;Oligodendrocyte precursor cells: 206.1;Oligodendrocytes: 202.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001328, CAB004552, HPA071048" Approved Approved Vesicles,Cytosol No No "Cluster 15: NK-cells - Transcription" "Cluster 34: Non-specific - Transcription" "Cluster 29: U-266 - Adaptive immune response" "Cluster 52: Non-specific - Transcription" Vesicles Cytosol "CAB004552: AB_626760, HPA001328: AB_1078296, HPA071048: AB_2686336" "unprognostic (2.98e-3)" "unprognostic (5.66e-2)" "unprognostic (2.20e-2)" "unprognostic (2.66e-3)" "unprognostic (2.44e-1)" "unprognostic (1.48e-2)" "unprognostic (2.07e-2)" "unprognostic (4.23e-2)" "unprognostic (4.07e-2)" "unprognostic (1.58e-2)" "unprognostic (6.53e-2)" "unprognostic (1.91e-2)" "unprognostic (3.79e-3)" "unprognostic (2.08e-1)" "unprognostic (1.76e-1)" "unprognostic (8.01e-2)" "unprognostic (5.46e-2)" 8.8 5.8 6.3 5.6 7.7 15.9 8.8 12.5 8.7 8.2 5.4 8.6 4.7 8.3 8.3 7.5 8.0 5.8 7.6 8.3 6.7 7.6 6.6 9.9 6.9 4.0 3.6 9.8 8.3 11.5 9.0 7.2 4.6 8.2 5.4 17.0 7.2 5.9 8.6 10.4 6.9 6.0 3.1 6.7 7.8 13.7 5.2 8.7 10.2 8.4 6.4 9.9 8.5 6.7 6.3 5.2 7.7 9.4 9.1 11.8 12.3 6.8 7.5 5.4 7.6 5.7 6.7 10.8 5.0 7.3 8.4 3.4 6.8 5.5 10.0 9.8 5.4 7.1 5.1 5.2 7.6 11.7 6.8 7.9 6.1 6.0 12.0 8.2 6.6 7.7 11.3 19.1 9.8 3.3 15.6 12.0 6.9 6.2 3.1 10.1 6.5 8.9 5.3 11.9 8.9 7.3 7.9 4.9 7.3 7.5 4.5 7.8 9.7 5.9 4.3 12.9 5.5 21.6 12.9 16.7 9.7 11.3 6.6 1.9 1.0 4.1 1.5 0.9 1.0 1.3 1.5 1.2 0.8 1.1 2.6 1.3 2.0 3.5 1.3 1.0 1.5 0.6 6.3 7.7 12.5 8.7 8.3 6.7 4.0 3.6 4.6 3.1 5.2 6.7 43.4 22.4 45.7 151.1 58.4 21.5 24.6 6.0 23.3 29.7 31.2 21.2 19.8 10.0 18.7 25.8 35.5 15.7 73.5 8.8 7.9 14.3 68.6 50.6 37.4 23.4 19.2 14.9 252.3 9.8 12.9 22.0 21.9 69.2 24.7 45.5 9.3 9.6 9.4 25.2 242.4 9.8 8.2 13.6 37.1 36.5 16.4 30.1 16.0 126.5 14.6 11.3 15.5 206.1 202.6 15.4 8.1 10.1 48.7 23.8 8.0 13.4 20.0 33.0 6.6 24.1 24.7 43.8 26.0 14.5 24.0 75.5 41.4 30.9 8.7 33.4 BST1 CD157 ENSG00000109743 "Bone marrow stromal cell antigen 1" Q10588 4 15703065-15738313 "CD markers, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Hydrolase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "bone marrow: 139.8;intestine: 48.6" "Cell type enhanced" "Detected in many" "Hofbauer cells: 40.8;Macrophages: 33.3;monocytes: 80.1;Proximal enterocytes: 79.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in many" "classical monocyte: 257.7;neutrophil: 292.7" "Group enriched" "Detected in many" 95 "dendritic cells: 78.9;granulocytes: 292.7;monocytes: 257.7" "Cell line enhanced" "Detected in many" "THP-1: 76.0;TIME: 40.4;U-937: 52.5;WM-115: 44.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA050121 Uncertain "Intracellular and membrane" NA NA 190000000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 43: THP-1 - Innate immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" "HPA050121: AB_2681025" "unprognostic (2.95e-1)" "unprognostic (3.61e-1)" "unprognostic (1.27e-1)" "unprognostic (4.00e-2)" "unprognostic (7.49e-2)" "unprognostic (2.89e-1)" "unprognostic (4.55e-2)" "unprognostic (2.70e-1)" "unprognostic (1.75e-1)" "unprognostic (1.84e-1)" "unprognostic (1.08e-1)" "unprognostic (4.06e-2)" "unprognostic (4.83e-3)" "unprognostic (1.94e-3)" "unprognostic (3.11e-1)" "unprognostic (1.57e-2)" "unprognostic (1.95e-1)" 21.2 2.7 1.9 13.7 2.1 139.8 9.4 2.1 4.7 11.0 1.6 8.3 48.6 6.3 2.9 4.6 7.9 18.2 19.1 2.1 2.0 17.0 8.5 12.7 7.1 1.9 1.4 9.3 3.1 1.7 1.3 13.7 2.2 3.7 9.7 1.0 3.9 4.6 2.7 5.0 29.3 9.7 0.8 18.6 3.2 2.7 3.0 3.9 4.9 6.8 3.5 16.8 7.4 3.3 0.6 10.5 1.2 1.0 28.8 7.0 1.6 21.0 2.1 20.4 22.2 0.3 12.1 0.8 1.9 12.2 0.6 0.3 3.3 0.5 17.2 0.8 0.7 5.6 0.8 0.6 6.7 7.2 15.1 5.7 1.5 12.9 1.0 0.9 3.0 5.0 0.7 0.5 12.5 0.3 2.3 4.3 2.7 0.9 2.2 0.8 1.8 0.5 0.5 0.6 1.4 4.3 0.4 0.7 14.2 1.2 0.5 76.0 40.4 0.6 1.0 7.9 1.1 0.6 0.2 0.7 2.7 52.5 44.8 41.8 257.7 20.8 1.1 97.4 1.7 2.2 0.9 0.8 78.9 0.9 1.1 0.7 292.7 0.4 73.9 26.6 1.0 109.8 1.9 2.1 2.1 4.7 2.1 2.0 1.9 1.4 2.2 0.8 3.0 3.3 5.4 3.2 3.7 1.3 0.3 4.6 0.8 0.1 1.8 0.6 1.2 2.0 1.5 2.8 1.0 1.8 0.0 16.0 5.5 3.7 1.9 4.4 4.4 8.0 9.9 3.8 1.2 2.5 0.7 2.5 24.0 22.5 0.0 16.2 15.9 20.6 6.4 2.1 40.8 0.0 0.7 8.1 0.0 26.3 11.5 1.2 3.1 33.3 14.2 3.7 80.1 0.6 3.1 0.5 3.6 1.1 11.9 2.2 0.4 0.6 79.0 9.6 3.0 0.2 6.6 3.9 15.5 2.5 1.4 1.7 3.0 7.1 1.8 1.4 23.2 3.3 BTK "AGMX1, ATK, IMD1, PSCTK1, XLA" ENSG00000010671 "Bruton tyrosine kinase" Q06187 X 101349447-101390796 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Apoptosis, Immunity, Innate immunity, Transcription, Transcription regulation" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 32.6;lymphoid tissue: 78.0" "Cell type enhanced" "Detected in some" "B-cells: 84.7;granulocytes: 211.4;Hofbauer cells: 56.6;Kupffer cells: 63.5;Macrophages: 61.1;monocytes: 71.1;Plasma cells: 43.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 4 "basophil: 557.5" "Lineage enriched" "Detected in many" 4 "granulocytes: 557.5" "Cell line enhanced" "Detected in some" "Daudi: 206.7;HEL: 287.4;HMC-1: 990.3;U-937: 149.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001198, HPA002028, CAB016689" Enhanced Supported "Plasma membrane,Cytosol" NA NA 2300000 "Cluster 38: Basophils - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 3: HMC-1 - Innate immune response" "Cluster 57: B-cells - Immune response" "Plasma membrane, Cytosol" "CAB016689: AB_1611894, HPA001198: AB_1078305, HPA002028: AB_1078306" "unprognostic (3.19e-2)" "unprognostic (2.51e-3)" "unprognostic (1.06e-2)" "unprognostic (3.66e-2)" "unprognostic (5.69e-2)" "unprognostic (3.76e-3)" "unprognostic (6.55e-2)" "unprognostic (3.58e-3)" "unprognostic (6.02e-2)" "unprognostic (3.12e-1)" "unprognostic (1.02e-1)" "unprognostic (1.41e-1)" "unprognostic (2.08e-3)" "unprognostic (7.80e-2)" "unprognostic (1.29e-2)" "unprognostic (1.56e-2)" "unprognostic (8.14e-2)" 6.3 2.9 2.3 30.7 2.6 32.6 4.4 2.8 3.4 3.9 3.1 6.6 4.8 2.5 1.5 3.6 1.9 7.6 1.6 2.3 3.1 1.3 5.4 19.6 55.5 4.7 3.6 0.8 1.2 0.9 0.9 7.0 4.7 1.9 9.1 0.3 2.8 2.3 0.6 2.9 14.7 7.1 3.8 38.4 7.0 1.4 3.9 9.3 1.3 2.0 78.0 9.3 1.5 6.5 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.0 206.7 0.0 0.0 0.1 0.5 0.0 0.0 0.1 0.0 0.3 287.4 0.0 0.0 0.0 116.7 990.3 0.0 0.0 0.1 0.0 0.0 0.0 0.2 61.9 2.3 0.0 0.0 0.6 81.5 1.6 0.0 0.0 87.2 0.1 13.2 0.0 0.0 0.2 0.0 0.3 0.1 0.5 1.0 0.0 68.5 0.4 0.0 0.3 0.2 0.1 2.6 1.4 98.3 0.5 149.8 0.3 557.5 62.2 110.5 0.2 99.9 0.2 72.4 0.2 0.1 72.7 73.0 0.4 0.1 24.7 0.2 123.9 33.1 0.1 38.4 2.3 2.6 2.8 3.4 2.3 3.1 4.7 3.6 4.7 3.8 3.9 6.5 1.5 3.2 8.9 0.3 84.7 1.0 0.2 0.0 0.6 0.0 0.9 1.4 0.6 0.0 0.6 0.0 0.0 1.4 30.1 0.1 0.0 0.0 0.2 1.3 0.3 0.8 0.0 27.1 0.5 0.0 0.5 0.9 1.1 2.3 211.4 0.0 0.7 0.3 56.6 0.0 0.3 0.3 0.0 63.5 31.0 0.1 0.3 61.1 3.6 10.3 71.1 0.0 2.1 0.0 0.1 0.1 0.5 0.0 43.8 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.5 0.7 1.7 0.5 0.3 1.9 5.7 0.2 0.1 0.1 CA1 Car1 ENSG00000133742 "Carbonic anhydrase 1" P00915 8 85327608-85379014 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 55 "bone marrow: 1798.9;intestine: 2109.9" "Cell type enriched" "Detected in some" 4 "Erythroid cells: 11487.3" "Group enriched" "Detected in some" 10 "colorectal cancer: 3.4;stomach cancer: 0.9" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 987 "HEL: 1022.7" "Not detected" "Not detected" "Not detected" "Not detected" "HPA006558, CAB025790" Enhanced NA NA 4600000000 "Cluster 43: B-cells - Humoral immune response" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 36: HEL - Hemostasis" "Cluster 6: Erythroid cells - Oxygen transport" "CAB025790: , HPA006558: AB_1845989" "unprognostic (1.44e-1)" "unprognostic (7.56e-2)" "unprognostic (1.70e-1)" "unprognostic (3.57e-3)" "unprognostic (2.08e-2)" "unprognostic (1.66e-1)" "unprognostic (2.84e-2)" "unprognostic (2.03e-2)" "unprognostic (1.73e-2)" "unprognostic (6.12e-2)" "unprognostic (1.63e-1)" "unprognostic (1.04e-1)" "unprognostic (5.61e-2)" "unprognostic (3.01e-2)" "unprognostic (2.38e-1)" "unprognostic (3.95e-2)" 2.0 0.4 0.4 0.5 0.3 1798.9 2.1 1.0 1.5 0.3 0.0 1023.3 0.2 1.6 0.1 0.7 2.2 0.3 1.6 0.2 0.2 2.0 6.7 5.9 0.2 0.3 0.3 0.4 0.3 0.1 1.9 20.7 0.3 0.4 2109.9 0.4 1.1 1.8 1.0 1.4 1.8 30.7 0.1 35.4 2.3 0.2 0.5 0.5 0.9 3.4 0.1 0.4 0.5 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1022.7 0.0 0.5 0.0 0.2 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 2.8 0.4 0.3 1.0 1.5 0.2 0.2 0.3 0.3 0.3 0.1 0.5 0.6 0.0 0.0 0.0 4.2 11.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 2.8 0.0 0.0 0.0 0.0 0.0 2565.3 0.0 0.0 0.5 0.1 0.0 0.5 45.8 11487.3 11.8 0.0 0.0 0.1 0.0 0.1 22.3 0.0 4.2 4.4 0.0 0.0 12.1 159.4 0.0 11.4 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 1.0 13.0 2.2 0.0 754.9 0.0 0.1 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 3.4 0.1 298.4 0.0 CA12 HsT18816 ENSG00000074410 "Carbonic anhydrase 12" O43570 15 63321378-63381846 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins" Lyase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 290.2;skin 1: 142.1" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 174.6;Distal enterocytes: 422.6;Paneth cells: 160.8;Squamous epithelial cells: 185.3;Suprabasal keratinocytes: 252.2;Undifferentiated cells: 138.8" "Cancer enhanced" "Detected in all" "renal cancer: 109.3" "Region enhanced" "Detected in many" "basal ganglia: 42.9" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "A549: 213.0;ASC TERT1: 213.0;RT4: 226.2;SK-BR-3: 177.9;T-47d: 286.8;U-138 MG: 300.5;U-87 MG: 361.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008773, CAB025181, CAB062549, CAB068179, HPA073203" Enhanced NA NA 52000 "Cluster 7: Kidney - Transmembrane transport" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 53: Intestinal epithelial cells - Unknown function" "CAB025181: , CAB062549: AB_2665617, CAB068179: AB_2665616, HPA008773: AB_1078394, HPA073203: AB_2686580" "unprognostic (2.01e-1)" "unprognostic (8.38e-3)" "unprognostic (3.47e-1)" "unprognostic (3.25e-3)" "unprognostic (2.73e-2)" "unprognostic (2.47e-2)" "unprognostic (7.48e-2)" "unprognostic (3.43e-3)" "unprognostic (2.29e-1)" "unprognostic (4.67e-2)" "prognostic unfavorable (3.80e-6)" "unprognostic (2.59e-1)" "unprognostic (1.51e-1)" "unprognostic (2.38e-1)" "unprognostic (6.56e-2)" "unprognostic (7.26e-2)" "unprognostic (1.21e-1)" 8.3 0.2 6.1 18.7 42.9 0.1 42.8 5.2 7.2 50.7 129.0 104.1 0.4 28.4 4.1 75.4 25.0 7.7 3.2 6.8 6.6 290.2 0.7 3.0 0.3 0.9 9.6 0.6 70.2 0.3 10.7 2.3 3.2 5.5 94.2 1.9 26.3 8.7 0.6 142.1 8.2 56.2 0.9 0.8 7.9 0.6 16.1 0.1 4.6 0.1 8.7 27.4 49.0 1.5 0.0 213.0 3.5 0.5 27.3 213.0 11.2 15.7 13.7 2.5 4.1 1.6 0.5 0.0 51.4 12.6 81.7 1.1 0.0 10.4 6.2 0.3 7.7 0.0 13.9 0.4 0.6 0.0 0.3 81.3 11.4 63.6 20.4 0.1 2.7 0.1 0.0 0.3 2.8 125.2 0.3 0.2 3.4 0.0 33.4 0.1 0.0 0.1 0.2 226.2 1.8 0.2 0.9 177.9 0.0 2.1 286.8 0.1 0.4 300.5 16.0 10.1 0.2 0.0 0.0 0.1 361.6 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 42.9 5.2 7.2 6.8 6.6 0.9 9.6 3.2 0.9 16.1 1.5 0.7 0.0 6.9 11.4 1.1 174.6 20.0 87.7 93.4 0.1 93.5 50.4 1.3 1.5 30.3 40.5 0.0 0.4 1.6 422.6 54.8 17.2 12.1 28.4 6.2 2.1 8.4 0.0 1.3 58.4 2.0 14.6 8.2 75.0 1.3 0.3 0.0 0.2 0.6 0.0 0.8 111.4 20.3 0.3 11.9 3.9 0.0 4.0 23.2 0.0 0.0 2.7 0.0 1.0 0.1 10.2 160.8 0.0 0.0 19.8 15.6 73.9 6.9 0.2 0.0 0.2 4.1 0.0 0.0 185.3 252.2 1.8 2.8 0.1 138.8 17.4 CA13 "CAXIII, FLJ37995, MGC59868" ENSG00000185015 "Carbonic anhydrase 13" Q8N1Q1 8 85220587-85284073 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 14.6" "Cell type enhanced" "Detected in many" "Cone photoreceptor cells: 33.3;Proximal enterocytes: 52.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "HEL: 15.6;OE19: 30.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA024689, CAB025567" Enhanced Approved Nucleoplasm,Nucleoli,Vesicles NA NA 27000 "Cluster 46: Basophils - DNA binding" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 21: OE19 - Mitochondria" "Cluster 45: Enterocytes - Digestion" Nucleoli "Nucleoplasm, Vesicles" "CAB025567: , HPA024689: AB_1846004" "unprognostic (1.12e-2)" "unprognostic (2.20e-1)" "unprognostic (1.75e-1)" "unprognostic (9.16e-5)" "unprognostic (2.21e-2)" "unprognostic (2.08e-1)" "unprognostic (9.39e-2)" "unprognostic (7.90e-3)" "unprognostic (1.97e-1)" "unprognostic (1.34e-2)" "unprognostic (3.58e-2)" "unprognostic (3.13e-1)" "prognostic favorable (9.40e-4)" "unprognostic (7.59e-2)" "unprognostic (1.59e-1)" "unprognostic (1.55e-2)" "unprognostic (3.00e-1)" 1.8 2.1 1.2 1.2 1.2 0.3 2.3 1.4 1.3 2.1 0.7 2.5 12.0 0.9 0.6 5.0 1.1 5.4 3.6 1.0 1.7 5.7 3.7 2.4 0.6 0.9 1.5 1.1 1.1 9.0 2.9 0.3 0.8 1.2 3.0 2.3 4.8 0.7 0.4 5.6 14.6 0.8 0.6 0.7 5.9 0.7 1.1 0.7 5.0 0.3 2.9 2.1 2.5 1.3 0.2 0.4 0.8 0.1 0.5 0.6 0.4 1.0 1.1 0.1 2.9 7.2 5.4 0.4 0.5 1.2 6.0 2.3 2.2 2.9 0.2 1.6 0.9 15.6 2.0 6.7 1.4 0.2 0.6 2.2 0.5 0.2 1.2 1.8 1.6 0.6 4.0 2.9 2.6 0.0 0.3 0.2 0.4 30.6 0.4 0.2 2.2 0.1 8.1 0.3 0.2 0.0 0.5 0.0 1.6 1.0 0.5 0.8 1.5 2.8 3.9 0.1 1.6 1.1 0.6 1.9 5.7 2.2 2.6 0.7 0.6 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.1 0.1 0.0 0.2 0.2 0.0 0.2 1.2 1.2 1.4 1.3 1.0 1.7 0.9 1.5 0.8 0.6 1.1 1.3 1.7 3.2 12.4 7.2 2.9 1.8 2.7 2.7 3.4 1.8 7.0 4.7 6.4 4.3 10.5 12.9 33.3 0.3 2.1 12.3 9.8 4.0 11.3 4.7 2.5 2.7 4.8 3.2 12.2 1.6 0.3 2.9 9.7 7.7 0.0 0.3 8.6 5.8 1.1 0.0 13.7 4.3 2.0 2.5 3.3 13.1 0.0 3.0 5.4 1.9 1.0 1.9 8.2 16.1 4.4 4.4 4.3 0.0 6.9 1.9 52.6 21.0 9.5 5.1 0.0 8.1 1.9 1.3 2.1 9.1 3.1 0.3 2.2 1.0 5.4 2.4 CA14 ENSG00000118298 "Carbonic anhydrase 14" Q9ULX7 1 150257251-150265078 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "choroid plexus: 33.3;retina: 39.4;skeletal muscle: 33.7;tongue: 47.4" "Cell type enhanced" "Detected in some" "Cardiomyocytes: 69.5;Melanocytes: 53.4;Muller glia cells: 164.5;Oligodendrocytes: 25.7" "Cancer enriched" "Detected in many" 5 "melanoma: 23.2" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "AF22: 102.2;AN3-CA: 65.9;NTERA-2: 83.9;SK-MEL-30: 217.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008482 Approved Approved "Plasma membrane" NA NA "Cluster 49: Eosinophils - Unknown function" "Cluster 54: Non-specific - Microtubule organization" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 5: Muller glia cells - Visual perception" "Plasma membrane" "HPA008482: AB_1078395" "unprognostic (3.06e-2)" "unprognostic (1.67e-1)" "unprognostic (2.10e-2)" "unprognostic (3.25e-2)" "prognostic favorable (8.47e-4)" "unprognostic (7.28e-2)" "unprognostic (4.48e-2)" "unprognostic (1.49e-1)" "unprognostic (2.10e-1)" "unprognostic (2.47e-1)" "unprognostic (5.46e-2)" "unprognostic (1.73e-1)" "unprognostic (5.89e-3)" "unprognostic (1.91e-1)" "unprognostic (1.49e-1)" "unprognostic (1.22e-1)" "unprognostic (5.80e-2)" 0.0 0.2 8.6 0.2 14.4 1.2 0.3 15.9 27.6 0.1 33.3 3.8 0.4 0.1 0.4 1.9 1.7 0.6 7.6 8.7 11.3 0.3 8.7 0.2 0.1 14.3 14.0 1.4 0.2 3.4 0.5 0.3 14.6 4.0 0.7 39.4 0.4 20.3 33.7 5.4 1.3 0.5 12.5 0.2 1.2 0.5 13.3 0.0 1.0 47.4 0.0 0.6 0.1 20.6 0.9 0.2 102.2 65.9 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.6 0.7 0.1 0.5 0.0 0.1 0.3 0.2 0.1 0.0 0.2 1.1 0.3 0.3 6.9 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.8 0.1 0.6 0.0 0.9 0.3 0.3 83.9 0.4 1.1 0.1 0.3 0.3 0.0 0.2 3.2 1.8 0.0 0.3 217.9 14.6 0.8 0.4 0.1 0.1 0.2 0.2 0.4 0.9 4.9 0.4 0.7 0.5 0.2 0.0 0.2 0.4 0.4 0.5 0.1 0.5 0.2 0.3 0.0 0.6 0.3 0.3 0.5 0.0 0.1 0.6 0.0 0.0 8.6 14.4 15.9 27.6 8.7 11.3 14.3 14.0 14.6 12.5 13.3 20.6 0.1 3.2 0.5 0.3 0.2 2.2 0.3 0.3 0.0 1.3 0.1 0.0 69.5 0.0 0.7 0.0 0.0 0.4 0.0 0.3 0.0 0.8 0.0 0.3 0.1 0.6 0.0 0.0 0.1 0.7 0.1 3.4 0.0 0.2 0.0 0.0 0.0 6.1 0.1 0.0 0.1 0.3 0.0 0.3 0.9 0.2 0.9 0.1 53.4 0.0 0.0 164.5 0.0 0.0 25.7 1.9 0.3 3.4 0.0 0.3 0.0 0.1 0.1 4.9 0.0 0.6 0.5 0.0 0.2 0.0 0.4 0.3 0.1 0.0 0.2 0.5 CA2 "CA-II, CAII, Car2" ENSG00000104267 "Carbonic anhydrase 2" P00918 8 85463968-85481493 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Lyase "Disease variant, FDA approved drug targets, Osteopetrosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 687.4;stomach 1: 1108.7" "Cell type enhanced" "Detected in many" "Distal enterocytes: 1773.2;Erythroid cells: 2448.1;Gastric mucus-secreting cells: 1380.7;Muller glia cells: 1536.4;Paneth cells: 781.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "basophil: 51.2" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HaCaT: 263.8;HEK 293: 1097.8;THP-1: 461.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001550, CAB010102" Enhanced NA Yes 570000000 "Cluster 38: Basophils - Unknown function" "Cluster 9: Intestine - Unknown function" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 6: Erythroid cells - Oxygen transport" "CAB010102: AB_626796, HPA001550: AB_1078393" "unprognostic (6.78e-2)" "unprognostic (3.06e-2)" "unprognostic (1.05e-2)" "unprognostic (1.63e-1)" "unprognostic (2.59e-1)" "unprognostic (9.24e-2)" "unprognostic (1.74e-1)" "unprognostic (1.72e-2)" "unprognostic (1.07e-1)" "unprognostic (5.23e-2)" "unprognostic (1.57e-1)" "unprognostic (9.89e-2)" "prognostic favorable (5.57e-6)" "unprognostic (2.45e-1)" "unprognostic (2.03e-1)" "unprognostic (1.32e-1)" "unprognostic (6.49e-3)" 7.4 10.1 95.9 36.8 127.5 246.8 37.9 122.1 143.8 5.0 444.0 687.4 285.2 2.9 10.6 19.8 2.7 112.7 15.9 105.2 107.8 331.2 273.5 43.1 6.6 115.5 112.0 0.4 55.1 10.1 6.1 19.6 114.2 1.9 643.6 390.4 74.7 68.4 42.7 81.0 31.3 32.3 98.2 8.4 1108.7 21.2 115.6 5.1 15.9 62.8 4.3 2.9 5.2 145.5 3.7 2.8 12.2 0.0 0.1 0.0 31.2 0.0 0.0 0.0 0.0 15.1 0.9 0.0 9.5 0.0 0.1 263.8 37.4 13.2 0.0 0.0 1097.8 35.8 17.0 0.5 0.0 23.7 5.1 0.0 63.9 0.0 3.7 0.0 0.0 0.0 0.3 0.2 0.0 0.4 0.4 41.4 3.7 86.5 0.0 21.2 1.3 0.5 3.7 8.8 0.2 0.3 5.0 0.0 0.1 9.6 0.0 461.5 0.0 0.0 6.6 0.0 0.4 0.4 1.0 0.1 1.8 0.1 0.0 51.2 5.3 8.6 0.2 15.0 7.4 1.3 0.1 0.8 15.4 3.0 0.0 0.0 12.6 0.1 13.4 1.4 0.0 33.3 95.9 127.5 122.1 143.8 105.2 107.8 115.5 112.0 114.2 98.2 115.6 145.5 19.4 16.0 79.9 34.0 19.6 90.6 1.3 152.5 17.6 23.1 56.9 18.4 19.8 430.4 22.4 161.8 64.6 15.2 2.4 1773.2 348.3 60.1 65.9 3.3 1.3 26.7 30.5 2448.1 1.4 11.3 403.1 6.4 1380.7 8.3 15.9 0.4 4.2 135.6 35.4 13.5 22.3 116.0 10.2 11.0 216.5 232.1 3.4 51.8 74.7 6.5 6.6 1536.4 1.0 3.0 226.4 16.1 781.9 2.2 10.3 3.5 0.3 468.2 3.9 66.1 0.0 12.1 8.2 3.1 2.8 31.2 111.7 17.1 11.7 0.7 390.8 0.5 CA3 "CAIII, Car3" ENSG00000164879 "Carbonic anhydrase 3" P07451 8 85373436-85449040 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "skeletal muscle: 5273.7" "Group enriched" "Detected in many" 8 "Erythroid cells: 221.3;Skeletal myocytes: 304.0" "Group enriched" "Detected in many" 7 "glioma: 23.1;prostate cancer: 9.4" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "HEL: 47.3;RH-30: 78.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB004967, HPA021775, HPA026700" Enhanced NA NA 53000000 "Cluster 33: Striated muscle - Muscle contraction" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 37: Myocytes - Muscle contraction" "CAB004967: AB_437014, HPA021775: AB_1845990, HPA026700: AB_1845991" "prognostic favorable (4.24e-6)" "unprognostic (1.40e-1)" "unprognostic (1.50e-2)" "unprognostic (2.22e-3)" "unprognostic (4.71e-2)" "unprognostic (8.43e-3)" "unprognostic (3.56e-2)" "unprognostic (4.04e-2)" "unprognostic (1.11e-1)" "unprognostic (3.68e-1)" "unprognostic (4.71e-2)" "unprognostic (3.54e-1)" "unprognostic (3.19e-2)" "unprognostic (1.18e-1)" "unprognostic (9.96e-2)" "unprognostic (1.39e-1)" "unprognostic (2.19e-1)" 43.4 3.8 2.4 0.3 2.3 9.9 6.4 2.7 3.7 5.1 1.4 1.7 1.8 8.3 2.1 64.8 9.8 2.2 19.5 2.3 2.8 3.7 2.4 24.6 0.4 2.9 2.3 1.4 1.3 1.0 3.8 0.3 2.0 89.5 1.1 5.5 15.4 2.7 5273.7 5.2 4.4 19.1 2.5 0.8 4.1 2.9 2.5 1.4 3.0 1018.8 0.6 1.5 5.5 2.8 2.0 0.0 1.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.8 1.1 0.0 0.1 0.0 0.1 0.2 0.3 0.3 0.0 0.5 0.2 47.3 0.0 1.2 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 7.6 0.0 0.0 78.0 0.0 1.5 0.0 0.1 0.0 0.0 0.0 0.0 1.4 0.0 2.1 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 2.4 2.3 2.7 3.7 2.3 2.8 2.9 2.3 2.0 2.5 2.5 2.8 0.3 3.2 4.2 2.3 0.1 0.5 1.7 0.6 1.2 0.0 14.5 0.6 1.0 5.7 0.6 0.0 6.2 1.1 0.4 0.4 0.0 0.6 24.1 0.4 0.2 2.2 0.0 221.3 2.2 0.2 0.2 9.1 0.0 0.7 0.0 0.2 2.5 0.3 0.4 0.0 2.5 0.4 0.0 0.3 0.4 7.0 0.3 2.5 0.0 0.0 0.0 29.6 0.0 1.5 0.7 0.2 1.7 0.0 0.0 0.5 8.5 0.6 1.0 1.6 0.0 304.0 5.1 0.6 1.3 0.2 1.0 1.6 1.4 0.3 0.9 0.3 CA4 "CAIV, Car4, RP17" ENSG00000167434 "Carbonic anhydrase 4" P22748 17 60149942-60170899 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" Lyase "Disease variant, FDA approved drug targets, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 263.6" "Group enriched" "Detected in many" 16 "Adipocytes: 704.2;Distal enterocytes: 1289.3;Paneth cells: 2368.3" "Cancer enhanced" "Detected in many" "colorectal cancer: 7.3" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in some" 7 "neutrophil: 99.5" "Lineage enriched" "Detected in single" 995 "granulocytes: 99.5" "Cell line enhanced" "Detected in single" "OE19: 1.1" "Region enriched" "Detected in all" 5 "cerebellum: 300.3" "Low region specificity" "Detected in all" "HPA011089, HPA017258" Enhanced Uncertain Vesicles,Cytosol NA NA 190000 "Cluster 9: Neutrophils - Innate immune response" "Cluster 37: Intestine - Unknown function" "Cluster 5: NTERA-2 - Transcription" "Cluster 53: Intestinal epithelial cells - Unknown function" Cytosol Vesicles "HPA011089: AB_1845996, HPA017258: AB_1845997" "unprognostic (2.07e-2)" "unprognostic (7.85e-2)" "unprognostic (1.55e-2)" "unprognostic (7.78e-3)" "unprognostic (8.42e-2)" "unprognostic (1.19e-1)" "unprognostic (3.19e-2)" "unprognostic (5.84e-2)" "unprognostic (7.76e-2)" "unprognostic (9.74e-2)" "unprognostic (1.54e-1)" "unprognostic (1.71e-2)" "unprognostic (2.68e-3)" "unprognostic (8.59e-2)" "unprognostic (1.43e-1)" "unprognostic (2.45e-1)" "unprognostic (4.57e-2)" 83.0 2.3 17.8 3.1 18.8 19.5 80.9 86.8 34.2 12.7 13.9 263.6 3.8 6.0 51.9 1.0 5.0 38.3 55.2 22.8 13.9 47.6 0.7 87.2 0.6 13.4 17.8 6.2 31.8 16.9 15.7 8.6 22.8 8.2 172.6 0.1 10.4 36.9 30.5 3.8 11.2 2.7 12.7 16.0 10.0 1.3 15.1 1.6 74.6 42.3 0.1 6.2 5.6 14.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.1 0.0 0.0 0.0 0.3 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 99.5 0.0 0.0 0.0 0.0 0.1 17.8 18.8 86.8 34.2 22.8 13.9 13.4 17.8 22.8 12.7 15.1 14.9 704.2 0.0 2.4 1.3 1.5 1.5 0.3 0.0 2.2 0.0 2.3 2.5 9.1 0.0 0.6 14.7 0.0 0.0 1.2 1289.3 33.2 11.7 0.5 0.6 13.0 88.3 19.3 0.0 3.8 0.2 0.0 4.4 0.0 0.2 11.4 23.2 1.4 0.0 0.6 0.0 1.4 24.6 0.0 0.0 1.2 0.1 0.6 1.1 0.0 23.4 0.0 0.1 0.0 1.0 0.4 0.1 2368.3 0.0 1.2 0.1 14.9 72.4 0.7 0.0 6.6 5.0 23.4 0.1 0.0 0.1 1.1 0.0 2.4 0.4 41.7 0.3 CA5A "CA5, CAV, CAVA" ENSG00000174990 "Carbonic anhydrase 5A" P35218 16 87881546-87936580 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" Lyase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 30 "liver: 24.2" "Cell type enriched" "Detected in many" 6 "Hepatocytes: 39.0" "Cancer enriched" "Detected in single" 26 "liver cancer: 2.0" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 36 "Hep G2: 25.5" "Not detected" "Not detected" "Low region specificity" "Detected in all" NA NA "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 15: Hepatocytes - Hemostasis" "unprognostic (1.91e-1)" "unprognostic (8.64e-3)" "unprognostic (3.36e-2)" "unprognostic (6.11e-2)" "unprognostic (2.49e-2)" "unprognostic (2.96e-1)" "unprognostic (8.39e-3)" "unprognostic (3.50e-3)" "unprognostic (1.42e-2)" "unprognostic (1.12e-1)" "unprognostic (6.55e-2)" "unprognostic (4.23e-2)" "unprognostic (7.99e-3)" "unprognostic (1.77e-1)" "unprognostic (5.03e-3)" "unprognostic (3.37e-2)" "unprognostic (2.76e-2)" 0.0 0.0 0.5 0.1 0.5 0.1 0.1 0.6 0.8 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.0 24.2 0.1 0.1 0.6 0.5 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 25.5 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.6 0.8 0.5 0.5 0.6 0.5 0.6 0.5 0.5 0.5 0.2 0.0 3.4 0.3 0.3 0.4 2.5 0.0 0.0 1.7 0.2 0.3 2.1 0.0 1.3 1.8 4.2 0.4 0.5 0.1 0.0 0.0 0.3 0.6 0.4 5.4 0.0 2.7 0.8 0.0 0.3 1.0 0.0 0.8 6.3 0.2 1.1 39.0 0.1 3.3 0.6 0.2 0.0 1.4 1.6 0.8 0.3 1.5 0.0 2.8 0.2 0.8 2.1 0.0 0.5 0.0 0.0 1.2 0.1 1.9 0.2 0.3 1.5 3.8 0.0 4.1 1.1 0.4 0.4 0.0 0.3 0.3 1.2 1.7 0.1 1.8 CA5B ENSG00000169239 "Carbonic anhydrase 5B" Q9Y2D0 X 15688830-15788411 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "dendritic cells: 37.9;Muller glia cells: 35.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC TERT1: 22.3;fHDF/TERT166: 27.0;hTERT-HME1: 34.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA012618 Uncertain Supported Mitochondria NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 42: Ciliated cells - Cilium & Cell projection" "Cluster 30: Epithelial cell lines - Translation" "Cluster 24: Non-specific - Transcription regulation" Mitochondria "HPA012618: AB_1846000" "unprognostic (1.62e-2)" "unprognostic (2.10e-3)" "unprognostic (2.86e-1)" "unprognostic (1.55e-3)" "unprognostic (1.16e-2)" "unprognostic (4.59e-5)" "unprognostic (2.50e-1)" "unprognostic (6.89e-4)" "unprognostic (4.11e-1)" "unprognostic (3.89e-3)" "unprognostic (1.54e-1)" "unprognostic (1.17e-1)" "prognostic favorable (6.66e-6)" "unprognostic (2.43e-1)" "unprognostic (1.38e-1)" "unprognostic (8.94e-2)" "unprognostic (3.08e-1)" 5.9 3.1 5.3 4.2 5.8 3.5 8.3 3.9 5.4 21.5 5.8 2.8 1.6 7.3 2.6 6.5 7.5 7.3 4.0 3.9 7.3 4.8 2.1 6.0 5.6 8.4 6.5 11.9 3.4 9.1 2.4 3.1 6.9 4.8 3.6 10.5 4.5 4.6 1.6 5.7 2.6 7.6 6.3 4.3 4.4 10.3 6.1 4.3 7.2 5.4 6.8 5.2 5.5 4.6 4.3 2.6 2.9 4.8 8.5 22.3 1.7 4.4 5.6 3.2 4.6 1.3 2.8 1.2 4.5 27.0 6.1 4.6 10.3 5.0 5.7 1.2 4.8 2.3 3.3 1.1 8.3 3.0 5.0 5.3 5.3 4.3 34.2 5.7 4.8 3.5 1.2 3.0 15.4 2.3 2.5 2.3 1.2 0.8 18.6 1.4 2.1 2.2 4.9 3.1 2.6 5.3 6.1 2.2 3.8 3.4 3.1 3.0 6.5 3.8 2.5 20.4 2.5 2.2 2.4 1.4 4.2 6.0 7.2 4.4 3.9 0.4 16.7 4.8 14.5 4.6 16.6 15.5 4.7 5.0 12.1 10.4 2.2 11.0 3.1 0.7 14.3 10.0 5.3 5.8 3.9 5.4 3.9 7.3 8.4 6.5 6.9 6.3 6.1 4.6 9.6 0.0 7.9 14.0 19.1 4.2 6.3 3.4 6.2 9.5 7.3 5.2 2.4 0.0 7.1 1.8 16.7 1.8 37.9 1.6 1.9 4.4 1.1 9.6 7.1 13.9 3.0 11.2 11.5 4.0 1.8 10.5 11.7 6.2 2.5 6.7 6.1 2.7 1.9 1.7 11.8 2.2 8.2 9.3 11.1 1.8 7.8 10.8 3.6 19.7 9.1 35.9 32.0 8.5 10.6 4.1 1.6 5.3 18.7 11.5 1.2 2.9 12.2 7.8 6.6 8.1 8.3 4.2 5.6 5.5 4.5 1.9 30.0 12.1 1.5 7.9 CA6 ENSG00000131686 "Carbonic anhydrase 6" P23280 1 8945867-8975092 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted secreted proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 295 "salivary gland: 9393.1" "Group enriched" "Detected in some" 44 "Breast glandular cells: 77.9;Ionocytes: 99.7;Melanocytes: 179.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in single" "Group enriched" "Detected in some" 4 "naive CD4 T-cell: 5.6;naive CD8 T-cell: 16.4" "Lineage enriched" "Detected in many" 11 "T-cells: 16.4" "Cell line enhanced" "Detected in some" "Daudi: 1.7;U-2197: 1.3" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA028550, HPA028692" Enhanced "Secreted to digestive system" NA NA 24000000 "Cluster 32: T-cells - Unknown function" "Cluster 24: Salivary gland - Salivary secretion" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 30: Mammary glandular cells - Lactation" "HPA028550: AB_10600105, HPA028692: AB_10601883" "unprognostic (2.54e-5)" "unprognostic (1.09e-1)" "unprognostic (1.10e-1)" "unprognostic (2.37e-1)" "unprognostic (2.90e-1)" "unprognostic (9.28e-2)" "unprognostic (2.70e-3)" "unprognostic (1.24e-1)" "unprognostic (1.73e-1)" "unprognostic (5.93e-2)" "unprognostic (4.41e-2)" "unprognostic (4.29e-5)" "unprognostic (1.14e-1)" "unprognostic (1.31e-1)" "unprognostic (2.35e-1)" 0.4 0.4 0.3 0.7 0.6 2.0 20.8 0.9 0.7 0.0 0.5 0.1 0.3 0.2 2.3 0.2 0.1 0.2 1.5 0.4 0.3 0.1 0.1 0.3 1.3 0.9 0.4 1.9 6.3 0.0 0.1 0.9 0.7 0.2 0.2 0.7 9393.1 0.0 0.4 31.8 0.5 0.0 0.1 1.2 0.4 0.3 0.7 1.2 0.3 0.0 1.0 0.1 0.0 1.8 0.2 0.0 0.2 0.4 0.1 0.0 0.3 0.1 0.0 0.0 0.2 0.3 0.4 1.7 0.1 0.1 0.4 0.3 0.1 0.0 0.2 0.2 0.2 0.2 0.6 0.2 0.0 0.5 0.5 0.0 0.1 0.2 0.0 0.2 0.2 0.3 0.2 0.4 0.0 0.2 0.2 0.4 0.3 0.2 0.1 0.3 0.1 0.0 0.0 0.3 0.2 0.1 0.0 0.2 0.1 0.1 0.4 0.2 0.1 0.6 0.3 1.3 0.2 0.4 0.1 0.4 0.1 0.4 0.4 1.4 0.3 0.2 0.3 0.2 0.3 0.3 0.7 2.7 0.0 0.5 5.6 16.4 1.3 0.4 0.2 0.3 0.3 1.6 0.3 0.6 0.9 0.7 0.4 0.3 0.9 0.4 0.7 0.1 0.7 1.8 0.2 0.0 0.0 0.0 0.1 0.1 0.1 1.4 0.0 0.0 77.9 2.7 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 99.7 0.0 1.3 0.2 0.0 0.2 179.7 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.1 0.0 0.1 0.0 0.6 0.5 0.0 0.0 CA7 ENSG00000168748 "Carbonic anhydrase 7" P43166 16 66844414-66854153 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "intestine: 57.0" "Cell type enriched" "Detected in some" 40 "Paneth cells: 3026.3" "Cancer enhanced" "Detected in some" "colorectal cancer: 0.9" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "REH: 1.1;THP-1: 1.9" "Region enhanced" "Detected in all" "cerebellum: 67.2" "Low region specificity" "Detected in many" HPA047237 Uncertain NA NA "Cluster 37: Intestine - Unknown function" "Cluster 43: THP-1 - Innate immune response" "Cluster 53: Intestinal epithelial cells - Unknown function" "HPA047237: AB_2679994" "unprognostic (8.77e-4)" "unprognostic (5.23e-4)" "unprognostic (1.57e-1)" "unprognostic (1.96e-2)" "unprognostic (2.19e-1)" "unprognostic (2.16e-2)" "unprognostic (7.90e-2)" "unprognostic (1.59e-1)" "unprognostic (1.84e-2)" "unprognostic (9.62e-2)" "unprognostic (1.69e-2)" "unprognostic (7.12e-3)" "unprognostic (8.47e-2)" "unprognostic (5.20e-1)" "unprognostic (1.90e-2)" "unprognostic (6.46e-2)" 0.0 0.0 5.1 0.2 6.7 0.0 0.1 4.8 10.7 0.0 2.1 57.0 6.9 0.1 0.9 0.1 0.0 0.0 0.0 8.0 3.1 0.0 0.0 0.0 0.0 3.8 3.5 0.0 0.0 0.0 0.1 0.0 3.5 0.0 48.6 0.0 0.0 0.2 0.0 0.0 10.0 1.1 2.6 0.0 0.0 0.5 4.7 0.1 0.0 0.2 0.0 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.3 1.1 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 6.7 4.8 10.7 8.0 3.1 3.8 3.5 3.5 2.6 4.7 5.6 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 74.2 0.0 0.0 0.0 0.0 0.0 0.0 16.3 0.0 9.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 4.1 16.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 3026.3 0.0 0.0 0.5 23.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.3 0.0 39.9 0.1 CA9 "CAIX, MN" ENSG00000107159 "Carbonic anhydrase 9" Q16790 9 35673918-35681159 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "stomach 1: 289.3" "Cell type enhanced" "Detected in some" "Basal respiratory cells: 275.3;Cholangiocytes: 62.9;Early spermatids: 205.8;Gastric mucus-secreting cells: 259.5" "Cancer enhanced" "Detected in many" "renal cancer: 85.9" "Region enriched" "Detected in single" 9 "cerebellum: 5.6" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 10 "A-431: 189.3;HDLM-2: 98.1;hTERT-RPE1: 113.1;U-87 MG: 374.4" "Region enhanced" "Detected in many" "cerebellum: 12.3" "Low region specificity" "Detected in all" "CAB005100, CAB017107, HPA055207" Enhanced Supported "Plasma membrane" "Intracellular and membrane" NA NA "Cluster 4: Stomach - Digestion" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 26: Respiratory epithelial cells - Mucosal defense" "Plasma membrane" "CAB005100: AB_2066539, CAB017107: , HPA055207: AB_2682738" "unprognostic (8.01e-3)" "unprognostic (1.34e-2)" "unprognostic (2.28e-1)" "unprognostic (2.00e-2)" "unprognostic (1.59e-2)" "unprognostic (1.15e-1)" "prognostic unfavorable (1.71e-5)" "unprognostic (1.47e-2)" "unprognostic (3.90e-2)" "unprognostic (1.29e-1)" "unprognostic (6.24e-3)" "unprognostic (1.13e-1)" "prognostic unfavorable (2.22e-7)" "unprognostic (7.29e-2)" "prognostic favorable (9.50e-4)" "unprognostic (2.97e-3)" "unprognostic (8.67e-2)" 3.8 0.4 0.0 0.2 0.0 0.0 0.1 5.6 0.6 0.5 0.0 0.6 14.5 0.2 0.1 0.8 0.4 24.4 2.0 0.2 0.1 0.2 1.3 0.2 0.0 0.0 0.1 0.7 6.6 0.0 0.5 0.0 0.2 0.5 0.0 1.0 0.1 0.1 0.1 8.2 13.6 0.1 0.0 0.0 289.3 5.5 0.5 0.0 0.0 0.0 0.0 0.7 0.7 0.0 189.3 0.3 0.0 0.0 0.0 0.0 0.0 0.2 3.6 0.3 2.5 0.0 0.1 0.0 0.1 0.0 0.5 5.7 0.0 0.9 1.5 98.1 0.0 0.0 0.7 0.4 0.0 0.0 0.2 0.4 0.0 0.0 0.3 113.1 0.1 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.3 0.2 0.5 0.0 0.0 10.6 0.0 0.6 1.6 0.0 0.0 0.1 0.7 0.0 0.0 0.2 0.0 18.9 0.4 0.0 4.7 0.0 0.4 0.1 374.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 5.6 0.6 0.2 0.1 0.0 0.1 0.2 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.2 4.5 0.7 275.3 0.0 0.4 0.1 0.0 0.4 62.9 28.1 0.0 0.0 0.0 0.0 0.1 0.0 49.1 205.8 0.0 0.1 0.2 0.0 0.0 0.1 50.9 0.6 1.2 259.5 0.2 0.0 0.4 0.7 0.0 0.1 0.0 0.6 4.0 18.3 0.0 0.0 19.6 1.5 0.1 0.0 0.0 0.6 1.3 0.0 0.0 0.0 26.6 0.0 0.7 0.3 0.8 0.7 0.1 5.5 0.0 0.0 0.0 1.5 0.9 4.0 0.0 3.1 0.3 0.1 0.7 5.3 0.4 CACNA1A "APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6" ENSG00000141837 "Calcium voltage-gated channel subunit alpha1 A" O00555 19 13206442-13633025 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "brain: 99.3" "Group enriched" "Detected in many" 8 "Bipolar cells: 101.4;Enteroendocrine cells: 214.1;Excitatory neurons: 318.3;Horizontal cells: 249.0;Inhibitory neurons: 372.1;Oligodendrocyte precursor cells: 271.9" "Low cancer specificity" "Detected in some" "Group enriched" "Detected in all" 4 "cerebellum: 99.3;cerebral cortex: 30.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "SCLC-21H: 45.1;U-87 MG: 23.9" "Low region specificity" "Detected in all" "HPA064258, HPA068138, HPA071902" Enhanced Supported Uncertain "Endoplasmic reticulum" NA NA "Cluster 42: Non-specific - Transcription" "Cluster 69: Cerebellum - Gene expression regulation" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Endoplasmic reticulum" "HPA064258: AB_2685229, HPA068138: , HPA071902: " "unprognostic (1.09e-1)" "unprognostic (3.73e-3)" "unprognostic (2.27e-1)" "unprognostic (2.78e-4)" "unprognostic (4.00e-2)" "unprognostic (2.29e-3)" "unprognostic (5.47e-2)" "unprognostic (3.13e-1)" "unprognostic (2.86e-1)" "unprognostic (1.14e-2)" "prognostic favorable (4.32e-4)" "unprognostic (5.31e-3)" "unprognostic (5.03e-6)" "unprognostic (6.29e-2)" "unprognostic (1.59e-1)" "unprognostic (2.61e-2)" "unprognostic (6.25e-2)" 1.0 2.3 15.4 0.3 15.8 0.1 0.9 99.3 30.4 0.6 0.0 0.7 1.2 0.8 1.1 0.2 3.2 0.1 0.6 15.1 6.8 0.5 0.2 0.2 0.4 7.2 11.2 0.9 2.6 0.1 4.2 0.0 10.6 0.4 0.4 7.1 0.2 0.1 0.5 0.3 1.7 0.2 9.4 0.6 2.7 2.3 11.3 0.1 0.7 0.1 0.2 0.3 0.7 15.2 0.0 0.1 0.1 6.0 0.2 0.2 0.0 2.2 2.5 0.3 0.0 0.0 0.0 0.2 0.0 0.2 5.1 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.9 2.8 0.0 1.9 0.0 0.0 0.0 0.0 0.0 7.2 0.2 0.0 0.1 0.2 1.4 0.1 0.3 0.6 0.0 0.1 0.0 0.1 45.1 0.0 0.0 0.0 0.4 0.1 0.0 1.9 0.1 0.1 0.9 0.2 0.1 0.0 0.0 0.0 23.9 0.1 0.6 0.5 0.0 0.1 0.0 0.0 0.1 0.5 0.1 0.0 0.0 0.3 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.0 15.4 15.8 99.3 30.4 15.1 6.8 7.2 11.2 10.6 9.4 11.3 15.2 7.7 6.4 3.2 31.3 9.6 0.6 3.4 0.0 0.0 101.4 3.1 7.4 2.8 0.0 1.3 1.8 16.7 0.0 2.9 0.6 0.0 0.5 27.1 1.2 6.3 6.5 214.1 0.4 318.3 0.4 0.2 4.7 10.7 2.6 1.3 5.2 1.8 1.2 0.5 249.0 372.1 5.0 4.1 1.9 1.4 28.0 1.2 2.1 0.0 28.1 1.2 3.0 4.1 271.9 11.5 1.5 0.1 0.4 0.5 0.8 0.2 2.0 3.7 7.0 0.0 5.1 17.6 4.3 7.1 0.4 0.1 0.3 2.0 2.5 1.0 0.9 CACNA1B "CACNL1A5, CACNN, Cav2.2" ENSG00000148408 "Calcium voltage-gated channel subunit alpha1 B" Q00975 9 137877782-138124624 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 10.2;pituitary gland: 6.8;testis: 5.1" "Group enriched" "Detected in some" 8 "Excitatory neurons: 388.8;Inhibitory neurons: 330.9" "Cancer enhanced" "Detected in some" "testis cancer: 2.2" "Group enriched" "Detected in many" 8 "amygdala: 5.9;basal ganglia: 7.8;cerebral cortex: 10.2;hippocampal formation: 3.5" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "SCLC-21H: 19.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA022919, HPA044347" Uncertain Approved Mitochondria NA NA "Cluster 58: Brain - Synaptic function" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" Mitochondria "HPA022919: , HPA044347: AB_10960837" "unprognostic (1.34e-3)" "unprognostic (2.70e-2)" "unprognostic (8.08e-2)" "unprognostic (2.51e-7)" "unprognostic (8.10e-2)" "unprognostic (1.51e-2)" "unprognostic (1.33e-1)" "unprognostic (3.10e-1)" "unprognostic (2.50e-1)" "unprognostic (2.36e-2)" "unprognostic (9.73e-4)" "unprognostic (5.98e-2)" "unprognostic (6.63e-6)" "unprognostic (4.25e-2)" "unprognostic (4.72e-1)" "unprognostic (7.77e-3)" "unprognostic (8.69e-2)" 0.0 2.8 5.9 0.1 7.8 0.0 0.0 0.8 10.2 0.3 0.0 0.4 0.0 0.0 0.6 0.0 3.1 0.4 0.3 3.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.8 6.8 0.0 0.0 0.5 0.1 3.5 0.0 0.4 0.0 0.2 0.2 0.1 0.0 0.0 0.3 5.1 0.0 1.2 0.2 0.0 0.0 0.0 0.1 0.7 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.5 3.7 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 7.8 0.8 10.2 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 43.4 0.0 0.0 0.1 0.0 0.0 11.7 0.2 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 3.4 0.0 0.2 0.1 0.0 0.0 388.8 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 6.7 330.9 0.0 0.0 0.0 0.0 5.2 0.0 0.0 0.0 17.8 0.6 1.7 0.0 16.1 10.1 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 1.6 0.0 0.0 0.2 8.2 9.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 CACNA1C "CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS" ENSG00000151067 "Calcium voltage-gated channel subunit alpha1 C" Q13936 12 1970786-2697950 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Host-virus interaction, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Brugada syndrome, Disease variant, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 20.7;heart muscle: 27.1;intestine: 29.9" "Group enriched" "Detected in many" 4 "Excitatory neurons: 606.7;Horizontal cells: 301.2;Inhibitory neurons: 476.2;Oligodendrocyte precursor cells: 194.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 16 "HDLM-2: 87.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039796, CAB079031" Enhanced Approved NA NA "Cluster 15: NK-cells - Transcription" "Cluster 46: Fibroblasts - ECM organization" "Cluster 44: HDLM-2 - Immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "CAB079031: , HPA039796: AB_10673019" "unprognostic (1.76e-1)" "unprognostic (1.19e-1)" "unprognostic (6.29e-2)" "unprognostic (9.35e-2)" "unprognostic (3.71e-2)" "unprognostic (1.60e-2)" "unprognostic (4.68e-2)" "unprognostic (7.99e-2)" "unprognostic (3.07e-2)" "unprognostic (1.03e-5)" "unprognostic (1.93e-2)" "unprognostic (1.01e-1)" "unprognostic (4.02e-7)" "unprognostic (8.85e-2)" "unprognostic (3.60e-2)" "unprognostic (6.90e-2)" "unprognostic (3.39e-2)" 3.0 0.9 4.5 1.4 0.9 0.0 1.9 0.0 3.0 5.6 0.0 29.9 0.7 20.7 0.5 2.1 4.2 2.3 27.1 2.0 0.5 2.5 0.4 4.6 0.3 0.0 0.5 1.9 0.9 0.1 5.2 2.1 0.0 6.5 1.3 1.7 1.0 3.3 0.9 1.3 5.0 10.2 0.0 3.0 5.4 2.5 1.8 0.2 1.3 0.8 0.3 12.3 3.4 0.1 0.0 0.0 0.1 0.0 3.3 2.0 0.2 3.4 4.1 2.2 1.5 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.8 87.0 0.8 0.1 0.0 0.0 2.1 0.0 0.1 5.1 0.0 1.1 0.0 0.2 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.4 0.0 0.0 0.0 1.2 0.0 0.0 0.0 5.4 0.6 5.2 0.0 0.1 0.2 0.0 4.3 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 4.5 0.9 0.0 3.0 2.0 0.5 0.0 0.5 0.0 0.0 1.8 0.1 2.2 0.0 0.0 96.6 0.2 0.6 1.0 0.0 0.0 20.7 0.8 8.3 48.8 0.0 0.0 0.0 2.1 0.2 1.3 0.6 0.0 0.1 35.6 5.1 14.6 5.2 36.6 0.8 606.7 0.0 0.4 4.2 2.0 0.9 0.0 2.7 2.2 0.1 0.3 301.2 476.2 0.6 0.0 0.0 1.1 90.3 0.9 0.2 0.0 72.1 0.0 6.0 1.0 194.5 21.7 0.4 1.2 4.1 0.2 1.2 0.0 0.1 0.0 1.3 13.1 1.6 26.7 3.4 5.8 0.1 0.1 0.1 1.1 0.2 0.5 3.1 CACNA1D "CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2" ENSG00000157388 "Calcium voltage-gated channel subunit alpha1 D" Q01668 3 53328963-53813733 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Cancer-related genes, Deafness, Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 10.4" "Cell type enhanced" "Detected in many" "Excitatory neurons: 251.2;Inhibitory neurons: 354.1;Microglial cells: 126.5;Oligodendrocyte precursor cells: 197.5" "Cancer enhanced" "Detected in many" "prostate cancer: 5.9" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in single" 10 "basophil: 3.7" "Lineage enriched" "Detected in single" 21 "granulocytes: 3.7" "Cell line enhanced" "Detected in some" "HMC-1: 22.7;RPMI-8226: 55.5;SK-BR-3: 10.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020215 Uncertain Approved "Nuclear membrane" NA NA "Cluster 46: Basophils - DNA binding" "Cluster 68: Epididymis - Unknown function" "Cluster 25: RPMI-8226 - Immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Nuclear membrane" "HPA020215: AB_1845860" "unprognostic (5.85e-2)" "unprognostic (4.90e-3)" "unprognostic (5.09e-2)" "unprognostic (2.24e-2)" "unprognostic (7.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.92e-1)" "unprognostic (2.32e-2)" "unprognostic (2.95e-1)" "unprognostic (4.42e-2)" "unprognostic (3.90e-3)" "unprognostic (1.53e-1)" "prognostic favorable (8.34e-8)" "unprognostic (1.14e-1)" "unprognostic (3.05e-2)" "unprognostic (8.09e-3)" "unprognostic (6.70e-3)" 0.1 6.6 7.0 0.2 4.3 0.7 1.8 2.3 10.4 6.0 0.0 1.5 1.7 3.7 7.3 0.5 7.7 2.0 0.6 3.6 0.8 2.2 1.0 3.7 0.1 0.0 1.2 0.5 2.8 1.2 3.5 0.6 0.4 3.0 1.5 4.3 0.5 1.8 0.2 0.7 2.4 0.7 3.5 1.8 0.8 1.6 6.1 0.2 2.9 0.2 0.1 0.6 0.1 6.0 0.0 0.5 0.1 0.0 0.0 0.0 1.4 0.0 0.1 0.0 0.0 2.7 2.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.0 22.7 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 2.1 0.1 0.0 0.4 0.9 0.0 0.0 0.2 55.5 0.5 3.6 4.7 2.1 0.3 10.1 1.1 0.0 2.8 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.4 3.7 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 7.0 4.3 2.3 10.4 3.6 0.8 0.0 1.2 0.4 3.5 6.1 6.0 0.6 3.2 36.2 7.8 0.6 0.9 0.8 4.6 2.2 33.3 7.2 1.8 2.3 10.0 9.1 1.8 35.5 0.9 0.5 3.0 0.0 7.2 4.9 4.3 40.1 2.4 59.4 2.7 251.2 2.3 0.2 3.4 5.1 3.3 12.6 1.7 0.0 3.4 0.2 8.4 354.1 3.8 2.0 0.8 4.0 8.3 4.4 2.1 5.4 126.5 0.5 4.0 0.0 197.5 29.9 3.8 5.6 27.1 0.1 1.7 9.5 2.7 9.5 12.9 0.0 0.2 8.6 1.0 3.7 0.5 1.0 0.3 1.7 9.6 7.6 0.9 CACNA1E "BII, CACH6, CACNL1A6, Cav2.3" ENSG00000198216 "Calcium voltage-gated channel subunit alpha1 E" Q15878 1 181317690-181808084 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 28 "brain: 42.8" "Cell type enhanced" "Detected in some" "Excitatory neurons: 188.7;Inhibitory neurons: 116.0;Oligodendrocyte precursor cells: 73.9;Oligodendrocytes: 34.2" "Low cancer specificity" "Detected in single" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CACO-2: 1.6;NB-4: 1.0;NTERA-2: 1.1;U-266/70: 2.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042515, CAB079032" Approved Approved "Plasma membrane,Actin filaments,Cytosol" NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 29: U-266 - Adaptive immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" "Actin filaments, Cytosol" "CAB079032: , HPA042515: " "unprognostic (3.96e-3)" "unprognostic (1.89e-1)" "unprognostic (1.05e-2)" "unprognostic (1.54e-5)" "unprognostic (6.56e-2)" "unprognostic (3.16e-2)" "unprognostic (4.30e-3)" "unprognostic (1.18e-1)" "unprognostic (2.40e-1)" "unprognostic (9.48e-3)" "unprognostic (1.04e-1)" "unprognostic (2.06e-1)" "unprognostic (9.85e-7)" "unprognostic (1.74e-2)" "unprognostic (2.07e-2)" "unprognostic (1.16e-1)" "unprognostic (3.75e-2)" 0.0 1.0 33.5 0.6 30.5 1.2 0.0 0.0 34.6 0.0 0.0 0.1 0.0 0.0 1.5 0.2 0.7 0.0 0.3 42.8 3.4 1.3 0.0 0.1 0.4 4.6 6.2 0.0 0.0 0.0 0.1 0.1 0.9 0.0 0.1 0.8 0.0 0.0 0.0 0.0 0.2 0.2 9.7 0.4 0.1 1.0 3.8 0.0 0.0 0.0 0.2 0.0 0.0 1.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.1 0.0 0.0 0.0 0.0 0.4 0.5 0.0 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 33.5 30.5 0.0 34.6 42.8 3.4 4.6 6.2 0.9 9.7 3.8 1.1 0.0 0.0 0.0 3.6 0.0 0.1 0.0 0.0 0.0 4.6 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.1 0.0 0.4 0.0 0.0 188.7 0.0 0.0 0.1 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 116.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 6.5 0.0 0.2 0.0 73.9 34.2 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.3 0.0 0.0 0.1 0.2 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 CACNA1F "AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2" ENSG00000102001 "Calcium voltage-gated channel subunit alpha1 F" O60840 X 49205063-49233371 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Sensory transduction, Transport, Vision" "Calcium channel, Ion channel, Voltage-gated channel" "Cone-rod dystrophy, Congenital stationary night blindness, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 53 "retina: 125.3" "Group enriched" "Detected in some" 13 "Bipolar cells: 66.5;Cone photoreceptor cells: 133.5;Rod photoreceptor cells: 97.5" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Immune cell enhanced" "Detected in single" "plasmacytoid DC: 1.3" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in single" "U-266/70: 1.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA068379 Enhanced NA NA "Cluster 33: Neutrophils - Chromatin organization" "Cluster 79: Retina - Phototransduction" "Cluster 29: U-266 - Adaptive immune response" "Cluster 9: Photoreceptor cells - Phototransduction" "HPA068379: AB_2732782" "unprognostic (1.20e-3)" "unprognostic (8.62e-2)" "unprognostic (4.25e-3)" "unprognostic (1.56e-2)" "unprognostic (8.46e-2)" "unprognostic (1.84e-1)" "unprognostic (1.23e-2)" "unprognostic (1.76e-1)" "unprognostic (1.23e-1)" "unprognostic (9.04e-2)" "unprognostic (7.36e-2)" "unprognostic (1.59e-1)" "unprognostic (6.08e-7)" "unprognostic (8.03e-2)" "unprognostic (1.09e-1)" "unprognostic (4.65e-2)" "unprognostic (3.77e-3)" 0.2 0.4 0.7 0.4 0.7 1.9 0.7 2.3 1.4 0.2 0.8 0.6 0.8 0.2 1.0 0.2 0.5 0.2 0.2 0.8 0.4 0.3 0.0 0.6 1.3 0.4 0.1 0.3 0.6 0.0 0.1 0.0 0.5 0.1 0.7 125.3 0.6 0.4 0.0 1.0 1.6 0.2 0.0 0.8 0.6 0.2 0.4 0.8 0.4 0.0 0.5 0.2 0.1 0.8 0.1 0.7 0.0 0.0 0.1 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.2 0.3 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.1 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.2 0.2 0.3 0.1 0.0 0.8 0.4 0.5 0.4 0.5 0.0 0.0 0.0 0.3 0.2 0.5 0.1 0.0 0.0 0.1 0.0 0.2 0.2 0.6 0.3 0.0 0.0 0.0 0.0 1.4 0.5 0.0 0.0 0.1 0.0 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.4 0.1 0.2 0.5 0.1 0.3 1.3 0.1 0.0 0.7 0.7 2.3 1.4 0.8 0.4 0.4 0.1 0.5 0.0 0.4 0.8 0.2 0.0 0.5 0.0 1.1 0.0 0.1 0.1 0.0 66.5 1.1 0.9 1.9 0.0 0.0 1.8 133.5 0.1 2.8 0.2 0.0 0.0 0.0 0.4 0.0 1.0 0.0 0.4 0.9 0.2 0.2 0.1 1.1 0.2 0.0 0.0 0.0 0.0 0.2 6.7 0.4 2.3 0.0 0.0 1.7 0.0 0.0 0.6 0.0 0.0 0.1 7.4 0.0 0.0 0.3 0.0 0.1 0.4 0.1 0.1 0.4 0.1 0.1 97.5 0.0 0.1 0.1 0.1 0.3 0.0 0.0 0.0 0.3 0.1 0.3 0.1 CACNA1G "Cav3.1, NBR13" ENSG00000006283 "Calcium voltage-gated channel subunit alpha1 G" O43497 17 50560715-50627474 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease variant, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 37.5;cervix: 9.9" "Cell type enriched" "Detected in some" 7 "Bipolar cells: 176.7" "Cancer enhanced" "Detected in some" "glioma: 1.6;testis cancer: 1.6" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 9.2;GAMG: 3.2;HeLa: 3.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004714 Uncertain NA NA "Cluster 69: Cerebellum - Gene expression regulation" "Cluster 20: HeLa - Mitochondria" "Cluster 56: Bipolar cells - Visual perception" "HPA004714: AB_1078368" "unprognostic (1.90e-2)" "unprognostic (5.83e-2)" "unprognostic (2.85e-2)" "unprognostic (1.08e-1)" "unprognostic (4.00e-1)" "unprognostic (9.89e-2)" "unprognostic (1.47e-2)" "unprognostic (2.73e-1)" "unprognostic (1.02e-4)" "unprognostic (1.47e-2)" "unprognostic (2.16e-2)" "unprognostic (9.76e-2)" "unprognostic (4.87e-12)" "unprognostic (3.34e-2)" "unprognostic (1.62e-1)" "unprognostic (1.56e-3)" "unprognostic (6.63e-2)" 1.6 0.2 7.1 0.2 5.3 0.3 1.0 19.3 9.9 9.9 0.0 0.4 0.2 2.8 0.1 0.4 3.4 0.2 3.6 2.6 10.3 0.0 0.0 0.3 0.3 4.1 19.4 5.4 0.1 0.0 0.2 0.4 1.4 1.1 0.1 8.8 0.3 0.4 0.1 1.4 0.1 0.6 12.8 0.1 0.2 0.6 37.5 0.1 0.3 0.1 0.2 0.1 3.7 6.2 0.0 9.2 2.1 2.4 0.6 0.1 0.1 0.1 0.0 0.0 0.1 1.8 0.2 0.0 0.6 0.1 3.2 0.3 1.1 0.0 0.2 1.1 0.4 0.6 3.2 0.3 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.1 0.5 0.0 0.0 0.7 0.5 0.4 1.0 0.8 0.0 0.0 0.1 2.7 1.1 1.8 0.1 0.0 1.5 0.0 0.1 0.2 0.8 2.5 0.3 0.1 0.6 0.0 0.0 0.4 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 7.1 5.3 19.3 9.9 2.6 10.3 4.1 19.4 1.4 12.8 37.5 6.2 0.2 0.0 0.0 0.3 0.0 1.9 0.2 0.0 0.6 176.7 0.3 0.5 4.5 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 1.6 0.6 11.2 0.6 0.0 0.0 16.0 0.0 0.6 4.5 0.0 0.6 0.0 0.1 0.0 0.0 0.4 5.0 21.5 0.0 0.0 0.0 5.7 0.2 0.0 0.9 3.6 1.0 0.0 2.3 0.0 22.6 0.8 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.0 5.9 0.0 0.3 3.7 0.7 0.9 0.8 2.8 0.1 0.3 0.0 0.1 0.1 CACNA1H Cav3.2 ENSG00000196557 "Calcium voltage-gated channel subunit alpha1 H" O95180 16 1153106-1221771 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 107.7" "Cell type enhanced" "Detected in many" "Bipolar cells: 22.8;Late spermatids: 15.5;Peritubular cells: 25.9;Sertoli cells: 26.3;Smooth muscle cells: 22.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 17.9;AN3-CA: 25.4;MCF7: 48.3;OE19: 16.0;T-47d: 13.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA039125 Approved Approved Nucleoplasm,Vesicles NA NA "Cluster 89: Fibroblasts - ECM organization" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 48: Smooth muscle cells - ECM organization" "Nucleoplasm, Vesicles" "HPA039125: AB_10795578" "unprognostic (1.66e-3)" "unprognostic (2.10e-1)" "unprognostic (4.07e-2)" "unprognostic (1.21e-3)" "unprognostic (1.37e-2)" "unprognostic (2.15e-1)" "unprognostic (4.39e-2)" "unprognostic (2.38e-2)" "unprognostic (1.06e-1)" "unprognostic (3.30e-2)" "prognostic favorable (3.12e-5)" "unprognostic (1.66e-2)" "prognostic unfavorable (1.78e-5)" "unprognostic (1.93e-2)" "unprognostic (4.65e-2)" "unprognostic (1.70e-2)" "unprognostic (5.55e-2)" 13.6 28.0 13.6 5.2 24.5 0.1 7.6 2.1 12.1 26.3 0.0 107.7 6.4 57.3 2.6 7.1 37.8 10.3 9.3 11.0 8.1 14.1 13.4 11.8 0.7 3.0 3.8 80.1 4.6 3.6 45.9 2.1 2.9 28.0 2.4 1.8 1.9 27.5 6.2 19.4 22.3 15.6 3.7 0.7 27.5 19.4 13.5 0.5 11.0 3.0 0.2 57.0 17.1 0.2 0.0 17.9 3.0 25.4 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.0 0.0 0.0 0.1 0.8 0.0 0.0 0.0 10.4 0.1 0.0 11.0 3.0 0.0 4.5 0.3 0.0 0.0 0.0 0.0 0.0 3.0 4.9 0.0 0.0 48.3 0.0 0.0 9.4 16.0 3.6 0.0 0.0 0.2 4.7 0.0 0.0 0.0 0.0 0.0 0.9 1.0 13.9 0.0 0.0 0.0 10.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.6 24.5 2.1 12.1 11.0 8.1 3.0 3.8 2.9 3.7 13.5 0.2 1.3 0.0 0.0 1.0 0.0 1.5 0.1 0.0 0.0 22.8 0.3 0.1 2.7 4.3 0.0 0.0 0.0 0.0 0.2 0.1 0.0 3.7 7.2 0.2 5.3 2.2 10.8 0.0 2.6 0.0 0.1 1.3 0.5 0.2 4.5 0.0 0.4 7.8 0.1 0.0 0.7 1.0 2.0 0.0 0.3 15.5 8.4 0.2 0.0 0.0 0.0 0.8 0.0 0.5 0.1 0.4 0.4 25.9 0.0 7.2 0.0 0.7 0.0 1.5 26.3 0.4 22.4 3.4 5.1 0.0 3.4 0.0 0.2 0.3 0.1 1.3 CACNA1I Cav3.3 ENSG00000100346 "Calcium voltage-gated channel subunit alpha1 I" Q9P0X4 22 39570753-39689735 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 9.7;thyroid gland: 5.3" "Group enriched" "Detected in some" 4 "Bipolar cells: 16.9;Excitatory neurons: 16.8;Inhibitory neurons: 12.3" "Cancer enriched" "Detected in single" 5 "thyroid cancer: 2.1" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "SK-BR-3: 1.9;T-47d: 1.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA066992 Uncertain "Plasma membrane,Cell Junctions" NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 62: Horizontal cells - Visual perception" "Plasma membrane" "Cell Junctions" "HPA066992: " "unprognostic (3.97e-2)" "unprognostic (1.42e-1)" "unprognostic (1.02e-1)" "unprognostic (4.60e-2)" "unprognostic (3.52e-2)" "unprognostic (1.58e-1)" "unprognostic (1.19e-1)" "unprognostic (2.63e-1)" "unprognostic (7.21e-2)" "unprognostic (5.20e-3)" "unprognostic (1.64e-2)" "unprognostic (8.64e-2)" "unprognostic (1.62e-2)" "unprognostic (6.14e-3)" "unprognostic (1.57e-1)" "unprognostic (3.78e-2)" "unprognostic (8.27e-4)" 0.2 3.3 5.0 0.8 5.6 0.6 0.1 1.5 9.7 0.1 0.0 0.5 0.1 0.1 0.0 0.2 0.2 0.1 0.0 8.7 1.3 0.1 0.0 0.5 1.9 7.6 1.4 0.0 0.1 0.0 0.3 0.0 7.9 0.1 0.0 2.6 0.1 0.0 0.0 0.2 3.3 0.0 0.7 1.5 0.6 0.8 2.2 0.2 5.3 0.0 0.5 0.4 0.2 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.1 1.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.1 0.0 5.0 5.6 1.5 9.7 8.7 1.3 7.6 1.4 7.9 0.7 2.2 4.7 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 16.9 0.2 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.9 0.2 0.0 0.1 0.0 0.4 16.8 0.0 0.0 0.1 0.5 0.2 0.0 0.0 0.0 0.0 0.0 3.3 12.3 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 3.0 1.0 2.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.1 0.0 0.2 0.0 0.0 0.0 1.0 0.0 0.1 0.1 CACNA1S "CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5" ENSG00000081248 "Calcium voltage-gated channel subunit alpha1 S" Q13698 1 201039512-201112451 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel, Voltage-gated channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 86 "skeletal muscle: 254.9;tongue: 193.2" "Cell type enhanced" "Detected in some" "Cardiomyocytes: 1.6;Cone photoreceptor cells: 6.2;Late spermatids: 5.9;Skeletal myocytes: 6.3" "Cancer enhanced" "Detected in single" "head and neck cancer: 0.9" "Low region specificity" "Detected in single" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 15 "BEWO: 1.1;HSkMC: 1.8" "Region enhanced" "Detected in single" "olfactory bulb: 1.8" "Region enriched" "Detected in single" 8 "olfactory bulb: 2.6" "CAB009507, HPA048892, HPA056815" Enhanced NA NA "Cluster 13: Striated muscle - Muscle contraction" "Cluster 28: BEWO - Transcription regulation" "Cluster 37: Myocytes - Muscle contraction" "CAB009507: AB_2069576, HPA048892: AB_2680548, HPA056815: AB_2683242" "unprognostic (2.14e-2)" "unprognostic (1.38e-1)" "unprognostic (1.12e-2)" "unprognostic (1.09e-1)" "unprognostic (3.52e-3)" "unprognostic (4.53e-2)" "unprognostic (2.84e-1)" "unprognostic (2.23e-1)" "unprognostic (2.53e-2)" "unprognostic (1.51e-1)" "unprognostic (4.72e-3)" "unprognostic (1.12e-1)" "unprognostic (5.28e-2)" "unprognostic (7.36e-2)" "unprognostic (1.57e-1)" 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.1 0.6 0.1 0.0 0.1 0.0 0.2 0.8 0.0 0.0 0.0 0.0 0.0 0.2 1.1 0.0 0.9 1.5 0.0 254.9 0.0 0.0 0.0 0.1 0.0 0.0 0.1 1.1 0.0 0.0 193.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.1 0.2 0.1 0.6 0.2 0.8 0.2 0.1 1.1 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.6 0.0 0.0 0.0 6.2 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 5.9 0.3 0.0 0.0 1.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 1.2 0.0 6.3 0.3 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CACNA2D1 "CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3" ENSG00000153956 "Calcium voltage-gated channel auxiliary subunit alpha2delta 1" P54289 7 81946444-82443777 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 78.7;tongue: 98.5" "Cell type enhanced" "Detected in many" "Excitatory neurons: 543.1;Inhibitory neurons: 383.3;Oligodendrocyte precursor cells: 357.9;Oligodendrocytes: 662.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "hTERT-RPE1: 127.4;HUVEC TERT2: 54.9;SH-SY5Y: 62.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008213, HPA008621" Enhanced "Intracellular and membrane" NA NA 390000000 "Cluster 80: Striated muscle - Unknown function" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA008213: AB_1233654, HPA008621: AB_1845863" "unprognostic (5.07e-3)" "unprognostic (2.21e-1)" "unprognostic (4.27e-3)" "unprognostic (2.92e-2)" "unprognostic (2.27e-1)" "unprognostic (1.39e-1)" "unprognostic (1.70e-1)" "unprognostic (3.22e-1)" "unprognostic (3.76e-1)" "unprognostic (2.05e-1)" "unprognostic (6.24e-3)" "unprognostic (2.23e-2)" "prognostic unfavorable (1.16e-4)" "unprognostic (4.28e-3)" "unprognostic (2.13e-1)" "unprognostic (9.18e-2)" "unprognostic (1.03e-4)" 11.6 14.5 9.8 4.3 11.9 0.0 4.1 1.2 15.4 5.3 0.0 13.0 5.1 7.4 2.4 5.3 3.9 6.4 31.3 18.8 13.3 8.4 1.3 3.4 1.9 4.6 26.0 7.9 1.5 1.2 6.3 4.2 9.5 13.7 5.1 8.3 2.6 6.4 78.7 4.7 3.4 12.2 8.1 4.4 5.6 3.7 34.2 3.9 18.9 98.5 3.1 7.1 3.4 12.8 0.0 12.7 10.6 0.0 18.2 22.9 0.0 23.4 15.0 11.4 11.1 0.0 3.5 0.0 0.0 20.4 14.1 0.0 11.2 0.0 14.8 0.0 15.0 0.7 14.4 0.0 11.9 5.3 0.0 13.6 0.1 39.6 0.1 127.4 54.9 0.0 0.0 0.2 25.7 0.1 0.0 0.0 12.6 0.0 5.0 2.3 2.1 0.0 0.9 0.9 21.1 62.3 4.6 0.1 0.0 11.1 0.1 0.0 39.6 20.1 15.0 20.1 0.0 0.1 0.0 0.0 16.9 0.0 12.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 11.9 1.2 15.4 18.8 13.3 4.6 26.0 9.5 8.1 34.2 12.8 6.3 0.0 1.7 137.1 0.0 5.7 4.5 0.1 8.0 47.7 6.6 3.9 88.0 0.0 1.3 7.3 18.8 0.1 0.1 0.0 0.0 0.0 64.2 0.5 20.7 6.8 38.8 0.0 543.1 0.0 0.0 20.6 14.3 0.4 25.3 29.9 1.4 0.4 0.2 25.2 383.3 2.6 16.2 0.0 2.9 42.4 10.2 0.4 1.8 87.1 0.6 5.6 0.0 357.9 662.8 0.8 0.0 6.0 0.2 11.2 0.0 9.5 0.7 6.1 6.6 17.6 21.5 1.5 1.9 1.9 6.5 0.1 0.4 32.7 0.2 1.4 CACNA2D2 KIAA0558 ENSG00000007402 "Calcium voltage-gated channel auxiliary subunit alpha2delta 2" Q9NY47 3 50362613-50504244 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 49.1" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 76.9;Alveolar cells type 2: 182.3;Inhibitory neurons: 36.0" "Cancer enhanced" "Detected in many" "testis cancer: 20.4" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enriched" "Detected in some" 8 "SH-SY5Y: 192.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA034771, HPA071829" Enhanced Approved Vesicles NA NA 9700000 "Cluster 35: T-regs - Unknown function" "Cluster 57: Non-specific - Angiogenesis" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 11: Alveolar cells - Smell perception" Vesicles "HPA034771: AB_10603555, HPA071829: AB_2686454" "unprognostic (2.06e-1)" "unprognostic (2.37e-1)" "unprognostic (1.72e-2)" "prognostic unfavorable (7.62e-5)" "unprognostic (6.59e-2)" "unprognostic (6.37e-2)" "unprognostic (6.91e-2)" "unprognostic (6.57e-3)" "unprognostic (4.39e-2)" "unprognostic (1.17e-1)" "prognostic favorable (1.21e-4)" "unprognostic (2.71e-2)" "unprognostic (1.57e-4)" "unprognostic (3.03e-1)" "unprognostic (4.14e-2)" "unprognostic (3.55e-1)" "unprognostic (4.22e-2)" 1.0 0.6 4.7 1.3 5.2 1.2 1.2 9.9 6.9 1.4 0.3 1.6 1.2 1.6 0.9 0.6 1.1 0.7 8.4 0.7 13.9 2.3 0.3 49.1 1.2 8.3 8.4 2.1 4.3 2.5 7.1 1.8 14.0 3.0 1.9 8.6 1.3 1.1 1.8 2.6 1.6 1.2 4.8 1.4 4.1 6.5 11.4 1.0 2.2 1.5 0.5 0.5 0.7 2.1 0.0 0.1 3.0 6.6 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.6 0.0 0.6 0.2 24.8 0.0 0.1 0.1 1.8 0.2 0.2 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.2 0.4 0.0 1.1 0.1 0.2 7.9 0.2 0.5 0.2 0.0 0.7 0.0 0.0 18.6 192.7 0.6 0.4 0.0 5.5 1.5 0.0 0.0 0.1 1.8 0.2 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.7 0.0 0.9 0.7 0.9 0.7 0.0 0.5 1.2 0.7 0.0 0.9 0.0 0.1 1.2 0.4 4.7 5.2 9.9 6.9 0.7 13.9 8.3 8.4 14.0 4.8 11.4 2.1 0.4 76.9 182.3 4.2 0.4 1.5 0.4 0.0 1.8 21.5 2.5 1.7 4.6 0.0 2.5 1.8 20.9 0.0 6.8 0.8 0.0 0.2 0.7 0.1 0.4 0.6 1.2 2.7 7.8 0.0 0.0 1.5 3.1 0.2 20.3 0.3 0.4 0.0 0.1 0.0 36.0 11.0 0.0 0.0 0.4 4.0 0.3 0.4 0.0 1.9 0.1 4.3 15.5 6.0 0.9 0.4 0.3 1.9 2.9 0.7 0.2 0.7 2.2 9.8 13.1 2.4 2.4 2.6 11.2 0.2 0.6 0.3 2.9 3.4 0.6 0.3 CACNA2D3 HSA272268 ENSG00000157445 "Calcium voltage-gated channel auxiliary subunit alpha2delta 3" Q8IZS8 3 54122547-55074557 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 15.8;skeletal muscle: 9.9;tongue: 10.7" "Cell type enhanced" "Detected in many" "Astrocytes: 160.9;Excitatory neurons: 828.3;Inhibitory neurons: 456.4;Oligodendrocyte precursor cells: 317.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ hTERT+: 4.1;HAP1: 1.9;HeLa: 9.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA030849 Uncertain Nucleoplasm NA NA 69000 "Cluster 47: Non-specific - Unknown function" "Cluster 20: HeLa - Mitochondria" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" Nucleoplasm "HPA030849: " "unprognostic (6.92e-2)" "unprognostic (1.35e-2)" "unprognostic (1.89e-1)" "unprognostic (4.34e-5)" "unprognostic (5.53e-3)" "unprognostic (2.64e-3)" "unprognostic (3.24e-1)" "unprognostic (1.17e-2)" "unprognostic (5.84e-3)" "unprognostic (7.22e-3)" "unprognostic (1.14e-2)" "unprognostic (2.43e-1)" "unprognostic (2.00e-1)" "unprognostic (1.47e-3)" "unprognostic (2.19e-1)" "unprognostic (3.62e-2)" "unprognostic (6.95e-2)" 0.2 4.1 8.8 0.1 11.6 0.0 0.2 0.0 15.8 0.3 0.0 0.7 0.1 0.1 1.3 0.5 0.4 0.2 2.6 9.4 8.4 1.3 0.0 0.5 0.5 2.1 10.2 2.5 0.0 0.3 0.8 0.5 1.3 1.0 0.3 2.9 0.4 1.5 9.9 0.1 0.3 0.6 0.0 0.2 0.4 1.4 3.5 0.1 0.4 10.7 0.5 0.1 0.4 9.9 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 1.1 0.1 9.2 0.0 0.5 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.0 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.8 11.6 0.0 15.8 9.4 8.4 2.1 10.2 1.3 0.0 3.5 9.9 0.5 0.0 0.0 160.9 0.6 0.3 0.4 0.2 7.4 10.8 0.2 0.5 30.2 0.0 0.7 0.0 8.4 9.9 5.5 0.1 7.9 0.0 83.4 0.9 0.8 0.6 0.0 1.3 828.3 0.6 3.2 3.4 1.5 1.8 0.0 1.1 0.4 0.0 5.9 0.0 456.4 0.0 2.0 8.9 2.7 56.1 2.8 11.0 0.0 97.4 22.2 5.0 0.0 317.7 11.3 1.2 0.0 1.5 0.1 0.4 0.0 0.2 0.8 1.4 6.6 1.7 1.9 5.7 2.9 3.4 0.1 68.0 0.7 0.8 0.0 0.4 CACNA2D4 ENSG00000151062 "Calcium voltage-gated channel auxiliary subunit alpha2delta 4" Q7Z3S7 12 1791963-1918666 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 39 "retina: 20.2" "Cell type enhanced" "Detected in many" "Bipolar cells: 56.3;Cone photoreceptor cells: 156.4;Early spermatids: 56.3;Late spermatids: 117.6;Rod photoreceptor cells: 98.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low immune cell specificity" "Detected in many" "Group enriched" "Detected in many" 8 "dendritic cells: 2.9;monocytes: 4.4;T-cells: 4.2" "Cell line enhanced" "Detected in some" "Hep G2: 4.7;HL-60: 2.8;HMC-1: 14.0;NB-4: 6.6" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA031952 Uncertain NA NA "Cluster 39: Non-specific - mRNA processing" "Cluster 79: Retina - Phototransduction" "Cluster 3: HMC-1 - Innate immune response" "Cluster 9: Photoreceptor cells - Phototransduction" "HPA031952: AB_10600798" "unprognostic (5.04e-2)" "unprognostic (2.82e-2)" "unprognostic (5.32e-1)" "unprognostic (7.50e-2)" "unprognostic (1.15e-1)" "unprognostic (8.18e-4)" "unprognostic (1.10e-2)" "unprognostic (1.31e-1)" "unprognostic (2.08e-1)" "unprognostic (3.30e-3)" "unprognostic (1.24e-2)" "unprognostic (1.41e-1)" "unprognostic (1.62e-5)" "unprognostic (1.11e-1)" "unprognostic (1.07e-1)" "unprognostic (2.04e-1)" "unprognostic (2.13e-1)" 0.3 0.1 0.0 0.1 0.0 0.3 0.1 0.0 0.0 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.3 0.1 0.1 0.0 20.2 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.3 0.0 0.3 0.2 0.1 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 4.7 0.2 2.8 14.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.3 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.9 0.4 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 1.8 0.0 0.0 4.4 0.0 2.1 1.7 4.2 0.0 1.0 1.5 2.9 0.0 0.5 0.3 0.1 0.4 0.5 0.1 0.6 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 1.7 0.0 1.9 0.7 2.4 0.9 0.4 0.1 1.2 56.3 0.7 1.0 0.9 2.8 0.8 0.0 156.4 0.1 5.5 2.4 0.0 0.8 56.3 0.2 1.2 1.5 1.2 0.4 0.8 0.4 0.2 1.8 1.1 0.2 15.2 0.8 1.4 1.2 23.7 0.0 0.4 2.1 0.0 29.2 5.7 117.6 0.9 23.2 3.6 0.0 17.3 6.9 18.6 0.0 1.8 0.3 3.4 0.4 0.8 0.2 12.2 1.3 1.1 98.5 0.0 0.3 2.3 9.0 4.9 0.4 0.6 0.1 8.6 0.6 3.4 0.3 CACNB1 CACNLB1 ENSG00000067191 "Calcium voltage-gated channel auxiliary subunit beta 1" Q02641 17 39173453-39197703 "FDA approved drug targets, Predicted intracellular proteins" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "skeletal muscle: 328.8;tongue: 216.0" "Cell type enhanced" "Detected in many" "Astrocytes: 20.9;Excitatory neurons: 14.3;Skeletal myocytes: 13.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023343 Approved NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 37: Myocytes - Muscle contraction" "HPA023343: AB_1845866" "unprognostic (3.44e-2)" "unprognostic (1.89e-2)" "unprognostic (1.69e-3)" "prognostic unfavorable (3.80e-4)" "unprognostic (3.99e-2)" "unprognostic (1.52e-2)" "unprognostic (1.37e-2)" "unprognostic (2.80e-3)" "unprognostic (4.43e-1)" "unprognostic (1.04e-3)" "unprognostic (5.98e-2)" "unprognostic (3.38e-1)" "unprognostic (1.94e-11)" "unprognostic (7.62e-2)" "unprognostic (2.30e-1)" "unprognostic (1.34e-2)" "unprognostic (7.44e-3)" 5.7 3.6 17.8 2.6 23.7 1.4 5.6 0.0 31.7 12.2 0.0 7.6 1.5 6.3 5.4 6.8 6.9 2.1 7.5 23.4 10.9 3.2 0.9 9.3 2.5 4.4 5.9 6.7 2.6 1.6 7.7 1.7 13.0 8.1 2.5 5.5 13.5 5.4 328.8 12.1 4.1 2.9 1.0 4.7 3.7 7.6 5.0 4.4 6.8 216.0 1.8 6.5 6.5 20.4 6.1 2.7 3.3 7.6 3.6 4.4 0.1 3.6 4.4 3.3 4.1 2.0 6.0 10.4 3.6 5.4 4.7 5.6 3.2 5.9 2.4 5.0 3.7 1.5 7.4 0.8 7.4 0.2 0.9 4.9 1.9 6.9 7.8 4.3 2.4 6.4 0.9 8.9 3.5 1.7 7.6 2.8 2.4 0.9 1.9 5.1 10.9 4.6 1.3 1.9 8.3 5.0 2.1 11.2 3.5 1.2 7.9 4.1 3.4 5.9 6.8 4.4 3.7 4.1 1.5 1.7 4.8 0.0 2.4 0.0 0.4 0.0 0.6 0.1 0.9 0.0 0.6 0.8 0.1 0.0 0.2 0.3 0.0 0.6 0.1 1.0 0.1 0.2 17.8 23.7 0.0 31.7 23.4 10.9 4.4 5.9 13.0 1.0 5.0 20.4 1.4 3.2 3.2 20.9 0.8 2.9 0.7 2.3 2.8 3.1 1.5 1.1 1.7 0.0 2.2 0.0 0.0 0.1 4.0 7.1 0.0 0.6 4.2 1.1 3.3 1.5 0.0 0.4 14.3 0.9 0.1 4.9 2.6 1.7 0.0 2.1 0.4 0.1 1.0 0.0 8.3 1.4 4.1 0.8 5.1 2.4 1.8 1.6 5.4 1.0 0.6 7.2 1.0 2.5 2.1 1.5 1.0 1.2 2.3 2.4 0.0 0.0 0.8 1.4 0.0 13.4 7.0 2.9 0.8 1.1 3.0 0.1 4.6 1.6 1.0 1.1 CACNB2 "CACNLB2, MYSB" ENSG00000165995 "Calcium voltage-gated channel auxiliary subunit beta 2" Q08289 10 18140424-18543557 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Brugada syndrome, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "retina: 35.1" "Group enriched" "Detected in many" 5 "Astrocytes: 863.5;Excitatory neurons: 545.7;Inhibitory neurons: 357.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HAP1: 6.4;HSkMC: 8.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035326 Enhanced NA NA "Cluster 10: Basophils - Unknown function" "Cluster 77: Retina - Visual perception" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA035326: AB_10669903" "unprognostic (3.03e-3)" "unprognostic (3.04e-1)" "unprognostic (1.49e-2)" "unprognostic (1.16e-1)" "unprognostic (4.58e-3)" "unprognostic (4.67e-4)" "unprognostic (8.03e-2)" "unprognostic (3.76e-2)" "unprognostic (8.10e-2)" "unprognostic (1.70e-1)" "unprognostic (7.78e-4)" "unprognostic (1.40e-1)" "prognostic favorable (3.56e-5)" "unprognostic (3.48e-2)" "unprognostic (5.72e-2)" "unprognostic (1.03e-1)" "unprognostic (8.16e-2)" 2.8 9.4 1.3 2.1 3.9 1.3 3.8 5.4 12.9 7.4 0.1 17.6 1.1 12.8 2.7 5.0 10.1 2.2 17.8 5.4 7.4 3.2 10.7 3.9 0.9 0.0 0.1 13.6 7.5 0.6 19.3 0.5 0.0 8.5 3.2 35.1 3.9 8.8 1.1 4.2 11.4 5.3 0.0 1.5 7.7 2.1 2.2 0.7 2.5 0.7 0.2 16.8 4.6 1.5 0.2 1.0 0.7 0.5 0.3 0.3 0.5 0.3 0.0 0.0 0.3 0.4 0.5 0.9 0.2 0.2 0.3 0.7 6.4 0.0 0.0 0.3 2.4 0.8 1.7 1.5 1.6 0.5 1.5 8.1 0.0 0.0 0.0 0.3 0.0 1.4 0.9 1.6 0.0 0.7 0.8 1.0 2.4 0.0 0.0 0.7 0.7 0.8 0.0 0.8 2.9 0.8 0.1 0.0 0.4 0.8 0.1 0.9 0.0 0.6 1.5 0.3 0.6 1.6 1.8 1.7 0.2 1.2 0.3 1.4 0.1 0.2 0.2 0.2 0.4 0.4 0.3 0.1 0.0 0.5 0.5 0.8 0.1 0.3 0.2 0.2 1.1 0.0 1.3 3.9 5.4 12.9 5.4 7.4 0.0 0.1 0.0 0.0 2.2 1.5 2.1 0.0 0.6 863.5 0.1 3.3 1.3 0.0 1.8 31.9 1.1 1.3 22.4 0.0 0.0 0.0 108.4 0.4 0.7 2.8 1.9 0.4 0.9 1.1 13.9 1.5 37.1 0.8 545.7 0.2 0.0 3.0 0.0 2.6 0.0 3.8 0.0 0.9 0.1 8.4 357.8 9.4 0.0 0.0 1.1 0.8 0.9 0.5 1.8 96.5 0.0 15.9 0.0 95.5 13.7 0.2 2.4 4.5 0.3 2.1 5.9 0.8 0.0 75.7 6.6 2.6 14.2 0.1 0.1 0.0 4.1 0.3 1.0 5.3 5.7 1.3 CACNB3 CACNLB3 ENSG00000167535 "Calcium voltage-gated channel auxiliary subunit beta 3" P54284 12 48813794-48828941 "FDA approved drug targets, Predicted intracellular proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 84.2" "Cell type enhanced" "Detected in many" "Endometrial stromal cells: 22.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in single" "T-reg: 1.8" "Lineage enriched" "Detected in single" 10 "T-cells: 1.8" "Cell line enhanced" "Detected in many" "hTERT-RPE1: 75.9;U-937: 109.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA059515 Approved "Golgi apparatus,Vesicles" NA NA "Cluster 35: T-regs - Unknown function" "Cluster 57: Non-specific - Angiogenesis" "Cluster 32: U-937 - Innate immune response" "Cluster 36: Stromal cells - Cell proliferation" "Golgi apparatus, Vesicles" "HPA059515: AB_2684047" "unprognostic (1.77e-2)" "unprognostic (4.84e-2)" "unprognostic (2.16e-3)" "unprognostic (2.12e-2)" "unprognostic (8.76e-2)" "unprognostic (2.68e-1)" "unprognostic (2.06e-1)" "unprognostic (3.60e-2)" "unprognostic (3.27e-2)" "unprognostic (2.24e-1)" "unprognostic (5.67e-3)" "unprognostic (1.04e-1)" "unprognostic (5.44e-3)" "unprognostic (6.31e-3)" "unprognostic (6.58e-2)" "unprognostic (1.98e-1)" "unprognostic (2.78e-3)" 10.1 3.9 67.9 2.8 69.9 1.3 9.0 56.8 84.2 33.7 44.1 18.1 4.1 31.1 8.5 21.5 19.6 7.2 8.4 72.6 56.7 12.4 1.9 11.8 1.8 50.2 56.2 43.7 4.5 5.1 12.3 5.8 53.4 13.7 8.2 4.7 13.0 9.1 2.8 11.5 10.8 23.1 49.9 6.1 9.2 8.6 59.6 7.6 9.6 5.9 4.1 14.5 20.2 58.7 17.3 13.2 21.1 46.1 26.8 18.0 12.9 16.8 39.4 25.6 14.5 4.5 13.4 2.2 21.5 30.7 4.4 17.2 21.6 19.5 10.1 18.4 5.9 8.5 11.7 0.6 11.0 1.7 9.1 11.7 10.6 10.2 5.5 75.9 31.1 18.6 1.2 7.2 16.9 42.6 22.1 2.2 13.3 18.1 10.9 24.0 5.0 6.6 19.9 31.6 32.9 31.8 5.5 37.1 12.0 18.6 25.2 7.7 27.3 15.5 21.7 7.7 9.5 7.1 3.5 0.7 12.9 109.9 5.0 0.0 0.1 0.0 0.3 0.0 0.1 0.1 0.6 0.6 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 1.8 0.2 67.9 69.9 56.8 84.2 72.6 56.7 50.2 56.2 53.4 49.9 59.6 58.7 5.6 3.2 4.3 1.0 0.5 2.9 3.2 5.9 4.0 3.2 8.7 5.7 2.8 1.5 5.1 1.8 4.2 0.8 2.1 12.6 1.9 9.5 1.0 10.0 22.0 5.9 10.2 0.8 15.1 4.3 10.4 7.9 6.1 7.1 1.3 12.0 3.6 0.2 1.6 0.0 4.5 9.5 16.2 0.6 2.9 2.7 13.4 2.4 1.8 3.7 3.7 1.0 2.1 2.0 1.1 10.4 4.6 10.9 1.3 2.9 8.7 0.7 9.4 1.0 0.0 1.5 12.2 1.6 8.1 9.6 5.1 1.1 3.5 6.1 14.4 1.9 CACNB4 EJM4 ENSG00000182389 "Calcium voltage-gated channel auxiliary subunit beta 4" O00305 2 151832771-152099167 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "brain: 16.4;skin 1: 7.3" "Cell type enhanced" "Detected in many" "Excitatory neurons: 495.6;Inhibitory neurons: 470.7;Microglial cells: 136.8;Oligodendrocyte precursor cells: 155.3" "Cancer enhanced" "Detected in single" "glioma: 0.9" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in single" 5 "neutrophil: 3.4" "Lineage enriched" "Detected in single" 5 "granulocytes: 3.4" "Cell line enhanced" "Detected in some" "Hep G2: 4.1;HMC-1: 20.2;U-937: 5.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA015601 Approved NA NA "Cluster 50: Neutrophils - Cellular senescence" "Cluster 6: Brain - Smell perception" "Cluster 3: HMC-1 - Innate immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA015601: AB_1845873" "unprognostic (2.92e-1)" "unprognostic (1.98e-1)" "unprognostic (1.80e-1)" "unprognostic (1.29e-1)" "unprognostic (1.14e-1)" "unprognostic (1.49e-2)" "unprognostic (3.70e-1)" "unprognostic (9.42e-4)" "unprognostic (1.23e-1)" "unprognostic (1.98e-1)" "unprognostic (1.05e-3)" "unprognostic (2.02e-1)" "unprognostic (1.55e-2)" "unprognostic (7.26e-3)" "unprognostic (3.93e-2)" "unprognostic (9.55e-3)" "unprognostic (2.45e-1)" 0.7 0.7 4.6 0.4 12.0 0.7 1.5 15.2 16.4 0.4 1.3 0.3 0.4 0.4 0.6 1.4 0.3 0.9 0.3 6.2 2.3 1.4 0.1 2.0 0.3 0.2 5.6 0.3 0.4 0.4 1.8 0.9 0.3 2.0 0.5 1.8 1.7 1.9 0.1 7.3 0.3 0.5 0.3 0.4 0.6 2.3 6.8 1.1 1.4 0.2 1.0 2.0 0.5 6.8 0.0 0.0 0.7 0.6 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.9 0.0 1.9 0.0 0.1 0.3 3.2 0.0 0.2 4.1 0.0 0.2 20.2 0.2 0.1 0.4 0.0 1.7 0.0 0.8 0.0 0.5 0.1 0.0 0.2 0.3 0.5 0.1 0.6 2.0 0.2 0.6 1.1 0.5 1.3 0.7 0.0 0.0 0.0 0.1 3.3 0.8 0.0 1.8 2.0 0.6 0.4 0.3 0.0 0.0 0.4 5.9 0.1 0.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 3.4 0.0 0.0 0.6 0.0 0.1 4.6 12.0 15.2 16.4 6.2 2.3 0.2 5.6 0.3 0.3 6.8 6.8 1.1 12.8 53.3 80.6 0.8 12.4 16.3 3.5 30.7 9.9 6.8 7.2 1.3 0.0 3.8 3.7 4.2 0.1 0.3 0.3 3.9 0.5 0.9 3.0 3.0 1.3 0.0 0.0 495.6 1.5 0.0 7.9 1.1 5.4 0.0 84.1 0.7 0.0 3.4 20.2 470.7 0.0 0.0 1.2 7.5 2.1 3.4 2.4 1.8 136.8 1.2 2.3 1.0 155.3 31.2 1.0 0.1 4.5 2.0 29.0 0.1 0.9 1.2 3.4 0.0 0.6 1.2 0.7 4.1 3.2 8.2 0.0 1.1 6.6 0.1 16.3 CACNG1 CACNLG ENSG00000108878 "Calcium voltage-gated channel auxiliary subunit gamma 1" Q06432 17 67044554-67056797 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 55 "skeletal muscle: 327.7;tongue: 121.8" "Cell type enriched" "Detected in single" 27 "Skeletal myocytes: 8.1" "Cancer enhanced" "Detected in some" "breast cancer: 1.6;head and neck cancer: 1.8" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "HSkMC: 2.9" "Region enriched" "Detected in single" 6 "basal ganglia: 3.4" "Not detected" "Not detected" NA NA "Cluster 33: Striated muscle - Muscle contraction" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 37: Myocytes - Muscle contraction" "unprognostic (1.76e-1)" "unprognostic (9.83e-3)" "unprognostic (1.75e-5)" "unprognostic (2.60e-1)" "unprognostic (6.72e-3)" "unprognostic (2.85e-1)" "unprognostic (1.44e-2)" "unprognostic (4.84e-3)" "unprognostic (1.07e-1)" "unprognostic (4.20e-2)" "unprognostic (1.60e-1)" "unprognostic (2.31e-1)" "unprognostic (3.03e-1)" "unprognostic (1.94e-1)" 0.0 1.6 0.6 0.0 0.7 0.0 0.4 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.2 0.0 0.0 0.3 0.2 0.0 0.0 0.1 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.2 1.4 0.0 0.0 3.3 0.0 327.7 0.3 0.0 0.0 0.2 0.0 0.1 0.0 0.4 0.6 0.0 121.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.7 0.1 0.6 0.3 0.2 0.2 0.2 0.2 0.2 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CACNG2 "MGC138502, MGC138504, stargazin" ENSG00000166862 "Calcium voltage-gated channel auxiliary subunit gamma 2" Q9Y698 22 36560857-36703752 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Disease variant, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "brain: 20.7" "Cell type enhanced" "Detected in some" "Excitatory neurons: 87.5;Horizontal cells: 26.9;Inhibitory neurons: 119.7;Oligodendrocyte precursor cells: 43.7" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "SCLC-21H: 1.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 6: Brain - Smell perception" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (7.54e-2)" "unprognostic (3.06e-1)" "unprognostic (8.80e-3)" "unprognostic (2.34e-2)" "unprognostic (3.07e-2)" 0.0 0.7 5.7 0.0 7.1 0.0 0.0 13.8 20.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.0 6.0 0.0 0.0 0.0 0.0 5.9 3.8 0.0 0.0 0.0 1.2 0.0 6.5 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.1 6.2 0.0 0.0 0.0 0.0 0.0 0.0 11.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.7 7.1 13.8 20.7 6.0 6.0 5.9 3.8 6.5 2.6 6.2 11.0 0.0 0.0 0.0 3.9 0.0 0.0 0.2 0.0 0.0 8.4 0.0 0.0 0.4 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 87.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.9 119.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 7.5 0.0 0.2 0.0 43.7 2.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 CACNG3 ENSG00000006116 "Calcium voltage-gated channel auxiliary subunit gamma 3" O60359 16 24256335-24362412 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Group enriched" "Detected in some" 14 "brain: 53.4;retina: 17.7" "Group enriched" "Detected in some" 24 "Excitatory neurons: 157.1;Horizontal cells: 176.7;Inhibitory neurons: 107.6" "Cancer enriched" "Detected in single" 15 "glioma: 0.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA077238 Enhanced NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA077238: " "unprognostic (5.61e-2)" "unprognostic (3.09e-1)" "unprognostic (2.12e-1)" "unprognostic (1.17e-1)" 0.0 1.8 22.1 0.0 32.0 0.0 0.0 2.9 53.4 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 36.2 7.1 0.0 0.0 0.0 0.0 6.1 15.5 0.0 0.0 0.0 0.1 0.0 11.9 0.0 0.0 17.7 0.0 0.0 0.0 0.0 0.0 0.0 5.8 0.0 0.0 0.2 7.3 0.0 0.0 0.0 0.0 0.0 0.0 26.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.1 32.0 2.9 53.4 36.2 7.1 6.1 15.5 11.9 5.8 7.3 26.9 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 5.8 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.1 0.0 0.0 157.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 176.7 107.6 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 5.6 0.0 0.4 0.0 6.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CACNG4 "MGC11138, MGC24983" ENSG00000075461 "Calcium voltage-gated channel auxiliary subunit gamma 4" Q9UBN1 17 66964707-67033398 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 35.1;prostate: 11.7" "Cell type enriched" "Detected in some" 6 "Oligodendrocyte precursor cells: 145.3" "Group enriched" "Detected in many" 5 "breast cancer: 30.3;glioma: 35.8;ovarian cancer: 14.8;prostate cancer: 10.3" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in many" 6 "SH-SY5Y: 387.4" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "basal ganglia: 118.1" "HPA005803, HPA065370" Enhanced Approved Vesicles NA NA "Cluster 65: Brain - Ion transport" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 68: Oligodendrocytes - Mixed function" Vesicles "HPA005803: AB_2667439, HPA065370: AB_2685480" "unprognostic (1.27e-1)" "unprognostic (3.16e-1)" "unprognostic (8.87e-2)" "unprognostic (1.05e-2)" "unprognostic (6.42e-2)" "unprognostic (8.64e-3)" "unprognostic (2.91e-1)" "unprognostic (7.08e-2)" "unprognostic (3.37e-2)" "unprognostic (3.85e-2)" "unprognostic (6.03e-2)" "unprognostic (3.87e-2)" "unprognostic (2.38e-10)" "unprognostic (8.57e-3)" "unprognostic (1.23e-1)" "unprognostic (8.71e-2)" "unprognostic (4.28e-1)" 0.5 0.8 26.5 0.1 35.1 0.0 5.3 6.9 26.8 0.4 4.2 0.8 0.2 0.5 0.1 0.2 4.2 0.4 0.2 14.5 17.9 0.2 0.0 5.7 0.0 11.7 16.7 0.1 0.4 1.2 0.3 0.7 15.0 11.7 0.1 0.7 1.7 1.3 0.1 0.5 0.1 1.1 14.3 0.0 1.5 0.2 29.6 0.0 0.1 0.0 0.0 0.4 0.7 9.5 6.4 4.1 15.6 0.0 0.0 0.0 4.4 0.0 0.0 1.4 0.0 4.6 0.2 0.0 0.2 0.0 41.2 64.1 0.1 0.0 0.0 0.0 0.3 0.0 1.8 3.7 0.0 0.0 0.0 0.0 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 34.5 0.1 0.3 15.7 7.3 0.0 0.0 0.4 8.7 0.0 11.1 15.8 387.4 3.6 10.4 0.0 38.1 38.5 0.0 0.0 0.0 0.0 0.1 3.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.5 35.1 6.9 26.8 14.5 17.9 11.7 16.7 15.0 14.3 29.6 9.5 0.0 3.2 1.3 0.0 0.0 0.0 1.1 0.3 0.0 0.2 6.4 3.4 1.3 0.0 1.4 0.0 0.0 0.3 0.1 0.6 0.0 0.1 2.6 1.0 0.2 0.1 7.7 0.0 1.8 0.2 0.2 0.2 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 20.8 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 3.7 0.0 3.4 0.0 145.3 0.3 0.7 0.2 0.0 0.0 2.6 0.0 0.0 1.9 0.2 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.7 CACNG5 ENSG00000075429 "Calcium voltage-gated channel auxiliary subunit gamma 5" Q9UF02 17 66835117-66894751 "FDA approved drug targets, Predicted membrane proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Group enriched" "Detected in some" 22 "brain: 11.2;retina: 15.8" "Cell type enriched" "Detected in some" 14 "Oligodendrocyte precursor cells: 74.9" "Cancer enhanced" "Detected in single" "glioma: 0.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in all" "olfactory bulb: 124.3" "Low region specificity" "Detected in many" HPA050115 Uncertain NA NA "Cluster 77: Retina - Visual perception" "Cluster 68: Oligodendrocytes - Mixed function" "HPA050115: AB_2681022" "unprognostic (1.85e-3)" "unprognostic (3.84e-2)" "unprognostic (1.44e-1)" "unprognostic (2.46e-6)" "unprognostic (4.52e-2)" "unprognostic (1.29e-1)" 0.0 0.0 4.8 0.0 3.3 0.1 0.0 1.3 5.9 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 3.5 0.1 0.0 0.0 0.4 3.6 6.4 0.0 0.1 0.0 0.1 0.0 2.3 0.0 0.0 15.8 0.0 0.0 0.1 0.1 0.0 0.0 6.2 0.2 0.0 0.1 11.2 0.1 0.0 0.0 0.3 0.0 0.0 3.7 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.8 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 3.3 1.3 5.9 2.1 3.5 3.6 6.4 2.3 6.2 11.2 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 74.9 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CACNG6 ENSG00000130433 "Calcium voltage-gated channel auxiliary subunit gamma 6" Q9BXT2 19 53991637-54012666 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "skeletal muscle: 90.7;tongue: 29.9" "Cell type enhanced" "Detected in some" "Endometrial ciliated cells: 8.3;Horizontal cells: 1.7;Respiratory ciliated cells: 9.1;Skeletal myocytes: 2.3" "Cancer enhanced" "Detected in many" "endometrial cancer: 2.2" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 107 "basophil: 13.3;eosinophil: 8.0" "Lineage enriched" "Detected in single" 133 "granulocytes: 13.3" "Cell line enhanced" "Detected in some" "A549: 12.7;EFO-21: 23.6;HHSteC: 5.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA056615 Approved "Nucleoli fibrillar center,Cytosol" NA NA "Cluster 10: Basophils - Unknown function" "Cluster 33: Striated muscle - Muscle contraction" "Cluster 38: EFO-21 - Unknown function" "Cluster 49: Ciliated cells - Cilium organization" "Nucleoli fibrillar center" Cytosol "HPA056615: AB_2683192" "unprognostic (1.83e-1)" "unprognostic (9.51e-2)" "unprognostic (7.07e-2)" "unprognostic (8.58e-2)" "unprognostic (2.89e-2)" "unprognostic (2.27e-1)" "unprognostic (7.69e-3)" "unprognostic (2.72e-1)" "unprognostic (1.53e-1)" "unprognostic (6.07e-8)" "unprognostic (9.79e-2)" "unprognostic (1.28e-1)" 0.0 0.0 0.4 0.1 0.3 0.0 0.0 0.1 0.9 0.3 0.2 0.1 0.2 0.2 0.0 0.3 8.8 0.0 0.0 0.6 0.6 0.0 0.0 2.2 0.0 1.0 2.0 0.0 0.0 2.9 1.9 0.0 0.8 0.4 0.0 0.1 1.0 0.0 90.7 0.0 0.2 0.0 1.0 0.1 0.3 2.3 0.4 0.0 0.0 29.9 0.1 0.0 0.0 0.5 0.0 12.7 0.2 0.0 0.0 0.0 2.0 0.0 0.1 0.0 0.0 0.1 1.1 0.0 23.6 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 5.6 0.0 0.1 0.1 0.0 0.0 0.0 1.9 3.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 1.1 1.6 0.5 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 3.2 0.0 2.8 0.0 0.0 0.0 3.5 0.1 0.2 0.0 0.0 13.3 0.0 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.1 0.9 0.6 0.6 1.0 2.0 0.8 1.0 0.4 0.5 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 8.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.7 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.5 0.2 0.0 0.0 0.4 0.1 0.0 0.0 0.0 9.1 0.0 0.0 2.3 0.1 0.5 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CACNG7 ENSG00000105605 "Calcium voltage-gated channel auxiliary subunit gamma 7" P62955 19 53909278-53943950 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 56.6;retina: 17.0" "Cell type enhanced" "Detected in some" "Excitatory neurons: 32.0;Horizontal cells: 134.6;Inhibitory neurons: 43.3;Oligodendrocyte precursor cells: 23.1;Oligodendrocytes: 16.3" "Cancer enriched" "Detected in some" 16 "glioma: 29.4" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 52.8;GAMG: 14.6;HMC-1: 40.8;hTERT-RPE1: 51.4;SH-SY5Y: 32.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 65: Brain - Ion transport" "Cluster 12: NES - Nervous system development" "Cluster 62: Horizontal cells - Visual perception" "unprognostic (3.11e-2)" "unprognostic (7.18e-2)" "unprognostic (6.24e-2)" "unprognostic (3.06e-1)" "unprognostic (1.24e-1)" "unprognostic (1.01e-5)" "unprognostic (1.51e-1)" "unprognostic (7.36e-2)" 0.0 0.4 44.2 0.0 38.8 0.0 0.0 37.5 56.6 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 43.9 38.9 0.0 0.0 0.0 0.0 39.9 41.2 0.0 0.1 0.1 6.6 0.0 38.9 0.0 0.0 17.0 0.0 0.0 0.0 0.0 0.1 0.0 31.9 0.0 0.1 0.5 50.5 0.0 0.0 0.0 0.0 0.0 0.0 45.8 0.0 7.0 52.8 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 14.6 0.1 5.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.7 0.0 40.8 0.4 0.0 0.1 0.0 51.4 0.8 0.0 0.0 0.1 0.1 0.0 0.0 0.0 14.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 32.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 10.9 0.0 0.0 0.0 3.3 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 44.2 38.8 37.5 56.6 43.9 38.9 39.9 41.2 38.9 31.9 50.5 45.8 0.0 0.0 0.0 12.4 0.0 0.0 0.0 0.0 0.0 8.1 0.1 0.3 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.1 0.0 0.0 32.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 134.6 43.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 5.6 0.0 0.2 0.0 23.1 16.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.9 0.0 0.3 0.1 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CACNG8 ENSG00000142408 "Calcium voltage-gated channel auxiliary subunit gamma 8" Q8WXS5 19 53962937-53990215 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in single" 37 "brain: 33.9" "Group enriched" "Detected in many" 7 "Excitatory neurons: 61.9;Horizontal cells: 50.5;Inhibitory neurons: 66.0;Oligodendrocyte precursor cells: 29.7" "Cancer enriched" "Detected in single" 5 "glioma: 1.6" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in single" 9 "basophil: 5.5" "Lineage enriched" "Detected in single" 26 "granulocytes: 5.5" "Group enriched" "Detected in some" 5 "AF22: 7.2;HMC-1: 23.7;hTERT-RPE1: 8.4;TIME: 14.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041351 Enhanced NA NA "Cluster 38: Basophils - Unknown function" "Cluster 10: Brain - Neuronal signaling" "Cluster 3: HMC-1 - Innate immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA041351: AB_10796666" "unprognostic (7.01e-2)" "unprognostic (6.27e-2)" "unprognostic (3.06e-1)" "unprognostic (5.29e-4)" "unprognostic (9.66e-2)" "unprognostic (2.17e-2)" "unprognostic (1.38e-1)" "unprognostic (9.40e-3)" "unprognostic (6.13e-2)" "unprognostic (2.03e-1)" "unprognostic (7.63e-2)" "unprognostic (2.58e-1)" "unprognostic (2.82e-8)" "unprognostic (1.10e-1)" "unprognostic (1.35e-1)" "unprognostic (1.63e-1)" "unprognostic (1.17e-1)" 0.0 0.0 9.6 0.1 9.3 0.2 0.0 0.0 33.9 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 32.6 3.7 0.0 0.0 0.0 0.1 0.7 1.2 0.0 0.0 0.3 0.6 0.0 0.4 0.1 0.0 0.9 0.1 0.0 0.4 0.2 0.1 0.1 1.8 0.1 0.2 0.6 6.4 0.0 0.1 0.2 0.0 0.0 0.0 9.4 0.0 2.4 7.2 0.2 0.0 0.1 0.1 0.1 0.4 0.0 0.1 0.5 0.4 0.0 0.2 0.0 0.3 0.2 0.0 0.1 0.0 0.0 1.0 2.7 0.7 0.1 1.1 0.0 23.7 0.3 0.0 0.1 0.3 8.4 2.4 0.1 0.1 0.2 0.0 0.1 0.0 0.0 1.5 0.3 3.0 0.0 0.0 0.0 0.0 0.1 0.1 1.5 0.1 0.1 0.0 0.2 0.2 0.0 14.9 0.1 1.3 0.0 0.0 0.1 0.0 0.0 2.3 0.0 0.1 5.5 0.1 0.6 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.0 9.6 9.3 0.0 33.9 32.6 3.7 0.7 1.2 0.4 1.8 6.4 9.4 3.6 0.0 0.0 5.9 0.4 1.7 1.5 0.0 0.0 6.9 0.1 1.5 3.3 0.0 0.7 1.8 0.0 0.0 0.0 0.4 0.0 1.9 2.3 0.7 1.0 6.4 0.0 2.7 61.9 0.0 0.0 0.6 0.0 1.0 0.0 0.0 5.7 0.0 0.1 50.5 66.0 0.3 0.0 0.8 2.1 1.7 0.0 0.5 0.0 0.0 0.3 1.1 1.0 29.7 4.3 0.2 0.1 0.4 0.0 1.5 0.1 0.2 2.6 1.7 0.0 3.8 1.0 6.2 7.1 0.0 1.1 0.1 0.6 0.5 0.9 1.3 CALCRL "CGRPR, CRLR" ENSG00000064989 "Calcitonin receptor like receptor" Q16602 2 187341964-187448460 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 70.7;lung: 76.8" "Cell type enhanced" "Detected in many" "Adipocytes: 138.3;Endometrial stromal cells: 92.7;Endothelial cells: 248.7;Hepatic stellate cells: 259.2;Oligodendrocyte precursor cells: 293.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "classical monocyte: 2.6;myeloid DC: 9.2;plasmacytoid DC: 2.6" "Group enriched" "Detected in many" 6 "dendritic cells: 9.2;monocytes: 2.6" "Cell line enriched" "Detected in some" 4 "HUVEC TERT2: 173.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008070, HPA046515" Uncertain Supported "Plasma membrane" NA NA "Cluster 28: Myeloid DCs - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "Plasma membrane" "HPA008070: AB_1845912, HPA046515: AB_2679681" "unprognostic (7.06e-2)" "unprognostic (5.71e-2)" "unprognostic (1.59e-1)" "unprognostic (2.13e-1)" "unprognostic (3.44e-3)" "unprognostic (7.60e-3)" "unprognostic (9.25e-3)" "unprognostic (4.14e-2)" "unprognostic (7.71e-3)" "unprognostic (3.32e-1)" "unprognostic (3.77e-1)" "unprognostic (3.44e-1)" "unprognostic (1.51e-3)" "unprognostic (1.90e-2)" "unprognostic (2.02e-1)" "unprognostic (1.30e-1)" "unprognostic (2.50e-2)" 70.7 6.3 3.4 12.3 4.0 0.4 15.8 6.1 4.4 27.8 3.4 6.9 6.0 21.5 4.6 8.6 11.4 24.4 20.4 3.9 3.8 14.0 12.6 76.8 7.9 11.1 6.2 15.7 4.3 13.0 3.6 11.7 10.8 7.3 9.5 0.9 7.1 7.7 6.2 3.9 6.3 27.1 15.5 8.6 7.1 2.7 3.9 4.6 28.3 20.2 9.1 14.1 4.7 15.2 0.2 0.0 8.8 0.0 6.2 1.6 0.0 0.8 1.3 0.1 1.0 0.0 1.0 0.0 2.3 0.7 0.2 0.0 0.0 0.6 0.2 1.5 0.5 1.5 0.0 0.2 4.9 0.2 0.0 4.6 0.2 0.3 2.1 0.5 173.6 0.1 0.0 2.5 1.2 0.0 0.8 0.1 0.5 0.0 0.0 0.0 3.1 0.5 40.5 0.0 0.4 0.2 0.0 0.0 0.4 0.5 0.0 0.2 25.3 0.7 0.1 0.1 0.4 6.2 0.1 0.7 0.4 0.0 0.0 0.0 2.6 0.0 0.0 0.5 0.0 0.2 0.0 0.0 9.2 0.0 0.8 0.1 0.1 1.0 1.0 2.6 0.0 0.9 3.4 4.0 6.1 4.4 3.9 3.8 11.1 6.2 10.8 15.5 3.9 15.2 138.3 0.0 11.9 19.6 1.2 9.3 2.3 1.7 21.6 0.2 0.8 1.8 12.3 2.8 3.6 0.0 0.0 0.4 2.4 0.0 3.9 0.3 0.8 3.1 92.7 248.7 0.0 4.8 15.4 0.4 0.2 56.5 1.1 1.7 5.1 12.3 259.2 1.8 0.9 0.0 2.1 0.0 2.0 10.3 29.7 1.0 7.8 15.4 10.6 47.8 16.1 0.0 1.0 293.0 1.0 0.1 0.0 2.6 4.9 1.9 0.0 13.2 2.8 0.1 6.6 4.1 21.5 1.3 0.7 18.2 6.8 0.3 3.0 6.0 0.0 1.8 CALM1 "CALML2, CAMI, DD132, PHKD" ENSG00000198668 "Calmodulin 1" P0DP23 14 90396502-90408268 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction" "Disease variant, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB018558, HPA044999" Supported Supported Cytosol NA NA 75000000 "Cluster 44: Non-specific - Transcription" "Cluster 10: Brain - Neuronal signaling" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 7: Non-specific - Mitochondria" Cytosol "CAB018558: AB_2069454, HPA044999: AB_2679177" "unprognostic (5.35e-3)" "unprognostic (3.96e-1)" "unprognostic (4.99e-3)" "unprognostic (2.91e-2)" "unprognostic (1.07e-1)" "unprognostic (2.87e-2)" "unprognostic (1.99e-3)" "unprognostic (1.52e-1)" "unprognostic (6.44e-2)" "unprognostic (1.16e-3)" "prognostic favorable (5.62e-4)" "unprognostic (2.77e-1)" "prognostic favorable (6.49e-4)" "unprognostic (2.66e-1)" "unprognostic (2.68e-1)" "unprognostic (1.11e-2)" "prognostic unfavorable (2.38e-5)" 264.2 143.5 429.9 152.3 537.5 349.1 123.1 442.8 839.7 134.2 259.8 332.9 289.6 105.1 209.7 304.6 251.4 153.8 287.0 635.9 371.6 326.3 210.9 209.1 165.7 466.2 374.6 104.4 121.7 225.5 143.9 207.4 447.5 169.5 312.2 241.6 188.0 215.3 588.9 104.0 279.2 227.2 328.7 166.6 202.2 123.6 443.5 146.5 118.0 185.6 210.5 191.6 125.2 527.2 189.3 256.3 308.0 115.7 332.2 286.5 256.9 347.4 295.3 260.0 283.2 278.1 320.9 200.8 171.1 413.0 123.4 309.4 194.6 490.1 431.0 398.3 119.7 212.4 211.0 264.1 185.9 327.6 167.2 188.0 232.7 261.6 93.1 173.6 592.9 140.3 101.3 270.0 353.9 653.7 112.4 316.2 178.4 521.1 351.6 216.9 264.9 134.4 215.3 574.5 621.2 259.1 292.3 507.7 195.5 254.0 335.6 112.0 363.1 212.9 137.7 224.8 289.0 149.5 371.0 222.2 335.9 267.6 301.5 1289.6 356.8 826.7 1005.3 420.4 1230.3 496.8 1039.1 1079.6 483.1 400.2 745.7 882.7 513.3 1036.9 647.3 453.3 1168.3 1477.9 429.9 537.5 442.8 839.7 635.9 371.6 466.2 374.6 447.5 328.7 443.5 527.2 1812.3 387.8 374.4 119.8 573.2 567.1 572.2 604.2 543.5 1729.1 343.7 514.8 867.5 346.0 523.1 399.1 123.0 427.7 1471.8 828.8 459.7 550.8 154.9 1026.1 249.0 996.0 599.8 143.5 367.6 444.7 984.2 521.4 317.0 377.6 490.3 148.5 652.5 333.7 795.1 604.0 258.9 513.9 730.4 286.5 837.4 101.5 210.6 639.9 627.9 131.2 856.3 1061.8 1100.9 108.0 188.9 534.2 615.8 500.2 591.8 287.7 1637.2 1430.5 1618.4 321.1 315.5 387.5 901.6 128.8 199.8 553.8 580.4 1147.6 1139.3 247.8 666.6 458.5 CALY "CALCYON, DRD1IP, NSG3" ENSG00000130643 "Calcyon neuron specific vesicular protein" Q9NYX4 10 133324072-133336935 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 11 "brain: 236.9;pituitary gland: 167.6" "Cell type enhanced" "Detected in some" "Bipolar cells: 155.7;Excitatory neurons: 72.6;Horizontal cells: 72.3;Inhibitory neurons: 128.5" "Cancer enriched" "Detected in some" 4 "pancreatic cancer: 7.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042283 Enhanced NA NA "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 56: Bipolar cells - Visual perception" "HPA042283: AB_10794417" "unprognostic (1.43e-2)" "unprognostic (7.84e-2)" "unprognostic (3.77e-3)" "unprognostic (1.41e-2)" "unprognostic (7.32e-2)" "unprognostic (9.81e-3)" "unprognostic (2.56e-1)" "unprognostic (7.48e-2)" "unprognostic (1.36e-1)" "unprognostic (1.18e-1)" "prognostic favorable (3.54e-4)" "unprognostic (1.23e-2)" "unprognostic (4.19e-10)" "unprognostic (8.04e-3)" "unprognostic (1.29e-1)" "unprognostic (3.60e-1)" "unprognostic (1.63e-1)" 0.2 17.9 55.4 0.8 42.4 0.1 0.1 2.5 75.0 0.2 0.0 4.7 2.4 0.0 0.1 0.1 0.2 0.0 0.2 38.1 236.9 0.2 0.3 0.4 0.2 47.6 74.8 0.2 3.4 0.6 167.6 0.0 71.8 0.5 0.5 11.1 0.2 0.1 0.1 0.3 2.3 0.3 30.1 0.6 2.4 4.3 88.5 0.0 0.4 0.0 0.1 0.2 0.9 35.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 55.4 42.4 2.5 75.0 38.1 236.9 47.6 74.8 71.8 30.1 88.5 35.0 0.2 0.0 0.0 26.1 0.1 0.3 0.0 0.0 0.0 155.7 0.8 0.9 2.8 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.1 2.2 0.0 0.5 0.6 19.5 0.0 72.6 0.0 0.0 1.3 2.0 0.0 0.0 0.0 0.0 0.0 0.1 72.3 128.5 1.5 0.0 0.0 0.4 2.0 0.0 0.2 0.0 18.7 0.0 11.5 0.0 10.6 20.1 0.6 0.0 0.4 0.1 0.6 0.0 0.4 0.0 31.7 0.0 0.2 0.5 16.3 7.9 0.0 0.0 0.3 2.8 0.2 0.1 0.0 CAMLG "CAML, GET2" ENSG00000164615 "Calcium modulating ligand" P49069 5 134738495-134752157 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "ER-Golgi transport, Host-virus interaction, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in all" 5 "Early spermatids: 845.6;Late spermatids: 1655.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA052636, HPA056472" Approved Approved Nucleoplasm,Nucleoli,Vesicles NA NA "Cluster 5: Granulocytes - Unknown function" "Cluster 35: Non-specific - Unknown function" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 31: Spermatids - Spermatogenesis" Vesicles "Nucleoplasm, Nucleoli" "HPA052636: AB_2681893, HPA056472: AB_2683143" "unprognostic (9.23e-2)" "unprognostic (8.54e-2)" "unprognostic (2.95e-1)" "unprognostic (2.21e-1)" "unprognostic (1.07e-1)" "unprognostic (1.07e-2)" "unprognostic (3.68e-2)" "unprognostic (5.41e-3)" "unprognostic (3.07e-1)" "unprognostic (8.54e-2)" "unprognostic (5.34e-3)" "unprognostic (4.58e-2)" "prognostic unfavorable (1.09e-5)" "unprognostic (3.26e-2)" "unprognostic (1.43e-2)" "unprognostic (2.19e-1)" "unprognostic (3.16e-1)" 52.3 37.2 50.6 17.5 52.1 31.7 42.1 50.7 69.4 57.0 48.2 54.8 34.4 45.8 48.2 29.5 45.3 27.4 26.9 52.3 55.9 29.7 29.3 28.6 26.2 51.9 53.8 68.6 30.7 27.0 43.1 17.9 54.3 34.9 15.9 29.1 29.0 31.8 60.4 36.7 30.4 28.5 52.8 26.1 36.5 51.3 52.1 25.8 27.0 35.6 25.3 44.2 41.1 53.3 27.5 22.2 33.0 64.1 76.3 118.3 14.4 39.0 55.8 26.8 52.8 38.9 40.1 113.9 56.2 27.5 42.7 34.2 29.2 46.9 35.0 54.3 54.5 29.9 33.2 32.8 56.3 13.7 89.2 96.9 49.5 35.1 57.9 92.3 54.8 49.0 18.6 47.1 39.9 31.2 43.1 58.2 17.1 34.7 21.5 46.2 40.7 44.3 46.0 26.4 52.2 36.9 27.1 15.3 97.1 40.8 48.4 33.9 53.2 24.5 16.4 40.2 35.2 45.8 55.1 42.5 46.2 48.5 14.8 62.0 26.4 60.7 30.5 31.8 41.1 43.5 43.5 38.4 29.1 39.5 45.0 44.2 47.9 31.4 44.6 26.1 52.6 31.6 50.6 52.1 50.7 69.4 52.3 55.9 51.9 53.8 54.3 52.8 52.1 53.3 86.8 38.5 36.4 13.7 92.9 167.1 107.0 113.6 157.1 80.5 121.9 124.7 45.1 100.1 68.9 42.3 25.0 50.3 93.3 42.8 92.0 63.9 845.6 57.6 116.4 99.5 62.4 76.6 29.4 90.9 62.5 107.4 32.6 61.7 123.4 66.6 102.4 69.1 69.9 55.5 32.0 69.4 107.8 111.5 130.8 1655.8 168.0 76.6 96.0 10.3 126.9 127.7 90.6 15.1 18.6 67.5 58.0 132.4 55.2 148.6 158.2 199.1 51.3 71.4 98.6 119.5 109.7 241.5 68.6 119.3 201.6 73.2 101.6 67.9 90.9 107.9 CARTPT CART ENSG00000164326 "CART prepropeptide" Q16568 5 71719275-71721048 "FDA approved drug targets, Human disease related genes, Predicted secreted proteins" "Neuropeptide, Neurotransmitter" "FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "adrenal gland: 118.6;brain: 183.6" "Group enriched" "Detected in some" 5 "Bipolar cells: 47.4;Early spermatids: 25.4;Prostatic glandular cells: 39.5;Spermatocytes: 55.7" "Cancer enriched" "Detected in many" 9 "breast cancer: 117.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "hippocampal formation: 209.0" "CAB025515, HPA046278, CAB079776" Enhanced Supported "Secreted to blood" NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 66: Spermatocytes - Spermatogenesis" "CAB025515: , CAB079776: , HPA046278: AB_10961570" "unprognostic (1.37e-1)" "unprognostic (1.43e-1)" "unprognostic (2.27e-1)" "unprognostic (3.45e-2)" "unprognostic (6.67e-2)" "prognostic unfavorable (4.36e-4)" "unprognostic (1.14e-1)" 2.4 118.6 85.6 4.4 10.1 0.0 9.3 2.6 48.9 0.0 3.9 16.8 5.5 2.8 0.7 0.3 0.4 0.2 0.1 28.0 134.0 0.3 0.0 0.1 0.0 69.8 111.9 0.1 0.5 0.0 5.2 0.0 183.6 8.6 4.5 21.4 0.1 0.0 0.0 0.1 3.4 15.1 24.5 0.0 14.6 7.1 102.4 0.2 5.4 0.0 0.0 0.0 0.3 9.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 85.6 10.1 2.6 48.9 28.0 134.0 69.8 111.9 183.6 24.5 102.4 9.8 0.1 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 47.4 0.2 0.3 0.1 0.0 0.0 0.0 8.4 0.0 0.0 0.0 0.0 0.0 25.4 1.6 0.1 1.0 7.1 0.0 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.2 0.6 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.1 0.0 0.0 1.2 0.0 39.5 0.0 0.0 0.0 8.1 0.0 0.0 0.1 55.7 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.2 CASP3 "apopain, CPP32, CPP32B, Yama" ENSG00000164305 "Caspase 3" P42574 4 184627696-184649509 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Apoptosis "Hydrolase, Protease, Thiol protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Plasma cells: 118.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 7 "basophil: 571.0;eosinophil: 408.6" "Lineage enriched" "Detected in all" 8 "granulocytes: 571.0" "Cell line enhanced" "Detected in all" "Karpas-707: 259.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000091, HPA002643, CAB008381" Enhanced Approved Nucleoplasm,Mitochondria NA NA 94000 "Cluster 2: Granulocytes - Unknown function" "Cluster 9: Intestine - Unknown function" "Cluster 2: Karpas-707 - Immune response" "Cluster 55: Plasma cells - Humoral immune response" Mitochondria Nucleoplasm "CAB000091: , CAB008381: AB_590737, HPA002643: AB_1846048" "unprognostic (1.38e-1)" "unprognostic (1.06e-1)" "unprognostic (2.21e-2)" "prognostic favorable (2.24e-4)" "unprognostic (2.29e-3)" "unprognostic (3.58e-2)" "unprognostic (9.57e-3)" "unprognostic (5.86e-2)" "unprognostic (3.56e-2)" "unprognostic (1.12e-2)" "unprognostic (1.70e-2)" "unprognostic (2.41e-1)" "prognostic unfavorable (2.30e-5)" "unprognostic (1.41e-2)" "unprognostic (5.74e-3)" "unprognostic (1.30e-1)" "unprognostic (4.05e-3)" 16.3 12.1 11.3 26.6 10.9 32.8 16.3 18.6 11.4 12.7 10.0 34.2 54.1 12.7 12.9 27.7 9.2 19.9 14.7 10.8 12.2 8.5 22.0 12.8 43.4 10.8 11.5 8.9 13.4 9.0 8.8 26.1 11.4 11.3 33.9 12.7 13.2 10.6 13.9 16.1 41.8 15.3 11.6 23.0 31.2 9.3 11.3 39.0 10.6 14.1 41.9 24.4 12.0 13.0 31.0 16.7 65.3 31.6 39.4 52.2 37.6 90.2 67.7 61.9 35.4 30.7 25.2 42.4 13.9 44.1 29.2 25.5 52.1 32.1 69.7 109.9 28.7 68.2 12.9 71.4 47.3 55.9 62.3 71.7 38.3 39.3 31.4 44.4 77.6 43.1 57.2 259.8 64.5 13.2 89.1 51.8 65.1 33.7 20.9 63.6 30.8 41.2 52.9 49.3 37.1 40.5 39.1 35.1 52.1 64.3 19.2 35.9 54.1 28.2 25.9 21.1 42.4 118.9 121.6 29.2 34.2 38.5 40.9 571.0 26.1 408.6 32.1 43.3 34.4 26.0 29.5 46.3 33.3 18.6 22.2 32.8 35.6 62.0 71.0 26.5 64.1 47.5 11.3 10.9 18.6 11.4 10.8 12.2 10.8 11.5 11.4 11.6 11.3 13.0 28.6 19.2 15.8 26.4 32.3 48.7 22.2 34.1 35.9 18.6 21.7 17.0 17.5 5.7 36.3 12.9 0.0 46.9 54.8 37.4 13.7 18.4 9.6 24.9 17.1 26.6 18.0 62.3 9.6 23.7 33.6 19.5 24.5 24.9 17.7 24.8 21.0 15.3 23.9 13.5 12.6 37.6 44.7 27.0 17.4 4.0 7.5 33.3 30.2 13.1 41.5 15.4 37.0 11.1 18.4 25.0 18.8 7.5 118.6 20.1 26.6 8.4 30.4 11.3 13.1 19.0 20.8 7.9 16.4 34.6 28.6 51.4 43.8 23.1 24.4 36.7 CASR "FHH, GPRC2A, HHC, HHC1, NSHPT" ENSG00000036828 "Calcium sensing receptor" P41180 3 122183668-122291629 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Plasma proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 29 "parathyroid gland: 654.4" "Cell type enhanced" "Detected in some" "Alveolar cells type 1: 25.6;Alveolar cells type 2: 20.2;Cholangiocytes: 27.1;Distal tubular cells: 13.7;Enteroendocrine cells: 11.5;Granulosa cells: 20.7;Respiratory ciliated cells: 15.3" "Cancer enriched" "Detected in some" 7 "pancreatic cancer: 5.5" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Not detected" "Not detected" "HPA039686, HPA050335" Enhanced NA NA "Cluster 48: Parathyroid gland - membrane proteins" "Cluster 40: Granulosa cells - Unknown function" "HPA039686: AB_10673536, HPA050335: AB_2681092" "unprognostic (1.97e-2)" "unprognostic (7.40e-2)" "unprognostic (8.20e-4)" "unprognostic (3.15e-1)" "unprognostic (8.55e-4)" "unprognostic (1.58e-1)" "unprognostic (7.32e-2)" "unprognostic (7.67e-2)" "unprognostic (1.62e-1)" "unprognostic (1.48e-1)" "unprognostic (1.91e-5)" "unprognostic (2.72e-1)" "unprognostic (2.26e-1)" "unprognostic (1.24e-2)" 0.1 0.1 1.5 0.1 1.0 0.8 0.0 1.7 1.6 0.0 0.3 0.1 0.8 0.0 0.1 0.0 0.1 4.2 0.0 1.0 0.6 22.4 0.2 0.0 0.2 0.6 1.1 0.5 9.6 654.4 0.2 0.0 0.8 0.1 0.2 1.5 0.1 0.0 0.1 0.2 0.5 0.0 0.2 0.1 2.8 0.2 1.7 0.1 0.7 0.0 0.2 0.3 0.0 1.7 0.1 0.2 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.3 0.2 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.3 0.0 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.8 0.3 0.1 0.1 0.2 0.1 0.0 0.3 0.2 0.0 0.2 0.2 0.3 0.2 0.0 0.3 0.2 0.1 0.1 0.1 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 1.5 1.0 1.7 1.6 1.0 0.6 0.6 1.1 0.8 0.2 1.7 1.7 0.0 25.6 20.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 27.1 5.6 3.7 0.0 0.0 0.0 0.0 13.7 4.3 0.5 0.0 0.0 0.5 11.5 0.0 0.3 0.2 0.0 1.6 0.0 0.0 1.3 20.7 0.0 0.1 0.1 0.0 0.1 0.6 0.0 1.0 0.0 1.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.1 0.4 0.0 0.0 0.0 0.2 15.3 1.0 0.0 0.0 1.5 0.0 0.5 0.0 0.0 0.0 0.9 0.8 0.0 0.0 CAT ENSG00000121691 Catalase P04040 11 34438934-34472060 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Hydrogen peroxide" "Mitogen, Oxidoreductase, Peroxidase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 1217.3" "Cell type enhanced" "Detected in many" "Erythroid cells: 722.4;Hepatocytes: 443.4;Proximal tubular cells: 333.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in all" 13 "eosinophil: 4736.8" "Lineage enriched" "Detected in all" 13 "granulocytes: 4736.8" "Cell line enhanced" "Detected in many" "HL-60: 391.4;THP-1: 321.2;U-937: 265.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001515, HPA051282, HPA055838" Enhanced Enhanced Vesicles NA NA 760000000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 85: Liver - Metabolism" "Cluster 32: U-937 - Innate immune response" "Cluster 6: Erythroid cells - Oxygen transport" Vesicles "CAB001515: AB_384710, HPA051282: AB_2681419, HPA055838: AB_2682937" "unprognostic (3.62e-2)" "unprognostic (2.72e-1)" "unprognostic (3.59e-3)" "unprognostic (5.43e-2)" "unprognostic (4.44e-2)" "unprognostic (5.80e-3)" "prognostic favorable (9.67e-4)" "unprognostic (9.95e-3)" "unprognostic (3.22e-1)" "unprognostic (7.23e-2)" "unprognostic (3.34e-2)" "unprognostic (9.77e-2)" "prognostic favorable (1.96e-8)" "unprognostic (1.01e-1)" "unprognostic (7.31e-2)" "unprognostic (4.77e-2)" "unprognostic (6.59e-3)" 281.3 115.1 27.1 52.1 29.6 407.7 123.6 27.9 35.5 82.0 39.4 82.6 145.1 53.1 34.8 40.1 86.8 59.8 58.1 26.6 29.4 296.6 1217.3 163.2 58.4 35.2 29.4 46.7 86.3 43.2 13.6 78.0 34.3 66.8 71.3 9.8 83.7 64.0 103.8 70.6 136.3 59.4 29.6 78.6 74.1 11.4 29.5 74.9 122.6 136.6 56.7 105.8 39.9 40.8 31.7 34.3 24.5 38.9 233.2 100.6 52.3 39.3 49.8 43.3 47.1 19.7 30.9 78.3 37.5 79.2 63.9 73.9 42.3 42.9 47.3 68.8 38.8 65.6 34.0 113.7 27.6 391.4 31.1 54.5 29.3 13.2 5.1 59.9 53.2 46.2 139.3 31.3 55.1 30.2 81.1 77.4 0.1 148.7 82.6 56.5 117.9 64.9 120.2 117.2 13.1 19.8 44.5 70.6 60.0 0.0 101.4 321.2 38.3 25.9 24.9 65.4 23.8 25.0 15.2 16.8 51.3 265.6 19.3 256.5 324.7 4736.8 54.4 265.1 64.6 133.9 63.7 61.0 353.5 124.1 61.7 66.7 290.2 105.7 298.5 235.8 92.7 397.9 27.1 29.6 27.9 35.5 26.6 29.4 35.2 29.4 34.3 29.6 29.5 40.8 196.9 227.6 275.9 41.1 53.8 28.9 93.7 44.9 27.9 13.5 42.6 36.1 44.9 82.9 66.9 73.5 27.1 96.8 92.0 59.4 225.0 36.0 2.7 72.2 41.4 43.8 48.0 722.4 12.6 26.2 30.0 53.1 54.6 29.3 24.0 38.7 57.1 443.4 138.5 0.0 1.2 56.9 91.6 125.5 95.8 6.2 78.3 93.9 26.6 16.9 253.4 19.5 28.8 22.6 45.6 15.3 44.8 77.5 25.4 37.0 151.6 333.2 96.9 19.4 78.9 46.6 68.0 6.3 11.3 24.4 27.1 40.5 37.7 57.7 95.6 97.5 CCDC51 FLJ12436 ENSG00000164051 "Coiled-coil domain containing 51" Q96ER9 3 48432164-48440456 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Proximal tubular cells: 43.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010980, HPA011408" Supported Supported Nucleoplasm,Centrosome,Mitochondria NA NA "Cluster 12: Non-specific - Basic cellular processes" "Cluster 39: Non-specific - Mitochondria" "Cluster 30: Epithelial cell lines - Translation" "Cluster 39: Non-specific - Basic cellular processes" "Nucleoplasm, Mitochondria" Centrosome "HPA010980: AB_1846155, HPA011408: AB_2072212" "unprognostic (1.24e-2)" "unprognostic (5.23e-2)" "unprognostic (5.03e-2)" "unprognostic (1.29e-1)" "unprognostic (1.95e-1)" "unprognostic (3.50e-1)" "unprognostic (2.75e-3)" "unprognostic (4.71e-3)" "unprognostic (1.26e-2)" "unprognostic (3.04e-1)" "unprognostic (3.26e-2)" "unprognostic (7.70e-2)" "unprognostic (1.47e-3)" "unprognostic (6.46e-3)" "unprognostic (1.17e-1)" "unprognostic (1.02e-1)" "unprognostic (1.77e-1)" 10.1 13.7 10.7 7.3 10.9 5.0 8.7 10.8 11.6 8.3 22.2 12.2 11.0 8.0 10.1 13.8 8.8 5.4 11.9 11.1 10.6 13.9 13.0 6.7 9.6 11.3 10.8 7.7 5.4 9.4 6.1 8.2 11.3 6.7 13.6 7.7 7.0 9.0 15.5 10.1 8.6 9.0 10.7 12.6 7.6 7.8 11.7 9.9 10.3 11.7 11.8 9.0 9.5 10.7 22.7 26.7 15.7 18.7 23.1 24.2 43.6 14.6 13.4 28.6 23.2 42.9 36.9 48.6 20.5 11.7 21.6 32.2 39.5 47.8 17.4 22.9 25.6 41.4 44.1 32.7 35.3 20.4 18.2 18.4 106.8 35.6 38.8 15.7 16.7 28.0 23.4 13.7 27.7 21.4 24.1 26.5 34.8 48.2 42.8 16.5 18.6 37.7 39.3 27.8 13.1 27.2 24.2 26.2 39.9 14.7 28.2 31.3 12.6 16.5 22.3 41.6 28.5 22.0 34.8 25.5 22.0 43.8 16.0 3.0 14.1 7.0 15.5 14.9 15.8 28.1 14.5 19.7 25.5 23.0 14.8 17.4 6.0 16.5 9.1 21.1 19.8 14.6 10.7 10.9 10.8 11.6 11.1 10.6 11.3 10.8 11.3 10.7 11.7 10.7 7.1 12.8 2.6 2.6 5.9 4.7 3.7 28.8 17.6 7.3 6.6 8.1 8.2 15.7 12.8 9.2 0.0 40.1 5.0 12.6 23.5 15.1 3.3 19.4 7.3 5.9 5.4 5.9 2.4 12.4 22.0 10.0 6.6 16.5 3.8 10.1 4.6 13.1 15.9 8.4 2.4 7.6 14.2 3.8 3.3 2.7 12.2 4.4 14.2 1.9 9.1 11.0 11.3 3.5 3.2 15.2 8.0 13.2 5.1 5.4 21.6 43.4 9.3 10.7 6.6 4.0 6.2 7.2 16.3 13.0 4.7 6.7 4.8 20.0 13.4 3.4 CCKAR ENSG00000163394 "Cholecystokinin A receptor" P32238 4 26481396-26490484 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.9;gallbladder: 29.2;stomach 1: 16.5" "Not detected" "Not detected" "Cancer enhanced" "Detected in single" "stomach cancer: 0.5" "Group enriched" "Detected in some" 5 "hypothalamus: 5.1;midbrain: 6.9" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in many" "hypothalamus: 7.2" "Region enhanced" "Detected in all" "midbrain: 12.6" HPA073900 Approved "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Cluster 12: Smooth muscle tissue - Mixed function" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane, Cytosol" Nucleoplasm "HPA073900: " "unprognostic (7.48e-2)" "unprognostic (3.70e-2)" "unprognostic (7.13e-2)" "unprognostic (3.08e-2)" "unprognostic (3.36e-1)" "unprognostic (3.79e-1)" 0.0 0.0 0.5 0.0 0.4 0.0 0.1 0.0 0.4 0.0 0.0 0.3 1.6 0.0 0.0 0.0 0.0 29.2 0.0 0.6 5.1 0.1 0.0 0.0 0.0 0.8 6.9 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 16.5 0.1 1.1 0.3 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.4 0.0 0.4 0.6 5.1 0.8 6.9 0.6 0.6 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CCKBR ENSG00000110148 "Cholecystokinin B receptor" P32239 11 6259806-6272127 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 29 "brain: 14.1;pancreas: 27.1;stomach 1: 42.0" "Group enriched" "Detected in some" 4 "Excitatory neurons: 14.6;Gastric mucus-secreting cells: 14.3;Granulosa cells: 23.3" "Cancer enriched" "Detected in some" 8 "testis cancer: 9.6" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 7 "NTERA-2: 73.4" "Low region specificity" "Detected in many" NA NA "Cluster 22: Non-specific - Unknown function" "Cluster 5: NTERA-2 - Transcription" "Cluster 40: Granulosa cells - Unknown function" "unprognostic (2.82e-1)" "unprognostic (4.62e-2)" "unprognostic (1.79e-3)" "unprognostic (2.19e-1)" "unprognostic (1.95e-1)" "unprognostic (6.34e-4)" "unprognostic (8.01e-2)" "unprognostic (3.01e-2)" "unprognostic (9.00e-2)" "unprognostic (3.30e-2)" "unprognostic (2.06e-1)" "unprognostic (2.92e-1)" "unprognostic (1.30e-2)" 0.1 0.2 8.2 0.0 11.7 0.0 0.0 6.3 14.1 0.0 0.3 0.2 0.3 0.3 0.0 0.0 0.3 0.0 0.0 11.9 1.7 0.0 0.0 0.0 0.0 3.7 1.8 0.1 27.1 0.0 0.9 0.0 3.8 0.5 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 1.3 0.0 42.0 0.5 2.6 0.0 0.2 0.0 0.0 0.0 0.0 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 8.4 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 73.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.0 10.5 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.2 11.7 6.3 14.1 11.9 1.7 3.7 1.8 3.8 1.3 2.6 6.6 0.0 0.0 0.0 0.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.0 14.6 1.3 0.0 0.2 14.3 0.1 0.0 23.3 0.0 0.0 0.1 0.0 4.0 0.0 0.0 0.0 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.5 0.7 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.7 1.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 CCND1 "BCL1, D11S287E, PRAD1, U21B31" ENSG00000110092 "Cyclin D1" P24385 11 69641156-69654474 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins" "Cell cycle, Cell division, DNA damage, Transcription, Transcription regulation" "Cyclin, Repressor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Basal respiratory cells: 499.7;Ductal cells: 504.0;Pancreatic endocrine cells: 622.1;Urothelial cells: 412.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in single" "myeloid DC: 1.1" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "U-266/70: 874.2;WM-115: 1239.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000024, HPA027802" Uncertain Supported Nucleoplasm Yes No "Cluster 23: Antigen presenting cells - Antigen presentation" "Cluster 18: Non-specific - Mitochondria" "Cluster 17: WM-115 - Nervous system development" "Cluster 1: Pancreatic cells - Digestion" Nucleoplasm "CAB000024: AB_563678, HPA027802: AB_2672390" "unprognostic (4.90e-2)" "unprognostic (1.54e-1)" "unprognostic (7.62e-2)" "unprognostic (1.39e-2)" "unprognostic (2.18e-1)" "prognostic unfavorable (5.51e-4)" "unprognostic (1.38e-1)" "unprognostic (2.53e-2)" "unprognostic (9.46e-2)" "unprognostic (4.84e-3)" "prognostic unfavorable (1.96e-4)" "unprognostic (4.39e-2)" "unprognostic (2.61e-3)" "unprognostic (4.38e-3)" "unprognostic (1.16e-1)" "unprognostic (6.40e-3)" "unprognostic (2.57e-1)" 55.6 29.2 12.1 10.0 14.6 1.5 40.2 15.0 11.9 17.0 33.4 19.8 22.7 14.8 27.6 72.9 30.8 19.5 64.9 10.8 14.6 32.2 107.3 61.1 10.5 17.5 15.5 4.6 86.3 82.7 25.7 63.7 18.3 53.3 17.2 3.2 30.4 50.4 3.6 120.3 16.0 23.3 15.9 37.2 52.7 3.2 21.7 9.9 45.5 5.2 19.0 29.5 43.9 24.0 467.3 183.0 59.5 1.8 178.3 186.7 127.4 717.5 264.9 82.1 47.6 206.9 349.9 0.1 317.6 375.5 137.2 332.1 6.5 195.2 146.0 1.2 36.5 0.3 46.7 211.7 43.3 3.3 6.7 106.5 37.9 116.0 44.0 192.5 142.1 0.2 0.6 1.3 654.2 197.1 0.4 26.6 109.0 190.7 198.3 1.2 187.9 11.3 379.4 282.8 10.0 231.4 9.2 167.7 458.4 143.5 102.6 9.5 600.4 399.5 111.0 176.1 496.2 874.2 559.4 1.5 341.6 5.9 1239.0 0.2 0.0 0.0 0.2 0.0 0.0 0.9 0.1 0.0 1.1 0.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 12.1 14.6 15.0 11.9 10.8 14.6 17.5 15.5 18.3 15.9 21.7 24.0 84.6 182.7 115.6 0.3 8.3 202.5 234.7 499.7 133.1 2.3 163.4 140.0 80.0 92.9 271.6 125.0 2.1 10.9 2.4 44.8 31.3 504.0 0.4 104.2 23.5 141.0 56.5 2.5 0.5 142.6 1.2 67.6 127.4 199.5 29.1 0.0 98.2 165.2 75.0 0.0 2.2 42.6 75.3 18.8 61.9 2.0 4.1 23.6 51.6 17.8 2.4 79.1 0.0 49.8 0.3 622.1 118.0 57.6 0.5 262.0 19.4 57.1 85.9 3.1 131.5 13.0 184.8 0.5 23.4 292.3 351.1 2.5 8.8 3.4 82.2 412.6 CCR5 "CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22" ENSG00000160791 "C-C motif chemokine receptor 5" P51681 3 46370854-46376206 "CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "Diabetes mellitus, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 15.0" "Cell type enhanced" "Detected in some" "Kupffer cells: 5.5;Langerhans cells: 32.6;Macrophages: 12.8;T-cells: 13.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in many" "MAIT T-cell: 39.7" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "JURKAT: 1.4;Karpas-707: 6.8;U-266/84: 3.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 2: Karpas-707 - Immune response" "Cluster 63: NK-cells & T-cells - Immune response" "unprognostic (4.32e-3)" "unprognostic (1.94e-3)" "unprognostic (1.89e-3)" "prognostic favorable (7.42e-5)" "unprognostic (1.80e-2)" "prognostic favorable (9.33e-5)" "unprognostic (3.38e-3)" "unprognostic (9.90e-3)" "unprognostic (7.65e-2)" "unprognostic (6.22e-2)" "unprognostic (1.36e-1)" "unprognostic (5.34e-2)" "unprognostic (1.14e-3)" "unprognostic (8.34e-2)" "unprognostic (4.69e-2)" "unprognostic (3.14e-2)" "unprognostic (2.42e-2)" 1.8 2.0 0.5 15.0 0.6 1.3 2.4 0.6 0.7 2.1 1.0 3.3 4.1 1.4 1.0 1.4 1.7 5.0 1.1 0.4 0.8 1.0 3.4 7.4 14.4 1.6 0.9 1.7 0.6 0.6 0.4 0.7 1.3 1.9 3.9 0.1 2.9 1.0 0.3 1.1 5.8 3.2 1.2 9.4 6.8 0.8 1.2 4.2 0.8 0.2 9.4 4.8 0.6 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 6.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.2 3.1 0.0 0.0 0.1 0.0 12.0 2.2 0.0 11.0 3.8 39.7 0.5 4.7 16.1 9.5 0.0 0.4 4.1 0.5 6.3 0.0 9.0 8.0 3.2 0.5 0.6 0.6 0.7 0.4 0.8 1.6 0.9 1.3 1.2 1.2 2.4 0.3 0.0 1.7 0.0 0.8 0.3 0.0 0.0 0.0 0.0 0.1 0.1 0.6 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.8 0.0 0.0 0.0 0.3 1.5 0.0 1.3 0.0 1.4 0.3 4.7 0.0 0.0 0.0 0.0 5.5 32.6 0.0 0.0 12.8 3.6 1.9 1.9 0.0 2.1 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.3 0.0 13.1 0.1 0.0 0.1 CD44 "CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1" ENSG00000026508 "CD44 molecule (Indian blood group)" P16070 11 35138882-35232402 "Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion" "Blood group antigen, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "salivary gland: 504.2" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 999.7;Ductal cells: 992.1;Exocrine glandular cells: 869.6;Langerhans cells: 1934.2;Suprabasal keratinocytes: 1024.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTERT-RPE1: 1650.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000112, CAB000316, HPA005785" Enhanced Supported "Golgi apparatus,Plasma membrane" "Secreted to blood" NA NA 1200000000 "Cluster 39: Non-specific - mRNA processing" "Cluster 11: Squamous epithelial cells - Epithelial cell function" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 1: Pancreatic cells - Digestion" "Plasma membrane" "Golgi apparatus" "CAB000112: , CAB000316: AB_2076596, HPA005785: AB_1078467" "unprognostic (5.33e-2)" "unprognostic (1.85e-1)" "unprognostic (4.97e-2)" "unprognostic (9.90e-3)" "unprognostic (3.50e-3)" "unprognostic (1.46e-2)" "unprognostic (1.56e-2)" "unprognostic (8.12e-2)" "unprognostic (1.57e-1)" "unprognostic (4.18e-2)" "unprognostic (1.51e-3)" "unprognostic (4.63e-2)" "prognostic unfavorable (1.78e-8)" "unprognostic (6.41e-2)" "unprognostic (4.14e-2)" "unprognostic (3.93e-2)" "unprognostic (7.98e-2)" 143.7 42.4 29.2 218.0 33.9 308.1 164.7 63.0 25.1 146.0 16.8 91.1 53.0 200.4 20.1 227.8 69.0 129.7 30.4 33.0 116.5 31.3 31.0 214.1 108.8 114.9 102.3 11.7 263.2 6.0 8.1 74.1 118.3 87.3 111.5 38.0 504.2 57.0 17.1 433.3 60.8 175.8 114.3 83.8 61.5 6.6 62.8 64.2 76.2 27.7 188.7 235.2 193.4 114.9 493.0 448.6 4.3 1.2 252.6 691.5 1.6 962.2 740.3 521.3 288.2 30.4 150.4 0.7 126.5 1350.2 1065.4 820.1 9.9 1013.9 716.4 110.3 6.2 18.9 198.3 0.3 262.3 254.6 1124.3 315.4 778.3 693.2 552.7 1650.0 184.3 0.1 4.0 157.9 518.9 3.0 25.6 166.9 9.8 8.7 136.4 1.4 89.3 7.5 777.4 138.1 2.0 1.4 185.2 5.5 462.8 38.6 25.7 15.1 547.3 646.6 120.0 815.8 1006.0 281.6 327.7 3.7 980.4 145.1 969.8 127.4 403.0 35.4 140.6 257.8 196.5 122.5 210.1 186.5 229.0 90.0 179.7 153.6 92.6 322.3 356.1 79.9 309.7 437.3 29.2 33.9 63.0 25.1 33.0 116.5 114.9 102.3 118.3 114.3 62.8 114.9 41.0 96.1 361.8 54.5 250.1 999.7 297.7 335.3 228.2 0.6 139.6 71.2 8.6 27.1 125.6 20.2 2.1 4.5 257.0 14.0 1.9 992.1 41.3 43.6 395.4 50.9 100.1 94.4 0.4 869.6 3.6 282.2 39.8 196.9 763.2 25.2 13.2 3.6 226.6 0.0 0.4 93.3 30.5 474.3 1934.2 24.3 22.4 523.9 604.7 8.4 594.2 29.6 62.8 0.5 11.2 813.1 10.9 0.4 216.3 386.7 6.0 1.6 18.8 2.0 157.8 197.2 227.9 0.4 0.4 279.3 1024.9 17.9 430.8 1.0 79.1 330.7 CDA CDD ENSG00000158825 "Cytidine deaminase" P32320 1 20589086-20618903 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 193.5;esophagus: 87.1;liver: 86.7" "Cell type enhanced" "Detected in many" "Distal enterocytes: 364.9;Hepatocytes: 107.8;Pancreatic endocrine cells: 120.2;Paneth cells: 400.5;Proximal enterocytes: 137.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 1234.7" "Lineage enriched" "Detected in many" 6 "granulocytes: 1234.7" "Cell line enhanced" "Detected in many" "A-431: 200.3;CAPAN-2: 141.9;HeLa: 207.1;PC-3: 107.0;SiHa: 249.9;U-937: 96.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA064202 Enhanced Approved Nucleoplasm NA NA 3700000 "Cluster 1: Neutrophils - Mixed function" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 53: Intestinal epithelial cells - Unknown function" Nucleoplasm "HPA064202: AB_2685211" "unprognostic (2.38e-1)" "prognostic unfavorable (5.05e-4)" "unprognostic (2.86e-1)" "unprognostic (2.56e-1)" "unprognostic (8.02e-2)" "unprognostic (3.84e-3)" "unprognostic (1.47e-1)" "unprognostic (1.68e-3)" "unprognostic (2.64e-1)" "unprognostic (4.01e-2)" "prognostic unfavorable (8.56e-5)" "unprognostic (2.94e-2)" "unprognostic (5.03e-2)" "unprognostic (8.47e-3)" "unprognostic (2.81e-1)" "unprognostic (3.38e-1)" "unprognostic (1.89e-3)" 7.1 3.0 8.0 9.6 8.1 193.5 3.7 8.3 10.6 19.7 7.4 23.7 6.4 5.3 5.5 87.1 6.4 4.3 6.7 7.9 8.3 14.0 86.7 7.1 1.5 9.0 8.2 1.5 0.8 3.2 1.2 10.8 9.5 4.3 27.8 0.5 15.0 3.1 1.7 17.1 16.3 11.3 8.3 23.4 2.1 1.0 8.9 2.0 4.5 6.4 4.4 5.5 38.5 8.7 200.3 21.4 0.0 0.0 0.2 5.5 0.0 16.7 4.3 4.1 16.2 1.0 141.9 0.0 8.1 30.8 8.7 63.9 4.5 46.8 10.7 0.1 3.9 0.0 207.1 34.4 1.4 0.0 0.0 8.8 8.9 31.4 0.0 0.5 2.7 0.0 0.0 0.0 1.6 0.2 0.0 1.0 0.1 24.7 107.0 0.0 0.1 3.4 1.5 0.0 0.1 0.0 249.9 0.0 0.3 2.2 0.0 4.3 3.4 0.2 8.3 18.5 1.2 0.0 0.1 0.0 2.4 96.9 0.0 216.2 207.2 471.1 0.5 124.7 0.8 0.1 0.4 0.9 12.7 0.2 0.3 0.4 1234.7 0.4 110.8 3.1 0.7 86.8 8.0 8.1 8.3 10.6 7.9 8.3 9.0 8.2 9.5 8.3 8.9 8.7 9.9 3.2 1.1 0.3 1.2 1.5 0.1 2.4 0.0 0.2 0.2 0.3 2.6 1.5 2.7 5.5 0.0 1.1 0.0 364.9 43.0 7.5 0.8 2.1 2.6 42.7 0.0 6.1 0.2 1.5 6.4 9.1 0.0 20.3 0.0 0.0 47.2 107.8 5.9 0.0 0.3 23.1 85.5 60.7 0.9 1.0 0.3 36.6 0.0 5.6 61.5 0.1 0.0 0.5 0.0 120.2 400.5 0.0 3.0 2.1 137.6 0.6 0.4 0.1 0.0 1.3 1.3 0.0 1.2 6.3 1.1 2.5 1.7 0.0 19.8 0.8 CDK4 PSK-J3 ENSG00000135446 "Cyclin dependent kinase 4" P11802 12 57747727-57756013 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Cancer enriched" "Detected in all" 5 "glioma: 175.8" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Group enriched" "Detected in all" 10 "HBEC3-KT: 2594.8;LHCN-M2: 2819.4;RH-30: 8902.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006024, CAB013116, CAB069405" Supported Supported "Nucleoplasm,Nuclear membrane,Nucleoli,Cytosol" NA NA "Cluster 12: Non-specific - Basic cellular processes" "Cluster 89: Fibroblasts - ECM organization" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 39: Non-specific - Basic cellular processes" Cytosol "Nucleoplasm, Nuclear membrane, Nucleoli" "CAB013116: AB_2536376, CAB069405: AB_1613464, HPA006024: AB_2667497" "unprognostic (8.88e-2)" "unprognostic (2.53e-1)" "unprognostic (5.27e-2)" "unprognostic (9.01e-2)" "unprognostic (2.21e-1)" "unprognostic (1.10e-1)" "prognostic unfavorable (2.09e-7)" "unprognostic (7.39e-2)" "unprognostic (3.23e-3)" "unprognostic (2.93e-2)" "unprognostic (3.19e-2)" "unprognostic (9.10e-2)" "prognostic unfavorable (3.15e-5)" "unprognostic (3.32e-1)" "unprognostic (1.67e-1)" "unprognostic (3.64e-1)" "unprognostic (1.57e-2)" 69.7 87.8 35.0 52.8 37.9 72.0 76.6 37.7 36.9 84.3 35.9 62.6 40.2 97.4 64.2 57.2 69.4 57.1 58.9 33.6 37.1 58.5 51.5 58.0 66.8 37.1 36.9 97.3 70.9 63.5 67.7 52.4 36.8 52.7 63.3 14.5 54.4 54.1 48.2 58.9 47.2 80.4 37.3 51.5 54.8 24.1 37.3 67.6 66.0 52.7 70.6 71.6 60.7 37.6 207.1 235.7 295.7 268.0 253.7 220.7 210.4 116.1 347.9 468.5 385.7 338.2 189.1 297.4 200.2 173.6 293.2 158.0 396.3 2594.8 354.9 150.9 209.0 275.4 149.5 237.9 297.0 309.7 182.5 221.5 180.9 294.2 326.7 326.4 304.8 280.0 301.3 242.7 2819.4 304.9 296.7 256.5 347.0 208.0 249.8 267.3 8902.5 272.1 147.2 320.6 271.2 251.7 205.3 150.2 310.0 195.1 202.8 380.7 146.1 233.6 217.0 265.8 233.1 122.2 206.1 450.8 214.1 291.3 286.9 9.5 46.5 10.3 79.6 65.6 81.8 93.5 70.0 72.5 66.7 90.0 93.0 84.4 4.4 56.6 41.9 84.9 57.0 73.6 35.0 37.9 37.7 36.9 33.6 37.1 37.1 36.9 36.8 37.3 37.3 37.6 47.1 22.4 30.8 7.8 40.0 89.7 78.6 83.4 74.0 15.9 67.2 82.2 0.7 51.5 35.3 47.8 10.4 82.9 26.1 15.9 70.5 93.1 13.5 14.9 77.7 50.8 45.6 98.0 5.2 62.5 134.5 79.4 28.5 22.6 69.1 60.2 39.7 35.8 132.9 18.5 6.7 42.2 40.7 25.1 44.1 8.0 64.0 31.2 53.4 6.5 41.9 51.4 29.9 5.5 8.0 48.3 18.9 63.2 57.8 113.9 14.0 80.9 7.4 17.9 32.9 62.1 61.9 32.1 48.3 74.5 86.1 46.8 32.3 78.8 78.7 49.4 CDK6 PLSTIRE ENSG00000105810 "Cyclin dependent kinase 6" Q00534 7 92604921-92836573 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Cell cycle, Cell division, Differentiation" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease variant, FDA approved drug targets, Primary microcephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 41.1" "Cell type enhanced" "Detected in many" "Early spermatids: 215.9;Erythroid cells: 213.5;Late spermatids: 237.0;Oligodendrocytes: 235.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "MOLT-4: 378.4;REH: 173.7" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA002637, CAB004363" Enhanced Supported Nucleoplasm,Cytosol NA NA 26000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 34: Spermatids - Unknown function" Nucleoplasm Cytosol "CAB004363: AB_627242, HPA002637: AB_1846432" "unprognostic (1.29e-1)" "unprognostic (5.98e-3)" "unprognostic (9.07e-2)" "unprognostic (2.78e-3)" "unprognostic (2.56e-2)" "unprognostic (3.24e-2)" "unprognostic (3.39e-1)" "unprognostic (2.42e-3)" "unprognostic (7.19e-2)" "unprognostic (7.78e-3)" "prognostic unfavorable (3.86e-6)" "unprognostic (4.06e-2)" "unprognostic (4.09e-3)" "unprognostic (1.09e-1)" "unprognostic (7.88e-2)" "unprognostic (1.93e-1)" "prognostic unfavorable (2.33e-5)" 3.7 7.3 6.7 4.7 7.1 18.1 4.9 5.4 5.1 4.8 2.6 5.9 6.1 3.1 2.1 4.2 2.9 3.6 4.7 4.0 5.0 4.4 5.9 4.1 6.6 6.3 6.7 2.7 6.2 9.9 1.7 17.3 6.3 3.0 7.5 0.5 5.7 4.2 1.0 6.8 7.2 3.2 5.8 4.9 9.1 3.3 9.6 41.1 2.4 2.3 6.2 3.8 4.6 8.8 27.1 11.3 34.9 23.9 10.6 11.5 5.8 27.2 18.4 14.3 13.5 34.7 20.9 21.7 14.4 19.9 8.4 15.8 20.8 42.6 34.4 43.0 10.6 50.8 23.3 34.7 6.3 33.0 2.7 11.5 23.1 17.9 90.8 13.4 5.6 75.1 49.3 55.5 26.7 5.9 378.4 3.8 9.8 37.4 9.1 173.7 112.0 36.4 20.3 0.7 18.1 113.8 3.7 9.8 17.1 26.0 0.6 54.9 19.3 44.1 63.7 18.0 54.2 27.4 0.5 27.6 6.9 112.1 60.8 0.9 0.2 0.6 0.6 0.4 0.9 0.2 0.6 0.8 0.5 0.3 0.7 0.7 0.1 0.7 0.4 0.9 0.3 0.3 6.7 7.1 5.4 5.1 4.0 5.0 6.3 6.7 6.3 5.8 9.6 8.8 38.6 25.6 3.7 2.9 17.7 60.3 23.5 55.0 62.6 0.4 20.7 21.2 18.1 22.8 32.8 22.0 0.0 53.8 30.5 12.1 9.8 37.0 215.9 3.1 29.0 30.7 16.8 213.5 114.7 23.3 5.3 28.5 42.3 6.9 25.3 39.2 11.4 27.0 16.0 0.0 60.3 63.7 28.5 23.0 48.6 237.0 5.0 27.6 19.6 108.7 22.4 0.8 39.1 119.6 235.3 94.7 22.8 3.4 85.3 47.1 20.1 8.2 11.9 0.0 6.6 100.8 32.2 2.7 33.6 36.7 50.4 17.6 42.5 62.8 92.7 27.3 CFTR "ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR" ENSG00000001626 "CF transmembrane conductance regulator" P13569 7 117287120-117715971 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Isomerase" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 54.6;intestine: 42.7;pancreas: 210.7" "Group enriched" "Detected in many" 4 "Ductal cells: 485.4;Ionocytes: 252.3" "Cancer enhanced" "Detected in many" "colorectal cancer: 23.9;pancreatic cancer: 28.0" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 25 "CACO-2: 29.5;MOLT-4: 98.9;U-266/70: 49.6" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "CAB001951, HPA021939, HPA079652" Enhanced NA NA "Cluster 25: Pancreas - Digestion" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 1: Pancreatic cells - Digestion" "CAB001951: , HPA021939: AB_1846578, HPA079652: " "unprognostic (6.38e-3)" "unprognostic (9.55e-2)" "unprognostic (1.77e-2)" "unprognostic (1.44e-2)" "unprognostic (8.74e-2)" "unprognostic (8.57e-2)" "prognostic unfavorable (9.44e-4)" "unprognostic (3.20e-3)" "unprognostic (1.13e-1)" "unprognostic (8.89e-2)" "unprognostic (1.55e-2)" "unprognostic (2.14e-2)" "unprognostic (4.78e-3)" "unprognostic (1.24e-1)" "unprognostic (2.58e-1)" "unprognostic (9.08e-2)" "unprognostic (6.64e-2)" 0.4 0.0 0.5 4.7 2.0 0.0 0.4 0.7 1.3 8.5 0.0 42.7 36.2 1.1 1.1 0.8 2.2 54.6 0.1 0.3 0.7 2.1 1.6 8.2 0.0 1.1 0.7 0.0 210.7 0.2 0.1 0.6 0.7 2.2 40.7 0.0 21.5 0.5 0.0 1.9 19.9 2.0 1.7 0.0 3.1 1.7 1.0 0.1 0.1 0.0 0.3 0.7 0.0 2.9 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.5 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 98.9 0.1 2.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.1 0.1 0.0 49.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 2.0 0.7 1.3 0.3 0.7 1.1 0.7 0.7 1.7 1.0 2.9 0.0 6.4 65.6 0.0 0.5 0.0 2.0 2.6 0.0 0.5 0.5 0.0 2.4 55.8 17.8 0.0 0.0 0.0 0.0 45.8 0.0 485.4 3.2 9.6 1.2 0.4 7.2 0.0 2.2 4.5 0.0 0.3 4.1 19.8 1.3 0.1 0.0 0.4 0.0 0.0 1.1 13.9 252.3 0.0 0.0 2.6 0.3 0.1 0.0 1.0 6.7 0.5 0.0 0.5 23.8 14.8 86.4 0.0 0.0 4.0 8.6 0.0 5.6 0.0 0.0 0.0 1.6 2.2 0.5 0.0 0.0 0.0 0.3 0.1 87.3 5.8 CHRM1 ENSG00000168539 "Cholinergic receptor muscarinic 1" P11229 11 62908679-62921807 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "brain: 27.0;prostate: 29.6;salivary gland: 28.8" "Cell type enhanced" "Detected in some" "Astrocytes: 2.9;Breast myoepithelial cells: 3.6;Excitatory neurons: 8.7;Inhibitory neurons: 7.8;Intestinal goblet cells: 3.2;Melanocytes: 3.6;Oligodendrocyte precursor cells: 3.0;Prostatic glandular cells: 4.4" "Cancer enriched" "Detected in some" 16 "prostate cancer: 27.9" "Group enriched" "Detected in many" 178 "amygdala: 12.4;basal ganglia: 18.7;cerebral cortex: 27.0;hippocampal formation: 22.6;white matter: 8.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "MCF7: 3.7;OE19: 12.3" "Low region specificity" "Detected in many" HPA014101 Enhanced Supported NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 21: OE19 - Mitochondria" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA014101: AB_1854210" "unprognostic (3.19e-2)" "unprognostic (2.14e-1)" "unprognostic (2.25e-1)" "unprognostic (1.31e-2)" "unprognostic (7.94e-2)" "unprognostic (2.29e-1)" "unprognostic (1.16e-2)" "unprognostic (2.89e-2)" "unprognostic (1.91e-1)" "unprognostic (2.76e-1)" "unprognostic (2.08e-1)" "unprognostic (8.57e-4)" "unprognostic (4.88e-1)" "unprognostic (6.43e-2)" "unprognostic (1.75e-1)" 0.0 3.3 12.4 0.3 18.7 0.0 2.7 0.0 27.0 0.0 0.0 0.8 0.4 0.1 0.0 0.3 0.2 0.1 0.1 22.6 0.0 0.2 0.0 2.5 0.0 0.0 0.0 0.0 0.6 0.3 0.2 0.2 0.0 29.6 0.7 0.1 28.8 0.0 0.0 2.8 0.7 0.0 0.0 0.0 1.4 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.1 0.0 12.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.9 0.4 0.1 1.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.4 18.7 0.0 27.0 22.6 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.1 0.0 0.0 2.9 0.0 0.1 0.2 0.0 0.0 0.0 1.8 3.6 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 8.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 7.8 3.2 0.0 0.0 0.3 0.0 0.0 0.0 3.6 1.0 0.0 0.0 0.0 3.0 1.0 0.0 0.1 0.0 0.0 4.4 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.5 0.1 CHRM2 ENSG00000181072 "Cholinergic receptor muscarinic 2" P08172 7 136868652-137020255 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "heart muscle: 36.1;intestine: 21.2" "Group enriched" "Detected in some" 7 "Cardiomyocytes: 59.9;Excitatory neurons: 49.4;Inhibitory neurons: 119.2" "Cancer enhanced" "Detected in single" "stomach cancer: 0.8" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "fHDF/TERT166: 86.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB022338, HPA029795" Approved NA NA "Cluster 44: Heart - Cardiac muscle contraction" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB022338: , HPA029795: AB_10601357" "unprognostic (3.51e-2)" "unprognostic (3.73e-4)" "unprognostic (5.77e-2)" "unprognostic (1.78e-2)" "unprognostic (1.97e-1)" "unprognostic (4.00e-1)" "unprognostic (2.69e-1)" "unprognostic (1.43e-2)" "unprognostic (1.80e-1)" "unprognostic (1.35e-3)" 0.1 0.2 2.8 1.3 2.0 0.1 0.0 0.1 2.3 0.3 0.0 21.2 0.7 0.4 0.0 0.3 0.3 10.7 36.1 0.1 2.5 0.0 1.1 0.8 0.0 9.3 5.4 0.2 0.1 0.0 0.0 1.4 9.1 0.2 3.5 0.8 0.0 0.0 0.0 0.1 4.4 9.7 1.8 0.0 5.9 0.6 6.8 0.1 0.0 0.0 0.0 8.9 0.6 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.4 17.6 0.2 0.0 0.0 0.0 0.0 0.0 86.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.5 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 2.0 0.1 2.3 0.1 2.5 9.3 5.4 9.1 1.8 6.8 1.3 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 59.9 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 9.7 0.0 0.2 0.2 0.0 0.0 49.4 0.0 0.0 2.9 0.0 0.0 0.0 0.0 1.4 0.1 0.1 0.0 119.2 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.0 1.9 0.0 0.1 0.0 0.5 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 CHRM3 ENSG00000133019 "Cholinergic receptor muscarinic 3" P20309 1 239386565-239915452 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 11.8;salivary gland: 17.5" "Group enriched" "Detected in many" 28 "Excitatory neurons: 802.9;Inhibitory neurons: 624.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "RPMI-8226: 17.2;SH-SY5Y: 53.5;U-266/70: 21.7;U-266/84: 16.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA024106, HPA048036" Approved Supported "Plasma membrane" NA NA "Cluster 32: T-cells - Unknown function" "Cluster 22: Non-specific - Unknown function" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" "HPA024106: AB_1854211, HPA048036: AB_2680238" "unprognostic (1.63e-1)" "unprognostic (4.82e-2)" "unprognostic (1.05e-1)" "unprognostic (4.11e-3)" "unprognostic (3.48e-3)" "unprognostic (5.81e-2)" "unprognostic (2.30e-3)" "unprognostic (5.18e-2)" "unprognostic (1.71e-1)" "unprognostic (1.27e-1)" "unprognostic (6.29e-2)" "unprognostic (6.44e-2)" "unprognostic (5.34e-4)" "unprognostic (3.04e-2)" "unprognostic (2.67e-1)" "unprognostic (1.02e-1)" "unprognostic (4.88e-2)" 0.3 0.4 4.6 0.8 7.3 0.2 0.8 0.0 11.8 0.4 0.0 7.0 1.4 1.9 0.4 7.5 0.8 0.7 0.4 7.5 0.0 1.1 0.4 1.1 0.1 0.0 0.0 4.8 10.6 0.5 0.5 0.8 0.0 1.1 2.8 1.7 17.5 3.0 0.0 1.3 1.5 4.1 0.0 0.7 5.0 2.5 4.1 0.1 2.0 0.1 0.1 7.0 0.4 2.9 0.0 0.1 0.4 0.4 0.0 0.0 0.9 0.6 0.1 0.3 0.1 0.0 0.0 0.0 2.1 0.0 0.0 5.8 0.6 3.8 2.7 0.0 3.7 0.6 0.4 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.8 0.0 0.0 1.1 9.1 0.9 1.4 0.0 0.0 4.6 4.6 9.1 0.0 1.1 17.2 0.7 0.8 0.1 53.5 0.0 0.1 0.1 4.0 1.8 0.0 0.3 2.3 0.8 0.1 0.5 21.7 16.3 0.0 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 4.6 7.3 0.0 11.8 7.5 0.0 0.0 0.0 0.0 0.0 4.1 2.9 6.1 0.0 3.7 6.2 0.0 0.0 2.1 0.0 0.6 19.0 4.6 3.2 1.2 0.0 0.8 0.0 0.0 3.2 0.3 11.0 1.9 0.4 19.6 0.1 0.1 3.0 3.5 4.6 802.9 17.3 0.7 3.9 11.7 0.2 1.3 7.5 4.2 0.3 0.5 0.0 624.0 6.0 0.0 0.0 0.0 3.9 0.0 0.2 7.2 22.5 0.0 0.3 0.0 8.5 11.2 2.6 25.3 0.4 0.2 2.5 2.2 1.4 1.6 0.6 0.0 0.2 1.1 12.9 3.0 0.2 0.0 0.5 0.1 0.8 15.5 0.2 CHRM4 ENSG00000180720 "Cholinergic receptor muscarinic 4" P08173 11 46385098-46386608 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 18.5;intestine: 6.8;lymphoid tissue: 15.9;testis: 5.0" "Not detected" "Not detected" "Low cancer specificity" "Detected in single" "Group enriched" "Detected in many" 6 "basal ganglia: 18.5;cerebral cortex: 4.6" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "RH-30: 3.4;SCLC-21H: 10.0;U-2 OS: 2.8" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 16.8" "CAB022444, HPA072083" Enhanced Uncertain "Nucleoplasm,Golgi apparatus" NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 53: Intestinal epithelial cells - Unknown function" "Golgi apparatus" Nucleoplasm "CAB022444: , HPA072083: " "unprognostic (7.11e-2)" "unprognostic (3.79e-1)" "unprognostic (5.31e-2)" "unprognostic (7.38e-2)" "unprognostic (8.63e-3)" "unprognostic (1.38e-1)" "unprognostic (6.02e-2)" "unprognostic (1.03e-1)" "unprognostic (1.48e-1)" "unprognostic (2.96e-3)" "unprognostic (4.08e-3)" "unprognostic (5.02e-2)" "unprognostic (3.83e-2)" "unprognostic (3.64e-1)" "unprognostic (1.71e-1)" "unprognostic (3.56e-1)" "unprognostic (5.08e-2)" 0.1 0.5 1.6 0.2 18.5 1.7 0.1 0.0 4.6 0.1 0.0 1.5 3.2 0.1 0.0 0.0 0.1 0.0 0.1 1.8 0.1 0.0 0.0 0.3 0.1 0.2 0.0 0.0 0.2 0.2 1.2 0.0 0.0 0.0 0.1 2.4 0.1 0.0 0.0 2.0 6.8 0.1 0.0 15.9 0.6 5.0 1.7 2.4 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.5 0.2 0.0 0.1 0.0 2.1 0.0 0.1 0.1 0.1 1.0 0.1 0.2 0.2 0.0 1.8 0.1 1.3 0.1 0.0 1.6 0.2 0.4 0.1 0.0 0.1 0.3 0.4 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.4 0.1 0.0 0.7 0.2 0.1 0.4 0.1 0.1 0.0 3.4 0.0 0.0 0.1 10.0 0.2 0.2 0.0 0.1 0.2 0.1 1.7 0.0 0.3 2.8 0.0 0.0 0.5 0.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 18.5 0.0 4.6 1.8 0.1 0.2 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CHRM5 ENSG00000184984 "Cholinergic receptor muscarinic 5" P08912 15 33968497-34067458 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "brain: 18.8" "Cell type enriched" "Detected in some" 9 "Oligodendrocytes: 178.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in single" "neutrophil: 1.4" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.4" "Cell line enhanced" "Detected in some" "BEWO: 4.6;HMC-1: 10.4;NB-4: 1.9" "Region enhanced" "Detected in many" "hypothalamus: 13.2" "Low region specificity" "Detected in many" HPA013172 Uncertain NA NA "Cluster 1: Neutrophils - Mixed function" "Cluster 70: Brain - Nervous system development" "Cluster 3: HMC-1 - Innate immune response" "Cluster 42: Oligodendrocytes - Myelin sheath organization" "HPA013172: AB_1854212" "unprognostic (8.19e-2)" "unprognostic (2.13e-1)" "unprognostic (7.67e-2)" "unprognostic (4.32e-1)" "unprognostic (3.05e-3)" "unprognostic (2.77e-1)" "unprognostic (2.49e-2)" "unprognostic (2.79e-1)" "unprognostic (3.02e-1)" "unprognostic (1.27e-2)" "unprognostic (4.61e-4)" "unprognostic (7.95e-2)" "unprognostic (1.33e-6)" "unprognostic (1.42e-1)" "unprognostic (4.53e-2)" "unprognostic (1.38e-1)" "unprognostic (9.07e-2)" 0.1 0.1 2.4 0.3 5.8 0.4 0.3 4.2 4.8 0.1 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.1 0.0 1.8 8.4 0.2 0.6 0.1 0.3 9.5 8.3 0.1 0.3 0.0 0.2 1.5 9.0 0.1 0.0 1.3 0.1 0.0 0.2 0.4 0.5 0.0 3.1 0.2 0.1 1.5 18.8 0.0 0.6 0.0 0.0 0.0 0.1 13.8 0.1 0.1 0.5 0.2 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.2 0.6 0.2 0.2 0.0 0.4 10.4 0.3 0.0 0.1 0.0 0.1 0.0 0.3 0.5 1.0 0.0 0.1 0.2 1.9 0.1 0.2 0.1 0.1 0.2 0.1 0.0 0.3 0.2 0.2 0.2 0.6 0.2 0.1 0.1 1.0 0.1 0.1 0.2 0.2 0.1 0.7 0.2 0.3 0.0 0.2 0.3 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.2 0.0 0.0 2.4 5.8 4.2 4.8 1.8 8.4 9.5 8.3 9.0 3.1 18.8 13.8 0.1 0.0 0.0 3.3 0.0 0.0 0.1 0.0 0.0 3.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 1.5 0.2 0.0 1.9 0.0 5.9 0.2 0.1 0.0 0.0 0.0 8.7 0.0 18.9 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.0 12.6 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 2.8 0.1 0.2 1.0 2.5 178.4 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 1.8 0.0 0.1 0.0 0.4 0.9 0.0 0.0 0.8 0.0 0.2 0.0 0.0 CHRNA10 ENSG00000129749 "Cholinergic receptor nicotinic alpha 10 subunit" Q9GZZ6 11 3665587-3671384 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 22 "skeletal muscle: 47.8" "Cell type enhanced" "Detected in some" "Glandular and luminal cells: 4.4;Ionocytes: 4.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in some" "Region enriched" "Detected in some" 6 "olfactory bulb: 7.2" "Not detected" "Not detected" NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 33: Striated muscle - Muscle contraction" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 44: Endometrium - Transcription" "unprognostic (3.04e-1)" "unprognostic (2.23e-1)" "unprognostic (4.04e-2)" "unprognostic (1.11e-4)" "unprognostic (1.50e-1)" "unprognostic (1.71e-2)" "unprognostic (8.22e-2)" "unprognostic (1.50e-1)" "unprognostic (3.79e-2)" "unprognostic (2.74e-1)" "unprognostic (6.90e-5)" "unprognostic (4.35e-2)" "unprognostic (1.06e-5)" "unprognostic (5.60e-2)" "unprognostic (1.70e-2)" "unprognostic (2.32e-1)" "unprognostic (4.39e-3)" 0.8 0.7 1.1 0.5 0.9 0.3 0.4 1.3 1.4 0.9 1.1 0.8 0.5 0.6 0.3 0.7 0.8 0.1 1.1 1.0 1.0 2.1 1.5 0.8 0.4 1.0 0.9 0.8 0.7 0.1 1.4 0.2 1.0 1.5 0.1 0.7 0.8 0.1 47.8 0.5 0.9 0.1 0.7 1.9 0.8 1.1 0.9 0.4 1.1 0.1 0.2 0.6 0.4 0.8 0.5 0.5 0.7 1.0 0.3 0.1 0.5 0.6 0.1 0.4 0.4 0.4 0.9 0.9 0.3 0.3 0.3 1.1 0.5 0.3 0.3 0.6 1.8 0.2 1.7 0.1 0.4 0.2 0.9 0.3 0.3 0.3 0.1 0.2 0.2 1.1 0.7 0.2 0.3 0.1 0.5 1.5 1.0 0.9 0.7 1.0 0.3 0.1 0.3 0.7 0.6 0.3 0.3 0.3 0.5 0.6 0.2 1.1 0.2 0.6 0.8 0.4 0.7 0.2 0.6 0.5 0.3 0.4 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 1.1 0.9 1.3 1.4 1.0 1.0 1.0 0.9 1.0 0.7 0.9 0.8 1.5 0.0 0.5 1.3 0.5 1.8 0.6 0.5 0.0 1.6 2.2 3.6 1.3 0.0 0.4 0.0 0.0 0.4 0.4 0.9 0.0 0.2 1.4 2.1 0.9 0.9 0.0 0.0 1.3 0.4 0.3 0.4 2.0 4.4 0.0 0.8 1.1 1.2 0.6 1.7 1.3 0.9 4.1 0.6 0.7 0.8 0.3 1.1 1.8 2.8 0.6 1.2 0.0 1.0 0.6 0.4 0.2 0.4 0.4 0.8 0.6 0.0 2.1 0.8 0.0 3.1 0.9 0.4 0.5 0.1 1.1 0.3 0.6 0.7 0.8 0.7 CHRNA2 ENSG00000120903 "Cholinergic receptor nicotinic alpha 2 subunit" Q15822 8 27459756-27479883 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 14 "brain: 72.1;prostate: 29.0" "Cell type enhanced" "Detected in some" "Bipolar cells: 6.5;Inhibitory neurons: 14.8;Prostatic glandular cells: 2.4;Theca cells: 3.4" "Cancer enriched" "Detected in single" 421 "prostate cancer: 30.2" "Region enhanced" "Detected in many" "thalamus: 72.1" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low region specificity" "Detected in some" HPA048348 Supported "Nucleoplasm,Plasma membrane,Cytokinetic bridge" Yes NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane" "Nucleoplasm, Cytokinetic bridge" "HPA048348: " "unprognostic (1.10e-2)" "unprognostic (1.47e-1)" "unprognostic (2.23e-2)" "unprognostic (3.19e-1)" "unprognostic (6.19e-2)" "unprognostic (6.29e-3)" "unprognostic (1.19e-2)" "unprognostic (2.13e-1)" "unprognostic (1.91e-1)" "unprognostic (7.60e-2)" "unprognostic (1.70e-1)" "unprognostic (1.47e-1)" 0.0 0.5 15.8 0.2 5.5 0.9 1.4 38.1 2.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.7 8.0 0.0 0.0 0.2 0.1 15.7 21.5 0.0 0.2 0.0 0.3 0.0 3.5 29.0 0.0 3.7 0.0 0.0 0.1 0.2 0.2 0.0 2.3 0.1 0.0 0.0 72.1 2.9 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 15.8 5.5 38.1 2.9 0.7 8.0 15.7 21.5 3.5 2.3 72.1 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.3 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 CHRNA3 ENSG00000080644 "Cholinergic receptor nicotinic alpha 3 subunit" P32297 15 78593052-78621295 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "adrenal gland: 39.3;lymphoid tissue: 65.8;retina: 53.5" "Cell type enriched" "Detected in some" 19 "Cone photoreceptor cells: 164.7" "Cancer enhanced" "Detected in some" "testis cancer: 1.6" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "SH-SY5Y: 356.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA029430 Enhanced Supported "Nuclear speckles,Plasma membrane" NA NA "Cluster 20: Retina & Lymphoid tissues - Unknown function" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 9: Photoreceptor cells - Phototransduction" "Plasma membrane" "Nuclear speckles" "HPA029430: AB_10603785" "unprognostic (2.28e-1)" "unprognostic (3.45e-1)" "unprognostic (2.58e-2)" "unprognostic (2.36e-1)" "unprognostic (1.32e-1)" "unprognostic (1.12e-1)" "unprognostic (9.16e-3)" "unprognostic (1.97e-1)" "unprognostic (4.28e-2)" "unprognostic (7.20e-2)" "unprognostic (3.12e-1)" "unprognostic (1.01e-1)" "unprognostic (1.86e-4)" "unprognostic (2.65e-3)" "unprognostic (2.76e-1)" "unprognostic (1.53e-1)" "unprognostic (4.48e-1)" 0.3 39.3 4.4 5.1 2.0 0.0 0.1 6.3 1.0 1.0 0.3 8.1 1.5 0.5 0.0 0.1 0.0 0.3 0.4 0.7 2.3 0.0 0.0 0.2 0.3 3.1 6.4 0.1 0.2 0.0 1.1 0.1 10.0 0.2 4.0 53.5 0.1 0.0 0.1 0.7 3.0 3.7 0.3 0.1 2.8 1.0 9.2 65.8 0.2 0.0 0.8 0.2 0.7 1.0 0.1 0.3 0.7 0.6 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.1 0.2 0.1 0.2 0.0 1.5 0.0 8.8 0.0 0.0 0.3 1.4 0.5 0.4 0.1 0.0 0.1 4.0 0.0 0.3 0.0 0.0 0.0 0.0 22.6 0.2 0.0 0.0 0.3 7.1 0.0 1.6 0.1 0.2 0.4 0.3 0.1 0.0 0.4 67.7 356.1 0.3 0.1 0.1 0.5 0.4 0.0 0.0 0.1 1.7 0.1 0.4 0.2 0.7 0.1 0.1 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 2.0 6.3 1.0 0.7 2.3 3.1 6.4 10.0 0.3 9.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.8 0.0 0.0 0.0 164.7 0.0 0.0 0.2 1.9 0.0 3.7 0.1 1.2 0.4 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.2 1.7 0.4 3.6 0.0 0.0 0.0 3.5 0.0 0.2 0.0 0.0 0.0 3.3 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.6 0.0 0.1 0.1 0.3 2.1 0.0 0.0 0.0 0.0 2.6 0.1 0.1 CHRNA4 "BFNC, EBN, EBN1" ENSG00000101204 "Cholinergic receptor nicotinic alpha 4 subunit" P43681 20 63343223-63378401 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 28.8;liver: 58.0" "Group enriched" "Detected in some" 4 "Hepatocytes: 42.0;Horizontal cells: 139.7" "Cancer enhanced" "Detected in some" "liver cancer: 1.4" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 5 "U-2 OS: 2.5" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 6 "midbrain: 21.8;pons: 20.5;thalamus: 33.5" CAB034064 Uncertain NA NA "Cluster 15: Liver - Metabolism" "Cluster 9: U-2 OS - Unknown function" "Cluster 62: Horizontal cells - Visual perception" "CAB034064: AB_2080535" "unprognostic (3.40e-1)" "unprognostic (1.71e-1)" "unprognostic (2.87e-2)" "unprognostic (3.98e-1)" "unprognostic (8.03e-2)" "unprognostic (1.75e-1)" "unprognostic (1.22e-1)" "unprognostic (1.74e-1)" "unprognostic (2.10e-3)" "unprognostic (5.72e-4)" "unprognostic (9.02e-3)" "unprognostic (9.79e-4)" "unprognostic (6.77e-2)" "unprognostic (1.08e-1)" "unprognostic (3.81e-2)" 0.0 0.2 6.7 0.0 6.5 0.0 0.0 0.6 6.2 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 6.7 8.7 3.4 58.0 0.0 0.0 5.7 15.7 0.1 0.0 12.7 0.8 0.0 6.2 0.2 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 2.5 0.0 1.6 28.8 0.0 0.5 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.7 6.5 0.6 6.2 6.7 8.7 5.7 15.7 6.2 0.5 28.8 4.9 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 22.4 0.0 0.1 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 4.7 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 42.0 0.0 139.7 8.8 0.0 0.0 1.0 0.0 1.1 0.0 0.0 0.0 1.0 0.0 0.9 0.0 7.5 2.1 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 2.7 0.0 1.7 0.1 0.1 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 CHRNA7 ENSG00000175344 "Cholinergic receptor nicotinic alpha 7 subunit" P36544 15 31923438-32173018 "FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 7.8;intestine: 9.7" "Cell type enhanced" "Detected in many" "Excitatory neurons: 9.0;Gastric mucus-secreting cells: 26.0;Horizontal cells: 16.8;Inhibitory neurons: 30.7;Proximal enterocytes: 14.4" "Cancer enhanced" "Detected in single" "stomach cancer: 0.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AN3-CA: 6.3;RT4: 12.9;SH-SY5Y: 8.3;SK-BR-3: 13.3;U-2 OS: 10.8" "HPA029422, CAB033624" Enhanced NA NA "Cluster 11: Basophils - Unknown function" "Cluster 48: Parathyroid gland - membrane proteins" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB033624: AB_784835, HPA029422: AB_10600863" "unprognostic (3.43e-2)" "unprognostic (8.44e-2)" "unprognostic (2.02e-1)" "unprognostic (4.61e-4)" "unprognostic (6.19e-2)" "unprognostic (1.31e-1)" "unprognostic (2.14e-2)" "unprognostic (5.08e-2)" "unprognostic (1.63e-1)" "unprognostic (4.31e-2)" "unprognostic (3.22e-1)" "unprognostic (1.05e-1)" "unprognostic (2.40e-2)" "unprognostic (4.36e-3)" "unprognostic (5.44e-2)" "unprognostic (7.41e-3)" "unprognostic (2.43e-1)" 0.3 7.8 1.2 0.4 1.1 0.9 1.0 1.8 1.8 0.4 2.1 1.5 4.4 0.5 0.3 0.3 0.4 0.9 0.5 1.0 4.5 0.4 0.1 0.5 0.7 4.5 3.9 1.6 2.4 6.4 1.0 0.0 7.0 1.2 2.3 2.5 0.5 0.7 0.5 0.3 9.7 0.4 1.5 1.2 6.6 2.5 3.3 0.4 2.2 0.8 0.7 1.5 0.7 1.1 0.0 1.3 2.7 6.3 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.3 0.0 3.1 0.0 0.0 0.0 1.7 0.6 0.0 2.2 0.0 0.4 1.0 0.0 0.0 0.2 0.0 0.1 0.4 2.5 0.0 0.2 0.3 0.2 0.0 0.2 1.5 3.7 0.0 0.0 4.2 0.3 0.5 12.9 0.5 8.3 0.2 13.3 0.0 0.7 0.0 0.5 1.2 0.0 10.8 0.3 0.0 0.0 0.0 0.3 0.0 1.3 0.0 0.4 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.3 0.0 0.1 0.0 0.0 1.2 1.1 1.8 1.8 1.0 4.5 4.5 3.9 7.0 1.5 3.3 1.1 0.5 0.0 0.0 1.0 0.0 0.3 3.0 0.0 7.4 1.8 1.1 1.3 1.1 2.8 0.0 0.0 0.0 0.0 0.0 3.8 0.0 1.3 0.1 0.2 0.3 1.5 3.0 0.0 9.0 2.5 0.0 0.4 26.0 0.6 1.3 4.6 0.7 0.0 0.1 16.8 30.7 8.9 0.0 0.0 0.9 0.2 0.0 0.4 0.0 0.0 0.0 0.1 0.0 1.5 1.1 1.6 2.9 0.0 0.2 0.7 14.4 0.2 0.0 0.0 0.0 0.4 0.3 0.2 5.9 3.2 0.0 0.0 0.1 0.2 2.0 1.2 CHRNB2 ENSG00000160716 "Cholinergic receptor nicotinic beta 2 subunit" P17787 1 154567778-154580013 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 17.4;retina: 8.3" "Cell type enhanced" "Detected in some" "Bipolar cells: 12.7;Cone photoreceptor cells: 14.6;Horizontal cells: 42.1;Inhibitory neurons: 7.8;Late spermatids: 11.8;Rod photoreceptor cells: 7.6" "Cancer enhanced" "Detected in some" "glioma: 1.9" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "SCLC-21H: 25.7;SH-SY5Y: 25.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 58: Brain - Synaptic function" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 62: Horizontal cells - Visual perception" "unprognostic (1.13e-1)" "unprognostic (6.33e-2)" "unprognostic (8.15e-3)" "unprognostic (3.32e-1)" "unprognostic (4.37e-3)" "unprognostic (2.25e-1)" "unprognostic (3.51e-1)" "unprognostic (1.28e-1)" "unprognostic (3.65e-2)" "unprognostic (2.37e-1)" "unprognostic (1.24e-3)" "unprognostic (1.83e-1)" "unprognostic (4.36e-1)" "unprognostic (2.32e-1)" "unprognostic (1.45e-1)" "unprognostic (5.65e-2)" "unprognostic (1.84e-1)" 0.0 1.0 6.5 0.1 7.5 0.0 0.4 2.2 17.4 0.0 0.0 0.2 0.2 0.0 0.0 0.1 0.0 0.0 0.0 8.7 5.3 0.0 0.0 0.0 0.0 3.8 5.5 0.0 0.6 0.1 3.6 0.0 3.8 0.0 0.1 8.3 0.0 0.0 0.0 0.2 0.1 0.1 0.3 0.0 0.3 0.7 11.8 0.0 0.0 0.0 0.0 0.0 0.0 6.5 0.0 0.6 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 4.3 0.2 0.0 0.1 0.0 0.0 0.0 0.0 25.7 25.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.5 7.5 2.2 17.4 8.7 5.3 3.8 5.5 3.8 0.3 11.8 6.5 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.0 0.0 12.7 0.1 0.3 1.5 0.0 0.0 0.0 14.6 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.1 0.2 3.6 0.0 5.8 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 42.1 7.8 0.0 0.0 0.0 0.0 11.8 0.0 0.0 0.0 1.0 0.0 1.3 0.0 1.5 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.6 0.0 0.0 0.0 1.5 0.4 0.0 0.3 0.0 0.0 0.1 0.0 0.0 CHRNB4 ENSG00000117971 "Cholinergic receptor nicotinic beta 4 subunit" P30926 15 78624111-78727754 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 3.0;retina: 2.7;testis: 5.8" "Group enriched" "Detected in some" 11 "Early spermatids: 44.1;Late spermatids: 54.9" "Cancer enhanced" "Detected in some" "testis cancer: 2.0" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 16 "SCLC-21H: 30.9;SH-SY5Y: 40.7" "Group enriched" "Detected in some" 5 "olfactory bulb: 5.3;pons and medulla: 1.4;thalamus: 4.2" HPA059484 Approved "Endoplasmic reticulum,Cell Junctions" NA NA "Cluster 77: Retina - Visual perception" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 34: Spermatids - Unknown function" "Endoplasmic reticulum" "Cell Junctions" "HPA059484: " "unprognostic (4.74e-2)" "unprognostic (4.54e-1)" "unprognostic (1.26e-2)" "unprognostic (8.77e-5)" "unprognostic (8.15e-2)" "unprognostic (6.43e-3)" "unprognostic (1.10e-1)" "unprognostic (2.30e-2)" "unprognostic (1.09e-1)" "unprognostic (3.19e-1)" "unprognostic (1.40e-1)" "unprognostic (1.49e-1)" "unprognostic (1.45e-4)" "unprognostic (7.00e-3)" "unprognostic (2.58e-1)" "unprognostic (8.50e-2)" "unprognostic (7.76e-2)" 0.0 2.4 0.2 0.6 0.1 0.3 0.0 0.1 0.2 0.2 0.2 1.1 0.0 0.3 0.3 0.6 0.0 0.0 0.0 0.2 0.5 0.2 0.0 0.0 0.5 0.7 1.8 0.1 0.0 0.2 0.4 0.0 1.4 0.0 0.4 2.7 0.1 0.0 0.3 0.1 0.3 0.4 0.0 0.4 0.3 5.8 0.2 3.0 0.1 0.0 0.4 0.0 0.2 0.3 0.3 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.7 0.1 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.3 0.0 0.6 0.4 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 30.9 40.7 0.2 0.5 0.1 0.3 0.1 0.1 0.0 0.2 0.5 0.0 0.0 2.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.2 0.2 0.5 0.7 1.8 1.4 0.0 0.2 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 2.1 0.1 0.0 0.0 0.0 0.0 44.1 0.3 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 54.9 0.0 0.0 0.0 0.0 0.6 0.4 0.0 0.5 0.1 0.2 0.0 0.4 0.0 0.0 0.3 0.4 0.1 0.1 0.0 0.0 0.0 1.6 2.0 0.0 0.0 0.0 0.0 4.5 0.0 0.1 CKB CKBB ENSG00000166165 "Creatine kinase B" P12277 14 103519667-103522833 "Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 694.7;intestine: 653.4" "Cell type enhanced" "Detected in many" "Bipolar cells: 2767.4;Distal enterocytes: 4691.8;Distal tubular cells: 2281.3;Horizontal cells: 5042.4;Muller glia cells: 3639.8;Rod photoreceptor cells: 3789.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 10 "non-classical monocyte: 290.8" "Lineage enriched" "Detected in many" 18 "monocytes: 290.8" "Cell line enhanced" "Detected in many" "CACO-2: 455.8;HEK 293: 1399.8;SCLC-21H: 792.2;SH-SY5Y: 352.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001254, CAB047313" Enhanced Supported Cytosol No No 38000000 "Cluster 51: Monocytes - Innate immune response" "Cluster 57: Non-specific - Angiogenesis" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 53: Intestinal epithelial cells - Unknown function" Cytosol "CAB047313: , HPA001254: AB_1078528" "unprognostic (9.97e-2)" "unprognostic (1.33e-3)" "unprognostic (4.25e-3)" "unprognostic (1.10e-1)" "unprognostic (7.63e-2)" "unprognostic (3.62e-2)" "unprognostic (1.64e-1)" "unprognostic (1.30e-1)" "unprognostic (4.24e-1)" "unprognostic (4.60e-2)" "unprognostic (2.68e-3)" "unprognostic (9.89e-3)" "prognostic favorable (4.02e-8)" "unprognostic (2.62e-1)" "unprognostic (1.10e-1)" "unprognostic (1.67e-2)" "unprognostic (2.13e-1)" 90.7 60.0 471.6 25.8 627.0 3.2 47.2 641.1 694.7 105.2 192.7 653.4 36.0 222.6 16.0 54.5 197.9 17.9 269.8 428.7 482.3 161.0 9.0 60.3 4.0 427.5 440.4 58.8 27.7 108.2 74.0 4.7 345.1 301.8 151.9 471.3 37.9 208.3 80.0 76.5 120.8 113.8 434.5 6.8 479.9 97.6 596.2 2.8 87.9 47.1 5.1 298.4 101.6 383.6 2.4 54.5 321.1 14.7 4.4 2.3 6.3 37.5 0.3 2.4 1.4 455.8 7.3 0.4 36.9 29.1 9.9 70.2 109.9 1.5 0.2 9.6 1399.8 111.0 242.1 165.4 16.6 0.7 87.9 14.7 0.6 3.9 0.8 3.3 0.0 5.1 198.7 3.7 4.8 20.0 2.3 3.9 109.1 48.3 213.6 13.9 6.8 275.9 65.9 2.5 792.2 352.2 65.3 10.6 25.2 21.6 21.1 40.9 2.2 1.5 56.3 4.7 147.3 21.1 2.7 7.2 6.4 2.1 14.1 2.4 0.5 14.6 0.3 28.5 0.4 0.0 0.2 0.1 16.4 0.2 0.1 0.5 1.0 0.2 290.8 0.0 0.7 6.0 471.6 627.0 641.1 694.7 428.7 482.3 427.5 440.4 345.1 434.5 596.2 383.6 14.8 195.5 103.5 515.8 13.5 153.7 296.2 257.6 56.3 2767.4 41.5 48.9 553.5 145.8 117.9 114.0 1909.9 4.4 3.4 4691.8 2281.3 127.6 445.8 773.2 205.7 60.8 467.1 9.9 178.0 42.5 11.7 96.6 359.4 408.5 28.6 476.1 74.6 9.2 8.2 5042.4 147.0 726.0 187.2 2.8 44.9 147.4 304.1 39.8 181.5 88.1 74.2 3639.8 0.0 93.5 161.2 131.4 1996.9 1089.3 6.6 279.8 9.5 118.0 456.1 3789.9 59.2 15.4 222.6 127.3 97.4 22.1 175.2 41.6 19.1 12.2 755.6 220.1 CKM CKMM ENSG00000104879 "Creatine kinase, M-type" P06732 19 45306413-45322875 "Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 11 "skeletal muscle: 73556.4;tongue: 26058.9" "Cell type enriched" "Detected in some" 8 "Cardiomyocytes: 5353.0" "Cancer enriched" "Detected in many" 4 "head and neck cancer: 64.4" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 4 "SCLC-21H: 68.8" "Region enriched" "Detected in single" 15 "olfactory bulb: 1.5" "Low region specificity" "Detected in many" HPA047859 Enhanced NA NA 170000000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 33: Striated muscle - Muscle contraction" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 54: Cardiomyocytes - Muscle contraction" "HPA047859: AB_2680186" "unprognostic (3.51e-1)" "unprognostic (7.63e-2)" "unprognostic (2.61e-2)" "unprognostic (4.14e-1)" "unprognostic (7.68e-3)" "unprognostic (4.04e-3)" "unprognostic (1.85e-2)" "unprognostic (4.23e-2)" "unprognostic (5.19e-2)" "unprognostic (1.81e-1)" "unprognostic (5.00e-1)" "unprognostic (9.46e-3)" "unprognostic (9.67e-8)" "unprognostic (3.23e-1)" "unprognostic (1.73e-1)" "unprognostic (2.33e-1)" "unprognostic (1.95e-1)" 8.5 2.7 0.1 0.0 0.3 0.7 12.4 0.2 0.3 0.9 0.0 6.6 0.1 1.8 0.0 512.5 0.4 0.2 4618.8 0.0 0.0 2.1 5.2 8.7 0.4 0.1 0.0 2.8 5.3 0.0 2.1 0.3 0.2 134.8 0.1 0.2 340.9 2.1 73556.4 23.4 4.3 2.4 0.0 2.5 23.5 9.9 0.0 2.5 8.5 26058.9 0.4 1.5 3.9 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.4 0.0 5.8 0.0 0.3 16.3 12.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 2.0 0.0 0.0 0.0 6.3 0.2 0.2 0.0 0.0 68.8 0.0 0.0 0.1 0.1 0.0 0.1 16.3 0.1 0.0 0.1 0.1 0.0 0.4 0.2 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.3 0.2 0.3 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 5353.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 11.7 0.1 15.3 0.8 0.9 51.2 0.0 0.0 0.4 0.0 0.7 141.8 0.0 0.1 1.3 0.4 0.4 0.0 6.6 0.0 0.5 0.0 0.0 0.9 0.3 53.2 1.5 3.2 0.0 0.0 0.9 0.0 0.0 0.5 0.4 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.8 0.0 0.0 639.9 47.3 16.5 1.6 0.0 0.1 0.3 2.6 3.6 0.0 0.1 CKMT1A CKMT1 ENSG00000223572 "Creatine kinase, mitochondrial 1A" P12532 15 43692886-43699222 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 83.9;intestine: 75.0" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 73.0;Distal enterocytes: 110.5;Intestinal goblet cells: 53.4;Paneth cells: 57.4;Proximal enterocytes: 94.5;Syncytiotrophoblasts: 94.0;Undifferentiated cells: 92.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "HaCaT: 127.5;hTCEpi: 56.8;OE19: 144.3;SK-BR-3: 107.8;T-47d: 100.3" HPA043491 Uncertain "Intracellular and membrane" NA NA 2000000 "Cluster 37: Intestine - Unknown function" "Cluster 21: OE19 - Mitochondria" "Cluster 53: Intestinal epithelial cells - Unknown function" "HPA043491: AB_2678510" "unprognostic (2.04e-2)" "unprognostic (2.53e-2)" "unprognostic (1.17e-1)" "unprognostic (4.02e-3)" "unprognostic (3.80e-1)" "unprognostic (7.44e-2)" "unprognostic (2.21e-1)" "unprognostic (3.10e-1)" "unprognostic (1.75e-1)" "unprognostic (1.31e-1)" "unprognostic (1.72e-1)" "unprognostic (2.51e-2)" "unprognostic (3.78e-9)" "unprognostic (3.52e-2)" "unprognostic (1.03e-1)" "unprognostic (7.37e-2)" "unprognostic (1.73e-3)" 1.8 3.8 20.8 7.1 22.1 0.0 7.7 29.3 46.4 10.1 12.6 75.0 70.6 0.5 0.4 83.9 2.1 9.4 0.8 21.9 27.3 6.0 0.2 0.9 0.1 24.9 15.8 0.1 3.5 12.3 8.5 9.5 26.9 4.4 69.4 31.8 31.4 1.1 0.1 38.0 63.1 3.4 10.7 0.1 23.3 0.3 23.0 0.2 2.8 0.0 14.7 8.3 26.1 25.7 0.3 2.9 0.7 0.1 1.3 0.0 31.9 0.0 0.0 0.0 0.0 6.8 22.1 0.1 1.4 0.0 2.4 127.5 22.4 39.0 0.0 0.0 17.1 0.0 2.1 0.7 0.0 0.0 6.1 0.2 56.8 0.0 10.3 0.0 0.0 5.0 5.7 0.1 0.0 34.8 0.0 0.2 10.1 144.3 8.2 0.1 0.0 6.7 6.7 4.7 47.1 20.0 0.0 107.8 8.6 2.9 100.3 0.8 0.0 0.0 2.3 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.8 22.1 29.3 46.4 21.9 27.3 24.9 15.8 26.9 10.7 23.0 25.7 0.1 0.0 0.0 2.3 0.3 17.7 10.5 30.3 1.8 6.7 4.2 5.2 0.5 10.0 14.9 1.8 20.9 73.0 0.1 110.5 27.4 4.2 0.0 0.7 0.0 0.3 18.0 0.0 10.6 20.2 23.5 0.4 26.0 0.8 8.9 1.5 0.0 0.0 4.5 6.7 9.0 53.4 12.2 0.0 0.7 0.2 0.0 0.0 5.4 1.0 0.0 4.8 0.0 1.5 1.6 12.9 57.4 0.0 0.0 2.7 94.5 1.0 4.1 11.6 0.0 0.0 0.9 0.0 0.1 16.1 18.5 94.0 0.4 0.0 92.7 20.1 CKMT1B "CKMT, CKMT1, UMTCK" ENSG00000237289 "Creatine kinase, mitochondrial 1B" P12532 15 43593054-43604901 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 58.5;esophagus: 74.3;intestine: 80.7" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 122.4;Distal enterocytes: 146.4;Intestinal goblet cells: 78.3;Paneth cells: 69.9;Proximal enterocytes: 124.6;Syncytiotrophoblasts: 137.9;Undifferentiated cells: 123.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "HaCaT: 139.8;hTCEpi: 69.2;OE19: 156.0;SK-BR-3: 183.1;T-47d: 100.7" HPA043491 Uncertain "Intracellular and membrane" NA NA 2000000 "Cluster 45: Intestine - Brush border" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 53: Intestinal epithelial cells - Unknown function" "HPA043491: AB_2678510" "unprognostic (3.47e-2)" "unprognostic (9.73e-3)" "unprognostic (3.10e-1)" "prognostic unfavorable (2.55e-5)" "unprognostic (1.29e-1)" "unprognostic (1.96e-1)" "unprognostic (5.19e-2)" "unprognostic (2.84e-1)" "unprognostic (3.64e-1)" "unprognostic (5.75e-2)" "unprognostic (2.39e-1)" "unprognostic (1.15e-2)" "unprognostic (2.26e-8)" "unprognostic (1.71e-2)" "unprognostic (1.69e-1)" "unprognostic (4.43e-2)" "unprognostic (4.36e-2)" 1.9 1.9 24.6 6.3 25.1 0.0 6.0 38.0 58.5 8.0 14.3 80.7 63.4 0.3 0.4 74.3 1.9 8.9 0.7 26.5 31.5 5.3 0.1 0.7 0.1 32.4 25.2 0.1 3.1 11.9 9.5 12.8 34.6 3.1 66.0 23.4 28.5 0.8 0.1 26.7 49.4 4.0 13.8 0.0 29.6 0.2 28.6 0.1 6.2 0.0 13.3 8.4 22.0 22.2 0.3 0.9 0.8 0.0 0.2 0.0 35.3 0.0 0.0 0.1 0.1 7.8 23.8 0.0 1.0 0.0 7.2 139.8 28.4 55.8 0.1 0.8 16.0 0.0 3.0 3.8 0.0 0.1 8.6 0.0 69.2 0.0 6.9 0.0 0.0 5.9 9.1 0.0 0.0 38.2 0.1 0.2 12.0 156.0 14.9 0.0 0.0 0.8 3.0 3.7 55.4 19.5 0.9 183.1 10.9 2.3 100.7 0.0 0.0 0.1 1.8 0.2 2.3 0.1 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.6 25.1 38.0 58.5 26.5 31.5 32.4 25.2 34.6 13.8 28.6 22.2 0.1 0.0 0.5 2.6 0.1 25.1 10.4 40.5 3.4 7.5 3.8 4.1 0.4 5.7 12.7 5.5 18.8 122.4 0.4 146.4 21.5 4.0 0.0 0.9 0.0 0.5 21.0 0.0 37.6 28.0 26.1 0.5 33.1 0.5 0.0 1.1 0.0 0.0 9.4 6.7 36.5 78.3 10.2 0.0 0.7 0.0 0.0 0.1 3.6 2.8 0.0 2.2 0.0 5.0 2.4 18.6 69.9 0.0 0.1 2.0 124.6 0.9 6.0 12.2 0.0 0.0 0.7 0.0 0.0 17.5 24.7 137.9 0.6 0.0 123.7 19.9 CKMT2 SMTCK ENSG00000131730 "Creatine kinase, mitochondrial 2" P17540 5 81233320-81266398 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 49 "heart muscle: 1240.1;skeletal muscle: 1430.8;tongue: 2324.4" "Cell type enriched" "Detected in many" 20 "Cardiomyocytes: 814.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 7 "NK-cell: 1.1" "Lineage enriched" "Detected in single" 7 "NK-cells: 1.1" "Cell line enhanced" "Detected in many" "BEWO: 3.5;T-47d: 6.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA051880 Enhanced NA NA 3000000 "Cluster 48: NK-cells - Unknown function" "Cluster 38: Heart - Muscle contraction" "Cluster 6: T47d - Mammary gland" "Cluster 54: Cardiomyocytes - Muscle contraction" "HPA051880: AB_2681650" "unprognostic (3.64e-3)" "unprognostic (1.15e-1)" "unprognostic (2.82e-3)" "unprognostic (1.88e-2)" "unprognostic (1.21e-2)" "unprognostic (2.41e-2)" "unprognostic (1.73e-2)" "unprognostic (3.57e-2)" "unprognostic (2.12e-1)" "unprognostic (1.03e-1)" "unprognostic (2.82e-1)" "unprognostic (1.84e-1)" "unprognostic (1.60e-2)" "unprognostic (5.34e-2)" "unprognostic (2.28e-1)" "unprognostic (1.76e-1)" "unprognostic (2.75e-3)" 18.2 33.6 12.3 0.8 15.0 0.1 4.6 17.3 12.3 8.1 24.4 3.2 1.1 6.4 11.4 20.2 6.9 8.1 1240.1 11.2 15.0 14.7 1.0 2.5 1.3 16.3 16.8 10.2 7.7 15.7 4.5 0.7 14.9 13.1 0.7 1.6 26.3 13.1 1430.8 4.7 2.8 8.8 12.0 1.8 17.9 3.6 16.1 0.8 4.9 2324.4 0.4 4.1 4.1 17.7 0.3 0.7 0.8 1.3 1.9 0.4 3.5 0.1 0.0 0.0 0.0 2.4 0.2 1.4 0.4 0.0 1.0 0.0 0.0 0.0 0.0 1.5 2.4 0.1 1.0 3.2 2.6 0.6 0.2 0.8 0.0 0.0 0.0 0.3 0.0 2.1 0.3 0.5 0.0 2.2 1.2 0.2 1.0 0.0 0.7 0.6 1.0 0.1 0.0 0.0 1.4 1.0 1.2 0.3 1.4 1.5 6.3 0.3 0.7 0.4 1.2 0.7 0.2 0.2 0.1 1.3 0.4 0.9 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 1.1 0.0 0.0 0.0 0.0 12.3 15.0 17.3 12.3 11.2 15.0 16.3 16.8 14.9 12.0 16.1 17.7 1.8 0.0 0.5 40.1 0.0 0.1 0.4 0.0 1.2 0.9 0.9 0.8 814.1 7.2 0.6 12.9 0.0 0.1 0.0 0.1 37.2 1.7 25.1 13.6 3.5 9.8 0.0 0.0 11.4 0.6 0.4 16.2 6.6 27.8 0.0 0.8 0.0 0.0 0.1 0.0 18.1 0.3 0.0 0.0 0.0 2.2 7.2 0.3 3.6 23.4 0.0 1.4 0.0 4.5 9.1 0.4 0.0 15.1 0.0 0.3 0.3 0.6 0.7 1.0 0.0 11.6 15.0 1.0 0.4 0.1 0.1 0.3 0.8 23.7 2.5 0.2 CLCN2 "ClC-2, CLC2, EJM6" ENSG00000114859 "Chloride voltage-gated channel 2" P51788 3 184346185-184361650 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 16.2" "Cell type enhanced" "Detected in many" "Distal enterocytes: 81.7;Proximal enterocytes: 27.4;Theca cells: 62.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009397, HPA014545, HPA024108" Approved Approved Cytosol NA NA "Cluster 45: Intestine - Brush border" "Cluster 39: CACO-2 - Unknown function" "Cluster 53: Intestinal epithelial cells - Unknown function" Cytosol "CAB009397: AB_2079256, HPA014545: AB_1846881, HPA024108: AB_1846883" "unprognostic (1.13e-1)" "unprognostic (4.01e-2)" "unprognostic (6.48e-2)" "unprognostic (5.11e-3)" "unprognostic (1.15e-1)" "unprognostic (2.53e-2)" "prognostic unfavorable (4.67e-8)" "unprognostic (1.72e-2)" "unprognostic (2.26e-1)" "unprognostic (1.23e-1)" "unprognostic (2.10e-1)" "unprognostic (2.50e-3)" "unprognostic (1.19e-1)" "unprognostic (4.40e-2)" "unprognostic (5.88e-2)" "unprognostic (4.60e-2)" "unprognostic (1.35e-1)" 1.4 5.1 2.2 1.8 3.1 1.0 1.6 3.1 3.0 3.0 1.6 16.2 9.2 3.6 3.8 1.7 2.4 7.5 1.2 2.0 2.4 3.0 1.7 1.2 0.7 3.4 3.0 4.0 4.5 3.4 2.8 1.0 2.7 2.3 10.8 0.6 2.8 2.9 0.9 1.6 8.4 1.6 2.9 1.5 2.2 10.6 3.3 1.3 2.7 0.5 0.9 2.1 2.0 4.3 8.9 3.2 2.5 6.9 2.2 1.8 5.8 2.9 1.7 3.1 2.0 16.8 3.0 3.0 8.2 1.6 8.0 15.1 3.6 3.5 0.9 2.8 4.2 2.7 7.0 7.7 1.3 1.2 2.6 3.6 2.7 2.6 3.0 1.5 2.9 3.3 1.0 1.6 1.1 5.9 0.8 1.6 3.7 7.6 4.4 5.4 2.3 10.7 3.8 6.9 4.0 2.4 3.3 11.4 5.2 1.6 9.4 1.2 1.4 1.5 4.5 7.7 7.7 3.6 5.5 2.1 2.7 5.3 7.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 3.1 3.1 3.0 2.0 2.4 3.4 3.0 2.7 2.9 3.3 4.3 2.2 3.2 4.1 16.6 0.4 1.0 0.9 0.8 1.2 2.1 2.5 2.8 1.2 14.3 1.1 0.0 0.0 1.0 1.9 81.7 0.0 3.7 2.3 2.5 4.5 1.9 3.0 0.8 4.1 2.0 0.6 2.6 2.6 4.4 1.3 11.3 2.5 0.6 0.7 1.7 8.1 3.7 0.0 1.0 0.3 2.7 5.3 1.1 0.0 1.9 0.6 1.7 0.0 6.0 15.1 2.2 16.0 4.9 0.8 0.6 27.4 2.3 2.6 2.5 0.0 0.9 2.1 3.3 1.7 1.1 0.4 1.5 1.2 62.5 9.0 0.5 CNR1 "CANN6, CB-R, CB1, CB1A, CB1K5, CNR" ENSG00000118432 "Cannabinoid receptor 1" P21554 6 88139864-88166359 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 23.0;brain: 25.1" "Cell type enhanced" "Detected in some" "Excitatory neurons: 44.6;Inhibitory neurons: 200.3;Sertoli cells: 98.6" "Cancer enriched" "Detected in many" 13 "glioma: 12.5" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "ASC diff: 81.4;HSkMC: 53.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA042256, HPA069945" Enhanced Supported Supported "Plasma membrane,Actin filaments" NA NA "Cluster 43: B-cells - Humoral immune response" "Cluster 10: Brain - Neuronal signaling" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane" "Actin filaments" "HPA042256: AB_2677917, HPA069945: " "unprognostic (1.28e-1)" "unprognostic (7.04e-2)" "unprognostic (4.61e-2)" "unprognostic (4.08e-3)" "unprognostic (1.21e-1)" "unprognostic (1.07e-3)" "unprognostic (1.37e-1)" "unprognostic (2.07e-2)" "unprognostic (2.49e-1)" "unprognostic (1.16e-2)" "unprognostic (2.74e-2)" "unprognostic (2.68e-1)" "unprognostic (1.70e-1)" "unprognostic (5.59e-3)" "unprognostic (2.68e-3)" "unprognostic (5.88e-2)" "unprognostic (7.00e-2)" 23.0 5.4 10.4 3.5 25.1 0.7 16.9 7.5 22.8 5.7 0.0 12.3 1.1 6.9 2.6 2.4 11.2 2.0 1.0 19.5 11.8 0.9 0.1 4.0 4.4 9.9 1.1 3.8 1.5 0.5 20.7 3.1 0.5 2.9 2.9 1.5 2.6 2.1 2.4 3.8 10.5 3.6 0.0 1.7 4.3 1.2 18.0 1.3 5.1 1.2 6.6 4.1 5.1 3.0 0.0 0.1 3.8 0.0 81.4 9.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 6.0 0.0 0.0 0.0 0.2 1.9 2.9 0.0 5.3 0.0 0.0 53.8 0.0 0.0 0.1 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.4 0.5 0.0 6.8 0.0 1.7 0.1 0.0 0.0 0.0 0.3 0.0 1.4 4.9 0.0 0.0 0.1 0.0 0.0 1.6 7.1 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 10.4 25.1 7.5 22.8 19.5 11.8 9.9 1.1 0.5 0.0 18.0 3.0 3.4 0.0 10.4 3.6 7.1 0.6 0.5 0.0 0.0 1.7 0.1 0.4 0.9 1.5 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.2 0.0 0.4 3.8 0.0 0.0 44.6 0.0 0.0 0.9 1.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 200.3 0.0 0.0 0.3 0.8 0.0 1.5 0.2 0.0 5.6 0.0 0.0 0.0 9.0 3.2 0.0 0.1 0.4 4.2 0.0 0.0 0.0 0.0 0.2 98.6 6.4 12.4 0.0 0.5 0.2 0.1 0.1 0.5 0.0 0.0 0.8 CNR2 CB2 ENSG00000188822 "Cannabinoid receptor 2" P34972 1 23870515-23913362 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Inflammatory response" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 3.4;lymphoid tissue: 8.8" "Cell type enriched" "Detected in some" 5 "B-cells: 27.8" "Cancer enriched" "Detected in single" 6 "testis cancer: 2.5" "Not detected" "Not detected" "Group enriched" "Detected in many" 8 "basophil: 49.3;eosinophil: 35.1;memory B-cell: 29.6;naive B-cell: 27.9;NK-cell: 19.4" "Group enriched" "Detected in many" 9 "B-cells: 29.6;granulocytes: 49.3;NK-cells: 19.4" "Cell line enhanced" "Detected in some" "Daudi: 5.3;HEL: 4.4;HMC-1: 19.7;U-698: 13.4" "Not detected" "Not detected" "Not detected" "Not detected" CAB009719 Uncertain NA NA "Cluster 10: Basophils - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 3: HMC-1 - Innate immune response" "Cluster 57: B-cells - Immune response" "CAB009719: AB_2082784" "unprognostic (9.45e-4)" "unprognostic (5.40e-3)" "unprognostic (8.50e-3)" "unprognostic (8.19e-3)" "unprognostic (3.55e-3)" "unprognostic (9.34e-6)" "unprognostic (5.58e-3)" "unprognostic (6.96e-3)" "unprognostic (1.74e-1)" "unprognostic (7.87e-2)" "unprognostic (1.53e-1)" "unprognostic (4.93e-2)" "unprognostic (1.04e-3)" "unprognostic (3.67e-1)" "unprognostic (1.80e-1)" "unprognostic (3.75e-2)" "unprognostic (4.91e-2)" 0.1 0.0 0.2 2.4 0.1 1.5 0.0 0.5 0.2 0.0 0.2 0.3 0.2 0.1 0.1 0.1 0.0 0.2 0.0 0.2 0.0 0.0 0.1 0.2 7.4 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.3 0.1 0.1 0.0 1.6 0.2 3.4 0.1 0.0 8.8 0.4 0.1 0.2 1.0 0.2 0.0 7.5 0.4 0.0 0.4 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 5.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.4 0.2 0.0 0.0 0.0 19.7 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.1 0.0 2.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 13.4 0.0 0.1 0.0 49.3 0.1 35.1 3.2 0.1 3.8 29.6 0.1 3.0 0.4 27.9 0.2 1.8 1.2 19.4 0.2 1.7 0.2 2.0 0.2 0.1 0.5 0.2 0.2 0.0 0.1 0.1 0.1 0.0 0.2 0.4 0.1 3.2 3.9 0.3 27.8 0.6 0.8 0.0 0.0 0.8 0.2 0.0 0.3 0.0 1.8 0.0 0.0 0.1 2.1 0.5 0.0 0.0 0.2 0.1 0.3 0.3 0.0 3.2 0.4 0.0 0.0 0.9 0.0 0.2 3.8 0.1 0.4 0.3 0.2 0.0 0.4 0.0 0.0 0.6 0.9 0.0 0.0 0.8 0.0 0.0 0.5 0.2 5.2 0.0 0.5 0.1 2.0 0.0 0.5 0.5 0.0 0.1 0.7 0.7 0.0 0.9 0.4 0.3 0.2 0.0 0.3 0.3 2.4 0.2 0.0 0.8 COMT ENSG00000093010 Catechol-O-methyltransferase P21964 22 19941371-19969975 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Catecholamine metabolism, Neurotransmitter degradation" "Methyltransferase, Transferase" "FDA approved drug targets, Schizophrenia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cytotrophoblasts: 885.9;Syncytiotrophoblasts: 648.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 818.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001169, CAB011233" Enhanced Enhanced "Endoplasmic reticulum,Vesicles" NA NA 43000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 15: Liver - Metabolism" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 47: Cytotrophoblasts - Unknown function" Vesicles "Endoplasmic reticulum" "CAB011233: , HPA001169: AB_1078402" "unprognostic (5.20e-2)" "unprognostic (2.73e-2)" "unprognostic (3.08e-2)" "prognostic favorable (3.68e-4)" "unprognostic (2.99e-2)" "unprognostic (2.32e-3)" "unprognostic (5.54e-3)" "unprognostic (9.14e-2)" "unprognostic (1.39e-1)" "unprognostic (1.40e-1)" "unprognostic (2.14e-3)" "prognostic favorable (5.67e-4)" "prognostic unfavorable (9.76e-4)" "unprognostic (2.27e-1)" "unprognostic (7.09e-2)" "unprognostic (3.97e-1)" "unprognostic (1.07e-2)" 78.1 180.7 99.3 39.6 108.9 71.8 85.5 114.4 140.4 105.3 119.6 80.1 55.0 76.9 47.7 198.0 65.2 60.3 81.7 96.6 107.4 94.2 292.3 93.3 49.7 117.4 107.9 107.4 74.0 61.5 48.7 116.9 117.3 87.2 20.7 17.2 133.7 70.5 98.6 119.7 64.1 38.3 109.2 63.6 99.8 51.7 102.7 26.9 59.1 49.9 26.0 86.9 124.1 124.3 131.3 131.7 15.0 128.3 141.2 122.5 6.0 143.9 178.8 120.3 133.6 112.1 148.6 51.7 62.7 208.9 48.6 172.9 23.6 152.0 26.2 115.1 163.4 92.5 65.1 267.1 265.1 155.0 35.3 159.2 180.7 104.3 101.3 116.6 113.2 82.0 383.2 109.4 100.6 818.5 63.4 267.9 32.4 361.1 42.9 88.2 127.9 72.8 129.0 404.5 60.4 53.8 47.7 405.7 125.7 7.6 84.0 436.6 137.5 212.7 82.2 71.0 109.6 37.5 18.0 41.2 236.0 211.3 152.5 62.2 312.2 59.6 77.9 218.1 64.0 56.8 52.6 62.6 251.5 57.8 45.5 51.7 12.0 73.5 151.5 291.4 72.6 178.6 99.3 108.9 114.4 140.4 96.6 107.4 117.4 107.9 117.3 109.2 102.7 124.3 99.1 125.0 88.1 22.9 33.1 102.1 231.9 248.1 188.4 73.4 174.9 218.4 41.9 104.4 162.7 152.6 10.4 885.9 80.1 53.0 320.8 201.0 4.6 59.1 72.2 86.7 84.5 70.0 16.8 193.0 113.5 103.1 46.4 46.9 71.7 95.7 77.1 262.0 311.4 25.2 17.2 97.7 191.2 177.0 107.7 13.3 134.2 137.0 240.1 20.6 137.0 158.7 41.2 25.1 45.7 170.2 108.8 179.8 45.5 132.4 179.9 73.8 135.8 43.2 138.1 143.3 113.1 8.4 5.7 236.4 123.5 648.5 41.8 222.0 122.3 206.6 CPS1 ENSG00000021826 "Carbamoyl-phosphate synthase 1" P31327 2 210477682-210679107 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Urea cycle" "Allosteric enzyme, Ligase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "liver: 1063.2" "Cell type enriched" "Detected in many" 19 "Hepatocytes: 2075.1" "Cancer enriched" "Detected in many" 8 "liver cancer: 136.1" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "HeLa: 347.6;SiHa: 65.1;SK-BR-3: 98.9" "Not detected" "Not detected" "Not detected" "Not detected" "CAB003781, HPA021400" Enhanced Supported "Nucleoli,Nucleoli rim" NA NA 8300000 "Cluster 85: Liver - Metabolism" "Cluster 20: HeLa - Mitochondria" "Cluster 2: Hepatocytes - Metabolism" "Nucleoli, Nucleoli rim" "CAB003781: , HPA021400: AB_1847197" "unprognostic (1.67e-2)" "unprognostic (3.72e-2)" "unprognostic (4.02e-2)" "unprognostic (7.21e-7)" "unprognostic (3.81e-2)" "unprognostic (2.52e-1)" "prognostic favorable (6.93e-5)" "unprognostic (1.23e-2)" "unprognostic (2.65e-1)" "unprognostic (1.35e-2)" "unprognostic (5.38e-2)" "unprognostic (1.94e-3)" "unprognostic (2.38e-4)" "unprognostic (5.90e-2)" "unprognostic (1.13e-1)" "unprognostic (3.14e-2)" "unprognostic (3.74e-2)" 2.5 0.4 1.0 0.4 10.0 0.1 1.5 4.9 1.7 0.9 0.1 0.8 211.8 1.6 2.8 1.5 0.9 1.6 1.2 0.7 2.3 1.9 1063.2 1.0 0.3 6.9 8.7 2.9 0.8 0.1 0.9 2.5 6.0 0.8 0.4 0.3 0.5 0.8 0.6 1.4 123.4 2.1 3.4 1.2 0.6 6.0 5.8 0.3 1.7 0.5 0.2 0.6 0.7 6.3 0.9 9.7 14.0 11.7 11.6 16.5 18.0 6.1 6.4 6.3 9.2 1.8 0.0 2.7 0.4 5.3 9.6 3.0 0.5 10.8 15.9 0.0 4.5 10.0 347.6 15.2 2.8 4.0 0.0 9.2 6.2 12.8 13.0 18.7 0.4 4.2 10.3 0.8 10.4 2.8 0.3 0.7 6.3 0.0 1.8 0.7 14.6 1.6 13.2 0.2 0.5 1.1 65.1 98.9 8.1 20.0 0.1 1.6 7.7 17.5 5.8 5.9 13.0 0.0 0.7 0.0 12.5 11.6 11.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 10.0 4.9 1.7 0.7 2.3 6.9 8.7 6.0 3.4 5.8 6.3 0.4 12.8 8.4 6.2 3.6 2.2 0.6 0.9 1.2 1.4 1.3 1.5 1.1 15.7 3.9 1.8 8.4 0.4 0.4 0.1 0.0 0.2 35.5 1.0 2.1 2.0 0.0 18.7 12.1 0.2 0.4 2.6 0.0 1.6 3.8 0.3 16.8 2075.1 0.2 0.0 6.2 13.5 0.0 27.2 2.9 6.5 2.5 0.8 1.8 3.7 0.2 0.7 0.0 3.0 8.8 0.0 2.5 1.2 0.1 1.1 105.6 1.0 1.3 2.3 0.0 1.8 2.3 0.6 1.8 1.5 1.8 20.8 1.8 3.5 41.2 0.4 CPT1A "CPT1, CPT1-L, L-CPT1" ENSG00000110090 "Carnitine palmitoyltransferase 1A" P50416 11 68754620-68844410 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Fatty acid metabolism, Lipid metabolism, Transport" "Acyltransferase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Distal enterocytes: 110.0;Hepatocytes: 108.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA008835 Supported Supported Mitochondria NA NA 45000 "Cluster 2: Granulocytes - Unknown function" "Cluster 41: Intestine & Liver - Lipid metabolism" "Cluster 25: RPMI-8226 - Immune response" "Cluster 53: Intestinal epithelial cells - Unknown function" Mitochondria "HPA008835: AB_1078563" "prognostic unfavorable (3.84e-4)" "unprognostic (1.38e-3)" "unprognostic (3.04e-3)" "unprognostic (2.46e-2)" "unprognostic (1.45e-1)" "unprognostic (7.25e-2)" "unprognostic (2.17e-1)" "unprognostic (4.99e-2)" "unprognostic (2.72e-1)" "unprognostic (1.47e-2)" "unprognostic (2.92e-2)" "unprognostic (2.34e-1)" "prognostic favorable (2.67e-7)" "unprognostic (9.76e-2)" "unprognostic (1.06e-1)" "unprognostic (1.49e-1)" "unprognostic (2.46e-3)" 24.3 27.7 16.0 22.3 18.4 38.9 22.7 20.2 17.3 20.4 32.0 67.4 70.7 25.1 7.3 22.0 25.4 27.7 25.4 14.7 17.7 38.4 67.9 25.3 15.9 20.6 22.0 18.3 23.6 27.6 14.3 18.4 19.3 20.3 44.6 22.6 26.0 21.9 9.9 17.0 71.3 34.9 15.9 27.4 35.6 13.5 22.1 14.0 15.4 14.3 12.3 18.7 18.0 13.9 29.4 50.9 7.3 48.6 31.2 28.0 2.1 22.9 18.8 17.7 3.6 2.0 96.0 0.1 82.2 60.4 62.2 93.5 63.9 13.6 5.3 46.8 6.3 71.5 52.3 24.0 46.4 41.9 82.6 29.2 6.6 35.5 21.4 24.1 63.5 28.2 7.6 56.8 16.5 83.6 34.4 73.7 0.8 149.7 53.2 94.7 1.2 127.1 41.7 71.7 1.0 31.8 63.0 119.9 20.2 4.8 107.4 40.0 64.5 38.3 0.9 77.7 33.5 43.9 60.1 29.2 40.3 30.3 42.8 8.2 6.6 9.5 7.3 7.7 4.2 1.9 4.4 4.4 4.4 2.0 2.7 5.5 3.2 4.9 6.7 10.4 2.8 2.7 16.0 18.4 20.2 17.3 14.7 17.7 20.6 22.0 19.3 15.9 22.1 13.9 44.4 38.5 28.8 35.6 13.5 9.4 11.0 9.0 28.5 4.8 9.6 7.6 25.5 22.8 18.0 23.9 64.6 15.9 39.3 110.0 19.6 13.8 14.7 33.2 22.6 30.4 16.2 30.9 5.6 9.5 3.9 16.6 31.1 56.7 29.7 23.0 40.7 108.3 15.7 1.7 5.7 48.9 10.2 39.1 11.5 43.9 9.6 24.6 0.0 28.1 31.4 12.7 23.7 7.1 1.7 8.5 43.4 32.0 28.6 9.6 83.4 11.8 23.8 43.0 39.5 18.3 21.1 14.5 10.0 14.8 7.7 7.8 24.0 17.3 67.4 9.2 CPT2 "CPT1, CPTASE" ENSG00000157184 "Carnitine palmitoyltransferase 2" P23786 1 53196792-53214197 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism, Transport" "Acyltransferase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 91.2" "Cell type enhanced" "Detected in all" "Cytotrophoblasts: 85.1;Hepatocytes: 88.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA028201, HPA028202, HPA028214" Enhanced Approved Nucleoplasm,Nucleoli,Mitochondria Yes No "Cluster 45: Eosinophils - Innate immune response" "Cluster 41: Intestine & Liver - Lipid metabolism" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 47: Cytotrophoblasts - Unknown function" "Nucleoplasm, Mitochondria" Nucleoli "HPA028201: AB_10599177, HPA028202: AB_10599942, HPA028214: AB_10601958" "unprognostic (2.43e-1)" "unprognostic (2.27e-1)" "prognostic favorable (5.27e-4)" "unprognostic (6.48e-2)" "unprognostic (1.88e-1)" "unprognostic (9.34e-2)" "unprognostic (6.48e-2)" "unprognostic (1.75e-2)" "unprognostic (2.86e-1)" "unprognostic (1.67e-1)" "unprognostic (3.00e-2)" "unprognostic (8.97e-2)" "prognostic favorable (1.46e-12)" "unprognostic (4.00e-2)" "unprognostic (2.06e-1)" "unprognostic (1.79e-2)" "unprognostic (2.95e-2)" 12.9 14.3 6.6 9.4 8.2 5.4 13.6 7.9 7.3 10.3 16.8 35.4 32.4 6.8 10.5 14.2 10.5 9.5 19.5 6.1 7.1 35.1 91.2 11.5 10.6 8.1 7.5 10.2 21.7 27.3 6.7 18.0 8.0 12.2 32.8 7.1 14.6 11.7 17.3 6.7 24.9 11.4 7.7 8.7 18.4 12.9 9.0 10.2 12.5 33.1 13.2 11.1 4.5 8.9 16.0 8.3 17.2 17.8 14.6 11.3 17.5 9.8 13.2 17.5 17.5 8.6 14.5 28.9 14.6 9.2 20.1 19.1 35.1 25.1 15.1 17.0 16.0 21.8 9.9 6.4 25.9 15.9 19.5 23.0 23.2 13.8 11.1 18.6 15.4 26.5 20.9 9.9 13.1 12.8 10.7 13.0 29.8 38.4 20.0 13.2 16.2 34.4 22.9 22.0 25.3 14.4 22.1 30.3 39.7 36.6 32.3 32.2 8.7 8.4 6.1 16.5 8.5 26.3 19.8 16.2 11.6 20.6 12.4 5.6 14.1 14.6 7.2 20.0 8.1 5.3 6.3 8.4 17.9 7.4 10.5 7.2 5.3 6.9 20.5 8.9 9.9 10.3 6.6 8.2 7.9 7.3 6.1 7.1 8.1 7.5 8.0 7.7 9.0 8.9 5.0 12.8 24.1 4.2 7.8 1.8 5.2 20.5 5.2 6.0 7.5 7.0 18.1 15.7 11.4 11.0 14.6 85.1 4.5 49.3 25.4 12.9 1.1 10.9 8.1 5.9 14.5 9.4 1.5 10.5 20.3 7.2 18.3 10.3 2.5 12.7 8.9 88.8 26.3 15.2 2.0 26.6 16.2 15.1 7.2 2.8 6.8 10.5 7.2 1.9 20.2 11.6 6.2 2.5 4.5 10.5 25.6 5.3 9.1 4.9 38.6 41.0 7.6 11.0 6.6 7.5 8.4 49.9 31.3 13.8 2.6 54.6 6.9 25.6 29.5 5.7 CRBN "MRT2, MRT2A" ENSG00000113851 Cereblon Q96SW2 3 3144628-3179727 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Transporters" "Ubl conjugation pathway" "Disease variant, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "basophil: 314.2" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA045910 Approved NA NA "Cluster 10: Basophils - Unknown function" "Cluster 76: Brain & Bone marrow - Chromatin organization" "Cluster 16: U-266 - Nucleosome" "Cluster 66: Spermatocytes - Spermatogenesis" "HPA045910: AB_10960409" "unprognostic (1.26e-1)" "unprognostic (4.14e-2)" "unprognostic (4.27e-2)" "unprognostic (4.05e-2)" "unprognostic (1.85e-2)" "unprognostic (3.31e-2)" "unprognostic (1.21e-1)" "unprognostic (6.40e-3)" "unprognostic (2.15e-1)" "unprognostic (2.38e-1)" "unprognostic (1.23e-1)" "unprognostic (4.79e-2)" "unprognostic (2.17e-3)" "unprognostic (1.70e-1)" "unprognostic (5.95e-2)" "unprognostic (2.28e-2)" "unprognostic (1.47e-2)" 25.1 20.9 25.6 17.1 30.2 44.0 33.8 32.7 41.6 22.9 42.0 21.4 21.8 26.2 23.9 20.6 21.7 21.0 30.9 29.2 28.5 31.0 35.4 24.4 28.6 33.7 26.8 32.1 21.9 29.9 11.1 29.5 35.5 23.5 22.9 26.8 36.3 23.6 41.8 24.8 22.8 24.8 22.9 30.6 22.9 48.2 29.1 23.5 31.9 38.5 21.6 20.0 14.6 48.1 12.9 10.5 32.5 14.4 38.8 37.3 13.6 14.3 23.9 18.4 24.6 15.6 18.7 13.9 19.4 17.8 22.3 12.2 19.9 24.1 20.0 24.0 30.9 35.9 20.1 19.4 26.0 32.5 22.4 28.7 31.1 19.9 15.1 36.1 25.2 29.9 21.5 29.4 16.1 18.7 28.6 32.5 27.3 17.8 24.8 25.9 19.5 30.5 21.8 20.0 16.3 23.7 15.9 21.6 35.7 24.1 28.9 24.0 16.3 18.8 9.8 30.0 18.6 33.2 55.8 35.2 29.2 29.5 23.5 314.2 44.3 99.3 61.6 53.6 65.2 46.4 82.6 66.8 39.8 36.9 84.3 72.4 28.1 103.6 58.1 21.4 63.0 96.1 25.6 30.2 32.7 41.6 29.2 28.5 33.7 26.8 35.5 22.9 29.1 48.1 89.7 44.8 39.1 30.3 46.5 36.1 35.5 70.9 33.0 61.5 30.6 43.4 73.5 38.6 45.2 38.6 27.1 52.6 81.2 21.4 72.4 33.3 184.2 23.9 31.7 72.0 15.6 54.5 72.6 21.2 35.3 47.9 17.3 22.3 140.4 50.2 68.6 35.0 36.0 43.7 74.1 24.6 54.9 52.7 33.4 56.6 62.7 54.8 33.8 28.1 68.8 66.4 121.5 42.7 74.0 20.4 33.5 66.5 34.1 26.0 53.4 73.2 36.4 64.5 59.2 58.0 46.2 206.2 96.2 19.2 38.5 50.2 70.9 49.4 30.5 24.7 CRHR1 "CRF-R, CRF1, CRHR" ENSG00000120088 "Corticotropin releasing hormone receptor 1" P34998 17 45784280-45835828 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 10.4;pituitary gland: 22.6" "Group enriched" "Detected in some" 4 "Early spermatids: 41.0;Late spermatids: 53.4" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in many" "cerebellum: 10.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "RT4: 3.4;SH-SY5Y: 1.8" CAB025251 Enhanced "Intracellular and membrane" NA NA "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 15: RT4 - Unknown function" "Cluster 34: Spermatids - Unknown function" "CAB025251: " "unprognostic (4.59e-2)" "unprognostic (1.43e-2)" "unprognostic (2.59e-7)" "unprognostic (1.76e-1)" "unprognostic (2.71e-1)" "unprognostic (3.94e-2)" "unprognostic (2.48e-1)" "unprognostic (4.55e-4)" "unprognostic (1.65e-2)" "unprognostic (2.21e-1)" "unprognostic (3.33e-4)" "unprognostic (2.07e-5)" "unprognostic (3.26e-1)" "unprognostic (1.49e-1)" "unprognostic (1.59e-1)" 0.2 0.0 4.1 0.0 1.7 0.0 0.4 10.4 4.8 2.3 0.0 0.0 0.0 1.1 0.1 0.1 0.7 0.0 0.0 1.9 0.4 0.1 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.1 22.6 0.0 0.2 0.6 0.0 3.5 0.2 0.3 0.1 0.5 0.1 0.1 0.0 0.0 0.0 0.2 2.8 0.0 0.2 0.0 0.0 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.8 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 1.7 10.4 4.8 1.9 0.4 0.0 1.5 0.2 0.0 2.8 0.0 0.0 0.0 0.0 0.0 2.8 1.1 1.3 1.2 10.2 0.7 0.1 0.0 0.4 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 41.0 0.0 0.0 0.4 0.0 2.1 0.0 0.0 0.0 1.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 53.4 0.6 0.3 0.0 0.0 0.0 0.7 1.0 0.0 0.0 0.0 0.1 0.4 3.2 1.6 0.1 0.1 0.4 0.5 0.0 0.5 1.6 5.1 1.5 9.9 3.3 0.0 2.5 0.0 0.1 1.7 CSF1R "C-FMS, CD115, CSFR, FMS" ENSG00000182578 "Colony stimulating factor 1 receptor" P07333 5 150053291-150113372 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Immunity, Inflammatory response, Innate immunity" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Neurodegeneration, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 113.3;placenta: 103.3" "Cell type enhanced" "Detected in many" "Extravillous trophoblasts: 103.2;Hofbauer cells: 340.4;Kupffer cells: 291.2;Langerhans cells: 73.4;Macrophages: 196.3;Microglial cells: 134.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "intermediate monocyte: 444.6;non-classical monocyte: 646.9" "Lineage enriched" "Detected in many" 5 "monocytes: 646.9" "Group enriched" "Detected in some" 4 "BEWO: 123.0;SK-BR-3: 47.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008970, HPA012323" Uncertain Supported "Vesicles,Plasma membrane" "Intracellular and membrane" NA NA 1600000000 "Cluster 51: Monocytes - Innate immune response" "Cluster 64: Macrophages - Immune response" "Cluster 28: BEWO - Transcription regulation" "Cluster 4: Macrophages - Innate immune response" "Vesicles, Plasma membrane" "CAB008970: , HPA012323: AB_1848977" "unprognostic (3.82e-2)" "unprognostic (1.31e-1)" "unprognostic (1.86e-3)" "unprognostic (9.83e-2)" "unprognostic (1.20e-1)" "unprognostic (7.33e-2)" "unprognostic (1.03e-1)" "unprognostic (1.45e-1)" "unprognostic (9.37e-2)" "unprognostic (1.11e-2)" "unprognostic (2.49e-1)" "unprognostic (1.65e-1)" "prognostic unfavorable (1.08e-4)" "unprognostic (3.67e-2)" "prognostic unfavorable (4.92e-4)" "unprognostic (1.72e-2)" "unprognostic (4.61e-2)" 51.3 31.0 19.6 75.1 17.1 5.6 19.3 20.2 21.4 21.6 19.3 21.9 24.3 12.1 5.8 21.0 17.2 40.6 16.6 19.8 33.8 7.1 27.5 36.6 54.4 41.4 35.5 12.7 9.9 11.8 5.7 103.3 40.1 9.1 21.5 1.5 10.1 20.8 3.2 13.4 37.3 41.9 36.6 113.3 21.0 7.0 40.6 14.3 6.0 11.8 21.7 42.6 3.8 67.6 4.5 0.2 0.0 0.0 1.9 0.4 123.0 0.2 0.2 0.0 0.0 3.8 0.0 5.9 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.2 1.1 3.0 0.0 6.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 6.1 0.1 0.0 0.0 0.0 1.9 0.6 0.0 0.0 0.2 0.2 0.0 47.8 0.0 1.9 0.0 20.7 0.0 0.8 0.2 0.1 3.3 0.0 0.3 0.1 6.6 2.6 0.0 3.0 138.4 4.0 0.6 444.6 0.6 0.3 0.2 0.4 139.0 0.2 0.3 0.2 21.6 0.2 646.9 11.1 0.5 132.7 19.6 17.1 20.2 21.4 19.8 33.8 41.4 35.5 40.1 36.6 40.6 67.6 2.0 0.0 3.8 0.0 4.3 2.8 0.0 0.0 1.2 0.0 0.5 2.3 3.1 4.3 0.0 0.0 0.0 6.2 2.8 0.0 0.0 0.0 4.8 0.0 0.1 10.5 0.0 2.5 0.4 0.0 103.2 2.2 1.5 0.2 2.5 8.3 2.9 1.5 340.4 0.0 0.5 0.3 0.0 291.2 73.4 5.4 1.8 196.3 3.6 134.9 39.4 0.0 1.0 1.5 0.3 0.1 1.7 0.0 1.0 0.0 0.0 0.1 0.7 0.5 13.1 1.2 2.0 2.2 0.2 0.4 1.3 26.4 1.3 2.2 0.2 0.0 CXCR4 "CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R" ENSG00000121966 "C-X-C motif chemokine receptor 4" P61073 2 136114349-136118149 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 1175.1;lymphoid tissue: 549.3" "Cell type enhanced" "Detected in many" "B-cells: 1446.9;dendritic cells: 1015.1;Langerhans cells: 486.2;Macrophages: 513.6;Plasma cells: 534.2;T-cells: 1436.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 580.8;JURKAT: 323.6;Karpas-707: 302.1;MOLT-4: 538.9;REH: 281.0;U-266/70: 648.5;U-698: 677.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 21: B-cells - Adaptive immune response" "Cluster 66: Lymphoid tissue - Immune response regulation" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 24: Non-specific - Transcription regulation" "unprognostic (1.19e-1)" "unprognostic (1.46e-2)" "unprognostic (2.69e-1)" "unprognostic (5.97e-2)" "unprognostic (1.29e-2)" "unprognostic (1.12e-2)" "unprognostic (4.99e-2)" "unprognostic (9.25e-2)" "unprognostic (6.06e-2)" "prognostic favorable (2.05e-4)" "unprognostic (1.23e-1)" "unprognostic (2.66e-1)" "prognostic unfavorable (1.41e-7)" "prognostic unfavorable (5.67e-4)" "unprognostic (1.57e-1)" "unprognostic (3.47e-2)" "unprognostic (9.33e-2)" 51.8 184.5 11.8 297.9 11.4 1175.1 39.6 14.6 23.8 36.1 20.1 33.2 12.6 35.2 5.5 34.9 64.9 84.5 21.8 10.6 19.7 29.0 52.4 95.5 383.8 24.3 12.8 12.9 10.0 12.3 32.6 57.5 18.2 34.1 48.6 7.8 30.2 11.8 5.2 9.8 246.5 28.1 16.7 346.5 64.0 4.0 15.2 491.2 36.7 12.0 549.3 99.3 26.9 32.3 0.8 0.3 9.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.9 0.0 580.8 1.8 0.0 0.4 0.7 1.7 0.0 0.0 29.6 6.9 35.1 84.3 0.0 0.0 81.5 60.7 0.0 0.0 0.0 0.0 0.0 54.5 323.6 1.0 302.1 0.0 1.5 538.9 72.8 9.3 45.4 2.9 281.0 62.6 102.5 4.5 0.0 30.9 26.1 0.6 2.0 0.3 2.9 0.7 156.7 8.1 0.0 2.0 0.5 0.4 648.5 116.7 677.4 0.1 131.8 0.1 87.0 28.5 117.8 83.8 15.6 67.3 115.6 76.5 79.6 25.7 166.2 113.1 109.5 143.3 17.2 9.1 63.7 76.1 51.9 11.8 11.4 14.6 23.8 10.6 19.7 24.3 12.8 18.2 16.7 15.2 32.3 32.0 16.0 42.2 8.5 1446.9 41.0 5.7 0.3 9.6 8.6 46.1 42.2 5.2 11.5 4.4 3.7 0.0 1.5 1015.1 1.1 13.7 5.1 1.2 20.0 8.9 67.6 1.8 67.5 0.0 0.9 4.2 28.9 52.0 71.0 12.6 9.0 29.6 9.1 159.9 0.0 0.2 2.0 10.2 270.0 486.2 2.9 1.5 513.6 113.8 3.7 189.2 1.0 153.5 0.0 2.0 2.3 1.1 2.6 534.2 3.2 0.0 3.2 2.4 0.8 46.0 99.1 23.1 0.5 7.8 8.5 35.7 6.3 1436.5 4.6 1.8 4.5 CYP11A1 "CYP11A, P450SCC" ENSG00000140459 "Cytochrome P450 family 11 subfamily A member 1" P05108 15 74337759-74367646 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Steroidogenesis, Sterol metabolism" "Monooxygenase, Oxidoreductase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 26 "adrenal gland: 1009.9" "Cell type enhanced" "Detected in some" "Extravillous trophoblasts: 345.1;Peritubular cells: 173.8;Syncytiotrophoblasts: 1452.0;Theca cells: 637.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 48 "basophil: 10.2" "Lineage enriched" "Detected in single" 48 "granulocytes: 10.2" "Group enriched" "Detected in some" 5 "BEWO: 55.2;HEL: 46.8" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "basal ganglia: 1.8;hippocampal formation: 1.1;hypothalamus: 1.3;midbrain: 4.5;pons: 1.1" HPA016436 Enhanced NA NA "Cluster 46: Basophils - DNA binding" "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 28: BEWO - Transcription regulation" "Cluster 18: Syncytiotrophoblasts - Pregnancy hormone signaling" "HPA016436: AB_1847423" "unprognostic (8.89e-2)" "unprognostic (6.96e-2)" "unprognostic (4.95e-3)" "unprognostic (9.31e-2)" "unprognostic (9.42e-4)" "unprognostic (1.90e-1)" "unprognostic (1.55e-3)" "unprognostic (8.06e-2)" "unprognostic (3.04e-1)" "unprognostic (2.95e-1)" "unprognostic (1.77e-2)" "unprognostic (5.45e-2)" "unprognostic (9.66e-4)" "unprognostic (2.40e-2)" "unprognostic (2.74e-1)" "unprognostic (3.04e-2)" "unprognostic (7.95e-2)" 2.0 1009.9 2.0 0.6 2.1 0.1 1.9 2.3 2.0 2.0 3.5 0.8 0.3 1.6 0.8 6.3 2.4 0.4 1.4 2.0 2.1 0.6 3.6 0.6 0.1 2.8 2.5 38.9 0.3 0.0 2.8 25.2 2.8 1.2 0.2 0.7 1.2 0.5 2.5 0.6 0.8 0.9 2.6 4.9 0.9 23.0 1.9 0.3 0.3 1.0 2.1 0.5 1.0 1.9 0.0 0.0 0.0 0.2 0.0 0.4 55.2 0.1 0.0 0.4 0.1 0.0 0.0 0.0 1.3 0.1 0.2 0.0 0.0 0.0 0.3 0.0 0.2 46.8 1.2 0.5 0.2 0.0 0.2 1.9 0.0 0.0 0.0 0.1 0.0 0.0 1.0 0.0 0.0 0.1 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 11.1 0.0 0.0 8.2 0.0 0.0 0.0 0.0 0.5 0.2 0.0 0.1 0.0 0.0 0.1 0.1 0.0 10.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.0 2.1 2.3 2.0 2.0 2.1 2.8 2.5 2.8 2.6 1.9 1.9 0.1 0.0 0.0 6.2 0.0 0.3 0.0 0.0 34.1 0.1 0.6 0.9 1.2 2.8 0.0 0.0 0.0 144.6 0.0 0.0 1.9 0.0 1.6 0.2 4.9 0.8 0.0 0.0 0.2 0.0 345.1 10.0 0.0 0.2 0.0 41.3 0.0 3.6 22.0 0.0 0.2 0.0 0.0 0.0 0.0 6.7 48.7 0.4 0.0 1.0 0.6 6.2 0.0 0.0 0.2 0.5 0.0 173.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.8 1.2 4.6 2.8 8.7 0.0 1452.0 0.0 637.4 0.0 0.0 CYP11B1 "CPN1, CYP11B, FHI, P450C11" ENSG00000160882 "Cytochrome P450 family 11 subfamily B member 1" P15538 8 142872356-142879846 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroidogenesis" "Monooxygenase, Oxidoreductase" "Congenital adrenal hyperplasia, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 877 "adrenal gland: 3686.5" "Group enriched" "Detected in some" 113 "Early spermatids: 53.3;Late spermatids: 83.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "HPA049171, HPA049565, HPA056348, HPA057752" Supported Approved Mitochondria NA NA "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 25: Spermatids - Spermatogenesis" Mitochondria "HPA049171: AB_2680661, HPA049565: , HPA056348: AB_2683104, HPA057752: AB_2683516" 0.2 3686.5 0.1 0.9 0.6 0.0 0.1 0.0 0.1 0.2 0.5 0.2 0.0 0.2 0.0 0.4 0.2 0.0 0.4 0.3 0.0 0.9 0.5 0.3 0.0 0.1 0.1 0.3 0.5 0.0 0.4 0.0 0.0 0.3 0.0 0.0 1.4 0.0 0.2 0.2 0.2 0.0 0.0 0.3 0.4 4.2 0.0 0.0 0.2 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.1 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 53.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 83.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CYP17A1 "CPT7, CYP17, P450C17, S17AH" ENSG00000148795 "Cytochrome P450 family 17 subfamily A member 1" P05093 10 102830531-102837472 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Steroidogenesis "Lyase, Monooxygenase, Oxidoreductase" "Congenital adrenal hyperplasia, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 84 "adrenal gland: 8229.5" "Cell type enriched" "Detected in some" 17 "Theca cells: 1871.0" "Cancer enriched" "Detected in many" 5 "liver cancer: 22.7" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HMC-1: 3.0;SCLC-21H: 1.5" "Not detected" "Not detected" "Not detected" "Not detected" HPA048533 Enhanced Approved Vesicles "Intracellular and membrane" NA NA "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 3: HMC-1 - Innate immune response" "Cluster 52: Non-specific - Transcription" Vesicles "HPA048533: AB_2680432" "unprognostic (1.07e-2)" "unprognostic (8.84e-2)" "unprognostic (3.01e-2)" "unprognostic (9.08e-2)" "unprognostic (1.91e-1)" "unprognostic (6.29e-2)" "unprognostic (2.92e-3)" "unprognostic (2.39e-4)" "unprognostic (8.26e-2)" "unprognostic (2.35e-1)" "unprognostic (5.92e-3)" "unprognostic (1.13e-1)" "prognostic favorable (5.43e-7)" "unprognostic (1.07e-1)" "unprognostic (5.56e-2)" "unprognostic (1.66e-2)" "unprognostic (2.94e-4)" 0.4 8229.5 0.0 2.1 0.0 0.0 0.4 0.1 0.1 1.1 0.0 0.5 0.0 0.8 0.1 0.9 1.0 0.4 1.0 0.0 0.0 52.9 6.7 1.4 0.0 0.0 0.1 16.6 1.7 10.5 0.7 0.0 0.0 0.7 0.0 0.2 3.4 0.0 1.0 0.7 0.6 0.0 0.0 0.9 1.3 98.3 0.0 0.0 2.9 0.0 0.0 0.8 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 2.2 0.1 0.4 0.1 0.0 0.5 0.0 0.1 0.7 0.0 0.0 1.8 0.0 0.4 0.1 0.1 21.5 0.0 41.6 0.1 0.0 0.7 0.0 2.7 0.1 0.2 0.0 1.3 0.0 0.1 0.0 0.1 0.4 6.1 0.1 1.7 0.1 0.0 0.0 0.6 0.7 10.6 1.8 0.9 0.0 0.0 0.1 0.2 3.1 0.5 0.1 0.7 0.0 0.0 0.0 0.3 0.0 104.3 0.0 1.2 0.0 1.2 0.6 0.3 0.1 0.0 0.0 0.3 0.4 1871.0 0.0 0.1 CYP19A1 "ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM" ENSG00000137869 "Cytochrome P450 family 19 subfamily A member 1" P11511 15 51208057-51338601 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Monooxygenase, Oxidoreductase" "Cancer-related genes, Disease variant, FDA approved drug targets, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 14 "placenta: 124.4" "Cell type enriched" "Detected in some" 10 "Syncytiotrophoblasts: 2007.5" "Cancer enhanced" "Detected in single" "glioma: 0.6" "Group enriched" "Detected in many" 4 "amygdala: 4.8;hypothalamus: 4.1;medulla oblongata: 1.4;midbrain: 2.0;thalamus: 3.7" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC TERT1: 92.8;HDLM-2: 17.5;HSkMC: 31.4;SuSa: 16.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB000355, HPA051194" Enhanced Uncertain Mitochondria NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 28: Placenta - Pregnancy" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 18: Syncytiotrophoblasts - Pregnancy hormone signaling" Mitochondria "CAB000355: , HPA051194: AB_2681381" "unprognostic (9.41e-2)" "unprognostic (7.44e-2)" "unprognostic (9.52e-5)" "unprognostic (6.81e-2)" "unprognostic (2.72e-1)" "unprognostic (4.25e-4)" "unprognostic (5.18e-5)" "unprognostic (1.54e-3)" "unprognostic (2.38e-2)" "unprognostic (2.52e-1)" "unprognostic (1.97e-1)" "unprognostic (5.37e-2)" "unprognostic (1.54e-5)" "unprognostic (2.52e-3)" "unprognostic (2.11e-1)" "unprognostic (1.40e-2)" "unprognostic (1.11e-1)" 8.3 9.0 4.8 0.4 0.6 0.2 2.1 0.1 0.5 0.6 0.0 0.2 0.7 0.3 0.0 0.1 0.3 0.5 1.2 0.3 4.1 0.1 0.1 0.7 0.0 1.4 2.0 3.2 1.3 0.2 0.0 124.4 0.7 0.6 0.1 0.6 0.9 2.7 0.6 1.8 0.2 1.3 0.2 0.6 0.2 6.5 3.7 0.2 2.4 0.3 0.0 3.5 0.5 0.7 0.1 0.0 0.0 0.0 1.7 92.8 6.0 0.1 0.3 0.0 0.1 0.2 0.0 0.0 0.3 0.5 0.4 0.0 0.0 0.0 0.0 17.5 0.0 0.6 0.2 8.1 0.6 0.0 0.1 31.4 0.0 0.3 4.0 0.3 0.0 0.0 0.0 0.8 0.4 0.7 0.0 0.1 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 2.4 0.2 16.3 0.0 0.5 0.1 0.3 0.1 0.2 0.0 3.0 1.6 0.0 0.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 4.8 0.6 0.1 0.5 0.3 4.1 1.4 2.0 0.7 0.2 3.7 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 52.8 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.7 0.0 0.0 0.1 0.0 7.9 1.5 0.0 0.0 0.0 191.3 0.0 0.0 14.0 0.0 0.3 0.0 0.0 0.9 0.0 5.1 0.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.2 0.9 12.3 0.3 0.0 0.0 2007.5 0.0 22.2 0.0 0.0 CYP51A1 "CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1" ENSG00000001630 "Cytochrome P450 family 51 subfamily A member 1" Q16850 7 92112153-92134803 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cholesterol biosynthesis, Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism" "Monooxygenase, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 204.7" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 67.3;Alveolar cells type 2: 169.7;Early spermatids: 74.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "GAMG: 481.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041325, HPA043508" Enhanced Enhanced "Endoplasmic reticulum" NA NA "Cluster 23: Antigen presenting cells - Antigen presentation" "Cluster 37: Intestine - Unknown function" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 11: Alveolar cells - Smell perception" "Endoplasmic reticulum" "HPA041325: AB_2677411, HPA043508: AB_2678520" "unprognostic (6.68e-2)" "prognostic unfavorable (6.12e-4)" "unprognostic (3.48e-2)" "unprognostic (1.18e-2)" "unprognostic (7.82e-2)" "unprognostic (3.60e-2)" "unprognostic (1.02e-1)" "unprognostic (1.97e-1)" "unprognostic (9.84e-2)" "unprognostic (1.36e-1)" "unprognostic (9.75e-2)" "unprognostic (1.34e-1)" "unprognostic (1.59e-9)" "unprognostic (1.82e-1)" "unprognostic (2.73e-1)" "unprognostic (5.13e-2)" "unprognostic (1.09e-3)" 19.4 58.2 22.3 20.6 24.9 30.3 30.6 39.8 32.3 26.4 21.0 52.7 86.6 21.2 35.8 43.7 16.7 24.3 20.7 24.2 39.0 38.7 204.7 53.2 13.1 60.1 42.3 29.0 48.7 59.6 17.1 21.9 50.6 43.8 41.5 31.4 20.3 17.5 7.9 26.5 40.0 20.4 46.6 13.4 45.1 86.4 31.8 6.6 33.6 11.7 16.6 21.3 26.2 57.0 113.7 54.3 134.0 86.4 92.0 149.6 18.7 37.7 112.7 47.1 128.8 131.8 201.7 98.1 57.9 65.3 481.6 96.2 118.1 237.0 55.3 40.3 82.6 27.9 51.1 99.7 125.7 56.0 39.4 109.1 105.7 185.6 194.0 42.2 49.4 19.8 108.2 217.8 56.4 115.6 12.5 53.8 100.7 45.9 53.4 40.3 27.8 222.8 216.7 187.9 94.1 62.5 80.0 156.3 117.2 60.6 56.9 69.5 59.5 65.0 70.6 95.2 49.8 72.8 70.5 88.1 49.8 75.5 85.2 2.8 11.1 3.9 11.6 16.3 7.7 15.6 8.0 8.9 16.3 12.3 7.1 9.6 1.5 7.8 10.3 14.3 6.7 8.2 22.3 24.9 39.8 32.3 24.2 39.0 60.1 42.3 50.6 46.6 31.8 57.0 3.1 67.3 169.7 35.9 24.0 2.5 1.6 4.6 48.9 2.6 6.7 3.7 1.6 7.2 44.5 1.8 2.1 1.5 8.9 20.3 1.9 10.7 74.4 10.7 8.1 7.7 10.8 11.6 34.3 19.8 1.0 9.1 43.3 16.4 28.5 4.1 5.3 45.2 1.5 0.0 39.6 13.1 2.0 5.6 1.9 34.4 3.7 9.2 0.0 15.9 1.3 2.4 0.0 39.2 53.1 14.2 11.7 1.5 34.3 1.4 9.6 1.5 15.7 1.9 0.0 4.0 6.5 7.8 4.2 51.4 5.4 4.4 12.2 9.3 11.9 2.5 CYSLTR1 "CysLT(1), CysLT1, CYSLT1R" ENSG00000173198 "Cysteinyl leukotriene receptor 1" Q9Y271 X 78271468-78327691 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 11.6" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 67.3;Alveolar cells type 2: 68.4;B-cells: 64.1;dendritic cells: 44.7;granulocytes: 78.6;Plasma cells: 44.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Immune cell enhanced" "Detected in many" "eosinophil: 85.8" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HL-60: 19.8;Karpas-707: 12.4;NB-4: 27.1;RPMI-8226: 41.9;THP-1: 25.2;U-937: 28.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA010546 Approved NA NA "Cluster 49: Eosinophils - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 25: RPMI-8226 - Immune response" "Cluster 57: B-cells - Immune response" "HPA010546: AB_1078268" "unprognostic (9.48e-2)" "unprognostic (6.01e-5)" "unprognostic (4.72e-3)" "unprognostic (3.04e-1)" "unprognostic (6.30e-2)" "unprognostic (2.80e-3)" "unprognostic (2.52e-1)" "unprognostic (8.19e-2)" "unprognostic (1.19e-1)" "unprognostic (2.53e-2)" "unprognostic (4.55e-1)" "unprognostic (2.43e-1)" "unprognostic (4.41e-4)" "unprognostic (5.82e-2)" "unprognostic (3.56e-2)" "unprognostic (9.87e-2)" "unprognostic (8.94e-2)" 4.7 1.7 0.6 7.6 0.6 3.5 2.3 0.7 0.8 2.6 0.8 3.6 2.4 1.7 0.7 7.3 1.7 5.6 1.7 0.6 0.8 1.0 1.6 7.3 9.5 1.0 0.7 0.4 0.6 1.4 0.3 3.5 1.0 2.3 4.9 0.3 1.9 1.0 0.5 3.3 3.9 4.5 1.0 10.6 2.9 0.2 0.7 4.1 2.0 1.8 11.6 6.9 0.7 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 19.8 7.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.4 0.0 0.0 0.0 27.1 0.1 0.0 0.0 5.7 0.0 41.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 25.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.2 0.1 28.1 0.0 19.5 15.1 85.8 0.0 26.5 0.1 19.1 5.5 0.2 11.7 15.2 8.3 0.1 45.2 10.6 31.2 18.0 1.4 6.9 0.6 0.6 0.7 0.8 0.6 0.8 1.0 0.7 1.0 1.0 0.7 0.9 20.4 67.3 68.4 0.7 64.1 3.7 3.7 0.6 5.2 3.7 1.6 0.9 1.4 0.0 36.7 0.0 6.2 0.3 44.7 1.1 0.0 0.2 0.0 0.3 0.3 21.5 0.0 3.8 0.5 0.2 0.3 7.6 0.0 0.3 78.6 1.3 5.7 0.3 29.8 0.0 0.3 0.3 2.0 39.3 14.7 0.0 0.6 37.5 7.2 16.9 21.4 0.5 23.7 0.0 0.0 0.2 0.0 0.0 44.9 1.4 1.7 0.5 35.9 0.7 0.0 0.7 3.2 0.1 0.3 1.4 3.7 0.8 20.6 0.2 0.5 3.4 CYSLTR2 "CysLT(2), CYSLT2R" ENSG00000152207 "Cysteinyl leukotriene receptor 2" Q9NS75 13 48653711-48711226 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 25.8;seminal vesicle: 17.5" "Cell type enhanced" "Detected in some" "Hepatic stellate cells: 9.3;Macrophages: 13.1;Melanocytes: 5.4;monocytes: 4.8;NK-cells: 5.2;Sertoli cells: 13.1" "Cancer enhanced" "Detected in many" "renal cancer: 6.6;thyroid cancer: 7.7" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 13 "eosinophil: 100.6" "Lineage enriched" "Detected in many" 13 "granulocytes: 100.6" "Cell line enriched" "Detected in some" 47 "HDLM-2: 89.9" HPA046528 Approved NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 28: Placenta - Pregnancy" "Cluster 44: HDLM-2 - Immune response" "Cluster 41: Macrophages - Immune response" "HPA046528: AB_2679687" "unprognostic (9.83e-3)" "unprognostic (2.72e-3)" "unprognostic (1.05e-2)" "unprognostic (6.81e-2)" "unprognostic (2.94e-2)" "unprognostic (3.11e-2)" "unprognostic (1.11e-1)" "unprognostic (7.41e-3)" "unprognostic (8.33e-2)" "unprognostic (1.83e-1)" "unprognostic (5.44e-2)" "unprognostic (5.93e-2)" "unprognostic (1.88e-3)" "unprognostic (3.79e-2)" "unprognostic (4.44e-2)" "unprognostic (2.35e-2)" "unprognostic (1.18e-2)" 2.4 7.2 3.1 3.0 3.0 1.1 1.1 2.6 4.0 0.8 2.3 1.2 2.4 1.5 1.3 0.8 3.8 1.8 10.0 3.1 3.9 1.9 1.3 1.8 4.7 3.7 3.2 1.8 0.5 0.6 1.3 25.8 3.7 0.8 1.2 1.0 0.3 17.5 0.4 1.3 2.9 0.8 2.4 8.3 1.3 0.9 3.4 1.8 1.3 0.0 1.8 0.9 0.5 2.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 89.9 0.0 0.1 0.6 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.4 0.1 0.1 0.0 0.0 0.0 1.0 0.0 0.7 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.1 0.2 0.0 0.0 0.0 1.9 0.0 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 7.8 2.5 100.6 0.6 8.0 0.0 0.0 1.1 0.2 2.5 0.0 1.1 0.4 0.3 1.1 5.8 0.0 0.9 1.0 3.1 3.0 2.6 4.0 3.1 3.9 3.7 3.2 3.7 2.4 3.4 2.9 0.3 0.0 1.1 0.0 0.6 0.5 0.1 0.0 0.0 0.0 0.0 0.1 2.1 0.0 0.0 3.7 0.0 0.4 3.4 0.0 0.0 0.0 0.3 0.0 0.1 2.0 0.0 0.8 0.0 0.0 1.5 3.8 0.0 0.1 1.3 0.3 9.3 0.0 0.6 0.0 0.0 0.0 0.0 4.7 0.8 0.4 0.3 13.1 5.4 0.0 4.8 0.0 5.2 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.1 13.1 0.0 3.7 0.0 0.2 0.0 0.0 2.9 2.9 0.1 0.0 0.0 DBH DBM ENSG00000123454 "Dopamine beta-hydroxylase" P09172 9 133636363-133659329 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Catecholamine biosynthesis" "Monooxygenase, Oxidoreductase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "adrenal gland: 272.7;brain: 236.6" "Cell type enriched" "Detected in some" 6 "Hepatic stellate cells: 10.0" "Cancer enhanced" "Detected in some" "liver cancer: 1.7" "Region enriched" "Detected in many" 8 "pons: 236.6" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 346 "SH-SY5Y: 1826.4" "Region enriched" "Detected in some" 6 "pons and medulla: 22.1" "Region enriched" "Detected in single" 26 "pons: 18.5" "HPA002130, HPA005960, HPA070789" Enhanced Supported "Endoplasmic reticulum,Vesicles" "Intracellular and membrane" NA NA 1600000000 "Cluster 32: T-cells - Unknown function" "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 43: Cardiomyocytes - Nuclear processes" Vesicles "Endoplasmic reticulum" "HPA002130: AB_2666554, HPA005960: AB_1078628, HPA070789: AB_2686312" "unprognostic (1.93e-3)" "unprognostic (7.52e-3)" "unprognostic (8.53e-2)" "unprognostic (2.10e-2)" "unprognostic (2.18e-3)" "unprognostic (3.38e-3)" "unprognostic (3.39e-3)" "unprognostic (3.97e-2)" "unprognostic (1.71e-1)" "unprognostic (8.99e-2)" "unprognostic (5.80e-2)" "unprognostic (7.69e-2)" "unprognostic (2.81e-7)" "unprognostic (9.31e-2)" "unprognostic (6.77e-2)" "unprognostic (1.49e-2)" "unprognostic (5.06e-3)" 2.8 272.7 0.1 1.0 0.2 0.2 0.1 0.0 0.8 0.4 0.0 0.1 0.4 0.3 0.2 0.1 0.3 0.3 0.5 0.3 0.2 1.3 36.1 0.8 2.3 9.8 29.4 0.4 4.3 0.0 1.4 1.4 236.6 0.4 0.0 0.1 0.6 0.2 0.1 0.2 0.6 0.0 0.0 0.9 0.4 0.2 0.6 0.2 0.4 0.0 0.0 0.4 1.1 1.0 0.0 0.0 0.1 0.9 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.2 3.2 0.9 0.1 0.0 0.0 0.3 5.2 4.7 0.0 0.0 2.1 1826.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.8 0.3 0.2 9.8 29.4 236.6 0.0 0.6 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 10.0 0.1 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.0 0.0 DCK ENSG00000156136 "Deoxycytidine kinase" P27707 4 70992538-71030914 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 105.8" "Cell type enhanced" "Detected in many" "B-cells: 105.7;Erythroid cells: 284.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Daudi: 232.9;U-698: 191.8" "Low region specificity" "Detected in all" "HPA059609, HPA062773" Enhanced Supported Nucleoplasm NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 3: T-cells - Adaptive immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 6: Erythroid cells - Oxygen transport" Nucleoplasm "HPA059609: AB_2684082, HPA062773: AB_2684865" "unprognostic (9.16e-2)" "unprognostic (2.44e-1)" "unprognostic (5.24e-3)" "unprognostic (4.77e-2)" "unprognostic (3.95e-1)" "unprognostic (6.45e-2)" "prognostic unfavorable (6.90e-7)" "unprognostic (3.04e-2)" "unprognostic (7.19e-2)" "unprognostic (8.28e-2)" "unprognostic (4.51e-1)" "unprognostic (1.33e-1)" "unprognostic (3.37e-2)" "unprognostic (4.47e-2)" "unprognostic (6.82e-2)" "unprognostic (1.33e-1)" "unprognostic (2.27e-2)" 11.1 15.2 10.1 36.3 11.2 43.9 12.5 9.7 13.6 9.9 11.0 15.7 13.7 13.4 7.2 14.6 9.8 12.4 10.4 10.7 10.7 9.8 9.2 13.4 92.9 10.9 10.4 10.6 8.3 8.8 3.5 15.3 10.8 10.2 18.9 17.1 7.7 7.1 9.5 14.7 15.9 13.9 11.4 32.3 14.2 9.0 9.7 105.8 15.7 12.1 79.6 14.2 6.1 13.4 25.8 17.2 38.5 23.9 12.4 20.4 21.0 65.3 25.6 53.3 43.6 11.3 56.1 232.9 24.7 28.3 31.0 14.8 34.6 21.4 71.0 43.5 16.2 46.6 18.6 20.5 11.8 95.8 58.5 11.2 25.5 32.2 19.5 26.0 31.0 64.4 19.0 93.2 62.0 15.5 126.6 39.5 17.2 45.6 15.6 96.0 74.0 18.6 26.6 18.8 35.1 31.8 24.9 49.6 29.7 17.4 22.3 54.3 22.0 60.1 41.8 47.6 37.1 31.7 21.2 191.8 40.7 60.0 45.0 25.6 17.2 28.9 24.2 20.5 32.0 44.5 33.0 30.6 23.8 41.1 34.2 34.2 8.1 34.4 21.0 63.6 41.2 45.1 10.1 11.2 9.7 13.6 10.7 10.7 10.9 10.4 10.8 11.4 9.7 13.4 16.4 0.0 8.6 6.8 105.7 43.0 10.1 11.9 27.9 16.1 10.4 5.2 6.5 7.2 7.5 12.9 6.2 11.9 97.7 10.4 29.4 19.2 0.7 5.9 7.0 16.3 21.0 284.8 17.1 6.2 19.3 11.0 8.6 7.4 22.9 7.5 22.9 7.2 38.2 18.5 21.0 16.4 22.4 63.2 74.5 2.3 8.4 56.0 46.2 18.7 61.4 15.8 84.5 8.0 11.1 10.5 8.0 10.1 24.6 11.6 7.1 10.0 4.7 10.7 6.6 9.3 15.9 52.0 33.9 28.0 43.3 4.5 62.4 4.8 16.5 8.4 DDC AADC ENSG00000132437 "Dopa decarboxylase" P20711 7 50458436-50565405 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Catecholamine biosynthesis" "Decarboxylase, Lyase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 165.8;kidney: 314.9;retina: 175.6" "Group enriched" "Detected in many" 4 "Enteroendocrine cells: 410.3;Proximal enterocytes: 391.5;Proximal tubular cells: 429.5;Rod photoreceptor cells: 498.9" "Group enriched" "Detected in many" 5 "colorectal cancer: 23.5;liver cancer: 13.4;pancreatic cancer: 6.4;renal cancer: 18.7;stomach cancer: 9.9" "Group enriched" "Detected in many" 9 "midbrain: 86.3;pons: 29.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "CACO-2: 54.5;Hep G2: 49.3;OE19: 83.6;SCLC-21H: 130.9;SH-SY5Y: 135.9" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 5 "midbrain: 74.5;pons: 29.4" HPA017742 Enhanced Approved "Actin filaments" NA NA 120000 "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "Actin filaments" "HPA017742: AB_1847832" "unprognostic (1.04e-1)" "unprognostic (3.68e-2)" "unprognostic (2.57e-2)" "unprognostic (3.49e-5)" "unprognostic (1.17e-1)" "unprognostic (1.03e-1)" "unprognostic (1.28e-1)" "unprognostic (5.15e-2)" "unprognostic (4.69e-2)" "unprognostic (5.44e-2)" "unprognostic (9.36e-3)" "unprognostic (5.24e-2)" "unprognostic (1.76e-3)" "unprognostic (1.60e-1)" "unprognostic (3.55e-1)" "unprognostic (7.65e-2)" "unprognostic (1.16e-1)" 0.5 48.9 0.1 2.3 0.7 0.0 1.0 0.0 0.6 0.0 0.2 36.5 154.8 0.0 9.1 0.1 0.0 0.1 0.0 0.2 2.2 314.9 54.6 2.0 0.1 6.1 86.3 0.8 15.8 0.0 0.0 0.0 29.4 0.6 37.5 175.6 0.0 0.0 0.0 0.1 165.8 1.7 0.0 0.1 18.1 1.5 1.9 0.0 0.2 0.0 0.0 0.0 0.1 0.2 0.0 1.7 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 54.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 49.3 0.0 0.0 11.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.1 83.6 0.0 0.0 0.0 0.7 1.3 0.0 130.9 135.9 0.0 4.4 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 0.6 0.2 2.2 6.1 86.3 29.4 0.0 1.9 0.2 0.0 0.0 12.2 0.0 2.5 0.0 0.0 0.0 0.0 89.3 0.1 0.1 0.4 2.8 0.6 3.7 41.7 0.0 0.0 34.4 25.4 0.1 6.6 0.1 0.0 1.8 410.3 0.0 0.3 0.9 0.1 0.1 0.0 0.4 0.0 0.0 1.1 67.2 0.1 3.3 0.4 67.8 0.0 1.3 0.0 5.4 0.0 2.5 0.0 0.0 0.0 45.1 0.0 0.0 0.1 0.2 31.8 0.0 0.0 0.3 391.5 429.5 0.0 498.9 0.0 0.0 0.0 4.0 0.4 0.0 0.0 0.1 1.3 0.1 88.7 0.2 DDR2 "NTRKR3, TKT, TYRO10" ENSG00000162733 "Discoidin domain receptor tyrosine kinase 2" Q16832 1 162631373-162787405 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" Osteogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Endometrial stromal cells: 89.8;Fibroblasts: 116.5;Leydig cells: 63.0;Peritubular cells: 88.4;Skeletal myocytes: 98.2;Smooth muscle cells: 78.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC diff: 233.3;ASC TERT1: 214.4;BJ hTERT+: 163.4;fHDF/TERT166: 137.6;HSkMC: 157.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA070112 Approved "Plasma membrane,Actin filaments" Yes No 770000 "Cluster 57: Non-specific - Angiogenesis" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 50: Fibroblasts - ECM organization" "Plasma membrane, Actin filaments" "HPA070112: AB_2686229" "unprognostic (4.12e-2)" "unprognostic (2.73e-1)" "unprognostic (6.97e-3)" "unprognostic (4.52e-2)" "unprognostic (1.17e-1)" "unprognostic (8.16e-2)" "unprognostic (1.81e-1)" "unprognostic (1.19e-1)" "unprognostic (6.62e-2)" "unprognostic (2.24e-2)" "unprognostic (1.00e-1)" "unprognostic (1.15e-1)" "prognostic unfavorable (1.73e-7)" "unprognostic (1.56e-3)" "unprognostic (8.26e-3)" "unprognostic (7.57e-2)" "unprognostic (4.10e-3)" 59.8 64.3 13.2 15.8 11.3 0.3 25.2 10.4 9.2 33.7 51.5 54.7 5.8 26.2 13.2 18.1 22.4 23.8 24.1 12.6 24.5 6.4 5.4 14.5 9.1 37.0 22.1 37.4 3.7 2.5 5.4 10.6 31.7 17.3 14.1 5.1 9.8 29.2 4.9 9.7 17.6 42.8 17.8 5.8 20.4 3.9 21.0 3.3 12.9 19.3 6.9 23.2 23.6 25.2 0.3 0.0 0.2 63.2 233.3 214.4 1.0 92.2 163.4 41.5 56.8 0.0 0.2 0.0 0.1 137.6 8.9 0.1 0.3 0.4 54.0 42.9 0.3 0.0 0.4 0.1 103.9 0.2 0.2 157.0 0.4 73.1 2.2 65.8 46.0 0.4 0.6 16.8 36.9 0.1 0.0 0.3 0.4 0.1 0.3 0.1 24.1 0.7 0.2 0.2 0.3 35.4 0.2 0.1 2.9 3.6 0.2 0.3 2.1 58.5 13.8 29.1 12.6 2.6 4.0 0.1 56.3 0.1 62.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.2 11.3 10.4 9.2 12.6 24.5 37.0 22.1 31.7 17.8 21.0 25.2 23.4 3.2 2.3 53.2 2.5 12.6 3.9 0.8 1.2 3.0 6.0 15.6 31.3 1.5 1.1 0.0 0.0 0.5 1.7 3.2 0.0 0.4 8.9 5.0 89.8 22.3 1.2 0.0 13.1 1.8 0.5 116.5 2.6 8.2 1.3 16.7 30.0 3.5 1.2 0.0 26.2 1.0 0.0 1.9 19.3 7.1 63.0 3.1 23.2 29.0 0.0 16.5 2.1 6.0 5.6 1.8 4.4 88.4 5.6 5.9 1.2 2.1 2.4 3.0 39.5 98.2 78.3 1.0 0.9 2.0 8.7 1.0 2.5 34.2 0.8 4.2 DGAT2 ENSG00000062282 "Diacylglycerol O-acyltransferase 2" Q96PD7 11 75759512-75801535 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Glycerol metabolism, Lipid biosynthesis, Lipid metabolism" "Acyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "adipose tissue: 476.0;breast: 133.6;liver: 331.8;skin 1: 151.5" "Cell type enhanced" "Detected in many" "Early spermatids: 259.3;Hepatocytes: 116.4;Late spermatids: 64.1;Spermatocytes: 53.9;Spermatogonia: 53.5" "Cancer enhanced" "Detected in many" "liver cancer: 19.9" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 11 "eosinophil: 137.7;neutrophil: 348.6" "Lineage enriched" "Detected in many" 16 "granulocytes: 348.6" "Cell line enhanced" "Detected in many" "ASC diff: 80.4;HDLM-2: 62.5;Hep G2: 64.9;OE19: 124.0" "Low region specificity" "Detected in all" "Region enriched" "Detected in all" 4 "basal ganglia: 22.0" HPA013351 Approved Vesicles,Cytosol NA NA "Cluster 5: Granulocytes - Unknown function" "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 21: OE19 - Mitochondria" "Cluster 29: Early spermatids - Spermatogenesis" "Vesicles, Cytosol" "HPA013351: AB_1847630" "unprognostic (2.28e-1)" "unprognostic (3.69e-1)" "unprognostic (9.38e-2)" "prognostic unfavorable (2.84e-4)" "unprognostic (3.63e-1)" "unprognostic (4.99e-2)" "unprognostic (1.10e-2)" "unprognostic (7.59e-2)" "unprognostic (4.46e-1)" "unprognostic (4.12e-3)" "unprognostic (2.87e-1)" "unprognostic (2.99e-1)" "unprognostic (1.49e-7)" "unprognostic (2.03e-1)" "unprognostic (2.85e-1)" "unprognostic (2.74e-2)" "unprognostic (5.60e-2)" 476.0 5.1 5.8 19.4 11.7 7.2 133.6 2.9 6.1 2.6 5.3 9.0 14.5 1.2 1.8 24.1 2.1 5.8 11.7 5.7 6.4 3.4 331.8 5.6 4.0 3.7 3.9 1.8 4.6 2.1 1.6 1.5 5.5 2.2 4.9 0.6 10.5 1.6 4.1 151.5 16.5 2.8 3.4 15.0 12.8 38.1 6.9 4.3 8.8 5.6 18.2 21.3 12.6 5.1 13.3 6.4 0.4 11.2 80.4 6.4 1.0 1.3 1.7 1.6 1.0 46.6 13.5 21.1 16.8 0.3 11.9 0.5 1.8 6.5 4.4 62.5 1.2 1.5 4.0 64.9 0.9 7.4 7.2 26.8 33.6 7.3 10.6 4.4 1.2 20.9 1.2 27.6 0.7 8.5 5.1 16.7 3.6 124.0 31.5 0.0 0.1 24.8 1.2 35.8 22.6 1.4 12.3 1.9 2.9 2.7 4.4 26.6 1.6 14.1 7.0 0.3 9.1 16.3 40.0 28.8 10.2 23.7 25.3 19.4 22.1 137.7 0.0 4.4 0.4 7.4 0.4 0.0 6.1 7.6 0.1 0.2 348.6 0.0 5.0 1.8 0.0 5.7 5.8 11.7 2.9 6.1 5.7 6.4 3.7 3.9 5.5 3.4 6.9 5.1 3.2 6.4 5.4 0.3 5.0 1.1 0.9 3.0 0.6 0.9 5.2 7.0 3.5 0.0 2.7 0.0 2.1 0.5 0.3 0.6 0.0 1.7 259.3 3.3 0.2 0.5 1.2 2.7 2.9 0.5 0.1 0.7 10.7 0.2 0.0 2.1 2.9 116.4 2.2 1.7 1.3 4.8 0.0 4.1 13.1 64.1 2.1 4.2 1.8 0.0 4.0 0.4 0.0 0.0 1.0 3.7 2.2 0.7 0.9 2.8 1.2 2.2 3.4 0.0 6.6 0.6 1.0 53.9 53.5 0.3 8.0 0.8 0.5 0.2 3.0 15.7 DHFR ENSG00000228716 "Dihydrofolate reductase" P00374 5 80626226-80654983 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Methotrexate resistance, One-carbon metabolism" "Oxidoreductase, RNA-binding" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Erythroid cells: 145.8;Spermatocytes: 132.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB037129, HPA051465" Uncertain Approved Mitochondria NA Yes "Cluster 4: T-regs - Cell cycle regulation" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" Mitochondria "CAB037129: AB_439683, HPA051465: AB_2681494" "unprognostic (1.44e-2)" "unprognostic (1.03e-2)" "unprognostic (2.24e-3)" "unprognostic (2.91e-3)" "unprognostic (3.27e-1)" "unprognostic (1.32e-1)" "unprognostic (2.83e-2)" "unprognostic (2.35e-2)" "unprognostic (2.02e-2)" "unprognostic (4.19e-3)" "unprognostic (1.83e-2)" "unprognostic (2.55e-1)" "unprognostic (1.15e-2)" "unprognostic (1.82e-2)" "unprognostic (2.49e-1)" "unprognostic (1.57e-1)" "unprognostic (1.09e-1)" 25.2 5.3 15.3 20.7 16.5 54.3 12.0 15.8 21.9 8.0 13.3 21.4 24.5 8.6 7.0 14.1 7.4 8.5 7.2 13.8 15.5 21.3 60.1 7.5 41.5 16.6 16.6 6.6 3.2 9.1 6.3 14.4 16.6 8.9 25.3 10.3 6.8 9.5 19.6 9.8 25.1 12.0 16.5 10.3 12.2 18.5 15.8 60.7 8.2 25.8 39.5 10.3 5.7 17.7 98.1 66.6 164.8 122.7 30.7 32.0 60.6 76.5 58.1 130.2 149.0 63.8 114.6 196.9 32.5 44.6 106.0 67.0 214.4 98.6 208.5 88.2 132.1 94.8 104.5 59.5 6.6 111.7 40.3 22.3 9.9 116.9 13.0 22.2 63.9 142.0 108.3 146.7 133.5 98.2 276.5 44.9 83.6 48.3 38.5 176.7 323.3 194.1 75.1 61.5 134.3 93.7 107.9 49.9 54.6 83.5 98.5 108.6 38.5 41.0 62.0 116.0 148.3 68.2 146.6 210.3 91.5 222.1 107.7 0.2 0.3 0.2 0.5 0.6 0.2 0.5 0.6 0.8 0.5 0.5 0.5 0.6 0.8 0.5 0.5 0.8 0.9 0.6 15.3 16.5 15.8 21.9 13.8 15.5 16.6 16.6 16.6 16.5 15.8 17.7 4.1 6.4 11.7 4.9 21.4 6.9 6.5 6.0 4.0 3.5 8.9 8.9 13.0 4.3 6.1 14.7 2.1 35.2 7.4 19.3 9.8 7.4 7.4 10.8 7.7 7.7 4.9 145.8 7.3 3.7 47.3 12.0 11.7 8.0 2.5 22.0 10.0 48.3 44.7 3.3 7.2 19.1 4.1 18.9 4.4 6.4 14.0 12.8 0.0 4.7 7.1 14.5 13.4 3.5 6.0 4.7 10.3 16.1 60.9 2.9 26.6 40.0 6.9 3.2 13.1 9.0 12.5 132.2 49.8 21.2 5.5 13.3 11.8 12.3 38.1 12.1 DHODH ENSG00000102967 "Dihydroorotate dehydrogenase (quinone)" Q02127 16 72008588-72027664 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Pyrimidine biosynthesis" Oxidoreductase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 8 "liver: 105.9" "Cell type enriched" "Detected in many" 5 "Hepatocytes: 124.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA010123, HPA011942" Approved Enhanced Nucleoplasm,Mitochondria,Cytosol NA NA "Cluster 12: Non-specific - Basic cellular processes" "Cluster 85: Liver - Metabolism" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 15: Hepatocytes - Hemostasis" Mitochondria "Nucleoplasm, Cytosol" "HPA010123: AB_1847648, HPA011942: AB_1847649" "unprognostic (4.88e-2)" "unprognostic (1.10e-1)" "unprognostic (1.90e-1)" "unprognostic (2.12e-2)" "unprognostic (1.41e-3)" "unprognostic (2.10e-1)" "unprognostic (4.27e-2)" "unprognostic (1.31e-2)" "unprognostic (1.26e-1)" "unprognostic (2.68e-1)" "unprognostic (2.14e-1)" "unprognostic (6.40e-2)" "unprognostic (9.26e-3)" "unprognostic (1.98e-1)" "unprognostic (1.97e-1)" "unprognostic (1.14e-1)" "unprognostic (1.81e-1)" 7.4 4.8 3.1 4.2 3.6 3.9 5.8 3.7 3.7 4.0 3.7 5.4 3.9 5.4 2.8 4.2 6.1 2.3 13.8 2.9 2.5 8.0 105.9 3.9 4.2 3.4 3.3 4.9 4.2 6.2 2.5 2.7 3.3 4.0 5.8 3.2 5.4 4.5 10.0 4.5 3.1 5.7 2.1 4.1 4.1 3.6 3.4 3.9 4.1 8.1 5.5 3.9 3.4 5.2 12.5 25.7 6.9 12.1 3.8 5.0 13.9 10.5 4.2 15.6 11.6 20.4 11.1 27.8 13.6 5.7 8.6 12.5 13.7 11.4 18.2 6.0 13.3 15.4 12.6 20.3 10.6 21.4 10.8 4.9 11.3 18.6 19.7 4.7 11.3 18.3 23.9 4.4 9.7 32.7 20.2 17.0 15.9 21.1 10.0 24.9 9.6 29.4 9.4 7.8 8.5 10.2 14.1 14.8 6.8 8.7 13.0 10.3 5.1 14.1 8.3 13.1 15.2 8.8 18.7 46.3 7.1 22.4 12.8 6.1 8.4 1.0 9.4 8.8 12.9 12.0 8.5 9.3 14.5 11.7 11.7 12.6 2.1 10.1 6.3 13.5 8.0 7.2 3.1 3.6 3.7 3.7 2.9 2.5 3.4 3.3 3.3 2.1 3.4 5.2 6.3 3.2 13.1 1.6 7.1 5.6 7.8 11.2 6.8 5.6 6.6 7.1 14.8 15.7 5.5 7.3 4.2 12.3 6.9 1.6 5.9 10.3 2.9 3.8 6.3 9.1 1.2 7.8 2.0 5.1 12.4 7.4 2.6 3.2 8.2 10.2 5.3 124.1 7.9 3.3 2.3 6.6 10.2 6.0 3.1 3.6 2.8 3.3 12.4 1.0 3.8 5.2 8.2 4.0 4.4 5.9 2.4 2.2 4.6 11.2 1.0 20.8 8.1 5.2 0.0 9.7 9.1 6.8 8.1 5.0 3.8 2.9 4.3 13.5 6.7 4.2 DIO3 TXDI3 ENSG00000197406 "Iodothyronine deiodinase 3" P55073 14 101561351-101563452 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins" "Thyroid hormones biosynthesis" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix: 25.0;placenta: 17.8" "Cell type enhanced" "Detected in some" "Endothelial cells: 7.8;Fibroblasts: 27.9;Leydig cells: 10.8;Muller glia cells: 8.1;Peritubular cells: 7.5;Skeletal myocytes: 16.3;Syncytiotrophoblasts: 28.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 10 "AF22: 54.2" "Low region specificity" "Detected in many" "Region enhanced" "Detected in some" "amygdala: 4.4;hippocampal formation: 5.6" HPA073684 Supported Vesicles NA NA "Cluster 89: Fibroblasts - ECM organization" "Cluster 12: NES - Nervous system development" "Cluster 33: Fibroblasts - ECM organization" Vesicles "HPA073684: " "unprognostic (4.52e-3)" "unprognostic (1.80e-1)" "unprognostic (3.04e-3)" "unprognostic (3.48e-1)" "unprognostic (5.16e-2)" "unprognostic (1.50e-1)" "unprognostic (4.24e-2)" "unprognostic (8.11e-2)" "unprognostic (2.58e-1)" "unprognostic (6.24e-2)" "unprognostic (2.34e-1)" "unprognostic (2.52e-1)" "unprognostic (7.46e-5)" "unprognostic (4.82e-3)" "unprognostic (2.43e-1)" "unprognostic (1.11e-4)" "unprognostic (9.80e-3)" 5.0 0.4 0.5 1.8 1.2 0.0 3.2 0.2 1.2 25.0 0.2 1.7 0.0 6.5 0.6 1.8 6.7 3.0 0.6 0.6 0.2 0.3 3.9 2.6 1.3 1.3 0.3 13.6 1.5 0.0 0.7 17.8 0.3 3.2 0.4 0.7 1.7 2.2 1.6 3.5 1.7 0.9 0.4 0.6 1.6 1.3 3.3 0.2 4.1 3.0 0.1 5.2 15.4 0.4 0.0 0.2 54.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.1 0.6 0.0 0.0 0.1 0.0 0.0 1.0 1.3 0.8 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 1.2 0.2 1.2 0.6 0.2 1.3 0.3 0.3 0.4 3.3 0.4 0.4 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.0 0.0 0.1 0.6 0.4 0.0 0.0 0.0 0.0 1.9 0.0 5.9 0.0 0.6 0.3 0.4 4.9 7.8 0.0 0.0 0.1 0.0 2.5 27.9 0.0 0.1 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.5 0.0 0.0 0.7 0.6 10.8 0.1 0.0 0.0 0.6 8.1 0.0 0.0 0.0 0.9 1.1 7.5 0.0 0.8 0.0 0.0 0.0 0.2 0.0 16.3 0.7 0.1 0.2 0.2 0.1 28.3 0.2 0.1 0.3 0.4 DNMT1 "CXXC9, DNMT, MCMT" ENSG00000130816 "DNA methyltransferase 1" P26358 19 10133342-10231286 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Chromatin regulator, DNA-binding, Methyltransferase, Repressor, Transferase" "Deafness, Disease variant, FDA approved drug targets, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in all" "Cytotrophoblasts: 388.1;Spermatocytes: 229.6;Syncytiotrophoblasts: 323.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002694, CAB005876" Enhanced Supported Nucleoplasm NA Yes "Cluster 6: Non-specific - Transcription" "Cluster 34: Non-specific - Transcription" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 47: Cytotrophoblasts - Unknown function" Nucleoplasm "CAB005876: AB_731983, HPA002694: AB_1847810" "unprognostic (3.51e-1)" "unprognostic (1.20e-2)" "unprognostic (1.26e-2)" "unprognostic (1.40e-1)" "unprognostic (3.62e-1)" "unprognostic (7.59e-3)" "prognostic unfavorable (1.46e-4)" "unprognostic (2.90e-1)" "unprognostic (4.23e-3)" "unprognostic (1.10e-2)" "unprognostic (1.07e-1)" "unprognostic (1.11e-2)" "unprognostic (1.28e-3)" "unprognostic (7.81e-3)" "unprognostic (1.73e-1)" "unprognostic (8.11e-2)" "unprognostic (1.46e-1)" 7.1 3.9 0.9 16.9 2.9 23.1 7.0 11.7 3.1 9.1 0.0 6.9 6.6 7.3 3.1 7.7 6.5 6.2 4.8 2.1 6.6 3.0 3.9 7.8 26.2 3.8 4.5 5.6 3.6 4.3 4.5 26.0 5.7 4.5 6.8 7.5 5.6 4.6 5.3 7.9 7.9 8.8 0.3 8.1 6.3 12.4 3.3 20.6 6.3 5.0 24.9 7.3 6.4 10.6 77.0 40.6 49.5 45.8 24.6 24.0 138.8 52.4 43.9 77.5 74.9 50.6 40.8 138.3 33.8 30.0 38.6 46.6 68.4 44.2 68.4 57.5 100.9 181.5 39.5 27.1 9.6 91.5 73.4 11.5 9.3 68.5 24.1 18.4 39.9 37.6 75.0 82.8 63.3 37.6 109.2 50.4 87.5 38.3 76.6 117.1 67.9 77.2 21.5 49.3 64.5 41.5 58.2 26.2 16.5 33.6 28.9 42.2 31.8 111.3 42.2 73.0 84.4 49.6 69.5 166.8 35.0 68.5 87.1 20.3 21.2 5.9 29.8 22.0 25.1 14.2 22.8 20.4 19.3 20.0 25.5 20.5 4.6 42.6 13.8 31.9 21.9 12.6 0.9 2.9 11.7 3.1 2.1 6.6 3.8 4.5 5.7 0.3 3.3 10.6 36.4 6.4 26.5 12.7 38.0 29.6 20.7 26.8 21.1 86.7 32.6 29.6 14.6 7.2 28.2 22.0 56.3 388.1 54.4 29.0 13.7 26.0 46.1 48.1 42.0 38.9 15.7 109.6 17.6 14.3 73.2 33.6 33.6 60.3 37.2 43.6 25.0 14.8 76.8 65.6 22.6 25.5 38.7 31.4 47.8 50.8 28.0 57.9 14.2 15.0 52.5 32.2 123.6 14.6 20.1 21.1 11.3 28.6 73.4 16.3 4.5 9.3 42.8 50.2 13.1 22.6 32.8 229.6 145.3 41.6 22.4 323.7 70.4 38.7 43.1 16.6 DPEP1 ENSG00000015413 "Dipeptidase 1" P16444 16 89613308-89638456 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Lipid metabolism" "Dipeptidase, Hydrolase, Metalloprotease, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 8 "intestine: 377.4;kidney: 255.9;pancreas: 440.7" "Cell type enhanced" "Detected in many" "Peritubular cells: 1217.5;Proximal enterocytes: 4683.5;Proximal tubular cells: 829.6" "Cancer enriched" "Detected in many" 8 "colorectal cancer: 107.4" "Low region specificity" "Detected in single" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CACO-2: 8.5;Hep G2: 33.1;HHSteC: 13.9;U-937: 46.8" "Not detected" "Not detected" "Not detected" "Not detected" "HPA009426, HPA012783" Enhanced Approved "Nucleoplasm,Cell Junctions" "Intracellular and membrane" NA NA 370000 "Cluster 29: Non-specific - Vesicular transport" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 45: Enterocytes - Digestion" "Nucleoplasm, Cell Junctions" "HPA009426: AB_1847842, HPA012783: AB_1847843" "unprognostic (3.31e-2)" "unprognostic (3.86e-1)" "unprognostic (1.37e-1)" "unprognostic (1.95e-2)" "unprognostic (1.91e-2)" "unprognostic (4.93e-2)" "unprognostic (1.04e-1)" "unprognostic (1.89e-1)" "unprognostic (3.45e-2)" "unprognostic (5.18e-1)" "unprognostic (8.68e-2)" "unprognostic (1.27e-1)" "prognostic favorable (6.84e-4)" "unprognostic (6.12e-3)" "unprognostic (1.92e-1)" "unprognostic (5.23e-2)" "unprognostic (3.93e-2)" 0.6 2.3 0.0 1.8 0.0 0.4 0.5 0.0 0.2 4.1 0.0 1.7 85.5 0.6 0.9 0.3 0.6 3.9 0.3 0.0 0.3 255.9 0.5 0.9 2.8 0.2 1.1 0.8 440.7 0.0 0.5 0.8 0.6 0.5 0.5 0.3 1.2 1.0 0.0 2.2 377.4 0.3 0.3 4.5 1.6 46.5 0.9 0.9 0.8 0.0 0.9 2.2 0.9 0.0 0.0 0.9 0.2 0.0 1.7 0.2 4.4 0.0 0.0 0.0 0.0 8.5 0.2 0.0 3.0 0.0 0.0 0.0 0.2 0.0 0.0 2.2 0.6 0.0 0.0 33.1 13.9 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.3 1.1 1.1 3.4 0.0 0.0 0.0 3.0 0.0 0.1 0.9 0.8 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.1 0.1 1.4 0.0 0.0 0.2 0.1 0.0 46.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.2 1.1 0.6 0.3 0.9 0.0 0.1 3.2 1.8 0.0 9.2 0.5 0.0 0.0 0.0 5.8 1.7 0.0 0.3 0.0 0.6 23.9 0.0 0.2 0.0 2.0 56.7 0.5 13.2 0.2 0.2 7.0 8.9 0.0 0.3 192.1 0.8 8.9 1.1 0.1 1.3 0.7 1.1 0.0 0.5 0.0 0.3 142.3 0.0 0.3 0.3 45.2 289.8 4.8 5.4 0.0 1.0 0.1 0.0 0.0 0.1 27.4 187.4 1217.5 61.2 0.0 4683.5 829.6 0.0 0.2 6.6 0.0 0.7 17.3 2.8 0.0 0.3 0.4 2.5 0.2 151.7 0.0 DPP4 "ADCP2, CD26, DPPIV" ENSG00000197635 "Dipeptidyl peptidase 4" P27487 2 161992245-162074394 "CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cell adhesion" "Aminopeptidase, Hydrolase, Protease, Receptor, Serine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 137.9;parathyroid gland: 155.7;placenta: 134.1;prostate: 107.3" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 140.3;Proximal enterocytes: 291.1;Proximal tubular cells: 101.4;Syncytiotrophoblasts: 172.0" "Cancer enhanced" "Detected in all" "prostate cancer: 55.2" "Not detected" "Not detected" "Immune cell enhanced" "Detected in many" "MAIT T-cell: 52.3" "Lineage enriched" "Detected in many" 10 "T-cells: 52.3" "Cell line enhanced" "Detected in many" "ASC diff: 194.4;ASC TERT1: 212.6;BJ hTERT+: 207.0;RPTEC TERT1: 263.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB045970, HPA068778, HPA071236" Enhanced "Secreted to blood" NA NA 190000000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "CAB045970: AB_11140529, HPA068778: , HPA071236: " "unprognostic (4.47e-2)" "unprognostic (4.47e-2)" "unprognostic (8.89e-2)" "unprognostic (3.36e-1)" "unprognostic (7.25e-2)" "unprognostic (5.40e-2)" "unprognostic (2.78e-1)" "unprognostic (3.54e-2)" "unprognostic (3.58e-1)" "unprognostic (4.73e-1)" "unprognostic (2.36e-1)" "prognostic unfavorable (1.98e-4)" "prognostic favorable (1.35e-6)" "unprognostic (4.68e-2)" "unprognostic (6.33e-2)" "prognostic favorable (4.99e-4)" "unprognostic (1.21e-2)" 13.3 3.1 0.2 5.3 0.2 0.6 8.4 0.1 0.6 10.9 0.1 14.6 107.0 3.6 4.0 3.0 7.4 6.7 3.4 0.2 0.1 94.9 57.2 16.0 5.8 0.2 0.2 3.5 3.5 155.7 0.1 134.1 0.3 107.3 16.9 0.1 84.5 23.5 1.5 5.7 137.9 3.0 0.1 11.2 7.6 1.3 0.8 12.4 5.0 3.9 4.4 5.7 3.5 0.4 0.2 0.2 1.0 0.0 194.4 212.6 0.6 37.7 207.0 10.9 37.2 38.0 1.0 0.0 13.6 71.0 30.2 1.1 0.4 0.0 6.2 12.3 0.0 0.0 0.0 57.1 77.0 0.0 0.0 22.0 0.1 66.3 0.5 9.1 6.6 0.7 0.0 0.0 3.6 0.0 3.6 0.5 2.0 1.3 72.7 0.0 0.0 0.6 263.3 0.0 0.1 0.4 0.0 0.0 0.0 4.4 0.0 0.3 37.0 21.8 1.1 0.7 0.0 0.0 0.0 0.0 22.5 0.0 0.0 0.0 0.0 0.0 6.6 0.0 52.3 0.2 16.2 10.7 1.2 0.0 15.7 6.6 0.4 5.3 0.0 4.0 2.0 4.7 0.2 0.2 0.1 0.6 0.2 0.1 0.2 0.2 0.3 0.1 0.8 0.4 10.8 6.4 26.0 0.3 2.1 4.1 0.4 0.1 0.0 1.8 0.2 0.8 3.3 12.8 2.8 14.7 10.4 140.3 10.4 27.4 1.9 3.0 15.0 2.3 7.1 9.4 55.2 0.4 31.6 0.0 59.1 35.3 2.0 68.0 13.9 5.3 9.3 34.5 14.5 0.0 6.3 16.4 0.0 0.9 7.6 7.9 0.0 4.8 5.4 3.7 1.1 0.0 1.0 2.5 0.7 1.4 23.8 0.0 2.1 32.7 291.1 101.4 2.2 0.1 0.0 2.1 1.5 4.0 1.1 0.1 4.1 172.0 25.8 29.2 29.1 0.3 DPYD DPD ENSG00000188641 "Dihydropyrimidine dehydrogenase" Q12882 1 97077743-97995000 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" Oxidoreductase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 68.5" "Cell type enriched" "Detected in many" 6 "Oligodendrocytes: 1712.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033241, HPA045210" Uncertain NA NA 1600000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 85: Liver - Metabolism" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 42: Oligodendrocytes - Myelin sheath organization" "CAB033241: AB_2094323, HPA045210: AB_2679256" "unprognostic (2.33e-2)" "unprognostic (1.69e-1)" "unprognostic (9.82e-3)" "unprognostic (1.04e-1)" "unprognostic (1.13e-2)" "unprognostic (8.81e-2)" "unprognostic (2.86e-1)" "unprognostic (3.05e-1)" "unprognostic (1.56e-1)" "unprognostic (9.29e-2)" "prognostic unfavorable (6.27e-4)" "unprognostic (6.54e-2)" "unprognostic (5.32e-2)" "unprognostic (1.43e-1)" "unprognostic (3.43e-2)" "unprognostic (3.71e-1)" "unprognostic (2.25e-1)" 22.2 13.2 7.2 22.6 12.8 10.3 16.7 5.7 10.4 18.8 2.4 11.9 21.9 14.9 8.4 17.1 14.3 25.7 8.9 7.4 12.9 12.6 68.5 29.6 16.6 12.4 9.4 24.0 11.8 9.2 6.2 4.5 12.1 9.9 10.1 3.3 15.0 13.4 5.8 7.1 19.4 18.2 6.9 24.7 8.4 3.7 12.9 17.0 10.3 10.1 12.0 18.2 14.2 24.4 22.2 6.2 7.8 0.2 42.4 72.5 0.1 35.2 31.9 32.1 23.6 0.0 9.2 11.7 50.6 32.9 5.1 5.2 0.0 8.3 58.7 11.6 7.3 10.0 11.1 0.2 18.8 4.5 0.6 57.5 3.0 25.7 29.3 67.7 26.8 6.8 0.4 36.4 17.0 0.0 23.6 6.4 0.9 0.2 7.5 0.1 37.1 18.6 39.4 0.1 11.1 8.8 30.1 2.5 0.3 0.8 0.0 10.2 30.9 69.2 5.0 56.4 70.6 3.0 0.1 0.2 10.2 12.6 56.2 18.2 61.1 4.1 11.6 29.5 14.8 2.2 13.3 11.0 32.7 4.9 12.5 11.1 59.8 13.3 27.1 0.9 15.8 21.9 7.2 12.8 5.7 10.4 7.4 12.9 12.4 9.4 12.1 6.9 12.9 24.4 25.5 16.0 39.1 23.8 15.4 7.6 8.8 9.4 18.8 2.5 8.4 8.3 5.3 40.0 11.5 7.3 0.0 0.2 19.2 3.3 5.9 2.5 7.0 1.5 15.2 14.7 3.0 13.3 258.6 6.4 0.2 30.0 10.7 1.7 9.5 4.5 17.2 54.2 17.1 0.0 30.5 5.5 6.1 130.4 27.0 4.0 33.5 73.7 3.6 105.9 98.1 4.8 27.8 34.2 1712.3 5.3 2.1 18.8 17.0 4.9 21.0 6.6 8.6 0.1 13.1 16.0 17.7 1.2 3.1 19.7 5.5 0.1 31.4 5.1 6.8 9.3 DRD1 ENSG00000184845 "Dopamine receptor D1" P21728 5 175440036-175444182 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 13 "brain: 21.3;retina: 8.4" "Group enriched" "Detected in some" 12 "Bipolar cells: 40.1;Horizontal cells: 33.7" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in many" "basal ganglia: 21.3" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "RT4: 26.4" "Region enriched" "Detected in many" 9 "basal ganglia: 164.4" "Region enriched" "Detected in many" 13 "basal ganglia: 86.7" "HPA013393, HPA017304" Supported Approved "Plasma membrane,Cytosol" NA NA "Cluster 58: Brain - Synaptic function" "Cluster 15: RT4 - Unknown function" "Cluster 62: Horizontal cells - Visual perception" "Plasma membrane" Cytosol "HPA013393: AB_1847833, HPA017304: " "unprognostic (2.74e-2)" "unprognostic (6.36e-3)" "unprognostic (2.02e-1)" "unprognostic (1.07e-1)" "unprognostic (7.63e-3)" "unprognostic (1.28e-1)" "unprognostic (1.15e-6)" "unprognostic (6.69e-2)" "unprognostic (1.05e-1)" "unprognostic (1.24e-1)" "unprognostic (1.49e-1)" "unprognostic (2.74e-2)" "unprognostic (8.60e-4)" "unprognostic (5.86e-2)" "unprognostic (5.43e-1)" "unprognostic (6.00e-3)" "unprognostic (1.10e-2)" 0.4 0.6 4.7 0.0 21.3 0.0 0.2 0.0 8.5 0.4 0.1 0.2 0.1 0.1 0.2 0.3 0.2 0.4 0.0 3.1 0.4 0.7 1.1 0.7 0.0 0.3 0.9 0.1 0.0 0.0 0.1 1.1 0.0 1.1 0.3 8.4 0.0 0.4 0.0 0.0 0.3 0.1 0.7 0.1 0.2 0.0 1.8 0.3 0.1 0.6 0.1 0.7 0.4 2.9 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 26.4 0.7 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 21.3 0.0 8.5 3.1 0.4 0.3 0.9 0.0 0.7 1.8 2.9 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 40.1 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.4 0.4 0.0 33.7 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 3.0 0.0 0.7 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 DRD2 ENSG00000149295 "Dopamine receptor D2" P14416 11 113409605-113475691 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 77.8;pituitary gland: 59.6" "Cell type enriched" "Detected in some" 12 "Horizontal cells: 60.6" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in many" "basal ganglia: 77.8" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 9 "SCLC-21H: 88.3" "Region enriched" "Detected in many" 10 "basal ganglia: 205.3" "Region enriched" "Detected in many" 4 "basal ganglia: 146.3" "HPA015139, HPA015691" Supported Supported NA NA "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 62: Horizontal cells - Visual perception" "HPA015139: , HPA015691: AB_1847834" "unprognostic (8.49e-2)" "unprognostic (2.11e-1)" "unprognostic (1.69e-1)" "unprognostic (1.29e-4)" "unprognostic (2.32e-2)" "unprognostic (1.15e-1)" "unprognostic (1.97e-2)" "unprognostic (5.89e-2)" "unprognostic (4.40e-2)" "unprognostic (8.33e-4)" "unprognostic (1.10e-1)" "unprognostic (6.65e-3)" "unprognostic (2.29e-1)" "unprognostic (1.71e-1)" "unprognostic (4.82e-2)" "unprognostic (8.49e-3)" 0.3 8.4 6.1 0.1 77.8 0.0 1.3 0.2 18.3 1.6 0.0 0.4 0.0 1.1 0.1 0.5 1.3 0.2 0.1 1.4 13.6 1.2 0.0 0.2 0.0 3.9 40.7 0.2 0.2 0.0 59.6 0.0 21.1 0.9 0.3 11.7 11.9 0.7 0.8 0.9 0.2 1.5 0.7 0.0 0.1 1.0 14.8 0.0 0.0 0.3 0.0 0.2 0.6 1.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 7.6 0.2 0.0 0.0 0.0 6.1 0.0 0.0 0.1 0.1 4.9 0.1 0.0 0.0 0.0 0.0 0.0 10.0 0.0 1.6 0.0 1.1 0.0 0.0 0.0 0.0 0.0 3.1 0.4 0.0 0.0 1.0 0.1 0.0 0.0 9.6 0.0 0.0 0.1 88.3 10.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 2.0 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 77.8 0.2 18.3 1.4 13.6 3.9 40.7 21.1 0.7 14.8 1.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 4.7 0.1 2.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 60.6 1.7 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 DRD3 ENSG00000151577 "Dopamine receptor D3" P35462 3 114127580-114199407 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets, Schizophrenia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 8 "brain: 5.6" "Group enriched" "Detected in some" 12 "Early spermatids: 6.2;Late spermatids: 19.6" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "basal ganglia: 5.6;cerebral cortex: 2.8;hypothalamus: 4.1" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 5 "basal ganglia: 7.4" "Region enriched" "Detected in many" 10 "basal ganglia: 17.9" NA NA "Cluster 4: T-regs - Cell cycle regulation" "Cluster 65: Brain - Ion transport" "Cluster 25: Spermatids - Spermatogenesis" "unprognostic (2.32e-1)" 0.0 0.0 0.3 0.0 5.6 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.3 5.6 0.0 2.8 0.1 4.1 0.0 0.2 0.5 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.2 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 19.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 DRD4 ENSG00000069696 "Dopamine receptor D4" P21917 11 637269-640706 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "Biological rhythms" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 5 "Bipolar cells: 168.8;Cone photoreceptor cells: 87.6;Rod photoreceptor cells: 206.9" "Cancer enhanced" "Detected in many" "ovarian cancer: 3.9" "Low region specificity" "Detected in single" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA062682 Uncertain "Plasma membrane,Centrosome" NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 71: Testis - DNA repair" "Cluster 56: Bipolar cells - Visual perception" "Plasma membrane" Centrosome "HPA062682: " "unprognostic (8.83e-2)" "unprognostic (2.99e-2)" "unprognostic (4.98e-4)" "unprognostic (3.81e-2)" "unprognostic (7.52e-2)" "unprognostic (7.89e-3)" "unprognostic (3.14e-2)" "unprognostic (2.96e-1)" "unprognostic (8.45e-2)" "unprognostic (5.07e-2)" "unprognostic (3.28e-1)" "unprognostic (8.59e-2)" "unprognostic (1.05e-4)" "unprognostic (1.26e-2)" "unprognostic (8.21e-2)" "unprognostic (2.36e-2)" "unprognostic (1.85e-1)" 0.9 0.8 0.5 0.0 0.6 0.0 0.8 1.3 0.6 2.5 0.1 1.9 0.0 1.6 0.0 1.1 2.5 0.0 1.1 0.4 0.0 1.3 1.5 1.3 0.0 0.6 0.2 3.5 1.5 0.0 4.2 0.0 0.5 2.3 0.0 0.0 0.5 0.0 1.0 1.5 1.1 0.0 0.1 0.6 0.8 2.5 0.3 0.0 1.8 0.0 0.0 1.7 1.7 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.5 0.6 1.3 0.6 0.4 0.0 0.6 0.2 0.5 0.1 0.3 0.6 0.5 0.0 0.5 4.2 0.2 0.0 0.3 0.2 0.0 168.8 0.3 0.4 1.7 0.0 0.1 1.8 87.6 0.6 8.6 0.8 0.0 0.1 0.7 0.3 0.4 1.5 0.0 0.0 0.8 0.4 0.3 0.5 2.0 0.7 0.0 1.5 0.0 0.1 0.2 6.7 1.2 1.3 0.0 0.3 0.3 0.2 0.6 0.9 0.0 0.0 0.1 26.0 0.0 0.0 2.6 0.4 0.2 0.7 0.1 1.1 8.3 1.9 0.1 206.9 0.0 0.8 0.6 1.2 2.6 0.8 0.4 0.1 0.1 0.5 1.3 0.3 DRD5 "DRD1B, DRD1L2" ENSG00000169676 "Dopamine receptor D5" P21918 4 9781634-9784009 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Dystonia, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.6;stomach 1: 4.4" "Cell type enhanced" "Detected in some" "Excitatory neurons: 1.2;Horizontal cells: 1.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "thalamus: 7.0" HPA048930 Supported NA NA "Cluster 65: Brain - Ion transport" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA048930: AB_2680562" "unprognostic (2.03e-2)" "unprognostic (2.63e-1)" "unprognostic (9.73e-2)" "unprognostic (4.27e-2)" "unprognostic (4.44e-3)" "unprognostic (1.98e-2)" "unprognostic (1.32e-4)" "unprognostic (5.09e-4)" "unprognostic (6.51e-2)" "unprognostic (1.46e-1)" "unprognostic (7.36e-3)" 0.0 0.0 3.2 1.4 6.6 0.0 0.0 0.0 3.3 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.6 0.0 0.0 0.0 0.0 2.0 1.1 0.0 0.0 0.0 0.4 0.0 2.2 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 4.4 0.4 2.5 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 6.6 0.0 3.3 1.6 1.6 2.0 1.1 2.2 1.0 2.5 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ECHS1 SCEH ENSG00000127884 "Enoyl-CoA hydratase, short chain 1" P30084 10 133362485-133373354 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism" Lyase "Disease variant, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 1128.7" "Cell type enhanced" "Detected in all" "Hepatocytes: 1476.3;Proximal tubular cells: 2336.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003783, HPA021995, HPA022476" Enhanced Enhanced Mitochondria NA NA 1200000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 85: Liver - Metabolism" "Cluster 39: CACO-2 - Unknown function" "Cluster 67: Proximal tubular cells - Tubular reabsorption" Mitochondria "CAB003783: , HPA021995: AB_1847974, HPA022476: AB_1847975" "unprognostic (3.68e-1)" "unprognostic (2.46e-3)" "unprognostic (9.57e-2)" "unprognostic (4.70e-2)" "unprognostic (1.59e-1)" "unprognostic (3.14e-1)" "unprognostic (2.51e-3)" "unprognostic (2.30e-1)" "unprognostic (1.82e-2)" "unprognostic (2.28e-2)" "unprognostic (1.60e-1)" "unprognostic (1.27e-1)" "prognostic favorable (8.57e-5)" "unprognostic (2.84e-2)" "unprognostic (1.19e-2)" "unprognostic (3.04e-2)" "unprognostic (2.50e-2)" 302.4 127.1 127.7 53.7 127.8 43.9 116.9 131.3 136.1 59.8 149.7 143.1 171.6 47.0 89.3 107.9 90.5 66.7 226.4 133.1 129.9 481.7 1128.7 48.5 52.4 129.4 129.9 71.3 96.8 98.7 74.3 73.6 128.8 102.0 104.6 39.8 163.4 123.2 294.3 68.2 153.6 59.4 130.3 48.4 84.5 52.6 134.6 40.0 88.5 271.6 59.0 87.4 57.8 136.0 185.1 229.2 120.4 303.4 173.0 111.4 110.5 132.2 175.9 183.2 154.1 509.5 174.0 139.2 111.9 151.4 94.4 167.7 160.2 136.1 132.0 107.4 281.2 138.5 128.1 367.2 145.0 180.4 93.5 124.5 115.9 121.2 153.6 160.8 165.1 98.3 127.8 117.4 181.6 443.9 90.7 352.0 84.4 289.8 272.1 152.8 146.4 74.6 227.8 236.0 78.1 123.4 137.0 224.1 178.9 69.4 174.8 171.5 132.1 81.3 115.9 169.9 177.4 87.0 58.8 159.8 192.4 98.8 68.7 96.1 184.7 86.8 105.5 212.2 137.6 178.7 117.8 115.8 242.6 148.9 119.3 115.8 19.8 166.0 168.1 104.9 123.0 233.0 127.7 127.8 131.3 136.1 133.1 129.9 129.4 129.9 128.8 130.3 134.6 136.0 99.2 44.8 82.7 16.3 60.5 68.2 86.9 271.8 62.6 57.0 98.5 119.6 255.2 210.1 161.5 174.7 6.2 470.2 34.0 298.6 565.4 162.8 29.9 148.9 92.7 71.4 131.7 72.2 11.6 101.1 163.5 92.5 87.7 226.4 91.2 120.0 88.5 1476.3 221.1 45.4 11.0 223.0 175.0 92.1 61.5 39.1 77.6 88.0 135.2 10.3 113.0 145.2 45.3 10.6 24.3 107.8 248.6 91.7 57.5 88.0 486.2 2336.5 93.2 55.2 85.5 57.0 98.8 52.9 66.1 125.2 76.3 299.1 62.5 220.0 317.2 127.8 EDNRA "ET-A, ETA-R, hET-AR" ENSG00000151617 "Endothelin receptor type A" P25101 4 147480917-147544954 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "seminal vesicle: 113.9" "Cell type enhanced" "Detected in many" "Endometrial stromal cells: 117.1;Leydig cells: 43.8;Peritubular cells: 68.1;Sertoli cells: 52.6;Smooth muscle cells: 108.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 9.4;ASC TERT1: 18.2;HHSteC: 9.3;LHCN-M2: 22.7;SH-SY5Y: 16.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013774, CAB018957" Uncertain Approved "Plasma membrane,Cytosol" NA NA "Cluster 89: Fibroblasts - ECM organization" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 48: Smooth muscle cells - ECM organization" "Plasma membrane, Cytosol" "CAB018957: AB_2039838, HPA013774: AB_1847994" "unprognostic (3.08e-2)" "unprognostic (6.28e-2)" "unprognostic (1.78e-1)" "unprognostic (3.42e-1)" "unprognostic (1.07e-2)" "unprognostic (1.39e-1)" "unprognostic (3.20e-2)" "unprognostic (7.20e-2)" "unprognostic (2.75e-3)" "unprognostic (1.47e-2)" "unprognostic (1.34e-3)" "unprognostic (2.88e-1)" "prognostic unfavorable (1.50e-7)" "prognostic unfavorable (3.93e-4)" "unprognostic (6.20e-3)" "unprognostic (3.11e-2)" "unprognostic (2.53e-3)" 14.0 5.5 2.1 3.3 2.8 0.0 8.3 2.7 4.2 57.0 2.1 3.2 3.4 44.7 23.3 4.4 18.4 12.7 26.0 2.2 2.2 4.2 3.1 22.7 3.8 2.9 3.1 37.5 1.1 3.4 2.8 12.1 2.9 30.7 3.4 0.3 6.4 113.9 4.0 4.6 2.9 45.1 2.5 8.4 5.4 6.2 2.9 4.9 6.8 5.5 2.6 11.8 24.0 3.0 0.0 1.2 5.2 0.0 9.4 18.2 0.0 2.9 3.8 0.4 0.1 0.2 0.0 0.0 0.0 0.9 0.6 0.0 0.4 0.7 0.2 0.0 1.9 0.0 2.8 0.0 9.3 0.0 0.0 6.9 0.6 0.5 0.0 3.4 0.0 0.0 0.0 1.4 22.7 0.3 0.0 0.1 1.5 0.0 1.1 0.0 0.9 0.1 1.3 1.0 0.0 16.3 0.0 0.0 0.0 3.4 0.0 0.0 0.0 3.6 0.7 0.0 0.0 1.3 0.4 0.0 7.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 2.8 2.7 4.2 2.2 2.2 2.9 3.1 2.9 2.5 2.9 3.0 7.7 3.2 5.3 1.0 0.0 3.1 0.8 1.7 27.3 0.1 0.8 5.2 24.9 0.0 4.5 0.0 0.0 0.2 0.1 0.0 0.0 0.1 2.9 3.4 117.1 8.0 0.0 0.0 5.3 0.0 0.1 15.9 0.0 2.7 0.0 14.3 0.0 0.0 0.6 0.0 22.5 0.0 0.0 0.0 3.9 3.5 43.8 0.8 3.6 9.4 0.0 0.1 0.0 2.0 1.0 0.2 0.0 68.1 0.0 1.4 0.0 0.5 0.0 0.5 52.6 0.6 108.6 0.7 0.7 7.1 2.7 0.1 0.9 0.3 0.0 0.4 EDNRB "ETB, HSCR, HSCR2" ENSG00000136160 "Endothelin receptor type B" P24530 13 77895481-77975529 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Albinism, Deafness, Disease variant, FDA approved drug targets, Hirschsprung disease, Waardenburg syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 127.8" "Cell type enhanced" "Detected in many" "Adipocytes: 120.5;Astrocytes: 126.3;Hepatic stellate cells: 112.5;Melanocytes: 110.3;Muller glia cells: 116.2;Sertoli cells: 216.9;Skeletal myocytes: 81.3;Smooth muscle cells: 102.1" "Cancer enhanced" "Detected in all" "melanoma: 127.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 68.0;ASC diff: 50.5;SK-MEL-30: 66.0;U-266/70: 40.7;WM-115: 131.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017842, HPA027546" Approved Supported "Plasma membrane,Cytosol" NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 57: Non-specific - Angiogenesis" "Cluster 17: WM-115 - Nervous system development" "Cluster 48: Smooth muscle cells - ECM organization" "Plasma membrane" Cytosol "CAB017842: , HPA027546: AB_2672327" "unprognostic (7.75e-2)" "unprognostic (6.73e-2)" "unprognostic (1.41e-3)" "unprognostic (2.59e-2)" "unprognostic (8.37e-2)" "unprognostic (2.45e-3)" "unprognostic (4.17e-3)" "unprognostic (5.43e-2)" "unprognostic (1.02e-1)" "unprognostic (1.38e-2)" "unprognostic (3.40e-2)" "unprognostic (3.01e-2)" "prognostic favorable (7.20e-5)" "unprognostic (1.59e-2)" "unprognostic (3.86e-2)" "unprognostic (4.58e-2)" "unprognostic (6.77e-3)" 58.8 41.2 34.7 19.5 50.8 0.9 39.8 44.6 26.1 18.7 6.7 13.0 20.0 13.1 3.7 8.2 14.1 14.9 28.1 27.5 51.6 33.0 50.9 51.2 10.4 76.2 66.0 4.7 11.4 15.3 9.6 127.8 47.9 25.3 13.2 17.9 27.0 6.9 11.3 12.5 21.9 12.9 97.2 16.8 10.6 2.3 64.9 4.0 31.8 18.8 4.7 23.6 15.5 78.7 5.7 0.0 68.0 0.0 50.5 2.0 1.0 0.0 0.1 0.0 0.0 25.9 0.0 0.0 2.6 0.0 0.1 0.2 0.0 0.0 0.0 0.3 0.3 0.3 0.0 0.0 3.5 0.0 0.2 13.2 0.0 0.0 0.0 0.1 0.6 0.0 0.2 0.2 1.7 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.1 0.7 0.1 0.1 0.5 0.1 0.0 66.0 8.9 0.0 0.3 0.3 0.6 0.1 0.0 0.4 40.7 24.9 0.1 1.2 0.0 131.8 0.0 0.4 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 34.7 50.8 44.6 26.1 27.5 51.6 76.2 66.0 47.9 97.2 64.9 78.7 120.5 12.8 51.0 126.3 0.2 14.8 1.0 0.0 1.2 5.8 1.2 2.8 10.8 0.0 2.5 0.0 6.2 14.7 0.3 0.1 0.0 0.0 2.9 2.9 20.7 73.3 0.0 0.0 1.3 0.0 13.9 51.1 1.1 35.9 6.3 2.1 112.5 1.1 13.4 0.0 1.6 0.0 0.0 18.7 10.6 2.2 79.9 5.2 110.3 6.5 0.1 116.2 0.0 48.2 0.9 0.1 0.0 2.6 0.1 2.6 0.0 0.1 1.5 4.4 216.9 81.3 102.1 0.4 2.1 0.2 7.2 5.7 1.6 2.5 0.0 1.5 EGF ENSG00000138798 "Epidermal growth factor" P01133 4 109912883-110013766 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Growth factor" "Cancer-related genes, Disease variant, FDA approved drug targets, Primary hypomagnesemia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "kidney: 110.2;pancreas: 89.5;skeletal muscle: 29.6" "Cell type enhanced" "Detected in some" "Breast glandular cells: 12.9;Breast myoepithelial cells: 8.1;Cardiomyocytes: 8.2;Distal tubular cells: 7.9;Excitatory neurons: 8.5;Inhibitory neurons: 11.2;Muller glia cells: 26.2;Skeletal myocytes: 8.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "EFO-21: 6.4;SK-BR-3: 11.6;U-251 MG: 3.6" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" NA NA 209000 680000 "Cluster 1: Neutrophils - Mixed function" "Cluster 7: Kidney - Transmembrane transport" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 37: Myocytes - Muscle contraction" "unprognostic (2.83e-2)" "unprognostic (1.02e-2)" "unprognostic (8.50e-3)" "unprognostic (1.88e-3)" "unprognostic (4.24e-2)" "unprognostic (1.64e-3)" "unprognostic (5.06e-4)" "unprognostic (8.30e-2)" "unprognostic (2.21e-3)" "unprognostic (4.25e-2)" "unprognostic (1.80e-2)" "unprognostic (2.95e-1)" "unprognostic (7.72e-3)" "unprognostic (4.64e-5)" "unprognostic (2.63e-1)" "unprognostic (9.80e-5)" "unprognostic (3.92e-3)" 0.0 0.0 1.0 0.1 1.0 0.2 14.7 0.2 0.8 0.0 0.2 0.8 0.0 0.4 2.4 0.7 0.3 1.0 2.8 0.9 2.0 110.2 0.0 0.5 0.0 1.4 0.9 0.0 89.5 0.2 0.4 0.0 1.5 1.4 1.1 13.6 15.7 0.4 29.6 0.7 0.2 0.5 1.2 0.1 0.0 0.1 0.7 0.0 3.0 17.4 0.0 0.4 0.1 1.8 0.2 0.2 1.9 0.0 0.0 0.1 0.0 0.4 1.1 0.5 0.4 0.1 0.0 0.0 6.4 0.6 1.6 0.0 0.3 0.0 0.4 0.0 0.3 0.1 0.6 1.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 1.4 0.0 0.0 1.3 0.1 0.6 0.1 0.0 0.0 2.3 0.0 0.4 0.1 0.1 0.5 0.4 0.2 0.0 0.0 0.0 11.6 0.4 1.2 2.8 0.0 0.0 0.9 1.3 0.0 3.6 0.0 0.0 0.0 1.1 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.5 1.0 1.0 0.2 0.8 0.9 2.0 1.4 0.9 1.5 1.2 0.7 1.8 0.1 0.0 0.0 3.3 0.0 1.0 0.2 0.1 0.0 1.0 12.9 8.1 8.2 0.0 0.5 0.0 0.0 0.0 0.2 2.0 7.9 0.2 5.6 0.2 0.1 0.6 0.0 0.0 8.5 5.7 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.1 1.7 11.2 0.1 0.0 0.0 0.0 1.5 0.0 1.0 0.0 0.0 0.3 26.2 0.0 1.5 0.3 1.0 0.4 0.0 0.0 1.1 0.1 1.2 1.0 1.2 0.0 8.2 0.2 0.5 0.4 0.0 1.4 0.0 0.1 0.1 1.6 0.3 EGFR "ERBB, ERBB1" ENSG00000146648 "Epidermal growth factor receptor" P00533 7 55019017-55211628 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Host-virus interaction" "Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 287.9;Skeletal myocytes: 251.2;Syncytiotrophoblasts: 376.8" "Cancer enhanced" "Detected in all" "glioma: 136.0" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in many" 13 "A-431: 5282.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000035, HPA001200, HPA018530, CAB068186, CAB073534" Enhanced Enhanced "Plasma membrane,Cell Junctions" "Secreted to blood" NA NA 4740000 88000000 "Cluster 31: Skin - Epidermis development" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 50: Fibroblasts - ECM organization" "Plasma membrane, Cell Junctions" "CAB000035: , CAB068186: AB_2665679, CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044" "unprognostic (2.62e-2)" "unprognostic (9.56e-3)" "unprognostic (1.59e-1)" "unprognostic (7.51e-2)" "unprognostic (1.08e-1)" "unprognostic (1.27e-2)" "unprognostic (6.11e-2)" "unprognostic (4.88e-2)" "unprognostic (2.85e-2)" "unprognostic (3.30e-3)" "unprognostic (1.78e-3)" "unprognostic (1.04e-1)" "unprognostic (1.93e-3)" "unprognostic (6.98e-3)" "unprognostic (1.72e-1)" "unprognostic (6.62e-2)" "prognostic unfavorable (2.04e-5)" 27.9 11.4 12.6 4.0 18.3 0.0 20.0 16.6 9.7 20.4 10.5 12.2 5.7 11.4 10.3 23.5 13.9 9.0 7.1 6.3 10.3 11.6 35.3 14.9 2.5 10.4 19.0 15.1 15.8 3.5 2.9 67.9 8.9 16.2 10.7 10.2 22.1 15.0 10.9 51.0 9.5 9.3 7.5 5.1 11.1 4.2 22.6 12.8 20.6 20.6 8.3 14.7 24.1 6.3 5282.1 61.9 16.5 22.4 102.7 63.5 16.7 47.9 68.7 30.8 23.8 11.5 54.2 2.7 11.4 43.8 130.7 197.1 0.4 230.2 37.1 2.2 3.6 0.1 27.3 3.4 27.0 0.0 0.2 31.2 205.4 74.1 409.9 45.5 4.0 0.0 0.0 0.5 68.0 3.0 0.1 0.1 5.1 21.2 30.4 0.1 9.1 0.2 38.1 52.6 0.8 20.0 42.7 50.6 9.3 16.8 4.9 12.0 15.6 27.1 7.2 215.7 45.8 0.1 4.8 3.1 37.9 1.6 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.6 18.3 16.6 9.7 6.3 10.3 10.4 19.0 8.9 7.5 22.6 6.3 16.4 96.1 49.9 147.6 1.2 85.8 77.1 101.5 116.1 3.5 12.1 30.4 11.1 47.1 50.6 22.0 6.2 287.9 0.0 45.9 0.0 32.9 4.9 25.9 57.2 12.5 4.2 8.0 1.2 24.3 37.1 91.6 22.4 39.8 0.0 50.6 6.8 79.5 28.3 0.0 107.5 21.6 48.8 7.7 11.6 5.8 128.3 1.9 17.8 40.3 1.6 90.0 0.0 63.3 1.4 54.8 19.9 133.5 0.0 75.4 14.1 13.4 21.7 3.8 78.9 251.2 34.7 2.4 2.5 73.3 89.9 376.8 2.2 41.9 24.9 55.8 ELOVL4 "CT118, SCA34, STGD2, STGD3" ENSG00000118402 "ELOVL fatty acid elongase 4" Q9GZR5 6 79914814-79947553 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" Transferase "Disease variant, FDA approved drug targets, Ichthyosis, Mental retardation, Neurodegeneration, Spinocerebellar ataxia, Stargardt disease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 105.5;retina: 176.7" "Cell type enhanced" "Detected in many" "Bipolar cells: 63.8;Cone photoreceptor cells: 148.0;Excitatory neurons: 55.3;Rod photoreceptor cells: 355.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in some" 6 "MAIT T-cell: 23.7" "Lineage enriched" "Detected in single" 238 "T-cells: 23.7" "Cell line enhanced" "Detected in many" "JURKAT: 41.2;MOLT-4: 32.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 20: Retina & Lymphoid tissues - Unknown function" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 46: Photoreceptor cells - Phototransduction" "unprognostic (1.67e-2)" "unprognostic (8.58e-3)" "unprognostic (2.38e-2)" "unprognostic (3.08e-6)" "unprognostic (1.49e-1)" "unprognostic (2.10e-1)" "unprognostic (1.27e-1)" "unprognostic (1.39e-1)" "unprognostic (1.85e-1)" "unprognostic (3.46e-1)" "unprognostic (6.91e-3)" "unprognostic (3.39e-1)" "unprognostic (1.38e-2)" "unprognostic (3.45e-3)" "unprognostic (1.66e-1)" "unprognostic (1.77e-1)" "prognostic unfavorable (6.27e-4)" 0.7 2.0 7.1 1.1 7.0 0.1 4.1 10.0 15.4 3.5 9.7 1.8 0.6 2.2 1.0 10.6 0.7 1.6 0.9 7.8 9.9 1.5 0.1 0.3 0.4 14.4 5.3 1.7 0.5 10.8 6.4 1.7 15.0 4.0 1.0 176.7 2.8 1.7 0.2 43.1 0.8 2.7 4.3 0.5 0.9 5.7 7.4 105.5 1.5 0.5 1.7 1.2 4.0 7.2 0.0 0.8 10.8 12.0 8.8 8.5 1.6 5.6 6.1 4.7 10.2 1.5 0.0 0.0 1.0 7.7 19.3 1.1 14.1 7.9 3.5 0.0 18.2 0.4 2.2 0.0 8.1 4.4 1.7 6.9 2.9 4.8 4.9 6.8 7.8 41.2 0.0 0.0 10.0 1.9 32.8 0.0 10.4 0.0 5.6 0.0 15.5 0.0 0.1 0.0 14.2 4.2 6.0 9.6 1.7 7.4 3.8 0.3 0.8 2.1 4.1 3.2 4.3 7.2 15.3 0.0 5.0 0.0 3.3 0.0 0.0 0.0 2.3 0.0 23.7 0.0 3.3 3.9 0.0 0.0 0.6 1.6 0.0 0.0 0.0 0.0 0.2 0.9 7.1 7.0 10.0 15.4 7.8 9.9 14.4 5.3 15.0 4.3 7.4 7.2 0.7 0.0 0.0 7.5 0.2 11.3 2.3 7.5 15.4 63.8 0.7 1.7 0.9 0.0 3.9 0.0 148.0 0.9 1.7 0.0 0.0 0.1 6.3 0.3 7.0 2.2 8.9 0.0 55.3 0.0 1.5 6.5 0.0 0.1 0.0 1.5 0.0 0.0 0.2 42.1 53.0 0.5 6.1 0.3 1.5 2.1 1.2 0.2 3.6 8.4 0.1 50.7 0.0 20.1 8.6 0.0 1.1 3.4 0.3 3.1 0.0 2.3 0.5 355.3 0.0 2.0 4.3 15.4 15.4 14.8 37.8 1.0 2.6 1.3 0.2 0.7 EPCAM "17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1" ENSG00000119888 "Epithelial cell adhesion molecule" P16422 2 47345158-47387601 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Tumor antigen" "Cancer-related genes, Disease variant, FDA approved drug targets, Hereditary nonpolyposis colorectal cancer" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 806.0" "Cell type enhanced" "Detected in many" "Distal enterocytes: 2317.0;Ductal cells: 999.6;Intestinal goblet cells: 1378.2;Paneth cells: 2437.0;Proximal enterocytes: 2681.1;Undifferentiated cells: 1607.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "A-431: 538.9;CACO-2: 680.9;CAPAN-2: 944.4;OE19: 911.8;RPTEC TERT1: 398.6" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "CAB003809, HPA026761, CAB030012, CAB055098, HPA067463" Enhanced Supported "Plasma membrane" NA NA 22000 "Cluster 9: Intestine - Unknown function" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 53: Intestinal epithelial cells - Unknown function" "Plasma membrane" "CAB003809: AB_562285, CAB030012: AB_756075, CAB055098: AB_2335685, HPA026761: AB_1848198, HPA067463: AB_2685846" "unprognostic (6.79e-2)" "unprognostic (2.28e-1)" "unprognostic (1.59e-2)" "unprognostic (1.16e-2)" "unprognostic (1.61e-1)" "unprognostic (3.49e-2)" "unprognostic (2.01e-1)" "unprognostic (3.61e-2)" "unprognostic (3.40e-1)" "prognostic favorable (3.30e-4)" "unprognostic (5.27e-2)" "unprognostic (3.28e-2)" "prognostic favorable (1.04e-6)" "unprognostic (6.38e-3)" "unprognostic (1.28e-1)" "unprognostic (6.45e-3)" "unprognostic (6.08e-2)" 4.4 12.2 3.1 77.0 4.0 10.2 99.7 1.5 3.1 116.2 1.0 806.0 726.5 33.0 238.9 10.8 114.3 71.1 0.6 3.3 9.2 223.1 3.1 74.7 0.9 2.8 3.2 1.2 125.4 219.5 86.9 1.7 3.4 60.5 751.0 0.6 119.8 52.8 0.1 8.8 769.6 22.2 2.6 1.4 172.4 21.7 10.4 6.4 286.8 0.1 2.8 30.9 4.2 2.6 538.9 5.4 0.4 1.2 0.0 0.0 321.3 0.2 0.0 0.6 0.0 680.9 944.4 0.1 141.5 1.0 0.4 247.3 4.6 62.2 2.0 0.1 56.3 0.3 2.5 261.6 0.1 0.3 0.4 0.0 17.6 0.0 0.0 0.0 0.8 0.0 160.9 0.0 0.3 269.7 0.5 24.0 164.3 911.8 31.4 0.3 0.0 136.9 398.6 231.3 354.0 3.2 4.3 187.7 0.6 132.7 158.3 1.0 0.7 0.3 6.3 2.0 1.1 39.2 0.6 0.8 0.5 0.2 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 3.1 4.0 1.5 3.1 3.3 9.2 2.8 3.2 3.4 2.6 10.4 2.6 3.7 310.9 148.1 1.3 7.0 9.3 227.6 127.4 14.2 0.5 184.7 112.9 2.0 243.1 222.8 448.8 0.0 16.4 2.3 2317.0 76.3 999.6 8.6 434.7 35.3 5.8 498.1 23.1 1.1 402.8 6.5 6.3 150.3 445.3 32.5 11.8 1.4 0.6 2.9 0.0 0.4 1378.2 486.2 0.0 5.2 5.6 20.5 5.6 35.6 0.0 11.5 15.7 0.0 0.5 1.2 617.5 2437.0 18.8 1.8 257.9 2681.1 195.9 219.0 0.7 13.1 0.5 13.7 83.5 130.3 33.3 10.4 6.0 9.4 70.3 1607.7 230.7 EPHA2 ECK ENSG00000142627 "EPH receptor A2" P29317 1 16124337-16156069 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, RAS pathway related proteins" "Angiogenesis, Apoptosis, Cell adhesion, Differentiation, Host-virus interaction" "Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cataract, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 147.9" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 202.3;Glandular and luminal cells: 182.9;Squamous epithelial cells: 156.3;Suprabasal keratinocytes: 248.3;Urothelial cells: 200.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 94 "plasmacytoid DC: 9.4" "Lineage enriched" "Detected in single" 94 "dendritic cells: 9.4" "Cell line enhanced" "Detected in many" "CAPAN-2: 201.1;PC-3: 229.0;U-251 MG: 242.1;WM-115: 258.2" "Low region specificity" "Detected in single" "Low region specificity" "Detected in all" CAB010464 Supported "Nuclear speckles,Golgi apparatus,Plasma membrane,Cell Junctions" NA Yes 12000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 84: Esophagus - Epithelial cell function" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 44: Endometrium - Transcription" "Plasma membrane, Cell Junctions" "Nuclear speckles, Golgi apparatus" "CAB010464: AB_631436" "unprognostic (9.41e-2)" "unprognostic (1.67e-1)" "unprognostic (4.13e-2)" "unprognostic (1.67e-2)" "unprognostic (6.22e-2)" "unprognostic (9.12e-2)" "unprognostic (5.24e-2)" "unprognostic (1.29e-3)" "unprognostic (2.52e-2)" "unprognostic (7.05e-3)" "unprognostic (1.52e-3)" "unprognostic (2.77e-1)" "unprognostic (2.65e-2)" "unprognostic (2.08e-1)" "unprognostic (1.73e-1)" "unprognostic (4.77e-3)" "unprognostic (4.40e-2)" 21.4 9.5 3.5 4.8 3.1 0.3 14.6 2.9 3.7 38.2 11.7 12.4 10.0 12.1 1.3 147.9 13.5 28.2 15.8 3.1 3.1 18.7 18.9 17.9 7.6 3.8 3.7 5.8 23.2 3.7 7.4 14.0 3.8 11.2 5.8 6.4 67.7 4.2 4.6 40.3 12.8 3.7 3.6 7.6 15.6 1.8 4.3 3.2 15.2 5.1 11.1 56.1 58.8 3.1 76.9 151.7 41.4 20.1 2.9 3.5 24.3 45.2 63.4 79.9 50.6 63.9 201.1 0.1 189.8 25.9 98.8 30.6 9.9 104.4 27.6 0.4 7.0 0.0 46.7 41.1 51.3 0.1 0.2 4.8 38.1 43.7 95.6 125.0 86.4 0.0 0.3 0.1 51.6 24.3 0.0 0.0 20.0 57.2 229.0 0.1 37.6 0.2 85.1 39.0 0.1 6.4 87.8 21.2 6.1 21.3 3.0 0.9 108.1 28.5 76.7 2.0 242.1 0.0 0.5 0.6 22.0 0.1 258.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.4 0.0 0.0 3.5 3.1 2.9 3.7 3.1 3.1 3.8 3.7 3.8 3.6 4.3 3.1 17.1 54.5 38.4 2.0 1.2 202.3 114.3 110.9 66.0 2.7 39.5 43.9 6.5 44.3 113.4 9.2 4.2 9.7 8.9 96.8 0.0 33.8 5.8 104.5 19.2 26.3 3.0 0.0 0.1 14.2 1.2 5.8 68.3 182.9 5.7 0.4 29.3 23.3 1.9 0.0 0.2 42.0 34.6 1.6 17.0 0.2 3.4 3.7 26.6 4.7 1.1 7.1 0.0 0.0 0.0 104.6 111.7 0.0 0.0 60.8 22.4 1.8 89.8 2.5 32.9 11.6 21.2 0.2 0.8 156.3 248.3 7.5 2.6 0.4 42.9 200.4 ERBB2 "CD340, HER-2, HER2, NEU, NGL" ENSG00000141736 "Erb-b2 receptor tyrosine kinase 2" P04626 17 39687914-39730426 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" "Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Collecting duct cells: 136.1;Distal enterocytes: 111.0;Proximal enterocytes: 121.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "gdT-cell: 5.0" "Lineage enriched" "Detected in many" 4 "T-cells: 5.0" "Group enriched" "Detected in many" 41 "OE19: 6565.0;SK-BR-3: 3115.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555" Enhanced Enhanced "Plasma membrane,Cytosol" NA NA 980000 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 7: Kidney - Transmembrane transport" "Cluster 21: OE19 - Mitochondria" "Cluster 53: Intestinal epithelial cells - Unknown function" "Plasma membrane" Cytosol "CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: AB_2665610, HPA001060: AB_2666185, HPA001338: AB_2666279, HPA001383: AB_1078500" "unprognostic (1.97e-1)" "unprognostic (6.60e-3)" "unprognostic (6.21e-2)" "prognostic unfavorable (8.99e-8)" "unprognostic (2.96e-2)" "unprognostic (1.40e-2)" "unprognostic (1.97e-2)" "unprognostic (9.04e-2)" "unprognostic (1.79e-2)" "unprognostic (1.20e-3)" "prognostic unfavorable (9.17e-4)" "unprognostic (3.92e-1)" "prognostic favorable (2.41e-14)" "unprognostic (9.29e-2)" "unprognostic (1.40e-1)" "unprognostic (3.75e-2)" "unprognostic (1.96e-1)" 13.0 5.4 16.1 12.1 20.5 1.6 56.0 14.3 13.1 37.6 23.3 68.2 63.6 25.2 26.6 102.4 64.2 31.0 57.0 13.3 16.0 73.5 31.1 36.2 4.8 22.4 22.7 23.9 37.6 81.7 17.3 27.0 17.1 55.6 48.5 8.1 68.7 50.5 20.7 91.0 67.3 25.0 18.5 6.9 49.7 11.7 15.4 7.4 56.5 15.0 28.0 40.0 52.9 16.4 38.7 45.7 50.4 31.7 59.3 41.2 67.7 27.2 44.9 58.6 48.9 34.4 102.7 2.9 54.6 62.7 31.5 117.6 2.8 61.2 26.9 5.2 38.6 1.8 36.0 56.3 35.3 0.9 1.0 41.0 56.6 36.2 21.9 56.2 24.4 1.9 6.2 2.4 43.3 59.4 7.1 3.0 90.7 6565.0 11.7 3.9 20.5 5.4 58.9 118.9 9.4 2.6 51.5 3115.9 16.9 62.2 88.1 2.2 2.9 30.2 37.7 37.7 17.6 5.3 3.3 3.6 3.0 0.9 98.5 1.1 0.2 0.4 5.0 0.1 0.3 0.6 0.2 1.4 0.2 0.6 0.5 1.4 1.2 0.4 0.1 0.1 0.2 1.7 16.1 20.5 14.3 13.1 13.3 16.0 22.4 22.7 17.1 18.5 15.4 16.4 3.9 41.7 40.1 12.7 2.2 14.0 19.0 37.1 17.6 4.6 62.7 34.9 20.7 32.9 43.8 136.1 12.5 12.0 5.1 111.0 7.9 30.9 0.3 48.7 13.9 6.1 15.6 1.3 0.9 25.5 84.8 15.7 53.5 61.3 0.0 20.3 11.7 10.7 4.0 6.7 1.0 47.5 42.7 2.2 3.1 1.0 18.3 1.7 10.6 1.0 1.2 24.1 26.8 2.0 1.0 32.5 54.8 23.0 1.1 34.9 121.7 19.5 42.0 5.8 0.0 13.1 12.7 6.8 5.7 43.5 18.9 22.7 2.8 4.4 75.4 31.3 ERBB4 "ALS19, HER4" ENSG00000178568 "Erb-b2 receptor tyrosine kinase 4" Q15303 2 211375717-212538841 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Apoptosis, Lactation, Transcription, Transcription regulation" "Activator, Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Amyotrophic lateral sclerosis, Cancer-related genes, Disease variant, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 16.9;fallopian tube: 11.2" "Cell type enhanced" "Detected in many" "Astrocytes: 2020.2;Inhibitory neurons: 6091.7;Oligodendrocyte precursor cells: 2369.0;Oligodendrocytes: 1049.9" "Group enriched" "Detected in many" 4 "breast cancer: 4.1;endometrial cancer: 2.1;glioma: 1.2;ovarian cancer: 2.8;testis cancer: 1.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 6.9;EFO-21: 5.1;HEK 293: 3.8;RPTEC TERT1: 5.6;SCLC-21H: 3.1;T-47d: 5.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000276, HPA012016, CAB025522" Enhanced NA NA 220000 "Cluster 57: Non-specific - Angiogenesis" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB000276: , CAB025522: , HPA012016: AB_1846541" "unprognostic (1.48e-1)" "unprognostic (3.28e-1)" "unprognostic (4.31e-3)" "unprognostic (1.76e-3)" "unprognostic (3.59e-1)" "unprognostic (2.75e-1)" "unprognostic (2.88e-1)" "unprognostic (9.56e-2)" "unprognostic (2.07e-1)" "unprognostic (4.67e-3)" "unprognostic (1.07e-1)" "unprognostic (3.61e-1)" "unprognostic (7.14e-3)" "unprognostic (1.49e-3)" "unprognostic (1.41e-1)" "unprognostic (1.14e-1)" "unprognostic (4.11e-2)" 0.3 0.4 10.0 0.0 13.3 0.0 5.6 10.5 11.5 2.9 0.0 0.1 0.0 0.2 0.0 0.1 11.2 0.0 3.0 9.9 12.7 5.1 0.0 0.8 0.0 4.9 16.9 0.1 0.6 3.1 2.4 0.1 7.6 0.3 0.0 2.0 4.7 1.2 1.5 0.3 0.0 0.0 4.3 0.0 0.4 3.3 8.0 0.0 1.6 1.7 0.0 0.1 0.1 6.1 0.0 0.0 6.9 0.2 0.0 0.0 0.0 0.0 0.2 0.3 0.1 0.0 0.0 0.0 5.1 0.7 0.0 0.3 0.2 0.0 0.0 0.1 3.8 0.0 1.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 2.1 0.0 0.0 0.3 0.0 5.6 0.3 3.1 0.2 0.0 0.1 0.1 0.1 5.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 13.3 10.5 11.5 9.9 12.7 4.9 16.9 7.6 4.3 8.0 6.1 0.4 0.0 12.6 2020.2 0.0 0.6 0.9 1.1 0.6 15.9 45.6 17.0 27.2 0.0 10.2 12.9 0.0 0.0 0.2 0.0 5.9 0.5 6.7 25.4 1.0 1.0 0.0 0.0 62.0 0.5 0.2 1.8 0.0 25.8 0.0 5.4 0.0 0.0 0.1 0.0 6091.7 0.0 2.0 0.0 0.3 2.2 1.8 0.3 3.6 96.5 0.0 9.1 0.0 2369.0 1049.9 0.0 0.0 0.4 0.0 1.6 0.0 0.2 28.1 1.9 6.6 4.1 3.0 1.8 2.6 0.2 1.3 0.0 0.2 0.0 0.0 1.2 ESR1 "ER-alpha, Era, ESR, NR3A1" ENSG00000091831 "Estrogen receptor 1" P03372 6 151656691-152129619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix: 83.8;endometrium 1: 110.9;fallopian tube: 64.9" "Cell type enhanced" "Detected in many" "Breast glandular cells: 86.6;Endometrial ciliated cells: 77.9;Endometrial stromal cells: 79.9;Glandular and luminal cells: 98.9;Hepatocytes: 52.1;Horizontal cells: 62.2;Skeletal myocytes: 56.7" "Cancer enhanced" "Detected in many" "breast cancer: 40.2;endometrial cancer: 24.3" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 10 "MCF7: 46.0;T-47d: 57.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB000037, HPA000449, HPA000450, CAB055099, CAB072858" Enhanced Approved Nucleoplasm,Vesicles NA NA "Cluster 89: Fibroblasts - ECM organization" "Cluster 6: T47d - Mammary gland" "Cluster 44: Endometrium - Transcription" Vesicles Nucleoplasm "CAB000037: AB_563706, CAB055099: AB_2101946, CAB072858: AB_2665701, HPA000449: AB_1078753, HPA000450: AB_1078754" "unprognostic (8.28e-2)" "unprognostic (3.02e-2)" "unprognostic (1.43e-2)" "prognostic favorable (5.47e-7)" "unprognostic (4.79e-1)" "unprognostic (2.43e-3)" "unprognostic (4.10e-5)" "unprognostic (9.92e-2)" "unprognostic (2.20e-1)" "unprognostic (7.17e-2)" "unprognostic (7.35e-2)" "unprognostic (3.45e-1)" "unprognostic (1.20e-2)" "unprognostic (7.91e-3)" "unprognostic (6.45e-2)" "unprognostic (1.25e-1)" "unprognostic (1.52e-1)" 4.2 1.8 3.2 1.5 1.3 0.8 29.1 2.9 1.3 83.8 3.2 0.9 0.4 110.9 1.2 0.5 64.9 1.2 1.8 0.6 6.7 2.8 16.9 2.0 1.6 0.4 0.5 9.0 1.0 0.2 6.6 0.4 0.3 6.1 0.5 3.5 0.9 9.8 5.8 1.1 0.8 50.4 0.2 1.7 0.6 2.3 5.9 1.0 3.4 2.6 2.3 2.1 46.9 0.3 0.6 0.0 0.1 0.1 0.1 1.9 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.1 0.2 0.0 1.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.2 0.6 0.0 0.0 0.0 1.2 0.1 46.0 0.1 0.0 0.0 0.0 0.0 1.4 0.0 0.7 0.0 3.3 0.1 0.0 0.0 0.6 0.0 0.2 57.4 0.0 0.1 0.2 0.2 0.5 0.0 5.2 1.1 0.1 0.2 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.2 0.0 0.1 0.1 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.1 3.2 1.3 2.9 1.3 0.6 6.7 0.4 0.5 0.3 0.2 5.9 0.3 0.6 0.0 1.1 1.3 2.3 1.0 1.7 0.0 0.0 3.9 86.6 16.4 4.4 0.0 1.0 0.0 8.4 0.1 0.4 0.1 1.9 0.0 40.1 77.9 79.9 2.7 1.8 0.0 4.5 0.2 0.1 11.3 0.0 98.9 2.5 36.9 5.0 52.1 0.9 62.2 5.4 0.0 0.0 4.0 3.1 10.3 4.1 2.5 1.8 1.0 0.2 2.4 0.0 25.1 0.6 0.1 0.0 2.2 8.5 0.6 0.0 3.7 1.3 4.6 0.0 56.7 11.7 1.8 1.3 0.4 1.7 0.1 2.2 4.8 0.1 6.8 ESR2 "ER-beta, Erb, NR3A2" ENSG00000140009 "Estrogen receptor 2" Q92731 14 64084232-64338112 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 6.1" "Cell type enhanced" "Detected in many" "Early spermatids: 61.4;Granulosa cells: 26.6;Late spermatids: 93.7;Rod photoreceptor cells: 35.6;Spermatocytes: 28.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "Karpas-707: 4.2;U-266/70: 9.8;U-698: 16.4" "Not detected" "Not detected" "Region enhanced" "Detected in many" "cerebellum: 6.1" "HPA068406, CAB079300" Enhanced Supported Nucleoplasm,Vesicles NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 71: Testis - DNA repair" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 40: Granulosa cells - Unknown function" Nucleoplasm Vesicles "CAB079300: , HPA068406: " "unprognostic (7.63e-3)" "unprognostic (2.28e-3)" "unprognostic (8.27e-3)" "unprognostic (5.41e-2)" "unprognostic (2.91e-2)" "unprognostic (1.06e-1)" "unprognostic (1.80e-1)" "unprognostic (4.38e-2)" "unprognostic (1.95e-1)" "unprognostic (8.75e-2)" "unprognostic (2.57e-2)" "unprognostic (1.65e-1)" "unprognostic (3.03e-5)" "unprognostic (1.57e-1)" "unprognostic (1.66e-1)" "unprognostic (4.21e-2)" "unprognostic (5.89e-2)" 1.5 6.1 1.2 1.2 0.6 1.0 0.9 3.0 0.8 1.4 3.5 0.9 1.0 1.2 0.4 0.7 1.0 0.5 0.6 0.5 0.9 1.5 0.7 0.6 2.1 0.7 0.6 5.4 2.1 0.1 0.8 0.2 1.0 1.5 1.0 2.0 0.8 0.2 1.4 1.0 1.3 0.3 0.3 1.8 1.0 5.7 1.7 2.5 0.6 0.2 1.6 1.1 0.6 0.9 0.8 0.4 0.7 0.6 0.0 0.1 1.5 0.2 0.0 0.1 0.1 0.3 0.9 3.1 0.1 0.1 0.4 1.0 0.8 0.0 0.1 0.7 0.4 0.3 1.0 0.1 0.1 0.1 0.3 0.0 0.0 0.1 0.2 0.2 0.3 1.1 0.5 4.2 0.2 0.8 0.5 0.2 0.7 0.6 0.4 0.5 0.4 0.3 0.1 1.3 2.2 0.6 0.4 0.2 1.1 0.4 0.7 0.1 0.5 0.4 1.0 0.2 0.1 9.8 3.1 16.4 0.2 0.1 0.8 0.3 0.1 0.5 0.3 0.2 0.2 0.5 0.2 0.4 0.0 0.7 0.4 0.3 0.6 0.2 0.3 1.1 0.2 0.1 1.2 0.6 3.0 0.8 0.5 0.9 0.7 0.6 1.0 0.3 1.7 0.9 0.9 6.4 0.0 6.8 5.5 0.3 2.2 0.4 2.8 1.6 0.3 0.1 0.9 4.3 0.9 0.0 6.2 0.7 5.2 0.1 0.0 0.3 61.4 3.5 0.9 3.0 0.0 0.4 12.4 0.7 0.5 2.2 0.0 4.9 1.3 26.6 1.1 0.1 0.1 0.0 17.9 0.8 0.0 0.0 0.3 93.7 0.9 0.2 1.8 7.5 0.1 0.9 6.2 10.6 7.6 0.5 0.1 1.2 16.6 3.8 0.4 0.1 1.7 35.6 0.0 1.5 1.4 28.0 1.4 0.5 0.1 1.1 3.0 16.4 0.8 1.8 ESRRG "ERR-gamma, ERRg, NR3B3" ENSG00000196482 "Estrogen related receptor gamma" P62508 1 216503246-217137755 "FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 49.6;parathyroid gland: 46.3;retina: 36.1;stomach 1: 35.1" "Group enriched" "Detected in many" 4 "Astrocytes: 330.7;Excitatory neurons: 415.2;Inhibitory neurons: 495.5;Oligodendrocyte precursor cells: 391.6;Oligodendrocytes: 218.7;Syncytiotrophoblasts: 214.9" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "RPMI-8226: 23.0;SH-SY5Y: 42.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044678 Uncertain Approved Nucleoplasm No NA "Cluster 48: Parathyroid gland - membrane proteins" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Nucleoplasm "HPA044678: AB_10963215" "unprognostic (6.48e-2)" "unprognostic (1.11e-1)" "unprognostic (7.06e-2)" "unprognostic (7.32e-2)" "unprognostic (2.34e-1)" "unprognostic (5.48e-2)" "unprognostic (1.66e-1)" "unprognostic (1.13e-1)" "unprognostic (4.55e-2)" "unprognostic (2.88e-1)" "unprognostic (2.35e-1)" "unprognostic (1.79e-2)" "prognostic favorable (1.13e-11)" "unprognostic (3.04e-1)" "unprognostic (2.55e-1)" "unprognostic (3.65e-4)" "unprognostic (2.05e-1)" 0.4 6.4 1.1 0.2 3.1 0.0 3.6 16.9 12.3 1.5 7.4 0.5 5.3 0.4 0.9 1.6 2.5 0.7 10.6 4.4 2.3 29.0 0.7 0.5 0.2 45.4 4.9 0.7 5.7 46.3 1.5 10.6 49.6 3.1 0.3 36.1 16.0 0.7 5.8 0.8 5.0 0.2 1.6 1.1 35.1 1.1 3.5 0.6 5.9 10.2 0.3 0.7 0.2 6.1 0.3 0.0 0.8 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 1.3 0.1 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 1.2 0.0 0.2 0.0 0.0 23.0 3.4 2.5 8.1 42.4 0.0 0.4 0.0 2.5 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.1 3.1 16.9 12.3 4.4 2.3 45.4 4.9 49.6 1.6 3.5 6.1 0.2 0.0 1.8 330.7 0.2 0.3 3.8 0.6 0.6 29.5 9.5 5.2 51.2 10.0 1.8 23.9 58.4 35.4 0.0 0.0 54.8 5.0 5.1 15.9 2.0 1.3 8.3 0.0 415.2 2.4 4.7 3.0 70.3 3.5 0.0 0.5 1.1 0.6 4.8 48.8 495.5 1.7 14.2 0.3 0.4 8.1 0.3 0.5 8.8 36.5 0.0 13.3 0.0 391.6 218.7 0.4 1.3 0.7 0.1 4.9 16.3 29.0 16.0 41.3 0.0 10.3 0.4 1.6 0.3 0.8 0.3 214.9 0.3 1.1 2.6 1.7 ETFDH ETFQO ENSG00000171503 "Electron transfer flavoprotein dehydrogenase" Q16134 4 158672125-158709623 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Electron transport, Transport" Oxidoreductase "Disease variant, FDA approved drug targets, Glutaricaciduria" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 196.4;tongue: 186.9" "Cell type enhanced" "Detected in all" "Cardiomyocytes: 146.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041978 Enhanced NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 8: Non-specific - Mitochondria" "Cluster 2: Karpas-707 - Immune response" "Cluster 54: Cardiomyocytes - Muscle contraction" "HPA041978: AB_10795605" "unprognostic (7.19e-2)" "unprognostic (2.28e-1)" "unprognostic (2.90e-2)" "unprognostic (5.92e-3)" "unprognostic (1.91e-1)" "unprognostic (8.45e-2)" "unprognostic (1.23e-3)" "unprognostic (7.17e-2)" "unprognostic (2.01e-1)" "unprognostic (4.55e-2)" "unprognostic (1.71e-2)" "unprognostic (5.76e-2)" "prognostic favorable (5.76e-10)" "unprognostic (2.51e-1)" "unprognostic (2.07e-1)" "unprognostic (8.85e-3)" "unprognostic (1.74e-1)" 34.6 38.0 13.3 10.7 14.8 9.4 16.0 13.9 15.1 10.2 25.5 32.6 63.7 10.4 8.4 25.0 9.3 11.1 93.3 12.8 14.5 46.5 196.4 9.2 8.7 12.3 13.8 10.8 20.4 32.8 9.8 13.0 12.8 13.7 26.9 15.8 21.8 13.2 111.0 18.7 51.4 14.8 12.5 9.5 26.9 11.2 15.0 9.4 13.2 186.9 14.3 12.9 12.8 15.1 13.2 9.2 12.2 21.4 47.2 28.8 6.6 21.3 19.4 13.9 14.3 3.7 24.6 27.8 4.6 24.1 15.8 13.8 22.1 20.9 19.2 51.5 20.3 26.5 17.3 8.0 20.8 24.0 23.4 26.5 23.8 15.8 12.8 20.8 27.3 20.7 15.6 53.8 22.2 14.7 22.7 11.0 5.0 33.2 19.4 18.4 4.3 21.9 21.2 10.6 18.7 8.0 21.0 39.5 21.8 10.0 30.4 17.6 13.6 11.9 6.7 18.5 12.2 31.3 42.1 20.3 24.6 19.2 13.5 3.7 21.5 41.5 10.1 22.6 12.7 10.3 9.8 10.4 18.3 9.6 11.6 9.9 7.8 10.5 20.9 13.1 16.1 9.5 13.3 14.8 13.9 15.1 12.8 14.5 12.3 13.8 12.8 12.5 15.0 15.1 18.1 12.8 10.3 55.2 18.5 33.0 46.0 27.2 29.6 29.2 12.6 13.8 146.6 14.3 22.8 18.4 64.6 24.9 18.0 34.4 29.4 14.4 4.2 12.5 12.5 17.7 18.0 30.7 43.2 11.7 9.9 23.9 44.4 14.2 5.1 19.2 12.8 85.7 13.4 25.2 71.9 22.5 30.5 14.4 15.8 4.7 23.0 13.3 8.8 15.0 12.2 13.9 10.3 55.8 58.0 11.7 29.4 23.7 30.1 21.3 58.3 26.8 13.1 43.9 32.9 27.4 30.4 43.2 29.8 32.7 36.9 43.0 19.7 15.7 26.2 38.7 EZH2 "ENX-1, EZH1, KMT6, KMT6A" ENSG00000106462 "Enhancer of zeste 2 polycomb repressive complex 2 subunit" Q15910 7 148807383-148884321 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Methyltransferase, Repressor, Transferase" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 47.9;lymphoid tissue: 43.0;testis: 27.8" "Cell type enhanced" "Detected in many" "Early spermatids: 109.3;Spermatocytes: 142.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009589, HPA029131" Enhanced Supported Nucleoplasm NA NA "Cluster 27: Non-specific - Gene expression" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 12: Non-specific - Cell cycle regulation" Nucleoplasm "CAB009589: , HPA029131: AB_2672920" "unprognostic (2.42e-1)" "unprognostic (3.95e-3)" "unprognostic (1.57e-1)" "unprognostic (3.30e-3)" "unprognostic (1.33e-1)" "unprognostic (3.85e-3)" "prognostic unfavorable (2.11e-6)" "unprognostic (2.21e-2)" "prognostic unfavorable (1.96e-4)" "unprognostic (2.32e-3)" "unprognostic (1.58e-3)" "unprognostic (1.69e-3)" "prognostic unfavorable (8.18e-12)" "prognostic favorable (6.97e-4)" "unprognostic (1.83e-1)" "unprognostic (2.12e-1)" "unprognostic (6.67e-2)" 1.5 1.5 1.1 10.1 1.1 47.9 2.7 2.0 1.3 2.7 1.5 7.0 6.4 2.0 1.2 10.8 1.1 1.9 1.2 1.1 1.1 2.1 3.3 2.3 22.1 1.2 1.2 1.6 3.7 1.3 0.5 4.8 1.2 1.3 8.2 3.3 2.8 0.2 2.9 10.7 6.9 2.8 1.0 5.6 4.0 27.8 1.5 43.0 1.3 1.9 21.1 3.5 3.8 1.2 65.6 30.1 99.7 66.9 3.1 5.1 54.6 49.7 19.9 39.9 40.2 45.6 73.2 114.3 23.5 18.7 36.3 39.0 52.1 17.1 50.6 164.9 51.8 48.9 38.4 35.5 8.0 110.1 38.5 4.3 9.6 29.9 15.9 12.1 24.0 108.9 105.9 73.6 36.2 74.0 215.7 91.7 79.6 57.0 39.9 131.3 56.0 70.9 18.6 31.0 95.1 60.3 62.3 46.8 16.5 25.3 34.3 46.7 14.8 42.4 19.8 85.2 90.4 65.7 76.6 115.3 38.6 74.2 84.9 0.4 1.7 1.1 1.2 1.2 0.9 1.1 2.6 2.2 3.8 0.6 1.4 0.9 0.1 7.2 3.6 0.8 8.3 1.2 1.1 1.1 2.0 1.3 1.1 1.1 1.2 1.2 1.2 1.0 1.5 1.2 14.4 0.0 6.7 1.3 14.5 26.5 6.7 6.3 10.2 6.0 15.1 12.2 6.1 2.8 7.1 7.3 35.5 28.8 35.9 14.7 3.9 9.5 109.3 16.3 17.0 9.4 9.0 57.0 6.2 8.5 32.2 9.9 15.8 24.2 21.6 45.9 3.3 2.2 11.9 15.2 9.2 20.5 6.1 9.0 33.6 27.7 3.1 19.1 14.2 14.0 14.9 2.6 12.3 16.6 7.0 12.4 10.5 0.7 37.4 4.8 6.8 1.2 9.7 21.3 6.6 13.8 24.1 142.2 58.2 35.8 29.0 30.5 25.7 4.7 22.1 5.9 F10 ENSG00000126218 "Coagulation factor X" P00742 13 113122799-113149529 "Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Hydrolase, Protease, Serine protease" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 160.0" "Cell type enhanced" "Detected in many" "Fibroblasts: 113.6;Hepatocytes: 195.1;Leydig cells: 215.9;Peritubular cells: 236.2" "Cancer enriched" "Detected in many" 11 "liver cancer: 95.4" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ: 14.4;BJ hTERT+: 11.5;CACO-2: 12.7;fHDF/TERT166: 13.1;Hep G2: 59.6;HHSteC: 11.5;SH-SY5Y: 27.9" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Secreted to blood" NA NA 13000000000 "Cluster 85: Liver - Metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 50: Fibroblasts - ECM organization" "unprognostic (4.18e-2)" "unprognostic (1.07e-1)" "unprognostic (7.62e-2)" "unprognostic (9.88e-2)" "unprognostic (9.44e-2)" "unprognostic (1.15e-2)" "unprognostic (4.90e-2)" "unprognostic (1.02e-2)" "unprognostic (2.54e-1)" "unprognostic (1.24e-1)" "prognostic favorable (1.82e-5)" "unprognostic (6.39e-2)" "prognostic unfavorable (5.14e-5)" "unprognostic (6.60e-2)" "unprognostic (1.21e-1)" "unprognostic (3.87e-2)" "unprognostic (2.23e-3)" 21.3 8.5 1.1 1.5 1.2 0.0 11.7 2.5 2.0 53.8 1.4 5.6 10.9 13.2 16.4 8.9 23.9 10.9 40.7 1.1 1.8 4.1 160.0 14.4 3.2 2.6 1.5 27.9 7.1 0.2 4.5 4.4 2.5 12.8 2.0 0.9 5.1 7.1 6.8 20.7 11.9 2.7 1.3 3.2 8.6 10.1 1.4 1.4 8.3 6.6 1.3 11.9 25.8 1.1 0.1 0.0 2.5 0.4 8.0 8.1 0.1 14.4 11.5 0.8 0.3 12.7 0.1 0.1 0.5 13.1 1.4 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.2 59.6 11.5 0.0 0.3 8.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.2 1.5 0.1 0.0 0.3 0.0 1.3 0.2 0.3 0.1 0.0 0.0 0.2 1.0 27.9 0.1 0.5 0.1 0.6 0.6 0.1 0.0 0.0 0.8 0.2 0.0 0.2 0.0 0.1 0.1 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 1.2 2.5 2.0 1.1 1.8 2.6 1.5 2.5 1.3 1.4 1.1 7.0 0.0 0.0 1.3 0.6 15.7 0.1 0.0 0.0 1.1 0.4 0.3 9.1 4.3 0.0 1.8 0.0 0.6 0.0 0.1 0.0 0.1 2.9 1.9 45.9 3.8 17.9 2.7 1.3 0.0 0.4 113.6 6.1 1.0 1.3 2.2 7.9 195.1 1.4 6.7 1.4 5.0 0.0 4.8 25.0 9.6 215.9 1.3 19.6 5.6 0.6 4.5 0.0 0.5 0.1 0.3 6.5 236.2 0.0 0.3 28.3 6.4 0.0 1.2 52.6 14.5 40.9 2.3 1.2 0.5 15.3 1.1 1.9 2.4 2.2 0.4 F2 ENSG00000180210 "Coagulation factor II, thrombin" P00734 11 46719196-46739506 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Acute phase, Blood coagulation, Hemostasis" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease variant, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 1518 "liver: 1217.3" "Cell type enriched" "Detected in some" 26 "Hepatocytes: 991.0" "Cancer enriched" "Detected in some" 110 "liver cancer: 508.2" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 22 "Hep G2: 281.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB016780, HPA051476, HPA054698" Enhanced "Secreted to blood" NA NA 108000000000 41000000000 "Cluster 62: Liver - Hemostasis" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 15: Hepatocytes - Hemostasis" "CAB016780: , HPA051476: AB_2681498, HPA054698: AB_2682578" "unprognostic (1.98e-1)" "unprognostic (2.52e-1)" "unprognostic (2.64e-2)" "unprognostic (1.85e-1)" "unprognostic (2.29e-1)" "unprognostic (2.81e-1)" "unprognostic (2.23e-2)" "unprognostic (3.94e-2)" "unprognostic (5.79e-2)" "unprognostic (8.29e-2)" "unprognostic (4.46e-2)" "prognostic unfavorable (6.75e-12)" "unprognostic (5.65e-3)" "unprognostic (5.80e-2)" "unprognostic (1.54e-3)" 0.1 0.0 0.2 0.0 0.2 0.0 0.0 0.8 0.3 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.2 0.2 1217.3 0.0 0.0 0.2 0.2 0.1 0.0 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.3 0.5 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 12.9 0.0 0.2 2.2 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.5 0.2 281.0 0.0 1.5 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.0 1.0 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.5 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.8 0.3 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.3 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 20.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.2 1.2 0.0 37.5 0.2 0.0 0.0 0.0 0.0 0.9 0.0 0.3 21.8 991.0 0.0 0.0 0.2 0.2 0.0 26.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.3 2.0 0.0 0.0 0.1 F2R "CF2R, PAR-1, PAR1, TR" ENSG00000181104 "Coagulation factor II thrombin receptor" P25116 5 76716126-76735770 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "Blood coagulation, Hemostasis" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 69.5" "Cell type enriched" "Detected in many" 5 "Hepatic stellate cells: 307.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "gdT-cell: 25.4" "Group enriched" "Detected in many" 14 "NK-cells: 7.0;T-cells: 25.4" "Cell line enhanced" "Detected in many" "hTERT-RPE1: 196.9;HUVEC TERT2: 366.2;WM-115: 345.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008973, CAB012962" Approved NA NA "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 64: Macrophages - Immune response" "Cluster 17: WM-115 - Nervous system development" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "CAB008973: , CAB012962: AB_2533198" "unprognostic (3.03e-1)" "unprognostic (7.76e-2)" "unprognostic (5.55e-2)" "unprognostic (7.76e-2)" "unprognostic (7.14e-2)" "unprognostic (3.46e-1)" "unprognostic (2.51e-1)" "unprognostic (3.75e-2)" "unprognostic (5.37e-2)" "unprognostic (1.36e-1)" "unprognostic (1.36e-1)" "unprognostic (2.22e-1)" "prognostic unfavorable (2.21e-7)" "unprognostic (2.72e-3)" "unprognostic (1.30e-1)" "unprognostic (1.12e-1)" "unprognostic (6.74e-3)" 14.5 13.5 1.2 12.1 1.4 4.0 18.3 1.6 1.5 15.4 1.6 10.0 14.2 23.2 4.2 11.1 3.9 39.5 30.4 1.2 1.5 19.1 23.9 22.8 16.2 2.5 2.6 2.9 9.9 7.3 4.3 10.5 2.1 7.2 11.6 0.7 30.5 12.0 3.6 45.7 18.8 18.8 1.8 69.5 10.3 8.8 1.9 4.9 15.2 11.9 8.6 15.4 4.5 1.5 5.7 17.5 53.3 8.8 98.4 170.5 2.6 30.3 102.5 19.5 69.8 3.9 47.0 0.1 50.1 13.0 88.1 13.2 23.1 18.1 36.6 4.4 19.3 120.2 3.8 14.7 147.7 0.6 4.9 96.9 60.2 37.2 10.5 196.9 366.2 21.4 22.8 22.1 40.1 2.4 9.6 0.4 17.0 0.3 93.5 17.1 31.9 4.3 91.2 0.8 6.3 28.7 8.9 0.2 45.2 48.0 0.7 1.3 169.0 121.8 26.7 1.3 56.7 59.0 18.5 0.2 32.4 2.3 345.5 1.1 0.2 0.4 25.4 0.5 6.5 0.6 5.7 17.7 0.0 0.2 0.9 12.7 1.1 7.0 0.1 0.3 0.6 11.2 1.2 1.4 1.6 1.5 1.2 1.5 2.5 2.6 2.1 1.8 1.9 1.5 25.8 0.0 9.2 1.6 4.4 17.2 0.7 9.3 1.2 3.5 3.4 2.4 2.6 7.2 4.5 7.3 0.0 0.2 56.2 0.3 0.0 2.0 10.7 2.8 47.1 51.8 6.6 11.6 1.0 2.2 0.4 39.5 8.2 5.4 6.3 13.0 307.0 4.3 2.1 0.0 3.3 3.9 16.2 16.6 10.7 6.0 0.9 5.4 12.4 5.6 1.1 0.1 54.6 0.5 0.1 10.8 0.2 10.5 35.8 1.4 0.5 3.4 4.2 1.4 0.0 8.1 24.9 12.7 5.4 1.5 40.1 0.3 40.1 9.5 1.3 0.4 FADS1 "D5D, FADS6, FADSD5, LLCDL1, TU12" ENSG00000149485 "Fatty acid desaturase 1" O60427 11 61799627-61829318 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Electron transport, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transport" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Rod photoreceptor cells: 91.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC TERT1: 521.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042705 Approved NA NA "Cluster 25: Monocytes - Inflammatory response" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 65: Plasmacytoid DCs - Unknown function" "HPA042705: AB_10795709" "unprognostic (8.28e-2)" "unprognostic (3.54e-1)" "unprognostic (1.29e-1)" "unprognostic (1.99e-1)" "unprognostic (8.17e-3)" "unprognostic (1.40e-1)" "unprognostic (1.99e-2)" "unprognostic (3.23e-3)" "unprognostic (7.88e-2)" "unprognostic (1.94e-2)" "unprognostic (4.10e-2)" "unprognostic (2.00e-1)" "prognostic unfavorable (1.95e-9)" "unprognostic (2.29e-2)" "unprognostic (3.59e-2)" "prognostic unfavorable (2.79e-4)" "prognostic unfavorable (1.33e-4)" 26.2 67.7 43.1 19.8 39.2 9.7 13.6 38.4 40.7 19.6 70.7 9.5 5.5 21.3 6.6 5.2 17.4 14.5 22.6 39.3 58.5 9.7 52.8 20.3 9.8 57.9 62.1 27.5 10.0 27.2 21.3 21.1 52.2 19.6 4.9 35.1 6.4 15.8 17.5 15.5 6.7 20.5 46.4 8.0 9.4 11.9 68.7 8.1 6.0 7.8 9.2 12.7 10.2 56.0 66.3 170.1 159.1 41.1 313.2 521.2 46.4 42.0 204.5 69.9 118.9 53.3 143.2 2.3 43.4 60.5 177.2 84.7 130.8 114.1 51.7 12.2 18.4 107.9 191.2 98.9 169.1 23.4 10.4 238.1 38.3 154.7 74.7 73.8 64.1 104.7 59.9 118.6 70.1 18.6 78.6 23.6 94.2 5.5 63.0 85.4 162.5 231.2 81.5 29.0 80.7 89.6 106.7 1.7 90.0 58.4 38.6 98.6 62.1 71.8 70.8 74.2 50.6 112.9 111.3 55.4 42.6 108.9 61.4 7.5 33.2 6.2 12.1 40.4 2.6 2.5 4.0 4.9 28.0 8.7 2.3 5.4 2.6 6.9 17.4 23.6 2.9 15.7 43.1 39.2 38.4 40.7 39.3 58.5 57.9 62.1 52.2 46.4 68.7 56.0 10.3 6.4 77.9 28.7 3.2 2.7 2.5 48.5 1.2 78.9 2.6 3.7 30.4 8.6 25.3 12.9 27.1 9.5 12.4 0.9 0.0 15.2 8.7 4.9 30.7 16.6 9.7 46.3 9.4 33.4 50.0 34.9 6.1 7.8 37.9 65.3 9.3 74.5 37.2 69.0 14.7 0.6 16.2 21.7 21.0 16.4 29.8 27.6 32.0 12.2 32.0 70.5 6.2 13.6 27.4 7.6 0.0 21.4 2.1 6.4 0.1 1.1 8.0 91.9 0.0 40.3 31.9 6.5 17.5 2.3 1.4 9.3 5.5 75.2 1.4 1.6 FADS2 "D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13" ENSG00000134824 "Fatty acid desaturase 2" O95864 11 61792980-61867354 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Electron transport, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transport" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adrenal gland: 364.1" "Cell type enhanced" "Detected in many" "Astrocytes: 69.9;Endometrial stromal cells: 57.7;Hepatocytes: 55.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "ASC TERT1: 1141.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006741 Approved NA NA "Cluster 40: NK-cells - Unknown function" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 33: Fibroblasts - ECM organization" "HPA006741: AB_1078796" "unprognostic (2.37e-2)" "unprognostic (1.02e-1)" "unprognostic (8.34e-2)" "unprognostic (4.33e-3)" "unprognostic (4.63e-2)" "unprognostic (2.42e-2)" "unprognostic (4.51e-2)" "unprognostic (4.35e-3)" "unprognostic (2.01e-1)" "unprognostic (4.21e-2)" "unprognostic (8.95e-3)" "unprognostic (7.80e-2)" "prognostic unfavorable (1.00e-7)" "unprognostic (6.19e-2)" "unprognostic (1.34e-1)" "unprognostic (1.41e-2)" "prognostic unfavorable (3.42e-4)" 23.7 364.1 140.2 34.7 126.7 28.0 59.6 128.5 135.0 68.0 157.0 24.2 31.9 86.3 27.7 10.6 34.6 20.2 27.7 131.8 164.8 20.3 126.7 33.4 16.5 175.1 186.2 29.1 9.8 80.0 50.8 40.6 155.1 97.7 13.2 41.5 24.3 188.7 12.3 131.6 15.9 125.3 152.0 11.5 14.1 27.8 222.9 34.1 10.4 8.8 31.2 24.6 27.9 134.2 14.6 492.6 655.8 345.0 551.3 1141.8 167.2 86.3 658.3 109.0 288.2 31.4 149.6 3.8 11.4 172.3 167.8 15.7 436.4 709.5 52.7 6.9 11.8 297.9 106.5 72.0 421.9 18.9 15.9 430.9 25.8 383.4 39.1 170.3 324.4 254.4 17.9 212.1 52.0 13.5 166.4 104.7 291.5 0.7 150.1 206.1 13.9 663.1 392.1 4.4 197.4 260.8 49.9 1.4 23.5 164.0 21.5 197.7 139.2 14.0 120.5 9.8 13.1 115.7 110.3 39.7 13.0 96.3 131.2 4.4 6.0 6.9 8.5 8.7 2.0 1.4 3.1 4.6 10.1 3.7 1.8 3.8 2.8 6.6 7.4 13.0 2.9 4.9 140.2 126.7 128.5 135.0 131.8 164.8 175.1 186.2 155.1 152.0 222.9 134.2 3.2 9.6 18.8 69.9 2.0 1.7 1.3 26.9 0.0 9.1 4.7 3.0 4.2 1.5 15.1 3.7 4.2 1.7 5.2 0.5 0.0 6.9 2.2 4.7 57.7 12.2 5.4 26.7 7.4 17.8 22.0 21.0 5.1 9.5 5.1 28.3 2.5 55.8 20.5 5.0 7.7 0.2 22.4 7.2 3.1 5.3 25.7 7.0 8.8 15.0 20.7 32.1 8.2 38.7 11.9 5.1 0.0 23.7 1.4 16.9 0.1 0.7 5.4 13.2 0.0 23.8 29.5 1.3 0.5 1.2 0.6 3.1 2.5 28.3 2.0 0.9 FASN "FAS, SDR27X1" ENSG00000169710 "Fatty acid synthase" P49327 17 82078338-82098294 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" "Hydrolase, Lyase, Multifunctional enzyme, Oxidoreductase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 372.8;breast: 271.6" "Cell type enhanced" "Detected in many" "Alveolar cells type 2: 126.0;Breast glandular cells: 442.9;Breast myoepithelial cells: 165.4;Hepatocytes: 244.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in all" "SK-BR-3: 1109.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005192, HPA006461, CAB015417, HPA056108" Enhanced Enhanced "Plasma membrane,Cytosol" No No 3400000 "Cluster 57: Non-specific - Angiogenesis" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 30: Mammary glandular cells - Lactation" "Plasma membrane, Cytosol" "CAB005192: AB_2101095, CAB015417: AB_2231427, HPA006461: AB_1848437, HPA056108: AB_2683039" "unprognostic (3.35e-2)" "prognostic unfavorable (1.42e-5)" "unprognostic (9.69e-3)" "unprognostic (4.09e-2)" "unprognostic (3.46e-3)" "unprognostic (1.55e-2)" "unprognostic (3.09e-2)" "unprognostic (4.74e-3)" "unprognostic (3.15e-1)" "unprognostic (3.15e-1)" "unprognostic (2.87e-3)" "unprognostic (1.05e-1)" "prognostic unfavorable (7.16e-5)" "unprognostic (4.50e-2)" "unprognostic (9.62e-2)" "unprognostic (1.35e-2)" "unprognostic (7.03e-3)" 372.8 30.9 25.0 14.9 44.2 18.7 271.6 67.3 49.9 31.7 0.0 25.5 11.5 18.0 6.2 63.6 15.2 6.6 21.9 39.9 15.0 11.8 191.4 54.1 7.2 84.4 75.7 16.3 18.6 8.5 72.4 12.1 101.7 69.0 3.0 4.3 38.3 14.3 27.9 89.4 28.8 5.3 12.5 8.8 63.6 11.9 33.7 9.6 21.2 2.3 3.0 27.0 31.8 60.8 179.1 182.0 81.7 56.7 130.1 87.2 176.9 34.3 43.3 35.5 64.6 190.6 116.7 58.8 29.2 26.3 99.5 144.0 79.2 157.8 6.5 30.0 358.0 123.9 140.0 257.2 36.8 67.5 19.2 84.2 40.4 90.8 21.0 12.1 40.1 54.8 193.2 50.7 12.6 304.1 78.9 105.5 161.1 28.1 107.1 64.1 47.8 116.5 40.3 220.7 205.0 117.0 50.6 1109.2 93.6 29.5 199.4 123.4 71.1 52.3 107.0 45.2 88.4 68.5 17.1 60.6 31.2 71.1 79.5 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.2 0.2 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 25.0 44.2 67.3 49.9 39.9 15.0 84.4 75.7 101.7 12.5 33.7 60.8 9.6 25.6 126.0 28.4 7.4 7.8 12.7 33.2 8.0 28.7 442.9 165.4 5.9 21.5 28.4 11.0 6.2 32.0 12.8 35.7 3.9 19.2 1.5 19.6 19.8 10.8 18.1 20.6 11.9 29.2 77.7 13.4 33.6 17.1 12.7 29.9 10.8 244.1 13.9 30.3 12.5 22.3 22.4 9.8 6.2 3.4 16.4 7.0 17.8 4.7 6.2 14.1 8.2 11.6 17.6 19.1 23.6 11.3 9.7 60.4 6.5 5.9 23.7 13.1 0.0 9.0 14.9 1.8 11.7 34.1 13.8 29.6 10.6 27.9 27.4 19.6 FCER1A FCE1A ENSG00000179639 "Fc fragment of IgE receptor Ia" P12319 1 159289714-159308224 "FDA approved drug targets, Predicted membrane proteins" "IgE-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skin 1: 33.6" "Cell type enriched" "Detected in many" 7 "Langerhans cells: 1962.9" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Immune cell enriched" "Detected in many" 8 "basophil: 21557.7" "Lineage enriched" "Detected in all" 8 "granulocytes: 21557.7" "Cell line enriched" "Detected in some" 99 "HEL: 447.9" "Not detected" "Not detected" "Not detected" "Not detected" "CAB022102, HPA036051, CAB055526" Approved NA NA "Cluster 38: Basophils - Unknown function" "Cluster 31: Skin - Epidermis development" "Cluster 36: HEL - Hemostasis" "Cluster 41: Macrophages - Immune response" "CAB022102: , CAB055526: , HPA036051: AB_2674919" "unprognostic (1.78e-2)" "unprognostic (2.26e-2)" "unprognostic (7.32e-2)" "unprognostic (7.51e-2)" "unprognostic (1.32e-2)" "unprognostic (1.44e-3)" "unprognostic (7.19e-2)" "unprognostic (1.97e-3)" "unprognostic (2.44e-1)" "unprognostic (7.20e-2)" "unprognostic (8.54e-2)" "unprognostic (2.74e-1)" "prognostic favorable (1.20e-4)" "unprognostic (1.68e-2)" "unprognostic (1.18e-1)" "unprognostic (2.70e-1)" "unprognostic (3.39e-2)" 3.9 1.7 0.4 5.7 0.4 14.2 17.3 0.5 0.8 10.6 0.5 7.0 7.1 7.1 5.4 23.0 2.9 14.9 3.2 0.4 0.6 4.7 4.4 14.5 2.5 0.6 0.5 0.7 1.2 2.6 0.8 0.2 0.7 5.9 10.7 0.1 4.0 9.1 2.8 33.6 8.8 7.4 0.4 8.0 3.5 2.3 0.6 4.8 1.2 3.9 10.9 11.9 2.7 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 447.9 0.0 0.0 0.0 0.5 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21557.7 14.4 36.4 0.4 4.1 4.4 2.8 4.4 1.5 2645.6 3.1 2.3 3.4 17.2 14.6 11.0 361.0 2.8 132.1 0.4 0.4 0.5 0.8 0.4 0.6 0.6 0.5 0.7 0.4 0.6 0.5 1.6 6.4 33.1 0.3 5.5 37.7 0.1 0.0 0.6 0.0 0.6 1.8 0.6 0.0 1.8 0.0 0.0 0.0 76.8 0.0 0.0 0.0 0.3 0.1 0.0 3.4 0.0 37.8 0.0 0.0 0.1 4.2 0.0 0.1 270.7 0.0 0.0 0.0 6.4 0.0 0.1 0.0 0.0 4.0 1962.9 1.1 0.0 169.1 46.2 0.0 46.8 0.0 3.1 0.0 0.0 0.0 0.1 0.0 1.3 0.1 0.0 0.0 1.5 0.0 13.1 0.1 2.6 0.1 0.3 0.2 34.1 0.0 6.8 0.0 0.0 0.0 FCER1G ENSG00000158869 "Fc fragment of IgE receptor Ig" P30273 1 161215234-161220699 "FDA approved drug targets, Predicted membrane proteins" "Immunity, Innate immunity" "IgE-binding protein, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 441.6;lymphoid tissue: 470.1" "Group enriched" "Detected in many" 9 "dendritic cells: 726.6;granulocytes: 705.6;Hofbauer cells: 2318.6;Kupffer cells: 1950.8;Langerhans cells: 1526.3;Macrophages: 1971.3;monocytes: 808.9;NK-cells: 1037.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 11 "basophil: 1987.3;classical monocyte: 3240.2;intermediate monocyte: 5333.6;myeloid DC: 2386.3;neutrophil: 1831.0;NK-cell: 1750.9;non-classical monocyte: 6984.5;plasmacytoid DC: 3315.6" "Low lineage specificity" "Detected in all" "Group enriched" "Detected in many" 4 "HEL: 77.8;HMC-1: 301.7;THP-1: 276.1;U-266/84: 90.1;U-937: 87.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022108, HPA026872" Supported NA NA 270000 "Cluster 51: Monocytes - Innate immune response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 3: HMC-1 - Innate immune response" "Cluster 4: Macrophages - Innate immune response" "CAB022108: , HPA026872: AB_1848473" "unprognostic (3.71e-2)" "unprognostic (2.52e-2)" "unprognostic (2.40e-2)" "unprognostic (8.73e-3)" "unprognostic (1.46e-1)" "unprognostic (4.28e-2)" "unprognostic (3.10e-3)" "unprognostic (1.84e-1)" "unprognostic (3.25e-1)" "unprognostic (9.63e-2)" "unprognostic (2.28e-2)" "unprognostic (5.67e-2)" "prognostic unfavorable (1.83e-6)" "unprognostic (1.99e-1)" "unprognostic (6.28e-2)" "unprognostic (2.04e-2)" "unprognostic (7.87e-2)" 251.7 86.5 34.0 275.6 33.8 441.6 62.9 35.5 66.0 52.5 47.5 82.7 44.9 30.7 38.7 30.6 72.0 101.5 53.1 33.7 42.0 40.3 177.3 286.6 160.9 53.4 48.7 19.9 22.3 26.8 26.9 211.0 50.1 31.0 113.2 8.3 42.9 38.8 11.9 21.0 60.6 160.3 41.5 470.1 39.4 14.5 49.9 62.7 25.5 34.6 82.5 254.6 21.7 65.4 0.2 0.0 0.7 1.3 1.8 0.7 0.4 0.5 0.2 0.5 0.8 2.2 0.1 0.5 0.7 0.0 0.3 0.2 0.5 0.0 0.4 0.3 1.5 77.8 0.6 14.0 0.3 16.1 301.7 6.0 3.3 2.3 0.2 0.7 0.4 1.8 0.1 7.3 2.4 0.5 1.4 37.9 1.6 0.0 0.0 0.1 6.7 0.2 0.5 0.4 0.3 1.0 0.6 0.1 2.7 1.4 0.2 276.1 0.4 1.8 0.4 0.9 1.1 3.0 90.1 0.9 1.7 87.1 0.5 1987.3 3240.2 307.3 13.6 5333.6 15.9 28.2 10.6 10.6 2386.3 9.0 17.3 45.0 1831.0 1750.9 6984.5 3315.6 21.8 4265.5 34.0 33.8 35.5 66.0 33.7 42.0 53.4 48.7 50.1 41.5 49.9 65.4 12.8 86.6 147.7 0.7 35.9 39.6 1.5 0.2 1.8 0.1 5.2 22.1 6.8 15.7 27.3 18.4 0.0 14.5 726.6 1.0 0.0 1.9 3.0 1.0 0.9 38.6 1.8 79.3 0.1 1.0 18.8 18.3 1.1 1.0 705.6 0.5 41.0 13.6 2318.6 0.0 0.2 0.5 0.0 1950.8 1526.3 9.4 5.3 1971.3 80.0 12.2 808.9 0.2 1037.1 0.0 0.1 1.0 1.4 1.2 10.1 1.3 0.4 5.4 15.3 2.3 72.3 3.8 11.2 1.0 2.5 1.4 35.9 23.7 133.3 0.4 0.6 1.8 FDPS ENSG00000160752 "Farnesyl diphosphate synthase" P14324 1 155308748-155320666 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Cholesterol biosynthesis, Cholesterol metabolism, Host-virus interaction, Isoprene biosynthesis, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism" Transferase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 355.7" "Cell type enhanced" "Detected in all" "Basal respiratory cells: 927.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HBEC3-KT: 1187.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028200 Approved Approved Nucleoplasm,Cytosol NA NA 1500000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 37: Intestine - Unknown function" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 26: Respiratory epithelial cells - Mucosal defense" Cytosol Nucleoplasm "HPA028200: AB_10612109" "unprognostic (1.23e-1)" "unprognostic (8.46e-3)" "unprognostic (2.47e-2)" "unprognostic (6.57e-2)" "unprognostic (4.58e-2)" "unprognostic (2.84e-2)" "prognostic unfavorable (7.35e-4)" "unprognostic (4.21e-2)" "unprognostic (6.78e-3)" "unprognostic (1.64e-3)" "unprognostic (7.19e-2)" "unprognostic (2.25e-2)" "unprognostic (1.11e-2)" "unprognostic (8.25e-2)" "unprognostic (2.07e-1)" "unprognostic (5.65e-2)" "unprognostic (8.44e-2)" 73.5 188.2 48.2 66.5 50.4 69.5 68.8 60.1 58.8 63.4 51.1 88.7 167.2 57.5 73.0 142.5 57.4 39.8 72.2 49.9 64.6 78.0 355.7 86.1 76.1 71.1 62.5 45.0 75.7 67.9 40.4 72.5 77.5 56.1 102.9 45.9 82.6 42.7 60.9 107.1 81.1 66.0 53.6 59.3 81.5 42.0 55.0 72.6 46.8 66.7 102.3 47.0 76.8 55.0 293.9 156.2 561.5 204.4 128.7 467.7 199.6 136.8 268.1 213.6 344.2 255.4 677.7 222.3 323.6 120.6 506.9 319.1 338.9 1187.5 198.9 122.4 242.5 129.4 260.1 311.5 210.8 212.1 142.0 335.5 184.6 339.6 168.8 96.4 377.6 322.3 235.1 579.9 225.3 315.1 273.6 205.0 338.9 216.4 225.5 231.6 243.2 620.0 567.7 193.0 217.4 185.6 140.7 253.0 243.0 317.3 182.6 567.6 277.1 118.4 144.3 74.3 254.9 244.3 202.3 401.1 115.3 221.7 191.1 90.6 85.5 124.1 89.2 92.9 79.7 102.8 77.8 91.1 95.6 95.1 69.9 87.1 38.9 115.2 70.0 76.2 113.7 134.7 48.2 50.4 60.1 58.8 49.9 64.6 71.1 62.5 77.5 53.6 55.0 55.0 154.2 73.7 181.6 38.5 68.4 36.8 83.3 927.7 42.1 69.4 84.6 56.9 1.8 97.2 431.5 53.3 62.6 207.8 74.9 343.0 137.0 180.9 216.6 56.7 38.2 161.9 71.4 133.4 30.8 329.9 198.7 59.8 52.0 77.8 62.8 116.6 168.1 361.9 112.0 55.5 28.1 135.7 299.1 54.8 44.4 67.9 60.9 52.8 96.0 15.0 144.7 81.1 87.6 22.6 39.7 256.7 324.3 70.3 91.3 206.1 194.1 145.0 129.6 90.8 72.3 47.0 177.5 42.0 14.2 49.7 59.8 143.5 68.3 230.6 165.4 148.2 FFAR1 "FFA1R, GPR40" ENSG00000126266 "Free fatty acid receptor 1" O14842 19 35351552-35353862 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "bone marrow: 2.8;brain: 4.8;ovary: 2.5;pancreas: 4.4" "Cell type enhanced" "Detected in some" "Enteroendocrine cells: 1.8;granulocytes: 1.3;Granulosa cells: 1.4" "Cancer enriched" "Detected in single" 13 "pancreatic cancer: 2.2" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "U-698: 1.6" "Not detected" "Not detected" HPA048933 Supported "Plasma membrane" NA NA "Cluster 76: Brain & Bone marrow - Chromatin organization" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "Plasma membrane" "HPA048933: " "unprognostic (9.49e-2)" "unprognostic (2.08e-1)" "unprognostic (1.59e-1)" "unprognostic (1.50e-1)" "unprognostic (1.03e-1)" "unprognostic (4.51e-2)" "unprognostic (1.03e-2)" "unprognostic (4.46e-2)" "unprognostic (6.19e-2)" "unprognostic (9.56e-3)" 0.0 0.0 1.5 0.1 2.1 2.8 0.0 1.4 1.9 0.0 0.8 0.0 0.3 0.0 0.0 0.0 0.6 0.0 0.0 1.3 1.5 0.0 0.0 0.1 0.4 2.1 1.6 2.5 4.4 0.0 0.1 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.3 0.3 0.6 0.2 1.9 0.0 0.0 0.0 0.1 0.0 0.0 4.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.5 2.1 1.4 1.9 1.3 1.5 2.1 1.6 2.1 1.3 1.9 4.8 0.1 0.0 0.5 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.1 0.4 0.0 0.0 1.3 1.4 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 FGF1 "AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1" ENSG00000113578 "Fibroblast growth factor 1" P05230 5 142592178-142698070 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 295.2;choroid plexus: 125.8" "Cell type enhanced" "Detected in many" "Astrocytes: 75.1;Cardiomyocytes: 62.4;Muller glia cells: 69.4;Oligodendrocytes: 119.8" "Cancer enriched" "Detected in many" 12 "glioma: 33.9" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 44.6;BJ hTERT+: 33.0;BJ hTERT+ SV40 Large T+: 35.9;BJ hTERT+ SV40 Large T+ RasG12V: 45.0;HBF TERT88: 64.3;hTEC/SVTERT24-B: 45.4;LHCN-M2: 30.6;U-2 OS: 33.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003265, CAB017519" Enhanced Supported Nucleoplasm "Secreted in other tissues" NA NA "Cluster 32: T-cells - Unknown function" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 5: Muller glia cells - Visual perception" Nucleoplasm "CAB017519: AB_629473, HPA003265: AB_1848522" "unprognostic (1.25e-2)" "unprognostic (2.43e-1)" "unprognostic (1.06e-1)" "unprognostic (3.41e-3)" "unprognostic (2.55e-2)" "unprognostic (3.52e-1)" "unprognostic (2.77e-1)" "unprognostic (2.39e-1)" "unprognostic (3.63e-1)" "unprognostic (1.57e-2)" "unprognostic (1.89e-1)" "unprognostic (1.54e-1)" "prognostic favorable (2.59e-5)" "unprognostic (3.72e-4)" "unprognostic (2.49e-1)" "prognostic favorable (3.45e-5)" "unprognostic (3.01e-4)" 17.9 3.3 206.3 1.6 259.3 1.1 12.5 213.9 295.2 1.3 125.8 2.4 1.0 3.1 7.9 2.0 1.7 2.5 50.2 183.5 245.5 66.5 1.7 2.8 1.2 236.2 237.7 0.9 0.8 4.3 6.5 2.1 259.9 1.8 1.3 18.8 7.3 2.3 2.2 1.7 1.2 2.5 225.4 6.9 0.8 2.0 244.3 1.5 5.6 7.8 2.0 1.2 1.0 272.8 5.6 0.3 0.3 1.5 1.1 3.3 1.8 44.6 33.0 35.9 45.0 0.2 0.2 1.3 3.1 15.4 2.1 0.7 0.0 3.5 64.3 0.2 0.0 0.0 0.8 0.4 0.6 0.0 0.4 1.6 1.1 45.4 2.7 9.7 0.0 0.2 0.0 1.6 30.6 0.7 0.1 0.9 1.4 0.1 1.4 0.2 1.5 0.6 1.5 0.2 1.1 2.3 0.1 0.9 0.6 8.0 0.0 0.2 1.1 5.8 33.0 0.8 21.3 0.8 0.4 0.3 8.2 0.3 1.6 0.0 0.0 0.4 0.4 0.0 0.3 0.0 0.1 0.1 0.0 0.2 0.1 0.3 0.3 0.0 0.1 0.2 0.1 0.0 206.3 259.3 213.9 295.2 183.5 245.5 236.2 237.7 259.9 225.4 244.3 272.8 1.4 0.0 0.0 75.1 0.1 0.4 5.0 5.7 7.4 3.5 1.2 25.4 62.4 0.0 2.1 20.2 16.7 1.1 0.1 0.0 0.0 1.1 0.4 0.0 0.7 4.8 0.0 0.0 13.0 0.0 0.5 4.7 0.0 0.2 0.0 0.0 1.1 0.0 0.1 0.0 14.6 0.0 12.2 0.0 0.0 1.4 0.0 0.2 3.6 29.0 0.0 69.4 0.0 15.1 119.8 0.6 0.0 0.4 0.0 5.3 0.0 0.3 0.1 11.6 6.6 0.5 23.4 0.1 0.1 0.6 0.0 0.8 0.4 0.0 0.0 0.7 FGF2 FGFB ENSG00000138685 "Fibroblast growth factor 2" P09038 4 122826708-122898236 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins, Transporters" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Adipocytes: 33.7;Astrocytes: 111.0;Endometrial stromal cells: 40.6;Fibroblasts: 77.1;Oligodendrocyte precursor cells: 42.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 243.8;BJ hTERT+: 148.4;fHDF/TERT166: 278.2;hTERT-HME1: 147.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000125, HPA065502" Enhanced Supported "Nucleoplasm,Nuclear bodies" "Secreted in other tissues" NA NA 92500 "Cluster 57: Non-specific - Angiogenesis" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 36: Stromal cells - Cell proliferation" "Nucleoplasm, Nuclear bodies" "CAB000125: , HPA065502: " "unprognostic (1.53e-2)" "unprognostic (3.12e-1)" "unprognostic (1.08e-1)" "unprognostic (7.42e-2)" "unprognostic (2.10e-1)" "unprognostic (3.33e-1)" "unprognostic (6.98e-2)" "unprognostic (1.25e-1)" "unprognostic (2.82e-1)" "unprognostic (1.79e-1)" "prognostic unfavorable (9.85e-4)" "unprognostic (3.37e-1)" "unprognostic (4.61e-3)" "unprognostic (2.36e-1)" "unprognostic (1.81e-1)" "unprognostic (4.45e-2)" "unprognostic (3.45e-3)" 24.3 2.6 14.8 5.3 16.1 0.1 9.5 12.2 14.7 8.7 14.2 14.1 1.7 14.2 4.5 4.7 8.0 7.1 5.0 12.2 18.8 4.0 2.0 8.3 1.8 18.6 20.5 12.6 1.5 4.7 3.2 6.4 15.6 7.6 4.0 3.4 3.5 8.7 1.4 1.9 3.7 12.6 16.8 1.1 6.2 1.9 18.3 1.6 2.4 4.8 1.8 14.8 6.1 13.3 4.7 14.1 7.8 30.5 18.8 31.1 0.0 243.8 148.4 104.3 60.2 0.2 0.4 0.0 20.5 278.2 81.8 0.7 8.1 0.5 104.3 12.3 3.3 0.0 28.7 0.2 55.3 1.4 0.1 16.8 1.7 103.6 147.6 52.0 11.8 0.0 6.9 8.4 27.4 0.1 0.1 0.2 21.6 0.1 5.4 0.0 3.9 0.1 33.0 0.0 4.4 4.0 48.4 0.1 2.0 44.7 0.1 0.5 10.6 85.7 12.2 32.0 20.0 8.6 10.3 0.0 24.7 0.1 9.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.8 16.1 12.2 14.7 12.2 18.8 18.6 20.5 15.6 16.8 18.3 13.3 33.7 6.4 0.0 111.0 0.3 1.7 1.6 0.8 2.8 4.6 4.5 8.9 4.7 0.0 1.3 7.3 0.0 2.7 0.4 0.0 3.9 8.2 10.9 1.5 40.6 11.5 1.8 0.4 1.8 1.0 0.1 77.1 0.0 1.6 0.0 5.7 17.2 1.3 0.5 0.0 6.6 0.0 0.0 0.0 2.4 3.8 9.9 1.7 5.4 15.9 0.6 9.3 0.0 42.3 5.8 11.0 0.0 8.2 1.6 16.0 0.0 0.6 0.0 2.0 0.0 15.2 14.2 4.7 1.1 0.3 1.3 4.8 0.5 0.1 0.0 2.0 FGFR1 "BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM" ENSG00000077782 "Fibroblast growth factor receptor 1" P11362 8 38400215-38468834 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Transcription, Transcription regulation" "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease variant, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Fibroblasts: 176.7;Leydig cells: 192.0;Oligodendrocyte precursor cells: 166.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "AN3-CA: 508.7;BJ hTERT+: 278.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033614, HPA056402" Approved NA NA 78000000 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 89: Fibroblasts - ECM organization" "Cluster 23: AN3-CA - Transcription regulation" "Cluster 50: Fibroblasts - ECM organization" "CAB033614: AB_783377, HPA056402: AB_2683118" "unprognostic (9.53e-2)" "unprognostic (7.33e-2)" "unprognostic (2.44e-1)" "unprognostic (1.35e-2)" "unprognostic (4.23e-3)" "unprognostic (7.02e-2)" "unprognostic (6.59e-2)" "unprognostic (2.77e-1)" "unprognostic (1.81e-1)" "unprognostic (3.99e-2)" "unprognostic (7.97e-3)" "unprognostic (4.59e-2)" "unprognostic (7.69e-2)" "unprognostic (6.87e-3)" "unprognostic (5.60e-2)" "unprognostic (4.59e-3)" "unprognostic (1.05e-3)" 95.1 12.8 27.5 15.9 24.6 14.1 87.1 48.8 22.4 79.8 37.2 97.2 8.8 74.2 15.8 35.8 85.9 57.1 89.9 30.9 28.8 40.1 9.1 55.7 16.6 35.9 37.3 108.2 98.6 20.4 57.1 51.3 63.7 60.5 17.9 15.8 31.4 53.6 24.8 35.6 41.7 57.1 30.3 9.9 40.4 20.4 33.4 17.1 33.7 23.3 16.1 79.3 63.9 29.6 12.9 42.0 198.0 508.7 120.1 91.2 142.9 136.7 278.8 90.0 95.8 27.3 6.5 1.8 38.3 127.7 103.9 0.2 90.0 6.8 104.3 39.2 24.1 0.0 7.7 27.8 69.7 31.1 0.6 80.5 0.7 70.9 13.3 45.6 86.9 6.0 11.9 0.4 40.5 12.5 91.5 9.2 145.9 1.6 21.6 86.3 21.1 0.4 35.6 0.3 7.9 19.4 23.4 1.0 5.1 93.4 9.3 5.4 51.4 49.2 28.9 149.6 29.7 2.4 4.1 0.5 60.3 1.7 27.1 0.2 0.3 0.1 1.7 0.1 1.1 0.3 0.7 1.2 0.0 0.6 0.5 1.5 0.6 0.4 0.2 0.2 1.0 0.1 27.5 24.6 48.8 22.4 30.9 28.8 35.9 37.3 63.7 30.3 33.4 29.6 101.0 3.2 15.8 55.8 1.8 31.5 95.9 1.1 37.0 4.4 28.7 77.7 52.5 24.3 5.1 9.2 4.2 8.3 6.3 0.4 0.0 27.3 15.3 48.2 40.6 75.5 25.0 3.6 25.4 65.2 80.5 176.7 3.1 75.3 8.2 40.4 47.5 0.8 25.3 21.9 21.1 0.6 4.1 5.6 75.2 15.0 192.0 11.7 33.8 19.7 1.7 88.1 6.2 166.4 14.2 21.6 0.3 99.6 6.4 94.7 0.1 7.9 1.0 3.3 13.1 118.9 59.9 1.6 14.1 4.8 19.7 10.4 14.1 2.1 0.7 11.7 FGFR2 "BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25" ENSG00000066468 "Fibroblast growth factor receptor 2" P21802 10 121478332-121598458 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Apoptosis "Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Disease variant, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 273.8;choroid plexus: 198.1" "Group enriched" "Detected in many" 5 "Astrocytes: 228.2;Cholangiocytes: 213.1;Oligodendrocytes: 562.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 24 "basophil: 13.2;eosinophil: 3.8" "Lineage enriched" "Detected in single" 58 "granulocytes: 13.2" "Cell line enhanced" "Detected in many" "AN3-CA: 189.0;BEWO: 60.9;CACO-2: 49.6;HaCaT: 55.6;HAP1: 63.7;NTERA-2: 57.8;T-47d: 49.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010886, HPA035305" Uncertain Supported "Nucleoplasm,Vesicles,Cell Junctions" "Secreted - unknown location" NA NA 1200000 "Cluster 34: Basophils - Unknown function" "Cluster 70: Brain - Nervous system development" "Cluster 23: AN3-CA - Transcription regulation" "Cluster 42: Oligodendrocytes - Myelin sheath organization" "Cell Junctions" "Nucleoplasm, Vesicles" "CAB010886: AB_259379, HPA035305: AB_10672862" "unprognostic (5.53e-2)" "prognostic favorable (8.79e-4)" "unprognostic (1.08e-1)" "unprognostic (5.23e-2)" "unprognostic (1.73e-1)" "prognostic favorable (9.32e-4)" "unprognostic (1.53e-1)" "unprognostic (4.96e-3)" "unprognostic (1.74e-1)" "unprognostic (1.56e-1)" "unprognostic (1.07e-1)" "unprognostic (3.74e-2)" "unprognostic (1.01e-1)" "unprognostic (6.11e-2)" "unprognostic (2.54e-1)" "unprognostic (6.93e-2)" "unprognostic (2.25e-1)" 5.7 21.3 103.9 8.2 186.8 0.3 22.9 178.9 198.9 19.7 198.1 44.8 10.4 54.6 15.3 25.2 29.6 31.3 5.6 109.9 124.7 26.3 41.0 30.9 2.9 250.9 185.9 18.0 31.0 61.0 6.8 15.7 220.5 27.4 21.2 1.2 59.1 54.6 0.5 109.3 12.2 43.6 165.5 0.8 22.5 7.6 148.0 10.1 54.6 0.2 9.1 16.6 27.4 273.8 7.2 0.4 30.2 189.0 0.1 0.0 60.9 0.4 0.0 0.0 0.0 49.6 1.1 0.1 12.5 2.8 0.1 55.6 63.7 13.0 0.0 0.1 12.7 0.0 0.2 1.2 1.5 0.2 11.7 0.1 26.2 0.0 0.6 0.0 0.0 0.3 0.2 0.2 0.0 11.7 0.2 0.1 57.8 8.7 0.0 0.1 0.0 7.5 18.0 15.8 0.5 0.5 0.4 33.4 0.0 36.6 49.3 0.0 0.1 0.3 8.5 0.2 0.7 0.1 0.1 0.0 0.3 0.0 0.5 13.2 0.0 3.8 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 103.9 186.8 178.9 198.9 109.9 124.7 250.9 185.9 220.5 165.5 148.0 273.8 1.4 19.2 36.0 228.2 0.6 40.1 34.3 18.4 58.6 0.2 8.7 25.4 9.1 213.1 38.4 36.8 0.0 16.5 0.3 7.3 0.0 7.4 4.1 28.1 4.4 1.0 2.4 2.7 14.8 0.2 3.0 9.0 13.3 53.1 0.0 0.1 1.8 5.0 2.3 0.0 31.2 40.8 10.2 0.6 4.4 9.6 1.2 1.1 5.4 10.3 0.6 2.0 1.0 6.0 562.5 0.7 3.0 6.0 0.1 15.0 1.8 13.6 15.3 0.2 0.0 1.6 2.6 0.7 9.9 18.7 27.7 4.0 1.5 0.4 3.8 31.4 FGFR3 "ACH, CD333, CEK2, JTK4" ENSG00000068078 "Fibroblast growth factor receptor 3" P22607 4 1793293-1808872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Apoptosis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Craniosynostosis, Deafness, Disease variant, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 148.3;esophagus: 139.7;skin 1: 271.5" "Cell type enhanced" "Detected in many" "Astrocytes: 410.4;Basal keratinocytes: 103.8;Cholangiocytes: 91.5;Suprabasal keratinocytes: 88.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "CACO-2: 48.2;HaCaT: 34.9;Hep G2: 80.6;NTERA-2: 36.1;RT4: 64.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004231, HPA067204" Enhanced Supported "Endoplasmic reticulum" "Secreted - unknown location" NA NA 2500000 "Cluster 27: Brain & Skin - Unknown function" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 64: Astrocytes - Nervous system maintenance" "Endoplasmic reticulum" "CAB004231: AB_627596, HPA067204: AB_2685804" "unprognostic (1.34e-1)" "unprognostic (5.29e-3)" "unprognostic (1.49e-1)" "prognostic unfavorable (3.77e-4)" "unprognostic (5.90e-2)" "unprognostic (1.24e-3)" "unprognostic (7.22e-2)" "unprognostic (2.54e-1)" "unprognostic (1.99e-1)" "unprognostic (2.17e-1)" "unprognostic (1.38e-1)" "unprognostic (2.88e-2)" "unprognostic (1.30e-1)" "unprognostic (9.11e-3)" "unprognostic (1.98e-1)" "unprognostic (4.74e-2)" "unprognostic (1.97e-1)" 1.6 1.6 118.0 1.5 140.6 1.4 5.5 115.6 104.0 23.7 37.4 12.2 19.5 1.5 2.8 139.7 2.2 7.9 4.8 100.8 107.6 39.3 40.7 7.4 0.4 144.7 129.2 0.5 76.4 0.2 16.1 9.3 109.8 13.8 5.2 0.2 20.2 15.0 1.3 271.5 14.7 0.4 108.9 4.0 7.8 17.6 148.3 1.7 1.5 0.9 11.1 23.1 60.9 81.2 0.0 3.8 19.5 5.6 0.0 0.3 22.1 2.4 0.3 0.8 0.4 48.2 1.0 0.0 17.8 0.7 0.7 34.9 5.5 0.3 0.3 0.2 19.3 14.2 3.9 80.6 0.1 0.0 0.6 0.0 10.9 0.2 0.1 0.1 0.1 2.3 16.7 0.1 0.0 23.9 0.8 0.5 36.1 19.5 0.1 1.2 1.0 0.3 2.8 64.1 5.7 1.6 1.9 4.0 0.0 22.2 20.4 2.5 1.0 0.0 2.1 0.5 1.6 0.1 0.0 0.0 0.2 1.7 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 118.0 140.6 115.6 104.0 100.8 107.6 144.7 129.2 109.8 108.9 148.3 81.2 2.2 0.0 32.5 410.4 1.1 103.8 4.1 29.8 23.9 0.0 4.8 1.5 3.1 91.5 37.6 14.7 0.0 0.5 1.6 36.1 0.0 5.0 7.9 3.0 1.7 3.4 4.2 0.0 0.5 0.7 12.0 3.2 3.6 4.0 0.0 0.1 16.1 30.4 0.6 0.0 1.3 20.7 4.1 1.2 6.5 1.3 0.6 0.6 12.4 14.0 0.6 0.1 0.0 34.2 2.2 0.4 18.0 0.4 0.0 4.2 21.2 9.9 9.8 0.6 0.0 0.7 2.9 0.4 25.9 55.0 88.7 0.8 0.7 0.1 17.0 12.8 FGFR4 "CD334, JTK2" ENSG00000160867 "Fibroblast growth factor receptor 4" P22455 5 177086905-177098144 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 82.5;lung: 65.4" "Cell type enhanced" "Detected in many" "Cholangiocytes: 78.6;Hepatocytes: 31.2;Skeletal myocytes: 141.2;Theca cells: 36.7;Undifferentiated cells: 38.6" "Cancer enhanced" "Detected in many" "liver cancer: 42.0" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "CACO-2: 173.9;Hep G2: 176.4;RH-30: 274.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB005196, HPA027273, HPA027369, HPA028251" Approved "Intracellular and membrane" NA NA 7400000 "Cluster 18: Non-specific - Mitochondria" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 50: Fibroblasts - ECM organization" "CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221" "unprognostic (1.96e-1)" "unprognostic (2.10e-2)" "unprognostic (1.12e-1)" "unprognostic (9.06e-3)" "unprognostic (2.87e-1)" "unprognostic (1.95e-2)" "unprognostic (7.85e-3)" "unprognostic (9.19e-2)" "unprognostic (4.25e-1)" "unprognostic (4.46e-2)" "unprognostic (1.16e-1)" "unprognostic (3.48e-2)" "unprognostic (1.78e-1)" "unprognostic (1.71e-3)" "unprognostic (2.41e-1)" "unprognostic (5.75e-2)" "unprognostic (4.68e-2)" 1.2 14.0 1.1 4.1 1.1 0.5 4.5 2.7 2.1 3.0 1.2 18.0 21.3 2.4 0.2 3.2 4.2 10.2 2.2 1.4 1.0 40.2 82.5 65.4 0.8 0.7 0.8 27.5 29.5 0.2 2.0 2.1 0.9 5.2 6.0 1.5 1.1 0.7 6.6 1.7 20.0 1.1 0.7 22.7 8.8 5.9 1.1 0.2 0.9 1.9 0.2 6.4 3.2 1.3 3.2 48.8 1.0 11.7 0.1 0.1 24.5 0.2 0.1 0.2 0.3 173.9 6.5 5.3 23.0 0.1 2.4 2.8 9.5 1.8 0.1 3.2 13.8 0.5 2.8 176.4 5.2 0.6 4.7 1.1 0.2 8.4 0.2 0.3 0.2 3.5 18.1 0.7 3.9 40.3 0.1 3.6 29.2 30.9 4.5 8.2 274.3 30.9 22.9 0.4 1.8 2.9 1.8 12.4 5.9 5.9 11.7 2.5 1.1 0.0 23.4 0.3 0.7 1.6 1.9 3.7 0.1 1.1 2.0 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 1.1 1.1 2.7 2.1 1.4 1.0 0.7 0.8 0.9 0.7 1.1 1.3 0.3 0.0 0.0 0.3 0.3 0.6 0.7 0.4 0.0 0.9 2.9 2.0 0.9 78.6 0.1 3.7 0.0 1.3 0.1 12.9 3.9 10.9 0.1 1.6 0.3 0.7 4.2 0.0 0.5 4.9 3.8 9.6 9.7 2.9 0.0 0.7 3.9 31.2 0.3 0.0 0.5 10.1 0.0 0.9 0.5 0.0 0.6 0.7 0.0 1.9 0.6 0.6 0.0 0.5 0.1 3.0 4.4 1.5 0.1 1.7 15.9 21.6 0.1 0.4 19.7 141.2 0.7 3.0 9.9 0.8 0.4 8.8 0.4 36.7 38.6 0.5 FKBP1A "FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE" ENSG00000088832 "FKBP prolyl isomerase 1A" P62942 20 1368977-1393164 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Isomerase, Rotamase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Paneth cells: 977.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Group enriched" "Detected in all" 5 "dendritic cells: 675.2;granulocytes: 974.2;monocytes: 1013.4" "Cell line enhanced" "Detected in all" "HUVEC TERT2: 1749.2;TIME: 1929.6" "CAB004639, HPA051798" Uncertain NA NA 12000000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 28: Placenta - Pregnancy" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "CAB004639: AB_425434, HPA051798: AB_2681615" "unprognostic (4.09e-2)" "unprognostic (2.29e-1)" "unprognostic (5.22e-3)" "unprognostic (1.28e-2)" "unprognostic (2.66e-1)" "unprognostic (7.18e-3)" "prognostic unfavorable (3.44e-7)" "unprognostic (7.05e-3)" "unprognostic (2.76e-1)" "unprognostic (8.81e-2)" "unprognostic (5.12e-3)" "unprognostic (6.65e-2)" "prognostic unfavorable (6.69e-5)" "unprognostic (1.97e-2)" "unprognostic (2.06e-1)" "unprognostic (1.21e-1)" "unprognostic (1.47e-1)" 272.7 185.0 138.4 178.8 177.5 167.0 188.2 88.5 163.2 123.0 112.6 158.6 108.9 165.4 150.1 169.8 131.7 104.5 171.4 166.7 115.8 186.7 98.1 235.2 162.7 92.4 98.9 135.1 114.6 123.0 79.5 218.7 95.6 125.4 188.5 11.8 111.0 119.8 110.3 127.3 117.0 225.1 97.8 185.7 118.3 56.9 120.5 188.1 190.9 150.6 202.2 206.8 126.2 118.9 718.1 299.5 172.9 240.3 654.1 771.3 202.9 423.9 337.1 382.7 354.2 278.4 295.2 272.5 149.3 555.7 656.3 337.7 255.1 1007.2 419.7 68.8 170.5 284.2 113.9 473.3 406.4 390.5 168.0 484.7 332.0 410.3 412.6 513.3 1749.2 401.0 271.0 145.8 443.3 125.8 401.9 453.7 307.1 335.3 276.4 307.0 254.1 351.9 540.0 243.4 248.7 173.8 208.0 479.3 728.8 231.8 177.2 293.0 1929.6 1363.6 201.8 278.1 329.5 76.4 168.1 292.9 248.1 332.3 307.5 316.3 870.8 974.2 112.9 1005.8 104.3 128.1 135.5 133.2 675.2 136.2 140.1 132.6 805.0 160.6 1013.4 312.7 195.0 1153.8 138.4 177.5 88.5 163.2 166.7 115.8 92.4 98.9 95.6 97.8 120.5 118.9 779.1 86.6 77.2 0.0 160.6 263.1 211.2 393.3 152.0 17.6 175.6 156.5 59.7 170.1 179.5 172.9 0.0 281.8 148.3 456.2 238.7 432.4 47.7 98.7 183.8 814.8 330.6 196.4 0.0 337.5 702.0 212.2 160.0 122.5 143.5 95.3 623.6 113.5 746.7 35.3 0.0 245.9 329.6 541.8 436.5 52.2 200.0 428.8 241.9 0.0 527.4 52.2 152.4 0.0 0.0 483.6 977.5 162.9 214.8 221.1 210.8 332.1 123.0 11.7 138.1 87.4 224.7 169.3 141.8 329.4 299.3 231.5 150.1 347.3 318.0 245.7 FLT1 "FLT, VEGFR1" ENSG00000102755 "Fms related receptor tyrosine kinase 1" P17948 13 28300346-28495145 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Chemotaxis, Differentiation" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 7 "placenta: 432.4" "Cell type enhanced" "Detected in many" "Adipocytes: 411.6;Endothelial cells: 263.1;Extravillous trophoblasts: 815.4;Hepatic stellate cells: 234.9;Microglial cells: 433.8;Syncytiotrophoblasts: 1127.1" "Cancer enhanced" "Detected in all" "renal cancer: 28.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 71.8;BJ hTERT+: 57.2;HMC-1: 349.2;HUVEC TERT2: 64.9;WM-115: 127.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA011740, HPA014290, CAB068189, CAB068190" Enhanced Supported "Plasma membrane,Actin filaments" "Secreted to blood" NA NA 876000 87000 "Cluster 21: B-cells - Adaptive immune response" "Cluster 28: Placenta - Pregnancy" "Cluster 3: HMC-1 - Innate immune response" "Cluster 18: Syncytiotrophoblasts - Pregnancy hormone signaling" "Plasma membrane" "Actin filaments" "CAB068189: AB_2665636, CAB068190: AB_2665637, HPA011740: AB_1858737, HPA014290: AB_1858738" "unprognostic (3.33e-2)" "unprognostic (3.52e-3)" "unprognostic (1.13e-3)" "unprognostic (5.02e-2)" "unprognostic (3.65e-1)" "unprognostic (5.03e-2)" "unprognostic (8.25e-2)" "unprognostic (2.27e-3)" "unprognostic (9.91e-2)" "unprognostic (6.61e-2)" "unprognostic (2.33e-1)" "unprognostic (1.57e-1)" "prognostic unfavorable (2.19e-4)" "unprognostic (4.20e-2)" "unprognostic (6.00e-2)" "unprognostic (1.57e-1)" "unprognostic (6.32e-2)" 47.6 9.6 37.6 9.1 36.2 1.1 31.2 37.0 43.0 16.4 24.6 9.4 7.5 17.2 3.7 5.9 11.7 16.6 46.0 33.3 39.8 34.9 18.2 25.8 5.3 44.6 40.0 4.4 12.7 30.5 9.0 432.4 50.1 13.9 6.1 52.5 7.0 11.0 19.9 5.9 9.3 17.4 33.4 18.6 10.9 17.4 59.6 3.6 48.9 38.8 5.7 14.0 9.5 38.7 0.1 0.0 0.0 0.6 0.6 0.9 0.3 71.8 57.2 25.8 14.9 0.0 0.2 0.1 0.1 9.6 0.0 0.3 6.7 0.0 45.4 0.0 2.0 0.2 0.1 0.0 0.1 0.0 349.2 0.6 0.0 0.1 1.0 0.1 64.9 6.1 1.7 0.3 0.0 0.3 4.5 3.7 37.5 0.0 0.1 2.9 0.0 0.1 0.1 0.1 8.1 0.6 0.0 0.1 0.2 44.4 0.3 0.2 6.3 0.2 1.2 0.1 0.1 2.1 1.0 0.2 0.4 0.3 127.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.8 0.1 0.1 0.5 0.0 0.0 0.1 0.0 0.0 37.6 36.2 37.0 43.0 33.3 39.8 44.6 40.0 50.1 33.4 59.6 38.7 411.6 0.0 6.0 2.0 4.7 4.1 0.7 0.2 3.4 17.8 1.2 1.5 26.5 2.8 2.9 0.0 4.2 197.2 1.4 0.1 1.9 0.6 157.2 0.5 1.5 263.1 0.0 0.0 0.9 0.0 815.4 32.1 0.5 2.1 1.3 0.1 234.9 6.9 30.8 1.7 14.5 0.0 0.0 12.5 23.6 173.8 18.6 15.3 0.0 433.8 0.0 153.2 0.0 9.5 2.0 0.0 0.0 48.5 4.1 1.3 0.0 0.1 1.8 9.7 92.1 11.4 30.1 14.6 4.6 1.0 4.8 1127.1 2.8 1.5 0.0 1.1 FLT3 "CD135, FLK2, STK1" ENSG00000122025 "Fms related receptor tyrosine kinase 3" P36888 13 28003274-28100592 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "bone marrow: 5.3;brain: 4.9;lymphoid tissue: 6.5" "Cell type enhanced" "Detected in some" "dendritic cells: 24.4;Inhibitory neurons: 59.9;Kupffer cells: 29.1;Langerhans cells: 21.4;Macrophages: 16.9;monocytes: 39.5" "Cancer enhanced" "Detected in some" "breast cancer: 1.8" "Region enhanced" "Detected in some" "cerebellum: 4.9" "Group enriched" "Detected in many" 13 "myeloid DC: 68.7;plasmacytoid DC: 26.2" "Lineage enriched" "Detected in many" 19 "dendritic cells: 68.7" "Group enriched" "Detected in some" 11 "REH: 42.5;THP-1: 26.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA047539 Approved "Endoplasmic reticulum" NA NA 210000 "Cluster 28: Myeloid DCs - Unknown function" "Cluster 66: Lymphoid tissue - Immune response regulation" "Cluster 14: REH - Unknown function" "Cluster 41: Macrophages - Immune response" "Endoplasmic reticulum" "HPA047539: AB_2680080" "unprognostic (2.19e-3)" "unprognostic (3.16e-3)" "unprognostic (6.54e-3)" "unprognostic (9.96e-2)" "unprognostic (3.88e-1)" "unprognostic (3.96e-7)" "unprognostic (7.99e-3)" "unprognostic (1.65e-2)" "unprognostic (5.37e-2)" "unprognostic (1.01e-2)" "unprognostic (1.96e-1)" "unprognostic (1.03e-1)" "unprognostic (4.56e-2)" "unprognostic (3.65e-1)" "unprognostic (3.91e-2)" "unprognostic (2.51e-1)" "unprognostic (2.22e-1)" 0.5 0.1 0.3 3.0 0.2 5.3 1.5 4.9 0.8 0.5 0.1 0.7 0.3 0.2 0.1 0.6 0.4 1.6 0.1 0.2 0.5 1.5 0.5 0.7 6.5 1.3 0.9 0.1 2.8 0.0 0.0 0.0 1.7 0.1 0.8 0.0 0.4 0.2 0.0 0.7 1.6 0.8 0.8 5.7 0.6 0.6 0.8 4.7 0.1 0.3 3.6 1.3 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 3.2 0.6 0.0 0.0 42.5 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 26.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 3.6 3.4 0.0 0.8 0.0 0.2 0.0 0.0 68.7 0.0 0.0 0.0 0.1 2.0 0.0 26.2 0.0 2.7 0.3 0.2 4.9 0.8 0.2 0.5 1.3 0.9 1.7 0.8 0.8 0.8 0.0 0.0 0.0 2.3 1.5 0.3 0.0 0.0 0.0 0.0 1.5 1.0 0.4 1.5 0.0 0.0 0.0 0.0 24.4 0.0 0.0 2.7 3.7 0.3 0.1 0.2 0.0 8.2 7.4 0.0 0.0 0.2 0.0 1.1 0.0 0.0 0.7 0.1 0.5 0.0 59.9 0.0 0.0 29.1 21.4 2.3 0.0 16.9 1.8 1.9 39.5 0.0 0.0 1.5 4.2 0.1 0.0 0.0 2.2 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.1 0.2 0.6 0.0 0.6 0.0 1.7 0.0 0.0 0.0 FLT4 "PCL, VEGFR-3, VEGFR3" ENSG00000037280 "Fms related receptor tyrosine kinase 4" P35916 5 180601506-180649624 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Angiogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in some" 7 "Adipocytes: 27.4;Endothelial cells: 27.1;Extravillous trophoblasts: 37.1;Hepatic stellate cells: 64.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 4 "MAIT T-cell: 3.8" "Lineage enriched" "Detected in single" 31 "T-cells: 3.8" "Cell line enhanced" "Detected in some" "AN3-CA: 10.1;BEWO: 12.4;HEK 293: 15.6;HL-60: 9.5;HUVEC TERT2: 9.9;JURKAT: 12.3;T-47d: 14.6;TIME: 15.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000099, HPA046519, HPA067906, HPA074389" Approved Supported "Nuclear speckles,Plasma membrane,Cell Junctions" "Secreted to blood" NA NA 20000000 290000000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 72: Non-specific - Transcription" "Cluster 6: T47d - Mammary gland" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "Nuclear speckles, Plasma membrane" "Cell Junctions" "CAB000099: , HPA046519: AB_2732527, HPA067906: AB_2732775, HPA074389: " "unprognostic (7.35e-2)" "unprognostic (1.63e-1)" "unprognostic (9.45e-3)" "unprognostic (3.81e-1)" "unprognostic (9.26e-2)" "unprognostic (3.20e-3)" "unprognostic (1.13e-2)" "unprognostic (1.80e-2)" "unprognostic (2.19e-1)" "unprognostic (1.70e-1)" "unprognostic (2.13e-2)" "unprognostic (3.69e-1)" "unprognostic (1.88e-2)" "unprognostic (9.41e-3)" "unprognostic (1.83e-1)" "unprognostic (8.26e-2)" "unprognostic (1.32e-1)" 17.2 11.3 3.5 4.7 4.6 0.8 14.7 2.6 3.4 9.0 2.6 4.9 2.8 8.0 3.0 4.4 9.8 3.8 9.7 5.1 2.6 20.1 6.2 16.9 5.5 3.4 3.0 4.5 2.0 2.3 7.8 6.4 3.6 5.6 1.3 0.3 2.0 2.5 4.7 4.0 7.2 4.1 2.8 17.6 3.5 3.1 4.2 1.0 25.7 4.1 1.4 5.6 5.5 2.7 0.1 2.5 3.2 10.1 0.0 0.0 12.4 0.3 0.1 0.0 0.0 0.4 0.3 0.3 0.9 0.1 0.6 0.4 3.4 0.2 0.3 0.1 15.6 1.2 0.5 0.5 0.1 9.5 0.3 0.2 0.1 0.2 0.4 0.3 9.9 12.3 0.4 0.4 2.1 5.6 0.1 0.5 7.0 0.3 0.6 8.2 0.1 0.1 0.1 0.3 0.3 1.1 0.1 0.2 0.1 3.1 14.6 0.3 15.7 0.2 6.9 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.5 0.0 3.8 0.0 0.2 0.8 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 3.5 4.6 2.6 3.4 5.1 2.6 3.4 3.0 3.6 2.8 4.2 2.7 27.4 0.0 1.7 0.7 0.7 0.9 0.2 0.0 1.2 0.2 1.4 1.4 4.5 0.0 0.6 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.1 0.1 27.1 0.0 0.0 0.2 0.0 37.1 0.8 0.0 0.1 2.5 2.4 64.6 0.6 1.2 0.0 0.1 0.0 0.0 3.3 0.8 0.7 0.3 0.6 0.0 3.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.8 0.0 0.2 0.0 0.7 0.7 0.1 5.2 0.1 1.1 1.0 1.8 0.2 0.0 0.1 FNTA "FPTA, PGGT1A, PTAR2" ENSG00000168522 "Farnesyltransferase, CAAX box, alpha" P49354 8 43034194-43085788 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Prenyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010149, HPA018830" Approved Approved Cytosol NA NA 170000 "Cluster 26: Non-specific - Mitochondria" "Cluster 70: Brain - Nervous system development" "Cluster 30: Epithelial cell lines - Translation" "Cluster 47: Cytotrophoblasts - Unknown function" Cytosol "CAB010149: AB_2106299, HPA018830: AB_1848992" "unprognostic (2.09e-1)" "unprognostic (1.35e-1)" "unprognostic (2.90e-1)" "unprognostic (1.86e-3)" "unprognostic (2.64e-1)" "unprognostic (4.70e-3)" "unprognostic (1.83e-2)" "unprognostic (3.69e-2)" "unprognostic (1.70e-2)" "unprognostic (5.37e-2)" "unprognostic (3.25e-2)" "unprognostic (4.10e-1)" "prognostic unfavorable (2.94e-12)" "unprognostic (3.63e-2)" "unprognostic (2.33e-1)" "unprognostic (3.19e-2)" "unprognostic (1.29e-3)" 53.6 33.4 57.7 26.3 69.3 26.8 46.1 74.0 74.0 41.3 52.7 46.3 35.9 34.0 43.2 45.4 33.4 27.1 48.1 54.2 63.7 37.4 47.2 34.7 45.5 75.1 64.8 33.0 43.9 34.3 36.6 50.0 73.6 38.3 32.5 33.8 36.5 34.1 74.3 51.0 32.9 31.4 73.2 36.7 35.4 26.9 61.9 39.9 31.6 64.7 44.2 40.9 43.1 87.6 78.8 37.5 50.9 16.7 88.6 112.5 43.4 44.9 52.4 50.1 46.3 62.1 56.9 88.5 35.5 54.1 67.6 41.9 63.1 71.5 59.4 26.2 42.2 70.9 25.5 54.2 112.7 30.4 35.8 87.6 119.0 36.3 104.2 74.4 89.4 47.9 86.1 50.4 58.5 9.9 72.3 47.1 91.3 66.4 27.1 63.1 83.0 47.8 70.5 58.4 29.7 47.4 56.6 47.3 78.9 59.1 59.1 55.3 69.9 17.9 22.1 68.6 48.0 47.7 46.2 89.2 43.0 56.4 41.3 3.1 7.7 14.3 9.5 10.7 11.3 14.1 9.7 12.6 13.3 15.2 12.9 12.9 4.3 16.1 7.8 12.6 14.3 6.4 57.7 69.3 74.0 74.0 54.2 63.7 75.1 64.8 73.6 73.2 61.9 87.6 68.7 57.7 20.3 33.0 57.4 87.7 82.3 55.3 58.1 22.5 35.5 34.8 44.9 34.3 41.2 33.1 37.5 135.6 69.1 29.6 70.5 73.0 41.2 40.7 55.1 55.8 32.2 38.9 27.9 70.1 124.4 58.7 28.5 46.2 32.4 58.6 56.0 25.9 80.5 20.2 31.9 39.6 34.6 47.5 60.7 52.8 48.1 49.2 94.3 33.7 75.7 42.8 69.0 25.6 79.8 69.4 41.2 60.2 40.8 109.3 67.0 54.8 46.7 57.5 52.6 56.2 47.2 65.9 37.1 73.9 95.6 207.6 60.4 69.6 49.1 76.6 FNTB FPTB ENSG00000257365 "Farnesyltransferase, CAAX box, beta" P49356 14 64986895-65062652 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Prenyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 70.0" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" HPA062743 Uncertain Approved Centrosome NA NA "Cluster 31: Non-specific - Inflammatory response" "Cluster 70: Brain - Nervous system development" "Cluster 17: WM-115 - Nervous system development" "Cluster 51: Myeloid cells - Hemostasis" Centrosome "HPA062743: AB_2684861" "unprognostic (2.79e-1)" "unprognostic (1.50e-2)" "unprognostic (1.54e-1)" "unprognostic (8.57e-3)" "unprognostic (1.88e-1)" "unprognostic (6.88e-2)" "prognostic unfavorable (6.03e-4)" "unprognostic (6.21e-2)" "unprognostic (3.11e-2)" "unprognostic (1.46e-2)" "unprognostic (1.70e-2)" "unprognostic (2.11e-1)" "unprognostic (2.49e-3)" "unprognostic (2.36e-2)" "unprognostic (3.60e-1)" "unprognostic (5.56e-2)" "unprognostic (1.11e-3)" 8.7 8.7 15.9 5.1 30.2 2.9 7.8 40.7 20.1 7.7 13.5 6.5 5.9 6.6 8.4 13.3 9.5 5.9 12.9 14.5 20.7 8.2 5.8 6.7 5.7 55.0 34.2 7.3 5.6 13.0 7.0 8.7 46.5 9.1 7.7 6.1 9.2 9.3 18.1 11.8 5.2 11.6 36.7 4.7 5.5 9.5 30.7 6.5 5.8 19.7 8.3 7.6 8.9 70.0 37.1 31.9 20.4 12.5 13.9 11.9 14.6 20.2 14.7 22.4 23.0 15.9 14.6 6.0 12.0 21.1 13.2 24.1 47.5 15.1 18.3 9.0 15.9 23.2 8.0 28.1 9.0 8.3 32.2 9.7 14.3 9.4 5.7 22.4 19.1 10.9 13.7 8.4 13.1 30.9 13.3 22.6 8.4 23.1 29.9 12.2 17.6 7.6 16.2 15.7 12.0 13.5 11.9 24.4 30.2 15.9 22.7 14.0 15.2 16.2 34.7 8.4 14.2 5.7 5.6 6.6 18.3 10.3 39.4 21.9 12.8 11.5 3.8 9.9 9.6 2.5 6.2 5.1 7.4 1.7 4.7 3.7 3.4 4.0 5.1 5.8 6.2 7.4 15.9 30.2 40.7 20.1 14.5 20.7 55.0 34.2 46.5 36.7 30.7 70.0 3.9 12.8 2.2 0.0 1.6 2.4 3.5 4.3 2.8 4.6 6.2 6.6 8.3 2.8 5.6 3.7 2.1 15.9 2.4 4.3 0.0 6.6 9.2 3.9 3.0 4.5 7.7 7.8 0.0 4.8 15.3 4.9 4.1 4.8 0.0 12.7 5.0 8.0 8.1 5.0 0.0 5.9 6.1 8.1 2.5 6.0 5.6 15.7 5.4 0.0 7.5 7.6 2.1 0.0 0.0 4.2 1.9 8.6 2.1 4.7 4.0 6.0 4.0 4.1 19.7 5.1 5.5 2.7 4.7 6.7 3.7 8.2 2.5 7.3 5.3 3.3 FRK "GTK, PTK5, RAK" ENSG00000111816 "Fyn related Src family tyrosine kinase" P42685 6 115931149-116060891 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "FDA approved drug targets, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "choroid plexus: 13.7" "Cell type enhanced" "Detected in many" "Early spermatids: 89.4;Oligodendrocytes: 97.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "OE19: 18.3;RT4: 7.6" "Not detected" "Not detected" "Not detected" "Not detected" "CAB025217, HPA030479, HPA072590" Approved Supported Nucleoplasm,Cytosol NA NA "Cluster 17: Basophils - Unknown function" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 21: OE19 - Mitochondria" "Cluster 44: Endometrium - Transcription" Nucleoplasm Cytosol "CAB025217: , HPA030479: AB_2732457, HPA072590: " "unprognostic (7.70e-3)" "unprognostic (1.99e-2)" "unprognostic (1.11e-1)" "unprognostic (4.68e-3)" "unprognostic (1.96e-1)" "unprognostic (3.49e-2)" "unprognostic (2.09e-1)" "unprognostic (1.58e-1)" "unprognostic (4.23e-2)" "unprognostic (5.82e-3)" "unprognostic (1.45e-1)" "unprognostic (7.54e-2)" "prognostic favorable (9.66e-7)" "unprognostic (1.52e-2)" "unprognostic (1.34e-1)" "unprognostic (2.02e-2)" "unprognostic (1.10e-1)" 0.8 1.1 1.3 1.2 2.1 1.5 2.4 5.8 5.0 1.8 13.7 4.6 6.2 1.0 2.5 2.9 2.6 2.6 1.8 1.8 0.0 9.0 6.8 1.8 0.7 0.3 0.1 0.9 2.8 1.0 0.4 0.8 1.0 2.2 4.8 2.9 4.0 2.4 2.2 1.9 6.3 0.8 0.2 0.9 4.9 1.9 1.1 1.2 1.0 0.8 1.6 2.1 1.0 5.7 2.5 4.0 0.5 0.9 0.2 0.2 0.6 0.5 0.1 0.0 0.1 3.1 3.8 0.9 3.5 0.5 0.5 5.8 0.2 1.1 0.1 3.3 0.3 1.3 3.3 2.7 0.2 0.9 0.7 0.2 1.5 0.3 0.4 0.4 0.2 0.6 0.6 2.3 1.0 1.3 0.7 0.5 1.0 18.3 0.7 1.1 3.3 1.2 4.8 7.6 0.7 0.8 0.7 5.1 0.5 0.9 1.5 0.7 0.8 1.0 1.0 0.7 0.5 3.6 2.7 1.6 1.1 0.6 0.6 0.9 0.2 0.2 0.4 0.1 0.5 0.2 0.3 0.4 0.1 0.4 0.2 0.3 0.8 0.3 0.2 0.3 0.2 0.0 1.3 2.1 5.8 5.0 1.8 0.0 0.3 0.1 1.0 0.2 1.1 5.7 0.4 0.0 10.3 10.4 0.5 2.7 20.8 23.3 6.8 0.6 7.3 2.9 9.2 11.5 22.6 23.9 0.0 4.4 0.1 34.9 11.7 20.3 89.4 28.1 1.7 0.7 19.8 0.0 12.2 16.4 4.3 3.5 29.0 30.4 3.8 0.2 1.4 21.9 0.9 6.7 7.7 14.5 34.6 0.6 0.4 38.1 0.6 0.6 0.0 1.0 1.0 0.2 0.0 2.5 97.8 21.9 23.3 1.2 0.5 23.4 49.3 28.4 36.6 0.3 13.1 9.9 16.2 4.6 1.0 16.4 3.1 0.8 1.0 2.3 19.1 46.2 FTH1 "FHC, FTH, FTHL6, PIG15, PLIF" ENSG00000167996 "Ferritin heavy chain 1" P02794 11 61959718-61967634 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Iron storage" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Langerhans cells: 49889.9;monocytes: 34409.9;Proximal enterocytes: 28837.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 23933.9;HHSteC: 24849.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB008623 Approved NA NA 5600000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 3: Monocytes - Immune response regulation" "CAB008623: " "unprognostic (7.15e-2)" "unprognostic (1.52e-2)" "unprognostic (2.27e-1)" "unprognostic (2.00e-2)" "unprognostic (2.53e-1)" "prognostic unfavorable (7.56e-5)" "prognostic unfavorable (6.18e-4)" "unprognostic (3.08e-2)" "unprognostic (2.48e-2)" "unprognostic (6.65e-2)" "unprognostic (2.44e-2)" "unprognostic (8.13e-2)" "prognostic unfavorable (5.20e-5)" "unprognostic (2.99e-1)" "unprognostic (4.89e-2)" "unprognostic (3.44e-1)" "unprognostic (5.83e-2)" 6767.7 5191.4 5741.8 3546.9 5464.0 4734.2 5696.1 5591.9 7973.3 3973.1 4801.2 4701.2 1819.9 3712.8 2421.8 4025.0 3195.6 1995.6 4779.5 5252.8 5737.2 6092.3 3500.8 6057.7 1460.4 6416.7 5812.4 3069.9 3883.8 1696.4 2105.4 1800.3 6188.9 2778.8 3357.4 3123.7 3533.1 1514.8 4695.5 2125.0 4331.6 2040.7 6506.2 3496.3 4044.1 769.5 6153.5 1109.8 3167.6 2766.8 1291.2 4718.0 3163.8 6630.2 3029.8 8290.2 1236.6 3293.8 23933.9 11490.1 6794.4 2684.1 11547.3 2694.6 2698.6 1011.0 4065.8 345.3 16669.6 7830.0 10259.7 5035.8 1118.8 2235.9 1733.9 1439.0 542.9 1720.3 10802.1 6692.1 24849.2 821.6 2626.6 15711.1 10758.7 5384.0 10038.1 8476.6 3427.6 1970.7 2622.1 3874.4 9546.5 4080.7 935.3 1361.8 2114.6 10461.4 13675.6 914.9 1508.5 2502.3 13877.6 8068.8 1044.8 1325.0 9113.3 1005.9 4645.6 4045.3 1790.3 1098.4 3791.5 8310.7 1978.7 3727.4 1732.0 662.7 2516.5 1088.1 11353.7 363.1 2030.4 29466.0 19068.5 15453.6 2306.3 22407.8 2274.9 4088.8 3267.1 2296.9 9762.5 4113.3 2710.5 2108.2 45110.1 1981.1 27515.2 7217.1 4321.5 22214.4 5741.8 5464.0 5591.9 7973.3 5252.8 5737.2 6416.7 5812.4 6188.9 6506.2 6153.5 6630.2 3864.7 1317.3 2890.3 319.3 3200.9 5157.7 7723.2 23426.3 3495.0 881.7 9884.9 10192.4 11.7 4466.7 11711.1 1918.2 573.4 4541.1 4513.5 13653.9 10888.0 10748.7 274.2 4921.8 2908.5 4303.3 2520.6 6318.6 252.8 11073.9 6803.9 5931.3 2059.7 8005.0 6736.0 1798.6 3266.1 5199.9 18411.3 738.6 153.7 3927.4 10379.8 13784.1 49889.9 527.7 4666.1 22792.0 7116.5 183.6 34409.9 12189.1 1699.3 153.3 1031.0 7813.2 7936.8 3818.1 1789.1 12995.8 28837.7 21355.6 5978.6 3311.6 2084.0 2686.9 6139.1 585.4 927.1 1983.6 3555.6 4622.6 5225.4 2496.8 4921.7 18650.3 FTL "MGC71996, NBIA3" ENSG00000087086 "Ferritin light chain" P02792 19 48965309-48966879 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Iron storage" "Cancer-related genes, Cataract, Disease variant, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 14422.9" "Cell type enhanced" "Detected in all" "Hofbauer cells: 74983.4;Kupffer cells: 70127.1;Macrophages: 34584.5;Proximal tubular cells: 58047.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Group enriched" "Detected in all" 5 "granulocytes: 125209.0;monocytes: 102128.9" "Cell line enhanced" "Detected in all" "HHSteC: 24796.9;HSkMC: 20811.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB020769, HPA041602" Enhanced Approved Cytosol NA NA 170000000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 4: Macrophages - Innate immune response" Cytosol "CAB020769: , HPA041602: AB_2677575" "unprognostic (2.95e-1)" "unprognostic (2.64e-2)" "unprognostic (1.31e-1)" "unprognostic (1.56e-3)" "unprognostic (7.48e-2)" "unprognostic (5.28e-2)" "unprognostic (2.16e-3)" "unprognostic (6.17e-3)" "unprognostic (1.18e-1)" "unprognostic (1.08e-1)" "unprognostic (2.66e-1)" "unprognostic (2.96e-1)" "prognostic unfavorable (4.40e-5)" "unprognostic (1.32e-1)" "unprognostic (2.43e-2)" "unprognostic (2.30e-2)" "unprognostic (1.87e-2)" 6778.7 3262.2 6806.2 2353.2 7172.4 4213.8 4226.0 6782.1 10053.2 2094.3 6429.7 2451.1 2427.0 1523.4 1010.8 1306.2 2169.9 4298.0 2537.3 6497.7 6998.4 8845.6 14422.9 7261.1 3353.2 7250.8 6998.4 2455.3 2166.2 931.7 1730.4 3423.2 7218.5 1946.5 1800.0 684.9 1663.5 1390.4 1345.9 1449.7 2806.6 1842.3 7149.5 6751.4 3204.5 455.9 7581.8 1168.9 3000.4 1072.0 1334.6 4239.9 1804.7 7334.0 869.7 12906.5 949.6 1457.0 16013.9 16478.6 1693.1 2194.1 12820.0 3090.7 6903.8 2852.3 3413.2 656.4 4104.3 13203.9 6755.6 505.8 788.2 1301.8 2765.6 8895.0 507.6 1740.0 3222.8 18949.7 24796.9 4133.3 5591.2 20811.1 1735.9 5272.5 2301.6 4590.4 4549.8 774.6 3284.9 1328.2 6198.4 213.0 1152.1 2402.8 1729.8 15140.6 1306.9 947.6 643.0 6763.9 1989.7 545.0 1209.9 701.5 5761.7 313.4 1239.5 5104.1 183.2 8493.4 3438.3 3353.4 1740.1 4364.3 3083.1 5690.2 13742.1 625.1 3563.9 4334.7 6017.7 64938.4 71067.8 77353.0 6560.6 102128.9 7527.7 17097.3 7247.4 7054.3 25176.6 15607.2 8656.4 7466.9 125209.0 4978.3 91398.0 10579.6 9634.4 94147.5 6806.2 7172.4 6782.1 10053.2 6497.7 6998.4 7250.8 6998.4 7218.5 7149.5 7581.8 7334.0 2757.2 1125.0 3379.9 88.5 3311.5 2793.9 6799.5 2785.4 2159.8 474.7 2597.9 3977.3 777.8 4398.0 2550.4 2021.2 177.2 941.5 2199.4 2314.2 10704.0 4251.2 290.2 504.9 1413.1 4867.0 1613.4 4331.2 60.6 6134.8 1447.8 5703.3 1715.1 617.4 2365.7 942.2 4598.0 23702.0 74983.4 533.3 113.8 2368.8 3039.4 70127.1 16939.0 1601.8 4175.9 34584.5 5085.3 129.3 22965.8 3161.9 2020.6 55.8 309.7 6905.5 5604.7 2010.8 4884.7 9790.5 21474.5 58047.8 1908.0 682.6 1341.1 1643.8 3455.6 82.1 311.2 1985.5 2226.7 1502.7 2590.4 1492.0 2816.8 13083.6 FXYD2 "ATP1G1, HOMG2, MGC12372" ENSG00000137731 "FXYD domain containing ion transport regulator 2" P54710 11 117800844-117828698 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport" "Disease variant, FDA approved drug targets, Primary hypomagnesemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "kidney: 3645.4" "Group enriched" "Detected in many" 5 "Cholangiocytes: 1595.6;Distal tubular cells: 2952.4;Ductal cells: 892.8;Proximal tubular cells: 3423.7" "Cancer enriched" "Detected in some" 8 "renal cancer: 49.9" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 4 "memory CD8 T-cell: 14.8;naive CD4 T-cell: 5.1;naive CD8 T-cell: 4.3;NK-cell: 9.6;plasmacytoid DC: 3.8" "Group enriched" "Detected in many" 7 "dendritic cells: 3.8;NK-cells: 9.6;T-cells: 14.8" "Group enriched" "Detected in some" 25 "MOLT-4: 2255.4;RPTEC TERT1: 4711.9" "Low region specificity" "Detected in many" "Region enriched" "Detected in some" 5 "spinal cord: 27.7" "HPA064218, HPA068838" Supported Approved Mitochondria NA NA "Cluster 48: NK-cells - Unknown function" "Cluster 7: Kidney - Transmembrane transport" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 67: Proximal tubular cells - Tubular reabsorption" Mitochondria "HPA064218: AB_2685214, HPA068838: AB_2686047" "unprognostic (4.11e-4)" "unprognostic (1.14e-2)" "unprognostic (1.63e-1)" "unprognostic (1.36e-3)" "unprognostic (1.09e-3)" "unprognostic (2.30e-2)" "unprognostic (3.65e-2)" "unprognostic (4.62e-1)" "unprognostic (4.01e-2)" "unprognostic (4.91e-2)" "unprognostic (1.24e-2)" "unprognostic (2.64e-1)" "prognostic favorable (3.23e-9)" "unprognostic (3.22e-3)" "unprognostic (4.38e-2)" "unprognostic (4.62e-1)" "unprognostic (3.00e-2)" 2.0 0.9 0.7 1.4 0.6 3.3 1.2 1.4 1.7 1.0 0.0 2.1 1.4 1.5 1.2 0.8 1.8 353.1 1.2 0.8 0.0 3645.4 23.8 4.4 8.9 0.0 0.1 2.4 612.6 0.2 1.6 0.8 0.0 1.7 0.8 1.1 835.6 0.7 0.3 1.0 1.6 2.2 0.0 3.1 2.8 0.6 0.0 74.8 1.0 0.6 4.5 1.8 0.9 0.4 0.0 118.6 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.4 3.5 0.0 0.2 0.4 0.2 0.0 0.3 0.2 0.0 0.1 0.2 83.6 0.1 0.2 0.7 0.0 0.0 0.0 0.0 0.0 1.9 140.3 0.0 0.0 0.2 0.3 2255.4 0.0 1.2 0.0 0.0 0.6 0.0 4.6 4711.9 0.0 1.9 0.0 0.0 2.9 0.2 0.2 0.8 0.3 0.8 0.0 1.3 0.5 0.0 1.0 0.3 0.2 0.1 0.2 0.0 0.0 1.2 0.0 1.0 0.0 1.0 0.2 1.8 14.8 0.2 0.3 5.1 4.3 0.0 9.6 0.0 3.8 1.7 2.1 0.7 0.6 1.4 1.7 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.4 1.0 0.0 0.6 0.0 33.6 1.1 0.1 0.8 0.6 0.2 0.1 0.5 1.2 1595.6 0.1 435.9 0.0 0.1 0.7 0.0 2952.4 892.8 21.8 1.6 4.1 2.2 15.1 2.7 0.0 10.0 0.1 3.5 0.5 41.3 0.0 0.6 4.2 3.9 3.6 0.0 0.0 0.3 16.2 4.5 4.1 25.9 9.3 24.8 0.0 0.0 8.8 0.5 1.0 0.0 0.0 23.2 0.0 7.5 0.4 0.2 0.0 3423.7 0.1 3.3 6.6 1.6 3.8 0.3 0.3 0.2 0.9 0.3 27.7 1.2 0.1 0.0 GAA ENSG00000171298 "Glucosidase alpha, acid" P10253 17 80101556-80119881 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Glycosidase, Hydrolase" "Disease variant, FDA approved drug targets, Glycogen storage disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cytotrophoblasts: 156.2;Extravillous trophoblasts: 143.9;Kupffer cells: 122.7;Syncytiotrophoblasts: 166.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 66.6;eosinophil: 22.8;intermediate monocyte: 50.3;myeloid DC: 39.7;neutrophil: 27.0;non-classical monocyte: 68.5" "Group enriched" "Detected in all" 10 "dendritic cells: 39.7;granulocytes: 27.0;monocytes: 68.5" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026970, HPA029126" Enhanced Approved Vesicles NA NA 3800000 "Cluster 14: Monocytes - Unknown function" "Cluster 18: Non-specific - Mitochondria" "Cluster 6: T47d - Mammary gland" "Cluster 4: Macrophages - Innate immune response" Vesicles "HPA026970: AB_2672065, HPA029126: AB_2672918" "unprognostic (1.13e-1)" "unprognostic (1.11e-1)" "prognostic unfavorable (7.66e-4)" "unprognostic (2.94e-2)" "unprognostic (1.14e-2)" "unprognostic (7.96e-2)" "unprognostic (2.05e-2)" "unprognostic (1.19e-1)" "unprognostic (2.90e-1)" "unprognostic (1.43e-1)" "unprognostic (1.29e-2)" "unprognostic (2.76e-1)" "unprognostic (1.46e-1)" "unprognostic (7.02e-2)" "unprognostic (2.38e-1)" "unprognostic (1.78e-2)" "unprognostic (1.18e-1)" 31.7 29.9 16.9 22.6 20.8 16.7 30.1 19.2 26.5 25.8 17.1 29.2 24.7 31.2 35.2 15.8 29.1 29.9 35.1 18.3 24.7 37.6 47.3 44.4 22.5 28.2 21.6 18.8 37.2 33.3 38.8 48.5 26.6 33.2 8.7 6.6 37.7 23.6 47.0 25.5 26.9 14.6 21.0 54.3 26.9 56.0 26.0 20.4 32.6 25.1 7.0 31.5 22.0 31.4 35.6 67.8 13.2 43.2 40.4 40.2 85.1 21.8 39.6 16.2 13.2 20.3 56.3 12.7 56.5 17.3 13.8 14.8 4.1 25.2 3.8 16.5 49.9 0.2 12.8 73.3 69.7 1.7 40.4 86.7 35.4 30.6 10.5 32.8 28.9 33.5 12.9 51.5 12.4 81.3 6.0 8.4 27.3 8.7 46.8 30.9 44.8 22.2 13.1 36.5 15.1 43.4 28.5 31.3 39.0 8.1 89.5 50.1 18.8 59.7 31.5 43.6 8.1 121.4 36.5 3.8 19.1 32.8 38.4 0.6 66.6 22.8 3.7 50.3 4.4 3.1 2.8 3.8 39.7 3.0 3.2 2.3 27.0 3.0 68.5 9.5 2.1 32.9 16.9 20.8 19.2 26.5 18.3 24.7 28.2 21.6 26.6 21.0 26.0 31.4 21.9 19.2 41.3 31.6 9.3 11.2 19.6 38.7 8.0 16.1 24.1 28.2 19.9 24.3 24.7 14.7 8.4 156.2 11.8 11.5 5.9 25.2 55.7 14.3 16.7 21.6 6.1 4.8 16.2 15.8 143.9 33.0 20.4 27.8 8.8 28.5 23.6 26.4 99.8 11.8 18.9 10.9 12.2 122.7 29.6 29.3 23.9 83.9 24.9 20.6 39.1 32.1 8.2 11.6 12.5 9.4 13.5 19.2 12.9 20.2 31.4 21.5 9.3 18.5 6.6 15.0 13.9 66.0 29.4 10.3 8.4 166.2 8.2 30.2 14.4 14.8 GABBR1 "GPRC3A, hGB1a" ENSG00000204681 "Gamma-aminobutyric acid type B receptor subunit 1" Q9UBS5 6 29555629-29633976 "FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Astrocytes: 150.5;Excitatory neurons: 58.7;Inhibitory neurons: 68.1;Oligodendrocyte precursor cells: 72.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AN3-CA: 6.3;HEL: 6.4;U-2 OS: 6.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA050483, HPA058459" Uncertain Approved Centrosome "Intracellular and membrane" NA NA "Cluster 72: Non-specific - Transcription" "Cluster 23: AN3-CA - Transcription regulation" "Cluster 64: Astrocytes - Nervous system maintenance" Centrosome "HPA050483: AB_2681140, HPA058459: " "unprognostic (1.01e-1)" "unprognostic (2.07e-3)" "unprognostic (3.22e-3)" "unprognostic (2.93e-3)" "unprognostic (3.37e-1)" "unprognostic (2.65e-1)" "unprognostic (7.95e-4)" "unprognostic (5.44e-2)" "unprognostic (4.24e-2)" "unprognostic (1.14e-1)" "prognostic favorable (2.54e-5)" "unprognostic (1.23e-3)" "prognostic unfavorable (3.77e-10)" "unprognostic (3.82e-2)" "unprognostic (2.26e-1)" "unprognostic (3.87e-2)" "unprognostic (2.55e-2)" 20.4 18.0 10.2 2.4 10.9 2.8 20.7 6.4 9.6 45.3 0.0 33.6 0.2 42.8 0.0 14.5 39.0 0.9 28.4 3.9 0.0 16.9 4.7 20.6 2.0 0.3 2.0 40.7 10.4 1.1 30.8 1.3 0.0 34.3 0.5 0.5 16.3 4.2 6.1 19.2 20.2 1.4 0.0 39.0 18.5 7.9 6.1 0.2 22.8 0.0 1.2 25.3 31.6 0.0 2.4 0.0 1.5 6.3 0.7 1.6 1.6 1.6 0.7 1.4 0.4 1.9 0.1 1.1 1.5 0.0 0.3 2.0 0.7 0.0 0.0 5.9 2.6 6.4 3.7 0.0 0.9 0.2 3.1 0.0 0.0 1.2 0.0 1.8 0.8 3.3 5.5 0.0 0.2 1.5 0.6 0.1 0.4 0.0 0.9 2.9 0.6 0.1 0.2 0.0 0.4 1.0 0.4 0.0 2.6 0.4 1.2 0.9 3.6 2.5 6.2 0.2 3.1 5.4 0.6 0.0 1.4 2.8 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 10.2 10.9 6.4 9.6 3.9 0.0 0.3 2.0 0.0 0.0 6.1 0.0 16.8 12.8 20.2 150.5 10.6 11.9 6.2 4.7 10.2 30.6 13.4 17.7 13.9 1.5 10.7 3.7 0.0 0.3 5.7 0.8 0.0 1.4 4.7 1.3 30.6 17.0 7.2 5.7 58.7 0.9 0.2 16.0 1.5 1.9 7.6 14.6 22.5 0.3 1.1 23.5 68.1 4.7 2.0 5.9 18.3 3.1 15.2 14.4 0.0 19.7 11.0 9.8 0.0 72.4 16.3 1.7 1.6 25.6 0.7 7.6 0.1 1.0 1.1 17.3 13.1 12.5 18.8 1.2 2.7 5.3 11.1 0.5 5.9 6.7 1.5 2.8 GABBR2 "GABABR2, GPR51, GPRC3B, HG20" ENSG00000136928 "Gamma-aminobutyric acid type B receptor subunit 2" O75899 9 98288109-98708935 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 11 "brain: 90.4" "Group enriched" "Detected in some" 4 "Excitatory neurons: 386.5;Inhibitory neurons: 395.1" "Group enriched" "Detected in many" 10 "glioma: 7.2;thyroid cancer: 11.6;urothelial cancer: 3.9" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ: 14.6;fHDF/TERT166: 7.3;HUVEC TERT2: 29.5;U-138 MG: 11.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013820, HPA031684, CAB079065" Enhanced Approved NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB079065: , HPA013820: AB_1849364, HPA031684: AB_2673993" "unprognostic (2.00e-1)" "unprognostic (7.56e-2)" "unprognostic (3.75e-1)" "unprognostic (3.09e-5)" "unprognostic (2.52e-1)" "unprognostic (1.16e-1)" "unprognostic (2.81e-2)" "unprognostic (1.42e-1)" "unprognostic (2.66e-1)" "unprognostic (4.43e-2)" "unprognostic (1.43e-2)" "unprognostic (2.06e-1)" "unprognostic (1.76e-2)" "unprognostic (3.52e-2)" "unprognostic (1.91e-1)" "unprognostic (2.68e-2)" "unprognostic (3.45e-2)" 0.0 3.6 26.0 0.2 40.8 0.0 0.0 10.6 90.4 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.6 39.9 18.0 0.0 0.0 0.3 0.0 12.7 19.6 0.0 0.1 0.2 0.6 0.1 12.5 0.0 0.0 8.5 0.0 0.1 2.8 0.2 0.0 0.1 8.3 0.0 0.2 0.6 39.5 0.0 1.4 0.5 0.2 0.5 0.0 36.3 0.0 0.0 0.0 0.0 0.1 0.1 1.2 14.6 2.9 3.0 5.5 0.1 0.1 0.0 0.9 7.3 0.6 0.0 0.1 0.2 1.0 0.0 0.5 0.0 0.0 0.0 1.3 0.0 0.0 0.4 0.0 0.9 0.2 0.0 29.5 0.0 0.3 0.1 0.0 0.4 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 4.0 0.0 0.1 3.5 0.0 0.0 0.0 0.1 1.2 11.5 0.7 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 26.0 40.8 10.6 90.4 39.9 18.0 12.7 19.6 12.5 8.3 39.5 36.3 0.1 0.0 0.0 14.0 0.0 0.1 0.0 0.0 0.0 86.4 0.5 0.1 1.9 0.0 0.1 0.0 0.0 0.5 0.0 0.1 0.0 0.0 90.3 0.1 0.0 0.6 0.0 0.0 386.5 0.2 1.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 395.1 0.0 0.0 0.0 0.0 34.5 0.3 0.1 1.8 11.2 0.0 1.8 0.0 26.2 7.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 7.4 0.0 0.3 1.3 0.7 0.9 0.0 0.1 0.4 0.0 0.3 0.1 0.0 GABRA1 EJM5 ENSG00000022355 "Gamma-aminobutyric acid type A receptor subunit alpha1" P14867 5 161847063-161899981 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 30 "brain: 55.1;retina: 17.8" "Group enriched" "Detected in some" 11 "Bipolar cells: 198.0;Excitatory neurons: 220.5;Inhibitory neurons: 215.2" "Cancer enriched" "Detected in single" 5 "glioma: 1.1" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022502, HPA029363, HPA055746" Enhanced Supported Approved "Nucleoplasm,Plasma membrane" NA NA "Cluster 6: Brain - Smell perception" "Cluster 56: Bipolar cells - Visual perception" "Plasma membrane" Nucleoplasm "CAB022502: , HPA029363: , HPA055746: AB_2682904" "unprognostic (2.58e-2)" "unprognostic (4.78e-3)" "unprognostic (1.84e-1)" "unprognostic (3.31e-1)" "unprognostic (2.43e-1)" 0.0 1.2 6.7 0.0 11.1 0.0 0.0 24.8 55.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 7.7 21.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 17.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.1 14.3 0.6 0.0 0.0 0.2 0.0 0.0 24.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.7 11.1 24.8 55.1 7.7 21.7 0.0 0.0 0.0 0.0 14.3 24.0 0.0 0.0 0.0 17.6 0.0 0.0 0.0 0.0 0.0 198.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.1 0.0 0.0 220.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.4 215.2 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 17.8 0.0 3.5 0.0 8.0 16.4 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 9.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GABRA2 ENSG00000151834 "Gamma-aminobutyric acid type A receptor subunit alpha2" P47869 4 46243548-46475230 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 31.5;epididymis: 8.8" "Group enriched" "Detected in many" 5 "Astrocytes: 425.4;Excitatory neurons: 156.2;Inhibitory neurons: 111.6" "Cancer enhanced" "Detected in some" "colorectal cancer: 0.6;glioma: 0.8" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "U-2 OS: 4.2;U-87 MG: 2.1;WM-115: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029363, CAB079061" Supported Uncertain "Nucleoplasm,Plasma membrane" "Intracellular and membrane" NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 9: U-2 OS - Unknown function" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" Nucleoplasm "CAB079061: , HPA029363: " "unprognostic (2.03e-2)" "unprognostic (2.77e-1)" "unprognostic (2.45e-4)" "unprognostic (6.87e-3)" "unprognostic (2.65e-1)" "unprognostic (2.08e-1)" "unprognostic (1.01e-1)" "unprognostic (4.09e-1)" "unprognostic (6.90e-3)" "unprognostic (8.83e-2)" "unprognostic (2.22e-5)" "unprognostic (1.75e-1)" "unprognostic (1.15e-1)" "unprognostic (2.67e-1)" "unprognostic (3.04e-2)" 1.2 0.3 20.2 0.4 29.9 0.2 1.3 2.6 31.5 0.5 0.0 3.0 0.9 0.4 8.8 0.7 0.0 0.5 0.2 29.4 16.0 6.3 0.4 0.1 0.3 0.3 1.9 0.7 0.1 0.0 0.5 0.4 0.0 0.1 2.1 2.4 0.2 0.7 0.1 0.2 6.0 0.2 1.3 1.2 0.5 0.5 13.8 0.4 0.1 0.1 0.4 0.2 0.7 8.8 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.1 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.1 0.0 0.1 0.4 0.6 0.0 0.0 0.3 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.2 4.2 0.2 0.0 0.2 0.6 0.0 2.1 0.1 2.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 20.2 29.9 2.6 31.5 29.4 16.0 0.3 1.9 0.0 1.3 13.8 8.8 4.9 0.0 0.0 425.4 0.0 0.1 0.0 0.0 1.2 15.3 0.2 0.0 0.6 0.0 0.0 40.5 4.2 0.0 0.0 23.1 3.9 0.0 9.1 1.2 31.7 1.0 31.8 0.0 156.2 0.0 0.0 0.5 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 111.6 3.4 0.0 0.0 0.0 17.1 0.6 0.1 1.8 16.9 0.0 0.2 0.0 13.0 5.5 0.0 4.7 0.0 0.0 0.0 38.1 0.1 0.0 1.1 0.0 0.0 0.2 0.0 1.3 0.0 0.1 0.0 0.1 0.0 2.7 0.0 GABRA3 ENSG00000011677 "Gamma-aminobutyric acid type A receptor subunit alpha3" P34903 X 152166234-152451315 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 15.5;choroid plexus: 16.3;retina: 9.0" "Cell type enhanced" "Detected in some" "Excitatory neurons: 70.3;Hofbauer cells: 16.2;Inhibitory neurons: 22.2;Oligodendrocyte precursor cells: 58.3" "Cancer enriched" "Detected in many" 7 "testis cancer: 16.6" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "GAMG: 9.9;HMC-1: 8.4;Karpas-707: 14.4;PC-3: 8.4;U-266/70: 7.7;U-266/84: 13.6;U-87 MG: 8.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000839, HPA029363" Approved Supported Uncertain "Nucleoplasm,Plasma membrane" NA NA "Cluster 58: Brain - Synaptic function" "Cluster 2: Karpas-707 - Immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" Nucleoplasm "HPA000839: AB_1078929, HPA029363: " "unprognostic (9.63e-3)" "unprognostic (2.04e-1)" "unprognostic (2.02e-1)" "unprognostic (1.18e-2)" "unprognostic (7.07e-2)" "unprognostic (5.42e-2)" "unprognostic (2.34e-6)" "unprognostic (1.24e-1)" "unprognostic (2.70e-1)" "unprognostic (2.39e-2)" "unprognostic (2.63e-2)" "unprognostic (1.73e-1)" "unprognostic (7.29e-6)" "unprognostic (7.42e-3)" "unprognostic (6.20e-2)" "unprognostic (8.13e-2)" 0.0 0.0 10.0 0.0 13.7 0.0 0.0 0.0 13.2 0.9 16.3 0.1 0.1 0.3 0.0 0.4 0.0 0.0 0.0 9.6 15.5 0.0 0.0 0.0 0.0 0.9 4.0 0.0 0.0 0.0 0.6 2.9 3.0 0.1 0.0 9.0 0.1 0.6 0.0 0.2 0.1 0.0 0.6 0.0 0.0 0.7 11.2 0.0 0.0 0.0 0.1 0.4 0.2 2.7 0.0 0.8 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 9.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 4.0 0.0 0.0 0.0 8.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 14.4 0.0 0.0 0.0 0.0 2.6 6.4 8.4 0.0 0.0 0.0 0.0 0.0 0.2 5.2 0.0 5.3 0.4 0.3 0.1 1.3 0.1 5.3 7.0 0.3 1.6 7.7 13.6 0.0 8.4 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 13.7 0.0 13.2 9.6 15.5 0.9 4.0 3.0 0.6 11.2 2.7 0.0 0.0 0.0 3.6 0.0 0.0 0.1 0.0 0.6 1.2 0.0 0.0 0.3 0.0 0.0 0.0 2.1 3.2 0.0 0.0 0.0 0.0 0.2 0.0 1.1 0.1 0.0 0.0 70.3 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 16.2 1.7 22.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 4.7 0.0 3.0 0.0 58.3 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.5 1.2 0.9 0.0 1.9 0.0 0.0 0.0 0.5 GABRA4 ENSG00000109158 "Gamma-aminobutyric acid type A receptor subunit alpha4" P48169 4 46918900-46993581 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "brain: 7.5;heart muscle: 2.5" "Group enriched" "Detected in some" 6 "Excitatory neurons: 124.9;Inhibitory neurons: 160.1" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 149 "REH: 14.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 14: REH - Unknown function" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (2.78e-2)" "unprognostic (6.57e-3)" "unprognostic (2.46e-1)" "unprognostic (2.23e-1)" "unprognostic (3.17e-1)" "unprognostic (1.11e-1)" "unprognostic (6.91e-2)" 0.0 0.0 1.8 0.0 7.5 0.0 0.0 0.0 6.8 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 2.5 4.0 2.6 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.3 0.0 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 7.5 0.0 6.8 4.0 2.6 0.7 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.0 21.5 0.0 0.5 0.0 0.0 0.6 0.3 0.0 0.6 15.8 0.0 0.0 0.0 0.0 0.2 0.0 0.2 1.9 0.0 1.3 0.0 0.0 0.1 0.0 0.0 124.9 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 160.1 0.4 0.0 0.0 0.0 0.3 0.0 0.1 0.0 8.4 0.0 6.1 0.0 3.5 3.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 1.4 3.8 0.1 0.4 0.1 0.0 0.0 0.0 0.9 0.0 GABRA5 ENSG00000186297 "Gamma-aminobutyric acid type A receptor subunit alpha5" P31644 15 26866911-26949208 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "brain: 111.0" "Group enriched" "Detected in some" 4 "Excitatory neurons: 27.6;Inhibitory neurons: 14.1" "Cancer enhanced" "Detected in some" "glioma: 0.8" "Group enriched" "Detected in many" 4 "amygdala: 52.0;basal ganglia: 73.5;cerebral cortex: 98.6;hippocampal formation: 111.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 10 "A549: 35.3;HAP1: 12.0;NTERA-2: 16.2;U-2 OS: 13.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA029363, HPA077031, CAB079022" Supported Approved "Nucleoplasm,Plasma membrane" NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 5: NTERA-2 - Transcription" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" Nucleoplasm "CAB079022: , HPA029363: , HPA077031: AB_2686825" "unprognostic (6.33e-2)" "unprognostic (8.94e-3)" "unprognostic (1.04e-1)" "unprognostic (2.50e-1)" "unprognostic (1.81e-1)" "unprognostic (3.75e-1)" "unprognostic (9.50e-3)" "unprognostic (2.57e-1)" "unprognostic (7.63e-2)" "unprognostic (8.50e-2)" "unprognostic (1.44e-2)" 0.0 0.0 52.0 0.1 73.5 0.0 0.0 0.0 98.6 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.7 0.5 111.0 7.2 0.1 0.1 0.0 0.0 0.0 3.0 0.0 0.1 0.7 0.5 0.0 0.0 0.2 0.0 1.6 0.0 0.1 0.0 0.0 0.1 0.6 0.0 0.0 1.2 0.7 12.0 9.0 0.1 0.1 0.3 0.0 0.0 19.6 0.0 35.3 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.8 0.0 0.0 12.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 16.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.5 0.0 0.1 0.2 1.8 0.0 0.0 0.0 0.0 13.4 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 52.0 73.5 0.0 98.6 111.0 7.2 0.0 3.0 0.0 0.0 12.0 19.6 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 27.6 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.1 0.0 14.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.0 0.0 0.8 0.0 1.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.1 0.0 2.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 GABRA6 ENSG00000145863 "Gamma-aminobutyric acid type A receptor subunit alpha6" Q16445 5 161547063-161702593 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in single" 114 "brain: 71.1" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 14 "cerebellum: 71.1" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in some" 40 "cerebellum: 1073.8" "Region enriched" "Detected in some" 37 "cerebellum: 262.3" CAB022462 Approved NA NA "Cluster 69: Cerebellum - Gene expression regulation" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB022462: " "unprognostic (3.79e-2)" 0.0 0.1 0.1 0.0 0.3 0.0 0.0 71.1 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.2 1.8 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 71.1 2.8 0.1 0.3 0.2 1.8 4.9 0.4 0.3 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GABRB1 ENSG00000163288 "Gamma-aminobutyric acid type A receptor subunit beta1" P18505 4 46993723-47426447 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "brain: 26.3" "Group enriched" "Detected in some" 15 "Astrocytes: 926.2;Excitatory neurons: 440.3;Inhibitory neurons: 507.4;Oligodendrocyte precursor cells: 266.9" "Cancer enhanced" "Detected in single" "glioma: 0.7" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "REH: 7.1;U-87 MG: 2.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 65: Brain - Ion transport" "Cluster 14: REH - Unknown function" "Cluster 64: Astrocytes - Nervous system maintenance" "unprognostic (3.11e-2)" "unprognostic (7.56e-3)" "unprognostic (5.10e-2)" "unprognostic (1.83e-1)" "unprognostic (1.11e-1)" "unprognostic (4.98e-3)" "unprognostic (8.16e-3)" "unprognostic (6.22e-2)" "unprognostic (2.72e-2)" "unprognostic (2.34e-1)" 0.0 0.2 19.1 0.0 24.8 0.0 0.0 0.3 26.3 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.2 3.6 26.2 24.6 0.3 0.0 0.0 0.0 0.5 7.4 0.0 0.0 0.3 1.5 0.1 0.6 0.0 0.1 2.4 0.1 0.0 0.0 0.0 0.1 0.0 1.1 0.0 0.0 0.0 26.1 0.0 0.1 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.1 24.8 0.3 26.3 26.2 24.6 0.5 7.4 0.6 1.1 26.1 2.3 0.0 0.0 0.0 926.2 0.0 0.0 0.0 0.0 0.0 0.8 0.1 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.3 0.1 1.2 0.0 440.3 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 507.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.7 0.1 32.9 0.0 266.9 16.3 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 1.3 0.0 0.0 0.1 0.3 1.9 0.0 0.0 0.1 0.0 0.0 0.3 0.0 GABRB2 ENSG00000145864 "Gamma-aminobutyric acid type A receptor subunit beta2" P47870 5 161288429-161549044 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 11 "brain: 71.7" "Group enriched" "Detected in many" 20 "Excitatory neurons: 570.3;Inhibitory neurons: 780.2" "Cancer enriched" "Detected in some" 20 "thyroid cancer: 10.2" "Group enriched" "Detected in many" 7 "cerebellum: 63.2;cerebral cortex: 71.7" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 10 "SCLC-21H: 22.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001964, HPA067632" Enhanced NA NA "Cluster 6: Brain - Smell perception" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB001964: , HPA067632: AB_2685874" "unprognostic (5.46e-2)" "unprognostic (1.03e-1)" "unprognostic (3.29e-1)" "unprognostic (2.26e-6)" "unprognostic (2.33e-2)" "unprognostic (6.65e-2)" "unprognostic (3.58e-2)" "unprognostic (1.82e-1)" "unprognostic (1.01e-2)" "unprognostic (1.22e-1)" "unprognostic (5.19e-3)" "unprognostic (2.24e-4)" "unprognostic (1.22e-1)" "unprognostic (1.33e-2)" "unprognostic (1.58e-1)" "unprognostic (7.18e-3)" "unprognostic (1.04e-2)" 0.7 2.3 0.6 0.0 5.8 0.0 0.1 63.2 71.7 0.5 0.0 0.6 1.2 0.1 3.4 0.0 0.4 0.0 0.1 9.2 10.0 1.8 0.0 0.9 0.0 0.0 0.0 0.1 0.1 0.1 0.5 0.2 0.0 0.1 1.1 6.5 0.5 0.6 0.1 0.1 0.6 0.1 0.0 2.4 0.5 0.6 7.9 0.1 0.5 0.4 0.0 0.0 0.0 9.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 1.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 22.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 2.2 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 5.8 63.2 71.7 9.2 10.0 0.0 0.0 0.0 0.0 7.9 9.5 0.0 0.0 0.0 21.5 0.0 0.3 0.0 0.1 0.0 19.8 0.1 0.0 1.9 0.0 0.0 0.0 27.1 0.0 0.0 1.0 5.9 0.0 1.6 0.0 0.3 0.3 1.2 0.0 570.3 0.0 0.0 2.6 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 780.2 1.8 4.1 0.0 0.4 1.4 0.0 1.3 0.0 20.6 0.0 2.3 0.0 33.7 17.9 0.0 0.5 0.4 0.0 0.1 0.0 3.2 0.0 10.6 0.0 0.3 3.5 3.1 1.8 0.1 0.4 0.0 0.0 1.9 4.2 0.1 GABRB3 ENSG00000166206 "Gamma-aminobutyric acid type A receptor subunit beta3" P28472 15 26543546-26939539 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 29.5;retina: 31.9" "Cell type enhanced" "Detected in many" "Bipolar cells: 152.4;Excitatory neurons: 519.6;Inhibitory neurons: 258.7;Oligodendrocyte precursor cells: 139.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 68.5;HAP1: 27.9;NTERA-2: 48.3;OE19: 21.6;SCLC-21H: 44.2;U-2 OS: 18.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 58: Brain - Synaptic function" "Cluster 5: NTERA-2 - Transcription" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "unprognostic (1.72e-1)" "unprognostic (4.91e-2)" "unprognostic (3.20e-2)" "unprognostic (4.25e-2)" "unprognostic (1.66e-1)" "unprognostic (7.07e-2)" "unprognostic (1.00e-1)" "unprognostic (8.87e-2)" "unprognostic (1.02e-1)" "unprognostic (2.44e-1)" "unprognostic (1.44e-2)" "unprognostic (3.62e-1)" "unprognostic (3.56e-3)" "unprognostic (2.99e-2)" "unprognostic (1.49e-1)" "unprognostic (3.33e-2)" "unprognostic (4.05e-1)" 0.6 5.5 16.6 0.5 24.3 0.0 0.8 3.9 29.5 2.3 0.0 1.2 0.8 1.7 1.0 1.2 2.3 13.6 6.2 28.0 18.0 7.3 0.9 0.9 0.1 0.0 1.3 1.9 4.8 2.1 15.7 0.0 0.3 5.0 0.9 31.9 0.5 1.2 0.1 0.7 0.6 1.4 3.1 0.6 5.7 4.0 11.6 1.5 8.7 0.1 0.2 1.1 0.5 13.8 0.0 68.5 10.7 0.0 0.0 0.0 2.6 1.1 0.0 0.0 0.0 0.1 0.0 0.9 0.0 0.1 0.0 0.0 27.9 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.1 0.0 5.4 3.3 0.0 0.0 0.0 0.0 0.0 14.8 2.1 0.1 0.0 0.0 4.8 0.0 48.3 21.6 3.4 0.0 0.0 0.0 4.7 0.0 44.2 16.6 0.0 0.1 0.0 5.0 0.1 0.0 0.0 0.0 18.1 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.6 24.3 3.9 29.5 28.0 18.0 0.0 1.3 0.3 3.1 11.6 13.8 0.4 12.8 3.6 33.3 0.0 0.0 0.8 0.7 1.2 152.4 1.0 0.8 15.3 24.3 1.7 5.5 39.6 0.4 0.0 1.4 0.0 4.6 10.7 1.4 4.0 1.2 10.3 0.0 519.6 0.4 0.0 1.7 2.6 0.6 0.0 1.1 0.7 0.4 0.0 75.7 258.7 1.9 0.0 0.6 0.0 5.6 1.8 0.0 0.0 5.6 0.2 7.9 0.0 139.7 8.7 1.7 0.4 3.4 0.0 3.3 0.2 7.0 13.5 53.7 0.0 1.0 0.9 8.6 29.3 0.7 0.1 0.3 0.1 0.5 0.9 0.4 GABRD ENSG00000187730 "Gamma-aminobutyric acid type A receptor subunit delta" O14764 1 2019329-2030758 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "brain: 49.6" "Cell type enhanced" "Detected in some" "Bipolar cells: 14.7;Excitatory neurons: 30.0;Horizontal cells: 13.5;Inhibitory neurons: 37.4;Spermatogonia: 11.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "EFO-21: 1.4;HMC-1: 1.2;MCF7: 4.4;NB-4: 2.7;SH-SY5Y: 1.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044371 Enhanced Uncertain "Golgi apparatus,Vesicles" NA NA "Cluster 6: Brain - Smell perception" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Golgi apparatus, Vesicles" "HPA044371: AB_2678916" "unprognostic (4.28e-2)" "unprognostic (1.90e-1)" "unprognostic (5.95e-8)" "unprognostic (6.34e-3)" "unprognostic (2.66e-3)" "unprognostic (1.04e-2)" "unprognostic (3.44e-3)" "unprognostic (2.14e-1)" "unprognostic (4.53e-2)" "unprognostic (1.12e-1)" "unprognostic (3.77e-2)" "unprognostic (1.99e-1)" "prognostic unfavorable (4.12e-8)" "unprognostic (1.72e-1)" "unprognostic (1.76e-1)" "unprognostic (2.77e-1)" "unprognostic (5.16e-2)" 0.3 1.5 12.8 0.0 16.9 0.0 0.5 49.6 40.5 0.1 0.1 0.2 0.0 0.3 0.1 0.3 0.2 0.4 0.7 14.7 5.4 0.7 0.2 0.9 0.2 14.3 18.1 0.2 0.1 0.7 2.7 0.1 20.2 0.2 0.0 1.4 0.3 0.0 0.3 0.4 0.2 0.3 1.0 0.3 0.1 3.6 29.7 0.1 0.9 0.4 0.0 0.2 0.2 14.7 0.0 0.3 0.0 0.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.4 0.0 0.1 0.0 0.7 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 2.7 1.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.6 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 12.8 16.9 49.6 40.5 14.7 5.4 14.3 18.1 20.2 1.0 29.7 14.7 1.0 3.2 3.6 4.9 0.1 0.5 0.0 0.0 0.0 14.7 0.3 0.0 0.9 0.0 6.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.2 0.2 0.2 3.4 0.0 0.0 30.0 0.0 0.3 0.5 0.0 0.2 2.5 0.3 0.0 0.0 0.1 13.5 37.4 0.0 0.0 0.0 0.3 0.2 0.0 0.9 0.0 8.4 0.0 1.4 0.0 3.0 4.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 4.4 1.6 0.0 0.0 4.8 0.1 11.3 0.1 0.0 0.3 0.4 0.2 0.1 0.1 GABRE ENSG00000102287 "Gamma-aminobutyric acid type A receptor subunit epsilon" P78334 X 151953124-151974680 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in many" 5 "brain: 52.3" "Cell type enhanced" "Detected in many" "Basal squamous epithelial cells: 30.7;Syncytiotrophoblasts: 61.4;Urothelial cells: 42.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 3.4;EFO-21: 11.6;HeLa: 6.1;SiHa: 5.6" "Region enriched" "Detected in many" 4 "hypothalamus: 18.4" "Region enhanced" "Detected in many" "hypothalamus: 32.3" HPA045918 Uncertain NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 38: EFO-21 - Unknown function" "Cluster 22: Epithelial cell types - Mixed function" "HPA045918: AB_10961281" "unprognostic (1.33e-2)" "unprognostic (6.75e-2)" "unprognostic (3.50e-3)" "unprognostic (1.39e-3)" "unprognostic (2.43e-1)" "unprognostic (7.52e-2)" "unprognostic (5.06e-3)" "unprognostic (1.27e-1)" "unprognostic (3.58e-2)" "unprognostic (1.55e-1)" "unprognostic (6.44e-2)" "unprognostic (6.73e-2)" "prognostic unfavorable (4.05e-11)" "unprognostic (1.96e-2)" "unprognostic (1.39e-1)" "unprognostic (2.29e-2)" "unprognostic (5.28e-2)" 9.7 0.4 6.3 0.3 4.5 0.0 4.4 0.0 9.7 1.7 0.9 0.4 0.7 0.6 1.8 1.0 0.7 0.5 9.5 0.8 52.3 1.1 0.1 0.6 0.2 5.1 38.0 0.8 0.8 0.9 2.2 3.3 33.0 1.8 0.3 0.1 0.8 3.4 0.3 3.2 0.4 0.3 0.2 0.2 0.3 0.1 14.0 0.1 1.0 0.0 0.2 0.6 2.3 0.2 0.2 0.0 0.1 0.0 3.4 0.0 0.0 0.5 0.0 0.8 0.4 1.9 0.6 0.0 11.6 2.5 0.0 1.9 0.0 0.6 0.5 0.0 0.4 1.3 6.1 0.7 0.2 0.0 0.1 0.8 0.5 0.9 0.2 1.1 0.4 0.0 0.4 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.7 0.0 0.8 0.0 0.0 1.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 4.5 0.0 9.7 0.8 52.3 5.1 38.0 33.0 0.2 14.0 0.2 7.7 16.0 9.3 0.7 0.7 17.2 22.9 18.6 30.7 0.0 6.8 4.6 7.3 11.5 25.2 1.8 0.0 25.0 0.5 10.0 0.0 4.1 2.0 7.6 12.8 9.0 1.8 0.0 0.0 0.4 3.5 9.2 0.0 29.2 0.0 0.1 4.2 0.9 3.0 0.0 0.0 2.3 4.1 0.6 4.6 3.5 1.5 0.3 1.8 2.8 0.7 0.6 1.0 0.0 0.0 6.1 7.4 2.2 0.0 19.2 21.6 0.2 5.6 0.3 0.0 19.6 5.7 1.2 2.1 22.5 10.9 61.4 1.3 0.1 3.6 42.2 GABRG1 ENSG00000163285 "Gamma-aminobutyric acid type A receptor subunit gamma1" Q8N1C3 4 46035769-46124054 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 44.7" "Cell type enriched" "Detected in some" 8 "Astrocytes: 135.5" "Cancer enriched" "Detected in single" 8 "glioma: 0.6" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "U-266/70: 1.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035622, HPA058102" Approved Supported "Plasma membrane" NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 29: U-266 - Adaptive immune response" "Cluster 64: Astrocytes - Nervous system maintenance" "Plasma membrane" "HPA035622: AB_10603669, HPA058102: " "unprognostic (2.50e-1)" "unprognostic (2.20e-1)" "unprognostic (6.06e-2)" "unprognostic (1.46e-2)" "unprognostic (7.39e-4)" "unprognostic (1.23e-1)" "unprognostic (1.28e-1)" "unprognostic (1.99e-1)" 0.1 0.1 21.6 0.0 20.6 0.0 0.0 19.0 27.3 0.0 9.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 19.4 31.7 0.0 0.0 0.0 0.0 24.8 38.0 1.2 0.0 0.0 0.6 0.0 23.9 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 21.1 0.1 0.0 0.2 44.7 0.0 0.1 0.0 0.0 0.0 0.0 23.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.4 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.6 20.6 19.0 27.3 19.4 31.7 24.8 38.0 23.9 21.1 44.7 23.1 0.3 0.0 0.0 135.5 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.3 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 8.2 0.0 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 12.5 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 11.2 0.0 15.4 0.0 2.5 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 6.6 0.0 1.8 0.1 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 GABRG2 ENSG00000113327 "Gamma-aminobutyric acid type A receptor subunit gamma2" P18507 5 162000057-162162977 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 20.0;retina: 10.9" "Group enriched" "Detected in some" 7 "Bipolar cells: 119.0;Excitatory neurons: 239.9;Inhibitory neurons: 167.8" "Cancer enhanced" "Detected in single" "glioma: 1.4" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in some" "basophil: 4.5" "Group enriched" "Detected in many" 5 "B-cells: 1.6;granulocytes: 4.5;T-cells: 1.5" "Cell line enhanced" "Detected in many" "CACO-2: 10.3;Karpas-707: 10.2;RPMI-8226: 13.4;SuSa: 13.0;U-266/70: 20.1;U-266/84: 18.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB079060 Supported NA NA "Cluster 6: Non-specific - Transcription" "Cluster 58: Brain - Synaptic function" "Cluster 16: U-266 - Nucleosome" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "CAB079060: " "unprognostic (2.88e-2)" "unprognostic (1.56e-2)" "unprognostic (6.31e-3)" "unprognostic (3.07e-3)" "unprognostic (1.52e-1)" 0.3 4.7 7.9 0.4 9.0 2.2 0.1 7.2 20.0 0.0 0.0 0.7 1.2 0.3 0.4 0.4 0.5 2.6 0.8 9.6 10.6 0.2 0.4 0.9 0.4 4.7 4.6 0.7 0.1 0.0 1.1 1.9 10.7 0.1 0.5 10.9 0.5 0.1 0.5 2.2 0.9 0.8 0.5 0.4 1.9 0.7 9.3 1.7 0.5 0.5 0.5 0.2 0.0 7.5 3.9 1.7 2.3 0.2 0.0 0.1 1.9 0.7 0.0 0.0 0.0 10.3 5.5 0.5 5.9 0.0 0.2 1.1 1.6 0.0 0.0 1.0 1.0 0.0 1.7 1.2 0.0 0.0 0.6 0.4 0.3 0.0 0.0 0.1 0.0 1.0 2.4 10.2 0.0 2.8 0.5 0.1 7.4 3.1 3.6 0.5 0.1 13.4 0.0 3.1 1.1 0.9 0.3 0.5 4.1 13.0 6.7 6.9 0.1 0.3 5.2 0.4 0.5 20.1 18.7 0.1 0.1 0.5 0.3 4.5 0.1 0.3 0.2 0.1 1.2 1.6 0.3 0.3 0.0 1.4 1.5 0.3 0.7 0.4 0.1 0.3 0.4 0.1 7.9 9.0 7.2 20.0 9.6 10.6 4.7 4.6 10.7 0.5 9.3 7.5 0.0 19.2 23.5 15.3 0.0 0.0 0.0 0.0 0.0 119.0 0.1 0.0 0.4 0.0 10.5 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 239.9 0.0 0.1 1.4 0.0 0.0 8.8 0.0 0.0 0.0 0.1 16.8 167.8 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 12.2 0.0 2.6 0.0 12.1 15.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 6.6 9.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.6 0.0 0.0 0.0 GABRG3 ENSG00000182256 "Gamma-aminobutyric acid type A receptor subunit gamma3" Q99928 15 26971181-27541984 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "brain: 17.6;retina: 27.1;testis: 9.3" "Group enriched" "Detected in some" 4 "Excitatory neurons: 444.7;Inhibitory neurons: 615.5;Late spermatids: 351.0;Muller glia cells: 179.9" "Cancer enhanced" "Detected in single" "prostate cancer: 1.5" "Region enhanced" "Detected in many" "hypothalamus: 17.6" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "K-562: 4.5;PC-3: 5.5;SK-MEL-30: 3.5;U-2 OS: 2.5;U-266/70: 3.2;U-87 MG: 14.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA054010 Approved NA NA "Cluster 77: Retina - Visual perception" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA054010: AB_2682342" "unprognostic (1.23e-1)" "unprognostic (1.67e-1)" "unprognostic (1.02e-2)" "unprognostic (3.50e-2)" "unprognostic (2.61e-1)" "unprognostic (2.33e-3)" "unprognostic (1.30e-1)" "unprognostic (2.39e-2)" "unprognostic (5.15e-2)" "unprognostic (2.95e-1)" "unprognostic (4.41e-1)" "unprognostic (1.43e-5)" "unprognostic (1.52e-1)" "unprognostic (1.32e-1)" "unprognostic (2.03e-2)" "unprognostic (1.83e-1)" 0.0 0.4 3.5 0.2 3.0 0.0 0.4 0.0 4.2 0.8 0.0 0.0 0.0 0.1 1.9 0.0 0.4 0.0 0.0 0.9 17.6 0.7 0.1 0.0 0.6 0.5 0.2 0.0 0.0 0.0 3.0 0.0 0.0 6.6 0.0 27.1 0.8 0.2 0.0 0.3 0.0 0.0 0.6 1.0 0.0 9.3 10.2 1.0 1.5 0.0 0.8 0.0 0.2 2.9 0.0 0.0 1.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.4 0.3 0.0 5.5 0.0 0.0 1.0 0.0 0.0 0.1 1.0 0.0 0.0 3.5 0.1 0.0 0.0 0.0 0.0 2.5 0.0 0.0 3.2 0.0 0.0 14.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 3.0 0.0 4.2 0.9 17.6 0.5 0.2 0.0 0.6 10.2 2.9 0.1 0.0 0.0 5.5 0.0 0.0 0.1 0.0 0.0 4.6 2.5 1.4 0.9 0.0 0.0 0.0 2.1 0.0 0.1 0.0 0.0 0.0 86.2 3.2 0.1 0.3 0.0 0.0 444.7 0.0 0.0 0.1 0.0 0.4 0.0 0.5 0.0 0.0 0.1 0.0 615.5 0.0 0.0 0.0 0.0 351.0 0.9 0.2 0.0 7.5 0.0 179.9 0.0 16.1 7.9 0.0 0.0 0.7 0.0 3.1 0.0 0.3 0.0 4.6 0.0 0.1 0.1 1.6 7.4 0.0 0.0 0.0 0.1 0.0 0.0 0.2 GABRP ENSG00000094755 "Gamma-aminobutyric acid type A receptor subunit pi" O00591 5 170763350-170814047 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "breast: 152.3;esophagus: 171.5" "Cell type enhanced" "Detected in many" "Breast glandular cells: 169.0;Breast myoepithelial cells: 113.2;Club cells: 83.1;Endometrial ciliated cells: 146.0;Glandular and luminal cells: 464.0;Urothelial cells: 146.6" "Group enriched" "Detected in many" 4 "breast cancer: 35.4;cervical cancer: 49.3;endometrial cancer: 16.8;pancreatic cancer: 41.9;stomach cancer: 25.2" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "basophil: 11.8" "Group enriched" "Detected in many" 8 "granulocytes: 11.8;monocytes: 5.7" "Cell line enhanced" "Detected in many" "A-431: 215.1;EFO-21: 236.8;HeLa: 166.8;PC-3: 331.3;SuSa: 418.8" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB014883 Uncertain NA NA "Cluster 41: Basophils - Cellular respiration" "Cluster 84: Esophagus - Epithelial cell function" "Cluster 38: EFO-21 - Unknown function" "Cluster 44: Endometrium - Transcription" "CAB014883: " "unprognostic (3.98e-3)" "prognostic favorable (3.37e-4)" "unprognostic (8.34e-2)" "unprognostic (1.57e-1)" "unprognostic (8.90e-2)" "unprognostic (1.27e-1)" "unprognostic (7.89e-2)" "unprognostic (4.97e-3)" "unprognostic (3.72e-1)" "unprognostic (4.93e-3)" "unprognostic (1.30e-3)" "unprognostic (2.30e-1)" "unprognostic (1.40e-2)" "unprognostic (1.60e-1)" "unprognostic (1.82e-1)" "unprognostic (5.92e-3)" "unprognostic (6.52e-3)" 4.5 3.6 10.4 7.3 10.5 9.9 152.3 15.8 16.2 13.1 5.4 4.2 15.4 48.6 19.0 171.5 12.9 27.3 5.4 7.6 23.0 6.1 7.1 14.7 5.7 12.5 6.1 3.9 23.8 2.0 2.0 9.1 10.6 12.7 4.9 42.1 35.8 16.6 13.7 19.0 16.2 2.6 2.7 7.4 27.4 8.3 10.4 4.7 6.1 2.7 42.2 5.4 29.4 17.9 215.1 9.9 10.1 7.0 0.7 4.3 23.8 3.8 1.5 0.5 0.6 38.1 23.6 3.3 236.8 1.1 2.3 75.7 6.4 0.5 0.6 3.5 7.6 14.1 166.8 5.7 0.8 5.1 11.2 1.6 3.0 2.8 1.8 8.0 1.4 13.4 57.6 26.5 0.4 6.7 9.5 4.7 84.5 3.7 331.3 13.7 6.6 8.2 13.8 11.6 8.2 4.0 76.5 3.9 2.2 418.8 4.2 2.4 8.8 19.1 69.3 15.7 15.7 10.0 6.7 6.3 2.6 13.9 2.9 11.8 1.9 6.1 0.4 1.5 1.1 0.3 0.4 0.3 0.6 0.7 0.5 0.5 4.5 0.2 5.7 0.9 0.6 2.3 10.4 10.5 15.8 16.2 7.6 23.0 12.5 6.1 10.6 2.7 10.4 17.9 1.1 3.2 0.6 0.0 0.9 0.0 14.9 44.4 0.0 0.0 169.0 113.2 0.7 51.5 83.1 1.8 0.0 5.2 2.3 0.0 0.0 10.4 0.0 146.0 48.8 3.8 0.0 0.0 0.3 13.8 0.6 2.4 2.0 464.0 0.0 0.0 0.0 0.1 2.3 0.0 0.2 0.3 12.2 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 56.6 0.1 0.0 0.0 24.2 0.1 0.1 34.0 0.0 0.0 0.2 5.9 0.0 0.0 4.5 0.0 5.7 2.7 0.0 0.6 146.6 GABRQ ENSG00000268089 "Gamma-aminobutyric acid type A receptor subunit theta" Q9UN88 X 152637895-152657542 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Chloride channel, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "brain: 72.4" "Cell type enhanced" "Detected in some" "Basal keratinocytes: 4.0;Glandular and luminal cells: 2.8;Spermatogonia: 1.4;Squamous epithelial cells: 2.5;Suprabasal keratinocytes: 1.8" "Cancer enhanced" "Detected in many" "testis cancer: 6.6" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HeLa: 11.4;SiHa: 11.6;SuSa: 5.0;U-87 MG: 37.2" "Region enriched" "Detected in many" 5 "hypothalamus: 52.6" "Group enriched" "Detected in some" 4 "hypothalamus: 7.7;midbrain: 20.8;pons: 6.3" NA NA "Cluster 65: Brain - Ion transport" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 44: Endometrium - Transcription" "unprognostic (3.68e-3)" "unprognostic (7.78e-2)" "unprognostic (9.16e-2)" "unprognostic (1.17e-4)" "unprognostic (3.38e-1)" "unprognostic (1.41e-1)" "unprognostic (1.45e-4)" "unprognostic (1.31e-1)" "unprognostic (1.84e-1)" "unprognostic (1.41e-1)" "unprognostic (3.73e-1)" "unprognostic (3.76e-2)" "unprognostic (3.10e-5)" "unprognostic (3.43e-3)" "unprognostic (1.84e-1)" "unprognostic (6.42e-2)" "unprognostic (7.70e-2)" 0.0 2.2 22.3 0.0 25.3 0.0 0.0 0.1 27.1 7.7 0.0 0.0 0.0 1.2 0.1 0.6 0.0 0.0 0.0 17.6 72.4 0.0 0.0 0.0 0.0 9.6 27.9 0.0 0.0 0.0 0.1 0.1 22.2 0.4 0.0 0.2 0.0 0.5 0.0 0.3 0.2 0.8 3.0 0.0 0.0 1.2 41.4 0.0 0.0 0.0 0.1 0.0 0.7 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.3 0.2 11.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 1.0 0.0 2.9 0.0 0.0 0.0 0.0 1.6 11.6 2.1 0.0 5.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 37.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.3 25.3 0.1 27.1 17.6 72.4 9.6 27.9 22.2 3.0 41.4 1.7 0.0 0.0 0.0 0.0 0.0 4.0 0.1 0.0 0.6 1.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.2 0.0 0.0 0.2 0.0 0.0 0.3 0.0 2.8 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 1.0 1.4 2.5 1.8 0.8 0.0 0.0 0.0 0.5 GAMT "PIG2, TP53I2" ENSG00000130005 "Guanidinoacetate N-methyltransferase" Q14353 19 1397026-1401570 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Methyltransferase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 615.1;skeletal muscle: 1234.9;tongue: 466.4" "Group enriched" "Detected in many" 4 "Hepatocytes: 718.3;Proximal tubular cells: 417.4" "Cancer enriched" "Detected in all" 5 "liver cancer: 173.2" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Hep G2: 176.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051806 Approved NA NA 420000 "Cluster 29: Plasmacytoid DCs - Unknown function" "Cluster 55: Non-specific - Mitochondria & Proteasome" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "HPA051806: AB_2681619" "unprognostic (3.25e-1)" "unprognostic (7.74e-3)" "unprognostic (3.22e-2)" "unprognostic (6.32e-2)" "unprognostic (4.35e-2)" "unprognostic (1.86e-1)" "unprognostic (2.92e-2)" "unprognostic (2.80e-2)" "unprognostic (1.14e-1)" "unprognostic (2.27e-1)" "unprognostic (3.41e-2)" "unprognostic (7.10e-2)" "unprognostic (6.36e-2)" "prognostic unfavorable (6.57e-4)" "unprognostic (1.78e-1)" "unprognostic (1.82e-1)" "unprognostic (1.54e-2)" 14.0 26.6 69.4 4.5 74.5 8.8 15.6 68.6 79.1 16.5 53.4 10.9 3.2 10.0 141.9 23.0 14.7 9.9 98.1 67.3 67.1 72.0 615.1 8.1 7.7 71.8 68.3 22.8 229.8 37.8 37.4 4.9 70.4 36.5 2.2 15.0 42.6 17.5 1234.9 32.8 6.4 4.6 68.8 10.7 31.8 55.0 76.1 24.8 22.2 466.4 4.3 12.9 15.3 94.5 21.6 24.1 25.2 56.9 30.9 37.3 34.3 25.2 41.2 31.8 28.7 54.8 15.1 11.3 17.2 30.0 3.8 9.1 39.8 15.5 8.5 81.5 46.2 34.9 20.3 176.7 18.2 0.7 11.5 41.8 5.5 33.8 0.1 44.0 6.9 43.0 50.6 26.6 52.6 22.1 103.9 12.0 28.6 10.7 75.4 103.1 22.3 81.4 38.1 19.5 8.4 58.5 1.9 14.3 32.0 16.1 65.3 48.1 12.2 34.6 35.6 1.9 11.6 119.0 24.8 19.5 32.2 46.1 40.7 3.7 2.5 15.3 18.8 3.4 27.3 22.0 26.3 23.8 11.2 32.3 40.6 30.8 1.5 18.2 6.1 47.3 15.8 14.9 69.4 74.5 68.6 79.1 67.3 67.1 71.8 68.3 70.4 68.8 76.1 94.5 9.2 0.0 7.2 5.5 18.0 58.9 42.1 57.8 116.7 41.0 60.3 99.9 99.3 127.2 12.9 16.5 56.3 35.7 15.4 0.8 92.0 39.9 5.2 6.5 7.4 9.2 7.2 35.8 7.4 33.6 41.2 30.9 10.2 4.0 4.5 43.3 18.9 718.3 81.7 18.5 10.1 1.5 6.1 29.5 13.3 16.0 83.9 13.9 32.0 3.7 4.7 57.3 10.3 4.0 36.7 13.5 0.1 139.5 12.5 24.1 0.1 417.4 6.1 61.7 32.9 77.8 47.1 4.3 22.6 42.1 42.9 12.0 19.7 31.1 3.3 23.2 GANAB "G2AN, GIIA, GluII, KIAA0088" ENSG00000089597 "Glucosidase II alpha subunit" Q14697 11 62624826-62646726 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Glycosidase, Hydrolase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026874, HPA061426" Enhanced Approved "Endoplasmic reticulum" "Intracellular and membrane" NA NA 23000000 "Cluster 39: Non-specific - mRNA processing" "Cluster 29: Non-specific - Vesicular transport" "Cluster 30: Epithelial cell lines - Translation" "Cluster 55: Plasma cells - Humoral immune response" "Endoplasmic reticulum" "HPA026874: AB_1849745, HPA061426: AB_2684516" "unprognostic (2.12e-1)" "unprognostic (5.95e-3)" "unprognostic (4.35e-2)" "unprognostic (2.12e-1)" "unprognostic (1.20e-2)" "unprognostic (3.65e-2)" "prognostic unfavorable (1.27e-5)" "unprognostic (5.80e-3)" "unprognostic (1.09e-1)" "unprognostic (1.79e-1)" "unprognostic (1.68e-3)" "unprognostic (5.91e-2)" "unprognostic (1.01e-3)" "unprognostic (3.81e-2)" "unprognostic (1.82e-2)" "unprognostic (1.39e-1)" "prognostic unfavorable (9.54e-4)" 93.9 73.7 31.8 88.2 34.5 83.7 92.8 36.6 36.7 112.6 51.6 104.7 95.6 102.1 151.7 66.4 106.9 75.3 67.9 31.7 41.2 98.5 171.7 86.8 81.7 38.5 34.9 115.5 88.1 130.6 21.8 141.8 38.1 97.5 116.8 79.4 101.8 111.1 39.4 74.7 90.5 126.0 36.5 86.7 85.2 66.1 39.8 105.2 132.6 53.0 94.8 90.7 34.2 43.4 298.2 245.9 318.2 552.0 464.1 389.0 332.9 312.4 480.4 436.2 362.1 222.2 515.9 201.2 616.0 572.5 337.8 376.4 375.2 376.7 443.8 155.8 191.3 202.9 317.8 125.6 389.0 325.7 248.7 397.2 248.4 433.6 475.3 533.0 422.3 199.6 278.5 352.9 398.2 313.6 167.6 193.4 262.3 236.6 237.7 209.5 368.7 513.1 285.7 230.3 168.6 221.2 451.1 308.2 370.8 321.6 380.9 304.8 311.6 430.0 272.2 342.9 309.9 360.8 423.8 152.2 473.9 173.1 421.7 23.9 19.3 19.1 23.8 23.4 23.1 15.9 17.2 20.0 20.8 14.9 20.9 21.3 8.9 29.8 22.2 18.4 17.3 22.6 31.8 34.5 36.6 36.7 31.7 41.2 38.5 34.9 38.1 36.5 39.8 43.4 42.7 12.8 20.7 17.3 29.8 28.3 29.4 45.8 13.6 31.4 57.4 53.8 7.8 52.9 24.2 68.0 60.5 81.7 33.4 40.1 5.9 47.0 18.5 31.4 59.1 42.2 31.8 25.0 12.6 42.6 137.3 45.9 27.5 46.5 11.4 72.8 48.2 98.0 57.9 35.3 16.0 48.9 34.6 45.8 25.1 16.4 58.4 32.7 35.6 15.9 38.9 36.5 38.1 11.1 16.5 39.5 29.3 68.1 50.4 34.0 47.8 27.0 26.3 41.4 32.9 36.4 34.7 25.3 47.4 21.2 31.3 80.2 25.2 63.1 56.3 32.4 GANC ENSG00000214013 "Glucosidase alpha, neutral C" Q8TET4 15 42273233-42356935 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Glycosidase, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Alveolar cells type 2: 47.9;Oligodendrocytes: 86.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA016949, HPA051522" Approved Approved Cytosol NA NA "Cluster 19: B-cells - Humoral immune response" "Cluster 68: Epididymis - Unknown function" "Cluster 32: U-937 - Innate immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Cytosol "HPA016949: AB_1849465, HPA051522: " "unprognostic (8.83e-2)" "unprognostic (1.68e-1)" "unprognostic (2.24e-1)" "unprognostic (3.04e-3)" "unprognostic (2.51e-2)" "unprognostic (9.85e-2)" "unprognostic (2.49e-2)" "prognostic favorable (9.76e-4)" "unprognostic (1.73e-1)" "unprognostic (1.43e-1)" "unprognostic (1.66e-2)" "unprognostic (1.46e-1)" "unprognostic (1.14e-1)" "unprognostic (1.05e-2)" "unprognostic (3.14e-1)" "unprognostic (1.55e-2)" "unprognostic (3.74e-2)" 8.9 7.6 8.2 10.3 13.0 14.3 8.8 9.8 10.4 9.6 10.4 10.6 8.9 11.0 17.8 12.1 8.6 9.4 8.5 7.8 9.2 9.4 13.3 20.4 10.0 12.4 11.1 13.0 8.4 11.3 7.9 8.0 13.2 8.5 12.4 9.7 14.5 8.7 12.9 10.1 9.8 9.8 10.0 11.9 8.5 12.3 10.8 10.3 12.1 10.6 10.2 8.3 9.3 19.2 9.0 4.9 10.7 11.6 12.3 17.2 7.1 19.2 19.7 19.7 16.4 6.4 6.2 4.9 10.2 18.6 14.3 18.3 12.6 19.5 13.6 12.3 6.0 11.9 12.1 12.8 10.4 11.6 10.1 11.8 11.4 8.1 13.6 11.7 13.5 12.0 12.6 13.0 15.8 1.7 7.9 12.7 6.7 4.3 5.5 14.7 12.4 17.0 14.7 8.4 8.2 11.7 10.8 9.4 7.0 5.6 3.3 27.0 13.6 21.6 5.7 17.8 12.1 13.9 20.7 9.7 10.4 20.9 12.1 16.8 11.8 10.2 4.5 13.1 6.2 19.6 7.2 8.6 15.5 23.1 8.9 5.4 6.7 5.7 10.9 12.3 7.3 6.5 8.2 13.0 9.8 10.4 7.8 9.2 12.4 11.1 13.2 10.0 10.8 19.2 6.2 19.2 47.9 35.6 14.5 10.5 17.1 7.9 12.0 5.6 5.6 6.2 8.2 4.3 8.9 1.8 10.4 5.3 4.0 9.5 5.9 5.9 18.6 7.7 11.1 5.0 4.2 5.0 18.9 3.8 5.1 8.1 9.7 11.9 10.8 8.1 5.7 12.4 6.5 3.3 28.5 5.7 10.2 11.7 5.4 4.7 7.2 10.9 14.2 36.5 14.0 9.5 7.2 31.7 86.7 5.4 15.7 6.4 7.1 9.1 7.9 7.7 9.8 8.5 13.1 9.2 7.0 20.5 15.7 18.9 5.3 2.9 6.9 6.4 8.5 20.7 GAPDH GAPD ENSG00000111640 "Glyceraldehyde-3-phosphate dehydrogenase" P04406 12 6534512-6538374 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Glycolysis, Immunity, Innate immunity, Translation regulation" "Oxidoreductase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "skeletal muscle: 27580.7;tongue: 18892.5" "Cell type enhanced" "Detected in all" "Extravillous trophoblasts: 10357.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Not detected" "Not detected" "CAB005197, CAB016392, HPA040067, HPA061280, CAB079968" Supported Enhanced "Nuclear membrane,Vesicles,Plasma membrane,Cytosol" No No 1400000000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 80: Striated muscle - Unknown function" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 16: Pancreatic endocrine cells - Mixed function" "Plasma membrane, Cytosol" "Nuclear membrane, Vesicles" "CAB005197: AB_641107, CAB016392: AB_627678, CAB079968: , HPA040067: AB_10965903, HPA061280: AB_2684463" "unprognostic (3.03e-1)" "unprognostic (2.62e-3)" "unprognostic (3.58e-2)" "unprognostic (4.20e-1)" "unprognostic (9.73e-3)" "unprognostic (1.77e-3)" "prognostic unfavorable (1.79e-6)" "unprognostic (2.89e-3)" "unprognostic (2.86e-1)" "unprognostic (2.06e-2)" "unprognostic (9.50e-3)" "unprognostic (4.52e-1)" "prognostic unfavorable (6.25e-10)" "unprognostic (2.33e-1)" "unprognostic (4.28e-1)" "unprognostic (1.40e-1)" "unprognostic (1.26e-2)" 1219.9 1815.8 2605.9 1191.3 2589.5 4608.5 1042.3 2869.0 3067.8 1163.8 2419.2 1720.0 1480.8 1080.9 769.9 2973.8 1042.8 1161.3 5572.8 2630.1 2880.0 2323.2 2557.9 1137.9 1388.3 2845.2 2861.3 1087.0 652.0 1616.0 1338.7 1190.6 2828.4 1241.0 1586.6 2386.8 1835.8 1238.7 27580.7 1775.5 1457.5 1424.4 2670.8 1208.5 1215.5 693.0 2985.1 1570.9 1022.1 18892.5 1861.0 1889.0 1672.9 2741.6 6063.0 10247.9 3109.5 4709.2 3026.2 5018.7 6516.0 4716.2 7218.1 7172.8 7491.2 7211.3 4091.6 7540.8 878.2 5947.4 4904.2 3359.8 3372.7 10829.1 5432.4 6263.1 3229.5 4224.9 5857.5 6279.2 3890.9 6710.2 3046.1 4089.0 3521.7 6553.0 7609.7 15565.8 7762.7 5052.4 2215.9 1484.1 8670.0 11849.8 7303.1 3247.3 10995.7 7254.7 3950.7 5849.8 5505.7 3512.8 7909.6 7115.9 2088.3 3331.0 4243.1 10206.4 5984.0 8874.7 1657.2 4311.2 4794.3 5049.0 5907.2 2717.1 7931.5 3178.4 2544.6 9374.4 10632.2 4050.5 8040.5 2575.4 4295.8 737.9 1325.8 2011.2 1171.4 1046.9 1364.8 1333.1 3253.6 652.5 757.6 886.9 1981.4 1227.8 1900.6 474.6 2126.1 6812.0 2605.9 2589.5 2869.0 3067.8 2630.1 2880.0 2845.2 2861.3 2828.4 2670.8 2985.1 2741.6 1036.7 237.2 259.5 228.2 1086.9 1818.8 2223.4 7367.5 4070.9 1157.6 1794.6 3689.2 40.4 1263.9 2213.7 1022.5 417.0 4237.7 1032.7 2579.6 3463.0 5198.9 759.8 770.1 702.4 1597.4 1324.3 1180.6 112.1 3794.5 10357.8 1127.1 1068.8 1021.8 562.3 2063.7 1242.9 1742.3 3895.3 2348.7 145.8 2351.2 2543.1 2586.7 2494.4 2257.7 889.4 2134.0 4220.8 86.2 3422.3 6177.9 1045.4 98.5 196.2 5681.8 3001.4 1026.9 2668.2 1714.0 5714.0 7286.7 864.3 1435.2 1150.4 1744.7 2827.8 429.9 476.2 3605.2 1600.7 4694.0 1514.9 1839.0 3140.9 2882.4 GART "GARS-AIRS-GART, PGFT, PRGS" ENSG00000159131 "Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase" P22102 21 33503931-33543491 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Purine biosynthesis" "Ligase, Multifunctional enzyme, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002119, HPA005779" Approved Approved Mitochondria,Cytosol NA NA 300000 "Cluster 27: Non-specific - Gene expression" "Cluster 3: T-cells - Adaptive immune response" "Cluster 1: K-562 - Erythropoiesis" "Cluster 39: Non-specific - Basic cellular processes" Cytosol Mitochondria "HPA002119: AB_1849482, HPA005779: AB_1849484" "unprognostic (3.77e-2)" "unprognostic (2.25e-2)" "unprognostic (4.51e-3)" "unprognostic (1.72e-2)" "unprognostic (2.30e-2)" "prognostic unfavorable (5.05e-5)" "prognostic unfavorable (9.82e-5)" "unprognostic (2.50e-2)" "unprognostic (2.76e-3)" "unprognostic (2.92e-1)" "prognostic unfavorable (2.19e-4)" "unprognostic (1.98e-3)" "prognostic unfavorable (3.95e-6)" "unprognostic (1.36e-2)" "unprognostic (2.31e-1)" "unprognostic (2.28e-1)" "unprognostic (1.57e-1)" 24.1 20.3 9.2 24.2 12.2 18.8 24.3 11.3 11.9 16.4 10.1 23.2 22.1 18.3 17.1 24.8 21.8 15.9 20.7 8.6 10.5 21.0 29.7 16.0 30.3 11.0 10.3 19.0 22.3 19.9 12.8 26.1 11.7 17.0 29.1 20.9 16.8 16.7 29.1 17.4 19.4 26.3 11.3 20.0 19.7 29.3 10.9 34.4 20.8 21.9 38.6 32.2 16.5 14.0 132.2 61.5 90.3 98.8 61.1 64.2 100.3 82.6 70.8 96.8 101.5 117.7 108.9 174.8 48.5 55.6 124.9 67.9 189.0 130.4 138.3 91.3 111.7 265.2 68.5 78.6 85.2 148.6 66.3 57.3 86.5 113.3 162.5 48.1 91.5 138.4 312.4 108.5 84.9 63.6 158.2 100.0 194.4 186.3 71.8 131.1 166.6 246.7 74.7 69.4 93.1 84.1 116.9 89.1 107.1 81.0 113.0 93.9 68.7 64.9 76.9 56.1 90.9 106.8 159.6 193.0 67.1 171.3 96.2 9.0 24.0 16.3 25.9 33.9 31.4 29.7 25.2 27.1 31.6 24.5 26.4 26.2 10.6 43.9 30.6 23.2 34.1 22.8 9.2 12.2 11.3 11.9 8.6 10.5 11.0 10.3 11.7 11.3 10.9 14.0 21.1 19.2 19.8 17.3 30.1 46.0 50.3 34.1 38.1 18.5 18.6 17.3 19.3 11.5 28.0 14.7 35.5 41.2 21.8 12.4 23.5 28.4 21.7 23.3 36.9 21.9 13.1 40.3 19.1 24.2 37.4 27.2 21.4 23.4 7.6 31.8 16.1 18.0 23.6 5.0 21.1 17.1 22.4 17.0 12.0 6.6 17.4 17.0 12.4 10.3 19.8 13.3 22.6 17.6 19.3 31.5 12.7 18.0 22.7 54.3 16.4 14.3 17.8 28.5 13.1 23.0 23.9 57.2 27.6 34.4 45.9 25.6 21.2 55.0 24.1 46.6 GAST GAS ENSG00000184502 Gastrin P01350 17 41712331-41715969 "Cancer-related genes, FDA approved drug targets, Predicted secreted proteins" Hormone "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 167 "stomach 1: 9556.1" "Cell type enriched" "Detected in some" 5 "Glandular and luminal cells: 103.7" "Group enriched" "Detected in many" 6 "pancreatic cancer: 38.8;stomach cancer: 23.5" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 6 "OE19: 34.8" "Low region specificity" "Detected in many" "Not detected" "Not detected" CAB000038 Enhanced "Secreted to digestive system" NA NA 87000 "Cluster 4: Stomach - Digestion" "Cluster 21: OE19 - Mitochondria" "Cluster 44: Endometrium - Transcription" "CAB000038: " "unprognostic (1.27e-1)" "unprognostic (4.27e-3)" "unprognostic (1.12e-1)" "unprognostic (1.07e-2)" "unprognostic (2.75e-2)" "unprognostic (5.68e-2)" "unprognostic (2.11e-1)" "unprognostic (2.85e-1)" "unprognostic (3.17e-1)" "unprognostic (9.07e-2)" 0.0 0.0 0.9 0.0 0.6 0.0 0.7 0.4 0.9 0.2 0.4 0.0 57.2 0.1 0.0 0.0 0.0 0.0 0.0 0.5 2.5 0.3 0.0 3.7 0.0 0.8 1.0 0.0 0.0 0.0 0.1 4.1 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.6 9.3 9556.1 0.3 2.5 4.3 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.1 0.0 0.0 0.0 0.3 0.0 0.1 0.4 0.0 0.0 5.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 34.8 0.0 0.6 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.6 0.4 0.9 0.5 2.5 0.8 1.0 1.0 0.6 2.5 0.6 0.8 0.0 0.0 0.0 0.0 0.4 0.3 0.1 0.0 0.0 0.3 0.9 0.4 0.0 0.1 0.0 0.0 0.4 0.1 0.1 0.0 0.1 2.2 13.5 18.7 0.7 0.0 0.0 0.0 0.0 0.1 1.0 0.5 103.7 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.3 0.8 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.1 0.0 0.0 0.3 0.8 0.2 0.2 0.0 0.0 8.8 1.0 0.0 0.0 0.4 GGCX VKCFD1 ENSG00000115486 "Gamma-glutamyl carboxylase" P38435 2 85544720-85561547 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins" Lyase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "liver: 118.8" "Cell type enhanced" "Detected in all" "Hepatocytes: 163.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA018284 Enhanced NA NA "Cluster 10: Basophils - Unknown function" "Cluster 85: Liver - Metabolism" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 24: Non-specific - Transcription regulation" "HPA018284: AB_1849641" "unprognostic (4.88e-3)" "unprognostic (1.13e-2)" "unprognostic (1.22e-2)" "prognostic unfavorable (1.82e-6)" "unprognostic (5.67e-2)" "unprognostic (1.85e-3)" "unprognostic (2.96e-2)" "unprognostic (3.77e-2)" "unprognostic (5.64e-2)" "unprognostic (2.18e-2)" "unprognostic (6.45e-3)" "unprognostic (5.23e-2)" "unprognostic (8.17e-3)" "unprognostic (7.85e-2)" "unprognostic (2.59e-1)" "unprognostic (7.63e-3)" "unprognostic (9.38e-2)" 13.8 11.0 6.0 8.3 7.4 3.2 10.8 8.3 7.7 10.7 11.7 7.8 7.4 10.5 13.8 9.2 10.5 11.3 9.5 6.9 6.2 16.3 118.8 13.8 6.3 7.4 6.9 12.4 15.8 18.0 7.8 23.4 7.5 10.0 9.9 7.7 14.7 12.1 7.9 9.2 7.3 13.4 7.3 6.2 9.1 4.7 7.0 4.8 12.6 8.6 7.2 12.2 8.8 11.2 17.1 27.2 19.0 21.3 93.8 26.6 42.2 29.9 35.1 21.6 30.4 47.3 20.6 6.1 29.7 49.3 27.1 27.2 13.7 37.7 23.7 10.9 18.7 11.1 17.4 45.2 34.8 7.0 10.1 33.1 22.0 43.8 29.7 35.6 31.0 10.8 13.5 8.7 63.5 22.4 3.5 5.3 8.9 47.7 23.4 6.6 44.6 15.3 30.0 32.5 7.2 12.1 26.8 52.2 28.2 32.1 25.6 6.8 28.6 27.5 23.9 27.1 20.9 6.8 20.1 5.1 26.5 7.1 39.4 3.7 4.2 2.2 1.7 4.4 1.6 0.4 0.7 0.7 2.9 0.4 1.7 1.6 1.7 1.4 2.6 2.4 1.2 2.0 6.0 7.4 8.3 7.7 6.9 6.2 7.4 6.9 7.5 7.3 7.0 11.2 27.1 28.9 40.3 10.1 25.1 18.7 20.6 27.8 13.6 21.6 22.9 19.8 27.9 32.9 24.1 29.5 16.7 60.8 28.4 16.1 7.9 29.9 4.2 16.9 19.4 20.8 14.4 5.7 10.9 39.5 50.2 29.4 11.7 26.8 15.8 17.8 23.9 163.0 31.3 8.4 8.9 17.6 22.4 26.9 29.0 2.2 20.2 24.5 21.4 5.6 29.6 19.5 17.5 9.5 12.6 25.0 12.6 20.3 38.4 16.4 16.2 27.1 16.9 33.6 6.6 42.3 22.8 23.5 11.2 20.0 15.2 53.8 20.8 15.1 16.4 23.6 GGPS1 GGPPS1 ENSG00000152904 "Geranylgeranyl diphosphate synthase 1" O95749 1 235327350-235344532 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Isoprene biosynthesis" Transferase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Early spermatids: 212.7;Late spermatids: 290.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029472, HPA050727" Enhanced Supported Nucleoplasm,Cytosol NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 21: Non-specific - Transcription" "Cluster 43: THP-1 - Innate immune response" "Cluster 25: Spermatids - Spermatogenesis" Cytosol Nucleoplasm "HPA029472: AB_10696206, HPA050727: " "unprognostic (7.45e-2)" "unprognostic (3.18e-2)" "unprognostic (1.25e-1)" "unprognostic (2.23e-2)" "unprognostic (1.43e-1)" "unprognostic (3.10e-3)" "prognostic unfavorable (6.69e-4)" "unprognostic (4.50e-2)" "unprognostic (3.66e-2)" "unprognostic (3.77e-3)" "unprognostic (2.66e-2)" "unprognostic (8.77e-3)" "unprognostic (1.95e-2)" "unprognostic (1.99e-1)" "unprognostic (3.35e-2)" "unprognostic (1.41e-1)" "unprognostic (1.70e-2)" 24.0 23.5 20.4 17.3 21.4 7.8 34.1 23.0 27.6 24.5 18.5 24.8 21.2 23.3 30.4 22.4 21.2 20.0 23.5 21.1 22.5 27.8 21.7 20.1 21.3 21.8 20.6 23.3 16.4 21.1 17.6 19.2 22.3 29.4 23.9 38.8 31.2 19.7 29.8 20.3 20.6 25.7 22.3 20.5 20.4 48.2 20.9 27.6 27.4 28.9 21.9 23.6 17.0 25.7 41.3 22.3 54.5 41.5 41.7 59.9 20.5 36.2 50.7 23.6 33.1 17.5 64.5 28.1 51.3 40.6 38.1 33.5 29.4 37.8 31.2 28.8 54.4 24.0 19.7 29.9 46.9 30.0 19.7 39.3 66.5 32.2 43.0 41.8 42.5 46.2 58.5 24.7 31.5 24.6 37.0 35.7 46.4 109.9 11.5 22.6 17.3 32.6 66.2 22.4 43.3 59.8 27.3 61.5 54.7 20.1 76.7 46.5 35.9 27.9 20.8 47.6 34.7 42.0 55.8 34.3 35.4 33.3 51.4 43.7 31.0 48.5 31.5 37.3 32.1 38.6 39.5 33.8 30.4 32.8 36.2 33.4 27.8 31.9 54.2 25.2 42.5 36.8 20.4 21.4 23.0 27.6 21.1 22.5 21.8 20.6 22.3 22.3 20.9 25.7 18.3 32.1 34.5 16.3 27.2 39.9 60.4 64.6 27.9 32.1 29.1 22.4 24.5 17.2 39.5 20.2 43.8 30.7 24.1 21.4 72.4 37.5 212.7 16.8 15.1 29.4 17.4 12.0 26.5 28.3 43.7 31.0 14.3 12.9 24.6 16.4 28.9 13.0 26.8 48.8 25.7 26.1 69.2 26.9 49.0 290.7 35.8 24.3 67.6 20.6 36.7 55.4 36.0 15.6 23.2 31.8 23.3 35.0 8.5 65.6 29.3 61.3 30.4 51.2 26.3 26.1 32.5 111.6 50.0 18.7 40.6 47.1 33.0 30.9 22.7 55.9 GHRHR ENSG00000106128 "Growth hormone releasing hormone receptor" Q02643 7 30938669-30993254 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 351 "pituitary gland: 211.7" "Cell type enhanced" "Detected in some" "Cholangiocytes: 1.5;Spermatocytes: 1.2;Spermatogonia: 3.0" "Cancer enhanced" "Detected in single" "liver cancer: 0.5" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Intracellular and membrane" NA NA "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 20: Spermatogonia & Spermatocytes - Spermatogenesis" "unprognostic (8.32e-2)" "unprognostic (1.45e-1)" "unprognostic (9.30e-2)" "unprognostic (1.39e-1)" "unprognostic (7.23e-2)" "unprognostic (4.15e-1)" "unprognostic (2.28e-2)" "unprognostic (1.54e-1)" "unprognostic (1.20e-1)" "unprognostic (1.27e-1)" "unprognostic (1.43e-2)" "unprognostic (1.47e-1)" "unprognostic (5.87e-3)" 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.3 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 211.7 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.9 0.0 0.0 0.0 0.0 0.1 1.2 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GLP1R GLP-1R ENSG00000112164 "Glucagon like peptide 1 receptor" P43220 6 39048781-39091303 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 3.7;heart muscle: 2.7;pancreas: 7.0" "Cell type enhanced" "Detected in some" "Cardiomyocytes: 2.2;Early spermatids: 1.0;Inhibitory neurons: 1.2" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "NTERA-2: 1.1;SCLC-21H: 2.7" "Region enriched" "Detected in many" 4 "basal ganglia: 20.7" "Low region specificity" "Detected in some" NA NA "Cluster 22: Non-specific - Unknown function" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (4.06e-3)" "unprognostic (5.38e-6)" "unprognostic (1.80e-2)" "unprognostic (4.16e-2)" "unprognostic (4.98e-2)" "unprognostic (3.55e-1)" "unprognostic (2.11e-1)" "unprognostic (1.38e-1)" "unprognostic (9.76e-2)" "unprognostic (3.29e-1)" "unprognostic (1.73e-1)" "unprognostic (8.60e-3)" "unprognostic (2.47e-1)" "unprognostic (1.15e-2)" "unprognostic (1.42e-2)" 0.1 0.0 0.4 0.0 0.9 0.0 0.6 0.3 0.5 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 2.7 0.6 3.7 0.1 0.0 0.3 0.1 1.1 0.5 0.0 7.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 2.2 0.0 0.0 0.1 0.1 0.0 1.1 0.0 0.9 0.2 1.6 0.1 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.9 0.3 0.5 0.6 3.7 1.1 0.5 1.2 1.1 1.6 0.3 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GLRA1 STHE ENSG00000145888 "Glycine receptor alpha 1" P23415 5 151822513-151924851 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 16 "brain: 40.7" "Cell type enhanced" "Detected in some" "Bipolar cells: 7.4;Excitatory neurons: 1.7;Horizontal cells: 1.7;Inhibitory neurons: 5.0;Oligodendrocyte precursor cells: 1.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "hypothalamus: 9.4;midbrain: 15.1;pons and medulla: 26.3" "Low region specificity" "Detected in many" CAB079042 Supported NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 56: Bipolar cells - Visual perception" "CAB079042: " "unprognostic (3.17e-1)" "unprognostic (2.47e-1)" "unprognostic (3.85e-7)" "unprognostic (8.24e-2)" "unprognostic (9.45e-3)" 0.0 0.3 1.9 0.0 0.6 0.0 0.0 12.2 1.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 7.0 0.0 0.0 0.0 0.0 40.7 13.9 0.0 0.2 0.0 0.0 0.0 31.4 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 20.9 0.0 0.0 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.0 10.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.6 12.2 1.8 0.2 7.0 40.7 13.9 31.4 20.9 12.1 10.9 0.0 0.0 0.0 0.7 0.0 0.1 0.9 0.0 0.0 7.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 1.7 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.7 5.0 0.0 0.0 0.0 0.8 0.2 0.0 0.0 0.0 1.0 0.1 0.2 0.0 1.5 1.3 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.7 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.4 0.0 0.0 0.5 GLRA2 GLR ENSG00000101958 "Glycine receptor alpha 2" P23416 X 14529298-14731812 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 28.4" "Cell type enriched" "Detected in some" 5 "Inhibitory neurons: 74.3" "Cancer enhanced" "Detected in some" "colorectal cancer: 0.6;glioma: 0.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 34 "AN3-CA: 17.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB070422 Approved NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 23: AN3-CA - Transcription regulation" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB070422: AB_11153055" "unprognostic (2.52e-1)" "unprognostic (3.13e-1)" "unprognostic (5.52e-2)" "unprognostic (1.90e-1)" "unprognostic (5.74e-2)" "unprognostic (1.81e-2)" "unprognostic (3.39e-1)" "unprognostic (5.82e-2)" "unprognostic (7.95e-3)" "unprognostic (1.13e-1)" "unprognostic (2.76e-1)" "unprognostic (6.69e-2)" 0.0 0.0 5.4 0.1 3.4 0.1 0.0 8.3 4.6 0.0 0.0 1.4 0.1 0.0 0.0 0.0 0.1 0.1 0.0 4.6 23.4 0.0 0.0 0.0 0.0 4.9 28.4 0.1 0.0 0.0 0.3 0.1 13.7 0.0 3.8 4.9 0.1 0.0 0.0 0.1 0.1 0.1 5.9 0.0 0.0 0.2 12.6 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.1 17.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 3.4 8.3 4.6 4.6 23.4 4.9 28.4 13.7 5.9 12.6 1.5 0.0 0.0 0.0 0.7 0.1 0.1 0.0 0.0 0.0 2.6 0.1 0.0 1.3 0.0 0.0 0.0 0.0 0.4 0.0 7.6 0.0 0.0 0.0 1.6 0.2 0.0 0.0 0.0 8.7 0.0 0.0 0.1 0.0 0.1 0.0 1.9 0.0 0.0 0.0 1.7 74.3 0.2 0.0 0.0 0.3 0.2 0.0 0.0 0.0 1.0 0.0 0.3 0.0 2.0 12.4 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.2 0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.5 1.1 0.0 GLRA3 ENSG00000145451 "Glycine receptor alpha 3" O75311 4 174636920-174829247 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Chloride channel, Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 10.5" "Cell type enhanced" "Detected in some" "Breast glandular cells: 25.3;Early spermatids: 24.7;Excitatory neurons: 52.4;Inhibitory neurons: 11.2;Late spermatids: 22.8" "Cancer enhanced" "Detected in single" "breast cancer: 1.2" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "Karpas-707: 1.9" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" NA NA "Cluster 43: B-cells - Humoral immune response" "Cluster 65: Brain - Ion transport" "Cluster 2: Karpas-707 - Immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "unprognostic (2.75e-3)" "unprognostic (3.14e-1)" "unprognostic (1.78e-2)" "unprognostic (1.36e-1)" "unprognostic (9.02e-2)" "unprognostic (3.82e-2)" "unprognostic (2.37e-1)" "unprognostic (1.22e-1)" "unprognostic (1.12e-2)" "unprognostic (4.26e-2)" "unprognostic (1.64e-5)" "unprognostic (4.61e-4)" "unprognostic (2.24e-1)" "unprognostic (1.15e-2)" 0.0 0.8 4.2 0.0 3.4 0.0 2.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 4.5 0.0 0.0 0.0 0.2 0.8 3.6 0.0 0.4 0.0 0.6 0.0 0.6 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.1 0.1 0.9 0.0 0.0 0.5 10.5 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 4.2 3.4 0.0 3.0 2.6 4.5 0.8 3.6 0.6 0.9 10.5 0.0 0.0 0.0 0.6 1.3 1.6 0.0 1.3 0.0 0.0 5.0 25.3 0.3 2.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.7 0.0 0.1 0.4 0.0 0.0 52.4 0.0 0.0 1.3 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 11.2 0.0 0.0 0.0 0.0 22.8 0.0 0.1 0.0 2.8 0.0 0.2 0.0 1.0 1.0 0.2 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.6 0.0 1.0 0.3 0.7 1.6 0.1 0.1 0.0 0.3 0.0 0.0 0.4 GNRHR "GRHR, LHRHR" ENSG00000109163 "Gonadotropin releasing hormone receptor" P30968 4 67737118-67754388 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets, Hypogonadotropic hypogonadism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "pituitary gland: 5.4" "Cell type enhanced" "Detected in some" "Excitatory neurons: 1.2;Inhibitory neurons: 1.3;Oligodendrocyte precursor cells: 1.0" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA013424 Enhanced NA NA "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA013424: AB_2668840" "unprognostic (2.77e-1)" "unprognostic (1.58e-1)" "unprognostic (4.05e-1)" "unprognostic (1.78e-1)" "unprognostic (4.65e-1)" "unprognostic (8.75e-3)" "unprognostic (3.09e-2)" "unprognostic (1.34e-1)" "unprognostic (1.90e-1)" "unprognostic (1.01e-1)" "unprognostic (6.84e-2)" "unprognostic (1.63e-1)" "unprognostic (9.03e-2)" "unprognostic (3.23e-2)" "unprognostic (9.67e-2)" "unprognostic (1.22e-3)" "unprognostic (3.99e-2)" 0.0 0.7 0.4 0.1 0.7 0.0 0.0 0.2 1.0 0.2 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.8 0.1 0.1 0.0 0.3 0.8 0.5 0.1 0.1 0.0 5.4 0.0 1.2 0.1 0.0 0.5 0.1 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 0.2 0.0 0.1 0.0 0.3 0.9 0.0 0.3 0.3 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.6 0.0 0.0 0.1 0.2 0.1 0.2 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.2 0.0 0.1 0.3 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.7 0.2 1.0 0.3 0.8 0.8 0.5 1.2 0.5 0.5 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 GRIA1 "GluA1, GLUR1, GLURA" ENSG00000155511 "Glutamate ionotropic receptor AMPA type subunit 1" P42261 5 153489615-153813869 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 83.7;retina: 32.6" "Group enriched" "Detected in some" 4 "Excitatory neurons: 322.4;Inhibitory neurons: 608.8" "Cancer enriched" "Detected in some" 15 "glioma: 9.9" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 11.6;ASC diff: 3.5;BJ: 5.5;BJ hTERT+: 2.9;LHCN-M2: 8.1;U-266/70: 5.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA035202 Enhanced NA NA "Cluster 58: Brain - Synaptic function" "Cluster 12: NES - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA035202: AB_2674516" "unprognostic (2.51e-1)" "unprognostic (4.76e-3)" "unprognostic (1.97e-1)" "unprognostic (4.20e-2)" "unprognostic (6.95e-2)" "unprognostic (2.43e-1)" "unprognostic (2.61e-1)" "unprognostic (1.18e-2)" "unprognostic (2.04e-1)" "unprognostic (2.35e-2)" "unprognostic (5.14e-4)" "unprognostic (7.97e-2)" "unprognostic (2.96e-2)" "unprognostic (1.01e-1)" "unprognostic (1.70e-1)" "unprognostic (2.80e-1)" "unprognostic (7.61e-2)" 1.2 0.4 38.7 0.1 42.8 0.0 0.4 43.5 79.8 0.2 0.0 0.6 0.2 0.1 0.7 0.1 0.1 0.0 0.8 83.7 23.2 0.1 0.0 9.3 0.0 3.4 3.6 0.2 0.3 0.2 1.2 0.0 2.7 0.1 0.1 32.6 0.1 0.5 0.2 0.3 0.3 1.0 5.3 0.0 0.6 0.9 27.9 0.1 0.3 0.4 0.0 0.1 0.3 18.1 0.0 0.0 11.6 0.0 3.5 2.3 0.0 5.5 2.9 0.3 0.1 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.1 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.7 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 38.7 42.8 43.5 79.8 83.7 23.2 3.4 3.6 2.7 5.3 27.9 18.1 0.2 0.0 0.0 43.1 0.0 0.0 0.0 0.0 0.0 36.3 0.3 0.0 1.2 0.0 0.0 0.0 6.2 0.0 0.0 0.2 0.0 0.0 5.1 0.1 5.6 0.4 0.0 0.0 322.4 0.0 0.0 1.4 0.0 0.1 0.0 0.0 0.0 0.0 0.1 1.7 608.8 0.0 0.0 0.0 0.0 3.4 0.0 0.9 0.0 7.5 0.0 49.0 0.0 94.5 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.1 0.3 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GRIK1 "GluK1, GLUR5" ENSG00000171189 "Glutamate ionotropic receptor kainate type subunit 1" P39086 21 29536933-29940033 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 11 "adrenal gland: 12.5;brain: 32.6;retina: 38.2" "Group enriched" "Detected in some" 10 "Inhibitory neurons: 2260.1;Oligodendrocyte precursor cells: 862.5" "Cancer enriched" "Detected in some" 5 "glioma: 4.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "Daudi: 1.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA014623, HPA073879" Uncertain Supported "Vesicles,Plasma membrane" NA NA "Cluster 77: Retina - Visual perception" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane" Vesicles "HPA014623: AB_1850305, HPA073879: " "unprognostic (1.39e-1)" "unprognostic (6.54e-2)" "unprognostic (1.32e-1)" "unprognostic (1.04e-2)" "unprognostic (1.03e-3)" "unprognostic (1.56e-1)" "unprognostic (1.07e-1)" "unprognostic (2.12e-3)" "unprognostic (1.25e-1)" "unprognostic (8.77e-2)" "unprognostic (4.89e-3)" "unprognostic (1.20e-3)" "unprognostic (1.47e-8)" "unprognostic (2.09e-1)" "unprognostic (2.68e-1)" "unprognostic (1.09e-1)" "unprognostic (3.15e-3)" 0.2 12.5 7.5 0.2 6.6 0.1 1.8 2.4 6.0 0.8 0.0 0.3 0.0 0.1 2.0 0.3 0.0 0.1 0.0 8.4 12.3 0.0 0.1 0.1 0.1 30.0 11.2 0.3 0.0 0.0 0.2 0.4 32.6 2.4 0.5 38.2 0.0 0.1 0.1 0.8 0.4 0.1 2.6 0.1 0.2 0.5 9.7 0.0 0.0 0.0 0.0 0.4 0.4 2.9 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.3 0.2 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.1 0.2 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.0 0.0 0.1 0.2 0.0 0.1 0.1 0.4 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 7.5 6.6 2.4 6.0 8.4 12.3 30.0 11.2 32.6 2.6 9.7 2.9 0.1 0.0 0.0 27.4 0.0 0.3 0.0 0.0 0.0 149.8 2.3 0.3 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.8 0.1 1.2 0.4 0.0 0.0 29.8 0.0 0.0 0.7 0.0 0.2 0.0 148.8 0.0 0.0 0.1 1.7 2260.1 0.0 0.0 0.0 0.4 13.2 0.3 0.2 3.6 10.3 0.0 2.5 0.0 862.5 8.9 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 4.9 0.0 0.0 5.7 0.0 0.0 0.0 0.1 0.0 0.1 33.8 0.1 0.0 GRIK2 "GluK2, GLUR6, MRT6" ENSG00000164418 "Glutamate ionotropic receptor kainate type subunit 2" Q13002 6 101181257-102070083 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 20 "brain: 93.3" "Group enriched" "Detected in some" 26 "Excitatory neurons: 724.6;Inhibitory neurons: 2376.0;Oligodendrocyte precursor cells: 1234.0" "Cancer enriched" "Detected in some" 5 "glioma: 3.9" "Region enhanced" "Detected in all" "cerebellum: 93.3" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ: 16.4;BJ hTERT+: 26.6;fHDF/TERT166: 20.8;HAP1: 10.2;SiHa: 11.1;WM-115: 24.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA014395, HPA014623, CAB022463" Approved "Intracellular and membrane" NA NA "Cluster 17: Basophils - Unknown function" "Cluster 69: Cerebellum - Gene expression regulation" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB022463: , HPA014395: AB_1850303, HPA014623: AB_1850305" "unprognostic (1.43e-3)" "unprognostic (1.26e-2)" "unprognostic (3.99e-2)" "unprognostic (3.20e-1)" "unprognostic (1.92e-1)" "unprognostic (3.48e-2)" "unprognostic (2.57e-1)" "unprognostic (4.32e-2)" "unprognostic (8.46e-2)" "unprognostic (9.19e-2)" "unprognostic (4.01e-2)" "unprognostic (1.36e-1)" "unprognostic (1.34e-5)" "unprognostic (1.94e-3)" "unprognostic (7.78e-2)" "unprognostic (1.09e-2)" "unprognostic (8.68e-4)" 0.2 1.8 18.7 0.4 20.3 0.3 0.2 93.3 25.2 1.4 0.0 0.5 0.6 0.4 1.1 0.4 0.3 0.5 4.5 20.7 28.4 0.8 0.1 0.1 0.1 1.0 6.8 0.4 2.6 0.0 1.6 2.4 7.9 0.9 0.4 4.2 0.7 1.2 0.9 1.6 0.6 0.3 1.6 0.4 0.3 0.7 19.8 0.0 3.4 0.1 0.0 0.5 0.4 7.6 0.1 0.1 3.1 0.2 3.6 0.1 0.0 16.4 26.6 0.8 0.5 0.0 0.3 0.1 0.0 20.8 0.0 5.1 10.2 0.0 0.3 0.0 0.0 1.7 8.5 0.0 0.9 0.0 0.2 0.3 0.0 0.0 1.0 2.3 0.0 0.0 0.0 0.4 6.2 0.0 0.0 0.2 2.7 0.0 0.2 0.1 0.4 0.1 0.7 0.0 3.3 7.0 11.1 0.0 0.5 0.5 0.0 0.8 0.0 2.1 0.5 0.1 1.3 0.1 0.0 0.1 1.5 0.0 24.6 0.5 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.3 0.2 0.1 0.1 0.0 0.0 18.7 20.3 93.3 25.2 20.7 28.4 1.0 6.8 7.9 1.6 19.8 7.6 0.2 0.0 0.5 54.9 0.0 0.6 1.0 0.1 0.6 11.4 0.1 0.0 5.9 0.0 1.3 0.0 0.0 0.1 0.0 0.1 0.0 0.0 3.8 3.4 1.9 0.4 1.8 0.0 724.6 0.6 0.0 1.8 0.0 0.5 0.0 13.0 0.0 0.0 0.1 0.0 2376.0 0.0 0.0 0.0 0.0 7.7 0.3 0.1 1.8 38.4 0.0 0.5 0.0 1234.0 40.5 0.1 1.1 0.4 0.0 0.8 0.1 0.0 2.2 1.1 0.0 0.7 4.6 0.0 0.5 0.1 0.6 0.0 0.0 4.3 0.1 0.9 GRIK3 "GluK3, GLUR7" ENSG00000163873 "Glutamate ionotropic receptor kainate type subunit 3" Q13003 1 36795527-37034515 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 17.0;intestine: 7.8;pituitary gland: 9.2" "Group enriched" "Detected in some" 5 "Excitatory neurons: 39.1;Inhibitory neurons: 108.1;Oligodendrocyte precursor cells: 72.9" "Cancer enriched" "Detected in some" 5 "glioma: 13.2" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 4 "T-47d: 39.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 6: T47d - Mammary gland" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (4.20e-2)" "unprognostic (1.90e-1)" "unprognostic (7.66e-2)" "unprognostic (9.26e-3)" "unprognostic (2.87e-1)" "unprognostic (1.60e-1)" "unprognostic (1.45e-1)" "unprognostic (2.60e-3)" "unprognostic (9.06e-2)" "unprognostic (1.04e-1)" "unprognostic (3.74e-3)" "unprognostic (1.08e-1)" "unprognostic (1.28e-2)" "unprognostic (3.53e-3)" "unprognostic (2.06e-1)" "unprognostic (9.37e-2)" "unprognostic (2.08e-2)" 0.5 1.9 12.1 0.6 10.3 0.0 2.4 3.2 5.4 1.0 0.0 7.8 0.7 0.2 1.8 1.2 0.3 0.8 1.1 11.2 9.9 0.1 0.0 0.1 0.1 15.7 9.0 0.3 0.5 0.6 9.2 0.0 17.0 1.6 1.3 4.4 0.8 2.4 0.1 0.3 2.2 0.6 1.8 0.2 1.5 0.7 8.4 0.0 0.2 0.4 0.4 1.0 0.9 8.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.2 0.0 0.2 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.5 0.0 0.0 0.0 0.0 0.4 39.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.1 10.3 3.2 5.4 11.2 9.9 15.7 9.0 17.0 1.8 8.4 8.3 0.1 0.0 0.0 2.3 0.0 0.1 0.0 0.0 0.0 0.7 1.9 1.8 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.7 0.0 0.0 0.1 0.0 0.0 39.1 0.0 0.0 0.7 0.0 0.0 0.0 3.2 0.0 0.0 0.1 0.0 108.1 0.0 0.0 0.0 0.3 6.9 0.3 0.0 1.8 1.0 0.0 14.3 0.0 72.9 1.3 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 GRIK4 "GluK4, GRIK, KA1" ENSG00000149403 "Glutamate ionotropic receptor kainate type subunit 4" Q16099 11 120511746-120988906 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "brain: 10.3" "Cell type enhanced" "Detected in some" "Astrocytes: 82.9;Cone photoreceptor cells: 35.5;Excitatory neurons: 115.6;Inhibitory neurons: 43.7;Oligodendrocyte precursor cells: 196.1;Oligodendrocytes: 108.3" "Cancer enriched" "Detected in some" 5 "glioma: 3.1" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "HDLM-2: 6.1;HEL: 18.9;T-47d: 4.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074453 Enhanced NA NA "Cluster 65: Brain - Ion transport" "Cluster 36: HEL - Hemostasis" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA074453: AB_2732255" "unprognostic (9.63e-2)" "unprognostic (4.96e-2)" "unprognostic (1.58e-1)" "unprognostic (2.49e-1)" "unprognostic (2.37e-1)" "unprognostic (6.64e-4)" "unprognostic (1.48e-2)" "unprognostic (7.26e-2)" "unprognostic (3.16e-1)" "unprognostic (2.38e-1)" "unprognostic (4.53e-2)" "unprognostic (2.50e-1)" "unprognostic (4.84e-11)" "unprognostic (1.35e-1)" "unprognostic (2.81e-1)" "unprognostic (4.47e-3)" "unprognostic (2.58e-2)" 0.0 1.7 6.8 0.0 6.5 0.0 0.4 5.6 6.4 0.1 0.9 0.1 0.1 0.1 0.0 0.1 0.3 0.1 0.3 10.3 6.0 0.2 0.0 1.5 0.1 7.2 6.2 2.8 0.0 0.0 1.6 0.2 7.3 0.3 0.1 1.0 0.1 0.0 0.0 0.2 0.1 0.1 4.9 0.4 0.0 0.8 9.6 0.1 2.0 0.1 0.1 0.1 0.2 5.5 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 0.0 6.1 0.6 18.9 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.2 0.0 0.0 0.0 0.6 4.7 0.0 0.2 0.0 0.2 0.0 0.0 2.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.8 6.5 5.6 6.4 10.3 6.0 7.2 6.2 7.3 4.9 9.6 5.5 0.0 0.0 0.6 82.9 0.1 0.0 0.1 0.0 1.2 0.8 0.5 0.5 1.6 0.0 0.0 0.0 35.5 0.0 0.7 0.0 0.0 0.0 4.4 0.3 0.0 0.2 0.0 0.0 115.6 0.0 0.0 0.7 0.0 0.0 1.3 0.0 0.0 0.1 0.0 0.0 43.7 0.0 0.0 0.8 0.0 7.5 0.3 1.0 0.0 4.7 0.2 0.0 8.2 196.1 108.3 0.1 1.1 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 7.8 0.2 0.8 3.3 0.1 0.0 0.1 0.4 0.1 0.0 0.5 GRIK5 "GluK5, GRIK2, KA2" ENSG00000105737 "Glutamate ionotropic receptor kainate type subunit 5" Q16478 19 41998321-42069498 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 36.5;testis: 32.9" "Cell type enhanced" "Detected in some" "Astrocytes: 17.9;Bipolar cells: 23.0;Excitatory neurons: 32.4;Horizontal cells: 18.5;Inhibitory neurons: 31.1;Oligodendrocyte precursor cells: 31.7;Rod photoreceptor cells: 21.2" "Group enriched" "Detected in many" 5 "glioma: 15.4;ovarian cancer: 6.6;thyroid cancer: 6.1" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEL: 13.7;hTERT-RPE1: 21.2;NTERA-2: 13.1;REH: 37.5;SCLC-21H: 10.3;SH-SY5Y: 22.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074001 Supported "Nucleoplasm,Plasma membrane" NA NA "Cluster 78: Testis - Spermatogenesis" "Cluster 14: REH - Unknown function" "Cluster 56: Bipolar cells - Visual perception" "Plasma membrane" Nucleoplasm "HPA074001: AB_2732248" "unprognostic (4.99e-2)" "unprognostic (3.40e-1)" "unprognostic (1.30e-3)" "unprognostic (6.68e-3)" "unprognostic (4.28e-2)" "unprognostic (3.86e-1)" "unprognostic (5.82e-1)" "unprognostic (2.23e-1)" "unprognostic (3.89e-2)" "unprognostic (1.73e-2)" "prognostic favorable (7.23e-4)" "unprognostic (8.43e-2)" "prognostic unfavorable (9.32e-4)" "unprognostic (6.47e-3)" "unprognostic (5.77e-2)" "unprognostic (4.57e-2)" "unprognostic (6.12e-2)" 1.6 4.0 20.0 1.7 17.3 3.0 1.2 6.2 26.7 5.3 0.1 16.4 0.7 7.3 1.8 1.6 6.8 1.9 4.9 36.5 15.5 7.0 0.3 0.5 0.7 3.6 4.8 3.6 2.7 14.8 18.3 0.0 7.0 6.2 1.0 12.5 0.7 6.5 0.5 0.9 3.4 5.2 3.0 1.3 5.3 32.9 14.6 0.9 11.3 0.7 0.6 5.0 2.7 6.6 0.1 0.2 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.2 0.1 0.0 0.2 0.2 0.0 0.0 0.4 0.3 13.7 0.0 0.0 0.3 0.0 0.0 0.2 0.1 0.1 0.0 21.2 0.0 0.6 0.1 0.6 0.0 0.2 0.2 0.0 13.1 0.1 0.0 37.5 0.0 0.1 5.8 0.1 10.3 22.7 0.1 0.0 0.2 0.6 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.8 0.0 0.1 1.4 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.0 17.3 6.2 26.7 36.5 15.5 3.6 4.8 7.0 3.0 14.6 6.6 0.2 0.0 0.0 17.9 0.1 0.4 0.1 0.0 0.0 23.0 0.2 0.8 3.1 0.0 0.0 1.8 2.1 0.0 0.0 0.1 0.0 0.8 1.6 0.2 0.2 0.4 0.0 0.0 32.4 0.0 0.0 0.6 0.0 0.3 4.5 7.2 0.0 0.0 0.0 18.5 31.1 0.0 0.0 0.0 0.0 2.3 0.9 0.1 0.0 2.8 0.0 9.1 0.0 31.7 0.9 0.1 0.0 0.4 0.0 0.4 0.0 0.0 0.0 21.2 0.0 4.9 1.7 4.2 2.2 0.2 0.4 0.0 0.0 0.0 0.0 0.1 GRIN1 "GluN1, NMDAR1" ENSG00000176884 "Glutamate ionotropic receptor NMDA type subunit 1" Q05586 9 137139154-137168756 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 49 "brain: 186.7" "Group enriched" "Detected in some" 4 "Excitatory neurons: 132.6;Inhibitory neurons: 134.4" "Cancer enhanced" "Detected in some" "glioma: 1.9;prostate cancer: 1.8" "Region enriched" "Detected in many" 4 "cerebral cortex: 186.7" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "OE19: 1.4;REH: 1.9;RPMI-8226: 2.5;SCLC-21H: 5.2;SH-SY5Y: 3.1;T-47d: 1.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067773 Enhanced NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA067773: " "unprognostic (3.58e-2)" "unprognostic (4.51e-1)" "unprognostic (2.68e-2)" "unprognostic (5.48e-4)" "unprognostic (5.20e-2)" "unprognostic (1.25e-1)" "unprognostic (2.34e-2)" "unprognostic (2.81e-2)" "unprognostic (6.46e-3)" "unprognostic (1.51e-1)" "unprognostic (1.69e-1)" "unprognostic (1.78e-1)" "unprognostic (1.21e-3)" "unprognostic (4.47e-2)" "unprognostic (1.44e-1)" "unprognostic (3.56e-3)" "unprognostic (4.72e-2)" 0.0 0.1 15.7 0.2 46.4 0.0 0.2 0.0 186.7 0.0 0.0 0.8 0.4 0.0 0.0 0.1 0.0 0.0 0.1 35.9 0.0 0.0 0.0 0.1 0.1 1.3 19.5 0.0 0.1 0.2 0.7 0.0 3.8 0.7 0.0 3.7 1.2 0.0 0.0 0.4 0.4 0.0 0.0 0.0 0.3 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 35.6 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.8 0.1 0.0 0.2 0.1 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.5 0.0 0.0 0.0 1.4 0.0 1.9 0.0 2.5 0.0 0.0 5.2 3.1 0.1 0.3 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.7 46.4 0.0 186.7 35.9 0.0 1.3 19.5 3.8 0.0 0.0 35.6 0.0 0.0 0.0 8.5 0.0 0.0 0.3 0.1 0.0 28.0 1.2 0.9 2.5 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.3 1.9 0.2 0.1 0.2 1.8 0.0 132.6 0.4 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.1 1.7 134.4 1.8 0.0 0.0 0.0 0.6 0.0 0.2 0.0 9.4 2.0 1.7 0.0 10.1 7.6 0.2 0.1 0.0 0.0 0.7 0.5 0.1 0.3 7.8 0.0 0.0 0.1 0.5 2.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 GRIN2A "GluN2A, NMDAR2A" ENSG00000183454 "Glutamate ionotropic receptor NMDA type subunit 2A" Q12879 16 9753404-10182928 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Cancer-related genes, Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 10 "brain: 31.7" "Group enriched" "Detected in some" 13 "Excitatory neurons: 839.8;Inhibitory neurons: 904.7" "Cancer enhanced" "Detected in some" "ovarian cancer: 0.9" "Region enhanced" "Detected in many" "cerebral cortex: 31.7" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ hTERT+ SV40 Large T+ RasG12V: 1.1;fHDF/TERT166: 4.4;hTERT-RPE1: 1.4;RPMI-8226: 1.8;U-138 MG: 4.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB022725 Enhanced NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB022725: " "unprognostic (6.43e-2)" "unprognostic (2.47e-1)" "unprognostic (5.97e-2)" "unprognostic (3.21e-2)" "unprognostic (3.13e-2)" "unprognostic (1.59e-2)" "unprognostic (1.62e-1)" "unprognostic (2.10e-1)" "unprognostic (2.08e-1)" "unprognostic (5.39e-2)" "unprognostic (1.47e-1)" "unprognostic (1.69e-1)" "unprognostic (3.75e-3)" "unprognostic (4.79e-3)" "unprognostic (2.05e-1)" "unprognostic (3.92e-3)" "unprognostic (3.33e-2)" 0.3 0.3 4.7 0.0 8.4 0.0 0.1 0.0 31.7 0.3 0.0 0.2 0.3 0.3 2.5 1.1 2.1 0.1 3.0 20.0 0.0 0.4 0.0 0.4 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.2 2.2 0.2 0.3 0.0 0.5 0.2 0.4 0.0 0.0 0.4 2.1 0.1 0.6 0.2 0.2 0.2 0.1 0.4 10.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.0 0.3 1.1 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.2 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 4.6 0.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 8.4 0.0 31.7 20.0 0.0 0.0 0.0 0.0 0.0 0.1 10.3 0.2 0.0 0.0 16.0 0.0 1.9 2.2 0.5 3.4 10.3 0.3 0.0 18.2 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 2.1 17.2 0.3 0.1 0.5 0.0 0.0 839.8 0.2 0.0 2.7 0.0 0.7 0.0 3.3 0.0 0.3 0.1 1.7 904.7 0.0 0.0 0.3 0.4 15.1 0.9 0.1 0.0 15.9 0.0 15.6 0.0 27.6 65.8 0.7 0.0 0.0 0.0 0.7 0.0 0.0 0.0 13.9 0.0 0.0 5.4 8.2 10.0 0.2 0.4 0.0 0.0 0.0 0.1 0.3 GRIN2B "GluN2B, NMDAR2B" ENSG00000273079 "Glutamate ionotropic receptor NMDA type subunit 2B" Q13224 12 13437942-13982002 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 85 "brain: 36.1" "Group enriched" "Detected in some" 4 "Excitatory neurons: 625.2;Inhibitory neurons: 882.5" "Not detected" "Not detected" "Group enriched" "Detected in many" 34 "amygdala: 11.5;basal ganglia: 15.6;cerebral cortex: 36.1;hippocampal formation: 29.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CACO-2: 1.3;NTERA-2: 1.6;RPTEC TERT1: 1.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA069762 Approved NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 5: NTERA-2 - Transcription" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA069762: AB_2686192" "unprognostic (2.01e-2)" "unprognostic (4.07e-2)" "unprognostic (7.89e-2)" "unprognostic (3.77e-3)" "unprognostic (3.39e-3)" "unprognostic (9.36e-2)" "unprognostic (5.92e-2)" "unprognostic (1.77e-2)" "unprognostic (6.85e-2)" "unprognostic (2.24e-1)" "unprognostic (4.68e-2)" "unprognostic (4.12e-2)" "unprognostic (4.48e-5)" "unprognostic (2.43e-1)" "unprognostic (8.76e-2)" "unprognostic (1.63e-1)" "unprognostic (2.37e-1)" 0.2 0.0 11.5 0.0 15.6 0.0 0.0 0.0 36.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.4 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.5 15.6 0.0 36.1 29.4 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.1 0.0 0.0 15.3 0.0 0.0 0.0 0.0 0.0 8.8 0.7 0.5 3.1 0.0 0.0 0.0 0.0 0.0 0.0 2.6 1.9 0.0 35.0 0.3 0.1 0.4 0.0 0.0 625.2 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 882.5 0.5 0.0 0.0 0.0 35.8 0.0 0.0 0.0 14.0 0.0 0.1 0.0 173.4 9.9 0.0 0.1 0.4 0.0 0.2 0.0 0.1 0.0 1.8 0.0 0.1 0.2 1.0 3.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 GRIN2C "GluN2C, NMDAR2C" ENSG00000161509 "Glutamate ionotropic receptor NMDA type subunit 2C" Q14957 17 74842023-74861504 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 58.7;heart muscle: 18.6;thyroid gland: 16.6" "Cell type enriched" "Detected in some" 6 "Astrocytes: 138.7" "Cancer enhanced" "Detected in some" "thyroid cancer: 2.3" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 6.3;RPMI-8226: 2.3;SCLC-21H: 2.8" "Low region specificity" "Detected in all" "Region enriched" "Detected in many" 14 "cerebellum: 43.2" NA NA "Cluster 69: Cerebellum - Gene expression regulation" "Cluster 28: BEWO - Transcription regulation" "Cluster 64: Astrocytes - Nervous system maintenance" "unprognostic (7.21e-3)" "unprognostic (4.68e-2)" "unprognostic (9.38e-3)" "unprognostic (2.24e-5)" "unprognostic (3.42e-1)" "unprognostic (1.53e-2)" "unprognostic (1.84e-1)" "unprognostic (1.82e-2)" "unprognostic (1.78e-1)" "unprognostic (2.95e-2)" "unprognostic (3.31e-3)" "unprognostic (3.25e-1)" "unprognostic (1.14e-3)" "unprognostic (4.20e-2)" "unprognostic (1.49e-1)" "unprognostic (1.51e-2)" "unprognostic (1.14e-1)" 0.7 2.4 27.3 0.2 29.5 0.6 0.2 58.7 27.6 0.4 8.9 0.6 0.2 0.2 0.1 0.2 0.2 0.2 18.6 23.2 18.0 0.3 0.1 0.1 0.1 33.8 19.7 0.3 0.2 0.1 0.6 1.8 36.7 0.2 0.1 3.3 10.5 0.2 0.4 0.2 0.4 0.2 14.5 0.2 0.3 3.8 24.9 0.0 16.6 0.2 0.0 0.3 0.3 22.0 0.0 0.2 0.2 0.0 0.0 0.0 6.3 0.0 0.0 0.0 0.0 0.8 0.1 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.2 0.1 0.2 0.2 0.0 0.4 0.5 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.2 0.1 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.2 0.5 2.3 0.0 0.1 2.8 0.2 1.2 0.1 0.4 0.4 0.4 0.0 0.1 0.2 1.1 0.2 0.1 0.6 0.0 0.1 0.2 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 27.3 29.5 58.7 27.6 23.2 18.0 33.8 19.7 36.7 14.5 24.9 22.0 0.5 0.0 0.0 138.7 0.0 0.1 0.1 0.0 0.0 6.9 0.2 0.0 16.6 1.5 0.2 1.8 0.0 0.2 0.7 0.0 0.0 0.1 1.1 0.7 0.4 0.4 0.0 0.0 0.4 0.2 0.2 0.9 0.0 3.4 0.0 21.5 0.7 0.1 12.5 1.7 1.3 0.4 0.0 0.6 0.3 6.5 0.0 0.5 1.8 11.2 0.1 20.7 2.1 4.5 0.5 0.0 0.0 0.4 0.0 0.2 0.0 0.0 0.1 2.4 0.0 0.9 2.8 5.8 3.4 0.0 0.0 0.7 0.6 8.5 0.1 0.1 GRIN2D "EB11, GluN2D, NMDAR2D, NR2D" ENSG00000105464 "Glutamate ionotropic receptor NMDA type subunit 2D" O15399 19 48393668-48444931 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "brain: 8.4" "Group enriched" "Detected in some" 5 "Inhibitory neurons: 36.5;Oligodendrocyte precursor cells: 15.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "A549: 17.3;EFO-21: 11.5;HMC-1: 28.4;NB-4: 17.6;SK-BR-3: 15.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" CAB009006 Approved NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 3: HMC-1 - Innate immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB009006: AB_2279191" "unprognostic (9.96e-2)" "unprognostic (6.98e-2)" "unprognostic (1.17e-1)" "unprognostic (5.08e-3)" "unprognostic (1.46e-1)" "unprognostic (4.17e-1)" "unprognostic (1.43e-4)" "unprognostic (7.84e-2)" "unprognostic (2.72e-1)" "unprognostic (2.23e-3)" "unprognostic (1.57e-1)" "unprognostic (1.80e-1)" "unprognostic (6.66e-13)" "unprognostic (2.15e-2)" "unprognostic (1.92e-2)" "unprognostic (1.26e-3)" "unprognostic (1.14e-1)" 0.6 0.3 3.0 0.3 1.4 0.1 0.3 3.0 2.8 0.1 0.0 0.2 0.5 0.1 0.0 0.1 0.4 0.3 0.3 1.2 4.8 0.1 0.1 0.2 0.1 4.7 5.8 0.2 0.1 0.9 0.2 0.9 4.8 0.3 0.0 0.8 0.2 0.0 0.1 0.6 0.7 0.1 2.4 0.2 0.2 1.1 8.4 0.0 0.7 0.0 0.0 0.1 0.3 0.6 1.5 17.3 0.4 0.0 1.2 3.5 9.8 2.1 0.0 0.5 0.1 1.3 10.0 0.5 11.5 1.1 0.1 0.1 0.1 0.2 0.3 2.3 0.4 5.4 0.6 2.2 1.8 0.4 28.4 1.3 0.0 1.0 0.0 0.1 0.4 0.1 9.9 0.5 0.1 3.2 0.0 17.6 0.5 8.6 0.3 0.1 0.0 0.3 0.3 0.0 1.8 1.7 0.8 15.0 0.1 0.2 0.0 6.6 5.8 0.0 0.1 0.0 0.0 5.8 3.5 0.0 0.0 2.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 1.4 3.0 2.8 1.2 4.8 4.7 5.8 4.8 2.4 8.4 0.6 0.3 0.0 0.0 1.6 0.0 0.0 0.1 0.0 0.0 2.9 0.0 0.3 2.6 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.1 0.9 0.2 0.3 0.4 0.0 0.0 2.3 0.2 4.6 0.9 0.0 0.1 0.0 0.1 1.8 0.2 1.3 0.0 36.5 0.0 0.0 0.3 0.2 1.5 0.6 0.6 0.0 1.0 0.2 0.7 0.0 15.6 1.3 0.4 0.0 0.4 0.0 0.1 0.0 0.0 0.0 1.9 0.0 0.0 0.5 0.2 0.4 0.0 0.0 1.8 0.2 0.2 0.1 0.0 GRIN3A GluN3A ENSG00000198785 "Glutamate ionotropic receptor NMDA type subunit 3A" Q8TCU5 9 101569352-101738647 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 5.8" "Cell type enriched" "Detected in some" 5 "Inhibitory neurons: 220.7" "Cancer enriched" "Detected in single" 7 "prostate cancer: 3.4" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 5 "SCLC-21H: 1.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 65: Brain - Ion transport" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (1.29e-1)" "unprognostic (7.10e-3)" "unprognostic (3.01e-5)" "unprognostic (3.39e-2)" "unprognostic (6.32e-2)" "unprognostic (7.06e-4)" "unprognostic (1.74e-1)" "unprognostic (2.59e-1)" "unprognostic (7.56e-2)" "unprognostic (7.34e-3)" "unprognostic (1.16e-2)" "unprognostic (1.38e-1)" "unprognostic (1.75e-1)" "unprognostic (1.80e-1)" "unprognostic (1.42e-1)" "unprognostic (4.87e-1)" "unprognostic (9.41e-2)" 0.1 0.1 3.9 0.2 4.0 0.1 0.2 0.0 3.8 1.5 0.0 0.3 0.1 0.3 0.3 0.1 0.1 0.0 0.6 3.0 1.7 0.1 0.2 0.2 0.4 1.3 1.7 0.8 0.1 0.0 0.1 0.0 1.4 0.6 0.2 0.8 0.2 0.9 0.1 0.3 0.2 0.1 1.1 0.7 0.1 0.3 5.8 0.1 0.1 0.1 0.2 0.1 0.1 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.1 1.8 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.2 0.0 0.1 0.3 0.0 0.2 0.0 0.3 0.0 0.1 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 3.9 4.0 0.0 3.8 3.0 1.7 1.3 1.7 1.4 1.1 5.8 0.4 0.2 0.0 0.0 5.2 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 1.0 0.0 0.0 0.0 4.2 0.0 0.0 0.1 0.0 0.0 1.8 0.2 0.1 0.6 0.0 0.0 37.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.9 0.0 220.7 0.0 0.0 2.4 1.1 0.8 0.9 0.2 0.0 0.0 0.1 0.1 0.0 1.5 1.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 6.6 0.0 0.8 0.2 0.0 0.0 0.3 0.0 0.0 0.3 0.0 0.0 GRIN3B GluN3B ENSG00000116032 "Glutamate ionotropic receptor NMDA type subunit 3B" O60391 19 1000419-1009732 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "brain: 2.9;fallopian tube: 4.1" "Group enriched" "Detected in some" 4 "Endometrial ciliated cells: 15.1;Respiratory ciliated cells: 18.5;Spermatogonia: 10.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "U-266/70: 3.5" "Region enhanced" "Detected in single" "pons and medulla: 1.6" "Region enriched" "Detected in single" 9 "spinal cord: 4.8" NA NA "Cluster 42: Ciliated cells - Cilium & Cell projection" "Cluster 29: U-266 - Adaptive immune response" "Cluster 49: Ciliated cells - Cilium organization" "unprognostic (7.86e-2)" "unprognostic (1.09e-1)" "unprognostic (2.61e-2)" "unprognostic (3.43e-3)" "unprognostic (1.35e-1)" "unprognostic (1.93e-1)" "unprognostic (1.36e-1)" "unprognostic (9.20e-2)" "unprognostic (1.49e-1)" "unprognostic (3.78e-3)" "unprognostic (9.35e-3)" "unprognostic (3.62e-2)" "unprognostic (3.34e-5)" "unprognostic (1.94e-1)" "unprognostic (1.63e-1)" "unprognostic (1.72e-1)" "unprognostic (1.33e-1)" 0.1 0.1 0.3 0.1 0.4 0.1 0.1 0.6 0.5 0.8 0.2 0.1 0.2 0.1 0.0 0.1 4.1 0.0 0.1 0.2 0.5 0.7 0.1 1.4 0.3 2.0 1.9 0.2 0.2 0.0 0.5 0.1 2.9 0.2 0.0 0.3 0.2 0.0 0.1 0.4 0.1 0.0 0.5 0.9 0.1 0.5 0.2 0.0 0.4 0.0 0.0 0.1 0.2 0.8 0.1 0.4 0.3 0.1 0.1 0.6 1.0 0.5 0.0 0.0 0.0 0.0 0.1 0.5 0.7 0.0 0.2 0.3 0.0 0.0 0.0 0.2 1.1 0.2 0.3 0.1 0.0 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.5 0.0 0.3 0.1 0.1 0.1 0.0 0.0 1.1 0.1 0.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.4 0.4 0.1 0.2 0.3 0.0 3.5 0.9 0.1 0.0 1.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.6 0.5 0.2 0.5 2.0 1.9 2.9 0.5 0.2 0.8 0.0 0.0 0.6 0.3 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 1.6 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.5 15.1 0.2 0.1 0.0 0.0 0.3 0.0 0.1 0.1 0.0 0.7 1.3 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 1.2 1.7 0.0 0.2 0.0 0.0 0.6 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 18.5 0.0 0.0 0.0 0.1 1.5 10.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 GRM5 "GPRC1E, mGlu5, MGLUR5, PPP1R86" ENSG00000168959 "Glutamate metabotropic receptor 5" P41594 11 88504576-89065945 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 23.8" "Group enriched" "Detected in some" 26 "Excitatory neurons: 903.1;Inhibitory neurons: 968.3;Oligodendrocyte precursor cells: 1040.5" "Not detected" "Not detected" "Group enriched" "Detected in many" 4 "amygdala: 14.9;basal ganglia: 17.3;cerebral cortex: 23.8;hippocampal formation: 20.4;white matter: 6.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "Intracellular and membrane" NA NA "Cluster 41: Basophils - Cellular respiration" "Cluster 10: Brain - Neuronal signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (1.94e-1)" "unprognostic (9.62e-2)" "unprognostic (9.57e-2)" "unprognostic (2.79e-2)" "unprognostic (1.80e-1)" "unprognostic (2.62e-1)" "unprognostic (1.26e-1)" "unprognostic (7.16e-2)" "unprognostic (8.15e-4)" "unprognostic (3.43e-2)" 0.0 0.0 14.9 0.0 17.3 0.0 0.0 0.0 23.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 20.4 1.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.1 0.3 0.0 0.0 2.8 0.0 0.0 1.7 3.7 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.9 17.3 0.0 23.8 20.4 1.0 0.0 0.0 0.0 2.8 3.7 6.4 0.1 0.0 0.0 36.6 0.0 0.0 0.0 0.0 0.0 28.9 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.4 7.5 0.1 0.0 0.0 0.0 903.1 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 1.7 968.3 0.0 0.0 0.0 0.0 23.6 0.3 0.0 0.0 22.5 0.0 0.8 0.0 1040.5 21.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.1 1.8 0.0 0.0 0.0 1.6 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 GSR ENSG00000104687 "Glutathione-disulfide reductase" P00390 8 30678066-30727846 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes, Disease variant, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "basophil: 32.3" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001538, CAB008632, HPA064806" Approved Supported Cytosol NA NA 81000000 "Cluster 46: Basophils - DNA binding" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 40: Granulosa cells - Unknown function" Cytosol "CAB008632: AB_1616690, HPA001538: AB_1078986, HPA064806: " "unprognostic (1.23e-1)" "prognostic favorable (3.37e-4)" "prognostic favorable (4.08e-5)" "unprognostic (2.89e-3)" "unprognostic (1.62e-1)" "unprognostic (3.50e-1)" "prognostic unfavorable (3.26e-5)" "unprognostic (3.61e-2)" "unprognostic (1.01e-1)" "unprognostic (4.15e-2)" "unprognostic (2.83e-2)" "unprognostic (6.92e-3)" "prognostic favorable (1.80e-4)" "unprognostic (2.31e-3)" "unprognostic (2.26e-1)" "unprognostic (1.01e-1)" "unprognostic (1.29e-1)" 13.6 23.3 12.3 18.7 11.1 25.9 11.0 10.6 11.7 28.5 25.8 42.5 54.3 16.0 21.6 37.3 21.6 30.5 25.4 12.9 12.5 45.3 35.8 17.4 23.6 9.5 14.2 23.1 26.5 82.3 14.8 23.5 12.0 35.3 46.6 12.8 25.8 29.4 28.9 12.8 50.8 17.9 10.7 22.1 41.8 11.6 17.6 26.7 16.9 21.3 24.0 22.5 27.7 11.2 49.4 197.8 35.9 40.1 35.8 38.3 29.1 23.4 46.8 31.8 36.7 66.0 31.3 95.8 94.8 32.0 96.1 59.2 62.3 51.1 33.1 22.6 40.7 104.6 67.0 197.8 88.4 38.6 159.7 72.6 28.5 48.9 20.9 33.5 43.3 57.3 73.2 55.1 67.9 44.1 147.1 32.0 65.4 191.9 31.5 43.8 41.9 59.3 56.0 124.3 28.2 31.8 31.2 87.8 58.8 40.7 37.5 32.6 63.8 21.0 34.7 37.3 35.2 20.2 29.4 70.0 51.9 51.8 62.4 32.3 5.9 15.0 5.0 5.4 8.8 3.6 4.5 5.4 6.0 2.3 2.8 3.7 8.2 3.6 7.9 3.9 4.5 3.1 12.3 11.1 10.6 11.7 12.9 12.5 9.5 14.2 12.0 10.7 17.6 11.2 8.2 3.2 20.8 12.7 13.7 4.2 15.2 9.4 52.3 6.7 6.7 5.0 26.8 30.0 15.0 12.9 16.7 17.0 20.3 61.8 9.8 11.4 8.4 61.4 13.4 9.9 34.1 28.6 18.1 19.8 6.3 10.0 33.1 41.3 6.3 64.3 12.1 43.4 18.2 3.3 27.4 51.7 8.2 40.5 5.8 18.9 7.2 22.1 8.8 11.2 20.6 12.6 17.5 12.5 10.0 15.2 32.0 10.9 15.6 27.5 75.7 19.0 11.7 8.0 6.6 7.0 8.6 1.2 3.4 39.6 5.4 6.4 17.3 17.2 47.5 33.5 GSS ENSG00000100983 "Glutathione synthetase" P48637 20 34928432-34956027 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Glutathione biosynthesis" Ligase "Disease variant, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Late spermatids: 164.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054508, HPA059315" Enhanced Supported Nucleoplasm NA NA 28000000 "Cluster 28: Myeloid DCs - Unknown function" "Cluster 27: Brain & Skin - Unknown function" "Cluster 39: CACO-2 - Unknown function" "Cluster 39: Non-specific - Basic cellular processes" Nucleoplasm "HPA054508: AB_2682509, HPA059315: AB_2683976" "unprognostic (5.80e-2)" "unprognostic (1.50e-1)" "unprognostic (1.14e-1)" "unprognostic (7.21e-2)" "unprognostic (3.63e-2)" "unprognostic (5.68e-2)" "prognostic unfavorable (7.21e-5)" "unprognostic (2.90e-2)" "unprognostic (8.52e-2)" "unprognostic (3.64e-1)" "unprognostic (6.49e-2)" "unprognostic (1.50e-1)" "prognostic favorable (7.31e-6)" "unprognostic (3.35e-3)" "unprognostic (1.96e-1)" "unprognostic (1.42e-3)" "unprognostic (1.52e-1)" 18.8 46.9 24.2 17.7 25.6 27.1 23.8 21.4 26.2 21.1 24.6 41.1 30.4 17.4 67.7 43.4 26.9 17.9 24.8 25.4 25.3 42.7 44.8 21.7 15.9 23.7 25.1 14.3 15.7 27.7 26.4 19.8 25.5 34.2 40.6 15.7 28.9 18.6 20.4 34.6 28.4 19.1 22.9 23.7 28.5 23.7 25.9 21.5 23.2 16.9 18.5 22.9 26.1 25.4 63.7 75.7 36.2 51.2 41.4 42.8 51.5 52.9 48.7 81.6 67.1 139.9 75.5 44.8 68.6 54.9 78.7 58.7 53.6 134.8 68.5 20.9 30.4 176.1 46.8 140.1 58.1 44.8 59.5 45.3 141.8 77.0 128.8 36.3 58.4 59.5 87.1 35.7 100.6 70.1 72.5 63.5 21.4 83.2 96.0 64.8 72.7 106.9 117.7 63.9 71.0 41.3 93.6 86.5 70.9 19.7 106.5 40.5 46.7 93.1 52.5 61.7 46.5 35.7 35.9 49.1 79.4 48.6 56.7 17.5 36.2 8.7 30.4 39.2 27.6 12.8 24.0 31.4 43.6 8.7 27.7 23.7 8.4 29.3 36.6 23.9 32.6 29.0 24.2 25.6 21.4 26.2 25.4 25.3 23.7 25.1 25.5 22.9 25.9 25.4 10.6 19.2 10.5 13.4 9.9 26.3 32.5 72.4 38.7 23.0 32.8 20.8 17.1 27.1 38.1 25.8 10.4 79.4 19.1 58.1 25.4 51.6 55.6 14.8 18.2 16.1 23.4 26.9 12.2 47.2 52.5 19.3 37.2 16.4 17.7 80.1 10.0 27.3 59.9 35.3 13.8 50.6 48.8 17.2 17.3 164.1 10.2 26.8 16.0 5.6 31.0 29.6 19.6 10.1 9.9 39.8 40.1 18.4 19.6 21.4 33.8 121.5 18.1 16.9 26.3 12.0 21.0 14.7 18.9 38.1 24.2 49.0 20.6 52.1 77.7 33.0 GUCY1A2 "GC-SA2, GUC1A2" ENSG00000152402 "Guanylate cyclase 1 soluble subunit alpha 2" P33402 11 106674019-107018476 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "cGMP biosynthesis" Lyase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 18.4;placenta: 17.9" "Group enriched" "Detected in many" 4 "Excitatory neurons: 353.8;Inhibitory neurons: 141.8;Oligodendrocyte precursor cells: 208.6;Sertoli cells: 105.2;Smooth muscle cells: 107.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ hTERT+: 11.8;BJ hTERT+ SV40 Large T+ RasG12V: 13.4;HBF TERT88: 7.1;TIME: 4.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009534 Uncertain NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "CAB009534: AB_2279509" "unprognostic (7.53e-2)" "unprognostic (6.67e-2)" "unprognostic (7.99e-2)" "unprognostic (1.10e-1)" "unprognostic (1.08e-1)" "unprognostic (1.22e-2)" "unprognostic (1.23e-2)" "unprognostic (1.24e-1)" "unprognostic (6.53e-3)" "unprognostic (9.70e-3)" "unprognostic (8.00e-2)" "unprognostic (2.03e-1)" "prognostic unfavorable (3.02e-5)" "unprognostic (2.48e-4)" "unprognostic (1.62e-1)" "unprognostic (3.50e-2)" "unprognostic (1.09e-2)" 3.4 2.0 5.3 0.6 18.4 0.0 1.9 1.6 13.8 12.7 0.0 0.7 0.2 12.3 3.1 0.4 5.9 1.5 2.7 7.1 3.9 1.8 1.7 4.6 0.7 4.7 2.6 1.2 4.3 0.6 0.5 17.9 4.9 1.8 0.5 3.5 0.6 6.8 1.8 0.6 0.4 13.1 0.4 6.0 0.3 1.7 8.6 0.2 1.4 3.6 0.3 0.9 2.8 7.4 0.0 0.2 4.0 0.0 0.2 2.4 2.2 0.3 11.8 1.5 13.4 0.0 0.0 0.0 0.0 0.9 0.4 0.0 0.1 0.0 7.1 0.0 1.1 0.0 0.1 0.0 0.2 0.0 1.6 0.6 0.0 1.8 0.2 0.0 0.8 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.4 3.6 0.0 0.7 0.5 0.8 0.2 4.6 3.7 3.0 0.8 1.2 0.0 0.0 0.0 0.1 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.3 18.4 1.6 13.8 7.1 3.9 4.7 2.6 4.9 0.4 8.6 7.4 29.5 0.0 0.5 20.2 0.5 1.7 2.2 0.0 1.2 24.0 0.4 0.9 5.1 0.0 0.0 3.7 12.5 0.1 0.0 0.1 0.0 5.8 2.5 0.9 24.2 12.5 0.0 2.7 353.8 0.2 0.0 8.2 0.0 1.1 0.0 42.7 2.2 0.2 0.4 18.5 141.8 0.0 0.0 0.8 1.5 6.5 24.5 1.1 3.6 18.7 0.0 29.3 0.0 208.6 10.7 0.3 0.0 25.2 1.2 2.4 0.0 0.1 0.0 4.8 105.2 20.7 107.0 1.6 1.5 0.7 1.1 0.3 0.5 19.6 0.0 1.5 GUCY2C "GUC2C, STAR" ENSG00000070019 "Guanylate cyclase 2C" P25092 12 14612632-14696599 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "cGMP biosynthesis" "Lyase, Receptor" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 20 "intestine: 68.2" "Cell type enhanced" "Detected in some" "Distal enterocytes: 34.4;Enteroendocrine cells: 176.7;Intestinal goblet cells: 56.0;Paneth cells: 97.9;Proximal enterocytes: 81.5;Undifferentiated cells: 47.6" "Group enriched" "Detected in many" 5 "colorectal cancer: 23.9;stomach cancer: 9.1" "Not detected" "Not detected" "Immune cell enhanced" "Detected in some" "memory B-cell: 1.5" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "AN3-CA: 1.4;CACO-2: 1.1;CAPAN-2: 1.7;SiHa: 1.6" "Region enhanced" "Detected in some" "midbrain: 1.8" "Low region specificity" "Detected in all" "HPA037655, HPA073759" Uncertain Uncertain Vesicles NA NA "Cluster 19: B-cells - Humoral immune response" "Cluster 9: Intestine - Unknown function" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 17: Intestinal endocrine cells - Hormone signaling" Vesicles "HPA037655: AB_10672388, HPA073759: " "unprognostic (1.08e-1)" "unprognostic (2.12e-1)" "unprognostic (3.58e-2)" "unprognostic (2.11e-2)" "unprognostic (1.60e-2)" "unprognostic (5.67e-3)" "prognostic unfavorable (1.37e-5)" "unprognostic (9.14e-2)" "unprognostic (1.49e-2)" "unprognostic (2.95e-1)" "unprognostic (1.58e-1)" "unprognostic (5.40e-2)" "unprognostic (2.35e-4)" "unprognostic (8.02e-2)" "unprognostic (1.64e-1)" "unprognostic (1.33e-1)" "unprognostic (1.98e-1)" 0.5 0.2 0.1 3.4 0.3 0.5 0.0 0.2 0.1 0.0 3.0 37.2 68.2 0.3 0.0 1.9 0.0 0.9 2.2 0.2 0.3 0.4 0.3 0.2 0.4 0.4 0.3 0.0 2.2 0.0 0.0 0.2 0.4 0.3 41.4 0.1 0.6 0.0 0.7 1.0 66.5 1.4 0.5 0.2 1.9 0.4 0.3 0.0 0.5 0.0 0.3 0.5 0.2 0.5 0.4 0.0 0.0 1.4 0.0 0.0 0.8 0.0 0.0 0.0 0.0 1.1 1.7 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.2 1.6 0.1 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.5 0.3 0.4 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.0 1.5 0.0 0.0 0.3 1.1 0.0 0.0 1.1 0.0 0.0 0.2 0.0 0.2 0.1 0.3 0.2 0.1 0.2 0.3 0.4 0.3 0.4 0.5 0.3 0.5 0.0 0.0 0.0 1.3 6.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 34.4 0.0 0.0 0.1 0.1 0.0 0.0 176.7 0.0 1.4 0.2 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.8 56.0 0.0 0.3 0.3 0.2 0.0 0.3 0.0 1.0 0.3 0.0 0.0 1.0 0.2 0.4 97.9 0.0 0.1 0.0 81.5 0.8 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 47.6 0.0 HADH "HADH1, HADHSC, SCHAD" ENSG00000138796 "Hydroxyacyl-CoA dehydrogenase" Q16836 4 107989714-108035174 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism" "Oxidoreductase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "tongue: 280.3" "Cell type enhanced" "Detected in all" "Hepatocytes: 272.4;Proximal enterocytes: 383.0;Proximal tubular cells: 318.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039588, HPA043888" Enhanced Supported Mitochondria No Yes 1000000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 8: Non-specific - Mitochondria" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 39: Non-specific - Basic cellular processes" Mitochondria "HPA039588: AB_10673425, HPA043888: AB_2678716" "unprognostic (1.73e-1)" "unprognostic (3.32e-3)" "unprognostic (3.05e-3)" "unprognostic (8.86e-3)" "unprognostic (1.83e-1)" "unprognostic (6.83e-2)" "unprognostic (9.26e-3)" "unprognostic (1.55e-2)" "unprognostic (9.22e-2)" "unprognostic (3.24e-2)" "unprognostic (2.96e-1)" "unprognostic (1.18e-2)" "prognostic favorable (0.00e+0)" "unprognostic (1.67e-1)" "unprognostic (4.22e-2)" "unprognostic (5.67e-2)" "unprognostic (1.88e-2)" 143.0 54.1 23.2 20.9 23.8 27.4 74.9 24.6 26.3 37.9 33.5 101.2 84.4 49.8 24.9 34.2 56.2 24.0 175.6 22.9 27.2 140.2 225.5 22.8 22.2 24.7 26.3 54.3 42.1 40.2 18.0 13.7 26.0 35.4 90.8 10.4 55.9 42.4 249.7 28.0 89.1 72.7 26.0 18.0 60.7 27.9 24.9 76.0 37.7 280.3 28.5 34.1 28.7 28.0 32.2 27.9 64.3 46.2 149.2 48.2 27.0 43.1 68.5 49.6 48.9 21.2 60.9 185.0 23.5 38.8 34.6 42.0 85.5 64.5 55.5 49.6 37.2 39.9 50.5 48.9 24.3 88.2 17.0 50.4 34.1 35.1 32.3 41.4 34.4 127.1 53.1 98.7 57.3 58.9 163.6 36.7 29.0 147.8 30.1 113.5 84.3 89.2 54.5 129.4 73.2 43.1 41.1 161.9 45.6 37.0 77.4 70.8 20.6 35.5 18.9 48.5 26.7 52.1 63.3 80.6 47.0 60.2 27.0 0.0 11.1 11.4 17.2 14.2 22.1 31.4 19.5 20.7 36.8 27.1 22.4 22.2 1.2 36.7 20.1 41.7 17.7 16.3 23.2 23.8 24.6 26.3 22.9 27.2 24.7 26.3 26.0 26.0 24.9 28.0 17.3 28.9 33.8 11.1 25.7 15.6 54.2 65.8 41.5 6.9 46.5 56.1 225.6 52.9 48.1 35.0 4.2 41.0 18.3 164.7 160.4 43.3 196.8 41.4 22.6 17.5 32.4 65.6 15.1 32.2 44.7 28.2 52.5 26.1 10.8 63.9 21.0 272.4 116.5 6.7 18.9 93.3 36.7 37.8 11.8 108.5 46.3 25.3 21.4 12.2 15.3 26.8 8.2 9.5 9.9 23.0 100.8 35.3 32.0 33.9 383.0 318.8 70.8 6.8 39.5 21.7 38.2 22.4 20.3 64.0 18.2 17.0 19.6 66.3 194.2 49.1 HBA1 HBA-T3 ENSG00000206172 "Hemoglobin subunit alpha 1" P69905 16 176680-177522 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Disease variant, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "bone marrow: 24344.4" "Cell type enriched" "Detected in many" 51 "Erythroid cells: 224916.4" "Group enriched" "Detected in many" 4 "endometrial cancer: 2.6;glioma: 6.3;ovarian cancer: 2.6;stomach cancer: 2.6" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 142.6;plasmacytoid DC: 101.1" "Group enriched" "Detected in all" 5 "dendritic cells: 101.1;granulocytes: 142.6" "Group enriched" "Detected in some" 36 "HEL: 3355.8;K-562: 2416.8" "CAB032534, HPA043780" Enhanced NA NA 14000000000 "Cluster 1: Neutrophils - Mixed function" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 1: K-562 - Erythropoiesis" "Cluster 6: Erythroid cells - Oxygen transport" "CAB032534: AB_2294993, HPA043780: AB_2678667" "unprognostic (1.16e-1)" "unprognostic (1.45e-2)" "unprognostic (8.87e-2)" "unprognostic (9.78e-3)" "unprognostic (3.02e-1)" "unprognostic (1.44e-1)" "unprognostic (1.67e-1)" "unprognostic (1.35e-1)" "unprognostic (6.21e-3)" "unprognostic (1.92e-2)" "unprognostic (1.64e-1)" "unprognostic (1.02e-2)" "unprognostic (3.59e-2)" "unprognostic (3.79e-1)" "unprognostic (6.61e-2)" "unprognostic (2.67e-2)" "unprognostic (9.56e-2)" 893.7 183.0 112.1 82.0 216.3 24344.4 316.6 159.4 246.9 237.7 340.5 141.4 10.6 41.4 2.4 244.9 350.9 60.1 1766.9 56.9 92.1 1405.5 1100.4 2201.7 5.0 141.5 169.4 159.7 100.5 5.1 465.7 1992.7 183.4 170.1 11.5 3.1 138.1 43.7 234.0 194.6 85.0 7.0 211.1 5527.7 135.9 104.8 125.3 20.7 609.2 1123.2 3.6 167.2 351.2 113.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 58.1 0.0 5.7 2.1 0.0 0.4 0.0 3.5 0.0 0.0 0.0 0.2 3355.8 0.0 37.1 0.0 1.3 0.0 0.3 0.0 0.0 0.7 0.0 0.0 1.7 2416.8 0.0 0.0 14.7 0.5 0.3 0.4 1.0 0.0 0.1 1.4 79.1 0.0 1.0 7.4 5.3 2.8 0.0 0.0 0.0 1.1 0.0 8.3 0.0 0.0 0.9 0.0 0.0 0.4 0.8 0.0 0.2 0.0 8.5 7.4 48.2 26.3 0.2 0.7 7.5 3.1 8.7 10.0 4.5 8.3 25.7 142.6 13.4 0.8 101.1 0.3 2806.3 112.1 216.3 159.4 246.9 56.9 92.1 141.5 169.4 183.4 211.1 125.3 113.5 72.7 0.0 0.0 0.0 56.8 10.6 0.1 0.0 0.0 0.4 11.3 12.3 1.8 55.8 0.1 0.0 0.0 0.0 93.2 3.2 7.9 0.0 6.0 0.5 0.5 20.4 1.2 224916.4 0.0 0.0 0.0 57.9 0.0 0.4 0.0 0.1 151.0 78.8 0.0 0.0 0.0 5.7 0.0 436.7 64.1 22.4 0.0 234.0 4338.2 0.0 12.7 1.3 1166.9 0.0 0.0 0.1 2.8 0.4 0.5 0.2 0.2 11.1 0.0 16.5 0.0 8.7 58.7 1.5 7.6 0.0 13.2 0.0 155.7 0.0 3.2 0.0 HBA2 HBA-T2 ENSG00000188536 "Hemoglobin subunit alpha 2" P69905 16 172876-173710 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Disease variant, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 5 "bone marrow: 38218.6" "Cell type enriched" "Detected in many" 22 "Erythroid cells: 198314.0" "Cancer enhanced" "Detected in all" "glioma: 59.7" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 5 "eosinophil: 315.1;neutrophil: 955.3;plasmacytoid DC: 486.7" "Group enriched" "Detected in all" 7 "dendritic cells: 486.7;granulocytes: 955.3" "Group enriched" "Detected in some" 18 "HEL: 1196.2;K-562: 328.3" "CAB038417, HPA043780" Enhanced NA NA 14000000000 "Cluster 1: Neutrophils - Mixed function" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 36: HEL - Hemostasis" "Cluster 6: Erythroid cells - Oxygen transport" "CAB038417: , HPA043780: AB_2678667" "unprognostic (1.57e-1)" "unprognostic (7.02e-2)" "unprognostic (2.59e-2)" "unprognostic (2.13e-1)" "unprognostic (3.59e-1)" "unprognostic (3.18e-1)" "unprognostic (3.39e-2)" "unprognostic (2.12e-1)" "unprognostic (4.99e-2)" "unprognostic (4.43e-1)" "unprognostic (1.09e-2)" "unprognostic (1.19e-2)" "unprognostic (1.72e-3)" "unprognostic (1.36e-1)" "unprognostic (2.11e-1)" "unprognostic (4.73e-2)" "unprognostic (8.92e-2)" 1592.0 322.5 162.6 186.3 292.4 38218.6 545.3 268.0 377.0 573.3 570.7 254.0 21.6 85.9 5.9 432.5 570.5 147.6 2590.3 86.6 156.5 2302.8 1853.6 4204.3 9.7 210.6 249.2 288.5 141.3 11.4 807.8 3618.9 260.6 302.7 26.7 4.0 305.4 131.9 568.3 188.5 154.3 12.9 316.4 8125.4 264.0 185.0 185.4 34.6 1192.5 1744.6 10.1 325.2 632.8 179.9 0.0 0.2 0.0 0.0 0.0 0.7 0.4 0.4 0.1 0.0 0.0 3.2 0.0 1.9 4.9 0.0 0.1 0.7 0.0 0.0 0.0 0.1 0.6 1196.2 0.5 0.0 0.0 0.2 1.7 0.4 0.1 0.4 0.0 0.0 0.0 0.1 328.3 0.0 0.1 0.6 0.0 0.3 0.1 0.5 0.0 0.0 0.0 43.4 0.0 0.9 11.9 9.7 1.1 0.0 0.0 0.1 1.4 0.2 5.6 0.0 0.3 0.4 0.0 0.4 0.0 0.0 0.3 0.6 0.2 119.6 28.1 315.1 99.6 1.7 3.7 39.2 8.5 7.1 42.5 19.1 22.8 73.9 955.3 49.5 3.3 486.7 1.0 15003.3 162.6 292.4 268.0 377.0 86.6 156.5 210.6 249.2 260.6 316.4 185.4 179.9 184.7 3.2 1.5 0.0 97.6 44.4 0.4 0.1 0.6 1.7 20.2 22.2 6.8 70.1 0.7 0.0 0.0 0.0 162.2 6.9 54.8 0.0 3.4 0.6 0.8 50.9 3.0 198314.0 0.0 0.0 0.0 241.0 4.1 0.9 1.3 0.3 142.8 131.2 0.0 0.0 0.0 7.5 4.1 770.6 149.6 16.9 0.0 402.9 8790.3 0.0 37.5 2.3 954.7 0.0 0.0 0.0 3.6 0.0 0.3 0.2 0.1 29.6 2.5 58.6 0.0 25.2 171.5 1.0 9.9 1.1 44.6 0.0 306.3 0.1 5.0 0.1 HBB "beta-globin, CD113t-C" ENSG00000244734 "Hemoglobin subunit beta" P68871 11 5225464-5229395 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Hypotensive agent, Vasoactive" "Congenital dyserythropoietic anemia, Disease variant, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 10 "bone marrow: 133301.6" "Cell type enriched" "Detected in many" 24 "Erythroid cells: 672352.3" "Group enriched" "Detected in all" 4 "cervical cancer: 66.4;glioma: 244.6;renal cancer: 65.1" "Region enriched" "Detected in all" 11 "cerebral cortex: 3368.5" "Group enriched" "Detected in all" 5 "neutrophil: 658.1;plasmacytoid DC: 379.7" "Group enriched" "Detected in all" 11 "dendritic cells: 379.7;granulocytes: 658.1" "Cell line enhanced" "Detected in some" "HEL: 6.0;SCLC-21H: 5.0;SH-SY5Y: 6.4;U-266/70: 23.1;U-266/84: 4.2" "CAB009526, HPA043234" Enhanced NA NA 10000000000 "Cluster 1: Neutrophils - Mixed function" "Cluster 67: Neutrophils - Humoral immune response" "Cluster 29: U-266 - Adaptive immune response" "Cluster 6: Erythroid cells - Oxygen transport" "CAB009526: AB_2143058, HPA043234: AB_2678378" "unprognostic (2.41e-1)" "unprognostic (8.55e-2)" "unprognostic (2.40e-1)" "unprognostic (4.40e-2)" "unprognostic (1.14e-1)" "unprognostic (3.22e-1)" "unprognostic (4.88e-2)" "unprognostic (7.46e-2)" "unprognostic (2.91e-2)" "unprognostic (1.76e-1)" "unprognostic (1.91e-1)" "unprognostic (8.11e-3)" "unprognostic (2.40e-2)" "unprognostic (5.81e-2)" "unprognostic (1.42e-1)" "unprognostic (8.87e-3)" "unprognostic (6.41e-2)" 1641.5 481.4 155.7 217.3 219.2 133301.6 637.4 235.7 3368.5 546.2 384.6 278.2 28.8 78.8 45.6 505.7 829.6 792.7 2658.8 108.9 154.4 2333.1 1907.3 4039.6 26.8 209.6 243.5 289.0 158.5 50.5 808.2 6345.0 303.0 312.0 148.9 31.0 548.1 290.6 578.8 135.3 169.8 66.3 316.2 9225.9 269.1 170.6 171.4 196.8 1152.0 12902.5 40.3 320.1 633.5 180.7 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 6.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 2.2 0.0 0.0 0.0 0.8 0.2 0.4 0.0 0.0 0.4 0.3 0.0 0.0 5.0 6.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 23.1 4.2 0.0 0.0 0.0 0.0 99.5 25.3 73.7 37.8 1.3 4.0 21.5 6.8 1.1 35.2 13.8 13.7 39.9 658.1 47.9 5.0 379.7 1.4 22388.9 155.7 219.2 235.7 3368.5 108.9 154.4 209.6 243.5 303.0 316.2 171.4 180.7 441.7 3.2 8.4 0.0 280.5 157.0 2.3 5.1 0.0 4.0 54.7 72.0 3.4 217.3 4.5 7.3 4.2 2.2 369.9 5.2 50.9 0.0 0.0 6.8 6.6 151.7 3.6 672352.3 0.0 0.0 11.3 276.1 0.0 5.1 0.0 4.6 443.4 420.5 7.3 3.3 0.0 7.2 6.1 1452.1 702.6 0.0 0.0 1091.0 27383.1 0.0 72.7 9.7 38.1 0.0 0.0 0.1 3.5 0.0 1.9 0.0 0.1 272.4 84.9 117.8 0.0 126.0 396.8 0.0 0.0 0.0 252.5 2.2 769.8 0.3 3.0 0.1 HCAR2 "GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG" ENSG00000182782 "Hydroxycarboxylic acid receptor 2" Q8TDS4 12 122701293-122703357 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" Apoptosis "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 40.8;skin 1: 30.2" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 94.4;Basal prostatic cells: 84.7;Basal respiratory cells: 52.0;Basal squamous epithelial cells: 120.1;Ionocytes: 87.5;Langerhans cells: 124.0;Suprabasal keratinocytes: 106.1" "Group enriched" "Detected in many" 8 "cervical cancer: 12.6;head and neck cancer: 16.1;lung cancer: 6.4;urothelial cancer: 9.2" "Region enriched" "Detected in some" 5 "cerebral cortex: 5.9" "Immune cell enriched" "Detected in many" 5 "neutrophil: 176.7" "Lineage enriched" "Detected in many" 7 "granulocytes: 176.7" "Cell line enriched" "Detected in some" 6 "HaCaT: 118.4" HPA028660 Approved Supported "Cell Junctions" NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 11: Squamous epithelial cells - Epithelial cell function" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 61: Squamous epithelial cells - Keratinization" "Cell Junctions" "HPA028660: AB_10602139" "unprognostic (5.43e-2)" "unprognostic (1.27e-1)" "unprognostic (1.77e-1)" "unprognostic (2.05e-1)" "unprognostic (6.65e-2)" "unprognostic (1.33e-1)" "unprognostic (3.33e-3)" "unprognostic (7.26e-2)" "unprognostic (2.17e-1)" "unprognostic (1.77e-2)" "unprognostic (7.10e-2)" "unprognostic (7.33e-2)" "unprognostic (4.83e-4)" "unprognostic (5.76e-2)" "unprognostic (5.07e-2)" "unprognostic (1.54e-1)" "unprognostic (4.63e-2)" 22.2 0.3 0.1 9.8 0.2 22.1 7.6 0.1 5.9 8.9 0.2 0.7 0.9 0.2 0.3 40.8 0.7 0.8 0.9 0.3 0.1 3.9 2.9 11.9 0.6 0.1 0.1 0.1 0.2 5.5 0.3 4.5 1.2 3.4 0.3 0.2 14.2 14.7 0.2 30.2 1.0 0.3 0.1 25.9 1.5 2.7 0.2 10.5 0.5 1.9 10.2 6.9 14.0 0.1 4.5 0.4 0.1 0.1 1.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 118.4 0.0 7.3 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.3 0.1 3.8 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 1.0 0.0 0.3 0.0 0.0 0.4 0.1 0.0 0.0 0.0 19.5 0.2 0.0 0.4 0.1 0.0 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.3 0.0 0.0 38.7 2.5 2.6 0.0 5.3 0.0 0.1 0.0 0.0 1.7 0.0 0.0 0.0 176.7 0.0 23.9 0.0 0.0 1.4 0.1 0.2 0.1 5.9 0.3 0.1 0.1 0.1 1.2 0.1 0.2 0.1 0.4 0.0 4.3 0.0 0.5 94.4 84.7 52.0 120.1 0.5 3.4 1.1 0.1 0.0 40.3 0.0 0.0 1.5 0.0 0.0 0.0 0.0 24.9 0.4 0.2 1.2 0.0 0.0 0.0 0.0 26.3 2.4 0.0 0.3 2.5 0.0 0.0 0.0 3.7 0.0 0.0 0.0 87.5 4.1 124.0 2.7 0.0 17.8 8.8 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.3 0.0 0.0 8.5 0.1 0.0 0.1 1.4 0.0 0.1 47.2 106.1 2.6 1.5 0.0 0.0 32.5 HCAR3 "GPR109B, HCA3, HM74" ENSG00000255398 "Hydroxycarboxylic acid receptor 3" P49019 12 122714756-122716811 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 27.4;esophagus: 16.8;lymphoid tissue: 19.6;skin 1: 17.4" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 94.4;Basal prostatic cells: 81.1;Basal respiratory cells: 57.3;Basal squamous epithelial cells: 159.4;Langerhans cells: 57.4;Squamous epithelial cells: 66.9;Suprabasal keratinocytes: 106.3;Urothelial cells: 66.1" "Group enriched" "Detected in some" 4 "cervical cancer: 2.1;head and neck cancer: 2.5;lung cancer: 1.0;urothelial cancer: 1.9" "Region enriched" "Detected in single" 5 "cerebral cortex: 4.7" "Group enriched" "Detected in many" 6 "basophil: 58.6;neutrophil: 177.2;non-classical monocyte: 84.4" "Group enriched" "Detected in many" 50 "granulocytes: 177.2;monocytes: 84.4" "Cell line enriched" "Detected in some" 4 "RT4: 37.1" HPA028660 Approved Approved "Cell Junctions" NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 15: RT4 - Unknown function" "Cluster 61: Squamous epithelial cells - Keratinization" "Cell Junctions" "HPA028660: AB_10602139" "unprognostic (2.32e-1)" "unprognostic (5.82e-2)" "unprognostic (8.23e-2)" "unprognostic (2.27e-1)" "unprognostic (1.17e-1)" "unprognostic (9.17e-2)" "unprognostic (1.64e-3)" "unprognostic (1.60e-1)" "unprognostic (6.29e-2)" "unprognostic (9.87e-2)" "unprognostic (1.50e-2)" "unprognostic (2.80e-1)" "unprognostic (1.23e-1)" "unprognostic (2.30e-2)" "unprognostic (2.83e-1)" "unprognostic (1.16e-1)" "unprognostic (9.28e-2)" 5.6 0.1 0.0 9.2 0.1 27.4 2.3 0.0 4.7 2.5 0.2 0.5 0.2 0.0 0.5 16.8 0.7 0.6 0.7 0.1 0.0 0.9 1.8 8.2 0.4 0.0 0.0 0.1 0.0 3.4 0.2 1.9 0.9 1.5 0.1 0.1 3.4 2.7 0.1 17.4 0.2 0.2 0.0 19.6 0.4 0.1 0.1 4.0 0.4 1.1 7.8 7.1 4.3 0.0 0.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 9.2 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.2 0.0 0.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 37.1 0.2 0.0 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.4 0.0 0.0 0.0 0.1 58.6 2.2 0.8 0.0 16.7 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.1 177.2 0.0 84.4 0.0 0.0 2.9 0.0 0.1 0.0 4.7 0.1 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.1 3.2 6.7 0.0 0.7 94.4 81.1 57.3 159.4 0.2 0.7 0.3 0.0 0.0 24.6 0.0 0.0 1.3 0.2 0.0 0.0 0.0 0.7 0.0 0.0 1.0 0.0 0.0 0.0 0.0 21.5 1.4 0.0 0.1 3.8 0.0 0.0 0.1 6.0 0.0 0.0 0.0 12.2 10.6 57.4 0.2 0.0 20.1 8.8 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 14.7 0.0 0.1 2.2 0.2 0.0 0.0 1.4 0.1 0.0 66.9 106.3 13.8 1.0 0.0 0.0 66.1 HCRTR1 OX1R ENSG00000121764 "Hypocretin receptor 1" O43613 1 31617686-31632518 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in single" "brain: 3.7" "Cell type enhanced" "Detected in some" "Early spermatids: 1.1;Inhibitory neurons: 1.0;Late spermatids: 4.1" "Not detected" "Not detected" "Group enriched" "Detected in many" 8 "hypothalamus: 1.5;medulla oblongata: 1.0;midbrain: 3.6;pons: 3.7;thalamus: 1.7" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA014018 Approved NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA014018: AB_1854810" "unprognostic (2.96e-2)" "unprognostic (2.34e-2)" "unprognostic (7.86e-3)" "unprognostic (3.72e-3)" "unprognostic (2.42e-1)" "unprognostic (3.45e-3)" "unprognostic (2.54e-5)" "unprognostic (3.58e-2)" "unprognostic (4.17e-2)" "unprognostic (1.19e-1)" "unprognostic (2.28e-1)" "unprognostic (2.93e-1)" "unprognostic (3.77e-3)" "unprognostic (2.16e-2)" "unprognostic (1.02e-1)" "unprognostic (1.43e-1)" "unprognostic (1.07e-1)" 0.3 0.9 0.3 0.0 0.0 0.4 0.2 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.4 0.1 1.5 0.4 0.0 0.0 0.1 1.0 3.6 0.0 0.0 0.0 0.3 0.5 3.7 0.0 0.0 0.1 0.1 0.0 0.6 0.2 0.1 0.0 0.1 0.1 0.0 0.1 1.7 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.1 0.1 1.5 1.0 3.6 3.7 0.1 1.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.3 0.0 0.0 0.9 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 HCRTR2 OX2R ENSG00000137252 "Hypocretin receptor 2" O43614 6 55106460-55282617 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 10 "brain: 7.0" "Cell type enhanced" "Detected in some" "Excitatory neurons: 11.7;Inhibitory neurons: 18.3;Peritubular cells: 3.8" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 5 "AF22: 1.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA054516 Enhanced NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 12: NES - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA054516: AB_2682513" "unprognostic (4.86e-1)" "unprognostic (2.69e-2)" "unprognostic (1.86e-2)" "unprognostic (2.32e-1)" "unprognostic (7.45e-2)" "unprognostic (7.39e-2)" 0.0 0.0 1.5 0.0 0.9 0.0 0.0 1.2 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.5 1.6 0.6 0.0 0.0 0.0 2.4 7.0 0.3 0.0 0.0 0.0 0.4 4.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.3 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.9 1.2 0.7 1.5 1.6 2.4 7.0 4.5 0.7 1.6 0.7 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.2 0.0 0.1 0.0 0.0 0.0 11.7 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 18.3 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HDAC1 "GON-10, HD1, KDAC1, RPD3L1" ENSG00000116478 "Histone deacetylase 1" Q13547 1 32292083-32333635 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005017, HPA029693, CAB068191" Enhanced Enhanced Nucleoplasm NA NA "Cluster 44: Non-specific - Transcription" "Cluster 14: B-cells - Humoral immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 53: Intestinal epithelial cells - Unknown function" Nucleoplasm "CAB005017: AB_2248344, CAB068191: AB_2665664, HPA029693: AB_10601659" "unprognostic (2.51e-2)" "unprognostic (9.10e-2)" "unprognostic (2.92e-1)" "unprognostic (2.98e-1)" "unprognostic (9.15e-2)" "unprognostic (3.57e-3)" "prognostic unfavorable (5.76e-7)" "unprognostic (9.57e-2)" "unprognostic (5.02e-2)" "unprognostic (3.47e-2)" "unprognostic (7.06e-2)" "unprognostic (4.44e-2)" "prognostic unfavorable (1.04e-5)" "unprognostic (6.86e-2)" "unprognostic (3.78e-1)" "unprognostic (7.16e-2)" "unprognostic (1.72e-1)" 31.4 42.8 20.8 76.7 22.1 59.3 56.0 21.9 28.0 56.6 20.3 119.5 74.5 48.1 51.4 81.3 56.8 55.4 29.0 20.4 21.9 47.9 41.7 41.2 119.7 23.3 21.8 65.7 40.0 62.3 31.6 53.0 23.1 57.6 108.3 18.9 52.1 57.2 15.3 38.0 80.8 46.8 21.8 61.7 84.1 36.2 22.0 103.9 78.4 17.5 123.9 63.7 51.7 23.4 152.5 90.6 57.4 114.7 32.9 39.0 118.7 105.1 117.1 138.0 126.6 168.0 266.3 233.4 190.3 116.9 140.2 173.1 178.1 143.1 151.5 219.3 176.8 161.3 105.7 130.1 77.4 288.1 223.4 70.7 77.0 107.1 70.3 107.7 106.1 298.5 215.2 90.1 61.6 115.7 331.6 161.4 133.2 180.2 229.6 225.0 136.0 104.0 149.5 216.1 44.7 56.6 176.0 117.0 227.9 224.0 137.9 220.6 123.8 91.3 106.2 28.5 261.1 54.4 124.9 319.2 75.3 235.8 121.4 147.5 87.7 200.1 130.0 115.9 107.5 151.6 126.2 140.6 103.0 142.0 143.7 133.6 63.7 144.2 156.4 64.9 142.0 204.6 20.8 22.1 21.9 28.0 20.4 21.9 23.3 21.8 23.1 21.8 22.0 23.4 45.3 25.6 45.4 25.5 82.7 24.9 57.4 99.1 38.7 15.1 35.1 29.1 22.1 61.5 73.4 68.0 16.7 93.1 64.0 142.4 95.9 75.7 20.2 33.7 39.8 56.2 86.3 60.8 1.9 73.6 110.9 25.8 65.2 39.5 30.4 23.6 63.5 28.1 43.6 11.8 8.8 122.8 52.9 38.2 19.0 8.7 41.0 35.0 28.4 16.9 52.7 34.2 69.0 14.6 19.4 92.5 141.5 44.4 38.4 28.5 57.0 30.0 67.3 14.6 59.2 22.8 38.1 72.5 69.8 60.2 25.4 93.4 73.6 102.6 136.0 55.8 HDAC10 DKFZP761B039 ENSG00000100429 "Histone deacetylase 10" Q969S8 22 50245183-50251405 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Autophagy, DNA damage, DNA recombination, DNA repair" Hydrolase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HMC-1: 27.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB045977 Supported NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 18: Non-specific - Mitochondria" "Cluster 25: RPMI-8226 - Immune response" "Cluster 63: NK-cells & T-cells - Immune response" "CAB045977: AB_11124034" "unprognostic (1.53e-1)" "prognostic favorable (4.46e-4)" "unprognostic (1.43e-2)" "prognostic favorable (2.45e-5)" "unprognostic (2.71e-2)" "unprognostic (3.70e-2)" "unprognostic (6.15e-3)" "unprognostic (5.48e-2)" "unprognostic (3.28e-1)" "unprognostic (2.56e-2)" "prognostic favorable (9.25e-4)" "unprognostic (4.93e-2)" "prognostic unfavorable (4.74e-11)" "unprognostic (2.21e-2)" "unprognostic (2.52e-2)" "unprognostic (1.43e-2)" "unprognostic (1.38e-3)" 8.9 9.8 4.9 6.0 4.8 9.6 7.1 3.6 10.3 9.3 5.4 9.9 6.6 6.8 1.2 10.7 8.0 3.9 4.9 5.1 4.5 11.5 16.8 8.5 6.7 5.1 4.5 7.6 11.2 2.2 13.2 3.3 4.5 10.8 1.5 0.2 8.7 2.8 5.1 9.2 12.6 1.9 3.9 17.2 11.4 2.2 5.1 4.2 9.5 0.5 2.8 7.2 8.1 4.1 6.1 3.3 0.9 5.0 4.2 3.3 11.4 4.2 3.4 2.3 1.4 6.4 6.6 4.0 5.7 3.1 2.2 10.2 2.1 5.9 0.5 5.4 5.7 8.5 10.1 10.4 7.5 10.9 27.0 7.0 4.4 2.3 1.3 4.8 4.2 7.8 6.3 6.1 2.0 18.7 5.8 25.9 2.0 6.5 7.4 13.4 3.3 24.6 3.8 10.5 2.7 6.5 4.2 1.4 7.2 1.2 10.8 15.8 7.4 3.9 5.7 6.7 2.5 7.8 2.6 3.6 6.4 6.7 2.8 0.4 1.6 2.5 0.7 1.8 0.6 0.4 0.3 0.5 1.3 0.4 0.3 0.3 0.8 0.5 1.0 1.2 0.6 1.1 4.9 4.8 3.6 10.3 5.1 4.5 5.1 4.5 4.5 3.9 5.1 4.1 13.9 0.0 3.4 12.1 17.7 8.7 4.8 10.3 9.1 5.7 14.3 13.6 0.6 12.8 6.8 14.7 16.7 11.6 28.6 25.4 7.9 6.3 3.3 9.3 6.9 8.5 20.9 8.4 8.9 3.8 16.2 8.1 32.6 9.0 5.1 16.6 10.0 7.9 21.1 0.0 10.6 17.3 6.1 20.0 13.3 8.3 11.1 19.9 8.8 4.7 18.1 2.9 20.6 3.5 2.4 6.1 17.8 7.9 12.3 3.4 29.2 16.3 14.3 6.5 0.0 3.0 6.3 1.0 2.3 13.1 9.5 10.3 26.0 13.5 18.3 4.4 HDAC11 ENSG00000163517 "Histone deacetylase 11" Q96DB2 3 13479724-13506424 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 122.7" "Group enriched" "Detected in many" 6 "Early spermatids: 357.7;Late spermatids: 692.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "SK-BR-3: 47.7;T-47d: 42.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 48: NK-cells - Unknown function" "Cluster 76: Brain & Bone marrow - Chromatin organization" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 25: Spermatids - Spermatogenesis" "unprognostic (5.22e-2)" "unprognostic (3.58e-2)" "unprognostic (1.83e-1)" "unprognostic (5.69e-3)" "unprognostic (1.76e-1)" "unprognostic (4.71e-2)" "prognostic unfavorable (1.20e-5)" "unprognostic (4.50e-2)" "unprognostic (5.67e-3)" "unprognostic (1.78e-2)" "unprognostic (9.87e-2)" "unprognostic (3.94e-1)" "prognostic favorable (7.88e-10)" "unprognostic (3.63e-2)" "unprognostic (1.65e-1)" "unprognostic (1.46e-1)" "unprognostic (1.39e-3)" 7.7 10.1 92.5 3.9 115.5 0.8 9.4 89.2 98.4 16.9 62.8 18.0 12.2 11.8 6.5 17.6 13.3 9.1 31.4 82.5 90.5 25.1 6.6 9.1 2.8 95.2 100.1 16.7 38.1 23.2 22.8 4.6 87.4 15.9 6.9 6.2 17.4 12.2 51.5 18.7 13.4 7.3 83.9 5.3 12.8 84.2 100.5 4.9 16.5 15.5 4.1 14.7 14.4 122.7 12.0 8.0 8.0 6.6 11.9 10.4 6.5 7.5 5.4 7.8 5.1 4.0 10.4 1.0 9.3 11.6 12.3 8.9 4.7 14.6 5.0 5.1 4.4 2.4 3.7 11.3 12.6 0.2 4.1 9.0 26.6 8.7 6.8 14.2 5.8 7.6 5.0 2.1 7.7 12.2 1.5 1.7 2.1 8.1 20.9 1.7 11.8 3.4 16.6 9.0 1.3 6.2 12.1 47.7 21.8 6.6 42.6 2.8 5.3 6.7 13.0 13.0 4.7 1.5 4.5 0.2 2.1 1.8 4.1 0.1 2.6 5.8 3.3 1.6 2.3 1.1 3.1 2.6 1.8 0.4 3.0 2.1 1.0 9.6 0.6 1.7 2.6 1.9 92.5 115.5 89.2 98.4 82.5 90.5 95.2 100.1 87.4 83.9 100.5 122.7 5.2 9.6 5.0 11.4 0.9 11.5 7.7 11.0 8.6 8.5 10.6 8.0 84.6 8.6 8.9 11.0 0.0 18.9 2.8 23.1 19.6 14.6 357.7 8.6 5.2 6.3 8.9 0.8 6.9 11.4 3.1 9.7 9.7 7.8 1.3 5.0 7.1 2.8 6.0 10.1 7.1 14.4 18.3 3.5 3.8 692.3 16.1 3.6 8.8 1.0 4.6 21.8 2.1 12.5 46.9 11.1 13.6 15.4 0.7 5.1 36.1 24.9 12.0 5.6 0.0 5.6 9.5 15.3 7.3 10.1 10.5 5.7 3.3 3.1 20.0 6.8 HDAC2 "KDAC2, RPD3, YAF1" ENSG00000196591 "Histone deacetylase 2" Q92769 6 113933028-114011308 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms, Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005054, HPA011727" Supported Supported Nucleoplasm NA NA 25000 "Cluster 27: Non-specific - Gene expression" "Cluster 23: Testis - Cell cycle regulation" "Cluster 1: K-562 - Erythropoiesis" "Cluster 20: Spermatogonia & Spermatocytes - Spermatogenesis" Nucleoplasm "CAB005054: AB_562295, HPA011727: AB_1850540" "prognostic unfavorable (7.07e-4)" "unprognostic (1.44e-1)" "unprognostic (2.67e-1)" "unprognostic (2.56e-2)" "unprognostic (2.61e-2)" "unprognostic (1.89e-2)" "prognostic unfavorable (5.39e-10)" "unprognostic (2.03e-1)" "unprognostic (2.63e-2)" "unprognostic (9.00e-2)" "unprognostic (2.01e-1)" "unprognostic (3.92e-1)" "unprognostic (1.84e-2)" "unprognostic (1.96e-1)" "unprognostic (2.42e-1)" "unprognostic (9.80e-2)" "unprognostic (3.51e-1)" 35.9 42.7 26.6 37.4 31.5 63.4 54.8 32.8 40.0 45.2 22.3 48.0 34.4 57.3 53.4 43.3 48.7 34.6 41.1 26.7 34.7 46.3 34.6 33.0 42.6 31.2 29.5 53.4 37.1 45.7 35.9 56.1 31.2 47.0 53.6 37.2 34.3 45.3 48.6 46.1 36.7 54.3 28.8 35.9 40.5 76.7 31.1 68.5 45.6 43.4 52.1 63.2 37.5 37.5 126.7 84.9 387.1 224.3 97.7 110.5 162.6 146.6 119.0 168.5 200.1 226.3 90.1 103.6 119.0 132.5 173.1 96.6 266.0 148.1 281.4 148.9 185.0 249.2 102.1 131.8 129.7 256.1 107.7 90.0 97.6 180.0 167.2 164.4 199.6 179.2 326.4 101.6 282.7 105.5 231.9 229.6 220.0 133.4 116.3 155.0 193.0 95.2 174.4 148.9 258.3 219.1 115.9 107.5 127.7 231.4 78.6 294.0 163.2 107.0 122.9 113.7 246.9 80.6 113.9 244.6 90.9 242.6 185.3 43.5 39.0 42.1 28.0 38.6 37.3 37.0 34.0 30.3 51.0 31.4 41.8 39.1 23.1 39.8 50.2 44.2 36.0 37.2 26.6 31.5 32.8 40.0 26.7 34.7 31.2 29.5 31.2 28.8 31.1 37.5 40.2 57.7 57.8 13.4 51.4 192.1 91.3 152.6 85.4 31.0 61.0 54.6 64.0 25.8 116.4 53.3 4.2 157.7 42.6 43.5 43.0 154.9 86.8 74.3 91.6 73.8 100.5 129.4 29.9 105.0 140.7 76.2 53.5 63.2 55.1 103.9 50.0 31.9 102.0 15.2 26.3 73.4 175.0 64.1 89.8 109.1 83.0 63.3 83.6 26.2 107.7 30.9 33.0 29.1 34.0 133.6 51.3 67.4 56.2 90.0 37.4 71.7 98.7 28.1 39.5 94.7 88.0 199.0 215.5 96.5 193.1 207.7 45.5 53.9 94.6 100.5 HDAC3 "HD3, KDAC3, RPD3, RPD3-2" ENSG00000171720 "Histone deacetylase 3" O15379 5 141620876-141636849 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction, Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005583, HPA052052, CAB072336" Supported Supported "Nucleoplasm,Golgi apparatus" NA NA "Cluster 28: Myeloid DCs - Unknown function" "Cluster 8: Non-specific - Mitochondria" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 3: Monocytes - Immune response regulation" Nucleoplasm "Golgi apparatus" "CAB005583: AB_562296, CAB072336: , HPA052052: AB_2681708" "unprognostic (6.65e-2)" "unprognostic (1.96e-1)" "prognostic favorable (3.39e-4)" "unprognostic (1.17e-1)" "unprognostic (1.24e-1)" "unprognostic (1.07e-1)" "unprognostic (1.19e-2)" "unprognostic (3.16e-1)" "unprognostic (5.56e-2)" "unprognostic (2.45e-2)" "prognostic favorable (3.95e-4)" "unprognostic (1.12e-1)" "prognostic unfavorable (2.65e-6)" "unprognostic (1.85e-1)" "unprognostic (1.63e-2)" "unprognostic (2.28e-3)" "unprognostic (2.17e-1)" 24.3 39.8 7.8 22.7 8.4 37.3 25.3 7.8 9.5 25.7 9.9 23.3 18.7 23.5 26.4 34.1 26.5 20.3 24.4 8.7 8.4 24.2 39.6 21.4 32.7 8.2 8.0 26.0 28.4 44.9 18.4 22.4 7.9 20.6 24.5 16.4 25.5 21.9 40.2 40.8 23.5 26.1 8.5 27.8 23.3 15.8 8.5 38.3 24.1 34.1 42.7 26.2 25.8 8.2 59.8 40.2 74.0 109.5 68.5 54.3 47.0 42.6 93.5 94.8 134.8 86.5 49.7 86.4 54.0 56.2 67.3 51.2 72.9 98.8 117.0 74.6 79.0 68.8 33.3 50.4 48.1 83.5 60.1 47.0 63.2 55.3 71.3 49.6 61.9 76.8 67.6 44.7 61.5 55.8 92.1 72.9 63.9 36.8 31.0 65.8 76.2 62.3 49.9 59.7 60.2 49.4 57.0 57.1 71.7 46.2 61.8 52.3 32.1 58.3 36.1 45.8 71.8 36.6 47.8 82.1 48.8 78.6 50.8 41.3 51.7 39.6 34.1 53.8 45.5 47.8 42.5 41.9 107.5 47.5 45.9 38.5 21.5 35.1 46.8 55.1 55.6 43.8 7.8 8.4 7.8 9.5 8.7 8.4 8.2 8.0 7.9 8.5 8.5 8.2 19.1 9.6 13.2 16.6 36.0 44.2 26.8 38.1 37.0 33.2 29.0 25.5 15.9 18.6 19.6 12.9 60.5 55.3 43.8 18.5 21.5 33.4 10.4 10.0 21.0 21.3 18.0 50.7 40.6 35.4 51.6 28.8 19.9 10.2 18.4 33.9 21.4 18.7 38.8 50.5 38.2 19.7 28.5 19.5 44.9 4.2 22.4 31.7 32.0 10.3 51.1 33.3 38.1 22.1 21.9 33.4 16.3 22.2 36.3 28.7 19.5 20.5 10.8 36.5 26.3 18.1 24.7 25.4 27.5 38.1 51.4 61.2 30.3 42.6 25.9 30.3 HDAC4 "BDMR, HA6116, HD4, HDAC-4, HDAC-A, HDACA, KIAA0288" ENSG00000068024 "Histone deacetylase 4" P56524 2 239048168-239401654 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Autism spectrum disorder, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "skeletal muscle: 58.2" "Group enriched" "Detected in many" 4 "Astrocytes: 62.0;Early spermatids: 69.9;Excitatory neurons: 118.1;Inhibitory neurons: 84.9;Late spermatids: 59.0;Microglial cells: 38.4;Oligodendrocyte precursor cells: 85.5;Oligodendrocytes: 124.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in many" "basophil: 32.0;neutrophil: 47.7" "Lineage enriched" "Detected in many" 5 "granulocytes: 47.7" "Cell line enhanced" "Detected in many" "JURKAT: 49.1;MOLT-4: 48.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA048723, HPA071448" Approved Supported "Nucleoplasm,Nuclear speckles,Cytosol" NA NA "Cluster 6: Non-specific - Transcription" "Cluster 80: Striated muscle - Unknown function" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Nuclear speckles" "Nucleoplasm, Cytosol" "HPA048723: AB_2680501, HPA071448: " "unprognostic (1.54e-1)" "unprognostic (1.76e-2)" "unprognostic (1.33e-1)" "unprognostic (1.18e-3)" "unprognostic (2.43e-2)" "unprognostic (2.39e-3)" "unprognostic (3.06e-4)" "unprognostic (1.00e-1)" "unprognostic (1.24e-1)" "prognostic unfavorable (6.33e-4)" "prognostic favorable (1.13e-4)" "unprognostic (1.40e-1)" "unprognostic (4.82e-3)" "unprognostic (2.40e-1)" "unprognostic (3.26e-2)" "unprognostic (1.32e-2)" "unprognostic (6.04e-2)" 4.4 6.3 9.3 5.0 12.0 17.0 3.8 0.6 13.4 7.5 0.1 29.0 2.7 9.1 2.5 8.0 6.7 7.1 5.2 9.0 6.5 3.7 2.4 3.9 3.5 9.9 6.1 7.5 3.7 2.7 6.5 1.5 11.2 5.6 3.4 2.4 3.3 5.9 58.2 5.9 7.2 6.2 2.3 5.6 7.2 9.2 6.7 9.7 4.2 35.6 2.5 10.0 4.5 10.1 3.2 5.8 4.1 6.1 4.5 3.9 5.9 3.0 2.3 2.3 1.7 2.9 7.5 2.0 1.9 3.4 3.6 3.4 4.0 2.0 1.4 12.8 1.8 3.1 5.1 5.8 3.8 5.5 4.6 4.4 2.6 4.6 3.3 2.3 2.4 49.1 3.7 4.5 2.7 4.7 48.1 10.7 4.0 6.0 2.8 7.6 7.2 4.0 5.3 4.4 4.6 6.4 5.3 2.5 16.2 2.6 1.0 17.9 1.9 5.0 0.4 6.8 4.6 3.3 3.2 3.1 6.9 6.9 7.4 32.0 10.2 2.3 1.0 3.3 1.2 0.2 1.1 1.0 1.0 0.1 0.5 0.5 47.7 3.2 1.7 0.6 1.7 1.1 9.3 12.0 0.6 13.4 9.0 6.5 9.9 6.1 11.2 2.3 6.7 10.1 8.6 3.2 7.4 62.0 5.2 7.9 2.9 3.0 8.6 12.2 6.2 4.8 13.3 7.2 2.9 11.0 2.1 1.5 12.8 4.1 0.0 2.8 69.9 7.0 15.1 7.1 6.0 6.1 118.1 2.2 1.7 14.0 7.7 7.4 2.5 6.6 11.7 6.7 3.2 16.8 84.9 5.2 2.0 17.2 10.0 59.0 11.8 10.3 5.4 38.4 14.9 8.6 15.5 85.5 124.0 1.9 1.6 12.4 7.0 6.4 5.0 1.6 2.6 7.1 0.0 18.7 6.5 2.8 3.3 11.1 9.7 1.4 12.2 4.9 6.4 2.7 HDAC5 "FLJ90614, KIAA0600, NY-CO-9" ENSG00000108840 "Histone deacetylase 5" Q9UQL6 17 44076746-44123702 "Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cone photoreceptor cells: 118.9;Syncytiotrophoblasts: 218.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019400, HPA030991" Approved Supported "Nuclear speckles,Golgi apparatus,Cytosol" NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 27: Brain & Skin - Unknown function" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 18: Syncytiotrophoblasts - Pregnancy hormone signaling" "Nuclear speckles" "Golgi apparatus, Cytosol" "CAB019400: AB_2116626, HPA030991: AB_10795286" "unprognostic (1.30e-2)" "prognostic favorable (6.14e-4)" "unprognostic (6.65e-2)" "unprognostic (8.06e-2)" "unprognostic (3.49e-1)" "unprognostic (3.52e-2)" "prognostic unfavorable (3.12e-5)" "unprognostic (8.80e-3)" "unprognostic (3.80e-2)" "unprognostic (2.37e-2)" "unprognostic (4.91e-3)" "unprognostic (4.30e-1)" "prognostic favorable (3.30e-5)" "unprognostic (1.51e-2)" "unprognostic (3.11e-1)" "unprognostic (6.00e-2)" "unprognostic (1.76e-2)" 30.8 24.7 39.3 10.9 33.5 20.7 28.8 48.8 48.5 40.6 3.3 36.3 11.6 33.2 15.5 45.1 34.1 15.9 53.5 40.4 31.6 24.8 17.4 33.6 14.0 37.6 41.1 45.0 22.5 31.5 48.1 22.6 35.1 29.2 7.3 24.3 22.9 15.1 77.5 71.3 22.9 14.8 22.4 26.4 24.0 19.7 40.0 10.4 30.8 28.6 11.6 29.2 37.0 50.3 8.7 5.5 14.9 3.5 28.2 21.7 53.6 22.8 56.1 11.3 18.1 12.3 9.1 13.5 9.0 54.4 16.5 6.9 17.6 9.8 4.7 21.2 28.7 26.3 18.6 28.6 12.2 8.7 35.7 31.2 16.5 12.8 15.8 19.0 9.3 10.6 20.0 26.5 65.5 6.7 14.3 26.2 16.4 6.7 13.0 54.7 41.6 35.4 1.2 3.8 38.6 20.3 6.7 27.6 31.2 21.8 39.3 49.6 5.1 27.8 17.5 6.6 11.7 43.6 39.7 16.2 16.0 10.7 13.4 11.6 9.2 9.7 5.4 13.5 3.8 7.2 4.3 5.4 11.1 7.5 4.5 4.0 20.9 4.5 16.8 9.7 4.1 7.3 39.3 33.5 48.8 48.5 40.4 31.6 37.6 41.1 35.1 22.4 40.0 50.3 24.0 12.8 13.7 11.1 20.4 29.2 32.3 9.0 26.2 87.8 23.8 21.3 27.1 30.0 11.9 20.2 118.9 21.9 19.6 22.4 21.5 17.2 20.2 17.1 10.7 22.1 46.0 9.3 18.9 8.7 53.1 24.1 10.2 25.1 12.6 47.0 24.3 9.3 22.7 82.4 31.0 14.9 6.1 18.5 17.8 10.0 48.4 29.8 14.2 12.2 16.5 18.9 11.3 14.1 26.2 11.5 16.5 43.6 14.2 41.2 21.5 7.3 12.4 60.4 65.7 31.8 40.1 4.2 32.7 28.1 32.8 218.1 17.0 29.9 11.3 25.3 HDAC6 "FLJ16239, HD6, JM21, KIAA0901, PPP1R90" ENSG00000094631 "Histone deacetylase 6" Q9UBN7 X 48801377-48824982 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins" "Autophagy, Transcription, Transcription regulation" "Actin-binding, Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Spermatocytes: 88.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003714, CAB004236, HPA026321" Supported Supported Nucleoplasm NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 43: Testis - Unknown function" "Cluster 1: K-562 - Erythropoiesis" "Cluster 13: Spermatocytes & Spermatogonia - Spermatogenesis" Nucleoplasm "CAB004236: AB_627708, HPA003714: AB_1850544, HPA026321: AB_1850546" "unprognostic (9.53e-2)" "unprognostic (1.59e-1)" "unprognostic (2.66e-2)" "unprognostic (2.42e-2)" "unprognostic (2.82e-2)" "unprognostic (4.11e-3)" "unprognostic (2.17e-2)" "unprognostic (1.16e-1)" "unprognostic (7.68e-2)" "unprognostic (2.83e-1)" "unprognostic (1.16e-3)" "unprognostic (2.33e-2)" "unprognostic (6.10e-2)" "unprognostic (1.47e-1)" "unprognostic (6.60e-2)" "unprognostic (2.34e-1)" "prognostic favorable (3.34e-4)" 21.9 26.0 26.6 14.2 30.7 22.9 23.6 31.1 54.2 29.6 29.8 27.8 17.8 26.8 10.6 24.4 28.2 11.1 26.0 26.7 33.0 57.9 97.3 25.2 15.6 32.6 32.7 32.5 26.3 22.3 45.6 13.8 33.9 24.4 16.1 27.9 21.6 12.2 26.1 21.4 28.0 15.3 28.9 29.4 26.6 53.8 30.6 18.8 27.1 16.1 15.1 23.7 22.8 31.0 31.0 25.7 49.6 19.1 20.2 16.6 33.4 14.4 12.4 27.2 26.2 24.9 25.7 29.9 13.8 17.1 34.6 21.3 30.6 15.5 23.2 27.7 19.1 40.7 32.2 26.0 18.3 19.2 60.4 25.7 25.1 21.5 25.3 24.8 23.5 37.4 45.9 31.9 17.7 10.9 27.0 29.3 18.5 14.2 24.5 23.1 53.5 31.3 15.8 13.3 25.9 25.3 29.5 8.7 17.4 63.4 36.1 17.5 19.1 21.5 26.7 29.3 14.2 29.6 31.3 21.3 21.3 24.0 21.5 0.0 5.1 5.8 4.7 8.3 3.4 3.7 3.3 3.4 7.6 5.3 3.1 2.9 2.5 3.6 11.7 8.3 4.0 4.9 26.6 30.7 31.1 54.2 26.7 33.0 32.6 32.7 33.9 28.9 30.6 31.0 11.4 19.2 25.1 20.9 12.5 7.5 10.2 8.8 6.2 37.6 10.7 10.4 10.6 8.6 17.5 18.4 50.1 11.5 12.6 21.4 19.6 7.9 48.1 10.0 13.0 10.3 14.4 11.4 15.2 7.4 12.3 10.7 21.9 13.2 6.3 22.5 13.6 51.9 11.1 40.4 18.4 15.5 10.2 12.3 9.8 18.4 14.0 13.2 5.4 10.3 12.7 21.9 18.6 17.1 19.0 7.2 13.2 11.3 12.8 7.1 17.8 47.6 12.4 34.0 13.1 15.5 11.1 88.4 41.7 8.6 5.8 9.7 9.7 21.8 16.2 7.2 HDAC7 "DKFZP586J0917, HDAC7A" ENSG00000061273 "Histone deacetylase 7" Q8WUI4 12 47782722-47833132 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Hepatic stellate cells: 101.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in some" 4 "neutrophil: 6.5" "Lineage enriched" "Detected in many" 4 "granulocytes: 6.5" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA004775 Supported Cytosol NA NA "Cluster 1: Neutrophils - Mixed function" "Cluster 89: Fibroblasts - ECM organization" "Cluster 38: EFO-21 - Unknown function" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" Cytosol "HPA004775: AB_1850548" "unprognostic (3.83e-1)" "unprognostic (9.49e-3)" "unprognostic (1.37e-2)" "unprognostic (4.46e-2)" "unprognostic (6.56e-3)" "unprognostic (2.22e-2)" "unprognostic (2.50e-3)" "unprognostic (1.26e-1)" "prognostic unfavorable (5.16e-4)" "unprognostic (1.28e-1)" "unprognostic (2.07e-1)" "unprognostic (2.38e-2)" "prognostic unfavorable (8.25e-4)" "unprognostic (6.24e-2)" "unprognostic (4.38e-2)" "unprognostic (9.69e-2)" "prognostic favorable (4.65e-4)" 52.5 41.8 7.7 28.5 8.1 23.6 45.3 3.2 9.7 46.2 24.6 44.2 8.9 51.4 13.6 23.5 50.3 16.8 31.6 4.1 4.8 29.3 6.0 55.0 27.3 17.2 7.1 44.9 14.5 20.1 20.6 19.5 10.2 34.4 4.8 2.8 30.6 17.1 16.2 40.1 28.6 16.9 3.4 38.4 27.2 7.9 10.7 80.0 39.2 9.4 15.2 44.3 38.5 7.6 41.6 28.1 28.6 46.9 21.9 60.2 25.3 39.4 30.7 28.3 18.8 37.4 38.4 80.5 126.8 37.1 13.9 37.8 6.7 31.4 10.5 38.8 13.6 27.6 29.9 8.6 23.6 9.1 1.2 39.4 10.8 28.6 15.4 51.6 58.6 45.9 29.9 33.4 18.6 18.0 83.2 21.8 39.4 9.1 29.1 64.2 14.7 29.6 12.1 26.9 8.1 18.8 30.6 14.1 14.4 18.4 13.4 12.0 66.6 56.9 61.0 47.6 28.9 70.8 58.8 67.4 23.8 41.9 19.1 0.0 1.4 0.0 0.8 0.5 0.9 0.8 0.7 0.7 0.4 0.5 0.8 0.6 6.5 0.9 0.5 0.3 0.3 1.5 7.7 8.1 3.2 9.7 4.1 4.8 17.2 7.1 10.2 3.4 10.7 7.6 80.6 41.7 32.1 34.9 32.7 13.8 26.8 28.7 8.6 20.3 22.5 17.4 13.4 28.6 28.6 36.8 0.0 4.8 18.6 5.3 1.9 31.6 15.5 26.2 39.4 79.3 7.3 40.4 19.9 23.0 3.5 37.8 25.5 58.4 8.8 20.2 101.7 2.0 15.6 28.6 17.5 9.6 24.4 32.7 14.1 6.9 55.0 13.3 14.2 46.9 20.5 11.7 28.8 10.6 13.6 66.8 7.3 33.1 42.9 69.1 0.6 3.8 31.8 4.0 26.3 18.3 26.9 1.1 3.7 10.3 21.6 2.9 28.2 9.3 8.1 46.8 HDAC8 "HDACL1, KDAC8, MRXS6, RPD3, WTS" ENSG00000147099 "Histone deacetylase 8" Q9BY41 X 72329516-72573101 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "Disease variant, FDA approved drug targets, Mental retardation, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Astrocytes: 120.8;Excitatory neurons: 186.8;Inhibitory neurons: 191.3;Microglial cells: 134.9;Oligodendrocyte precursor cells: 146.8;Oligodendrocytes: 141.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" HPA048560 Supported NA NA "Cluster 22: NK-cells - Unknown function" "Cluster 68: Epididymis - Unknown function" "Cluster 24: NB-4 - Immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA048560: AB_2680442" "unprognostic (1.42e-1)" "unprognostic (6.62e-3)" "unprognostic (3.20e-2)" "unprognostic (9.24e-3)" "unprognostic (1.10e-1)" "unprognostic (1.10e-1)" "unprognostic (4.64e-2)" "unprognostic (6.03e-2)" "unprognostic (1.58e-1)" "unprognostic (2.81e-2)" "unprognostic (3.17e-2)" "unprognostic (9.68e-2)" "unprognostic (8.42e-2)" "unprognostic (2.33e-3)" "unprognostic (9.10e-2)" "unprognostic (7.15e-3)" "unprognostic (2.12e-3)" 9.2 21.2 16.1 9.8 16.2 17.5 10.3 23.2 19.1 10.3 14.4 9.8 8.5 9.5 22.8 10.2 8.8 9.7 11.9 15.8 19.4 15.1 16.3 9.0 10.9 14.4 13.2 11.2 11.0 11.5 13.4 9.5 15.1 11.2 11.8 16.5 11.4 8.1 10.7 11.5 8.1 10.6 9.7 8.4 10.2 4.2 16.2 8.6 13.0 10.4 10.9 9.7 9.6 20.8 21.0 27.2 20.5 29.9 26.9 24.4 13.5 14.0 21.3 15.9 19.1 20.8 23.3 15.2 38.6 17.2 27.5 14.5 37.0 23.1 21.7 25.9 25.5 21.5 32.7 22.4 14.2 29.9 30.4 22.3 15.4 20.2 15.1 27.6 27.1 20.3 22.4 38.4 24.4 24.8 15.9 53.8 25.9 31.2 38.1 19.7 24.0 26.7 32.8 21.0 16.5 33.0 26.7 19.7 26.9 25.9 12.0 26.9 21.8 15.0 21.3 19.4 13.5 13.5 28.1 18.1 18.5 34.7 20.3 13.8 16.5 28.1 10.5 13.8 8.7 11.9 11.2 9.6 17.2 12.2 8.4 7.5 1.7 10.9 14.5 6.0 15.6 9.8 16.1 16.2 23.2 19.1 15.8 19.4 14.4 13.2 15.1 9.7 16.2 20.8 13.0 3.2 25.7 120.8 14.5 6.1 12.7 15.3 17.1 15.4 9.5 9.7 11.3 12.8 15.7 7.3 43.8 16.4 8.0 7.2 9.8 13.9 0.9 8.8 11.3 12.5 9.1 17.1 186.8 12.4 13.2 14.0 10.7 8.4 12.0 19.2 12.5 10.3 15.8 23.5 191.3 9.3 16.2 8.2 9.0 1.2 11.8 13.3 7.2 134.9 10.9 10.3 8.2 146.8 141.1 11.2 4.7 10.5 19.9 10.6 9.3 22.6 17.4 17.3 26.3 10.1 16.0 4.7 0.8 12.6 6.3 13.5 11.8 15.1 9.7 12.6 HDAC9 "HD7, HDAC, HDAC7B, KIAA0744, MITR" ENSG00000048052 "Histone deacetylase 9" Q9UKV0 7 18086949-19002416 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Transcription, Transcription regulation" "Chromatin regulator, Hydrolase, Repressor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "choroid plexus: 47.5" "Group enriched" "Detected in many" 4 "Early spermatids: 244.6;Excitatory neurons: 376.2;Inhibitory neurons: 442.3;Microglial cells: 334.5;Oligodendrocyte precursor cells: 322.7;Oligodendrocytes: 233.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "myeloid DC: 74.1" "Group enriched" "Detected in all" 9 "B-cells: 52.6;dendritic cells: 74.1;monocytes: 24.4" "Cell line enhanced" "Detected in many" "HAP1: 163.6;hTERT-HME1: 79.4;SH-SY5Y: 65.7;U-698: 64.5;WM-115: 69.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA028926 Uncertain Approved Nucleoplasm NA NA "Cluster 23: Antigen presenting cells - Antigen presentation" "Cluster 20: Retina & Lymphoid tissues - Unknown function" "Cluster 30: Epithelial cell lines - Translation" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Nucleoplasm "HPA028926: AB_10602327" "unprognostic (2.06e-2)" "unprognostic (2.67e-1)" "unprognostic (2.30e-1)" "unprognostic (1.17e-1)" "unprognostic (2.74e-1)" "unprognostic (5.54e-2)" "unprognostic (2.20e-2)" "unprognostic (2.32e-1)" "unprognostic (2.21e-1)" "unprognostic (2.45e-1)" "unprognostic (5.01e-1)" "unprognostic (7.58e-2)" "unprognostic (1.29e-1)" "unprognostic (3.94e-2)" "unprognostic (1.32e-1)" "unprognostic (1.02e-1)" "unprognostic (6.87e-3)" 8.2 12.3 5.8 8.8 6.6 5.9 5.1 4.8 7.9 10.1 47.5 5.4 3.4 13.2 6.0 2.9 9.3 6.7 14.3 5.5 3.8 2.8 2.8 5.1 18.9 6.0 6.7 2.4 1.5 1.8 6.5 6.3 6.0 11.0 5.5 25.4 7.1 14.5 16.7 2.2 4.5 13.0 3.8 17.5 8.7 5.6 12.9 6.8 2.9 5.8 18.7 5.2 4.9 7.3 40.2 0.2 6.3 0.1 0.9 8.4 0.2 2.4 23.0 9.5 16.1 0.3 12.7 16.7 41.9 26.0 51.6 5.8 163.6 3.2 24.2 0.2 1.1 0.0 0.2 0.0 0.2 3.5 0.1 3.0 3.1 29.7 79.4 8.4 0.4 2.7 0.0 25.1 13.3 0.0 1.6 3.5 20.3 0.0 3.9 4.7 2.5 10.2 5.2 10.6 11.6 65.7 0.5 0.3 12.7 9.7 0.6 15.2 1.8 34.4 11.1 1.9 22.3 28.8 13.3 64.5 9.0 1.6 69.2 0.3 24.4 0.1 4.2 16.5 4.1 52.6 1.4 2.0 74.1 43.2 0.0 2.1 1.4 5.5 10.3 15.9 5.6 12.9 5.8 6.6 4.8 7.9 5.5 3.8 6.0 6.7 6.0 3.8 12.9 7.3 31.4 6.4 2.8 28.1 46.1 2.4 0.7 6.8 6.2 33.0 1.4 0.8 15.2 0.0 12.9 0.0 16.7 0.1 16.3 15.3 3.9 6.8 244.6 24.2 2.3 16.5 7.2 5.7 376.2 0.7 0.2 5.3 13.7 26.1 1.3 0.0 8.9 1.0 12.9 20.2 442.3 0.7 4.1 51.2 64.2 80.1 1.5 34.8 16.0 334.5 21.0 5.1 11.3 322.7 233.1 10.6 6.7 0.7 46.7 1.6 0.0 0.1 17.5 26.2 6.6 2.3 9.0 34.3 8.7 0.7 2.0 0.1 7.8 0.1 0.3 12.1 HMGCR ENSG00000113161 "3-hydroxy-3-methylglutaryl-CoA reductase" P04035 5 75336329-75364001 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cholesterol biosynthesis, Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 105.7" "Cell type enhanced" "Detected in all" "Glandular and luminal cells: 239.5;Theca cells: 148.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008338, CAB016797, CAB078688" Supported NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 37: Intestine - Unknown function" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 44: Endometrium - Transcription" "CAB016797: , CAB078688: AB_2665607, HPA008338: AB_10960401" "unprognostic (5.07e-2)" "unprognostic (1.65e-2)" "unprognostic (3.65e-3)" "unprognostic (1.02e-2)" "unprognostic (1.65e-3)" "unprognostic (1.02e-1)" "unprognostic (1.45e-1)" "unprognostic (4.41e-2)" "unprognostic (5.45e-2)" "unprognostic (1.90e-2)" "unprognostic (1.41e-1)" "unprognostic (3.99e-2)" "prognostic favorable (9.42e-6)" "unprognostic (2.44e-1)" "unprognostic (2.55e-2)" "unprognostic (3.64e-3)" "unprognostic (4.37e-2)" 10.8 39.5 19.8 18.1 20.7 24.6 30.8 15.7 23.0 20.1 16.2 45.2 38.1 16.8 25.3 49.1 12.2 15.2 7.4 21.5 25.0 21.1 105.7 24.2 14.7 26.6 21.3 9.7 16.5 24.8 8.2 17.7 25.2 23.3 37.3 18.7 15.5 8.1 6.4 55.2 26.5 12.9 14.2 14.8 27.6 23.3 20.5 17.8 23.4 7.1 18.6 14.1 26.7 17.5 68.5 25.6 260.7 89.2 54.9 103.4 65.5 19.3 53.6 38.6 85.0 95.8 163.7 60.3 68.7 31.7 245.2 84.5 136.4 225.9 39.4 20.8 50.8 47.0 36.7 78.6 80.8 39.8 32.9 66.8 130.7 133.6 65.6 19.2 31.5 84.8 50.4 86.4 61.0 45.2 72.7 39.9 112.5 17.7 19.7 50.7 78.7 86.5 155.2 154.5 91.0 41.3 41.4 43.7 38.3 89.6 43.1 102.4 37.2 20.5 30.0 22.4 32.8 28.1 38.1 83.2 29.7 75.2 43.7 10.0 14.8 8.8 7.7 8.9 6.2 5.1 5.2 7.8 16.9 5.2 5.3 7.2 28.8 12.5 10.5 4.9 9.0 7.5 19.8 20.7 15.7 23.0 21.5 25.0 26.6 21.3 25.2 14.2 20.5 17.5 11.6 19.2 43.3 23.2 14.9 41.4 10.1 37.6 43.3 23.5 19.0 12.1 7.0 12.8 33.3 27.6 18.8 19.7 25.7 80.4 3.9 13.5 46.6 124.4 34.3 13.4 43.0 11.6 49.9 22.0 24.0 13.7 28.5 239.5 24.1 71.3 7.9 97.5 13.1 40.4 35.8 56.0 28.5 14.8 11.8 22.2 9.3 19.5 16.0 15.0 12.1 9.7 7.2 28.1 24.7 15.0 40.0 6.0 14.4 18.4 15.5 6.9 31.6 15.2 13.1 7.0 20.2 23.4 12.0 69.8 91.6 46.7 19.2 148.7 30.4 18.8 HMMR "CD168, RHAMM" ENSG00000072571 "Hyaluronan mediated motility receptor" O75330 5 163460203-163491941 "CD markers, FDA approved drug targets, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 20.6;lymphoid tissue: 27.3;testis: 27.5" "Cell type enhanced" "Detected in many" "Early spermatids: 86.2;Erythroid cells: 133.3;Extravillous trophoblasts: 55.1;Late spermatids: 60.9;Spermatocytes: 100.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Immune cell enhanced" "Detected in single" "T-reg: 1.5" "Low lineage specificity" "Detected in single" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in some" "Low region specificity" "Detected in many" "CAB002433, HPA040025, HPA043926, HPA061524" Enhanced Enhanced Microtubules,Centrosome,Cytosol Yes Yes "Cluster 4: T-regs - Cell cycle regulation" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" Microtubules "Centrosome, Cytosol" "CAB002433: AB_564080, HPA040025: AB_2676805, HPA043926: , HPA061524: AB_2684551" "unprognostic (3.53e-3)" "unprognostic (1.01e-1)" "unprognostic (3.38e-3)" "unprognostic (8.88e-3)" "unprognostic (2.12e-1)" "prognostic unfavorable (5.52e-4)" "prognostic unfavorable (1.93e-7)" "prognostic unfavorable (1.09e-4)" "unprognostic (5.68e-2)" "unprognostic (2.50e-1)" "prognostic unfavorable (3.71e-5)" "unprognostic (1.02e-1)" "unprognostic (0.00e+0)" "unprognostic (1.65e-2)" "unprognostic (4.98e-2)" "unprognostic (2.39e-1)" "unprognostic (1.77e-2)" 0.8 0.7 0.2 10.1 0.3 20.6 2.1 0.3 0.4 1.1 0.1 6.6 7.4 0.8 0.2 4.0 0.5 0.9 0.8 0.2 0.2 0.7 1.7 0.9 18.1 0.5 0.3 0.2 0.3 0.9 0.2 6.2 0.4 0.5 8.8 0.8 0.8 0.2 1.2 4.2 6.5 2.9 0.3 2.9 3.6 27.5 0.7 27.3 0.7 0.4 17.7 2.2 1.4 0.5 77.0 47.2 94.5 50.8 5.0 9.0 70.3 71.4 34.9 88.0 78.9 96.8 145.1 127.5 66.0 22.2 118.5 86.3 112.4 69.0 148.6 116.1 34.4 76.7 32.3 48.4 1.4 68.7 67.3 2.4 4.1 82.8 64.0 14.7 50.6 85.7 73.2 101.0 93.2 28.5 72.3 38.8 81.9 51.2 51.6 78.0 126.3 63.9 34.8 20.4 78.8 43.8 106.3 32.8 38.6 45.1 97.3 54.5 32.9 63.2 52.4 50.6 97.2 53.7 96.3 102.4 41.4 104.2 61.1 0.2 0.2 0.0 0.1 0.1 0.3 0.3 0.3 0.1 0.2 0.2 0.1 0.2 0.1 0.5 0.0 0.6 1.5 0.2 0.2 0.3 0.3 0.4 0.2 0.2 0.5 0.3 0.4 0.3 0.7 0.5 0.4 0.0 1.1 1.3 6.0 2.5 1.8 4.5 2.8 0.6 3.2 3.7 2.5 4.3 3.2 0.0 0.0 37.3 2.3 5.3 0.0 0.8 86.2 3.8 3.1 3.1 1.2 133.3 0.6 0.2 55.1 4.6 11.7 5.7 0.0 21.6 5.3 3.8 22.2 0.0 0.4 7.8 6.1 8.8 2.7 60.9 2.1 7.6 0.0 0.0 2.3 0.1 1.0 0.5 1.2 0.2 0.3 0.7 22.9 1.5 1.3 2.6 2.8 1.0 6.6 0.6 3.8 100.9 23.3 14.1 1.4 4.5 5.2 1.6 15.6 3.0 HPD "4-HPPD, 4HPPD, GLOD3, PPD" ENSG00000158104 "4-hydroxyphenylpyruvate dioxygenase" P32754 12 121839527-121863596 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Phenylalanine catabolism, Tyrosine catabolism" "Dioxygenase, Oxidoreductase" "Disease variant, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "liver: 2530.4" "Group enriched" "Detected in some" 9 "Hepatocytes: 1373.6;Proximal tubular cells: 2144.0" "Cancer enriched" "Detected in many" 100 "liver cancer: 540.9" "Region enhanced" "Detected in many" "hippocampal formation: 7.8" "Immune cell enhanced" "Detected in some" "eosinophil: 7.8" "Group enriched" "Detected in many" 4 "dendritic cells: 3.8;granulocytes: 7.8" "Cell line enriched" "Detected in some" 31 "Hep G2: 516.4" "Not detected" "Not detected" "Not detected" "Not detected" "HPA038321, HPA038322" Enhanced Uncertain "Nuclear speckles" NA NA 26000000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 85: Liver - Metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "Nuclear speckles" "HPA038321: AB_2675957, HPA038322: AB_10670778" "unprognostic (3.01e-2)" "unprognostic (2.30e-1)" "unprognostic (4.81e-3)" "unprognostic (1.42e-3)" "unprognostic (1.10e-2)" "unprognostic (9.08e-2)" "unprognostic (1.13e-2)" "unprognostic (8.84e-2)" "unprognostic (5.58e-2)" "unprognostic (6.14e-3)" "unprognostic (9.72e-3)" "unprognostic (8.61e-3)" "unprognostic (7.16e-2)" "unprognostic (1.97e-1)" "unprognostic (4.12e-1)" "unprognostic (3.06e-2)" "unprognostic (2.34e-1)" 2.3 5.3 0.6 0.7 0.4 0.9 4.6 3.2 0.6 2.0 119.0 1.2 0.1 4.1 0.7 0.7 6.4 1.1 3.5 7.8 0.5 531.0 2530.4 2.0 0.3 1.5 1.0 4.7 3.9 0.1 1.1 0.3 0.8 2.3 0.5 0.3 0.2 7.3 2.2 0.2 0.9 1.4 0.6 2.3 1.9 10.2 3.5 0.1 0.7 0.1 0.1 3.7 1.9 1.0 0.3 0.9 0.6 0.6 0.3 0.6 0.6 0.0 0.1 0.0 0.0 0.2 0.5 0.2 0.6 1.1 0.2 0.4 0.2 0.0 0.0 0.3 0.8 1.2 5.4 516.4 11.5 1.8 16.4 3.6 0.3 0.0 0.0 1.3 0.0 0.5 0.8 0.0 1.3 1.3 0.2 0.4 9.9 0.4 0.0 0.3 1.6 0.5 0.0 1.4 0.1 0.1 1.5 0.1 0.1 6.9 1.1 0.9 0.2 0.0 0.3 0.1 0.1 0.8 0.6 0.7 0.2 1.2 0.0 0.0 0.6 7.8 0.0 0.8 0.0 0.1 0.1 0.1 1.0 0.1 0.2 0.2 3.9 0.0 1.3 3.8 0.0 0.3 0.6 0.4 3.2 0.6 7.8 0.5 1.5 1.0 0.8 0.6 3.5 1.0 0.0 0.0 0.0 0.7 15.8 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.3 55.8 0.0 92.0 0.0 0.8 0.0 0.0 193.7 0.5 38.0 0.1 0.0 2.6 0.0 80.2 1.0 16.2 0.3 0.4 0.0 0.1 0.0 0.0 38.9 1373.6 0.3 0.0 1.0 0.0 0.0 37.8 0.3 121.0 2.5 10.8 0.0 0.0 0.4 0.0 0.0 1.5 0.7 0.2 0.0 5.3 0.0 0.0 0.0 2144.0 0.0 0.0 0.0 2.0 0.2 1.8 1.4 0.0 0.0 1.1 8.0 7.1 0.0 0.0 HPRT1 "HGPRT, HPRT" ENSG00000165704 "Hypoxanthine phosphoribosyltransferase 1" P00492 X 134460165-134520513 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Purine salvage" "Glycosyltransferase, Transferase" "Disease variant, FDA approved drug targets, Gout" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Distal tubular cells: 226.9;Spermatocytes: 213.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA006360, CAB012200" Enhanced Supported Cytosol NA NA 9400000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 58: Brain - Synaptic function" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 13: Spermatocytes & Spermatogonia - Spermatogenesis" Cytosol "CAB012200: AB_297217, HPA006360: AB_1079082" "unprognostic (2.02e-1)" "unprognostic (2.18e-1)" "unprognostic (1.46e-1)" "unprognostic (2.32e-3)" "unprognostic (8.55e-2)" "prognostic unfavorable (1.35e-5)" "unprognostic (1.58e-2)" "unprognostic (4.77e-3)" "unprognostic (4.93e-2)" "unprognostic (2.02e-2)" "unprognostic (7.05e-2)" "unprognostic (1.38e-3)" "unprognostic (6.00e-2)" "unprognostic (2.12e-1)" "unprognostic (2.04e-1)" "unprognostic (2.70e-2)" "unprognostic (1.51e-1)" 15.6 26.2 37.3 24.3 39.4 54.7 20.4 26.0 63.7 13.6 22.9 25.5 20.4 14.0 62.7 20.3 16.9 14.6 24.5 40.3 47.1 45.5 45.8 14.5 32.1 31.2 32.1 16.8 37.1 21.9 31.5 16.3 34.7 15.4 23.5 74.1 13.5 16.0 22.6 14.8 26.5 17.3 24.6 16.9 32.2 76.1 31.4 31.3 22.1 17.8 30.6 25.4 13.9 31.3 138.0 64.9 18.0 37.2 39.4 56.1 54.1 71.6 68.7 89.5 116.8 58.7 85.5 154.4 158.7 46.7 106.8 82.0 117.4 98.2 153.4 129.2 219.3 84.0 85.0 60.2 38.9 182.9 74.0 41.6 36.1 80.1 126.4 49.5 104.9 90.3 65.5 3.8 71.0 141.0 141.9 157.0 37.0 160.7 171.8 83.8 91.1 158.6 109.6 65.7 113.0 61.6 51.7 41.5 50.1 48.8 35.5 75.2 52.4 60.5 45.6 175.0 181.5 56.5 105.1 0.9 74.6 199.5 33.8 5.8 21.9 20.4 20.8 36.5 30.0 24.0 30.4 27.6 37.9 24.8 24.8 26.9 5.6 39.4 35.5 15.7 57.4 25.3 37.3 39.4 26.0 63.7 40.3 47.1 31.2 32.1 34.7 24.6 31.4 31.3 32.1 19.2 8.2 11.1 39.6 39.6 55.7 75.6 18.8 38.3 26.4 22.0 23.8 30.0 29.9 57.0 4.2 17.9 28.1 16.8 226.9 50.1 11.9 30.1 28.3 39.2 27.5 101.8 55.3 32.3 30.5 29.5 30.1 41.8 34.9 29.0 20.7 22.2 71.2 25.2 43.1 30.4 63.1 60.7 81.7 32.2 40.7 56.2 55.2 10.3 122.5 37.2 26.8 22.1 30.7 36.6 28.2 26.7 30.9 78.1 24.1 30.2 28.9 78.0 52.6 31.6 39.4 213.5 172.6 40.4 38.8 6.0 53.8 30.2 51.3 46.8 HRH1 ENSG00000196639 "Histamine receptor H1" P35367 3 11137093-11263557 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 46.1;Distal enterocytes: 44.9;Glandular and luminal cells: 41.6;Suprabasal keratinocytes: 41.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "hTEC/SVTERT24-B: 30.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029740 Uncertain Supported "Plasma membrane,Cytosol" NA NA "Cluster 4: T-regs - Cell cycle regulation" "Cluster 57: Non-specific - Angiogenesis" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 44: Endometrium - Transcription" "Plasma membrane" Cytosol "HPA029740: AB_10601578" "unprognostic (4.60e-3)" "unprognostic (3.41e-2)" "unprognostic (6.37e-3)" "unprognostic (9.55e-2)" "unprognostic (3.32e-2)" "unprognostic (1.07e-2)" "unprognostic (9.60e-3)" "unprognostic (4.00e-3)" "unprognostic (7.54e-2)" "unprognostic (4.98e-2)" "prognostic unfavorable (1.27e-5)" "unprognostic (1.43e-1)" "unprognostic (1.70e-2)" "unprognostic (1.66e-1)" "unprognostic (3.13e-2)" "unprognostic (7.19e-2)" "unprognostic (1.20e-1)" 5.7 3.0 5.5 3.1 6.2 0.1 3.4 1.7 6.5 5.0 2.1 8.8 2.7 4.3 4.8 3.3 7.4 7.1 1.5 6.1 5.3 4.2 0.7 4.1 1.2 4.6 2.9 5.9 0.6 0.9 0.5 3.9 3.6 2.4 5.1 0.2 1.8 3.5 0.9 5.1 4.3 5.4 3.2 1.0 1.7 0.8 5.8 1.2 1.2 2.2 1.4 14.3 5.0 4.1 2.6 6.1 0.0 0.0 2.7 28.5 4.2 4.6 15.3 13.3 8.8 1.1 21.8 0.0 13.4 10.6 13.5 17.3 0.0 6.3 17.7 10.1 0.0 1.4 9.7 0.0 8.4 4.5 2.4 10.0 3.7 30.4 10.5 18.4 19.1 0.2 0.0 0.1 5.8 0.0 0.0 1.9 0.0 2.6 5.4 0.4 1.6 0.6 23.2 3.6 0.2 0.0 6.6 4.6 0.0 0.2 0.0 3.5 28.8 14.8 9.4 15.3 23.4 0.0 1.7 0.1 22.5 3.9 13.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.9 0.0 5.5 6.2 1.7 6.5 6.1 5.3 4.6 2.9 3.6 3.2 5.8 4.1 11.5 6.4 1.1 33.3 0.1 46.1 8.9 7.4 6.8 0.0 0.5 0.5 0.5 0.0 19.3 1.8 0.0 0.2 0.0 44.9 0.0 0.6 0.3 20.5 6.9 20.2 3.5 0.0 34.6 0.7 1.0 16.7 8.6 41.6 2.5 28.8 2.5 0.0 27.2 0.0 19.1 15.1 4.1 12.5 12.3 0.2 3.7 9.8 0.0 2.8 0.1 0.0 0.0 2.0 1.1 14.0 21.0 0.0 0.0 6.2 29.1 0.7 5.0 0.2 0.0 6.8 2.8 1.8 3.3 2.2 41.5 0.5 1.0 0.2 15.8 19.3 HRH2 ENSG00000113749 "Histamine receptor H2" P25021 5 175658030-175710756 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 37.0;heart muscle: 26.3" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 26.2;Excitatory neurons: 62.2;Inhibitory neurons: 19.1;Kupffer cells: 29.4;Macrophages: 36.2;monocytes: 24.3;Smooth muscle cells: 33.6" "Group enriched" "Detected in many" 5 "melanoma: 2.9;renal cancer: 4.6" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "basophil: 134.4;neutrophil: 161.7" "Group enriched" "Detected in many" 5 "granulocytes: 161.7;monocytes: 51.6" "Group enriched" "Detected in some" 4 "RPMI-8226: 65.6;SK-MEL-30: 19.2;THP-1: 18.0;U-937: 21.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA013770 Approved NA NA "Cluster 6: Non-specific - Transcription" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 25: RPMI-8226 - Immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" "HPA013770: AB_1851086" "unprognostic (8.56e-3)" "unprognostic (1.62e-1)" "unprognostic (6.66e-2)" "unprognostic (5.96e-2)" "unprognostic (3.49e-2)" "unprognostic (1.80e-1)" "unprognostic (1.20e-1)" "unprognostic (4.77e-2)" "unprognostic (9.93e-2)" "unprognostic (5.76e-2)" "unprognostic (1.52e-1)" "unprognostic (2.35e-1)" "unprognostic (3.71e-3)" "unprognostic (2.01e-2)" "unprognostic (1.97e-2)" "unprognostic (1.97e-3)" "unprognostic (1.77e-2)" 7.6 1.5 4.5 12.0 14.4 37.0 3.0 1.1 9.6 5.1 0.5 1.4 6.2 2.2 0.9 1.4 2.9 2.5 26.3 5.3 1.4 2.3 1.0 7.2 3.8 1.2 1.6 1.1 1.5 1.3 0.8 10.2 1.1 4.7 1.1 0.3 1.4 4.6 0.8 2.2 6.4 3.6 1.7 18.0 19.5 0.5 3.9 8.5 1.5 1.5 3.1 4.1 2.0 5.1 0.0 1.5 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 2.1 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 1.9 0.0 0.3 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.1 5.0 2.9 0.0 0.0 7.1 0.0 65.6 0.0 0.3 0.5 0.0 0.0 0.0 19.2 1.7 0.1 18.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 21.6 4.3 134.4 45.8 52.8 0.2 44.9 0.3 0.0 3.8 1.0 23.5 0.1 7.9 4.8 161.7 2.1 51.6 18.3 3.3 15.3 4.5 14.4 1.1 9.6 5.3 1.4 1.2 1.6 1.1 1.7 3.9 5.1 1.1 0.0 2.5 1.0 1.0 0.8 0.1 0.0 0.6 9.3 3.7 0.9 26.2 0.0 2.5 0.0 0.0 0.1 8.4 0.0 0.0 0.0 0.6 0.1 0.8 1.9 0.0 3.0 62.2 2.4 0.2 3.3 7.1 0.1 2.5 3.0 0.0 0.2 11.8 1.7 19.1 0.6 0.0 29.4 8.5 1.0 0.0 36.2 0.0 10.3 24.3 0.1 0.0 1.5 1.7 0.3 0.0 0.4 0.3 0.2 0.6 0.3 0.7 0.2 0.0 0.1 33.6 0.2 0.9 0.1 0.3 0.0 4.7 0.1 0.5 0.0 HRH3 GPCR97 ENSG00000101180 "Histamine receptor H3" Q9Y5N1 20 62214960-62220278 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 29 "brain: 59.6" "Cell type enriched" "Detected in some" 4 "Inhibitory neurons: 23.8" "Cancer enhanced" "Detected in single" "glioma: 0.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 6 "SCLC-21H: 15.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 65: Brain - Ion transport" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (1.56e-1)" "unprognostic (3.22e-1)" "unprognostic (4.15e-2)" "unprognostic (1.79e-1)" "unprognostic (2.77e-2)" "unprognostic (1.62e-2)" "unprognostic (7.30e-2)" "unprognostic (3.17e-4)" "unprognostic (2.40e-1)" "unprognostic (3.66e-3)" "unprognostic (3.30e-1)" "unprognostic (3.59e-2)" 0.0 0.4 21.4 0.0 51.1 0.0 0.0 10.1 22.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.1 31.6 0.0 0.0 0.0 0.0 3.5 26.3 0.0 0.0 0.0 2.0 0.0 3.9 0.1 0.0 0.6 0.1 0.0 0.0 0.2 0.0 0.0 3.6 0.0 0.1 0.8 59.6 0.0 0.0 0.0 0.0 0.2 0.0 11.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.5 0.0 0.0 0.0 0.0 1.1 0.0 0.1 15.6 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.4 51.1 10.1 22.2 16.1 31.6 3.5 26.3 3.9 3.6 59.6 11.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 0.1 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 3.3 23.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 1.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HRH4 "AXOR35, GPCR105, GPRv53, H4R, HH4R" ENSG00000134489 "Histamine receptor H4" Q9H3N8 18 24460637-24479961 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "Club cells: 1.3;Early spermatids: 1.2;granulocytes: 1.3;Late spermatids: 1.3;Melanocytes: 1.8;Spermatocytes: 1.3" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 123 "basophil: 212.9;eosinophil: 61.1" "Lineage enriched" "Detected in many" 191 "granulocytes: 212.9" "Cell line enhanced" "Detected in single" "HL-60: 1.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA035009 Uncertain NA NA "Cluster 2: Granulocytes - Unknown function" "Cluster 32: U-937 - Innate immune response" "Cluster 50: Fibroblasts - ECM organization" "HPA035009: AB_10671507" "unprognostic (1.88e-1)" "unprognostic (2.62e-1)" "unprognostic (4.68e-2)" "unprognostic (9.83e-6)" "unprognostic (1.31e-2)" "unprognostic (3.61e-2)" "unprognostic (1.22e-1)" "unprognostic (8.96e-2)" "unprognostic (2.20e-1)" "unprognostic (3.30e-1)" "unprognostic (7.25e-2)" "unprognostic (2.91e-1)" "unprognostic (6.65e-7)" "unprognostic (1.89e-2)" "unprognostic (2.41e-1)" "unprognostic (2.03e-4)" "unprognostic (7.70e-2)" 0.1 0.1 0.2 0.4 0.1 0.8 0.0 0.3 0.3 0.1 0.3 0.1 0.5 0.2 0.0 0.1 0.0 0.2 0.2 0.2 0.1 0.0 0.2 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.2 0.0 0.3 0.6 0.5 0.1 0.0 0.3 0.2 0.2 0.2 0.1 0.2 0.1 0.3 0.3 0.0 0.3 0.1 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.8 0.3 0.2 0.0 1.3 0.7 0.0 0.2 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.2 0.1 212.9 0.1 61.1 0.0 0.1 0.1 0.0 1.1 0.0 0.0 0.1 0.0 0.1 0.5 0.0 0.1 0.2 0.5 0.5 0.2 0.1 0.3 0.3 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.3 0.2 0.0 0.6 0.3 0.0 0.0 0.5 0.0 0.0 0.1 0.1 0.3 0.4 0.0 1.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.2 0.1 0.1 0.2 0.0 0.0 0.5 0.0 0.0 0.2 0.0 0.0 1.3 0.2 0.0 0.0 0.1 0.0 0.8 0.0 0.0 0.0 0.7 1.3 0.0 0.1 1.8 1.0 0.0 0.3 0.0 1.0 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.7 0.0 0.8 0.3 1.3 0.3 0.0 0.6 0.0 0.5 0.2 0.0 0.4 HSD11B1 "HSD11, HSD11B, SDR26C1" ENSG00000117594 "Hydroxysteroid 11-beta dehydrogenase 1" P28845 1 209686178-209734949 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Lipid metabolism, Steroid metabolism" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 13 "liver: 968.3" "Cell type enriched" "Detected in many" 9 "Hepatocytes: 646.2" "Cancer enriched" "Detected in all" 28 "liver cancer: 197.4" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "memory CD4 T-cell: 5.6" "Lineage enriched" "Detected in single" 17 "T-cells: 5.6" "Cell line enriched" "Detected in some" 5 "ASC diff: 989.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA047729 Enhanced NA NA 110000 "Cluster 35: T-regs - Unknown function" "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 2: Hepatocytes - Metabolism" "HPA047729: AB_2680135" "unprognostic (1.08e-3)" "unprognostic (2.13e-1)" "unprognostic (2.32e-1)" "unprognostic (1.40e-1)" "unprognostic (1.57e-1)" "unprognostic (3.68e-1)" "unprognostic (2.02e-2)" "unprognostic (1.12e-1)" "unprognostic (1.30e-1)" "unprognostic (3.63e-2)" "unprognostic (8.35e-3)" "unprognostic (8.69e-2)" "prognostic unfavorable (1.97e-10)" "unprognostic (3.41e-2)" "unprognostic (3.91e-2)" "unprognostic (6.45e-2)" "unprognostic (1.59e-2)" 22.4 7.7 9.8 14.6 15.4 0.3 12.0 23.0 22.0 2.8 8.1 4.2 1.2 4.2 15.7 2.1 5.1 8.0 7.5 11.0 16.0 24.3 968.3 39.9 4.3 14.3 21.4 59.9 3.2 0.2 8.8 72.5 16.3 27.8 3.3 0.6 2.5 13.0 5.5 33.8 5.0 12.9 9.4 7.3 7.1 7.2 12.8 0.6 5.2 10.6 1.9 27.9 6.3 17.5 0.4 0.0 0.0 0.0 989.2 102.8 0.0 0.1 36.0 0.0 0.1 0.0 0.2 0.0 0.2 0.3 0.1 0.1 0.0 43.9 0.0 0.0 0.0 0.0 0.0 0.0 206.6 0.2 0.1 5.4 0.0 6.9 0.4 0.9 0.0 0.0 0.0 51.2 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.7 16.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 34.9 8.4 4.0 0.2 0.2 0.3 1.4 0.3 0.3 5.7 1.4 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.1 5.6 1.2 0.0 0.0 0.1 0.0 0.1 0.3 0.0 0.0 1.7 0.4 9.8 15.4 23.0 22.0 11.0 16.0 14.3 21.4 16.3 9.4 12.8 17.5 0.4 3.2 0.0 1.3 0.8 0.1 0.4 4.8 0.6 0.5 0.2 0.0 1.4 30.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 5.2 0.9 0.6 1.0 0.0 5.3 3.3 0.0 0.1 66.4 0.5 2.8 0.0 0.0 7.5 646.2 8.3 0.0 2.8 0.0 0.0 7.9 2.3 2.8 29.2 3.7 0.0 28.1 0.6 16.2 0.0 0.5 55.7 0.4 0.0 7.9 0.0 0.9 0.0 0.2 0.1 0.5 0.0 2.6 5.5 0.0 0.2 0.1 0.1 0.3 1.1 0.3 0.0 1.7 HSD17B10 "17b-HSD10, ABAD, CAMR, ERAB, HADH2, MHBD, MRPP2, MRXS10, SDR5C1" ENSG00000072506 "Hydroxysteroid 17-beta dehydrogenase 10" Q99714 X 53431258-53434370 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Fatty acid metabolism, Lipid metabolism, Steroid metabolism, tRNA processing" Oxidoreductase "Disease variant, FDA approved drug targets, Mental retardation, Neurodegeneration" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Hepatocytes: 444.0;Proximal tubular cells: 427.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001432 Approved NA NA 290000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 18: Non-specific - Mitochondria" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "HPA001432: AB_1078740" "unprognostic (1.27e-1)" "prognostic favorable (2.80e-4)" "unprognostic (2.60e-1)" "unprognostic (2.15e-1)" "unprognostic (2.10e-1)" "unprognostic (1.30e-1)" "unprognostic (8.37e-2)" "unprognostic (5.24e-2)" "unprognostic (1.02e-1)" "unprognostic (8.64e-3)" "unprognostic (4.08e-3)" "unprognostic (2.04e-1)" "unprognostic (1.95e-2)" "unprognostic (8.38e-2)" "unprognostic (3.07e-3)" "unprognostic (2.92e-1)" "unprognostic (9.51e-2)" 71.1 110.7 63.5 52.5 67.5 64.8 62.7 70.0 64.7 58.1 64.6 62.8 58.0 62.0 56.2 111.6 55.4 33.4 103.8 62.0 68.4 99.1 261.3 48.4 59.4 70.4 68.2 67.1 74.8 73.4 66.1 37.2 67.8 50.7 62.9 12.7 55.0 46.0 90.5 90.0 50.3 62.0 66.6 52.0 66.4 21.5 69.1 60.1 66.4 81.6 76.3 56.3 59.8 69.2 121.9 203.1 97.2 181.3 93.4 41.0 146.5 73.7 72.9 192.0 125.3 210.3 101.8 205.8 65.6 84.9 124.2 124.5 316.1 148.7 104.3 164.1 177.7 97.1 283.6 177.0 156.3 185.1 145.5 87.6 138.9 148.7 82.8 41.6 142.2 181.2 141.6 158.1 90.3 426.7 165.3 277.0 269.9 163.0 259.5 166.2 179.2 364.9 149.3 132.2 171.1 225.1 211.7 250.2 138.6 123.0 263.3 169.8 64.2 81.7 129.7 171.9 113.4 128.3 194.1 256.5 113.4 384.9 123.2 54.2 127.8 40.4 84.8 125.1 87.2 98.8 78.0 84.1 176.7 111.4 64.4 67.9 10.5 98.7 94.5 96.5 114.8 126.6 63.5 67.5 70.0 64.7 62.0 68.4 70.4 68.2 67.8 66.6 69.1 69.2 42.8 48.1 37.3 4.9 61.8 86.4 90.2 150.8 44.9 11.8 72.5 74.9 62.0 107.2 70.2 101.2 4.2 173.2 55.0 73.8 283.7 131.5 1.6 26.1 64.7 58.3 104.6 71.3 2.5 135.4 228.1 72.0 28.1 51.9 56.5 75.3 56.4 444.0 136.8 13.5 3.3 78.2 99.7 73.9 98.6 5.7 78.3 65.4 96.0 3.7 118.7 61.3 89.6 6.6 6.2 101.9 54.1 94.8 83.3 74.6 78.5 427.8 31.5 13.2 78.9 63.1 117.9 23.6 56.3 91.3 116.2 151.6 62.4 104.1 103.0 83.7 HSD3B1 "HSD3B, HSDB3, SDR11E1" ENSG00000203857 "Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1" P14060 1 119507198-119515054 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Lipid metabolism, Steroid metabolism, Steroidogenesis" "Isomerase, Multifunctional enzyme, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "placenta: 77.7" "Group enriched" "Detected in some" 8 "Extravillous trophoblasts: 140.8;Syncytiotrophoblasts: 502.0" "Cancer enriched" "Detected in single" 4 "urothelial cancer: 1.6" "Region enhanced" "Detected in some" "basal ganglia: 1.0;cerebral cortex: 1.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "CACO-2: 64.1;SuSa: 26.5" "HPA043261, HPA043264, HPA044028" Supported Approved "Nucleoli,Endoplasmic reticulum,Cytokinetic bridge" Yes NA "Cluster 28: Placenta - Pregnancy" "Cluster 39: CACO-2 - Unknown function" "Cluster 18: Syncytiotrophoblasts - Pregnancy hormone signaling" "Nucleoli, Endoplasmic reticulum" "Cytokinetic bridge" "HPA043261: AB_2630368, HPA043264: AB_2678398, HPA044028: AB_2678781" "unprognostic (1.53e-1)" "unprognostic (7.11e-2)" "unprognostic (1.15e-1)" "unprognostic (1.04e-1)" "prognostic favorable (4.59e-5)" 0.1 1.2 0.2 0.0 1.0 0.0 1.5 0.0 1.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 77.7 0.0 0.1 0.5 0.0 0.1 0.0 0.1 4.5 8.7 0.5 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.7 0.2 0.0 0.0 0.0 64.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 7.0 0.7 0.8 26.5 0.0 0.0 0.2 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.0 0.0 1.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 23.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 140.8 0.8 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 37.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 502.0 0.0 0.1 1.0 0.0 HSD3B2 SDR11E2 ENSG00000203859 "Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2" P26439 1 119414931-119423035 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" Steroidogenesis "Isomerase, Multifunctional enzyme, Oxidoreductase" "Congenital adrenal hyperplasia, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 56 "adrenal gland: 2174.8" "Group enriched" "Detected in some" 4 "Granulosa cells: 40.6;Proximal enterocytes: 38.8;Theca cells: 68.9" "Cancer enhanced" "Detected in single" "testis cancer: 0.6" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "SK-MEL-30: 1.4" "HPA043261, HPA043264, HPA044028" Supported Uncertain "Nucleoli,Endoplasmic reticulum,Cytokinetic bridge" Yes NA "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 52: Non-specific - Transcription" "Nucleoli, Endoplasmic reticulum" "Cytokinetic bridge" "HPA043261: AB_2630368, HPA043264: AB_2678398, HPA044028: AB_2678781" "unprognostic (3.56e-1)" "unprognostic (1.85e-1)" "unprognostic (2.80e-1)" "unprognostic (2.72e-2)" "unprognostic (8.87e-2)" "unprognostic (3.91e-2)" "unprognostic (3.43e-2)" "unprognostic (1.94e-1)" "unprognostic (6.51e-2)" "unprognostic (1.97e-2)" "unprognostic (1.55e-1)" 0.2 2174.8 0.3 2.1 0.8 0.0 0.1 0.0 0.7 0.2 0.0 7.7 0.0 0.2 0.0 0.2 0.4 0.0 0.3 0.2 0.0 0.9 1.0 0.5 0.0 0.0 0.0 0.9 0.5 0.0 0.1 3.6 0.1 0.4 1.0 0.0 1.0 0.0 0.1 0.2 38.7 0.1 0.0 0.2 0.3 2.9 0.2 0.5 0.2 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 1.4 0.5 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.8 0.0 0.7 0.2 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 11.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.1 3.5 0.0 0.0 0.0 40.6 0.0 0.0 0.1 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 2.6 0.0 0.0 38.8 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 68.9 1.7 0.0 HTR1A "5-HT1A, ADRB2RL1, ADRBRL1" ENSG00000178394 "5-hydroxytryptamine receptor 1A" P08908 5 63957874-63962507 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "brain: 24.3" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in many" "midbrain: 24.3" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 12 "NTERA-2: 1.2;SCLC-21H: 1.1" "Low region specificity" "Detected in many" HPA018073 Uncertain NA NA "Cluster 65: Brain - Ion transport" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA018073: AB_1856704" "unprognostic (1.81e-1)" 0.0 0.0 0.7 0.0 6.2 0.0 0.0 0.0 9.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 11.4 0.0 0.0 0.0 0.0 0.0 3.4 24.3 3.2 0.0 0.0 0.0 0.0 7.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 6.2 0.0 9.1 11.4 0.0 3.4 24.3 7.9 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HTR1B "5-HT1B, 5-HT1DB, HTR1D2, S12" ENSG00000135312 "5-hydroxytryptamine receptor 1B" P28222 6 77460924-77463491 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 9.6;placenta: 6.7;stomach 1: 5.0" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "pancreatic cancer: 0.7;stomach cancer: 0.8;testis cancer: 1.0" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 16 "HUVEC TERT2: 79.4;TIME: 35.1" "Region enriched" "Detected in all" 4 "basal ganglia: 38.6" "Region enhanced" "Detected in many" "basal ganglia: 11.7" HPA028808 Enhanced Supported "Endoplasmic reticulum,Plasma membrane" NA NA "Cluster 38: Basophils - Unknown function" "Cluster 57: Non-specific - Angiogenesis" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Plasma membrane" "Endoplasmic reticulum" "HPA028808: AB_2672782" "unprognostic (3.86e-2)" "unprognostic (3.56e-1)" "unprognostic (7.68e-2)" "unprognostic (2.58e-1)" "unprognostic (1.88e-1)" "unprognostic (1.18e-2)" "unprognostic (2.67e-1)" "unprognostic (2.11e-1)" "unprognostic (8.96e-2)" "unprognostic (4.03e-1)" "unprognostic (1.77e-2)" "unprognostic (1.24e-1)" "unprognostic (1.10e-3)" "unprognostic (3.08e-2)" "unprognostic (2.81e-2)" "unprognostic (1.34e-1)" "unprognostic (1.02e-1)" 0.8 0.6 2.1 0.4 6.0 0.0 0.2 0.0 3.8 0.8 0.0 0.1 0.1 0.5 0.0 0.0 0.5 0.5 0.0 1.2 2.1 0.5 0.0 0.4 0.0 0.6 4.3 0.3 0.1 0.0 0.2 6.7 1.2 0.2 0.1 0.3 0.2 0.5 0.1 0.2 0.1 0.1 0.1 0.0 5.0 0.5 9.6 0.0 0.2 0.3 0.0 1.3 0.5 1.4 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.4 3.5 1.7 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.6 0.0 0.0 0.1 0.0 0.0 1.2 0.0 0.0 0.4 0.2 0.6 2.2 1.4 79.4 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.2 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 35.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 6.0 0.0 3.8 1.2 2.1 0.6 4.3 1.2 0.1 9.6 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HTR1D "5-HT1D, HT1DA, HTRL, RDC4" ENSG00000179546 "5-hydroxytryptamine receptor 1D" P28221 1 23191895-23194729 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "brain: 12.4;intestine: 9.4" "Group enriched" "Detected in some" 7 "Cholangiocytes: 5.7;Proximal enterocytes: 6.9" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "midbrain: 12.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 10.5;hTERT-RPE1: 9.8;OE19: 14.3;TIME: 26.4;U-2 OS: 8.4" NA NA "Cluster 45: Intestine - Brush border" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 45: Enterocytes - Digestion" "unprognostic (1.73e-2)" "unprognostic (8.69e-3)" "unprognostic (8.86e-3)" "unprognostic (2.03e-1)" "unprognostic (2.65e-2)" "unprognostic (5.97e-4)" "prognostic unfavorable (1.86e-4)" "unprognostic (3.87e-3)" "unprognostic (8.88e-2)" "unprognostic (4.00e-2)" "prognostic unfavorable (5.30e-4)" "unprognostic (3.17e-2)" "unprognostic (3.28e-6)" "unprognostic (9.14e-2)" "unprognostic (2.27e-1)" "unprognostic (2.45e-1)" "unprognostic (8.02e-3)" 0.0 0.0 1.9 0.2 5.7 0.2 0.1 0.3 3.8 0.0 0.1 0.2 9.4 0.1 0.0 0.0 0.5 1.6 0.0 1.4 1.3 0.0 0.0 0.1 0.0 0.6 12.4 0.0 0.2 0.1 0.1 0.2 1.7 0.1 0.2 0.1 0.0 0.1 0.1 0.1 8.2 0.1 2.0 0.1 0.1 0.2 4.4 0.0 0.1 0.0 0.1 0.1 0.0 0.7 3.2 10.5 0.1 0.0 0.0 0.2 0.9 0.0 0.8 0.3 0.4 0.7 7.5 0.0 3.0 0.4 5.2 2.2 2.1 0.0 0.5 0.0 0.9 0.0 6.0 0.1 0.4 0.0 0.0 0.1 0.2 1.3 0.4 9.8 6.1 0.1 0.1 0.0 0.2 1.3 0.0 0.0 2.5 14.3 0.1 0.0 0.0 0.0 0.2 0.0 2.5 0.0 7.0 0.4 0.1 0.8 0.1 0.0 26.4 0.0 8.4 0.1 2.5 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.0 1.9 5.7 0.3 3.8 1.4 1.3 0.6 12.4 1.7 2.0 4.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 5.7 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.3 0.5 0.2 0.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.5 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.6 0.7 HTR1E 5-HT1E ENSG00000168830 "5-hydroxytryptamine receptor 1E" P28566 6 86937528-87016679 "FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 4.2;ovary: 4.2" "Group enriched" "Detected in some" 15 "Excitatory neurons: 125.4;Inhibitory neurons: 104.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 11 "PC-3: 1.7;SH-SY5Y: 6.6" "Low region specificity" "Detected in many" HPA004931 Approved NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA004931: AB_1856706" "unprognostic (2.25e-2)" "unprognostic (1.32e-1)" "unprognostic (6.29e-2)" "unprognostic (4.52e-2)" "unprognostic (1.25e-1)" 0.0 0.0 1.7 0.0 3.0 0.0 0.0 0.0 4.2 0.3 0.0 0.0 0.0 1.5 0.2 0.0 0.0 0.1 0.0 2.6 1.3 0.0 0.0 0.0 0.0 0.2 0.3 4.2 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.8 0.0 0.0 1.3 0.3 1.2 0.0 0.8 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.1 6.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 3.0 0.0 4.2 2.6 1.3 0.2 0.3 0.1 0.0 1.2 2.5 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.0 1.1 0.0 0.0 0.0 125.4 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 104.7 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 1.0 0.0 0.0 0.0 1.5 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 1.7 0.0 0.0 HTR1F "5-HT1F, HTR1EL" ENSG00000179097 "5-hydroxytryptamine receptor 1F" P30939 3 87792706-87993839 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "placenta: 1.8;retina: 3.6" "Group enriched" "Detected in some" 7 "Excitatory neurons: 232.6;Inhibitory neurons: 79.0" "Not detected" "Not detected" "Region enhanced" "Detected in single" "cerebral cortex: 1.5" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "K-562: 1.3;LHCN-M2: 1.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA005555 Uncertain NA NA "Cluster 46: Basophils - DNA binding" "Cluster 77: Retina - Visual perception" "Cluster 1: K-562 - Erythropoiesis" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA005555: AB_1856708" "unprognostic (1.66e-1)" "unprognostic (2.62e-1)" "unprognostic (2.58e-1)" "unprognostic (9.03e-2)" "unprognostic (1.09e-1)" "unprognostic (1.01e-2)" "unprognostic (4.78e-1)" "unprognostic (1.58e-1)" "unprognostic (2.77e-2)" "unprognostic (2.24e-1)" "unprognostic (1.33e-1)" "unprognostic (9.80e-2)" "unprognostic (2.67e-6)" "unprognostic (1.25e-4)" "unprognostic (1.55e-2)" "unprognostic (3.33e-2)" "unprognostic (3.31e-2)" 0.7 0.2 0.0 0.0 0.1 0.6 0.4 0.0 1.5 0.4 0.0 0.1 0.0 0.4 0.1 0.1 0.1 0.1 0.1 0.5 0.0 0.2 0.0 0.3 0.1 0.0 0.4 0.1 0.3 0.1 0.3 1.8 0.0 0.1 0.0 3.6 0.0 0.3 0.1 0.1 0.0 0.4 0.0 0.6 0.0 0.1 0.0 0.3 0.5 0.1 0.2 0.2 0.1 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.5 0.5 0.0 0.0 0.4 0.0 0.0 0.0 0.5 2.2 0.0 0.0 4.6 0.0 0.4 0.0 0.0 0.0 0.1 0.8 0.3 0.2 1.5 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 2.2 0.0 3.0 232.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 79.0 0.1 0.0 0.6 0.5 0.2 0.0 0.4 1.8 13.1 0.2 20.4 0.0 2.5 3.9 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 1.5 19.7 0.1 12.7 0.3 1.9 0.0 0.0 0.0 0.2 0.2 0.1 0.1 HTR2A "5-HT2A, HTR2" ENSG00000102468 "5-hydroxytryptamine receptor 2A" P28223 13 46831546-46897076 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "Behavior, Host-virus interaction" "G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 15.2;choroid plexus: 5.6" "Cell type enriched" "Detected in some" 8 "Excitatory neurons: 81.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 1.8;ASC TERT1: 4.6;BEWO: 1.4;HEL: 1.5;U-138 MG: 2.3;U-2 OS: 1.4;U-87 MG: 1.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA014011 Enhanced NA NA "Cluster 65: Brain - Ion transport" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA014011: AB_1856709" "unprognostic (8.01e-2)" "unprognostic (2.71e-2)" "unprognostic (9.49e-2)" "unprognostic (7.40e-2)" "unprognostic (2.78e-1)" "unprognostic (1.99e-1)" "unprognostic (2.70e-2)" "unprognostic (4.31e-2)" "unprognostic (5.27e-2)" "unprognostic (3.97e-2)" "unprognostic (2.61e-1)" "unprognostic (2.90e-1)" "unprognostic (9.94e-5)" "unprognostic (4.78e-3)" "unprognostic (2.54e-1)" "unprognostic (2.91e-2)" "unprognostic (8.28e-2)" 0.9 0.3 6.7 0.8 9.7 0.1 0.5 0.0 15.2 0.6 5.6 0.5 0.4 0.5 0.0 0.5 0.3 1.6 0.7 11.8 8.7 0.1 0.1 0.3 0.0 0.5 1.4 0.3 0.0 0.0 0.2 0.0 2.9 0.2 0.6 0.8 0.0 0.6 0.3 0.1 0.4 2.6 0.1 0.0 0.2 0.6 1.6 0.7 0.1 0.6 0.2 0.8 0.5 5.8 0.0 0.0 0.0 0.0 1.8 4.6 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 2.3 1.4 0.0 0.1 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.2 6.7 9.7 0.0 15.2 11.8 8.7 0.5 1.4 2.9 0.1 1.6 5.8 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.5 0.2 1.8 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 0.2 8.6 0.1 0.0 0.0 81.7 0.0 0.0 1.9 0.0 0.2 0.0 0.0 0.4 0.1 0.1 0.0 10.1 0.0 0.0 0.3 0.0 2.2 0.9 1.9 0.0 3.7 0.0 4.6 0.0 2.5 3.2 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.3 0.0 1.0 1.0 0.0 0.8 0.0 0.1 0.0 0.0 0.0 0.1 0.1 HTR2B "5-HT(2B), 5-HT2B" ENSG00000135914 "5-hydroxytryptamine receptor 2B" P41595 2 231108230-231125042 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 17.4;cervix: 21.5;endometrium 1: 18.8;smooth muscle: 16.8" "Cell type enhanced" "Detected in some" "Cone photoreceptor cells: 4.2;Endometrial stromal cells: 17.7;Endothelial cells: 4.1;Hepatic stellate cells: 5.7;Microglial cells: 4.7;monocytes: 6.2;Peritubular cells: 5.3" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 15 "basophil: 1.8;T-reg: 1.0" "Group enriched" "Detected in many" 15 "granulocytes: 1.8;T-cells: 1.0" "Group enriched" "Detected in some" 4 "HHSteC: 8.7;HSkMC: 16.5;SK-MEL-30: 32.7" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA012867, HPA063658" Enhanced Supported Nucleoplasm NA NA "Cluster 41: Basophils - Cellular respiration" "Cluster 89: Fibroblasts - ECM organization" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 36: Stromal cells - Cell proliferation" Nucleoplasm "HPA012867: AB_1856710, HPA063658: AB_2685079" "unprognostic (1.86e-1)" "unprognostic (3.55e-2)" "unprognostic (1.20e-3)" "unprognostic (1.45e-2)" "unprognostic (1.12e-1)" "unprognostic (1.16e-1)" "unprognostic (1.53e-2)" "unprognostic (1.00e-1)" "unprognostic (1.33e-2)" "unprognostic (1.15e-4)" "unprognostic (3.59e-1)" "unprognostic (2.17e-2)" "unprognostic (1.42e-3)" "unprognostic (7.44e-4)" "unprognostic (1.81e-1)" "unprognostic (1.17e-1)" "unprognostic (1.14e-2)" 0.9 17.4 0.4 1.5 0.4 1.2 0.8 0.9 0.6 21.5 1.2 9.0 1.5 18.8 11.8 0.7 2.4 1.2 4.7 0.4 0.6 3.4 3.6 0.9 1.0 0.5 0.4 0.8 0.2 0.6 0.3 4.1 0.5 0.3 2.1 0.2 0.5 1.4 0.1 0.1 4.8 16.8 0.2 0.4 4.5 0.4 0.4 1.2 3.2 0.3 0.8 2.2 0.8 0.6 0.2 0.3 0.0 0.1 0.5 4.5 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 8.7 0.1 0.3 16.5 0.0 0.0 0.0 0.0 3.2 1.4 0.1 0.0 0.0 0.2 0.0 0.7 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 1.3 0.0 0.1 32.7 0.0 0.0 0.4 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.1 1.1 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.4 0.4 0.9 0.6 0.4 0.6 0.5 0.4 0.5 0.2 0.4 0.6 0.4 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.5 0.1 0.0 0.3 0.0 0.2 0.0 4.2 0.1 0.1 0.0 0.0 0.0 0.2 1.5 17.7 4.1 0.0 0.0 0.7 0.7 0.1 0.8 0.0 3.4 0.0 0.1 5.7 1.5 3.4 1.7 0.9 0.0 0.0 0.8 0.0 0.2 0.6 2.2 0.0 4.7 6.2 0.0 1.0 0.5 0.6 0.2 0.0 5.3 0.0 0.0 0.0 0.0 2.0 0.7 0.0 0.1 0.9 0.0 0.0 0.1 0.0 0.3 0.2 0.3 0.0 0.2 HTR2C "5-HT2C, 5HTR2C, HTR1C" ENSG00000147246 "5-hydroxytryptamine receptor 2C" P28335 X 114584078-114910061 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 12 "choroid plexus: 271.1" "Cell type enhanced" "Detected in some" "Excitatory neurons: 24.2;Inhibitory neurons: 55.3;Oligodendrocyte precursor cells: 10.1" "Cancer enhanced" "Detected in single" "testis cancer: 0.9" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "EFO-21: 2.7;RPMI-8226: 1.4;U-266/70: 4.8;U-266/84: 4.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 88: Choroid plexus - Transmembrane transport" "Cluster 29: U-266 - Adaptive immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (2.14e-1)" "unprognostic (6.09e-3)" "unprognostic (9.54e-2)" "unprognostic (3.47e-2)" "unprognostic (2.89e-2)" "unprognostic (3.42e-2)" "unprognostic (9.22e-4)" "unprognostic (1.37e-1)" "unprognostic (6.84e-2)" 0.0 0.0 8.5 0.0 23.1 0.0 0.0 1.2 8.1 0.3 271.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.7 17.4 0.0 0.0 0.0 0.0 13.2 9.9 0.0 0.0 0.0 0.4 0.1 9.8 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 12.1 0.0 0.0 0.0 0.0 0.0 0.3 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.2 0.6 0.0 0.0 0.0 1.4 0.0 0.7 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.0 0.0 0.0 0.5 0.0 0.0 4.8 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.5 23.1 1.2 8.1 12.7 17.4 13.2 9.9 9.8 3.2 12.1 2.0 0.0 0.0 0.0 1.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 24.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 55.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 2.8 0.0 0.0 0.0 10.1 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HTR3A "5-HT3A, 5-HT3R, HTR3" ENSG00000166736 "5-hydroxytryptamine receptor 3A" P46098 11 113974881-113990313 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 8.0;salivary gland: 5.0" "Group enriched" "Detected in some" 11 "Ductal cells: 23.9;Exocrine glandular cells: 53.3;Pancreatic endocrine cells: 34.7" "Cancer enriched" "Detected in many" 7 "ovarian cancer: 15.2" "Low region specificity" "Detected in some" "Group enriched" "Detected in some" 15 "memory B-cell: 3.9;naive B-cell: 13.8;plasmacytoid DC: 11.6" "Group enriched" "Detected in many" 127 "B-cells: 13.8;dendritic cells: 11.6" "Cell line enhanced" "Detected in some" "CAPAN-2: 6.0;Daudi: 5.9;NTERA-2: 3.6;SCLC-21H: 18.7" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 16 "amygdala: 1.7;cerebral cortex: 2.7;hippocampal formation: 2.5" HPA069442 Supported NA NA "Cluster 24: B-cells - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 1: Pancreatic cells - Digestion" "HPA069442: AB_2732132" "unprognostic (6.46e-3)" "prognostic favorable (6.26e-4)" "unprognostic (1.09e-1)" "prognostic unfavorable (1.26e-4)" "unprognostic (3.36e-3)" "unprognostic (8.36e-3)" "unprognostic (1.65e-5)" "unprognostic (1.46e-2)" "unprognostic (8.87e-2)" "unprognostic (6.21e-2)" "unprognostic (6.80e-3)" "unprognostic (3.00e-2)" "unprognostic (1.65e-2)" "unprognostic (8.72e-2)" "unprognostic (2.01e-1)" "unprognostic (3.79e-1)" "unprognostic (3.40e-2)" 0.0 0.4 0.7 2.1 1.2 0.0 0.0 0.4 1.0 0.0 0.4 2.1 0.6 0.1 0.0 0.5 0.0 0.0 0.0 1.1 0.5 0.1 0.0 0.0 6.5 0.4 0.5 0.0 2.6 0.0 0.0 0.0 0.4 0.0 0.4 0.0 5.0 0.0 0.0 0.7 1.7 0.7 0.4 0.5 0.8 0.1 0.5 0.4 0.0 0.0 8.0 0.1 0.3 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.0 5.9 0.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.6 0.0 0.0 0.0 18.7 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 0.6 13.8 0.0 0.0 0.0 0.0 0.0 11.6 0.0 0.2 0.7 1.2 0.4 1.0 1.1 0.5 0.4 0.5 0.4 0.4 0.5 0.6 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 1.8 0.0 0.0 3.0 0.1 0.0 23.9 0.0 0.3 0.0 0.0 0.0 0.0 0.3 53.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.0 0.0 0.0 0.0 0.1 34.7 0.1 0.0 0.1 0.1 0.0 0.0 0.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 HTR3B 5-HT3B ENSG00000149305 "5-hydroxytryptamine receptor 3B" O95264 11 113904677-113949078 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 4 "brain: 2.5" "Cell type enhanced" "Detected in some" "Excitatory neurons: 4.4;Oligodendrocytes: 1.2" "Not detected" "Not detected" "Region enhanced" "Detected in some" "cerebral cortex: 2.5" "Low immune cell specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA039559 Approved NA NA "Cluster 11: Basophils - Unknown function" "Cluster 10: Brain - Neuronal signaling" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA039559: AB_10672779" "unprognostic (1.60e-2)" "unprognostic (8.37e-2)" "unprognostic (2.84e-1)" "unprognostic (3.28e-1)" "unprognostic (1.71e-1)" "unprognostic (2.46e-1)" 0.0 0.1 0.0 0.2 0.5 0.5 0.0 0.0 2.5 0.0 0.0 0.1 0.1 0.1 0.2 0.5 0.0 0.1 0.0 1.5 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.3 0.3 0.1 0.0 0.0 0.1 0.1 0.4 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.3 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.3 0.0 0.1 0.2 0.1 0.0 0.0 0.2 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 1.0 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.3 0.1 0.2 0.9 0.4 0.1 0.3 0.2 0.1 0.0 0.5 0.0 2.5 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HTR3C ENSG00000178084 "5-hydroxytryptamine receptor 3C" Q8WXA8 3 184053047-184060673 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 6 "lung: 2.4" "Cell type enhanced" "Detected in single" "Enteroendocrine cells: 1.8" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" NA NA "Cluster 19: Lung - Lung function" "Cluster 31: Spermatids - Spermatogenesis" "unprognostic (4.56e-2)" "unprognostic (2.01e-1)" "unprognostic (1.39e-1)" "unprognostic (1.61e-1)" "unprognostic (2.88e-2)" "unprognostic (1.68e-2)" "unprognostic (8.72e-2)" "unprognostic (1.75e-1)" "unprognostic (3.88e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.1 1.8 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 HTR3D ENSG00000186090 "5-hydroxytryptamine receptor 3D" Q70Z44 3 184031544-184039369 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" NA NA "unprognostic (3.08e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HTR3E ENSG00000186038 "5-hydroxytryptamine receptor 3E" A5X5Y0 3 184097064-184106995 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "Enteroendocrine cells: 3.5;Inhibitory neurons: 1.1;Microglial cells: 1.0;Oligodendrocyte precursor cells: 2.5;Paneth cells: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 6 "RH-30: 1.3" HPA049764 Enhanced NA NA "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 17: Intestinal endocrine cells - Hormone signaling" "HPA049764: AB_2680869" "unprognostic (4.12e-2)" "unprognostic (5.86e-2)" "unprognostic (2.15e-1)" "unprognostic (4.57e-4)" "unprognostic (3.61e-3)" "unprognostic (1.15e-1)" "unprognostic (3.16e-1)" "unprognostic (4.47e-1)" "unprognostic (3.32e-1)" "unprognostic (2.67e-1)" "unprognostic (4.16e-2)" 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.6 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.3 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 2.5 0.9 0.0 1.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.2 HTR4 5-HT4 ENSG00000164270 "5-hydroxytryptamine receptor 4" Q13639 5 148451032-148677235 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "brain: 12.1;heart muscle: 4.5;intestine: 9.1" "Group enriched" "Detected in some" 4 "Excitatory neurons: 42.0;Inhibitory neurons: 44.5" "Not detected" "Not detected" "Region enhanced" "Detected in many" "basal ganglia: 12.1" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA040591 Enhanced NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA040591: AB_2677028" "unprognostic (1.12e-1)" "unprognostic (4.60e-2)" "unprognostic (7.74e-2)" "unprognostic (2.37e-1)" "unprognostic (5.02e-2)" "unprognostic (3.77e-2)" "unprognostic (4.68e-2)" "unprognostic (1.10e-2)" "unprognostic (1.13e-1)" "unprognostic (1.46e-1)" "unprognostic (3.40e-2)" "unprognostic (2.25e-1)" "unprognostic (4.49e-2)" "unprognostic (8.83e-5)" 0.2 0.7 1.8 0.4 12.1 0.0 0.0 0.0 4.5 0.2 0.0 2.6 4.8 0.1 0.0 0.1 0.2 0.8 4.5 7.6 2.4 0.0 0.0 0.1 0.0 0.1 0.9 0.0 0.0 0.0 1.1 0.0 0.2 0.0 2.8 1.0 0.0 0.0 0.0 0.0 9.1 0.5 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.8 12.1 0.0 4.5 7.6 2.4 0.1 0.9 0.2 0.0 0.8 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.6 0.0 0.0 0.3 0.0 0.0 42.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 44.5 2.6 0.0 0.0 0.0 1.2 0.0 0.0 0.0 3.7 0.0 0.0 0.0 2.0 6.1 0.0 1.5 0.0 0.0 0.0 10.8 0.0 0.0 0.8 0.0 1.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 8.7 0.0 HTR6 "5-HT6, 5-HT6R" ENSG00000158748 "5-hydroxytryptamine receptor 6" P50406 1 19664875-19680966 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 18 "brain: 9.7" "Cell type enhanced" "Detected in single" "Excitatory neurons: 1.6" "Cancer enhanced" "Detected in single" "renal cancer: 0.6" "Group enriched" "Detected in many" 4 "basal ganglia: 9.7;cerebral cortex: 2.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "SH-SY5Y: 2.0" "Low region specificity" "Detected in many" HPA068165 Uncertain NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 10: Brain - Neuronal signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA068165: " "unprognostic (2.34e-2)" "unprognostic (1.84e-1)" "unprognostic (7.19e-3)" "unprognostic (3.84e-5)" "unprognostic (1.38e-4)" "unprognostic (2.69e-2)" "unprognostic (1.36e-1)" "unprognostic (2.80e-2)" "unprognostic (1.03e-1)" "unprognostic (5.33e-3)" "unprognostic (8.63e-2)" "unprognostic (5.47e-4)" "unprognostic (1.28e-1)" "unprognostic (2.49e-1)" "unprognostic (6.13e-3)" "unprognostic (2.02e-1)" 0.0 0.0 1.2 0.2 9.7 0.0 0.0 0.0 2.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.4 0.0 0.0 0.0 0.5 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.2 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 9.7 0.0 2.4 0.7 0.1 0.1 0.0 0.0 0.0 1.4 0.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 HTR7 5-HT7 ENSG00000148680 "5-hydroxytryptamine receptor 7" P34969 10 90740823-90858039 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 7.6;parathyroid gland: 13.1;testis: 8.7" "Cell type enhanced" "Detected in some" "Early spermatids: 7.0;Excitatory neurons: 5.9;Inhibitory neurons: 24.2;Spermatocytes: 13.1" "Group enriched" "Detected in some" 5 "cervical cancer: 0.9;head and neck cancer: 3.3;lung cancer: 0.9;urothelial cancer: 1.3" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in single" 12 "myeloid DC: 1.4" "Lineage enriched" "Detected in single" 12 "dendritic cells: 1.4" "Cell line enhanced" "Detected in many" "HBEC3-KT: 11.3;hTCEpi: 10.1;hTERT-HME1: 33.4;LHCN-M2: 13.5;U-251 MG: 9.6;U-87 MG: 10.2;WM-115: 13.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB022708, HPA073617" Approved Supported Supported "Nuclear speckles,Plasma membrane,Cytosol" NA NA "Cluster 28: Myeloid DCs - Unknown function" "Cluster 48: Parathyroid gland - membrane proteins" "Cluster 30: Epithelial cell lines - Translation" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane" "Nuclear speckles, Cytosol" "CAB022708: , HPA073617: AB_2732228" "unprognostic (1.17e-1)" "unprognostic (1.24e-2)" "unprognostic (4.72e-2)" "unprognostic (1.33e-1)" "unprognostic (5.51e-3)" "unprognostic (1.71e-2)" "unprognostic (1.89e-1)" "unprognostic (1.44e-1)" "unprognostic (1.15e-1)" "unprognostic (4.58e-3)" "unprognostic (3.32e-1)" "unprognostic (1.45e-1)" "unprognostic (2.89e-1)" "unprognostic (1.23e-3)" "unprognostic (1.38e-1)" "unprognostic (1.84e-2)" "unprognostic (6.49e-2)" 0.5 0.2 2.4 0.9 1.4 0.3 0.3 0.0 2.5 0.4 0.4 0.6 0.5 0.2 0.1 0.7 0.2 0.9 0.1 2.7 7.1 0.1 0.4 0.2 0.6 1.5 3.2 0.1 0.2 13.1 0.1 0.3 1.9 0.2 0.9 0.1 0.3 0.1 0.9 0.5 1.4 0.3 0.5 1.1 0.7 8.7 7.6 0.2 0.1 0.5 0.3 2.3 0.6 0.8 0.3 0.0 0.0 0.0 0.2 0.9 0.0 0.7 0.3 0.7 1.0 0.0 1.2 0.0 0.0 0.1 2.0 4.7 1.3 11.3 2.8 0.0 0.2 0.0 0.0 0.0 5.1 0.0 0.6 7.8 10.1 3.3 33.4 6.3 0.0 0.0 0.1 0.0 13.5 0.0 0.0 0.2 1.2 0.0 1.6 1.0 0.1 0.0 0.0 1.2 0.4 0.0 0.5 0.0 5.4 0.6 0.0 0.2 0.3 6.1 0.0 0.1 9.6 0.0 0.0 0.0 10.2 0.0 13.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.4 1.4 0.0 2.5 2.7 7.1 1.5 3.2 1.9 0.5 7.6 0.8 0.1 0.0 0.0 0.7 0.3 0.0 0.2 0.7 0.0 0.0 0.0 0.3 0.7 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 0.0 0.3 0.0 0.0 0.4 5.9 0.0 0.0 0.1 0.0 0.1 0.0 0.4 0.4 0.0 1.7 0.0 24.2 0.0 2.0 2.2 0.0 2.7 0.0 2.5 0.0 0.0 0.4 0.0 0.0 0.5 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.2 0.1 13.1 1.3 0.0 0.1 0.1 0.2 0.0 0.0 0.3 ICAM1 "BB2, CD54" ENSG00000090339 "Intercellular adhesion molecule 1" P05362 19 10271093-10286615 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lung: 219.3;urinary bladder: 215.3" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 612.2;Alveolar cells type 2: 561.6;Endothelial cells: 240.8;Langerhans cells: 232.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HHSteC: 158.3;Karpas-707: 459.7;RPMI-8226: 148.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002126, CAB002142, HPA004877" Enhanced Approved "Vesicles,Plasma membrane,Cytosol" NA NA 87900000 2200000000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 2: Karpas-707 - Immune response" "Cluster 11: Alveolar cells - Smell perception" "Plasma membrane" "Vesicles, Cytosol" "CAB002142: AB_563596, HPA002126: AB_1078470, HPA004877: AB_1846317" "prognostic favorable (7.09e-4)" "unprognostic (1.88e-1)" "unprognostic (1.94e-1)" "unprognostic (2.63e-2)" "unprognostic (3.25e-3)" "unprognostic (3.05e-1)" "unprognostic (1.45e-2)" "unprognostic (3.48e-1)" "unprognostic (3.18e-2)" "unprognostic (1.09e-2)" "unprognostic (1.49e-2)" "unprognostic (1.79e-1)" "prognostic unfavorable (1.32e-6)" "unprognostic (2.77e-1)" "unprognostic (2.16e-2)" "unprognostic (2.25e-1)" "unprognostic (3.70e-3)" 87.9 23.6 9.1 44.6 9.6 117.1 32.4 7.9 12.0 11.2 9.9 17.7 16.8 23.9 3.5 11.0 26.2 56.4 39.1 8.8 9.9 43.9 67.1 219.3 38.3 12.3 8.7 13.0 11.1 8.3 9.3 27.8 10.2 22.2 18.1 10.5 18.0 6.3 15.1 17.9 22.6 23.4 10.0 55.9 21.5 5.6 15.4 28.4 30.8 12.8 32.9 215.3 12.5 10.2 46.3 0.5 7.9 0.2 2.0 4.4 9.7 8.6 91.6 21.8 62.0 14.0 49.8 39.6 130.3 3.8 99.3 8.9 1.7 0.4 45.6 123.8 0.1 3.8 1.4 62.0 158.3 1.3 23.9 55.7 4.0 13.7 20.3 2.0 10.7 4.9 15.0 459.7 1.5 3.3 0.5 34.9 3.1 0.5 24.7 1.0 0.2 148.5 36.8 0.3 0.3 1.1 61.2 3.3 94.5 3.7 6.9 2.8 34.3 22.3 1.9 12.3 0.8 137.4 142.7 25.5 35.1 26.3 32.6 5.0 28.3 5.2 5.3 25.8 9.8 3.8 4.0 6.3 24.7 1.5 1.9 3.8 40.8 15.2 17.0 14.1 6.1 20.8 9.1 9.6 7.9 12.0 8.8 9.9 12.3 8.7 10.2 10.0 15.4 10.2 150.3 612.2 561.6 0.3 31.7 85.3 22.2 62.6 28.5 0.0 50.2 24.9 1.1 21.5 133.5 3.7 0.0 1.1 28.9 2.9 0.0 176.8 2.0 14.1 15.5 240.8 2.4 1.3 0.5 98.7 3.3 136.6 13.7 29.8 139.8 0.1 48.2 12.1 86.7 0.0 0.4 0.7 32.6 53.6 232.6 1.3 4.7 168.3 76.5 7.5 101.9 4.6 5.2 0.5 0.2 113.7 0.3 1.5 57.6 27.1 0.3 15.0 83.2 0.4 6.6 38.2 57.6 0.8 1.6 4.3 69.3 1.2 28.8 0.5 1.6 14.1 IDE ENSG00000119912 "Insulin degrading enzyme" P14735 10 92451684-92574096 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Host-virus interaction" "Allosteric enzyme, Host cell receptor for virus entry, Hydrolase, Metalloprotease, Protease, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA063478 Approved "Secreted in other tissues" NA NA 310000 "Cluster 27: Non-specific - Gene expression" "Cluster 31: Skin - Epidermis development" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 66: Spermatocytes - Spermatogenesis" "HPA063478: AB_2685020" "unprognostic (1.70e-1)" "unprognostic (6.40e-2)" "prognostic favorable (3.69e-4)" "prognostic favorable (3.53e-4)" "unprognostic (2.54e-1)" "unprognostic (1.78e-1)" "unprognostic (2.51e-1)" "unprognostic (3.79e-1)" "unprognostic (8.88e-2)" "unprognostic (2.57e-1)" "unprognostic (6.58e-2)" "unprognostic (7.79e-2)" "unprognostic (6.81e-2)" "unprognostic (9.24e-3)" "unprognostic (6.13e-2)" "unprognostic (3.89e-2)" "unprognostic (3.91e-1)" 6.7 10.1 3.4 2.8 3.6 3.5 6.1 3.7 4.2 8.1 5.9 8.6 3.3 7.4 9.7 9.8 6.5 2.9 11.7 3.4 3.7 5.9 11.4 5.9 3.4 3.8 3.7 5.4 12.3 9.5 4.7 2.7 3.9 9.1 3.8 10.3 7.8 4.2 28.8 36.4 6.8 3.7 3.6 6.3 8.2 25.8 3.6 2.4 6.7 9.7 4.1 8.9 7.9 3.8 12.1 22.9 6.2 15.1 10.5 5.8 8.5 10.4 13.3 6.1 5.2 19.4 9.5 12.5 16.4 14.3 7.2 16.3 14.6 10.0 3.9 14.7 8.8 5.1 13.7 25.9 11.5 14.9 6.5 5.4 6.6 9.1 14.0 7.8 8.6 3.3 10.0 8.1 5.4 18.0 6.6 8.8 10.2 10.4 5.2 10.2 10.8 9.0 10.9 19.3 2.2 5.6 14.3 6.4 6.7 6.8 12.6 6.3 15.3 4.4 8.2 5.0 10.4 11.2 12.2 14.5 6.9 10.9 4.4 0.3 3.5 1.4 2.0 4.2 2.2 2.9 2.6 2.9 4.6 2.1 1.9 2.0 0.0 3.7 5.9 1.3 3.9 2.3 3.4 3.6 3.7 4.2 3.4 3.7 3.8 3.7 3.9 3.6 3.6 3.8 12.9 9.6 14.1 20.9 11.1 5.2 6.1 10.5 5.2 15.0 8.7 4.3 45.7 7.2 10.6 7.3 47.9 11.2 10.0 14.0 1.9 14.0 46.4 14.9 19.3 10.8 10.8 19.6 43.3 20.2 5.7 9.1 22.4 16.5 1.3 9.9 11.7 24.1 11.9 6.7 42.6 12.7 18.3 16.6 5.4 12.0 6.5 12.5 8.8 23.4 7.8 7.8 4.1 20.6 24.0 16.5 5.7 10.1 24.2 12.2 9.0 10.7 23.3 26.9 6.6 7.6 13.2 51.5 11.0 19.6 16.3 3.8 8.5 9.8 9.8 9.6 IDH1 ENSG00000138413 "Isocitrate dehydrogenase (NADP(+)) 1" O75874 2 208236229-208266074 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Glyoxylate bypass, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 536.3" "Cell type enhanced" "Detected in all" "Cytotrophoblasts: 320.2;Granulosa cells: 257.5;Hepatocytes: 328.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Hep G2: 768.1;RT4: 524.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033218, HPA035248, HPA057936, CAB062556" Enhanced Approved "Nuclear bodies,Cytosol" NA NA 16000000 "Cluster 25: Monocytes - Inflammatory response" "Cluster 85: Liver - Metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 40: Granulosa cells - Unknown function" "Nuclear bodies, Cytosol" "CAB033218: AB_2123166, CAB062556: AB_2665593, HPA035248: AB_10600714, HPA057936: AB_2683559" "unprognostic (2.79e-1)" "unprognostic (1.00e-1)" "unprognostic (1.02e-1)" "unprognostic (2.47e-3)" "unprognostic (1.93e-1)" "unprognostic (2.39e-2)" "prognostic unfavorable (6.93e-5)" "unprognostic (3.32e-1)" "unprognostic (2.20e-3)" "unprognostic (8.03e-2)" "unprognostic (5.54e-2)" "unprognostic (4.18e-3)" "prognostic unfavorable (2.45e-5)" "unprognostic (2.09e-1)" "unprognostic (1.77e-1)" "unprognostic (1.13e-1)" "unprognostic (2.69e-2)" 150.8 230.8 24.0 37.5 23.9 10.7 63.0 24.6 30.9 67.9 40.8 124.9 179.4 22.9 164.9 92.2 36.6 69.5 25.3 23.5 26.1 122.0 536.3 49.8 33.3 26.4 25.7 84.4 39.9 42.0 16.7 82.5 25.9 214.6 131.2 35.0 59.3 79.1 25.7 23.6 117.4 43.8 25.5 40.1 113.6 57.0 30.0 21.8 45.5 28.1 29.8 153.1 39.9 30.6 66.5 109.6 152.5 63.3 275.1 191.4 86.7 26.3 122.3 44.2 107.3 176.1 159.1 13.1 168.8 84.4 181.6 101.4 112.4 130.7 43.0 8.8 41.7 56.7 87.3 768.1 367.3 37.0 54.7 169.5 278.0 102.7 74.2 69.8 126.1 37.2 58.1 44.5 68.9 42.8 26.3 66.2 284.5 479.7 43.9 25.2 54.8 37.8 206.3 524.0 25.9 45.2 100.5 99.7 351.7 161.2 37.9 111.0 81.1 45.2 44.1 65.3 29.6 20.8 34.5 16.9 148.2 226.7 37.0 12.4 70.1 11.0 9.1 32.3 10.6 10.6 8.2 10.9 50.9 10.1 6.7 7.8 13.8 17.2 15.5 18.8 15.1 29.9 24.0 23.9 24.6 30.9 23.5 26.1 26.4 25.7 25.9 25.5 30.0 30.6 13.9 12.8 49.5 39.2 20.2 12.4 18.8 60.5 52.3 19.5 61.8 31.5 21.8 45.8 69.1 29.5 25.0 320.2 23.7 106.8 21.5 31.1 13.8 31.0 23.4 22.0 58.4 30.3 16.6 86.5 178.8 29.6 76.0 108.8 14.0 257.5 39.7 328.2 175.3 11.8 16.2 98.4 57.0 130.2 23.8 11.2 24.5 71.7 26.6 19.7 47.8 25.4 18.6 66.4 20.0 44.8 55.5 29.3 13.7 53.2 181.2 108.5 21.9 56.6 13.1 7.8 23.6 8.0 26.2 82.4 14.9 95.6 19.8 127.1 129.3 46.7 IDH2 ENSG00000182054 "Isocitrate dehydrogenase (NADP(+)) 2" P48735 15 90083045-90102477 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Glyoxylate bypass, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in all" 4 "heart muscle: 492.6;skeletal muscle: 1302.3;tongue: 1611.3" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 732.5;Distal tubular cells: 1168.0;Extravillous trophoblasts: 586.7;Syncytiotrophoblasts: 573.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MOLT-4: 425.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007831 Enhanced Supported Mitochondria NA NA 5200000 "Cluster 51: Monocytes - Innate immune response" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 14: REH - Unknown function" "Cluster 47: Cytotrophoblasts - Unknown function" Mitochondria "HPA007831: AB_1851397" "unprognostic (2.45e-2)" "prognostic favorable (5.15e-5)" "unprognostic (2.92e-1)" "unprognostic (1.53e-1)" "unprognostic (3.53e-1)" "unprognostic (8.46e-2)" "unprognostic (3.83e-2)" "unprognostic (2.55e-3)" "unprognostic (1.86e-2)" "unprognostic (1.89e-2)" "unprognostic (2.76e-1)" "unprognostic (4.90e-2)" "unprognostic (2.19e-3)" "unprognostic (3.92e-3)" "unprognostic (4.46e-1)" "unprognostic (1.30e-2)" "unprognostic (2.58e-2)" 32.8 10.5 56.5 60.2 67.8 161.1 51.1 57.1 59.8 36.6 76.6 95.9 97.2 29.0 12.5 140.6 32.7 31.7 492.6 47.2 55.0 208.3 274.7 32.0 77.1 61.0 61.3 13.6 128.7 104.0 15.5 87.3 54.4 76.2 84.1 5.4 163.1 90.4 1302.3 61.8 84.3 79.8 52.9 36.8 175.7 5.3 71.6 148.7 16.0 1611.3 66.0 53.3 49.4 57.6 61.3 33.5 169.9 169.8 23.3 28.3 144.5 74.5 110.8 68.0 72.6 16.1 51.1 72.7 21.0 61.2 65.1 20.8 25.1 22.4 32.0 143.8 16.9 122.9 12.7 119.7 28.1 85.1 118.2 59.7 12.7 16.3 13.0 82.1 141.0 246.4 18.9 59.3 53.0 175.3 425.0 131.2 51.8 81.9 14.3 352.0 122.4 213.7 105.6 71.3 244.5 125.3 92.1 359.8 29.9 94.2 290.9 256.9 34.0 120.4 17.0 16.1 34.9 101.5 20.5 9.0 38.4 175.0 71.2 45.0 112.8 75.6 105.9 199.1 53.2 70.1 77.0 120.1 136.9 47.7 42.9 71.8 22.9 99.9 252.1 79.4 72.4 163.4 56.5 67.8 57.1 59.8 47.2 55.0 61.0 61.3 54.4 52.9 71.6 57.6 16.9 6.4 21.0 40.1 64.2 39.9 98.8 91.6 12.5 6.2 90.5 48.1 445.9 114.4 95.8 75.4 10.4 732.5 84.0 70.0 1168.0 252.8 5.6 96.4 25.7 41.6 61.7 193.8 11.8 288.8 586.7 44.7 88.2 50.9 31.6 29.2 38.2 283.1 263.7 10.1 8.3 158.3 229.9 77.7 101.1 3.2 14.0 79.0 58.7 5.6 85.3 20.9 119.4 16.6 27.3 116.6 105.0 35.3 185.9 170.3 69.6 205.0 167.9 5.4 13.1 60.8 73.4 0.6 15.6 113.3 67.1 573.0 88.1 14.7 305.1 140.1 IDH3A ENSG00000166411 "Isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha" P50213 15 78131498-78171945 "Citric acid cycle related proteins, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Tricarboxylic acid cycle" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "tongue: 99.7" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "plasmacytoid DC: 144.4" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA041465, HPA062971" Supported Enhanced Mitochondria No No 110000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 8: Non-specific - Mitochondria" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Mitochondria "HPA041465: AB_10794377, HPA062971: AB_2684913" "unprognostic (2.33e-1)" "unprognostic (1.21e-1)" "unprognostic (5.76e-3)" "unprognostic (2.26e-1)" "unprognostic (1.02e-1)" "unprognostic (4.01e-1)" "unprognostic (2.29e-1)" "unprognostic (6.47e-2)" "unprognostic (1.69e-2)" "unprognostic (2.30e-1)" "unprognostic (3.05e-1)" "unprognostic (1.42e-1)" "prognostic favorable (6.49e-8)" "unprognostic (1.40e-1)" "unprognostic (3.08e-2)" "unprognostic (4.49e-2)" "unprognostic (3.39e-2)" 22.6 25.1 11.5 19.9 12.6 9.7 9.6 17.0 14.7 12.4 21.4 26.2 36.6 13.7 7.8 17.0 11.0 9.0 62.5 14.8 13.2 16.8 14.2 11.9 17.1 13.0 13.1 10.8 13.0 54.7 6.9 12.1 15.2 13.9 26.7 26.2 16.2 16.1 79.4 15.8 36.0 17.1 10.1 15.3 11.9 16.9 14.3 35.0 11.2 99.7 24.8 17.7 11.1 14.8 43.8 58.5 10.4 36.5 25.5 26.1 22.6 50.8 24.5 40.6 30.5 41.6 25.8 91.6 36.8 29.9 59.9 64.2 98.2 39.3 37.0 40.7 32.2 35.7 62.4 19.2 21.8 69.8 48.8 19.9 23.6 39.4 41.2 19.3 25.7 32.0 46.4 35.9 26.0 41.4 51.4 17.4 12.9 25.2 21.8 29.3 44.4 28.1 33.4 58.3 41.4 15.8 58.2 82.1 47.1 19.1 32.7 37.4 26.4 47.6 43.9 63.1 83.1 41.5 99.9 48.8 33.2 64.9 37.7 16.9 27.9 8.3 15.1 52.9 16.4 27.7 14.7 13.5 43.5 32.6 15.2 16.4 15.5 17.3 54.8 144.4 17.7 23.2 11.5 12.6 17.0 14.7 14.8 13.2 13.0 13.1 15.2 10.1 14.3 14.8 18.0 9.6 16.5 22.9 30.6 56.0 58.7 51.4 33.0 35.1 10.9 12.6 17.5 14.3 22.6 25.8 37.5 38.3 63.0 69.0 82.2 26.1 52.2 19.9 13.4 17.5 19.2 9.4 45.9 17.9 40.4 21.2 11.7 9.2 27.3 14.5 10.8 22.4 26.5 26.9 53.3 37.6 69.2 24.9 28.6 23.4 20.8 26.4 26.6 12.2 16.0 29.3 12.3 19.6 17.9 21.5 37.9 23.7 33.2 40.6 49.6 48.1 38.2 34.6 13.1 23.8 25.5 45.7 26.2 28.4 41.2 68.4 17.7 37.2 56.0 42.0 IFNAR2 IFNABR ENSG00000159110 "Interferon alpha and beta receptor subunit 2" P48551 21 33229901-33265675 "Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Plasma cells: 188.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Karpas-707: 211.2;U-266/70: 261.6;U-266/84: 145.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "Secreted to blood" NA NA 1500000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 16: Immune cells - Immune response" "Cluster 29: U-266 - Adaptive immune response" "Cluster 55: Plasma cells - Humoral immune response" "unprognostic (2.00e-2)" "unprognostic (7.83e-3)" "unprognostic (4.98e-2)" "unprognostic (1.22e-2)" "unprognostic (1.09e-2)" "unprognostic (1.04e-1)" "unprognostic (4.50e-3)" "unprognostic (8.05e-2)" "unprognostic (4.17e-2)" "unprognostic (2.11e-2)" "unprognostic (7.65e-2)" "unprognostic (4.42e-1)" "prognostic unfavorable (7.54e-7)" "unprognostic (9.70e-3)" "unprognostic (2.39e-1)" "unprognostic (5.12e-3)" "unprognostic (1.85e-2)" 21.3 9.0 13.2 33.2 13.6 29.1 16.4 11.5 14.8 12.7 9.7 16.7 17.4 11.7 8.2 8.0 11.7 21.0 13.4 11.0 14.3 14.3 28.7 22.6 33.5 16.7 14.0 11.8 10.0 12.5 10.1 22.9 15.1 10.1 17.4 8.3 13.7 11.3 9.0 7.0 16.2 18.3 13.6 41.0 14.8 5.3 15.8 33.9 10.7 10.8 36.4 38.2 9.0 14.0 17.0 18.4 9.9 23.7 11.9 27.3 16.2 18.1 45.1 14.2 15.7 24.4 20.8 28.3 12.8 25.4 22.8 10.9 15.2 9.2 15.0 18.3 19.9 100.9 19.1 22.2 17.5 17.5 38.0 20.7 8.7 16.8 18.5 24.8 46.0 41.5 30.2 211.2 13.7 9.1 44.0 19.6 18.3 24.2 11.7 14.9 53.4 50.7 30.8 31.9 26.6 14.2 29.5 28.2 23.9 10.4 4.4 30.5 32.2 15.3 9.3 12.5 10.1 261.6 145.3 64.3 20.5 60.3 37.5 44.5 38.5 63.8 31.2 65.0 32.2 25.7 37.9 29.3 36.6 17.1 27.5 30.8 101.2 35.2 73.4 101.0 65.8 41.3 13.2 13.6 11.5 14.8 11.0 14.3 16.7 14.0 15.1 13.6 15.8 14.0 35.6 60.9 16.1 19.6 49.4 6.8 43.8 41.7 2.8 6.6 11.4 12.4 2.2 20.0 23.6 11.0 6.2 28.9 64.4 6.0 3.9 67.5 3.0 6.7 10.0 39.0 3.0 27.6 44.4 62.7 72.1 15.4 4.6 8.5 31.7 11.8 44.6 19.6 44.9 20.2 42.3 4.4 4.1 73.5 17.1 3.3 7.5 58.5 19.6 74.9 47.9 6.4 89.6 51.3 29.4 73.8 5.9 9.1 188.8 89.5 17.3 10.2 35.2 5.6 0.0 16.8 12.5 4.2 19.9 4.3 5.7 23.5 43.9 2.5 4.9 83.2 IFNG ENSG00000111537 "Interferon gamma" P01579 12 68154768-68159740 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Antiviral defense, Growth regulation" Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "bone marrow: 11.5;lymphoid tissue: 7.4" "Group enriched" "Detected in many" 12 "dendritic cells: 283.2;T-cells: 200.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "gdT-cell: 5.5;memory CD4 T-cell: 2.4;memory CD8 T-cell: 6.6;naive CD8 T-cell: 3.7" "Lineage enriched" "Detected in single" 7 "T-cells: 6.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" CAB010344 Approved "Secreted to blood" NA NA 1470 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 7: Non-specific - Mitochondria" "CAB010344: AB_2123447" "unprognostic (2.16e-4)" "unprognostic (1.93e-3)" "unprognostic (9.21e-2)" "unprognostic (1.04e-4)" "unprognostic (5.14e-1)" "unprognostic (3.96e-3)" "unprognostic (1.33e-1)" "unprognostic (3.17e-4)" "unprognostic (7.79e-2)" "unprognostic (7.97e-3)" "unprognostic (1.63e-2)" "unprognostic (5.36e-2)" "unprognostic (7.62e-9)" "unprognostic (3.54e-2)" "unprognostic (5.36e-1)" "unprognostic (6.32e-2)" "unprognostic (7.38e-3)" 0.7 0.7 0.1 3.5 0.2 11.5 0.3 0.0 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.5 0.2 0.0 0.0 0.3 1.5 1.8 7.4 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.3 0.3 0.0 0.9 0.2 0.0 0.0 0.3 0.2 0.0 1.3 0.4 0.1 0.1 0.5 0.3 0.0 0.6 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 2.4 6.6 0.0 0.4 0.5 3.7 0.1 0.9 0.0 0.0 0.1 0.9 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 7.7 0.0 0.0 0.0 3.1 3.2 1.3 0.0 0.0 0.0 4.8 5.5 0.2 1.5 0.0 0.0 0.0 0.0 283.2 0.1 0.0 0.0 0.2 1.0 1.1 1.3 0.0 0.4 0.0 0.0 0.0 1.5 6.1 1.1 0.0 0.0 1.4 1.2 0.1 0.0 0.0 0.5 0.0 4.4 5.5 0.0 0.0 10.4 7.2 0.0 0.0 0.0 19.6 0.0 0.1 0.0 1.1 0.0 10.9 0.2 0.0 0.3 0.0 0.0 0.0 1.0 2.9 0.0 0.0 0.8 4.0 0.0 200.1 0.0 0.2 0.2 IKBKB "IKK-beta, IKK2, IKKB, NFKBIKB" ENSG00000104365 "Inhibitor of nuclear factor kappa B kinase subunit beta" O14920 8 42271302-42332460 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Host-virus interaction" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease variant, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cone photoreceptor cells: 135.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001249, CAB004447" Enhanced Supported Cytosol NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 80: Striated muscle - Unknown function" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 9: Photoreceptor cells - Phototransduction" Cytosol "CAB004447: AB_627785, HPA001249: AB_1079126" "unprognostic (1.04e-1)" "unprognostic (2.30e-2)" "unprognostic (1.31e-1)" "unprognostic (1.73e-3)" "unprognostic (1.26e-1)" "unprognostic (1.27e-3)" "unprognostic (1.95e-1)" "unprognostic (1.25e-3)" "unprognostic (1.75e-1)" "unprognostic (1.55e-1)" "unprognostic (3.27e-1)" "unprognostic (1.73e-1)" "unprognostic (1.20e-2)" "unprognostic (1.89e-2)" "unprognostic (9.20e-2)" "unprognostic (3.02e-1)" "prognostic favorable (1.46e-6)" 9.4 8.2 9.1 4.7 9.8 4.8 8.3 9.2 10.9 7.2 11.7 6.8 4.8 8.1 7.3 10.2 11.6 8.6 5.6 9.2 9.5 6.8 6.6 11.3 12.2 10.5 9.9 6.1 6.2 13.5 4.0 8.2 10.0 7.9 6.8 12.3 8.9 9.3 13.7 11.4 4.9 12.7 9.7 10.5 5.5 3.2 10.1 10.8 9.4 24.3 11.6 11.1 6.8 10.2 6.2 15.7 8.0 13.6 17.3 18.9 5.8 9.2 18.2 15.2 17.2 3.1 13.9 14.1 10.0 16.5 12.5 5.6 8.4 18.3 17.8 9.8 10.8 17.8 7.8 5.9 20.9 6.1 24.0 12.3 13.7 15.0 19.1 36.1 20.7 11.6 12.8 6.9 34.6 5.1 13.9 11.3 6.1 18.9 6.0 11.1 15.3 10.0 19.6 5.7 1.3 4.7 6.4 6.4 11.7 10.0 8.7 23.6 13.6 7.2 3.9 13.9 6.1 2.8 4.0 10.3 13.8 7.6 16.7 7.4 5.0 5.6 4.6 4.1 4.3 4.4 5.1 5.5 3.7 4.8 4.8 4.7 5.2 5.1 5.5 8.5 5.9 2.9 9.1 9.8 9.2 10.9 9.2 9.5 10.5 9.9 10.0 9.7 10.1 10.2 31.3 12.8 26.9 19.2 28.4 24.3 34.1 13.9 25.6 12.7 20.6 15.5 8.8 14.3 15.4 16.5 135.5 10.4 34.1 15.9 1.9 13.4 2.3 13.9 15.6 27.4 11.4 10.1 19.7 13.6 5.3 12.4 21.9 16.5 38.0 24.0 19.6 12.0 18.6 18.5 20.6 16.4 8.2 32.3 24.0 3.4 16.4 23.4 19.6 58.1 33.7 8.7 47.4 17.1 30.2 16.6 15.0 12.8 18.2 31.9 13.2 5.5 20.2 47.9 6.6 13.1 11.4 4.8 7.0 17.8 29.1 15.2 24.3 6.2 14.1 30.8 IL1B "IL-1B, IL1-BETA, IL1F2" ENSG00000125538 "Interleukin 1 beta" P01584 2 112829751-112836816 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters" "Inflammatory response" "Cytokine, Mitogen, Pyrogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 201.7;urinary bladder: 126.2" "Group enriched" "Detected in many" 11 "Langerhans cells: 1451.9;Macrophages: 1510.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 5 "neutrophil: 94.1" "Lineage enriched" "Detected in many" 5 "granulocytes: 94.1" "Cell line enhanced" "Detected in many" "BJ hTERT+: 649.3;HBEC3-KT: 293.3;HMC-1: 235.1;hTEC/SVTERT24-B: 319.1;hTERT-RPE1: 277.0;U-87 MG: 571.5" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Secreted to blood" NA NA 2330 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 41: Macrophages - Immune response" "unprognostic (1.55e-3)" "prognostic unfavorable (1.31e-4)" "unprognostic (2.75e-2)" "unprognostic (5.71e-2)" "unprognostic (1.34e-1)" "unprognostic (7.12e-2)" "unprognostic (2.63e-2)" "unprognostic (1.61e-2)" "unprognostic (1.07e-1)" "unprognostic (3.63e-3)" "unprognostic (3.72e-2)" "unprognostic (5.57e-2)" "prognostic unfavorable (7.49e-5)" "unprognostic (1.29e-2)" "unprognostic (4.42e-2)" "unprognostic (5.09e-2)" "unprognostic (4.01e-2)" 43.9 7.6 2.5 53.6 2.2 201.7 2.0 3.1 4.6 3.7 4.2 8.1 3.0 7.4 2.0 3.4 4.1 19.0 3.3 2.3 3.4 7.7 9.1 17.4 9.5 4.8 4.6 0.8 4.4 3.0 2.6 7.8 3.8 6.1 6.5 0.3 3.8 1.8 0.1 0.7 3.5 9.2 4.4 17.8 25.5 1.1 2.8 9.4 2.6 7.0 12.8 126.2 1.0 6.6 6.3 0.1 0.2 0.0 0.4 0.0 0.0 2.1 649.3 3.1 6.5 0.0 0.0 0.0 18.0 0.5 11.3 14.7 0.0 293.3 39.2 0.0 0.0 29.5 0.4 0.0 2.2 0.0 235.1 1.1 8.9 319.1 103.5 277.0 0.0 0.1 0.0 0.8 0.6 0.0 0.0 2.9 0.1 1.2 26.2 1.0 0.0 0.0 0.0 48.2 0.0 0.0 1.7 0.0 2.5 0.0 0.0 2.8 0.0 15.3 0.2 0.7 0.5 0.1 0.0 0.2 571.5 14.0 22.7 1.7 12.3 4.4 0.0 19.5 0.0 0.0 0.0 0.0 19.5 0.0 0.0 0.0 94.1 0.2 7.7 0.0 0.0 3.4 2.5 2.2 3.1 4.6 2.3 3.4 4.8 4.6 3.8 4.4 2.8 6.6 23.8 9.6 28.2 0.0 14.1 30.8 5.4 25.4 0.0 0.2 8.2 13.3 4.8 0.0 16.2 1.8 0.0 1.5 7.5 2.8 0.0 33.2 0.3 4.9 5.0 20.0 0.0 58.9 0.0 0.6 2.6 8.1 44.4 8.4 41.7 0.0 1.4 0.4 108.1 0.0 0.0 12.7 14.2 130.5 1451.9 0.7 0.0 1510.7 23.2 1.9 7.9 0.3 0.0 0.0 0.0 2.9 10.0 0.0 9.3 4.7 0.2 0.7 8.6 0.3 0.0 1.5 4.3 0.0 0.4 8.3 20.3 4.4 6.3 0.0 1.9 6.1 IMPDH1 "LCA11, RP10, sWSS2608" ENSG00000106348 "Inosine monophosphate dehydrogenase 1" P20839 7 128392277-128410252 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "GMP biosynthesis, Purine biosynthesis" "DNA-binding, Oxidoreductase, RNA-binding" "Disease variant, FDA approved drug targets, Leber congenital amaurosis, Retinitis pigmentosa" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "retina: 106.2" "Cell type enhanced" "Detected in many" "Bipolar cells: 165.8;Cone photoreceptor cells: 141.8;Horizontal cells: 121.1;Rod photoreceptor cells: 205.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 5 "classical monocyte: 89.1;eosinophil: 89.1;intermediate monocyte: 104.5;myeloid DC: 59.9;neutrophil: 197.5;non-classical monocyte: 135.9" "Group enriched" "Detected in all" 5 "dendritic cells: 59.9;granulocytes: 197.5;monocytes: 135.9" "Cell line enhanced" "Detected in all" "SK-BR-3: 374.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA001400 Approved Supported "Cytosol,Rods & Rings" NA NA 17000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 79: Retina - Phototransduction" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 56: Bipolar cells - Visual perception" Cytosol "Rods & Rings" "HPA001400: AB_1079139" "unprognostic (2.84e-1)" "prognostic unfavorable (3.87e-4)" "unprognostic (2.23e-2)" "unprognostic (6.45e-2)" "prognostic unfavorable (7.31e-5)" "unprognostic (6.03e-2)" "prognostic unfavorable (1.12e-7)" "unprognostic (1.24e-1)" "unprognostic (7.45e-3)" "unprognostic (1.03e-2)" "unprognostic (1.79e-1)" "unprognostic (2.50e-1)" "prognostic unfavorable (1.78e-12)" "unprognostic (1.65e-1)" "unprognostic (1.19e-1)" "unprognostic (1.10e-1)" "prognostic unfavorable (3.72e-5)" 54.8 15.9 19.2 33.8 18.5 44.1 38.7 15.7 23.7 18.5 12.7 24.8 8.3 15.1 2.5 30.0 17.7 11.9 23.7 18.1 17.8 15.8 5.7 31.7 25.5 26.3 18.7 20.5 30.1 5.3 26.7 11.4 25.6 27.8 9.8 106.2 29.5 13.1 4.7 23.2 19.1 19.6 17.1 55.9 48.9 16.5 20.0 8.4 11.5 6.2 15.9 29.4 20.4 17.1 111.5 93.2 13.8 102.8 56.5 40.7 38.8 74.1 46.4 61.9 40.1 68.3 35.0 70.8 24.7 111.1 64.4 83.3 78.6 104.1 30.9 25.8 87.1 46.4 66.8 49.1 51.4 62.1 21.1 49.4 49.5 63.2 62.5 29.2 74.5 42.0 46.9 51.8 21.0 76.1 44.1 164.9 77.4 87.7 108.0 51.9 25.2 150.8 27.5 35.1 58.3 55.6 48.0 374.6 68.3 8.6 42.7 119.7 68.5 103.6 37.7 55.0 53.6 38.5 38.3 90.6 53.0 134.0 64.6 11.2 89.1 89.1 22.7 104.5 24.4 15.5 17.9 20.2 59.9 8.9 10.3 12.7 197.5 11.7 135.9 6.0 21.5 58.3 19.2 18.5 15.7 23.7 18.1 17.8 26.3 18.7 25.6 17.1 20.0 17.1 66.8 0.0 11.2 4.6 13.5 8.8 9.3 13.6 9.6 165.8 12.8 9.9 5.1 2.8 8.6 5.5 141.8 3.3 11.1 6.3 5.9 8.1 0.5 4.0 10.9 20.3 9.6 9.7 8.2 17.8 21.3 15.1 44.9 6.5 21.0 46.0 13.6 1.0 46.1 121.1 11.2 10.1 28.5 58.5 21.7 2.0 4.7 38.2 16.0 3.7 65.3 27.3 24.7 2.0 1.5 10.9 3.1 6.8 29.6 21.5 0.8 1.1 7.4 205.5 0.0 9.0 17.3 2.9 16.9 15.8 7.4 2.3 20.4 18.6 11.9 10.3 IMPDH2 ENSG00000178035 "Inosine monophosphate dehydrogenase 2" P12268 3 49024325-49029447 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "GMP biosynthesis, Purine biosynthesis" "DNA-binding, Oxidoreductase, RNA-binding" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001400, CAB020717" Approved Supported "Cytosol,Rods & Rings" NA NA 340000 "Cluster 30: Non-specific - Translation" "Cluster 50: Non-specific - Ribosome" "Cluster 30: Epithelial cell lines - Translation" "Cluster 10: Non-specific - Unknown function" Cytosol "Rods & Rings" "CAB020717: , HPA001400: AB_1079139" "unprognostic (2.09e-2)" "unprognostic (2.91e-1)" "unprognostic (5.96e-2)" "unprognostic (1.20e-1)" "unprognostic (7.31e-3)" "unprognostic (1.56e-1)" "prognostic unfavorable (3.22e-4)" "unprognostic (1.30e-1)" "unprognostic (2.65e-1)" "unprognostic (2.17e-1)" "unprognostic (5.44e-2)" "unprognostic (4.24e-2)" "unprognostic (1.30e-1)" "unprognostic (3.85e-1)" "unprognostic (5.80e-2)" "unprognostic (2.24e-1)" "unprognostic (4.47e-2)" 109.1 89.3 42.1 68.0 43.0 105.3 188.6 44.2 41.6 169.6 37.3 100.8 75.3 113.5 48.2 169.0 199.3 64.9 70.0 39.5 45.2 67.5 63.5 83.3 78.7 46.9 43.2 331.0 313.9 55.7 65.0 81.0 46.6 97.6 121.2 22.0 87.9 66.4 272.8 180.0 74.1 100.9 45.1 68.6 93.4 36.1 43.8 95.9 75.1 124.4 122.0 119.7 137.5 48.9 271.8 150.6 201.6 211.3 309.2 558.4 200.6 180.8 298.2 425.5 361.0 265.8 235.2 485.7 128.2 220.7 119.5 183.1 433.6 369.8 371.1 119.9 135.3 362.2 205.0 257.8 264.4 388.4 139.0 497.7 403.1 414.6 756.5 331.8 313.5 337.7 221.7 266.2 354.1 213.4 327.0 258.9 269.0 255.4 300.2 143.5 218.4 487.9 251.7 166.2 130.2 128.9 198.1 216.5 341.3 170.2 277.3 166.1 151.4 181.0 347.7 449.5 468.8 253.3 193.3 227.3 214.1 421.9 188.1 21.8 27.8 10.7 43.6 46.8 81.9 79.7 58.4 47.7 51.1 79.6 84.9 71.6 10.9 60.5 41.6 38.0 40.2 45.2 42.1 43.0 44.2 41.6 39.5 45.2 46.9 43.2 46.6 45.1 43.8 48.9 40.5 64.1 60.9 3.9 92.2 202.7 255.0 253.8 229.9 16.1 202.7 231.8 32.3 74.4 122.4 36.8 14.6 327.3 34.5 51.1 80.3 133.6 2.7 49.0 120.5 60.9 60.7 112.5 2.9 187.1 280.6 104.4 70.3 51.2 66.1 98.0 52.8 24.9 95.3 15.2 4.1 124.4 114.0 55.9 105.4 6.7 123.3 50.0 88.9 1.0 67.3 26.5 24.7 4.0 5.2 108.8 70.8 71.1 64.6 160.1 47.4 92.0 53.7 15.8 39.5 149.4 215.1 22.6 62.5 195.7 195.6 314.0 52.3 166.8 266.5 157.2 INSR CD220 ENSG00000171105 "Insulin receptor" P06213 19 7112255-7294414 "CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Carbohydrate metabolism" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Diabetes mellitus, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Group enriched" "Detected in many" 8 "dendritic cells: 9.8;granulocytes: 5.9;monocytes: 12.5" "Cell line enhanced" "Detected in many" "Karpas-707: 54.9;U-266/70: 40.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036302, HPA036303" Uncertain Approved "Vesicles,Plasma membrane" NA Yes 190000 "Cluster 31: Non-specific - Inflammatory response" "Cluster 22: Non-specific - Unknown function" "Cluster 2: Karpas-707 - Immune response" "Cluster 52: Non-specific - Transcription" Vesicles "Plasma membrane" "HPA036302: AB_2675048, HPA036303: " "unprognostic (4.64e-2)" "unprognostic (2.42e-1)" "unprognostic (9.65e-3)" "unprognostic (9.70e-2)" "unprognostic (1.44e-1)" "unprognostic (1.15e-2)" "unprognostic (2.58e-1)" "unprognostic (5.09e-2)" "unprognostic (1.97e-1)" "unprognostic (3.05e-1)" "unprognostic (9.29e-2)" "unprognostic (1.86e-1)" "unprognostic (6.33e-2)" "unprognostic (3.45e-3)" "unprognostic (2.43e-1)" "unprognostic (2.75e-1)" "unprognostic (8.82e-2)" 13.0 22.6 12.5 2.8 16.8 5.6 13.0 17.3 12.8 14.6 18.8 15.0 10.0 18.4 6.3 4.1 16.9 8.2 26.3 10.0 12.2 21.8 33.0 7.2 2.3 18.3 16.3 39.9 64.2 13.0 16.3 7.4 18.7 15.2 10.4 6.5 16.9 9.9 23.5 11.5 12.2 11.5 14.1 48.2 12.5 5.4 16.6 2.7 14.5 13.3 3.5 12.3 9.2 22.5 6.2 3.2 3.6 5.7 18.8 6.1 11.1 3.5 2.9 1.6 1.6 8.4 7.0 9.0 8.2 6.8 4.0 1.6 8.9 1.4 1.2 0.0 6.4 0.0 2.3 22.6 8.2 4.3 6.7 10.0 4.5 0.2 4.9 4.2 3.8 4.8 9.5 54.9 1.8 3.2 3.1 7.8 3.3 3.8 5.2 29.0 2.1 7.6 0.1 27.8 6.6 5.2 6.5 3.8 3.3 6.4 1.4 21.6 3.6 3.4 2.1 8.2 5.1 40.4 23.9 20.2 4.3 7.3 0.0 2.7 8.6 5.9 0.2 8.8 0.3 0.8 0.3 0.1 9.8 1.1 0.7 0.1 1.9 1.0 12.5 8.2 0.0 1.6 12.5 16.8 17.3 12.8 10.0 12.2 18.3 16.3 18.7 14.1 16.6 22.5 75.6 48.1 34.7 64.9 10.6 64.9 63.6 34.7 8.0 40.4 134.0 76.2 92.1 137.2 83.3 62.5 79.2 17.8 6.7 124.1 15.6 55.1 4.7 26.8 106.8 123.9 163.6 25.0 68.3 78.7 53.7 43.7 20.4 42.1 3.8 168.4 255.2 246.0 9.2 38.7 100.8 97.3 32.6 49.0 31.1 9.0 96.3 35.0 51.6 62.8 24.2 31.6 0.0 62.8 183.5 50.7 68.8 245.3 21.8 107.9 122.9 114.1 65.3 23.6 59.2 37.6 44.2 5.2 3.6 3.2 68.8 38.3 4.7 81.4 65.2 130.0 ITGA2B "CD41, CD41B, GP2B, PPP1R93" ENSG00000005961 "Integrin subunit alpha 2b" P08514 17 44372180-44389649 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Integrin, Receptor" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 16.6;epididymis: 10.7;lymphoid tissue: 11.2" "Cell type enhanced" "Detected in many" "Early spermatids: 16.1;Erythroid cells: 43.5;granulocytes: 17.8;Late spermatids: 24.8;Macrophages: 23.0" "Cancer enhanced" "Detected in some" "testis cancer: 2.1" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in some" 14 "basophil: 64.5" "Lineage enriched" "Detected in single" 75 "granulocytes: 64.5" "Group enriched" "Detected in some" 14 "HEL: 404.6;HMC-1: 631.7" "Not detected" "Not detected" "CAB018611, HPA031168, HPA031169, HPA031170, HPA031171" Enhanced Approved "Plasma membrane" NA NA 90000000 "Cluster 41: Basophils - Cellular respiration" "Cluster 76: Brain & Bone marrow - Chromatin organization" "Cluster 3: HMC-1 - Innate immune response" "Cluster 51: Myeloid cells - Hemostasis" "Plasma membrane" "CAB018611: AB_2265153, HPA031168: AB_10664706, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773" "unprognostic (6.11e-2)" "unprognostic (3.23e-2)" "unprognostic (1.23e-1)" "unprognostic (4.85e-2)" "unprognostic (1.59e-2)" "unprognostic (3.98e-3)" "unprognostic (4.23e-5)" "unprognostic (1.25e-1)" "unprognostic (1.33e-2)" "unprognostic (7.22e-2)" "unprognostic (2.97e-3)" "unprognostic (1.30e-1)" "unprognostic (8.83e-9)" "unprognostic (7.82e-2)" "unprognostic (1.85e-1)" "unprognostic (1.95e-1)" "unprognostic (2.25e-1)" 0.8 0.2 3.7 0.2 3.6 16.6 0.4 4.0 4.8 1.5 3.8 0.3 0.0 0.9 10.7 0.3 1.5 0.8 1.4 3.5 3.6 1.0 0.5 5.1 0.2 3.6 3.5 1.5 0.1 1.3 1.9 1.1 3.6 0.6 0.1 1.6 0.1 0.8 0.6 0.1 0.3 0.2 3.3 11.2 0.3 2.9 3.5 0.1 3.1 1.1 0.1 0.2 0.7 3.7 0.5 0.7 2.2 0.3 0.1 0.3 18.4 0.3 0.1 0.8 0.6 0.0 0.2 0.0 0.3 0.0 0.2 0.6 1.8 0.0 0.4 0.4 1.1 404.6 0.3 1.3 0.0 0.2 631.7 0.4 0.0 0.2 0.0 0.0 0.0 0.3 0.7 1.1 0.0 0.7 0.5 36.4 0.8 0.0 0.7 0.7 0.2 0.0 0.0 0.1 0.4 1.0 0.5 0.5 0.1 1.5 4.5 0.9 0.3 0.2 0.7 0.0 0.0 0.4 0.2 0.3 0.4 0.3 0.8 64.5 0.3 4.0 0.1 0.0 0.3 0.0 0.0 0.0 0.5 0.1 0.0 0.0 4.5 0.0 0.0 0.8 0.0 19.3 3.7 3.6 4.0 4.8 3.5 3.6 3.6 3.5 3.6 3.3 3.5 3.7 0.3 0.0 1.5 1.0 0.4 0.3 0.4 0.1 1.8 5.1 0.2 1.1 1.5 1.5 1.3 5.5 8.4 1.3 0.1 0.6 0.0 0.0 16.1 1.0 0.7 2.1 0.0 43.5 4.1 0.0 1.4 1.1 0.0 3.2 17.8 0.1 3.6 0.0 0.2 3.3 2.8 0.0 0.0 3.1 0.7 24.8 1.8 23.0 0.0 1.0 2.9 1.3 0.0 9.5 4.6 0.1 0.0 1.9 0.1 0.3 0.0 0.0 0.0 3.0 0.0 1.8 0.7 3.4 7.4 0.5 0.0 0.7 0.6 0.1 0.3 0.3 ITGAL "CD11A, LFA-1" ENSG00000005844 "Integrin subunit alpha L" P20701 16 30472658-30523567 "CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction, Phagocytosis" "Integrin, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 36.8;lymphoid tissue: 64.9" "Cell type enhanced" "Detected in many" "dendritic cells: 118.6;monocytes: 36.8;NK-cells: 152.4;Plasma cells: 46.6;T-cells: 84.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in all" "non-classical monocyte: 121.7" "Low lineage specificity" "Detected in all" "Cell line enriched" "Detected in some" 5 "HMC-1: 608.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB025011 Enhanced NA NA 1600000 "Cluster 51: Monocytes - Innate immune response" "Cluster 16: Immune cells - Immune response" "Cluster 3: HMC-1 - Innate immune response" "Cluster 63: NK-cells & T-cells - Immune response" "CAB025011: " "unprognostic (1.10e-2)" "unprognostic (4.26e-3)" "unprognostic (3.72e-3)" "prognostic favorable (5.63e-5)" "unprognostic (2.88e-1)" "prognostic favorable (3.34e-4)" "unprognostic (1.63e-1)" "unprognostic (5.69e-3)" "prognostic favorable (5.57e-4)" "unprognostic (3.37e-2)" "unprognostic (4.98e-2)" "unprognostic (1.84e-1)" "prognostic unfavorable (2.69e-5)" "unprognostic (2.89e-1)" "unprognostic (3.05e-2)" "unprognostic (1.39e-1)" "unprognostic (1.71e-2)" 4.2 1.4 0.3 36.7 0.5 36.8 2.3 0.3 1.0 2.4 0.5 5.5 6.0 2.3 1.0 2.5 3.0 7.0 1.4 0.3 0.4 2.6 10.6 22.0 62.4 1.6 1.1 1.3 1.0 0.5 1.2 3.0 1.4 2.4 8.6 0.0 5.3 1.4 0.9 1.4 19.7 3.6 0.7 64.9 8.6 1.0 1.6 55.2 3.5 0.9 46.4 6.9 2.3 2.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 32.8 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.9 0.0 1.7 0.0 0.1 0.0 1.1 608.0 0.0 0.0 0.1 0.0 0.0 0.0 5.6 0.0 134.3 0.0 0.0 43.3 3.5 0.0 0.0 0.0 0.1 0.0 9.7 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.4 26.0 0.0 0.0 0.0 0.0 0.0 36.6 12.5 0.0 0.1 3.8 0.0 5.3 24.4 17.0 56.6 48.0 27.7 4.8 21.4 42.7 22.3 1.7 9.4 29.7 14.3 24.2 121.7 6.0 15.6 43.6 0.3 0.5 0.3 1.0 0.3 0.4 1.6 1.1 1.4 0.7 1.6 2.1 1.2 6.4 10.5 0.7 19.1 0.8 0.3 0.0 0.0 0.4 1.2 1.0 1.9 0.0 1.9 1.8 0.0 0.2 118.6 0.3 0.0 0.1 0.5 4.1 0.6 2.3 0.0 4.8 3.6 0.0 0.6 1.4 1.1 0.9 5.1 0.1 5.3 4.9 19.3 0.0 2.8 0.2 0.0 30.0 3.4 0.7 0.0 31.5 1.8 15.9 36.8 0.1 152.4 0.5 1.6 0.0 0.0 0.0 46.6 0.1 0.9 0.3 6.7 0.9 0.0 1.2 0.7 0.2 0.2 0.1 0.3 0.7 84.9 0.1 0.0 0.2 ITGAV "CD51, MSK8, VNRA, VTNR" ENSG00000138448 "Integrin subunit alpha V" P06756 2 186590056-186680901 "Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in some" 6 "basophil: 6.2" "Lineage enriched" "Detected in many" 6 "granulocytes: 6.2" "Cell line enhanced" "Detected in many" "RT4: 369.7;SuSa: 297.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002499, HPA004856" Supported Approved "Focal adhesion sites,Cytosol" NA NA 2000000 "Cluster 34: Basophils - Unknown function" "Cluster 57: Non-specific - Angiogenesis" "Cluster 15: RT4 - Unknown function" "Cluster 44: Endometrium - Transcription" "Focal adhesion sites, Cytosol" "CAB002499: AB_563594, HPA004856: AB_1846316" "unprognostic (4.03e-2)" "unprognostic (5.17e-3)" "unprognostic (1.22e-2)" "unprognostic (5.22e-2)" "unprognostic (1.33e-1)" "unprognostic (1.18e-1)" "prognostic unfavorable (2.08e-4)" "unprognostic (1.48e-2)" "unprognostic (6.95e-2)" "unprognostic (2.89e-1)" "prognostic unfavorable (5.07e-4)" "unprognostic (5.84e-2)" "unprognostic (2.67e-2)" "prognostic unfavorable (1.05e-6)" "unprognostic (2.61e-1)" "unprognostic (9.11e-2)" "unprognostic (8.07e-2)" 39.9 38.7 20.1 36.5 30.8 6.4 27.7 39.7 23.5 39.7 40.3 20.1 15.9 36.8 10.5 24.5 26.3 47.3 80.0 18.2 32.7 52.1 18.0 25.7 15.8 42.5 33.0 64.7 25.7 82.7 11.9 47.4 46.4 29.8 21.6 80.4 32.1 28.1 16.3 41.4 16.3 56.7 45.3 21.4 34.2 14.7 30.2 18.0 62.6 30.5 21.6 43.1 16.0 54.6 49.1 57.5 37.4 119.9 134.1 90.0 141.7 93.8 75.5 32.5 32.5 50.7 164.0 0.4 179.7 106.3 113.4 60.2 19.3 88.5 46.7 9.7 17.2 11.7 69.1 69.6 52.8 8.3 7.0 65.8 41.3 72.7 61.1 194.1 78.7 5.9 11.6 23.9 87.4 19.4 5.0 6.8 28.3 29.1 28.5 0.1 76.2 6.8 83.5 369.7 7.7 23.0 108.6 33.2 40.1 297.0 26.2 22.4 240.5 199.4 61.9 41.4 80.3 5.9 10.4 5.5 80.3 3.3 100.6 6.2 0.6 0.9 0.4 1.1 0.3 0.1 0.2 0.4 0.4 0.0 0.2 0.2 0.2 0.2 0.6 0.2 0.6 0.2 20.1 30.8 39.7 23.5 18.2 32.7 42.5 33.0 46.4 45.3 30.2 54.6 39.8 28.9 22.9 134.8 4.9 128.4 64.0 127.7 42.7 118.4 50.4 23.4 145.5 80.1 35.3 77.3 77.2 55.1 9.4 32.4 1.9 78.7 0.6 61.7 61.1 47.2 7.3 2.1 36.3 101.8 26.9 65.4 57.6 100.2 49.5 21.2 27.8 18.2 27.6 15.2 35.9 19.9 14.2 44.3 56.7 3.1 19.3 29.3 46.2 75.9 17.4 70.9 2.1 184.5 156.1 165.9 23.8 25.9 9.2 103.4 11.2 32.4 27.0 60.2 32.9 29.0 63.3 1.7 2.4 27.7 103.7 39.7 10.9 18.1 15.5 77.7 ITGB3 "CD61, GP3A, GPIIIa" ENSG00000259207 "Integrin subunit beta 3" P05106 17 47253827-47313743 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion, Host-virus interaction" "Host cell receptor for virus entry, Integrin, Receptor" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "thyroid gland: 51.4" "Cell type enhanced" "Detected in some" "Early spermatids: 3.9;Late spermatids: 8.8;Macrophages: 15.8;Proximal tubular cells: 4.6;Sertoli cells: 6.6" "Group enriched" "Detected in many" 6 "melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 19 "basophil: 5.4;neutrophil: 2.5" "Lineage enriched" "Detected in single" 26 "granulocytes: 5.4" "Cell line enhanced" "Detected in many" "EFO-21: 167.8;HEL: 163.4;RPTEC TERT1: 109.8;U-87 MG: 78.3;WM-115: 255.9" HPA027852 Approved Supported "Nucleoplasm,Plasma membrane" "Intracellular and membrane" NA NA 38000000 "Cluster 34: Basophils - Unknown function" "Cluster 1: Thyroid gland - Transcription" "Cluster 17: WM-115 - Nervous system development" "Cluster 51: Myeloid cells - Hemostasis" "Plasma membrane" Nucleoplasm "HPA027852: AB_10601760" "unprognostic (1.13e-2)" "unprognostic (1.97e-3)" "unprognostic (2.47e-1)" "unprognostic (3.00e-2)" "unprognostic (1.91e-2)" "unprognostic (6.04e-3)" "unprognostic (3.70e-1)" "unprognostic (3.00e-1)" "unprognostic (1.44e-1)" "unprognostic (3.85e-1)" "unprognostic (6.35e-2)" "unprognostic (7.22e-2)" "unprognostic (1.36e-1)" "unprognostic (1.03e-2)" "unprognostic (2.72e-2)" "unprognostic (1.48e-1)" "unprognostic (1.17e-3)" 8.0 0.6 0.3 9.5 0.7 6.2 5.3 0.7 1.0 3.8 1.0 16.9 3.5 13.2 2.6 4.2 7.6 3.5 5.5 0.5 0.8 15.0 3.4 5.6 0.9 2.3 1.0 1.5 0.7 1.2 1.2 4.5 2.0 4.8 7.0 0.9 2.6 16.1 1.5 2.7 5.8 22.9 1.2 2.9 3.8 2.5 1.2 0.3 51.4 2.4 1.2 9.6 2.6 1.1 0.1 1.5 0.7 0.1 8.6 3.8 0.1 4.7 23.1 9.6 8.6 0.3 0.1 0.6 167.8 1.2 13.4 0.0 0.1 0.0 12.6 3.4 0.0 163.4 0.5 0.0 7.8 0.0 0.2 3.4 0.0 54.6 1.4 6.7 43.6 2.5 0.5 0.3 2.1 0.0 1.0 0.1 0.1 0.0 0.8 0.0 4.2 0.0 109.8 0.2 0.0 0.5 5.6 0.0 33.2 8.8 0.1 0.2 47.1 2.1 2.4 1.3 11.7 0.2 0.1 1.1 78.3 0.0 255.9 5.4 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 2.5 0.1 0.1 0.1 0.0 6.8 0.3 0.7 0.7 1.0 0.5 0.8 2.3 1.0 2.0 1.2 1.2 1.1 1.3 0.0 0.0 0.0 0.5 0.1 0.2 0.9 0.0 0.0 0.1 0.3 0.8 0.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 1.1 3.9 0.8 0.9 3.1 0.0 0.0 0.4 0.4 0.0 2.1 0.0 0.9 0.0 0.6 1.8 0.7 0.8 0.0 0.6 0.0 0.0 0.3 0.7 8.8 0.3 15.8 0.0 1.0 0.4 0.0 0.0 0.0 0.4 1.5 0.0 1.2 0.0 0.3 0.0 4.6 0.2 0.0 6.6 0.3 2.1 0.0 2.0 0.1 0.4 1.2 0.3 0.4 0.0 0.2 JAK1 "JAK1A, JAK1B, JTK3" ENSG00000162434 "Janus kinase 1" P23458 1 64833229-65067754 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "NK-cells: 700.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 336.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB013088 Approved NA NA "Cluster 48: NK-cells - Unknown function" "Cluster 16: Immune cells - Immune response" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 63: NK-cells & T-cells - Immune response" "CAB013088: " "prognostic favorable (9.63e-4)" "unprognostic (1.24e-1)" "prognostic favorable (2.81e-4)" "unprognostic (5.10e-2)" "unprognostic (1.16e-1)" "unprognostic (4.21e-2)" "unprognostic (1.53e-1)" "unprognostic (7.00e-3)" "unprognostic (8.40e-2)" "unprognostic (7.88e-3)" "unprognostic (1.66e-2)" "unprognostic (8.84e-2)" "prognostic favorable (2.67e-4)" "unprognostic (2.35e-1)" "unprognostic (2.04e-1)" "unprognostic (7.30e-2)" "unprognostic (3.51e-1)" 99.6 38.2 44.8 73.9 42.6 51.4 60.7 46.7 45.4 58.2 61.7 50.5 33.9 56.7 60.8 38.7 40.7 64.2 49.5 46.0 53.9 55.4 86.6 62.1 110.1 56.0 47.0 77.1 46.7 55.0 35.6 57.0 49.1 42.2 54.5 41.7 34.2 55.2 83.4 79.2 50.8 64.2 44.0 88.3 49.5 46.8 59.8 103.8 45.0 118.6 101.7 81.2 39.3 45.5 50.4 66.2 27.7 3.0 336.8 177.2 35.1 76.3 116.1 64.6 75.7 21.4 27.7 76.5 59.1 142.8 118.7 27.8 19.4 63.6 93.8 102.7 29.5 104.0 32.1 56.2 126.6 40.2 68.4 159.9 92.6 97.2 103.0 78.4 208.7 37.0 37.9 78.9 80.1 31.2 22.3 39.6 18.6 65.3 37.4 30.5 77.8 28.5 213.8 84.9 19.8 57.9 107.4 51.6 52.9 56.6 104.3 28.6 180.8 74.7 34.1 174.2 42.0 47.7 23.6 60.4 70.5 57.9 34.1 162.4 52.1 146.8 94.0 66.3 105.7 89.1 90.2 100.7 69.4 73.1 97.0 80.6 177.9 305.4 76.2 55.0 117.1 130.8 44.8 42.6 46.7 45.4 46.0 53.9 56.0 47.0 49.1 44.0 59.8 45.5 211.2 51.3 94.9 62.3 219.8 116.6 150.7 91.3 78.0 37.0 66.2 71.6 112.8 87.2 84.2 112.2 22.9 9.0 345.0 89.2 43.0 171.3 125.2 90.1 167.0 183.0 66.4 52.8 59.6 213.8 105.2 131.9 91.3 151.2 57.0 48.7 174.2 91.4 58.5 21.9 85.3 62.0 69.2 160.2 148.9 101.7 96.0 177.9 49.8 80.6 234.8 53.5 700.3 61.3 42.7 217.5 58.6 84.7 175.2 183.8 53.7 79.0 61.9 38.6 164.3 70.6 191.8 40.8 53.1 71.2 166.1 12.2 256.0 95.7 47.6 200.1 JAK2 JTK10 ENSG00000096968 "Janus kinase 2" O60674 9 4984390-5129948 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Excitatory neurons: 93.4;Inhibitory neurons: 122.3;Microglial cells: 106.8;Oligodendrocyte precursor cells: 69.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "basophil: 132.5" "Lineage enriched" "Detected in all" 5 "granulocytes: 132.5" "Group enriched" "Detected in many" 5 "ASC diff: 42.2;HDLM-2: 75.0;HEL: 154.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013089, HPA040820, HPA043870" Approved Supported "Nucleoplasm,Plasma membrane,Focal adhesion sites" No No "Cluster 46: Basophils - DNA binding" "Cluster 16: Immune cells - Immune response" "Cluster 36: HEL - Hemostasis" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Nucleoplasm "Plasma membrane, Focal adhesion sites" "CAB013089: AB_2533647, HPA040820: AB_2677151, HPA043870: AB_2678708" "unprognostic (2.24e-3)" "unprognostic (2.76e-2)" "unprognostic (1.50e-2)" "unprognostic (7.67e-2)" "unprognostic (5.50e-2)" "unprognostic (3.09e-2)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (1.09e-1)" "unprognostic (5.49e-3)" "unprognostic (1.58e-1)" "unprognostic (1.72e-2)" "unprognostic (3.85e-1)" "unprognostic (4.53e-2)" "unprognostic (3.43e-2)" "unprognostic (1.96e-1)" "unprognostic (7.37e-3)" 15.6 7.6 3.2 19.2 3.7 21.7 8.9 6.3 9.1 8.5 1.1 6.7 6.5 11.3 8.6 8.8 8.0 10.5 24.5 2.7 3.1 6.8 4.5 10.9 18.2 3.3 1.8 11.5 3.8 6.5 2.9 11.0 2.0 6.8 6.5 12.8 4.0 6.2 9.8 11.2 7.7 9.5 3.5 17.6 13.4 9.8 1.7 7.5 4.8 8.9 12.7 11.7 9.1 3.9 6.8 3.7 3.7 6.3 42.2 12.4 1.1 9.1 8.6 7.2 4.6 1.2 2.0 0.3 2.1 5.4 5.4 2.3 4.4 5.1 4.9 75.0 1.4 154.7 7.6 1.7 10.0 10.5 7.1 9.5 2.1 2.8 4.5 7.6 6.6 5.1 10.9 17.4 11.6 2.2 2.9 12.8 3.3 3.3 4.3 5.1 8.2 2.2 4.7 3.5 4.2 2.4 2.6 3.5 2.8 3.6 2.0 15.4 13.1 10.2 3.6 10.7 6.4 3.1 6.4 1.5 13.6 4.7 5.3 132.5 20.5 38.2 5.6 20.1 4.5 5.6 4.1 3.1 26.5 4.9 2.2 2.8 19.2 9.6 16.4 9.7 4.5 7.7 3.2 3.7 6.3 9.1 2.7 3.1 3.3 1.8 2.0 3.5 1.7 3.9 14.3 16.0 7.9 31.6 12.9 9.7 3.3 4.9 10.8 8.0 5.2 3.4 30.0 0.0 6.7 7.3 8.4 1.9 13.9 11.7 1.9 3.3 8.6 5.1 11.2 9.4 3.0 19.8 93.4 3.9 0.9 8.9 38.7 5.6 14.0 11.4 4.6 1.9 14.2 8.4 122.3 4.5 0.0 33.6 28.8 7.1 23.6 38.9 5.4 106.8 49.5 12.6 8.2 69.9 42.3 7.0 20.9 33.4 10.7 3.0 3.9 3.3 7.1 11.2 0.0 9.7 12.5 15.0 5.5 11.6 8.4 3.4 10.4 5.1 4.1 4.5 JAK3 "JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK" ENSG00000105639 "Janus kinase 3" P52333 19 17824780-17848071 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Adaptive immunity, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, SCID" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 55.1" "Cell type enhanced" "Detected in many" "B-cells: 27.8;dendritic cells: 20.1;Macrophages: 17.9;NK-cells: 18.6;Plasma cells: 18.4;T-cells: 37.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HDLM-2: 35.7;HEL: 15.9;HMC-1: 15.5;Karpas-707: 40.2;U-266/70: 15.4;U-266/84: 24.7;U-937: 24.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA070314 Enhanced Approved "Plasma membrane,Cytosol" NA NA "Cluster 39: Non-specific - mRNA processing" "Cluster 2: Immune cells - Immune response" "Cluster 2: Karpas-707 - Immune response" "Cluster 58: T-cells - T-cell receptor" "Plasma membrane, Cytosol" "HPA070314: AB_2686251" "unprognostic (5.59e-3)" "prognostic favorable (6.42e-5)" "unprognostic (5.71e-2)" "unprognostic (2.34e-1)" "unprognostic (6.13e-3)" "unprognostic (1.11e-3)" "unprognostic (4.21e-2)" "unprognostic (2.60e-1)" "unprognostic (2.38e-2)" "unprognostic (2.36e-1)" "unprognostic (3.58e-2)" "unprognostic (1.94e-1)" "prognostic unfavorable (2.89e-14)" "unprognostic (2.28e-1)" "unprognostic (2.21e-2)" "unprognostic (4.43e-2)" "unprognostic (7.61e-2)" 6.7 2.5 4.0 36.3 4.4 18.6 4.0 3.9 5.6 3.3 3.7 4.0 3.0 2.2 2.4 2.8 5.3 4.8 3.2 4.1 6.7 6.2 2.9 13.1 40.5 7.3 6.1 15.5 1.8 1.9 3.1 5.7 6.4 4.4 3.1 0.6 3.5 1.9 0.7 1.7 15.4 3.5 5.5 55.1 4.6 2.6 6.6 11.3 4.9 0.9 29.7 7.4 3.1 6.1 0.2 0.6 0.5 1.8 0.6 2.4 0.4 0.8 0.0 0.1 0.1 0.0 1.6 0.7 3.3 0.7 0.4 0.2 0.0 0.4 0.0 35.7 0.0 15.9 0.1 1.5 1.2 0.0 15.5 8.4 0.5 0.1 0.0 0.1 0.3 3.6 0.1 40.2 0.0 0.7 6.5 0.0 0.3 0.9 1.3 8.2 0.0 0.7 0.8 0.0 0.0 0.6 0.2 0.4 0.1 0.2 3.5 2.4 0.7 0.0 0.7 0.0 0.0 15.4 24.7 4.3 0.1 24.2 0.3 2.0 7.5 0.3 17.8 14.6 20.2 9.4 21.1 18.6 6.8 10.3 20.2 18.5 25.1 13.4 14.2 5.5 18.0 12.4 4.0 4.4 3.9 5.6 4.1 6.7 7.3 6.1 6.4 5.5 6.6 6.1 5.5 0.0 4.6 2.3 27.8 0.8 0.6 0.5 0.6 0.6 0.5 0.8 1.9 0.0 1.0 1.8 0.0 1.1 20.1 0.0 0.0 0.5 1.0 0.3 2.1 8.0 0.0 6.1 4.3 0.4 0.8 4.6 2.0 0.4 5.1 0.8 9.7 0.4 14.5 0.0 2.6 0.0 0.0 9.2 1.9 2.0 12.5 17.9 3.6 4.7 16.6 0.9 18.6 0.0 0.4 0.5 0.0 14.7 18.4 0.5 0.0 0.3 0.9 0.7 6.6 0.3 2.9 0.3 0.7 0.3 1.0 1.4 37.7 14.8 0.1 0.6 JUN "AP-1, c-Jun" ENSG00000177606 "Jun proto-oncogene, AP-1 transcription factor subunit" P05412 1 58776845-58784048 "Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "RH-30: 295.6" "Low region specificity" "Detected in all" "CAB003801, CAB007780, HPA031174, HPA059474" Enhanced Enhanced Nucleoplasm Yes No "Cluster 21: B-cells - Adaptive immune response" "Cluster 82: Adipose tissue - ECM organization" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 7: Non-specific - Mitochondria" Nucleoplasm "CAB003801: AB_365485, CAB007780: AB_562268, HPA031174: , HPA059474: AB_2684030" "unprognostic (2.06e-2)" "unprognostic (1.76e-2)" "unprognostic (1.34e-1)" "unprognostic (7.85e-2)" "unprognostic (1.60e-1)" "unprognostic (1.70e-1)" "unprognostic (4.11e-2)" "unprognostic (5.21e-2)" "unprognostic (1.24e-1)" "unprognostic (5.00e-2)" "unprognostic (2.14e-1)" "unprognostic (2.82e-1)" "unprognostic (5.15e-2)" "unprognostic (1.45e-1)" "unprognostic (2.83e-1)" "unprognostic (2.37e-1)" "unprognostic (2.81e-3)" 331.1 92.7 34.4 36.3 37.0 129.1 308.2 41.6 38.1 172.0 28.0 154.7 34.7 116.4 15.8 100.2 314.1 89.6 158.4 39.1 37.2 94.0 205.2 202.8 52.1 32.7 30.7 197.0 192.2 59.8 75.0 40.1 30.5 153.4 55.0 29.7 154.5 71.7 114.3 286.6 79.1 113.3 34.3 62.0 239.5 20.2 33.8 71.5 189.5 158.8 5.4 156.4 164.5 36.9 49.8 2.8 22.4 2.6 35.3 40.0 0.2 69.4 27.0 57.1 34.3 10.1 3.5 1.7 23.8 57.4 133.6 12.9 2.0 27.7 40.6 29.8 128.9 0.5 1.9 16.9 29.4 5.3 10.2 42.0 74.0 78.1 34.0 27.7 47.2 2.4 15.6 29.6 24.9 8.0 2.5 32.5 13.5 34.6 32.2 1.1 295.6 7.0 60.7 5.8 43.7 12.8 49.9 62.3 26.4 24.5 17.2 3.0 61.6 127.5 37.3 35.3 96.8 37.9 9.8 4.4 133.9 8.4 35.2 0.0 0.2 0.0 0.2 0.0 0.0 0.3 0.2 0.0 0.0 0.6 0.0 0.1 0.2 0.6 0.0 0.0 0.0 0.0 34.4 37.0 41.6 38.1 39.1 37.2 32.7 30.7 30.5 34.3 33.8 36.9 2721.4 538.5 543.8 187.7 1018.8 1235.5 2850.5 772.6 2825.1 103.4 1647.1 2067.3 1487.5 1315.4 449.3 104.8 262.7 675.8 651.1 1653.6 50.9 987.0 49.3 1337.1 2845.2 1443.8 1497.4 174.3 12.2 516.4 93.9 2730.7 2663.1 1822.2 541.9 333.4 737.2 158.6 650.5 87.5 4.9 1909.1 836.2 584.9 632.0 48.2 1227.4 1034.9 757.7 65.6 140.1 1234.2 8.2 17.6 10.0 562.8 1529.6 258.8 1540.3 1489.1 1654.1 48.6 216.3 453.5 1538.3 1892.9 2392.5 17.4 20.9 2146.3 964.4 415.6 1065.5 846.5 1199.5 545.7 KCNA1 "AEMK, HUK1, Kv1.1, MBK1, RBK1" ENSG00000111262 "Potassium voltage-gated channel subfamily A member 1" Q09470 12 4909905-4918256 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 13 "brain: 50.1" "Group enriched" "Detected in some" 6 "Bipolar cells: 15.1;Excitatory neurons: 39.6;Inhibitory neurons: 18.6;Oligodendrocyte precursor cells: 16.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "SCLC-21H: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA074471 Approved NA NA "Cluster 65: Brain - Ion transport" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA074471: " "unprognostic (6.39e-3)" "unprognostic (2.64e-1)" "unprognostic (1.09e-1)" "unprognostic (8.44e-2)" "unprognostic (1.33e-1)" "unprognostic (1.79e-2)" "unprognostic (4.69e-3)" "unprognostic (2.48e-1)" "unprognostic (8.77e-5)" "unprognostic (6.30e-2)" "unprognostic (1.08e-4)" 0.2 0.0 10.6 0.0 22.5 0.0 0.3 27.6 50.1 0.6 3.9 1.3 0.0 0.1 0.0 0.0 0.0 0.1 0.0 21.0 7.9 0.0 0.0 0.0 0.0 24.9 10.7 0.0 0.0 0.8 0.9 0.0 25.2 0.0 0.0 1.3 0.5 0.0 0.0 0.0 0.2 0.1 9.5 0.0 1.2 0.0 24.3 1.2 0.6 0.0 0.0 0.3 0.3 28.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.6 22.5 27.6 50.1 21.0 7.9 24.9 10.7 25.2 9.5 24.3 28.2 0.1 0.0 0.0 2.0 0.0 0.4 0.0 0.0 0.0 15.1 0.0 0.1 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 39.6 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 18.6 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 2.8 0.0 0.2 0.0 16.1 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 3.6 0.5 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KCNA10 Kv1.8 ENSG00000143105 "Potassium voltage-gated channel subfamily A member 10" Q16322 1 110517217-110519175 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA015061, CAB022564" Uncertain Nucleoplasm,Cytosol No NA "Nucleoplasm, Cytosol" "CAB022564: , HPA015061: AB_1855573" "unprognostic (2.96e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KCNA2 "HK4, Kv1.2" ENSG00000177301 "Potassium voltage-gated channel subfamily A member 2" P16389 1 110519837-110631474 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 8 "brain: 81.3" "Group enriched" "Detected in some" 4 "Astrocytes: 49.9;Excitatory neurons: 36.7;Inhibitory neurons: 37.1;Muller glia cells: 19.8;Oligodendrocyte precursor cells: 36.2" "Cancer enhanced" "Detected in some" "glioma: 1.2;testis cancer: 1.0" "Region enhanced" "Detected in many" "cerebral cortex: 81.3" "Immune cell enhanced" "Detected in single" "T-reg: 1.3" "Lineage enriched" "Detected in single" 8 "T-cells: 1.3" "Cell line enhanced" "Detected in some" "Karpas-707: 4.8;SCLC-21H: 1.4;U-2 OS: 1.2;U-266/70: 1.9;U-266/84: 3.1;WM-115: 1.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB001976 Enhanced NA NA "Cluster 35: T-regs - Unknown function" "Cluster 10: Brain - Neuronal signaling" "Cluster 2: Karpas-707 - Immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB001976: " "unprognostic (1.84e-2)" "unprognostic (9.70e-3)" "unprognostic (1.97e-1)" "unprognostic (2.98e-1)" "unprognostic (7.17e-3)" "unprognostic (6.68e-3)" "unprognostic (5.05e-3)" "unprognostic (2.02e-1)" "unprognostic (1.29e-1)" "unprognostic (4.50e-3)" "unprognostic (3.08e-3)" "unprognostic (2.93e-4)" "unprognostic (2.15e-1)" "unprognostic (3.55e-1)" "unprognostic (6.41e-2)" "unprognostic (2.83e-1)" 1.3 0.3 5.0 0.7 7.4 0.0 0.6 11.1 81.3 0.2 0.0 1.6 0.4 0.1 0.3 0.4 0.1 0.3 0.7 4.5 12.5 0.1 0.0 0.1 0.6 28.0 7.5 0.1 0.8 0.0 2.1 0.0 32.0 0.5 0.5 9.6 0.5 0.8 1.0 0.5 0.6 0.4 0.1 0.3 0.7 0.9 27.1 3.0 2.3 2.1 1.5 0.3 0.3 20.7 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 4.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.3 0.0 0.7 0.0 0.0 1.4 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 0.0 1.2 0.0 0.0 1.9 3.1 0.1 0.0 0.0 1.4 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.5 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.3 0.0 5.0 7.4 11.1 81.3 4.5 12.5 28.0 7.5 32.0 0.1 27.1 20.7 0.1 0.0 0.0 49.9 0.2 0.0 0.0 0.0 0.0 7.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.5 0.2 0.0 0.0 36.7 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 37.1 0.0 0.0 0.0 0.0 1.1 0.0 0.9 0.0 8.4 0.0 19.8 0.0 36.2 6.8 0.0 0.0 5.3 1.6 0.0 0.0 0.0 0.0 4.2 0.0 0.4 1.0 0.0 2.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 KCNA3 "HLK3, HPCN3, Kv1.3, MK3" ENSG00000177272 "Potassium voltage-gated channel subfamily A member 3" P22001 1 110672465-110674940 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 25.4" "Cell type enhanced" "Detected in some" "Excitatory neurons: 13.1;Inhibitory neurons: 60.2;Plasma cells: 61.6;T-cells: 20.3" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in many" "Group enriched" "Detected in many" 7 "B-cells: 4.9;T-cells: 14.3" "Cell line enhanced" "Detected in some" "HDLM-2: 23.1;Karpas-707: 45.6;U-266/70: 32.6;U-266/84: 31.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA016625 Approved NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 3: T-cells - Adaptive immune response" "Cluster 2: Karpas-707 - Immune response" "Cluster 58: T-cells - T-cell receptor" "HPA016625: AB_2669407" "unprognostic (2.17e-2)" "unprognostic (5.07e-3)" "unprognostic (3.92e-3)" "unprognostic (1.20e-2)" "unprognostic (2.35e-1)" "unprognostic (1.76e-5)" "unprognostic (1.70e-4)" "unprognostic (8.48e-2)" "unprognostic (1.49e-2)" "unprognostic (5.92e-4)" "unprognostic (1.81e-2)" "unprognostic (3.96e-2)" "unprognostic (1.39e-1)" "unprognostic (3.13e-2)" "unprognostic (2.99e-2)" "unprognostic (1.73e-1)" "unprognostic (1.40e-1)" 0.5 0.9 3.4 6.4 2.0 4.6 0.9 1.1 4.9 1.1 0.0 2.4 2.5 0.5 0.0 0.5 0.3 1.3 0.4 5.0 7.2 0.2 0.8 5.9 9.4 1.1 3.3 0.7 0.4 0.4 0.4 0.7 5.0 0.5 1.9 0.6 1.4 0.2 0.1 0.2 2.6 0.6 0.2 6.0 4.3 0.5 3.3 25.4 0.7 0.1 7.6 2.6 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.1 0.0 0.0 8.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.5 0.0 45.6 0.0 0.0 10.0 0.0 0.9 0.0 0.0 0.0 0.0 9.6 0.0 0.0 6.3 0.5 0.0 0.0 0.0 0.0 0.0 7.6 0.0 0.0 0.7 0.0 0.0 32.6 31.9 11.6 0.0 2.7 0.0 0.0 1.1 0.0 8.9 0.0 10.0 2.8 13.4 14.3 1.4 4.9 10.4 7.9 0.0 1.3 0.1 0.6 13.4 4.4 3.4 2.0 1.1 4.9 5.0 7.2 1.1 3.3 5.0 0.2 3.3 0.0 0.2 0.0 1.9 1.3 11.5 0.4 0.0 0.0 0.0 2.5 0.1 0.0 0.6 0.0 0.0 1.8 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 1.3 13.1 0.0 0.0 0.7 1.5 0.0 0.0 0.0 1.8 0.0 0.4 0.0 60.2 0.0 0.0 1.6 2.4 0.0 0.0 3.1 3.6 2.8 2.4 0.3 3.1 7.5 1.3 0.0 0.0 0.0 61.6 0.0 0.0 0.1 0.0 0.2 6.6 0.0 0.1 4.3 0.9 0.1 0.6 0.0 20.3 0.0 0.0 0.1 KCNA4 "HK1, HPCN2, KCNA4L, Kv1.4" ENSG00000182255 "Potassium voltage-gated channel subfamily A member 4" P22459 11 30009730-30017030 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Cataract, Disease variant, Dystonia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "adrenal gland: 6.1;brain: 20.0" "Cell type enhanced" "Detected in some" "Bipolar cells: 11.7;Excitatory neurons: 8.2;Horizontal cells: 13.5;Muller glia cells: 6.4" "Not detected" "Not detected" "Region enhanced" "Detected in many" "basal ganglia: 20.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB001977, HPA016422" Approved NA NA "Cluster 65: Brain - Ion transport" "Cluster 62: Horizontal cells - Visual perception" "CAB001977: , HPA016422: AB_1855574" "unprognostic (1.12e-2)" "unprognostic (1.80e-2)" "unprognostic (1.31e-2)" "unprognostic (2.73e-2)" "unprognostic (1.00e-1)" "unprognostic (4.09e-3)" "unprognostic (2.24e-1)" "unprognostic (1.15e-2)" "unprognostic (6.71e-2)" "unprognostic (1.17e-1)" 1.5 6.1 4.7 0.0 20.0 0.0 0.1 0.0 6.5 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 2.2 4.7 4.4 0.2 0.0 0.7 0.0 1.6 1.7 0.0 0.0 0.0 1.3 0.2 1.3 0.0 0.0 1.9 0.0 0.4 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 6.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 20.0 0.0 6.5 4.7 4.4 1.6 1.7 1.3 0.1 6.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 11.7 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.9 0.0 0.0 0.0 8.2 0.0 0.0 0.3 0.0 0.0 0.0 0.7 0.0 0.0 0.0 13.5 2.6 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 6.4 0.0 2.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KCNA5 "HK2, HPCN1, Kv1.5" ENSG00000130037 "Potassium voltage-gated channel subfamily A member 5" P22460 12 5043879-5046788 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Atrial fibrillation, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "choroid plexus: 52.7;heart muscle: 39.8" "Cell type enriched" "Detected in some" 4 "Bipolar cells: 143.1" "Cancer enhanced" "Detected in some" "pancreatic cancer: 2.2" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 122 "plasmacytoid DC: 12.2" "Lineage enriched" "Detected in single" 122 "dendritic cells: 12.2" "Cell line enriched" "Detected in single" 13 "NTERA-2: 4.2" "Low region specificity" "Detected in many" "HPA021516, CAB022562" Approved NA NA "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 88: Choroid plexus - Transmembrane transport" "Cluster 5: NTERA-2 - Transcription" "Cluster 56: Bipolar cells - Visual perception" "CAB022562: , HPA021516: AB_2670732" "unprognostic (3.87e-1)" "unprognostic (9.91e-3)" "unprognostic (1.94e-1)" "unprognostic (3.23e-1)" "unprognostic (2.64e-1)" "unprognostic (7.06e-3)" "unprognostic (1.20e-1)" "unprognostic (4.61e-3)" "unprognostic (1.34e-1)" "unprognostic (2.14e-1)" "unprognostic (2.37e-2)" "unprognostic (5.08e-3)" "unprognostic (6.73e-4)" "unprognostic (1.92e-3)" "unprognostic (1.90e-1)" "unprognostic (2.86e-2)" "unprognostic (3.08e-2)" 2.2 0.5 3.1 0.2 4.6 0.1 1.4 2.2 3.8 0.8 52.7 3.6 0.3 1.5 0.3 4.9 1.8 0.8 39.8 6.0 7.5 1.1 0.2 2.8 0.2 3.7 6.2 2.4 1.3 0.0 7.1 1.9 2.7 0.6 0.5 7.5 0.3 0.9 3.8 0.5 1.2 0.5 4.3 0.5 3.6 0.2 5.4 0.1 1.3 4.8 0.4 3.6 1.1 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.2 0.0 0.0 3.1 4.6 2.2 3.8 6.0 7.5 3.7 6.2 2.7 4.3 5.4 4.7 0.7 0.0 0.0 0.3 1.6 0.9 0.0 0.0 0.0 143.1 0.0 0.0 20.9 0.0 0.0 0.0 2.1 0.1 10.7 0.0 0.0 0.0 0.0 0.0 0.1 2.9 3.5 0.0 0.3 0.0 0.0 3.7 0.0 0.0 0.0 4.2 0.0 0.0 0.3 0.0 1.0 0.0 0.0 0.0 1.4 0.0 0.0 0.3 0.0 3.7 0.1 1.9 0.0 1.5 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 4.0 13.1 3.5 29.0 0.0 0.0 0.0 0.3 0.1 0.1 0.0 0.0 0.1 KCNA6 "HBK2, Kv1.6, PPP1R96" ENSG00000151079 "Potassium voltage-gated channel subfamily A member 6" P17658 12 4809176-4813412 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 8.6" "Group enriched" "Detected in some" 8 "Astrocytes: 14.0;Excitatory neurons: 27.8;Inhibitory neurons: 53.3;Oligodendrocyte precursor cells: 22.1" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "Daudi: 1.7;JURKAT: 2.4;NTERA-2: 4.9;SuSa: 8.3;U-2 OS: 3.9;U-698: 1.6" "Low region specificity" "Detected in many" NA NA "Cluster 4: T-regs - Cell cycle regulation" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 5: NTERA-2 - Transcription" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" 0.4 1.3 3.8 0.4 3.5 0.0 0.6 0.0 3.0 0.2 0.0 0.3 0.1 0.1 0.0 0.0 0.2 0.1 0.9 3.0 5.4 0.0 0.0 0.1 0.7 2.8 8.6 0.0 0.5 0.0 0.0 0.0 3.6 0.0 0.3 0.7 0.1 0.0 0.0 0.4 0.4 0.6 1.5 0.4 0.2 0.3 3.4 0.1 0.0 0.7 0.5 0.0 0.0 5.9 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 1.0 0.0 0.0 0.2 0.0 4.9 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.3 0.0 0.0 0.3 0.0 3.9 0.0 0.0 0.0 0.3 1.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 3.8 3.5 0.0 3.0 3.0 5.4 2.8 8.6 3.6 1.5 3.4 5.9 0.0 0.0 0.0 14.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 53.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 22.1 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KCNA7 "HAK6, Kv1.7" ENSG00000104848 "Potassium voltage-gated channel subfamily A member 7" Q96RP8 19 49067418-49072941 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Group enriched" "Detected in some" 51 "skeletal muscle: 75.7;tongue: 19.5" "Cell type enhanced" "Detected in some" "Alveolar cells type 1: 6.4;Alveolar cells type 2: 16.9;Cone photoreceptor cells: 6.2;granulocytes: 3.8;Pancreatic endocrine cells: 3.8;Skeletal myocytes: 4.7" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "U-251 MG: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" NA NA "Cluster 11: Basophils - Unknown function" "Cluster 33: Striated muscle - Muscle contraction" "Cluster 3: HMC-1 - Innate immune response" "Cluster 37: Myocytes - Muscle contraction" "unprognostic (2.00e-1)" "unprognostic (2.10e-2)" "unprognostic (1.19e-1)" "unprognostic (2.72e-1)" "unprognostic (1.68e-1)" "unprognostic (4.31e-2)" "unprognostic (3.17e-2)" "unprognostic (6.97e-2)" "unprognostic (2.94e-2)" "unprognostic (1.26e-1)" "unprognostic (2.21e-8)" "unprognostic (1.70e-1)" "unprognostic (2.62e-1)" "unprognostic (5.80e-2)" "unprognostic (5.29e-2)" 0.0 0.0 0.2 0.1 0.2 0.3 0.0 0.3 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.9 0.2 0.1 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.1 0.4 0.0 75.7 0.3 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.0 0.0 19.5 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.4 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.4 0.0 0.0 0.1 0.0 0.3 0.1 0.3 0.1 0.1 1.0 0.1 0.0 0.0 0.1 0.1 0.0 0.9 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.5 0.1 0.1 0.2 0.0 0.0 0.2 0.2 0.3 0.3 0.2 0.1 0.3 0.2 0.3 0.0 0.2 0.5 0.2 6.4 16.9 0.0 0.1 0.4 1.2 0.1 0.0 0.4 0.3 0.1 3.4 0.0 3.2 0.0 6.2 0.1 0.1 0.0 0.0 0.1 0.2 0.4 0.9 0.8 0.0 0.0 0.1 0.2 0.2 1.8 0.0 0.9 3.8 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 1.1 0.0 0.0 1.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 3.8 0.0 0.0 0.0 0.7 0.0 0.2 0.9 1.4 0.0 4.7 0.6 0.2 0.6 0.0 0.3 1.1 1.5 0.0 0.0 0.5 KCNB1 Kv2.1 ENSG00000158445 "Potassium voltage-gated channel subfamily B member 1" Q14721 20 49293394-49484297 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Exocytosis, Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "retina: 113.3" "Cell type enhanced" "Detected in many" "Bipolar cells: 115.6;Cone photoreceptor cells: 212.7;Excitatory neurons: 150.6;Inhibitory neurons: 89.9;Rod photoreceptor cells: 386.9" "Cancer enhanced" "Detected in some" "glioma: 1.3" "Region enhanced" "Detected in many" "cerebral cortex: 17.8" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 1.4;CACO-2: 2.2;HL-60: 1.1;hTCEpi: 1.2;U-2 OS: 1.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001979, HPA042434" Enhanced NA NA "Cluster 77: Retina - Visual perception" "Cluster 39: CACO-2 - Unknown function" "Cluster 46: Photoreceptor cells - Phototransduction" "CAB001979: , HPA042434: AB_2677996" "unprognostic (4.51e-1)" "unprognostic (1.72e-1)" "unprognostic (6.54e-3)" "unprognostic (4.87e-2)" "unprognostic (1.94e-1)" "unprognostic (1.82e-1)" "unprognostic (8.09e-2)" "unprognostic (6.22e-2)" "unprognostic (5.31e-1)" "unprognostic (8.32e-2)" "unprognostic (1.87e-3)" "unprognostic (1.37e-1)" "unprognostic (1.31e-2)" "unprognostic (2.07e-3)" "unprognostic (8.17e-2)" "unprognostic (9.35e-2)" "unprognostic (5.25e-4)" 10.7 1.5 4.3 0.3 6.6 0.0 2.8 0.0 17.8 1.2 0.0 6.2 0.2 7.3 0.8 1.7 6.0 0.6 1.2 6.6 0.0 0.3 2.4 0.3 0.0 0.0 0.0 0.4 0.3 0.2 2.7 0.1 0.0 2.2 0.6 113.3 1.6 3.1 7.3 0.5 2.0 5.0 0.0 0.3 3.4 0.4 0.0 0.1 0.1 4.4 0.0 3.8 0.9 7.9 0.0 0.0 0.3 0.0 1.4 0.1 0.0 0.0 0.1 0.1 0.0 2.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.2 1.2 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.5 0.1 0.0 0.9 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.0 0.9 0.7 0.6 0.9 0.0 0.0 0.7 0.0 0.0 0.9 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 6.6 0.0 17.8 6.6 0.0 0.0 0.0 0.0 0.0 0.0 7.9 20.2 0.0 2.2 7.8 0.5 0.8 0.2 0.0 0.0 115.6 0.9 0.5 3.4 1.5 0.7 0.0 212.7 0.0 0.4 0.0 0.0 0.0 0.7 19.8 2.9 8.0 0.0 0.0 150.6 0.0 0.0 1.4 0.0 4.2 3.8 1.5 0.0 5.7 0.1 18.5 89.9 0.0 0.0 0.0 0.3 0.8 4.4 0.4 0.0 12.2 0.0 38.2 0.0 43.2 3.3 0.1 0.0 34.6 0.1 0.1 0.0 0.2 4.0 386.9 0.0 0.9 7.0 0.2 0.5 0.2 0.3 0.1 0.4 0.2 0.0 0.1 KCNB2 Kv2.2 ENSG00000182674 "Potassium voltage-gated channel subfamily B member 2" Q92953 8 72537225-72938349 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 2.6;lymphoid tissue: 2.3;retina: 4.6" "Group enriched" "Detected in some" 14 "Cone photoreceptor cells: 264.8;Excitatory neurons: 279.1;Inhibitory neurons: 241.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "HaCaT: 1.4;HDLM-2: 1.4;HEK 293: 3.4;SCLC-21H: 2.7" "Low region specificity" "Detected in many" HPA065970 Approved "Nucleoli,Plasma membrane,Midbody" Yes NA "Cluster 58: Brain - Synaptic function" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane" "Nucleoli, Midbody" "HPA065970: AB_2685591" "unprognostic (9.87e-3)" "unprognostic (1.71e-1)" "unprognostic (7.57e-2)" "unprognostic (1.10e-3)" "unprognostic (1.22e-1)" "unprognostic (1.34e-1)" "unprognostic (1.44e-2)" "unprognostic (2.72e-1)" "unprognostic (6.93e-5)" "unprognostic (5.53e-3)" "unprognostic (3.30e-2)" "unprognostic (1.62e-1)" "unprognostic (3.35e-2)" "unprognostic (3.26e-1)" 0.1 0.4 1.7 0.0 2.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.4 0.0 0.0 2.4 2.2 0.0 0.0 0.0 0.0 1.0 2.6 0.0 0.5 0.0 1.1 0.0 0.4 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.3 0.0 1.3 2.3 0.4 0.3 1.5 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 1.4 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 2.0 0.0 1.4 2.4 2.2 1.0 2.6 0.4 1.3 1.5 0.0 0.1 0.0 0.0 4.6 0.0 0.0 0.0 0.0 1.2 17.4 0.0 0.0 0.3 0.0 0.0 1.8 264.8 0.0 0.0 0.1 0.0 0.0 4.0 0.0 0.0 0.1 17.9 0.0 279.1 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 241.2 0.6 0.0 0.0 0.0 6.8 1.2 0.0 0.0 3.7 0.0 0.7 0.0 11.6 4.7 0.1 0.0 0.4 0.0 0.0 0.0 0.1 0.0 4.0 0.0 0.1 0.1 0.4 1.1 0.2 0.0 0.0 0.0 0.0 0.1 0.0 KCNC1 Kv3.1 ENSG00000129159 "Potassium voltage-gated channel subfamily C member 1" P48547 11 17734774-17856804 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "brain: 47.3" "Group enriched" "Detected in some" 5 "Bipolar cells: 79.6;Excitatory neurons: 48.2;Inhibitory neurons: 120.2" "Group enriched" "Detected in some" 5 "glioma: 1.1;testis cancer: 0.7" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "basophil: 3.2;neutrophil: 1.4" "Lineage enriched" "Detected in single" 6 "granulocytes: 3.2" "Cell line enhanced" "Detected in some" "HeLa: 1.6;RH-30: 3.7;SCLC-21H: 3.5;SH-SY5Y: 2.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA047634, HPA048249" Enhanced Approved "Nucleoplasm,Nuclear membrane,Vesicles,Cytosol" NA NA "Cluster 18: Basophils - Vesicular transport" "Cluster 6: Brain - Smell perception" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Nucleoplasm, Nuclear membrane" "Vesicles, Cytosol" "HPA047634: AB_2680109, HPA048249: " "unprognostic (1.79e-2)" "unprognostic (2.68e-1)" "unprognostic (1.33e-1)" "unprognostic (4.09e-3)" "unprognostic (1.12e-1)" "unprognostic (8.02e-2)" "unprognostic (2.40e-1)" "unprognostic (1.27e-1)" "unprognostic (8.37e-2)" "unprognostic (2.14e-1)" "unprognostic (7.04e-5)" "unprognostic (5.89e-2)" "unprognostic (7.32e-4)" "unprognostic (1.29e-1)" "unprognostic (5.44e-2)" "unprognostic (1.05e-2)" "unprognostic (7.83e-2)" 0.1 0.8 1.1 0.1 3.3 0.9 0.2 41.0 47.3 0.9 0.0 0.3 0.3 0.3 0.0 0.2 0.1 0.2 0.1 4.5 8.0 0.1 0.2 0.1 0.2 8.8 3.0 0.2 0.4 0.0 2.2 0.0 9.3 0.2 0.0 7.0 0.3 0.0 0.5 0.5 0.3 0.0 1.0 0.2 0.3 1.4 12.3 0.1 0.3 1.2 0.0 0.3 0.5 18.8 0.1 0.0 1.5 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.4 0.9 0.0 0.1 0.2 1.1 0.3 1.6 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.7 0.0 0.2 0.2 0.4 0.7 0.0 0.0 0.4 3.7 0.4 0.0 0.2 3.5 2.1 0.0 0.1 0.0 0.0 0.3 0.1 0.0 0.1 1.0 0.1 0.0 0.2 0.3 0.4 0.2 0.2 0.4 3.2 0.3 0.4 0.3 0.2 0.2 0.2 0.3 0.2 0.0 0.5 0.2 0.2 1.4 0.2 0.3 0.3 0.1 0.1 1.1 3.3 41.0 47.3 4.5 8.0 8.8 3.0 9.3 1.0 12.3 18.8 0.2 0.0 0.0 5.5 1.1 0.0 0.2 0.0 0.0 79.6 0.3 0.4 2.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.5 9.5 0.2 0.5 0.4 7.7 0.0 48.2 0.2 0.0 0.3 0.0 0.3 0.0 2.8 0.0 0.0 0.0 1.7 120.2 0.0 0.0 0.0 0.0 10.2 0.3 0.2 0.0 7.5 0.6 1.5 0.0 16.1 5.6 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.0 7.7 0.0 0.2 0.5 6.1 5.0 0.0 0.0 0.0 0.6 1.8 0.0 0.0 KCNC2 Kv3.2 ENSG00000166006 "Potassium voltage-gated channel subfamily C member 2" Q96PR1 12 75040077-75209839 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 46.9" "Group enriched" "Detected in some" 51 "Excitatory neurons: 389.6;Inhibitory neurons: 1425.5" "Group enriched" "Detected in some" 8 "breast cancer: 1.5;prostate cancer: 4.6" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019664, CAB022571" Uncertain NA NA "Cluster 65: Brain - Ion transport" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB022571: , HPA019664: AB_1855578" "unprognostic (2.01e-1)" "unprognostic (1.14e-1)" "unprognostic (2.68e-1)" "unprognostic (5.58e-3)" "unprognostic (4.46e-2)" "unprognostic (3.39e-2)" 0.0 0.0 9.2 0.0 18.4 0.0 1.7 0.0 46.9 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 6.5 17.2 0.0 0.2 0.0 0.0 22.3 15.9 0.0 0.0 0.0 7.0 0.0 24.5 2.6 0.0 8.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 45.5 0.0 0.0 0.1 0.0 0.0 0.0 9.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.2 18.4 0.0 46.9 6.5 17.2 22.3 15.9 24.5 0.0 45.5 9.4 0.0 0.0 0.0 17.6 0.0 0.0 2.9 0.0 0.0 15.9 16.7 7.7 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.1 0.3 0.0 0.0 389.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1425.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.2 0.0 2.6 0.0 14.1 14.8 0.2 0.0 0.0 0.0 1.0 0.0 0.0 0.0 7.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 KCNC3 "Kv3.3, SCA13" ENSG00000131398 "Potassium voltage-gated channel subfamily C member 3" Q14003 19 50311937-50333515 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease variant, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 75.8;thyroid gland: 52.1" "Cell type enhanced" "Detected in many" "Collecting duct cells: 20.2;Endometrial ciliated cells: 23.9;Excitatory neurons: 15.6;Glandular and luminal cells: 16.3;Inhibitory neurons: 18.3" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "cerebral cortex: 75.8" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CACO-2: 7.7;CAPAN-2: 7.2;HDLM-2: 7.0;HMC-1: 20.3;K-562: 7.0;SK-BR-3: 14.0;T-47d: 12.0;U-2 OS: 8.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA018041 Approved NA NA "Cluster 7: Kidney - Transmembrane transport" "Cluster 3: HMC-1 - Innate immune response" "Cluster 44: Endometrium - Transcription" "HPA018041: AB_1855579" "unprognostic (8.05e-2)" "unprognostic (2.34e-2)" "unprognostic (3.01e-4)" "unprognostic (4.41e-2)" "unprognostic (3.84e-2)" "unprognostic (1.91e-2)" "unprognostic (2.79e-2)" "unprognostic (1.12e-2)" "unprognostic (1.46e-1)" "unprognostic (1.59e-1)" "unprognostic (3.94e-3)" "unprognostic (2.10e-5)" "prognostic unfavorable (1.23e-4)" "unprognostic (1.68e-2)" "unprognostic (1.45e-1)" "unprognostic (2.85e-2)" "unprognostic (1.19e-1)" 0.8 1.3 3.1 2.8 1.9 0.7 3.5 17.3 75.8 6.2 0.0 0.8 0.6 2.8 2.6 1.6 23.2 0.5 2.4 12.5 0.0 17.8 4.4 4.6 2.6 20.0 3.4 0.4 5.7 14.1 21.1 1.2 11.4 4.4 0.5 8.0 3.0 8.1 1.3 2.9 3.3 0.7 3.1 5.7 1.2 3.6 15.0 2.5 52.1 0.1 1.9 2.0 1.5 20.2 0.0 0.5 0.0 1.2 0.0 0.0 3.8 0.1 0.0 0.0 0.0 7.7 7.2 0.7 0.9 0.0 0.5 1.1 0.2 0.0 0.0 7.0 1.7 0.0 0.0 2.0 0.0 0.0 20.3 0.1 0.0 0.0 0.0 0.0 0.1 0.3 7.0 0.0 0.0 2.7 0.1 0.0 0.9 1.1 3.3 0.0 0.1 0.0 0.5 0.3 0.0 1.2 1.7 14.0 0.0 0.1 12.0 2.4 0.2 0.0 8.2 0.0 0.0 0.0 0.1 0.5 0.3 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 3.1 1.9 17.3 75.8 12.5 0.0 20.0 3.4 11.4 3.1 15.0 20.2 0.3 0.0 0.5 3.3 2.4 0.8 1.0 0.2 0.0 8.8 4.4 2.5 2.7 1.5 2.4 20.2 8.4 2.3 0.2 0.2 0.0 1.6 0.3 23.9 1.2 0.7 4.2 0.0 15.6 1.4 0.9 0.2 0.5 16.3 0.0 0.1 1.1 2.4 2.8 1.7 18.3 0.1 4.1 7.3 1.9 0.6 0.6 6.3 0.0 3.7 3.2 0.8 0.0 2.0 1.9 0.3 0.1 0.0 0.3 1.3 0.0 3.3 1.1 6.2 0.0 0.1 1.1 1.3 1.2 0.4 0.6 2.3 0.4 0.0 0.1 0.9 KCND1 Kv4.1 ENSG00000102057 "Potassium voltage-gated channel subfamily D member 1" Q9NSA2 X 48961378-48971844 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in some" "Enteroendocrine cells: 3.5;Peritubular cells: 3.8;Rod photoreceptor cells: 3.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "HSkMC: 10.6;NB-4: 9.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA000524, HPA001066" Supported Uncertain Nucleoplasm Yes No "Cluster 1: Neutrophils - Mixed function" "Cluster 21: Non-specific - Transcription" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 46: Photoreceptor cells - Phototransduction" Nucleoplasm "HPA000524: AB_2666013, HPA001066: AB_1079662" "unprognostic (6.00e-2)" "unprognostic (2.58e-1)" "unprognostic (1.01e-4)" "unprognostic (2.19e-4)" "unprognostic (1.41e-1)" "unprognostic (3.79e-2)" "unprognostic (2.79e-1)" "unprognostic (8.13e-3)" "unprognostic (1.13e-2)" "unprognostic (2.41e-3)" "prognostic favorable (2.66e-6)" "unprognostic (2.61e-1)" "unprognostic (4.30e-11)" "unprognostic (3.13e-2)" "unprognostic (3.49e-1)" "unprognostic (7.64e-2)" "unprognostic (2.22e-3)" 3.8 0.9 2.8 1.5 2.8 2.7 1.8 5.5 2.7 2.7 0.1 2.0 0.8 3.6 1.4 1.1 5.4 2.4 2.3 2.9 3.0 1.7 1.4 2.6 1.3 3.6 2.9 2.7 1.1 0.4 2.3 1.0 3.9 2.3 0.8 6.1 0.9 2.1 0.5 1.3 2.2 2.5 3.3 3.3 1.8 1.5 3.2 0.7 1.8 0.4 1.4 2.3 2.3 3.8 0.3 1.6 0.7 3.9 5.1 4.1 1.3 0.8 3.3 2.3 1.5 1.1 0.5 1.3 2.8 2.6 0.6 0.5 0.6 0.3 2.2 2.3 2.7 1.2 1.8 0.1 1.9 0.3 2.5 10.6 1.4 4.2 0.4 3.7 0.8 1.9 0.9 3.0 1.7 3.1 0.4 9.2 2.1 0.2 0.6 1.1 0.7 1.3 2.6 1.3 0.4 1.8 0.7 0.0 1.8 7.9 1.7 1.3 2.0 0.5 2.1 0.5 0.2 2.5 3.5 3.2 1.4 3.2 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 2.8 2.8 5.5 2.7 2.9 3.0 3.6 2.9 3.9 3.3 3.2 3.8 0.9 0.0 1.1 1.0 0.4 0.8 0.0 0.4 0.0 0.2 0.3 0.3 0.8 0.0 0.2 1.8 0.0 0.1 0.4 0.3 1.9 0.2 0.1 0.2 1.0 0.6 3.5 0.0 0.7 0.0 0.1 1.2 0.5 0.5 0.0 1.7 1.1 0.0 0.1 0.0 1.1 0.3 0.0 0.6 0.0 0.2 1.8 0.4 0.0 1.0 0.1 0.4 0.0 2.0 0.1 0.1 0.0 3.8 0.1 0.2 0.2 0.1 0.3 3.0 0.0 0.1 0.6 0.6 0.0 0.1 0.0 0.1 0.2 0.1 0.2 0.2 KCND2 "KIAA1044, Kv4.2, RK5" ENSG00000184408 "Potassium voltage-gated channel subfamily D member 2" Q9NZV8 7 120273175-120750337 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 11 "brain: 47.3" "Group enriched" "Detected in some" 11 "Excitatory neurons: 690.0;Inhibitory neurons: 1068.2;Oligodendrocyte precursor cells: 1952.8" "Cancer enhanced" "Detected in many" "glioma: 6.2" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC TERT1: 4.8;HSkMC: 2.9;NTERA-2: 2.4;RT4: 2.7;SCLC-21H: 13.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029068 Enhanced NA NA "Cluster 69: Cerebellum - Gene expression regulation" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA029068: AB_10601436" "unprognostic (4.22e-1)" "unprognostic (2.79e-4)" "unprognostic (3.79e-2)" "unprognostic (3.40e-1)" "unprognostic (1.23e-1)" "unprognostic (3.91e-2)" "unprognostic (4.98e-3)" "unprognostic (9.07e-3)" "unprognostic (1.03e-1)" "unprognostic (1.14e-1)" "unprognostic (9.77e-3)" "unprognostic (1.51e-1)" "unprognostic (4.51e-4)" "unprognostic (4.07e-5)" "unprognostic (2.71e-2)" "unprognostic (2.92e-2)" "unprognostic (1.83e-3)" 1.7 0.5 8.1 0.5 10.5 0.0 1.0 47.3 8.6 1.1 0.0 0.3 0.3 3.2 0.1 0.1 1.2 4.2 0.2 5.5 10.1 0.0 0.1 0.2 0.1 29.3 15.4 3.3 0.2 0.7 1.9 0.4 26.8 0.2 0.2 1.0 0.3 0.9 0.2 0.1 0.1 2.0 4.9 0.0 0.2 1.7 19.2 0.3 0.4 2.8 0.0 1.1 0.5 2.5 0.0 0.0 0.2 0.0 1.3 4.8 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.1 2.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.5 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.2 0.0 0.0 0.0 2.4 0.0 0.2 0.0 0.0 0.0 0.0 2.7 13.2 0.0 0.0 0.0 0.0 0.1 0.2 0.7 0.0 0.4 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.1 10.5 47.3 8.6 5.5 10.1 29.3 15.4 26.8 4.9 19.2 2.5 0.6 0.0 0.0 108.7 0.0 0.0 0.0 0.0 0.0 3.4 0.2 0.0 1.2 4.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 3.1 2.7 1.0 1.9 0.3 0.0 2.7 690.0 0.2 0.0 6.0 0.0 0.8 0.0 6.6 0.7 0.0 0.0 0.0 1068.2 0.0 2.0 0.0 0.0 1.7 3.7 0.1 0.0 40.3 0.0 0.0 0.0 1952.8 9.7 0.3 0.0 0.4 0.1 0.0 0.0 0.0 0.3 0.5 0.0 10.9 3.0 5.0 3.4 0.0 0.1 0.0 0.0 4.3 0.0 0.1 KCND3 "KSHIVB, Kv4.3, SCA19, SCA22" ENSG00000171385 "Potassium voltage-gated channel subfamily D member 3" Q9UK17 1 111770662-111989668 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Brugada syndrome, Disease variant, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 35.6" "Cell type enhanced" "Detected in many" "Bipolar cells: 46.8;Cardiomyocytes: 38.1;Excitatory neurons: 105.7;Hepatocytes: 37.8;Inhibitory neurons: 88.4;Oligodendrocyte precursor cells: 45.8" "Cancer enhanced" "Detected in many" "prostate cancer: 8.4" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "OE19: 4.8;SCLC-21H: 10.1;U-2 OS: 1.6;WM-115: 2.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029452 Approved NA NA "Cluster 15: Liver - Metabolism" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA029452: AB_10602239" "unprognostic (1.11e-2)" "unprognostic (1.73e-3)" "unprognostic (1.71e-1)" "unprognostic (2.60e-2)" "unprognostic (1.37e-1)" "unprognostic (2.42e-1)" "unprognostic (1.41e-1)" "unprognostic (9.48e-2)" "unprognostic (1.15e-1)" "unprognostic (9.17e-2)" "unprognostic (1.86e-2)" "unprognostic (1.40e-1)" "unprognostic (7.44e-2)" "unprognostic (3.64e-1)" "unprognostic (1.23e-1)" "unprognostic (2.51e-3)" "unprognostic (6.64e-3)" 4.5 1.5 17.0 4.7 13.8 0.2 3.0 18.1 17.9 2.3 0.0 5.9 0.9 5.3 12.6 4.1 5.1 5.5 8.4 16.2 6.4 1.3 15.4 1.7 0.5 1.0 35.6 0.5 4.5 3.9 3.4 0.5 3.4 11.3 2.4 12.7 1.6 12.0 2.6 7.1 2.2 9.8 0.9 3.2 3.3 2.0 9.2 0.3 1.1 1.7 0.5 5.9 3.2 10.8 0.0 0.0 0.2 0.0 0.4 0.1 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 1.0 0.4 0.0 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.1 0.2 4.8 0.0 0.0 0.0 0.0 0.0 0.2 10.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 17.0 13.8 18.1 17.9 16.2 6.4 1.0 35.6 3.4 0.9 9.2 10.8 1.1 0.0 9.3 18.3 0.3 7.5 11.9 2.9 0.0 46.8 7.8 1.5 38.1 0.0 1.5 0.0 4.2 0.1 0.4 1.5 0.0 0.8 35.7 0.5 14.5 1.6 0.0 2.7 105.7 23.8 0.2 3.7 0.0 0.7 0.0 0.0 1.8 37.8 0.2 30.3 88.4 0.4 4.1 0.8 1.9 32.3 18.0 0.5 3.6 1.0 0.0 6.2 0.0 45.8 8.7 4.8 1.2 1.9 0.0 21.9 0.1 0.3 0.1 4.8 0.0 0.8 1.7 1.5 1.0 2.0 6.7 0.0 0.5 0.1 2.4 13.4 KCNH2 "erg1, HERG, Kv11.1, LQT2" ENSG00000055118 "Potassium voltage-gated channel subfamily H member 2" Q12809 7 150944961-150978321 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Deafness, Disease variant, FDA approved drug targets, Long QT syndrome, Short QT syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 42.3;pituitary gland: 43.3" "Group enriched" "Detected in many" 4 "Bipolar cells: 217.3;Cardiomyocytes: 83.2;Erythroid cells: 76.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "K-562: 197.7;NB-4: 97.8;SH-SY5Y: 78.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 76: Brain & Bone marrow - Chromatin organization" "Cluster 1: K-562 - Erythropoiesis" "Cluster 56: Bipolar cells - Visual perception" "unprognostic (2.22e-1)" "unprognostic (1.75e-2)" "unprognostic (1.06e-2)" "prognostic unfavorable (6.06e-5)" "unprognostic (9.79e-3)" "unprognostic (1.95e-2)" "unprognostic (3.40e-2)" "unprognostic (3.84e-2)" "unprognostic (3.53e-2)" "unprognostic (3.52e-1)" "prognostic favorable (5.61e-4)" "unprognostic (6.08e-2)" "unprognostic (2.26e-2)" "unprognostic (4.90e-2)" "unprognostic (2.83e-1)" "unprognostic (6.24e-2)" "unprognostic (3.02e-2)" 0.8 3.7 9.8 2.6 8.0 42.3 0.1 13.5 9.0 4.4 4.4 36.1 2.7 16.9 1.7 1.5 7.3 3.2 29.6 5.6 14.8 1.1 0.2 2.0 0.3 23.5 14.7 3.2 3.4 18.1 43.3 1.4 23.0 9.8 1.0 6.7 1.1 8.0 0.2 0.3 8.3 7.8 6.3 1.8 10.9 30.8 17.1 0.4 0.2 0.0 0.1 12.9 2.7 4.1 0.0 0.3 0.9 4.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.5 8.0 2.9 0.0 0.2 0.0 3.1 0.0 0.0 0.8 0.4 18.3 0.0 0.0 0.2 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 4.4 197.7 0.0 0.0 0.9 1.6 97.8 1.3 0.2 0.0 0.1 0.1 10.1 0.0 0.0 3.8 78.2 0.0 0.1 0.0 1.1 0.0 1.8 0.6 0.0 1.5 0.0 0.0 5.3 0.2 2.1 0.0 11.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 8.0 13.5 9.0 5.6 14.8 23.5 14.7 23.0 6.3 17.1 4.1 0.0 0.0 0.0 1.6 1.6 0.0 0.2 0.1 0.0 217.3 0.4 0.3 83.2 0.0 0.0 0.0 4.2 0.2 0.0 0.0 0.0 2.1 2.0 0.5 0.8 0.9 16.3 76.4 5.2 0.2 0.9 5.0 0.5 0.1 26.1 6.3 1.4 0.1 0.3 16.8 13.9 0.7 12.2 0.0 0.3 4.8 2.5 0.0 0.0 2.8 0.0 4.5 0.0 5.5 1.7 0.3 0.0 13.2 1.4 0.1 0.2 0.1 0.4 10.3 0.0 1.7 2.6 2.5 5.1 0.0 0.0 0.3 0.9 0.7 0.3 0.4 KCNH6 "erg2, HERG2, Kv11.2" ENSG00000173826 "Potassium voltage-gated channel subfamily H member 6" Q9H252 17 63523334-63548977 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 4.8;kidney: 7.0;pituitary gland: 5.3;prostate: 3.9;retina: 4.4" "Group enriched" "Detected in some" 8 "Bipolar cells: 44.8;Cardiomyocytes: 25.6;Cone photoreceptor cells: 31.3;Enteroendocrine cells: 34.6;Proximal enterocytes: 40.3;Proximal tubular cells: 14.1" "Cancer enhanced" "Detected in some" "prostate cancer: 5.3" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "SCLC-21H: 3.3;SH-SY5Y: 1.1" "Low region specificity" "Detected in many" "Group enriched" "Detected in some" 5 "medulla oblongata: 1.1;olfactory bulb: 2.4;spinal cord: 2.5" HPA061704 Approved NA NA "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "HPA061704: " "unprognostic (8.00e-2)" "unprognostic (1.80e-1)" "unprognostic (5.46e-2)" "unprognostic (5.68e-2)" "unprognostic (5.98e-5)" "unprognostic (3.39e-1)" "unprognostic (1.15e-1)" "unprognostic (3.03e-1)" "unprognostic (1.28e-2)" "unprognostic (3.25e-1)" "unprognostic (1.74e-3)" "unprognostic (3.95e-1)" "unprognostic (1.19e-1)" "unprognostic (9.80e-2)" "unprognostic (3.66e-1)" "unprognostic (8.05e-2)" "unprognostic (9.15e-2)" 0.0 0.1 0.9 0.0 1.1 0.2 0.0 0.9 1.1 0.0 0.3 0.2 2.2 0.0 0.0 0.0 0.1 0.0 0.0 0.6 1.6 7.0 0.0 0.3 0.0 1.6 1.5 0.0 1.3 0.0 5.3 0.1 1.7 3.9 0.2 4.4 0.0 0.0 0.1 0.1 4.8 0.0 1.1 0.1 0.8 1.2 1.5 0.7 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 3.3 1.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.9 1.1 0.9 1.1 0.6 1.6 1.6 1.5 1.7 1.1 1.5 1.1 0.0 0.0 0.0 0.3 0.0 0.3 0.2 0.0 0.0 44.8 0.0 0.3 25.6 0.0 0.0 0.0 31.3 0.0 0.0 0.1 0.0 0.0 3.0 0.6 0.1 1.3 34.6 0.0 1.1 0.0 0.0 0.8 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.9 3.8 0.0 0.0 0.0 3.4 0.0 0.1 1.8 0.0 0.0 1.1 0.0 0.5 0.1 0.1 1.2 0.0 0.0 1.4 40.3 14.1 0.0 3.1 0.0 0.2 1.0 0.0 0.7 0.0 0.1 0.1 0.1 0.0 0.8 0.1 KCNH7 "erg3, HERG3, Kv11.3" ENSG00000184611 "Potassium voltage-gated channel subfamily H member 7" Q9NS40 2 162371407-162838767 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 5.9;retina: 1.6" "Group enriched" "Detected in some" 7 "Excitatory neurons: 685.6;Inhibitory neurons: 352.4" "Not detected" "Not detected" "Region enriched" "Detected in some" 5 "cerebral cortex: 5.9" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 12 "SCLC-21H: 6.0;SK-BR-3: 5.8" "Low region specificity" "Detected in many" "Region enhanced" "Detected in all" "cerebral cortex: 53.0" HPA018039 Uncertain NA NA "Cluster 49: Eosinophils - Unknown function" "Cluster 58: Brain - Synaptic function" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA018039: AB_1852125" "unprognostic (1.80e-1)" "unprognostic (2.68e-1)" "unprognostic (2.66e-1)" "unprognostic (5.55e-2)" "unprognostic (3.05e-2)" "unprognostic (5.51e-2)" "unprognostic (8.12e-3)" "unprognostic (7.31e-2)" "unprognostic (1.73e-1)" "unprognostic (2.69e-1)" "unprognostic (3.30e-2)" "unprognostic (3.52e-2)" "unprognostic (7.55e-3)" "unprognostic (2.76e-3)" "unprognostic (2.13e-1)" "unprognostic (4.71e-2)" "unprognostic (1.68e-2)" 0.0 0.1 0.7 0.1 0.8 0.1 0.0 1.2 5.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 1.2 0.0 0.0 0.6 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 1.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.0 0.4 0.0 5.8 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.7 0.8 1.2 5.9 1.2 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 0.1 0.0 0.0 0.0 0.0 11.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 25.1 0.0 0.0 0.1 0.0 0.0 685.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.3 0.0 0.1 21.9 352.4 0.0 0.0 0.6 0.0 68.3 0.0 0.1 0.0 4.7 0.0 0.2 0.0 20.1 11.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.6 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.1 KCNJ1 "Kir1.1, ROMK1" ENSG00000151704 "Potassium inwardly rectifying channel subfamily J member 1" P48048 11 128836315-128867373 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Bartter syndrome, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 117 "kidney: 198.0" "Cell type enriched" "Detected in some" 5 "Distal tubular cells: 195.6" "Cancer enriched" "Detected in some" 7 "renal cancer: 3.4" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 39 "RPTEC TERT1: 116.8" "Not detected" "Not detected" "Not detected" "Not detected" HPA026962 Enhanced NA NA "Cluster 7: Kidney - Transmembrane transport" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 39: Non-specific - Basic cellular processes" "HPA026962: AB_10601934" "unprognostic (1.75e-1)" "unprognostic (4.38e-2)" "unprognostic (1.14e-1)" "unprognostic (3.19e-1)" "unprognostic (7.55e-2)" "unprognostic (1.29e-1)" "unprognostic (3.01e-2)" "unprognostic (2.69e-1)" "unprognostic (1.46e-1)" "unprognostic (2.44e-2)" "unprognostic (6.47e-2)" "unprognostic (2.78e-1)" "unprognostic (6.05e-2)" "unprognostic (4.99e-2)" "unprognostic (1.61e-1)" "unprognostic (1.28e-1)" "unprognostic (7.81e-3)" 0.2 0.1 1.0 0.1 1.6 0.1 0.1 0.1 0.3 0.0 0.1 0.1 0.0 0.0 1.4 0.1 0.1 0.0 0.1 0.5 0.1 198.0 0.1 0.2 0.1 0.2 0.2 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.0 0.0 1.0 0.1 0.0 0.1 0.2 0.1 0.1 0.3 0.1 0.5 0.0 0.2 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 116.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 2.9 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.6 0.1 0.3 0.5 0.1 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 38.6 0.0 0.0 0.1 0.0 195.6 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.8 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 KCNJ10 "Kir1.2, Kir4.1" ENSG00000177807 "Potassium inwardly rectifying channel subfamily J member 10" P78508 1 159998651-160070160 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Deafness, Disease variant, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 100.7;kidney: 28.0;retina: 36.7" "Group enriched" "Detected in some" 5 "Astrocytes: 93.0;Muller glia cells: 75.7;Oligodendrocyte precursor cells: 35.7;Oligodendrocytes: 93.7" "Cancer enriched" "Detected in some" 6 "glioma: 27.4" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "Hep G2: 6.7;SK-MEL-30: 2.1;U-266/70: 2.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA078302 Enhanced NA NA "Cluster 35: T-regs - Unknown function" "Cluster 70: Brain - Nervous system development" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 5: Muller glia cells - Visual perception" "HPA078302: AB_2732378" "unprognostic (2.64e-2)" "unprognostic (3.54e-3)" "unprognostic (6.19e-2)" "unprognostic (1.33e-1)" "unprognostic (2.84e-1)" "unprognostic (6.98e-4)" "unprognostic (1.96e-1)" "unprognostic (7.13e-2)" "unprognostic (3.43e-1)" "unprognostic (1.28e-3)" "unprognostic (5.80e-4)" "unprognostic (9.52e-2)" "unprognostic (2.09e-2)" "unprognostic (2.08e-2)" "unprognostic (1.41e-1)" "unprognostic (3.77e-1)" "unprognostic (6.70e-3)" 0.1 0.3 56.7 2.1 86.3 0.0 0.1 100.2 58.4 0.2 8.7 0.5 0.2 0.1 0.0 0.1 0.1 0.1 0.1 51.4 78.7 28.0 2.1 0.1 7.3 92.7 94.7 0.1 0.1 0.1 0.4 0.0 87.5 0.2 0.2 36.7 0.3 0.2 0.1 0.4 0.5 0.0 71.8 10.5 0.9 0.6 83.6 0.4 0.2 0.1 1.9 0.1 0.1 100.7 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.2 0.0 0.1 1.0 0.1 0.0 0.6 0.2 0.1 0.0 0.1 0.0 0.1 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.5 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.0 1.2 0.1 0.0 0.0 0.1 0.2 0.0 0.1 2.1 0.5 0.0 0.3 0.1 0.0 0.2 0.5 0.0 2.0 1.0 0.0 0.1 0.1 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.6 0.0 56.7 86.3 100.2 58.4 51.4 78.7 92.7 94.7 87.5 71.8 83.6 100.7 0.1 0.0 0.0 93.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.3 0.5 0.0 0.0 3.7 4.2 0.0 0.0 0.0 11.7 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.0 13.0 0.0 1.1 0.0 1.1 0.0 3.7 0.0 75.7 0.0 35.7 93.7 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.0 3.5 0.0 0.1 0.1 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KCNJ11 "BIR, Kir6.2" ENSG00000187486 "Potassium inwardly rectifying channel subfamily J member 11" Q14654 11 17385248-17389331 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Diabetes mellitus, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "skeletal muscle: 134.7;tongue: 40.7" "Cell type enhanced" "Detected in some" "Cardiomyocytes: 14.1;Collecting duct cells: 5.5;Enteroendocrine cells: 4.2;Excitatory neurons: 5.5;Inhibitory neurons: 5.9;Oligodendrocyte precursor cells: 4.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "Daudi: 6.6;HEK 293: 12.3;MCF7: 10.0;SCLC-21H: 8.5;U-266/84: 6.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA048891 Approved NA NA "Cluster 80: Striated muscle - Unknown function" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 54: Cardiomyocytes - Muscle contraction" "HPA048891: AB_2680547" "unprognostic (1.95e-2)" "unprognostic (6.18e-3)" "unprognostic (7.79e-2)" "unprognostic (2.26e-1)" "unprognostic (1.77e-1)" "unprognostic (1.25e-1)" "unprognostic (4.81e-5)" "unprognostic (1.83e-3)" "unprognostic (5.45e-2)" "unprognostic (8.09e-3)" "unprognostic (3.72e-3)" "unprognostic (9.23e-3)" "prognostic favorable (1.56e-4)" "unprognostic (4.05e-2)" "unprognostic (2.10e-2)" "unprognostic (1.67e-1)" "unprognostic (4.75e-2)" 2.7 0.6 5.1 0.4 8.3 0.2 3.0 12.4 11.9 0.6 0.0 1.1 1.0 0.9 1.6 1.5 0.7 0.5 13.8 5.3 4.2 4.7 1.5 2.5 0.8 8.0 3.4 0.3 11.3 5.0 7.4 0.1 8.2 2.2 0.4 1.3 2.2 2.4 134.7 1.5 1.3 0.1 2.6 1.6 13.1 0.6 6.4 0.3 5.1 40.7 0.5 0.9 0.4 5.9 1.5 2.1 0.2 4.0 0.0 0.0 1.4 0.0 0.0 0.0 0.1 2.0 0.2 6.6 0.2 0.0 0.3 0.3 4.1 0.1 0.2 1.6 12.3 3.4 0.9 0.5 0.1 0.5 0.3 0.1 0.2 0.0 0.1 0.1 0.0 5.6 3.5 3.6 0.0 10.0 0.7 0.1 1.1 4.0 0.3 1.3 1.6 2.0 0.3 0.9 8.5 0.7 0.0 3.4 0.0 0.0 4.2 0.2 0.0 0.0 1.1 0.0 0.0 0.2 6.5 0.8 0.0 0.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 5.1 8.3 12.4 11.9 5.3 4.2 8.0 3.4 8.2 2.6 6.4 5.9 1.5 0.0 2.7 3.3 0.1 0.0 0.1 0.0 0.0 2.1 2.6 0.9 14.1 0.0 0.6 5.5 0.0 0.0 0.0 0.2 0.0 0.4 0.1 0.3 0.3 0.3 4.2 0.0 5.5 0.4 0.0 0.9 0.0 0.6 0.0 0.2 0.4 1.3 0.1 0.0 5.9 0.9 0.0 1.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 4.0 0.8 0.1 0.0 0.0 0.0 0.8 0.1 0.2 0.0 0.7 0.0 1.3 0.2 0.2 0.3 1.0 0.0 0.0 0.0 0.1 0.4 0.2 KCNJ12 "hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v" ENSG00000184185 "Potassium inwardly rectifying channel subfamily J member 12" Q14500 17 21376357-21419870 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "brain: 25.5;skeletal muscle: 69.1;tongue: 25.7" "Cell type enriched" "Detected in many" 6 "Horizontal cells: 89.2" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in all" "cerebellum: 25.5" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "EFO-21: 2.3;HeLa: 3.9;PC-3: 4.3;SCLC-21H: 4.8;SiHa: 2.5;SuSa: 5.2;U-2197: 4.2" HPA027021 Approved Uncertain "Nucleoplasm,Golgi apparatus,Cytosol" NA NA "Cluster 80: Striated muscle - Unknown function" "Cluster 20: HeLa - Mitochondria" "Cluster 62: Horizontal cells - Visual perception" "Golgi apparatus" "Nucleoplasm, Cytosol" "HPA027021: AB_10602912" "unprognostic (3.81e-3)" "unprognostic (2.69e-2)" "unprognostic (8.60e-2)" "prognostic unfavorable (7.84e-5)" "unprognostic (2.29e-1)" "unprognostic (1.73e-2)" "unprognostic (3.80e-2)" "unprognostic (1.54e-2)" "unprognostic (4.39e-2)" "unprognostic (4.91e-2)" "unprognostic (8.12e-2)" "unprognostic (1.16e-1)" "unprognostic (4.22e-2)" "unprognostic (2.23e-1)" "unprognostic (1.51e-1)" "unprognostic (5.90e-2)" "unprognostic (9.70e-3)" 1.3 1.1 2.9 0.6 2.2 0.4 0.8 25.5 3.3 1.2 0.0 0.9 0.1 0.5 0.6 1.4 2.1 0.4 6.4 1.5 2.9 1.3 0.1 1.9 0.1 4.0 6.0 0.4 0.2 5.5 0.8 0.4 3.1 0.6 0.3 1.3 0.7 0.6 69.1 3.6 0.4 0.6 1.1 1.2 1.1 0.8 10.8 0.1 1.1 25.7 1.0 0.7 0.5 1.4 0.0 0.7 0.3 1.5 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 2.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 3.9 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.1 0.0 1.0 0.0 4.3 0.0 0.6 1.1 0.0 0.0 4.8 0.2 2.5 0.0 1.1 5.2 0.0 0.0 2.0 0.0 0.3 4.2 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 2.2 25.5 3.3 1.5 2.9 4.0 6.0 3.1 1.1 10.8 1.4 1.4 0.0 0.0 0.7 0.0 1.5 0.0 2.3 0.0 2.9 0.0 0.3 14.3 0.0 1.2 1.8 0.0 0.0 0.1 1.1 1.9 0.0 0.5 0.4 0.5 3.4 1.2 0.0 2.8 0.0 0.0 3.4 0.5 1.8 0.0 0.0 6.8 0.1 0.2 89.2 5.7 1.4 4.1 0.0 1.2 0.5 7.5 0.1 0.0 2.8 0.0 10.2 0.0 0.0 0.2 0.0 0.5 4.1 0.0 0.2 0.0 0.8 0.1 1.5 0.0 3.0 0.7 0.6 2.5 0.0 2.3 0.1 0.5 0.0 1.8 0.2 KCNJ14 "IRK4, Kir2.4" ENSG00000182324 "Potassium inwardly rectifying channel subfamily J member 14" Q9UNX9 19 48455574-48466980 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 16 "retina: 58.7" "Cell type enriched" "Detected in many" 7 "Rod photoreceptor cells: 326.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in single" "basophil: 1.1" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "NB-4: 7.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA071765 Approved Nucleoli NA NA "Cluster 17: Basophils - Unknown function" "Cluster 77: Retina - Visual perception" "Cluster 24: NB-4 - Immune response" "Cluster 46: Photoreceptor cells - Phototransduction" Nucleoli "HPA071765: AB_2686444" "unprognostic (1.38e-1)" "unprognostic (1.23e-2)" "unprognostic (1.33e-5)" "unprognostic (5.77e-2)" "unprognostic (9.41e-2)" "unprognostic (5.26e-2)" "unprognostic (7.05e-4)" "unprognostic (7.83e-4)" "unprognostic (1.26e-1)" "unprognostic (6.48e-2)" "unprognostic (4.43e-3)" "unprognostic (4.92e-2)" "unprognostic (5.02e-6)" "unprognostic (1.47e-1)" "unprognostic (4.98e-2)" "unprognostic (6.82e-3)" "unprognostic (4.41e-2)" 0.9 0.3 1.9 0.3 2.7 2.0 0.7 3.1 2.1 0.8 1.7 0.5 0.3 0.6 0.6 1.3 0.9 0.4 0.4 2.1 1.8 0.8 0.9 0.7 0.5 2.8 2.8 1.0 0.6 0.2 0.9 0.3 3.5 1.4 0.3 58.7 0.6 0.2 1.6 2.2 0.6 0.3 1.8 0.6 0.5 1.2 2.9 0.3 1.2 0.2 0.3 0.6 1.0 2.5 0.9 2.3 0.4 1.5 0.9 0.9 1.5 0.3 0.2 0.5 0.7 2.2 1.2 1.1 0.4 0.3 1.1 3.2 0.7 0.4 1.2 0.8 1.2 0.6 1.5 0.6 0.5 0.9 1.8 0.9 1.6 1.1 1.3 0.6 0.3 1.0 1.0 1.1 0.3 1.4 0.4 7.6 0.8 1.2 1.1 1.5 0.9 0.2 0.3 2.7 0.8 1.0 1.0 1.5 0.9 0.8 1.0 0.8 0.5 1.5 2.0 1.6 1.8 1.2 1.9 0.7 0.4 2.4 1.6 1.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.1 0.3 0.1 0.2 0.6 0.1 0.0 0.1 0.1 0.0 1.9 2.7 3.1 2.1 2.1 1.8 2.8 2.8 3.5 1.8 2.9 2.5 3.7 0.0 3.4 5.2 1.2 4.5 3.6 1.0 1.8 17.0 4.9 2.4 0.6 2.8 0.7 1.8 41.7 1.4 0.3 1.3 0.0 1.1 4.7 4.1 2.8 2.3 0.0 0.8 2.3 1.1 2.4 1.3 0.5 5.6 0.0 2.4 0.7 0.5 0.6 15.2 3.1 1.4 0.0 0.0 0.7 0.6 1.2 1.0 0.0 1.9 0.6 24.5 0.0 0.0 0.9 3.1 0.3 0.4 0.7 4.4 0.5 0.1 1.8 326.4 0.0 6.5 1.5 3.9 3.3 2.6 5.4 1.0 0.9 1.2 1.7 2.9 KCNJ15 "IRKK, Kir1.3, Kir4.2" ENSG00000157551 "Potassium inwardly rectifying channel subfamily J member 15" Q99712 21 38155549-38307357 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 241.6;thyroid gland: 129.5" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 60.9;Alveolar cells type 2: 197.9;Cholangiocytes: 88.6;Proximal tubular cells: 236.9" "Cancer enhanced" "Detected in many" "thyroid cancer: 29.6" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in some" 20 "neutrophil: 395.3" "Lineage enriched" "Detected in many" 20 "granulocytes: 395.3" "Cell line enhanced" "Detected in many" "ASC TERT1: 68.7;GAMG: 103.6;HBEC3-KT: 69.6;RPTEC TERT1: 67.5;RT4: 80.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA016702 Approved Approved "Vesicles,Plasma membrane,Cytosol" NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 7: Kidney - Transmembrane transport" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "Plasma membrane" "Vesicles, Cytosol" "HPA016702: AB_1855560" "unprognostic (6.34e-2)" "unprognostic (5.04e-2)" "unprognostic (7.92e-2)" "unprognostic (2.07e-3)" "unprognostic (1.21e-1)" "unprognostic (3.54e-3)" "unprognostic (2.72e-3)" "unprognostic (3.03e-2)" "unprognostic (6.79e-2)" "unprognostic (2.89e-3)" "unprognostic (3.77e-2)" "unprognostic (1.95e-2)" "prognostic favorable (4.09e-10)" "unprognostic (9.46e-3)" "unprognostic (1.82e-1)" "unprognostic (5.27e-2)" "prognostic favorable (1.95e-4)" 8.7 0.5 0.8 20.7 0.7 14.1 2.8 0.9 6.7 12.7 0.5 0.9 1.5 0.5 11.0 8.5 1.2 30.4 0.8 0.8 0.6 241.6 2.8 42.2 1.2 0.9 0.6 0.3 57.8 0.7 0.4 4.6 1.8 2.6 0.4 0.5 25.5 14.6 0.5 3.0 0.7 2.4 0.3 11.7 40.5 1.8 5.4 1.9 129.5 3.0 1.9 25.1 8.1 1.1 1.6 0.0 0.3 0.6 13.7 68.7 0.6 1.0 4.8 0.0 0.0 0.0 0.6 0.2 0.0 7.5 103.6 23.5 0.0 69.6 0.6 0.0 0.0 0.0 0.5 0.3 0.0 0.2 0.1 21.0 7.2 17.8 3.8 1.5 3.2 0.1 0.2 0.7 31.6 0.0 0.1 0.2 0.0 0.1 0.7 1.5 0.3 0.7 67.5 80.2 0.1 0.0 0.3 0.0 0.0 0.1 0.0 0.5 0.0 1.5 0.4 3.5 0.2 1.7 0.4 0.1 5.6 4.3 0.4 0.3 19.3 0.1 0.0 0.8 0.0 0.0 0.1 0.0 1.2 0.0 0.2 0.3 395.3 0.0 0.0 0.4 0.0 4.6 0.8 0.7 0.9 6.7 0.8 0.6 0.9 0.6 1.8 0.3 5.4 1.1 2.9 60.9 197.9 0.0 1.1 2.8 10.4 20.7 13.6 0.0 0.5 0.0 1.6 88.6 33.1 31.3 0.0 0.1 0.0 0.0 17.6 27.8 1.9 0.0 0.0 4.6 0.0 0.0 0.3 8.6 0.8 1.5 15.8 0.1 6.3 0.0 0.7 0.4 0.4 0.0 0.1 0.0 2.0 2.9 3.0 2.2 0.6 5.9 1.8 0.0 2.1 0.0 0.0 0.0 0.1 44.7 0.0 0.0 0.1 0.7 0.0 236.9 7.0 0.0 0.0 1.5 0.8 1.1 1.1 16.8 1.6 0.1 1.7 0.1 0.0 9.0 KCNJ2 "IRK1, Kir2.1, LQT7" ENSG00000123700 "Potassium inwardly rectifying channel subfamily J member 2" P63252 17 70168673-70180044 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Atrial fibrillation, Disease variant, FDA approved drug targets, Long QT syndrome, Short QT syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 42.9;parathyroid gland: 36.0" "Group enriched" "Detected in many" 4 "Horizontal cells: 240.6;Oligodendrocytes: 164.7" "Cancer enhanced" "Detected in many" "thyroid cancer: 6.6" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 4 "neutrophil: 30.4" "Lineage enriched" "Detected in many" 4 "granulocytes: 30.4" "Cell line enhanced" "Detected in some" "hTERT-RPE1: 8.9;HUVEC TERT2: 6.3;REH: 7.5;RH-30: 29.2;U-138 MG: 10.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029109 Approved NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 48: Parathyroid gland - membrane proteins" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 62: Horizontal cells - Visual perception" "HPA029109: AB_10602913" "unprognostic (1.32e-1)" "unprognostic (1.24e-1)" "unprognostic (1.18e-1)" "unprognostic (6.22e-2)" "unprognostic (3.50e-1)" "unprognostic (6.36e-3)" "unprognostic (1.22e-2)" "unprognostic (3.14e-1)" "unprognostic (1.09e-1)" "unprognostic (1.62e-1)" "unprognostic (3.64e-2)" "unprognostic (1.03e-1)" "unprognostic (1.74e-3)" "unprognostic (6.15e-3)" "unprognostic (9.60e-3)" "unprognostic (4.89e-2)" "unprognostic (5.49e-3)" 1.9 0.8 7.2 5.1 19.5 1.9 4.9 13.4 13.1 0.9 0.0 3.9 0.9 0.9 0.6 2.9 6.6 1.4 9.8 5.9 11.8 1.0 1.3 2.1 1.3 18.6 16.2 0.7 0.4 36.0 0.6 6.3 18.2 1.8 3.2 7.6 1.3 1.8 9.7 4.7 1.4 1.0 10.5 7.3 0.8 0.3 14.5 1.8 1.2 8.4 1.5 1.9 1.8 42.9 0.0 0.9 1.8 0.0 1.9 0.5 0.0 0.6 4.5 0.1 0.1 0.0 0.0 0.0 0.4 0.5 1.2 0.5 0.1 0.3 0.1 0.0 0.2 0.0 0.6 0.0 5.4 0.0 0.0 2.0 0.1 2.8 0.3 8.9 6.3 0.0 0.0 0.0 1.9 0.0 0.7 0.0 0.2 0.8 0.2 7.5 29.2 0.0 0.7 0.0 0.4 0.8 0.5 0.1 0.0 3.5 0.3 0.5 0.1 10.6 0.1 0.1 2.4 0.0 0.0 0.1 2.3 0.0 1.5 4.2 3.5 5.6 0.0 6.9 0.0 0.2 0.0 0.0 1.0 0.0 0.0 0.0 30.4 0.0 7.3 0.2 0.0 0.8 7.2 19.5 13.4 13.1 5.9 11.8 18.6 16.2 18.2 10.5 14.5 42.9 12.0 0.0 3.2 0.0 0.6 8.2 4.1 4.9 16.5 43.5 5.8 9.3 19.3 0.0 1.9 1.8 0.0 0.5 0.1 13.5 0.0 0.1 0.3 2.3 0.2 16.0 10.7 0.4 3.8 0.0 0.4 1.7 4.1 1.6 0.0 0.1 3.3 0.1 6.8 240.6 16.2 2.7 0.0 36.9 7.4 0.0 1.5 7.8 3.6 2.8 8.2 5.8 0.0 1.5 164.7 0.0 12.3 1.2 0.0 2.2 0.9 0.1 4.9 5.2 0.0 3.9 2.6 0.1 0.9 6.9 3.3 1.4 0.8 0.2 8.5 0.3 KCNJ3 "GIRK1, KGA, Kir3.1" ENSG00000162989 "Potassium inwardly rectifying channel subfamily J member 3" P48549 2 154697855-154858354 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 32.7" "Group enriched" "Detected in many" 5 "Excitatory neurons: 309.6;Horizontal cells: 124.5;Inhibitory neurons: 431.3" "Group enriched" "Detected in many" 5 "breast cancer: 12.2;renal cancer: 4.4" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ: 1.5;SH-SY5Y: 1.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA024231, HPA064138" Uncertain Approved "Plasma membrane,Mitochondria" NA NA "Cluster 42: Non-specific - Transcription" "Cluster 6: Brain - Smell perception" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Mitochondria "Plasma membrane" "HPA024231: AB_1855558, HPA064138: " "unprognostic (1.45e-1)" "unprognostic (9.42e-2)" "unprognostic (2.66e-2)" "unprognostic (4.49e-4)" "unprognostic (8.89e-2)" "unprognostic (6.81e-2)" "unprognostic (7.24e-3)" "unprognostic (1.15e-2)" "unprognostic (4.25e-3)" "unprognostic (3.72e-3)" "unprognostic (3.33e-1)" "unprognostic (8.90e-3)" "unprognostic (3.75e-2)" "unprognostic (5.59e-1)" "unprognostic (2.32e-1)" "unprognostic (1.17e-1)" 0.5 1.4 5.7 0.1 8.7 0.1 0.3 32.7 17.0 1.6 4.7 0.8 10.7 0.1 1.1 0.1 0.4 1.3 15.1 14.6 3.7 10.5 3.1 0.2 0.0 2.2 4.3 0.1 2.1 10.4 6.8 0.0 2.4 6.5 0.8 5.0 0.0 11.3 5.3 0.1 9.5 0.2 1.6 0.4 0.7 0.4 4.1 0.0 0.1 0.2 0.0 0.4 0.6 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.4 1.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.9 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.3 0.3 0.2 0.1 0.1 0.1 5.7 8.7 32.7 17.0 14.6 3.7 2.2 4.3 2.4 1.6 4.1 6.4 0.3 0.0 0.0 38.8 0.0 0.8 5.3 0.0 0.0 10.9 3.7 1.7 49.0 5.7 0.0 20.2 14.6 0.0 0.0 0.1 5.9 0.1 0.3 0.0 0.0 1.3 31.1 0.0 309.6 3.2 0.0 5.4 0.0 0.0 0.0 0.0 0.0 1.3 0.1 124.5 431.3 7.0 0.0 0.0 2.1 0.0 6.2 0.6 1.8 5.6 0.0 0.7 0.0 32.6 6.8 0.0 1.2 4.1 0.0 6.1 16.2 8.7 0.0 3.9 0.0 8.0 1.6 0.4 0.3 0.0 1.8 0.0 0.8 1.9 8.4 4.7 KCNJ4 "HIR, hIRK2, HRK1, IRK3, Kir2.3" ENSG00000168135 "Potassium inwardly rectifying channel subfamily J member 4" P48050 22 38426327-38455199 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 15 "brain: 28.9;heart muscle: 33.3" "Cell type enhanced" "Detected in some" "Cardiomyocytes: 3.3;Excitatory neurons: 14.3;Horizontal cells: 10.1;Inhibitory neurons: 11.1;Microglial cells: 3.7;Muller glia cells: 6.2" "Cancer enhanced" "Detected in some" "glioma: 2.1;liver cancer: 1.8" "Group enriched" "Detected in many" 5 "amygdala: 10.5;basal ganglia: 18.9;cerebral cortex: 28.9;hippocampal formation: 21.9;white matter: 10.3" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 6 "SCLC-21H: 11.4" "Low region specificity" "Detected in many" "Group enriched" "Detected in many" 14 "amygdala: 5.9;basal ganglia: 13.7;cerebral cortex: 14.7;hippocampal formation: 12.3;olfactory bulb: 15.9" NA NA "Cluster 44: Heart - Cardiac muscle contraction" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "unprognostic (4.76e-2)" "unprognostic (2.60e-3)" "unprognostic (2.21e-3)" "unprognostic (1.65e-1)" "unprognostic (1.66e-1)" "unprognostic (2.50e-2)" "unprognostic (9.68e-3)" "unprognostic (3.12e-1)" "unprognostic (8.96e-2)" "unprognostic (2.07e-1)" "unprognostic (3.15e-3)" "unprognostic (1.28e-3)" "unprognostic (1.05e-1)" "unprognostic (5.41e-2)" 0.1 0.2 10.5 0.0 18.9 0.0 0.0 0.0 28.9 0.0 0.0 0.0 0.2 0.1 0.0 0.0 1.8 0.6 33.3 21.9 3.5 0.3 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.0 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.4 0.8 0.0 0.0 0.0 0.0 1.1 0.0 1.2 0.0 0.0 0.0 0.0 0.0 10.3 0.0 0.1 1.2 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.4 0.8 0.0 0.3 0.1 0.0 1.7 0.0 0.1 0.0 0.0 11.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.7 0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.5 18.9 0.0 28.9 21.9 3.5 0.0 0.0 0.0 0.0 0.0 10.3 0.0 0.0 0.0 1.6 0.0 0.3 0.0 0.0 0.0 0.5 0.1 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.8 0.1 0.1 0.0 0.0 0.0 14.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.1 11.1 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 3.7 0.0 6.2 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.1 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 KCNJ8 Kir6.1 ENSG00000121361 "Potassium inwardly rectifying channel subfamily J member 8" Q15842 12 21764955-21775600 "Disease related genes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Voltage-gated channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 71.3" "Group enriched" "Detected in many" 4 "Sertoli cells: 197.2;Smooth muscle cells: 61.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 15 "eosinophil: 1.5" "Lineage enriched" "Detected in single" 15 "granulocytes: 1.5" "Cell line enhanced" "Detected in some" "BJ: 11.1;CACO-2: 58.4;SH-SY5Y: 30.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA031066 Uncertain NA NA "Cluster 49: Eosinophils - Unknown function" "Cluster 18: Non-specific - Mitochondria" "Cluster 39: CACO-2 - Unknown function" "Cluster 48: Smooth muscle cells - ECM organization" "HPA031066: AB_10602240" "unprognostic (8.12e-3)" "unprognostic (1.89e-1)" "prognostic unfavorable (9.29e-4)" "unprognostic (7.81e-2)" "unprognostic (8.71e-2)" "unprognostic (2.34e-1)" "unprognostic (3.15e-2)" "unprognostic (1.27e-1)" "unprognostic (1.36e-2)" "unprognostic (3.90e-2)" "unprognostic (3.66e-3)" "unprognostic (2.88e-2)" "prognostic unfavorable (1.62e-6)" "unprognostic (4.70e-3)" "unprognostic (9.61e-2)" "unprognostic (1.73e-2)" "unprognostic (3.54e-3)" 28.6 17.3 4.9 3.2 5.4 0.0 22.1 4.8 5.7 17.0 11.6 15.6 1.2 18.8 0.7 3.6 14.8 1.8 71.3 4.7 5.0 13.9 41.9 13.8 2.5 5.2 5.3 16.8 42.4 1.8 7.8 3.0 5.1 13.0 0.3 0.8 6.4 8.4 17.1 5.8 5.9 5.5 5.2 8.0 12.7 1.0 7.2 0.6 16.1 4.5 0.4 15.1 11.5 4.7 0.0 0.1 0.9 0.0 1.4 3.2 0.0 11.1 4.4 6.5 1.9 58.4 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 1.1 0.0 4.3 2.9 0.0 0.0 0.0 0.0 0.0 4.5 0.0 3.2 0.0 0.7 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 30.2 0.0 0.0 0.0 5.0 0.0 0.0 0.0 6.6 2.7 0.0 3.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 5.4 4.8 5.7 4.7 5.0 5.2 5.3 5.1 5.2 7.2 4.7 18.7 3.2 29.5 2.9 0.0 1.3 0.4 0.0 0.6 0.0 9.2 3.0 28.3 0.0 0.6 1.8 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.7 10.8 12.8 1.2 0.0 3.6 1.3 0.0 9.8 0.0 0.9 0.0 1.0 2.9 23.0 0.3 0.0 0.2 0.0 0.0 0.8 1.5 0.1 0.3 0.3 1.8 0.0 0.0 13.2 0.0 0.5 0.4 1.2 0.0 0.7 0.1 0.4 0.0 0.0 0.0 2.0 197.2 3.3 61.6 0.0 1.0 0.1 0.9 0.3 0.3 0.5 0.2 0.6 KCNK2 "K2p2.1, TREK-1" ENSG00000082482 "Potassium two pore domain channel subfamily K member 2" O95069 1 215005775-215237090 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "adrenal gland: 53.0" "Group enriched" "Detected in some" 10 "Excitatory neurons: 19.7;Inhibitory neurons: 53.9;Microglial cells: 30.0;Oligodendrocyte precursor cells: 45.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC TERT1: 79.7;fHDF/TERT166: 76.3;hTERT-RPE1: 49.2;T-47d: 108.5;U-2197: 39.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 6: T47d - Mammary gland" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (3.43e-2)" "unprognostic (1.02e-1)" "unprognostic (6.91e-2)" "unprognostic (3.81e-4)" "unprognostic (2.58e-1)" "unprognostic (3.58e-2)" "unprognostic (3.48e-3)" "unprognostic (1.26e-1)" "unprognostic (1.49e-2)" "unprognostic (1.82e-1)" "unprognostic (1.03e-1)" "unprognostic (1.38e-1)" "unprognostic (2.98e-6)" "unprognostic (1.63e-2)" "unprognostic (4.37e-2)" "unprognostic (7.69e-3)" "unprognostic (7.46e-3)" 1.6 53.0 4.3 0.8 8.5 0.0 6.5 0.0 5.6 2.0 0.0 0.8 0.3 0.4 0.7 0.9 1.2 1.4 0.2 5.0 7.5 1.9 0.0 0.3 0.0 0.7 2.5 3.3 0.5 0.0 0.5 0.0 0.1 0.8 1.3 0.2 0.8 3.5 0.9 3.4 2.2 1.2 2.2 0.0 4.2 0.5 6.1 0.7 9.6 1.3 0.0 2.7 1.2 2.0 0.0 0.0 2.2 0.1 20.3 79.7 0.1 29.8 19.7 9.3 21.6 0.0 1.1 0.0 0.0 76.3 0.1 0.0 13.2 0.1 15.8 0.0 0.1 0.0 0.8 0.0 1.0 0.0 0.0 21.0 0.2 22.7 2.2 49.2 0.0 0.0 0.0 0.1 10.8 0.0 0.4 0.0 2.3 4.1 0.6 0.1 0.0 0.0 0.1 0.0 7.0 0.1 5.1 0.5 0.4 0.2 108.5 0.0 0.0 15.6 0.6 39.2 1.3 1.6 4.1 0.0 0.1 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 8.5 0.0 5.6 5.0 7.5 0.7 2.5 0.1 2.2 6.1 2.0 0.0 0.0 0.0 1.0 0.0 0.6 0.0 0.0 0.0 0.0 3.4 0.9 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.2 0.3 0.0 0.0 19.7 0.0 0.0 2.8 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 53.9 0.0 0.0 0.0 0.8 0.1 0.0 0.0 3.6 30.0 0.0 0.0 0.0 45.8 0.7 0.1 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.3 0.1 0.3 0.0 1.4 0.0 0.1 0.0 0.0 0.0 KCNK3 "K2p3.1, TASK, TASK-1, TASK1" ENSG00000171303 "Potassium two pore domain channel subfamily K member 3" O14649 2 26692690-26733420 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "adrenal gland: 181.6" "Cell type enhanced" "Detected in many" "Bipolar cells: 82.1;Collecting duct cells: 103.0;Enteroendocrine cells: 23.4;Exocrine glandular cells: 95.2" "Cancer enhanced" "Detected in many" "renal cancer: 9.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 5.1;EFO-21: 11.0;HeLa: 3.6;SCLC-21H: 25.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" NA NA "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 1: Pancreatic cells - Digestion" "unprognostic (4.16e-3)" "unprognostic (7.13e-2)" "unprognostic (1.04e-1)" "unprognostic (1.67e-4)" "unprognostic (2.08e-1)" "unprognostic (2.91e-1)" "unprognostic (5.01e-2)" "unprognostic (2.16e-1)" "unprognostic (3.31e-1)" "unprognostic (5.48e-2)" "unprognostic (3.77e-2)" "unprognostic (1.48e-2)" "prognostic unfavorable (2.37e-7)" "unprognostic (3.09e-2)" "unprognostic (7.45e-2)" "unprognostic (1.44e-2)" "unprognostic (9.24e-3)" 3.8 181.6 5.1 1.3 4.4 0.1 2.9 4.9 6.0 8.4 0.0 5.5 1.2 6.3 1.5 2.1 4.0 1.2 13.1 3.0 14.3 2.7 0.5 25.7 0.1 27.0 19.3 2.1 35.5 12.1 8.4 24.8 26.8 6.3 0.9 3.3 0.4 3.3 0.8 0.7 2.4 2.7 5.4 1.1 4.2 0.6 10.4 0.1 3.6 0.0 0.0 4.2 2.8 3.9 0.0 0.7 0.2 0.0 5.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 11.0 0.0 1.7 0.0 0.0 0.0 0.0 2.1 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.2 0.0 0.0 1.4 0.0 25.9 2.3 0.2 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.3 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 5.1 4.4 4.9 6.0 3.0 14.3 27.0 19.3 26.8 5.4 10.4 3.9 0.3 0.0 2.8 0.3 0.1 0.0 0.2 0.3 0.0 82.1 0.2 3.6 12.7 0.0 0.0 103.0 0.0 0.2 0.1 0.0 0.0 1.0 0.4 0.3 7.7 1.2 23.4 0.0 2.1 95.2 0.2 2.7 0.0 0.2 0.0 1.2 0.4 0.0 0.4 1.7 14.5 1.8 0.0 0.0 0.9 1.9 0.9 0.3 0.0 0.0 0.6 1.4 0.0 1.5 0.3 19.2 0.0 0.0 0.3 1.6 0.1 0.1 0.0 4.1 6.6 0.6 4.9 0.0 1.5 0.0 0.1 0.5 0.4 11.5 0.1 0.4 KCNK9 "K2p9.1, TASK-3, TASK3" ENSG00000169427 "Potassium two pore domain channel subfamily K member 9" Q9NPC2 8 139600838-139704109 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel" "Disease variant, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 7.8" "Group enriched" "Detected in some" 4 "Excitatory neurons: 16.0;Inhibitory neurons: 8.0;Late spermatids: 9.7" "Low cancer specificity" "Detected in some" "Region enriched" "Detected in some" 4 "cerebellum: 7.8" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA075842 Approved "Plasma membrane" NA NA "Cluster 69: Cerebellum - Gene expression regulation" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" "HPA075842: " "unprognostic (1.84e-2)" "unprognostic (2.57e-1)" "unprognostic (1.58e-1)" "unprognostic (8.96e-8)" "unprognostic (1.91e-1)" "unprognostic (8.17e-3)" "unprognostic (2.19e-3)" "unprognostic (1.65e-1)" "unprognostic (3.87e-1)" "unprognostic (1.69e-1)" "unprognostic (1.00e-2)" "unprognostic (3.21e-1)" "unprognostic (5.12e-6)" "unprognostic (2.94e-2)" "unprognostic (1.64e-1)" "unprognostic (9.99e-3)" "unprognostic (1.76e-1)" 0.0 1.6 0.0 0.1 0.0 0.0 0.0 7.8 1.9 0.2 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.0 0.8 0.3 0.0 0.0 0.0 0.7 0.0 0.9 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.1 0.0 0.4 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.8 1.9 0.2 0.1 0.8 0.3 0.9 0.0 0.4 0.3 0.0 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.4 0.0 0.0 1.8 0.0 0.0 0.0 0.1 1.9 0.3 2.1 0.0 0.0 0.0 0.0 0.0 16.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.0 0.0 0.0 0.0 9.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.5 0.8 0.3 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KCNMA1 "KCa1.1, mSLO1, SLO" ENSG00000156113 "Potassium calcium-activated channel subfamily M alpha 1" Q12791 10 76869601-77638369 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 138.7" "Cell type enhanced" "Detected in many" "Astrocytes: 471.1;Bipolar cells: 409.8;Excitatory neurons: 1023.7;Inhibitory neurons: 635.9;Oligodendrocyte precursor cells: 708.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "intermediate monocyte: 2.4;non-classical monocyte: 1.7" "Lineage enhanced" "Detected in single" "monocytes: 2.4" "Cell line enhanced" "Detected in many" "BJ: 100.8;hTERT-HME1: 115.3;PC-3: 159.6;U-138 MG: 112.6;U-87 MG: 109.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054648 Approved NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA054648: AB_2682556" "unprognostic (1.25e-1)" "unprognostic (2.23e-2)" "unprognostic (1.86e-2)" "unprognostic (5.29e-2)" "unprognostic (9.43e-2)" "unprognostic (2.25e-1)" "unprognostic (1.77e-1)" "unprognostic (2.81e-2)" "unprognostic (1.87e-1)" "unprognostic (1.34e-1)" "unprognostic (4.12e-3)" "unprognostic (1.20e-1)" "unprognostic (2.26e-2)" "unprognostic (1.42e-2)" "unprognostic (5.19e-2)" "unprognostic (1.42e-2)" "unprognostic (3.99e-3)" 10.9 12.6 36.2 8.9 38.0 1.0 15.8 1.0 45.0 54.4 4.2 118.2 7.3 138.7 31.4 33.7 47.8 22.4 3.7 36.4 10.1 11.4 19.2 9.6 7.8 4.8 15.2 13.9 8.0 0.2 26.9 4.8 5.7 48.3 21.1 40.2 42.8 76.1 96.6 5.0 23.3 92.8 1.0 24.1 33.6 5.8 15.6 2.1 3.0 18.7 3.5 44.3 24.6 28.4 0.3 30.3 0.1 0.3 4.6 24.8 0.3 100.8 89.2 23.9 11.8 6.7 0.6 0.0 0.7 75.9 56.8 0.2 0.0 59.0 14.6 60.9 0.6 0.0 0.0 0.0 45.0 0.0 0.4 17.4 10.7 38.3 115.3 84.0 9.8 0.5 0.0 0.0 42.6 1.2 1.9 0.2 1.8 0.2 159.6 0.1 3.6 0.1 15.3 0.2 9.1 1.1 0.0 2.5 0.1 11.9 12.2 0.1 65.4 112.6 12.7 20.6 90.0 0.0 0.2 0.0 109.8 0.1 45.1 0.0 0.1 0.0 0.0 2.4 0.0 0.7 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.0 1.7 0.0 0.0 0.1 36.2 38.0 1.0 45.0 36.4 10.1 4.8 15.2 5.7 1.0 15.6 28.4 0.9 0.0 4.3 471.1 2.8 2.0 71.7 5.7 17.6 409.8 30.4 43.9 3.5 5.7 4.8 1.8 60.5 0.3 0.5 2.8 29.4 3.3 74.4 20.9 17.9 3.4 4.9 0.0 1023.7 10.7 0.2 16.2 0.5 29.7 0.0 1.9 2.5 27.3 10.8 6.7 635.9 59.6 46.8 106.0 3.9 63.1 3.7 36.7 48.0 133.0 4.0 52.3 0.0 708.2 33.9 8.7 1.4 1.2 8.7 64.0 1.4 0.9 0.1 17.2 6.6 20.6 19.2 3.4 2.5 7.7 0.3 0.3 0.7 177.2 1.7 2.4 KCNMB1 hslo-beta ENSG00000145936 "Potassium calcium-activated channel subfamily M regulatory beta subunit 1" Q16558 5 170374671-170389634 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 59.2;intestine: 75.1;smooth muscle: 53.1" "Cell type enriched" "Detected in many" 6 "Peritubular cells: 354.3" "Cancer enhanced" "Detected in many" "prostate cancer: 6.0" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Group enriched" "Detected in many" 4 "dendritic cells: 5.7;monocytes: 5.9" "Cell line enhanced" "Detected in some" "REH: 8.8;SK-BR-3: 2.1;U-937: 3.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 12: Smooth muscle tissue - Mixed function" "Cluster 14: REH - Unknown function" "Cluster 48: Smooth muscle cells - ECM organization" "unprognostic (2.06e-2)" "unprognostic (2.70e-4)" "unprognostic (1.69e-2)" "unprognostic (1.27e-1)" "unprognostic (3.37e-2)" "unprognostic (8.88e-2)" "unprognostic (1.61e-2)" "unprognostic (3.46e-1)" "unprognostic (2.28e-1)" "unprognostic (4.68e-2)" "unprognostic (5.37e-1)" "unprognostic (1.00e-1)" "prognostic unfavorable (4.13e-6)" "unprognostic (1.08e-1)" "unprognostic (2.49e-1)" "unprognostic (4.31e-2)" "unprognostic (1.04e-2)" 5.7 1.8 2.7 10.5 2.3 1.7 6.9 2.5 2.7 16.8 1.4 75.1 4.3 59.2 6.2 16.6 20.6 7.3 4.2 2.1 2.4 1.4 0.7 4.0 1.7 5.9 4.0 4.0 0.7 0.3 0.5 1.1 6.2 24.5 8.9 1.1 6.8 50.6 1.0 2.9 14.3 53.1 3.4 2.3 21.5 2.7 4.2 1.0 1.4 1.1 1.3 32.6 11.2 3.9 0.1 0.1 1.5 0.3 0.1 0.0 0.2 0.2 0.0 0.0 0.0 0.3 0.3 0.1 1.0 0.1 0.4 0.1 0.0 0.0 0.0 0.3 0.1 1.2 0.6 0.2 0.0 0.4 0.2 0.2 0.0 0.1 0.2 0.1 0.1 0.4 0.3 0.7 0.1 0.7 0.0 0.8 0.3 0.0 0.1 8.8 0.0 0.2 0.0 0.2 0.4 0.2 0.1 2.1 0.0 0.7 0.1 1.0 0.5 0.2 0.3 0.3 0.0 0.4 0.2 0.1 0.1 3.8 0.1 1.3 3.3 0.3 0.1 5.9 0.1 0.2 0.2 0.1 5.7 0.3 0.1 0.1 0.9 0.4 5.1 2.0 0.2 1.0 2.7 2.3 2.5 2.7 2.1 2.4 5.9 4.0 6.2 3.4 4.2 3.9 1.3 0.0 6.3 0.3 1.2 2.0 1.2 0.4 0.0 1.6 2.5 55.1 3.7 4.3 4.5 1.8 6.2 0.5 1.7 0.1 0.0 0.1 0.6 0.6 14.4 3.6 0.0 1.3 0.1 0.4 0.6 9.8 0.0 0.6 19.7 0.4 1.8 0.4 7.4 1.7 0.3 0.2 0.0 18.9 10.9 4.5 38.5 15.6 3.6 4.7 27.8 0.6 2.1 0.0 0.1 0.0 0.0 354.3 0.3 1.3 0.0 0.1 4.5 2.3 46.0 2.2 43.6 0.7 1.2 0.1 1.7 0.5 1.7 1.4 0.0 0.7 KCNMB2 ENSG00000197584 "Potassium calcium-activated channel subfamily M regulatory beta subunit 2" Q9Y691 3 178272932-178844429 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "epididymis: 35.4;fallopian tube: 13.9;ovary: 12.7" "Group enriched" "Detected in some" 4 "Inhibitory neurons: 791.1;Oligodendrocyte precursor cells: 1982.5" "Cancer enhanced" "Detected in some" "pancreatic cancer: 1.0" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ hTERT+: 2.4;SCLC-21H: 3.3" CAB022649 Uncertain NA NA "Cluster 68: Epididymis - Unknown function" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB022649: " "unprognostic (9.52e-2)" "unprognostic (1.13e-1)" "unprognostic (6.82e-2)" "unprognostic (2.07e-1)" "unprognostic (2.19e-2)" "unprognostic (1.04e-2)" "unprognostic (2.43e-2)" "unprognostic (6.97e-2)" "unprognostic (6.74e-2)" "unprognostic (2.15e-1)" "unprognostic (3.58e-3)" "unprognostic (3.57e-2)" "unprognostic (1.71e-2)" "unprognostic (2.07e-1)" "unprognostic (1.68e-1)" "unprognostic (6.89e-4)" "unprognostic (7.85e-2)" 0.3 5.1 2.5 0.0 3.0 0.0 0.7 1.5 4.0 1.4 0.9 1.2 0.5 2.9 35.4 0.4 13.9 0.5 5.8 4.0 2.3 3.4 0.2 1.1 0.0 3.0 2.7 12.7 4.0 0.2 1.7 0.1 2.3 0.5 0.3 0.2 0.2 1.1 0.2 0.3 0.5 1.9 2.2 1.3 3.0 0.2 2.1 0.0 0.3 0.2 0.0 0.2 0.7 2.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.2 0.0 0.0 0.6 0.9 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.9 0.0 0.5 3.3 0.0 0.0 0.1 0.0 0.2 0.7 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 3.0 1.5 4.0 4.0 2.3 3.0 2.7 2.3 2.2 2.1 2.1 0.0 0.0 0.0 18.3 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 3.3 0.0 0.8 0.0 0.0 0.0 0.0 0.1 3.9 0.0 0.1 8.7 0.2 0.0 13.8 0.0 311.8 0.0 0.0 2.7 0.0 1.9 0.0 12.7 1.8 0.0 0.0 0.0 791.1 0.0 4.1 0.0 0.0 0.1 2.8 0.1 0.0 12.2 0.0 0.0 0.0 1982.5 6.8 0.1 0.0 0.0 0.0 0.0 0.0 1.3 10.0 0.0 0.0 0.8 0.4 0.0 0.0 0.1 0.0 0.0 0.1 1.7 0.0 0.1 KCNMB3 "KCNMB2, KCNMBL" ENSG00000171121 "Potassium calcium-activated channel subfamily M regulatory beta subunit 3" Q9NPA1 3 179236691-179267002 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Cone photoreceptor cells: 14.6;Early spermatids: 11.2;Late spermatids: 13.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CACO-2: 4.8;HEL: 8.1;NB-4: 5.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA015665, HPA019185" Approved Approved Nucleoplasm,Mitochondria NA NA "Cluster 15: NK-cells - Transcription" "Cluster 18: Non-specific - Mitochondria" "Cluster 32: U-937 - Innate immune response" "Cluster 9: Photoreceptor cells - Phototransduction" Nucleoplasm Mitochondria "HPA015665: AB_1852142, HPA019185: AB_1852144" "unprognostic (2.50e-1)" "unprognostic (1.32e-1)" "unprognostic (6.76e-5)" "unprognostic (2.65e-2)" "unprognostic (2.22e-2)" "unprognostic (2.08e-1)" "unprognostic (4.59e-3)" "unprognostic (1.14e-1)" "unprognostic (9.15e-3)" "unprognostic (5.09e-2)" "unprognostic (1.87e-2)" "unprognostic (1.95e-5)" "unprognostic (5.93e-10)" "unprognostic (7.22e-2)" "unprognostic (4.72e-1)" "unprognostic (8.69e-2)" "unprognostic (3.49e-2)" 4.9 3.6 1.5 2.2 1.8 1.1 4.6 1.7 1.9 3.5 1.6 4.0 1.5 3.2 1.5 2.0 2.9 1.7 3.5 1.5 1.7 4.8 5.5 3.0 2.2 1.9 1.7 3.2 5.3 1.2 3.3 4.2 1.8 4.2 1.5 2.3 3.1 1.1 1.3 2.4 3.5 1.4 1.3 7.5 3.7 3.9 1.7 0.9 3.2 0.5 1.9 3.7 2.7 1.7 2.2 0.5 0.8 0.0 0.9 0.8 1.3 0.6 0.3 0.9 0.4 4.8 1.9 0.1 2.1 0.4 1.8 0.8 0.0 0.1 1.0 2.7 0.3 8.1 2.6 1.8 0.8 0.1 2.5 1.3 0.4 0.6 0.0 0.7 0.8 0.0 0.3 0.0 1.1 1.5 0.1 5.7 0.0 0.9 1.6 2.4 0.0 0.1 0.7 1.5 1.1 0.2 0.7 0.8 0.5 0.7 2.1 4.4 0.5 0.4 0.7 0.2 0.6 0.7 0.3 2.6 0.4 3.1 0.6 0.8 0.1 0.1 0.3 0.1 0.2 1.2 0.2 0.3 0.0 0.6 0.2 0.2 0.6 1.1 0.0 0.1 0.4 0.0 1.5 1.8 1.7 1.9 1.5 1.7 1.9 1.7 1.8 1.3 1.7 1.7 4.2 0.0 3.6 3.9 2.9 0.3 1.4 0.3 0.0 2.5 2.1 1.3 1.1 2.8 1.5 0.0 14.6 1.2 0.6 3.8 0.0 5.0 11.2 1.5 2.3 5.3 4.9 0.8 3.4 3.6 1.3 1.5 0.5 2.0 2.5 3.4 2.9 1.4 1.1 0.0 4.6 1.4 0.0 2.1 1.9 13.3 2.8 1.4 0.0 5.6 1.4 1.8 1.0 4.0 6.4 3.3 0.8 3.0 0.9 1.7 1.9 0.3 1.1 7.8 6.6 1.6 1.6 2.0 2.6 0.3 0.1 1.2 1.0 2.3 1.4 1.0 KCNMB4 ENSG00000135643 "Potassium calcium-activated channel subfamily M regulatory beta subunit 4" Q86W47 12 70366290-70434292 "FDA approved drug targets, Predicted membrane proteins" "Ion transport, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 54.2;choroid plexus: 18.9" "Cell type enhanced" "Detected in many" "Excitatory neurons: 95.7;Hepatic stellate cells: 37.1;Inhibitory neurons: 45.0;Oligodendrocytes: 86.9" "Cancer enhanced" "Detected in many" "glioma: 10.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "NTERA-2: 7.7;RH-30: 8.2;RT4: 9.3;SuSa: 7.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA072287 Enhanced Approved Approved Cytosol NA NA "Cluster 70: Brain - Nervous system development" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" Cytosol "HPA072287: AB_2686507" "unprognostic (3.90e-1)" "unprognostic (1.72e-2)" "unprognostic (2.69e-2)" "unprognostic (2.62e-2)" "unprognostic (6.98e-2)" "unprognostic (1.13e-3)" "unprognostic (1.85e-1)" "unprognostic (2.48e-2)" "unprognostic (3.50e-1)" "unprognostic (2.95e-2)" "unprognostic (3.75e-1)" "unprognostic (2.47e-2)" "unprognostic (2.19e-2)" "unprognostic (1.96e-1)" "unprognostic (1.78e-1)" "unprognostic (4.62e-2)" "unprognostic (1.05e-2)" 2.3 14.9 35.3 1.1 39.5 0.2 2.0 29.7 43.5 3.1 18.9 8.6 1.0 1.8 1.1 1.0 1.7 1.4 4.7 36.4 29.7 3.7 0.5 6.1 1.3 38.5 32.2 2.6 0.5 0.2 1.9 2.5 32.1 3.2 1.2 1.9 1.7 2.1 2.4 2.6 3.0 1.2 28.9 1.2 2.1 2.1 38.4 1.3 2.1 1.5 1.0 2.5 2.6 54.2 0.0 0.3 4.9 2.7 0.3 0.2 0.5 0.6 0.9 0.2 0.7 0.2 1.8 2.4 0.3 0.0 1.0 0.0 5.3 0.8 0.2 1.1 3.1 1.3 1.1 2.9 0.0 0.1 0.1 1.4 0.1 0.0 0.0 0.5 0.2 3.5 0.0 0.0 0.9 0.7 1.8 0.4 7.7 0.1 5.6 2.6 8.2 0.2 0.2 9.3 2.4 2.9 0.7 0.9 0.0 7.3 2.7 0.1 0.1 0.3 1.3 0.1 0.3 1.7 0.0 2.5 0.4 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.3 0.4 0.6 0.0 0.0 0.0 0.0 0.1 0.1 35.3 39.5 29.7 43.5 36.4 29.7 38.5 32.2 32.1 28.9 38.4 54.2 8.5 0.0 0.6 2.6 1.1 3.2 0.2 0.4 0.6 23.1 2.8 1.9 4.3 0.0 0.2 23.9 0.0 0.2 2.1 0.1 0.0 0.1 0.9 4.7 1.1 8.7 0.0 3.2 95.7 0.0 0.4 9.6 0.0 3.4 0.0 7.2 37.1 0.7 1.2 0.0 45.0 0.4 0.0 10.8 2.6 2.2 6.5 2.9 1.8 20.6 0.7 1.5 0.0 13.6 86.9 0.0 0.0 18.0 0.2 0.8 0.0 9.7 0.0 3.0 0.0 12.8 5.1 2.2 7.8 0.2 5.5 0.3 1.4 14.0 0.5 0.0 KCNN1 "hSK1, KCa2.1" ENSG00000105642 "Potassium calcium-activated channel subfamily N member 1" Q92952 19 17951293-18000080 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Transport" "Calmodulin-binding, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in some" 41 "brain: 92.2" "Cell type enhanced" "Detected in many" "Excitatory neurons: 12.8;Langerhans cells: 19.8;Skeletal myocytes: 6.8" "Cancer enhanced" "Detected in some" "testis cancer: 3.5" "Group enriched" "Detected in many" 7 "amygdala: 34.8;basal ganglia: 30.6;cerebral cortex: 67.2;hippocampal formation: 92.2;white matter: 30.6" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 12 "REH: 155.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA065938 Approved "Actin filaments,Cytosol" Yes No "Cluster 10: Brain - Neuronal signaling" "Cluster 14: REH - Unknown function" "Cluster 50: Fibroblasts - ECM organization" "Actin filaments, Cytosol" "HPA065938: AB_2685582" "unprognostic (7.55e-2)" "unprognostic (4.03e-2)" "unprognostic (1.82e-1)" "unprognostic (7.80e-2)" "unprognostic (1.90e-1)" "unprognostic (8.94e-5)" "unprognostic (3.92e-3)" "unprognostic (1.01e-1)" "unprognostic (8.42e-2)" "unprognostic (3.59e-1)" "unprognostic (2.71e-3)" "unprognostic (3.38e-1)" "unprognostic (5.21e-3)" "unprognostic (2.70e-2)" "unprognostic (1.14e-1)" "unprognostic (7.24e-3)" "unprognostic (3.24e-1)" 0.3 0.2 34.8 0.4 30.6 0.1 0.2 0.0 67.2 0.9 0.0 0.3 0.1 0.6 0.1 0.2 0.1 0.1 1.1 92.2 0.0 0.2 0.0 0.1 0.1 4.4 0.0 1.8 0.1 1.6 1.0 0.0 6.8 0.6 0.0 0.8 0.4 0.2 0.1 0.1 0.2 0.0 0.0 0.1 0.2 2.2 0.0 0.1 0.1 0.0 0.1 0.1 0.2 30.6 0.1 0.6 0.2 6.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 1.6 0.0 0.5 0.2 5.3 0.0 0.2 0.2 2.5 5.0 0.3 0.1 0.0 0.0 12.8 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.3 0.2 0.0 0.4 0.0 0.0 1.8 0.0 0.1 155.3 0.0 0.2 0.0 0.0 0.2 8.6 0.0 0.0 0.1 0.4 0.3 0.2 0.1 0.0 4.7 0.0 0.0 0.1 0.0 0.1 0.0 0.3 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 34.8 30.6 0.0 67.2 92.2 0.0 4.4 0.0 6.8 0.0 0.0 30.6 0.4 0.0 0.0 3.6 1.1 2.5 3.7 0.0 0.0 2.3 0.2 0.3 0.8 0.0 0.7 0.0 2.1 0.1 1.5 0.2 0.0 0.0 0.2 1.3 1.5 1.9 0.0 0.0 12.8 0.0 0.2 2.6 0.0 1.9 0.0 3.6 0.4 0.2 0.1 0.0 4.4 0.0 0.0 0.3 19.8 0.4 0.9 2.1 5.4 1.9 2.2 1.4 1.0 3.0 0.7 0.2 0.0 1.9 0.7 2.8 0.0 0.2 0.0 1.0 0.0 6.8 1.8 0.6 4.0 0.0 3.8 0.1 1.5 2.2 0.0 1.8 KCNN2 "hSK2, KCa2.2" ENSG00000080709 "Potassium calcium-activated channel subfamily N member 2" Q9H2S1 5 114055926-114496500 "FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Transport" "Calmodulin-binding, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 27.8;brain: 20.8;liver: 31.3" "Cell type enhanced" "Detected in some" "Astrocytes: 36.2;Excitatory neurons: 149.9;Inhibitory neurons: 97.0;Oligodendrocyte precursor cells: 63.3" "Group enriched" "Detected in some" 7 "glioma: 3.5;melanoma: 3.2;prostate cancer: 12.6" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ: 17.5;NTERA-2: 6.4;SK-MEL-30: 12.9;THP-1: 21.8;U-937: 7.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA038221 Uncertain Uncertain "Nucleoplasm,Plasma membrane" NA NA "Cluster 15: Liver - Metabolism" "Cluster 43: THP-1 - Innate immune response" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Nucleoplasm, Plasma membrane" "HPA038221: AB_10673044" "unprognostic (9.22e-3)" "unprognostic (1.90e-1)" "unprognostic (2.04e-1)" "unprognostic (5.65e-2)" "unprognostic (1.43e-1)" "unprognostic (1.40e-1)" "unprognostic (2.94e-1)" "unprognostic (1.42e-1)" "unprognostic (1.11e-2)" "unprognostic (1.56e-1)" "unprognostic (1.09e-1)" "unprognostic (1.15e-1)" "unprognostic (1.66e-1)" "unprognostic (1.23e-2)" "unprognostic (4.61e-1)" "unprognostic (3.16e-1)" "unprognostic (4.25e-1)" 0.4 27.8 7.8 0.2 10.8 0.0 0.5 11.3 14.0 2.0 2.2 1.4 0.3 2.9 0.3 0.2 0.4 0.4 6.8 20.8 7.5 3.9 31.3 2.3 0.4 11.1 4.7 0.7 4.5 0.4 7.6 0.0 6.7 9.6 0.7 2.5 0.5 4.3 9.5 1.3 0.3 2.0 9.0 0.5 0.7 3.0 8.2 0.2 0.3 6.7 0.2 2.3 1.0 11.1 0.1 0.0 0.0 0.0 0.0 0.0 2.1 17.5 2.7 0.3 0.0 0.0 0.2 0.0 0.5 0.0 2.3 0.0 2.3 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 3.8 0.0 0.2 0.0 0.3 0.0 1.4 6.4 0.0 0.0 0.0 0.0 0.8 0.2 0.1 2.1 0.0 0.0 0.2 12.9 0.4 0.3 21.8 0.3 0.0 0.5 1.8 0.0 0.1 0.0 0.1 2.0 7.9 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.8 10.8 11.3 14.0 20.8 7.5 11.1 4.7 6.7 9.0 8.2 11.1 1.4 0.0 1.1 36.2 0.0 0.3 0.3 0.0 0.0 7.9 0.6 1.3 15.1 0.0 0.0 0.0 2.1 0.0 0.0 0.3 0.0 0.6 0.6 0.5 0.0 8.2 0.0 0.0 149.9 0.9 0.0 0.8 0.0 1.3 0.0 0.8 5.0 18.3 0.0 0.0 97.0 1.0 0.0 1.0 0.3 0.5 0.0 0.1 21.4 6.5 0.0 0.4 0.0 63.3 9.2 1.0 0.1 0.0 1.2 4.7 0.0 0.7 0.0 7.8 0.0 0.1 0.3 0.3 6.5 0.3 0.3 0.0 0.0 0.2 0.5 0.6 KCNN3 "hSK3, KCa2.3, SKCA3" ENSG00000143603 "Potassium calcium-activated channel subfamily N member 3" Q9UGI6 1 154697455-154870281 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Transport" "Calmodulin-binding, Ion channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 33.1" "Group enriched" "Detected in many" 4 "Astrocytes: 168.8;Skeletal myocytes: 121.5" "Cancer enhanced" "Detected in many" "glioma: 5.8" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "basophil: 4.7;memory B-cell: 2.6" "Group enriched" "Detected in many" 11 "B-cells: 2.6;granulocytes: 4.7;monocytes: 1.4" "Cell line enhanced" "Detected in some" "Daudi: 39.3;HMC-1: 26.1;Karpas-707: 65.5;RPMI-8226: 18.7;U-266/70: 62.3;U-698: 21.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA057127 Enhanced Approved Nucleoplasm NA NA "Cluster 34: Basophils - Unknown function" "Cluster 70: Brain - Nervous system development" "Cluster 29: U-266 - Adaptive immune response" "Cluster 64: Astrocytes - Nervous system maintenance" Nucleoplasm "HPA057127: AB_2683345" "unprognostic (2.09e-1)" "unprognostic (2.91e-2)" "unprognostic (3.41e-2)" "unprognostic (1.04e-1)" "unprognostic (7.22e-2)" "unprognostic (4.06e-2)" "unprognostic (2.19e-2)" "unprognostic (2.03e-1)" "unprognostic (3.43e-2)" "unprognostic (9.51e-2)" "unprognostic (4.07e-3)" "unprognostic (4.89e-2)" "prognostic unfavorable (1.97e-4)" "unprognostic (1.71e-2)" "unprognostic (1.54e-1)" "unprognostic (6.93e-2)" "unprognostic (1.80e-2)" 0.9 1.1 24.9 3.9 24.2 0.3 0.7 15.1 12.8 2.7 0.0 7.4 3.0 4.9 0.6 1.7 5.7 1.5 2.1 16.9 18.5 2.1 0.2 1.5 3.5 14.4 33.1 0.8 0.3 1.1 1.2 0.0 16.5 1.6 2.4 0.3 1.3 1.2 6.1 0.3 2.2 6.0 12.9 3.5 2.4 0.5 25.7 1.0 1.9 5.3 5.5 3.1 1.6 11.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 39.3 3.1 0.0 0.1 0.1 0.9 0.0 0.0 0.1 0.1 0.3 0.0 0.0 0.0 0.0 26.1 0.5 0.0 0.3 0.0 0.1 0.8 0.1 0.0 65.5 0.6 0.1 0.2 0.0 0.8 0.0 2.5 0.0 16.2 18.7 0.0 0.0 0.8 0.4 0.0 0.1 0.0 0.2 0.0 0.0 1.2 1.1 0.0 0.0 0.0 62.3 8.8 21.4 0.6 0.0 6.2 4.7 0.0 0.0 0.0 0.1 0.0 2.6 0.0 0.0 0.2 0.8 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.1 24.9 24.2 15.1 12.8 16.9 18.5 14.4 33.1 16.5 12.9 25.7 11.0 8.7 12.8 2.7 168.8 3.9 1.3 0.6 0.7 0.6 0.5 0.1 0.0 3.4 0.0 2.1 0.0 2.1 0.1 0.0 0.0 3.9 0.2 3.4 26.6 0.6 25.9 4.2 0.0 18.2 0.2 0.0 16.3 0.0 5.8 0.0 2.0 13.9 0.3 0.4 0.0 13.6 0.0 4.1 0.0 3.0 7.7 0.3 0.9 0.0 11.2 0.0 2.2 0.0 12.1 5.0 0.0 2.2 0.0 30.9 0.5 0.0 0.3 18.3 0.4 0.0 121.5 1.3 0.7 0.2 0.8 1.7 0.0 0.5 22.5 0.0 0.7 KCNN4 "hIKCa1, hKCa4, hSK4, IK, KCa3.1" ENSG00000104783 "Potassium calcium-activated channel subfamily N member 4" O15554 19 43766533-43781257 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Immunity, Ion transport, Transport" "Calmodulin-binding, Ion channel" "Disease variant, FDA approved drug targets, Hereditary hemolytic anemia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "salivary gland: 130.8" "Group enriched" "Detected in many" 6 "Cytotrophoblasts: 231.1;Syncytiotrophoblasts: 763.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CAPAN-2: 85.7;WM-115: 258.6" "Region enhanced" "Detected in single" "olfactory bulb: 1.9" "Not detected" "Not detected" "HPA013367, HPA053841, HPA059622" Approved Approved "Plasma membrane,Cytosol" NA NA "Cluster 19: B-cells - Humoral immune response" "Cluster 24: Salivary gland - Salivary secretion" "Cluster 17: WM-115 - Nervous system development" "Cluster 18: Syncytiotrophoblasts - Pregnancy hormone signaling" "Plasma membrane, Cytosol" "HPA013367: , HPA053841: AB_2682278, HPA059622: AB_2684085" "unprognostic (1.23e-2)" "unprognostic (3.22e-2)" "unprognostic (4.29e-1)" "unprognostic (3.74e-3)" "prognostic unfavorable (2.68e-4)" "unprognostic (1.98e-2)" "unprognostic (7.33e-2)" "unprognostic (1.42e-2)" "unprognostic (2.48e-3)" "unprognostic (4.12e-2)" "prognostic unfavorable (4.56e-4)" "unprognostic (9.96e-3)" "prognostic unfavorable (1.05e-14)" "unprognostic (3.70e-2)" "unprognostic (2.17e-2)" "unprognostic (7.50e-2)" "prognostic favorable (1.75e-4)" 3.6 0.7 1.7 11.8 1.9 18.3 12.4 1.3 1.8 11.8 1.4 18.5 6.4 1.6 1.8 6.5 5.8 3.5 1.1 1.5 1.6 1.4 0.8 7.3 12.5 1.6 1.6 0.6 1.0 0.0 0.7 14.3 1.7 28.6 6.2 0.2 130.8 7.5 0.4 29.1 26.0 0.7 1.9 20.5 35.1 2.7 2.0 5.0 2.1 0.2 9.2 18.2 6.5 2.3 22.4 35.2 0.1 0.2 0.0 2.2 55.0 0.8 1.7 0.7 0.1 0.5 85.7 6.7 9.8 0.9 9.1 13.6 0.0 28.8 1.7 40.9 0.0 29.8 48.6 0.5 0.0 0.3 0.3 0.0 2.9 1.3 6.6 52.7 0.0 0.3 2.6 2.3 0.3 18.7 4.8 17.9 0.2 43.1 42.4 16.8 0.7 21.0 13.0 55.3 0.2 0.1 62.2 70.1 32.6 1.7 0.3 15.1 1.5 12.6 75.9 0.4 45.3 0.1 1.4 2.6 45.9 5.1 258.6 5.8 21.1 0.0 0.5 35.3 0.7 37.3 10.4 5.0 30.7 21.6 6.6 6.3 1.1 0.0 20.1 0.9 15.2 11.2 1.7 1.9 1.3 1.8 1.5 1.6 1.6 1.6 1.7 1.9 2.0 2.3 1.6 0.0 1.9 1.3 24.7 2.8 45.7 79.5 3.4 0.2 69.7 56.6 0.4 7.2 18.4 1.8 4.2 231.1 4.1 22.0 0.0 5.9 1.2 1.7 0.2 4.0 0.0 32.4 1.5 3.9 14.1 2.3 57.1 4.2 0.0 0.0 0.4 0.0 43.7 0.0 1.1 8.9 2.0 7.2 78.2 0.3 0.0 23.3 21.4 1.0 2.5 0.1 1.0 0.5 0.8 63.8 22.3 0.0 22.4 63.5 1.0 0.1 2.2 0.5 0.0 0.3 1.4 0.4 1.4 2.1 2.3 763.3 9.5 0.0 51.1 65.6 KCNQ1 "JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1" ENSG00000053918 "Potassium voltage-gated channel subfamily Q member 1" P51787 11 2444684-2849105 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Calmodulin-binding, Ion channel, Potassium channel, Voltage-gated channel" "Atrial fibrillation, Deafness, Diabetes mellitus, Disease variant, FDA approved drug targets, Long QT syndrome, Short QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 197.1;stomach 1: 98.9" "Cell type enhanced" "Detected in many" "Granulosa cells: 47.6;Microglial cells: 71.2;Undifferentiated cells: 57.8" "Cancer enhanced" "Detected in all" "colorectal cancer: 42.5" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "HMC-1: 33.4;OE19: 41.4;RPMI-8226: 23.2;U-266/70: 11.5;U-937: 13.4" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB018656, HPA048553, HPA071107" Enhanced Supported "Endoplasmic reticulum,Plasma membrane" NA NA "Cluster 14: Monocytes - Unknown function" "Cluster 29: Non-specific - Vesicular transport" "Cluster 21: OE19 - Mitochondria" "Cluster 53: Intestinal epithelial cells - Unknown function" "Endoplasmic reticulum" "Plasma membrane" "CAB018656: AB_2131551, HPA048553: AB_2680438, HPA071107: " "unprognostic (6.02e-2)" "unprognostic (2.48e-1)" "unprognostic (6.39e-3)" "unprognostic (4.38e-1)" "unprognostic (1.86e-1)" "unprognostic (1.83e-1)" "unprognostic (3.46e-2)" "unprognostic (7.36e-2)" "unprognostic (8.07e-2)" "unprognostic (8.81e-2)" "unprognostic (1.58e-1)" "unprognostic (5.39e-2)" "unprognostic (2.46e-3)" "prognostic favorable (9.85e-4)" "unprognostic (3.99e-2)" "unprognostic (4.19e-2)" "unprognostic (5.27e-2)" 5.4 197.1 2.1 9.0 2.4 14.2 3.0 2.4 2.6 16.5 5.7 22.6 47.8 2.9 14.1 2.9 8.9 19.5 28.4 2.6 2.6 25.3 1.8 15.9 5.0 4.1 3.1 1.4 61.2 21.4 5.5 7.6 3.9 6.1 15.2 0.7 20.0 50.2 1.0 1.2 39.7 3.1 4.0 8.2 98.9 1.6 4.2 3.6 71.6 1.6 2.9 14.7 1.6 4.4 0.0 0.1 0.0 5.8 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.6 2.6 1.9 5.2 0.0 0.4 0.1 0.7 0.0 0.0 0.4 1.3 0.0 3.7 0.4 0.3 0.0 33.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.7 0.0 0.7 1.3 41.4 0.2 0.1 0.0 23.2 8.0 2.7 0.7 5.6 0.7 0.0 0.0 0.5 0.2 10.3 0.0 0.0 0.3 0.2 0.0 11.5 0.0 0.0 0.0 13.4 0.0 0.7 3.1 3.1 0.0 1.8 0.0 0.8 0.4 0.1 3.8 0.3 1.0 1.2 3.3 0.0 2.8 1.3 0.3 1.0 2.1 2.4 2.4 2.6 2.6 2.6 4.1 3.1 3.9 4.0 4.2 4.4 7.1 3.2 12.9 0.3 8.4 0.6 8.0 4.2 0.0 1.7 6.1 1.8 18.6 14.3 7.1 29.5 0.0 1.1 0.3 34.0 15.6 23.2 2.0 3.3 0.4 6.3 6.6 0.4 13.7 21.7 1.4 1.0 23.4 4.9 19.7 47.6 9.3 1.1 17.3 0.0 20.0 26.1 8.2 25.4 15.9 0.9 0.3 19.6 1.8 71.2 11.0 0.5 1.0 43.7 34.9 15.3 20.2 0.0 6.4 5.2 30.9 2.0 4.4 0.5 6.6 0.4 1.7 0.2 0.2 0.1 1.0 2.1 4.0 16.6 57.8 20.4 KDR "CD309, FLK1, VEGFR, VEGFR2" ENSG00000128052 "Kinase insert domain receptor" P35968 4 55078481-55125595 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Angiogenesis, Differentiation, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 9 "Adipocytes: 157.8;Endothelial cells: 143.8;Hepatic stellate cells: 158.1;Muller glia cells: 206.6" "Cancer enhanced" "Detected in all" "renal cancer: 27.3" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 9 "HUVEC TERT2: 74.8;TIME: 83.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004028, HPA073577" Enhanced Approved "Nuclear membrane,Vesicles" "Intracellular and membrane" NA NA 11000000 "Cluster 82: Adipose tissue - ECM organization" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 5: Muller glia cells - Visual perception" Vesicles "Nuclear membrane" "CAB004028: AB_2212507, HPA073577: " "unprognostic (1.61e-1)" "unprognostic (2.03e-1)" "unprognostic (9.65e-2)" "unprognostic (1.97e-1)" "unprognostic (9.63e-2)" "unprognostic (1.22e-2)" "unprognostic (1.78e-3)" "unprognostic (2.59e-2)" "unprognostic (1.19e-2)" "unprognostic (1.10e-1)" "unprognostic (8.79e-3)" "unprognostic (1.34e-1)" "prognostic unfavorable (7.26e-4)" "unprognostic (4.00e-2)" "unprognostic (2.30e-1)" "unprognostic (3.22e-1)" "unprognostic (1.86e-1)" 41.6 11.7 2.7 4.3 3.8 0.0 26.1 2.8 4.1 14.8 10.4 6.3 2.2 39.5 2.9 4.0 17.9 5.6 20.6 2.1 2.8 15.7 9.2 23.5 2.8 3.2 3.6 5.2 6.2 8.6 11.0 30.9 3.5 11.7 1.0 16.4 5.3 10.0 6.5 5.9 7.5 7.5 3.3 4.4 8.4 1.8 4.5 1.0 34.4 4.6 1.0 8.6 7.5 3.4 0.0 0.0 4.4 0.0 0.4 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.0 0.0 8.5 0.0 0.0 0.9 0.0 0.0 0.4 0.2 74.8 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.9 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 83.4 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 3.8 2.8 4.1 2.1 2.8 3.2 3.6 3.5 3.3 4.5 3.4 157.8 0.0 4.9 0.0 1.4 2.5 0.5 0.1 1.8 11.7 1.3 2.5 9.4 1.5 18.4 0.0 0.0 0.1 0.8 0.0 0.0 0.5 0.8 0.4 2.6 143.8 0.0 2.7 0.1 0.0 0.1 8.3 0.0 0.8 2.5 0.0 158.1 3.3 0.4 0.0 1.3 0.0 0.0 10.6 2.1 0.9 0.0 1.2 7.2 7.5 0.0 206.6 0.0 0.0 6.1 0.5 0.0 0.4 1.3 0.5 0.0 0.0 3.9 7.9 0.0 0.9 7.5 0.3 0.9 0.8 2.7 0.1 0.6 1.6 0.0 1.4 KEAP1 "INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454" ENSG00000079999 "Kelch like ECH associated protein 1" Q14145 19 10486125-10503558 "Cancer-related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins" "Host-virus interaction, Ubl conjugation pathway" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 178.2" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005558, CAB025337" Approved Supported "Nucleoplasm,Centriolar satellite,Cytosol" NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 80: Striated muscle - Unknown function" "Cluster 24: NB-4 - Immune response" "Cluster 25: Spermatids - Spermatogenesis" "Nucleoplasm, Centriolar satellite" Cytosol "CAB025337: , HPA005558: AB_1079175" "unprognostic (1.98e-1)" "prognostic favorable (3.28e-4)" "unprognostic (1.61e-1)" "unprognostic (1.02e-1)" "unprognostic (1.42e-1)" "unprognostic (1.63e-2)" "unprognostic (2.64e-2)" "unprognostic (1.46e-1)" "unprognostic (1.48e-1)" "unprognostic (5.22e-3)" "unprognostic (2.04e-1)" "unprognostic (9.99e-2)" "unprognostic (1.29e-1)" "unprognostic (7.71e-3)" "unprognostic (5.06e-1)" "unprognostic (8.18e-2)" "unprognostic (1.60e-2)" 31.3 41.2 54.8 20.5 61.6 20.4 30.3 61.8 60.9 32.7 49.7 37.6 26.5 31.3 22.2 55.4 28.9 24.3 60.7 53.2 59.4 32.5 60.9 25.3 23.2 61.4 60.5 25.3 32.8 24.3 30.0 17.0 60.3 36.8 16.5 16.4 34.7 24.9 178.2 38.7 27.5 18.7 58.8 32.2 33.2 20.5 59.6 23.0 35.6 75.7 18.5 41.4 36.3 68.4 58.0 102.8 27.2 35.1 55.8 45.4 30.3 48.1 35.9 46.6 41.6 73.7 54.2 82.9 122.9 53.3 34.8 49.7 55.6 36.9 23.7 78.3 61.7 126.3 29.9 87.9 54.5 65.4 63.9 50.0 51.0 53.5 25.1 39.1 46.3 23.7 79.1 135.4 41.6 79.9 46.1 177.8 80.8 54.2 88.6 84.6 34.8 95.1 30.4 67.4 75.3 40.4 66.8 42.4 42.1 23.9 37.8 82.3 56.5 72.9 41.0 86.0 57.0 86.8 113.0 81.1 58.0 78.5 56.0 36.4 37.9 41.4 55.3 33.8 53.1 26.3 38.5 52.0 45.4 11.7 23.6 33.7 20.9 42.5 34.6 31.4 50.2 41.8 54.8 61.6 61.8 60.9 53.2 59.4 61.4 60.5 60.3 58.8 59.6 68.4 18.3 28.9 20.8 5.5 13.8 21.9 24.4 40.3 27.9 21.5 15.7 11.4 24.0 21.5 25.4 11.0 8.4 27.3 11.6 33.2 13.7 32.8 27.5 13.4 17.1 27.8 26.9 45.2 5.3 36.3 25.2 23.5 18.8 13.3 12.0 22.8 35.3 34.4 29.0 26.9 5.9 21.4 40.7 15.1 13.4 43.9 29.2 16.1 10.6 3.7 41.8 43.0 7.2 11.6 18.3 29.8 27.1 25.9 26.6 33.3 36.8 24.9 17.2 13.9 13.1 17.7 22.4 21.2 16.6 34.7 22.0 26.8 20.1 29.6 31.5 24.8 KIT "C-Kit, CD117, PBT, SCFR" ENSG00000157404 "KIT proto-oncogene, receptor tyrosine kinase" P10721 4 54657918-54740715 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "breast: 114.9" "Cell type enhanced" "Detected in many" "Breast glandular cells: 83.1;granulocytes: 529.3;Inhibitory neurons: 111.2;Ionocytes: 101.7;Melanocytes: 211.7" "Cancer enhanced" "Detected in many" "testis cancer: 28.6" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 7 "basophil: 20.3;eosinophil: 12.8;NK-cell: 13.1" "Group enriched" "Detected in many" 7 "granulocytes: 20.3;NK-cells: 13.1" "Group enriched" "Detected in many" 13 "HEL: 247.2;HMC-1: 496.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003288, HPA004471, CAB068253, CAB072867, HPA073252" Enhanced Supported Supported "Plasma membrane" NA NA 49000000 "Cluster 2: Granulocytes - Unknown function" "Cluster 5: Breast - Unknown function" "Cluster 3: HMC-1 - Innate immune response" "Cluster 60: Granulocytes - Receptor signaling" "Plasma membrane" "CAB003288: AB_2335702, CAB068253: AB_2665717, CAB072867: AB_2665718, HPA004471: AB_1078431, HPA073252: AB_2686589" "unprognostic (1.55e-2)" "unprognostic (1.91e-1)" "unprognostic (4.04e-2)" "unprognostic (8.19e-2)" "unprognostic (3.96e-2)" "unprognostic (2.18e-2)" "unprognostic (2.33e-2)" "unprognostic (1.97e-2)" "unprognostic (3.60e-2)" "unprognostic (1.64e-1)" "unprognostic (2.20e-1)" "unprognostic (1.92e-2)" "prognostic favorable (5.63e-4)" "unprognostic (1.34e-3)" "unprognostic (1.87e-1)" "unprognostic (1.29e-2)" "unprognostic (2.30e-1)" 6.6 1.8 8.2 5.3 6.3 6.4 114.9 21.4 6.5 17.6 5.1 13.5 9.2 9.6 5.9 13.0 2.9 20.3 3.4 23.9 5.1 12.4 0.8 21.8 3.4 6.8 12.3 45.0 2.6 1.7 1.9 10.0 8.8 5.6 16.0 3.2 21.4 8.7 1.1 24.5 13.4 10.1 5.9 5.0 17.4 6.2 16.7 3.1 47.1 6.9 6.2 14.5 4.9 5.1 0.0 0.0 3.9 0.0 0.7 0.3 0.0 3.3 4.6 12.6 15.8 0.0 0.0 0.0 0.0 7.3 0.6 0.3 2.6 0.0 10.8 0.0 5.9 247.2 0.0 0.0 0.0 0.0 496.2 0.0 0.0 0.0 0.0 0.0 28.4 4.3 3.5 0.5 0.0 0.0 1.4 2.5 6.9 0.0 0.0 0.8 0.0 0.0 0.0 24.2 6.0 2.1 0.0 0.0 0.0 14.1 0.0 2.6 0.3 0.5 0.0 4.9 0.1 0.4 0.0 0.0 0.5 0.9 0.6 20.3 0.0 12.8 0.1 0.0 2.3 0.0 0.4 0.9 2.3 0.0 0.0 0.0 1.0 13.1 1.4 0.1 0.0 0.2 8.2 6.3 21.4 6.5 23.9 5.1 6.8 12.3 8.8 5.9 16.7 5.1 7.3 6.4 21.9 9.8 1.0 14.3 0.9 0.4 2.2 4.5 83.1 59.2 0.7 4.3 3.6 3.7 0.0 0.1 5.2 0.4 3.9 1.0 0.0 0.2 0.7 9.2 5.4 15.5 0.9 0.0 0.1 2.8 8.6 0.7 529.3 0.5 1.8 0.0 0.3 0.0 111.2 0.5 101.7 0.3 4.2 0.4 1.2 1.6 211.7 14.0 0.2 2.4 0.0 16.1 3.7 0.0 0.1 0.0 3.2 0.5 0.0 0.8 0.1 0.2 0.0 0.7 0.8 0.1 12.3 2.2 3.8 0.3 8.8 63.7 0.6 0.3 KLK3 "APS, PSA" ENSG00000142515 "Kallikrein related peptidase 3" P07288 19 50854915-50860764 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Hydrolase, Protease, Serine protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 320 "prostate: 8011.8" "Cell type enriched" "Detected in some" 77 "Prostatic glandular cells: 3438.6" "Cancer enriched" "Detected in some" 3905 "prostate cancer: 4241.6" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 173 "BEWO: 31.7;NB-4: 27.8;RPMI-8226: 19.3;SH-SY5Y: 10.5;U-2197: 10.7" "CAB000070, HPA000764" Enhanced "Secreted in male reproductive system" NA NA 7000000 "Cluster 51: Non-specific - Unknown function" "Cluster 24: NB-4 - Immune response" "Cluster 35: Glandular cells - Unknown function" "CAB000070: , HPA000764: AB_1079700" "unprognostic (5.06e-3)" "unprognostic (5.60e-2)" "unprognostic (9.93e-2)" "unprognostic (3.90e-2)" "unprognostic (1.09e-2)" "unprognostic (1.26e-2)" "unprognostic (1.88e-2)" "unprognostic (1.54e-1)" "unprognostic (5.13e-3)" "unprognostic (1.94e-1)" "unprognostic (4.64e-1)" "unprognostic (3.15e-1)" 4.3 7.6 0.0 5.6 0.0 0.0 9.0 0.0 0.0 0.5 0.0 2.6 4.8 1.6 14.4 0.2 4.0 0.0 0.5 0.0 0.0 1.4 1.5 1.2 1.7 0.0 0.0 0.3 0.9 0.6 0.2 0.3 0.0 8011.8 1.1 0.0 4.5 25.0 0.3 0.5 3.7 0.0 0.0 0.2 1.0 6.9 0.0 0.0 0.8 0.0 0.0 0.5 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 31.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.8 0.0 0.0 0.0 0.0 0.0 19.3 0.1 0.0 0.0 10.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 39.0 0.0 0.0 0.0 12.4 1.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.0 0.0 0.4 2.6 0.0 0.0 0.2 0.0 0.0 3.4 0.0 0.0 0.0 12.9 0.0 0.0 0.0 0.0 0.1 9.0 0.0 0.0 0.0 1.8 0.0 11.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 3438.6 0.1 0.1 0.0 0.0 0.0 0.0 6.9 0.1 0.0 0.0 0.0 0.0 4.2 0.2 0.4 44.6 KLKB1 KLK3 ENSG00000164344 "Kallikrein B1" P03952 4 186208979-186258471 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Blood coagulation, Fibrinolysis, Hemostasis, Inflammatory response" "Hydrolase, Protease, Serine protease" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 25 "liver: 328.4" "Cell type enriched" "Detected in many" 5 "Hepatocytes: 280.5" "Cancer enriched" "Detected in some" 17 "liver cancer: 27.6" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "NTERA-2: 3.1;SCLC-21H: 2.1;U-937: 1.3" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Secreted to blood" NA NA 28900000000 5300000000 "Cluster 62: Liver - Hemostasis" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 2: Hepatocytes - Metabolism" "unprognostic (4.80e-2)" "unprognostic (4.53e-3)" "unprognostic (4.36e-2)" "unprognostic (4.17e-2)" "unprognostic (5.93e-2)" "unprognostic (1.90e-2)" "unprognostic (1.15e-2)" "unprognostic (2.83e-1)" "unprognostic (8.14e-2)" "unprognostic (1.35e-1)" "unprognostic (1.38e-2)" "unprognostic (1.15e-1)" "unprognostic (1.45e-2)" "unprognostic (6.01e-2)" "unprognostic (7.30e-2)" "unprognostic (1.20e-1)" "unprognostic (1.59e-2)" 0.6 1.8 5.9 0.3 6.5 0.0 0.6 6.0 7.6 1.4 9.3 2.3 2.8 0.6 1.0 0.4 1.3 2.5 2.6 6.3 6.2 7.7 328.4 1.0 0.7 7.0 6.5 0.7 4.8 1.0 3.6 0.2 6.4 1.7 1.4 13.1 0.7 0.6 2.4 0.3 2.6 0.6 6.1 2.4 0.8 2.0 6.0 0.4 1.9 1.8 0.4 1.5 0.9 6.3 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.2 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.5 0.0 2.1 0.1 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 6.5 6.0 7.6 6.3 6.2 7.0 6.5 6.4 6.1 6.0 6.3 0.1 0.0 0.0 48.3 0.7 0.0 0.1 0.2 0.6 5.1 0.3 0.5 4.3 14.3 0.1 1.8 16.7 0.0 0.5 0.6 0.0 1.8 2.8 0.6 0.2 1.0 3.0 2.7 10.2 0.5 0.0 0.4 0.0 0.4 0.0 0.2 5.7 280.5 0.2 0.0 15.6 0.4 0.0 4.4 0.0 2.2 0.6 0.3 0.0 6.5 0.1 10.6 2.1 8.0 7.7 0.4 1.4 0.0 0.1 0.0 2.6 1.6 1.1 5.1 0.0 0.6 0.3 1.3 1.3 0.1 0.0 0.0 0.6 0.1 0.7 0.1 KRT12 K12 ENSG00000187242 "Keratin 12" Q99456 17 40861303-40867223 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Corneal dystrophy, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in single" "intestine: 1.0" "Group enriched" "Detected in some" 5 "Distal enterocytes: 3.9;Paneth cells: 12.8" "Low cancer specificity" "Detected in single" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA055217, HPA055835" Enhanced NA NA "Cluster 31: Skin - Epidermis development" "Cluster 53: Intestinal epithelial cells - Unknown function" "HPA055217: AB_2682742, HPA055835: AB_2682935" "unprognostic (1.89e-1)" "unprognostic (2.40e-2)" "unprognostic (1.01e-1)" "unprognostic (4.82e-1)" "unprognostic (2.19e-1)" "unprognostic (2.04e-1)" "unprognostic (1.74e-2)" "unprognostic (5.52e-2)" "unprognostic (9.41e-3)" "unprognostic (3.49e-1)" "unprognostic (1.73e-1)" "unprognostic (3.94e-3)" "unprognostic (2.01e-2)" "unprognostic (1.27e-1)" "unprognostic (2.60e-4)" "unprognostic (6.31e-3)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.9 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.0 0.0 1.6 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 12.8 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 KRT2 "KRT2A, KRTE" ENSG00000172867 "Keratin 2" P35908 12 52644558-52652211 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Disease variant, FDA approved drug targets, Ichthyosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 57 "skin 1: 4660.3" "Cell type enriched" "Detected in some" 14 "Suprabasal keratinocytes: 265.4" "Cancer enriched" "Detected in some" 5 "melanoma: 23.4" "Not detected" "Not detected" "Immune cell enhanced" "Detected in single" "naive CD4 T-cell: 1.4" "Lineage enriched" "Detected in single" 14 "T-cells: 1.4" "Cell line enhanced" "Detected in single" "HEL: 2.0" "Group enriched" "Detected in some" 6 "amygdala: 1.7;hippocampal formation: 2.7" "Not detected" "Not detected" "HPA006299, CAB037321" Enhanced Approved "Golgi apparatus,Intermediate filaments,Cytosol" NA NA 9700000000 "Cluster 32: T-cells - Unknown function" "Cluster 61: Skin - Cornification" "Cluster 3: HMC-1 - Innate immune response" "Cluster 28: Keratinocytes - Keratinization" "Intermediate filaments, Cytosol" "Golgi apparatus" "CAB037321: , HPA006299: AB_1079180" "unprognostic (1.22e-1)" "unprognostic (1.60e-1)" "unprognostic (1.34e-1)" "unprognostic (2.56e-1)" "unprognostic (8.47e-3)" "unprognostic (1.69e-2)" "unprognostic (1.84e-1)" "unprognostic (3.59e-1)" "unprognostic (2.12e-1)" "unprognostic (4.76e-2)" "unprognostic (3.56e-7)" "unprognostic (6.43e-2)" "unprognostic (5.98e-3)" "unprognostic (6.69e-2)" "unprognostic (3.46e-1)" 3.0 0.5 0.0 0.1 0.0 1.0 81.9 0.0 0.0 0.8 0.0 0.9 1.6 0.4 0.3 1.1 0.1 0.0 1.7 0.0 0.0 0.5 1.2 1.0 0.5 0.0 0.0 0.5 1.0 0.0 0.5 0.0 0.0 0.4 0.1 0.0 1.6 0.0 47.8 4660.3 0.8 0.0 0.0 0.5 0.7 1.0 0.0 6.8 0.8 0.0 6.1 0.1 6.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.4 0.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.8 0.0 0.1 0.0 0.0 0.0 0.1 0.4 1.5 0.0 0.0 0.0 0.0 3.1 0.1 0.0 0.0 0.0 0.0 0.0 0.6 1.2 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 0.0 0.3 9.5 0.0 0.0 0.1 8.8 0.0 0.1 0.0 2.1 0.0 0.0 0.1 0.0 0.0 0.3 0.3 0.5 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 265.4 0.1 1.0 0.0 0.6 0.1 LCK ENSG00000182866 "LCK proto-oncogene, Src family tyrosine kinase" P06239 1 32251239-32286165 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Host-virus interaction" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 15 "lymphoid tissue: 343.0" "Group enriched" "Detected in many" 9 "dendritic cells: 143.9;NK-cells: 272.9;T-cells: 255.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in all" 12 "gdT-cell: 1109.8;MAIT T-cell: 1034.8;memory CD4 T-cell: 1123.8;memory CD8 T-cell: 1201.7;naive CD4 T-cell: 1260.7;naive CD8 T-cell: 1168.7;NK-cell: 641.5;T-reg: 1682.7" "Group enriched" "Detected in all" 12 "NK-cells: 641.5;T-cells: 1682.7" "Group enriched" "Detected in some" 6 "JURKAT: 365.7;MOLT-4: 536.9;U-698: 302.7" "Low region specificity" "Detected in some" "Low region specificity" "Detected in single" "HPA003494, CAB003816" Enhanced Approved "Golgi apparatus" NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 63: T-cells - Adaptive immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 63: NK-cells & T-cells - Immune response" "Golgi apparatus" "CAB003816: AB_562158, HPA003494: AB_1852751" "unprognostic (6.38e-3)" "unprognostic (5.45e-3)" "unprognostic (8.39e-2)" "prognostic favorable (2.96e-6)" "unprognostic (2.20e-2)" "prognostic favorable (2.91e-4)" "unprognostic (4.78e-3)" "unprognostic (1.33e-2)" "prognostic favorable (5.65e-5)" "unprognostic (3.07e-2)" "unprognostic (3.80e-2)" "unprognostic (2.83e-1)" "prognostic unfavorable (2.60e-5)" "unprognostic (8.15e-2)" "unprognostic (4.05e-2)" "unprognostic (7.39e-2)" "unprognostic (1.17e-2)" 3.4 2.2 0.4 50.6 0.5 13.7 2.3 0.4 0.5 2.2 0.7 6.9 7.6 1.7 13.0 3.9 2.1 9.4 1.9 0.5 0.4 3.8 3.8 11.4 111.0 0.8 0.5 1.6 0.9 0.5 0.8 1.1 0.6 2.8 6.5 0.0 4.8 1.4 1.3 1.9 23.1 2.3 0.6 39.9 12.1 1.1 0.5 343.0 3.7 1.4 79.6 13.2 2.7 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.6 0.7 64.1 3.5 0.0 0.3 0.1 0.0 0.2 0.0 0.1 0.6 0.0 0.0 1.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 365.7 0.2 0.0 0.0 0.0 536.9 0.2 5.9 4.6 0.3 20.6 0.1 0.3 0.3 0.2 0.1 0.0 0.1 0.3 0.3 0.4 0.6 0.4 0.0 0.0 1.7 0.1 0.1 0.7 0.3 302.7 0.0 0.1 0.0 12.8 5.2 6.0 1109.8 4.9 1034.8 62.0 1123.8 1201.7 5.2 98.9 1260.7 1168.7 33.6 641.5 6.0 7.7 1682.7 1836.9 0.4 0.5 0.4 0.5 0.5 0.4 0.8 0.5 0.6 0.6 0.5 0.6 4.9 0.0 9.3 0.0 23.4 4.6 1.2 0.4 0.0 0.0 3.5 5.2 1.8 4.3 1.6 3.7 0.0 0.3 143.9 0.9 0.0 0.6 0.1 1.0 0.5 3.4 2.4 10.1 0.2 0.5 0.2 3.1 7.7 0.7 5.1 0.0 4.6 1.5 0.3 0.0 0.2 0.3 0.0 7.8 7.3 0.0 0.0 8.1 3.6 0.0 8.7 0.0 272.9 0.5 0.1 4.7 0.0 0.4 15.7 1.0 0.0 1.4 1.8 0.0 0.0 1.5 2.4 4.5 2.0 0.5 3.1 0.4 255.5 2.9 1.3 1.1 LDHA ENSG00000134333 "Lactate dehydrogenase A" P00338 11 18394560-18408425 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Cancer-related genes, Disease variant, FDA approved drug targets, Glycogen storage disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Basal keratinocytes: 2198.1;Basal respiratory cells: 2133.0;Extravillous trophoblasts: 2086.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015336, CAB069404" Uncertain Supported Vesicles,Cytosol NA NA 170000000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 55: Non-specific - Mitochondria & Proteasome" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 16: Pancreatic endocrine cells - Mixed function" Cytosol Vesicles "CAB015336: AB_2134947, CAB069404: " "unprognostic (8.83e-2)" "prognostic unfavorable (2.78e-5)" "unprognostic (3.81e-2)" "unprognostic (1.73e-1)" "unprognostic (3.43e-3)" "unprognostic (4.66e-3)" "prognostic unfavorable (3.26e-8)" "prognostic unfavorable (2.27e-6)" "unprognostic (1.08e-1)" "unprognostic (1.88e-2)" "prognostic unfavorable (8.09e-6)" "unprognostic (1.76e-2)" "prognostic unfavorable (9.69e-9)" "unprognostic (4.15e-2)" "unprognostic (1.89e-1)" "unprognostic (3.07e-1)" "unprognostic (1.05e-2)" 444.5 358.1 64.3 139.5 68.4 184.6 330.4 54.0 72.1 203.1 58.4 278.5 158.1 151.1 43.8 450.6 189.2 75.5 361.2 68.4 73.7 440.2 729.2 242.0 97.2 73.6 74.9 149.7 171.5 26.6 95.9 113.9 94.9 170.1 117.4 443.8 267.5 81.8 947.5 468.6 296.6 124.2 58.5 185.3 181.1 95.2 67.4 115.3 180.8 500.3 146.5 266.2 314.4 65.9 1261.4 730.9 28.4 415.2 599.8 399.3 400.6 1186.1 1148.5 936.9 1366.4 324.5 196.6 909.3 380.3 1110.8 727.1 979.2 716.1 1715.1 2082.2 331.3 422.6 329.6 629.4 588.5 148.9 811.2 235.8 411.1 760.3 380.3 373.7 1670.8 550.8 292.3 462.8 431.7 1127.7 319.4 674.8 509.3 182.7 413.2 849.4 432.0 298.0 768.0 1546.6 284.5 220.5 279.3 642.7 518.6 230.8 431.4 241.7 192.9 546.9 1228.3 455.3 1094.7 14.3 348.0 545.1 899.4 1767.1 415.0 434.1 98.4 147.1 79.7 93.8 165.0 105.2 70.4 122.1 99.6 202.1 54.4 78.1 81.0 47.1 91.3 169.3 68.0 140.8 237.6 64.3 68.4 54.0 72.1 68.4 73.7 73.6 74.9 94.9 58.5 67.4 65.9 421.7 73.7 201.6 21.5 220.8 2198.1 475.6 2133.0 523.0 464.2 213.6 229.5 241.8 175.8 837.3 309.0 146.0 509.8 427.2 696.1 434.3 1293.9 204.4 180.0 317.4 492.8 45.6 123.2 38.7 1532.3 2086.2 544.4 163.6 485.8 262.9 205.3 205.6 514.4 659.3 514.8 33.5 285.1 649.0 224.4 1155.1 129.6 287.7 373.9 1177.5 20.6 973.4 444.2 170.0 9.5 12.6 1771.4 590.3 205.0 376.0 546.8 1765.0 682.5 178.1 481.4 190.7 251.6 706.3 195.5 44.0 422.9 1723.2 501.7 410.9 196.2 362.1 530.8 LDHB ENSG00000111716 "Lactate dehydrogenase B" P07195 12 21635342-21757857 "Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 1947.7;kidney: 1726.6" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 2502.3;Cytotrophoblasts: 1693.0;Distal tubular cells: 3306.5;Proximal tubular cells: 3483.9;Syncytiotrophoblasts: 1639.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "RPTEC TERT1: 6021.8" "CAB004641, HPA019007" Enhanced Supported Cytosol No No 560000000 "Cluster 20: T-cells - T-cell receptor" "Cluster 39: Non-specific - Mitochondria" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 39: Non-specific - Basic cellular processes" Cytosol "CAB004641: AB_425525, HPA019007: AB_2670008" "unprognostic (2.93e-1)" "unprognostic (9.20e-3)" "unprognostic (6.10e-2)" "unprognostic (1.11e-1)" "unprognostic (5.39e-3)" "unprognostic (1.36e-3)" "unprognostic (1.61e-2)" "unprognostic (1.72e-2)" "unprognostic (5.34e-2)" "unprognostic (8.40e-2)" "unprognostic (2.91e-1)" "unprognostic (6.41e-2)" "prognostic favorable (2.51e-4)" "unprognostic (1.31e-1)" "unprognostic (1.71e-1)" "unprognostic (2.55e-1)" "unprognostic (9.32e-2)" 549.9 424.8 509.1 259.2 528.2 352.8 321.1 593.7 617.0 238.6 549.8 320.2 84.4 273.1 169.0 166.6 252.9 232.9 1947.7 484.1 581.9 1726.6 70.5 220.4 425.8 564.4 575.4 472.4 370.3 447.3 161.3 298.2 556.2 240.9 277.0 290.0 162.3 287.2 309.4 81.4 171.3 309.7 537.8 182.0 459.1 119.5 582.5 534.5 348.5 950.4 449.4 417.9 171.2 517.8 647.2 1697.3 1457.5 966.0 1021.7 1126.6 1689.4 879.8 873.0 1201.5 1179.4 2712.9 3.6 2268.6 561.5 597.3 1170.1 315.8 2031.4 1631.4 1518.4 586.5 1413.1 2339.5 1619.0 3.0 975.0 2212.8 967.9 1300.5 572.1 1056.8 1423.4 1416.9 1395.2 1610.8 1304.6 332.6 1342.7 3.2 1895.9 2665.6 4216.4 1051.1 727.7 1681.3 2032.0 1838.7 6021.8 2832.7 467.2 1077.8 403.6 618.1 1586.1 3842.2 5.3 1704.6 548.3 803.7 1048.1 578.5 1684.5 291.0 420.9 2953.4 891.8 1037.5 978.2 540.8 201.9 25.1 346.8 124.7 583.1 349.4 1341.5 723.8 367.2 250.9 1722.4 1124.1 31.7 459.0 95.2 427.7 1405.8 1431.2 509.1 528.2 593.7 617.0 484.1 581.9 564.4 575.4 556.2 537.8 582.5 517.8 89.8 141.1 316.4 68.2 242.2 73.0 439.5 1103.1 221.4 151.5 332.4 325.0 2502.3 298.8 433.9 474.5 68.8 1693.0 208.0 69.6 3306.5 18.4 10.5 224.3 325.0 227.3 92.4 361.2 39.4 314.9 870.1 299.4 222.8 309.4 268.6 412.6 155.7 11.2 612.9 141.3 55.6 152.2 956.2 189.8 104.3 34.3 274.6 174.8 179.7 33.7 197.3 277.6 159.6 47.7 40.3 99.7 84.3 415.2 303.1 310.6 0.2 3483.9 363.0 118.1 236.7 195.2 363.7 21.5 124.3 216.3 64.2 1639.5 398.1 1105.3 257.0 344.9 LHCGR "HHG, LCGR, LGR2, LHR, ULG5" ENSG00000138039 "Luteinizing hormone/choriogonadotropin receptor" P22888 2 48686774-48755730 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 3.2;ovary: 2.1;testis: 2.2" "Cell type enriched" "Detected in some" 22 "Theca cells: 143.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" CAB009814 Uncertain NA NA "Cluster 21: Non-specific - Transcription" "Cluster 52: Non-specific - Transcription" "CAB009814: AB_2135467" "unprognostic (8.57e-2)" "unprognostic (1.08e-1)" "unprognostic (1.54e-1)" "unprognostic (1.41e-1)" "unprognostic (3.14e-2)" "unprognostic (2.97e-2)" "unprognostic (2.24e-2)" "unprognostic (5.22e-2)" 1.3 0.8 0.3 0.0 0.4 0.0 0.7 0.9 0.5 0.0 0.7 0.2 0.0 0.1 0.0 0.3 0.0 0.0 0.1 0.2 0.6 0.2 0.0 0.1 0.0 3.2 0.7 2.1 0.0 0.0 0.5 0.0 2.0 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 1.6 0.0 0.1 2.2 0.8 0.2 0.6 0.1 0.0 0.3 0.0 1.5 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.9 0.5 0.2 0.6 3.2 0.7 2.0 1.6 0.8 1.5 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.6 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.8 0.0 0.0 1.4 0.0 0.0 0.0 5.3 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 1.3 1.0 1.2 0.1 0.0 6.5 0.0 0.0 0.0 2.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 1.4 0.0 0.0 143.2 0.0 0.0 LIPF "HGL, HLAL" ENSG00000182333 "Lipase F, gastric type" P07098 10 88664441-88678814 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted secreted proteins" "Lipid degradation, Lipid metabolism" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 142 "stomach 1: 37213.5" "Cell type enriched" "Detected in some" 444 "Gastric mucus-secreting cells: 1509.7" "Cancer enriched" "Detected in some" 75 "stomach cancer: 278.5" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HMC-1: 4.1;MOLT-4: 3.4;NTERA-2: 3.4;REH: 2.1;RPMI-8226: 1.8;THP-1: 6.8;U-2 OS: 2.2;U-266/70: 3.1" "Region enriched" "Detected in single" 77 "olfactory bulb: 7.6" HPA045930 Enhanced "Secreted to digestive system" NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 4: Stomach - Digestion" "Cluster 3: HMC-1 - Innate immune response" "Cluster 16: Pancreatic endocrine cells - Mixed function" "HPA045930: AB_10959518" "unprognostic (1.53e-1)" "unprognostic (1.83e-1)" 6.3 2.8 0.0 0.0 0.0 0.0 4.6 0.1 0.0 3.9 0.0 13.0 262.0 1.9 0.0 117.9 5.4 0.0 3.2 0.0 0.0 11.4 4.9 7.3 0.0 0.3 0.1 2.2 4.5 0.0 7.3 0.5 0.1 6.7 0.0 0.0 2.6 0.0 1.6 2.0 1.9 0.0 0.0 2.6 37213.5 2.9 0.0 0.0 1.3 0.0 0.1 2.5 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 3.4 0.0 0.0 2.1 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.8 0.0 0.0 2.2 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1509.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 LPL LIPD ENSG00000175445 "Lipoprotein lipase" P06858 8 19901717-19967259 "Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Lipid degradation, Lipid metabolism" "Heparin-binding, Hydrolase" "Disease variant, FDA approved drug targets, Hyperlipidemia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 937.4;heart muscle: 407.8" "Cell type enhanced" "Detected in many" "Adipocytes: 453.0;Cardiomyocytes: 489.0;Granulosa cells: 495.2;Horizontal cells: 206.9;Sertoli cells: 236.7" "Cancer enhanced" "Detected in all" "glioma: 39.2" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "non-classical monocyte: 4.2" "Lineage enriched" "Detected in single" 6 "monocytes: 4.2" "Cell line enriched" "Detected in some" 5 "AF22: 391.6" "Region enhanced" "Detected in many" "basal ganglia: 45.3" "Group enriched" "Detected in all" 5 "basal ganglia: 79.2;spinal cord: 59.3" HPA048749 Supported Vesicles "Secreted to blood" NA NA 4200000 "Cluster 7: Monocytes - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 12: NES - Nervous system development" "Cluster 40: Granulosa cells - Unknown function" Vesicles "HPA048749: AB_2680511" "unprognostic (5.52e-2)" "unprognostic (3.16e-1)" "unprognostic (6.41e-2)" "unprognostic (3.03e-1)" "unprognostic (4.14e-2)" "unprognostic (1.01e-2)" "unprognostic (1.88e-4)" "unprognostic (1.05e-1)" "unprognostic (6.78e-2)" "unprognostic (8.20e-2)" "unprognostic (2.54e-2)" "unprognostic (5.28e-1)" "unprognostic (1.18e-1)" "unprognostic (4.20e-3)" "unprognostic (4.16e-3)" "unprognostic (1.19e-1)" "prognostic unfavorable (6.07e-4)" 937.4 15.9 6.8 9.1 53.2 0.9 255.4 20.3 12.2 2.7 8.9 12.0 1.5 3.7 0.5 2.8 2.7 8.6 407.8 10.7 9.5 19.1 0.7 62.1 8.5 7.4 7.7 10.6 6.3 181.5 4.1 14.7 7.9 3.8 5.8 11.1 24.4 64.7 86.4 8.3 13.3 4.1 5.5 1.6 8.4 1.0 11.5 4.3 10.6 127.3 2.8 6.1 4.7 8.8 0.0 0.0 391.6 0.1 8.1 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.0 0.7 0.0 0.8 0.0 0.0 0.1 0.3 0.0 71.5 0.0 0.2 8.6 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.1 0.0 0.0 0.1 0.7 9.6 0.0 0.0 0.0 0.0 68.4 0.0 0.0 8.4 0.2 0.0 0.0 0.1 13.5 0.0 1.8 0.0 0.0 8.1 0.0 3.5 0.0 0.1 0.1 0.1 0.1 32.6 0.0 0.9 0.7 0.0 1.7 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.2 6.8 53.2 20.3 12.2 10.7 9.5 7.4 7.7 7.9 5.5 11.5 8.8 453.0 12.8 104.9 1.0 0.4 1.5 0.1 0.0 0.6 2.8 114.7 5.7 489.0 0.0 0.6 0.0 2.1 0.4 0.9 0.1 15.6 0.0 0.8 0.2 2.5 56.1 0.0 0.0 1.9 0.0 0.7 13.6 0.0 0.3 6.3 495.2 2.9 0.0 108.5 206.9 0.4 1.0 0.0 14.8 4.2 1.3 1.2 38.2 14.2 1.9 2.0 2.3 0.0 9.0 0.1 0.0 0.0 0.0 0.0 0.3 0.3 0.4 2.9 2.7 236.7 91.4 68.1 0.4 0.2 0.2 0.6 0.4 2.3 4.3 2.8 0.1 MAOA ENSG00000189221 "Monoamine oxidase A" P21397 X 43654907-43746824 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins" "Catecholamine metabolism, Neurotransmitter degradation" Oxidoreductase "Disease variant, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 230.3" "Cell type enhanced" "Detected in many" "Proximal enterocytes: 819.8;Proximal tubular cells: 569.9;Undifferentiated cells: 285.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC diff: 162.1;HHSteC: 302.9;HSkMC: 76.1;hTCEpi: 87.2;RT4: 131.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009437, HPA054807, HPA059299" Enhanced Supported Mitochondria,Cytosol No No "Cluster 41: Intestine & Liver - Lipid metabolism" "Cluster 30: Epithelial cell lines - Translation" "Cluster 67: Proximal tubular cells - Tubular reabsorption" Mitochondria Cytosol "CAB009437: AB_2137260, HPA054807: AB_2682607, HPA059299: AB_2683970" "unprognostic (9.54e-3)" "unprognostic (1.63e-1)" "unprognostic (7.99e-2)" "unprognostic (3.07e-1)" "unprognostic (6.75e-2)" "unprognostic (3.32e-1)" "unprognostic (9.51e-2)" "unprognostic (6.89e-3)" "unprognostic (2.21e-1)" "unprognostic (4.29e-2)" "unprognostic (3.94e-1)" "unprognostic (3.54e-1)" "unprognostic (1.45e-3)" "unprognostic (1.16e-2)" "unprognostic (1.47e-1)" "unprognostic (4.04e-2)" "unprognostic (2.98e-3)" 143.9 27.7 24.7 8.6 27.6 0.4 71.6 26.5 26.6 26.6 13.9 116.4 163.4 24.0 14.1 46.7 39.1 16.9 49.6 22.3 31.7 76.9 119.1 63.5 2.4 26.9 32.5 40.7 39.1 31.4 4.0 30.2 56.4 46.3 117.9 28.2 77.3 35.0 33.5 37.4 230.3 24.0 21.3 6.3 55.9 3.7 41.4 9.9 118.4 34.3 5.3 65.0 38.8 19.0 0.0 3.7 0.6 9.9 162.1 0.0 0.6 0.2 0.0 0.0 0.0 0.4 0.4 0.0 0.2 0.0 4.6 17.2 6.1 22.3 0.1 0.0 2.5 6.9 0.5 18.6 302.9 0.0 16.9 76.1 87.2 0.2 45.2 0.1 20.0 0.0 0.3 0.4 5.7 2.9 0.1 0.8 1.6 20.7 5.0 0.0 0.3 0.5 22.3 131.8 3.1 7.8 0.0 0.0 0.3 0.4 0.5 0.0 8.7 0.0 8.2 0.7 0.0 0.3 0.0 0.0 9.5 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 24.7 27.6 26.5 26.6 22.3 31.7 26.9 32.5 56.4 21.3 41.4 19.0 35.2 70.5 146.9 23.2 4.6 11.0 177.7 32.3 116.7 5.0 13.6 10.2 101.3 94.4 49.3 60.7 22.9 11.5 0.2 248.0 121.3 36.7 25.2 50.4 42.5 43.6 38.0 4.8 4.0 13.4 21.3 24.3 40.2 175.1 5.7 7.3 53.6 193.7 6.6 3.3 5.0 137.5 67.1 12.2 2.1 33.9 5.6 6.7 10.6 21.5 17.1 25.4 0.0 7.5 1.3 49.5 140.5 0.0 2.6 64.6 819.8 569.9 32.8 27.4 6.6 4.4 30.5 1.3 0.8 120.6 14.3 207.0 3.7 3.5 285.1 129.0 MAOB ENSG00000069535 "Monoamine oxidase B" P27338 X 43766610-43882450 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 317.6" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 120.6;granulocytes: 137.8;Hepatocytes: 221.1;Peritubular cells: 95.2;Proximal enterocytes: 178.8;Proximal tubular cells: 182.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "Hep G2: 41.4;SiHa: 78.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002328, CAB037200" Enhanced NA NA 110000 "Cluster 15: Liver - Metabolism" "Cluster 20: HeLa - Mitochondria" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "CAB037200: AB_1841012, HPA002328: AB_1854062" "unprognostic (1.19e-2)" "unprognostic (1.36e-1)" "unprognostic (5.16e-2)" "unprognostic (1.85e-2)" "unprognostic (4.39e-2)" "unprognostic (2.69e-2)" "unprognostic (5.61e-2)" "unprognostic (4.37e-2)" "unprognostic (1.56e-1)" "unprognostic (1.04e-2)" "unprognostic (1.20e-1)" "unprognostic (1.54e-2)" "unprognostic (9.74e-2)" "unprognostic (5.35e-3)" "unprognostic (1.48e-2)" "unprognostic (3.53e-1)" "unprognostic (1.90e-3)" 78.0 51.1 99.3 6.5 102.8 0.1 45.7 89.1 117.7 32.3 83.5 46.5 73.5 119.4 55.0 31.4 98.0 17.3 97.8 93.9 149.1 124.2 317.6 33.0 6.1 143.8 134.2 155.4 10.9 15.6 25.9 11.2 125.9 82.9 16.5 13.9 78.5 155.5 114.6 9.9 79.0 103.3 115.8 2.4 23.7 9.0 145.2 3.8 5.6 65.1 7.1 28.3 25.4 115.8 0.0 1.0 0.1 0.0 0.6 0.1 0.3 0.0 0.0 0.0 0.0 5.4 4.7 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 8.1 41.4 0.0 0.2 0.0 0.3 0.1 0.1 0.0 0.9 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.3 3.5 0.0 0.0 0.0 0.0 0.4 4.0 0.0 0.1 1.1 78.2 0.0 0.5 0.6 0.0 0.0 0.0 0.0 3.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 99.3 102.8 89.1 117.7 93.9 149.1 143.8 134.2 125.9 115.8 145.2 115.8 5.9 0.0 4.1 53.5 0.4 5.5 0.4 1.2 1.8 1.4 3.5 22.4 120.6 52.9 1.9 5.5 4.2 0.4 0.0 10.2 62.6 20.1 0.4 26.4 81.6 10.3 0.0 2.7 36.9 2.8 0.5 17.0 16.3 6.0 137.8 69.6 7.5 221.1 1.5 15.2 7.6 6.4 12.2 4.3 3.6 2.1 46.0 1.8 7.2 9.4 0.0 27.2 0.0 11.6 1.3 7.9 7.8 95.2 0.3 0.6 178.8 182.6 11.8 1.0 13.1 2.6 18.4 0.3 0.4 2.3 4.0 0.4 5.5 0.5 10.5 0.5 MAP1A MAP1L ENSG00000166963 "Microtubule associated protein 1A" P78559 15 43510958-43531620 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 14 "brain: 325.5" "Cell type enhanced" "Detected in many" "dendritic cells: 90.9;Horizontal cells: 299.5;Peritubular cells: 76.3" "Cancer enhanced" "Detected in many" "glioma: 18.1" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 61 "plasmacytoid DC: 10.5" "Lineage enriched" "Detected in single" 61 "dendritic cells: 10.5" "Cell line enhanced" "Detected in many" "ASC diff: 60.7;BJ hTERT+: 61.8;fHDF/TERT166: 94.0;hTEC/SVTERT24-B: 58.1;U-87 MG: 121.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA039063, HPA039064, HPA066488" Enhanced Approved Cytosol No No 55000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 65: Brain - Ion transport" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 62: Horizontal cells - Visual perception" Cytosol "HPA039063: AB_2676327, HPA039064: AB_10673302, HPA066488: AB_2685676" "unprognostic (1.60e-1)" "unprognostic (1.31e-1)" "unprognostic (3.29e-2)" "unprognostic (1.86e-3)" "unprognostic (4.45e-2)" "unprognostic (3.58e-2)" "unprognostic (5.66e-2)" "unprognostic (1.12e-1)" "unprognostic (2.65e-2)" "unprognostic (1.13e-3)" "unprognostic (8.36e-3)" "unprognostic (3.45e-3)" "prognostic unfavorable (6.59e-5)" "unprognostic (5.83e-2)" "unprognostic (2.53e-1)" "prognostic unfavorable (1.09e-5)" "prognostic unfavorable (1.66e-5)" 7.2 6.0 65.3 3.8 78.6 0.9 4.4 39.5 325.5 8.0 0.0 16.5 1.2 8.2 2.4 3.0 7.2 4.2 15.5 92.8 37.5 1.2 0.2 2.2 1.0 201.4 41.4 5.0 1.0 2.0 11.7 2.7 186.0 4.8 3.5 21.7 2.5 7.5 4.5 3.2 4.0 13.1 22.5 0.9 4.3 3.8 85.8 24.0 4.1 5.1 0.9 11.9 4.5 156.7 0.3 2.5 11.1 6.4 60.7 41.5 0.1 36.3 61.8 10.5 10.1 4.4 0.1 0.2 15.3 94.0 3.3 0.5 15.0 0.1 6.1 5.5 1.4 14.2 3.5 0.3 5.8 0.4 5.8 31.3 0.1 58.1 0.3 15.8 8.0 41.3 24.0 0.3 42.8 0.5 26.6 0.8 8.1 0.0 1.0 7.2 32.1 0.1 0.2 0.1 34.8 10.6 1.2 0.1 0.3 14.6 2.3 0.6 1.5 33.7 11.3 11.3 0.5 0.0 1.6 5.0 121.4 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.5 0.1 0.1 65.3 78.6 39.5 325.5 92.8 37.5 201.4 41.4 186.0 22.5 85.8 156.7 6.7 3.2 1.1 11.8 2.2 5.5 1.4 1.4 2.8 43.4 1.7 3.6 55.1 0.0 7.9 3.7 25.0 0.3 90.9 1.0 0.0 0.4 13.1 33.2 19.5 5.7 11.4 3.0 34.4 0.0 0.6 46.9 2.6 1.0 7.0 16.7 4.2 0.0 2.4 299.5 45.1 1.7 10.2 0.3 7.4 5.6 51.0 9.4 8.8 12.2 0.7 16.7 0.0 9.5 51.4 0.7 0.0 76.3 1.1 0.5 0.0 0.5 63.6 27.2 32.9 45.7 48.2 10.6 25.6 1.1 4.1 1.1 5.6 3.1 1.4 0.5 MAP2 "MAP2A, MAP2B, MAP2C" ENSG00000078018 "Microtubule associated protein 2" P11137 2 209424058-209734118 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" Calmodulin-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "brain: 253.3;retina: 411.0" "Group enriched" "Detected in many" 5 "Cone photoreceptor cells: 875.7;Excitatory neurons: 883.3;Inhibitory neurons: 823.6;Oligodendrocyte precursor cells: 688.6;Rod photoreceptor cells: 514.5" "Group enriched" "Detected in many" 4 "glioma: 30.4;thyroid cancer: 8.0" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AF22: 296.9;NTERA-2: 106.7;SCLC-21H: 148.6;SH-SY5Y: 82.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001984, HPA008273, HPA012558, HPA012828" Enhanced Supported Approved "Plasma membrane,Cytosol" NA NA "Cluster 21: B-cells - Adaptive immune response" "Cluster 58: Brain - Synaptic function" "Cluster 12: NES - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane, Cytosol" "CAB001984: , HPA008273: AB_1853945, HPA012558: , HPA012828: AB_1853946" "unprognostic (2.47e-2)" "unprognostic (2.81e-1)" "unprognostic (2.58e-2)" "prognostic unfavorable (1.98e-6)" "unprognostic (2.29e-2)" "unprognostic (1.79e-1)" "unprognostic (1.13e-2)" "unprognostic (6.06e-2)" "unprognostic (1.31e-1)" "unprognostic (9.84e-2)" "unprognostic (1.09e-2)" "unprognostic (1.60e-1)" "unprognostic (1.23e-1)" "unprognostic (2.69e-3)" "unprognostic (2.54e-1)" "unprognostic (7.28e-2)" "unprognostic (4.10e-5)" 5.5 11.6 89.2 1.2 115.9 0.3 5.5 2.7 253.3 4.3 0.0 2.9 0.9 2.3 3.9 6.5 2.5 7.6 8.4 135.2 215.6 5.4 3.8 13.5 1.8 37.7 52.2 7.4 10.7 15.5 33.8 0.8 75.3 7.6 1.7 411.0 7.8 4.9 1.7 16.9 1.6 2.8 14.5 1.7 3.3 6.5 123.9 3.5 16.7 4.6 2.4 1.6 5.3 88.2 2.6 0.6 296.9 0.0 3.9 2.2 0.1 1.9 2.1 0.7 2.2 0.0 16.1 0.0 1.7 3.8 14.0 4.1 23.4 1.8 1.0 0.1 1.4 1.2 8.9 0.1 36.7 0.3 0.2 3.1 9.6 0.1 5.8 17.3 7.8 0.1 0.0 3.1 0.3 1.1 0.1 0.0 106.7 0.5 0.5 0.0 0.6 0.3 3.8 0.1 148.6 82.7 6.3 0.9 3.7 34.8 8.2 0.0 0.2 0.3 1.7 0.1 4.1 1.9 0.0 0.0 15.5 0.0 45.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 89.2 115.9 2.7 253.3 135.2 215.6 37.7 52.2 75.3 14.5 123.9 88.2 16.8 96.1 3.2 127.3 1.8 5.9 3.3 12.0 4.6 144.7 6.2 8.0 4.9 27.1 3.7 5.5 875.7 0.4 0.1 0.0 3.9 26.8 22.1 2.2 1.1 15.7 32.4 2.7 883.3 11.0 0.1 5.3 3.6 4.4 1.3 1.6 18.5 0.4 0.5 33.7 823.6 0.2 6.1 1.4 1.5 10.7 28.6 1.4 19.6 74.0 0.0 129.7 0.0 688.6 53.8 10.0 0.0 15.4 0.1 12.3 0.0 0.4 3.4 514.5 32.9 5.1 26.1 6.6 22.7 2.3 6.5 0.3 0.3 6.6 0.0 0.7 MAP2K1 "MAPKK1, MEK1, PRKMK1" ENSG00000169032 "Mitogen-activated protein kinase kinase 1" Q02750 15 66386837-66491544 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease variant, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Hepatocytes: 172.5;Langerhans cells: 265.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003834, HPA026430" Approved Enhanced "Plasma membrane,Cytosol" NA NA 120000 "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 39: Non-specific - Mitochondria" "Cluster 18: U-2197 - ECM organization" "Cluster 41: Macrophages - Immune response" "Plasma membrane, Cytosol" "CAB003834: AB_562310, HPA026430: AB_1853742" "unprognostic (4.05e-2)" "unprognostic (1.23e-2)" "unprognostic (2.07e-1)" "unprognostic (4.92e-2)" "prognostic unfavorable (1.95e-4)" "unprognostic (1.81e-3)" "unprognostic (5.78e-2)" "unprognostic (9.91e-3)" "unprognostic (1.11e-1)" "unprognostic (1.77e-1)" "unprognostic (1.45e-1)" "unprognostic (7.62e-3)" "unprognostic (1.20e-1)" "unprognostic (2.71e-1)" "unprognostic (1.96e-1)" "unprognostic (1.15e-1)" "unprognostic (9.40e-3)" 57.9 31.0 47.6 38.3 79.7 63.7 32.5 30.2 61.3 31.1 22.5 26.5 19.4 26.3 29.6 51.8 23.7 27.0 40.7 69.4 44.3 31.2 105.3 34.7 49.5 31.6 32.6 25.7 22.4 38.5 26.8 29.6 40.1 26.2 23.6 34.1 29.3 21.8 85.5 23.7 27.0 31.9 35.7 32.6 24.1 15.2 42.8 33.8 22.8 51.3 55.4 31.2 33.7 49.9 105.8 55.3 94.4 39.0 55.3 41.3 53.8 83.6 61.6 76.6 68.1 79.0 82.1 96.8 93.2 59.9 58.2 93.3 88.8 106.4 89.8 79.1 56.8 30.9 50.4 40.7 45.1 41.0 45.3 32.3 64.0 55.9 81.6 81.5 60.7 48.0 54.3 116.7 113.4 40.3 33.5 51.9 47.9 93.9 42.9 39.2 58.1 84.7 74.8 48.5 58.3 31.7 60.8 45.5 63.0 74.9 41.0 33.7 90.8 99.5 63.8 71.1 112.4 74.0 143.1 60.6 105.1 69.9 48.4 3.0 7.5 5.4 6.4 7.7 5.8 2.8 5.6 6.1 7.7 4.6 6.9 4.2 3.5 8.3 7.7 15.1 4.6 2.8 47.6 79.7 30.2 61.3 69.4 44.3 31.6 32.6 40.1 35.7 42.8 49.9 24.5 28.9 24.8 24.2 40.0 82.8 45.9 32.3 21.1 10.0 22.2 10.2 21.5 40.0 24.9 25.8 14.6 48.1 45.0 25.1 46.9 69.4 12.1 16.3 13.9 34.6 21.7 19.0 69.7 23.1 48.8 30.3 17.9 35.4 8.9 19.8 18.9 172.5 51.4 10.1 46.4 15.4 20.3 90.7 265.3 23.6 22.4 115.1 53.4 48.7 87.9 34.9 35.0 28.1 31.7 103.9 23.5 21.8 49.1 87.7 22.2 35.9 17.7 7.8 6.6 16.3 52.4 35.6 42.7 30.3 67.3 51.7 54.0 5.9 19.1 65.4 MAP2K2 "MEK2, PRKMK2" ENSG00000126934 "Mitogen-activated protein kinase kinase 2" P36507 19 4090321-4124122 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Cardiomyopathy, Disease variant, Ectodermal dysplasia, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Late spermatids: 724.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003835, HPA051993" Supported Supported Cytosol NA NA 140000 "Cluster 52: Eosinophils - Transcription" "Cluster 39: Non-specific - Mitochondria" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 25: Spermatids - Spermatogenesis" Cytosol "CAB003835: AB_562312, HPA051993: AB_2681685" "unprognostic (4.39e-1)" "prognostic favorable (3.72e-4)" "unprognostic (4.24e-1)" "unprognostic (1.26e-3)" "unprognostic (2.58e-1)" "prognostic favorable (7.98e-4)" "unprognostic (2.08e-3)" "unprognostic (2.11e-1)" "unprognostic (2.65e-1)" "unprognostic (1.06e-1)" "unprognostic (7.45e-3)" "unprognostic (4.95e-2)" "unprognostic (1.32e-1)" "prognostic favorable (5.43e-5)" "unprognostic (2.91e-2)" "unprognostic (2.25e-1)" "unprognostic (4.90e-2)" 73.9 118.4 145.5 54.1 143.1 102.4 69.1 151.5 190.7 76.6 150.4 103.4 134.0 72.3 23.2 121.6 64.7 30.4 156.6 145.9 147.3 82.6 123.3 66.8 57.1 149.6 152.9 84.1 134.3 54.9 99.3 36.4 154.3 93.9 42.7 68.0 79.6 37.6 289.0 95.8 101.0 31.7 143.5 89.1 92.7 131.6 150.7 69.3 74.6 132.1 41.0 77.2 75.2 142.8 163.1 175.4 93.7 132.8 127.1 151.9 93.8 104.5 138.8 139.6 125.8 153.0 85.5 137.7 95.9 120.0 111.9 114.3 74.2 111.6 107.4 118.1 90.4 50.5 91.4 171.7 194.0 93.6 101.8 168.8 106.8 98.2 129.5 185.5 125.2 123.0 98.1 263.1 119.3 203.5 186.3 130.6 107.8 118.6 125.9 140.7 61.9 159.1 123.5 102.7 126.8 126.3 95.7 130.6 344.1 107.3 101.0 158.5 111.8 113.6 98.2 293.4 163.9 263.1 172.4 100.2 176.5 166.8 199.3 27.5 13.0 45.4 16.9 16.6 13.6 13.0 13.3 17.2 15.9 18.2 12.3 15.9 21.2 18.8 14.1 9.0 14.3 7.3 145.5 143.1 151.5 190.7 145.9 147.3 149.6 152.9 154.3 143.5 150.7 142.8 77.7 9.6 31.9 22.5 62.3 35.4 93.3 21.3 15.4 85.1 92.9 95.4 62.9 44.3 22.8 40.5 41.7 28.7 102.3 300.5 146.8 20.7 248.1 59.5 68.3 52.1 63.2 123.1 17.6 45.5 38.6 60.3 64.7 48.8 19.7 124.4 49.2 48.1 55.0 121.1 23.2 107.7 16.2 56.0 38.2 724.3 35.8 65.6 42.7 10.3 28.5 121.1 62.8 13.0 24.2 47.0 151.8 23.0 79.9 103.2 166.1 92.8 18.9 106.8 26.3 93.1 71.8 23.5 17.4 42.9 63.9 35.6 77.0 120.2 119.9 113.1 MAP3K1 "MAPKKK1, MEKK, MEKK1" ENSG00000095015 "Mitogen-activated protein kinase kinase kinase 1" Q13233 5 56815549-56896152 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Oligodendrocyte precursor cells: 210.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "SH-SY5Y: 52.5;THP-1: 51.0" "Region enriched" "Detected in all" 6 "olfactory bulb: 18.2" "Low region specificity" "Detected in all" "CAB004500, HPA046509" Approved Approved Cytosol NA NA "Cluster 38: Basophils - Unknown function" "Cluster 20: Retina & Lymphoid tissues - Unknown function" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 57: B-cells - Immune response" Cytosol "CAB004500: AB_627926, HPA046509: AB_2679678" "unprognostic (1.77e-1)" "unprognostic (1.71e-2)" "unprognostic (4.09e-1)" "unprognostic (2.18e-1)" "unprognostic (3.48e-2)" "unprognostic (5.39e-3)" "unprognostic (5.20e-3)" "unprognostic (2.52e-2)" "unprognostic (1.35e-1)" "unprognostic (1.41e-1)" "unprognostic (1.05e-2)" "unprognostic (6.73e-2)" "unprognostic (1.97e-3)" "unprognostic (2.18e-2)" "unprognostic (1.58e-1)" "unprognostic (9.92e-3)" "unprognostic (1.11e-1)" 5.5 3.8 3.0 13.3 2.6 24.0 20.1 4.0 2.1 7.0 6.2 5.4 6.3 7.5 6.6 10.0 9.7 5.7 3.7 2.1 2.7 9.9 6.0 7.5 18.1 3.9 3.2 7.2 9.8 7.1 1.3 11.4 3.7 5.4 6.3 26.9 18.5 8.3 1.7 19.7 6.5 5.7 3.8 20.5 8.1 8.3 3.5 9.9 16.2 4.4 24.0 6.7 6.4 3.9 13.3 7.9 12.1 8.1 1.9 1.5 20.3 2.5 3.3 7.6 10.6 37.1 9.7 11.9 0.9 3.0 6.5 6.7 10.1 4.6 10.5 4.0 4.4 6.6 3.4 17.5 4.7 10.6 17.6 1.9 4.8 2.4 3.8 2.1 3.3 4.0 5.8 20.7 2.0 5.8 7.4 14.2 5.6 6.8 1.0 11.5 8.6 41.1 13.2 13.6 5.1 52.5 7.6 9.5 21.5 10.7 26.0 51.0 9.8 0.7 6.4 2.9 4.7 15.0 8.2 22.1 1.2 6.1 13.2 6.3 3.1 0.7 0.8 4.5 0.7 4.0 2.4 1.1 1.8 3.3 1.5 0.5 1.7 1.7 4.9 1.0 3.8 1.7 3.0 2.6 4.0 2.1 2.1 2.7 3.9 3.2 3.7 3.8 3.5 3.9 20.8 6.4 9.8 17.9 102.5 52.4 15.1 17.1 43.9 14.9 73.2 30.6 3.5 48.6 15.9 36.8 47.9 15.1 31.9 7.3 7.9 18.9 2.0 25.0 20.6 24.0 10.2 14.5 11.7 14.8 8.6 10.7 14.3 43.7 7.6 20.0 21.8 15.0 32.3 28.6 31.8 11.4 6.1 76.0 48.4 3.6 5.3 66.5 37.4 69.3 99.1 11.6 9.2 210.1 12.5 12.9 7.7 1.9 41.5 14.8 10.6 20.7 11.0 38.5 6.6 9.3 11.9 8.6 17.9 69.1 54.7 6.7 31.6 15.4 9.7 12.0 MAP4 ENSG00000047849 "Microtubule associated protein 4" P27816 3 47850690-48089272 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 743.9" "Cell type enhanced" "Detected in all" "Bipolar cells: 392.2;Cardiomyocytes: 921.5;Cone photoreceptor cells: 625.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA038149, HPA038150" Enhanced Approved "Plasma membrane,Microtubules,Cytosol" NA NA 880000 "Cluster 27: Non-specific - Gene expression" "Cluster 80: Striated muscle - Unknown function" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 54: Cardiomyocytes - Muscle contraction" "Microtubules, Cytosol" "Plasma membrane" "HPA038149: AB_10672471, HPA038150: AB_10672505" "unprognostic (2.51e-1)" "unprognostic (4.48e-1)" "unprognostic (2.72e-1)" "unprognostic (1.95e-2)" "unprognostic (3.36e-1)" "unprognostic (4.57e-1)" "prognostic unfavorable (1.82e-4)" "unprognostic (6.82e-2)" "unprognostic (1.46e-2)" "unprognostic (5.02e-2)" "unprognostic (2.23e-2)" "unprognostic (1.30e-2)" "unprognostic (2.25e-2)" "unprognostic (8.89e-2)" "unprognostic (6.45e-2)" "unprognostic (1.88e-1)" "unprognostic (1.21e-3)" 127.4 55.7 475.5 50.4 483.4 16.1 98.0 433.2 406.8 118.0 215.5 193.2 35.1 111.7 69.7 90.7 94.7 52.9 380.9 351.2 408.7 88.3 66.0 105.0 35.0 567.9 490.6 90.0 71.4 31.4 56.1 64.8 509.2 92.7 47.6 149.0 71.4 88.1 743.9 120.6 80.6 94.5 526.1 64.0 93.9 80.0 552.3 42.1 61.1 491.0 37.8 135.5 115.2 533.2 121.9 95.7 117.1 89.3 168.6 298.5 49.5 222.6 241.2 184.1 204.9 81.3 74.4 102.3 50.7 337.9 172.8 79.2 151.4 201.6 204.7 148.7 63.8 69.3 102.8 106.0 228.6 48.6 53.9 251.4 246.4 224.0 271.6 167.1 245.1 70.6 91.2 115.3 146.9 69.1 69.5 58.9 70.9 59.9 195.0 36.6 110.1 128.1 118.2 100.1 46.4 72.3 171.0 68.3 118.6 163.0 50.1 44.8 334.5 172.7 132.3 182.9 144.4 80.4 66.9 47.8 222.2 58.6 167.3 10.5 6.6 3.7 15.6 10.6 7.5 12.3 10.2 12.7 7.1 11.5 4.9 7.6 2.6 13.4 27.3 10.8 13.0 9.7 475.5 483.4 433.2 406.8 351.2 408.7 567.9 490.6 509.2 526.1 552.3 533.2 147.9 70.5 48.2 124.4 45.1 74.8 55.4 53.1 42.7 392.2 34.7 36.2 921.5 48.6 53.4 80.9 625.5 33.8 54.6 43.7 27.4 97.8 116.2 78.2 143.2 110.4 28.8 21.6 63.7 65.3 81.0 105.5 39.8 93.4 27.8 81.6 50.0 57.3 38.0 47.1 71.2 31.7 34.6 28.3 50.5 38.8 77.0 40.0 78.2 95.5 72.0 82.8 47.4 77.9 167.2 92.0 28.0 103.0 47.2 89.0 37.1 39.2 43.6 97.5 72.3 149.0 119.0 65.6 64.3 58.7 69.6 22.4 60.5 137.4 39.5 44.7 MAPK1 "ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2" ENSG00000100030 "Mitogen-activated protein kinase 1" P28482 22 21759657-21867680 "Cancer-related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Kinase, Repressor, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "K-562: 341.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003995, CAB004229, HPA005700, HPA030069, CAB079930, CAB079932, CAB079933" Enhanced Supported "Nuclear speckles,Cytosol" NA NA 140000 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 65: Brain - Ion transport" "Cluster 1: K-562 - Erythropoiesis" "Cluster 63: NK-cells & T-cells - Immune response" Cytosol "Nuclear speckles" "CAB004229: AB_627547, CAB079930: , CAB079932: , CAB079933: , HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035" "unprognostic (9.41e-3)" "unprognostic (2.68e-1)" "unprognostic (2.50e-3)" "unprognostic (4.17e-1)" "unprognostic (4.44e-3)" "unprognostic (1.72e-1)" "prognostic unfavorable (4.95e-4)" "unprognostic (2.29e-1)" "unprognostic (1.67e-1)" "unprognostic (1.58e-1)" "unprognostic (8.43e-3)" "unprognostic (1.04e-1)" "unprognostic (1.35e-2)" "unprognostic (2.08e-1)" "unprognostic (1.94e-1)" "unprognostic (1.41e-1)" "unprognostic (6.49e-2)" 31.1 33.1 64.8 35.9 84.4 41.2 29.8 37.3 80.9 31.4 32.9 36.1 25.8 29.6 30.1 43.0 29.0 28.9 42.2 91.3 46.4 42.1 34.2 38.5 36.8 29.1 45.1 29.2 38.1 51.7 12.0 33.1 35.9 32.8 36.2 30.3 28.9 32.7 38.1 45.0 29.5 39.1 43.8 40.5 33.9 43.7 60.1 44.4 46.1 41.9 41.9 35.5 18.9 43.2 78.7 48.0 60.5 37.2 75.9 76.7 25.9 84.7 77.5 73.2 72.0 43.8 40.8 45.8 41.3 112.7 67.5 74.6 73.9 67.9 97.8 180.4 72.1 78.9 43.0 67.7 73.5 113.2 80.5 56.9 60.1 89.4 81.6 58.0 101.7 45.4 341.9 50.5 97.5 36.6 72.0 38.5 24.4 104.5 46.8 79.4 149.6 13.2 55.5 62.9 50.0 28.6 91.5 64.2 57.2 60.4 42.4 47.1 90.1 61.5 79.6 71.9 54.2 47.1 59.4 65.8 60.0 60.0 68.4 1.4 4.9 7.2 15.9 6.0 4.9 2.3 3.6 6.0 4.1 2.6 3.5 6.1 16.5 9.3 6.9 4.0 3.4 4.0 64.8 84.4 37.3 80.9 91.3 46.4 29.1 45.1 35.9 43.8 60.1 43.2 36.8 48.1 35.8 97.6 44.0 60.2 28.4 25.1 28.5 25.5 32.5 24.5 41.5 42.9 31.2 51.5 54.2 21.8 151.7 74.4 19.6 28.5 49.0 33.5 40.3 39.9 59.6 63.8 109.2 39.2 23.2 38.4 52.0 45.0 92.8 28.8 52.1 63.5 53.2 28.6 91.2 42.2 26.4 89.0 77.1 14.7 32.6 74.9 40.9 68.4 75.0 35.8 143.2 82.4 75.1 45.3 35.2 44.4 37.0 43.8 32.8 46.0 32.2 22.4 32.9 44.6 37.3 74.1 53.4 44.9 61.8 19.2 91.4 43.3 38.6 38.8 MAPK11 "p38-2, p38Beta, PRKM11, SAPK2" ENSG00000185386 "Mitogen-activated protein kinase 11" Q15759 22 50263713-50270767 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Stress response, Transcription, Transcription regulation" "Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 70.9" "Cell type enhanced" "Detected in many" "Adipocytes: 29.5;Astrocytes: 16.6;Endothelial cells: 21.1;Excitatory neurons: 15.8;Hepatic stellate cells: 20.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB012961, HPA045069" Approved Approved Mitochondria NA NA "Cluster 57: Non-specific - Angiogenesis" "Cluster 17: WM-115 - Nervous system development" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" Mitochondria "CAB012961: AB_2533144, HPA045069: AB_2679207" "unprognostic (1.11e-1)" "unprognostic (1.28e-1)" "unprognostic (1.49e-2)" "unprognostic (1.92e-1)" "unprognostic (1.18e-2)" "unprognostic (1.64e-3)" "unprognostic (1.02e-1)" "unprognostic (5.84e-2)" "unprognostic (5.89e-2)" "unprognostic (2.46e-1)" "unprognostic (4.96e-3)" "unprognostic (2.18e-1)" "prognostic unfavorable (6.02e-6)" "unprognostic (9.84e-2)" "unprognostic (4.25e-2)" "unprognostic (9.16e-2)" "unprognostic (2.10e-2)" 27.5 6.8 52.3 7.9 56.0 1.1 24.0 48.2 70.9 15.1 40.6 7.3 1.9 15.5 5.8 9.4 16.7 8.7 18.9 55.2 49.6 18.6 4.8 16.8 9.4 48.2 47.2 12.5 5.7 5.4 28.4 8.3 48.2 18.2 2.6 8.6 7.2 7.2 6.4 7.5 8.3 9.4 47.4 16.3 10.9 6.1 50.2 3.5 11.0 5.8 6.1 11.6 12.3 51.0 2.8 6.8 7.4 27.8 9.5 14.3 0.2 10.2 7.4 6.8 2.7 2.8 5.2 0.0 8.7 9.9 11.3 6.9 4.9 4.2 0.5 13.9 3.4 10.1 10.4 0.6 10.9 2.5 15.0 19.9 12.3 1.9 0.8 7.7 15.2 10.6 8.1 26.8 6.9 12.4 0.5 9.4 0.6 8.4 7.7 26.7 0.1 9.9 10.3 0.0 6.8 18.4 9.0 3.7 7.7 0.9 12.2 7.9 24.0 20.4 16.5 1.5 3.7 1.2 3.2 11.8 10.4 2.9 17.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 52.3 56.0 48.2 70.9 55.2 49.6 48.2 47.2 48.2 47.4 50.2 51.0 29.5 0.0 1.1 16.6 2.2 1.9 1.8 3.2 8.0 3.3 1.1 1.5 6.6 1.5 1.7 0.0 6.2 0.0 1.8 0.1 1.9 1.0 4.7 0.6 1.8 21.1 0.0 0.4 15.8 0.2 0.4 2.7 0.5 1.7 0.0 0.1 20.0 2.1 0.3 0.0 3.6 0.2 2.0 1.3 2.1 9.7 3.1 0.5 5.4 13.1 0.1 5.9 0.0 1.0 0.9 0.7 0.0 2.2 1.6 2.9 0.0 1.9 1.3 11.4 0.0 0.6 1.8 1.3 3.2 1.8 1.3 0.0 3.3 0.7 0.1 1.1 MAPK3 "ERK1, p44erk1, p44mapk, PRKM3" ENSG00000102882 "Mitogen-activated protein kinase 3" P27361 16 30114105-30123506 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Apoptosis, Cell cycle, Host-virus interaction" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Distal enterocytes: 336.9;Early spermatids: 267.2;Proximal enterocytes: 235.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 5 "eosinophil: 49.1;neutrophil: 21.5" "Lineage enriched" "Detected in all" 7 "granulocytes: 49.1" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002683, HPA003995, HPA005700, HPA030069" Approved Supported Nucleoplasm NA NA 46000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 57: Non-specific - Angiogenesis" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 53: Intestinal epithelial cells - Unknown function" Nucleoplasm "CAB002683: , HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035" "unprognostic (5.03e-2)" "unprognostic (4.62e-2)" "unprognostic (3.46e-2)" "unprognostic (1.60e-1)" "unprognostic (4.70e-3)" "unprognostic (2.75e-1)" "prognostic unfavorable (1.11e-4)" "unprognostic (2.09e-2)" "unprognostic (3.59e-2)" "unprognostic (1.12e-1)" "unprognostic (1.55e-1)" "unprognostic (3.51e-2)" "unprognostic (8.78e-2)" "unprognostic (1.45e-1)" "unprognostic (3.01e-2)" "unprognostic (2.38e-1)" "unprognostic (1.19e-2)" 99.5 64.3 178.7 42.4 162.3 45.2 86.3 113.0 200.9 93.3 86.0 117.2 103.1 74.9 27.4 129.6 71.6 65.3 65.4 168.6 132.7 49.4 21.2 71.3 37.8 135.6 148.7 78.7 33.7 61.2 55.8 70.2 142.3 49.2 91.9 71.5 61.0 43.3 51.7 77.6 113.2 58.7 127.4 57.4 86.4 31.6 129.5 31.4 58.0 57.0 49.3 64.8 89.0 130.9 56.3 30.0 62.2 35.7 153.7 202.4 35.1 40.7 101.1 63.4 75.3 36.4 110.0 56.3 39.7 115.5 73.2 20.6 53.3 47.8 61.0 106.9 61.8 17.3 31.6 61.8 154.2 13.0 46.2 125.8 27.3 72.5 32.2 96.1 163.7 60.3 24.3 70.0 85.2 147.1 59.2 21.5 16.9 113.6 26.1 68.9 37.3 127.4 58.0 35.0 55.2 39.3 23.2 81.8 24.1 50.5 53.5 30.7 117.2 41.7 35.4 48.4 14.5 79.1 39.3 29.6 83.3 27.1 30.0 6.2 5.1 49.1 1.6 3.7 2.6 2.3 3.7 3.0 2.8 2.5 2.6 2.9 21.5 2.2 2.0 2.8 6.6 2.8 178.7 162.3 113.0 200.9 168.6 132.7 135.6 148.7 142.3 127.4 129.5 130.9 95.5 22.4 17.5 7.5 10.7 9.8 22.2 11.4 5.7 30.4 23.3 19.9 15.4 20.0 13.0 9.2 22.9 77.6 15.2 336.9 23.5 39.8 267.2 24.8 25.1 68.1 54.7 6.1 7.7 61.2 134.2 34.7 79.0 15.7 2.5 19.1 71.7 7.0 45.2 8.4 10.3 159.3 22.4 26.4 12.3 176.0 32.3 20.6 23.2 7.5 24.5 67.0 13.4 7.1 9.8 118.8 167.2 27.4 6.2 13.5 235.6 23.9 24.7 41.5 19.7 18.8 29.3 10.9 19.8 15.8 13.2 33.8 14.5 40.0 94.9 22.4 MAPT "DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau" ENSG00000186868 "Microtubule associated protein tau" P10636 17 45894527-46028334 "Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Alzheimer disease, Disease variant, FDA approved drug targets, Neurodegeneration, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 67.7;skeletal muscle: 79.0" "Cell type enhanced" "Detected in many" "Astrocytes: 142.4;Bipolar cells: 314.4;Early spermatids: 199.9;Excitatory neurons: 189.2;Horizontal cells: 361.7;Inhibitory neurons: 153.7;Late spermatids: 416.6;Muller glia cells: 145.7;Oligodendrocytes: 163.8" "Cancer enhanced" "Detected in many" "breast cancer: 9.5;glioma: 13.3" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in single" "non-classical monocyte: 1.7" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in many" 5 "HDLM-2: 69.0;SCLC-21H: 21.1;T-47d: 34.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000151, HPA048895, HPA069524, HPA069570, CAB072344" Enhanced Supported "Nuclear speckles,Plasma membrane" "Secreted to blood" NA NA 7100 "Cluster 35: T-regs - Unknown function" "Cluster 47: Non-specific - Unknown function" "Cluster 44: HDLM-2 - Immune response" "Cluster 62: Horizontal cells - Visual perception" "Plasma membrane" "Nuclear speckles" "CAB000151: , CAB072344: , HPA048895: AB_2680550, HPA069524: AB_2686145, HPA069570: AB_2686155" "unprognostic (1.78e-3)" "unprognostic (7.51e-2)" "unprognostic (3.71e-2)" "unprognostic (8.40e-5)" "unprognostic (1.40e-1)" "unprognostic (1.31e-2)" "unprognostic (4.06e-5)" "unprognostic (6.04e-2)" "unprognostic (2.19e-2)" "unprognostic (3.49e-2)" "unprognostic (3.88e-3)" "unprognostic (2.65e-1)" "unprognostic (1.72e-3)" "unprognostic (6.53e-2)" "unprognostic (3.43e-1)" "unprognostic (1.85e-2)" "unprognostic (5.47e-2)" 4.7 4.3 26.2 0.3 27.1 0.0 9.1 8.3 67.7 2.4 0.0 8.4 0.5 1.0 0.2 8.4 1.0 0.8 9.4 30.0 20.4 14.7 0.6 0.8 0.3 11.6 11.4 0.6 1.5 2.9 29.5 3.4 22.4 5.4 0.3 17.6 8.5 3.4 79.0 6.3 1.8 0.3 2.7 0.4 1.7 20.3 14.8 0.4 0.9 27.4 0.2 10.2 2.3 19.7 2.9 0.5 0.3 6.4 0.3 0.9 1.8 0.1 0.3 0.1 0.0 0.2 0.0 0.0 0.6 0.4 0.5 0.1 2.3 0.3 0.0 69.0 3.4 0.0 0.3 4.2 0.0 0.1 0.1 0.0 0.5 0.1 0.3 0.1 0.0 4.4 0.7 3.6 0.0 7.7 1.0 0.2 0.2 0.7 2.0 0.0 4.0 8.5 0.0 9.1 21.1 9.1 2.5 0.0 1.8 1.0 34.7 0.1 0.1 0.3 0.8 1.7 0.3 0.9 0.3 0.0 0.6 2.0 0.5 0.1 0.0 0.0 0.2 0.7 0.2 0.0 0.1 0.5 0.0 0.0 0.2 0.3 0.2 0.1 1.7 0.0 0.7 0.0 26.2 27.1 8.3 67.7 30.0 20.4 11.6 11.4 22.4 2.7 14.8 19.7 1.9 0.0 9.8 142.4 1.0 1.0 1.4 0.2 1.2 314.4 26.7 21.2 35.2 0.0 0.1 1.8 64.6 0.2 0.4 0.1 7.9 0.5 199.9 0.4 1.7 1.8 0.0 0.0 189.2 0.4 9.1 3.7 0.5 1.3 4.5 1.6 1.1 0.5 0.3 361.7 153.7 0.0 2.0 0.6 1.7 416.6 2.8 0.8 5.4 8.4 0.7 145.7 0.0 129.7 163.8 0.6 0.0 2.6 0.1 2.5 0.1 76.1 0.0 28.3 0.0 28.2 6.0 18.4 8.1 22.7 3.3 0.3 1.5 0.8 0.3 0.6 MB PVALB ENSG00000198125 Myoglobin P02144 22 35606764-35637951 "Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Oxygen transport, Transport" "Muscle protein" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 38 "heart muscle: 13154.5;skeletal muscle: 40709.4;tongue: 29085.2" "Cell type enriched" "Detected in many" 12 "Cardiomyocytes: 5182.1" "Group enriched" "Detected in many" 7 "breast cancer: 13.6;head and neck cancer: 31.1;prostate cancer: 30.4" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 6 "NK-cell: 1.3" "Lineage enriched" "Detected in single" 6 "NK-cells: 1.3" "Cell line enriched" "Detected in some" 4 "SK-BR-3: 175.6" "Low region specificity" "Detected in many" "CAB000060, HPA003123" Enhanced NA NA 13500000 140000000 "Cluster 48: NK-cells - Unknown function" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 54: Cardiomyocytes - Muscle contraction" "CAB000060: , HPA003123: AB_1079442" "unprognostic (7.51e-2)" "unprognostic (3.92e-3)" "unprognostic (1.07e-1)" "unprognostic (7.71e-2)" "unprognostic (2.35e-1)" "unprognostic (4.66e-3)" "unprognostic (5.78e-3)" "unprognostic (1.18e-1)" "unprognostic (2.74e-1)" "unprognostic (1.72e-1)" "unprognostic (2.74e-3)" "unprognostic (1.17e-2)" "unprognostic (8.34e-2)" "unprognostic (1.51e-2)" "unprognostic (2.35e-1)" "unprognostic (3.44e-3)" "unprognostic (1.19e-2)" 8.1 4.6 1.2 1.5 1.2 0.3 43.4 1.2 2.2 2.9 0.9 14.6 1.8 2.3 0.3 736.1 18.7 4.1 13154.5 1.0 1.9 2.8 5.8 14.9 5.3 1.4 1.4 5.3 26.9 16.1 10.6 3.1 1.2 214.2 12.9 0.2 367.1 0.5 40709.4 23.0 11.1 1.4 1.2 2.1 3.8 4.5 1.5 0.8 8.5 29085.2 1.8 1.3 4.5 1.0 1.9 7.6 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.2 0.0 0.0 4.6 0.7 0.1 0.3 1.0 0.8 0.2 0.0 0.0 5.4 0.3 0.1 0.5 0.1 0.0 0.0 0.2 0.1 0.2 0.4 0.0 0.2 0.0 0.0 0.5 0.5 0.0 19.2 0.1 0.6 0.0 1.9 2.3 0.9 0.5 8.0 0.0 6.4 1.5 0.2 19.0 175.6 0.0 0.3 39.4 0.1 0.4 0.5 1.2 2.2 0.2 0.0 0.0 0.2 0.3 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 1.2 1.2 1.2 2.2 1.0 1.9 1.4 1.4 1.2 1.2 1.5 1.0 0.3 0.0 0.0 0.3 0.1 0.3 4.3 12.5 0.0 0.0 30.7 23.9 5182.1 0.0 30.8 0.0 0.0 0.1 0.5 3.8 0.0 4.7 20.1 20.2 0.1 40.7 11.5 0.0 0.0 0.2 0.0 145.2 0.0 0.2 0.0 0.8 0.0 0.4 0.0 0.0 0.1 114.6 14.2 0.0 0.4 70.0 0.0 2.1 12.4 0.0 0.0 0.0 0.0 0.0 0.0 0.6 2.8 0.7 0.0 21.8 2.6 0.1 19.9 0.0 0.0 420.9 42.0 0.3 0.7 0.6 0.1 0.3 2.8 0.1 2.9 15.1 MC1R MSH-R ENSG00000258839 "Melanocortin 1 receptor" Q01726 16 89912119-89920973 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "pituitary gland: 27.9;testis: 29.0" "Cell type enhanced" "Detected in many" "granulocytes: 17.2;Melanocytes: 17.8;Spermatocytes: 10.6" "Cancer enriched" "Detected in many" 5 "melanoma: 6.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "MCF7: 23.0;SK-MEL-30: 47.6" "Not detected" "Not detected" "Low region specificity" "Detected in all" NA NA "Cluster 43: Testis - Unknown function" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 60: Granulocytes - Receptor signaling" "unprognostic (3.90e-2)" "unprognostic (9.05e-2)" "unprognostic (5.39e-7)" "unprognostic (5.00e-2)" "unprognostic (1.39e-1)" "unprognostic (1.30e-1)" "unprognostic (1.00e-2)" "unprognostic (1.73e-1)" "unprognostic (1.55e-2)" "unprognostic (8.26e-2)" "prognostic favorable (7.88e-4)" "unprognostic (1.02e-2)" "unprognostic (5.20e-3)" "unprognostic (4.25e-2)" "unprognostic (5.17e-2)" "unprognostic (2.58e-2)" "unprognostic (1.16e-2)" 3.6 4.4 6.5 2.1 7.6 1.0 3.3 10.4 8.2 7.8 4.8 6.4 1.9 5.1 2.6 2.6 8.7 3.0 4.4 6.3 8.1 8.3 2.6 4.1 1.9 6.8 6.3 7.9 3.5 0.6 27.9 3.1 6.9 9.9 0.9 3.1 5.1 1.8 1.2 7.2 5.2 2.1 5.9 4.4 3.8 29.0 7.4 1.0 15.7 0.2 0.9 6.2 4.7 6.4 3.3 14.6 2.4 3.8 2.4 4.5 3.3 4.4 3.9 3.2 2.0 3.9 3.6 2.8 6.2 4.7 1.6 7.4 1.5 1.1 1.2 1.6 4.2 0.6 5.8 11.0 0.6 0.8 3.3 6.5 2.0 4.3 1.3 2.8 2.8 0.9 3.1 3.5 2.2 23.0 0.1 20.9 3.0 3.6 2.8 1.7 3.1 2.6 2.7 1.8 4.8 2.5 4.9 1.8 47.6 1.5 20.3 3.3 1.9 4.6 9.8 2.2 1.6 14.0 8.5 1.3 5.9 10.1 13.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 6.5 7.6 10.4 8.2 6.3 8.1 6.8 6.3 6.9 5.9 7.4 6.4 1.0 3.2 1.7 2.3 1.0 2.3 0.8 1.2 0.0 7.1 2.4 1.3 0.9 1.5 1.6 1.8 8.4 1.3 1.6 2.0 0.0 0.9 1.0 2.2 2.8 1.5 4.2 0.4 2.2 1.8 2.3 2.0 5.1 2.8 17.2 0.7 2.9 2.2 0.8 6.7 2.3 2.3 2.0 0.6 1.0 1.0 0.6 1.1 17.8 1.0 0.2 2.0 2.1 2.0 1.0 1.2 1.5 0.4 0.8 1.5 2.1 0.3 1.9 2.6 0.0 1.6 1.7 10.6 2.8 1.2 2.4 4.5 1.2 0.6 1.9 0.9 MC2R ACTHR ENSG00000185231 "Melanocortin 2 receptor" Q01718 18 13882044-13915707 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 33 "adrenal gland: 57.9" "Cell type enhanced" "Detected in single" "Late spermatids: 1.4" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA079148 Enhanced NA NA "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 31: Spermatids - Spermatogenesis" "HPA079148: " "unprognostic (2.09e-1)" "unprognostic (3.63e-2)" "unprognostic (1.85e-2)" 0.0 57.9 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 MC4R ENSG00000166603 "Melanocortin 4 receptor" P32245 18 60371062-60372775 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "brain: 3.5;fallopian tube: 3.0;retina: 3.9" "Cell type enriched" "Detected in some" 7 "Bipolar cells: 7.3" "Cancer enhanced" "Detected in single" "ovarian cancer: 0.6" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 70 "fHDF/TERT166: 94.7" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "cerebellum: 10.2" HPA016719 Uncertain NA NA "Cluster 77: Retina - Visual perception" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 56: Bipolar cells - Visual perception" "HPA016719: AB_1853617" "unprognostic (2.29e-1)" "unprognostic (5.31e-3)" "unprognostic (5.78e-2)" "unprognostic (1.41e-1)" "unprognostic (1.35e-1)" "unprognostic (3.33e-1)" "unprognostic (2.54e-1)" "unprognostic (1.48e-1)" "unprognostic (2.49e-2)" "unprognostic (2.30e-1)" "unprognostic (2.59e-1)" 0.0 0.2 2.2 0.0 2.4 0.0 0.2 0.1 1.7 0.0 0.0 0.0 0.1 0.0 0.3 0.0 3.0 0.0 0.0 1.8 3.5 0.0 0.0 0.0 0.0 1.0 1.5 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.0 3.9 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.1 0.1 2.7 0.3 0.0 0.0 0.3 0.0 0.0 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 94.7 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 2.4 0.1 1.7 1.8 3.5 1.0 1.5 0.7 0.4 2.7 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MDH2 ENSG00000146701 "Malate dehydrogenase 2" P40926 7 76048051-76067508 "Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Tricarboxylic acid cycle" Oxidoreductase "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 697.1;tongue: 601.9" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019714, HPA019716, HPA019848, HPA026720" Enhanced Enhanced Mitochondria No No 14000000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 39: Non-specific - Basic cellular processes" Mitochondria "HPA019714: AB_1853678, HPA019716: AB_1853680, HPA019848: AB_1853683, HPA026720: AB_1853685" "unprognostic (3.20e-2)" "unprognostic (2.85e-1)" "unprognostic (1.11e-1)" "unprognostic (1.43e-2)" "unprognostic (5.55e-3)" "unprognostic (8.94e-2)" "unprognostic (6.45e-2)" "unprognostic (3.77e-2)" "unprognostic (3.60e-1)" "unprognostic (2.02e-2)" "unprognostic (1.40e-1)" "unprognostic (9.70e-2)" "prognostic favorable (1.49e-5)" "unprognostic (8.57e-2)" "unprognostic (9.64e-2)" "unprognostic (5.68e-2)" "unprognostic (2.66e-1)" 76.9 163.4 68.0 51.4 73.6 71.9 73.9 62.1 83.9 67.4 81.3 118.7 112.7 69.2 34.7 144.9 66.8 38.0 367.5 73.5 69.9 121.7 215.5 60.7 62.4 66.7 61.4 64.1 118.3 90.5 70.7 45.2 67.0 67.3 80.3 40.2 98.8 56.8 697.1 119.5 94.4 60.0 56.3 75.6 103.2 60.2 64.1 60.4 62.3 601.9 66.2 85.6 82.4 66.6 176.5 278.4 99.2 250.7 110.3 121.2 172.0 113.9 145.8 159.4 143.2 246.2 204.7 261.3 51.1 151.1 172.6 174.4 256.3 170.0 112.7 192.1 368.3 144.6 138.7 229.9 135.2 229.3 144.6 153.7 149.7 155.2 229.3 124.9 150.9 160.5 466.3 149.4 149.7 389.6 206.4 402.1 222.8 306.6 344.3 164.3 121.7 379.9 149.9 225.5 247.4 226.9 114.6 567.5 247.0 124.9 323.4 260.0 117.7 160.0 151.6 175.5 232.7 166.5 148.1 290.8 138.6 289.1 249.1 95.4 129.9 63.3 102.4 148.8 107.1 122.2 113.7 111.2 176.0 110.2 109.0 102.6 34.0 107.4 164.2 157.2 156.6 175.8 68.0 73.6 62.1 83.9 73.5 69.9 66.7 61.4 67.0 56.3 64.1 66.6 98.8 51.3 65.9 7.8 110.2 135.9 190.8 437.9 118.4 68.0 151.8 165.5 486.2 135.8 217.3 115.8 18.8 328.1 104.9 242.3 448.0 269.8 263.7 108.0 97.9 96.8 169.7 97.2 13.0 333.1 334.0 112.6 111.1 104.8 54.5 150.9 88.5 246.6 248.1 72.3 15.0 280.6 288.9 132.6 113.5 161.5 99.4 117.6 181.5 9.4 171.4 85.7 126.7 8.0 12.8 255.0 252.1 99.3 149.8 197.3 433.3 466.3 139.0 67.3 85.5 114.7 150.9 157.8 65.3 256.6 166.1 294.8 105.4 233.4 372.7 234.7 MET "DFNB97, HGFR, RCCP2" ENSG00000105976 "MET proto-oncogene, receptor tyrosine kinase" P08581 7 116672196-116798377 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Deafness, Disease variant, FDA approved drug targets, Non-syndromic deafness, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 42.9" "Cell type enhanced" "Detected in many" "Alveolar cells type 2: 103.6;Club cells: 99.8;Glandular and luminal cells: 161.4;Pancreatic endocrine cells: 93.9;Prostatic glandular cells: 149.3;Urothelial cells: 128.6" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in many" 5 "cerebral cortex: 7.5;hippocampal formation: 6.6;midbrain: 2.5;pons: 4.9;white matter: 7.8" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "A-431: 203.8;CAPAN-2: 219.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB005282, CAB018577, HPA055607" Approved Approved "Plasma membrane,Cytosol" "Secreted to blood" NA NA 179000000 100000000 "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 44: Endometrium - Transcription" "Plasma membrane, Cytosol" "CAB005282: AB_631940, CAB018577: AB_649068, HPA055607: AB_2682860" "unprognostic (1.60e-2)" "unprognostic (7.71e-2)" "unprognostic (2.53e-2)" "unprognostic (1.58e-1)" "unprognostic (3.57e-3)" "prognostic unfavorable (6.75e-4)" "unprognostic (1.68e-1)" "unprognostic (3.22e-2)" "unprognostic (3.81e-2)" "unprognostic (2.52e-2)" "prognostic unfavorable (1.21e-7)" "unprognostic (1.86e-1)" "unprognostic (1.25e-1)" "unprognostic (5.53e-2)" "unprognostic (8.88e-2)" "unprognostic (2.01e-2)" "unprognostic (2.20e-1)" 10.3 0.8 0.1 3.4 0.6 7.4 8.9 0.1 7.5 13.1 9.6 9.7 6.5 6.4 2.5 6.1 4.7 11.9 6.2 6.6 0.8 20.1 42.9 20.3 2.3 1.1 2.5 0.8 6.6 0.8 3.8 26.4 4.9 6.7 9.3 3.9 8.7 11.2 14.3 7.7 8.2 5.7 0.3 6.0 15.4 0.5 0.5 3.7 17.6 11.0 3.2 18.4 4.4 7.8 203.8 115.3 0.1 0.6 8.6 8.7 7.9 113.7 48.2 60.3 51.1 25.0 219.0 8.4 179.0 72.1 163.3 51.8 19.7 110.0 123.7 0.3 23.4 0.1 112.5 21.4 1.5 0.3 0.2 11.4 42.4 40.6 129.1 109.4 42.4 0.2 4.5 0.8 114.1 5.0 0.1 0.1 17.3 32.9 113.0 0.2 95.3 0.2 105.8 24.0 16.5 0.0 45.4 15.4 44.9 19.8 0.4 0.9 72.3 89.7 30.6 46.7 88.9 2.5 19.1 1.5 99.3 0.3 12.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.1 7.5 6.6 0.8 1.1 2.5 4.9 0.3 0.5 7.8 32.6 28.9 103.6 0.3 1.0 39.0 70.5 58.1 38.1 6.7 6.5 6.9 12.3 11.5 99.8 31.3 0.0 76.0 0.4 20.5 0.0 38.5 0.0 52.5 11.6 20.1 7.2 0.0 2.6 46.9 7.5 7.4 32.6 161.4 0.0 0.0 3.9 30.5 7.0 0.0 1.0 20.5 18.3 1.3 2.2 0.1 0.6 4.4 3.6 1.9 1.0 7.6 0.0 0.5 7.7 93.9 5.5 0.0 0.4 149.3 11.2 15.6 34.5 0.3 0.0 37.8 5.2 0.0 0.6 7.9 17.8 21.8 1.2 0.0 16.4 128.6 MGAM MGA ENSG00000257335 Maltase-glucoamylase O43451 7 141907813-142106747 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins" "Glycosidase, Hydrolase, Multifunctional enzyme" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "epididymis: 25.5;intestine: 87.6" "Group enriched" "Detected in some" 5 "Late spermatids: 156.4;Proximal enterocytes: 521.4" "Cancer enriched" "Detected in some" 7 "renal cancer: 4.9" "Region enhanced" "Detected in single" "cerebral cortex: 2.3" "Immune cell enriched" "Detected in some" 7 "neutrophil: 13.5" "Lineage enriched" "Detected in single" 102 "granulocytes: 13.5" "Cell line enhanced" "Detected in some" "A549: 1.8;BJ hTERT+: 1.6;HL-60: 2.8;U-937: 4.3;WM-115: 1.0" "Region enriched" "Detected in single" 12 "olfactory bulb: 2.0" "Low region specificity" "Detected in many" HPA002270 Enhanced NA NA 310000 "Cluster 9: Neutrophils - Innate immune response" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 32: U-937 - Innate immune response" "Cluster 45: Enterocytes - Digestion" "HPA002270: AB_1079366" "unprognostic (1.02e-2)" "unprognostic (1.45e-1)" "unprognostic (1.13e-1)" "unprognostic (6.95e-3)" "unprognostic (2.80e-1)" "unprognostic (7.81e-2)" "unprognostic (7.32e-3)" "unprognostic (3.83e-2)" "unprognostic (4.97e-1)" "unprognostic (2.17e-2)" "unprognostic (6.86e-2)" "unprognostic (1.99e-1)" "prognostic favorable (6.16e-5)" "unprognostic (1.82e-1)" "unprognostic (2.82e-1)" "unprognostic (1.34e-3)" "unprognostic (3.03e-1)" 2.6 0.1 0.2 2.5 0.4 18.1 0.2 0.2 2.3 0.4 0.3 0.5 58.9 0.1 25.5 0.3 1.2 0.4 0.3 0.1 0.3 18.7 0.5 3.2 0.1 0.5 0.4 0.1 0.2 0.0 0.1 0.3 0.6 0.1 0.2 0.0 0.1 7.1 0.1 0.1 87.6 0.4 0.2 12.6 1.8 1.3 0.6 0.4 0.1 1.0 0.0 0.5 0.1 0.4 0.0 1.8 0.1 0.0 0.0 0.0 0.2 0.0 1.6 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.2 0.0 0.1 0.0 0.0 0.0 4.3 1.0 0.0 0.1 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.5 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.2 2.3 0.1 0.3 0.5 0.4 0.6 0.2 0.6 0.4 0.0 0.0 2.5 3.3 0.1 0.0 0.0 0.6 0.0 0.2 0.5 0.1 1.4 0.0 3.2 12.9 0.0 0.0 2.8 1.8 1.9 0.1 59.7 0.1 0.2 0.3 1.2 0.0 0.7 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.3 0.2 0.0 0.7 17.8 0.0 0.0 2.5 156.4 0.6 1.1 0.0 0.0 0.7 0.6 5.2 1.5 0.6 0.2 16.3 0.4 0.0 0.1 521.4 24.4 6.7 0.0 0.0 0.5 0.1 1.8 1.2 0.0 0.0 0.0 0.4 0.0 7.3 0.3 MME "CALLA, CD10, NEP" ENSG00000196549 "Membrane metalloendopeptidase" P08473 3 155024124-155183704 "Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, Charcot-Marie-Tooth disease, Disease variant, FDA approved drug targets, Neurodegeneration, Neuropathy, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 333.5;kidney: 302.5" "Cell type enhanced" "Detected in many" "Endometrial stromal cells: 273.3;Proximal enterocytes: 372.4;Proximal tubular cells: 125.7;Syncytiotrophoblasts: 126.0" "Cancer enhanced" "Detected in many" "prostate cancer: 17.6" "Group enriched" "Detected in many" 5 "basal ganglia: 17.3;medulla oblongata: 9.3;pons: 10.9;thalamus: 4.6" "Immune cell enriched" "Detected in some" 122 "neutrophil: 139.4" "Lineage enriched" "Detected in many" 122 "granulocytes: 139.4" "Cell line enhanced" "Detected in many" "ASC TERT1: 684.4;BJ hTERT+: 1116.9;HSkMC: 651.1" "Region enhanced" "Detected in many" "basal ganglia: 28.1" "Group enriched" "Detected in many" 4 "basal ganglia: 32.3;olfactory bulb: 8.5;spinal cord: 15.9" "CAB000013, HPA052583, HPA056072" Enhanced NA NA 320000 "Cluster 9: Neutrophils - Innate immune response" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 45: Enterocytes - Digestion" "CAB000013: AB_563478, HPA052583: AB_2681872, HPA056072: AB_2683027" "unprognostic (1.36e-1)" "unprognostic (1.02e-3)" "unprognostic (8.52e-2)" "unprognostic (2.95e-1)" "unprognostic (2.78e-2)" "unprognostic (6.52e-3)" "unprognostic (1.20e-1)" "unprognostic (1.67e-2)" "unprognostic (8.67e-2)" "unprognostic (1.96e-1)" "unprognostic (7.30e-3)" "unprognostic (1.31e-1)" "unprognostic (2.71e-3)" "unprognostic (1.50e-1)" "unprognostic (7.29e-2)" "unprognostic (1.06e-2)" "unprognostic (1.37e-2)" 103.9 1.0 0.7 4.5 17.3 11.5 38.5 1.5 1.9 22.7 0.3 1.9 333.5 13.3 22.5 2.3 1.9 13.4 4.3 0.1 0.6 302.5 56.1 27.6 10.3 9.3 2.3 0.9 1.2 0.5 0.6 73.0 10.9 79.6 3.4 0.1 6.1 44.5 20.3 1.9 289.7 1.5 0.9 7.9 1.6 1.3 4.6 16.6 1.2 23.5 12.3 6.0 7.6 0.4 0.1 0.0 0.9 0.3 280.1 684.4 1.6 160.3 1116.9 82.2 209.8 0.0 0.3 172.9 0.1 130.1 107.4 0.5 5.2 6.1 201.3 0.0 0.8 0.0 0.1 0.2 229.6 0.0 0.0 651.1 1.0 40.4 308.1 89.4 59.5 0.4 0.2 0.3 135.1 0.7 0.4 1.0 6.1 0.5 1.1 303.3 139.9 1.6 5.2 1.9 0.5 1.5 0.1 0.5 31.9 68.3 0.2 0.2 165.8 356.4 0.8 115.7 27.9 0.1 0.0 217.3 42.5 0.1 7.3 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.0 139.4 0.0 0.0 1.1 0.0 0.0 0.7 17.3 1.5 1.9 0.1 0.6 9.3 2.3 10.9 0.9 4.6 0.4 5.9 9.6 13.0 0.3 2.3 0.8 74.1 2.5 0.0 0.0 1.5 64.1 1.6 21.5 11.2 22.0 0.0 82.1 6.9 0.0 9.8 0.2 0.5 6.2 273.3 6.6 0.0 0.0 2.2 0.0 57.8 40.6 0.0 5.7 2.5 0.0 2.9 53.2 8.9 0.0 8.1 9.9 2.0 3.1 1.2 0.5 4.1 10.7 0.0 0.0 0.2 0.0 0.0 0.5 0.3 0.6 13.8 1.2 0.1 40.0 372.4 125.7 1.6 0.0 0.0 17.4 11.1 0.2 0.5 0.1 0.3 126.0 2.5 0.1 12.6 33.6 MMP9 CLG4B ENSG00000100985 "Matrix metallopeptidase 9" P14780 20 46008908-46016561 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Collagen degradation" "Hydrolase, Metalloprotease, Protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 11 "bone marrow: 376.0;lymphoid tissue: 105.3" "Group enriched" "Detected in many" 5 "Hofbauer cells: 260.1;Langerhans cells: 606.0;Macrophages: 230.6" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in some" 4 "cerebral cortex: 3.1;thalamus: 4.8" "Immune cell enriched" "Detected in some" 127 "neutrophil: 272.2" "Lineage enriched" "Detected in single" 341 "granulocytes: 272.2" "Cell line enriched" "Detected in some" 13 "NB-4: 360.6" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201" Enhanced Approved Cytosol "Secreted to blood" NA NA 43300000 61000000 "Cluster 9: Neutrophils - Innate immune response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 24: NB-4 - Immune response" "Cluster 4: Macrophages - Innate immune response" Cytosol "CAB000348: , CAB068199: AB_2665675, CAB068200: AB_2665676, CAB068201: AB_2665677, HPA001238: AB_1079398, HPA063909: AB_2685150" "unprognostic (4.62e-2)" "unprognostic (1.64e-1)" "unprognostic (2.85e-2)" "prognostic favorable (2.55e-4)" "unprognostic (6.65e-3)" "unprognostic (2.82e-1)" "prognostic unfavorable (7.19e-4)" "unprognostic (1.54e-1)" "unprognostic (8.57e-2)" "unprognostic (3.21e-2)" "unprognostic (4.15e-2)" "unprognostic (1.96e-1)" "prognostic unfavorable (4.05e-5)" "unprognostic (4.65e-1)" "unprognostic (9.85e-3)" "unprognostic (2.48e-2)" "unprognostic (2.17e-3)" 19.5 0.6 0.5 61.9 0.8 376.0 8.2 0.4 3.1 2.9 0.8 5.7 11.6 1.0 0.0 2.2 2.2 3.0 3.2 0.3 0.9 2.6 3.8 21.1 103.2 0.8 0.5 0.8 1.6 0.1 1.1 2.0 0.7 1.9 3.4 0.6 3.6 0.4 0.7 3.2 12.4 1.9 0.4 105.3 11.3 1.3 4.8 17.0 2.1 0.9 36.5 12.0 1.1 0.2 0.2 0.4 0.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 3.3 0.3 28.8 0.0 0.3 0.4 0.0 1.4 0.0 0.3 0.5 0.1 0.0 0.0 0.0 0.6 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.0 4.0 0.0 360.6 0.8 0.0 0.2 0.4 0.3 0.1 0.0 0.0 0.6 0.6 0.0 0.6 0.0 3.7 0.3 1.2 0.3 10.3 10.9 0.1 0.3 0.3 0.2 0.2 0.1 0.8 0.2 0.0 0.7 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 272.2 0.0 0.3 0.0 0.0 0.5 0.5 0.8 0.4 3.1 0.3 0.9 0.8 0.5 0.7 0.4 4.8 0.2 0.7 0.0 5.5 0.0 3.9 34.3 0.1 61.5 0.0 3.8 0.5 2.0 0.4 1.5 0.9 0.0 8.4 1.5 2.0 0.0 0.0 0.8 0.9 0.0 0.1 7.2 0.0 0.0 0.1 1.8 2.4 2.5 0.0 0.1 1.3 0.2 0.0 0.0 260.1 3.3 0.2 0.5 0.0 1.3 606.0 0.3 0.0 230.6 56.9 0.0 2.3 1.2 0.0 0.0 0.0 1.8 0.0 0.0 0.9 0.1 0.0 0.3 6.9 5.3 0.0 0.2 45.5 6.7 11.2 0.2 28.1 1.9 3.4 0.3 0.0 0.1 MMUT "MCM, MUT" ENSG00000146085 "Methylmalonyl-CoA mutase" P22033 6 49430360-49463253 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Isomerase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 199.0" "Cell type enhanced" "Detected in some" "Cardiomyocytes: 62.5;Cytotrophoblasts: 26.5;Extravillous trophoblasts: 13.3;Hofbauer cells: 12.4;Syncytiotrophoblasts: 33.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035971, HPA035972" Enhanced Approved Mitochondria,Cytosol NA NA 150000 "Cluster 27: Non-specific - Gene expression" "Cluster 85: Liver - Metabolism" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 24: Non-specific - Transcription regulation" Cytosol Mitochondria "HPA035971: AB_10696648, HPA035972: AB_2674895" "unprognostic (1.34e-2)" "unprognostic (1.12e-1)" "unprognostic (1.17e-2)" "unprognostic (3.72e-2)" "unprognostic (3.18e-3)" "unprognostic (1.20e-1)" "unprognostic (1.16e-2)" "unprognostic (1.16e-2)" "unprognostic (3.62e-2)" "unprognostic (1.89e-2)" "unprognostic (6.57e-2)" "unprognostic (9.89e-2)" "prognostic favorable (8.71e-13)" "unprognostic (5.38e-2)" "unprognostic (3.78e-1)" "unprognostic (6.01e-3)" "unprognostic (1.91e-1)" 19.8 23.3 12.1 11.5 13.2 8.6 18.4 14.2 16.2 14.0 19.3 22.6 27.1 15.2 15.6 17.9 13.9 14.2 31.0 12.1 13.5 50.6 199.0 12.5 11.8 13.0 12.7 24.2 24.6 31.1 11.7 13.2 13.2 20.8 21.5 17.2 18.7 15.8 23.6 15.0 20.1 14.9 14.1 9.4 20.1 14.6 13.3 12.2 19.2 36.1 11.2 13.0 11.9 16.3 23.9 8.3 24.6 28.8 47.8 45.1 13.6 20.9 27.3 21.6 31.7 9.7 12.1 21.9 16.3 22.4 32.6 13.3 27.6 14.8 30.2 18.9 20.0 11.7 17.5 25.4 34.8 15.1 10.8 27.4 21.6 22.0 25.4 19.3 21.1 23.4 21.6 25.6 25.7 15.0 17.9 14.9 10.5 25.0 6.0 15.8 30.8 30.7 24.9 22.6 22.7 15.8 23.0 16.3 35.7 25.6 14.2 23.9 15.4 20.0 14.6 27.4 28.7 10.0 12.2 18.8 28.1 17.6 17.9 16.0 6.5 11.4 6.4 8.8 8.2 7.6 7.7 8.1 7.8 6.9 9.6 7.2 3.8 12.5 14.7 5.5 10.9 5.8 12.1 13.2 14.2 16.2 12.1 13.5 13.0 12.7 13.2 14.1 13.3 16.3 6.6 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 62.5 0.0 0.0 0.0 0.0 26.5 2.2 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 13.3 5.3 0.0 0.0 0.0 0.0 0.0 0.0 12.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0 0.0 0.0 33.4 0.6 0.0 0.0 0.0 MPL "CD110, THPOR, TPOR" ENSG00000117400 "MPL proto-oncogene, thrombopoietin receptor" P40238 1 43337818-43354466 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" Receptor "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in some" "Group enriched" "Detected in some" 5 "Erythroid cells: 3.0;Excitatory neurons: 2.0;Oligodendrocytes: 1.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in single" "neutrophil: 1.4" "Lineage enriched" "Detected in single" 4 "granulocytes: 1.4" "Cell line enriched" "Detected in some" 57 "HEL: 77.4" "Region enhanced" "Detected in single" "cerebral cortex: 1.5" "Low region specificity" "Detected in many" HPA007619 Supported "Nuclear membrane,Plasma membrane" NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 69: Cerebellum - Gene expression regulation" "Cluster 36: HEL - Hemostasis" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" "Nuclear membrane" "HPA007619: AB_1854080" "unprognostic (2.74e-1)" "unprognostic (6.56e-2)" "unprognostic (2.95e-1)" "unprognostic (8.71e-2)" "unprognostic (1.37e-2)" "unprognostic (1.06e-3)" "unprognostic (1.19e-1)" "unprognostic (1.22e-2)" "unprognostic (5.83e-2)" "unprognostic (1.03e-1)" "unprognostic (5.94e-4)" "unprognostic (1.51e-1)" "unprognostic (1.19e-4)" "unprognostic (2.39e-1)" "unprognostic (3.26e-1)" "unprognostic (1.03e-4)" "unprognostic (1.42e-1)" 0.6 0.4 0.8 0.2 1.7 1.8 0.4 0.8 1.3 0.3 0.1 0.3 0.3 0.7 1.2 0.5 0.8 0.3 1.0 0.6 1.2 0.4 0.4 0.6 0.2 1.2 1.0 2.9 0.8 0.4 0.0 0.3 1.1 0.9 0.4 1.5 0.4 0.7 0.6 0.5 0.2 0.7 0.7 0.4 0.5 1.2 1.1 0.1 0.9 0.3 0.1 0.2 0.0 2.8 0.4 0.7 0.1 0.2 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.7 1.3 0.1 0.3 0.1 0.0 0.6 0.0 0.2 0.0 0.4 0.1 77.4 1.2 0.4 0.0 0.1 0.0 0.0 0.2 0.0 0.2 0.3 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.2 0.5 0.1 0.1 0.2 0.0 0.2 0.7 0.6 0.4 0.2 0.6 0.1 0.2 0.2 0.3 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.0 0.0 0.0 0.0 0.9 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.2 0.2 0.2 1.4 0.1 0.1 0.3 0.1 1.8 0.8 1.7 0.8 1.3 0.6 1.2 1.2 1.0 1.1 0.7 1.1 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MRC1 "bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1" ENSG00000260314 "Mannose receptor C-type 1" P22897 10 17809348-17911164 "CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins" "Endocytosis, Host-virus interaction" "Host cell receptor for virus entry, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 122.3" "Group enriched" "Detected in many" 4 "Breast glandular cells: 128.9;Hepatic stellate cells: 397.7;Hofbauer cells: 176.1;Kupffer cells: 361.4;Macrophages: 316.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in single" 16 "myeloid DC: 4.8" "Lineage enriched" "Detected in single" 16 "dendritic cells: 4.8" "Group enriched" "Detected in some" 19 "MOLT-4: 19.3;TIME: 17.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004114, HPA045134, CAB068203" Enhanced NA NA 170000000 "Cluster 28: Myeloid DCs - Unknown function" "Cluster 19: Lung - Lung function" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 4: Macrophages - Innate immune response" "CAB068203: AB_2665652, HPA004114: AB_1846270, HPA045134: AB_2679228" "unprognostic (2.20e-1)" "unprognostic (2.07e-1)" "unprognostic (1.03e-2)" "unprognostic (2.58e-1)" "unprognostic (5.62e-2)" "unprognostic (4.30e-1)" "unprognostic (6.36e-3)" "unprognostic (1.35e-1)" "unprognostic (1.05e-2)" "unprognostic (6.05e-2)" "unprognostic (5.61e-2)" "unprognostic (4.12e-1)" "unprognostic (2.94e-2)" "unprognostic (4.97e-2)" "unprognostic (3.05e-2)" "unprognostic (1.74e-2)" "unprognostic (7.02e-2)" 54.4 28.7 0.8 24.0 1.7 0.7 16.3 0.3 3.5 17.2 9.2 16.1 9.9 7.2 1.7 13.1 11.9 27.7 10.2 1.1 0.7 7.6 40.9 122.3 15.2 1.4 0.9 6.2 8.1 4.6 1.5 54.3 1.1 2.2 18.5 0.1 4.9 8.0 1.8 2.8 17.5 30.3 0.7 50.6 9.7 7.5 2.8 8.0 5.5 8.7 3.0 29.0 2.6 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 19.3 0.0 0.2 0.0 0.0 0.1 0.3 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 17.3 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.8 1.7 0.3 3.5 1.1 0.7 1.4 0.9 1.1 0.7 2.8 1.3 4.0 32.1 43.5 1.3 3.5 0.4 0.0 0.0 0.0 0.0 128.9 1.7 3.6 11.5 7.4 0.0 0.0 0.9 1.0 1.4 0.0 0.1 27.3 0.0 0.1 39.0 0.0 3.2 0.8 0.4 1.4 2.5 0.0 0.1 13.9 0.1 397.7 13.1 176.1 0.0 1.3 0.9 0.0 361.4 46.8 19.4 1.5 316.5 0.0 60.9 0.5 0.0 0.0 0.5 0.5 0.1 1.5 0.0 1.0 0.0 2.2 0.1 5.8 0.0 32.9 3.0 2.2 0.4 2.3 1.2 0.4 2.1 4.7 1.7 0.8 0.1 MS4A1 "B1, Bp35, CD20, MS4A2" ENSG00000156738 "Membrane spanning 4-domains A1" P11836 11 60455846-60470752 "CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "B-cell activation" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "lymphoid tissue: 673.3" "Cell type enriched" "Detected in some" 35 "B-cells: 970.5" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 96 "memory B-cell: 625.4;naive B-cell: 627.0" "Lineage enriched" "Detected in many" 96 "B-cells: 627.0" "Group enriched" "Detected in some" 26 "Daudi: 731.3;U-698: 364.1" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000015, HPA014341, HPA014391" Enhanced Supported "Plasma membrane" NA NA "Cluster 43: B-cells - Humoral immune response" "Cluster 16: Immune cells - Immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "Plasma membrane" "CAB000015: AB_2282030, HPA014341: AB_1846265, HPA014391: AB_1846264" "prognostic favorable (4.34e-5)" "unprognostic (4.45e-4)" "unprognostic (1.19e-4)" "unprognostic (2.04e-3)" "unprognostic (1.06e-1)" "unprognostic (5.53e-7)" "unprognostic (2.46e-3)" "unprognostic (1.85e-3)" "unprognostic (3.06e-2)" "unprognostic (2.89e-4)" "unprognostic (6.96e-2)" "unprognostic (2.84e-2)" "unprognostic (3.96e-5)" "unprognostic (2.23e-1)" "unprognostic (8.04e-2)" "unprognostic (1.44e-1)" "unprognostic (1.30e-1)" 3.6 0.4 0.0 149.7 0.0 19.1 0.8 0.0 0.1 0.5 0.1 9.0 3.0 2.2 1.0 4.2 0.5 8.4 1.8 0.0 0.1 3.4 2.1 4.0 500.4 0.2 0.0 0.3 0.2 7.3 0.3 0.9 0.1 5.1 10.6 0.0 8.9 0.3 0.8 0.1 123.5 1.2 0.1 253.8 18.4 1.2 0.1 50.6 6.7 0.1 673.3 16.3 1.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 731.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.3 0.5 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.4 0.0 0.5 0.2 0.0 0.1 0.0 364.1 0.0 0.2 0.0 0.8 0.5 0.3 2.4 0.1 3.7 625.4 2.8 5.5 0.5 627.0 0.5 2.1 2.0 6.5 0.6 0.5 0.8 32.1 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.3 0.0 3.8 0.0 970.5 0.1 0.1 0.0 0.0 0.0 0.4 0.3 0.4 0.0 0.0 0.0 0.0 0.0 14.5 0.3 0.0 0.0 4.5 0.7 0.1 0.3 0.0 7.0 0.0 0.0 0.1 1.8 2.0 0.1 2.5 0.0 1.1 0.3 0.1 0.0 0.0 0.2 0.0 0.6 0.3 2.0 0.0 4.6 7.2 0.0 2.5 0.0 2.1 0.0 0.0 0.0 0.3 0.0 9.1 0.0 0.0 0.6 0.0 0.0 0.0 0.1 0.5 0.2 0.1 0.8 0.1 0.0 27.3 0.7 0.2 0.0 MT-ND1 "MTND1, NAD1, ND1" ENSG00000198888 "Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1" P03886 MT 3307-4262 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins" "Electron transport, Respiratory chain, Transport" Translocase "Alzheimer disease, Amyloidosis, Diabetes mellitus, Disease variant, Epilepsy, FDA approved drug targets, Leber hereditary optic neuropathy, MELAS syndrome, Neurodegeneration, Primary mitochondrial disease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 111350.7;heart muscle: 127951.9" "Cell type enriched" "Detected in many" 5 "Cardiomyocytes: 101184.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "basophil: 9432.2" "Lineage enriched" "Detected in all" 7 "granulocytes: 9432.2" "Cell line enhanced" "Detected in all" "HeLa: 28480.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB033779, HPA066847" Approved NA NA "Cluster 41: Basophils - Cellular respiration" "Cluster 39: Non-specific - Mitochondria" "Cluster 20: HeLa - Mitochondria" "Cluster 54: Cardiomyocytes - Muscle contraction" "CAB033779: AB_2149736, HPA066847: " "prognostic favorable (3.63e-4)" "unprognostic (3.55e-1)" "unprognostic (3.77e-2)" "unprognostic (3.65e-1)" "unprognostic (3.50e-1)" "unprognostic (1.28e-1)" "unprognostic (1.95e-3)" "unprognostic (5.84e-2)" "unprognostic (1.06e-1)" "unprognostic (5.05e-2)" "prognostic favorable (3.26e-4)" "unprognostic (8.67e-2)" "unprognostic (8.66e-2)" "unprognostic (3.24e-2)" "unprognostic (1.42e-2)" "unprognostic (3.99e-2)" "unprognostic (2.85e-2)" 19099.4 24937.1 77977.0 2682.9 79000.3 3456.4 17901.1 73833.1 111350.7 4652.6 82243.3 19464.4 6416.3 5929.7 6428.9 8365.1 6119.1 2846.9 127951.9 74131.5 81543.6 47946.3 45024.8 7877.3 2245.9 84675.5 84925.4 4636.3 15523.0 12519.5 7993.9 5163.4 88069.3 11358.6 8792.2 6455.8 11429.4 7047.3 69102.4 14504.0 16935.3 3849.2 68588.4 8228.4 26033.5 12223.4 81883.1 2158.8 7231.1 61460.4 2986.2 10333.3 5443.7 72626.3 3533.6 3499.2 2812.3 2571.1 10434.4 1879.8 3604.8 2946.1 872.8 805.7 835.0 6132.0 3710.1 4259.8 1831.7 2239.3 810.9 2285.7 316.3 1774.7 1592.0 3064.7 2432.6 4755.7 28480.4 8841.6 2231.9 2279.1 4495.2 4494.5 4734.4 1241.1 1773.2 3240.7 877.2 1226.5 2235.4 2580.5 2400.4 4813.7 1841.1 9325.6 757.8 2191.3 2603.6 1916.7 1277.6 2295.7 4312.3 5574.2 1165.0 1844.2 1632.5 2572.1 2943.6 3403.7 2306.2 7771.2 4632.1 2652.3 2396.0 3427.2 2511.3 2841.3 1883.7 2015.4 1784.6 3937.3 744.7 9432.2 1265.2 2347.3 512.4 662.6 732.0 1155.4 614.6 683.5 439.9 1185.3 800.8 960.2 3270.7 759.6 733.2 677.2 480.0 507.7 77977.0 79000.3 73833.1 111350.7 74131.5 81543.6 84675.5 84925.4 88069.3 68588.4 81883.1 72626.3 1754.9 1352.6 1511.3 0.0 3159.5 2265.8 3355.3 1632.2 2928.1 0.0 3174.3 3513.1 101184.9 9771.1 1985.3 4610.8 0.0 0.0 2175.7 12456.8 1033.1 1511.9 1087.5 3160.1 1985.1 4881.6 3135.6 8308.9 0.0 3595.1 0.0 2970.8 2347.6 5039.6 1402.2 7165.4 7745.2 16276.4 0.0 0.0 0.0 10835.1 927.7 12435.2 1651.4 5233.2 7049.5 2982.5 1497.7 0.0 4450.1 0.0 2385.2 0.0 0.0 2180.4 8080.9 3546.9 2046.0 3735.0 18353.7 8183.6 1760.8 0.0 6409.6 6534.6 4075.7 4806.0 5071.3 2061.1 2073.2 0.0 2839.0 4329.0 10735.4 5236.0 MTNR1A MEL-1A-R ENSG00000168412 "Melatonin receptor 1A" P48039 4 186533655-186555567 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 1.0;intestine: 1.2;kidney: 2.1;testis: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 9 "cerebellum: 1.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" NA NA "Cluster 7: Kidney - Transmembrane transport" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "unprognostic (7.99e-2)" "unprognostic (2.27e-1)" "unprognostic (2.16e-1)" "unprognostic (3.67e-1)" "unprognostic (2.14e-1)" "unprognostic (9.88e-2)" "unprognostic (9.20e-2)" "unprognostic (8.81e-2)" 0.0 0.0 0.0 0.6 0.1 0.0 0.0 1.0 0.1 0.0 0.0 1.2 0.2 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 MTNR1B ENSG00000134640 "Melatonin receptor 1B" P49286 11 92969651-92985066 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 3.1;placenta: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 19 "GAMG: 4.9;SuSa: 1.3" "Not detected" "Not detected" "Low region specificity" "Detected in some" HPA074024 Supported NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 64: Astrocytes - Nervous system maintenance" "HPA074024: " "unprognostic (3.61e-1)" "unprognostic (1.43e-1)" 0.0 0.0 2.2 0.0 2.8 0.0 0.0 0.7 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 1.2 0.0 0.0 0.0 0.0 3.0 2.8 0.0 0.0 0.0 0.0 1.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.5 1.2 0.0 0.0 0.0 0.3 0.0 0.0 1.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 2.8 0.7 1.1 2.3 1.2 3.0 2.8 3.1 2.1 1.2 1.4 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 MTOR "FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1" ENSG00000198793 "Mechanistic target of rapamycin kinase" P42345 1 11106535-11262551 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease variant, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB069425, HPA071227" Approved Approved Vesicles,Cytosol NA NA "Cluster 35: T-regs - Unknown function" "Cluster 77: Retina - Visual perception" "Cluster 20: HeLa - Mitochondria" "Cluster 10: Non-specific - Unknown function" "Vesicles, Cytosol" "CAB069425: , HPA071227: AB_2686367" "unprognostic (3.18e-1)" "unprognostic (1.50e-1)" "unprognostic (1.20e-1)" "unprognostic (2.45e-3)" "unprognostic (5.50e-2)" "unprognostic (2.55e-2)" "unprognostic (1.39e-1)" "unprognostic (1.68e-1)" "unprognostic (1.18e-1)" "unprognostic (8.24e-3)" "unprognostic (3.48e-2)" "unprognostic (1.88e-1)" "prognostic favorable (1.49e-5)" "unprognostic (1.27e-1)" "unprognostic (2.45e-1)" "unprognostic (6.60e-2)" "unprognostic (7.55e-2)" 16.3 19.4 18.2 13.5 19.0 14.0 16.8 18.4 20.1 15.2 18.6 22.8 11.0 17.5 21.8 18.3 14.6 9.0 23.6 19.7 17.7 24.1 27.6 15.2 15.3 16.5 21.2 14.2 18.3 20.6 21.8 11.8 18.4 19.8 16.0 26.9 16.5 13.8 36.4 17.1 19.6 13.8 14.6 21.2 18.7 33.8 22.7 19.2 17.8 17.8 15.9 17.1 14.9 18.7 28.5 25.2 33.3 25.4 39.4 18.6 16.6 23.4 22.3 30.6 29.9 26.0 25.5 31.4 19.6 27.8 18.8 33.1 45.3 35.8 39.3 25.2 33.2 41.7 53.8 33.4 24.7 41.1 29.7 24.0 26.8 43.7 44.0 14.5 39.3 29.6 47.4 26.1 21.6 32.4 28.5 31.2 25.3 29.6 23.5 28.2 39.2 21.0 27.2 25.3 33.4 24.5 50.1 26.8 31.2 36.5 21.8 24.0 42.3 26.5 23.9 20.5 31.8 25.5 25.5 60.5 19.1 43.6 28.6 0.3 1.1 1.3 1.9 2.4 1.6 1.4 1.1 1.0 1.6 1.1 1.3 1.1 0.8 1.1 1.3 1.2 2.4 1.0 18.2 19.0 18.4 20.1 19.7 17.7 16.5 21.2 18.4 14.6 22.7 18.7 9.2 16.0 11.8 40.8 10.0 3.4 5.2 7.6 8.6 0.0 7.7 7.5 25.1 2.8 10.3 9.2 0.0 7.9 9.8 9.4 1.9 8.5 42.0 13.8 16.1 11.0 10.3 14.3 43.8 6.2 7.2 9.2 16.8 18.6 13.3 12.9 5.3 13.4 6.9 0.0 49.2 7.8 6.1 8.2 4.1 36.1 7.8 9.1 8.8 36.5 9.2 0.0 10.3 38.2 37.4 10.4 5.4 8.2 17.2 8.9 7.0 4.5 6.3 0.0 39.5 11.4 12.1 49.3 37.4 15.6 5.7 9.9 9.8 15.3 10.0 5.7 MTR cblG ENSG00000116984 "5-methyltetrahydrofolate-homocysteine methyltransferase" Q99707 1 236795260-236921278 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Amino-acid biosynthesis, Methionine biosynthesis" "Methyltransferase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 100.0;Glandular and luminal cells: 130.9;Inhibitory neurons: 106.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA044474, HPA054915" Approved Supported Cytosol NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 8: Non-specific - Mitochondria" "Cluster 24: NB-4 - Immune response" "Cluster 44: Endometrium - Transcription" Cytosol "HPA044474: AB_10966696, HPA054915: AB_2732589" "unprognostic (2.12e-1)" "unprognostic (1.03e-1)" "unprognostic (6.96e-2)" "unprognostic (1.99e-1)" "unprognostic (1.35e-1)" "unprognostic (1.76e-1)" "unprognostic (4.87e-1)" "unprognostic (1.02e-1)" "unprognostic (2.48e-2)" "unprognostic (3.34e-1)" "unprognostic (5.73e-2)" "unprognostic (1.63e-1)" "unprognostic (1.67e-2)" "unprognostic (8.84e-3)" "unprognostic (1.88e-1)" "prognostic unfavorable (5.75e-4)" "unprognostic (8.10e-2)" 9.1 6.6 4.3 6.9 5.4 4.6 8.0 5.2 5.4 10.1 6.5 11.1 4.8 10.2 10.5 5.0 11.9 8.9 15.0 4.9 4.6 12.7 6.0 7.1 8.1 6.7 5.3 14.6 13.0 20.2 6.4 11.6 6.9 7.6 5.0 5.6 6.4 9.1 16.6 9.3 7.1 8.7 4.8 9.4 9.0 9.0 4.8 10.0 13.4 18.1 7.0 10.3 7.6 6.5 17.6 11.0 13.0 8.8 22.6 20.3 15.3 14.9 14.8 18.8 19.0 12.6 12.5 40.0 13.2 16.6 8.7 10.6 18.4 13.1 20.4 19.8 13.7 23.7 14.2 18.3 15.1 37.2 13.3 28.9 7.0 22.9 17.9 11.5 22.3 19.8 33.1 16.4 13.1 10.1 19.6 10.3 16.2 12.9 5.4 20.9 24.8 24.2 11.2 21.3 11.1 27.8 17.7 11.9 14.8 9.3 16.7 13.0 28.8 24.1 9.1 19.6 18.8 34.4 12.3 22.7 17.2 21.1 26.2 0.6 0.5 1.5 1.1 0.8 2.3 0.7 1.4 1.4 0.7 0.8 1.4 1.5 0.0 0.9 0.5 0.5 0.9 0.9 4.3 5.4 5.2 5.4 4.9 4.6 6.7 5.3 6.9 4.8 4.8 6.5 23.0 57.7 35.0 53.8 25.8 8.2 8.3 8.3 17.1 0.0 10.7 11.9 100.0 20.0 10.9 40.5 0.0 24.2 25.9 3.4 1.9 13.8 9.8 57.5 80.1 21.4 8.4 23.5 87.7 14.8 9.2 22.8 15.8 130.9 30.4 35.0 15.4 10.8 14.4 0.0 106.8 7.7 4.1 16.6 6.8 6.2 23.9 17.1 10.6 47.8 15.3 0.0 19.6 62.8 73.6 12.3 8.0 33.1 20.3 14.9 9.7 9.1 13.3 0.0 6.6 39.4 23.2 17.2 22.0 11.5 5.1 22.6 26.1 40.2 12.0 6.4 MTTP "ABL, MTP" ENSG00000138823 "Microsomal triglyceride transfer protein" P55157 4 99564081-99623997 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Lipid transport, Transport" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 21 "intestine: 275.2;liver: 266.6" "Group enriched" "Detected in many" 9 "Hepatocytes: 244.2;Proximal enterocytes: 605.4" "Cancer enriched" "Detected in many" 13 "liver cancer: 28.7" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "AF22: 10.8;Hep G2: 12.2" "Low region specificity" "Detected in all" "Not detected" "Not detected" "HPA051170, HPA054862" Uncertain Approved "Endoplasmic reticulum,Cytosol" "Intracellular and membrane" NA NA 640000 "Cluster 41: Intestine & Liver - Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 45: Enterocytes - Digestion" "Endoplasmic reticulum, Cytosol" "HPA051170: , HPA054862: AB_2682628" "unprognostic (1.66e-2)" "unprognostic (1.14e-1)" "unprognostic (5.64e-2)" "unprognostic (5.33e-2)" "unprognostic (3.49e-3)" "unprognostic (7.38e-2)" "unprognostic (1.05e-1)" "unprognostic (2.74e-2)" "unprognostic (1.08e-1)" "unprognostic (3.66e-2)" "unprognostic (1.00e-2)" "unprognostic (1.62e-1)" "unprognostic (1.27e-3)" "unprognostic (2.02e-2)" "unprognostic (3.64e-1)" "unprognostic (1.53e-2)" "unprognostic (1.31e-1)" 0.3 0.1 0.9 0.2 0.9 0.0 0.2 0.8 0.9 0.1 0.3 1.3 243.2 0.1 1.0 0.1 0.6 1.3 0.9 0.8 1.5 12.9 266.6 0.3 0.3 1.1 1.6 2.0 0.0 0.0 0.5 0.0 1.3 0.5 0.3 5.6 0.1 0.2 0.4 0.1 275.2 0.5 1.2 0.0 0.8 9.6 1.2 0.2 0.1 0.3 0.1 0.9 0.0 1.9 0.0 0.2 10.8 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.1 0.3 0.0 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 2.7 0.0 0.2 0.1 12.2 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.6 0.5 0.1 0.2 0.1 0.1 1.0 0.0 0.0 0.7 0.8 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.9 0.8 0.9 0.8 1.5 1.1 1.6 1.3 1.2 1.2 1.9 0.1 0.0 0.0 4.6 0.9 0.0 0.0 0.0 0.0 0.0 0.3 0.4 2.8 4.3 0.1 1.8 0.0 0.2 0.2 0.2 0.0 0.0 44.2 1.0 0.1 0.1 0.0 2.7 1.6 0.0 0.0 0.8 1.5 0.2 0.0 30.1 3.6 244.2 0.1 0.0 0.7 16.7 2.0 3.5 0.0 12.0 0.9 0.2 0.0 0.0 0.6 0.0 0.0 0.0 2.0 0.2 12.5 0.4 0.1 0.0 605.4 23.5 1.0 0.0 6.6 0.5 0.5 32.1 5.7 0.0 0.0 0.0 0.4 12.0 21.0 0.0 NDUFV3 CI-10k ENSG00000160194 "NADH:ubiquinone oxidoreductase subunit V3" P56181 21 42879644-42913304 "FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Electron transport, Respiratory chain, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 88.0" "Cell type enhanced" "Detected in all" "Cardiomyocytes: 770.8;Early spermatids: 502.9;Late spermatids: 1712.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019791, HPA020463, HPA030427, CAB034142" Enhanced Enhanced Mitochondria NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 59: Non-specific - Translation" "Cluster 36: HEL - Hemostasis" "Cluster 31: Spermatids - Spermatogenesis" Mitochondria "CAB034142: AB_2298212, HPA019791: AB_1854357, HPA020463: AB_1854358, HPA030427: AB_10603024" "unprognostic (1.62e-1)" "unprognostic (2.17e-3)" "unprognostic (1.31e-1)" "unprognostic (1.04e-1)" "unprognostic (1.10e-1)" "unprognostic (1.11e-2)" "unprognostic (4.69e-1)" "unprognostic (2.97e-2)" "unprognostic (1.05e-1)" "unprognostic (3.13e-1)" "unprognostic (3.85e-3)" "unprognostic (1.54e-1)" "unprognostic (1.45e-1)" "unprognostic (6.56e-2)" "unprognostic (9.30e-3)" "unprognostic (2.14e-1)" "unprognostic (1.94e-1)" 20.5 18.1 9.2 3.2 9.3 6.8 17.5 9.5 8.9 16.6 7.5 24.2 5.1 19.1 7.9 18.9 17.3 2.4 47.2 7.6 8.0 18.0 26.9 13.7 3.1 9.5 9.7 19.1 24.0 7.5 16.6 3.0 9.2 16.3 4.1 7.7 17.3 4.0 88.0 19.0 16.1 3.6 8.4 17.0 19.7 20.9 9.2 2.5 14.9 21.1 3.2 18.4 15.9 10.1 3.3 4.9 9.1 8.1 7.9 5.0 10.4 6.6 4.2 5.2 3.4 10.6 6.2 4.9 4.2 4.1 11.7 5.4 8.8 8.1 3.5 2.8 7.4 20.1 8.7 9.0 9.4 6.0 7.8 8.0 8.2 6.9 12.0 4.2 6.1 5.6 13.5 7.3 5.6 10.5 3.7 6.2 10.2 15.7 6.9 4.6 5.3 12.3 9.5 7.5 5.8 4.7 9.0 10.3 4.8 4.4 10.2 4.6 8.9 3.2 3.0 4.4 4.8 12.1 7.1 3.5 5.7 7.7 4.6 3.1 5.7 3.8 2.8 7.1 2.4 2.9 2.4 2.2 5.0 3.5 2.9 2.8 3.3 4.4 6.6 4.4 2.7 2.8 9.2 9.3 9.5 8.9 7.6 8.0 9.5 9.7 9.2 8.4 9.2 10.1 42.8 54.5 46.7 14.4 36.5 19.9 53.7 97.7 24.5 81.2 64.9 65.7 770.8 92.9 58.6 90.1 68.8 57.5 32.5 89.3 230.9 86.5 502.9 84.5 64.9 48.1 78.3 112.4 19.4 101.5 59.5 57.2 55.5 56.9 31.6 45.5 68.2 334.5 114.4 57.2 22.1 114.8 87.5 88.3 38.1 1712.0 66.5 62.3 37.4 17.8 86.4 88.7 49.4 15.6 19.5 98.6 80.9 62.4 39.0 109.3 176.4 372.6 85.9 104.7 72.3 54.0 66.1 243.5 77.1 50.0 23.4 89.9 29.9 83.8 95.4 65.3 NFKB1 "KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50" ENSG00000109320 "Nuclear factor kappa B subunit 1" P19838 4 102501331-102617302 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors" "Apoptosis, Transcription, Transcription regulation" "Activator, DNA-binding" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Langerhans cells: 610.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004031, HPA027305" Enhanced Supported Nucleoplasm,Cytosol NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 3: T-cells - Adaptive immune response" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 41: Macrophages - Immune response" Nucleoplasm Cytosol "CAB004031: AB_330564, HPA027305: AB_1854429" "unprognostic (1.06e-1)" "unprognostic (1.61e-2)" "unprognostic (4.37e-2)" "unprognostic (2.38e-2)" "unprognostic (1.60e-1)" "unprognostic (1.20e-1)" "unprognostic (2.04e-2)" "unprognostic (8.98e-2)" "unprognostic (1.96e-1)" "unprognostic (9.03e-3)" "unprognostic (2.28e-1)" "unprognostic (2.71e-1)" "prognostic favorable (1.76e-4)" "unprognostic (1.84e-2)" "unprognostic (6.75e-3)" "unprognostic (1.74e-1)" "unprognostic (6.92e-3)" 26.7 16.2 3.9 30.3 7.0 34.6 19.8 6.5 5.7 22.0 5.5 20.4 15.2 18.9 2.7 23.0 19.1 20.8 15.8 4.2 5.8 17.4 16.4 25.0 33.1 7.6 6.1 18.8 16.0 11.7 7.7 21.2 7.8 17.3 19.6 4.9 18.9 17.8 20.9 23.7 20.3 17.0 5.6 23.0 17.5 7.6 6.4 37.0 16.3 10.7 35.1 48.5 19.9 10.1 36.8 19.2 11.2 13.6 27.0 28.5 10.9 20.0 64.2 27.7 27.1 21.5 40.8 58.0 17.6 32.6 39.4 29.5 22.0 34.5 35.2 53.6 10.8 22.7 14.5 15.0 20.0 44.3 44.3 19.7 20.2 22.0 34.4 15.0 34.5 18.1 25.8 34.1 17.6 17.7 4.1 9.1 5.0 24.3 15.4 33.4 25.9 24.0 15.3 38.8 7.1 11.8 38.3 37.2 16.3 8.3 8.6 24.2 40.5 32.5 16.6 14.5 26.4 17.0 13.3 52.0 20.8 19.4 44.1 0.0 2.1 2.6 0.9 3.0 1.9 1.9 3.0 1.6 4.8 1.7 4.5 3.2 1.9 3.7 3.1 1.5 0.8 1.6 3.9 7.0 6.5 5.7 4.2 5.8 7.6 6.1 7.8 5.6 6.4 10.1 32.5 41.7 49.4 42.1 90.0 165.4 91.5 57.1 31.3 6.6 41.5 32.6 19.1 24.3 40.8 20.2 6.2 14.4 119.6 41.1 3.9 28.5 7.6 82.5 62.0 47.6 33.6 13.0 78.4 37.3 16.9 63.1 29.6 207.0 111.1 19.8 23.9 23.9 24.8 20.2 77.2 43.2 18.3 56.2 610.3 2.4 23.9 178.3 55.2 59.0 207.9 9.5 23.7 66.9 127.4 46.3 27.1 34.6 56.3 78.5 21.1 24.4 31.5 6.7 0.0 73.7 41.2 2.5 8.1 35.3 150.3 14.2 88.2 16.7 35.4 90.2 NFKB2 "LYT-10, NF-kB2, p105, p49/p100, p52" ENSG00000077150 "Nuclear factor kappa B subunit 2" Q00653 10 102394110-102402524 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Repressor" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Langerhans cells: 122.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 5.6" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "HDLM-2: 168.0;Karpas-707: 157.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA008422, CAB022098, HPA023900" Enhanced Approved Nucleoplasm,Cytosol NA NA "Cluster 5: Granulocytes - Unknown function" "Cluster 2: Immune cells - Immune response" "Cluster 2: Karpas-707 - Immune response" "Cluster 41: Macrophages - Immune response" Cytosol Nucleoplasm "CAB022098: , HPA008422: AB_1854434, HPA023900: AB_1854435" "unprognostic (1.10e-2)" "unprognostic (1.43e-1)" "prognostic unfavorable (3.86e-4)" "unprognostic (1.53e-2)" "unprognostic (8.08e-3)" "unprognostic (2.15e-1)" "unprognostic (2.38e-3)" "unprognostic (3.98e-2)" "prognostic favorable (8.45e-5)" "unprognostic (4.04e-1)" "unprognostic (8.34e-2)" "unprognostic (4.14e-2)" "prognostic unfavorable (6.69e-12)" "unprognostic (2.37e-3)" "unprognostic (1.63e-1)" "unprognostic (4.90e-2)" "unprognostic (1.56e-1)" 26.5 21.0 7.6 44.4 7.4 69.3 19.6 7.1 9.2 22.9 8.5 39.1 15.5 21.6 2.3 17.7 20.4 18.5 20.6 7.2 7.2 34.6 28.2 41.0 40.7 8.5 7.5 21.4 24.1 6.1 10.8 14.7 8.0 29.0 6.8 1.1 21.3 9.1 18.4 20.0 26.5 12.2 7.5 50.6 22.7 10.0 8.4 16.9 20.1 7.6 25.7 37.0 19.1 8.0 67.9 48.6 7.7 31.7 11.1 16.6 19.3 18.5 61.0 19.6 25.9 28.6 55.2 32.9 43.5 11.9 48.8 40.9 20.5 28.2 6.8 168.0 11.2 7.0 11.7 15.9 30.1 5.1 45.5 22.0 14.6 34.1 32.3 26.5 7.8 16.1 7.6 157.8 7.4 26.4 7.1 22.7 10.3 15.7 16.6 16.8 24.5 27.0 34.3 22.1 1.7 8.2 16.2 36.7 26.3 7.2 29.3 16.4 21.2 19.0 28.9 25.4 47.0 113.1 105.0 32.6 31.1 14.8 10.9 0.0 1.3 0.0 0.7 0.9 0.7 2.6 0.8 0.7 0.7 2.1 0.8 0.8 5.6 0.8 2.1 0.6 1.1 0.5 7.6 7.4 7.1 9.2 7.2 7.2 8.5 7.5 8.0 7.5 8.4 8.0 20.8 9.6 8.8 3.3 88.3 43.5 59.3 41.2 34.7 2.2 17.1 14.5 3.1 25.8 29.9 18.4 16.7 6.3 39.0 33.3 5.9 33.2 1.1 33.7 14.4 26.1 16.3 0.4 0.1 21.0 15.8 26.0 80.0 52.0 71.8 5.5 11.7 3.7 20.9 0.0 0.1 30.4 22.4 19.4 122.9 1.7 7.5 52.5 30.2 1.9 75.1 3.9 12.3 1.5 0.7 44.9 37.4 4.9 49.1 49.3 33.2 8.6 19.9 5.3 0.0 36.4 43.6 4.7 11.1 17.5 44.6 23.1 54.6 8.8 17.9 45.6 NISCH "I-1, IRAS, KIAA0975" ENSG00000010322 Nischarin Q9Y2I1 3 52455118-52493068 "FDA approved drug targets, Predicted intracellular proteins" Apoptosis Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Enteroendocrine cells: 169.3;Peritubular cells: 246.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA023189 Approved Approved "Nucleoplasm,Vesicles,Microtubules,Cytokinetic bridge,Cytosol" Yes NA "Cluster 34: Basophils - Unknown function" "Cluster 72: Non-specific - Transcription" "Cluster 20: HeLa - Mitochondria" "Cluster 17: Intestinal endocrine cells - Hormone signaling" "Nucleoplasm, Cytosol" "Vesicles, Microtubules, Cytokinetic bridge" "HPA023189: AB_1854495" "unprognostic (6.66e-2)" "unprognostic (1.58e-1)" "unprognostic (1.59e-3)" "unprognostic (4.11e-3)" "unprognostic (1.64e-1)" "unprognostic (8.08e-3)" "unprognostic (1.60e-2)" "unprognostic (6.56e-3)" "unprognostic (4.96e-2)" "unprognostic (8.33e-3)" "prognostic favorable (1.91e-4)" "unprognostic (1.40e-2)" "unprognostic (5.10e-2)" "unprognostic (1.19e-1)" "unprognostic (2.94e-2)" "unprognostic (1.47e-1)" "unprognostic (7.05e-3)" 55.2 69.8 46.5 28.7 55.5 38.7 60.5 78.2 56.6 105.8 22.2 68.5 24.3 76.2 34.0 51.3 72.0 29.9 48.5 56.3 38.7 54.6 45.6 56.2 32.5 20.9 32.6 93.0 54.1 32.5 181.8 39.1 32.9 107.5 20.6 19.0 53.6 51.6 36.3 80.7 55.3 33.0 9.1 54.1 52.7 84.5 35.2 30.1 60.8 16.3 23.3 78.1 71.6 35.2 15.6 16.0 48.8 40.1 35.7 39.2 40.0 32.8 21.5 25.7 26.0 24.2 22.8 21.7 9.0 45.6 21.0 20.4 26.1 35.7 15.1 22.3 28.2 39.2 65.2 23.9 32.4 23.2 33.6 61.9 28.2 27.7 23.5 54.0 42.0 42.4 21.1 23.4 24.3 22.2 41.8 51.2 30.1 19.8 27.1 24.5 13.4 25.4 29.2 30.6 20.6 35.9 35.6 9.3 23.1 42.3 28.9 38.5 46.3 36.0 34.1 36.9 24.1 38.7 23.8 27.3 24.7 37.3 22.4 5.2 4.5 3.5 3.0 4.0 3.1 2.5 2.6 4.0 2.3 2.8 3.1 3.3 1.5 3.2 0.6 3.4 3.0 3.6 46.5 55.5 78.2 56.6 56.3 38.7 20.9 32.6 32.9 9.1 35.2 35.2 26.1 25.6 32.3 34.0 14.9 27.5 14.6 23.3 40.5 40.9 29.2 37.1 20.4 8.6 19.1 14.7 8.4 32.4 24.2 20.5 9.8 12.1 10.3 14.5 26.7 22.1 169.3 4.6 64.9 9.4 14.0 23.4 23.4 18.9 25.3 40.2 46.1 15.3 30.5 28.6 44.0 19.1 22.4 50.5 14.5 25.9 88.3 24.3 19.6 15.0 13.0 12.1 17.5 21.1 26.1 10.0 14.2 246.0 12.4 12.6 16.5 15.6 15.2 22.4 26.3 17.2 24.8 31.2 18.0 16.7 22.3 24.2 18.4 47.6 15.7 11.7 NNMT ENSG00000166741 "Nicotinamide N-methyltransferase" P40261 11 114257787-114313536 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Methyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 388.9" "Group enriched" "Detected in many" 6 "Hepatocytes: 3913.2;Skeletal myocytes: 1639.1" "Cancer enhanced" "Detected in all" "renal cancer: 204.9" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "HSkMC: 255.3;LHCN-M2: 144.1;RPTEC TERT1: 479.6" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA059180 Approved Approved "Golgi apparatus,Cytosol" NA NA 410000 "Cluster 85: Liver - Metabolism" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 2: Hepatocytes - Metabolism" "Golgi apparatus" Cytosol "HPA059180: AB_2683940" "unprognostic (1.62e-1)" "unprognostic (2.33e-2)" "unprognostic (1.61e-2)" "unprognostic (6.14e-2)" "unprognostic (3.51e-1)" "prognostic unfavorable (2.07e-4)" "unprognostic (1.76e-1)" "unprognostic (5.84e-2)" "unprognostic (2.71e-2)" "unprognostic (2.48e-2)" "unprognostic (1.20e-1)" "unprognostic (1.69e-2)" "prognostic unfavorable (1.02e-6)" "prognostic unfavorable (1.75e-4)" "unprognostic (1.11e-1)" "unprognostic (3.37e-3)" "unprognostic (2.77e-2)" 130.9 11.4 1.0 25.2 1.1 0.9 91.9 1.4 1.5 36.0 1.9 37.1 1.5 31.0 2.8 15.4 55.0 43.1 35.5 1.3 1.4 24.1 388.9 64.6 9.6 3.9 1.6 21.3 11.4 1.6 10.6 23.8 2.2 31.9 8.7 0.3 21.1 3.1 73.1 49.3 32.2 30.1 1.7 36.7 30.1 2.2 1.2 2.7 33.0 5.3 8.8 48.6 33.9 3.1 0.2 17.6 0.3 18.6 92.0 118.3 0.1 21.2 58.7 35.2 69.2 0.0 17.5 0.2 58.1 45.1 4.2 0.2 0.0 8.0 34.1 0.2 0.0 0.2 16.7 0.0 123.3 0.2 0.0 255.3 89.4 24.1 37.3 29.8 50.1 0.1 0.3 0.2 144.1 0.1 0.1 0.2 0.1 0.0 0.5 0.2 79.0 0.0 479.6 0.1 0.2 0.2 97.7 0.1 0.3 5.3 0.0 0.2 37.4 18.3 34.3 23.8 3.1 0.3 0.3 0.4 6.4 0.3 1.4 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 1.0 1.1 1.4 1.5 1.3 1.4 3.9 1.6 2.2 1.7 1.2 3.1 411.8 44.8 411.3 1.0 11.2 103.6 13.2 16.5 2.2 1.9 38.5 73.9 4.7 75.8 13.3 80.9 0.0 1.0 1.6 0.0 9.8 238.3 0.3 19.0 89.9 190.0 5.3 147.2 1.3 157.0 2.5 452.2 5.1 80.5 13.9 0.5 195.2 3913.2 28.4 0.0 1.6 0.0 0.0 126.8 142.1 1.6 74.3 9.2 96.0 1.9 5.7 0.0 0.0 0.0 0.2 323.1 0.0 13.2 1.5 10.8 0.0 99.2 11.9 0.2 0.0 1639.1 154.3 0.3 0.8 1.9 92.1 2.2 20.1 0.0 0.0 3.1 NNT ENSG00000112992 "Nicotinamide nucleotide transhydrogenase" Q13423 5 43602692-43707405 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" Translocase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 239.1;tongue: 384.0" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 344.3;Hepatocytes: 314.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004829, CAB004975" Enhanced Approved Mitochondria,Cytosol NA NA 110000 "Cluster 27: Non-specific - Gene expression" "Cluster 8: Non-specific - Mitochondria" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 54: Cardiomyocytes - Muscle contraction" Mitochondria Cytosol "CAB004975: AB_425908, HPA004829: AB_1079495" "unprognostic (1.51e-1)" "unprognostic (1.07e-1)" "unprognostic (3.33e-2)" "unprognostic (4.81e-2)" "unprognostic (5.02e-2)" "unprognostic (1.81e-1)" "unprognostic (4.04e-2)" "unprognostic (1.96e-3)" "unprognostic (2.20e-2)" "unprognostic (3.98e-2)" "unprognostic (1.65e-1)" "unprognostic (8.33e-2)" "prognostic favorable (1.22e-15)" "unprognostic (8.24e-2)" "unprognostic (1.11e-1)" "unprognostic (2.76e-2)" "unprognostic (2.58e-1)" 26.0 16.5 12.8 11.8 16.0 15.0 13.7 11.2 21.7 16.4 34.9 25.9 17.2 11.0 16.7 16.8 10.7 15.0 137.7 16.1 11.5 57.0 116.4 13.2 16.5 10.3 12.0 10.1 17.8 55.6 9.6 12.7 9.5 18.3 27.8 12.9 26.6 18.2 239.1 10.4 16.1 20.6 9.3 11.5 31.2 6.2 15.8 26.8 31.1 384.0 17.2 17.3 9.3 15.1 15.4 12.6 30.5 59.6 44.0 50.3 9.9 17.5 39.8 24.8 20.8 19.0 30.4 18.5 21.5 43.9 22.3 16.6 120.5 5.4 27.4 31.1 33.6 24.0 70.7 23.8 27.5 50.2 43.1 37.9 17.5 16.3 18.6 42.6 56.3 22.7 21.4 81.3 60.0 15.1 55.8 35.8 6.4 0.1 15.2 54.7 73.8 70.8 58.0 15.5 44.2 37.7 62.9 1.4 46.7 6.9 47.7 58.3 23.2 29.5 28.3 12.0 8.3 36.1 45.1 26.5 7.1 68.8 22.1 12.5 18.2 16.0 16.7 23.0 17.1 12.0 17.1 15.5 32.0 12.0 15.5 14.7 2.9 23.2 24.7 9.1 22.2 19.3 12.8 16.0 11.2 21.7 16.1 11.5 10.3 12.0 9.5 9.3 15.8 15.1 12.0 54.5 37.8 60.7 19.6 11.5 9.5 19.0 13.1 17.9 9.6 6.3 344.3 38.6 27.0 27.6 35.5 8.7 20.4 34.4 27.4 14.4 16.7 18.5 16.6 19.2 19.9 34.9 124.8 10.7 2.3 27.2 23.9 25.1 25.2 26.8 21.0 314.3 25.0 6.7 110.6 22.6 20.3 40.6 11.9 4.6 14.9 19.8 14.2 45.9 25.9 12.5 35.0 77.9 63.4 9.5 16.7 19.2 20.0 11.7 23.6 21.7 18.1 12.8 0.0 14.0 20.1 4.0 1.4 17.6 8.1 2.1 20.9 18.8 28.9 9.9 NOD2 "BLAU, CARD15, CD, CLR16.3, IBD1, NLRC2, PSORAS1" ENSG00000167207 "Nucleotide binding oligomerization domain containing 2" Q9HC29 16 50693588-50734041 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins" "Immunity, Innate immunity" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 13.6;esophagus: 11.7;skin 1: 14.4;vagina: 12.3" "Cell type enhanced" "Detected in many" "Glandular and luminal cells: 8.3;Kupffer cells: 9.0;Langerhans cells: 22.5;Macrophages: 15.2;monocytes: 15.6;Suprabasal keratinocytes: 15.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in some" "Group enriched" "Detected in many" 4 "classical monocyte: 23.0;eosinophil: 6.0;intermediate monocyte: 13.1;myeloid DC: 21.3;neutrophil: 10.5;non-classical monocyte: 9.0" "Group enriched" "Detected in many" 5 "dendritic cells: 21.3;granulocytes: 10.5;monocytes: 23.0" "Cell line enhanced" "Detected in some" "HMC-1: 11.6;T-47d: 5.8;THP-1: 7.3;U-266/70: 15.9;U-266/84: 7.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA041985, HPA054494" Enhanced Approved "Golgi apparatus,Cytosol" No NA "Cluster 25: Monocytes - Inflammatory response" "Cluster 11: Squamous epithelial cells - Epithelial cell function" "Cluster 3: HMC-1 - Innate immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" "Golgi apparatus, Cytosol" "HPA041985: AB_2677780, HPA054494: AB_2682505" "unprognostic (1.01e-1)" "unprognostic (4.38e-1)" "unprognostic (1.07e-1)" "unprognostic (1.02e-3)" "unprognostic (9.91e-3)" "unprognostic (5.84e-2)" "unprognostic (5.90e-3)" "unprognostic (1.23e-1)" "unprognostic (4.17e-1)" "unprognostic (3.88e-2)" "unprognostic (6.94e-3)" "unprognostic (1.48e-2)" "unprognostic (2.31e-9)" "unprognostic (4.38e-2)" "unprognostic (1.08e-2)" "unprognostic (1.53e-1)" "unprognostic (1.13e-1)" 1.5 0.5 0.5 5.9 0.2 13.6 1.5 0.2 1.0 5.6 0.7 0.9 1.5 0.6 0.3 11.7 0.9 1.3 0.7 0.2 0.4 0.6 1.7 4.3 2.7 1.0 0.9 0.4 0.3 0.2 0.4 1.2 0.7 0.9 0.9 0.0 4.3 0.4 0.6 14.4 1.3 1.8 0.7 4.4 1.4 0.5 1.4 0.8 0.4 0.3 2.3 1.6 12.3 0.8 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.2 0.0 11.6 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 2.8 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.2 0.1 0.0 1.5 0.0 0.0 5.8 7.3 0.0 0.0 0.0 0.0 0.0 15.9 7.2 0.0 0.3 0.1 0.0 3.0 23.0 6.0 0.4 13.1 0.7 0.1 1.3 1.4 21.3 0.0 0.1 0.5 10.5 3.4 9.0 1.0 0.9 11.1 0.5 0.2 0.2 1.0 0.2 0.4 1.0 0.9 0.7 0.7 1.4 0.8 0.2 0.0 3.7 0.0 1.9 5.9 0.3 1.2 0.0 0.0 1.4 1.1 0.4 1.5 2.3 0.0 0.0 0.0 1.9 0.0 0.0 0.1 0.0 5.6 0.8 0.6 1.2 0.8 0.1 0.0 0.0 0.4 0.0 8.3 1.3 0.5 0.0 0.5 2.5 0.0 0.1 0.0 2.0 9.0 22.5 0.0 0.0 15.2 1.8 1.9 15.6 0.0 1.0 0.0 0.2 0.0 0.0 0.4 4.3 0.4 0.0 0.1 1.0 0.0 0.0 0.1 0.4 0.1 0.4 6.1 15.5 0.3 2.3 0.1 0.1 0.3 NOS1 "nNOS, NOS" ENSG00000089250 "Nitric oxide synthase 1" P29475 12 117208142-117452170 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 11 "brain: 23.0;skeletal muscle: 36.9;tongue: 57.2" "Cell type enhanced" "Detected in some" "Basal prostatic cells: 10.0;Hepatic stellate cells: 18.2;Inhibitory neurons: 32.1;Oligodendrocyte precursor cells: 48.2" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HaCaT: 4.6;RH-30: 9.4;RPTEC TERT1: 5.8;U-2 OS: 1.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002167, HPA058312, HPA069509" Enhanced Supported "Nucleoplasm,Plasma membrane" NA NA "Cluster 80: Striated muscle - Unknown function" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane" Nucleoplasm "CAB002167: AB_564073, HPA058312: AB_2683676, HPA069509: " "unprognostic (1.63e-1)" "unprognostic (3.14e-2)" "unprognostic (2.18e-2)" "unprognostic (6.64e-3)" "unprognostic (4.91e-2)" "unprognostic (2.74e-1)" "unprognostic (2.54e-1)" "unprognostic (9.12e-3)" "unprognostic (2.51e-1)" "unprognostic (1.10e-1)" "unprognostic (1.07e-1)" "unprognostic (7.56e-2)" "unprognostic (1.01e-1)" "unprognostic (3.73e-2)" "unprognostic (1.34e-1)" "unprognostic (5.97e-4)" "unprognostic (1.87e-1)" 0.1 0.1 12.7 0.4 12.4 0.2 0.1 5.7 7.0 0.3 0.0 2.2 0.1 0.1 0.2 0.8 0.3 0.0 0.0 4.0 16.2 1.3 0.0 0.8 0.1 12.1 11.0 0.0 1.4 0.0 0.9 0.0 12.2 0.9 0.4 0.3 3.4 0.1 36.9 1.9 0.4 0.3 2.3 0.0 0.2 0.5 23.0 0.0 0.1 57.2 0.1 0.0 0.7 3.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 4.6 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 1.1 0.0 9.4 0.0 5.8 0.0 0.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 12.7 12.4 5.7 7.0 4.0 16.2 12.1 11.0 12.2 2.3 23.0 3.3 0.0 0.0 0.0 1.3 0.0 3.8 10.0 2.4 4.0 0.0 0.0 0.0 1.9 0.0 0.1 0.0 0.0 0.0 0.0 0.1 1.9 0.0 3.0 5.1 0.4 3.0 0.0 0.0 2.0 0.0 0.0 0.7 0.0 8.4 0.0 0.0 18.2 0.0 0.0 0.0 32.1 0.2 0.0 0.3 0.7 0.6 0.3 0.2 1.8 1.9 0.0 0.0 0.0 48.2 5.7 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 1.9 0.5 0.1 1.8 0.1 0.6 0.0 0.2 0.0 0.0 1.0 NOS2 "HEP-NOS, iNOS, NOS, NOS2A" ENSG00000007171 "Nitric oxide synthase 2" P35228 17 27756766-27800529 "Cancer-related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "intestine: 21.1;lymphoid tissue: 14.4" "Cell type enhanced" "Detected in some" "Distal enterocytes: 40.3;Extravillous trophoblasts: 27.7;Granulosa cells: 57.3;Proximal enterocytes: 10.7;Undifferentiated cells: 10.2" "Cancer enhanced" "Detected in many" "colorectal cancer: 16.0" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 9 "CACO-2: 16.5;SCLC-21H: 13.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" CAB002014 Enhanced NA NA "Cluster 56: Intestine - Transmembrane transport" "Cluster 39: CACO-2 - Unknown function" "Cluster 53: Intestinal epithelial cells - Unknown function" "CAB002014: " "unprognostic (1.95e-3)" "unprognostic (3.08e-3)" "unprognostic (4.75e-3)" "unprognostic (4.42e-3)" "unprognostic (3.49e-1)" "unprognostic (2.13e-2)" "unprognostic (5.61e-2)" "unprognostic (5.09e-2)" "unprognostic (9.91e-3)" "unprognostic (1.93e-1)" "unprognostic (2.39e-2)" "unprognostic (1.34e-1)" "unprognostic (6.04e-2)" "unprognostic (8.02e-2)" "unprognostic (3.68e-1)" "unprognostic (8.69e-2)" "unprognostic (4.03e-2)" 0.9 0.5 0.2 14.4 0.5 0.0 0.3 0.1 2.1 0.3 0.0 6.8 12.1 0.2 0.0 0.7 0.4 0.4 0.4 0.7 0.2 1.6 0.1 1.8 0.8 0.3 0.1 0.6 0.3 0.1 1.3 0.6 0.5 0.6 8.9 0.2 0.1 0.2 0.8 0.2 21.1 1.8 0.1 0.1 0.1 0.3 1.0 0.1 0.4 0.7 0.1 3.6 0.2 0.9 0.0 0.1 0.1 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 16.5 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 13.0 0.9 0.0 0.1 0.1 0.7 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.1 2.1 0.7 0.2 0.3 0.1 0.5 0.1 1.0 0.9 1.2 0.0 0.0 1.3 0.6 0.0 0.2 3.6 0.0 0.5 0.0 0.3 0.2 0.0 0.7 0.0 0.0 0.2 0.0 40.3 0.0 0.0 0.2 0.0 0.0 0.7 2.4 0.0 4.1 0.0 27.7 0.2 0.0 0.1 0.0 57.3 0.0 0.0 0.7 0.0 2.2 3.8 2.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 4.9 0.4 0.0 1.4 10.7 0.1 0.5 0.1 0.0 0.3 1.2 0.0 1.5 0.0 0.0 0.5 0.3 0.1 10.2 1.0 NOS3 "ECNOS, eNOS" ENSG00000164867 "Nitric oxide synthase 3" P29474 7 150991017-151014588 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 62.4" "Cell type enhanced" "Detected in some" "Adipocytes: 20.4;Early spermatids: 81.9;Endothelial cells: 32.6;Hepatic stellate cells: 29.3;Late spermatids: 29.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in some" "Lineage enriched" "Detected in single" 4 "T-cells: 2.3" "Cell line enhanced" "Detected in some" "BEWO: 23.1;HUVEC TERT2: 44.7;K-562: 16.6;TIME: 82.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB002168 Enhanced NA NA "Cluster 20: T-cells - T-cell receptor" "Cluster 64: Macrophages - Immune response" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "CAB002168: AB_564072" "unprognostic (6.53e-2)" "unprognostic (3.36e-1)" "unprognostic (1.63e-2)" "unprognostic (8.46e-2)" "unprognostic (2.96e-2)" "unprognostic (1.47e-1)" "unprognostic (1.35e-1)" "unprognostic (1.36e-1)" "unprognostic (6.97e-2)" "unprognostic (2.56e-1)" "unprognostic (9.40e-2)" "unprognostic (2.36e-1)" "prognostic unfavorable (3.63e-4)" "unprognostic (1.25e-2)" "unprognostic (6.63e-2)" "unprognostic (1.05e-1)" "unprognostic (1.01e-1)" 19.3 6.3 8.4 5.8 6.8 0.8 13.2 5.7 6.7 7.3 3.4 5.9 2.6 9.7 0.4 5.8 8.1 4.7 20.6 5.7 6.1 24.2 4.3 11.2 2.7 9.2 7.7 3.2 2.9 1.2 7.2 4.8 8.6 7.6 1.2 0.8 4.4 1.7 3.9 4.2 6.7 3.7 7.5 62.4 5.4 7.2 11.0 0.6 9.1 3.5 1.2 9.7 7.4 6.0 0.4 0.1 1.3 4.0 0.0 0.0 23.1 0.0 0.0 0.0 0.0 0.3 2.2 0.4 2.1 0.0 0.2 0.7 0.0 0.1 0.0 0.0 0.4 2.2 0.3 6.4 0.6 0.5 10.4 0.1 0.2 0.0 0.0 0.1 44.7 5.1 16.6 3.6 0.0 0.0 0.2 0.5 1.7 0.7 0.1 3.0 0.0 1.8 0.0 0.3 0.5 0.4 0.2 1.4 0.0 0.4 0.1 1.4 82.5 0.2 0.7 0.4 0.1 2.4 8.9 2.2 0.0 7.5 0.0 0.2 0.1 0.1 1.1 0.2 0.7 0.3 1.7 0.9 0.2 0.5 2.3 0.9 0.3 0.2 0.2 0.2 2.1 0.5 8.4 6.8 5.7 6.7 5.7 6.1 9.2 7.7 8.6 7.5 11.0 6.0 20.4 9.6 2.2 0.3 0.7 0.9 0.1 0.1 0.0 0.2 0.2 0.3 3.1 0.0 0.7 0.0 0.0 0.2 0.7 0.1 0.0 1.0 81.9 4.9 0.7 32.6 0.0 0.0 0.2 0.0 0.1 2.9 0.5 3.2 5.7 0.7 29.3 0.7 0.4 0.0 0.2 0.4 0.0 0.6 0.5 29.3 0.9 0.4 0.0 7.5 0.0 0.3 0.0 0.0 0.0 0.8 0.0 1.2 1.5 0.4 0.1 0.2 2.2 0.3 0.0 0.6 2.6 6.9 5.3 0.2 0.6 3.6 1.6 0.9 0.1 0.9 NPC1L1 SLC65A2 ENSG00000015520 "NPC1 like intracellular cholesterol transporter 1" Q9UHC9 7 44512535-44541330 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 9 "intestine: 54.2;liver: 48.1" "Group enriched" "Detected in some" 5 "Early spermatids: 12.3;Hepatocytes: 44.7" "Group enriched" "Detected in many" 5 "liver cancer: 8.5;pancreatic cancer: 7.8;stomach cancer: 4.8" "Low region specificity" "Detected in single" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "CACO-2: 6.8;Hep G2: 17.9;SCLC-21H: 14.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB070127, CAB070128" Enhanced NA NA "Cluster 41: Intestine & Liver - Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 15: Hepatocytes - Hemostasis" "CAB070127: AB_10002744, CAB070128: AB_10000815" "unprognostic (2.96e-2)" "unprognostic (2.23e-1)" "unprognostic (7.57e-3)" "unprognostic (8.43e-2)" "unprognostic (1.62e-1)" "unprognostic (2.07e-1)" "unprognostic (9.40e-2)" "unprognostic (6.75e-2)" "unprognostic (1.44e-1)" "unprognostic (1.96e-2)" "unprognostic (4.51e-2)" "unprognostic (7.59e-2)" "unprognostic (8.08e-10)" "unprognostic (1.64e-2)" "unprognostic (2.83e-1)" "unprognostic (3.62e-2)" "unprognostic (5.83e-2)" 0.6 0.1 0.4 0.0 0.7 0.0 0.4 0.9 1.1 0.6 0.3 1.6 54.2 0.4 0.0 0.4 0.5 5.8 0.1 0.7 0.2 0.9 48.1 0.2 0.0 0.3 0.4 0.6 0.6 0.0 0.0 0.0 0.4 0.4 0.1 0.0 0.1 0.1 0.1 0.3 50.5 0.1 0.3 0.0 1.5 1.1 0.3 0.0 0.0 0.0 0.0 0.5 0.5 0.6 0.0 0.0 0.0 0.1 0.3 0.1 0.2 0.0 0.0 0.0 0.0 6.8 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 17.9 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 14.3 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.7 0.9 1.1 0.7 0.2 0.3 0.4 0.4 0.3 0.3 0.6 0.2 0.0 0.0 0.3 0.2 0.6 0.0 0.0 0.0 0.0 0.7 0.8 0.8 5.7 0.0 1.8 0.0 0.0 0.1 0.0 0.0 0.3 12.3 0.3 0.1 0.2 1.8 2.7 0.3 0.5 0.0 0.2 0.0 0.5 0.0 0.0 1.4 44.7 0.0 0.0 0.1 0.3 0.0 1.0 0.3 2.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.5 0.0 0.0 0.0 0.2 3.4 1.3 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.6 0.3 0.1 0.3 0.7 0.2 0.1 NPR1 "ANPa, ANPRA, GUCY2A, NPRA" ENSG00000169418 "Natriuretic peptide receptor 1" P16066 1 153678688-153693992 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "cGMP biosynthesis" "Lyase, Receptor, Vasoactive" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 67.1" "Group enriched" "Detected in many" 6 "Adipocytes: 99.6;Endothelial cells: 52.5;Hepatic stellate cells: 132.8" "Group enriched" "Detected in all" 4 "ovarian cancer: 39.2;renal cancer: 12.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 6 "ASC diff: 158.5" "Region enriched" "Detected in all" 5 "olfactory bulb: 18.7" "Low region specificity" "Detected in many" HPA031087 Approved "Nucleoplasm,Nucleoli,Plasma membrane" NA NA "Cluster 82: Adipose tissue - ECM organization" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" Nucleoli "Nucleoplasm, Plasma membrane" "HPA031087: AB_10601975" "unprognostic (2.54e-1)" "unprognostic (3.03e-3)" "unprognostic (6.31e-2)" "prognostic unfavorable (3.97e-4)" "unprognostic (1.55e-1)" "unprognostic (6.60e-2)" "unprognostic (1.54e-2)" "unprognostic (2.03e-1)" "unprognostic (2.46e-1)" "unprognostic (3.27e-2)" "prognostic favorable (2.49e-4)" "unprognostic (1.27e-1)" "unprognostic (6.69e-2)" "unprognostic (1.16e-2)" "unprognostic (1.09e-1)" "unprognostic (4.06e-1)" "unprognostic (1.74e-2)" 67.1 8.7 1.7 3.4 1.5 0.0 44.3 1.4 1.4 8.8 1.5 10.1 1.5 31.0 5.5 4.3 36.4 5.9 15.8 1.3 1.4 28.8 4.3 24.2 2.3 1.5 1.5 27.7 3.9 8.4 3.8 17.7 1.5 4.4 2.0 0.1 3.7 12.1 7.2 6.6 9.3 9.7 1.8 2.2 8.8 1.3 2.4 1.9 14.0 11.1 1.3 12.8 9.7 1.4 0.0 1.3 0.1 0.0 158.5 0.6 0.1 0.0 0.0 0.1 0.1 0.1 0.6 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 28.0 0.0 19.0 0.0 0.0 0.3 0.0 0.3 0.0 0.1 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.0 0.0 15.9 0.0 0.0 2.1 0.0 0.1 0.0 1.9 0.0 5.7 1.0 0.1 0.0 0.2 0.0 0.0 8.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 1.5 1.4 1.4 1.3 1.4 1.5 1.5 1.5 1.8 2.4 1.4 99.6 0.0 6.9 0.0 0.2 1.5 0.5 0.0 0.6 0.0 0.5 0.5 4.5 2.8 0.0 14.7 0.0 0.2 0.1 0.0 0.0 0.7 9.1 6.2 8.8 52.5 0.0 0.0 0.0 0.0 1.3 15.2 0.0 15.4 0.0 0.0 132.8 2.4 0.3 0.0 0.0 0.0 0.0 4.7 4.0 11.5 10.2 0.5 0.0 0.0 5.2 0.0 0.0 0.0 0.0 1.0 0.0 4.1 0.0 0.5 0.0 4.0 0.0 0.0 0.0 1.4 2.2 0.5 0.1 0.2 1.0 0.7 0.3 1.4 0.2 0.0 NPR2 "AMDM, ANPb, ANPRB, GUCY2B, NPRB" ENSG00000159899 "Natriuretic peptide receptor 2" P20594 9 35791591-35809732 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "cGMP biosynthesis, Osteogenesis" "Lyase, Receptor" "Disease variant, Dwarfism, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Astrocytes: 35.6;Excitatory neurons: 69.1;Inhibitory neurons: 68.9;Microglial cells: 34.7;Oligodendrocyte precursor cells: 51.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC diff: 30.9;ASC TERT1: 21.1;BJ hTERT+: 20.2;HHSteC: 20.1;HSkMC: 23.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 35: Non-specific - Unknown function" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (2.93e-2)" "unprognostic (8.22e-3)" "unprognostic (9.25e-3)" "unprognostic (3.59e-2)" "unprognostic (6.13e-2)" "unprognostic (2.63e-2)" "unprognostic (1.41e-1)" "unprognostic (1.56e-1)" "unprognostic (1.56e-1)" "unprognostic (2.40e-1)" "unprognostic (3.06e-1)" "unprognostic (1.49e-1)" "unprognostic (3.99e-2)" "unprognostic (6.99e-3)" "unprognostic (7.10e-2)" "unprognostic (3.24e-1)" "unprognostic (7.86e-2)" 12.4 8.2 9.3 1.7 9.4 0.3 10.3 14.4 9.9 25.7 7.7 15.6 1.8 20.5 8.7 3.2 15.1 3.2 12.8 9.1 11.4 6.7 8.6 9.1 2.3 11.8 9.4 9.4 3.2 1.3 13.8 4.7 11.5 10.9 2.8 4.1 5.3 6.5 10.8 8.3 7.5 9.9 8.2 4.9 7.8 4.8 10.7 2.2 6.0 8.6 1.7 12.1 14.7 7.9 0.0 2.9 2.2 0.0 30.9 21.1 1.9 9.3 20.2 7.0 6.4 4.5 4.3 1.8 3.0 17.9 12.8 1.2 3.6 0.2 6.1 2.2 1.0 1.8 4.3 3.4 20.1 0.4 0.0 23.8 1.8 8.9 0.6 7.6 12.7 2.5 0.7 0.2 13.4 1.0 0.5 0.8 3.5 1.0 3.7 2.4 0.2 0.5 1.8 1.4 1.1 0.7 0.4 0.1 0.6 3.8 0.2 0.0 8.2 8.5 7.8 3.2 1.2 0.5 0.6 4.8 10.4 0.6 5.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.3 0.0 9.3 9.4 14.4 9.9 9.1 11.4 11.8 9.4 11.5 8.2 10.7 7.9 2.7 3.2 3.4 35.6 0.0 1.1 0.6 0.6 1.2 5.1 0.7 1.4 0.7 1.5 0.3 0.0 2.1 0.4 0.5 0.7 0.0 0.6 0.3 1.4 9.2 4.4 0.0 0.0 69.1 0.8 0.2 7.2 0.5 2.0 1.3 9.6 6.1 4.5 0.4 3.3 68.9 0.7 0.0 0.3 2.1 0.3 9.3 0.3 0.0 34.7 0.0 6.8 0.0 51.8 16.3 0.6 3.6 7.9 0.2 2.7 0.2 0.6 1.1 2.2 0.0 5.1 3.4 4.5 3.1 0.1 1.6 0.3 0.7 0.8 1.1 0.4 NPY PYY4 ENSG00000122585 "Neuropeptide Y" P01303 7 24284188-24291862 "FDA approved drug targets, Plasma proteins, Predicted secreted proteins" Neuropeptide "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 12 "adrenal gland: 122.6;brain: 423.9;prostate: 332.8" "Group enriched" "Detected in some" 4 "Inhibitory neurons: 56.7;Prostatic glandular cells: 100.6" "Cancer enriched" "Detected in many" 187 "prostate cancer: 1214.9" "Region enriched" "Detected in all" 7 "hypothalamus: 423.9" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 34 "SH-SY5Y: 700.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB016733, CAB034368, HPA036636, HPA044572, HPA056798" Supported Supported Enhanced "Golgi apparatus" "Secreted to blood" NA NA 30700000 21000 "Cluster 26: Pituitary gland - Hormone signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 35: Glandular cells - Unknown function" "Golgi apparatus" "CAB016733: , CAB034368: AB_2298657, HPA036636: , HPA044572: AB_2678996, HPA056798: AB_2630371" "unprognostic (2.00e-1)" "prognostic unfavorable (5.78e-4)" "unprognostic (4.15e-1)" "unprognostic (3.76e-2)" "unprognostic (1.59e-2)" "unprognostic (1.87e-1)" "unprognostic (6.30e-2)" "unprognostic (1.24e-2)" "unprognostic (1.78e-1)" "unprognostic (2.52e-1)" 1.8 122.6 32.8 12.8 59.0 5.6 2.2 11.0 39.1 1.3 11.3 2.9 9.7 0.3 0.3 2.3 0.5 1.1 0.8 31.7 423.9 0.5 0.2 0.3 0.0 24.2 25.1 0.5 8.8 0.1 4.7 0.0 15.2 332.8 1.9 4.4 0.3 3.9 0.2 0.2 13.1 1.2 18.8 0.0 8.8 1.1 29.2 0.2 0.9 0.2 0.0 1.4 23.8 33.1 0.0 0.0 2.5 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.0 0.0 0.5 1.4 2.0 0.0 0.2 20.5 0.0 0.6 0.0 0.0 0.8 700.2 0.0 0.0 0.0 0.2 0.0 1.5 0.0 0.0 0.1 1.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 32.8 59.0 11.0 39.1 31.7 423.9 24.2 25.1 15.2 18.8 29.2 33.1 0.0 0.0 0.0 2.0 0.5 0.1 1.3 0.0 0.0 1.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 5.3 0.0 0.0 0.0 0.1 13.4 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.5 0.8 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 56.7 0.0 0.0 0.0 0.0 16.1 0.3 0.7 1.8 1.0 0.0 0.8 0.0 2.0 1.9 0.3 0.0 0.4 0.0 100.6 0.0 0.0 0.0 0.7 0.0 15.6 0.3 2.4 2.8 0.0 0.0 5.1 0.3 0.0 0.0 2.0 NR1H4 "FXR, HRR-1, HRR1, RIP14" ENSG00000012504 "Nuclear receptor subfamily 1 group H member 4" Q96RI1 12 100473708-100564414 "Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters" "Immunity, Inflammatory response, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Disease variant, FDA approved drug targets, Intrahepatic cholestasis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 39.1;liver: 120.6" "Cell type enhanced" "Detected in some" "Cholangiocytes: 92.9;Hepatocytes: 105.1;Proximal enterocytes: 331.0;Proximal tubular cells: 153.8" "Group enriched" "Detected in some" 11 "liver cancer: 18.7;renal cancer: 12.6" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 30 "Hep G2: 28.3;HHSteC: 14.1;RPTEC TERT1: 44.9" "Not detected" "Not detected" "Not detected" "Not detected" HPA047699 Approved Nucleoplasm NA NA "Cluster 85: Liver - Metabolism" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 45: Enterocytes - Digestion" Nucleoplasm "HPA047699: AB_10965320" "unprognostic (1.78e-1)" "unprognostic (1.81e-1)" "unprognostic (6.68e-2)" "unprognostic (2.49e-1)" "unprognostic (1.60e-1)" "unprognostic (9.39e-2)" "unprognostic (2.01e-1)" "unprognostic (1.88e-2)" "unprognostic (1.16e-1)" "unprognostic (2.43e-1)" "unprognostic (3.77e-3)" 0.2 22.6 0.1 1.4 0.1 0.4 1.0 0.5 0.4 0.2 1.8 8.3 29.6 0.1 0.1 0.2 0.2 12.6 0.4 0.2 0.1 28.2 120.6 0.4 0.3 0.1 0.1 14.0 3.1 0.0 1.4 0.0 0.1 0.3 1.6 0.3 0.3 0.0 0.3 0.5 39.1 0.8 0.0 0.4 0.5 0.7 0.2 0.1 0.3 0.1 0.2 6.5 0.1 0.5 0.0 0.9 0.1 0.3 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.3 28.3 14.1 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.1 0.0 0.6 0.1 0.0 0.0 44.9 0.4 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.2 0.1 0.0 0.1 0.1 0.2 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.5 0.4 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.5 0.0 0.0 0.0 0.3 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 92.9 0.0 22.0 0.0 0.0 0.0 8.0 43.0 11.5 0.7 0.0 0.0 0.3 0.0 2.7 0.4 0.0 0.0 0.5 0.0 0.0 0.0 0.6 8.9 105.1 0.0 0.0 1.6 17.0 0.0 3.5 0.0 2.0 0.9 0.8 0.0 1.0 0.0 0.0 0.0 0.5 0.3 0.4 19.9 0.0 0.0 0.0 331.0 153.8 0.0 0.0 0.0 0.0 0.1 0.4 1.3 0.0 0.0 0.0 0.9 1.1 30.4 3.7 NR1I2 "BXR, ONR1, PAR2, PXR, SXR" ENSG00000144852 "Nuclear receptor subfamily 1 group I member 2" O75469 3 119780484-119818487 "FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors, Transporters" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "intestine: 31.2;liver: 47.4" "Cell type enhanced" "Detected in some" "Distal enterocytes: 26.1;Hepatocytes: 32.2;Paneth cells: 13.8;Proximal enterocytes: 51.7;Undifferentiated cells: 9.0" "Group enriched" "Detected in some" 24 "colorectal cancer: 9.0;liver cancer: 5.7;pancreatic cancer: 2.6;stomach cancer: 2.7" "Not detected" "Not detected" "Immune cell enriched" "Detected in single" 15 "NK-cell: 2.8" "Lineage enriched" "Detected in single" 15 "NK-cells: 2.8" "Cell line enriched" "Detected in some" 5 "Hep G2: 14.8" "Not detected" "Not detected" "Not detected" "Not detected" "HPA029309, HPA055121, HPA073926" Enhanced Nucleoplasm NA NA "Cluster 15: NK-cells - Transcription" "Cluster 41: Intestine & Liver - Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 45: Enterocytes - Digestion" Nucleoplasm "HPA029309: AB_2672990, HPA055121: AB_2682703, HPA073926: AB_2686643" "unprognostic (6.76e-3)" "unprognostic (2.25e-1)" "unprognostic (5.84e-2)" "unprognostic (1.24e-4)" "unprognostic (4.51e-2)" "unprognostic (4.52e-2)" "unprognostic (4.03e-3)" "unprognostic (3.97e-2)" "unprognostic (5.78e-2)" "unprognostic (5.05e-2)" "unprognostic (5.21e-2)" "unprognostic (3.60e-2)" "unprognostic (5.51e-6)" "unprognostic (4.86e-1)" "unprognostic (6.95e-2)" "unprognostic (3.13e-1)" "unprognostic (6.12e-3)" 0.1 0.1 0.2 1.0 0.1 0.6 0.1 0.0 0.1 0.0 0.2 12.3 28.2 0.0 0.1 0.0 0.1 5.2 0.0 0.1 0.3 0.0 47.4 0.0 0.2 0.2 0.3 0.0 0.1 0.0 0.0 0.0 0.2 0.0 13.3 0.2 0.0 0.1 0.0 0.0 31.2 0.6 0.1 0.1 1.7 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.8 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 2.7 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 1.2 0.3 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.1 0.0 0.2 0.1 0.0 0.1 0.1 0.3 0.2 0.3 0.2 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.7 1.5 0.0 1.8 0.0 0.0 0.1 26.1 1.9 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.6 0.2 0.0 0.1 3.1 0.0 0.0 1.7 0.0 32.2 0.2 0.0 0.4 6.4 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.9 13.8 0.0 0.1 0.2 51.7 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.0 0.2 0.5 9.0 0.0 NR3C1 "GR, GRL" ENSG00000113580 "Nuclear receptor subfamily 3 group C member 1" P04150 5 143277931-143435512 "Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Apoptosis, Cell cycle, Cell division, Chromosome partition, Mitosis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Receptor, RNA-binding" "Disease variant, FDA approved drug targets, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Excitatory neurons: 411.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004248, CAB010435" Supported Supported Nucleoplasm,Mitochondria,Cytosol NA NA "Cluster 38: Basophils - Unknown function" "Cluster 3: T-cells - Adaptive immune response" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 65: Plasmacytoid DCs - Unknown function" "Nucleoplasm, Cytosol" Mitochondria "CAB010435: AB_2155784, HPA004248: AB_1078976" "unprognostic (1.38e-1)" "unprognostic (1.93e-1)" "unprognostic (1.17e-1)" "prognostic unfavorable (3.64e-5)" "unprognostic (1.43e-2)" "unprognostic (2.74e-1)" "unprognostic (4.19e-1)" "unprognostic (1.39e-1)" "unprognostic (2.46e-2)" "unprognostic (3.87e-2)" "unprognostic (2.15e-1)" "unprognostic (6.85e-2)" "prognostic unfavorable (1.72e-6)" "unprognostic (9.06e-3)" "unprognostic (1.02e-1)" "unprognostic (2.43e-3)" "unprognostic (2.45e-2)" 35.3 11.8 15.2 22.6 18.1 49.4 25.5 34.0 24.7 19.7 18.2 13.7 19.2 18.8 13.6 25.7 18.8 21.1 24.2 14.9 25.0 19.2 39.8 31.9 25.6 18.1 14.9 21.1 14.7 33.8 16.2 46.9 16.1 19.7 14.5 9.5 16.1 20.0 45.0 20.4 18.0 23.8 15.0 24.5 16.0 11.1 21.6 40.0 25.6 40.1 27.3 18.2 16.0 28.5 30.4 60.6 4.4 0.1 38.2 42.3 5.2 46.5 55.3 39.3 45.1 4.5 39.7 26.8 20.8 68.6 46.0 28.1 0.3 36.6 48.3 15.2 21.0 6.9 77.0 13.5 35.7 28.1 20.6 30.8 46.3 64.7 62.5 49.0 15.0 12.1 10.3 98.8 35.1 10.9 16.7 20.0 11.9 5.1 13.0 6.0 41.4 58.0 11.5 2.1 8.0 6.1 81.3 11.7 19.4 4.9 5.3 39.8 35.8 94.7 18.7 45.7 35.9 20.1 19.7 41.5 49.7 28.5 33.6 67.4 21.3 38.9 18.3 24.2 15.1 15.9 18.6 17.9 28.5 22.3 17.8 17.2 68.4 23.1 23.6 25.9 12.8 17.3 15.2 18.1 34.0 24.7 14.9 25.0 18.1 14.9 16.1 15.0 21.6 28.5 152.3 67.3 69.1 71.2 134.1 58.8 35.9 37.9 79.6 13.1 39.0 55.8 43.4 57.2 41.2 25.8 16.7 48.9 158.3 22.9 17.6 30.8 165.6 8.1 30.1 82.3 28.1 55.9 411.4 33.3 39.5 112.2 23.9 10.4 89.3 7.5 63.5 193.9 53.2 37.0 169.5 4.1 10.2 66.3 99.2 144.1 63.0 97.4 53.4 241.7 87.6 34.6 83.4 240.3 237.5 35.9 17.9 71.5 115.1 46.2 25.3 67.9 37.9 65.0 151.2 181.9 105.0 24.5 40.1 57.4 56.3 36.5 204.5 12.6 12.9 14.3 NR3C2 "MLR, MR" ENSG00000151623 "Nuclear receptor subfamily 3 group C member 2" P08235 4 148078762-148444698 "Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Astrocytes: 265.8;Excitatory neurons: 275.7;Inhibitory neurons: 269.9;Microglial cells: 176.1;Oligodendrocyte precursor cells: 230.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "MAIT T-cell: 1.8" "Lineage enriched" "Detected in single" 6 "T-cells: 1.8" "Cell line enhanced" "Detected in some" "hTERT-RPE1: 9.7;HUVEC TERT2: 6.0;Karpas-707: 6.9;PC-3: 6.1;RPTEC TERT1: 7.8;TIME: 8.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009155, HPA074979" Enhanced Supported Nucleoplasm NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Nucleoplasm "CAB009155: AB_2155949, HPA074979: AB_2686724" "unprognostic (2.75e-3)" "unprognostic (2.63e-2)" "unprognostic (6.70e-3)" "unprognostic (1.52e-1)" "unprognostic (4.09e-1)" "unprognostic (7.82e-3)" "unprognostic (1.04e-2)" "unprognostic (1.11e-2)" "unprognostic (1.14e-1)" "unprognostic (4.35e-2)" "unprognostic (4.97e-2)" "unprognostic (2.39e-1)" "prognostic favorable (3.10e-11)" "unprognostic (1.42e-1)" "unprognostic (1.87e-1)" "unprognostic (1.57e-1)" "unprognostic (1.27e-1)" 4.6 4.5 4.5 3.7 5.6 1.0 4.8 9.2 11.7 5.6 4.0 21.8 8.7 6.2 3.8 3.1 5.9 5.8 9.4 13.7 3.5 12.1 8.5 7.3 3.1 3.0 5.9 14.7 7.6 12.5 5.5 1.8 3.0 3.7 26.2 8.5 10.7 4.3 12.1 3.0 15.3 4.9 3.2 5.2 8.3 4.3 6.1 2.9 19.7 14.1 2.1 5.9 3.3 4.8 0.0 0.0 0.0 0.0 0.4 0.3 0.4 0.0 0.0 0.0 0.4 0.0 0.0 1.4 2.6 1.0 0.2 0.0 1.3 0.7 0.1 0.2 2.3 0.2 0.6 0.0 0.0 1.7 0.3 0.1 0.0 0.0 0.0 9.7 6.0 0.9 0.0 6.9 2.0 0.0 0.0 0.0 0.1 1.2 6.1 0.5 0.0 0.1 7.8 0.1 0.1 0.0 0.0 1.4 0.6 0.1 0.7 0.0 8.7 4.3 2.5 0.1 0.8 0.0 0.0 0.1 1.4 0.6 1.0 0.0 0.0 0.0 0.5 0.0 1.8 0.1 0.7 0.4 0.0 0.2 1.0 1.1 0.0 0.0 0.2 0.0 0.2 0.1 4.5 5.6 9.2 11.7 13.7 3.5 3.0 5.9 3.0 3.2 6.1 4.8 11.9 28.9 13.9 265.8 5.1 2.0 2.2 0.4 6.2 10.3 6.2 5.8 20.3 7.2 6.7 11.0 18.8 0.9 1.0 76.1 9.8 3.0 68.2 2.1 1.1 8.2 18.0 0.0 275.7 5.8 0.5 5.9 13.7 2.6 5.7 6.4 8.6 7.0 0.6 13.5 269.9 44.6 6.1 2.9 2.4 41.8 4.4 1.7 7.2 176.1 1.2 8.1 1.0 230.2 95.7 3.2 26.8 3.8 0.8 1.8 26.4 2.3 4.7 9.6 0.0 14.7 5.1 1.8 5.6 2.6 1.7 0.1 4.9 1.8 21.5 2.1 NTRK1 "MTC, TRK, TRKA" ENSG00000198400 "Neurotrophic receptor tyrosine kinase 1" P04629 1 156815640-156881850 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "adrenal gland: 7.0;brain: 21.7" "Group enriched" "Detected in some" 10 "Bipolar cells: 22.8;granulocytes: 55.9;Horizontal cells: 57.2" "Cancer enhanced" "Detected in some" "glioma: 1.3" "Group enriched" "Detected in many" 6 "cerebral cortex: 7.6;medulla oblongata: 19.8;pons: 21.7" "Immune cell enriched" "Detected in single" 116 "basophil: 94.5" "Lineage enriched" "Detected in single" 768 "granulocytes: 94.5" "Cell line enriched" "Detected in some" 4 "HMC-1: 82.1" "Region enhanced" "Detected in many" "basal ganglia: 8.4" "Region enriched" "Detected in single" 6 "basal ganglia: 4.1" "CAB004606, HPA035799, HPA076570" Approved Approved Vesicles,Cytosol NA NA 79000 "Cluster 38: Basophils - Unknown function" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 3: HMC-1 - Innate immune response" "Cluster 62: Horizontal cells - Visual perception" "Vesicles, Cytosol" "CAB004606: AB_628397, HPA035799: AB_2674788, HPA076570: " "unprognostic (5.89e-3)" "unprognostic (7.56e-2)" "unprognostic (2.74e-2)" "unprognostic (5.99e-3)" "unprognostic (7.26e-2)" "unprognostic (1.43e-3)" "unprognostic (1.56e-1)" "unprognostic (7.42e-3)" "unprognostic (7.63e-2)" "unprognostic (1.35e-1)" "unprognostic (6.73e-2)" "unprognostic (2.29e-2)" "unprognostic (3.18e-11)" "unprognostic (2.18e-3)" "unprognostic (3.79e-2)" "unprognostic (1.07e-1)" "unprognostic (4.89e-1)" 0.8 7.0 0.7 0.4 1.8 0.7 0.2 1.8 7.6 0.7 0.7 0.8 0.5 1.0 0.0 0.1 0.5 0.4 1.0 0.3 2.8 3.0 0.0 0.5 0.1 19.8 1.5 0.1 0.2 0.0 0.7 0.2 21.7 1.4 0.0 1.9 0.5 0.3 0.4 0.1 0.3 0.6 0.2 0.1 0.5 1.6 0.4 0.3 0.2 0.2 0.0 0.3 0.5 0.6 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.2 0.1 0.0 0.0 0.0 11.9 0.0 14.0 0.0 0.0 0.0 0.0 82.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 4.4 1.6 0.0 0.2 0.0 2.4 0.2 0.0 1.5 2.5 0.0 0.2 0.0 0.5 1.5 18.2 0.0 0.1 0.0 0.3 0.0 0.1 0.3 0.0 1.1 0.0 0.0 3.5 0.6 0.0 0.0 0.0 0.1 94.5 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.2 0.7 1.8 1.8 7.6 0.3 2.8 19.8 1.5 21.7 0.2 0.4 0.6 0.1 0.0 1.3 0.3 0.0 0.0 0.0 0.0 0.0 22.8 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 1.6 0.2 0.0 4.2 0.7 0.0 0.0 4.3 0.0 0.1 55.9 0.0 0.0 0.0 0.1 57.2 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 2.8 0.0 0.5 0.0 0.5 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.9 3.2 2.7 0.0 0.1 0.0 1.0 0.1 0.0 0.0 NTRK2 TRKB ENSG00000148053 "Neurotrophic receptor tyrosine kinase 2" Q16620 9 84668551-85027054 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, Epilepsy, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 230.0;thyroid gland: 116.9" "Cell type enhanced" "Detected in many" "Astrocytes: 1144.3;Excitatory neurons: 750.1;Inhibitory neurons: 877.7;Oligodendrocyte precursor cells: 557.9" "Group enriched" "Detected in many" 5 "glioma: 31.6;head and neck cancer: 8.0;lung cancer: 9.8;thyroid cancer: 26.4" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 8.7;HaCaT: 3.0;RPTEC TERT1: 9.7;SH-SY5Y: 11.2;SuSa: 4.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007637, CAB010346, HPA074873" Enhanced Supported "Plasma membrane" NA NA 20000000 "Cluster 73: Brain - Neuropeptide signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane" "CAB010346: AB_2155274, HPA007637: AB_1080385, HPA074873: " "unprognostic (2.75e-3)" "unprognostic (3.48e-2)" "unprognostic (1.82e-2)" "unprognostic (3.26e-1)" "unprognostic (9.26e-2)" "unprognostic (2.56e-2)" "unprognostic (1.29e-2)" "unprognostic (9.16e-2)" "unprognostic (6.13e-2)" "unprognostic (1.05e-1)" "unprognostic (4.25e-2)" "unprognostic (2.18e-2)" "unprognostic (2.66e-2)" "unprognostic (1.20e-2)" "unprognostic (1.21e-2)" "unprognostic (1.31e-1)" "unprognostic (1.39e-3)" 40.5 2.7 201.9 1.7 177.8 0.1 62.2 133.3 190.6 9.8 69.8 5.9 0.4 3.9 3.9 8.2 5.6 33.3 15.2 173.3 230.0 20.4 1.8 10.0 3.1 119.4 218.9 9.7 34.3 2.5 10.1 1.8 151.7 4.7 3.6 41.2 14.4 19.1 2.9 11.6 1.6 3.3 116.6 10.9 1.9 2.4 222.1 4.0 116.9 13.8 4.3 4.9 12.0 117.7 0.0 0.0 8.7 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 1.4 0.0 0.2 0.0 0.0 3.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 9.7 0.7 0.7 11.2 0.0 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.1 0.0 0.3 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 201.9 177.8 133.3 190.6 173.3 230.0 119.4 218.9 151.7 116.6 222.1 117.7 17.4 0.0 0.5 1144.3 0.7 56.6 1.0 1.8 93.9 30.3 144.1 116.8 11.4 0.0 0.2 9.2 6.2 0.0 1.0 8.7 27.4 36.1 1.8 1.2 0.4 8.0 0.0 0.0 750.1 0.7 0.1 76.6 0.0 2.3 0.0 0.1 5.0 0.0 0.2 242.3 877.7 0.7 0.0 0.0 14.2 3.6 104.1 1.4 17.8 65.6 0.6 241.0 0.0 557.9 109.5 0.5 7.0 48.2 0.3 0.9 0.0 7.1 1.7 12.2 124.9 9.9 114.4 0.8 2.3 5.2 24.6 0.0 3.3 0.2 7.2 0.9 NTRK3 TRKC ENSG00000140538 "Neurotrophic receptor tyrosine kinase 3" Q16288 15 87859751-88256768 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Differentiation, Neurogenesis" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 38.8" "Cell type enhanced" "Detected in many" "Astrocytes: 239.3;Early spermatids: 119.6;Excitatory neurons: 360.0;Inhibitory neurons: 277.8;Late spermatids: 148.9;Microglial cells: 177.1;Oligodendrocyte precursor cells: 499.6" "Group enriched" "Detected in some" 4 "glioma: 2.5;testis cancer: 1.0" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 8 "U-138 MG: 100.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009233, HPA027484, HPA048065" Approved Supported "Nuclear membrane,Nucleoli,Nucleoli rim" NA NA 19000000 "Cluster 10: Brain - Neuronal signaling" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Nucleoli, Nucleoli rim" "Nuclear membrane" "CAB009233: AB_632555, HPA027484: AB_2672297, HPA048065: AB_2680245" "unprognostic (1.27e-3)" "unprognostic (1.24e-2)" "unprognostic (1.98e-2)" "unprognostic (2.04e-2)" "unprognostic (1.65e-1)" "unprognostic (3.34e-1)" "unprognostic (3.18e-2)" "unprognostic (2.23e-2)" "unprognostic (2.34e-1)" "unprognostic (3.91e-1)" "unprognostic (2.88e-1)" "unprognostic (1.09e-1)" "unprognostic (5.78e-3)" "unprognostic (6.45e-3)" "unprognostic (1.06e-2)" "unprognostic (1.26e-2)" "unprognostic (2.49e-3)" 12.8 3.7 31.3 0.8 33.2 0.1 7.8 30.7 34.3 12.8 0.0 3.4 0.5 10.4 3.2 1.3 15.0 1.6 5.8 38.8 25.8 5.1 1.0 5.3 1.2 21.5 19.6 7.2 1.0 0.1 12.2 1.0 22.1 9.0 2.0 5.2 6.8 4.3 1.8 4.8 2.2 3.7 10.9 2.5 3.2 9.8 33.4 1.2 3.0 1.9 2.0 8.7 7.4 21.5 0.0 13.1 2.7 0.3 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.0 0.0 0.2 0.3 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 0.3 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 2.5 0.0 0.0 0.0 2.6 0.1 0.1 0.1 0.7 0.1 0.0 0.0 0.0 0.9 0.1 0.1 0.0 100.6 1.8 0.0 1.3 0.0 0.0 0.0 3.0 0.1 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 31.3 33.2 30.7 34.3 38.8 25.8 21.5 19.6 22.1 10.9 33.4 21.5 0.5 0.0 0.0 239.3 0.0 0.5 6.4 0.0 0.0 53.8 3.7 6.0 5.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 119.6 0.4 25.0 1.2 0.0 0.0 360.0 0.0 0.0 5.7 0.0 0.5 0.0 0.0 2.2 0.0 1.0 1.7 277.8 0.0 0.0 0.0 0.6 148.9 3.4 0.6 0.0 177.1 0.0 8.6 0.0 499.6 7.4 0.0 0.0 27.4 0.0 1.3 0.0 0.1 0.0 3.7 52.6 20.3 40.9 11.0 3.7 0.0 0.1 0.1 0.2 0.0 0.0 0.7 NTSR2 NTR2 ENSG00000169006 "Neurotensin receptor 2" O95665 2 11658178-11670195 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 58 "brain: 85.4;choroid plexus: 43.7" "Cell type enriched" "Detected in some" 32 "Astrocytes: 32.7" "Cancer enriched" "Detected in single" 15 "glioma: 6.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 64: Astrocytes - Nervous system maintenance" "unprognostic (5.40e-2)" "unprognostic (2.30e-2)" "unprognostic (2.36e-2)" "unprognostic (5.32e-2)" "unprognostic (2.23e-1)" "unprognostic (1.80e-1)" "unprognostic (2.75e-1)" "unprognostic (4.98e-1)" "unprognostic (1.64e-1)" 0.5 0.9 74.8 0.0 84.2 0.0 0.2 67.7 78.2 0.0 43.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 65.7 75.8 0.0 0.0 0.0 0.0 65.8 85.4 1.1 0.2 0.0 0.2 0.0 68.9 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 60.5 0.0 0.0 0.2 82.9 0.0 0.0 0.0 0.0 0.0 0.0 60.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 74.8 84.2 67.7 78.2 65.7 75.8 65.8 85.4 68.9 60.5 82.9 60.8 0.0 0.0 0.0 32.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ODC1 ODC ENSG00000115758 "Ornithine decarboxylase 1" P11926 2 10439968-10448327 "Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Polyamine biosynthesis" "Decarboxylase, Lyase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Early spermatids: 560.8;Late spermatids: 834.9;Prostatic glandular cells: 412.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001536, CAB035996" Approved Approved "Plasma membrane,Cytosol" NA NA "Cluster 19: B-cells - Humoral immune response" "Cluster 34: Non-specific - Transcription" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 51: Myeloid cells - Hemostasis" "Plasma membrane, Cytosol" "CAB035996: , HPA001536: AB_1079521" "unprognostic (2.33e-1)" "unprognostic (3.41e-1)" "unprognostic (7.25e-3)" "unprognostic (5.21e-3)" "unprognostic (4.22e-2)" "unprognostic (2.70e-1)" "prognostic unfavorable (3.07e-5)" "unprognostic (3.06e-2)" "unprognostic (4.18e-2)" "unprognostic (6.27e-2)" "unprognostic (3.04e-1)" "unprognostic (6.65e-2)" "unprognostic (1.67e-3)" "unprognostic (1.18e-1)" "unprognostic (1.05e-1)" "unprognostic (2.26e-2)" "unprognostic (5.86e-2)" 47.2 23.2 31.0 69.3 31.5 172.9 33.0 30.5 32.2 33.5 48.5 64.8 32.4 66.0 49.2 29.4 56.3 43.7 55.9 29.9 33.0 132.2 92.1 52.4 111.0 32.4 33.0 54.8 61.8 99.6 92.5 20.0 30.6 91.1 72.0 46.2 27.0 55.1 163.3 29.2 41.6 71.2 34.1 42.9 51.5 133.3 34.0 77.1 58.5 73.5 149.1 113.6 26.9 35.7 166.8 130.6 177.1 211.4 31.1 92.4 410.1 234.6 114.9 216.3 99.9 697.3 75.4 870.2 114.6 143.6 208.6 30.2 549.1 265.5 261.2 334.0 231.5 398.1 212.2 429.9 250.8 680.1 91.8 62.5 70.5 490.1 608.3 111.4 176.3 237.6 674.2 274.3 121.7 109.0 680.1 267.3 324.9 228.3 418.8 478.5 556.0 586.3 130.9 119.5 246.6 209.9 293.6 88.8 121.8 135.7 60.0 300.5 124.7 174.4 362.6 227.9 511.7 128.0 416.1 780.8 156.7 443.6 109.9 0.0 1.5 3.0 2.9 2.9 3.3 14.8 4.1 4.8 3.4 15.0 2.8 4.5 0.5 1.4 1.8 12.2 4.4 3.2 31.0 31.5 30.5 32.2 29.9 33.0 32.4 33.0 30.6 34.1 34.0 35.7 78.2 44.8 161.4 7.5 228.9 58.0 123.7 48.8 19.4 36.8 53.2 68.3 55.1 81.5 33.9 40.5 31.3 1.5 188.1 77.7 72.4 50.6 560.8 90.9 66.2 52.2 271.0 111.3 7.5 27.6 70.0 63.2 204.4 127.6 58.9 103.8 14.6 50.3 46.8 6.7 4.1 234.1 22.4 32.1 22.4 834.9 15.5 191.8 23.2 8.4 22.1 126.3 37.0 4.5 2.4 28.6 64.5 11.3 287.4 412.4 31.6 154.1 21.9 77.4 0.0 223.0 79.9 186.5 75.8 52.2 87.5 3.4 133.0 30.2 180.5 142.2 OGDH "E1k, KGD1, OGDC-E1, OGDH2" ENSG00000105953 "Oxoglutarate dehydrogenase" Q02218 7 44606572-44709066 "Citric acid cycle related proteins, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Glycolysis Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 324.0;skeletal muscle: 363.6;tongue: 374.7" "Cell type enhanced" "Detected in all" "Cardiomyocytes: 114.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019514, HPA020347" Supported Enhanced Mitochondria No No 130000 "Cluster 39: Non-specific - mRNA processing" "Cluster 8: Non-specific - Mitochondria" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 54: Cardiomyocytes - Muscle contraction" Mitochondria "HPA019514: AB_1854772, HPA020347: AB_1854773" "unprognostic (1.96e-2)" "unprognostic (1.40e-1)" "unprognostic (4.39e-1)" "unprognostic (5.64e-3)" "unprognostic (3.02e-3)" "unprognostic (1.20e-1)" "unprognostic (3.45e-1)" "unprognostic (7.58e-2)" "unprognostic (1.74e-1)" "unprognostic (1.52e-2)" "unprognostic (3.38e-1)" "unprognostic (3.30e-2)" "prognostic favorable (2.22e-14)" "unprognostic (1.53e-1)" "unprognostic (1.62e-1)" "unprognostic (2.23e-2)" "unprognostic (5.88e-3)" 64.9 67.4 35.0 39.2 39.4 32.1 32.0 42.8 45.4 33.8 119.6 56.3 95.6 40.9 16.6 61.6 34.0 26.9 324.0 34.4 50.6 89.7 39.8 43.4 40.0 44.6 44.4 24.8 27.5 99.9 34.9 33.1 44.2 37.9 41.5 25.9 43.0 46.9 363.6 56.4 87.5 51.0 35.7 39.0 52.5 36.2 43.6 32.1 54.9 374.7 41.5 42.5 37.7 35.6 35.8 73.5 42.2 66.0 63.4 69.8 41.9 54.2 51.3 59.5 50.9 67.2 71.7 156.0 63.0 79.2 119.2 108.2 85.7 81.4 58.4 92.0 22.8 47.4 140.6 33.5 32.8 59.4 51.2 66.0 60.5 85.4 60.9 43.0 82.4 50.7 55.8 45.4 63.7 50.1 59.2 34.1 39.8 97.7 81.8 55.9 30.1 175.9 68.5 104.4 73.2 35.0 78.8 107.6 34.4 75.8 64.2 58.7 66.4 43.4 38.5 76.3 64.0 40.9 84.0 85.9 78.4 65.7 80.4 9.9 21.8 12.6 17.9 28.5 19.5 11.1 20.7 18.1 22.0 9.3 8.5 10.8 12.2 19.3 35.4 10.8 42.1 23.2 35.0 39.4 42.8 45.4 34.4 50.6 44.6 44.4 44.2 35.7 43.6 35.6 19.6 6.4 22.5 49.3 23.1 19.5 12.3 15.9 22.8 21.4 14.4 18.2 114.3 12.8 14.2 47.8 18.8 24.0 20.0 64.5 31.3 14.9 51.0 26.1 15.6 16.0 23.4 32.0 43.3 16.9 16.4 20.6 35.2 38.9 21.5 15.5 17.9 22.6 33.8 62.2 53.1 32.6 12.2 24.5 43.4 24.5 11.8 33.8 21.4 29.0 22.7 14.3 16.5 22.1 36.6 20.9 38.0 17.3 27.8 16.4 82.0 51.8 17.0 24.0 19.7 24.7 20.2 10.6 19.9 28.1 26.3 36.7 27.7 30.3 33.5 18.1 OPRD1 ENSG00000116329 "Opioid receptor delta 1" P41143 1 28812142-28871267 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 4.7" "Cell type enhanced" "Detected in some" "Bipolar cells: 3.7;Excitatory neurons: 11.8;Inhibitory neurons: 15.7;Skeletal myocytes: 2.6" "Cancer enhanced" "Detected in single" "melanoma: 1.0" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 11 "RH-30: 16.4;SCLC-21H: 6.4;SH-SY5Y: 6.5;WM-115: 22.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA070831 Approved NA NA "Cluster 17: Basophils - Unknown function" "Cluster 65: Brain - Ion transport" "Cluster 17: WM-115 - Nervous system development" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA070831: AB_2732167" "unprognostic (1.44e-1)" "unprognostic (4.07e-1)" "unprognostic (1.25e-1)" "unprognostic (3.89e-2)" "unprognostic (2.68e-1)" "unprognostic (5.84e-3)" "unprognostic (6.28e-3)" "unprognostic (5.92e-2)" "unprognostic (1.82e-2)" "unprognostic (5.95e-3)" "unprognostic (4.28e-3)" "unprognostic (2.98e-1)" "unprognostic (1.52e-7)" "unprognostic (1.44e-2)" "unprognostic (1.28e-1)" "unprognostic (1.26e-1)" "unprognostic (2.18e-3)" 0.1 0.5 1.4 0.1 1.6 0.4 0.0 0.0 3.2 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.0 1.9 0.0 0.0 0.0 0.1 0.1 4.4 0.1 0.1 0.3 0.0 0.1 0.1 4.7 0.1 0.1 0.5 0.2 0.0 1.0 0.2 0.1 0.0 0.0 0.1 0.1 0.2 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.5 0.2 0.2 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.3 0.2 0.1 0.0 0.2 1.0 0.0 0.0 0.0 16.4 0.1 0.0 0.1 6.4 6.5 0.0 0.1 1.1 0.3 0.1 0.1 0.0 0.1 0.3 0.2 0.0 0.2 0.0 0.2 0.1 0.4 22.0 0.9 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.5 0.2 0.0 0.2 0.0 0.0 1.4 1.6 0.0 3.2 1.9 0.0 4.4 0.1 4.7 0.0 0.2 0.8 0.0 0.0 0.0 0.0 0.2 0.0 1.0 0.0 0.0 3.7 0.1 0.1 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.5 0.0 0.0 11.8 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 15.7 0.0 0.0 0.0 0.0 0.4 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.5 0.3 0.1 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.4 0.0 2.6 0.3 0.0 0.7 0.0 0.0 0.0 0.3 0.1 0.0 1.2 OPRK1 "KOR, OPRK" ENSG00000082556 "Opioid receptor kappa 1" P41145 8 53225724-53251637 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Behavior "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "brain: 14.5" "Group enriched" "Detected in some" 5 "Endometrial ciliated cells: 4.5;Excitatory neurons: 6.7;Extravillous trophoblasts: 8.0;Glandular and luminal cells: 9.8;Inhibitory neurons: 10.1;Leydig cells: 4.7" "Cancer enhanced" "Detected in some" "prostate cancer: 1.8" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "U-937: 21.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA067549 Enhanced Supported "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Cluster 65: Brain - Ion transport" "Cluster 32: U-937 - Innate immune response" "Cluster 44: Endometrium - Transcription" "Plasma membrane" "Nucleoplasm, Cytosol" "HPA067549: AB_2732770" "unprognostic (1.01e-1)" "unprognostic (1.17e-2)" "unprognostic (8.70e-3)" "unprognostic (3.73e-2)" "unprognostic (6.74e-2)" "unprognostic (2.22e-3)" "unprognostic (8.09e-2)" "unprognostic (9.71e-2)" "unprognostic (4.28e-3)" "unprognostic (3.29e-1)" "unprognostic (3.35e-2)" "unprognostic (9.54e-4)" "unprognostic (1.61e-1)" 0.1 0.1 7.3 0.0 14.5 0.0 0.0 1.3 8.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 3.9 5.4 0.0 0.0 0.1 0.0 5.8 1.7 0.0 0.0 0.0 0.0 0.2 5.1 1.6 0.0 0.6 0.0 0.0 1.1 0.0 0.0 0.0 0.3 0.0 0.0 0.7 6.9 0.1 0.1 0.0 0.0 0.0 0.0 2.6 0.0 0.0 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 1.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.3 21.6 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.3 14.5 1.3 8.3 3.9 5.4 5.8 1.7 5.1 0.3 6.9 2.6 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.6 1.3 0.0 0.0 0.0 0.2 4.5 0.6 0.1 0.0 0.0 6.7 0.0 8.0 0.1 0.0 9.8 0.0 0.0 0.0 0.0 0.2 0.0 10.1 0.0 0.0 0.0 0.0 0.3 4.7 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.4 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.0 1.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 OPRM1 MOR1 ENSG00000112038 "Opioid receptor mu 1" P35372 6 154010496-154246867 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 10.6;testis: 2.8" "Group enriched" "Detected in some" 13 "Early spermatids: 29.2;Excitatory neurons: 41.1;Inhibitory neurons: 23.5;Late spermatids: 29.7;Microglial cells: 10.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enriched" "Detected in single" 11 "SH-SY5Y: 6.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA014509, HPA067435" Enhanced Supported NA NA "Cluster 42: Non-specific - Transcription" "Cluster 69: Cerebellum - Gene expression regulation" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA014509: AB_1854801, HPA067435: " "unprognostic (7.34e-2)" "unprognostic (6.91e-2)" 0.1 0.8 2.9 0.3 2.5 0.7 0.4 8.8 3.5 0.2 0.0 0.2 0.2 0.3 0.6 1.1 0.2 0.3 0.1 1.5 2.6 0.2 0.2 0.2 0.4 2.2 5.2 0.4 0.2 0.2 0.0 0.2 1.0 0.3 0.2 0.9 0.3 0.2 0.4 0.6 0.2 0.2 1.7 0.4 0.4 2.8 10.6 0.2 0.5 0.1 0.3 0.1 0.0 0.0 0.1 0.0 0.3 0.3 0.1 0.3 0.2 0.3 0.2 0.2 0.1 0.2 0.5 0.4 0.2 0.1 0.4 0.2 0.4 0.4 0.2 0.3 0.2 0.3 0.5 0.2 0.3 0.4 0.3 0.2 0.6 0.2 0.5 0.2 0.2 0.3 0.3 0.6 0.4 0.2 0.2 0.4 0.1 0.2 0.1 0.3 0.2 0.2 0.3 0.4 0.4 6.8 0.1 0.2 0.4 0.4 0.3 0.2 0.1 0.4 0.2 0.3 0.1 0.5 0.2 0.3 0.3 0.3 0.2 1.1 0.1 0.3 0.2 0.1 0.3 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.7 0.4 0.2 0.4 0.2 0.1 2.9 2.5 8.8 3.5 1.5 2.6 2.2 5.2 1.0 1.7 10.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 29.2 0.0 0.0 0.0 0.0 0.0 41.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.7 0.0 0.0 0.0 23.5 0.0 0.0 0.0 0.0 29.7 0.0 0.2 0.0 10.3 0.0 0.0 0.0 1.5 2.0 0.0 0.0 0.7 0.7 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.6 0.4 0.0 0.0 0.0 1.0 0.0 0.0 0.2 OXTR ENSG00000180914 "Oxytocin receptor" P30559 3 8750381-8769628 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 10 "brain: 14.7;breast: 54.1" "Cell type enhanced" "Detected in many" "Breast myoepithelial cells: 122.6;Excitatory neurons: 25.8;Oligodendrocyte precursor cells: 21.1;Respiratory ciliated cells: 57.1" "Cancer enhanced" "Detected in many" "ovarian cancer: 7.0" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 421.2;BJ hTERT+: 127.9;BJ hTERT+ SV40 Large T+: 119.4;fHDF/TERT166: 424.5;HBF TERT88: 92.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" NA NA "Cluster 57: Non-specific - Angiogenesis" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 49: Ciliated cells - Cilium organization" "unprognostic (1.18e-1)" "unprognostic (7.94e-2)" "unprognostic (4.76e-2)" "unprognostic (1.29e-2)" "unprognostic (2.02e-2)" "unprognostic (2.02e-1)" "unprognostic (1.46e-2)" "unprognostic (2.56e-3)" "unprognostic (2.12e-1)" "unprognostic (3.42e-1)" "unprognostic (2.76e-1)" "unprognostic (3.80e-2)" "unprognostic (4.24e-4)" "unprognostic (8.25e-2)" "unprognostic (4.60e-2)" "unprognostic (2.71e-1)" "unprognostic (1.84e-1)" 0.4 0.2 4.0 0.1 8.1 0.6 54.1 3.3 4.1 0.5 0.3 0.2 0.1 3.5 0.3 1.6 3.0 0.3 0.5 3.1 13.7 0.5 0.2 0.9 0.2 14.7 12.4 3.1 0.1 0.1 0.3 0.5 6.6 0.8 0.1 2.7 0.2 0.8 0.2 0.2 0.2 0.5 12.0 0.3 0.2 0.3 13.7 0.3 0.3 0.1 0.1 0.8 0.2 3.7 1.1 4.6 2.5 0.5 0.5 1.2 0.8 421.2 127.9 119.4 63.4 0.6 11.3 0.3 0.9 424.5 1.7 0.9 2.0 0.9 92.4 3.9 2.1 1.1 1.9 0.7 2.2 1.0 1.0 0.7 0.5 1.7 0.9 36.1 0.2 1.3 0.2 0.8 67.5 0.3 0.9 3.3 2.7 1.4 18.7 0.9 1.6 25.5 4.5 0.4 0.7 0.8 0.7 0.9 0.2 8.1 0.3 0.6 0.6 5.9 1.5 1.2 1.2 0.7 1.2 0.2 0.6 1.4 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 4.0 8.1 3.3 4.1 3.1 13.7 14.7 12.4 6.6 12.0 13.7 3.7 1.3 9.6 1.1 3.3 0.3 0.4 0.6 1.0 0.0 0.8 2.3 122.6 1.5 1.5 6.5 0.0 0.0 0.2 0.4 0.3 0.0 2.7 1.4 4.7 0.6 0.7 0.0 0.0 25.8 0.0 0.1 2.0 0.0 0.9 0.0 4.3 1.4 0.0 0.2 0.0 14.0 0.0 2.0 0.0 0.0 2.0 0.0 3.1 0.0 5.6 0.1 7.9 0.0 21.1 15.4 1.2 0.1 0.4 0.2 2.2 0.0 0.1 57.1 0.2 0.0 2.0 16.9 1.0 1.8 0.0 0.1 0.0 0.3 3.1 0.1 0.3 P2RX4 P2X4 ENSG00000135124 "Purinergic receptor P2X 4" Q99571 12 121209861-121234106 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 135.3;Distal enterocytes: 133.7;Hofbauer cells: 129.5;Syncytiotrophoblasts: 155.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA039494 Enhanced NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 53: Intestinal epithelial cells - Unknown function" "HPA039494: AB_10969132" "unprognostic (4.02e-3)" "unprognostic (1.06e-1)" "unprognostic (5.43e-2)" "prognostic favorable (6.30e-10)" "unprognostic (2.98e-2)" "unprognostic (2.52e-1)" "unprognostic (2.06e-3)" "unprognostic (1.68e-1)" "unprognostic (1.21e-1)" "unprognostic (5.42e-2)" "unprognostic (7.71e-2)" "unprognostic (2.18e-1)" "unprognostic (1.81e-2)" "unprognostic (1.13e-1)" "unprognostic (6.06e-2)" "unprognostic (1.42e-2)" "unprognostic (4.76e-3)" 10.1 9.9 4.8 15.1 5.0 14.1 12.7 8.3 5.6 18.8 4.6 33.5 28.9 8.5 3.7 5.0 15.3 16.8 7.2 5.1 5.3 13.0 11.5 20.4 15.9 6.7 5.4 18.1 37.4 33.1 5.1 32.7 6.0 12.1 30.2 2.0 30.1 12.0 1.0 4.5 32.8 10.7 6.3 12.6 20.2 6.0 6.3 7.8 12.9 2.3 8.9 12.1 4.1 7.6 6.6 15.4 1.1 21.7 10.3 8.3 40.6 4.9 26.1 6.7 13.3 10.9 23.1 6.4 18.5 17.4 48.2 2.3 4.7 3.2 4.1 17.5 11.8 3.1 0.9 12.5 25.3 7.6 42.5 11.9 6.8 11.0 14.5 20.4 24.2 7.7 6.1 16.2 5.0 31.8 4.7 10.7 5.5 31.8 10.5 6.6 29.5 34.6 3.1 18.0 6.1 9.0 16.0 8.8 55.0 5.7 38.5 21.2 2.1 10.0 11.2 1.2 5.2 28.0 26.1 3.7 19.6 10.2 9.1 72.3 59.1 10.7 13.6 63.1 15.1 11.3 21.9 13.3 32.5 7.1 16.4 9.6 0.8 29.6 54.6 4.4 17.1 32.6 4.8 5.0 8.3 5.6 5.1 5.3 6.7 5.4 6.0 6.3 6.3 7.6 8.4 6.4 19.2 6.5 14.0 3.8 8.9 11.9 6.8 11.1 17.7 11.9 3.8 21.5 11.2 20.2 2.1 135.3 13.7 133.7 0.0 69.7 15.2 9.8 8.9 9.2 21.5 2.1 6.4 35.4 73.8 14.3 19.4 15.1 13.9 14.3 23.6 9.4 129.5 15.2 5.3 90.3 20.3 43.7 20.8 25.1 8.7 53.7 10.6 18.7 57.9 6.5 19.6 4.5 8.0 33.1 80.6 9.8 21.9 10.2 98.7 23.2 6.4 8.6 19.7 7.4 12.0 8.1 6.6 3.4 4.0 155.7 17.8 15.4 24.7 9.7 P2RY12 "HORK3, P2Y12, SP1999" ENSG00000169313 "Purinergic receptor P2Y12" Q9H244 3 151336843-151384753 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "Blood coagulation, Hemostasis" "G-protein coupled receptor, Receptor, Transducer" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 13.8;lymphoid tissue: 9.8" "Cell type enriched" "Detected in some" 27 "Microglial cells: 421.6" "Cancer enriched" "Detected in many" 14 "glioma: 17.3" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "intermediate monocyte: 8.3" "Group enriched" "Detected in many" 11 "dendritic cells: 3.2;monocytes: 8.3" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013796, HPA014518" Enhanced NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 68: Oligodendrocytes - Mixed function" "HPA013796: AB_1854884, HPA014518: AB_2669027" "unprognostic (2.39e-2)" "unprognostic (1.60e-3)" "unprognostic (5.93e-2)" "unprognostic (1.77e-1)" "unprognostic (2.41e-2)" "unprognostic (2.52e-2)" "unprognostic (8.09e-2)" "unprognostic (1.72e-3)" "unprognostic (6.46e-2)" "unprognostic (8.64e-4)" "unprognostic (4.84e-2)" "unprognostic (5.96e-2)" "unprognostic (2.03e-1)" "unprognostic (8.92e-2)" "unprognostic (1.65e-1)" "unprognostic (3.52e-2)" "unprognostic (4.04e-1)" 8.6 4.0 4.8 1.9 5.1 0.5 3.7 5.1 6.1 1.3 2.4 1.6 1.2 0.7 0.6 1.2 2.5 2.2 1.3 5.7 6.9 0.6 2.5 2.5 9.8 10.2 8.1 1.6 0.8 1.6 0.3 2.3 11.8 0.9 1.4 0.3 2.9 2.0 0.1 0.4 2.8 1.6 11.5 5.5 1.1 0.2 8.5 0.9 0.5 0.6 8.7 1.1 0.4 13.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 8.3 0.0 0.3 0.0 0.0 3.2 0.5 0.0 0.0 0.3 0.0 2.2 0.3 0.0 1.3 4.8 5.1 5.1 6.1 5.7 6.9 10.2 8.1 11.8 11.5 8.5 13.8 0.2 0.0 0.0 2.6 0.1 0.0 0.0 0.0 0.6 0.0 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 2.5 0.0 0.0 0.3 0.0 0.0 1.3 0.0 0.0 0.0 0.2 0.0 2.1 0.0 0.0 2.6 0.0 0.0 0.0 3.1 0.0 421.6 0.7 0.4 0.0 15.6 4.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 PAH PH ENSG00000171759 "Phenylalanine hydroxylase" P00439 12 102836889-102958410 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Phenylalanine catabolism" "Allosteric enzyme, Monooxygenase, Oxidoreductase" "Disease variant, FDA approved drug targets, Phenylketonuria" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 12 "kidney: 496.6;liver: 1408.4" "Group enriched" "Detected in some" 6 "Cholangiocytes: 250.2;Hepatocytes: 807.7;Proximal tubular cells: 344.4" "Cancer enriched" "Detected in some" 17 "liver cancer: 94.7" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 31 "Hep G2: 238.2" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA028407, HPA031642" Enhanced Approved "Endoplasmic reticulum,Vesicles" No NA 40000 "Cluster 85: Liver - Metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "Endoplasmic reticulum, Vesicles" "HPA028407: AB_10601241, HPA031642: AB_2673974" "unprognostic (1.16e-1)" "unprognostic (1.52e-1)" "unprognostic (4.47e-2)" "unprognostic (9.13e-3)" "unprognostic (5.19e-2)" "unprognostic (5.99e-2)" "prognostic favorable (4.30e-4)" "unprognostic (1.27e-1)" "unprognostic (6.60e-2)" "unprognostic (4.45e-3)" "unprognostic (1.94e-3)" "unprognostic (1.83e-1)" "unprognostic (1.10e-2)" "unprognostic (3.51e-1)" "unprognostic (1.64e-1)" "unprognostic (3.96e-2)" "unprognostic (1.68e-2)" 0.2 6.4 2.1 0.0 1.9 0.0 0.2 1.8 3.4 0.1 1.1 0.3 0.1 0.1 0.5 0.0 0.1 79.4 0.0 2.2 2.3 496.6 1408.4 0.0 0.1 2.8 2.3 0.1 9.2 0.8 3.0 0.0 2.3 1.5 0.0 2.4 0.1 0.1 0.0 0.0 0.1 0.0 2.6 0.3 0.4 3.3 2.5 0.7 0.6 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.7 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.3 238.2 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 0.3 0.2 1.0 0.1 0.2 0.6 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 1.9 1.8 3.4 2.2 2.3 2.8 2.3 2.3 2.6 2.5 2.8 0.0 0.0 0.0 1.0 2.7 0.0 0.0 0.0 0.0 1.4 0.2 0.1 0.5 250.2 0.0 5.5 0.0 0.0 0.0 0.0 21.5 2.4 66.8 0.0 0.1 1.1 1.8 21.5 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.9 807.7 0.0 3.3 2.3 0.0 0.0 22.2 0.0 15.7 0.6 1.8 0.0 0.0 0.0 0.6 0.0 4.5 0.0 0.0 0.0 1.2 0.0 0.4 0.0 344.4 0.0 0.2 0.0 0.0 0.0 2.1 0.4 0.0 0.0 0.0 3.3 0.0 0.0 0.1 PARP1 "ADPRT, ARTD1, PARP, PPOL" ENSG00000143799 "Poly(ADP-ribose) polymerase 1" P09874 1 226360210-226408154 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, Transcription, Transcription regulation" "DNA-binding, Glycosyltransferase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Cytotrophoblasts: 469.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727" Supported Supported Enhanced Nucleoplasm,Nucleoli NA NA 150000 "Cluster 43: B-cells - Humoral immune response" "Cluster 16: Immune cells - Immune response" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 47: Cytotrophoblasts - Unknown function" Nucleoplasm Nucleoli "CAB000147: AB_430876, CAB003839: AB_365493, CAB003840: AB_562187, CAB075726: AB_2665732, CAB075727: AB_2665733, HPA045168: AB_2679240" "unprognostic (2.02e-1)" "unprognostic (9.40e-2)" "unprognostic (7.44e-3)" "unprognostic (1.32e-1)" "unprognostic (4.29e-1)" "unprognostic (9.22e-2)" "prognostic unfavorable (3.40e-4)" "unprognostic (2.20e-1)" "unprognostic (3.62e-2)" "unprognostic (1.39e-1)" "unprognostic (2.13e-1)" "unprognostic (1.66e-1)" "prognostic unfavorable (1.35e-5)" "unprognostic (2.38e-2)" "unprognostic (1.82e-1)" "unprognostic (3.14e-2)" "unprognostic (2.64e-1)" 32.0 26.4 33.9 63.9 41.9 29.4 29.5 46.2 33.2 26.2 20.6 43.5 29.3 30.2 19.8 31.3 28.9 20.4 55.1 30.3 36.2 22.4 37.1 27.4 125.5 48.4 39.7 27.5 50.8 94.7 38.0 58.2 47.7 40.7 37.2 44.9 28.9 46.4 94.5 21.1 36.8 45.6 41.9 57.7 29.6 40.5 40.9 64.6 28.4 70.2 150.8 38.7 24.6 58.1 182.4 108.9 295.4 209.3 75.9 61.3 137.1 101.3 119.1 178.2 144.9 175.4 98.1 559.3 147.2 80.9 77.9 135.1 411.6 132.4 144.4 204.1 396.6 216.2 135.9 114.5 44.6 372.2 93.3 61.7 50.5 144.2 101.3 49.3 140.5 132.2 346.9 291.8 94.1 99.6 114.7 110.0 476.2 290.5 165.1 334.2 484.5 533.4 76.4 144.5 264.0 229.2 165.2 190.3 100.1 205.3 159.6 225.8 99.3 93.3 140.9 120.6 235.1 110.9 151.8 472.6 78.2 125.7 214.3 11.1 11.7 12.3 31.2 20.5 45.3 72.2 37.3 36.7 28.2 69.9 28.2 32.5 2.2 22.0 42.3 16.2 49.3 25.7 33.9 41.9 46.2 33.2 30.3 36.2 48.4 39.7 47.7 41.9 40.9 58.1 33.4 54.5 73.6 13.7 169.1 72.3 83.9 56.4 51.2 96.1 58.8 43.3 115.0 44.3 69.8 57.0 141.8 469.2 53.8 27.7 72.4 88.9 34.1 53.3 66.5 62.0 75.0 100.5 16.5 107.0 111.7 49.8 37.8 55.2 122.1 116.2 34.2 69.4 139.6 90.9 17.5 50.0 57.0 47.8 35.7 20.5 40.0 48.3 62.2 16.9 76.9 80.1 95.8 10.1 31.9 48.5 24.2 35.0 186.9 82.8 25.6 48.5 56.4 118.1 46.0 58.7 48.0 88.8 199.6 77.2 48.2 137.6 85.0 103.5 61.9 41.7 PARP2 "ADPRTL2, ARTD2" ENSG00000129484 "Poly(ADP-ribose) polymerase 2" Q9UGN5 14 20343615-20357904 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "DNA-binding, Glycosyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA052003 Approved Supported Nucleoplasm,Nucleoli NA Yes "Cluster 16: MAIT-cells - Unknown function" "Cluster 54: Non-specific - Microtubule organization" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 10: Non-specific - Unknown function" Nucleoplasm Nucleoli "HPA052003: AB_2681689" "unprognostic (3.93e-1)" "unprognostic (7.92e-2)" "unprognostic (4.12e-1)" "unprognostic (1.24e-1)" "unprognostic (3.40e-2)" "unprognostic (7.30e-2)" "prognostic unfavorable (6.48e-4)" "unprognostic (1.97e-2)" "unprognostic (4.43e-2)" "unprognostic (9.35e-3)" "unprognostic (1.44e-2)" "unprognostic (1.42e-2)" "unprognostic (3.37e-3)" "unprognostic (2.83e-1)" "unprognostic (9.19e-2)" "unprognostic (1.91e-1)" "unprognostic (2.89e-2)" 17.7 21.1 21.1 10.7 22.0 26.8 17.5 21.4 31.4 18.1 16.4 19.3 12.8 20.9 17.8 14.6 17.5 10.0 17.1 22.5 21.0 15.5 17.2 13.5 14.5 19.5 18.9 22.9 17.9 11.1 21.0 12.9 19.8 13.9 14.0 26.4 14.2 13.4 32.4 19.2 14.2 15.8 19.0 16.5 16.3 23.8 19.8 11.9 16.7 27.1 17.9 13.8 15.3 22.1 55.5 39.5 59.7 45.3 19.4 18.4 43.4 60.2 32.5 74.8 91.8 36.8 51.3 40.4 26.5 19.0 64.8 50.1 78.3 27.5 87.8 32.4 38.3 37.2 46.6 63.3 17.3 77.9 20.4 12.5 23.0 45.5 51.1 20.5 38.5 48.0 39.2 53.4 52.3 33.5 40.1 33.0 33.0 62.8 60.0 49.7 79.7 26.5 30.0 28.2 41.3 28.3 65.3 36.8 17.9 37.4 34.2 25.8 26.6 45.3 68.1 31.5 48.1 49.3 67.7 53.4 19.0 33.3 51.4 1.9 5.0 0.5 8.9 4.8 11.7 6.8 8.4 7.9 5.5 4.1 9.0 8.6 0.1 7.6 2.6 5.6 5.3 4.8 21.1 22.0 21.4 31.4 22.5 21.0 19.5 18.9 19.8 19.0 19.8 22.1 12.1 25.6 6.5 7.2 9.5 6.5 10.5 16.1 18.8 29.2 7.4 10.0 14.0 5.7 19.9 7.3 12.5 25.8 10.2 4.5 7.9 12.8 9.3 9.9 13.3 11.0 4.8 30.3 17.6 8.7 22.2 11.6 7.7 11.3 8.2 18.4 6.8 10.1 11.9 30.3 15.5 5.0 14.2 4.6 5.1 9.8 11.5 6.6 8.8 9.4 4.2 20.7 6.2 6.0 9.3 10.1 4.5 17.0 19.1 4.5 5.3 7.4 28.0 23.2 6.6 9.8 18.5 20.9 41.5 11.3 4.8 14.9 6.2 16.7 7.4 7.0 PARP3 "ADPRT3, ADPRTL3, ARTD3, hPARP-3, IRT1, pADPRT-3" ENSG00000041880 "Poly(ADP-ribose) polymerase family member 3" Q9Y6F1 3 51942345-51948867 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "DNA damage, DNA repair" "Glycosyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Proximal enterocytes: 33.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020984, HPA067657" Supported Supported "Nucleoplasm,Nuclear bodies" Yes No "Cluster 15: NK-cells - Transcription" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 45: Enterocytes - Digestion" "Nucleoplasm, Nuclear bodies" "HPA020984: , HPA067657: AB_2685881" "prognostic favorable (6.39e-5)" "unprognostic (1.25e-1)" "unprognostic (1.54e-2)" "unprognostic (2.85e-2)" "unprognostic (7.31e-2)" "unprognostic (1.56e-1)" "unprognostic (4.13e-1)" "unprognostic (3.53e-2)" "unprognostic (2.26e-1)" "unprognostic (2.01e-1)" "unprognostic (7.44e-3)" "unprognostic (4.30e-1)" "prognostic favorable (1.25e-8)" "unprognostic (5.63e-2)" "unprognostic (1.77e-1)" "unprognostic (1.40e-2)" "unprognostic (4.65e-3)" 16.0 33.4 12.7 9.9 13.5 3.1 15.3 12.9 14.6 9.6 14.4 17.1 28.1 11.4 5.9 10.4 11.2 11.3 13.6 11.6 14.2 21.2 29.2 13.4 10.9 13.8 14.9 8.9 4.4 35.8 10.9 5.9 13.7 14.6 10.2 4.7 14.5 15.5 15.8 7.5 25.2 9.3 12.9 14.8 16.4 5.4 14.9 8.2 19.6 17.6 8.0 15.4 10.8 12.4 10.0 6.6 2.0 17.3 17.8 30.0 4.8 15.4 29.0 23.1 24.9 3.9 28.1 14.1 4.5 29.4 12.6 1.6 5.0 14.5 9.1 34.8 1.2 7.8 15.1 13.2 18.8 5.3 10.9 24.4 12.4 16.2 9.1 35.7 10.8 10.2 3.5 14.7 19.9 3.4 4.6 12.5 2.4 4.2 16.4 7.3 2.8 13.9 14.0 13.5 2.0 6.4 16.3 4.8 10.7 1.4 6.5 5.9 24.0 42.5 9.9 7.4 10.4 22.5 26.0 6.0 27.2 14.4 13.6 0.0 1.6 1.2 2.4 3.0 2.2 6.3 2.6 1.8 2.6 2.5 3.6 3.5 0.1 5.7 1.6 0.9 3.2 1.8 12.7 13.5 12.9 14.6 11.6 14.2 13.8 14.9 13.7 12.9 14.9 12.4 5.3 6.4 10.0 6.2 8.1 2.7 10.6 15.9 21.1 2.0 8.6 8.9 7.4 8.6 8.6 0.0 0.0 0.6 2.1 13.1 7.9 9.7 7.8 2.4 3.8 5.3 3.0 1.7 2.6 6.3 0.4 4.7 17.3 2.7 4.5 0.8 2.5 9.5 3.7 0.0 3.0 11.3 6.1 3.2 2.2 15.3 4.7 3.7 7.2 3.7 5.0 3.8 0.0 1.0 1.8 11.5 6.5 1.5 4.9 4.3 33.4 20.6 9.5 2.1 6.6 4.1 5.7 3.4 3.3 7.8 1.4 0.5 5.9 1.6 13.8 9.3 PDE10A ENSG00000112541 "Phosphodiesterase 10A" Q9Y233 6 165327287-165988078 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Allosteric enzyme, Hydrolase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 11 "brain: 67.2" "Cell type enhanced" "Detected in many" "Excitatory neurons: 204.7;Inhibitory neurons: 209.6;Microglial cells: 89.0;Oligodendrocyte precursor cells: 48.7;Oligodendrocytes: 51.8" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 6 "basal ganglia: 67.2" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HeLa: 9.0;LHCN-M2: 12.5;RT4: 6.9;SH-SY5Y: 8.1;TIME: 11.3;U-2 OS: 7.0" "Region enriched" "Detected in all" 11 "basal ganglia: 350.1" "Region enriched" "Detected in all" 5 "basal ganglia: 194.1" "CAB045998, HPA047200" Supported NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB045998: AB_2162589, HPA047200: AB_2679981" "unprognostic (1.02e-1)" "unprognostic (3.63e-2)" "unprognostic (3.58e-2)" "unprognostic (2.91e-1)" "unprognostic (1.20e-1)" "unprognostic (1.25e-1)" "unprognostic (1.76e-1)" "unprognostic (1.23e-1)" "unprognostic (9.36e-2)" "unprognostic (6.03e-2)" "unprognostic (3.79e-2)" "unprognostic (9.24e-2)" "prognostic unfavorable (4.44e-7)" "unprognostic (3.59e-3)" "unprognostic (2.37e-2)" "unprognostic (3.44e-2)" "unprognostic (5.90e-3)" 2.6 1.3 3.1 0.8 67.2 0.0 2.3 5.5 10.7 1.3 0.0 1.0 0.2 2.0 2.4 0.4 2.4 1.5 3.6 2.1 2.5 3.8 0.3 1.0 0.5 1.6 2.3 2.3 0.5 0.5 2.7 2.5 0.9 1.7 0.2 1.9 0.4 1.7 0.4 0.3 0.7 2.1 0.5 1.4 1.1 3.4 9.6 0.3 6.0 0.5 0.4 3.2 0.9 0.1 0.0 2.4 5.5 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.3 0.8 0.0 0.0 0.0 3.8 0.1 2.2 0.0 0.0 0.1 3.9 0.0 9.0 0.0 0.4 0.0 0.0 0.0 0.0 0.6 0.0 0.0 5.5 0.0 0.0 0.0 12.5 0.3 0.9 0.0 1.1 0.0 4.7 1.5 5.8 0.0 5.9 6.9 1.8 8.1 0.0 0.0 0.4 0.7 0.0 0.0 11.3 0.1 7.0 0.5 0.0 0.0 0.0 0.0 0.1 0.0 3.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 67.2 5.5 10.7 2.1 2.5 1.6 2.3 0.9 0.5 9.6 0.1 13.8 0.0 0.0 10.4 0.1 0.4 3.3 0.4 0.0 7.2 0.3 0.3 7.3 0.0 1.2 5.5 2.1 7.8 0.0 0.0 3.9 2.0 14.3 0.2 1.7 13.4 0.0 0.0 204.7 0.0 6.1 6.6 1.1 0.4 1.3 0.1 7.9 0.0 0.8 16.8 209.6 0.0 0.0 0.0 0.0 14.9 0.0 0.2 1.8 89.0 0.0 12.6 0.0 48.7 51.8 0.1 0.0 0.4 0.0 17.9 0.0 7.2 0.9 1.1 0.0 12.4 5.0 8.8 2.1 0.1 0.3 2.9 0.1 1.6 0.1 6.9 PDE1B PDES1B ENSG00000123360 "Phosphodiesterase 1B" Q01064 12 54549601-54579239 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 8 "brain: 76.9" "Cell type enhanced" "Detected in many" "Excitatory neurons: 18.6;Inhibitory neurons: 10.2;Kupffer cells: 13.0;Macrophages: 9.4;Sertoli cells: 13.1;Smooth muscle cells: 13.7" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in many" 6 "basal ganglia: 76.9" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HDLM-2: 12.7;HMC-1: 14.9;NB-4: 10.7;THP-1: 9.0;U-937: 7.2" "Region enriched" "Detected in all" 6 "basal ganglia: 999.4" "Region enriched" "Detected in all" 7 "basal ganglia: 228.7" HPA018492 Enhanced NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 3: HMC-1 - Innate immune response" "Cluster 48: Smooth muscle cells - ECM organization" "HPA018492: AB_1855119" "unprognostic (2.90e-1)" "unprognostic (1.51e-1)" "unprognostic (7.67e-4)" "unprognostic (5.63e-3)" "unprognostic (7.02e-2)" "unprognostic (7.51e-2)" "unprognostic (1.97e-1)" "unprognostic (9.39e-2)" "unprognostic (1.14e-1)" "unprognostic (5.11e-2)" "unprognostic (3.84e-3)" "unprognostic (2.70e-2)" "prognostic unfavorable (4.77e-6)" "unprognostic (6.64e-4)" "unprognostic (2.14e-1)" "unprognostic (3.09e-1)" "unprognostic (2.83e-2)" 9.1 1.1 8.4 4.0 76.9 4.8 4.6 0.0 13.7 2.0 0.0 7.4 1.0 2.7 1.8 1.7 2.0 2.2 1.4 6.3 0.1 0.8 1.0 2.3 1.3 0.0 0.0 8.6 0.4 6.1 0.3 0.2 0.0 1.3 1.0 0.4 1.0 1.4 0.6 1.4 3.4 4.0 0.0 4.0 3.3 0.7 2.4 0.9 2.0 1.0 0.8 8.7 1.5 4.9 0.0 0.0 0.6 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.2 0.1 0.0 0.0 0.0 2.1 0.0 0.0 12.7 0.6 4.3 0.0 0.0 0.0 5.5 14.9 0.7 0.0 0.0 0.0 0.0 0.0 5.5 0.0 2.3 0.0 0.0 0.5 10.7 3.5 0.0 0.0 2.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 9.0 0.0 0.0 0.3 0.0 0.0 0.1 0.2 2.5 0.0 7.2 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.4 76.9 0.0 13.7 6.3 0.1 0.0 0.0 0.0 0.0 2.4 4.9 2.3 0.0 1.1 1.6 1.8 1.0 0.2 0.0 0.6 2.7 0.2 0.6 3.6 0.0 0.6 3.7 0.0 0.1 1.4 0.0 0.0 0.0 6.3 0.1 0.0 0.8 1.8 3.6 18.6 0.0 0.0 1.5 0.0 0.0 0.0 4.4 0.0 0.3 8.5 5.0 10.2 0.0 0.0 13.0 2.5 4.9 2.1 9.4 0.0 2.8 6.7 0.1 4.1 1.0 0.9 0.0 0.0 3.0 2.6 0.4 0.0 0.0 0.0 0.2 13.1 0.6 13.7 0.8 0.6 0.2 0.4 0.3 2.8 0.4 0.1 0.1 PDE3A CGI-PDE ENSG00000172572 "Phosphodiesterase 3A" Q14432 12 20368537-20688583 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins" Hydrolase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 43.4" "Cell type enhanced" "Detected in many" "Astrocytes: 98.2;Bipolar cells: 38.4;Cardiomyocytes: 131.3;Horizontal cells: 52.2;Inhibitory neurons: 78.8;Smooth muscle cells: 49.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 8.6;HEL: 15.3;HeLa: 42.5;HUVEC TERT2: 7.4;SH-SY5Y: 17.9;U-138 MG: 11.9" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "cerebellum: 18.8" "HPA014492, HPA074258" Approved Approved "Plasma membrane" NA NA 37000000 "Cluster 46: Fibroblasts - ECM organization" "Cluster 20: HeLa - Mitochondria" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Plasma membrane" "HPA014492: AB_1855120, HPA074258: " "unprognostic (2.59e-2)" "unprognostic (2.94e-2)" "unprognostic (1.25e-1)" "unprognostic (3.23e-1)" "unprognostic (2.27e-1)" "unprognostic (1.21e-1)" "unprognostic (3.50e-2)" "unprognostic (1.67e-2)" "unprognostic (8.14e-2)" "unprognostic (1.49e-1)" "unprognostic (4.25e-1)" "unprognostic (3.37e-1)" "prognostic unfavorable (1.72e-6)" "unprognostic (5.58e-2)" "unprognostic (5.94e-2)" "unprognostic (4.28e-2)" "unprognostic (2.76e-4)" 6.5 1.0 1.6 3.1 1.3 0.2 3.8 3.1 1.3 6.7 1.8 15.0 1.9 4.2 1.4 2.2 4.1 4.7 43.4 1.3 1.5 3.3 1.3 3.9 1.0 1.9 2.3 3.4 6.2 0.6 2.1 11.3 1.2 5.4 7.6 5.7 2.7 3.5 2.2 1.3 9.6 5.2 1.6 2.2 5.1 0.4 2.5 0.6 2.8 1.8 0.5 2.5 3.1 1.4 0.0 0.2 8.6 0.0 1.9 1.3 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 15.3 42.5 0.2 0.6 0.0 0.0 1.8 0.0 0.4 0.1 0.1 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.4 0.0 1.1 0.0 0.0 0.0 2.7 0.0 0.1 17.9 0.0 0.0 0.1 3.3 0.0 0.0 0.3 11.9 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 1.3 3.1 1.3 1.3 1.5 1.9 2.3 1.2 1.6 2.5 1.4 2.7 0.0 0.0 98.2 0.0 0.3 0.2 0.0 0.6 38.4 0.2 0.3 131.3 4.3 0.6 0.0 0.0 0.0 0.0 28.4 0.0 5.8 0.7 0.5 1.6 3.9 4.2 0.0 4.1 0.5 0.0 11.3 0.0 1.4 17.1 0.0 2.2 0.0 0.7 52.2 78.8 7.0 0.0 0.0 0.7 0.6 1.5 3.1 1.8 27.2 0.5 4.4 0.0 27.6 3.9 0.4 26.9 0.7 0.0 0.5 33.4 3.1 0.0 2.8 6.6 3.6 49.9 0.3 0.9 0.9 0.3 0.0 0.6 0.5 16.4 0.2 PDE3B HcGIP1 ENSG00000152270 "Phosphodiesterase 3B" Q13370 11 14643804-14872044 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins" Angiogenesis Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 64.5" "Cell type enhanced" "Detected in many" "Astrocytes: 171.7;Excitatory neurons: 140.5;Inhibitory neurons: 158.0;Microglial cells: 192.0;Oligodendrocyte precursor cells: 118.6" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 5 "cerebellum: 13.5" "Low immune cell specificity" "Detected in many" "Group enriched" "Detected in many" 5 "granulocytes: 3.8;T-cells: 6.3" "Cell line enhanced" "Detected in many" "HL-60: 23.5;Karpas-707: 25.7;THP-1: 28.4;U-266/70: 28.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA056111 Approved "Endoplasmic reticulum" NA NA "Cluster 32: T-cells - Unknown function" "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 29: U-266 - Adaptive immune response" "Cluster 24: Non-specific - Transcription regulation" "Endoplasmic reticulum" "HPA056111: AB_2683041" "unprognostic (1.05e-1)" "unprognostic (2.86e-2)" "unprognostic (4.12e-2)" "unprognostic (2.76e-3)" "unprognostic (4.25e-1)" "unprognostic (1.84e-3)" "unprognostic (3.40e-2)" "unprognostic (3.24e-2)" "unprognostic (5.39e-2)" "unprognostic (1.20e-1)" "prognostic favorable (7.91e-4)" "unprognostic (1.77e-1)" "unprognostic (2.33e-2)" "unprognostic (1.39e-2)" "unprognostic (3.42e-1)" "unprognostic (2.47e-1)" "unprognostic (9.03e-3)" 64.5 1.1 1.3 12.4 2.1 10.1 12.2 13.5 2.6 3.4 0.0 25.2 2.9 0.7 0.5 2.9 0.5 3.7 4.7 1.9 2.6 3.0 25.8 10.2 14.9 2.8 1.7 0.5 8.3 0.2 4.4 7.6 1.9 8.7 10.7 0.5 14.0 1.6 0.4 0.5 6.0 1.7 2.3 8.9 2.6 9.6 2.0 7.3 0.8 2.4 7.9 8.5 1.9 2.6 0.0 2.5 5.6 9.2 10.9 0.1 2.2 0.6 0.1 0.0 0.0 8.5 0.0 0.0 0.1 0.0 2.6 0.0 8.5 0.0 0.0 0.2 18.7 0.3 13.1 17.5 3.9 23.5 0.1 0.8 0.0 0.0 0.5 0.0 0.1 6.6 20.6 25.7 0.0 0.3 4.7 11.4 7.6 3.1 4.1 11.0 2.5 17.7 0.0 1.9 8.5 15.8 2.3 14.6 5.1 2.5 0.0 28.4 0.0 0.0 1.3 0.0 0.0 28.8 9.4 0.7 0.2 4.0 1.7 0.0 0.5 2.5 1.0 0.6 2.1 0.2 3.1 2.4 0.3 0.1 6.3 5.7 3.8 0.1 1.0 0.1 3.5 1.5 1.3 2.1 13.5 2.6 1.9 2.6 2.8 1.7 1.9 2.3 2.0 2.6 1.5 16.0 8.9 171.7 6.4 0.3 0.9 0.0 0.6 1.0 0.3 0.3 11.1 0.0 6.2 1.8 0.0 1.4 26.7 11.5 1.9 0.0 19.0 0.3 5.1 4.0 1.2 12.8 140.5 5.0 2.8 9.7 7.7 0.3 36.1 0.5 4.2 64.1 7.6 0.0 158.0 13.7 0.0 13.1 3.7 13.4 1.5 15.6 0.0 192.0 10.8 6.3 8.2 118.6 5.4 1.8 22.3 9.1 28.9 3.3 0.7 2.0 3.6 0.5 0.0 3.4 3.0 48.8 19.5 0.1 0.1 2.5 60.9 0.0 9.4 1.1 PDE4A DPDE2 ENSG00000065989 "Phosphodiesterase 4A" P27815 19 10416773-10469630 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Langerhans cells: 190.8;Late spermatids: 197.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "HMC-1: 36.5;NB-4: 43.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017632, HPA043310, HPA076091" Uncertain Supported "Nucleoplasm,Plasma membrane" NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 47: Non-specific - Unknown function" "Cluster 3: HMC-1 - Innate immune response" "Cluster 25: Spermatids - Spermatogenesis" "Plasma membrane" Nucleoplasm "CAB017632: AB_1127109, HPA043310: AB_2678419, HPA076091: AB_2686775" "unprognostic (1.29e-2)" "unprognostic (3.98e-2)" "unprognostic (8.91e-2)" "unprognostic (1.82e-1)" "unprognostic (7.00e-2)" "unprognostic (6.84e-2)" "unprognostic (1.54e-2)" "unprognostic (4.39e-2)" "unprognostic (7.91e-2)" "unprognostic (1.52e-2)" "unprognostic (6.90e-2)" "unprognostic (2.41e-1)" "unprognostic (2.27e-2)" "unprognostic (1.64e-2)" "unprognostic (2.57e-2)" "unprognostic (1.67e-1)" "unprognostic (2.15e-1)" 13.7 5.6 10.9 5.9 12.5 5.4 9.7 3.0 32.3 12.4 0.0 11.0 2.7 9.8 1.4 4.1 7.5 6.6 12.5 11.8 7.9 7.0 2.5 13.0 3.2 21.9 7.1 1.5 12.7 22.2 3.9 6.5 20.8 8.4 4.0 5.3 9.8 4.8 37.9 5.4 6.5 6.2 1.1 8.2 12.9 24.5 13.0 1.6 11.0 16.9 2.6 8.2 8.2 15.7 0.1 2.5 0.5 6.7 18.7 11.1 3.7 5.6 11.1 0.7 1.9 6.0 5.4 2.6 16.1 14.6 0.4 0.6 3.9 0.7 0.4 6.7 5.5 23.7 8.1 6.7 12.3 3.9 36.5 8.3 0.8 6.2 0.0 0.7 5.3 2.1 18.9 5.5 4.0 1.7 2.3 43.3 2.9 6.7 4.7 15.6 3.7 20.3 0.9 1.4 4.2 1.5 0.4 0.2 6.2 1.0 0.8 7.8 11.2 8.3 10.5 5.7 3.7 10.9 0.9 12.4 3.5 0.3 6.7 4.1 1.7 3.4 0.8 2.5 0.4 0.1 0.3 1.1 2.0 0.0 0.0 0.4 0.1 3.0 2.7 0.1 0.7 1.1 10.9 12.5 3.0 32.3 11.8 7.9 21.9 7.1 20.8 1.1 13.0 15.7 9.4 3.2 11.6 6.2 10.8 10.1 2.6 2.5 1.8 25.6 6.4 4.3 7.7 8.6 5.5 9.2 0.0 0.5 58.9 7.1 0.0 3.1 48.9 2.1 20.7 8.6 0.0 1.7 39.4 12.9 4.8 12.1 7.1 3.6 31.8 0.3 10.4 0.9 10.2 55.5 43.5 5.1 6.1 22.1 190.8 197.0 17.4 53.9 14.2 12.2 15.4 1.2 22.6 12.5 1.5 12.3 3.8 18.0 27.0 3.0 0.1 0.2 6.9 3.6 6.6 9.0 10.2 8.6 8.5 0.5 8.1 0.4 37.0 1.0 6.8 1.3 PDE4B DPDE4 ENSG00000184588 "Phosphodiesterase 4B" Q07343 1 65792514-66374579 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 75.5;brain: 109.1" "Group enriched" "Detected in many" 5 "Oligodendrocyte precursor cells: 1722.6;Oligodendrocytes: 4039.6" "Cancer enhanced" "Detected in all" "glioma: 18.9" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "neutrophil: 88.9" "Group enriched" "Detected in all" 5 "B-cells: 37.4;granulocytes: 88.9;T-cells: 34.7" "Cell line enhanced" "Detected in many" "AN3-CA: 61.8;HUVEC TERT2: 93.2;NTERA-2: 56.1;SK-MEL-30: 58.6;TIME: 52.6;U-266/84: 51.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA003005 Uncertain Approved "Golgi apparatus,Cytosol" NA NA "Cluster 1: Neutrophils - Mixed function" "Cluster 70: Brain - Nervous system development" "Cluster 12: NES - Nervous system development" "Cluster 42: Oligodendrocytes - Myelin sheath organization" "Golgi apparatus" Cytosol "HPA003005: AB_1079587" "unprognostic (7.86e-2)" "unprognostic (3.13e-1)" "unprognostic (4.62e-2)" "unprognostic (2.90e-1)" "unprognostic (3.21e-1)" "unprognostic (3.33e-3)" "unprognostic (1.35e-1)" "unprognostic (1.15e-3)" "unprognostic (1.04e-2)" "unprognostic (6.10e-2)" "unprognostic (8.78e-2)" "unprognostic (4.24e-2)" "prognostic unfavorable (5.04e-4)" "unprognostic (2.89e-2)" "unprognostic (3.54e-1)" "unprognostic (9.04e-3)" "unprognostic (8.33e-3)" 18.3 3.1 40.1 39.5 82.5 75.5 20.0 63.3 53.5 7.2 1.6 8.3 4.6 8.3 1.1 4.5 4.2 10.1 21.4 45.7 68.4 5.4 10.9 14.7 23.2 85.9 74.4 2.1 1.6 1.4 3.8 17.2 78.5 23.0 10.5 14.1 21.1 12.1 44.3 8.9 12.2 12.4 66.4 22.6 5.1 3.8 62.9 14.0 7.2 15.0 19.9 32.1 4.6 109.1 0.2 18.5 34.7 61.8 1.6 1.7 0.1 11.5 13.3 10.1 13.4 0.0 0.0 5.3 0.2 20.7 0.4 0.1 0.3 0.0 9.7 15.5 0.1 0.3 5.2 0.0 1.2 13.1 0.0 3.4 0.5 4.5 0.2 1.6 93.2 0.0 0.0 3.3 4.7 0.3 0.0 7.5 56.1 0.0 0.7 2.6 6.2 3.6 8.7 0.0 0.2 26.6 0.0 3.0 58.6 2.9 0.2 4.5 52.6 7.2 1.9 4.6 1.9 1.5 51.6 19.3 8.6 13.4 3.7 10.8 6.8 22.0 10.1 5.8 19.5 36.8 19.4 14.8 6.2 37.4 21.3 15.0 88.9 11.3 5.7 6.4 34.7 9.6 40.1 82.5 63.3 53.5 45.7 68.4 85.9 74.4 78.5 66.4 62.9 109.1 24.7 9.6 12.2 531.8 233.3 20.3 28.4 0.5 27.9 40.9 51.6 34.3 25.4 0.0 6.9 5.5 0.0 7.3 79.8 0.4 0.0 0.8 14.4 1.7 14.9 36.8 4.2 0.0 315.6 0.9 2.0 20.2 9.7 4.2 15.2 0.2 11.7 2.4 13.0 114.4 559.7 1.9 8.2 40.6 187.4 9.4 0.3 176.9 51.6 173.3 67.0 19.3 1.0 1722.6 4039.6 0.1 0.4 2.6 351.9 93.6 0.0 2.1 1.5 4.0 0.0 54.0 10.3 0.7 0.8 4.8 8.1 5.6 143.1 0.4 1.3 9.4 PDE4C DPDE1 ENSG00000105650 "Phosphodiesterase 4C" Q08493 19 18208652-18248200 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" Hydrolase "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "tongue: 21.3" "Cell type enhanced" "Detected in many" "Distal enterocytes: 255.9;Gastric mucus-secreting cells: 141.2;Paneth cells: 251.4;Proximal enterocytes: 73.0;Skeletal myocytes: 106.5;Undifferentiated cells: 103.3" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in some" 4 "basal ganglia: 1.2;cerebral cortex: 1.1" "Immune cell enhanced" "Detected in single" "basophil: 1.0" "Lineage enriched" "Detected in single" 4 "granulocytes: 1.0" "Cell line enhanced" "Detected in some" "BEWO: 2.9;Hep G2: 2.0;U-87 MG: 4.4" "HPA048975, HPA054218" Approved Approved "Midbody ring,Centrosome,Cytosol" Yes NA "Cluster 17: Basophils - Unknown function" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 53: Intestinal epithelial cells - Unknown function" "Centrosome, Cytosol" "Midbody ring" "HPA048975: AB_2680581, HPA054218: " "unprognostic (4.20e-2)" "unprognostic (4.02e-2)" "unprognostic (1.20e-1)" "unprognostic (1.27e-1)" "unprognostic (5.22e-4)" "unprognostic (1.44e-2)" "unprognostic (7.70e-2)" "unprognostic (1.15e-1)" "unprognostic (4.01e-2)" "unprognostic (5.69e-2)" "unprognostic (2.50e-3)" "unprognostic (2.21e-1)" "unprognostic (7.25e-10)" "unprognostic (2.73e-2)" "unprognostic (2.65e-1)" "unprognostic (9.21e-2)" "unprognostic (2.45e-2)" 1.4 0.6 0.2 0.1 1.2 0.5 0.7 0.0 1.1 3.2 0.0 4.3 0.7 3.4 3.4 0.7 3.0 1.1 4.4 0.2 0.0 4.8 1.3 3.4 0.2 0.0 0.0 1.8 0.7 0.2 2.8 3.7 0.0 2.3 0.6 0.2 0.5 2.7 8.3 0.3 2.4 1.8 0.0 2.1 3.8 2.5 0.0 0.0 1.1 21.3 0.1 1.0 1.7 0.0 0.0 0.1 0.0 0.1 0.0 0.1 2.9 0.0 0.0 0.1 0.1 0.6 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 2.0 0.1 0.0 0.2 0.3 0.0 1.2 0.0 0.2 0.0 0.1 0.4 0.9 0.0 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.4 0.1 0.2 0.0 0.7 0.2 0.2 0.0 0.1 0.0 0.3 0.0 0.6 0.3 0.1 4.4 0.1 0.0 1.0 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.7 0.2 0.1 0.1 0.0 0.0 0.2 1.2 0.0 1.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 3.2 10.6 2.0 0.8 5.5 5.8 8.6 5.2 3.9 0.2 0.4 35.3 4.3 22.4 0.0 6.2 2.1 0.0 255.9 0.0 0.0 32.9 0.1 0.1 4.6 7.2 0.0 8.2 0.0 4.3 6.3 141.2 0.1 4.5 0.0 1.1 0.3 0.5 0.0 2.1 55.2 4.1 1.4 4.5 38.4 0.6 2.1 1.8 0.0 0.4 1.9 1.0 0.5 0.9 0.0 251.4 4.1 1.6 1.8 73.0 0.0 9.4 3.0 46.0 106.5 17.2 1.9 2.2 28.6 3.8 1.1 1.2 0.0 103.3 17.3 PDE4D DPDE3 ENSG00000113448 "Phosphodiesterase 4D" Q08499 5 58969038-60522120 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" Hydrolase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 74.9;skeletal muscle: 70.4" "Cell type enhanced" "Detected in many" "Astrocytes: 619.3;Excitatory neurons: 2969.7;Inhibitory neurons: 1116.9;Oligodendrocyte precursor cells: 848.0;Oligodendrocytes: 443.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in many" 5 "eosinophil: 57.9" "Lineage enriched" "Detected in many" 5 "granulocytes: 57.9" "Cell line enhanced" "Detected in many" "A549: 62.2;AN3-CA: 70.4;HeLa: 104.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA045895 Uncertain Supported "Plasma membrane,Cytosol" NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 59: Non-specific - Translation" "Cluster 20: HeLa - Mitochondria" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" Cytosol "HPA045895: AB_10960275" "unprognostic (1.14e-1)" "unprognostic (8.73e-3)" "unprognostic (4.35e-2)" "unprognostic (7.87e-2)" "unprognostic (5.97e-2)" "unprognostic (2.03e-1)" "unprognostic (8.10e-4)" "unprognostic (1.17e-1)" "unprognostic (6.59e-2)" "unprognostic (1.84e-1)" "unprognostic (2.71e-1)" "unprognostic (2.65e-1)" "prognostic favorable (4.00e-5)" "unprognostic (1.51e-1)" "unprognostic (8.20e-2)" "unprognostic (1.77e-2)" "unprognostic (2.56e-2)" 8.9 1.3 3.3 9.8 9.9 74.9 4.6 0.0 11.3 5.3 0.0 21.0 5.5 7.4 18.4 13.7 7.3 9.1 15.7 4.4 4.2 17.2 2.8 13.3 5.3 7.0 2.0 3.0 3.7 5.5 6.7 16.6 1.2 19.9 15.0 21.4 7.4 21.2 70.4 4.5 7.0 15.3 0.8 4.0 10.3 3.4 3.8 8.6 7.4 34.4 5.6 22.0 8.2 5.7 0.1 62.2 12.8 70.4 2.3 4.4 10.1 1.6 1.8 3.4 4.9 24.5 2.0 4.8 0.2 0.5 10.3 10.6 0.0 2.8 5.9 2.9 7.0 9.2 104.6 5.3 9.1 4.4 0.7 9.3 2.3 9.6 1.7 1.1 7.3 0.3 0.0 1.6 5.9 4.5 3.6 10.3 2.4 1.8 3.2 1.2 16.0 10.5 15.9 23.5 2.3 8.0 16.4 27.1 14.2 11.4 1.9 9.3 8.5 0.9 0.2 12.0 3.3 3.5 0.1 0.5 10.3 17.3 2.7 4.2 2.0 57.9 1.5 0.1 1.5 11.0 1.4 0.7 1.4 11.3 0.9 0.7 3.1 0.4 0.2 0.0 0.8 1.1 3.3 9.9 0.0 11.3 4.4 4.2 7.0 2.0 1.2 0.8 3.8 5.7 22.5 32.1 110.0 619.3 32.3 10.6 30.1 6.6 35.3 20.2 5.1 2.7 35.7 8.6 30.2 42.3 73.0 11.3 118.6 28.1 11.7 0.6 21.4 19.0 8.6 16.9 33.4 2.1 2969.7 1.8 25.7 27.5 40.2 21.9 22.2 0.3 17.2 0.8 5.2 1.7 1116.9 18.2 6.1 4.8 11.1 36.6 1.5 29.5 10.6 407.5 6.0 12.0 29.9 848.0 443.3 8.2 11.9 4.9 44.4 43.3 8.9 27.5 19.4 52.8 0.0 64.0 6.3 1.1 7.7 40.6 8.8 3.1 94.3 1.1 11.7 26.5 PDE5A ENSG00000138735 "Phosphodiesterase 5A" O76074 4 119494397-119628804 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Allosteric enzyme, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Excitatory neurons: 66.1;Inhibitory neurons: 58.3;Oligodendrocyte precursor cells: 56.8;Peritubular cells: 104.9;Smooth muscle cells: 80.9" "Group enriched" "Detected in all" 4 "prostate cancer: 7.0;thyroid cancer: 27.3" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ hTERT+: 47.5;HHSteC: 65.9;hTERT-RPE1: 24.6" "Region enhanced" "Detected in all" "cerebellum: 18.2" "Low region specificity" "Detected in all" "HPA004729, HPA012873" Approved Approved Cytosol NA NA 850000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 12: Smooth muscle tissue - Mixed function" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 48: Smooth muscle cells - ECM organization" Cytosol "HPA004729: AB_1079588, HPA012873: AB_1855124" "unprognostic (6.95e-2)" "prognostic favorable (5.20e-4)" "unprognostic (1.28e-1)" "unprognostic (1.56e-1)" "unprognostic (1.25e-1)" "unprognostic (3.66e-2)" "unprognostic (7.36e-2)" "unprognostic (2.58e-2)" "unprognostic (2.29e-2)" "unprognostic (6.97e-2)" "unprognostic (2.05e-2)" "unprognostic (2.54e-1)" "unprognostic (2.16e-2)" "unprognostic (1.52e-2)" "unprognostic (8.98e-2)" "unprognostic (8.71e-3)" "prognostic unfavorable (1.17e-4)" 15.4 11.3 0.9 10.9 3.5 2.1 9.6 4.9 3.7 32.7 12.6 37.0 15.5 14.4 41.5 41.3 22.9 10.4 12.8 1.4 3.6 5.9 1.5 22.1 6.4 4.9 8.2 5.4 12.4 8.3 3.5 13.2 5.2 59.8 25.9 9.6 9.8 49.8 6.9 5.0 18.9 11.4 0.0 5.8 9.6 9.4 3.4 3.7 16.8 5.6 3.5 14.6 15.8 1.9 16.7 0.8 11.0 1.2 3.7 5.5 1.9 10.7 47.5 0.5 1.0 1.0 1.3 1.6 0.5 13.4 3.0 5.8 3.5 1.7 1.3 0.4 7.4 18.5 2.6 0.9 65.9 3.9 1.7 6.1 3.3 1.1 0.1 24.6 1.4 3.7 2.0 2.9 1.6 0.9 5.0 0.6 2.3 1.8 2.8 0.7 5.9 4.3 4.1 4.9 4.3 8.8 13.0 15.3 1.3 8.1 2.7 2.1 2.5 6.2 5.2 3.4 1.5 4.1 2.0 1.5 5.9 1.0 0.9 0.0 0.0 0.0 0.1 0.0 0.5 0.4 0.3 0.1 0.0 0.3 0.1 0.2 0.4 0.2 0.1 0.1 0.1 1.2 0.9 3.5 4.9 3.7 1.4 3.6 4.9 8.2 5.2 0.0 3.4 1.9 7.8 6.4 3.9 19.9 1.3 3.4 2.8 1.1 5.7 8.1 11.0 8.4 5.5 14.3 3.7 1.8 14.6 0.4 0.9 15.5 0.0 15.8 30.6 5.0 12.6 7.8 2.4 0.0 66.1 2.9 0.3 28.1 1.1 3.9 1.3 1.6 0.7 0.9 0.3 5.0 58.3 9.5 2.0 0.0 3.5 11.5 20.8 11.3 5.4 40.3 1.3 28.5 2.1 56.8 41.1 3.9 10.3 104.9 1.4 3.6 7.9 0.5 0.8 5.8 19.7 5.5 80.9 5.4 6.3 3.5 2.4 0.3 1.7 7.0 11.1 2.6 PDGFRA "CD140a, GAS9, PDGFR2" ENSG00000134853 "Platelet derived growth factor receptor alpha" P16234 4 54229280-54298245 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" "Chemotaxis, Host-virus interaction" "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "ovary: 190.2" "Group enriched" "Detected in many" 8 "Endometrial stromal cells: 423.9;Fibroblasts: 256.4;Leydig cells: 449.8;Oligodendrocyte precursor cells: 499.6;Peritubular cells: 408.9" "Cancer enhanced" "Detected in all" "glioma: 30.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC diff: 468.1;ASC TERT1: 216.1;BJ hTERT+: 279.4;fHDF/TERT166: 195.9;HHSteC: 156.3;HSkMC: 392.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004947, CAB018143" Supported Approved "Nucleoplasm,Plasma membrane,Cell Junctions" "Intracellular and membrane" NA NA 300000 "Cluster 34: Basophils - Unknown function" "Cluster 89: Fibroblasts - ECM organization" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 36: Stromal cells - Cell proliferation" "Nucleoplasm, Plasma membrane, Cell Junctions" "CAB018143: AB_2162351, HPA004947: AB_2732399" "unprognostic (1.67e-1)" "unprognostic (9.35e-2)" "unprognostic (4.59e-3)" "unprognostic (1.60e-1)" "unprognostic (8.92e-2)" "prognostic favorable (9.33e-4)" "unprognostic (1.24e-1)" "unprognostic (2.00e-2)" "unprognostic (1.46e-1)" "unprognostic (2.18e-2)" "unprognostic (2.18e-1)" "unprognostic (7.01e-2)" "prognostic unfavorable (9.79e-6)" "unprognostic (9.58e-3)" "unprognostic (9.87e-2)" "unprognostic (2.16e-2)" "unprognostic (1.72e-3)" 46.0 28.9 13.9 40.4 13.7 1.6 40.1 8.1 12.8 50.8 18.1 37.7 22.4 44.3 21.8 22.5 50.9 38.5 32.1 11.9 11.0 26.5 16.0 37.9 8.5 16.7 11.9 190.2 13.4 3.0 3.7 62.7 15.1 15.0 35.2 5.3 16.6 18.9 9.6 14.8 31.3 48.1 12.1 46.2 29.4 13.6 8.9 7.6 16.5 41.9 7.2 63.9 38.0 20.0 0.1 0.0 1.0 0.8 468.1 216.1 0.5 25.4 279.4 0.1 0.7 67.6 0.5 0.5 0.5 195.9 0.8 0.6 19.6 0.2 0.1 2.6 1.0 0.7 0.7 1.2 156.3 0.3 0.4 392.0 0.0 31.4 0.0 5.4 0.0 0.7 0.6 0.9 1.1 0.1 0.4 1.2 3.5 0.3 1.1 0.5 0.1 0.1 0.0 0.4 0.6 37.9 0.0 0.5 0.2 2.0 0.7 0.1 0.8 84.9 3.2 93.9 0.2 0.4 0.1 0.8 2.6 0.1 2.2 0.7 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 13.9 13.7 8.1 12.8 11.9 11.0 16.7 11.9 15.1 12.1 8.9 20.0 11.1 0.0 0.5 0.3 0.6 17.1 0.6 2.4 1.2 5.5 4.3 3.2 4.8 0.0 0.8 0.0 0.0 1.4 0.9 0.1 1.9 4.2 2.2 11.7 423.9 5.7 0.0 0.0 1.1 6.7 2.0 256.4 5.1 9.0 0.0 2.6 26.0 1.0 3.1 0.0 19.5 0.2 10.2 0.6 27.3 17.2 449.8 5.4 23.2 39.4 4.7 17.5 0.0 499.6 0.4 20.0 0.0 408.9 0.2 0.9 0.0 0.1 0.5 0.6 0.0 25.7 13.9 1.0 3.4 8.1 15.8 1.4 2.5 49.6 0.0 1.0 PDGFRB "CD140b, JTK12, PDGFR, PDGFR1" ENSG00000113721 "Platelet derived growth factor receptor beta" P09619 5 150113839-150155872 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins" Chemotaxis "Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enriched" "Detected in many" 4 "Sertoli cells: 1288.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in single" "non-classical monocyte: 1.6" "Low lineage specificity" "Detected in single" "Group enriched" "Detected in many" 4 "ASC diff: 1350.1;ASC TERT1: 462.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003842, CAB018144, HPA028499" Enhanced Supported "Golgi apparatus,Vesicles" NA NA 39000000 "Cluster 14: Monocytes - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 48: Smooth muscle cells - ECM organization" Vesicles "Golgi apparatus" "CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018" "unprognostic (4.75e-2)" "unprognostic (2.48e-1)" "unprognostic (5.21e-2)" "unprognostic (3.60e-2)" "unprognostic (3.27e-1)" "unprognostic (5.61e-2)" "unprognostic (1.02e-1)" "unprognostic (3.36e-2)" "unprognostic (2.12e-2)" "unprognostic (2.57e-3)" "unprognostic (6.72e-2)" "unprognostic (1.25e-1)" "prognostic unfavorable (5.87e-8)" "unprognostic (3.13e-3)" "unprognostic (1.25e-2)" "unprognostic (5.47e-2)" "prognostic unfavorable (8.11e-4)" 171.2 25.1 25.4 27.5 27.2 0.7 106.3 20.5 33.3 155.9 43.5 41.6 11.9 101.1 24.2 24.1 89.6 124.5 75.7 22.1 23.2 49.7 13.4 98.3 27.5 22.1 24.6 105.5 20.8 21.9 23.0 113.3 22.8 56.2 14.1 6.3 34.5 43.3 38.1 65.0 37.9 68.9 19.4 41.4 27.9 18.4 27.7 8.7 66.5 44.1 13.8 58.3 98.6 21.6 0.1 0.3 8.3 0.4 1350.1 462.7 3.0 48.9 202.3 33.5 56.4 5.4 0.0 0.0 6.4 142.0 19.0 0.1 0.1 0.4 15.8 0.0 0.0 0.1 3.3 3.5 190.7 0.0 0.4 210.0 0.0 46.3 0.6 106.6 0.1 0.1 0.1 5.5 5.5 0.0 0.1 0.6 9.0 0.2 0.2 3.7 2.5 0.2 0.0 0.0 0.1 24.8 0.5 0.1 0.0 38.2 0.1 0.6 0.4 53.7 17.2 23.1 2.8 0.4 0.0 0.3 33.4 0.1 1.5 0.0 0.0 0.0 0.9 0.2 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 1.6 0.0 0.0 0.2 25.4 27.2 20.5 33.3 22.1 23.2 22.1 24.6 22.8 19.4 27.7 21.6 50.8 0.0 1.1 81.9 0.5 24.0 0.5 0.0 2.2 6.6 1.4 3.3 17.3 1.5 0.0 1.8 4.2 0.6 6.0 0.3 0.0 0.8 1.6 2.8 99.5 32.2 0.0 0.0 7.9 0.0 1.1 123.5 2.0 2.3 0.0 2.5 6.4 1.9 1.5 0.0 1.3 0.7 0.0 0.0 35.6 10.9 165.3 3.1 24.9 45.0 0.7 50.7 23.7 10.1 3.3 0.1 0.1 203.8 2.3 0.7 0.3 0.1 0.7 2.9 1288.5 6.6 288.3 1.9 1.6 0.8 15.3 0.8 4.8 4.0 0.4 1.1 PDK1 ENSG00000152256 "Pyruvate dehydrogenase kinase 1" Q15118 2 172555373-172608669 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Carbohydrate metabolism, Glucose metabolism" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Early spermatids: 130.4;Plasma cells: 144.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Group enriched" "Detected in all" 5 "B-cells: 8.6;granulocytes: 25.2;T-cells: 21.2" "Cell line enhanced" "Detected in all" "U-266/70: 71.8;U-87 MG: 72.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB017554, HPA027376" Approved NA NA "Cluster 5: Granulocytes - Unknown function" "Cluster 20: Retina & Lymphoid tissues - Unknown function" "Cluster 29: U-266 - Adaptive immune response" "Cluster 55: Plasma cells - Humoral immune response" "CAB017554: AB_2161138, HPA027376: AB_1855139" "unprognostic (2.14e-1)" "prognostic unfavorable (7.30e-5)" "unprognostic (1.21e-1)" "unprognostic (3.94e-2)" "unprognostic (6.47e-2)" "unprognostic (1.58e-1)" "unprognostic (1.02e-2)" "unprognostic (1.45e-1)" "unprognostic (9.69e-3)" "unprognostic (6.44e-2)" "unprognostic (5.44e-3)" "unprognostic (1.55e-1)" "prognostic unfavorable (1.10e-8)" "unprognostic (1.82e-1)" "unprognostic (1.94e-1)" "unprognostic (2.56e-2)" "unprognostic (5.34e-2)" 7.7 16.0 2.5 11.6 3.0 15.8 10.1 5.6 5.3 5.5 2.7 16.7 16.5 4.0 3.1 8.5 3.6 6.0 28.1 3.1 2.1 4.8 11.2 4.2 13.1 2.7 6.7 12.2 6.9 4.3 3.8 6.4 3.2 4.7 13.3 27.1 10.2 5.0 9.0 18.1 9.1 4.4 1.3 10.5 13.6 12.2 5.0 8.3 3.9 7.6 19.1 11.0 7.6 2.5 34.0 1.4 8.4 21.0 3.4 5.1 12.1 29.1 23.4 14.3 30.4 8.6 7.1 32.1 15.8 9.1 11.9 14.5 5.8 18.2 45.5 6.6 11.7 39.3 7.1 10.2 6.2 19.6 14.0 6.6 6.4 10.0 16.6 19.8 7.7 16.7 8.5 21.5 19.2 3.5 12.5 24.5 20.8 6.9 9.2 13.1 13.8 52.5 7.4 10.8 15.7 18.0 7.6 8.8 11.1 7.0 5.6 8.0 9.2 22.7 7.4 12.0 7.9 71.8 44.8 26.9 72.6 14.0 4.6 19.6 3.4 25.2 3.7 2.3 4.2 7.3 5.9 4.0 3.5 8.6 21.2 13.5 12.7 2.2 3.2 0.6 12.2 9.2 2.5 3.0 5.6 5.3 3.1 2.1 2.7 6.7 3.2 1.3 5.0 2.5 9.2 3.2 5.0 12.1 33.7 50.1 5.1 15.8 4.6 29.4 7.0 4.7 35.5 2.8 7.0 3.7 47.9 10.2 9.9 11.9 5.9 8.7 130.4 6.4 7.2 9.6 7.8 4.2 35.4 3.7 13.2 8.5 9.7 12.1 5.7 13.3 19.6 20.2 10.2 55.5 32.7 6.6 12.2 12.0 15.2 43.8 3.4 12.9 30.2 30.9 11.4 7.4 10.3 12.1 14.8 9.6 17.5 3.8 144.8 7.2 6.7 1.9 5.0 18.5 6.6 4.6 11.6 9.6 10.4 8.9 43.3 4.1 17.3 5.3 7.0 6.1 PDXK "C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79" ENSG00000160209 "Pyridoxal kinase" O00764 21 43719094-43762307 "Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase" "Charcot-Marie-Tooth disease, Disease variant, FDA approved drug targets, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 87.0" "Group enriched" "Detected in all" 4 "Early spermatids: 1717.4;Late spermatids: 4366.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030196, HPA030197, HPA030198, CAB033918" Enhanced Enhanced Nucleoplasm NA NA 830000 "Cluster 24: B-cells - Unknown function" "Cluster 65: Brain - Ion transport" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 31: Spermatids - Spermatogenesis" Nucleoplasm "CAB033918: AB_2162502, HPA030196: AB_10599735, HPA030197: AB_10601792, HPA030198: AB_10603570" "unprognostic (1.01e-1)" "unprognostic (1.99e-1)" "unprognostic (5.88e-2)" "unprognostic (1.87e-1)" "unprognostic (8.29e-2)" "unprognostic (4.31e-3)" "unprognostic (3.64e-3)" "unprognostic (1.32e-1)" "unprognostic (8.66e-2)" "unprognostic (9.34e-2)" "unprognostic (2.10e-1)" "unprognostic (3.54e-1)" "unprognostic (3.70e-2)" "unprognostic (1.31e-3)" "unprognostic (1.10e-1)" "unprognostic (4.78e-2)" "unprognostic (1.51e-3)" 25.6 21.8 79.4 7.6 62.2 12.9 18.4 23.9 87.0 14.3 17.5 17.1 14.1 12.3 10.2 19.7 14.0 7.0 15.5 62.5 51.7 50.4 21.5 20.9 7.0 48.8 59.7 19.1 21.3 17.8 37.3 7.8 54.7 17.2 9.4 10.0 22.7 10.6 6.7 13.9 19.7 6.9 34.4 12.5 16.6 23.9 70.5 10.2 19.1 5.4 9.3 10.9 12.6 57.6 43.4 51.9 8.1 15.5 19.4 27.3 9.9 15.2 23.8 14.5 12.1 42.5 65.7 14.4 15.7 21.9 20.0 31.9 15.8 43.4 9.5 16.2 13.4 14.7 60.9 31.7 38.1 14.0 20.6 38.9 40.7 15.3 16.9 23.6 6.9 6.3 26.2 31.9 13.8 29.1 2.0 24.9 22.3 41.9 19.7 16.7 4.8 40.4 62.9 51.9 7.8 9.3 63.3 57.7 23.2 3.3 19.0 19.4 12.5 10.5 20.3 14.2 14.4 19.3 9.8 8.4 43.2 39.9 10.3 0.6 2.4 0.1 0.8 2.2 1.5 0.6 0.8 0.9 1.3 1.7 0.8 0.6 0.6 0.9 4.3 0.6 0.7 1.4 79.4 62.2 23.9 87.0 62.5 51.7 48.8 59.7 54.7 34.4 70.5 57.6 15.8 80.1 66.6 44.1 37.7 28.4 142.4 72.2 27.3 46.3 74.8 53.5 48.0 34.3 73.2 101.2 22.9 42.9 23.6 97.6 180.0 146.4 1717.4 66.9 28.3 36.1 30.1 15.8 49.3 196.6 86.3 39.4 63.2 73.2 31.8 23.8 17.2 54.2 207.6 52.2 48.7 55.4 12.2 58.2 101.0 4366.5 50.1 118.7 42.7 61.8 38.4 14.9 20.6 16.6 13.5 223.4 36.4 54.2 146.4 184.7 108.4 95.7 71.1 43.3 6.6 17.0 35.0 678.1 30.4 60.7 28.4 124.1 27.3 22.1 57.5 239.8 PGA5 ENSG00000256713 "Pepsinogen A5" P0DJD9 11 61241175-61251444 "Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins" Digestion "Aspartyl protease, Hydrolase, Protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 2014 "stomach 1: 39870.8" "Cell type enriched" "Detected in some" 77 "Exocrine glandular cells: 4383.1" "Cancer enriched" "Detected in some" 12 "stomach cancer: 15.0" "Not detected" "Not detected" "Group enriched" "Detected in some" 29 "classical monocyte: 1.8;intermediate monocyte: 4.3;non-classical monocyte: 2.4" "Lineage enriched" "Detected in single" 44 "monocytes: 4.3" "Cell line enriched" "Detected in some" 19 "BJ hTERT+: 28.8" HPA046875 Supported "Secreted to digestive system" NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 4: Stomach - Digestion" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 1: Pancreatic cells - Digestion" "HPA046875: AB_2679851" "unprognostic (1.36e-3)" "unprognostic (2.98e-2)" "unprognostic (5.83e-3)" "unprognostic (2.11e-1)" "unprognostic (4.22e-1)" "unprognostic (4.36e-2)" "unprognostic (2.16e-2)" "unprognostic (1.05e-1)" "unprognostic (7.10e-2)" 19.7 4.4 0.3 1.1 0.3 0.0 4.5 0.1 0.6 4.0 0.0 6.2 0.6 1.9 0.0 7.0 5.1 0.1 3.5 0.7 0.0 2.4 7.0 5.4 0.0 0.1 0.0 2.6 8.2 0.0 3.8 0.5 0.1 1.8 0.1 1.5 2.5 0.5 1.9 2.1 2.1 0.9 0.0 3.9 39870.8 2.3 0.0 0.2 3.1 0.2 0.1 2.3 2.5 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 28.8 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 1.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.3 0.3 0.3 0.1 0.6 0.7 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.5 0.0 0.0 0.0 0.0 0.0 0.1 4383.1 0.0 0.1 56.6 0.0 0.0 0.2 0.0 0.0 6.7 0.0 0.0 0.0 0.0 5.1 0.0 1.6 0.9 1.3 0.0 0.0 1.0 25.1 0.0 0.0 0.0 8.2 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.4 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 PGR "NR3C3, PR" ENSG00000082175 "Progesterone receptor" P06401 11 101029624-101129813 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "cervix: 63.9;endometrium 1: 103.4;fallopian tube: 34.3;smooth muscle: 78.4" "Cell type enhanced" "Detected in many" "Early spermatids: 64.0;Endometrial ciliated cells: 90.1;Endometrial stromal cells: 177.1;Glandular and luminal cells: 76.3;Late spermatids: 40.9" "Group enriched" "Detected in some" 13 "breast cancer: 10.1;endometrial cancer: 11.1" "Group enriched" "Detected in many" 5 "hypothalamus: 7.7;thalamus: 9.2" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 338 "T-47d: 170.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000068, HPA004751, HPA008428, HPA017176, CAB055100" Enhanced NA NA "Cluster 89: Fibroblasts - ECM organization" "Cluster 6: T47d - Mammary gland" "Cluster 36: Stromal cells - Cell proliferation" "CAB000068: AB_442124, CAB055100: AB_2532076, HPA004751: AB_1079681, HPA008428: AB_1079680, HPA017176: AB_1855728" "unprognostic (2.59e-2)" "unprognostic (9.80e-3)" "unprognostic (5.23e-3)" "prognostic favorable (5.76e-8)" "unprognostic (2.81e-2)" "unprognostic (1.56e-1)" "unprognostic (4.11e-1)" "unprognostic (1.64e-1)" "unprognostic (2.08e-1)" "unprognostic (2.50e-1)" "unprognostic (3.29e-2)" "unprognostic (1.77e-1)" "unprognostic (7.71e-3)" "unprognostic (1.90e-2)" "unprognostic (2.35e-2)" "unprognostic (1.15e-1)" "unprognostic (5.44e-3)" 1.4 1.7 1.3 0.3 1.0 0.0 7.0 0.8 0.9 63.9 0.6 2.4 0.5 103.4 0.8 0.7 34.3 0.9 3.7 0.8 7.7 1.1 0.3 1.4 0.2 1.7 1.7 16.3 0.6 0.3 1.0 1.7 1.7 3.7 0.7 0.1 3.8 9.0 0.6 0.5 0.7 78.4 1.5 1.7 0.6 3.5 9.2 0.2 1.3 1.8 0.2 1.6 10.3 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 170.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.0 0.8 0.9 0.8 7.7 1.7 1.7 1.7 1.5 9.2 1.2 1.3 3.2 0.0 0.3 0.7 0.1 1.1 0.0 0.0 1.3 35.9 19.8 18.7 0.0 1.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 64.0 90.1 177.1 3.5 0.0 0.0 0.1 0.0 0.1 12.5 0.0 76.3 0.0 34.7 2.9 0.0 0.1 0.0 0.3 0.0 0.0 0.0 1.3 40.9 14.6 1.9 0.0 22.5 0.0 0.0 0.0 1.0 0.3 0.1 0.0 10.5 0.0 0.3 0.0 0.0 0.0 0.2 6.6 1.4 14.9 3.9 2.3 0.0 0.6 0.0 2.3 15.1 0.0 1.0 PIK3CA PI3K ENSG00000121879 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha" P42336 3 179148114-179240093 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Angiogenesis, Lipid metabolism, Phagocytosis" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in all" "Excitatory neurons: 126.7;Inhibitory neurons: 122.0;Oligodendrocyte precursor cells: 130.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009985, CAB017804" Approved Supported Mitochondria,Cytosol NA NA "Cluster 1: Neutrophils - Mixed function" "Cluster 34: Non-specific - Transcription" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" Cytosol Mitochondria "CAB017804: , HPA009985: AB_1079610" "unprognostic (1.81e-1)" "unprognostic (2.77e-1)" "unprognostic (2.18e-1)" "unprognostic (2.69e-3)" "unprognostic (6.49e-3)" "unprognostic (1.43e-1)" "unprognostic (2.65e-2)" "unprognostic (1.00e-2)" "unprognostic (1.03e-1)" "unprognostic (2.37e-1)" "unprognostic (2.57e-3)" "unprognostic (5.21e-2)" "unprognostic (4.50e-2)" "unprognostic (1.16e-2)" "unprognostic (2.48e-1)" "unprognostic (9.74e-2)" "unprognostic (3.82e-2)" 14.7 7.9 3.1 8.1 3.7 12.4 8.5 9.7 8.3 8.7 0.3 6.7 4.2 8.3 4.8 7.9 5.7 8.4 9.5 3.7 3.6 8.2 7.1 7.9 9.2 5.1 4.2 10.3 4.3 11.5 3.4 11.1 5.1 7.3 5.8 12.4 4.5 7.1 7.1 5.5 5.3 8.9 2.3 8.8 5.8 6.1 3.7 13.7 7.9 13.0 9.2 8.6 5.8 6.4 19.9 6.5 9.6 9.2 22.7 27.7 6.5 10.8 16.5 10.9 16.0 5.1 13.0 16.1 21.7 10.8 14.1 5.9 8.4 9.8 16.5 32.0 6.2 22.4 5.2 4.4 10.7 13.1 12.6 16.8 10.6 12.4 15.0 13.4 15.8 12.9 10.6 17.3 18.9 6.9 10.9 8.5 8.0 8.8 7.8 13.9 10.0 16.7 8.5 10.0 5.2 9.9 13.1 10.8 16.1 9.1 19.0 11.1 21.1 10.4 6.5 18.1 13.3 9.3 13.8 29.0 11.3 9.6 5.4 1.3 1.2 0.4 1.2 1.0 0.8 1.5 0.8 0.6 0.8 1.6 1.0 0.8 2.2 0.7 0.9 0.9 0.8 0.3 3.1 3.7 9.7 8.3 3.7 3.6 5.1 4.2 5.1 2.3 3.7 6.4 31.3 32.1 26.8 60.7 28.3 14.7 17.9 11.2 2.2 27.9 14.4 15.2 18.5 5.7 15.9 7.3 31.3 10.2 17.9 8.7 1.9 10.7 2.0 14.1 21.7 25.6 2.4 9.2 126.7 13.9 6.1 23.5 8.6 21.6 31.6 19.9 33.5 21.9 11.1 38.7 122.0 10.3 14.2 23.5 24.3 3.4 32.6 20.9 14.2 75.9 24.5 17.4 18.6 130.2 84.2 16.9 10.8 39.5 15.1 34.6 9.5 14.8 20.1 27.1 26.3 25.7 28.6 11.8 10.2 9.8 14.9 8.8 19.9 19.6 9.2 32.0 PIK3CD p110D ENSG00000171608 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta" O00329 1 9651731-9729114 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Adaptive immunity, Chemotaxis, Differentiation, Immunity, Inflammatory response, Innate immunity" "Kinase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 60.9;lymphoid tissue: 50.4" "Cell type enhanced" "Detected in many" "dendritic cells: 44.0;granulocytes: 25.3;Kupffer cells: 35.2;Microglial cells: 29.0;NK-cells: 29.9;T-cells: 37.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 153.3;NB-4: 65.9;REH: 68.9;THP-1: 65.4;U-937: 78.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015420, HPA044953" Enhanced Approved "Vesicles,Cytokinetic bridge" Yes No "Cluster 8: Neutrophils - Inflammatory response" "Cluster 2: Immune cells - Immune response" "Cluster 43: THP-1 - Innate immune response" "Cluster 63: NK-cells & T-cells - Immune response" Vesicles "Cytokinetic bridge" "CAB015420: AB_831654, HPA044953: AB_2679153" "unprognostic (5.73e-3)" "unprognostic (2.75e-3)" "unprognostic (8.93e-2)" "unprognostic (4.05e-2)" "unprognostic (4.71e-2)" "unprognostic (1.40e-2)" "unprognostic (2.13e-1)" "unprognostic (7.42e-2)" "unprognostic (2.78e-2)" "unprognostic (1.54e-2)" "unprognostic (3.46e-2)" "unprognostic (6.75e-2)" "unprognostic (8.65e-3)" "unprognostic (2.09e-1)" "unprognostic (1.34e-1)" "unprognostic (2.04e-1)" "unprognostic (6.78e-2)" 7.2 3.1 6.8 33.4 6.3 60.9 3.9 6.1 7.5 6.2 6.4 5.4 5.2 4.9 1.7 4.9 6.1 7.0 3.3 7.0 5.3 6.4 3.5 12.0 46.9 7.3 6.6 7.0 3.0 2.9 2.8 4.2 7.8 4.6 3.4 0.6 5.1 2.7 1.2 3.0 17.2 4.7 6.6 50.4 5.7 4.0 9.3 24.3 5.5 3.5 32.0 7.4 5.1 8.5 8.1 5.2 0.4 1.4 1.3 1.1 0.7 12.1 24.5 26.0 21.1 0.3 3.3 21.5 4.9 9.8 12.4 2.4 2.0 11.0 16.2 153.3 0.4 2.4 1.3 9.0 5.1 56.0 18.7 4.3 4.5 29.2 9.8 11.4 3.8 14.9 8.0 0.1 15.0 0.6 5.4 65.9 2.2 0.3 1.4 68.9 13.0 0.7 10.9 0.0 1.7 1.5 2.7 4.9 11.9 6.8 0.8 65.4 9.8 7.7 7.9 0.2 11.5 4.9 4.9 30.1 16.7 78.6 4.4 18.0 23.5 40.2 21.6 23.0 22.6 12.8 16.3 19.9 22.5 13.6 20.9 23.1 63.2 25.9 29.2 25.7 13.3 38.3 6.8 6.3 6.1 7.5 7.0 5.3 7.3 6.6 7.8 6.6 9.3 8.5 1.7 9.6 13.4 2.0 22.2 1.5 2.2 1.8 4.0 0.7 2.0 1.7 3.1 0.0 1.1 0.0 2.1 0.3 44.0 0.1 1.9 3.9 3.0 2.0 1.7 2.7 0.0 10.3 6.7 2.0 0.5 2.9 0.0 1.0 25.3 4.2 3.6 0.0 14.7 0.0 13.4 0.1 0.0 35.2 6.0 2.8 1.2 23.1 3.6 29.0 19.3 2.5 29.9 1.0 1.1 11.3 0.0 1.5 8.2 4.1 0.2 3.8 3.3 1.3 6.6 2.0 4.7 1.5 3.4 2.9 1.1 0.3 37.1 1.5 0.2 2.1 PIK3CG ENSG00000105851 "Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma" P48736 7 106865278-106908980 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Angiogenesis, Chemotaxis, Endocytosis, Immunity, Inflammatory response" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "bone marrow: 43.6;lymphoid tissue: 19.7" "Cell type enhanced" "Detected in some" "B-cells: 24.9;dendritic cells: 26.5;Early spermatids: 28.9;granulocytes: 20.8;monocytes: 23.8;NK-cells: 25.7;Plasma cells: 88.4" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "Daudi: 29.4;HL-60: 28.8;HMC-1: 34.9;Karpas-707: 29.1;MOLT-4: 56.0;U-266/70: 71.4;U-937: 52.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA069976 Enhanced Supported "Plasma membrane,Cytosol" NA NA "Cluster 51: Monocytes - Innate immune response" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 29: U-266 - Adaptive immune response" "Cluster 55: Plasma cells - Humoral immune response" "Plasma membrane" Cytosol "HPA069976: AB_2686224" "unprognostic (8.34e-2)" "unprognostic (2.01e-2)" "unprognostic (1.44e-2)" "unprognostic (1.71e-2)" "unprognostic (3.20e-2)" "unprognostic (3.82e-3)" "unprognostic (3.02e-1)" "unprognostic (6.77e-2)" "unprognostic (1.16e-1)" "unprognostic (7.06e-3)" "unprognostic (1.15e-1)" "unprognostic (1.97e-1)" "unprognostic (1.77e-2)" "unprognostic (9.08e-2)" "unprognostic (1.23e-1)" "unprognostic (5.38e-1)" "unprognostic (5.24e-2)" 3.1 1.8 0.5 11.5 0.6 43.6 1.9 0.8 1.3 1.9 1.3 4.2 4.1 1.3 0.5 1.7 1.4 3.2 1.6 0.5 1.0 1.0 2.0 4.9 19.0 2.5 1.3 1.6 0.3 0.7 0.2 2.9 2.7 1.0 3.8 0.1 1.3 0.9 0.3 0.8 4.3 2.7 1.8 11.0 4.0 5.2 2.0 16.4 1.1 1.0 19.7 4.3 0.2 3.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.4 2.7 0.0 0.1 0.1 0.0 0.0 0.0 0.3 0.0 17.9 0.0 0.0 0.0 28.8 34.9 0.0 0.0 0.0 0.0 0.0 11.0 16.9 20.6 29.1 0.0 0.0 56.0 17.6 0.0 0.0 0.0 14.6 0.0 19.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 20.6 2.9 0.1 0.2 0.1 0.0 71.4 0.0 27.3 0.1 52.1 6.7 10.8 6.0 24.3 8.8 17.8 8.1 7.3 4.1 6.7 9.4 10.2 4.2 5.9 22.7 9.8 43.7 8.6 4.4 6.8 0.5 0.6 0.8 1.3 0.5 1.0 2.5 1.3 2.7 1.8 2.0 3.9 1.5 0.0 1.8 0.3 24.9 0.8 0.0 0.0 0.6 0.0 0.1 0.1 0.5 0.0 0.6 0.0 0.0 0.0 26.5 0.2 0.0 0.0 28.9 0.1 0.2 1.7 0.0 7.8 5.5 0.0 0.0 0.1 3.6 0.1 20.8 0.4 2.5 0.5 6.8 0.0 0.3 0.0 0.0 11.9 8.3 18.8 0.6 18.9 7.2 15.0 23.8 0.0 25.7 0.0 0.2 0.0 0.0 0.0 88.4 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.2 6.6 3.7 0.2 0.3 0.1 18.1 0.6 0.6 0.1 PLA2G2A "PLA2B, PLA2L" ENSG00000188257 "Phospholipase A2 group IIA" P14555 1 19975431-19980416 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Inflammatory response, Lipid metabolism, Phospholipid metabolism" "Antimicrobial, Bacteriolytic enzyme, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "adipose tissue: 1302.4;intestine: 1973.9;placenta: 756.7;urinary bladder: 813.6" "Cell type enhanced" "Detected in many" "Distal enterocytes: 536.5;Exocrine glandular cells: 1031.5;Fibroblasts: 656.0;Intestinal goblet cells: 393.6;Paneth cells: 574.1;Prostatic glandular cells: 921.1;Undifferentiated cells: 861.9" "Cancer enhanced" "Detected in all" "prostate cancer: 875.7" "Low region specificity" "Detected in single" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 6 "Hep G2: 645.0;OE19: 2384.4" "Not detected" "Not detected" HPA015236 Enhanced "Secreted to blood" NA NA 1000000 680000 "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 21: OE19 - Mitochondria" "Cluster 50: Fibroblasts - ECM organization" "HPA015236: AB_10601047" "unprognostic (2.33e-2)" "unprognostic (1.28e-1)" "unprognostic (2.79e-2)" "unprognostic (7.85e-3)" "unprognostic (8.71e-2)" "unprognostic (9.27e-2)" "unprognostic (2.02e-1)" "unprognostic (1.80e-1)" "prognostic favorable (1.49e-4)" "unprognostic (1.68e-1)" "unprognostic (1.06e-1)" "unprognostic (1.58e-2)" "unprognostic (3.77e-15)" "unprognostic (2.72e-2)" "unprognostic (9.14e-2)" "unprognostic (1.24e-1)" "unprognostic (1.51e-1)" 1302.4 7.0 0.1 280.2 0.1 0.0 27.4 0.1 0.7 5.4 2.9 1474.0 786.8 4.3 3.3 29.3 14.8 57.7 137.4 0.0 0.2 6.6 238.6 16.8 5.4 0.6 0.7 44.1 7.8 0.9 2.5 756.7 0.2 203.9 1668.0 0.1 24.6 6.1 6.0 18.1 1973.9 164.4 0.1 0.4 11.6 36.8 1.3 1.7 11.1 114.2 15.0 813.6 12.1 0.1 0.0 0.0 1.6 0.0 248.3 0.0 8.5 0.0 0.1 0.1 0.0 11.2 0.0 0.0 1.1 0.0 0.8 18.7 0.0 0.0 0.0 0.1 0.3 0.0 0.3 645.0 0.0 0.1 1.1 2.6 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 6.2 0.4 2384.4 0.0 0.0 0.0 7.6 0.0 198.2 1.0 4.7 0.0 20.1 0.0 31.1 0.1 0.0 0.0 0.0 0.0 44.7 0.2 0.4 0.3 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.7 0.0 0.2 0.6 0.7 0.2 0.1 1.3 0.1 20.6 6.4 6.7 0.0 9.1 13.9 10.8 0.2 0.6 0.9 1.0 0.8 14.9 12.8 9.3 0.0 0.0 3.6 0.4 536.5 1.9 0.7 4.0 0.7 43.1 6.9 62.3 13.5 0.0 1031.5 4.6 656.0 6.1 0.6 4.5 0.0 30.0 310.9 9.5 0.0 0.0 393.6 2.0 18.8 31.1 11.6 171.2 3.5 14.2 0.0 0.0 0.0 0.0 0.0 0.0 4.7 574.1 1.2 2.6 921.1 328.2 0.2 1.9 0.0 0.0 2.4 37.8 0.9 1.5 4.9 16.8 6.8 6.2 0.1 861.9 32.2 PLAT ENSG00000104368 "Plasminogen activator, tissue type" P00750 8 42174718-42207709 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Plasminogen activation" "Hydrolase, Protease, Serine protease" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "parathyroid gland: 246.0;urinary bladder: 181.4" "Group enriched" "Detected in many" 4 "Basal prostatic cells: 763.3;Urothelial cells: 992.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "CAPAN-2: 604.7;HMC-1: 425.2;hTERT-RPE1: 344.9;LHCN-M2: 298.2;U-2197: 441.2;WM-115: 806.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003412, CAB009335" Supported Approved "Actin filaments" "Secreted to blood" NA NA 9900000 110000 "Cluster 4: T-regs - Cell cycle regulation" "Cluster 48: Parathyroid gland - membrane proteins" "Cluster 17: WM-115 - Nervous system development" "Cluster 22: Epithelial cell types - Mixed function" "Actin filaments" "CAB009335: AB_2237146, HPA003412: AB_1858205" "prognostic favorable (7.57e-4)" "unprognostic (2.23e-1)" "unprognostic (4.08e-1)" "unprognostic (3.39e-1)" "unprognostic (4.88e-3)" "unprognostic (9.39e-2)" "unprognostic (4.65e-3)" "unprognostic (5.78e-2)" "unprognostic (1.55e-1)" "unprognostic (1.75e-1)" "unprognostic (2.98e-3)" "unprognostic (2.46e-1)" "prognostic unfavorable (4.95e-4)" "unprognostic (8.72e-3)" "unprognostic (1.37e-2)" "unprognostic (2.63e-2)" "unprognostic (6.09e-2)" 58.9 44.0 14.0 35.6 13.7 0.1 35.1 14.6 17.4 21.8 10.3 55.3 29.9 49.6 16.8 33.7 49.8 40.4 19.3 12.5 16.6 91.9 5.3 41.3 2.3 15.4 15.4 21.5 16.0 246.0 13.3 44.4 16.6 54.0 25.0 2.1 15.6 29.1 8.8 6.2 34.6 32.9 16.0 2.0 41.8 11.9 18.8 4.4 30.9 9.8 2.7 181.4 33.1 14.0 4.2 1.4 29.0 9.1 43.1 61.9 0.9 125.8 216.4 54.2 43.4 1.4 604.7 0.0 4.4 17.1 28.4 14.5 0.3 23.9 78.5 64.6 8.4 0.7 1.0 0.6 253.9 0.2 425.2 65.6 0.4 140.3 6.0 344.9 103.9 0.2 4.6 0.8 298.2 0.0 0.6 0.5 42.3 0.3 48.2 0.2 103.5 0.3 12.6 0.4 0.3 7.4 0.2 0.4 158.7 39.7 1.0 0.3 189.3 11.6 43.1 441.2 15.6 0.2 1.1 0.2 9.7 0.2 806.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 14.0 13.7 14.6 17.4 12.5 16.6 15.4 15.4 16.6 16.0 18.8 14.0 63.5 0.0 13.7 0.0 2.9 10.8 763.3 155.9 7.4 4.7 103.9 66.3 7.4 1.5 19.1 0.0 4.2 0.6 0.9 0.1 0.0 9.3 0.9 4.8 104.2 98.2 0.0 0.0 1.6 0.6 1.3 136.5 2.0 5.1 164.0 89.7 36.4 0.8 1.9 1.7 4.0 0.0 4.1 1.0 17.7 1.5 3.7 4.7 23.2 25.3 1.6 2.1 1.0 42.7 0.3 52.0 0.0 2.6 2.8 193.3 0.2 0.3 4.0 3.8 13.1 10.8 48.3 1.1 0.6 13.6 13.5 0.7 6.0 0.5 0.5 992.1 PLG ENSG00000122194 Plasminogen P00747 6 160702238-160754097 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Fibrinolysis, Hemostasis, Tissue remodeling" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease variant, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 11 "liver: 2666.4" "Cell type enriched" "Detected in some" 7 "Hepatocytes: 1772.7" "Cancer enriched" "Detected in some" 84 "liver cancer: 180.7" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "CAB000668, CAB016678, HPA021602, HPA048823" Supported "Secreted to blood" NA NA 140000000000 45000000000 "Cluster 85: Liver - Metabolism" "Cluster 15: Hepatocytes - Hemostasis" "CAB000668: , CAB016678: AB_1621208, HPA021602: AB_1855453, HPA048823: AB_2680532" "unprognostic (1.70e-1)" "unprognostic (2.16e-3)" "unprognostic (2.44e-1)" "unprognostic (8.54e-3)" "unprognostic (1.41e-1)" "unprognostic (1.76e-3)" "unprognostic (6.28e-2)" "unprognostic (7.25e-2)" "prognostic favorable (4.22e-4)" "unprognostic (3.97e-3)" "unprognostic (5.21e-2)" "unprognostic (2.33e-2)" 0.4 0.4 0.3 0.2 0.4 0.0 0.0 0.0 0.3 0.1 0.0 0.1 0.3 0.2 0.0 0.1 2.4 0.5 0.1 0.2 0.3 240.9 2666.4 0.4 0.7 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.0 0.6 0.0 0.1 0.9 0.0 0.1 0.2 0.1 0.0 0.0 0.5 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.5 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.1 0.3 0.2 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.5 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.0 0.3 0.2 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 5.4 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.6 30.0 0.0 1.8 0.0 0.0 0.3 0.0 19.6 0.0 0.2 3.0 0.1 1.2 0.0 24.0 0.6 0.0 0.0 0.0 0.0 0.1 1.3 0.0 28.5 1772.7 0.1 0.0 0.5 0.0 0.0 35.4 0.0 0.2 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 235.7 1.5 0.1 0.0 0.4 0.2 0.4 0.4 0.0 0.0 0.0 2.3 0.1 0.0 0.0 PNLIP PL ENSG00000175535 "Pancreatic lipase" P16233 10 116545931-116567855 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted secreted proteins" "Lipid degradation, Lipid metabolism" Hydrolase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 2058 "pancreas: 444687.5" "Cell type enriched" "Detected in some" 8 "Exocrine glandular cells: 4086.8" "Cancer enriched" "Detected in some" 4854 "pancreatic cancer: 2731.7" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "U-2 OS: 1.3" "Low region specificity" "Detected in some" "Not detected" "Not detected" "HPA062430, HPA062494" Enhanced "Secreted to digestive system" NA NA 14000000 "Cluster 25: Pancreas - Digestion" "Cluster 9: U-2 OS - Unknown function" "Cluster 1: Pancreatic cells - Digestion" "HPA062430: AB_2684761, HPA062494: AB_2684782" "unprognostic (2.05e-2)" "unprognostic (4.46e-2)" 13.8 3.1 0.0 10.5 0.0 1.1 8.9 0.0 0.0 7.2 0.0 3.8 64.8 9.1 0.4 4.8 1.5 0.0 78.2 0.0 0.0 3.0 10.2 2.1 16.9 0.0 0.0 216.0 444687.5 0.0 2.5 24.4 0.0 4.5 0.0 0.0 71.7 0.0 2.9 4.6 34.0 0.0 0.0 3.8 28.2 2.3 0.0 0.0 2.0 0.0 0.0 1.2 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.3 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.9 0.5 0.0 0.0 0.3 0.0 0.0 0.1 4086.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.5 0.0 0.0 14.5 0.0 0.0 0.5 0.1 507.4 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 PNP "NP, PUNP" ENSG00000198805 "Purine nucleoside phosphorylase" P00491 14 20468954-20477089 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Purine salvage" "Glycosyltransferase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 333.9;epididymis: 594.8" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 360.6;Erythroid cells: 227.3;Syncytiotrophoblasts: 646.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HL-60: 531.3;U-937: 593.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA001625 Enhanced Supported Cytosol NA NA 58000000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 68: Epididymis - Unknown function" "Cluster 32: U-937 - Innate immune response" "Cluster 47: Cytotrophoblasts - Unknown function" Cytosol "HPA001625: AB_1854577" "unprognostic (1.20e-3)" "unprognostic (2.68e-2)" "unprognostic (1.04e-2)" "unprognostic (1.70e-1)" "unprognostic (3.10e-1)" "unprognostic (7.06e-2)" "prognostic unfavorable (4.43e-4)" "unprognostic (4.94e-3)" "unprognostic (3.87e-2)" "unprognostic (7.45e-2)" "unprognostic (1.85e-2)" "unprognostic (2.21e-1)" "prognostic favorable (2.24e-4)" "unprognostic (1.69e-1)" "unprognostic (7.54e-2)" "unprognostic (2.46e-1)" "unprognostic (1.64e-3)" 78.6 24.8 16.1 46.8 16.6 333.9 34.6 22.6 22.7 25.3 18.9 52.2 120.3 14.2 594.8 87.4 18.2 56.8 29.0 17.7 19.6 206.8 98.0 48.6 46.7 20.3 18.1 5.0 23.2 32.0 19.8 132.6 20.1 15.0 61.8 27.1 22.6 27.4 7.3 29.6 60.3 38.7 23.1 44.5 50.6 7.4 21.1 33.5 17.8 10.0 64.4 100.4 41.5 20.1 86.1 113.4 24.0 53.9 26.0 21.0 71.8 85.2 40.3 68.2 67.0 66.1 76.5 227.1 96.8 45.5 81.5 89.9 125.2 159.8 89.5 75.0 109.6 189.1 89.9 109.3 24.2 531.3 94.7 14.4 57.4 206.0 91.0 37.8 295.9 141.0 95.4 137.4 86.7 79.1 157.6 311.3 67.5 215.7 186.1 130.2 35.9 88.3 243.7 79.6 101.9 22.6 163.4 205.0 13.2 32.6 75.5 92.5 240.0 46.1 62.6 105.1 148.4 63.1 113.3 258.9 39.3 593.0 4.6 12.0 30.6 10.3 39.8 27.3 73.6 25.7 44.2 45.0 48.1 28.8 27.6 35.9 3.7 38.5 26.6 27.3 16.7 31.1 16.1 16.6 22.6 22.7 17.7 19.6 20.3 18.1 20.1 23.1 21.1 20.1 149.6 0.0 23.5 5.9 50.3 84.6 67.4 12.6 112.7 4.7 56.3 62.6 3.5 27.1 13.4 82.8 14.6 360.6 45.2 61.1 39.2 43.2 1.3 36.0 12.7 139.4 46.4 227.3 0.6 51.5 41.8 32.4 106.5 65.3 57.7 5.0 24.3 30.6 70.9 16.8 1.1 51.3 18.3 18.1 58.4 0.8 0.3 83.3 30.2 3.7 13.2 78.8 29.9 3.0 0.9 130.8 83.9 0.7 88.6 27.5 41.2 118.9 10.5 18.1 0.0 23.9 41.3 0.4 0.7 114.7 63.9 646.2 62.3 3.1 51.4 77.1 POLA1 "NSX, p180, POLA" ENSG00000101868 "DNA polymerase alpha 1, catalytic subunit" P09884 X 24693873-24996986 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "DNA replication, Host-virus interaction" "DNA-binding, DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase" "Disease variant, Dwarfism, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Astrocytes: 38.5;Excitatory neurons: 42.3;Inhibitory neurons: 65.7;Microglial cells: 57.1;Oligodendrocyte precursor cells: 59.3;Oligodendrocytes: 97.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002947, CAB012274" Supported Supported Nucleoplasm,Cytosol NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 34: Non-specific - Transcription" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Nucleoplasm Cytosol "CAB012274: , HPA002947: AB_1079652" "unprognostic (6.92e-2)" "unprognostic (4.43e-3)" "unprognostic (3.27e-3)" "unprognostic (1.53e-2)" "unprognostic (2.53e-1)" "unprognostic (1.49e-1)" "prognostic unfavorable (4.80e-5)" "unprognostic (1.87e-1)" "unprognostic (9.25e-3)" "unprognostic (2.48e-2)" "unprognostic (8.41e-2)" "unprognostic (7.42e-2)" "unprognostic (2.09e-1)" "unprognostic (1.44e-1)" "unprognostic (3.66e-2)" "unprognostic (3.48e-2)" "unprognostic (3.08e-1)" 3.7 2.0 1.9 4.8 2.5 7.3 5.1 2.2 1.8 4.3 0.8 4.1 2.4 4.2 1.4 3.9 3.7 2.1 3.5 1.3 1.9 2.9 2.0 3.1 6.8 2.3 2.3 5.8 2.8 3.4 1.8 5.6 2.4 3.1 5.2 3.7 3.0 3.5 4.9 4.0 3.5 4.8 2.2 3.5 3.7 2.6 2.1 11.9 3.1 3.1 7.7 3.7 3.8 2.6 32.7 24.6 30.3 24.1 5.2 6.5 6.9 23.6 12.7 25.0 28.3 20.4 17.0 41.1 7.7 9.6 23.4 26.0 59.7 18.7 33.6 21.1 24.8 31.0 42.8 13.5 2.4 41.6 15.5 4.1 3.6 31.2 8.4 5.8 13.0 20.8 28.7 20.0 16.8 22.4 45.2 7.2 30.7 20.3 19.1 39.0 81.5 30.7 7.1 21.1 27.9 16.7 28.1 11.2 11.6 33.0 25.7 11.5 10.1 21.3 14.9 42.4 22.6 11.6 18.1 32.7 12.4 18.3 24.9 0.0 0.2 0.2 0.6 1.4 0.8 1.0 0.8 1.0 0.7 0.4 0.4 0.5 0.0 0.8 0.2 0.2 0.9 0.5 1.9 2.5 2.2 1.8 1.3 1.9 2.3 2.3 2.4 2.2 2.1 2.6 5.8 9.6 6.5 38.5 5.2 2.8 4.6 1.8 5.7 3.9 4.7 4.3 11.8 0.0 7.2 1.8 2.1 6.1 3.2 2.5 3.9 3.2 0.2 3.2 4.7 6.3 4.2 24.2 42.3 3.0 4.9 4.6 4.6 3.8 9.5 8.3 3.3 3.4 4.4 1.7 65.7 4.2 4.1 4.4 1.5 1.7 6.2 4.5 0.0 57.1 3.7 4.8 5.2 59.3 97.7 1.4 1.2 3.4 8.6 2.0 2.3 1.6 6.1 7.4 6.6 9.2 6.0 6.4 4.5 5.5 2.3 2.3 4.9 5.0 4.2 2.4 POLB ENSG00000070501 "DNA polymerase beta" P06746 8 42338454-42371808 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication, DNA synthesis" "DNA-binding, DNA-directed DNA polymerase, Lyase, Nucleotidyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Early spermatids: 254.5;Late spermatids: 133.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HMC-1: 280.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011616, HPA049104, HPA069013" Enhanced Uncertain Vesicles NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 21: Non-specific - Transcription" "Cluster 3: HMC-1 - Innate immune response" "Cluster 65: Plasmacytoid DCs - Unknown function" Vesicles "CAB011616: AB_731977, HPA049104: AB_2680632, HPA069013: " "unprognostic (1.67e-1)" "unprognostic (2.68e-3)" "unprognostic (2.43e-1)" "prognostic unfavorable (1.46e-4)" "unprognostic (8.49e-2)" "unprognostic (2.64e-2)" "unprognostic (4.24e-2)" "unprognostic (1.02e-1)" "unprognostic (2.31e-2)" "unprognostic (1.99e-1)" "unprognostic (4.57e-2)" "unprognostic (4.77e-1)" "prognostic unfavorable (2.15e-5)" "unprognostic (1.06e-2)" "unprognostic (1.40e-1)" "unprognostic (4.22e-2)" "prognostic favorable (5.65e-4)" 12.4 17.5 26.6 13.5 27.4 51.3 27.4 82.3 35.5 18.9 24.3 12.3 10.8 12.9 19.7 26.5 13.2 17.4 26.1 28.1 29.0 18.0 33.9 14.2 20.2 27.1 27.8 20.4 16.9 18.8 26.7 11.1 28.9 24.8 13.2 18.0 30.3 11.3 85.3 23.1 10.8 10.6 27.6 17.2 14.0 53.1 30.2 24.8 14.2 70.0 22.2 30.8 18.9 28.9 40.2 23.5 40.6 80.4 21.8 20.7 33.8 25.2 29.3 41.5 37.7 33.1 46.0 36.4 31.1 16.5 43.4 20.0 34.1 29.5 50.3 23.8 36.7 26.5 18.2 45.3 34.1 18.6 280.6 18.8 34.4 30.1 35.4 51.8 32.1 77.2 58.4 22.4 40.3 23.6 78.0 52.6 54.4 48.4 26.7 44.2 40.8 31.4 78.4 32.1 22.7 41.8 29.9 19.9 79.0 41.4 52.5 31.5 17.8 19.1 27.0 48.8 24.6 32.5 58.4 52.2 19.3 39.4 52.2 47.6 15.1 48.1 12.0 18.8 13.3 12.2 12.5 13.0 15.7 11.1 14.1 13.3 63.6 22.2 26.3 84.9 19.3 11.5 26.6 27.4 82.3 35.5 28.1 29.0 27.1 27.8 28.9 27.6 30.2 28.9 13.9 3.2 13.6 6.8 20.2 16.8 30.1 14.2 31.3 2.9 14.3 15.1 21.6 7.2 20.7 7.3 8.4 7.5 51.9 3.1 5.9 11.7 254.5 13.8 7.7 12.5 6.0 7.6 15.8 9.6 7.0 9.7 10.2 9.9 23.4 12.7 8.6 12.7 7.4 6.7 20.3 5.4 4.1 5.7 9.9 133.9 7.2 18.2 7.2 19.7 11.2 8.3 13.4 12.5 16.7 33.6 5.8 3.8 21.9 41.6 4.3 6.8 16.4 4.4 0.0 6.6 12.3 19.4 15.4 27.3 20.0 11.1 16.2 7.8 6.6 31.6 POLE POLE1 ENSG00000177084 "DNA polymerase epsilon, catalytic subunit" Q07864 12 132623753-132687376 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "DNA damage, DNA repair, DNA replication" "DNA-binding, DNA-directed DNA polymerase, Hydrolase, Nucleotidyltransferase, Transferase" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Spermatocytes: 46.6" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in some" 4 "cerebellum: 4.1;cerebral cortex: 1.1;hippocampal formation: 1.6" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in single" "Not detected" "Not detected" "HPA058210, HPA067385" Supported "Nucleoplasm,Plasma membrane" NA NA "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 24: NB-4 - Immune response" "Cluster 12: Non-specific - Cell cycle regulation" Nucleoplasm "Plasma membrane" "HPA058210: AB_2683639, HPA067385: AB_2685830" "unprognostic (1.60e-1)" "unprognostic (1.77e-3)" "unprognostic (2.00e-1)" "unprognostic (9.17e-2)" "unprognostic (1.68e-1)" "unprognostic (2.01e-2)" "unprognostic (3.96e-3)" "unprognostic (2.23e-1)" "prognostic unfavorable (1.44e-4)" "unprognostic (7.12e-2)" "unprognostic (2.21e-1)" "unprognostic (1.67e-1)" "prognostic unfavorable (3.19e-8)" "unprognostic (8.60e-2)" "unprognostic (3.18e-1)" "unprognostic (1.28e-1)" "unprognostic (9.95e-2)" 6.0 2.9 0.2 6.1 0.2 24.7 6.0 4.1 1.1 6.4 0.3 7.3 6.5 5.4 2.1 7.0 6.2 3.1 4.3 1.6 0.0 3.0 8.6 5.0 7.2 0.3 0.1 7.8 6.5 2.6 2.7 5.3 0.3 6.4 6.3 2.4 6.1 3.3 7.5 13.2 8.5 3.7 0.1 16.2 8.0 16.2 0.5 15.7 4.7 3.0 7.1 6.1 6.2 0.3 25.3 33.3 48.7 22.0 10.2 7.6 39.9 26.0 11.7 30.3 21.8 38.3 14.5 28.7 10.2 14.1 11.6 33.6 35.4 16.7 18.8 13.3 41.2 45.4 45.7 15.2 1.9 37.2 24.9 5.5 6.0 31.8 10.5 8.1 10.8 35.1 53.4 15.7 14.9 33.3 61.8 46.8 36.9 9.3 18.5 48.0 27.6 13.0 6.9 40.8 40.6 22.0 30.0 22.7 4.7 23.4 35.0 19.1 9.9 26.5 24.7 20.6 25.9 20.3 14.5 44.8 14.7 26.3 19.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.2 4.1 1.1 1.6 0.0 0.3 0.1 0.3 0.1 0.5 0.3 3.2 0.0 6.7 7.5 4.0 5.7 3.8 3.0 4.0 8.7 7.8 6.7 6.9 1.5 1.6 1.8 0.0 8.8 5.6 18.8 0.0 2.3 8.2 3.2 3.8 4.9 7.2 14.9 13.6 3.3 10.8 5.1 11.2 6.8 2.5 16.2 8.9 10.5 13.2 0.0 7.6 9.1 2.0 6.9 5.4 9.7 6.8 2.9 5.4 4.7 1.6 2.6 2.1 3.5 2.9 2.6 6.0 3.4 6.3 4.0 4.1 1.0 1.9 6.1 26.3 7.0 6.1 46.6 18.2 5.8 7.7 4.0 5.8 2.9 10.9 2.8 POLE2 DPE2 ENSG00000100479 "DNA polymerase epsilon 2, accessory subunit" P56282 14 49643555-49688422 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "DNA replication" DNA-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 18.2" "Cell type enhanced" "Detected in many" "Erythroid cells: 21.0;Spermatogonia: 24.4" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in some" HPA027555 Uncertain Supported "Nucleoplasm,Nuclear bodies,Vesicles" No No "Cluster 48: NK-cells - Unknown function" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 10: Non-specific - Unknown function" "Nucleoplasm, Nuclear bodies" Vesicles "HPA027555: AB_10610282" "unprognostic (1.42e-1)" "unprognostic (6.57e-3)" "unprognostic (3.53e-2)" "unprognostic (7.44e-2)" "unprognostic (2.04e-2)" "unprognostic (4.99e-3)" "unprognostic (7.60e-3)" "unprognostic (2.32e-3)" "unprognostic (1.10e-3)" "unprognostic (2.69e-2)" "unprognostic (1.88e-2)" "unprognostic (1.37e-3)" "unprognostic (5.13e-11)" "unprognostic (9.97e-2)" "unprognostic (1.66e-1)" "unprognostic (1.27e-1)" "unprognostic (1.50e-3)" 0.9 0.9 0.5 5.1 0.3 18.2 3.0 0.5 0.6 2.1 0.0 3.8 2.5 2.5 0.7 3.7 1.0 0.9 0.6 0.2 0.2 0.7 3.1 1.2 5.1 0.2 0.4 1.0 0.8 0.7 0.5 3.0 0.2 1.4 4.5 3.0 1.0 0.7 0.5 3.5 3.6 2.3 0.3 1.5 2.1 4.1 0.2 5.5 0.9 0.9 6.2 1.4 1.9 0.6 37.2 18.6 34.3 16.3 1.7 9.9 18.2 20.4 10.4 31.9 36.7 19.3 27.5 23.6 11.6 11.6 17.5 22.3 35.3 12.8 36.9 27.4 19.6 35.4 20.6 23.9 0.8 41.2 14.6 2.8 0.8 18.5 2.9 4.1 19.0 30.5 30.9 14.3 31.6 32.7 43.6 28.4 20.2 30.9 42.6 35.9 31.7 21.0 11.6 20.6 24.8 14.3 20.5 11.9 6.7 16.5 24.5 15.8 6.7 5.3 38.5 21.4 16.9 10.7 22.7 52.7 9.8 30.1 20.9 0.0 0.0 0.2 0.2 0.0 0.1 0.3 0.2 0.4 0.1 0.2 0.0 0.2 0.0 0.9 0.0 0.2 0.7 0.1 0.5 0.3 0.5 0.6 0.2 0.2 0.2 0.4 0.2 0.3 0.2 0.6 2.0 3.2 0.5 4.2 2.4 4.8 2.1 1.9 2.2 0.8 1.5 1.1 1.2 1.5 1.3 0.0 0.0 9.1 1.0 2.2 0.0 1.3 1.2 0.8 2.6 1.5 1.2 21.0 9.5 1.5 10.6 2.7 1.1 1.5 0.0 4.3 5.0 5.5 5.5 0.0 11.9 2.8 0.0 1.9 1.6 0.8 1.5 1.1 1.8 7.5 1.0 2.0 4.1 12.1 11.5 0.8 0.5 3.0 5.7 1.9 1.1 1.2 0.9 3.1 0.0 2.1 7.4 5.3 24.4 6.0 3.7 3.4 1.7 1.8 4.7 1.5 POLE3 "CHARAC17, CHRAC17, CHRAC2, p17, Ybl1" ENSG00000148229 "DNA polymerase epsilon 3, accessory subunit" Q9NRF9 9 113407235-113410675 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" DNA-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA047945 Uncertain Approved Nucleoplasm,Nucleoli NA NA "Cluster 12: Non-specific - Basic cellular processes" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 39: Non-specific - Basic cellular processes" "Nucleoplasm, Nucleoli" "HPA047945: AB_2680218" "unprognostic (9.55e-2)" "unprognostic (3.39e-3)" "unprognostic (1.56e-1)" "unprognostic (1.67e-1)" "unprognostic (6.52e-2)" "unprognostic (1.86e-2)" "prognostic unfavorable (8.35e-4)" "unprognostic (1.04e-2)" "unprognostic (1.60e-2)" "unprognostic (1.10e-1)" "unprognostic (4.59e-3)" "unprognostic (2.31e-3)" "unprognostic (1.75e-2)" "unprognostic (1.56e-2)" "unprognostic (1.04e-1)" "unprognostic (1.28e-1)" "unprognostic (1.18e-1)" 25.4 32.9 20.3 34.9 20.9 113.5 31.7 24.7 24.2 25.8 17.3 29.6 25.4 25.2 26.0 39.7 28.2 18.0 26.4 21.2 19.7 23.6 38.1 23.7 53.6 21.9 19.6 22.6 27.4 26.7 11.2 26.6 21.5 23.0 32.8 16.4 27.2 22.8 79.1 37.3 26.3 27.8 20.8 33.0 24.9 41.1 19.8 55.1 21.8 56.4 56.7 28.5 24.8 21.5 85.0 103.3 71.2 107.6 39.8 35.3 62.5 110.3 56.0 122.1 95.6 96.5 75.0 305.5 66.9 65.0 74.5 141.4 140.3 121.4 112.0 58.8 84.7 158.9 97.7 99.5 42.4 333.5 92.2 40.5 82.2 106.3 135.5 44.3 86.0 152.7 225.7 165.6 85.9 215.1 230.6 178.4 92.1 180.7 184.8 232.4 296.3 171.8 53.4 79.8 153.8 88.7 160.2 100.0 89.4 43.0 149.7 148.1 71.3 90.0 122.3 115.2 191.2 86.0 301.5 407.4 82.2 193.5 110.1 77.4 85.4 90.4 83.8 87.0 104.2 86.3 78.9 79.8 83.3 82.4 84.8 79.3 17.5 77.4 71.6 83.6 102.0 135.2 20.3 20.9 24.7 24.2 21.2 19.7 21.9 19.6 21.5 20.8 19.8 21.5 37.2 38.5 30.2 2.0 61.4 93.8 30.8 37.0 66.0 15.0 51.9 49.9 43.6 21.5 35.8 31.3 6.2 60.7 73.9 28.9 43.0 35.7 5.1 45.4 53.7 33.9 24.6 101.6 4.7 45.4 62.5 37.6 22.4 44.1 57.5 41.4 25.7 43.1 49.3 13.5 3.9 36.9 28.5 36.5 66.4 16.4 35.8 44.7 40.9 1.9 60.3 29.9 48.4 3.5 3.6 37.6 13.9 42.5 67.8 36.0 18.3 34.4 35.5 18.3 13.1 47.9 45.7 40.2 93.1 87.6 94.9 34.9 65.5 36.3 42.5 22.6 POLE4 p12 ENSG00000115350 "DNA polymerase epsilon 4, accessory subunit" Q9NR33 2 74958643-74970128 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" DNA-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "NB-4: 110.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA054979, HPA071815" Approved Approved Nucleoplasm,Cytosol NA NA "Cluster 26: Non-specific - Mitochondria" "Cluster 47: Non-specific - Unknown function" "Cluster 24: NB-4 - Immune response" "Cluster 39: Non-specific - Basic cellular processes" Nucleoplasm Cytosol "HPA054979: AB_2682661, HPA071815: AB_2686453" "unprognostic (2.56e-2)" "unprognostic (4.27e-2)" "unprognostic (1.17e-1)" "unprognostic (4.19e-2)" "unprognostic (4.85e-2)" "unprognostic (1.59e-2)" "prognostic unfavorable (6.49e-4)" "unprognostic (3.09e-1)" "unprognostic (1.99e-1)" "unprognostic (2.95e-1)" "unprognostic (1.39e-2)" "unprognostic (4.44e-2)" "unprognostic (8.64e-3)" "unprognostic (6.61e-2)" "unprognostic (3.73e-1)" "unprognostic (3.47e-2)" "unprognostic (1.95e-1)" 19.7 17.1 16.0 5.4 16.1 23.3 19.9 14.5 25.3 14.7 13.9 16.4 5.9 12.0 2.7 11.4 11.9 7.7 15.0 15.8 14.9 14.5 15.2 12.1 12.5 15.4 15.2 13.6 8.6 3.0 3.1 6.5 15.8 10.7 6.0 7.1 12.2 6.7 29.0 10.5 13.2 7.3 15.1 12.1 14.6 6.8 15.5 5.3 10.3 16.9 7.3 15.0 12.0 17.2 37.4 33.5 3.3 3.3 11.2 23.4 0.0 24.3 29.1 36.6 30.7 43.1 16.2 33.3 19.9 26.6 10.1 16.0 15.6 19.5 39.6 15.5 42.2 28.0 20.3 46.7 38.8 40.4 41.5 23.8 37.0 15.3 33.3 12.6 16.1 4.8 33.9 21.2 28.1 35.6 12.0 110.1 24.2 23.0 59.1 14.1 28.8 29.4 30.3 1.0 10.8 15.9 33.5 13.9 19.1 1.9 10.4 13.6 18.4 8.7 9.6 6.0 24.7 7.3 5.0 12.8 31.2 58.8 43.4 7.0 53.6 19.1 13.3 32.7 14.5 35.2 19.2 16.1 29.7 33.3 20.5 14.7 3.5 10.6 30.2 33.8 20.4 31.8 16.0 16.1 14.5 25.3 15.8 14.9 15.4 15.2 15.8 15.1 15.5 17.2 156.9 25.6 40.4 3.9 83.9 84.5 96.6 82.4 62.0 33.9 89.9 80.4 40.3 48.6 52.6 73.5 43.8 156.3 69.5 116.4 148.7 53.6 12.1 37.3 34.2 96.0 12.2 50.9 6.2 80.7 154.7 66.4 30.5 33.4 61.6 53.9 94.2 147.1 115.6 18.5 6.6 100.8 44.7 113.7 111.5 24.0 67.1 91.9 97.8 9.4 134.1 174.9 87.6 4.0 11.1 83.5 157.5 54.5 55.8 100.3 190.7 182.3 49.2 126.8 78.9 99.4 68.8 45.9 91.5 57.8 97.7 94.0 70.3 108.1 88.3 95.4 PPARA "hPPAR, NR1C1, PPAR" ENSG00000186951 "Peroxisome proliferator activated receptor alpha" Q07869 22 46150521-46243756 "FDA approved drug targets, Metabolic proteins, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "tongue: 44.6" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 99.4;Hepatocytes: 144.5;Proximal enterocytes: 93.2;Rod photoreceptor cells: 148.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "eosinophil: 10.3;plasmacytoid DC: 3.1" "Group enriched" "Detected in many" 5 "dendritic cells: 3.1;granulocytes: 10.3" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058901, HPA067049, CAB075701" Supported Enhanced Nucleoplasm NA NA "Cluster 49: Eosinophils - Unknown function" "Cluster 39: Non-specific - Mitochondria" "Cluster 3: HMC-1 - Innate immune response" "Cluster 46: Photoreceptor cells - Phototransduction" Nucleoplasm "CAB075701: , HPA058901: AB_2683849, HPA067049: AB_2685770" "unprognostic (1.96e-1)" "unprognostic (2.19e-1)" "unprognostic (1.02e-1)" "unprognostic (4.76e-2)" "unprognostic (3.94e-3)" "unprognostic (4.30e-2)" "unprognostic (1.24e-1)" "unprognostic (4.94e-2)" "unprognostic (2.95e-1)" "unprognostic (5.52e-3)" "unprognostic (4.50e-2)" "unprognostic (1.01e-1)" "prognostic favorable (4.39e-9)" "unprognostic (4.84e-2)" "unprognostic (2.76e-1)" "unprognostic (1.23e-1)" "unprognostic (3.18e-2)" 7.9 6.3 9.6 4.5 12.7 6.6 3.8 9.5 6.9 4.1 23.5 11.8 18.4 3.8 3.6 7.7 4.1 4.4 26.3 7.7 8.8 22.4 33.2 4.0 3.4 11.0 11.2 11.2 8.2 7.4 2.6 4.3 10.0 6.2 9.1 18.2 7.8 5.7 26.2 7.7 18.4 4.3 8.6 4.4 6.1 1.3 11.7 3.7 7.0 44.6 3.9 5.1 4.0 10.5 7.8 1.9 2.4 8.4 13.0 8.3 5.3 6.7 13.2 7.0 7.2 3.8 3.7 2.8 3.3 15.6 6.5 3.5 7.1 8.7 6.3 8.1 8.9 8.7 4.8 8.0 8.1 6.0 14.3 6.6 6.9 5.2 11.8 6.0 1.5 6.3 3.2 6.4 6.6 2.0 6.8 2.2 0.3 6.5 1.9 8.0 8.6 3.6 4.7 4.6 2.4 7.0 2.6 2.4 8.0 3.2 2.7 4.6 2.6 7.3 7.7 6.7 2.9 6.3 4.0 1.2 11.4 6.6 2.3 1.4 0.8 10.3 1.0 1.0 0.8 0.8 0.5 0.5 0.6 1.0 0.6 0.4 0.7 0.7 0.7 3.1 1.4 0.2 9.6 12.7 9.5 6.9 7.7 8.8 11.0 11.2 10.0 8.6 11.7 10.5 15.0 3.2 13.6 49.6 8.0 23.3 15.0 7.8 9.1 15.0 14.3 11.4 99.4 22.8 8.9 7.3 62.6 8.0 18.4 58.8 9.8 10.3 0.6 9.4 26.4 15.5 19.9 32.0 1.4 16.6 6.7 16.0 14.8 18.4 5.1 19.1 22.5 144.5 8.8 5.0 13.8 31.4 0.0 24.8 10.2 1.1 19.6 10.4 3.6 10.3 12.2 16.0 8.2 19.6 27.2 13.0 24.5 30.1 10.6 19.1 93.2 40.8 5.0 148.0 6.6 31.0 15.8 0.7 1.7 19.3 34.2 3.0 9.6 14.6 37.9 19.9 PPARD "FAAR, NR1C2, NUC1, NUCII" ENSG00000112033 "Peroxisome proliferator activated receptor delta" Q03181 6 35342558-35428191 "FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Distal enterocytes: 67.7;Pancreatic endocrine cells: 102.5;Syncytiotrophoblasts: 98.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB017635 Approved NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 27: Brain & Skin - Unknown function" "Cluster 28: BEWO - Transcription regulation" "Cluster 53: Intestinal epithelial cells - Unknown function" "CAB017635: AB_1128605" "unprognostic (3.70e-2)" "unprognostic (8.75e-2)" "unprognostic (1.00e-1)" "unprognostic (1.89e-1)" "unprognostic (1.57e-1)" "unprognostic (8.68e-2)" "prognostic unfavorable (4.57e-4)" "unprognostic (4.59e-3)" "unprognostic (4.34e-1)" "unprognostic (1.45e-1)" "unprognostic (1.05e-1)" "unprognostic (1.51e-3)" "unprognostic (7.27e-3)" "unprognostic (1.43e-1)" "unprognostic (9.42e-2)" "unprognostic (5.95e-2)" "unprognostic (2.00e-2)" 21.0 20.6 31.9 18.7 30.2 9.1 18.4 27.4 35.3 25.3 22.2 24.2 11.6 19.1 18.4 45.9 19.7 14.9 23.0 35.9 26.5 29.9 31.8 31.5 15.5 31.3 31.5 32.0 12.2 14.2 24.6 28.3 31.2 28.2 12.3 10.9 20.5 17.2 29.4 28.9 27.4 11.3 29.1 30.7 29.8 14.1 36.1 7.6 40.9 13.4 13.8 23.5 33.7 27.8 51.0 8.9 13.7 29.3 20.0 34.9 74.3 40.6 36.1 34.2 28.4 12.0 9.4 8.1 11.6 29.1 19.4 17.8 13.0 39.4 23.8 11.8 11.8 7.7 12.2 17.9 35.0 1.9 8.3 59.7 13.0 50.7 25.9 39.0 16.2 9.9 8.1 8.9 29.1 16.1 5.6 8.2 6.7 19.1 23.9 7.9 23.5 8.2 8.5 44.7 7.7 21.4 16.3 27.9 34.5 9.4 10.4 28.1 35.1 46.3 17.5 28.1 49.1 7.5 11.2 8.7 15.2 16.3 21.2 0.5 1.5 3.3 1.2 1.3 0.9 1.3 1.3 1.2 1.3 1.7 2.2 2.1 2.3 1.0 0.9 0.8 1.4 1.1 31.9 30.2 27.4 35.3 35.9 26.5 31.3 31.5 31.2 29.1 36.1 27.8 14.8 9.6 7.8 11.8 8.8 18.7 19.5 7.5 5.7 7.6 6.6 6.2 11.0 10.0 11.6 1.8 2.1 35.6 3.2 67.7 3.9 30.9 3.0 9.7 8.5 11.9 6.6 1.7 24.4 24.1 32.1 8.0 31.6 18.3 22.9 5.5 6.1 5.6 14.9 5.0 18.7 9.2 10.2 6.6 18.3 3.6 5.9 17.0 12.4 59.0 4.3 8.0 6.2 23.1 42.8 102.5 38.6 8.2 6.1 18.5 22.6 6.3 5.1 7.5 13.1 9.6 10.2 6.2 7.7 7.2 12.8 98.1 7.1 18.8 8.1 51.4 PPARG "NR1C3, PPARG1, PPARG2, PPARgamma" ENSG00000132170 "Peroxisome proliferator activated receptor gamma" P37231 3 12287368-12434356 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Diabetes mellitus, Disease variant, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 165.1" "Cell type enhanced" "Detected in many" "Adipocytes: 284.1;Extravillous trophoblasts: 217.8;Granulosa cells: 232.9;Urothelial cells: 239.6" "Cancer enhanced" "Detected in all" "urothelial cancer: 33.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC diff: 198.7;ASC TERT1: 113.7;BEWO: 247.5;CAPAN-2: 111.6;HSkMC: 118.9;PC-3: 112.0;RT4: 157.5" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB004282, HPA051239, HPA063663" Approved Enhanced Nucleoplasm,Vesicles NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 28: BEWO - Transcription regulation" "Cluster 40: Granulosa cells - Unknown function" "Nucleoplasm, Vesicles" "CAB004282: AB_628115, HPA051239: AB_2681400, HPA063663: AB_2685081" "unprognostic (7.35e-3)" "unprognostic (3.27e-2)" "unprognostic (4.05e-2)" "unprognostic (8.37e-2)" "unprognostic (2.41e-2)" "unprognostic (5.27e-3)" "prognostic unfavorable (3.41e-5)" "unprognostic (9.13e-2)" "unprognostic (2.32e-2)" "unprognostic (1.38e-1)" "unprognostic (1.02e-2)" "unprognostic (2.77e-1)" "prognostic favorable (1.59e-8)" "unprognostic (1.51e-2)" "unprognostic (1.46e-1)" "unprognostic (9.68e-3)" "prognostic favorable (5.52e-5)" 165.1 3.9 4.0 8.7 3.0 3.0 74.3 3.2 4.7 9.7 0.6 48.7 23.6 7.0 1.2 6.2 7.0 10.5 14.6 4.0 2.7 14.3 17.1 28.5 4.9 3.7 3.5 14.5 2.8 7.9 0.5 43.6 3.4 5.5 40.6 1.0 5.7 1.7 5.2 6.2 15.1 8.7 3.2 12.0 35.5 6.9 3.5 4.1 13.2 8.1 2.1 67.7 9.1 5.0 44.0 38.6 0.0 0.2 198.7 113.7 247.5 3.7 44.7 5.4 2.1 7.8 111.6 0.0 0.1 4.0 72.9 17.3 14.4 0.7 1.0 106.4 20.3 0.0 8.1 10.3 51.8 0.2 0.1 118.9 9.7 9.8 37.5 20.6 0.7 1.0 0.0 0.0 8.3 11.0 0.1 0.8 0.7 99.2 112.0 0.0 0.0 0.2 30.6 157.5 0.1 1.2 18.8 6.7 2.2 6.7 0.0 34.2 35.0 7.8 10.6 4.6 0.2 0.0 0.1 0.3 3.2 0.5 1.2 0.0 0.3 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 4.0 3.0 3.2 4.7 4.0 2.7 3.7 3.5 3.4 3.2 3.5 5.0 284.1 3.2 7.2 1.6 0.6 1.0 50.5 0.4 4.6 0.9 1.9 2.8 9.2 1.5 2.5 5.5 0.0 110.4 1.8 93.4 1.9 1.1 4.9 5.2 1.4 26.1 8.4 0.0 39.3 0.7 217.8 12.3 83.1 20.8 8.9 232.9 25.7 3.4 49.9 0.0 74.1 21.3 0.0 19.4 4.8 2.2 4.1 19.1 3.6 38.4 1.8 0.6 0.0 6.6 1.2 17.3 84.1 0.0 1.6 42.1 17.0 14.3 1.5 0.2 13.1 1.9 31.3 10.9 22.8 4.6 1.1 88.9 2.2 0.8 24.5 239.6 PPIA CYPA ENSG00000196262 "Peptidylprolyl isomerase A" P62937 7 44796680-44824564 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Apoptosis, Host-virus interaction" "Isomerase, Rotamase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "CAB004655, HPA058345" Uncertain "Secreted to blood" NA NA 230000000 "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 32: Non-specific - Translation" "CAB004655: AB_425607, HPA058345: AB_2683685" "unprognostic (3.10e-1)" "unprognostic (2.28e-1)" "unprognostic (1.27e-1)" "unprognostic (7.86e-2)" "unprognostic (9.27e-2)" "unprognostic (2.19e-2)" "prognostic unfavorable (2.27e-6)" "unprognostic (1.12e-3)" "unprognostic (3.30e-2)" "unprognostic (3.92e-2)" "unprognostic (8.68e-3)" "unprognostic (2.52e-1)" "unprognostic (6.35e-3)" "unprognostic (2.77e-1)" "unprognostic (1.24e-1)" "unprognostic (7.84e-2)" "unprognostic (1.16e-1)" 1148.4 1085.6 1707.2 714.4 1757.6 1052.9 1368.0 1733.9 2245.6 943.7 1718.8 1352.6 603.7 854.8 981.6 2149.0 771.3 548.8 781.6 1785.4 1791.4 1412.8 1318.6 1099.2 1067.1 1857.4 1728.1 799.5 967.7 1286.3 670.1 805.9 1860.7 766.1 1196.0 496.7 1020.3 782.9 566.1 1516.0 953.4 943.4 1767.2 1134.4 896.7 366.0 1742.4 2333.2 884.9 517.9 1647.3 1339.3 1208.7 1822.8 2141.8 3020.1 3731.1 2509.6 2798.6 4154.8 1115.0 3173.6 4588.0 5531.3 5393.2 3414.3 3127.1 4614.1 1893.1 3828.8 6554.2 3209.5 4495.7 5727.5 5062.6 2674.3 3204.3 1883.6 3911.6 4682.5 2255.3 3890.0 2246.2 3103.5 3820.5 3988.9 4295.5 2888.1 5717.2 3277.9 3933.2 3789.6 5790.6 3665.7 4667.5 7562.4 4612.9 7628.9 3689.2 3554.4 2050.1 5969.7 8018.9 4215.4 2548.3 2218.7 2500.5 7185.8 2493.3 4091.8 4303.8 5202.3 2587.0 2865.0 3656.5 2027.1 4050.5 3861.7 6522.3 9409.0 2614.0 4314.6 4455.2 475.6 1239.3 594.8 1421.6 1449.2 1534.2 2104.8 1500.3 1491.1 2196.1 1769.5 1217.2 1394.4 133.3 1349.0 1374.8 2618.5 2085.4 3631.4 1707.2 1757.6 1733.9 2245.6 1785.4 1791.4 1857.4 1728.1 1860.7 1767.2 1742.4 1822.8 713.8 794.9 759.9 37.2 1037.1 866.6 867.8 1097.5 1878.1 94.3 1226.2 1628.0 47.6 526.1 743.6 603.2 18.8 852.7 1067.7 658.4 1414.6 1172.4 78.2 539.3 770.8 719.7 529.6 1120.3 57.3 1218.7 1683.7 672.4 820.1 862.1 622.1 650.0 669.7 766.9 1582.1 111.0 50.4 1003.5 587.9 1110.0 786.1 81.4 582.2 988.1 691.9 41.2 1283.2 221.6 995.9 27.2 79.8 1222.6 715.0 613.1 1215.3 922.1 831.6 1636.8 481.4 101.5 394.4 588.7 942.7 366.7 246.1 2608.3 990.4 609.2 924.5 1157.5 1262.6 947.0 PPIF "Cyp-D, hCyP3" ENSG00000108179 "Peptidylprolyl isomerase F" P30405 10 79347469-79355334 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Necrosis" "Isomerase, Rotamase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Langerhans cells: 370.9;Macrophages: 160.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "neutrophil: 75.0" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA077416 Supported Mitochondria NA NA 320000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 55: Non-specific - Mitochondria & Proteasome" "Cluster 1: K-562 - Erythropoiesis" "Cluster 41: Macrophages - Immune response" Mitochondria "HPA077416: AB_2686840" "unprognostic (2.21e-1)" "unprognostic (5.48e-2)" "unprognostic (1.68e-1)" "unprognostic (1.72e-3)" "unprognostic (1.69e-1)" "unprognostic (3.16e-3)" "unprognostic (3.45e-1)" "unprognostic (4.33e-3)" "unprognostic (1.66e-1)" "unprognostic (1.97e-1)" "unprognostic (2.82e-1)" "unprognostic (9.37e-3)" "unprognostic (1.02e-3)" "unprognostic (1.23e-1)" "unprognostic (1.66e-1)" "unprognostic (1.69e-3)" "unprognostic (4.88e-2)" 62.7 227.7 42.7 42.8 48.4 168.8 42.4 57.9 69.6 27.6 63.7 50.0 36.3 14.0 7.2 66.0 22.9 19.5 119.1 38.1 45.2 63.3 174.9 29.1 32.3 49.0 56.2 19.3 86.9 77.6 18.3 27.1 48.8 18.8 52.4 8.9 39.5 45.5 99.5 71.9 31.3 21.0 50.6 58.7 98.2 35.0 57.1 28.3 26.0 133.6 55.5 60.0 35.1 60.8 220.4 90.6 62.3 123.5 57.0 73.6 79.8 124.2 161.2 265.7 249.6 213.5 102.7 224.8 68.0 87.4 188.6 127.8 195.3 115.4 410.5 72.2 186.4 352.8 87.5 380.7 96.4 245.7 80.4 173.2 81.3 264.5 262.3 86.5 47.5 86.4 351.6 268.3 91.6 111.7 64.1 204.2 53.0 99.6 500.6 109.8 96.4 114.7 103.9 200.0 124.1 92.0 63.6 253.8 97.9 40.5 111.4 187.2 43.5 116.1 106.3 137.9 242.0 124.7 137.7 181.9 114.5 313.9 32.0 15.2 34.3 18.0 10.4 27.5 10.9 19.1 9.1 9.6 43.3 7.7 8.1 7.9 75.0 9.0 10.4 5.4 10.0 16.6 42.7 48.4 57.9 69.6 38.1 45.2 49.0 56.2 48.8 50.6 57.1 60.8 8.4 6.4 6.8 7.2 32.7 42.6 30.2 23.8 31.3 4.0 41.8 40.8 124.6 14.3 14.4 12.9 6.2 99.4 26.4 39.9 92.0 42.1 14.5 12.4 24.0 10.1 21.6 37.0 4.1 28.0 127.1 25.1 78.0 15.5 13.4 73.4 6.1 98.5 91.1 8.4 5.7 69.5 18.3 40.3 370.9 14.1 6.2 160.8 35.6 4.7 32.0 13.0 5.2 5.5 15.0 39.8 26.6 6.0 48.7 41.4 21.3 41.2 12.6 5.2 19.7 18.2 28.6 14.8 22.5 52.9 37.6 142.3 23.9 60.2 81.1 34.2 PPP3R2 PPP3RL ENSG00000188386 "Protein phosphatase 3 regulatory subunit B, beta" Q96LZ3 9 101591604-101595021 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 161 "testis: 80.8" "Group enriched" "Detected in some" 38 "Early spermatids: 399.2;Late spermatids: 198.3;Spermatocytes: 600.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA047157 Uncertain Approved "Plasma membrane,Cytosol" NA NA "Cluster 74: Testis - Spermatogenesis" "Cluster 66: Spermatocytes - Spermatogenesis" "Plasma membrane" Cytosol "HPA047157: AB_2679960" "unprognostic (8.81e-2)" "unprognostic (2.65e-1)" 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 80.8 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.5 0.1 0.0 0.4 0.1 0.4 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 399.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 198.3 10.5 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 6.6 0.1 0.2 600.6 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PRDX5 "ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10" ENSG00000126432 "Peroxiredoxin 5" P30044 11 64318121-64321811 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Antioxidant, Oxidoreductase, Peroxidase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Respiratory ciliated cells: 2430.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB008661, HPA037915, HPA037916" Enhanced Supported Mitochondria NA NA 6900000 "Cluster 31: Non-specific - Inflammatory response" "Cluster 39: Non-specific - Mitochondria" "Cluster 25: RPMI-8226 - Immune response" "Cluster 26: Respiratory epithelial cells - Mucosal defense" Mitochondria "CAB008661: AB_1620988, HPA037915: AB_2675735, HPA037916: AB_2675736" "unprognostic (2.75e-1)" "unprognostic (4.08e-1)" "unprognostic (1.33e-1)" "unprognostic (1.46e-1)" "unprognostic (9.43e-2)" "unprognostic (6.71e-3)" "unprognostic (1.08e-3)" "unprognostic (3.11e-1)" "unprognostic (9.30e-2)" "unprognostic (1.07e-3)" "unprognostic (1.57e-2)" "unprognostic (2.20e-1)" "prognostic favorable (1.24e-5)" "unprognostic (8.19e-2)" "unprognostic (2.30e-1)" "unprognostic (9.63e-2)" "unprognostic (5.03e-2)" 181.8 400.3 346.0 112.7 342.6 285.7 170.1 375.9 429.4 227.2 480.2 346.6 213.3 153.7 176.6 448.5 400.3 120.7 467.4 340.4 384.6 377.1 280.3 217.2 110.1 382.8 373.3 246.0 224.9 254.5 313.3 164.1 387.0 165.5 299.6 109.0 286.2 164.4 504.0 181.1 226.1 97.1 365.2 162.9 313.9 150.1 377.8 167.7 354.5 439.6 137.8 192.5 244.8 346.4 225.3 453.4 267.9 444.5 284.3 424.4 308.5 274.9 442.3 199.8 247.4 332.9 451.8 329.2 467.0 447.4 712.6 503.5 253.3 589.4 125.8 456.6 200.8 333.3 728.8 386.3 581.0 127.8 271.3 432.4 757.2 334.9 337.8 387.6 308.4 380.6 191.5 755.6 285.5 572.0 220.9 547.8 402.6 356.5 573.9 210.9 274.5 1178.8 760.1 442.9 224.7 424.9 230.8 506.8 818.8 254.3 370.5 283.3 298.3 281.8 258.6 326.7 123.1 383.1 490.8 392.4 340.7 253.7 223.6 703.9 465.4 630.7 251.0 432.9 218.3 393.5 229.0 205.1 369.8 409.0 224.5 225.9 802.3 368.5 399.0 487.9 297.1 639.6 346.0 342.6 375.9 429.4 340.4 384.6 382.8 373.3 387.0 365.2 377.8 346.4 213.7 266.0 463.4 17.6 182.1 326.5 760.2 1591.9 405.2 159.0 266.2 435.9 617.6 371.8 931.2 450.6 70.9 1122.2 185.8 846.1 1612.1 788.4 79.6 865.2 221.3 204.7 801.9 200.6 12.4 1039.2 1144.0 296.1 365.4 285.9 104.7 299.8 205.6 405.2 476.9 92.5 14.0 1041.6 1072.1 206.5 261.0 294.9 279.0 210.8 435.8 8.4 339.7 309.6 278.1 14.1 15.3 1487.3 641.3 226.8 288.9 401.3 922.4 1468.5 2430.7 150.3 197.2 176.2 433.1 150.2 333.9 482.8 257.7 978.9 165.2 713.3 1231.7 1077.1 PRKAA1 AMPKa1 ENSG00000132356 "Protein kinase AMP-activated catalytic subunit alpha 1" Q13131 5 40759379-40798374 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Autophagy, Biological rhythms, Cholesterol biosynthesis, Cholesterol metabolism, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism, Transcription, Transcription regulation, Wnt signaling pathway" "Chromatin regulator, Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 4 "Early spermatids: 292.5;Late spermatids: 478.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005050, HPA035409, HPA064946" Supported Supported "Nuclear speckles,Cytosol" NA NA "Cluster 31: Non-specific - Inflammatory response" "Cluster 34: Non-specific - Transcription" "Cluster 20: HeLa - Mitochondria" "Cluster 31: Spermatids - Spermatogenesis" "Nuclear speckles" Cytosol "CAB005050: AB_562037, HPA035409: AB_2674613, HPA064946: AB_2685390" "unprognostic (2.07e-1)" "unprognostic (1.41e-2)" "unprognostic (2.51e-2)" "unprognostic (3.57e-2)" "unprognostic (3.97e-1)" "unprognostic (1.05e-1)" "unprognostic (3.51e-2)" "unprognostic (7.53e-2)" "unprognostic (1.66e-2)" "unprognostic (2.88e-1)" "unprognostic (3.34e-3)" "unprognostic (2.63e-1)" "unprognostic (2.82e-2)" "unprognostic (1.35e-1)" "unprognostic (1.60e-1)" "unprognostic (1.27e-2)" "unprognostic (1.10e-2)" 33.3 21.0 7.9 27.2 9.6 52.6 30.2 10.3 11.0 26.7 12.3 30.0 35.4 26.3 18.6 20.6 21.0 33.5 20.2 6.9 11.3 32.0 49.9 27.4 29.2 11.8 9.9 19.1 23.1 32.0 9.2 21.2 12.2 31.9 34.7 19.0 27.4 24.7 16.9 23.1 30.9 26.4 10.2 27.8 33.7 41.1 10.0 21.8 32.3 19.9 23.9 28.8 17.8 10.3 28.4 28.9 22.8 30.2 55.0 57.0 21.6 47.3 48.1 34.7 30.8 27.6 35.9 16.6 21.4 48.8 45.3 22.4 21.3 43.1 64.9 49.2 19.2 33.1 66.1 22.1 45.3 31.9 33.5 52.8 20.6 46.5 47.5 38.4 52.1 21.0 15.9 46.7 52.4 13.6 29.7 24.9 9.9 28.9 34.6 24.5 48.7 24.6 53.3 47.5 19.6 19.7 83.0 54.3 28.8 12.3 28.4 26.0 56.0 62.1 33.5 36.2 39.2 18.5 15.4 19.6 38.9 67.9 33.9 17.0 6.5 12.8 8.9 7.9 11.5 8.2 8.4 8.6 6.4 7.9 10.1 9.0 15.4 10.9 9.3 1.9 11.6 6.5 7.9 9.6 10.3 11.0 6.9 11.3 11.8 9.9 12.2 10.2 10.0 10.3 47.3 41.7 26.5 19.2 34.1 24.1 24.7 40.5 15.4 20.3 36.1 17.9 18.3 42.9 43.4 47.8 35.5 13.8 45.8 44.1 7.9 27.9 292.5 19.7 35.8 42.4 21.1 25.4 24.5 44.9 13.7 36.2 36.7 20.7 18.3 17.8 37.1 83.4 20.0 15.2 30.3 28.8 42.7 25.3 28.5 478.5 30.4 24.1 35.6 24.4 40.9 15.4 44.3 30.7 43.8 36.0 32.8 25.9 23.4 33.4 33.7 35.4 42.9 27.9 0.0 22.7 43.1 82.8 17.6 19.9 32.7 18.6 44.0 19.2 36.9 35.0 PRKAA2 "AMPK, AMPKa2, PRKAA" ENSG00000162409 "Protein kinase AMP-activated catalytic subunit alpha 2" P54646 1 56645314-56715335 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Autophagy, Biological rhythms, Cholesterol biosynthesis, Cholesterol metabolism, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism, Transcription, Transcription regulation, Wnt signaling pathway" "Chromatin regulator, Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 40.8;skeletal muscle: 38.7;tongue: 36.4" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 328.5;Excitatory neurons: 109.4;Inhibitory neurons: 119.0;Oligodendrocyte precursor cells: 84.9;Rod photoreceptor cells: 115.5" "Cancer enhanced" "Detected in many" "renal cancer: 5.8" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "RPTEC TERT1: 14.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044540 Approved Supported "Nuclear speckles,Golgi apparatus" NA NA "Cluster 38: Heart - Muscle contraction" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 54: Cardiomyocytes - Muscle contraction" "Nuclear speckles" "Golgi apparatus" "HPA044540: AB_2678977" "unprognostic (4.17e-3)" "unprognostic (1.62e-2)" "unprognostic (4.17e-1)" "prognostic unfavorable (4.80e-4)" "unprognostic (9.35e-2)" "unprognostic (1.92e-3)" "prognostic unfavorable (5.30e-4)" "unprognostic (7.30e-2)" "unprognostic (3.94e-1)" "unprognostic (1.82e-1)" "unprognostic (1.97e-1)" "unprognostic (8.64e-2)" "prognostic favorable (4.95e-5)" "unprognostic (1.30e-2)" "unprognostic (4.52e-2)" "unprognostic (1.57e-2)" "unprognostic (1.85e-1)" 1.4 1.4 2.0 0.5 3.5 0.0 3.3 3.0 3.5 1.4 4.1 5.0 0.5 1.8 1.1 4.7 2.7 1.9 40.8 3.9 2.1 13.6 0.7 1.4 0.1 0.9 1.3 1.5 1.8 8.3 1.3 0.5 0.9 3.8 1.4 13.5 4.3 2.6 38.7 0.7 1.3 3.1 0.3 1.3 2.2 1.1 1.3 0.4 3.3 36.4 0.1 1.8 1.3 1.5 0.0 3.8 2.1 0.0 0.7 0.5 2.3 1.9 1.5 2.5 4.3 3.9 4.9 0.0 0.6 0.6 7.5 0.1 8.0 0.0 7.1 0.0 8.8 0.0 7.0 5.5 0.0 0.0 0.1 0.6 0.0 3.5 0.3 5.8 0.8 2.0 0.0 0.0 1.1 0.1 0.0 0.0 5.6 0.0 5.5 0.0 0.0 0.0 14.1 1.3 2.0 5.5 6.0 0.1 0.0 6.0 3.3 0.0 0.0 1.5 2.3 2.8 6.6 0.0 0.0 0.0 4.5 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 3.5 3.0 3.5 3.9 2.1 0.9 1.3 0.9 0.3 1.3 1.5 1.1 9.6 4.8 30.7 2.0 0.9 8.0 6.7 2.2 42.0 19.4 9.5 328.5 24.3 14.3 49.7 50.1 1.0 0.2 6.1 54.8 9.5 3.9 14.4 2.9 10.3 14.4 0.0 109.4 4.8 0.4 15.3 5.1 17.4 2.5 11.7 9.7 8.1 0.1 26.9 119.0 6.3 8.2 0.0 1.6 4.8 6.8 1.4 5.4 18.7 0.0 18.6 0.0 84.9 20.4 6.2 3.0 29.3 0.0 21.2 0.2 82.4 10.7 115.5 6.6 24.5 17.2 7.2 3.7 17.7 0.4 0.4 1.2 5.3 6.1 13.4 PRKAB1 ENSG00000111725 "Protein kinase AMP-activated non-catalytic subunit beta 1" Q9Y478 12 119667864-119681624 "FDA approved drug targets, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004247, CAB005058" Enhanced Approved Nucleoplasm,Cytosol NA NA "Cluster 2: Granulocytes - Unknown function" "Cluster 7: Kidney - Transmembrane transport" "Cluster 1: K-562 - Erythropoiesis" "Cluster 11: Alveolar cells - Smell perception" Cytosol Nucleoplasm "CAB005058: AB_562038, HPA004247: AB_1078149" "unprognostic (1.20e-1)" "unprognostic (3.08e-2)" "unprognostic (7.42e-2)" "prognostic favorable (8.66e-4)" "unprognostic (2.33e-1)" "unprognostic (2.89e-2)" "unprognostic (8.97e-3)" "unprognostic (1.46e-2)" "unprognostic (6.26e-2)" "unprognostic (3.63e-2)" "unprognostic (2.85e-1)" "unprognostic (1.23e-1)" "prognostic favorable (5.40e-9)" "unprognostic (5.60e-2)" "unprognostic (2.28e-1)" "unprognostic (1.92e-1)" "unprognostic (1.32e-2)" 16.8 16.9 11.9 13.9 13.1 44.0 15.3 12.8 13.2 25.3 12.6 34.8 32.5 16.8 16.3 21.4 17.2 14.5 12.2 11.7 13.0 53.3 17.3 25.3 18.1 14.6 13.5 14.3 33.4 18.9 10.7 27.6 14.1 11.9 33.4 19.4 16.0 15.6 12.6 10.6 22.7 17.0 12.7 24.1 29.0 21.4 13.1 19.7 20.8 10.5 23.9 15.1 10.7 15.7 11.4 30.8 22.1 21.5 17.8 16.7 29.7 18.3 22.7 28.2 20.4 39.9 24.0 36.6 21.8 23.6 12.6 15.2 22.6 32.1 24.9 22.4 36.5 57.8 17.1 51.5 35.6 26.7 66.0 22.4 29.9 24.4 29.7 30.0 21.2 54.5 89.4 13.5 21.6 33.0 60.4 35.4 32.3 16.5 50.1 33.9 20.8 22.7 32.7 33.7 18.7 31.8 22.1 8.6 25.3 26.7 27.2 34.1 25.0 16.9 20.2 13.3 17.8 45.8 45.7 26.8 16.5 19.7 25.5 50.6 28.5 70.3 28.5 32.6 34.4 47.1 30.0 31.0 30.8 39.5 32.3 29.7 34.7 42.0 38.6 27.8 36.1 36.4 11.9 13.1 12.8 13.2 11.7 13.0 14.6 13.5 14.1 12.7 13.1 15.7 20.6 48.1 49.7 3.3 11.9 3.3 6.5 15.3 15.4 16.2 10.0 6.3 5.3 8.6 16.6 22.0 4.2 18.4 7.5 27.0 46.9 8.3 1.2 12.7 7.7 13.2 19.7 34.5 7.1 30.2 10.9 8.6 12.8 15.4 12.0 18.5 5.3 7.1 12.3 21.9 6.2 15.3 14.2 7.0 5.2 2.2 5.6 9.6 3.6 8.4 10.3 13.4 11.3 7.5 7.6 11.7 17.9 6.4 6.4 5.2 16.2 38.2 12.7 17.9 6.6 4.8 8.2 25.6 13.2 13.7 4.3 15.1 9.9 26.3 23.7 8.3 PRKAB2 ENSG00000131791 "Protein kinase AMP-activated non-catalytic subunit beta 2" O43741 1 147155106-147172550 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 97.2;tongue: 103.8" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 66.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044342 Enhanced Approved Nucleoplasm,Cytosol NA NA "Cluster 15: NK-cells - Transcription" "Cluster 8: Non-specific - Mitochondria" "Cluster 30: Epithelial cell lines - Translation" "Cluster 45: Enterocytes - Digestion" Nucleoplasm Cytosol "HPA044342: AB_10966508" "prognostic unfavorable (4.55e-4)" "unprognostic (2.03e-2)" "unprognostic (1.84e-1)" "unprognostic (4.03e-2)" "unprognostic (9.59e-3)" "prognostic unfavorable (7.32e-4)" "unprognostic (6.30e-2)" "unprognostic (1.23e-1)" "unprognostic (3.06e-2)" "unprognostic (6.78e-2)" "unprognostic (4.65e-2)" "unprognostic (1.98e-1)" "unprognostic (5.34e-2)" "unprognostic (1.31e-1)" "unprognostic (3.57e-1)" "prognostic unfavorable (6.78e-7)" "unprognostic (4.78e-2)" 12.4 10.8 9.4 7.8 10.1 9.0 11.8 12.5 13.1 14.8 6.0 23.4 32.0 18.7 8.5 10.3 12.9 7.1 25.8 10.1 9.5 9.5 56.3 10.0 6.5 10.8 10.1 11.7 34.8 64.7 6.7 12.3 11.0 12.7 10.7 14.7 8.2 19.4 97.2 15.4 20.8 19.8 10.8 8.5 18.1 6.7 10.6 5.9 6.3 103.8 5.6 18.6 14.0 11.2 7.8 4.2 11.1 8.6 25.7 22.1 39.7 14.3 7.9 9.5 10.3 17.1 15.1 13.9 7.1 11.6 5.5 20.2 13.1 16.1 9.2 5.5 9.0 6.2 15.2 27.8 17.7 7.4 2.6 17.4 31.7 9.9 46.0 14.1 9.4 10.6 8.9 5.6 8.2 7.8 5.5 4.1 23.3 13.4 18.4 8.5 14.8 6.9 6.8 6.1 7.1 13.2 10.8 12.1 52.8 39.6 11.4 9.1 10.8 10.6 23.3 9.9 23.6 8.9 10.1 7.1 11.0 6.4 14.1 0.9 0.3 0.6 0.4 0.4 0.7 0.3 0.4 0.3 0.5 0.3 0.5 0.3 0.1 1.5 0.5 0.2 0.2 0.2 9.4 10.1 12.5 13.1 10.1 9.5 10.8 10.1 11.0 10.8 10.6 11.2 10.4 3.2 2.0 14.0 10.6 16.6 11.8 11.4 18.2 14.5 6.7 8.1 66.2 20.0 5.3 18.4 14.6 21.9 10.3 22.7 1.9 6.1 0.8 5.4 15.1 8.2 11.4 3.4 23.2 7.0 42.1 13.6 13.7 10.4 1.3 11.8 6.8 44.9 5.7 11.8 18.8 12.6 10.2 8.9 12.5 1.8 9.6 7.3 16.0 10.3 12.2 6.4 11.3 25.1 21.3 9.9 12.0 16.1 9.0 7.2 55.1 5.4 7.0 19.5 19.7 11.3 20.4 13.9 11.2 13.1 14.1 20.5 9.7 43.4 10.1 4.8 PRKAG1 ENSG00000181929 "Protein kinase AMP-activated non-catalytic subunit gamma 1" P54619 12 49002274-49018807 "FDA approved drug targets, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "OE19: 339.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA077805 Approved Nucleoplasm,Cytosol NA NA "Cluster 31: Non-specific - Inflammatory response" "Cluster 8: Non-specific - Mitochondria" "Cluster 21: OE19 - Mitochondria" "Cluster 39: Non-specific - Basic cellular processes" Cytosol Nucleoplasm "HPA077805: AB_2686855" "unprognostic (3.24e-2)" "unprognostic (1.94e-1)" "unprognostic (1.41e-1)" "unprognostic (1.63e-2)" "unprognostic (3.44e-1)" "unprognostic (2.03e-2)" "prognostic unfavorable (2.84e-7)" "unprognostic (1.45e-1)" "unprognostic (4.68e-2)" "unprognostic (1.93e-2)" "unprognostic (5.35e-2)" "unprognostic (8.49e-2)" "prognostic favorable (1.83e-4)" "unprognostic (3.40e-1)" "unprognostic (2.57e-1)" "unprognostic (1.97e-2)" "unprognostic (5.57e-2)" 42.8 54.5 36.4 29.8 40.5 47.4 50.5 39.9 46.3 37.6 41.9 40.7 32.6 32.9 59.1 44.2 33.4 31.3 80.9 38.2 38.6 50.5 49.4 30.8 38.7 34.5 35.5 25.6 37.4 59.1 33.9 35.1 36.5 37.7 47.8 42.3 36.1 39.9 122.7 43.0 29.9 44.8 33.5 28.6 33.5 33.5 34.9 41.8 37.7 112.4 50.8 40.1 30.8 41.5 79.8 45.8 50.5 76.3 157.8 141.6 33.2 85.5 117.4 84.4 55.7 50.9 66.1 50.4 72.9 98.9 53.9 65.4 42.5 115.6 80.4 69.6 57.1 70.4 66.5 34.2 120.2 97.7 54.6 110.0 94.6 65.9 141.4 123.6 90.3 67.6 60.1 70.0 108.6 52.8 45.8 31.5 29.1 339.6 96.8 24.1 53.3 59.7 114.0 67.6 42.1 57.7 61.0 99.1 142.5 39.7 134.1 49.5 72.5 44.4 52.3 87.7 63.5 109.1 113.3 36.0 89.3 69.9 34.5 87.3 59.8 59.9 53.0 58.7 50.0 51.9 46.1 47.6 68.7 51.3 41.3 43.0 70.9 71.8 56.0 45.2 66.8 73.0 36.4 40.5 39.9 46.3 38.2 38.6 34.5 35.5 36.5 33.5 34.9 41.5 20.2 9.6 22.7 16.6 31.2 20.0 30.3 64.5 11.4 29.2 24.3 20.8 49.8 18.6 29.9 36.8 37.5 65.6 30.5 24.5 76.3 48.3 11.3 11.4 21.3 21.9 21.0 30.3 18.1 46.4 57.7 26.7 15.8 12.9 21.5 31.4 30.4 23.2 52.2 15.2 24.1 31.6 63.1 36.2 26.5 15.7 36.7 26.7 37.4 9.4 55.5 41.6 55.6 23.1 21.1 47.8 16.5 27.1 25.0 24.2 38.6 69.3 19.2 30.1 19.7 18.5 27.5 49.3 43.9 19.1 26.0 67.0 26.3 33.6 32.2 23.6 PRKAG2 "AAKG, AAKG2, CMH6, H91620p, WPWS" ENSG00000106617 "Protein kinase AMP-activated non-catalytic subunit gamma 2" Q9UGJ0 7 151556124-151877125 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" "Cardiomyopathy, Disease variant, FDA approved drug targets, Glycogen storage disease" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 143.0" "Cell type enhanced" "Detected in all" "Excitatory neurons: 208.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "GAMG: 178.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004246, CAB018641" Uncertain Approved Nucleoplasm NA NA "Cluster 34: Basophils - Unknown function" "Cluster 44: Heart - Cardiac muscle contraction" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" Nucleoplasm "CAB018641: AB_2170355, HPA004246: AB_1078151" "unprognostic (4.11e-2)" "unprognostic (2.82e-1)" "unprognostic (1.46e-2)" "unprognostic (9.29e-2)" "unprognostic (1.76e-1)" "unprognostic (4.33e-3)" "unprognostic (7.13e-2)" "unprognostic (8.09e-2)" "unprognostic (1.77e-1)" "unprognostic (1.18e-1)" "unprognostic (2.46e-2)" "unprognostic (1.42e-1)" "unprognostic (1.35e-1)" "unprognostic (1.67e-1)" "unprognostic (3.80e-1)" "unprognostic (3.61e-2)" "unprognostic (4.52e-1)" 27.1 7.7 21.7 12.8 20.3 8.1 18.4 16.7 22.8 16.2 11.1 25.8 24.4 19.8 14.3 16.2 17.9 12.8 143.0 23.7 21.1 22.5 36.1 14.2 11.6 19.3 17.4 10.9 10.9 9.2 9.5 16.1 19.7 25.3 18.9 2.9 15.0 19.5 15.0 13.5 26.2 16.5 15.8 17.6 26.7 12.8 18.5 7.9 16.6 21.7 9.8 47.9 17.5 19.6 46.6 13.6 9.1 10.6 36.4 28.6 14.4 21.5 19.5 22.7 22.3 8.6 52.5 0.0 34.0 28.9 178.2 13.9 5.7 22.4 30.0 15.8 6.2 11.5 1.8 0.9 60.8 8.5 11.4 16.5 49.7 21.8 21.0 34.1 40.2 14.9 4.1 5.6 66.2 17.2 3.5 6.7 9.7 18.8 37.5 5.6 6.9 9.7 39.2 10.9 38.5 6.7 10.7 19.9 10.0 22.9 4.0 13.6 52.8 5.0 4.3 2.8 13.1 3.5 5.1 0.0 63.5 29.8 45.9 26.2 9.3 10.9 5.3 7.0 4.1 9.6 4.9 4.8 6.5 4.0 4.8 7.3 11.1 4.4 6.4 6.0 2.9 5.3 21.7 20.3 16.7 22.8 23.7 21.1 19.3 17.4 19.7 15.8 18.5 19.6 19.2 6.4 19.8 37.5 24.8 10.6 39.9 25.0 19.9 22.3 20.6 14.5 122.3 8.6 22.9 46.0 8.4 3.9 43.8 29.5 64.6 14.1 49.3 75.1 16.9 20.4 13.1 3.8 208.5 22.7 31.2 24.9 21.9 98.1 22.2 4.6 18.9 76.8 17.7 3.3 85.2 34.5 105.8 57.2 48.2 35.8 7.5 50.9 16.0 73.1 62.9 14.7 37.0 39.2 4.4 27.5 21.9 7.9 23.4 45.7 77.7 19.7 14.2 6.1 13.1 6.9 27.3 4.0 32.3 12.8 10.9 50.6 27.3 5.0 28.0 45.2 PRKAG3 ENSG00000115592 "Protein kinase AMP-activated non-catalytic subunit gamma 3" Q9UGI9 2 218822383-218832086 "FDA approved drug targets, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 30 "skeletal muscle: 70.4;tongue: 17.9" "Cell type enhanced" "Detected in single" "Skeletal myocytes: 3.2" "Not detected" "Not detected" "Region enhanced" "Detected in single" "basal ganglia: 1.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "HSkMC: 1.1" "Not detected" "Not detected" "Low region specificity" "Detected in some" NA NA "Cluster 33: Striated muscle - Muscle contraction" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 37: Myocytes - Muscle contraction" "unprognostic (3.51e-1)" "unprognostic (4.41e-3)" "unprognostic (2.05e-1)" "unprognostic (1.53e-1)" "unprognostic (2.47e-2)" "unprognostic (1.80e-1)" "unprognostic (1.86e-3)" "unprognostic (7.74e-2)" "unprognostic (3.44e-2)" "unprognostic (5.85e-2)" "unprognostic (3.27e-1)" "unprognostic (9.04e-2)" "unprognostic (9.95e-2)" "unprognostic (1.49e-1)" "unprognostic (2.97e-1)" "unprognostic (7.69e-2)" 0.0 0.0 0.0 0.0 1.4 0.0 0.2 0.1 0.4 0.0 0.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.1 0.8 0.0 70.4 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.0 17.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 PRKCA "PKCA, PKCα" ENSG00000154229 "Protein kinase C alpha" P17252 17 66302613-66810743 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins" "Angiogenesis, Apoptosis, Cell adhesion" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 76.8" "Cell type enhanced" "Detected in many" "Astrocytes: 564.8;Excitatory neurons: 247.6;Inhibitory neurons: 400.0;Microglial cells: 281.1;Oligodendrocyte precursor cells: 849.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-87 MG: 157.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003844, HPA006563, HPA006564, CAB016290" Enhanced Approved Enhanced "Plasma membrane,Cytosol" NA NA 190000 "Cluster 14: Monocytes - Unknown function" "Cluster 10: Brain - Neuronal signaling" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 68: Oligodendrocytes - Mixed function" Cytosol "Plasma membrane" "CAB003844: AB_562331, CAB016290: AB_628141, HPA006563: AB_1079626, HPA006564: AB_1079625" "unprognostic (3.06e-1)" "unprognostic (3.56e-2)" "unprognostic (1.38e-2)" "unprognostic (1.01e-1)" "unprognostic (1.53e-1)" "unprognostic (7.41e-3)" "unprognostic (7.43e-2)" "unprognostic (6.86e-3)" "unprognostic (4.93e-2)" "unprognostic (1.50e-1)" "unprognostic (2.09e-1)" "unprognostic (2.24e-2)" "unprognostic (5.50e-2)" "unprognostic (2.46e-1)" "unprognostic (1.83e-1)" "unprognostic (1.35e-3)" "unprognostic (8.77e-2)" 3.1 21.1 37.0 6.9 35.0 1.8 2.3 20.8 51.4 7.5 11.8 18.5 11.9 11.7 4.8 3.2 4.6 7.5 4.4 76.8 32.8 12.8 7.3 4.5 4.9 37.3 36.1 15.7 5.1 0.9 6.3 5.0 25.3 13.0 8.6 30.1 2.3 16.9 5.8 3.0 10.6 10.7 30.1 6.5 8.4 2.6 36.9 3.1 3.2 4.3 4.6 8.9 5.6 27.3 7.3 38.0 7.7 7.8 18.2 46.0 1.0 40.8 26.4 28.8 24.3 4.5 4.6 9.6 10.9 65.9 48.1 0.9 3.9 4.8 61.9 16.4 9.3 0.0 22.2 20.2 24.9 12.2 62.8 20.2 1.8 36.0 30.5 41.8 25.0 45.6 25.8 0.2 44.8 2.3 24.9 7.4 3.1 18.9 20.2 4.5 56.5 0.2 10.2 6.4 4.6 25.6 13.5 7.7 0.4 8.0 0.8 17.0 75.1 49.6 28.6 31.4 25.8 0.1 0.0 1.2 157.6 0.1 25.1 0.0 0.2 0.0 0.1 0.2 0.5 0.0 0.8 0.4 0.3 0.0 1.2 0.7 0.0 0.0 1.1 0.4 0.1 0.3 37.0 35.0 20.8 51.4 76.8 32.8 37.3 36.1 25.3 30.1 36.9 27.3 10.0 0.0 8.4 564.8 5.7 10.6 15.0 10.3 13.6 198.3 7.9 11.2 9.8 45.8 7.2 40.5 2.1 4.1 24.6 27.1 7.9 16.1 3.2 5.5 40.1 5.6 8.4 5.7 247.6 6.8 3.4 17.5 23.9 6.3 20.3 39.9 27.8 14.7 25.4 10.1 400.0 38.4 2.0 11.9 7.6 3.0 53.4 20.9 10.6 281.1 6.8 34.3 12.3 849.0 198.3 8.8 21.0 48.5 11.8 12.8 27.0 21.3 7.0 77.1 26.3 6.5 41.4 1.3 3.9 6.1 10.4 15.2 36.9 47.1 26.4 17.2 PRKCB "PKCβ, PKCB, PRKCB1, PRKCB2" ENSG00000166501 "Protein kinase C beta" P05771 16 23835983-24220611 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transporters" "Adaptive immunity, Apoptosis, Immunity, Transcription, Transcription regulation" "Chromatin regulator, Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 84.0;lymphoid tissue: 47.2" "Cell type enhanced" "Detected in many" "B-cells: 185.1;Bipolar cells: 208.6;Excitatory neurons: 877.7;Inhibitory neurons: 320.2;Kupffer cells: 221.9" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 95 "amygdala: 28.9;basal ganglia: 53.9;cerebral cortex: 84.0;hippocampal formation: 35.3;white matter: 36.6" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HEL: 161.8;HMC-1: 154.8;K-562: 234.9;THP-1: 72.7;U-937: 64.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003843, HPA048321, HPA054203" Approved Supported Nucleoplasm,Cytosol NA NA 380000 "Cluster 6: Non-specific - Transcription" "Cluster 10: Brain - Neuronal signaling" "Cluster 1: K-562 - Erythropoiesis" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" Nucleoplasm Cytosol "CAB003843: AB_562197, HPA048321: AB_2680357, HPA054203: AB_2682416" "unprognostic (1.53e-3)" "unprognostic (4.53e-4)" "unprognostic (2.52e-3)" "unprognostic (3.07e-2)" "unprognostic (1.72e-1)" "unprognostic (7.13e-3)" "unprognostic (2.06e-1)" "unprognostic (1.67e-3)" "unprognostic (3.19e-2)" "unprognostic (1.79e-1)" "unprognostic (7.38e-2)" "unprognostic (1.06e-1)" "unprognostic (3.17e-3)" "unprognostic (2.08e-1)" "unprognostic (2.12e-2)" "unprognostic (3.28e-1)" "unprognostic (4.95e-2)" 4.4 1.6 28.9 30.8 53.9 32.1 1.5 0.5 84.0 4.2 0.0 9.7 5.9 3.8 0.6 3.5 3.8 4.4 1.1 35.3 0.0 2.8 4.2 7.8 47.1 0.0 0.0 0.6 1.0 0.2 1.4 2.7 0.0 7.3 5.1 18.2 1.5 10.2 0.8 5.5 19.4 7.2 0.0 46.2 5.7 8.4 0.0 47.2 4.5 1.0 40.0 8.7 1.7 36.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 30.5 1.0 0.0 0.3 0.5 0.5 0.0 0.0 0.0 3.2 161.8 7.5 0.0 0.0 23.6 154.8 0.0 0.7 0.0 0.0 0.0 0.0 27.3 234.9 0.6 0.0 0.0 52.1 51.4 1.5 0.0 0.0 49.0 0.4 9.5 0.5 14.1 27.2 0.0 0.2 0.2 2.4 0.8 0.0 72.7 1.1 0.0 0.3 0.1 0.0 4.1 0.0 1.4 0.2 64.4 0.3 39.3 13.3 27.8 24.8 20.0 11.5 44.2 15.9 29.9 11.3 40.0 13.0 32.0 39.1 39.9 28.6 33.8 12.7 15.5 28.9 53.9 0.5 84.0 35.3 0.0 0.0 0.0 0.0 0.0 0.0 36.6 1.1 3.2 4.9 21.5 185.1 6.0 4.1 0.1 0.6 208.6 0.9 0.8 2.0 2.8 1.8 1.8 2.1 0.2 166.3 1.4 0.0 0.0 26.5 0.1 0.1 4.1 0.0 26.3 877.7 0.2 0.3 1.7 1.5 0.1 71.5 1.9 11.4 3.1 50.5 79.1 320.2 1.5 0.0 221.9 20.5 11.7 0.0 100.9 3.6 110.5 154.4 10.8 120.5 102.1 132.5 0.0 9.6 0.4 61.8 1.0 6.7 0.8 1.6 9.9 0.0 4.4 1.6 3.4 3.6 0.5 14.3 0.8 68.1 0.2 3.8 4.5 PRKCD ENSG00000163932 "Protein kinase C delta" Q05655 3 53156009-53192717 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Apoptosis, Cell cycle" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Late spermatids: 75.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Group enriched" "Detected in all" 7 "dendritic cells: 57.0;granulocytes: 52.9;monocytes: 73.7" "Cell line enhanced" "Detected in all" "SK-BR-3: 267.7;THP-1: 194.0" "Group enriched" "Detected in all" 5 "basal ganglia: 121.4;thalamus: 334.6" "Low region specificity" "Detected in all" "HPA001863, HPA001890, CAB010469, CAB013225" Enhanced Enhanced "Endoplasmic reticulum,Golgi apparatus,Cytosol" NA NA 30000 "Cluster 52: Eosinophils - Transcription" "Cluster 64: Macrophages - Immune response" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 53: Intestinal epithelial cells - Unknown function" Cytosol "Endoplasmic reticulum, Golgi apparatus" "CAB010469: AB_632229, CAB013225: , HPA001863: AB_1079627, HPA001890: AB_1079628" "unprognostic (3.59e-1)" "unprognostic (4.85e-2)" "unprognostic (2.66e-2)" "unprognostic (1.90e-1)" "unprognostic (1.17e-1)" "unprognostic (6.97e-2)" "prognostic unfavorable (2.24e-4)" "prognostic favorable (9.01e-4)" "unprognostic (1.95e-2)" "unprognostic (1.42e-1)" "unprognostic (1.79e-1)" "unprognostic (2.89e-1)" "unprognostic (2.05e-1)" "unprognostic (1.73e-1)" "unprognostic (2.48e-2)" "unprognostic (2.06e-3)" "unprognostic (2.95e-3)" 46.1 59.7 10.4 45.4 11.1 90.3 28.9 4.4 11.7 25.9 7.3 43.5 54.8 9.1 39.1 32.7 42.3 32.8 19.6 12.8 11.0 25.6 8.8 44.3 46.8 9.9 8.5 13.6 33.2 20.7 8.2 20.5 7.5 39.3 41.5 2.2 25.9 31.9 6.8 34.0 55.7 16.2 9.5 54.2 65.1 20.8 9.0 16.3 41.8 9.2 62.1 44.2 23.2 12.3 33.5 14.4 5.2 8.7 35.9 21.6 46.2 20.4 25.7 24.5 23.7 34.4 31.9 86.5 8.3 45.6 42.9 14.5 34.1 49.8 20.6 75.2 23.6 50.1 18.3 32.0 23.6 64.8 103.4 17.1 35.8 25.6 23.2 21.8 22.4 9.3 9.7 11.8 36.1 85.0 7.0 81.0 13.0 51.5 23.0 7.6 13.6 20.6 25.5 72.8 8.3 6.5 15.4 267.7 39.6 24.0 22.6 194.0 31.5 11.7 14.4 15.4 19.2 18.1 33.6 45.9 27.6 116.4 22.6 51.8 73.7 50.1 3.6 71.3 2.2 6.2 2.1 2.5 57.0 8.2 2.2 2.0 52.9 6.9 47.7 16.3 2.6 24.1 10.4 11.1 4.4 11.7 12.8 11.0 9.9 8.5 7.5 9.5 9.0 12.3 4.3 3.2 23.5 2.0 25.7 29.2 26.3 8.0 23.9 0.3 11.8 4.3 6.4 14.3 16.1 14.7 0.0 3.1 24.7 61.8 3.9 8.9 34.5 18.5 4.4 2.7 26.5 5.2 3.4 10.7 16.0 6.7 54.0 17.8 5.7 8.9 3.3 2.3 44.8 1.7 4.2 37.1 4.1 47.4 43.0 75.6 9.0 41.5 10.6 20.6 44.9 2.0 8.2 1.0 0.5 13.2 55.4 6.8 25.8 19.7 64.5 13.1 16.5 0.2 6.6 6.5 12.1 23.1 3.7 23.9 27.8 8.8 10.0 10.4 23.0 34.6 PRKCE ENSG00000171132 "Protein kinase C epsilon" Q02156 2 45651345-46187990 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Cell adhesion, Cell cycle, Cell division, Immunity" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 34.5" "Cell type enhanced" "Detected in many" "Early spermatids: 206.5;Excitatory neurons: 394.4;Inhibitory neurons: 531.9;Late spermatids: 456.4;Oligodendrocyte precursor cells: 147.8" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in many" 4 "amygdala: 18.5;basal ganglia: 20.0;cerebral cortex: 34.5;hippocampal formation: 33.1;white matter: 17.1" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "REH: 27.0;TIME: 26.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB001948, HPA008236, HPA044496" Enhanced Supported Supported "Vesicles,Plasma membrane,Intermediate filaments,Cytosol" NA NA "Cluster 37: B-cells - Transcription" "Cluster 58: Brain - Synaptic function" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Intermediate filaments, Cytosol" "Vesicles, Plasma membrane" "CAB001948: , HPA008236: , HPA044496: AB_2678959" "unprognostic (1.10e-1)" "unprognostic (1.78e-1)" "unprognostic (2.27e-1)" "prognostic unfavorable (2.42e-4)" "unprognostic (9.61e-2)" "unprognostic (5.70e-2)" "unprognostic (1.51e-1)" "prognostic favorable (9.62e-4)" "unprognostic (3.05e-1)" "unprognostic (6.72e-2)" "unprognostic (7.49e-3)" "unprognostic (9.99e-2)" "prognostic favorable (2.63e-7)" "unprognostic (1.21e-1)" "unprognostic (7.11e-2)" "unprognostic (6.43e-3)" "unprognostic (2.23e-2)" 4.4 5.6 18.5 3.7 20.0 8.0 4.2 5.5 34.5 4.6 0.0 5.7 2.6 4.4 2.3 4.1 5.7 3.0 6.2 33.1 0.0 10.0 12.5 20.1 5.7 6.0 0.2 2.8 3.3 9.4 5.2 8.3 4.4 2.9 3.3 15.4 2.7 3.0 7.6 2.7 3.5 4.1 0.0 3.9 4.1 7.6 1.1 3.1 4.9 5.3 4.2 4.9 3.4 17.1 7.7 2.7 3.8 3.8 5.8 6.7 3.1 4.9 9.5 4.3 4.5 0.7 7.0 11.3 4.8 5.5 6.1 1.8 2.5 2.8 6.1 6.9 4.4 0.1 1.8 1.5 6.5 0.9 3.8 5.8 3.0 6.5 4.7 3.6 16.0 2.4 1.6 2.6 5.0 3.8 3.8 0.5 1.3 4.2 1.4 27.0 18.3 12.4 3.9 5.1 2.6 5.7 2.4 7.6 17.1 1.4 6.1 2.6 26.8 8.2 8.5 6.1 5.1 0.0 0.0 9.3 6.7 6.3 8.4 0.0 0.5 0.7 0.3 0.1 0.4 1.5 0.2 0.2 0.8 1.8 0.5 0.1 0.1 0.4 0.6 0.3 0.0 0.3 18.5 20.0 5.5 34.5 33.1 0.0 6.0 0.2 4.4 0.0 1.1 17.1 12.6 6.4 9.2 90.4 20.7 5.0 8.4 5.0 9.1 55.3 6.4 5.7 11.9 8.6 17.2 11.0 14.6 0.5 9.3 6.1 3.9 3.7 206.5 6.8 7.0 13.8 7.7 0.4 394.4 3.8 7.2 8.7 11.2 6.9 7.0 2.9 13.2 12.5 2.8 11.8 531.9 5.8 0.0 19.0 10.7 456.4 5.3 11.5 14.2 70.3 9.4 6.5 1.0 147.8 96.0 3.6 2.9 6.0 4.2 5.3 4.1 30.2 19.3 7.6 13.1 2.9 6.4 2.8 2.3 9.0 4.8 2.9 6.8 1.2 6.2 8.8 PRKCG "MGC57564, PKCγ, PKCC, PKCG, SCA14" ENSG00000126583 "Protein kinase C gamma" P05129 19 53879190-53907652 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "Disease variant, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 20 "brain: 103.3" "Cell type enhanced" "Detected in some" "Excitatory neurons: 22.6;Glandular and luminal cells: 5.1;Horizontal cells: 5.0;Inhibitory neurons: 12.8" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "hippocampal formation: 103.3" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 2.2;OE19: 4.0;SH-SY5Y: 1.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA054560 Enhanced NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 21: OE19 - Mitochondria" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA054560: AB_2682523" "unprognostic (7.14e-2)" "unprognostic (5.42e-2)" "unprognostic (1.85e-1)" "unprognostic (3.86e-2)" "unprognostic (1.41e-1)" "unprognostic (5.38e-2)" "unprognostic (5.96e-2)" "unprognostic (4.46e-2)" "unprognostic (2.09e-1)" "unprognostic (2.64e-2)" "unprognostic (7.48e-3)" "unprognostic (2.68e-1)" "unprognostic (2.22e-7)" "unprognostic (2.41e-2)" "unprognostic (2.61e-1)" "unprognostic (1.06e-1)" "unprognostic (1.83e-1)" 0.1 0.0 47.5 0.2 44.8 0.9 0.0 5.8 64.8 0.0 0.0 0.3 0.4 0.1 0.0 0.0 0.5 0.1 0.0 103.3 4.0 0.0 0.0 0.0 0.0 0.0 3.5 0.1 1.8 3.9 1.4 0.0 0.0 0.0 0.2 0.3 0.1 0.0 0.1 0.0 0.5 0.1 0.6 0.0 0.6 5.2 12.6 3.4 0.0 0.2 0.0 0.0 0.0 18.3 0.1 2.2 0.4 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.5 0.6 0.1 0.6 0.0 0.2 0.2 1.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.9 0.0 0.0 0.2 0.0 0.4 0.0 0.5 0.0 0.0 0.0 0.2 0.2 0.0 0.3 4.0 0.1 0.4 0.2 0.0 0.4 0.0 0.0 1.5 0.6 0.0 0.0 0.7 0.7 0.0 0.4 0.0 0.7 0.0 0.0 0.6 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 47.5 44.8 5.8 64.8 103.3 4.0 0.0 3.5 0.0 0.6 12.6 18.3 1.1 0.0 0.0 1.0 0.7 0.1 0.1 0.0 0.0 0.0 2.3 4.6 0.7 0.0 0.0 0.0 0.0 0.0 0.8 0.2 0.0 0.1 4.2 1.2 2.0 0.5 0.0 0.0 22.6 0.0 0.2 0.6 2.0 5.1 0.0 0.0 0.0 0.0 0.1 5.0 12.8 1.5 0.0 0.0 0.0 1.8 0.0 0.6 0.0 2.8 0.0 0.0 0.0 3.0 2.0 0.2 0.0 0.0 1.0 0.1 0.0 0.0 0.1 0.2 0.0 4.0 0.4 2.9 0.9 0.1 0.0 0.0 0.2 0.0 0.4 0.1 PRKCI "DXS1179E, PKCI" ENSG00000163558 "Protein kinase C iota" P41743 3 170222424-170305977 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026574, HPA038635" Approved Supported "Microtubules,Cytokinetic bridge,Cytosol" Yes No "Cluster 15: NK-cells - Transcription" "Cluster 46: Fibroblasts - ECM organization" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 44: Endometrium - Transcription" Cytosol "Microtubules, Cytokinetic bridge" "HPA026574: AB_1855428, HPA038635: AB_2676124" "unprognostic (2.26e-1)" "unprognostic (6.75e-2)" "unprognostic (4.57e-2)" "prognostic unfavorable (3.93e-6)" "unprognostic (1.59e-1)" "unprognostic (1.84e-2)" "prognostic unfavorable (3.02e-4)" "unprognostic (2.52e-1)" "unprognostic (7.10e-2)" "unprognostic (1.73e-2)" "prognostic unfavorable (1.22e-4)" "unprognostic (5.32e-3)" "prognostic favorable (3.10e-4)" "unprognostic (1.16e-1)" "unprognostic (2.65e-1)" "unprognostic (1.06e-1)" "unprognostic (9.73e-2)" 6.7 5.0 2.0 6.9 2.4 2.6 10.4 2.0 3.2 12.7 0.3 12.4 11.6 11.0 8.2 15.1 15.9 11.4 6.9 3.4 1.1 13.5 7.3 16.6 4.6 0.4 0.2 13.6 7.0 13.0 3.1 10.9 0.5 17.3 13.1 6.2 17.5 12.7 6.2 6.9 10.8 11.0 0.2 5.2 34.5 12.5 0.9 10.9 24.5 9.8 10.4 16.1 6.2 1.1 81.6 20.2 20.0 21.6 17.3 23.9 32.2 20.4 29.9 26.4 28.3 29.7 38.6 24.7 65.3 28.8 36.4 37.3 37.9 40.0 44.8 18.2 23.5 22.9 24.3 16.6 27.9 20.9 10.0 21.8 27.5 22.6 35.1 42.8 20.9 13.3 25.8 19.8 27.4 28.0 30.5 8.5 42.3 86.4 22.1 21.8 30.7 41.2 42.3 24.4 31.5 25.8 44.1 57.7 20.0 29.5 63.0 14.5 22.4 27.5 21.1 26.0 34.3 33.9 34.9 35.2 19.8 16.4 11.0 0.0 0.6 0.4 1.1 0.6 1.7 0.9 1.5 2.0 0.8 1.2 1.6 0.9 0.3 2.6 0.5 0.8 1.1 0.7 2.0 2.4 2.0 3.2 3.4 1.1 0.4 0.2 0.5 0.2 0.9 1.1 17.6 73.7 82.1 23.2 5.8 57.1 49.5 39.8 30.7 16.4 29.0 19.7 16.2 24.3 45.3 49.7 14.6 30.2 15.0 29.0 25.4 16.5 8.4 42.0 29.7 20.5 29.3 10.5 77.2 22.0 26.6 32.2 59.7 72.3 8.8 20.4 17.5 17.7 10.0 15.2 55.2 28.3 50.8 18.6 26.8 6.8 23.3 11.6 17.8 22.5 12.7 8.8 6.2 33.2 33.5 55.2 18.6 28.6 29.4 99.4 18.7 20.4 31.9 9.4 19.7 23.7 18.7 15.8 20.6 38.5 63.6 20.7 14.8 14.3 28.5 80.1 PRKCQ ENSG00000065675 "Protein kinase C theta" Q04759 10 6427143-6580301 "Cancer-related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Immunity, Inflammatory response" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "lymphoid tissue: 33.6;skeletal muscle: 124.5;tongue: 112.6" "Cell type enhanced" "Detected in many" "Astrocytes: 22.9;dendritic cells: 22.4;NK-cells: 32.0;Oligodendrocyte precursor cells: 24.6;Oligodendrocytes: 75.2;T-cells: 31.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 9 "gdT-cell: 23.0;MAIT T-cell: 18.0;memory CD4 T-cell: 24.5;memory CD8 T-cell: 24.5;naive CD4 T-cell: 19.1;naive CD8 T-cell: 17.9;NK-cell: 13.3;T-reg: 39.7" "Group enriched" "Detected in many" 11 "NK-cells: 13.3;T-cells: 39.7" "Cell line enhanced" "Detected in many" "HEL: 57.8;JURKAT: 40.0;MOLT-4: 43.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA065279, HPA073098" Enhanced "Centriolar satellite" NA NA "Cluster 4: T-regs - Cell cycle regulation" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 24: Non-specific - Transcription regulation" "Centriolar satellite" "HPA065279: AB_2685453, HPA073098: AB_2686571" "unprognostic (6.61e-3)" "unprognostic (2.12e-1)" "unprognostic (1.87e-1)" "unprognostic (1.48e-1)" "unprognostic (1.50e-1)" "unprognostic (2.24e-1)" "unprognostic (2.69e-3)" "unprognostic (2.46e-1)" "unprognostic (8.40e-2)" "unprognostic (2.66e-1)" "unprognostic (1.17e-1)" "unprognostic (3.22e-1)" "unprognostic (5.26e-2)" "unprognostic (7.74e-2)" "unprognostic (2.79e-1)" "prognostic unfavorable (5.27e-4)" "unprognostic (3.51e-2)" 0.8 0.7 5.3 5.2 8.5 5.7 0.9 6.1 6.3 1.6 12.1 1.4 1.5 2.5 8.3 2.2 3.9 1.5 0.3 5.5 8.2 10.9 1.0 5.3 12.3 6.5 8.6 1.3 3.4 0.7 0.8 0.2 6.4 1.8 1.7 1.5 1.4 1.1 124.5 0.3 3.3 0.7 5.5 5.0 2.1 1.1 7.2 33.6 14.9 112.6 9.4 2.2 0.6 9.8 0.1 5.3 0.1 0.0 0.0 0.0 1.6 0.0 0.0 0.2 0.2 0.4 3.4 0.3 0.0 0.0 0.0 0.0 3.3 6.0 0.0 0.0 3.9 57.8 0.0 0.4 0.7 2.8 0.6 0.3 3.5 0.1 0.2 0.0 0.5 40.0 12.8 0.1 0.0 0.0 43.9 8.0 5.8 0.5 0.0 8.5 1.3 0.0 11.6 2.9 0.4 2.1 0.0 0.0 0.0 3.4 0.0 5.8 0.0 0.0 5.6 0.0 0.0 0.1 0.0 0.0 0.0 7.1 0.0 2.4 0.1 0.3 23.0 0.4 18.0 0.1 24.5 24.5 0.2 0.0 19.1 17.9 1.6 13.3 0.0 0.0 39.7 10.5 5.3 8.5 6.1 6.3 5.5 8.2 6.5 8.6 6.4 5.5 7.2 9.8 0.2 3.2 7.0 22.9 0.8 0.0 0.3 0.3 0.6 1.6 0.3 0.3 0.4 0.0 0.7 1.8 0.0 0.0 22.4 0.0 7.9 0.3 2.1 0.5 1.2 0.2 1.8 8.0 13.7 0.8 0.1 0.7 1.5 3.0 1.3 8.2 1.1 0.0 0.5 0.0 14.7 0.5 0.0 1.3 0.5 5.6 0.0 1.7 0.0 7.5 0.8 1.2 32.0 24.6 75.2 0.1 0.1 0.0 10.2 0.2 0.0 0.3 0.9 0.4 0.0 4.2 0.4 1.0 2.2 0.5 0.0 0.0 31.7 0.3 0.4 0.1 PRKCZ PKC2 ENSG00000067606 "Protein kinase C zeta" Q05513 1 2050411-2185395 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Inflammatory response" "Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 58.0" "Group enriched" "Detected in many" 4 "Late spermatids: 708.3;Syncytiotrophoblasts: 1107.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in some" 6 "eosinophil: 16.3" "Lineage enriched" "Detected in many" 6 "granulocytes: 16.3" "Cell line enhanced" "Detected in many" "BEWO: 44.5;OE19: 41.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA021851 Enhanced Supported "Plasma membrane,Cytosol" NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 6: Brain - Smell perception" "Cluster 28: BEWO - Transcription regulation" "Cluster 18: Syncytiotrophoblasts - Pregnancy hormone signaling" Cytosol "Plasma membrane" "HPA021851: AB_1855433" "unprognostic (1.25e-2)" "unprognostic (2.61e-1)" "unprognostic (5.10e-2)" "unprognostic (1.14e-2)" "unprognostic (2.08e-1)" "unprognostic (3.61e-2)" "unprognostic (1.73e-2)" "unprognostic (5.13e-2)" "unprognostic (1.18e-1)" "unprognostic (3.10e-1)" "unprognostic (1.12e-1)" "unprognostic (2.86e-1)" "prognostic favorable (1.64e-9)" "unprognostic (3.57e-2)" "unprognostic (3.27e-2)" "unprognostic (1.39e-1)" "unprognostic (7.85e-2)" 1.7 11.1 23.6 4.6 25.7 2.1 5.6 58.0 41.3 4.3 0.0 13.2 29.3 2.2 7.8 16.0 9.5 4.4 9.7 23.7 10.2 16.0 11.0 31.6 8.0 18.6 8.3 2.7 12.5 14.7 17.6 43.8 19.0 8.4 11.3 14.8 10.8 3.9 0.3 13.8 28.0 1.6 5.6 10.5 8.9 31.9 7.2 3.7 21.8 0.6 7.8 5.8 8.0 24.8 14.7 9.7 3.4 17.2 0.0 0.0 44.5 1.2 0.5 11.1 0.7 23.8 31.0 0.1 27.4 3.9 9.4 25.4 20.5 25.5 7.9 1.0 21.8 0.0 15.2 33.5 3.2 0.1 11.0 0.6 14.9 0.0 8.6 0.0 0.0 4.0 6.6 0.2 0.2 17.9 0.9 0.0 6.4 41.9 22.5 0.0 0.0 5.1 18.6 16.0 24.1 18.7 11.6 27.5 5.2 28.7 17.7 4.0 0.0 0.1 13.1 0.1 0.1 6.8 1.3 0.3 1.2 0.3 16.8 0.3 0.0 16.3 0.5 0.3 2.5 0.3 0.9 0.6 0.0 0.4 0.8 0.3 1.1 0.9 0.0 0.3 0.9 0.3 23.6 25.7 58.0 41.3 23.7 10.2 18.6 8.3 19.0 5.6 7.2 24.8 0.9 121.8 72.2 2.3 6.5 13.0 11.8 11.0 10.2 27.1 11.3 11.0 1.4 5.7 21.1 7.3 4.2 118.7 7.5 48.9 7.9 12.3 224.4 14.0 4.7 6.3 10.2 6.6 39.5 10.7 66.3 3.1 17.9 11.7 8.2 12.5 10.0 16.5 14.5 62.2 35.2 25.5 10.2 0.8 2.9 708.3 9.6 4.4 7.2 2.8 4.5 19.1 8.2 13.0 41.3 14.2 45.7 8.6 7.4 19.5 78.4 24.7 22.1 25.9 0.0 0.3 4.1 28.3 28.4 13.4 13.4 1107.9 9.8 2.6 31.3 14.3 PROC ENSG00000115718 "Protein C, inactivator of coagulation factors Va and VIIIa" P04070 2 127418427-127429242 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Hydrolase, Protease, Serine protease" "Cancer-related genes, Disease variant, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 40 "liver: 598.5" "Cell type enriched" "Detected in some" 5 "Hepatocytes: 432.9" "Cancer enriched" "Detected in many" 22 "liver cancer: 118.3" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in some" 9 "plasmacytoid DC: 59.7" "Lineage enriched" "Detected in many" 9 "dendritic cells: 59.7" "Cell line enriched" "Detected in some" 16 "Hep G2: 156.1" "Low region specificity" "Detected in all" "HPA005550, CAB016721, CAB016792" Approved "Secreted to blood" NA NA 5200000000 "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 62: Liver - Hemostasis" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "CAB016721: , CAB016792: , HPA005550: AB_1079687" "unprognostic (2.46e-2)" "unprognostic (1.08e-1)" "unprognostic (1.38e-1)" "unprognostic (1.58e-1)" "unprognostic (6.64e-2)" "unprognostic (3.13e-2)" "unprognostic (4.90e-3)" "unprognostic (2.63e-1)" "unprognostic (1.67e-1)" "unprognostic (3.29e-1)" "unprognostic (3.74e-3)" "unprognostic (2.56e-2)" "unprognostic (8.12e-3)" "unprognostic (2.01e-2)" "unprognostic (1.71e-1)" "unprognostic (4.60e-3)" "unprognostic (8.06e-2)" 0.2 0.0 0.6 0.1 1.1 1.1 0.1 0.6 1.0 0.4 0.0 1.0 0.8 0.1 0.1 0.1 0.2 0.6 0.1 0.6 1.0 14.8 598.5 0.2 0.6 1.6 0.8 0.2 0.3 0.0 0.3 0.1 1.5 0.2 0.6 0.2 0.2 0.1 0.2 0.6 0.8 0.0 0.4 0.4 2.6 0.1 0.8 0.6 0.2 0.0 0.3 0.4 0.2 1.1 0.1 2.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 4.1 0.0 0.9 0.1 0.4 9.5 0.0 0.3 0.0 0.0 0.2 0.1 7.8 156.1 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.0 0.0 0.0 0.0 0.3 1.6 0.4 2.3 0.7 0.0 0.1 0.0 0.0 0.9 0.4 0.0 1.0 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.3 0.1 0.0 0.0 6.3 0.0 0.0 59.7 0.0 0.3 0.6 1.1 0.6 1.0 0.6 1.0 1.6 0.8 1.5 0.4 0.8 1.1 0.0 0.0 0.0 0.3 4.1 0.8 0.4 11.2 0.0 0.0 0.1 0.0 0.4 47.1 1.2 0.0 0.0 0.0 24.0 3.9 5.9 0.5 0.1 3.4 0.1 0.6 10.3 18.7 0.1 0.2 0.0 0.7 2.0 0.2 0.0 0.0 12.1 432.9 3.7 0.0 0.5 9.3 0.0 9.3 4.0 0.1 0.0 2.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.7 8.1 0.0 0.0 0.0 3.8 84.8 3.4 0.0 0.0 0.2 0.3 0.1 0.2 0.0 0.1 0.1 1.1 0.0 1.8 0.3 PROCR "CCD41, CD201, EPCR" ENSG00000101000 "Protein C receptor" Q9UNN8 20 35172072-35216240 "Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Blood coagulation, Hemostasis" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adipose tissue: 126.8" "Cell type enhanced" "Detected in many" "Extravillous trophoblasts: 114.2;Fibroblasts: 83.4;granulocytes: 63.1;Hepatic stellate cells: 74.6;Sertoli cells: 170.9;Syncytiotrophoblasts: 69.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HMC-1: 385.0;HUVEC TERT2: 611.1;TIME: 365.5" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "spinal cord: 8.9" HPA039461 Enhanced NA NA 980000000 "Cluster 16: MAIT-cells - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 50: Fibroblasts - ECM organization" "HPA039461: AB_10673359" "unprognostic (1.51e-1)" "unprognostic (1.03e-1)" "unprognostic (4.12e-2)" "unprognostic (1.68e-1)" "unprognostic (2.64e-1)" "unprognostic (4.69e-2)" "unprognostic (4.69e-2)" "unprognostic (1.84e-1)" "unprognostic (1.52e-1)" "unprognostic (4.76e-2)" "unprognostic (5.22e-2)" "unprognostic (4.27e-1)" "prognostic unfavorable (7.62e-6)" "unprognostic (3.37e-2)" "unprognostic (2.29e-1)" "unprognostic (1.05e-1)" "unprognostic (2.19e-2)" 126.8 23.1 6.8 19.6 7.3 8.6 53.9 12.0 7.7 31.2 14.6 25.2 16.3 36.2 13.4 12.0 42.9 21.2 43.5 7.0 6.8 15.6 6.8 19.8 10.0 8.9 7.3 18.0 12.6 6.1 8.6 31.3 8.8 19.5 21.4 1.8 8.7 17.3 10.1 25.2 21.4 28.4 7.5 27.5 23.2 5.0 8.9 3.0 26.0 10.3 4.0 34.2 28.4 10.1 15.2 88.9 0.2 9.2 93.6 76.1 20.2 20.8 90.4 33.7 65.2 115.2 76.7 2.9 63.3 21.0 93.6 48.5 20.2 131.8 27.8 0.7 27.5 33.2 19.8 4.7 22.8 1.3 385.0 65.1 48.8 159.0 131.1 49.2 611.1 1.1 11.8 4.2 35.3 5.0 1.1 1.6 12.2 18.8 90.4 0.6 16.7 0.4 58.3 5.8 2.7 1.2 11.3 23.9 18.8 11.0 8.1 5.0 365.5 86.0 43.2 32.8 35.4 0.3 1.1 0.9 99.1 33.5 18.6 5.0 1.5 0.8 8.2 1.8 14.8 0.9 2.5 5.2 7.8 1.3 0.6 5.9 4.0 3.3 1.3 1.3 2.2 2.2 6.8 7.3 12.0 7.7 7.0 6.8 8.9 7.3 8.8 7.5 8.9 10.1 19.9 0.0 12.6 2.3 0.5 13.9 18.5 10.1 10.2 0.5 1.1 4.4 2.4 5.7 4.9 5.5 0.0 12.1 2.0 0.5 1.9 32.2 1.6 1.0 24.0 58.8 6.0 2.7 3.6 16.4 114.2 83.4 1.5 0.9 63.1 15.9 74.6 1.9 21.9 1.7 2.5 0.7 0.0 1.6 8.8 1.0 15.5 13.5 3.6 9.4 2.2 0.3 7.2 0.5 5.6 15.6 0.5 2.6 0.6 9.7 9.8 6.3 1.8 0.6 170.9 4.3 45.9 20.4 19.7 2.8 8.4 69.0 4.4 4.2 2.0 11.9 PROS1 PROS ENSG00000184500 "Protein S" P07225 3 93873051-93980003 "Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Blood coagulation, Fibrinolysis, Hemostasis" "Disease variant, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "choroid plexus: 107.5;heart muscle: 116.6;liver: 283.1" "Cell type enhanced" "Detected in many" "Fibroblasts: 83.1;Hepatocytes: 307.1" "Cancer enhanced" "Detected in all" "thyroid cancer: 64.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "ASC diff: 112.3;ASC TERT1: 100.1;HSkMC: 78.2;SK-MEL-30: 157.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007724, HPA023974, CAB032610" Approved "Secreted to blood" NA NA 22500000000 5000000000 "Cluster 28: Myeloid DCs - Unknown function" "Cluster 85: Liver - Metabolism" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 2: Hepatocytes - Metabolism" "CAB032610: AB_2237647, HPA007724: AB_1079688, HPA023974: AB_1855738" "unprognostic (2.00e-2)" "unprognostic (2.81e-2)" "unprognostic (9.21e-2)" "unprognostic (8.03e-3)" "unprognostic (3.35e-2)" "unprognostic (2.41e-1)" "unprognostic (6.48e-2)" "unprognostic (3.07e-1)" "unprognostic (5.18e-2)" "unprognostic (3.12e-1)" "unprognostic (1.10e-1)" "unprognostic (1.91e-1)" "unprognostic (1.10e-1)" "prognostic unfavorable (8.35e-4)" "unprognostic (4.90e-2)" "unprognostic (1.05e-2)" "prognostic unfavorable (4.42e-5)" 33.6 8.7 1.7 8.1 1.3 0.3 24.7 1.6 2.7 14.9 107.5 17.3 13.5 16.4 2.0 16.6 19.4 33.7 116.6 3.2 2.2 37.7 283.1 39.2 4.7 2.1 2.4 32.6 5.6 13.5 8.5 32.0 2.2 8.4 21.6 4.6 12.3 10.3 4.9 20.5 20.6 19.2 1.6 11.2 10.5 5.0 2.3 1.5 17.0 16.9 3.7 18.5 15.1 1.7 0.4 2.7 3.0 27.1 112.3 100.1 1.6 4.6 9.4 1.0 6.6 12.7 1.4 0.0 30.0 3.0 18.8 0.0 1.4 0.9 1.8 0.1 7.3 51.4 1.4 29.8 8.7 1.5 1.2 78.2 0.4 4.0 0.6 63.0 7.2 3.7 32.8 0.1 49.2 0.0 0.1 0.0 3.1 2.7 6.5 0.3 1.2 0.0 27.7 0.0 7.6 19.8 5.0 0.0 157.0 0.6 0.0 19.9 9.4 14.8 2.8 8.2 1.7 0.0 0.0 0.0 60.4 30.4 27.8 0.0 0.2 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.6 0.0 0.1 0.0 0.0 3.2 1.7 1.3 1.6 2.7 3.2 2.2 2.1 2.4 2.2 1.6 2.3 1.7 55.9 64.1 33.8 17.9 1.9 14.8 3.6 2.1 4.0 0.5 1.7 14.0 44.6 14.3 7.5 1.8 10.4 0.6 0.5 7.5 3.9 9.8 3.2 2.1 30.7 47.1 15.7 16.4 28.4 4.4 0.7 83.1 2.0 1.1 30.9 5.0 65.7 307.1 12.8 1.7 19.7 11.6 0.0 31.5 20.6 6.3 28.6 14.6 19.6 27.2 1.3 22.8 0.0 10.6 4.6 5.6 19.3 36.9 0.3 4.5 1.9 42.2 56.6 8.1 13.1 32.4 28.4 0.4 0.7 11.8 33.2 1.6 2.1 10.8 12.6 2.3 PSMB1 "HC5, PMSB1" ENSG00000008018 "Proteasome 20S subunit beta 1" P20618 6 170535120-170553307 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Syncytiotrophoblasts: 1197.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA029635, HPA029637, CAB033911" Enhanced Supported Nucleoplasm NA NA 15000000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 55: Non-specific - Mitochondria & Proteasome" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 10: Non-specific - Unknown function" Nucleoplasm "CAB033911: AB_2268890, HPA029635: AB_10599738, HPA029637: AB_10601793" "unprognostic (2.78e-2)" "unprognostic (3.10e-2)" "unprognostic (6.73e-2)" "unprognostic (1.34e-1)" "unprognostic (1.20e-1)" "unprognostic (5.41e-3)" "unprognostic (2.36e-2)" "unprognostic (3.32e-2)" "unprognostic (8.39e-2)" "unprognostic (4.28e-2)" "unprognostic (3.07e-1)" "unprognostic (1.09e-1)" "prognostic unfavorable (3.76e-6)" "unprognostic (3.63e-1)" "unprognostic (7.50e-2)" "unprognostic (1.45e-3)" "unprognostic (9.62e-2)" 214.3 191.2 127.8 138.1 131.9 206.8 186.4 129.8 150.7 146.1 131.9 175.9 147.4 174.9 279.4 175.2 157.1 114.5 222.3 127.7 139.0 179.7 308.6 158.3 175.8 129.2 127.5 136.6 153.1 169.2 151.8 173.8 133.2 130.9 166.9 98.5 141.7 151.3 355.2 192.2 149.1 164.3 137.6 165.7 156.8 114.3 132.9 180.5 142.4 239.2 206.8 168.8 143.4 143.0 309.8 284.9 396.2 514.9 347.3 271.2 421.6 288.3 422.7 471.6 478.5 628.9 259.3 449.1 366.2 390.0 430.8 303.7 446.0 459.8 488.7 460.2 502.1 384.4 277.6 799.6 406.3 455.8 327.1 311.5 277.6 455.6 293.1 322.4 409.9 278.1 774.3 373.2 436.9 835.1 343.5 633.0 362.7 558.1 387.9 326.9 314.1 571.6 495.1 183.6 394.5 321.6 277.1 424.5 231.5 351.1 290.9 648.4 313.3 190.4 304.8 466.9 543.2 315.8 454.8 565.8 443.7 510.9 417.5 258.4 431.9 290.2 265.2 416.1 313.5 386.4 306.0 290.7 523.1 305.7 288.1 279.8 249.3 408.2 384.4 297.4 442.6 652.5 127.8 131.9 129.8 150.7 127.7 139.0 129.2 127.5 133.2 137.6 132.9 143.0 242.7 112.2 148.5 19.9 182.1 217.2 351.4 750.7 117.8 120.2 168.2 236.3 232.3 208.8 335.5 141.6 41.7 876.6 175.0 222.0 401.1 498.3 332.4 224.6 190.2 243.8 165.3 223.9 23.5 651.4 790.8 245.5 109.6 215.1 189.5 226.1 168.8 349.8 394.3 119.5 25.1 251.6 417.1 165.3 222.3 81.9 256.3 207.3 231.3 20.6 364.5 237.8 206.0 19.6 43.3 525.5 240.1 235.9 253.4 334.9 327.6 537.0 310.0 135.9 190.7 181.2 500.2 247.8 196.3 153.3 215.8 1197.8 182.1 283.7 276.7 365.4 PSMB10 "beta2i, LMP10, MECL1, MGC1665" ENSG00000205220 "Proteasome 20S subunit beta 10" P40306 16 67934506-67936864 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Hydrolase, Protease, Threonine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 122.3" "Cell type enhanced" "Detected in many" "Proximal enterocytes: 173.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "REH: 183.4;RPMI-8226: 169.4;THP-1: 171.3;U-266/70: 189.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA030224, HPA030225, CAB034384" Enhanced Approved Vesicles,Cytosol NA NA 1400000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 14: B-cells - Humoral immune response" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 58: T-cells - T-cell receptor" Cytosol Vesicles "CAB034384: AB_2171876, HPA030224: AB_2673382, HPA030225: AB_10603231" "unprognostic (1.18e-2)" "unprognostic (1.90e-3)" "unprognostic (2.00e-1)" "unprognostic (2.53e-3)" "unprognostic (2.00e-1)" "unprognostic (1.85e-2)" "unprognostic (7.22e-2)" "unprognostic (3.35e-2)" "unprognostic (1.07e-1)" "unprognostic (2.60e-1)" "unprognostic (8.22e-2)" "unprognostic (1.79e-1)" "unprognostic (1.32e-2)" "unprognostic (2.97e-2)" "unprognostic (1.98e-1)" "unprognostic (1.32e-2)" "prognostic favorable (5.44e-4)" 26.3 26.9 5.7 81.8 6.0 71.3 24.9 6.9 8.8 18.9 6.6 51.6 110.5 18.4 5.7 22.8 30.4 31.2 16.2 5.6 8.0 35.1 37.1 42.2 122.3 12.6 7.4 14.6 15.0 6.3 13.2 23.1 8.6 28.9 22.9 0.4 65.1 22.4 6.8 18.1 95.8 14.0 9.5 102.7 62.5 5.3 7.8 61.9 23.6 3.5 37.5 36.4 18.6 11.7 31.8 26.9 0.7 2.2 6.7 17.2 99.6 10.8 42.3 38.5 50.6 13.9 148.5 111.9 23.4 13.2 12.9 47.9 0.0 13.4 2.9 50.3 1.9 39.2 7.6 16.4 65.7 78.5 115.2 26.9 8.4 15.2 1.5 12.1 20.6 32.1 3.6 48.2 9.0 42.6 140.7 84.9 1.0 1.1 10.2 183.4 8.3 169.4 31.6 52.5 0.9 2.3 31.1 67.5 17.2 0.4 14.5 171.3 32.0 21.2 6.6 9.7 15.3 189.8 43.9 88.4 57.1 97.9 47.0 539.5 714.6 571.1 511.7 787.1 376.4 402.6 397.9 437.3 594.8 390.2 326.2 364.6 786.2 588.6 607.4 604.4 495.9 1155.7 5.7 6.0 6.9 8.8 5.6 8.0 12.6 7.4 8.6 9.5 7.8 11.7 24.7 22.4 26.8 4.6 72.9 17.2 14.3 101.2 26.2 1.0 15.8 13.8 1.6 28.6 43.9 18.4 0.0 29.5 66.2 80.8 23.5 58.5 14.0 17.6 20.1 22.8 16.3 32.6 3.4 104.3 30.0 23.4 110.6 12.3 51.9 7.2 37.1 10.2 87.4 0.0 5.0 74.6 52.9 81.9 66.4 35.9 30.1 88.5 48.0 9.4 123.3 3.0 112.3 2.5 7.3 51.2 139.7 21.1 110.5 12.1 173.5 69.4 83.9 1.1 19.7 10.3 26.6 16.4 7.5 24.1 9.9 22.6 93.9 16.9 79.5 24.8 PSMB2 HC7-I ENSG00000126067 "Proteasome 20S subunit beta 2" P49721 1 35599541-35641526 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA026322, HPA026324" Approved Enhanced Nucleoplasm NA NA 9700000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 55: Non-specific - Mitochondria & Proteasome" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 10: Non-specific - Unknown function" Nucleoplasm "HPA026322: AB_1855821, HPA026324: AB_1855822" "unprognostic (3.54e-2)" "unprognostic (8.53e-2)" "unprognostic (1.63e-3)" "unprognostic (6.93e-2)" "unprognostic (6.41e-2)" "unprognostic (1.37e-1)" "prognostic unfavorable (3.49e-7)" "unprognostic (2.81e-2)" "unprognostic (5.23e-2)" "unprognostic (3.34e-3)" "unprognostic (7.87e-2)" "unprognostic (4.45e-1)" "prognostic unfavorable (2.80e-6)" "unprognostic (1.65e-1)" "unprognostic (2.83e-1)" "unprognostic (3.77e-2)" "unprognostic (2.93e-2)" 26.4 29.3 10.0 13.9 10.3 21.7 25.0 9.7 11.6 23.6 9.4 24.3 12.9 26.9 11.5 31.8 21.9 9.1 27.3 10.6 10.4 22.6 45.9 25.6 15.8 9.9 9.7 21.0 25.2 11.3 19.6 15.2 11.0 20.0 12.7 12.1 22.3 10.8 63.1 30.9 23.2 13.4 9.9 25.4 24.2 15.6 9.5 20.5 18.7 14.8 16.7 22.9 23.9 11.8 68.8 42.4 45.5 32.2 23.3 27.9 55.5 31.8 36.6 63.2 51.1 51.6 79.3 68.8 71.3 37.6 38.6 41.2 59.3 53.4 54.5 54.5 54.1 63.4 44.5 50.1 41.4 66.1 34.7 30.4 33.4 77.0 36.8 25.9 50.8 54.1 76.6 37.7 41.9 30.7 85.5 50.1 59.3 29.7 44.0 52.3 47.5 48.7 45.3 35.9 39.8 30.1 36.0 34.5 52.1 50.3 24.9 29.3 35.2 32.0 37.5 30.9 76.5 31.8 55.0 66.9 49.9 70.4 55.6 20.5 23.6 18.2 19.6 30.3 19.9 22.3 19.3 20.6 26.4 18.5 14.0 17.3 8.8 23.6 35.4 27.4 26.3 26.1 10.0 10.3 9.7 11.6 10.6 10.4 9.9 9.7 11.0 9.9 9.5 11.8 110.8 64.1 68.9 6.2 80.4 111.1 145.2 298.5 50.7 48.0 65.8 95.1 59.8 67.2 145.0 66.2 16.7 406.6 83.6 72.4 144.8 286.2 118.0 95.4 78.8 115.9 98.3 78.7 20.8 227.3 341.0 101.3 61.2 75.9 35.4 109.6 85.6 158.1 222.6 58.9 20.9 96.9 187.2 92.7 70.3 22.8 100.6 94.1 76.5 15.9 184.1 68.4 87.6 17.1 23.4 252.0 76.6 91.4 141.7 186.0 108.5 221.7 126.8 50.4 92.1 66.8 291.4 224.4 144.0 80.4 111.5 442.1 81.4 123.9 111.7 178.9 PSMB5 MB1 ENSG00000100804 "Proteasome 20S subunit beta 5" P28074 14 23016543-23035230 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction" "Hydrolase, Protease, Threonine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "Hep G2: 1146.8" "Low region specificity" "Detected in all" "HPA049518, HPA061796" Approved Supported Nucleoplasm,Centrosome NA NA 6200000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 80: Striated muscle - Unknown function" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 10: Non-specific - Unknown function" "Nucleoplasm, Centrosome" "HPA049518: AB_2680802, HPA061796: AB_2684612" "unprognostic (3.03e-1)" "unprognostic (1.99e-2)" "unprognostic (8.35e-2)" "unprognostic (6.13e-2)" "unprognostic (1.24e-1)" "prognostic unfavorable (2.85e-4)" "prognostic unfavorable (2.90e-5)" "unprognostic (2.55e-2)" "unprognostic (9.95e-2)" "prognostic favorable (1.08e-4)" "unprognostic (2.06e-1)" "unprognostic (1.19e-1)" "unprognostic (5.30e-2)" "unprognostic (1.75e-1)" "unprognostic (1.95e-1)" "unprognostic (4.95e-2)" "prognostic unfavorable (4.73e-4)" 84.0 116.0 129.1 58.7 134.2 32.0 81.0 141.4 134.3 71.3 141.1 80.8 61.1 71.0 129.5 102.3 93.3 61.0 136.8 136.4 141.1 98.5 119.1 64.7 49.0 137.9 138.4 61.6 80.9 143.5 80.1 90.1 145.2 76.8 88.7 59.7 73.5 78.6 332.4 76.0 53.0 103.4 141.3 50.3 81.0 57.8 136.5 79.5 72.3 274.1 68.6 92.1 68.4 146.5 181.0 398.9 250.6 245.5 360.4 318.9 261.8 252.0 307.3 446.1 376.1 329.2 282.2 228.0 228.1 352.1 298.4 239.7 428.4 320.2 401.9 139.9 311.4 146.9 260.3 1146.8 287.3 170.2 162.1 354.2 292.0 331.8 264.1 289.7 475.5 190.5 218.6 121.5 376.0 557.2 97.6 218.4 285.7 341.6 631.4 133.8 197.7 150.7 349.9 256.6 336.0 251.0 179.9 354.8 245.4 322.2 175.0 217.7 254.1 212.4 210.1 197.3 247.8 99.7 218.4 158.8 164.9 140.8 274.6 97.8 127.6 58.0 89.4 125.6 103.5 103.8 101.1 85.1 137.6 99.7 135.0 102.5 48.1 67.4 92.7 172.4 91.3 147.8 129.1 134.2 141.4 134.3 136.4 141.1 137.9 138.4 145.2 141.3 136.5 146.5 94.2 76.9 69.2 16.0 47.3 140.2 174.1 461.5 100.7 61.0 130.4 135.5 157.6 112.9 240.4 95.6 29.2 400.1 40.2 75.0 275.9 277.7 93.0 149.0 109.5 150.0 154.6 82.5 17.6 231.3 435.2 139.9 73.9 88.0 31.0 162.6 89.6 171.6 221.6 70.7 18.0 109.2 329.6 57.5 80.9 106.4 118.7 64.0 115.6 15.9 138.2 170.8 25.7 11.6 29.4 285.7 88.0 122.2 78.2 185.1 81.2 437.8 268.9 71.8 98.6 87.1 355.1 174.4 81.6 144.7 157.1 430.2 43.4 215.7 148.9 215.3 PSMB8 "beta5i, D6S216E, LMP7, PSMB5i, RING10" ENSG00000204264 "Proteasome 20S subunit beta 8" P28062 6 32840717-32844679 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Differentiation, Host-virus interaction, Immunity" "Hydrolase, Protease, Threonine protease" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046995, HPA050327" Enhanced Approved "Vesicles,Cytokinetic bridge" Yes No 2700000 "Cluster 8: Neutrophils - Inflammatory response" "Cluster 64: Macrophages - Immune response" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 63: NK-cells & T-cells - Immune response" Vesicles "Cytokinetic bridge" "HPA046995: AB_2679896, HPA050327: AB_2681088" "prognostic favorable (5.08e-4)" "unprognostic (4.22e-2)" "unprognostic (2.39e-2)" "prognostic favorable (7.16e-4)" "unprognostic (1.92e-1)" "unprognostic (1.68e-1)" "unprognostic (7.78e-2)" "unprognostic (1.09e-1)" "unprognostic (5.71e-2)" "unprognostic (1.17e-2)" "unprognostic (2.79e-2)" "unprognostic (1.47e-1)" "unprognostic (4.14e-2)" "unprognostic (1.24e-1)" "unprognostic (4.35e-2)" "unprognostic (1.97e-3)" "unprognostic (7.11e-3)" 62.7 76.9 3.3 11.2 3.4 9.8 56.5 3.3 7.3 42.7 3.4 79.9 12.9 41.3 3.2 59.5 41.6 5.8 34.2 3.4 3.5 63.7 99.2 78.2 18.2 4.3 3.4 32.1 29.5 8.2 26.6 4.4 3.7 45.2 20.4 0.7 44.2 6.4 14.4 58.0 93.9 8.9 4.0 150.4 57.0 5.9 3.6 13.5 40.8 0.1 17.2 41.3 48.1 4.1 15.1 3.9 0.3 0.0 5.1 13.1 11.2 4.9 22.9 29.1 39.3 0.0 20.9 45.7 9.4 10.5 25.5 8.1 6.8 16.6 8.0 19.2 0.0 27.6 5.9 0.3 30.3 5.2 7.5 14.9 10.3 12.9 6.8 1.9 18.1 11.8 1.1 8.1 6.1 0.1 12.9 11.7 0.1 0.0 7.3 29.3 1.3 24.1 21.3 4.9 0.8 0.2 8.6 10.4 8.5 0.1 7.0 41.0 4.3 8.8 7.6 7.8 0.6 21.0 15.9 11.2 2.2 27.7 9.0 56.8 70.3 94.6 58.1 88.0 51.2 73.4 49.1 61.1 67.5 71.1 34.8 49.6 90.2 63.0 78.2 58.5 81.2 156.0 3.3 3.4 3.3 7.3 3.4 3.5 4.3 3.4 3.7 4.0 3.6 4.1 237.0 38.5 55.8 2.9 162.0 84.4 64.1 183.7 54.7 1.8 85.3 92.5 8.7 71.4 103.2 62.5 0.0 2.7 211.2 219.9 86.1 219.4 0.6 63.2 74.9 158.5 65.7 45.0 0.1 247.6 18.3 60.7 93.8 81.5 50.7 51.4 114.5 75.0 165.9 6.7 0.5 243.8 120.1 143.5 94.9 1.9 39.1 128.2 56.9 10.3 214.3 39.9 279.1 3.0 0.7 179.6 287.9 30.5 153.2 100.1 319.8 78.9 103.2 3.0 39.5 33.2 56.8 0.4 1.2 60.5 79.6 2.7 181.6 110.9 222.6 121.6 PSMB9 "beta1i, LMP2, PSMB6i, RING12" ENSG00000240065 "Proteasome 20S subunit beta 9" P28065 6 32844136-32859851 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Host-virus interaction, Immunity" "Hydrolase, Protease, Threonine protease" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "lymphoid tissue: 160.9" "Cell type enhanced" "Detected in many" "monocytes: 323.0;NK-cells: 495.4;Proximal enterocytes: 318.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BJ hTERT+ SV40 Large T+ RasG12V: 27.7;Daudi: 40.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB015180, HPA042818, HPA053280" Enhanced Supported Cytosol NA NA 340000 "Cluster 31: Non-specific - Inflammatory response" "Cluster 64: Macrophages - Immune response" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 63: NK-cells & T-cells - Immune response" Cytosol "CAB015180: AB_2172368, HPA042818: AB_2678186, HPA053280: AB_2682098" "unprognostic (1.09e-2)" "unprognostic (1.68e-2)" "unprognostic (1.26e-2)" "unprognostic (2.18e-3)" "unprognostic (7.84e-2)" "unprognostic (1.89e-1)" "unprognostic (5.68e-2)" "unprognostic (6.67e-2)" "unprognostic (1.56e-2)" "unprognostic (6.50e-3)" "unprognostic (1.87e-3)" "unprognostic (1.84e-1)" "prognostic unfavorable (1.33e-4)" "unprognostic (2.65e-1)" "unprognostic (1.09e-1)" "unprognostic (4.96e-3)" "unprognostic (5.99e-2)" 47.0 31.1 4.8 18.4 4.9 6.9 41.4 4.3 5.5 28.8 2.6 38.4 10.2 26.8 2.3 25.7 25.9 4.7 31.6 4.8 5.6 36.3 37.4 60.2 26.2 7.6 4.9 18.1 12.1 1.5 14.0 3.4 5.9 26.5 8.7 1.3 20.3 5.0 11.9 27.7 78.1 5.7 5.7 160.9 26.5 4.9 5.1 15.0 28.7 3.8 22.2 23.6 30.8 5.8 5.5 0.3 0.0 0.2 3.4 8.5 3.0 0.7 11.5 17.3 27.7 0.0 3.1 40.8 1.3 2.9 14.3 10.0 0.2 5.8 2.6 9.3 0.1 17.6 0.7 0.8 17.3 1.8 2.2 2.1 0.3 7.0 1.0 3.3 2.7 10.1 1.4 12.8 1.9 1.0 16.1 8.0 0.0 0.0 0.8 19.0 1.2 7.4 2.1 2.5 0.0 0.0 1.0 2.1 10.7 0.0 4.4 10.3 0.0 2.5 1.6 14.7 1.2 11.3 23.9 9.3 7.5 6.8 4.0 92.7 30.3 75.6 56.1 55.8 45.9 59.7 45.1 55.9 26.6 45.3 41.0 49.6 96.3 61.5 60.9 20.5 61.0 46.2 4.8 4.9 4.3 5.5 4.8 5.6 7.6 4.9 5.9 5.7 5.1 5.8 258.6 41.7 51.1 1.3 197.2 72.5 37.4 155.6 30.1 2.4 25.3 47.0 7.3 50.1 64.8 25.8 0.0 1.5 216.2 88.0 19.6 116.6 1.3 28.9 47.5 146.5 33.5 29.9 0.0 115.6 6.6 45.1 34.1 42.6 77.3 20.0 119.6 26.6 117.2 0.0 0.1 148.0 99.7 126.8 155.7 2.1 29.2 145.2 35.6 8.4 323.0 22.7 495.4 0.5 8.3 67.8 150.3 15.8 136.1 40.4 318.5 40.5 133.7 1.7 32.9 23.1 50.8 1.5 7.4 21.0 58.7 1.4 241.8 45.3 110.6 39.1 PTAFR ENSG00000169403 "Platelet activating factor receptor" P25105 1 28147166-28193936 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" Chemotaxis "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 41.1;lymphoid tissue: 30.8" "Cell type enhanced" "Detected in many" "granulocytes: 75.4;Hofbauer cells: 71.7;Kupffer cells: 93.0;Langerhans cells: 67.8;Macrophages: 64.5;monocytes: 52.8;Pancreatic endocrine cells: 89.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "classical monocyte: 256.7;eosinophil: 906.5;neutrophil: 747.1" "Group enriched" "Detected in many" 5 "granulocytes: 906.5;monocytes: 256.7" "Group enriched" "Detected in some" 4 "HBEC3-KT: 36.6;HMC-1: 131.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA027543 Approved Uncertain "Nucleoplasm,Vesicles,Plasma membrane" NA NA "Cluster 45: Eosinophils - Innate immune response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 3: HMC-1 - Innate immune response" "Cluster 4: Macrophages - Innate immune response" "Nucleoplasm, Vesicles" "Plasma membrane" "HPA027543: AB_10610287" "unprognostic (2.22e-2)" "unprognostic (2.59e-2)" "unprognostic (6.73e-2)" "unprognostic (1.24e-1)" "unprognostic (2.75e-1)" "unprognostic (3.74e-2)" "unprognostic (1.07e-1)" "unprognostic (1.72e-1)" "unprognostic (3.35e-1)" "unprognostic (1.23e-1)" "unprognostic (2.39e-1)" "unprognostic (1.60e-1)" "unprognostic (2.79e-2)" "unprognostic (3.52e-1)" "unprognostic (2.59e-2)" "unprognostic (5.48e-2)" "unprognostic (1.38e-2)" 10.4 2.4 4.3 30.8 4.7 41.1 3.4 4.7 5.6 3.4 4.1 5.5 4.1 1.7 1.2 7.2 2.6 7.2 2.0 3.8 5.1 2.7 4.1 17.8 13.5 8.9 6.6 1.3 2.0 1.6 0.6 7.3 7.7 1.5 6.7 0.5 2.3 1.5 0.7 5.4 6.3 7.9 8.1 14.4 3.8 1.3 7.2 3.6 1.9 2.6 18.0 14.4 1.9 11.8 20.1 0.2 0.1 0.4 0.2 0.0 0.5 0.0 0.0 0.7 0.2 0.2 5.7 1.3 0.1 0.1 0.3 13.5 0.5 36.6 0.8 0.4 0.6 7.7 0.2 0.9 0.1 1.9 131.3 0.0 6.0 0.4 0.4 0.0 0.2 0.1 0.5 0.4 0.0 1.3 0.2 19.3 0.6 0.5 0.2 0.3 0.1 0.1 8.7 2.1 0.3 0.1 0.1 18.1 0.2 0.4 0.4 5.4 0.1 0.2 0.7 0.0 0.2 1.2 1.1 5.6 0.1 2.4 0.6 61.7 256.7 906.5 0.6 77.9 1.2 12.5 0.4 0.4 116.1 6.7 0.5 0.7 747.1 0.7 34.1 1.3 1.2 112.4 4.3 4.7 4.7 5.6 3.8 5.1 8.9 6.6 7.7 8.1 7.2 11.8 2.1 6.4 6.7 0.0 4.1 6.5 2.0 37.9 5.2 1.5 0.8 0.5 2.2 1.5 20.9 1.8 2.1 0.6 2.9 0.4 0.0 18.1 0.4 0.5 0.2 7.3 0.0 4.0 0.9 5.1 0.5 1.3 1.1 0.5 75.4 2.0 2.9 1.0 71.7 0.0 0.7 0.0 18.3 93.0 67.8 0.2 0.6 64.5 0.0 15.0 52.8 0.2 0.0 1.5 6.6 89.8 0.6 0.0 0.5 0.6 0.3 0.2 20.2 0.9 0.0 0.6 1.0 2.3 0.7 3.2 2.8 1.5 2.0 0.0 0.4 9.4 PTGER1 EP1 ENSG00000160951 "Prostaglandin E receptor 1" P34995 19 14472466-14475354 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 5 "kidney: 30.9" "Cell type enriched" "Detected in some" 70 "Collecting duct cells: 198.6" "Cancer enhanced" "Detected in many" "ovarian cancer: 4.1" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HEL: 2.4;NB-4: 1.3;PC-3: 3.2;SH-SY5Y: 1.8" "Not detected" "Not detected" "Not detected" "Not detected" NA NA "Cluster 48: NK-cells - Unknown function" "Cluster 7: Kidney - Transmembrane transport" "Cluster 36: HEL - Hemostasis" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "unprognostic (3.44e-2)" "unprognostic (3.31e-1)" "unprognostic (2.68e-1)" "unprognostic (3.50e-4)" "unprognostic (8.69e-2)" "unprognostic (5.58e-2)" "unprognostic (2.39e-2)" "unprognostic (3.19e-2)" "unprognostic (2.05e-1)" "unprognostic (3.53e-2)" "unprognostic (1.41e-1)" "unprognostic (1.42e-1)" "unprognostic (7.74e-8)" "unprognostic (1.19e-1)" "unprognostic (4.41e-2)" "unprognostic (4.27e-3)" "unprognostic (4.88e-2)" 0.9 1.4 0.4 0.5 0.7 0.0 0.4 0.3 2.2 1.2 0.9 0.5 0.3 0.5 0.0 0.8 1.0 0.0 0.1 0.3 1.0 30.9 0.3 2.4 0.0 0.4 0.3 0.1 0.3 0.1 1.4 0.0 0.5 0.7 0.0 0.0 0.3 0.0 0.1 0.1 1.4 0.4 0.1 6.5 3.0 0.2 0.5 0.0 0.5 0.0 0.0 1.1 0.6 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.4 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.3 0.1 0.0 3.2 0.3 0.0 0.1 0.0 0.0 0.2 1.8 0.0 0.0 0.1 0.0 0.1 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.4 0.7 0.3 2.2 0.3 1.0 0.4 0.3 0.5 0.1 0.5 0.9 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.7 0.3 0.3 0.9 2.8 0.0 198.6 0.0 0.1 1.3 0.3 0.0 0.1 0.1 1.5 0.4 0.2 0.0 0.0 0.0 0.0 0.2 2.5 1.1 1.4 0.0 0.4 0.4 0.5 0.3 0.0 0.1 0.2 0.0 0.3 0.0 0.5 0.3 0.1 0.0 0.0 0.1 0.6 0.0 0.0 0.6 1.8 0.0 0.0 0.0 0.8 0.0 0.8 0.1 0.1 0.0 0.4 2.5 0.3 0.9 0.3 0.0 0.0 0.6 0.8 0.2 0.4 PTGER2 EP2 ENSG00000125384 "Prostaglandin E receptor 2" P43116 14 52314305-52328598 "FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 38.4" "Cell type enhanced" "Detected in many" "dendritic cells: 55.6;Macrophages: 33.2;NK-cells: 177.1;T-cells: 63.1" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "ASC diff: 26.1;ASC TERT1: 68.3;HHSteC: 43.8;HL-60: 25.2;HSkMC: 56.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" NA NA "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 63: NK-cells & T-cells - Immune response" "unprognostic (1.48e-1)" "unprognostic (2.48e-2)" "unprognostic (1.36e-2)" "unprognostic (4.04e-3)" "unprognostic (1.55e-2)" "unprognostic (3.24e-1)" "unprognostic (3.11e-3)" "unprognostic (1.79e-1)" "unprognostic (2.42e-1)" "unprognostic (1.20e-3)" "unprognostic (1.18e-1)" "unprognostic (1.83e-1)" "prognostic unfavorable (4.16e-4)" "unprognostic (8.48e-3)" "unprognostic (5.26e-3)" "unprognostic (6.71e-2)" "unprognostic (5.74e-2)" 8.7 1.4 0.1 12.6 0.6 38.4 3.6 0.0 0.4 17.2 3.0 8.0 6.2 9.4 0.6 1.8 4.6 9.7 1.1 0.1 0.2 3.2 3.6 5.4 4.5 0.7 0.5 8.2 1.2 0.4 0.7 14.4 0.3 9.9 6.6 0.0 3.2 2.8 0.7 1.3 9.4 5.1 0.6 11.8 17.5 2.9 0.3 3.2 1.7 0.3 1.7 5.8 2.2 0.3 1.3 0.5 0.0 0.0 26.1 68.3 0.1 2.1 0.4 2.3 2.8 0.0 0.1 0.0 1.8 1.4 0.0 9.3 0.0 0.5 3.3 0.0 13.2 0.0 0.7 0.0 43.8 25.2 0.3 56.2 1.1 5.8 0.9 7.4 0.0 0.0 0.0 0.0 13.4 1.2 0.0 1.0 1.0 4.5 8.8 0.2 0.0 0.0 20.6 0.1 0.7 20.6 0.0 0.0 0.0 0.0 0.0 7.3 0.0 0.9 1.5 15.5 0.0 0.0 0.0 0.0 6.1 14.2 0.2 5.8 35.9 35.5 106.7 30.6 129.3 0.2 91.0 114.3 19.0 0.1 21.7 67.7 4.7 73.5 61.5 0.9 50.0 66.3 0.1 0.6 0.0 0.4 0.1 0.2 0.7 0.5 0.3 0.6 0.3 0.3 4.0 3.2 1.7 0.0 3.2 1.8 0.4 0.8 1.2 0.0 2.0 2.5 1.2 1.5 0.7 3.7 0.0 0.1 55.6 0.7 0.0 0.3 0.0 24.0 1.6 0.9 6.0 3.0 0.1 0.0 0.3 13.9 15.3 7.7 20.8 2.9 4.2 0.6 10.0 0.0 0.1 6.0 0.0 28.0 19.6 0.5 4.1 33.2 3.6 0.0 16.6 0.0 177.1 0.0 0.0 1.5 0.1 3.0 3.7 1.4 0.0 0.3 9.6 0.0 0.0 1.3 11.6 0.1 1.2 0.2 1.6 0.3 63.1 0.2 0.6 0.2 PTGER3 "EP3, lnc003875" ENSG00000050628 "Prostaglandin E receptor 3" P43115 1 70852353-71047808 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 95.2;kidney: 81.2;smooth muscle: 68.0" "Group enriched" "Detected in many" 7 "Distal tubular cells: 225.0;Langerhans cells: 79.8" "Group enriched" "Detected in some" 7 "breast cancer: 4.1;renal cancer: 9.4" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in single" 59 "basophil: 43.3" "Lineage enriched" "Detected in single" 59 "granulocytes: 43.3" "Cell line enhanced" "Detected in some" "ASC diff: 28.6;HAP1: 20.9;HDLM-2: 32.8;HEL: 15.6;T-47d: 72.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA010689 Uncertain NA NA "Cluster 38: Basophils - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 6: T47d - Mammary gland" "Cluster 39: Non-specific - Basic cellular processes" "HPA010689: AB_1855883" "unprognostic (1.53e-3)" "unprognostic (3.48e-1)" "unprognostic (1.11e-1)" "unprognostic (3.86e-3)" "unprognostic (1.47e-1)" "unprognostic (3.37e-2)" "unprognostic (4.80e-2)" "unprognostic (2.01e-2)" "unprognostic (1.24e-1)" "unprognostic (4.64e-3)" "unprognostic (1.54e-1)" "unprognostic (1.97e-1)" "prognostic unfavorable (3.50e-4)" "unprognostic (8.83e-3)" "unprognostic (1.86e-1)" "unprognostic (1.92e-2)" "unprognostic (1.41e-4)" 54.5 6.7 7.1 5.0 4.3 0.2 28.6 0.0 8.5 4.7 10.4 13.9 1.2 95.2 3.7 3.9 10.1 8.9 1.6 4.7 10.9 81.2 0.3 1.0 1.3 5.6 0.6 1.7 6.6 0.9 0.6 0.6 3.2 3.0 2.3 0.7 11.9 7.9 0.4 13.8 3.7 68.0 2.4 0.3 22.4 1.0 4.7 0.9 1.0 1.4 1.4 6.6 6.1 1.1 0.0 0.0 0.0 0.0 28.6 0.7 0.1 0.7 0.0 0.1 0.7 0.0 0.0 0.0 0.0 3.5 0.0 0.0 20.9 0.0 0.1 32.8 0.0 15.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 4.9 0.0 0.0 0.1 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 1.1 0.0 0.3 0.0 0.2 72.5 0.0 0.0 0.3 0.1 0.1 0.1 0.0 0.0 0.0 0.1 7.2 0.0 43.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 7.1 4.3 0.0 8.5 4.7 10.9 5.6 0.6 3.2 2.4 4.7 1.1 6.9 0.0 0.5 0.0 0.0 5.0 0.2 0.0 0.0 1.6 13.7 6.1 1.8 1.5 0.0 20.2 0.0 0.0 0.2 0.4 225.0 3.0 1.6 0.6 4.6 1.7 2.4 0.0 2.2 0.0 2.4 12.2 1.5 1.2 9.5 0.0 0.7 0.0 0.1 3.3 3.4 1.0 12.2 0.0 79.8 1.0 1.2 3.2 8.8 0.0 0.6 0.2 0.0 0.5 0.3 0.0 0.0 0.0 0.1 1.3 0.1 7.2 0.0 0.2 6.6 0.5 11.7 0.1 0.1 0.1 7.5 0.1 1.2 6.2 0.0 0.2 PTGER4 EP4 ENSG00000171522 "Prostaglandin E receptor 4" P35408 5 40679915-40693735 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 85.7;pancreas: 54.2" "Cell type enhanced" "Detected in many" "dendritic cells: 134.8;Langerhans cells: 130.7;Macrophages: 90.2;T-cells: 214.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HDLM-2: 43.2;HUVEC TERT2: 28.7;LHCN-M2: 27.6;RT4: 43.1;THP-1: 27.4;TIME: 54.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA011226, HPA012756" Approved NA NA "Cluster 51: Monocytes - Innate immune response" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 24: Non-specific - Transcription regulation" "HPA011226: AB_1855885, HPA012756: AB_1855884" "unprognostic (1.79e-2)" "unprognostic (6.53e-3)" "unprognostic (9.43e-3)" "unprognostic (6.77e-3)" "unprognostic (1.44e-1)" "unprognostic (7.16e-2)" "unprognostic (7.28e-3)" "unprognostic (1.86e-2)" "unprognostic (2.19e-1)" "unprognostic (2.83e-1)" "unprognostic (1.02e-1)" "unprognostic (2.76e-1)" "unprognostic (3.61e-2)" "unprognostic (2.17e-1)" "unprognostic (2.48e-2)" "unprognostic (1.44e-1)" "prognostic favorable (2.48e-4)" 11.7 9.7 0.7 15.1 0.5 85.7 6.3 0.9 1.0 3.1 1.1 20.3 20.6 2.7 1.2 5.6 12.1 11.2 6.4 0.8 0.8 8.5 4.1 18.3 15.4 1.8 2.4 1.2 54.2 1.0 1.1 3.0 1.7 3.0 17.0 0.1 3.5 2.5 3.9 3.8 24.8 5.9 1.7 12.5 19.7 2.9 1.0 19.4 2.8 6.8 9.3 11.6 2.4 3.3 3.7 0.8 0.0 0.1 16.7 19.7 0.1 0.3 1.4 1.0 0.7 0.0 1.1 0.4 0.3 0.0 17.5 2.8 0.2 6.7 1.7 43.2 0.8 0.0 1.5 0.0 15.1 15.2 3.0 2.1 1.0 10.2 4.1 2.3 28.7 14.7 0.0 10.2 27.6 0.0 16.3 7.0 0.1 0.7 6.5 10.7 2.7 1.4 3.9 43.1 0.0 0.0 0.6 1.3 0.1 0.6 6.6 27.4 54.0 5.5 0.0 0.1 1.3 0.1 0.3 2.0 2.4 11.3 1.5 5.3 7.1 14.6 15.8 19.0 9.0 1.8 9.5 9.9 8.1 1.6 5.7 8.1 12.8 3.8 24.7 1.1 8.4 7.3 0.7 0.5 0.9 1.0 0.8 0.8 1.8 2.4 1.7 1.7 1.0 3.3 44.5 12.8 9.0 1.3 46.4 61.2 5.8 16.2 22.8 0.0 9.4 9.1 3.9 0.0 10.2 7.3 0.0 0.2 134.8 45.7 0.0 0.9 3.7 1.6 1.4 18.0 13.1 2.5 2.8 7.7 0.9 30.0 29.6 2.2 10.1 4.6 3.6 0.8 29.5 0.0 3.4 53.8 4.1 49.7 130.7 1.8 0.9 90.2 19.6 3.7 48.8 0.1 57.7 1.5 7.1 2.9 28.1 0.4 38.6 6.7 16.3 0.1 13.0 0.3 0.0 39.1 11.8 7.1 1.0 17.5 30.4 0.3 214.9 0.1 31.4 1.4 PTGFR FP ENSG00000122420 "Prostaglandin F receptor" P43088 1 78303884-78540701 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "tongue: 20.1" "Cell type enhanced" "Detected in many" "Club cells: 14.3;Fibroblasts: 22.7;Inhibitory neurons: 10.4;Langerhans cells: 10.6;Microglial cells: 17.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 7 "ASC TERT1: 271.2;HSkMC: 85.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA "Cluster 46: Fibroblasts - ECM organization" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 50: Fibroblasts - ECM organization" "unprognostic (4.14e-2)" "unprognostic (1.35e-2)" "unprognostic (5.89e-3)" "unprognostic (6.03e-2)" "unprognostic (5.63e-2)" "unprognostic (1.45e-3)" "unprognostic (7.61e-2)" "unprognostic (2.25e-1)" "unprognostic (9.90e-2)" "unprognostic (8.46e-4)" "unprognostic (2.21e-1)" "unprognostic (5.34e-2)" "unprognostic (2.16e-4)" "unprognostic (3.21e-4)" "unprognostic (8.48e-2)" "unprognostic (2.16e-2)" "unprognostic (1.21e-3)" 9.9 3.4 0.6 5.7 0.4 0.0 7.2 0.1 1.8 4.6 0.3 2.0 1.0 17.9 2.4 0.9 4.6 6.9 1.7 1.9 2.7 3.9 1.3 2.5 1.2 0.7 0.5 4.6 0.9 0.0 0.2 8.1 1.8 3.1 2.7 0.2 4.7 2.0 2.1 5.2 2.4 16.7 0.4 0.6 1.6 1.4 3.5 0.1 0.8 20.1 4.3 11.9 4.4 0.2 0.0 0.0 1.0 0.0 26.5 271.2 0.0 20.5 20.0 7.0 2.7 0.0 0.0 0.0 0.0 12.4 3.8 0.0 0.0 0.1 6.0 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 85.7 0.0 1.8 17.6 18.3 0.1 0.0 0.0 0.7 10.9 0.0 0.0 0.0 0.1 0.0 15.9 0.0 0.0 0.0 2.4 0.0 0.0 0.4 0.3 0.0 0.0 0.1 0.0 0.2 5.9 8.5 4.7 2.1 1.6 1.1 0.0 0.0 0.5 0.0 2.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.4 0.1 1.8 1.9 2.7 0.7 0.5 1.8 0.4 3.5 0.2 1.2 0.0 8.0 0.3 0.0 6.4 0.0 1.0 0.0 1.2 0.2 0.0 0.4 5.7 14.3 9.2 0.0 0.1 0.0 0.0 3.9 4.2 8.5 0.4 0.6 0.6 0.0 0.0 0.4 0.0 0.0 22.7 0.5 0.1 0.0 0.1 0.0 2.3 0.1 0.0 10.4 0.0 0.0 0.0 10.6 9.3 5.6 0.4 5.4 17.8 0.0 0.3 0.0 0.0 0.2 0.0 1.1 0.4 0.2 0.1 0.0 0.3 6.3 0.0 6.6 7.1 1.4 1.1 0.2 0.1 4.7 0.3 0.5 0.3 0.0 0.0 PTGIR IP ENSG00000160013 "Prostaglandin I2 receptor" P43119 19 46620468-46625089 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 55.5" "Group enriched" "Detected in some" 5 "Langerhans cells: 177.2;monocytes: 160.9" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Group enriched" "Detected in many" 10 "classical monocyte: 28.2;intermediate monocyte: 65.3;myeloid DC: 20.9;non-classical monocyte: 38.7" "Group enriched" "Detected in many" 11 "dendritic cells: 20.9;monocytes: 65.3" "Cell line enhanced" "Detected in some" "BJ: 10.8;BJ hTERT+: 12.2;fHDF/TERT166: 15.4;HDLM-2: 7.6;HEL: 28.3;HHSteC: 7.2" "Not detected" "Not detected" "Low region specificity" "Detected in some" NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 82: Adipose tissue - ECM organization" "Cluster 36: HEL - Hemostasis" "Cluster 3: Monocytes - Immune response regulation" "unprognostic (3.79e-1)" "unprognostic (1.95e-1)" "unprognostic (2.94e-2)" "unprognostic (2.39e-1)" "unprognostic (1.03e-1)" "unprognostic (3.49e-3)" "unprognostic (4.22e-2)" "unprognostic (6.09e-2)" "unprognostic (2.12e-1)" "unprognostic (7.45e-2)" "unprognostic (4.47e-1)" "unprognostic (1.14e-1)" "prognostic unfavorable (2.09e-8)" "unprognostic (1.66e-2)" "prognostic unfavorable (1.74e-4)" "unprognostic (1.16e-1)" "unprognostic (5.66e-2)" 13.7 6.8 0.5 6.0 0.4 3.4 5.2 0.4 0.9 6.0 0.4 4.8 2.0 4.6 0.3 2.1 4.5 2.9 27.3 0.6 0.4 26.1 9.2 55.5 3.5 0.6 0.5 2.4 5.7 0.6 1.9 4.4 0.5 2.6 1.0 0.0 4.1 0.9 2.8 4.3 5.8 2.9 0.6 10.8 6.7 0.3 0.5 1.5 16.6 0.8 2.6 6.0 5.2 0.5 0.0 0.0 0.0 0.0 0.2 5.5 0.0 10.8 12.2 1.5 4.3 0.0 0.0 0.0 0.9 15.4 0.1 0.0 0.0 0.0 0.9 7.6 0.0 28.3 0.0 0.0 7.2 0.0 0.0 1.7 0.0 3.9 0.2 0.0 3.1 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.9 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.5 1.4 1.7 0.2 0.3 0.0 0.0 0.0 0.0 0.4 0.7 0.7 0.0 28.2 0.0 0.0 65.3 0.4 1.5 0.3 0.0 20.9 0.7 3.3 0.1 1.1 0.0 38.7 2.0 3.9 17.6 0.5 0.4 0.4 0.9 0.6 0.4 0.6 0.5 0.5 0.6 0.5 0.5 1.5 0.0 0.6 0.3 3.7 4.2 0.8 0.4 0.0 0.4 0.2 0.5 0.9 0.0 0.1 1.8 0.0 0.1 2.7 0.2 0.0 0.3 0.2 0.1 1.5 2.3 0.0 0.4 0.7 0.4 0.1 10.3 0.5 0.1 3.8 0.1 4.2 0.2 2.6 0.0 0.6 0.0 0.0 7.9 177.2 0.0 2.1 23.7 7.2 0.0 160.9 0.1 1.0 0.5 0.3 0.4 0.0 0.0 0.1 0.8 0.0 0.2 0.7 0.8 6.6 1.1 30.9 0.1 0.4 0.0 4.4 0.3 2.0 0.1 0.0 0.7 PTGIS "CYP8A1, PGIS" ENSG00000124212 "Prostaglandin I2 synthase" Q16647 20 49503874-49568137 "Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" "Isomerase, Lyase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "fallopian tube: 80.7;urinary bladder: 81.7" "Cell type enhanced" "Detected in many" "Endothelial cells: 28.1;Fibroblasts: 70.8;Hepatic stellate cells: 117.8;Leydig cells: 26.8;Peritubular cells: 104.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "ASC diff: 45.1;ASC TERT1: 45.2;U-2197: 143.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB009517, HPA014193, HPA052244" Enhanced Approved "Endoplasmic reticulum" NA NA "Cluster 17: Basophils - Unknown function" "Cluster 89: Fibroblasts - ECM organization" "Cluster 18: U-2197 - ECM organization" "Cluster 50: Fibroblasts - ECM organization" "Endoplasmic reticulum" "CAB009517: AB_2173209, HPA014193: AB_1855746, HPA052244: AB_2732574" "unprognostic (7.68e-2)" "unprognostic (1.90e-1)" "unprognostic (5.09e-3)" "unprognostic (1.38e-2)" "unprognostic (1.80e-2)" "unprognostic (1.74e-1)" "unprognostic (1.21e-2)" "unprognostic (1.29e-2)" "unprognostic (1.25e-1)" "unprognostic (4.02e-2)" "unprognostic (2.45e-2)" "unprognostic (5.22e-2)" "prognostic unfavorable (4.74e-8)" "unprognostic (2.29e-2)" "unprognostic (7.61e-2)" "unprognostic (4.89e-3)" "prognostic unfavorable (9.99e-5)" 43.2 4.7 0.7 9.0 2.5 0.3 24.0 0.3 1.9 29.5 1.8 38.9 3.2 79.0 16.1 16.5 80.7 31.3 40.4 0.5 0.8 4.0 6.0 18.2 0.7 0.6 0.4 38.1 2.5 0.3 0.9 1.1 0.4 22.2 6.6 0.2 7.6 8.3 4.0 7.2 10.5 40.5 0.6 0.5 17.9 5.1 1.0 0.3 7.8 2.4 0.8 81.7 18.2 0.6 0.0 0.1 1.9 0.1 45.1 45.2 0.5 1.0 5.7 0.2 0.0 0.0 0.0 0.1 18.4 13.7 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 5.6 0.0 0.1 3.3 0.0 0.6 0.0 15.1 0.7 0.0 0.0 0.1 0.1 0.0 0.1 0.2 8.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.4 0.4 0.1 0.2 0.0 8.2 0.1 0.0 0.0 0.8 2.4 143.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.1 0.0 0.1 0.0 0.0 0.7 2.5 0.3 1.9 0.5 0.8 0.6 0.4 0.4 0.6 1.0 0.6 5.3 3.2 2.7 0.0 0.0 3.7 0.7 0.0 0.0 1.1 2.2 1.3 5.0 2.8 1.9 3.7 0.0 0.3 0.3 0.0 0.0 0.6 1.8 0.0 0.9 28.1 0.0 2.7 2.7 0.0 0.2 70.8 1.5 0.1 0.0 25.0 117.8 1.0 0.3 0.0 2.4 0.0 0.0 3.1 6.7 3.3 26.8 1.0 1.8 6.5 0.1 0.4 0.0 1.0 0.2 1.2 0.0 104.9 0.3 0.4 0.0 0.2 2.2 4.5 0.0 7.9 3.5 0.7 1.4 0.5 4.8 0.3 1.0 0.5 0.0 0.6 PTGS1 "COX1, PGHS-1, PTGHS" ENSG00000095303 "Prostaglandin-endoperoxide synthase 1" P23219 9 122370530-122395703 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" "Dioxygenase, Oxidoreductase, Peroxidase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 108.3;skin 1: 152.5;urinary bladder: 175.0" "Cell type enhanced" "Detected in many" "Endometrial ciliated cells: 109.9;Glandular and luminal cells: 191.9;granulocytes: 208.0;Hepatic stellate cells: 61.8;Macrophages: 55.3;Suprabasal keratinocytes: 58.7" "Cancer enhanced" "Detected in all" "ovarian cancer: 53.4" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "basophil: 28.9" "Group enriched" "Detected in many" 6 "dendritic cells: 20.0;granulocytes: 28.9;monocytes: 13.1" "Cell line enhanced" "Detected in many" "ASC diff: 113.7;ASC TERT1: 89.5;BJ: 115.2;BJ hTERT+: 156.0;HEL: 73.6;HMC-1: 298.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA002834, CAB020315" Enhanced Supported "Golgi apparatus,Vesicles" "Intracellular and membrane" NA NA 2100000 "Cluster 2: Granulocytes - Unknown function" "Cluster 31: Skin - Epidermis development" "Cluster 3: HMC-1 - Innate immune response" "Cluster 44: Endometrium - Transcription" "Golgi apparatus" Vesicles "CAB020315: , HPA002834: AB_1079711" "unprognostic (4.20e-1)" "unprognostic (6.23e-2)" "unprognostic (1.08e-2)" "unprognostic (2.27e-2)" "unprognostic (5.88e-2)" "unprognostic (2.00e-2)" "unprognostic (1.22e-3)" "unprognostic (3.32e-1)" "unprognostic (2.24e-1)" "unprognostic (3.16e-2)" "unprognostic (1.23e-1)" "unprognostic (1.46e-1)" "prognostic unfavorable (8.68e-4)" "unprognostic (4.03e-2)" "unprognostic (1.78e-2)" "unprognostic (2.08e-1)" "prognostic unfavorable (9.35e-4)" 12.8 2.9 3.1 10.5 3.2 9.0 6.7 4.2 4.8 5.8 5.5 108.3 10.8 6.1 2.2 67.3 43.2 9.6 12.6 7.4 5.5 9.3 3.0 11.3 4.6 6.5 5.2 2.0 1.8 2.0 4.8 2.2 6.3 21.1 24.2 0.7 4.3 6.1 2.1 152.5 17.7 16.1 6.7 8.0 20.5 0.9 7.0 2.2 3.2 4.0 11.6 175.0 15.9 11.9 0.3 0.5 0.4 0.0 113.7 89.5 0.0 115.2 156.0 1.0 1.1 0.0 0.2 4.2 5.4 19.7 0.3 7.1 0.4 10.5 0.9 0.0 0.2 73.6 0.6 0.0 32.9 5.2 298.4 46.1 1.2 5.7 0.3 0.0 42.3 0.1 0.1 0.3 2.3 0.0 0.2 6.6 1.6 0.0 0.5 0.3 1.4 8.6 14.7 0.0 0.5 0.6 0.6 9.5 0.2 0.5 0.3 8.4 1.0 0.7 0.6 1.7 0.1 0.3 0.2 0.0 0.4 31.6 0.3 28.9 12.1 23.3 0.0 13.1 0.0 2.4 0.0 0.0 20.0 3.5 0.1 0.0 5.2 2.8 10.2 1.4 0.2 21.9 3.1 3.2 4.2 4.8 7.4 5.5 6.5 5.2 6.3 6.7 7.0 11.9 0.9 0.0 6.6 0.0 5.9 9.9 2.6 7.7 0.0 0.1 1.1 1.4 1.6 4.3 2.2 42.3 0.0 0.1 0.2 0.1 0.0 0.6 0.1 109.9 10.4 24.7 1.8 18.7 0.8 0.5 0.3 10.7 2.0 191.9 208.0 0.1 61.8 0.8 26.1 0.0 0.5 0.6 4.1 15.5 20.7 0.3 1.5 55.3 3.6 16.9 11.7 0.0 7.2 1.0 0.1 0.6 0.6 0.0 0.3 2.8 0.0 0.0 0.8 0.1 0.0 1.4 3.6 0.0 0.2 18.2 58.7 0.4 3.4 0.1 1.0 0.8 PTGS2 COX2 ENSG00000073756 "Prostaglandin-endoperoxide synthase 2" P35354 1 186671791-186680922 "Cancer-related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism" "Dioxygenase, Oxidoreductase, Peroxidase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 116.7;seminal vesicle: 127.4;urinary bladder: 162.5" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 342.9;Fibroblasts: 270.7;granulocytes: 347.6;Langerhans cells: 305.6;Macrophages: 173.1;Urothelial cells: 151.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 16 "neutrophil: 11.7" "Lineage enriched" "Detected in single" 16 "granulocytes: 11.7" "Cell line enriched" "Detected in many" 4 "BJ hTERT+: 405.5" "Region enhanced" "Detected in many" "hippocampal formation: 15.1" "Low region specificity" "Detected in many" "CAB000113, HPA001335" Enhanced Approved "Endoplasmic reticulum,Vesicles" "Intracellular and membrane" NA NA "Cluster 50: Neutrophils - Cellular senescence" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 41: Macrophages - Immune response" "Endoplasmic reticulum, Vesicles" "CAB000113: , HPA001335: AB_1079712" "unprognostic (1.36e-3)" "unprognostic (9.97e-3)" "unprognostic (3.97e-2)" "unprognostic (3.31e-2)" "unprognostic (1.55e-1)" "unprognostic (1.11e-1)" "unprognostic (5.96e-2)" "unprognostic (9.50e-2)" "unprognostic (9.03e-3)" "unprognostic (2.81e-1)" "unprognostic (3.24e-2)" "unprognostic (3.07e-2)" "prognostic unfavorable (9.79e-4)" "unprognostic (8.04e-3)" "unprognostic (4.38e-2)" "unprognostic (8.89e-2)" "unprognostic (3.74e-2)" 17.0 7.9 1.4 13.9 2.5 116.7 3.0 1.1 4.1 62.2 2.7 14.9 2.6 8.9 0.7 6.9 5.1 31.6 11.7 1.9 1.4 10.2 8.0 34.3 8.9 2.0 1.6 2.6 2.2 5.6 3.1 8.4 1.5 25.0 9.9 0.3 1.2 127.4 0.4 1.6 3.6 12.2 1.9 2.8 14.8 0.2 1.8 5.2 3.2 6.5 0.6 162.5 2.2 2.6 0.0 21.8 0.1 0.0 2.5 2.1 0.0 93.4 405.5 0.6 3.6 15.0 17.2 0.0 0.0 0.1 2.5 12.2 0.0 7.6 1.3 0.0 0.0 0.8 2.2 0.0 13.2 0.0 0.2 0.8 2.7 11.3 28.7 1.0 4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.8 0.0 0.0 0.0 0.0 0.0 5.5 1.5 0.0 1.0 0.0 0.9 2.7 0.0 0.1 1.5 19.3 0.6 13.5 0.6 0.2 0.0 0.0 27.7 0.4 2.3 0.0 0.3 0.2 0.0 0.7 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 11.7 0.0 0.4 0.0 0.0 0.0 1.4 2.5 1.1 4.1 1.9 1.4 2.0 1.6 1.5 1.9 1.8 2.6 5.2 342.9 77.7 0.0 7.4 118.8 59.1 72.8 12.5 0.0 2.6 12.8 2.5 0.0 79.7 0.0 0.0 0.2 4.2 0.3 0.0 0.8 0.2 50.0 9.9 31.1 1.2 3.6 3.8 0.2 0.3 270.7 2.0 98.9 347.6 3.8 13.6 0.2 12.1 0.0 1.0 1.0 8.2 21.0 305.6 0.0 0.0 173.1 35.6 3.7 3.4 0.1 0.0 0.0 0.1 4.9 0.1 0.0 2.0 122.6 0.2 0.3 13.1 0.3 0.0 1.8 12.8 0.1 0.4 3.3 28.4 0.5 10.8 3.7 1.2 151.6 PTK2B "CADTK, CAKB, FAK2, PTK, PYK2, RAFTK" ENSG00000120899 "Protein tyrosine kinase 2 beta" Q14289 8 27311482-27459391 "Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Adaptive immunity, Angiogenesis, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 106.3;brain: 102.9" "Cell type enhanced" "Detected in many" "Excitatory neurons: 109.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 127.4;REH: 141.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB003850, HPA026091, HPA026276" Approved Supported "Plasma membrane,Cytosol" NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 10: Brain - Neuronal signaling" "Cluster 14: REH - Unknown function" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane, Cytosol" "CAB003850: AB_562205, HPA026091: AB_10599739, HPA026276: AB_10601234" "unprognostic (2.36e-2)" "prognostic favorable (3.32e-4)" "unprognostic (1.06e-1)" "unprognostic (7.36e-3)" "unprognostic (3.72e-2)" "unprognostic (3.11e-2)" "unprognostic (2.70e-2)" "unprognostic (2.13e-2)" "unprognostic (3.23e-1)" "unprognostic (1.45e-1)" "unprognostic (5.74e-2)" "unprognostic (3.32e-1)" "unprognostic (2.40e-3)" "unprognostic (1.44e-1)" "unprognostic (1.38e-1)" "prognostic favorable (5.11e-4)" "unprognostic (3.33e-3)" 19.7 10.8 46.9 52.6 54.4 106.3 11.5 22.8 102.9 11.5 38.3 29.8 34.1 9.9 8.9 19.2 15.6 12.7 10.6 96.3 8.5 15.9 15.2 28.6 78.3 0.0 26.0 4.7 12.6 7.1 13.7 8.0 0.0 25.5 23.5 4.4 26.6 12.3 5.0 45.2 48.8 10.7 0.2 78.3 22.2 9.5 27.0 86.0 12.5 5.4 73.6 21.0 15.1 37.0 38.2 10.4 2.8 3.0 76.6 5.5 21.5 2.9 1.9 1.9 2.7 9.9 21.5 127.4 4.0 5.8 3.1 34.3 1.1 31.3 1.1 8.7 0.8 26.4 10.6 2.0 15.7 28.5 45.5 41.6 46.0 2.6 17.3 13.0 1.0 36.0 31.7 85.6 2.1 4.0 49.1 57.0 2.2 33.0 2.6 141.2 0.7 88.3 8.5 29.5 19.2 3.5 13.4 9.3 5.0 6.5 11.5 72.1 17.5 1.3 2.8 2.5 1.0 68.0 32.0 68.9 5.2 60.6 2.4 47.3 48.4 36.9 33.9 43.0 22.2 46.0 17.0 24.3 36.1 46.6 20.8 25.9 45.8 29.0 53.5 11.7 18.2 50.1 46.9 54.4 22.8 102.9 96.3 8.5 0.0 26.0 0.0 0.2 27.0 37.0 6.9 3.2 29.8 16.6 64.3 37.7 38.7 19.7 6.8 5.4 5.9 7.7 3.7 8.6 13.0 14.7 0.0 2.9 33.4 65.5 0.0 8.0 1.2 7.1 1.8 9.6 7.8 20.2 109.2 8.3 26.5 3.5 22.4 5.3 28.5 1.1 5.0 24.1 23.1 8.4 9.2 21.9 10.2 68.4 32.1 1.0 1.5 55.3 8.8 22.5 62.5 2.8 70.0 7.5 15.1 13.3 42.0 0.7 68.1 18.6 44.6 16.1 13.9 3.9 0.0 3.3 3.3 4.2 6.4 4.8 30.1 1.9 46.6 1.0 18.1 17.9 QPRT QPRTase ENSG00000103485 "Quinolinate phosphoribosyltransferase" Q15274 16 29663279-29698699 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Pyridine nucleotide biosynthesis" "Glycosyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "kidney: 119.4;liver: 183.5" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 404.7;Extravillous trophoblasts: 315.1;Hepatocytes: 367.4;Proximal tubular cells: 598.8;Syncytiotrophoblasts: 215.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "classical monocyte: 4.2;intermediate monocyte: 5.3;myeloid DC: 5.8;non-classical monocyte: 9.0;plasmacytoid DC: 3.1" "Group enriched" "Detected in many" 8 "dendritic cells: 5.8;monocytes: 9.0" "Cell line enhanced" "Detected in many" "EFO-21: 597.1;Hep G2: 258.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA011887, HPA076010" Enhanced Approved Vesicles "Intracellular and membrane" NA NA 780000 "Cluster 7: Monocytes - Unknown function" "Cluster 81: Kidney & Liver - Metabolism" "Cluster 38: EFO-21 - Unknown function" "Cluster 67: Proximal tubular cells - Tubular reabsorption" Vesicles "HPA011887: AB_2668555, HPA076010: " "prognostic unfavorable (5.10e-5)" "unprognostic (2.00e-1)" "unprognostic (9.48e-2)" "unprognostic (2.88e-1)" "prognostic unfavorable (9.31e-4)" "unprognostic (1.44e-2)" "unprognostic (8.75e-2)" "unprognostic (1.22e-1)" "unprognostic (8.16e-2)" "unprognostic (1.01e-2)" "unprognostic (2.39e-1)" "unprognostic (6.81e-2)" "unprognostic (3.37e-2)" "unprognostic (1.33e-2)" "unprognostic (2.65e-1)" "unprognostic (1.63e-1)" "unprognostic (1.58e-2)" 8.4 89.4 20.6 4.3 20.2 4.8 6.7 25.8 19.8 50.6 19.4 19.2 61.6 26.1 95.2 4.0 43.6 10.2 26.8 18.5 22.2 119.4 183.5 9.2 6.8 28.6 26.6 31.0 34.5 16.2 5.8 27.3 32.4 7.0 15.2 7.5 13.4 26.1 5.1 5.1 30.3 13.7 23.6 17.2 7.1 4.1 22.8 8.2 6.5 1.2 5.2 10.5 11.5 23.3 0.6 1.4 51.8 56.4 8.8 21.6 167.8 6.0 5.2 8.6 11.0 145.9 91.9 2.3 597.1 10.8 10.0 1.0 18.5 0.6 4.5 0.8 16.7 27.1 2.2 258.0 52.5 4.1 10.4 69.8 1.4 4.8 0.2 12.8 0.2 28.2 75.1 2.9 0.4 154.6 17.6 100.3 162.1 1.9 0.2 89.3 16.3 58.5 47.9 4.2 48.6 103.5 0.0 142.1 118.8 85.1 106.5 112.8 0.6 2.5 24.9 0.9 0.5 1.8 4.9 18.8 4.4 10.4 8.1 0.0 4.2 0.3 0.8 5.3 0.9 0.1 0.6 0.7 5.8 0.0 0.1 0.4 0.8 0.4 9.0 3.1 0.9 1.9 20.6 20.2 25.8 19.8 18.5 22.2 28.6 26.6 32.4 23.6 22.8 23.3 3.1 9.6 24.8 5.2 10.1 3.6 11.7 0.5 1.8 3.3 5.0 2.0 43.2 8.6 3.0 64.4 0.0 404.7 5.8 84.5 50.9 1.2 0.0 93.8 49.5 5.5 28.3 10.5 1.3 55.2 315.1 35.8 0.5 81.0 5.1 6.7 9.7 367.4 147.5 6.7 5.6 47.3 0.0 21.2 18.3 0.5 29.2 19.8 42.7 12.2 4.4 20.8 3.1 11.1 0.5 11.5 78.5 27.1 8.7 4.2 161.0 598.8 1.5 5.0 6.6 3.3 16.2 0.5 3.0 0.2 2.0 215.6 5.7 36.5 104.7 8.3 RAF1 "c-Raf, CRAF, Raf-1" ENSG00000132155 "Raf-1 proto-oncogene, serine/threonine kinase" P04049 3 12583601-12664125 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Cancer-related genes, Cardiomyopathy, Deafness, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "neutrophil: 175.1" "Lineage enriched" "Detected in all" 5 "granulocytes: 175.1" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA002639, HPA002640, CAB019291" Approved Supported "Plasma membrane,Cytosol" NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 59: Non-specific - Translation" "Cluster 28: BEWO - Transcription regulation" "Cluster 40: Granulosa cells - Unknown function" "Plasma membrane, Cytosol" "CAB019291: , HPA002639: , HPA002640: AB_1856047" "unprognostic (6.33e-2)" "unprognostic (1.29e-1)" "unprognostic (5.92e-2)" "unprognostic (2.17e-3)" "unprognostic (6.51e-3)" "unprognostic (7.66e-3)" "unprognostic (2.66e-3)" "unprognostic (1.53e-2)" "unprognostic (2.72e-1)" "unprognostic (7.66e-2)" "unprognostic (2.92e-2)" "unprognostic (1.29e-2)" "unprognostic (2.79e-2)" "unprognostic (1.79e-1)" "unprognostic (1.27e-1)" "unprognostic (2.64e-2)" "unprognostic (2.36e-2)" 42.4 34.2 36.7 33.8 37.9 77.4 39.2 42.6 37.4 47.6 40.4 46.8 40.5 45.6 34.0 55.5 43.2 31.0 89.6 36.9 35.8 46.7 68.9 44.7 36.3 38.3 36.9 52.0 50.6 63.6 28.3 39.1 37.0 41.9 42.0 37.4 39.6 38.0 194.9 56.0 43.4 45.5 36.7 48.3 55.5 26.8 38.1 52.8 48.8 122.5 47.7 46.1 46.2 39.8 49.9 57.9 85.5 66.6 74.3 59.6 168.0 73.9 129.1 100.1 112.5 46.6 41.3 52.7 34.6 120.1 51.6 31.9 93.4 67.5 103.8 91.4 70.2 72.0 69.4 42.9 74.2 70.1 64.7 55.3 67.8 102.3 82.0 67.6 73.1 78.2 52.6 136.0 98.3 88.6 91.1 47.8 86.5 64.0 76.4 72.6 75.7 66.4 60.9 76.9 26.1 56.2 61.1 59.8 40.9 66.1 99.1 91.5 51.1 65.6 62.5 55.7 85.0 103.3 178.4 112.3 57.2 80.4 73.9 40.4 32.7 62.5 22.3 32.6 22.5 19.5 21.9 22.3 30.3 20.4 21.9 22.8 175.1 29.8 34.2 13.5 28.3 28.2 36.7 37.9 42.6 37.4 36.9 35.8 38.3 36.9 37.0 36.7 38.1 39.8 28.5 22.4 37.6 47.7 36.1 34.4 35.2 22.1 27.9 56.7 27.5 22.6 29.0 35.8 25.7 27.6 66.7 40.0 41.5 31.3 13.7 25.6 8.8 33.2 37.1 32.7 29.3 46.7 46.1 37.0 46.8 32.3 27.5 43.8 34.2 78.7 36.0 41.2 28.6 43.7 52.9 31.0 30.5 39.3 43.4 4.6 39.1 34.7 26.6 44.0 49.5 31.9 51.5 65.4 64.0 35.5 29.9 41.3 43.3 46.9 47.3 20.1 31.2 81.9 32.9 56.2 39.1 28.3 33.6 31.8 43.5 62.3 40.8 35.6 31.2 47.1 RAMP1 ENSG00000132329 "Receptor activity modifying protein 1" O60894 2 237858893-237912106 "FDA approved drug targets, Predicted membrane proteins, Transporters" Transport Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "endometrium 1: 706.0" "Cell type enhanced" "Detected in many" "Cardiomyocytes: 190.0;Endometrial stromal cells: 546.4;Exocrine glandular cells: 278.2;monocytes: 433.5" "Cancer enhanced" "Detected in all" "prostate cancer: 152.7" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in some" 18 "NK-cell: 70.1" "Lineage enriched" "Detected in many" 18 "NK-cells: 70.1" "Cell line enhanced" "Detected in many" "CAPAN-2: 47.4;HDLM-2: 146.0;PC-3: 173.8;SH-SY5Y: 201.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA057814 Approved "Nucleoplasm,Nuclear membrane" NA NA "Cluster 48: NK-cells - Unknown function" "Cluster 35: Non-specific - Unknown function" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 36: Stromal cells - Cell proliferation" "Nucleoplasm, Nuclear membrane" "HPA057814: AB_2683536" "unprognostic (1.13e-2)" "unprognostic (5.96e-2)" "unprognostic (3.03e-3)" "unprognostic (3.69e-1)" "unprognostic (4.29e-1)" "unprognostic (1.75e-1)" "prognostic favorable (7.61e-4)" "unprognostic (2.54e-1)" "unprognostic (3.49e-1)" "unprognostic (5.45e-3)" "unprognostic (2.32e-1)" "unprognostic (1.43e-1)" "unprognostic (2.46e-3)" "prognostic unfavorable (1.68e-4)" "unprognostic (1.74e-1)" "unprognostic (3.98e-2)" "unprognostic (2.08e-3)" 18.7 29.2 170.9 21.0 171.2 0.9 7.4 168.7 253.4 362.4 153.7 349.6 57.5 706.0 25.0 9.4 256.6 28.5 287.6 176.0 181.8 26.0 82.7 32.5 6.6 198.8 164.5 45.2 225.0 1.4 15.2 8.6 163.0 142.2 6.4 0.8 10.0 54.6 212.3 11.6 73.5 125.4 171.7 12.3 103.4 5.1 183.5 2.9 6.8 68.8 2.9 171.4 75.1 173.2 29.8 0.0 0.5 0.0 12.4 17.9 1.1 2.1 3.6 1.7 1.5 0.0 47.4 0.3 0.4 0.9 0.1 0.2 7.6 0.1 0.2 146.0 4.0 0.1 0.0 1.2 40.6 0.0 0.2 15.6 22.3 0.1 0.3 0.2 0.0 0.0 0.0 0.3 3.7 2.7 0.1 1.3 0.4 0.1 173.8 0.0 1.5 0.8 0.0 0.0 1.5 201.7 3.5 0.0 0.1 1.8 1.3 0.1 0.0 0.8 0.6 0.4 0.5 0.3 0.3 0.0 0.6 0.1 2.7 0.0 0.0 0.0 3.8 0.0 0.0 0.3 0.6 0.1 1.0 0.0 0.5 0.2 0.4 70.1 0.0 0.2 0.0 3.4 170.9 171.2 168.7 253.4 176.0 181.8 198.8 164.5 163.0 171.7 183.5 173.2 1.0 0.0 1.5 64.9 3.1 11.6 13.2 26.9 10.2 2.0 4.4 4.4 190.0 78.6 43.8 11.0 0.0 3.0 44.0 2.1 0.0 62.7 0.2 26.5 546.4 6.2 115.4 4.4 14.2 278.2 5.5 41.7 31.1 11.3 1.3 0.6 30.7 104.0 22.7 1.7 19.2 73.7 10.2 3.1 50.3 0.6 8.4 20.3 64.0 13.1 433.5 6.9 61.8 71.9 11.5 63.5 87.7 11.3 1.9 66.1 96.8 0.2 97.0 2.7 6.6 16.6 78.6 0.3 5.8 2.6 5.8 2.3 7.3 0.5 105.8 28.5 RAMP2 ENSG00000131477 "Receptor activity modifying protein 2" O60895 17 42758447-42763041 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Group enriched" "Detected in many" 5 "Adipocytes: 1066.8;Endothelial cells: 562.9;Hepatic stellate cells: 344.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 21 "plasmacytoid DC: 2.9" "Lineage enriched" "Detected in single" 21 "dendritic cells: 2.9" "Cell line enhanced" "Detected in many" "ASC diff: 120.4;EFO-21: 80.5;HUVEC TERT2: 37.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA052020 Approved Vesicles NA NA "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 82: Adipose tissue - ECM organization" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" Vesicles "HPA052020: AB_2681697" "unprognostic (8.64e-2)" "unprognostic (2.12e-2)" "unprognostic (8.03e-2)" "unprognostic (1.16e-2)" "unprognostic (5.24e-2)" "unprognostic (4.13e-3)" "unprognostic (2.68e-2)" "unprognostic (1.04e-1)" "unprognostic (4.50e-2)" "unprognostic (5.18e-2)" "unprognostic (1.02e-2)" "unprognostic (6.79e-2)" "unprognostic (1.28e-2)" "unprognostic (6.96e-3)" "unprognostic (4.42e-2)" "unprognostic (2.20e-1)" "unprognostic (1.25e-1)" 190.0 29.0 60.4 19.2 61.8 0.1 168.9 61.7 72.3 100.7 67.7 35.7 12.5 63.1 27.8 25.1 51.7 39.6 123.2 59.3 65.8 70.5 16.7 163.3 26.2 65.7 68.1 33.0 17.1 23.8 20.8 97.0 72.7 42.1 21.1 4.1 45.9 27.5 43.3 55.9 44.1 72.6 62.7 40.2 33.9 11.9 66.6 11.4 71.7 98.7 24.5 45.9 49.6 62.4 0.1 1.1 4.9 0.1 120.4 6.2 4.0 0.9 2.1 10.2 4.9 11.5 0.1 0.0 80.5 3.0 0.5 0.0 4.6 0.1 8.9 0.0 0.2 0.0 0.7 3.7 3.0 0.0 0.0 4.2 0.1 1.8 0.4 3.5 37.6 1.5 0.1 0.2 0.6 0.0 0.6 0.8 23.3 0.0 0.0 0.1 0.1 0.0 0.6 0.6 4.8 9.8 2.9 0.0 17.3 4.8 1.2 3.2 6.7 19.3 7.1 0.4 2.4 0.0 0.1 0.3 0.0 0.1 8.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.1 0.0 60.4 61.8 61.7 72.3 59.3 65.8 65.7 68.1 72.7 62.7 66.6 62.4 1066.8 0.0 5.7 1.6 6.2 34.4 5.4 0.9 9.6 0.6 24.0 24.8 2.2 0.0 1.0 3.7 0.0 1.1 3.7 0.1 3.9 0.6 1.6 22.2 52.8 562.9 4.2 0.0 0.2 0.7 1.7 126.9 3.1 38.5 0.0 1.4 344.8 1.3 3.4 0.0 1.0 0.2 20.3 8.4 40.5 3.6 38.8 4.1 23.2 45.0 2.6 15.5 0.0 1.5 0.3 0.0 0.0 21.8 5.2 4.8 0.0 1.0 0.1 1.8 6.6 10.5 26.3 26.6 59.1 2.6 27.6 1.5 4.0 14.0 0.1 4.3 RAMP3 ENSG00000122679 "Receptor activity modifying protein 3" O60896 7 45157791-45186302 "FDA approved drug targets, Predicted membrane proteins, Transporters" Transport Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lung: 144.6" "Group enriched" "Detected in many" 12 "Adipocytes: 287.8;Endothelial cells: 366.0;Hepatic stellate cells: 555.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 7 "Karpas-707: 2.5" "Group enriched" "Detected in all" 4 "cerebellum: 62.2;cerebral cortex: 49.2;thalamus: 174.9;white matter: 60.0" "Low region specificity" "Detected in all" HPA075527 Supported "Plasma membrane" NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 82: Adipose tissue - ECM organization" "Cluster 2: Karpas-707 - Immune response" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "Plasma membrane" "HPA075527: " "unprognostic (1.62e-3)" "prognostic favorable (2.89e-4)" "unprognostic (4.85e-2)" "unprognostic (6.88e-3)" "unprognostic (3.68e-2)" "unprognostic (1.44e-3)" "prognostic favorable (2.50e-6)" "unprognostic (1.14e-1)" "unprognostic (2.35e-1)" "unprognostic (3.19e-1)" "unprognostic (2.79e-2)" "unprognostic (9.49e-2)" "unprognostic (1.09e-2)" "unprognostic (1.20e-2)" "unprognostic (2.43e-1)" "unprognostic (1.91e-1)" "unprognostic (9.21e-2)" 86.9 32.6 17.7 23.0 19.7 0.2 71.7 26.9 22.7 33.5 21.3 24.4 10.2 25.9 3.9 18.9 22.8 28.7 91.3 19.2 25.8 84.1 23.9 144.6 55.0 37.3 25.7 7.4 19.7 28.1 22.3 8.6 34.2 29.7 8.6 1.1 22.1 12.9 19.3 22.8 30.0 24.4 31.6 11.4 25.7 6.3 23.5 7.3 71.9 26.9 30.3 28.5 30.5 42.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.1 0.2 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.3 17.7 19.7 26.9 22.7 19.2 25.8 37.3 25.7 34.2 31.6 23.5 42.4 287.8 0.0 1.9 0.3 3.6 16.3 0.3 0.0 2.2 0.6 5.9 2.8 8.7 1.5 0.0 0.0 0.0 0.1 1.2 0.0 0.0 0.1 20.8 0.4 7.3 366.0 0.0 13.5 3.5 0.7 0.1 10.7 0.0 0.2 0.0 0.0 555.4 7.3 0.5 0.0 0.2 0.0 0.0 31.2 19.1 6.7 1.2 1.3 26.6 5.6 0.0 0.2 0.0 0.0 6.5 0.0 0.0 1.2 1.3 0.6 0.0 0.0 0.0 0.5 0.0 2.8 4.9 0.3 0.9 0.9 14.5 0.0 1.7 1.5 0.0 0.5 RARA "NR1B1, RAR" ENSG00000131759 "Retinoic acid receptor alpha" P10276 17 40309180-40357643 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "neutrophil: 52.6" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 221.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058282, HPA071548" Supported "Nucleoplasm,Nucleoli,Actin filaments,Cytosol" NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 59: Non-specific - Translation" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 41: Macrophages - Immune response" Nucleoplasm "Nucleoli, Actin filaments, Cytosol" "HPA058282: AB_2683666, HPA071548: " "unprognostic (8.05e-3)" "unprognostic (1.89e-1)" "unprognostic (9.48e-3)" "prognostic favorable (2.60e-4)" "unprognostic (8.67e-3)" "unprognostic (4.87e-3)" "unprognostic (2.77e-1)" "unprognostic (5.73e-2)" "unprognostic (1.45e-1)" "unprognostic (3.54e-2)" "unprognostic (1.19e-1)" "unprognostic (1.79e-1)" "unprognostic (2.29e-3)" "unprognostic (1.59e-2)" "unprognostic (5.60e-2)" "unprognostic (1.60e-1)" "unprognostic (1.09e-2)" 47.6 21.1 3.2 28.3 4.4 59.6 37.2 7.2 16.5 43.7 5.1 31.0 28.4 32.2 10.7 14.9 40.7 41.3 40.8 7.0 5.7 24.1 42.3 58.4 16.4 5.3 2.7 40.8 14.7 11.3 30.6 25.7 2.8 29.8 13.2 18.3 20.6 21.3 62.6 24.8 32.2 28.6 1.8 41.7 22.9 28.8 4.9 10.0 26.9 17.4 11.8 30.3 30.2 4.3 18.0 41.9 11.8 20.5 23.4 35.9 12.5 14.9 21.8 21.5 13.6 28.6 15.1 9.6 22.7 33.2 18.9 51.1 14.2 33.9 12.0 77.5 21.4 26.6 21.2 29.8 37.0 9.4 81.3 48.2 10.0 22.7 29.2 75.8 30.9 8.4 17.6 20.2 23.7 221.5 6.4 34.2 10.7 16.2 13.3 12.9 71.3 37.0 12.2 14.4 5.4 40.5 31.0 124.8 42.1 11.7 119.1 36.6 35.8 25.3 45.3 44.2 15.4 48.7 16.9 8.3 38.4 18.7 77.1 26.3 8.9 34.6 3.2 14.6 5.1 2.0 3.6 3.8 12.4 1.7 1.5 2.8 52.6 5.9 19.5 3.8 3.1 5.0 3.2 4.4 7.2 16.5 7.0 5.7 5.3 2.7 2.8 1.8 4.9 4.3 35.6 3.2 7.0 2.3 43.4 19.5 25.6 8.4 18.8 23.2 35.4 17.5 3.8 10.0 5.5 7.3 6.2 2.2 36.9 41.2 13.7 16.7 60.5 20.7 22.0 28.4 9.6 5.7 5.4 19.2 5.8 28.5 10.7 18.4 35.5 13.9 26.0 28.8 12.3 3.3 2.6 13.1 6.1 45.4 65.5 66.2 41.7 56.9 28.4 2.8 26.1 11.8 6.2 4.0 0.3 22.0 33.1 23.0 21.0 13.4 70.9 17.7 4.9 10.2 32.9 42.1 26.7 3.6 7.6 7.1 18.9 5.2 31.7 6.5 16.5 19.3 RARB "HAP, NR1B2, RRB2" ENSG00000077092 "Retinoic acid receptor beta" P10826 3 25174332-25597932 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Disease variant, FDA approved drug targets, Microphthalmia, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Astrocytes: 41.4;Excitatory neurons: 66.8;Inhibitory neurons: 92.6;Microglial cells: 29.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 13.7;HEK 293: 16.0;hTERT-RPE1: 82.3;WM-115: 36.5" "Region enriched" "Detected in all" 9 "basal ganglia: 109.2" "CAB002617, HPA004174" Enhanced Enhanced Nucleoplasm NA NA "Cluster 82: Adipose tissue - ECM organization" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" Nucleoplasm "CAB002617: , HPA004174: AB_1079744" "unprognostic (2.04e-2)" "unprognostic (3.53e-2)" "unprognostic (1.93e-1)" "unprognostic (1.09e-1)" "unprognostic (1.56e-1)" "unprognostic (6.72e-2)" "unprognostic (1.30e-2)" "unprognostic (2.70e-2)" "unprognostic (2.43e-1)" "unprognostic (4.71e-2)" "unprognostic (1.62e-1)" "unprognostic (2.86e-1)" "prognostic favorable (3.43e-5)" "unprognostic (9.24e-3)" "unprognostic (2.28e-1)" "unprognostic (9.99e-2)" "unprognostic (6.56e-3)" 4.1 7.0 3.5 2.6 15.0 0.0 6.9 2.2 6.6 9.3 7.2 6.0 1.7 7.4 6.7 7.9 6.0 5.3 14.0 3.5 1.4 15.1 6.5 5.3 6.7 3.4 1.7 11.5 1.3 6.0 7.5 14.4 0.9 12.5 2.2 13.6 13.1 11.2 2.4 1.1 2.0 5.9 1.4 4.9 3.9 0.6 2.4 1.2 9.1 5.3 4.2 7.2 6.1 3.7 0.0 1.9 1.2 6.4 13.7 3.6 0.0 1.6 0.8 0.0 0.6 0.3 0.1 0.1 0.2 2.5 0.3 0.4 0.0 0.3 0.0 0.1 16.0 0.1 0.1 1.1 0.3 0.2 0.1 7.1 0.0 0.0 0.0 82.3 13.4 0.1 0.1 5.6 0.1 0.1 0.0 0.1 0.3 0.1 0.0 0.3 0.0 0.0 0.0 0.2 0.6 8.3 0.0 0.2 0.1 9.1 0.0 0.1 0.0 1.1 0.1 2.1 7.0 0.2 0.0 0.1 5.6 0.2 36.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 15.0 2.2 6.6 3.5 1.4 3.4 1.7 0.9 1.4 2.4 3.7 2.4 0.0 0.5 41.4 0.3 0.1 18.0 6.4 1.8 4.5 1.7 7.5 12.0 12.8 14.9 11.0 25.0 0.2 0.8 0.0 0.0 1.6 1.5 8.3 4.2 10.5 0.0 0.0 66.8 0.9 0.1 6.8 7.7 3.0 0.0 0.1 22.1 2.1 0.4 5.0 92.6 0.0 2.0 1.9 0.4 1.2 0.0 0.3 0.0 29.0 0.0 24.8 0.0 19.6 2.9 1.4 0.0 0.0 0.2 10.2 0.6 0.6 9.2 6.3 0.0 2.9 9.7 0.2 1.0 6.6 0.1 0.3 0.5 0.2 0.2 9.7 RARG "NR1B3, RARC" ENSG00000172819 "Retinoic acid receptor gamma" P13631 12 53210567-53232980 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 141.6;skin 1: 121.4" "Cell type enhanced" "Detected in many" "Basal squamous epithelial cells: 42.7;Squamous epithelial cells: 69.9;Suprabasal keratinocytes: 55.8;Urothelial cells: 45.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "MAIT T-cell: 18.8" "Group enriched" "Detected in all" 4 "dendritic cells: 6.7;T-cells: 18.8" "Cell line enhanced" "Detected in many" "CAPAN-2: 101.0;MCF7: 110.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA053883 Supported Supported Nucleoplasm NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 11: Squamous epithelial cells - Epithelial cell function" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 61: Squamous epithelial cells - Keratinization" Nucleoplasm "HPA053883: AB_2682292" "unprognostic (7.29e-2)" "unprognostic (1.95e-2)" "unprognostic (6.11e-2)" "prognostic unfavorable (3.68e-6)" "unprognostic (2.53e-1)" "unprognostic (5.43e-2)" "unprognostic (2.28e-1)" "unprognostic (1.08e-2)" "unprognostic (3.54e-3)" "unprognostic (7.21e-3)" "unprognostic (3.78e-3)" "unprognostic (4.44e-2)" "prognostic unfavorable (3.08e-6)" "unprognostic (5.41e-3)" "unprognostic (1.98e-2)" "unprognostic (5.94e-3)" "unprognostic (7.41e-2)" 17.4 16.2 10.2 5.7 9.7 3.7 19.4 13.0 10.9 55.0 10.8 22.7 2.5 23.3 6.0 141.6 27.2 15.7 17.3 9.7 9.5 12.5 3.2 15.2 5.9 10.3 10.0 20.5 8.5 7.2 8.7 9.5 9.3 26.9 7.8 3.9 30.6 16.2 6.9 121.4 10.4 13.0 10.0 10.2 14.5 4.8 9.5 5.1 22.6 10.6 22.5 26.2 69.3 10.0 22.8 24.7 5.5 50.9 55.0 46.8 1.7 23.2 50.0 29.7 23.3 8.3 101.0 0.5 12.5 93.6 16.2 74.3 18.4 44.6 7.4 5.7 9.4 3.3 18.6 7.4 23.2 0.0 9.1 34.8 63.9 28.5 6.4 74.7 12.7 4.6 0.8 9.8 11.9 110.3 1.3 1.1 16.3 30.4 42.7 7.3 1.9 18.1 8.9 37.1 4.4 22.9 47.0 50.6 32.1 6.8 43.9 1.4 13.8 35.4 16.5 23.6 1.5 4.2 2.6 1.8 43.4 3.8 51.3 1.8 3.1 0.9 7.4 0.9 18.8 2.0 6.5 5.4 6.7 0.6 5.2 4.7 0.0 2.3 0.0 0.6 1.8 4.0 10.2 9.7 13.0 10.9 9.7 9.5 10.3 10.0 9.3 10.0 9.5 10.0 10.7 3.2 7.0 21.2 2.5 34.2 24.1 21.6 42.7 0.5 18.0 15.6 3.7 11.5 11.1 3.7 2.1 7.5 6.2 3.2 0.0 10.5 0.1 3.6 14.4 11.0 1.8 0.8 2.5 5.1 1.2 19.6 13.7 3.4 1.3 0.3 20.3 0.1 2.7 0.0 3.0 2.1 12.2 4.1 13.3 0.5 5.3 4.9 8.8 6.5 1.8 3.6 5.2 7.1 0.7 14.3 4.4 5.3 3.0 19.2 0.2 0.5 3.9 5.2 6.6 9.5 22.0 0.8 5.6 69.9 55.8 1.8 7.2 0.4 5.5 45.7 REN ENSG00000143839 Renin P00797 1 204154819-204190324 "Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted secreted proteins" "Aspartyl protease, Hydrolase, Protease" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 10 "kidney: 162.2" "Cell type enhanced" "Detected in some" "Early spermatids: 6.8;Late spermatids: 28.4;Paneth cells: 5.6;Smooth muscle cells: 10.7;Urothelial cells: 7.0" "Cancer enriched" "Detected in many" 8 "renal cancer: 39.4" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A-431: 1.0;BJ: 2.0;HMC-1: 2.6;SK-BR-3: 1.8" "Not detected" "Not detected" "Not detected" "Not detected" HPA005131 Approved "Secreted to blood" NA NA 692000 10000 "Cluster 7: Kidney - Transmembrane transport" "Cluster 3: HMC-1 - Innate immune response" "Cluster 33: Fibroblasts - ECM organization" "HPA005131: AB_1079174" "unprognostic (4.45e-2)" "unprognostic (3.35e-1)" "unprognostic (1.62e-1)" "unprognostic (8.58e-2)" "unprognostic (2.89e-1)" "unprognostic (1.23e-2)" "unprognostic (1.24e-1)" "unprognostic (1.13e-1)" "unprognostic (7.20e-3)" "unprognostic (1.37e-1)" "unprognostic (1.57e-1)" "prognostic unfavorable (6.45e-5)" "unprognostic (1.22e-1)" "unprognostic (1.70e-1)" "unprognostic (4.98e-2)" "unprognostic (6.49e-2)" 1.0 1.4 0.3 0.2 0.9 0.0 0.1 0.0 0.2 4.3 3.2 0.4 0.3 9.6 0.3 0.2 2.3 0.1 1.8 0.2 0.0 162.2 0.7 0.7 0.0 0.3 0.4 16.3 0.0 0.0 0.6 15.2 0.1 0.3 0.2 0.1 0.8 0.8 0.0 0.1 0.1 1.5 0.0 0.1 0.0 0.9 0.2 0.5 0.0 0.0 0.5 5.2 0.3 0.0 1.0 0.0 0.0 0.0 0.1 0.0 0.0 2.0 0.4 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.7 0.1 0.0 0.0 1.8 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.9 0.0 0.2 0.2 0.0 0.3 0.4 0.1 0.0 0.2 0.0 0.0 0.0 1.5 1.0 0.0 0.0 0.8 0.7 0.0 0.7 0.1 0.0 0.2 0.0 0.3 1.8 0.0 0.3 0.0 0.0 0.0 1.2 6.8 0.2 0.5 0.4 0.0 0.0 0.3 1.1 0.2 2.8 0.0 0.5 0.0 0.0 0.0 0.0 0.5 0.0 0.3 0.0 0.0 0.0 0.0 28.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.0 5.6 0.4 0.0 1.8 0.0 0.0 0.0 0.3 0.0 0.0 10.7 0.3 0.2 0.0 0.0 1.1 0.1 1.3 0.0 7.0 RET "CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51" ENSG00000165731 "Ret proto-oncogene" P07949 10 43077064-43130351 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Cell adhesion" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Hirschsprung disease, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "adrenal gland: 20.8;brain: 27.3;parathyroid gland: 31.8" "Group enriched" "Detected in some" 4 "Horizontal cells: 79.1;Ionocytes: 26.4;Skeletal myocytes: 23.1" "Cancer enhanced" "Detected in many" "breast cancer: 11.0" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "MCF7: 74.6;NB-4: 42.2;SH-SY5Y: 329.3;THP-1: 95.9" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 5 "midbrain: 53.3;spinal cord: 19.4" "CAB002581, HPA008356, HPA008495" Approved Supported Approved "Golgi apparatus,Plasma membrane,Cytosol" No NA 2100000 "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 48: Parathyroid gland - membrane proteins" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 50: Fibroblasts - ECM organization" "Golgi apparatus, Cytosol" "Plasma membrane" "CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: " "unprognostic (7.94e-2)" "unprognostic (3.68e-2)" "unprognostic (4.49e-1)" "prognostic unfavorable (5.02e-4)" "unprognostic (1.15e-1)" "unprognostic (9.13e-4)" "unprognostic (1.27e-2)" "unprognostic (3.62e-2)" "unprognostic (2.86e-1)" "unprognostic (2.01e-1)" "unprognostic (1.54e-3)" "unprognostic (4.43e-1)" "unprognostic (9.35e-5)" "unprognostic (1.64e-3)" "unprognostic (8.28e-2)" "unprognostic (3.67e-3)" "unprognostic (2.02e-2)" 1.8 20.8 1.0 1.3 0.9 0.4 1.1 5.1 5.6 1.0 0.2 3.4 1.4 0.6 0.3 0.4 0.5 0.6 2.2 0.3 5.5 0.9 3.0 0.4 0.6 14.4 27.3 0.4 1.3 31.8 5.3 0.5 12.0 1.8 1.4 4.7 5.1 2.0 5.9 0.9 1.4 1.0 4.8 0.2 2.2 2.7 7.6 1.6 0.8 3.1 0.2 0.6 1.4 5.8 0.1 0.4 0.1 1.7 0.0 0.0 0.1 0.7 0.2 0.4 0.1 0.0 0.0 0.0 0.1 0.0 0.6 0.0 5.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 7.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 74.6 0.0 42.2 7.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 4.7 329.3 0.1 0.0 0.1 0.5 4.1 95.9 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.9 0.7 0.1 0.0 1.0 0.9 5.1 5.6 0.3 5.5 14.4 27.3 12.0 4.8 7.6 5.8 0.4 0.0 0.5 1.6 0.0 0.3 0.8 0.0 0.0 1.7 6.0 0.5 2.1 0.0 0.0 0.0 0.0 0.0 2.1 0.2 0.0 0.0 1.5 0.0 0.3 1.1 0.0 0.0 4.2 0.2 2.3 6.8 0.0 0.0 1.3 0.5 0.0 1.2 0.1 79.1 8.6 1.9 26.4 0.0 0.6 1.5 0.3 0.5 0.0 1.0 0.0 0.8 0.0 1.0 0.6 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.8 1.7 0.0 23.1 1.2 1.1 4.7 0.0 0.6 0.0 0.2 0.3 0.2 0.1 RFK "FLJ11149, RIFK" ENSG00000135002 "Riboflavin kinase" Q969G6 9 76385526-76394517 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Extravillous trophoblasts: 352.0;Pancreatic endocrine cells: 220.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA023259, CAB033887, HPA057163" Approved Approved "Golgi apparatus" NA NA "Cluster 51: Monocytes - Innate immune response" "Cluster 45: Intestine - Brush border" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 53: Intestinal epithelial cells - Unknown function" "Golgi apparatus" "CAB033887: AB_2178617, HPA023259: AB_2671127, HPA057163: AB_2683357" "unprognostic (1.79e-1)" "unprognostic (3.98e-2)" "unprognostic (1.83e-1)" "unprognostic (1.03e-1)" "unprognostic (1.34e-1)" "unprognostic (1.76e-3)" "unprognostic (8.61e-3)" "unprognostic (3.11e-1)" "unprognostic (1.39e-1)" "unprognostic (2.88e-1)" "unprognostic (1.02e-1)" "unprognostic (4.61e-2)" "unprognostic (1.22e-3)" "unprognostic (3.22e-2)" "unprognostic (1.83e-1)" "unprognostic (2.70e-1)" "unprognostic (3.88e-2)" 11.6 20.6 18.0 14.6 18.4 25.0 11.7 12.6 21.1 11.7 12.5 30.8 33.1 12.8 18.2 12.9 13.6 19.9 16.3 20.6 27.2 27.0 29.2 12.4 11.6 16.9 18.4 11.7 16.4 23.8 12.0 13.2 27.0 13.0 22.9 14.7 11.0 9.9 14.9 5.1 28.2 11.9 14.2 10.2 29.0 16.7 21.6 12.0 19.7 18.7 11.2 13.9 5.9 13.5 21.9 23.2 13.9 18.1 20.5 20.3 41.8 25.2 18.6 17.8 13.9 8.2 13.3 35.3 28.7 18.2 32.3 22.9 19.3 16.5 35.3 10.4 18.0 11.2 30.4 26.2 36.7 37.9 25.6 13.5 29.3 21.4 23.2 19.9 58.3 30.4 30.6 28.7 36.1 20.8 49.3 13.3 18.1 51.2 22.7 26.7 18.3 8.9 82.0 10.6 35.0 12.7 26.9 37.2 22.9 18.1 9.4 20.2 35.9 18.5 33.3 40.1 35.6 30.7 32.3 12.4 30.7 33.3 25.9 5.2 9.8 3.6 5.0 19.9 7.5 5.8 7.3 6.0 11.8 4.4 7.0 6.7 1.4 8.5 21.1 4.3 7.4 9.8 18.0 18.4 12.6 21.1 20.6 27.2 16.9 18.4 27.0 14.2 21.6 13.5 27.3 16.0 9.2 5.9 22.9 45.4 23.8 15.3 22.2 50.4 24.5 20.6 37.9 34.3 20.1 42.3 20.9 54.1 18.4 158.8 60.7 64.9 191.7 37.8 18.5 46.2 28.2 48.8 18.0 189.3 352.0 33.5 33.1 42.3 12.0 18.0 124.2 40.9 33.2 11.8 19.3 23.1 40.7 57.6 26.6 118.1 22.1 29.9 30.2 10.3 25.2 44.7 9.2 7.1 6.5 220.6 68.3 65.1 12.7 33.6 79.9 142.8 27.7 28.7 0.0 23.0 21.7 91.8 64.1 18.8 40.5 123.5 23.1 18.8 33.7 22.6 ROCK1 p160ROCK ENSG00000067900 "Rho associated coiled-coil containing protein kinase 1" Q13464 18 20946906-21111813 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Apoptosis "Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Early spermatids: 406.2;Late spermatids: 505.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004562, HPA007567, HPA045639" Approved NA NA "Cluster 1: Neutrophils - Mixed function" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 32: U-937 - Innate immune response" "Cluster 10: Non-specific - Unknown function" "CAB004562: AB_628223, HPA007567: AB_1856393, HPA045639: AB_2679401" "unprognostic (7.86e-2)" "unprognostic (2.86e-2)" "unprognostic (1.22e-1)" "unprognostic (6.63e-2)" "unprognostic (9.90e-2)" "unprognostic (1.17e-1)" "unprognostic (6.74e-2)" "unprognostic (1.00e-1)" "unprognostic (1.63e-1)" "unprognostic (8.89e-3)" "prognostic unfavorable (9.93e-4)" "unprognostic (3.85e-2)" "unprognostic (8.93e-3)" "unprognostic (3.04e-2)" "unprognostic (5.47e-2)" "unprognostic (3.19e-1)" "unprognostic (1.28e-1)" 8.0 4.2 3.8 5.7 4.8 18.2 6.0 4.4 3.9 5.3 4.6 5.0 3.6 5.9 4.6 4.2 6.3 4.2 5.5 2.8 3.5 4.4 4.8 7.6 5.5 5.4 4.0 5.4 5.1 2.9 2.9 4.4 4.9 4.4 3.2 4.8 4.4 3.4 2.6 3.7 5.2 3.2 4.4 6.2 5.8 2.6 4.5 5.5 4.5 1.9 4.2 6.6 5.4 5.3 6.5 3.9 3.9 3.8 7.2 7.7 6.3 8.9 4.3 3.9 4.2 6.6 2.7 8.0 6.2 10.5 2.1 5.2 3.6 5.2 7.8 11.4 4.1 6.4 7.3 2.9 3.6 17.9 9.6 5.6 4.6 5.8 4.7 3.2 6.0 3.1 3.7 7.9 4.6 4.1 8.5 3.8 3.2 4.3 6.6 11.9 4.5 3.1 3.7 5.9 4.5 3.5 7.1 4.6 3.6 3.4 4.6 6.7 9.9 7.7 6.4 7.1 7.2 10.7 5.3 9.0 5.8 7.5 4.8 3.0 5.0 6.8 5.0 3.2 4.0 3.9 3.6 3.8 4.2 5.0 3.5 3.5 18.0 2.8 4.0 5.5 3.6 2.5 3.8 4.8 4.4 3.9 2.8 3.5 5.4 4.0 4.9 4.4 4.5 5.3 98.2 96.1 88.7 64.6 112.6 46.3 60.4 30.7 43.9 100.4 32.2 35.6 138.6 28.6 61.4 33.1 131.3 57.5 136.9 36.6 15.6 62.5 406.2 64.8 86.9 94.4 99.0 47.9 81.3 38.0 64.9 78.4 62.7 73.8 72.7 68.5 60.0 47.4 60.3 60.6 74.2 45.8 40.7 135.3 126.7 505.0 97.6 166.2 65.8 106.8 137.1 52.3 204.9 87.0 140.0 70.9 62.8 138.8 83.2 63.2 32.3 21.0 44.6 128.6 170.9 81.4 197.6 107.4 80.9 38.7 36.7 43.0 127.4 70.5 38.9 73.3 ROCK2 ENSG00000134318 "Rho associated coiled-coil containing protein kinase 2" O75116 2 11179759-11348330 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "Kinase, Serine/threonine-protein kinase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in all" "Excitatory neurons: 280.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007459, CAB008666, HPA044109" Approved Supported Cytosol NA NA 710000 "Cluster 15: NK-cells - Transcription" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 48: Smooth muscle cells - ECM organization" Cytosol "CAB008666: AB_1622617, HPA007459: AB_1079828, HPA044109: AB_2678813" "unprognostic (4.55e-2)" "unprognostic (1.05e-2)" "unprognostic (4.18e-3)" "unprognostic (4.87e-2)" "unprognostic (1.49e-1)" "unprognostic (2.71e-1)" "unprognostic (1.39e-2)" "unprognostic (2.72e-1)" "unprognostic (3.62e-2)" "unprognostic (6.66e-2)" "unprognostic (3.83e-2)" "unprognostic (1.48e-1)" "prognostic unfavorable (1.57e-5)" "unprognostic (1.51e-1)" "unprognostic (1.99e-1)" "unprognostic (2.52e-2)" "unprognostic (3.47e-2)" 36.4 9.3 6.7 13.5 16.3 6.8 22.3 19.1 14.3 18.7 0.8 22.6 16.7 22.0 10.3 16.2 13.6 15.6 17.0 12.1 3.5 14.5 16.5 16.9 10.1 1.7 4.4 19.0 11.7 12.8 5.9 24.9 1.4 17.4 26.2 13.5 14.6 18.1 30.4 8.5 19.2 27.9 2.0 16.4 14.1 7.8 6.4 8.4 13.9 28.9 8.8 21.1 11.0 10.4 17.5 41.7 33.8 33.2 59.7 41.6 21.6 40.4 37.7 25.8 27.1 39.8 37.2 21.9 23.4 64.5 31.3 18.9 24.7 23.4 40.6 31.2 14.7 43.8 70.6 79.7 21.4 24.7 12.1 32.6 14.6 31.9 22.6 21.0 42.0 11.9 38.6 8.6 38.8 14.8 18.2 12.7 18.8 36.9 25.3 21.7 74.2 7.0 14.0 48.8 15.9 16.9 79.6 27.4 27.4 25.5 11.3 13.6 57.3 52.9 38.2 21.2 36.0 6.8 8.9 18.8 22.8 28.2 75.4 0.9 0.4 0.4 0.6 0.4 0.7 0.3 0.4 0.4 0.3 0.5 0.4 0.4 0.6 0.8 0.4 0.6 0.4 0.2 6.7 16.3 19.1 14.3 12.1 3.5 1.7 4.4 1.4 2.0 6.4 10.4 114.5 115.4 79.1 81.3 16.0 39.9 43.0 15.3 21.1 35.7 33.5 41.1 107.0 37.1 53.1 22.0 58.4 26.3 20.4 97.7 1.9 27.1 11.0 53.6 141.2 90.3 21.2 22.5 280.4 39.5 19.1 64.0 18.3 55.3 29.0 36.9 56.0 43.1 19.6 80.8 158.1 92.2 10.2 20.3 27.0 4.9 43.8 30.4 23.2 107.7 20.6 38.4 15.5 99.0 66.9 39.1 43.6 78.6 16.2 53.5 45.3 15.7 32.7 48.5 131.5 70.0 118.5 30.3 24.6 19.9 27.8 31.5 18.5 34.2 54.8 40.7 ROS1 "c-ros-1, MCF3, ROS" ENSG00000047936 "ROS proto-oncogene 1, receptor tyrosine kinase" P08922 6 117287353-117425942 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 18 "epididymis: 58.6;lung: 31.7" "Cell type enriched" "Detected in some" 4 "Alveolar cells type 2: 78.5" "Cancer enriched" "Detected in some" 13 "lung cancer: 6.9" "Region enriched" "Detected in single" 4 "cerebral cortex: 2.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "GAMG: 19.3;HSkMC: 10.1;hTCEpi: 21.7;LHCN-M2: 14.9" "Not detected" "Not detected" "Not detected" "Not detected" "HPA049098, HPA072424" Uncertain Approved Vesicles NA NA "Cluster 30: Epididymis - Antimicrobial activity" "Cluster 30: Epithelial cell lines - Translation" "Cluster 11: Alveolar cells - Smell perception" Vesicles "HPA049098: AB_2680628, HPA072424: AB_2686519" "unprognostic (8.18e-2)" "unprognostic (4.64e-3)" "unprognostic (1.60e-1)" "unprognostic (2.37e-2)" "unprognostic (7.57e-2)" "unprognostic (2.05e-2)" "unprognostic (1.57e-1)" "unprognostic (1.79e-1)" "unprognostic (2.79e-2)" "unprognostic (1.00e-2)" "unprognostic (2.42e-1)" "unprognostic (5.20e-2)" "unprognostic (1.56e-12)" "unprognostic (1.09e-2)" "unprognostic (2.81e-1)" "unprognostic (1.91e-1)" "unprognostic (2.12e-1)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.2 0.0 0.4 0.0 0.0 58.6 0.0 0.1 0.0 0.0 0.6 0.0 0.3 0.1 31.7 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.4 0.0 0.0 0.4 0.0 0.0 2.2 0.4 0.3 0.2 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.3 0.3 0.0 0.0 0.1 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 10.1 21.7 0.2 1.9 0.0 0.0 0.0 0.0 0.0 14.9 0.0 0.0 0.2 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 2.0 0.0 3.1 1.7 0.2 2.1 0.0 0.0 0.0 1.9 3.5 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 16.0 78.5 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.6 0.0 0.8 0.0 3.7 0.0 0.0 0.0 0.0 0.3 0.0 0.0 1.3 1.8 0.2 0.0 0.0 0.0 17.8 0.0 0.0 0.2 0.0 1.5 1.3 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 1.3 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 RPL3 L3 ENSG00000100316 "Ribosomal protein L3" P39023 22 39312882-39320389 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins" "Ribonucleoprotein, Ribosomal protein" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003365, HPA055361" Uncertain Supported Nucleoli,Cytosol NA NA 470000 "Cluster 30: Non-specific - Translation" "Cluster 50: Non-specific - Ribosome" "Cluster 30: Epithelial cell lines - Translation" "Cluster 32: Non-specific - Translation" "Nucleoli, Cytosol" "HPA003365: AB_1079841, HPA055361: AB_2732594" "unprognostic (9.79e-3)" "unprognostic (2.06e-1)" "unprognostic (2.31e-1)" "unprognostic (1.68e-3)" "unprognostic (5.44e-3)" "unprognostic (1.72e-1)" "unprognostic (3.51e-2)" "unprognostic (1.22e-1)" "unprognostic (3.63e-1)" "unprognostic (5.81e-2)" "unprognostic (5.87e-2)" "unprognostic (7.09e-2)" "unprognostic (2.54e-2)" "unprognostic (1.85e-1)" "unprognostic (6.09e-2)" "unprognostic (2.72e-1)" "unprognostic (4.32e-2)" 2058.6 1934.3 965.6 1484.2 985.8 2965.1 2704.2 936.9 1071.1 2705.4 1023.2 2078.1 1515.1 2007.3 1653.7 2522.3 2423.9 1128.4 1326.4 894.6 951.2 1745.2 1894.1 1421.2 2460.9 984.1 951.1 4838.0 4514.8 1462.2 1861.5 1099.8 977.1 2180.0 1361.7 809.1 2210.1 1551.8 558.4 3337.9 1722.9 1388.1 1050.0 1824.1 1982.0 752.6 1002.9 2006.1 1709.0 417.1 2320.5 2012.9 2317.5 996.1 2010.5 1836.9 2035.9 2149.6 2535.3 5394.1 2745.1 1497.8 2703.5 1400.5 1249.7 2327.8 1425.1 8262.2 2062.9 1734.1 873.2 1246.8 2275.3 3060.5 923.2 1448.3 2207.4 2039.5 2153.8 3438.2 3887.7 2932.6 1619.9 5321.2 4063.7 1265.0 4504.5 3956.7 2765.5 2217.6 2407.8 2657.6 2135.0 2597.5 2974.5 4241.1 2054.6 2172.9 1273.8 2369.5 1924.0 4017.5 2609.2 2927.6 1823.4 2180.2 936.2 2925.4 5031.9 1242.2 2226.2 4761.3 2864.1 951.4 1534.4 1027.8 1788.2 2074.0 1741.6 3606.5 2111.3 2564.4 1093.9 638.7 1690.8 351.4 3488.7 1481.6 5383.7 5629.1 4993.5 4037.9 2821.8 5113.1 6376.7 5111.7 215.7 4472.3 1339.8 3182.6 3668.7 11623.3 965.6 985.8 936.9 1071.1 894.6 951.2 984.1 951.1 977.1 1050.0 1002.9 996.1 2118.4 984.0 2299.9 16.3 4551.5 10412.0 9836.0 9475.4 2792.1 1065.7 9967.6 10172.3 182.6 4213.6 3849.3 1441.9 425.4 5623.9 4123.0 1288.7 5893.0 2943.4 2097.6 1061.7 2644.4 3666.1 2726.6 2263.9 17.0 6539.7 7508.2 2678.8 1207.4 1390.0 1784.7 4203.6 3429.3 2085.8 3282.5 358.4 18.3 3696.8 2925.6 3062.8 6215.2 4622.8 5581.1 2203.8 5104.8 17.8 3733.3 2455.8 4243.1 9.5 25.1 3814.3 2946.3 3499.2 2308.1 8261.9 3481.6 5422.4 1350.6 1305.5 1577.7 4469.5 4329.1 1074.6 1014.8 3712.4 12290.3 5489.4 4201.1 4673.7 4830.3 9407.7 RRM1 ENSG00000167325 "Ribonucleotide reductase catalytic subunit M1" P23921 11 4094707-4138932 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "DNA replication" "Allosteric enzyme, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Spermatocytes: 102.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022093, HPA057265, HPA064297" Enhanced Supported Cytosol NA Yes 140000 "Cluster 4: T-regs - Cell cycle regulation" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" Cytosol "CAB022093: , HPA057265: AB_2683386, HPA064297: AB_2685236" "unprognostic (4.47e-2)" "unprognostic (1.73e-2)" "unprognostic (1.99e-3)" "unprognostic (3.65e-1)" "unprognostic (2.83e-1)" "unprognostic (2.19e-1)" "prognostic unfavorable (1.53e-4)" "unprognostic (1.31e-2)" "unprognostic (3.43e-2)" "unprognostic (6.90e-2)" "unprognostic (1.06e-3)" "unprognostic (4.21e-2)" "unprognostic (6.88e-3)" "unprognostic (9.20e-3)" "unprognostic (6.16e-2)" "unprognostic (8.41e-2)" "unprognostic (9.93e-3)" 16.6 21.2 5.1 24.8 5.3 32.8 22.7 7.1 6.1 16.9 4.7 25.7 19.3 16.2 10.1 26.5 15.5 11.8 16.4 5.1 5.7 13.4 18.4 12.8 34.4 6.1 5.5 16.4 14.6 24.7 7.1 20.4 6.6 18.5 29.4 23.6 14.7 16.0 30.3 36.1 20.2 20.1 6.2 13.0 17.6 17.9 5.1 56.7 15.6 30.0 45.2 15.6 18.9 6.2 221.6 117.8 188.4 110.0 28.4 56.2 73.0 198.0 98.2 220.7 225.9 106.8 163.8 237.4 47.0 100.1 95.9 173.0 176.9 143.2 259.3 117.3 187.9 121.0 159.8 83.1 11.2 208.9 84.6 26.6 37.8 121.7 86.4 48.3 107.8 140.1 161.1 107.3 186.8 99.6 246.7 41.9 118.2 152.2 119.2 196.1 147.0 84.3 59.4 61.8 159.8 88.1 175.1 104.8 30.0 75.8 102.8 71.4 62.3 203.4 106.0 206.9 147.4 70.3 103.5 252.5 114.1 137.6 130.3 8.3 4.0 4.5 11.3 11.2 21.1 9.2 22.3 16.6 7.3 5.2 17.2 15.0 0.0 10.5 15.6 4.4 41.7 10.3 5.1 5.3 7.1 6.1 5.1 5.7 6.1 5.5 6.6 6.2 5.1 6.2 12.4 19.2 14.4 4.9 17.0 33.4 26.8 31.0 17.6 15.6 15.1 14.4 33.5 14.3 24.7 18.4 6.2 62.8 14.9 13.3 7.9 25.6 69.9 11.5 14.5 15.7 18.0 81.2 11.2 22.2 62.5 22.0 20.4 13.9 7.0 27.3 10.8 15.0 28.3 18.5 12.0 25.0 16.2 11.7 10.3 83.9 13.1 13.9 10.6 6.5 10.7 24.0 5.2 12.1 11.9 15.8 10.4 16.6 31.3 10.1 12.5 8.4 15.5 22.7 13.1 19.5 27.1 102.8 63.1 36.5 29.0 39.7 23.2 18.1 34.3 20.6 RRM2 "C2orf48, FLJ25102" ENSG00000171848 "Ribonucleotide reductase regulatory subunit M2" P31350 2 10120698-10211725 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins" "DNA replication" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "bone marrow: 44.2;esophagus: 18.4;intestine: 19.7;lymphoid tissue: 58.1" "Group enriched" "Detected in many" 4 "Erythroid cells: 214.0;Extravillous trophoblasts: 254.1;Plasma cells: 248.0" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Low immune cell specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA056994 Enhanced Supported Cytosol Yes Yes 13000 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" Cytosol "HPA056994: AB_2683304" "unprognostic (2.10e-2)" "unprognostic (1.62e-1)" "unprognostic (6.40e-3)" "unprognostic (4.42e-3)" "unprognostic (5.70e-2)" "unprognostic (1.69e-1)" "prognostic unfavorable (1.39e-5)" "unprognostic (1.04e-3)" "unprognostic (6.67e-3)" "unprognostic (4.53e-2)" "prognostic unfavorable (1.62e-4)" "unprognostic (5.11e-3)" "prognostic unfavorable (0.00e+0)" "unprognostic (3.05e-2)" "unprognostic (2.24e-1)" "unprognostic (1.38e-1)" "unprognostic (2.09e-2)" 1.5 1.3 0.3 12.4 0.3 44.2 2.9 0.5 0.4 3.0 1.9 14.2 9.4 2.2 0.7 18.4 0.8 1.1 0.5 0.3 0.3 0.9 3.2 2.4 35.5 0.4 0.4 0.3 1.1 0.3 0.2 4.6 0.4 0.9 19.7 0.2 2.1 0.5 0.1 3.7 7.5 6.1 0.3 11.1 6.0 2.9 0.8 58.1 0.9 0.1 37.6 6.0 4.6 0.5 110.2 25.0 127.1 49.9 7.4 22.5 116.8 209.2 128.6 170.2 187.9 70.8 59.1 114.4 9.5 88.6 151.1 55.0 188.0 136.6 198.0 210.7 41.8 146.3 52.1 105.1 0.8 146.7 87.4 8.1 3.4 234.6 16.2 27.7 103.3 110.4 63.4 328.6 214.3 57.1 167.3 90.9 83.0 133.3 103.6 87.6 187.0 67.8 87.1 62.7 67.7 56.2 198.0 116.6 17.3 51.8 69.2 31.4 57.6 93.1 125.1 66.9 289.6 212.1 184.9 195.9 51.0 134.4 107.7 0.3 0.1 0.1 1.2 0.0 0.0 0.1 0.3 0.8 0.1 0.1 0.1 0.4 0.4 0.8 0.0 0.1 0.2 0.2 0.3 0.3 0.5 0.4 0.3 0.3 0.4 0.4 0.4 0.3 0.8 0.5 0.2 3.2 1.5 0.0 25.0 10.5 3.0 9.2 1.2 0.0 3.9 4.4 1.4 1.5 2.3 0.0 0.0 42.3 5.6 12.9 1.9 1.2 3.9 2.2 3.5 4.2 0.0 214.0 0.1 0.0 254.1 11.2 11.7 3.6 5.7 12.2 3.9 3.7 47.9 0.0 0.0 26.9 2.0 7.2 8.8 6.8 0.3 5.0 0.0 1.0 0.0 0.0 7.2 0.0 0.0 0.5 0.3 0.4 248.0 1.5 2.4 2.1 4.6 0.0 0.0 0.2 14.6 22.9 34.0 51.5 1.6 48.7 11.9 1.2 36.7 5.6 RRM2B p53R2 ENSG00000048392 "Ribonucleotide reductase regulatory TP53 inducible subunit M2B" Q7LG56 8 102204502-102238961 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "DNA damage, DNA repair, DNA replication" Oxidoreductase "Disease variant, FDA approved drug targets, Neuropathy, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB006854, HPA028812" Approved Enhanced Nucleoplasm,Cytosol NA NA "Cluster 9: Neutrophils - Innate immune response" "Cluster 8: Non-specific - Mitochondria" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 65: Plasmacytoid DCs - Unknown function" "Nucleoplasm, Cytosol" "CAB006854: , HPA028812: AB_10602246" "unprognostic (7.76e-3)" "unprognostic (4.14e-2)" "unprognostic (9.41e-3)" "unprognostic (3.41e-1)" "unprognostic (1.13e-2)" "unprognostic (1.28e-1)" "unprognostic (5.51e-2)" "unprognostic (1.35e-2)" "unprognostic (1.66e-1)" "unprognostic (9.40e-2)" "unprognostic (1.74e-2)" "unprognostic (1.03e-1)" "unprognostic (1.70e-2)" "unprognostic (4.32e-1)" "unprognostic (1.47e-1)" "unprognostic (2.52e-1)" "unprognostic (7.17e-2)" 11.5 21.2 10.5 11.5 12.1 7.1 12.1 13.6 11.5 12.5 26.5 15.3 15.0 11.6 15.1 11.2 13.5 11.9 16.7 10.1 13.7 24.4 22.6 22.0 20.1 13.6 12.4 12.0 13.5 45.0 10.3 13.8 13.9 15.7 15.5 21.9 10.9 13.8 30.4 11.0 10.1 11.7 14.1 14.3 9.5 9.7 12.6 10.1 39.9 34.9 19.6 11.2 5.4 16.8 15.3 26.5 30.7 18.3 43.7 41.3 24.6 34.8 41.4 18.1 21.0 9.6 11.9 97.5 31.8 38.7 18.5 5.7 15.1 35.2 25.3 15.8 16.2 24.4 10.3 20.9 35.3 7.6 50.0 53.1 66.1 20.2 30.5 43.0 51.8 16.3 18.2 14.6 59.1 15.2 13.1 14.6 17.7 16.5 19.2 8.2 12.7 20.1 43.1 17.1 7.8 15.4 17.9 9.7 21.1 76.3 25.5 17.1 39.4 27.8 53.7 19.6 9.6 15.3 15.3 88.0 41.0 11.5 30.2 15.7 6.3 7.0 2.7 5.4 3.8 6.6 2.3 3.2 7.7 8.6 2.6 2.8 23.1 4.1 11.5 2.2 1.8 3.3 10.5 12.1 13.6 11.5 10.1 13.7 13.6 12.4 13.9 14.1 12.6 16.8 16.2 57.7 29.3 10.1 33.5 19.4 8.2 11.8 34.1 13.5 17.0 9.4 22.8 20.0 23.9 40.5 14.6 13.8 13.9 7.3 25.4 6.8 2.3 36.2 11.1 14.9 29.4 3.8 14.6 8.2 5.9 14.8 6.1 11.8 11.4 11.2 18.5 23.6 12.6 10.1 17.6 9.7 10.2 26.2 39.5 1.4 14.3 23.8 17.8 20.6 18.2 24.5 7.2 16.1 12.1 5.7 5.7 14.7 9.3 10.7 8.1 22.7 39.9 18.3 6.6 16.2 16.8 13.2 14.5 26.2 18.5 4.8 12.2 8.6 12.1 6.7 RXRA NR2B1 ENSG00000186350 "Retinoid X receptor alpha" P19793 9 134317098-134440585 "Cancer-related genes, FDA approved drug targets, Metabolic proteins, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 106.5" "Cell type enhanced" "Detected in many" "Hepatocytes: 218.9;Kupffer cells: 134.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 19.5" "Group enriched" "Detected in many" 5 "granulocytes: 19.5;monocytes: 12.9" "Cell line enhanced" "Detected in many" "HaCaT: 105.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004565, CAB005352" Supported Supported "Nucleoplasm,Golgi apparatus" NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 80: Striated muscle - Unknown function" "Cluster 43: THP-1 - Innate immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" Nucleoplasm "Golgi apparatus" "CAB004565: AB_2184877, CAB005352: AB_2184874" "unprognostic (2.68e-1)" "unprognostic (7.94e-2)" "unprognostic (3.67e-2)" "unprognostic (7.22e-2)" "unprognostic (2.07e-2)" "unprognostic (6.69e-2)" "unprognostic (1.52e-1)" "unprognostic (2.15e-1)" "unprognostic (3.45e-2)" "unprognostic (1.65e-3)" "prognostic favorable (7.02e-4)" "unprognostic (7.72e-2)" "prognostic unfavorable (5.58e-4)" "unprognostic (1.25e-2)" "unprognostic (2.58e-1)" "unprognostic (1.49e-2)" "unprognostic (2.59e-1)" 40.5 22.7 33.5 14.5 36.4 18.9 11.2 25.5 29.4 12.2 16.9 16.6 25.8 13.5 8.7 28.5 16.5 13.6 19.4 27.1 30.2 16.0 32.9 18.8 8.2 32.9 31.3 21.7 25.4 45.1 3.5 14.5 30.8 15.6 10.0 5.4 21.7 17.1 106.5 88.1 28.0 11.1 30.4 25.1 14.7 7.9 42.7 6.0 17.6 51.9 7.6 16.2 8.2 22.6 19.6 36.4 14.7 21.9 42.8 19.1 66.7 14.1 16.1 9.6 6.5 20.7 28.0 0.0 25.8 22.5 15.1 105.5 7.7 32.8 2.9 26.3 7.2 0.1 47.5 30.0 20.4 18.8 4.8 29.0 52.1 11.5 10.6 12.9 12.8 1.6 26.0 1.1 8.7 61.8 1.1 59.5 17.5 63.4 16.9 7.4 30.3 36.7 12.2 64.3 17.2 10.5 37.3 46.9 10.6 7.1 44.9 78.8 16.5 16.2 23.4 17.4 9.7 1.7 0.2 0.4 11.6 33.9 12.7 1.3 8.1 6.6 1.4 12.9 0.2 0.3 0.9 1.0 3.2 0.1 0.2 1.2 19.5 2.2 11.2 0.7 1.2 3.2 33.5 36.4 25.5 29.4 27.1 30.2 32.9 31.3 30.8 30.4 42.7 22.6 32.1 32.1 22.9 36.2 4.6 34.5 16.5 21.1 12.5 6.0 16.7 14.4 38.8 72.9 26.2 9.2 25.0 30.1 11.0 72.3 1.9 13.9 4.3 19.8 16.6 28.9 9.6 30.9 9.1 14.1 29.5 23.7 17.9 17.4 1.3 21.3 71.0 218.9 31.9 33.7 17.6 21.2 10.2 134.2 30.0 18.8 32.3 50.4 12.4 10.3 80.4 36.5 14.4 29.1 6.0 15.9 32.4 21.1 7.4 17.7 55.6 19.9 34.4 19.9 19.7 34.6 30.6 0.9 9.4 34.4 46.9 23.9 12.6 15.5 27.5 32.8 RXRB "H-2RIIBP, NR2B2, RCoR-1" ENSG00000204231 "Retinoid X receptor beta" P28702 6 33193588-33200665 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in some" "GAMG: 11.0;RH-30: 14.4;RT4: 12.1;T-47d: 16.1;U-266/70: 11.1;U-266/84: 11.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002003, HPA063653" Supported Supported Nucleoplasm NA NA "Cluster 41: Basophils - Cellular respiration" "Cluster 72: Non-specific - Transcription" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 7: Non-specific - Mitochondria" Nucleoplasm "CAB002003: , HPA063653: AB_2685076" "unprognostic (3.51e-1)" "unprognostic (8.46e-2)" "unprognostic (1.94e-1)" "unprognostic (2.22e-2)" "unprognostic (2.00e-2)" "unprognostic (4.71e-3)" "unprognostic (4.18e-2)" "unprognostic (2.21e-2)" "unprognostic (1.86e-1)" "unprognostic (2.03e-1)" "unprognostic (1.67e-3)" "unprognostic (8.13e-3)" "unprognostic (9.53e-3)" "unprognostic (8.30e-2)" "unprognostic (1.55e-1)" "unprognostic (6.38e-2)" "unprognostic (8.53e-3)" 26.8 29.1 1.5 2.0 1.5 2.3 27.1 1.6 5.7 33.9 1.4 34.4 3.9 31.9 7.4 27.0 31.4 3.3 31.4 1.5 2.6 29.5 34.4 27.2 1.4 1.5 1.7 32.9 32.3 0.0 33.0 2.5 1.5 32.8 1.6 3.2 27.0 3.3 42.5 26.3 28.6 9.6 1.6 38.3 28.3 20.0 1.6 2.8 37.7 12.3 9.1 30.6 29.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.0 0.0 10.0 0.0 10.4 7.1 0.0 11.0 4.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 7.5 0.0 9.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.2 0.0 8.9 0.0 0.0 0.5 3.2 0.0 0.0 0.1 14.4 0.0 8.0 12.1 0.0 7.4 0.0 0.0 0.0 0.0 16.1 0.0 0.0 0.0 4.8 0.0 0.0 11.1 11.8 9.2 0.0 0.0 0.0 2.3 0.4 1.7 1.1 0.3 0.8 1.0 1.3 1.3 0.6 0.3 1.1 0.8 0.7 0.8 0.6 0.6 1.1 0.3 1.5 1.5 1.6 5.7 1.5 2.6 1.5 1.7 1.5 1.6 1.6 1.7 21.2 41.7 13.3 14.4 19.2 17.3 14.9 8.9 18.2 25.2 22.4 18.9 16.1 15.7 14.7 5.5 20.9 23.6 26.3 21.8 25.4 19.9 2.7 10.6 14.7 18.2 22.0 8.6 14.9 16.2 17.9 18.3 23.0 11.9 10.2 22.5 14.3 15.9 15.8 18.5 12.9 21.8 16.2 14.7 9.2 8.6 16.1 12.2 16.0 10.3 18.8 16.6 33.0 14.1 15.2 13.6 20.2 16.1 12.0 16.3 23.2 14.1 10.8 20.4 26.3 19.3 20.0 17.7 12.5 16.8 18.8 28.7 19.4 18.7 24.5 12.7 RXRG NR2B3 ENSG00000143171 "Retinoid X receptor gamma" P48443 1 165400922-165445355 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 32.1;pituitary gland: 29.9;retina: 24.3;skeletal muscle: 49.7" "Group enriched" "Detected in some" 4 "Astrocytes: 13.4;Cone photoreceptor cells: 25.0;Melanocytes: 28.4;Muller glia cells: 16.8;Sertoli cells: 13.1;Skeletal myocytes: 35.9" "Group enriched" "Detected in many" 13 "melanoma: 25.7;thyroid cancer: 34.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 8 "SK-MEL-30: 39.4" "Region enriched" "Detected in many" 5 "basal ganglia: 100.2" "Low region specificity" "Detected in many" "CAB002615, HPA012933" Uncertain Approved "Nucleoplasm,Nuclear bodies" NA NA "Cluster 80: Striated muscle - Unknown function" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 50: Fibroblasts - ECM organization" "Nucleoplasm, Nuclear bodies" "CAB002615: , HPA012933: AB_2732406" "unprognostic (2.29e-1)" "unprognostic (1.08e-2)" "unprognostic (1.51e-1)" "unprognostic (1.66e-1)" "unprognostic (4.29e-2)" "unprognostic (6.19e-2)" "unprognostic (1.35e-1)" "unprognostic (1.05e-2)" "unprognostic (9.13e-2)" "unprognostic (6.86e-2)" "unprognostic (2.95e-2)" "unprognostic (5.41e-3)" "unprognostic (2.52e-2)" "unprognostic (6.12e-3)" "unprognostic (1.18e-1)" "prognostic favorable (9.40e-5)" "unprognostic (5.03e-2)" 2.4 3.2 14.6 0.4 16.6 0.0 1.0 11.7 17.4 3.0 11.7 4.1 0.7 1.1 0.7 1.0 2.8 0.6 5.3 12.4 21.5 0.2 0.3 2.8 0.3 25.6 14.8 1.0 2.1 0.1 29.9 0.7 22.2 1.1 2.0 24.3 1.2 1.4 49.7 2.3 1.6 1.2 13.6 0.4 1.4 1.0 32.1 0.1 0.7 7.6 0.0 1.6 2.1 15.6 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.6 0.0 0.0 0.0 1.6 0.0 0.0 0.0 39.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 5.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.6 16.6 11.7 17.4 12.4 21.5 25.6 14.8 22.2 13.6 32.1 15.6 0.9 0.0 0.0 13.4 0.0 0.6 0.0 0.0 0.0 1.0 0.0 0.0 1.8 0.0 0.0 0.0 25.0 0.0 0.0 0.0 0.0 0.0 3.4 0.1 0.1 0.6 0.0 0.0 0.1 0.0 0.0 1.6 0.0 0.3 0.0 0.0 4.2 0.0 0.0 0.0 4.0 0.0 0.0 0.0 0.3 2.8 5.0 0.0 28.4 0.0 0.0 16.8 0.0 1.0 1.3 0.1 0.0 2.2 0.0 0.0 0.0 0.0 0.0 4.5 13.1 35.9 3.4 0.4 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 RYR1 "CCO, MHS, MHS1, PPP1R137, RYR" ENSG00000196218 "Ryanodine receptor 1" P21817 19 38433691-38587564 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Developmental protein, Ion channel, Ligand-gated ion channel, Receptor" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "skeletal muscle: 1618.9" "Cell type enhanced" "Detected in many" "Astrocytes: 29.4;Basal squamous epithelial cells: 22.8;Microglial cells: 49.6;Muller glia cells: 50.6;Skeletal myocytes: 41.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 7 "intermediate monocyte: 1.8;myeloid DC: 2.9;non-classical monocyte: 3.8" "Group enriched" "Detected in many" 8 "dendritic cells: 2.9;monocytes: 3.8" "Cell line enhanced" "Detected in some" "A549: 7.7;HaCaT: 18.9;hTCEpi: 7.6;RH-30: 15.3;SiHa: 30.7;U-2 OS: 12.4" "Low region specificity" "Detected in single" HPA056416 Enhanced Approved "Golgi apparatus,Vesicles,Cytosol" NA NA 46000 "Cluster 51: Monocytes - Innate immune response" "Cluster 33: Striated muscle - Muscle contraction" "Cluster 20: HeLa - Mitochondria" "Cluster 37: Myocytes - Muscle contraction" "Golgi apparatus, Vesicles" Cytosol "HPA056416: AB_2683121" "unprognostic (2.22e-3)" "unprognostic (1.91e-3)" "unprognostic (9.59e-2)" "unprognostic (5.34e-4)" "unprognostic (2.50e-1)" "unprognostic (6.00e-2)" "unprognostic (2.11e-1)" "unprognostic (1.06e-1)" "unprognostic (1.18e-1)" "unprognostic (3.20e-3)" "unprognostic (3.52e-1)" "unprognostic (2.35e-1)" "unprognostic (1.07e-5)" "unprognostic (1.13e-2)" "unprognostic (8.10e-2)" "unprognostic (6.62e-3)" "unprognostic (1.34e-1)" 1.4 2.4 10.3 1.6 8.0 0.3 2.1 8.5 9.3 2.1 1.0 1.2 0.5 0.7 1.3 17.2 1.7 1.1 0.9 7.5 20.5 1.9 0.4 2.6 2.1 8.6 9.7 0.9 0.4 1.9 1.5 1.8 7.7 3.8 0.3 10.6 14.0 1.4 1618.9 13.3 1.3 0.8 2.6 1.7 1.0 8.9 22.6 1.5 1.2 286.6 2.6 1.0 3.3 6.1 0.0 7.7 0.1 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 2.8 0.4 0.5 6.3 0.0 0.0 18.9 0.2 0.0 0.0 0.0 0.4 1.5 0.0 0.0 0.0 0.0 0.6 1.7 7.6 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.2 0.0 0.0 0.5 1.0 0.0 0.0 15.3 1.5 0.8 0.0 0.0 1.5 30.7 0.0 0.0 0.6 0.7 5.9 0.0 0.0 12.4 0.3 0.0 0.4 1.4 0.4 0.1 0.0 0.0 0.0 0.3 0.0 0.2 1.8 0.2 0.2 0.1 0.3 2.9 0.3 0.0 0.0 0.0 0.0 3.8 0.0 0.4 0.3 10.3 8.0 8.5 9.3 7.5 20.5 8.6 9.7 7.7 2.6 22.6 6.1 0.3 0.0 1.1 29.4 1.4 11.3 3.8 6.6 22.8 8.9 0.5 7.9 3.6 0.0 1.1 0.0 2.1 0.2 1.2 0.0 5.9 0.1 6.7 0.2 0.9 1.0 0.0 0.4 10.2 0.0 0.4 0.9 0.0 0.5 0.0 0.3 0.7 0.0 8.8 1.7 17.2 0.0 2.0 2.9 15.2 5.9 3.1 6.2 0.0 49.6 1.3 50.6 0.0 13.6 2.0 0.0 0.0 1.9 0.9 0.8 0.0 0.2 0.4 1.8 0.0 41.7 1.2 6.3 7.4 7.5 4.7 0.3 2.6 0.4 0.0 0.7 RYR2 "ARVC2, ARVD2, VTSIP" ENSG00000198626 "Ryanodine receptor 2" Q92736 1 237042184-237833988 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Developmental protein, Ion channel, Ligand-gated ion channel, Receptor" "Cardiomyopathy, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "heart muscle: 132.0" "Group enriched" "Detected in many" 10 "Cardiomyocytes: 2180.6;Excitatory neurons: 1320.5;Inhibitory neurons: 790.6" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HDLM-2: 7.7;HEK 293: 8.5;K-562: 2.3;NB-4: 2.7;NTERA-2: 3.1;U-937: 4.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA020028 Approved Uncertain "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 44: Heart - Cardiac muscle contraction" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Nucleoplasm, Plasma membrane, Cytosol" "HPA020028: AB_1856528" "unprognostic (5.23e-3)" "unprognostic (2.15e-2)" "unprognostic (5.02e-4)" "unprognostic (6.26e-2)" "unprognostic (8.74e-2)" "unprognostic (2.99e-3)" "unprognostic (5.28e-2)" "unprognostic (1.45e-3)" "unprognostic (2.69e-2)" "unprognostic (1.04e-1)" "unprognostic (1.10e-1)" "unprognostic (4.04e-2)" "unprognostic (0.00e+0)" "unprognostic (2.36e-2)" "unprognostic (1.42e-1)" "unprognostic (3.13e-2)" "unprognostic (1.06e-2)" 0.7 0.7 9.1 0.8 15.9 0.0 0.6 8.7 24.0 1.5 0.0 2.0 0.2 0.7 0.4 2.9 0.7 1.9 132.0 10.5 0.0 0.1 0.1 1.8 0.1 0.0 0.0 2.9 8.4 0.0 1.8 1.2 0.0 2.9 0.5 6.5 0.5 1.7 0.1 0.3 0.5 0.7 0.0 1.3 1.5 1.1 0.0 0.1 4.4 0.3 0.0 1.2 0.4 13.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.2 0.0 0.0 0.9 0.3 0.0 0.0 7.7 8.5 2.2 0.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.0 0.0 2.3 0.4 0.0 0.0 0.0 2.7 3.1 0.6 0.3 0.0 0.1 0.2 0.0 0.0 0.1 0.3 0.0 0.0 0.1 0.7 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.1 4.9 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.2 9.1 15.9 8.7 24.0 10.5 0.0 0.0 0.0 0.0 0.0 0.0 13.2 0.2 0.0 0.5 17.0 0.0 0.4 0.0 0.0 0.0 74.2 0.3 0.1 2180.6 0.0 1.3 1.8 10.4 0.1 0.1 0.0 0.0 0.0 21.1 0.2 3.4 10.6 3.5 0.0 1320.5 2.9 0.1 53.6 0.0 0.5 0.0 0.5 1.1 0.0 0.1 1.7 790.6 0.0 0.0 0.0 0.2 15.3 1.2 1.3 8.8 48.7 0.0 1.3 0.0 29.7 140.6 0.4 0.0 0.0 0.1 0.0 1.0 0.2 0.7 5.3 0.0 0.5 21.6 5.8 2.1 0.0 0.0 0.0 0.2 0.1 0.0 0.0 S1PR1 "CD363, D1S3362, edg-1, EDG1" ENSG00000170989 "Sphingosine-1-phosphate receptor 1" P21453 1 101236865-101243713 "Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "Angiogenesis, Chemotaxis" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Adipocytes: 236.1;Endothelial cells: 122.3;Hepatic stellate cells: 114.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "basophil: 1248.4" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "BJ: 73.0;HUVEC TERT2: 198.9;TIME: 113.3;U-251 MG: 147.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010104, HPA075568" Supported Supported Vesicles No NA "Cluster 38: Basophils - Unknown function" "Cluster 57: Non-specific - Angiogenesis" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" Vesicles "CAB010104: AB_2238920, HPA075568: AB_2686758" "unprognostic (1.41e-1)" "unprognostic (9.35e-2)" "unprognostic (2.46e-2)" "unprognostic (2.61e-1)" "unprognostic (9.78e-2)" "unprognostic (4.49e-3)" "unprognostic (1.34e-3)" "unprognostic (1.99e-1)" "unprognostic (1.36e-1)" "unprognostic (9.12e-2)" "unprognostic (2.34e-2)" "unprognostic (2.23e-1)" "unprognostic (5.82e-3)" "unprognostic (2.54e-2)" "unprognostic (1.04e-1)" "unprognostic (3.64e-1)" "prognostic unfavorable (8.78e-4)" 114.7 14.4 58.8 29.8 62.7 18.5 91.9 59.8 59.0 18.5 27.8 19.5 9.4 24.7 3.9 26.8 22.9 28.0 71.8 51.3 65.1 18.0 31.3 78.3 46.3 65.2 73.0 8.2 20.3 23.3 8.7 48.1 61.3 13.7 10.1 14.6 15.0 7.8 27.9 17.9 22.3 31.2 57.6 63.1 17.1 2.6 76.5 21.4 35.9 51.5 26.9 34.3 19.2 52.6 15.6 0.2 14.2 0.0 1.4 32.7 0.1 73.0 13.5 47.9 16.6 0.1 0.7 0.0 17.8 25.2 0.4 0.0 1.8 0.8 27.0 6.1 1.2 6.8 0.3 0.0 6.6 0.0 3.5 45.0 0.3 0.1 3.7 1.7 198.9 5.8 0.2 14.4 13.5 0.0 20.6 0.0 3.9 0.4 4.8 0.0 13.4 0.5 0.1 0.0 0.0 0.1 0.7 0.0 0.2 0.9 0.0 0.2 113.3 6.8 2.9 2.0 147.1 1.3 0.0 1.0 0.7 0.0 0.4 1248.4 2.2 55.4 589.4 2.1 441.5 294.7 502.6 492.1 2.6 346.9 383.3 396.3 15.4 397.5 3.4 3.1 329.4 438.7 58.8 62.7 59.8 59.0 51.3 65.1 65.2 73.0 61.3 57.6 76.5 52.6 236.1 0.0 8.9 37.9 36.0 7.6 0.2 0.0 2.2 0.4 1.1 1.1 23.8 2.8 1.3 0.0 0.0 5.9 25.0 0.0 0.0 0.0 0.0 1.1 1.0 122.3 0.0 0.4 0.1 0.0 0.3 11.7 0.5 1.8 7.6 9.7 114.2 8.9 9.9 0.0 0.3 0.0 0.0 6.5 5.7 0.0 0.9 3.0 5.4 13.1 9.9 31.1 40.2 0.5 0.2 0.0 0.0 0.0 18.2 0.5 0.0 0.1 0.0 1.4 0.0 3.6 4.8 0.7 0.7 0.6 5.1 2.6 29.9 1.8 0.1 0.4 S1PR3 "EDG-3, EDG3" ENSG00000213694 "Sphingosine-1-phosphate receptor 3" "Q99500, Q6ZRZ4" 9 88990863-89005155 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Endometrial stromal cells: 55.5;Sertoli cells: 65.7;Smooth muscle cells: 35.0;Theca cells: 65.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 18 "classical monocyte: 7.0" "Lineage enriched" "Detected in single" 18 "monocytes: 7.0" "Cell line enhanced" "Detected in many" "AF22: 116.0;ASC diff: 157.9;ASC TERT1: 158.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "Intracellular and membrane" NA NA "Cluster 25: Monocytes - Inflammatory response" "Cluster 12: Smooth muscle tissue - Mixed function" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 48: Smooth muscle cells - ECM organization" "prognostic favorable (5.91e-4)" "unprognostic (3.32e-1)" "prognostic unfavorable (1.30e-4)" "unprognostic (6.91e-3)" "unprognostic (2.02e-1)" "unprognostic (4.41e-2)" "unprognostic (2.77e-2)" "unprognostic (5.22e-2)" "unprognostic (1.94e-2)" "unprognostic (3.15e-1)" "unprognostic (1.47e-1)" "unprognostic (1.02e-1)" "prognostic unfavorable (7.91e-6)" "unprognostic (4.43e-2)" "unprognostic (1.48e-2)" "unprognostic (3.93e-2)" "unprognostic (1.37e-1)" 18.3 25.0 5.8 10.6 6.4 3.2 11.2 6.9 6.7 32.2 10.7 14.8 4.5 17.2 6.2 17.6 26.0 14.2 17.5 6.3 11.2 36.9 6.1 8.9 11.4 16.1 9.8 5.1 11.7 1.7 17.0 15.1 7.7 20.1 3.4 4.2 3.9 11.9 4.4 3.1 10.7 36.0 8.4 13.2 12.5 2.2 12.4 4.7 4.8 8.2 9.4 20.4 20.9 13.2 0.5 17.7 116.0 6.0 157.9 158.7 0.1 24.8 61.4 17.0 17.0 0.2 0.0 0.0 0.3 37.2 16.6 0.2 0.3 18.0 11.5 0.0 1.2 0.0 23.3 0.1 13.7 8.1 0.1 28.6 1.0 22.2 4.0 13.2 29.9 17.0 2.1 0.1 4.7 17.1 14.3 8.7 11.2 0.8 6.2 1.5 0.0 0.1 0.3 7.1 1.5 8.1 23.4 5.7 0.0 22.8 2.7 7.4 60.3 25.4 10.3 27.8 4.1 0.0 0.1 0.0 36.8 7.1 9.1 0.3 7.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.2 0.1 0.0 2.1 5.8 6.4 6.9 6.7 6.3 11.2 16.1 9.8 7.7 8.4 12.4 13.2 3.0 0.0 1.7 3.6 0.0 10.1 9.5 1.8 2.8 1.0 9.9 3.7 9.2 1.5 1.7 1.8 2.1 17.9 0.1 0.0 0.0 0.3 0.0 2.1 55.5 10.6 0.0 0.0 0.5 0.5 1.3 21.5 0.5 2.4 0.0 3.8 1.8 1.6 2.4 3.3 1.7 0.0 0.0 1.8 4.0 0.5 3.7 4.4 0.0 7.5 6.9 7.1 0.0 0.0 0.2 0.9 0.0 6.8 0.2 7.0 0.0 1.4 2.9 1.6 65.7 16.1 35.0 0.0 1.2 1.5 3.3 5.5 2.2 65.8 0.0 6.4 S1PR5 "Edg-8, EDG8" ENSG00000180739 "Sphingosine-1-phosphate receptor 5" Q9H228 19 10512742-10517931 "FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 19.7;brain: 60.2" "Cell type enhanced" "Detected in some" "dendritic cells: 93.9;NK-cells: 164.8;Oligodendrocytes: 26.6;T-cells: 33.1" "Group enriched" "Detected in many" 5 "cervical cancer: 11.7;head and neck cancer: 8.0;lung cancer: 3.7;urothelial cancer: 6.2" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "gdT-cell: 299.4;MAIT T-cell: 184.9;memory CD8 T-cell: 144.9;naive CD8 T-cell: 109.3" "Lineage enriched" "Detected in many" 7 "T-cells: 299.4" "Cell line enhanced" "Detected in many" "HaCaT: 28.5;HBEC3-KT: 10.9;RT4: 18.7;T-47d: 11.6;U-2 OS: 10.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029683 Enhanced NA NA "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 27: Brain & Skin - Unknown function" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 63: NK-cells & T-cells - Immune response" "HPA029683: AB_10603237" "unprognostic (9.07e-3)" "unprognostic (1.27e-1)" "unprognostic (1.28e-2)" "unprognostic (5.55e-4)" "unprognostic (4.21e-1)" "unprognostic (4.85e-2)" "unprognostic (9.30e-2)" "unprognostic (1.55e-1)" "unprognostic (3.48e-2)" "unprognostic (2.29e-1)" "unprognostic (1.81e-1)" "unprognostic (1.27e-1)" "prognostic unfavorable (6.71e-7)" "unprognostic (2.46e-2)" "unprognostic (2.90e-2)" "unprognostic (1.19e-1)" "unprognostic (1.52e-1)" 0.8 0.4 21.1 0.8 35.7 19.7 0.6 32.4 44.7 5.4 8.6 0.3 0.2 0.3 4.4 12.8 0.2 0.2 0.6 19.7 23.2 0.8 1.6 3.0 1.0 39.0 34.0 0.2 1.4 0.1 0.4 1.7 35.8 2.5 0.1 0.0 2.4 0.5 0.6 18.7 0.3 0.2 26.0 11.1 0.3 0.7 30.1 0.9 0.5 0.2 2.1 2.2 10.9 60.2 1.9 2.8 0.6 0.0 0.0 0.1 0.2 0.6 0.5 0.9 0.5 0.3 0.1 0.0 7.6 0.3 1.2 28.5 1.8 10.9 2.0 0.0 1.8 0.2 2.3 0.0 0.1 0.0 0.1 0.0 5.0 3.0 0.6 0.2 0.0 0.0 0.2 0.0 0.0 3.7 1.1 0.0 4.5 0.6 0.5 0.0 2.1 0.0 0.0 18.7 0.0 0.0 4.7 0.0 0.5 1.9 11.6 3.3 0.0 1.5 10.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 3.3 0.5 0.5 1.2 299.4 0.2 184.9 0.6 36.3 144.9 0.6 0.5 10.8 109.3 3.9 44.5 1.1 0.8 0.6 64.2 21.1 35.7 32.4 44.7 19.7 23.2 39.0 34.0 35.8 26.0 30.1 60.2 1.0 3.2 1.9 0.0 0.6 3.6 2.2 10.9 7.4 0.0 0.1 0.9 0.9 1.5 0.9 0.0 0.0 0.1 93.9 0.0 0.0 0.0 6.2 0.1 0.2 0.6 0.0 0.8 0.1 0.2 0.3 1.7 0.5 0.0 2.5 0.0 1.8 0.3 0.2 0.0 0.1 0.0 0.0 0.8 0.3 2.3 0.0 0.6 0.0 2.8 1.2 0.0 164.8 0.0 26.6 0.2 0.0 0.0 14.7 0.2 0.0 0.1 0.4 0.0 0.0 0.1 1.9 0.0 0.2 4.8 5.1 0.1 33.1 0.0 0.0 0.4 SCN10A "hPN3, Nav1.8, PN3, SNS" ENSG00000185313 "Sodium voltage-gated channel alpha subunit 10" Q9Y5Y9 3 38696802-38816286 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Not detected" "Not detected" "Cell type enhanced" "Detected in single" "Cardiomyocytes: 1.5" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" NA NA "Cluster 43: Cardiomyocytes - Nuclear processes" "unprognostic (6.57e-2)" "unprognostic (7.85e-2)" "unprognostic (2.09e-4)" "unprognostic (1.42e-1)" "unprognostic (2.69e-2)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SCN11A "NaN, Nav1.9, SCN12A, SNS-2" ENSG00000168356 "Sodium voltage-gated channel alpha subunit 11" Q9UI33 3 38845764-39052157 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease variant, FDA approved drug targets, Neurodegeneration, Neuropathy" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "lymphoid tissue: 3.0;placenta: 1.9" "Cell type enhanced" "Detected in some" "Adipocytes: 5.4;Astrocytes: 7.8;Early spermatids: 7.0;Sertoli cells: 6.6;Spermatocytes: 4.4;Spermatogonia: 6.3" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "HDLM-2: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "HPA036746, HPA036747" Uncertain NA NA "Cluster 64: Macrophages - Immune response" "Cluster 44: HDLM-2 - Immune response" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "HPA036746: AB_10696785, HPA036747: AB_2675287" "unprognostic (6.11e-2)" "unprognostic (5.16e-1)" "unprognostic (1.66e-1)" "unprognostic (4.75e-2)" "unprognostic (4.21e-2)" "unprognostic (2.34e-2)" "unprognostic (2.79e-2)" "unprognostic (5.66e-2)" "unprognostic (4.44e-2)" "unprognostic (5.21e-2)" "unprognostic (2.30e-4)" "unprognostic (1.91e-2)" "unprognostic (5.43e-2)" "unprognostic (5.02e-2)" "unprognostic (2.95e-1)" "unprognostic (3.12e-2)" "unprognostic (8.30e-4)" 0.5 0.1 0.4 0.2 0.2 0.0 0.3 0.2 0.3 0.1 0.1 0.6 0.3 0.0 0.4 0.0 0.1 0.1 0.0 0.4 0.3 0.5 0.2 0.1 0.2 0.3 0.4 0.1 0.1 0.0 0.3 1.9 0.3 0.1 0.6 0.1 0.0 0.1 0.1 0.4 0.5 0.3 0.3 3.0 0.1 1.3 0.5 0.2 0.1 0.0 0.1 0.8 0.2 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.2 0.3 0.4 0.3 0.3 0.4 0.3 0.3 0.5 0.4 5.4 0.0 0.0 7.8 0.1 0.8 0.9 0.0 0.0 0.2 0.2 0.3 1.2 0.0 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.1 7.0 0.4 0.5 2.5 0.0 2.7 1.6 0.2 0.1 0.6 0.0 0.2 0.0 1.1 1.4 0.4 0.3 0.0 1.0 0.0 0.0 0.3 1.6 2.1 0.0 0.2 1.8 0.0 0.1 0.5 0.0 1.5 2.4 0.1 0.0 0.0 0.1 0.7 0.0 0.2 2.3 0.5 6.6 1.0 0.4 4.4 6.3 0.0 0.9 0.3 0.6 0.7 0.0 0.8 SCN1A "FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI" ENSG00000144285 "Sodium voltage-gated channel alpha subunit 1" P35498 2 165984641-166149214 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "brain: 24.7" "Group enriched" "Detected in some" 11 "Excitatory neurons: 409.9;Inhibitory neurons: 494.6;Oligodendrocyte precursor cells: 692.1" "Cancer enriched" "Detected in single" 8 "glioma: 1.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "ASC TERT1: 6.1;Hep G2: 3.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA078664 Supported "Nucleoplasm,Nuclear bodies,Plasma membrane" NA NA "Cluster 65: Brain - Ion transport" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Nucleoplasm, Plasma membrane" "Nuclear bodies" "HPA078664: AB_2686888" "unprognostic (9.25e-2)" "unprognostic (3.97e-2)" "unprognostic (6.88e-2)" "unprognostic (7.44e-2)" "unprognostic (1.50e-1)" "unprognostic (2.74e-1)" "unprognostic (4.70e-2)" "unprognostic (2.88e-1)" "unprognostic (1.67e-1)" "unprognostic (9.59e-2)" "unprognostic (1.23e-1)" "unprognostic (5.03e-9)" "unprognostic (6.92e-2)" "unprognostic (3.69e-2)" "unprognostic (5.06e-3)" "unprognostic (6.93e-1)" 0.0 0.0 4.2 0.0 4.2 0.0 0.0 2.1 24.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.1 2.1 6.9 0.0 0.0 1.4 0.0 14.2 6.2 0.0 0.0 0.0 2.0 0.0 18.5 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.1 10.9 0.0 0.0 0.0 0.0 0.0 0.0 10.9 0.0 0.0 0.9 0.0 0.0 6.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 3.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 4.2 2.1 24.7 2.1 6.9 14.2 6.2 18.5 2.2 10.9 10.9 0.0 6.4 33.9 27.4 0.0 0.0 0.0 0.0 0.0 47.4 0.6 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 4.5 0.0 0.3 1.8 0.0 409.9 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.3 0.0 494.6 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 18.7 0.0 2.8 0.0 692.1 11.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 SCN1B ENSG00000105711 "Sodium voltage-gated channel beta subunit 1" Q07699 19 35030470-35040449 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" "Cell adhesion, Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Brugada syndrome, Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 256.5;skeletal muscle: 572.0;tongue: 227.8" "Cell type enhanced" "Detected in many" "Bipolar cells: 67.9;Excitatory neurons: 50.4;Hofbauer cells: 31.3;Inhibitory neurons: 48.3;Kupffer cells: 35.1;Macrophages: 29.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "A549: 17.5;EFO-21: 12.7;TIME: 26.1" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "cerebral cortex: 349.1" "Secreted in other tissues" NA NA "Cluster 17: Basophils - Unknown function" "Cluster 80: Striated muscle - Unknown function" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 51: Myeloid cells - Hemostasis" "unprognostic (8.18e-2)" "unprognostic (1.30e-1)" "unprognostic (1.30e-2)" "unprognostic (6.40e-2)" "unprognostic (1.17e-2)" "unprognostic (2.69e-2)" "unprognostic (4.40e-2)" "unprognostic (1.20e-1)" "unprognostic (3.34e-2)" "unprognostic (4.72e-3)" "prognostic favorable (1.38e-4)" "unprognostic (2.25e-1)" "unprognostic (2.05e-2)" "unprognostic (9.68e-3)" "unprognostic (5.81e-2)" "unprognostic (4.12e-2)" "unprognostic (4.78e-2)" 20.2 13.6 48.2 3.3 53.0 2.3 16.3 95.8 256.5 15.5 7.7 9.7 1.9 9.4 2.2 8.6 21.7 4.8 95.4 45.0 97.2 8.3 8.5 11.1 3.0 120.4 67.0 7.8 12.3 18.2 17.4 5.3 115.7 8.7 2.7 10.7 15.4 3.6 572.0 6.3 8.0 4.5 52.2 19.8 8.4 2.8 153.5 1.3 11.1 227.8 0.8 13.4 10.5 113.6 0.4 17.5 0.2 1.0 5.2 7.8 0.1 7.1 6.1 3.4 0.9 0.7 0.2 0.2 12.7 7.1 3.0 0.3 1.1 0.7 1.6 0.2 0.8 0.2 2.5 4.5 6.9 0.1 0.1 2.5 0.1 0.4 0.2 6.8 11.6 0.2 0.4 0.1 2.2 1.7 0.2 0.2 0.8 1.6 5.1 0.9 1.8 0.2 0.5 0.1 8.1 4.3 0.9 0.1 1.4 0.6 1.6 0.4 26.1 6.7 6.6 0.3 4.6 0.3 0.5 1.0 4.0 0.8 4.8 0.7 0.2 0.1 0.3 0.1 0.6 0.1 0.1 0.1 0.6 0.2 0.1 0.1 0.7 0.2 0.1 0.1 0.3 0.7 48.2 53.0 95.8 256.5 45.0 97.2 120.4 67.0 115.7 52.2 153.5 113.6 12.8 0.0 3.3 11.8 1.1 1.8 0.8 1.6 0.0 67.9 1.6 7.7 20.3 0.0 0.6 0.0 2.1 0.4 2.9 0.0 9.8 0.3 0.3 2.0 2.0 9.7 0.0 0.4 50.4 2.6 0.6 9.9 2.0 1.8 2.5 0.1 20.7 1.2 31.3 8.4 48.3 1.6 0.0 35.1 3.7 0.0 7.5 29.5 3.6 15.9 3.0 13.3 0.0 6.0 18.5 0.7 0.1 2.2 2.7 1.1 0.1 2.5 1.0 22.8 0.0 25.3 3.6 0.2 0.7 0.1 1.1 1.0 2.0 0.1 0.8 0.3 SCN2A "HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2" ENSG00000136531 "Sodium voltage-gated channel alpha subunit 2" Q99250 2 165194993-165392310 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 26.1" "Group enriched" "Detected in some" 5 "Excitatory neurons: 440.4;Inhibitory neurons: 364.7;Oligodendrocyte precursor cells: 246.3" "Cancer enhanced" "Detected in single" "glioma: 1.3" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HSkMC: 2.1;U-138 MG: 3.4;U-266/84: 8.1;U-87 MG: 2.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB022567 Enhanced NA NA "Cluster 6: Brain - Smell perception" "Cluster 16: U-266 - Nucleosome" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "CAB022567: " "unprognostic (1.16e-1)" "unprognostic (3.56e-4)" "unprognostic (5.28e-2)" "unprognostic (6.12e-3)" "unprognostic (2.97e-1)" "unprognostic (8.62e-3)" "unprognostic (1.18e-1)" "unprognostic (7.25e-3)" "unprognostic (1.40e-1)" "unprognostic (2.78e-1)" "unprognostic (1.32e-2)" "unprognostic (5.21e-2)" "unprognostic (3.44e-2)" "unprognostic (1.76e-1)" "unprognostic (1.05e-1)" "unprognostic (4.88e-2)" "unprognostic (2.14e-1)" 0.2 1.3 15.8 0.1 17.5 0.0 0.7 26.1 20.1 0.2 0.0 0.1 0.2 0.5 0.9 0.0 0.1 0.8 0.1 22.2 8.0 3.5 0.1 0.2 0.0 0.0 0.0 0.2 0.1 0.0 3.7 0.1 0.0 0.1 0.1 4.6 0.2 0.4 0.0 0.0 0.2 0.6 0.0 0.1 0.3 0.3 2.5 0.3 0.0 0.0 0.0 0.1 0.3 5.8 0.0 0.0 0.3 0.0 0.1 0.4 0.0 0.0 1.7 0.0 1.6 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.7 0.4 0.0 0.2 0.0 0.3 0.0 0.1 2.1 0.0 0.1 0.0 1.5 0.0 0.0 0.0 0.2 0.9 0.0 0.1 0.0 1.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.8 1.9 0.0 0.0 0.0 0.7 0.0 0.0 0.0 3.4 0.2 0.2 0.0 0.3 8.1 0.0 2.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.8 17.5 26.1 20.1 22.2 8.0 0.0 0.0 0.0 0.0 2.5 5.8 0.1 0.0 1.7 18.3 0.5 0.3 0.1 0.2 0.0 49.8 0.3 4.7 0.8 0.0 0.0 11.0 47.9 0.1 0.2 0.0 5.9 0.2 1.6 0.1 2.3 0.3 0.0 0.0 440.4 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 15.2 364.7 0.0 0.0 0.0 0.0 1.4 1.2 0.0 0.0 60.9 0.0 3.4 0.0 246.3 17.0 0.3 0.0 6.0 0.0 0.0 0.0 0.3 0.0 4.3 0.0 0.0 0.6 0.0 0.9 0.1 0.1 0.0 0.4 1.0 0.0 0.0 SCN2B ENSG00000149575 "Sodium voltage-gated channel beta subunit 2" O60939 11 118162806-118176639 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Brugada syndrome, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 34.0;heart muscle: 12.8" "Cell type enhanced" "Detected in some" "Bipolar cells: 8.8;Cardiomyocytes: 16.8;Excitatory neurons: 21.9;Horizontal cells: 13.5;Inhibitory neurons: 32.0;Oligodendrocytes: 7.4" "Cancer enhanced" "Detected in some" "glioma: 1.3;thyroid cancer: 1.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "unprognostic (9.01e-2)" "unprognostic (3.50e-2)" "unprognostic (7.58e-2)" "unprognostic (2.12e-2)" "unprognostic (1.41e-2)" "unprognostic (4.02e-1)" "unprognostic (2.71e-4)" "unprognostic (5.17e-2)" "unprognostic (8.59e-2)" "unprognostic (2.77e-1)" "unprognostic (7.89e-2)" "unprognostic (1.61e-2)" "unprognostic (3.51e-2)" "unprognostic (1.27e-2)" "unprognostic (4.35e-2)" "unprognostic (4.55e-1)" "unprognostic (2.88e-3)" 0.6 1.5 19.1 0.3 20.7 0.0 0.7 14.9 34.0 1.4 0.0 1.7 0.6 1.6 1.3 1.8 1.3 1.3 12.8 20.9 12.3 0.4 0.0 1.1 0.0 5.7 13.3 1.3 0.1 0.0 0.8 0.0 9.1 1.0 0.7 3.7 0.5 1.2 7.3 0.2 1.1 1.9 4.9 0.1 0.3 0.2 19.5 1.8 0.7 7.5 0.0 0.3 0.4 22.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 19.1 20.7 14.9 34.0 20.9 12.3 5.7 13.3 9.1 4.9 19.5 22.1 0.1 0.0 0.0 3.9 0.0 0.4 0.6 0.7 1.8 8.8 0.1 2.0 16.8 0.0 0.0 0.0 2.1 0.0 0.0 0.2 0.0 0.0 0.1 0.2 0.5 0.2 0.0 0.0 21.9 0.0 0.0 1.6 0.0 0.3 0.0 0.2 0.0 0.0 0.1 13.5 32.0 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.0 1.9 0.0 0.9 0.0 2.5 7.4 0.0 0.0 2.2 0.0 0.2 0.0 0.0 0.1 1.9 0.0 0.9 0.8 0.1 0.6 0.0 0.1 0.0 0.1 0.5 0.0 0.3 SCN3A Nav1.3 ENSG00000153253 "Sodium voltage-gated channel alpha subunit 3" Q9NY46 2 165087526-165204050 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "brain: 16.9" "Cell type enhanced" "Detected in some" "Early spermatids: 78.4;Excitatory neurons: 227.3;Inhibitory neurons: 169.4;Oligodendrocyte precursor cells: 358.4" "Cancer enriched" "Detected in some" 6 "glioma: 3.4" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 30 "memory B-cell: 13.2;naive B-cell: 15.3" "Lineage enriched" "Detected in single" 32 "B-cells: 15.3" "Cell line enhanced" "Detected in some" "JURKAT: 5.9;Karpas-707: 10.3;MOLT-4: 30.3;RPTEC TERT1: 14.9;SH-SY5Y: 6.7" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA035396 Uncertain NA NA "Cluster 37: B-cells - Transcription" "Cluster 65: Brain - Ion transport" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "HPA035396: AB_2674607" "unprognostic (1.80e-3)" "unprognostic (1.84e-2)" "unprognostic (1.20e-3)" "unprognostic (1.50e-2)" "unprognostic (6.69e-2)" "unprognostic (1.10e-2)" "unprognostic (4.96e-4)" "unprognostic (2.46e-1)" "unprognostic (1.48e-1)" "unprognostic (1.90e-1)" "unprognostic (1.21e-4)" "unprognostic (4.55e-2)" "unprognostic (5.87e-3)" "unprognostic (2.88e-2)" "unprognostic (6.85e-2)" "unprognostic (2.66e-1)" "unprognostic (4.93e-2)" 1.0 1.5 10.9 0.5 10.9 0.2 1.0 7.2 12.1 0.6 0.0 0.6 0.3 0.4 0.1 0.4 0.4 0.5 0.6 10.1 16.9 0.5 0.2 0.2 0.8 6.0 8.8 0.6 0.5 0.4 0.1 0.1 9.2 0.2 0.7 1.0 0.1 0.4 0.9 0.0 0.5 0.5 3.0 0.5 0.9 0.5 13.4 3.1 0.2 0.6 1.2 0.5 0.0 6.5 0.0 0.2 2.7 0.0 0.0 0.1 0.0 0.0 0.3 0.6 2.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.3 0.1 0.1 0.1 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.0 4.9 0.0 5.9 0.0 10.3 0.1 0.0 30.3 0.0 0.0 0.1 2.4 0.1 1.3 0.0 14.9 0.0 3.8 6.7 0.0 0.0 0.0 0.1 0.0 0.1 0.0 2.2 0.1 0.8 0.0 1.4 0.6 0.0 0.7 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 13.2 0.0 0.0 0.0 15.3 0.1 0.0 0.0 0.2 0.0 0.4 0.1 0.1 10.9 10.9 7.2 12.1 10.1 16.9 6.0 8.8 9.2 3.0 13.4 6.5 0.9 0.0 0.5 8.5 6.5 0.0 0.2 0.0 0.6 4.4 0.1 0.4 6.5 0.0 0.0 1.8 12.5 0.0 0.0 0.0 0.0 0.2 78.4 0.0 0.0 2.9 8.9 0.0 227.3 0.0 0.0 0.5 1.1 0.0 0.0 0.3 0.0 0.2 0.1 5.0 169.4 1.2 0.0 0.0 0.3 11.5 0.3 0.2 1.8 19.7 0.0 0.3 0.0 358.4 9.2 0.1 0.0 0.7 5.3 0.0 0.0 0.0 0.0 0.8 13.1 0.3 31.8 0.7 2.4 0.0 0.1 0.0 0.1 0.3 0.1 0.1 SCN3B HSA243396 ENSG00000166257 "Sodium voltage-gated channel beta subunit 3" Q9NY72 11 123629187-123655244 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Brugada syndrome, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 54.2;pituitary gland: 28.0" "Cell type enhanced" "Detected in many" "Bipolar cells: 31.6;Excitatory neurons: 58.8;Horizontal cells: 20.2;Inhibitory neurons: 35.7;Late spermatids: 31.3" "Cancer enhanced" "Detected in some" "glioma: 2.2" "Group enriched" "Detected in many" 8 "amygdala: 34.3;basal ganglia: 40.6;cerebral cortex: 49.7;hippocampal formation: 54.2;white matter: 15.3" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "CACO-2: 1.8;GAMG: 1.8;hTCEpi: 5.8;RH-30: 2.0;SCLC-21H: 5.5;SH-SY5Y: 4.5" "Low region specificity" "Detected in all" "Region enhanced" "Detected in all" "hippocampal formation: 166.1" HPA041707 Approved "Intermediate filaments,Cytosol" NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "Intermediate filaments" Cytosol "HPA041707: AB_2732493" "unprognostic (1.41e-1)" "unprognostic (8.72e-2)" "unprognostic (8.13e-4)" "unprognostic (3.93e-3)" "unprognostic (7.05e-2)" "unprognostic (3.29e-3)" "unprognostic (5.64e-2)" "unprognostic (3.34e-4)" "unprognostic (1.72e-1)" "unprognostic (1.13e-2)" "unprognostic (9.16e-4)" "unprognostic (4.01e-1)" "unprognostic (1.89e-4)" "unprognostic (2.01e-2)" "unprognostic (9.01e-2)" "unprognostic (8.23e-2)" "unprognostic (1.43e-2)" 1.9 8.4 34.3 0.6 40.6 0.4 1.8 0.0 49.7 1.0 0.0 1.4 0.8 1.5 0.7 0.7 1.2 0.5 1.4 54.2 2.4 1.4 0.1 1.0 0.3 0.0 4.7 1.0 1.1 4.4 28.0 0.1 0.5 0.8 0.8 10.0 0.7 0.5 14.1 1.5 1.3 1.4 0.9 0.5 0.7 2.2 0.9 0.2 4.1 3.3 0.2 0.8 1.0 15.3 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 1.8 0.0 0.0 0.9 0.1 1.8 0.0 0.6 0.0 0.0 0.1 0.3 0.0 0.2 0.2 0.1 0.0 0.1 0.0 5.8 0.1 0.1 0.0 0.1 0.2 0.3 0.2 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 2.0 0.0 0.0 0.1 5.5 4.5 0.4 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.4 0.1 0.0 0.1 0.0 0.0 34.3 40.6 0.0 49.7 54.2 2.4 0.0 4.7 0.5 0.9 0.9 15.3 7.7 0.0 0.5 3.9 0.0 5.7 1.1 0.0 1.2 31.6 1.3 1.0 2.1 0.0 0.0 1.8 6.2 0.1 0.0 0.3 0.0 0.3 13.9 0.2 0.3 13.0 4.2 0.0 58.8 1.0 0.1 1.5 0.0 0.2 0.0 1.4 5.3 0.0 0.2 20.2 35.7 0.0 0.0 0.0 2.3 31.3 0.0 0.4 0.0 5.6 0.0 6.3 1.0 4.5 2.5 0.3 0.0 0.4 0.0 1.0 0.1 0.5 0.0 6.0 6.6 5.7 0.8 1.0 2.0 0.4 5.5 0.0 0.1 1.4 0.1 0.5 SCN4A "HYKPP, HYPP, Nav1.4, SkM1" ENSG00000007314 "Sodium voltage-gated channel alpha subunit 4" P35499 17 63938554-63972918 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Congenital myasthenic syndrome, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "skeletal muscle: 137.4;tongue: 54.0" "Cell type enriched" "Detected in some" 6 "Adipocytes: 46.4" "Cancer enhanced" "Detected in some" "thyroid cancer: 2.2" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 11 "REH: 15.0;RH-30: 45.0" "Not detected" "Not detected" "Not detected" "Not detected" HPA053992 Approved "Nucleoplasm,Centriolar satellite" NA NA "Cluster 33: Striated muscle - Muscle contraction" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" Nucleoplasm "Centriolar satellite" "HPA053992: AB_2797249" "unprognostic (2.47e-1)" "unprognostic (1.74e-1)" "unprognostic (1.57e-2)" "unprognostic (1.78e-3)" "unprognostic (2.80e-2)" "unprognostic (1.63e-2)" "unprognostic (3.87e-4)" "unprognostic (3.84e-3)" "unprognostic (1.61e-1)" "unprognostic (1.36e-1)" "unprognostic (1.59e-3)" "unprognostic (3.15e-2)" "unprognostic (2.70e-2)" "unprognostic (4.38e-3)" "unprognostic (3.46e-1)" "unprognostic (4.15e-1)" "unprognostic (6.45e-2)" 17.9 0.7 0.0 0.2 0.1 0.0 16.0 0.3 0.1 0.1 0.0 1.1 0.0 0.1 0.0 1.1 0.2 0.3 0.8 0.0 0.0 0.7 0.1 0.0 0.4 0.0 0.0 0.2 0.2 0.7 1.5 0.1 0.0 0.5 0.1 0.0 1.8 0.0 137.4 0.7 0.3 0.0 0.0 0.8 0.5 1.7 0.0 0.2 4.3 54.0 0.1 0.5 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.0 1.5 0.0 0.0 15.0 45.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 2.8 1.4 1.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.4 0.0 0.0 0.0 0.6 0.3 0.0 0.0 0.0 0.0 0.2 0.3 1.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.5 0.0 0.0 2.3 0.0 0.0 0.2 0.0 0.0 0.3 0.0 0.1 0.0 1.1 2.2 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 4.6 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 7.1 5.9 0.3 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.0 SCN4B LQT10 ENSG00000177098 "Sodium voltage-gated channel beta subunit 4" Q8IWT1 11 118133377-118152888 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Disease variant, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 109.6;tongue: 56.8" "Cell type enhanced" "Detected in many" "Adipocytes: 12.3;Excitatory neurons: 18.2;Sertoli cells: 46.0;Smooth muscle cells: 38.8" "Cancer enhanced" "Detected in many" "glioma: 8.6" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AN3-CA: 1.3;HBEC3-KT: 1.0;NTERA-2: 1.4;U-2 OS: 1.2" "Region enriched" "Detected in all" 11 "basal ganglia: 816.3" "Region enriched" "Detected in many" 4 "basal ganglia: 134.6" HPA017293 Approved NA NA "Cluster 65: Brain - Ion transport" "Cluster 5: NTERA-2 - Transcription" "Cluster 48: Smooth muscle cells - ECM organization" "HPA017293: AB_2184174" "unprognostic (1.98e-1)" "unprognostic (1.13e-1)" "unprognostic (1.13e-1)" "unprognostic (2.43e-1)" "unprognostic (1.45e-1)" "unprognostic (1.07e-1)" "unprognostic (9.82e-3)" "unprognostic (9.17e-3)" "unprognostic (1.20e-2)" "unprognostic (1.23e-2)" "unprognostic (1.03e-2)" "unprognostic (3.27e-2)" "unprognostic (1.07e-1)" "unprognostic (2.07e-2)" "unprognostic (2.18e-3)" "unprognostic (1.53e-1)" "unprognostic (5.31e-4)" 23.5 5.4 2.6 1.2 86.6 0.0 9.2 41.3 109.6 2.1 0.0 2.6 2.4 3.1 1.6 5.3 5.4 3.2 11.8 2.1 14.0 2.1 0.4 8.9 2.1 53.3 15.4 0.5 5.1 6.8 2.7 1.8 45.9 2.2 2.1 0.9 2.5 2.3 30.4 3.9 4.7 7.1 15.2 0.0 2.9 0.7 23.1 8.6 14.5 56.8 0.7 3.0 1.4 28.5 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 1.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 86.6 41.3 109.6 2.1 14.0 53.3 15.4 45.9 15.2 23.1 28.5 12.3 0.0 0.0 2.9 0.0 1.3 0.6 2.0 2.8 1.7 0.5 5.7 4.6 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.3 0.1 3.0 0.0 0.0 18.2 0.0 0.1 3.9 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 8.2 0.0 2.0 1.2 1.4 8.7 2.1 1.1 0.0 1.9 0.0 0.5 0.0 1.5 1.4 0.0 0.0 1.5 0.0 0.1 0.0 0.1 5.8 0.8 46.0 0.6 38.8 0.1 0.6 0.5 1.1 0.0 0.1 0.0 0.0 0.2 SCN5A "CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1" ENSG00000183873 "Sodium voltage-gated channel alpha subunit 5" Q14524 3 38548057-38649687 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Calmodulin-binding, Ion channel, Sodium channel, Voltage-gated channel" "Atrial fibrillation, Brugada syndrome, Cardiomyopathy, Disease variant, FDA approved drug targets, Long QT syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 16 "heart muscle: 42.8" "Cell type enriched" "Detected in some" 5 "Cardiomyocytes: 77.1" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "LHCN-M2: 27.6;RH-30: 22.8" "Group enriched" "Detected in many" 5 "amygdala: 3.1;basal ganglia: 10.1;hypothalamus: 6.0" "Region enhanced" "Detected in many" "basal ganglia: 5.4" HPA063346 Supported "Nucleoplasm,Nucleoli,Plasma membrane" NA NA "Cluster 44: Heart - Cardiac muscle contraction" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 43: Cardiomyocytes - Nuclear processes" "Plasma membrane" "Nucleoplasm, Nucleoli" "HPA063346: " "unprognostic (9.29e-4)" "unprognostic (4.05e-2)" "unprognostic (9.95e-2)" "unprognostic (1.74e-1)" "unprognostic (9.21e-2)" "unprognostic (1.24e-2)" "unprognostic (1.15e-1)" "unprognostic (1.48e-1)" "unprognostic (7.36e-2)" "unprognostic (8.48e-2)" "unprognostic (7.12e-3)" "unprognostic (5.28e-2)" "unprognostic (1.16e-4)" "unprognostic (4.85e-3)" "unprognostic (1.09e-1)" "unprognostic (5.35e-2)" "unprognostic (4.95e-3)" 0.2 0.1 1.9 0.1 1.2 0.2 0.2 0.0 0.7 1.7 0.0 0.2 0.2 0.7 0.0 0.1 0.3 0.1 42.8 0.2 1.5 0.0 0.0 0.1 0.0 0.0 0.7 0.5 0.0 0.0 0.4 0.2 0.0 0.3 0.1 2.0 0.2 0.5 1.6 0.1 0.2 0.3 0.2 0.1 0.1 0.3 2.6 0.0 0.2 1.0 0.0 0.4 0.7 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.1 1.1 0.4 0.1 0.0 0.2 3.6 0.0 0.0 0.0 1.0 0.5 2.7 0.0 0.4 0.0 1.0 1.0 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.4 0.0 2.1 2.8 0.4 0.0 0.0 27.6 1.4 0.0 0.0 2.6 0.0 0.0 0.0 22.8 0.0 0.0 3.2 0.4 3.1 0.0 0.0 0.0 0.8 0.0 0.0 5.7 0.0 5.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 1.2 0.0 0.7 0.2 1.5 0.0 0.7 0.0 0.2 2.6 0.2 0.1 0.0 0.0 0.0 0.0 0.3 1.3 0.0 0.0 2.7 0.0 0.3 77.1 0.0 0.1 0.0 14.6 0.2 0.0 0.0 0.0 0.1 1.2 0.1 3.2 2.8 0.0 0.0 0.5 0.0 0.3 3.1 0.0 0.3 0.0 0.8 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 6.3 0.3 0.6 0.2 0.0 3.7 0.0 0.6 0.0 1.5 0.1 0.1 0.0 0.0 0.0 1.0 0.0 0.1 0.0 0.9 0.0 7.3 3.1 0.2 1.0 0.0 0.0 0.0 0.1 0.1 0.0 1.4 SCN7A "NaG, Nav2.1, Nav2.2, SCN6A" ENSG00000136546 "Sodium voltage-gated channel alpha subunit 7" Q01118 2 166403573-166611482 "FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 45.4" "Group enriched" "Detected in many" 4 "Fibroblasts: 102.0;Leydig cells: 100.9;Peritubular cells: 159.9;Sertoli cells: 151.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in single" "basophil: 1.1" "Lineage enriched" "Detected in single" 5 "granulocytes: 1.1" "Group enriched" "Detected in some" 5 "HDLM-2: 7.9;HMC-1: 4.5;Karpas-707: 5.8;SK-BR-3: 15.4" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "spinal cord: 7.6" HPA072715 Approved Approved "Plasma membrane" NA NA "Cluster 38: Basophils - Unknown function" "Cluster 12: Smooth muscle tissue - Mixed function" "Cluster 8: SK-BR-3 - Unknown function" "Cluster 50: Fibroblasts - ECM organization" "Plasma membrane" "HPA072715: " "unprognostic (1.22e-1)" "unprognostic (6.42e-3)" "unprognostic (9.72e-2)" "unprognostic (7.43e-2)" "unprognostic (2.18e-1)" "unprognostic (1.78e-1)" "unprognostic (1.86e-1)" "unprognostic (4.00e-3)" "unprognostic (5.21e-2)" "unprognostic (6.84e-3)" "unprognostic (6.88e-2)" "unprognostic (1.27e-1)" "unprognostic (5.80e-2)" "unprognostic (3.71e-2)" "unprognostic (1.47e-2)" "unprognostic (1.35e-1)" "unprognostic (1.22e-4)" 4.6 8.6 3.4 3.4 3.0 0.3 10.2 0.1 1.8 7.8 0.0 35.8 3.4 9.0 6.3 10.1 10.9 3.8 20.6 1.1 7.1 1.8 1.2 27.6 0.5 4.0 7.1 45.4 4.9 0.7 1.0 12.3 5.4 11.0 8.5 10.6 6.1 10.1 7.2 2.4 6.8 7.6 2.9 3.2 7.8 5.6 9.8 3.2 1.2 15.0 0.4 4.7 7.1 1.2 0.1 0.1 0.7 0.9 0.2 0.0 0.8 0.7 0.0 1.3 0.0 0.6 0.2 0.4 0.1 0.0 0.3 0.3 0.1 0.1 0.0 7.9 0.5 0.2 1.5 0.6 0.0 0.2 4.5 0.0 0.0 0.4 0.1 0.4 0.0 0.4 1.2 5.8 0.0 1.0 0.8 0.5 1.1 0.3 0.3 0.0 0.5 0.0 0.1 0.8 0.2 0.4 0.3 15.4 0.0 0.3 0.4 0.1 0.4 0.2 1.0 0.7 0.4 1.0 0.3 1.1 0.2 0.2 0.4 1.1 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.2 0.0 0.8 3.4 3.0 0.1 1.8 1.1 7.1 4.0 7.1 5.4 2.9 9.8 1.2 1.4 0.0 1.1 1.0 0.0 0.3 0.2 0.0 5.7 21.5 0.2 0.3 16.2 0.0 0.6 0.0 0.0 0.1 0.0 0.0 1.9 0.0 2.4 0.0 0.3 4.1 0.0 0.0 7.7 0.0 0.0 102.0 0.0 0.0 15.9 0.1 9.3 0.0 0.2 0.0 20.9 0.0 0.0 0.0 1.2 4.1 100.9 1.8 5.4 14.0 0.0 4.9 0.0 14.1 0.3 0.1 0.0 159.9 1.2 0.5 0.0 0.5 0.0 1.8 151.2 16.7 26.1 0.5 1.2 1.7 1.1 0.0 0.2 0.3 0.0 0.3 SCN8A "CerIII, CIAT, MED, NaCh6, Nav1.6, PN4" ENSG00000196876 "Sodium voltage-gated channel alpha subunit 8" Q9UQD0 12 51590266-51812864 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "brain: 35.0" "Group enriched" "Detected in many" 8 "Excitatory neurons: 336.7;Inhibitory neurons: 280.1;Oligodendrocyte precursor cells: 104.5" "Low cancer specificity" "Detected in some" "Region enhanced" "Detected in many" "cerebral cortex: 35.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AF22: 13.7;ASC TERT1: 13.5;WM-115: 13.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022169, HPA043937, HPA073590" Approved "Vesicles,Plasma membrane,Cell Junctions" NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Plasma membrane" "Vesicles, Cell Junctions" "CAB022169: , HPA043937: , HPA073590: " "unprognostic (2.96e-2)" "unprognostic (8.49e-2)" "unprognostic (6.93e-2)" "unprognostic (3.52e-6)" "unprognostic (8.13e-2)" "unprognostic (1.51e-2)" "unprognostic (1.16e-1)" "unprognostic (7.77e-2)" "unprognostic (5.44e-2)" "unprognostic (1.16e-1)" "unprognostic (4.73e-4)" "unprognostic (1.69e-2)" "unprognostic (1.29e-5)" "unprognostic (4.38e-1)" "unprognostic (1.56e-1)" "unprognostic (2.37e-1)" "unprognostic (4.75e-2)" 0.2 1.0 5.6 0.4 8.9 0.7 0.5 2.5 35.0 0.4 0.0 0.7 0.2 0.4 0.7 0.1 0.2 0.9 0.1 11.4 0.2 0.9 2.6 0.1 0.4 4.2 0.0 0.5 1.6 0.5 6.7 0.1 3.8 0.6 0.9 7.9 0.6 0.2 0.3 0.3 0.2 0.1 0.0 0.6 1.0 1.7 2.4 0.5 0.5 0.1 0.2 0.2 0.2 11.5 1.7 1.3 13.7 0.2 1.8 13.5 0.3 8.0 12.5 9.1 8.5 2.8 1.6 0.4 1.9 9.9 4.4 0.1 2.3 0.0 10.5 1.6 0.8 0.1 0.3 0.3 0.1 0.2 1.1 1.8 0.0 6.5 1.4 3.4 9.8 3.5 0.2 0.2 5.5 1.0 2.5 0.2 4.9 0.9 4.8 0.1 0.7 0.0 0.0 0.5 5.6 2.2 4.5 2.1 0.3 2.1 0.4 0.2 2.8 8.9 6.3 3.3 5.2 0.2 0.1 0.0 1.8 1.9 13.0 0.5 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.4 0.1 0.0 0.1 0.0 0.0 5.6 8.9 2.5 35.0 11.4 0.2 4.2 0.0 3.8 0.0 2.4 11.5 1.2 0.0 0.0 27.1 0.0 0.0 0.5 0.0 3.4 16.7 2.6 1.8 1.4 1.5 0.0 0.0 10.4 0.0 0.3 1.0 0.0 0.5 0.6 0.0 0.7 1.3 11.4 0.0 336.7 0.5 0.0 0.1 3.1 0.0 0.0 0.7 1.1 4.3 0.0 5.0 280.1 1.3 0.0 0.0 0.0 0.7 0.0 0.0 0.0 20.6 0.0 4.7 0.0 104.5 14.2 0.7 0.5 0.7 0.0 0.4 0.0 0.7 0.0 11.2 0.0 0.4 0.3 3.8 10.2 0.1 0.0 0.0 0.3 0.0 0.9 0.3 SCN9A "ETHA, Nav1.7, NE-NA, NENA, PN1" ENSG00000169432 "Sodium voltage-gated channel alpha subunit 9" Q15858 2 166195185-166376001 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sodium transport, Transport" "Ion channel, Sodium channel, Voltage-gated channel" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 21.9" "Cell type enhanced" "Detected in many" "dendritic cells: 43.2;Hofbauer cells: 67.5;Inhibitory neurons: 48.2;Langerhans cells: 42.8;Oligodendrocyte precursor cells: 133.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in some" 16 "plasmacytoid DC: 23.6" "Lineage enriched" "Detected in single" 26 "dendritic cells: 23.6" "Cell line enhanced" "Detected in many" "BJ: 23.0;BJ hTERT+: 16.8;HHSteC: 19.0;hTERT-RPE1: 15.6" "Region enriched" "Detected in many" 5 "hypothalamus: 9.3" "Low region specificity" "Detected in many" "CAB013679, HPA061843" Uncertain Approved "Plasma membrane,Actin filaments,Focal adhesion sites" NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 68: Oligodendrocytes - Mixed function" "Plasma membrane, Actin filaments, Focal adhesion sites" "CAB013679: , HPA061843: AB_2684625" "unprognostic (2.10e-1)" "unprognostic (2.83e-1)" "unprognostic (1.13e-1)" "unprognostic (8.98e-5)" "unprognostic (1.47e-3)" "unprognostic (9.43e-3)" "unprognostic (2.28e-2)" "unprognostic (2.24e-1)" "unprognostic (2.23e-1)" "unprognostic (3.64e-1)" "unprognostic (1.45e-1)" "unprognostic (2.27e-1)" "prognostic unfavorable (2.30e-5)" "unprognostic (1.69e-3)" "unprognostic (6.74e-2)" "unprognostic (2.46e-2)" "unprognostic (2.46e-1)" 1.7 1.7 5.3 0.9 4.2 2.0 0.6 0.1 3.4 0.6 0.0 3.2 0.5 0.2 0.1 0.5 0.4 1.2 0.4 2.9 21.9 1.7 3.9 2.0 0.6 8.2 19.4 0.3 2.0 0.1 1.5 4.3 12.0 0.3 3.1 0.7 0.4 0.4 0.2 0.7 1.8 2.4 2.2 3.1 0.4 5.1 18.2 1.6 0.3 0.6 0.4 0.5 0.5 1.7 0.0 2.5 0.1 0.0 9.6 7.9 0.0 23.0 16.8 5.2 1.7 0.5 0.1 0.0 0.0 2.8 0.2 0.1 6.5 0.6 8.6 0.0 2.1 1.7 1.8 1.9 19.0 0.1 0.0 0.6 0.2 9.1 1.7 15.6 1.1 1.2 6.1 6.6 0.8 0.0 3.6 0.0 1.9 0.1 0.6 0.8 3.3 9.0 2.4 9.5 1.0 9.5 0.0 0.1 0.3 4.8 0.3 0.0 0.1 0.0 1.5 0.1 0.4 0.1 0.1 0.0 3.2 0.0 2.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.9 0.5 0.1 23.6 0.0 0.1 5.3 4.2 0.1 3.4 2.9 21.9 8.2 19.4 12.0 2.2 18.2 1.7 0.9 12.8 23.8 0.7 1.3 1.0 0.4 0.5 0.6 0.6 0.8 0.9 2.5 8.6 4.4 5.5 0.0 0.3 43.2 9.0 3.9 23.4 2.5 0.1 0.1 5.7 33.0 4.2 15.8 31.5 0.3 2.0 0.0 0.1 3.8 18.1 13.6 9.5 67.5 0.0 48.2 19.3 10.2 1.9 42.8 3.2 1.2 11.3 3.6 2.8 1.0 2.3 0.0 133.7 0.4 12.7 7.8 0.0 1.2 0.3 14.7 11.5 2.2 0.2 0.0 7.8 1.6 1.3 0.4 0.5 0.4 1.1 0.9 4.4 12.9 0.2 SCNN1A "ENaCalpha, SCNN1" ENSG00000111319 "Sodium channel epithelial 1 subunit alpha" P37088 12 6346843-6377730 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "salivary gland: 157.3" "Cell type enhanced" "Detected in many" "Collecting duct cells: 114.0;Distal enterocytes: 230.9;Glandular and luminal cells: 189.8;Intestinal goblet cells: 180.3" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in some" 5 "hippocampal formation: 6.8" "Immune cell enhanced" "Detected in some" "neutrophil: 1.5" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "CAPAN-2: 300.5;HBEC3-KT: 202.4;hTCEpi: 85.3;RPTEC TERT1: 103.7;RT4: 114.1;SK-BR-3: 96.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" HPA012743 Enhanced NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 7: Kidney - Transmembrane transport" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 44: Endometrium - Transcription" "HPA012743: AB_1856627" "unprognostic (1.68e-1)" "unprognostic (4.16e-2)" "unprognostic (1.62e-1)" "unprognostic (2.19e-1)" "unprognostic (5.16e-2)" "unprognostic (6.77e-3)" "unprognostic (3.09e-2)" "unprognostic (2.62e-2)" "unprognostic (5.13e-2)" "prognostic unfavorable (8.86e-4)" "prognostic unfavorable (2.30e-4)" "unprognostic (5.56e-2)" "prognostic favorable (9.21e-8)" "unprognostic (2.38e-1)" "unprognostic (3.93e-2)" "unprognostic (1.16e-1)" "unprognostic (1.01e-2)" 3.4 12.5 0.2 5.6 0.1 0.5 20.6 1.1 0.2 64.7 113.6 66.4 18.7 7.6 43.2 140.1 57.9 17.7 0.7 6.8 0.0 148.5 8.2 62.9 0.2 0.1 0.3 3.5 40.0 0.7 16.6 0.4 0.1 43.7 65.4 0.0 157.3 49.5 0.5 54.6 26.0 2.9 0.1 0.7 63.6 4.7 1.3 1.9 94.3 0.1 12.5 20.8 57.6 0.1 21.6 4.1 0.0 1.9 0.3 0.4 17.6 0.0 0.1 0.1 0.0 6.1 300.5 0.3 0.8 0.1 0.1 14.0 0.0 202.4 0.0 0.0 0.0 0.0 17.5 3.1 20.9 0.0 0.1 5.1 85.3 0.0 61.6 0.4 0.0 0.5 0.0 0.1 0.5 1.9 0.1 0.3 17.6 38.9 0.8 0.2 0.0 0.5 103.7 114.1 1.2 0.1 2.3 96.7 0.1 17.1 22.3 0.0 0.0 0.2 0.7 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.5 0.1 1.5 0.0 0.0 1.0 0.5 0.1 0.2 0.1 1.1 0.2 6.8 0.0 0.1 0.3 0.1 0.1 1.3 0.1 1.7 73.7 75.7 0.0 1.3 1.9 25.1 17.0 10.8 0.9 17.7 21.2 0.8 54.3 52.5 114.0 4.2 1.4 1.8 230.9 5.9 45.0 0.5 85.3 17.8 3.2 27.1 0.0 0.3 33.9 0.3 2.0 97.3 189.8 2.5 1.3 1.4 3.2 0.3 1.7 0.2 180.3 63.1 1.9 3.1 0.6 1.8 2.5 0.0 0.0 1.6 0.3 1.0 0.5 0.1 39.4 95.8 1.5 0.3 30.9 12.2 6.2 36.7 1.4 0.0 5.6 4.3 1.2 3.7 48.1 8.8 1.6 3.6 0.2 31.5 42.1 SCNN1B ENaCbeta ENSG00000168447 "Sodium channel epithelial 1 subunit beta" P51168 16 23278231-23381294 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "esophagus: 82.8;intestine: 94.2" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 99.3;Club cells: 64.8;Collecting duct cells: 57.0;Distal enterocytes: 262.8;Ionocytes: 107.8;Paneth cells: 73.7" "Cancer enhanced" "Detected in many" "urothelial cancer: 26.4" "Region enriched" "Detected in single" 9 "cerebellum: 1.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "hTCEpi: 33.3;RPMI-8226: 9.2;RT4: 18.5;U-266/70: 55.4;U-266/84: 20.2" "Region enriched" "Detected in single" 5 "cerebellum: 1.0" "Low region specificity" "Detected in many" HPA015612 Uncertain NA NA "Cluster 37: Intestine - Unknown function" "Cluster 29: U-266 - Adaptive immune response" "Cluster 53: Intestinal epithelial cells - Unknown function" "HPA015612: AB_1856629" "unprognostic (7.45e-2)" "unprognostic (1.76e-3)" "unprognostic (1.39e-1)" "unprognostic (6.74e-3)" "unprognostic (1.74e-2)" "unprognostic (5.11e-3)" "unprognostic (7.74e-2)" "unprognostic (5.49e-3)" "unprognostic (2.60e-1)" "unprognostic (2.40e-1)" "unprognostic (3.68e-1)" "unprognostic (2.84e-1)" "prognostic unfavorable (2.09e-6)" "unprognostic (2.32e-1)" "unprognostic (4.66e-2)" "unprognostic (3.93e-3)" "unprognostic (1.25e-2)" 18.5 0.4 0.0 1.1 0.0 0.2 17.7 1.0 0.0 48.5 0.0 94.2 2.5 2.8 0.1 82.8 3.7 0.5 0.3 0.0 0.0 31.7 0.2 23.9 0.8 0.0 0.0 0.7 2.1 0.3 1.0 3.6 0.1 10.5 35.6 0.0 39.5 2.4 1.4 36.0 4.3 0.8 0.0 3.7 24.1 0.3 0.0 0.7 9.2 0.8 5.4 8.3 56.4 0.0 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.3 0.0 0.1 0.0 0.0 0.0 0.0 2.0 0.0 1.8 0.0 0.0 0.0 0.0 7.0 0.0 0.0 9.2 0.0 18.5 0.2 0.0 0.0 0.5 0.0 0.1 3.6 0.0 0.0 0.0 0.0 0.0 0.0 55.4 20.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 25.7 99.3 28.3 0.0 7.1 3.1 15.4 27.8 5.7 0.0 4.4 3.0 0.7 0.0 64.8 57.0 0.0 0.7 0.1 262.8 0.0 0.0 0.1 11.9 1.6 6.2 7.7 0.0 0.3 0.4 0.3 1.0 36.7 23.4 8.2 0.0 1.1 0.1 0.1 0.0 0.3 21.4 107.8 0.0 0.0 0.2 0.0 1.0 10.6 0.0 0.0 0.0 0.0 0.0 0.1 0.4 73.7 0.0 38.7 6.1 0.0 0.1 9.2 0.0 0.0 0.1 0.7 0.1 0.4 29.8 5.4 2.2 1.4 0.0 15.2 19.7 SCNN1D "dNaCh, ENaCdelta" ENSG00000162572 "Sodium channel epithelial 1 subunit delta" P51172 1 1280436-1292029 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "testis: 35.5" "Cell type enhanced" "Detected in many" "Astrocytes: 10.7;Early spermatids: 10.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "U-266/70: 9.3" "Low region specificity" "Detected in all" HPA026884 Enhanced Supported "Plasma membrane,Actin filaments" NA NA "Cluster 43: Testis - Unknown function" "Cluster 20: HeLa - Mitochondria" "Cluster 29: Early spermatids - Spermatogenesis" "Plasma membrane, Actin filaments" "HPA026884: AB_10601501" "unprognostic (2.08e-2)" "unprognostic (2.08e-1)" "unprognostic (7.39e-4)" "unprognostic (1.06e-2)" "unprognostic (2.74e-1)" "prognostic favorable (1.60e-4)" "unprognostic (1.44e-2)" "unprognostic (1.81e-1)" "unprognostic (2.08e-2)" "unprognostic (1.14e-1)" "prognostic favorable (1.32e-4)" "unprognostic (5.27e-2)" "prognostic unfavorable (6.67e-5)" "unprognostic (3.13e-1)" "unprognostic (4.18e-2)" "unprognostic (2.13e-1)" "unprognostic (7.06e-2)" 5.6 7.1 10.3 1.7 10.4 3.2 6.0 11.7 18.1 11.1 5.9 9.4 5.2 8.0 0.9 4.0 14.0 1.2 6.2 9.7 7.5 7.7 13.7 3.7 2.3 10.7 8.5 14.7 4.8 0.7 18.5 1.1 10.9 9.7 0.3 1.7 5.8 1.7 3.4 4.7 7.6 0.8 6.9 8.0 6.3 35.5 9.9 0.9 6.3 1.4 0.7 5.1 7.6 11.7 0.5 4.2 1.6 4.3 1.1 0.6 0.7 2.8 0.8 1.3 1.5 0.8 2.4 3.0 1.5 1.2 2.2 0.7 0.7 0.6 0.2 5.8 2.5 0.4 5.9 1.1 1.1 0.1 2.9 1.8 0.9 2.3 0.0 1.8 0.4 5.5 2.1 7.0 0.3 1.5 1.2 2.0 0.8 0.5 3.0 8.1 0.3 0.7 0.6 0.2 2.2 3.1 1.2 1.2 1.9 0.6 5.4 1.6 1.2 2.6 2.1 4.1 0.9 9.3 0.6 2.5 2.3 5.2 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.3 10.4 11.7 18.1 9.7 7.5 10.7 8.5 10.9 6.9 9.9 11.7 1.7 3.2 2.3 10.7 1.0 0.8 0.2 1.2 1.2 3.7 2.2 3.4 4.0 0.0 1.7 0.0 4.2 0.1 0.6 1.0 0.0 0.5 10.5 0.6 2.1 0.6 1.2 2.7 5.2 0.5 0.4 1.7 4.1 1.3 2.5 3.2 0.7 3.5 0.4 5.0 6.0 0.4 0.0 0.8 0.5 4.0 0.9 1.1 0.0 1.0 0.1 1.4 0.0 4.5 5.4 2.0 3.8 1.9 0.7 0.1 3.9 0.7 1.9 2.8 0.0 1.8 1.5 2.8 2.2 0.8 1.6 0.0 1.0 0.5 0.9 0.3 SCNN1G "ENaCgamma, SCNEG" ENSG00000166828 "Sodium channel epithelial 1 subunit gamma" P51170 16 23182745-23216883 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Ion transport, Sensory transduction, Sodium transport, Taste, Transport" "Ion channel, Sodium channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "kidney: 42.4" "Cell type enriched" "Detected in some" 4 "Collecting duct cells: 90.1" "Cancer enhanced" "Detected in many" "urothelial cancer: 15.6" "Region enriched" "Detected in single" 6 "cerebellum: 4.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 7 "hTCEpi: 46.8;RT4: 21.7" "Region enriched" "Detected in single" 13 "cerebellum: 2.5" "Not detected" "Not detected" HPA071194 Supported "Nucleoplasm,Plasma membrane" NA NA "Cluster 7: Kidney - Transmembrane transport" "Cluster 30: Epithelial cell lines - Translation" "Cluster 44: Endometrium - Transcription" "Plasma membrane" Nucleoplasm "HPA071194: AB_2686359" "unprognostic (2.90e-1)" "unprognostic (5.21e-3)" "unprognostic (5.79e-2)" "unprognostic (4.31e-2)" "unprognostic (1.92e-3)" "unprognostic (1.71e-3)" "unprognostic (1.97e-1)" "unprognostic (4.85e-2)" "unprognostic (7.84e-3)" "unprognostic (1.90e-1)" "unprognostic (2.57e-2)" "prognostic unfavorable (3.20e-7)" "unprognostic (2.80e-2)" "unprognostic (1.34e-1)" "unprognostic (2.63e-1)" "unprognostic (4.17e-3)" 0.7 0.2 0.4 0.0 0.3 0.3 2.3 4.4 0.2 16.0 0.2 10.3 0.0 1.8 0.7 9.9 0.4 0.0 0.0 0.8 0.2 42.4 0.0 7.4 0.0 0.2 0.2 0.0 3.2 0.0 3.8 0.5 0.4 13.8 1.2 0.2 17.7 3.4 0.0 9.7 0.4 0.1 0.0 0.0 10.1 0.1 0.1 2.0 5.7 0.0 1.2 1.4 15.3 0.3 1.1 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 46.8 0.0 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 2.9 0.0 0.0 0.1 0.0 21.7 1.5 0.0 0.0 0.6 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.3 4.4 0.2 0.8 0.2 0.2 0.2 0.4 0.0 0.1 0.3 0.4 19.2 4.2 0.0 0.0 0.4 4.7 8.8 19.9 0.0 0.8 1.3 0.8 0.0 17.4 90.1 0.0 0.2 0.0 3.4 0.0 2.0 0.0 9.8 1.1 0.1 0.0 0.0 0.2 1.7 0.0 0.4 15.3 18.6 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.2 10.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.5 1.1 0.0 0.1 5.3 0.0 0.2 1.9 0.0 0.0 0.0 0.2 0.1 0.1 4.4 0.3 0.1 0.2 0.0 0.4 1.8 SDHA "FP, SDH2, SDHF" ENSG00000073578 "Succinate dehydrogenase complex flavoprotein subunit A" P31040 5 218241-257082 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Transporters" "Electron transport, Transport, Tricarboxylic acid cycle" Oxidoreductase "Cancer-related genes, Cardiomyopathy, Disease variant, FDA approved drug targets, Leigh syndrome, Primary mitochondrial disease, Tumor suppressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "heart muscle: 601.0;skeletal muscle: 479.0" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "CAB034929, HPA041981, HPA064582" Enhanced Supported Nucleoli,Mitochondria No No 360000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 8: Non-specific - Mitochondria" "Cluster 20: HeLa - Mitochondria" "Cluster 39: Non-specific - Basic cellular processes" Mitochondria Nucleoli "CAB034929: AB_2183443, HPA041981: AB_2677779, HPA064582: AB_2685293" "prognostic unfavorable (6.00e-4)" "unprognostic (1.93e-1)" "unprognostic (5.97e-2)" "unprognostic (1.36e-1)" "unprognostic (1.89e-1)" "unprognostic (1.62e-1)" "unprognostic (2.80e-1)" "unprognostic (3.14e-2)" "unprognostic (2.88e-1)" "unprognostic (1.67e-2)" "unprognostic (1.97e-1)" "unprognostic (1.24e-1)" "prognostic favorable (9.53e-8)" "unprognostic (1.11e-2)" "unprognostic (2.62e-1)" "unprognostic (3.57e-1)" "unprognostic (1.79e-1)" 70.6 148.0 60.5 29.6 62.7 38.4 65.8 78.7 71.3 50.2 63.2 131.9 148.9 53.2 27.3 67.1 50.3 33.9 601.0 60.8 73.4 139.1 276.8 54.3 43.1 74.1 62.7 65.8 71.5 122.9 44.8 28.8 75.7 46.3 82.1 42.7 66.8 35.6 479.0 58.9 116.8 36.1 61.7 66.4 115.6 56.4 71.7 41.8 49.6 224.8 36.5 63.2 56.3 63.7 88.4 154.2 54.8 95.0 96.9 68.5 154.1 63.3 81.8 107.2 108.4 163.9 115.9 108.3 218.6 70.2 92.1 111.8 102.4 129.7 66.3 241.9 98.9 50.1 390.8 224.1 60.0 69.5 70.7 70.6 84.3 83.6 33.7 93.6 123.9 83.5 84.6 83.1 48.7 155.8 93.9 206.9 19.3 101.4 193.5 119.0 84.6 223.2 245.4 122.7 62.3 35.4 332.5 205.5 90.7 36.1 115.0 93.2 91.1 80.3 82.1 48.2 52.5 93.0 40.9 79.8 81.6 99.9 52.5 66.6 70.8 88.1 95.2 85.7 86.8 79.5 92.5 94.5 93.3 73.3 89.2 85.0 14.1 85.5 74.7 59.5 149.3 111.3 60.5 62.7 78.7 71.3 60.8 73.4 74.1 62.7 75.7 61.7 71.7 63.7 29.4 35.3 71.1 20.2 50.9 61.2 81.4 105.8 31.3 51.0 24.6 17.0 272.6 64.3 78.5 75.4 102.2 109.6 39.3 169.7 142.8 94.7 58.7 39.1 30.1 39.1 47.5 56.8 34.4 44.9 102.8 49.4 47.9 48.5 43.7 64.8 47.5 167.0 67.5 101.0 39.9 96.3 105.8 41.0 55.0 28.8 68.3 38.8 90.7 12.2 60.2 50.7 52.5 19.1 37.9 54.2 100.1 55.7 67.5 37.0 274.4 190.7 75.2 87.2 78.9 33.2 51.7 96.9 54.3 40.9 35.9 154.7 56.7 85.0 160.1 88.2 SDHD "cybS, PGL, PGL1" ENSG00000204370 "Succinate dehydrogenase complex subunit D" O14521 11 112086824-112120016 "Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Electron transport, Transport, Tricarboxylic acid cycle" "Cancer-related genes, Disease variant, FDA approved drug targets, Primary mitochondrial disease" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Distal tubular cells: 530.2;Proximal tubular cells: 449.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" HPA045727 Approved "Intracellular and membrane" NA NA "Cluster 31: Non-specific - Inflammatory response" "Cluster 8: Non-specific - Mitochondria" "Cluster 1: K-562 - Erythropoiesis" "Cluster 39: Non-specific - Basic cellular processes" "HPA045727: AB_10963114" "unprognostic (9.13e-2)" "unprognostic (3.51e-2)" "unprognostic (4.47e-3)" "unprognostic (4.21e-2)" "unprognostic (1.93e-1)" "unprognostic (4.98e-2)" "unprognostic (5.69e-2)" "unprognostic (2.50e-1)" "unprognostic (1.83e-3)" "unprognostic (7.10e-2)" "unprognostic (3.03e-2)" "unprognostic (1.80e-1)" "prognostic favorable (1.99e-10)" "unprognostic (5.14e-2)" "unprognostic (1.58e-2)" "unprognostic (1.56e-2)" "unprognostic (7.51e-2)" 117.5 95.7 60.0 84.5 63.1 72.9 102.6 68.6 76.3 92.5 65.1 185.2 208.1 88.2 96.7 126.7 92.6 85.6 254.7 60.1 65.4 319.9 391.8 79.3 131.7 63.4 62.5 91.6 77.8 152.4 37.0 95.0 63.2 87.9 190.8 37.4 112.6 100.9 354.7 64.3 175.6 98.1 64.7 85.1 101.1 34.1 63.7 102.5 136.8 449.6 124.8 117.9 76.4 68.2 84.0 67.3 58.1 89.4 212.0 170.7 97.3 97.5 147.6 106.8 132.2 244.8 222.1 155.5 288.4 131.0 156.1 203.5 175.4 139.8 129.8 129.9 92.4 142.8 51.9 140.1 165.6 222.4 107.5 189.6 160.2 110.5 189.1 124.6 153.0 109.6 156.0 208.7 135.0 95.2 143.9 215.0 77.4 333.8 211.6 126.2 145.8 294.4 221.6 175.2 83.5 55.8 135.3 194.8 107.0 81.8 198.9 164.2 108.0 103.8 132.3 114.7 95.0 59.1 73.2 270.7 58.8 297.0 100.5 233.7 293.3 208.8 158.4 390.1 173.1 235.2 170.8 168.8 308.7 198.1 204.3 191.8 257.5 207.9 322.9 151.7 189.9 348.9 60.0 63.1 68.6 76.3 60.1 65.4 63.4 62.5 63.2 64.7 63.7 68.2 104.3 80.1 51.1 12.4 78.0 81.6 102.2 262.2 83.6 12.2 61.0 78.4 216.5 120.1 108.1 90.1 8.4 154.3 55.2 203.8 530.2 82.9 9.9 41.6 67.6 76.4 50.4 70.2 9.6 58.9 124.1 104.6 75.4 41.2 65.9 32.3 76.8 169.7 162.9 11.8 11.2 129.1 154.6 97.1 74.4 37.0 104.1 94.2 76.5 9.4 118.6 52.9 75.2 8.0 9.7 54.1 134.2 99.6 80.9 61.6 253.1 449.9 60.5 18.9 92.1 78.3 110.7 70.4 55.8 127.1 74.4 179.0 71.4 86.2 176.0 98.6 SERPINC1 "AT3, ATIII, MGC22579" ENSG00000117601 "Serpin family C member 1" P01008 1 173903800-173917327 "Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Heparin-binding, Protease inhibitor, Serine protease inhibitor" "Disease variant, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 1341 "liver: 5056.6" "Cell type enriched" "Detected in some" 49 "Hepatocytes: 2707.9" "Cancer enriched" "Detected in some" 871 "liver cancer: 1504.0" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 37 "Hep G2: 84.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA001816, CAB016790, HPA024007" Supported "Secreted to blood" NA NA 120000000000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 62: Liver - Hemostasis" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 2: Hepatocytes - Metabolism" "CAB016790: , HPA001816: AB_1079926, HPA024007: AB_1856732" "unprognostic (1.28e-2)" "unprognostic (2.22e-1)" "unprognostic (3.83e-2)" "unprognostic (5.98e-2)" "unprognostic (6.91e-2)" "unprognostic (1.93e-2)" "prognostic favorable (3.40e-5)" "unprognostic (1.75e-2)" "unprognostic (8.67e-2)" "unprognostic (3.48e-2)" "unprognostic (4.74e-2)" "unprognostic (1.91e-1)" "unprognostic (2.36e-2)" "unprognostic (5.28e-3)" "unprognostic (5.80e-2)" "unprognostic (6.35e-2)" "unprognostic (8.21e-2)" 0.3 0.1 0.2 0.0 0.3 0.0 0.1 0.3 0.3 0.1 0.2 0.2 0.0 0.0 0.1 0.2 0.1 0.0 0.3 0.3 0.2 3.7 5056.6 0.3 0.1 0.3 0.2 0.1 0.2 0.0 0.2 0.1 0.3 0.1 0.0 0.7 0.1 0.0 0.3 0.1 0.2 0.0 0.2 1.5 0.2 0.4 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.0 0.0 0.0 0.2 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.6 0.1 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.5 0.1 84.2 0.0 1.6 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.1 0.4 0.3 0.0 0.2 1.8 0.1 0.0 0.1 0.0 0.1 1.2 0.0 0.0 0.1 0.0 0.2 0.3 0.0 0.0 0.0 0.1 0.3 0.0 1.0 0.1 1.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.3 0.3 0.3 0.2 0.3 0.2 0.3 0.2 0.2 0.3 0.1 3.2 0.0 0.0 4.6 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.2 37.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.3 0.2 0.0 1.6 0.0 34.7 0.1 0.4 0.0 0.1 0.0 0.2 0.0 0.1 42.1 2707.9 0.2 0.0 0.1 0.0 0.0 55.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.1 4.6 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.3 0.3 3.7 0.0 0.0 0.2 SERPIND1 "D22S673, HC-II, HC2, HCF2, HLS2" ENSG00000099937 "Serpin family D member 1" P05546 22 20774113-20787720 "Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Chemotaxis, Hemostasis" "Heparin-binding, Protease inhibitor, Serine protease inhibitor" "Disease variant, FDA approved drug targets, Thrombophilia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "liver: 1253.1" "Cell type enriched" "Detected in some" 25 "Hepatocytes: 283.7" "Cancer enriched" "Detected in many" 80 "liver cancer: 334.4" "Low region specificity" "Detected in some" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 10 "Hep G2: 208.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in single" "CAB008639, HPA055767" Supported Approved Vesicles "Secreted to blood" NA NA 50000000000 "Cluster 24: B-cells - Unknown function" "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 15: Hepatocytes - Hemostasis" Vesicles "CAB008639: AB_1618010, HPA055767: AB_2682912" "unprognostic (1.68e-1)" "unprognostic (8.27e-2)" "unprognostic (4.40e-2)" "prognostic favorable (4.09e-4)" "unprognostic (5.42e-2)" "unprognostic (1.23e-1)" "unprognostic (1.12e-3)" "unprognostic (1.56e-1)" "unprognostic (1.13e-1)" "unprognostic (1.74e-1)" "unprognostic (1.21e-2)" "unprognostic (2.88e-1)" "unprognostic (3.94e-9)" "unprognostic (2.01e-1)" "unprognostic (4.66e-2)" "unprognostic (8.36e-3)" "unprognostic (1.46e-1)" 0.3 0.2 0.1 0.0 0.8 0.2 0.4 1.7 0.8 1.0 87.7 0.0 0.0 2.0 0.0 0.1 0.9 0.4 1.1 1.7 0.0 0.3 1253.1 2.5 0.0 0.0 0.0 1.8 0.5 10.1 0.8 1.6 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 1.2 0.0 0.2 0.4 0.1 0.2 0.0 0.7 0.0 0.0 0.8 0.5 0.1 0.0 0.1 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.2 208.2 0.1 0.8 0.5 0.1 0.0 1.6 0.0 0.0 20.4 0.0 0.2 0.1 0.3 0.0 0.0 0.0 0.1 2.4 16.5 0.0 0.7 0.0 0.0 3.3 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.6 0.4 0.1 0.0 0.1 0.1 0.0 0.2 7.2 0.2 13.9 0.0 0.1 0.0 0.2 0.0 0.3 0.0 0.1 0.1 0.0 0.5 0.2 0.1 0.1 0.3 0.0 0.5 0.1 0.0 0.1 0.8 1.7 0.8 1.7 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 11.3 0.3 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.4 0.0 2.7 1.6 0.0 0.1 2.3 0.0 0.0 1.3 0.0 3.9 283.7 0.1 0.0 0.9 0.0 0.0 6.3 0.0 0.0 1.2 0.2 0.0 1.0 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.5 3.4 0.0 0.0 SHBG "ABP, MGC126834, MGC138391, TEBG" ENSG00000129214 "Sex hormone binding globulin" P04278 17 7613946-7633382 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 5 "liver: 63.4" "Cell type enhanced" "Detected in some" "Early spermatids: 51.6;Late spermatids: 124.5;Proximal enterocytes: 31.1" "Cancer enriched" "Detected in some" 28 "liver cancer: 14.3" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 4.4;Hep G2: 3.0;HSkMC: 4.3" "Not detected" "Not detected" "Secreted to blood" NA NA 9100000000 "Cluster 85: Liver - Metabolism" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 25: Spermatids - Spermatogenesis" "unprognostic (3.35e-3)" "unprognostic (6.47e-2)" "unprognostic (5.65e-2)" "unprognostic (2.35e-1)" "unprognostic (8.84e-2)" "unprognostic (3.08e-1)" "unprognostic (3.50e-1)" "unprognostic (2.27e-1)" "unprognostic (6.55e-2)" "unprognostic (1.32e-3)" "unprognostic (3.58e-3)" "unprognostic (2.21e-1)" "unprognostic (4.49e-2)" "unprognostic (7.83e-3)" "unprognostic (4.35e-1)" "unprognostic (5.50e-3)" "unprognostic (1.06e-1)" 0.7 1.3 1.8 0.0 1.8 0.1 0.4 1.7 2.0 0.7 1.9 0.3 5.3 0.5 0.9 0.2 0.6 0.3 0.6 1.9 1.8 3.5 63.4 0.3 0.1 1.8 1.8 0.7 0.4 0.5 0.7 0.3 1.9 0.5 0.2 0.9 0.2 0.4 0.8 0.1 7.1 0.2 1.7 0.4 0.3 12.4 1.7 0.2 0.8 0.7 0.1 0.3 0.2 1.8 0.1 2.4 2.4 0.3 4.4 2.0 0.1 0.6 0.9 0.9 0.5 0.9 0.3 0.0 0.5 0.8 1.2 0.3 0.1 0.1 0.5 0.1 0.3 0.0 0.6 3.0 1.4 0.0 0.1 4.3 0.3 1.6 0.8 0.8 0.1 0.0 0.2 0.1 0.2 0.5 0.0 0.2 0.3 0.0 0.0 0.0 0.1 0.3 0.3 0.3 0.1 0.3 1.8 0.0 0.2 0.8 0.4 0.0 0.8 0.4 0.0 0.0 0.2 0.3 0.3 0.2 1.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 1.8 1.7 2.0 1.9 1.8 1.8 1.8 1.9 1.7 1.7 1.8 0.2 0.0 0.0 0.7 0.5 0.0 0.3 0.1 0.0 0.4 0.5 0.6 0.5 0.0 0.2 0.0 0.0 0.4 0.0 0.2 5.9 0.5 51.6 0.4 0.6 0.1 0.0 0.0 1.0 0.2 0.1 0.4 0.0 0.2 0.0 0.6 1.1 13.8 0.3 0.0 0.9 1.3 2.0 0.8 0.0 124.5 0.9 0.5 0.0 0.0 0.0 2.4 0.0 0.5 0.6 0.1 1.3 0.7 0.0 0.3 31.1 12.8 0.4 1.3 6.6 0.2 0.3 7.2 0.8 0.0 0.0 0.3 0.1 1.1 0.5 0.3 SI ENSG00000090402 Sucrase-isomaltase P14410 3 164978898-165078496 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins" "Glycosidase, Hydrolase, Multifunctional enzyme" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 150 "intestine: 545.1" "Cell type enriched" "Detected in some" 8 "Proximal enterocytes: 1083.9" "Cancer enhanced" "Detected in some" "stomach cancer: 6.9" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 1.1;CACO-2: 1.5;HeLa: 1.2;NB-4: 1.3;RPMI-8226: 2.0;SH-SY5Y: 1.1" "Not detected" "Not detected" "Not detected" "Not detected" HPA011897 Enhanced NA NA "Cluster 56: Intestine - Transmembrane transport" "Cluster 24: NB-4 - Immune response" "Cluster 45: Enterocytes - Digestion" "HPA011897: AB_1856840" "unprognostic (2.71e-2)" "unprognostic (1.62e-2)" "unprognostic (2.68e-1)" "unprognostic (2.05e-1)" "unprognostic (4.41e-2)" 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.6 545.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 31.0 0.0 0.0 0.0 0.0 0.0 448.2 0.8 0.0 0.0 0.6 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.2 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 37.1 0.0 0.0 9.7 0.0 0.0 0.1 5.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 123.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 124.7 0.0 0.0 0.3 1083.9 0.1 0.0 0.0 0.0 0.0 0.0 0.9 0.3 0.0 0.0 0.0 0.0 0.0 77.8 0.0 SIGMAR1 "OPRS1, SR-BP1" ENSG00000147955 "Sigma non-opioid intracellular receptor 1" Q99720 9 34634722-34637844 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Lipid transport, Transport" Receptor "Amyotrophic lateral sclerosis, Disease variant, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 187.6" "Cell type enhanced" "Detected in many" "Extravillous trophoblasts: 98.7;Hepatocytes: 97.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB013470, HPA018002, HPA024071" Enhanced NA NA "Cluster 35: T-regs - Unknown function" "Cluster 85: Liver - Metabolism" "Cluster 30: Epithelial cell lines - Translation" "Cluster 33: Fibroblasts - ECM organization" "CAB013470: AB_2533521, HPA018002: AB_1854802, HPA024071: AB_1854803" "unprognostic (1.39e-1)" "unprognostic (2.64e-1)" "unprognostic (1.56e-1)" "unprognostic (1.95e-1)" "unprognostic (8.06e-2)" "unprognostic (3.71e-2)" "unprognostic (4.89e-2)" "unprognostic (2.50e-2)" "unprognostic (2.58e-2)" "unprognostic (2.01e-3)" "unprognostic (3.88e-2)" "unprognostic (4.28e-1)" "unprognostic (2.78e-2)" "unprognostic (2.46e-1)" "unprognostic (2.39e-1)" "unprognostic (6.44e-3)" "prognostic unfavorable (3.42e-4)" 42.0 52.4 25.2 19.4 25.3 20.5 38.1 26.2 27.1 53.0 27.4 42.0 46.0 50.7 45.0 54.1 46.9 22.1 34.0 25.8 30.2 25.5 187.6 27.5 16.9 28.3 28.7 46.1 45.7 39.0 22.0 27.6 29.4 35.5 31.2 7.2 35.0 38.5 17.6 53.9 40.0 34.8 26.2 24.2 42.1 20.2 33.3 19.1 29.7 13.5 22.2 46.3 43.5 27.1 184.3 162.6 59.8 175.3 205.7 138.7 66.5 127.1 91.2 115.8 105.9 97.6 76.8 87.8 71.9 151.7 69.8 108.8 94.5 151.3 57.8 144.7 175.6 78.0 225.0 112.7 131.7 145.0 67.6 142.9 163.0 131.2 197.7 59.4 90.2 114.5 30.1 156.2 139.7 1.8 88.2 215.2 68.8 101.5 184.4 101.4 59.6 258.3 111.0 36.5 57.6 65.5 123.3 89.5 70.0 32.0 106.9 98.7 68.5 90.0 69.9 96.4 19.2 43.2 71.6 2.5 97.2 123.9 191.8 24.3 39.5 24.2 43.0 39.3 46.2 26.5 62.5 51.3 48.9 21.1 51.7 43.6 10.7 28.7 42.5 35.1 65.5 43.5 25.2 25.3 26.2 27.1 25.8 30.2 28.3 28.7 29.4 26.2 33.3 27.1 11.0 3.2 13.6 6.8 12.3 18.4 16.8 24.6 14.2 10.1 26.8 18.9 9.2 15.7 12.1 7.3 0.0 44.8 10.7 33.0 0.0 33.0 0.9 7.0 23.7 14.4 10.3 23.5 5.6 33.5 98.7 29.2 18.3 10.1 7.0 19.4 13.9 97.5 38.8 5.0 6.4 28.2 12.2 10.5 7.8 1.8 27.4 10.8 19.6 5.6 9.5 13.8 14.4 5.0 4.4 32.1 31.5 25.6 22.4 25.9 58.4 13.7 6.8 7.7 19.7 12.1 23.9 6.0 10.3 40.0 21.5 36.5 13.6 26.2 47.3 16.1 SLC12A1 NKCC2 ENSG00000074803 "Solute carrier family 12 member 1" Q13621 15 48178438-48304078 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Symport, Transport" "Bartter syndrome, Disease variant, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in single" 878 "kidney: 705.6" "Cell type enriched" "Detected in some" 5 "Distal tubular cells: 209.4" "Cancer enriched" "Detected in single" 4 "renal cancer: 1.0" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 26 "RPTEC TERT1: 25.1" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA014967, HPA018107" Enhanced Approved Nucleoplasm,Vesicles NA NA "Cluster 7: Kidney - Transmembrane transport" "Cluster 35: RPTEC-TERT1 - Kidney processes" "Cluster 39: Non-specific - Basic cellular processes" Vesicles Nucleoplasm "HPA014967: AB_1854503, HPA018107: AB_1854504" "unprognostic (3.52e-2)" "unprognostic (1.30e-2)" "unprognostic (9.65e-2)" "unprognostic (1.74e-2)" "unprognostic (7.77e-2)" "unprognostic (1.04e-1)" "unprognostic (8.72e-2)" "unprognostic (2.06e-1)" "unprognostic (9.85e-3)" "unprognostic (2.81e-4)" "unprognostic (9.75e-2)" "unprognostic (2.61e-1)" "unprognostic (5.47e-2)" "unprognostic (2.03e-1)" "unprognostic (5.20e-4)" "unprognostic (8.52e-2)" 0.1 0.0 0.3 0.1 0.2 0.2 0.1 0.5 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.6 705.6 0.4 0.0 0.0 0.5 0.6 0.0 0.0 0.0 0.1 0.0 0.4 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.1 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.5 0.4 0.2 0.6 0.5 0.6 0.4 0.2 0.3 0.1 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.7 0.0 0.0 38.6 0.0 0.0 0.0 0.0 209.4 0.0 13.5 0.0 0.0 0.0 0.0 0.0 9.7 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.7 0.0 0.0 0.0 0.0 13.2 0.3 0.1 0.0 1.0 0.0 0.0 0.0 1.5 1.6 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.2 0.0 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SLC12A2 "BSC, BSC2, NKCC1, PPP1R141" ENSG00000064651 "Solute carrier family 12 member 2" P55011 5 128083766-128189677 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Sodium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "salivary gland: 75.6" "Cell type enhanced" "Detected in all" "Intestinal goblet cells: 480.6;Oligodendrocytes: 566.6;Undifferentiated cells: 370.0" "Cancer enhanced" "Detected in all" "colorectal cancer: 54.3" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "plasmacytoid DC: 6.4" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "OE19: 153.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA020130, HPA063697" Approved Approved "Vesicles,Plasma membrane" NA NA "Cluster 40: NK-cells - Unknown function" "Cluster 45: Intestine - Brush border" "Cluster 21: OE19 - Mitochondria" "Cluster 27: Mucus-secreting cells - Mucin production" Vesicles "Plasma membrane" "HPA020130: AB_1854502, HPA063697: AB_2685094" "unprognostic (4.61e-2)" "unprognostic (2.63e-1)" "unprognostic (4.20e-3)" "prognostic favorable (8.60e-4)" "unprognostic (3.99e-1)" "unprognostic (5.65e-3)" "unprognostic (1.44e-3)" "unprognostic (1.81e-1)" "unprognostic (3.30e-1)" "unprognostic (2.95e-2)" "unprognostic (7.22e-2)" "unprognostic (1.39e-1)" "prognostic favorable (7.09e-4)" "unprognostic (1.63e-1)" "unprognostic (2.30e-1)" "unprognostic (3.79e-1)" "unprognostic (3.88e-3)" 8.4 17.5 15.0 10.8 48.4 4.4 43.9 46.3 23.2 7.2 40.4 48.5 41.7 8.4 2.4 4.6 6.0 39.4 6.1 13.5 31.1 6.6 4.2 10.3 5.6 40.8 43.1 5.4 6.1 14.7 5.5 4.9 38.6 23.5 58.9 16.8 75.6 2.6 15.4 28.4 49.1 10.2 27.1 4.5 61.8 8.0 32.4 4.1 8.6 8.3 6.0 7.3 3.5 64.8 13.5 65.3 65.8 25.6 16.1 10.4 13.6 12.2 9.1 8.6 8.9 26.4 20.9 19.9 16.1 10.6 7.8 39.5 12.7 14.0 13.2 20.0 15.8 5.7 11.4 3.8 4.9 7.3 9.5 11.1 5.0 19.1 11.2 6.4 14.2 8.5 9.4 13.2 13.4 14.2 13.0 6.1 7.7 153.6 21.1 7.1 18.5 8.2 10.0 45.0 11.5 7.3 24.6 10.6 9.9 7.0 5.9 3.7 24.1 21.2 14.2 16.3 15.7 11.0 10.7 21.6 11.2 4.2 17.6 0.3 0.4 0.2 1.1 0.7 1.9 1.7 1.0 1.4 0.6 2.1 1.1 1.6 0.2 2.4 0.5 6.4 1.1 0.3 15.0 48.4 46.3 23.2 13.5 31.1 40.8 43.1 38.6 27.1 32.4 64.8 38.3 16.0 46.2 23.8 20.5 22.9 20.1 44.9 10.8 76.6 186.9 86.7 18.0 137.2 52.1 33.1 127.2 1.4 34.4 48.2 1.9 68.6 55.8 33.1 43.1 44.2 74.4 2.5 160.6 48.2 2.7 21.3 199.3 38.4 18.4 28.8 12.8 8.8 4.2 80.8 73.2 480.6 57.0 8.6 12.0 95.3 85.4 11.4 204.5 105.9 2.5 22.6 11.3 55.3 566.6 50.1 60.6 29.0 20.2 131.6 38.8 10.6 19.6 86.4 72.3 33.9 64.3 29.1 27.1 14.9 30.0 1.4 21.1 14.1 370.0 21.5 SLC12A3 NCCT ENSG00000070915 "Solute carrier family 12 member 3" P55017 16 56865207-56915850 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 101 "kidney: 101.7" "Cell type enhanced" "Detected in some" "Collecting duct cells: 3.7;dendritic cells: 4.2;Distal tubular cells: 5.9;Endometrial ciliated cells: 2.1;Glandular and luminal cells: 4.7;monocytes: 4.2" "Cancer enhanced" "Detected in some" "renal cancer: 2.5" "Low region specificity" "Detected in single" "Immune cell enriched" "Detected in single" 20 "plasmacytoid DC: 14.9" "Lineage enriched" "Detected in single" 20 "dendritic cells: 14.9" "Group enriched" "Detected in some" 11 "BEWO: 7.0;HAP1: 4.0;HeLa: 8.9;SuSa: 2.6" "Not detected" "Not detected" "Not detected" "Not detected" HPA028748 Enhanced NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 7: Kidney - Transmembrane transport" "Cluster 20: HeLa - Mitochondria" "Cluster 65: Plasmacytoid DCs - Unknown function" "HPA028748: AB_10603886" "unprognostic (1.54e-3)" "unprognostic (7.09e-5)" "unprognostic (1.35e-1)" "unprognostic (1.41e-2)" "unprognostic (2.91e-1)" "unprognostic (2.38e-4)" "unprognostic (1.81e-1)" "unprognostic (9.70e-2)" "unprognostic (1.34e-1)" "unprognostic (7.25e-2)" "unprognostic (6.84e-2)" "unprognostic (1.83e-1)" "unprognostic (1.43e-1)" "unprognostic (2.09e-1)" "unprognostic (1.38e-1)" "unprognostic (1.40e-2)" "unprognostic (1.70e-1)" 0.0 0.0 0.3 0.4 0.8 0.0 0.1 0.0 1.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.6 0.0 101.7 0.0 0.1 0.8 0.2 0.2 0.0 0.2 0.0 0.0 0.2 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.5 0.1 0.0 0.2 0.4 0.0 0.0 0.7 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.5 4.0 0.0 0.0 0.0 0.0 0.0 8.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 14.9 0.0 0.1 0.3 0.8 0.0 1.0 0.6 0.0 0.2 0.2 0.3 0.0 0.2 0.2 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 3.7 0.0 0.0 4.2 0.0 5.9 0.0 0.4 2.1 0.4 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.0 4.7 0.0 0.0 0.0 0.0 0.1 0.0 1.2 0.0 0.0 0.0 0.0 0.3 0.0 0.9 0.0 0.0 4.2 0.0 0.0 1.0 0.6 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 SLC12A4 KCC1 ENSG00000124067 "Solute carrier family 12 member 4" Q9UP95 16 67943474-67969601 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Syncytiotrophoblasts: 63.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "basophil: 7.1" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041138 Approved Approved Endosomes NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 46: Fibroblasts - ECM organization" "Cluster 28: BEWO - Transcription regulation" "Cluster 18: Syncytiotrophoblasts - Pregnancy hormone signaling" Endosomes "HPA041138: AB_10794544" "unprognostic (5.07e-2)" "unprognostic (6.18e-2)" "unprognostic (1.25e-1)" "unprognostic (2.68e-2)" "unprognostic (9.28e-2)" "unprognostic (1.48e-2)" "unprognostic (4.28e-2)" "unprognostic (3.26e-3)" "unprognostic (9.58e-2)" "unprognostic (1.55e-1)" "unprognostic (2.01e-2)" "unprognostic (1.81e-2)" "prognostic favorable (2.25e-6)" "unprognostic (6.42e-2)" "unprognostic (1.42e-1)" "unprognostic (7.64e-2)" "unprognostic (2.26e-1)" 30.2 29.1 11.0 11.8 13.6 5.0 28.9 15.2 10.9 33.5 60.6 32.4 7.2 34.0 8.6 13.0 27.5 14.7 46.1 10.8 13.7 20.2 17.4 34.7 9.4 17.5 17.0 23.9 19.1 23.2 13.0 27.2 14.8 30.4 5.8 3.7 18.0 26.8 20.9 24.3 16.5 27.3 14.9 15.4 18.6 12.3 14.8 12.0 35.4 16.8 5.7 27.3 23.2 15.3 13.4 17.5 13.3 25.3 43.0 37.5 71.6 39.9 41.1 33.5 29.1 35.2 20.8 4.7 19.3 55.3 18.7 23.7 6.2 49.2 25.2 4.8 5.3 3.4 23.4 38.9 48.7 0.4 16.0 41.6 31.6 45.3 16.3 39.1 21.0 8.6 10.9 3.8 46.6 2.1 5.2 13.3 10.0 3.8 9.2 5.3 25.1 4.4 18.5 11.4 0.1 8.0 76.1 4.5 6.8 32.8 35.8 5.4 28.8 47.6 33.4 21.4 17.6 23.2 6.3 8.0 27.9 3.6 42.1 7.1 2.5 1.2 0.8 3.3 0.5 0.3 0.5 0.5 1.4 0.5 0.4 0.4 0.9 1.9 2.4 0.7 0.9 1.1 11.0 13.6 15.2 10.9 10.8 13.7 17.5 17.0 14.8 14.9 14.8 15.3 25.8 16.0 9.1 10.4 2.4 10.1 15.8 13.3 17.6 1.2 3.9 6.6 26.9 2.8 10.6 14.7 0.0 30.1 2.2 0.5 0.0 13.7 3.5 4.0 10.7 15.6 0.0 2.5 0.2 8.3 16.4 19.5 3.1 3.2 1.3 10.9 12.1 10.3 8.0 0.0 0.3 0.1 24.4 5.3 4.3 2.7 19.9 4.2 10.6 4.7 11.4 20.5 3.1 2.0 0.7 15.5 0.1 36.5 10.8 16.9 0.1 5.3 8.3 1.0 39.5 17.3 23.1 12.0 9.1 2.4 5.3 63.5 2.6 13.9 0.2 12.9 SLC12A5 "KCC2, KIAA1176" ENSG00000124140 "Solute carrier family 12 member 5" Q9H2X9 20 46021690-46060150 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Potassium transport, Symport, Transport" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 145.8;retina: 117.4" "Cell type enhanced" "Detected in many" "Bipolar cells: 244.0;Cone photoreceptor cells: 383.7;Excitatory neurons: 92.7;Inhibitory neurons: 91.3;Rod photoreceptor cells: 170.9" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "naive CD4 T-cell: 2.4" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "Hep G2: 24.9;NB-4: 50.8;SK-BR-3: 24.8;U-2 OS: 28.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA072058 Enhanced NA NA "Cluster 35: T-regs - Unknown function" "Cluster 58: Brain - Synaptic function" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 9: Photoreceptor cells - Phototransduction" "HPA072058: AB_2686485" "unprognostic (2.01e-1)" "unprognostic (3.58e-1)" "unprognostic (7.55e-2)" "unprognostic (9.44e-4)" "prognostic unfavorable (5.60e-4)" "unprognostic (2.48e-1)" "unprognostic (5.16e-3)" "unprognostic (3.61e-1)" "unprognostic (2.49e-1)" "unprognostic (6.63e-2)" "unprognostic (3.72e-3)" "unprognostic (5.61e-4)" "unprognostic (8.78e-4)" "unprognostic (3.25e-2)" "unprognostic (9.22e-2)" "unprognostic (1.99e-1)" "unprognostic (2.34e-2)" 1.5 26.7 101.3 0.9 103.5 0.4 1.0 97.6 145.8 0.9 14.9 1.4 1.0 0.7 0.9 0.4 0.5 0.7 5.1 107.0 96.6 1.1 1.2 2.5 2.2 76.3 80.5 2.3 2.2 1.8 41.5 2.0 69.9 1.0 0.9 117.4 0.7 0.5 0.4 0.6 1.6 0.4 69.3 3.0 1.9 7.8 86.7 2.9 0.7 0.2 1.4 0.6 0.7 88.4 0.0 15.2 6.6 4.9 0.6 0.0 1.5 0.6 0.0 0.0 0.5 2.0 0.0 5.8 22.5 0.4 5.9 1.4 4.3 2.3 0.4 3.7 5.7 4.9 3.0 24.9 2.5 0.0 6.5 0.8 0.0 0.0 0.3 10.0 1.4 5.4 9.3 0.0 0.0 23.1 3.5 50.8 2.4 2.1 7.7 5.8 4.2 1.3 2.3 0.0 8.1 11.5 2.9 24.8 7.9 6.0 9.0 14.4 2.3 2.7 28.0 0.2 1.1 0.0 4.2 8.2 5.9 5.9 0.2 0.0 0.6 0.0 1.1 0.4 0.5 0.4 0.1 0.1 0.1 0.5 2.4 1.3 0.0 0.4 0.1 0.0 1.9 0.3 101.3 103.5 97.6 145.8 107.0 96.6 76.3 80.5 69.9 69.3 86.7 88.4 2.2 0.0 0.0 10.4 0.4 0.5 0.0 0.0 0.0 244.0 0.8 2.2 1.2 0.0 0.0 0.0 383.7 1.6 0.9 0.0 1.9 0.1 1.9 0.4 0.1 2.9 19.9 4.4 92.7 0.2 2.5 0.4 1.5 0.6 0.0 14.4 4.6 1.3 19.8 13.5 91.3 0.7 0.0 2.6 5.3 6.1 0.0 3.4 5.4 10.3 0.6 28.2 0.0 3.5 6.3 0.4 0.0 0.0 0.8 0.2 0.0 0.3 0.0 170.9 0.0 0.0 2.2 4.2 7.7 0.1 0.6 1.6 1.0 8.5 0.3 0.1 SLC18A1 "CGAT, VAT1, VMAT1" ENSG00000036565 "Solute carrier family 18 member A1" P54219 8 20144855-20183206 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "adrenal gland: 25.1" "Cell type enriched" "Detected in some" 27 "Enteroendocrine cells: 139.0" "Cancer enhanced" "Detected in some" "colorectal cancer: 0.8" "Region enriched" "Detected in single" 19 "midbrain: 3.9" "Immune cell enhanced" "Detected in single" "non-classical monocyte: 2.8" "Lineage enriched" "Detected in single" 19 "monocytes: 2.8" "Cell line enriched" "Detected in some" 8 "SH-SY5Y: 67.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" "HPA006877, HPA063797" Enhanced NA NA "Cluster 14: Monocytes - Unknown function" "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 17: Intestinal endocrine cells - Hormone signaling" "HPA006877: AB_2667690, HPA063797: AB_2685125" "unprognostic (8.03e-4)" "unprognostic (1.02e-1)" "unprognostic (3.75e-3)" "unprognostic (3.50e-1)" "unprognostic (6.61e-2)" "unprognostic (3.09e-3)" "unprognostic (1.67e-1)" "unprognostic (2.16e-2)" "unprognostic (3.45e-2)" "unprognostic (1.48e-1)" "unprognostic (1.32e-3)" "unprognostic (1.61e-1)" "unprognostic (2.48e-2)" "unprognostic (8.25e-2)" "unprognostic (4.41e-2)" "unprognostic (2.06e-1)" "unprognostic (1.05e-1)" 0.1 25.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.3 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 3.9 0.0 0.0 0.0 0.0 0.0 0.1 0.2 3.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.3 1.1 0.1 0.2 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 7.9 0.0 0.0 0.0 3.8 67.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 2.8 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 3.9 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.6 139.0 0.0 0.0 0.0 0.0 3.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 3.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.9 1.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.1 SLC18A2 "SVAT, SVMT, VMAT2" ENSG00000165646 "Solute carrier family 18 member A2" Q05940 10 117241093-117279430 "Disease related genes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "Disease variant, Dystonia, FDA approved drug targets, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 81.1;cervix: 30.0" "Cell type enriched" "Detected in many" 5 "granulocytes: 636.0" "Low cancer specificity" "Detected in some" "Group enriched" "Detected in many" 11 "hypothalamus: 20.8;midbrain: 81.1;pons: 70.5" "Immune cell enriched" "Detected in some" 15 "basophil: 59.5" "Lineage enriched" "Detected in many" 15 "granulocytes: 59.5" "Cell line enriched" "Detected in some" 19 "HMC-1: 351.0" "Region enhanced" "Detected in many" "midbrain: 62.7" "Region enriched" "Detected in all" 4 "midbrain: 111.6" HPA073224 Enhanced Approved Vesicles,Centrosome NA NA "Cluster 38: Basophils - Unknown function" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 3: HMC-1 - Innate immune response" "Cluster 60: Granulocytes - Receptor signaling" "Vesicles, Centrosome" "HPA073224: AB_2732222" "unprognostic (1.49e-1)" "unprognostic (2.48e-1)" "unprognostic (2.33e-3)" "unprognostic (9.00e-2)" "unprognostic (2.85e-1)" "unprognostic (5.33e-3)" "unprognostic (2.23e-1)" "unprognostic (1.71e-2)" "unprognostic (1.40e-1)" "unprognostic (4.55e-2)" "unprognostic (2.00e-1)" "unprognostic (6.06e-3)" "unprognostic (7.94e-5)" "unprognostic (2.95e-2)" "unprognostic (2.31e-1)" "unprognostic (2.43e-1)" "unprognostic (3.57e-2)" 1.1 14.6 0.1 0.9 1.1 2.4 1.8 0.1 0.3 30.0 0.2 2.3 1.5 2.6 1.6 2.5 0.5 3.6 0.7 0.2 20.8 0.9 2.8 7.4 0.6 3.8 81.1 10.4 3.4 0.2 0.2 0.1 70.5 9.2 3.5 0.4 0.8 1.3 0.8 6.3 2.1 2.3 0.0 0.3 4.4 0.9 5.0 6.1 0.0 0.5 0.9 2.9 7.9 0.2 0.2 1.1 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.7 0.3 0.6 0.0 0.1 0.7 0.0 0.0 0.0 0.1 0.7 18.6 0.1 0.2 0.0 1.0 351.0 0.0 0.0 0.0 0.0 0.2 0.0 3.7 0.0 0.7 0.0 0.1 1.0 0.3 0.2 0.3 0.6 0.2 0.4 0.2 0.0 0.2 3.4 0.7 0.3 0.1 0.0 0.2 0.0 0.1 0.3 0.1 2.5 0.3 0.8 0.5 0.4 0.2 0.4 1.9 0.3 59.5 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.3 0.0 0.0 3.8 0.0 2.0 0.1 1.1 0.1 0.3 0.2 20.8 3.8 81.1 70.5 0.0 5.0 0.2 0.0 9.6 16.2 1.0 0.2 1.9 0.0 0.0 0.0 2.1 0.2 0.0 0.3 0.0 2.5 0.0 4.2 0.0 5.7 0.4 0.0 0.0 0.0 13.1 16.1 0.7 8.9 4.2 1.1 0.0 0.0 3.4 4.1 112.4 636.0 2.4 9.7 0.3 0.8 0.0 1.7 0.0 0.0 1.0 3.6 0.2 0.6 3.5 1.8 0.0 0.1 0.4 0.0 0.5 0.6 0.1 0.1 4.9 1.9 3.8 0.0 0.1 0.7 0.8 0.0 0.4 1.3 0.2 2.1 0.0 2.7 0.0 5.6 9.8 0.1 0.1 SLC1A5 "AAAT, ASCT2, M7V1, RDRC" ENSG00000105281 "Solute carrier family 1 member 5" Q15758 19 46774883-46788594 "FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Host-virus interaction, Symport, Transport" "Host cell receptor for virus entry, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Basal prostatic cells: 148.6;Erythroid cells: 143.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "plasmacytoid DC: 95.8" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA035239, HPA035240" Enhanced Enhanced "Plasma membrane" NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 24: Salivary gland - Salivary secretion" "Cluster 30: Epithelial cell lines - Translation" "Cluster 61: Squamous epithelial cells - Keratinization" "Plasma membrane" "HPA035239: AB_10670587, HPA035240: AB_10604092" "unprognostic (8.26e-3)" "unprognostic (6.38e-2)" "unprognostic (7.24e-2)" "unprognostic (7.94e-2)" "unprognostic (2.32e-1)" "unprognostic (1.24e-1)" "prognostic unfavorable (1.66e-8)" "unprognostic (2.08e-1)" "unprognostic (1.06e-2)" "unprognostic (9.82e-2)" "unprognostic (9.40e-3)" "unprognostic (9.57e-3)" "prognostic unfavorable (1.18e-7)" "unprognostic (1.28e-2)" "unprognostic (6.30e-2)" "unprognostic (1.06e-2)" "unprognostic (9.83e-2)" 97.2 15.9 5.8 29.6 6.5 60.9 77.7 6.6 6.1 57.4 6.1 50.1 16.2 39.1 98.0 98.0 48.9 36.5 26.4 5.9 8.5 45.6 8.1 65.3 27.9 15.8 11.1 45.8 73.2 2.9 24.5 46.9 13.3 98.6 42.4 1.4 120.5 77.0 8.5 55.7 36.2 33.0 9.5 40.4 55.5 40.3 9.8 19.9 14.1 10.7 30.3 109.6 83.0 11.5 179.6 323.6 76.3 116.1 194.7 164.3 180.0 249.6 283.0 183.2 264.1 296.1 197.1 194.8 118.9 624.2 105.2 281.1 224.9 296.9 135.5 130.1 203.7 324.3 115.1 281.9 501.3 228.2 182.9 268.6 727.3 215.5 541.1 61.3 98.9 255.0 348.9 500.1 99.5 304.5 105.4 611.1 134.0 636.5 140.9 117.8 86.5 282.7 104.2 384.8 117.3 86.0 123.4 331.8 275.4 58.8 191.6 296.6 74.1 109.4 174.1 86.4 205.7 308.0 325.3 164.0 206.3 281.0 274.3 0.1 36.1 2.9 14.1 55.0 11.4 17.8 8.0 9.9 50.2 8.1 1.9 6.0 1.0 21.0 66.3 95.8 15.5 27.8 5.8 6.5 6.6 6.1 5.9 8.5 15.8 11.1 13.3 9.5 9.8 11.5 63.6 0.0 17.3 0.0 31.1 57.7 148.6 95.9 64.9 0.2 52.0 43.1 20.3 21.5 41.2 0.0 0.0 80.8 86.3 44.6 3.9 38.5 27.0 2.6 32.9 29.0 10.7 143.3 0.6 65.7 129.3 48.0 21.9 2.7 29.2 20.9 29.6 0.7 38.4 0.0 0.8 111.3 40.7 21.6 34.7 14.0 19.0 39.8 19.6 3.7 26.0 0.6 12.3 0.0 0.6 43.4 74.8 19.5 68.6 59.0 6.5 23.1 13.0 0.8 6.6 15.8 44.0 35.9 4.0 69.0 28.3 24.4 38.7 6.1 62.9 100.0 SLC22A11 OAT4 ENSG00000168065 "Solute carrier family 22 member 11" Q9NSA0 11 64555690-64572875 "FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 72 "epididymis: 10.6;kidney: 31.9;placenta: 33.4" "Group enriched" "Detected in some" 19 "Cytotrophoblasts: 654.0;Syncytiotrophoblasts: 1520.6" "Cancer enriched" "Detected in some" 4 "renal cancer: 15.2" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 1.3;Hep G2: 1.0" "Not detected" "Not detected" HPA026076 Enhanced NA NA "Cluster 7: Kidney - Transmembrane transport" "Cluster 28: BEWO - Transcription regulation" "Cluster 18: Syncytiotrophoblasts - Pregnancy hormone signaling" "HPA026076: AB_1854756" "unprognostic (8.21e-5)" "unprognostic (3.29e-2)" "unprognostic (3.57e-1)" "unprognostic (1.57e-1)" "unprognostic (3.20e-2)" "unprognostic (4.57e-3)" "unprognostic (3.48e-1)" "unprognostic (1.93e-1)" "unprognostic (4.86e-2)" "unprognostic (4.51e-2)" "unprognostic (7.56e-2)" "unprognostic (1.13e-1)" "prognostic favorable (3.68e-5)" "unprognostic (4.62e-2)" "unprognostic (6.52e-2)" "unprognostic (3.50e-2)" "unprognostic (8.24e-3)" 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.6 0.0 0.0 0.0 0.0 0.0 0.0 31.9 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 33.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.8 0.0 0.0 0.0 0.0 654.0 0.0 0.0 5.9 0.0 1.2 0.0 0.2 1.7 0.0 0.0 0.0 0.4 22.5 3.4 0.0 0.0 0.0 0.0 0.4 0.2 50.3 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.3 0.3 0.0 1.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 54.8 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 1520.6 0.2 0.1 0.2 0.0 SLC22A12 "OAT4L, RST, URAT1" ENSG00000197891 "Solute carrier family 22 member 12" Q96S37 11 64590641-64602353 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Ion transport, Transport" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 204 "kidney: 109.4" "Cell type enriched" "Detected in some" 17 "Proximal tubular cells: 173.1" "Cancer enriched" "Detected in some" 4 "renal cancer: 16.5" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Not detected" "Not detected" HPA024575 Enhanced NA NA "Cluster 7: Kidney - Transmembrane transport" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "HPA024575: AB_1858650" "unprognostic (5.88e-2)" "unprognostic (2.33e-1)" "prognostic favorable (2.63e-4)" "unprognostic (6.19e-2)" "unprognostic (3.91e-2)" 0.5 0.0 0.2 0.0 0.0 0.0 0.1 0.5 0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 109.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 1.8 0.0 0.0 0.0 0.0 9.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 173.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 SLC22A6 "OAT1, PAHT, ROAT1" ENSG00000197901 "Solute carrier family 22 member 6" Q4U2R8 11 62936385-62984967 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 26 "kidney: 196.5" "Cell type enriched" "Detected in some" 17 "Proximal tubular cells: 310.4" "Cancer enriched" "Detected in single" 102 "renal cancer: 18.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA074559, CAB075704" Enhanced NA NA "Cluster 7: Kidney - Transmembrane transport" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "CAB075704: , HPA074559: AB_2732260" "unprognostic (2.42e-2)" "unprognostic (2.25e-3)" "unprognostic (4.43e-1)" 0.0 0.0 1.3 0.0 2.5 0.0 0.0 3.6 2.3 0.0 1.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 3.8 196.5 0.0 0.0 0.0 7.0 5.5 0.0 0.0 0.0 0.6 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.1 0.0 7.6 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 2.5 3.6 2.3 1.3 3.8 7.0 5.5 3.1 3.3 7.6 1.2 0.0 0.0 0.0 4.9 1.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.1 0.0 0.0 7.3 0.0 0.0 0.0 0.0 17.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.3 0.0 1.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 310.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 SLC22A8 OAT3 ENSG00000149452 "Solute carrier family 22 member 8" Q8TCC7 11 62989154-63015841 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Detoxification, Ion transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 61 "choroid plexus: 111.4;kidney: 335.0" "Cell type enriched" "Detected in some" 38 "Proximal tubular cells: 347.6" "Cancer enhanced" "Detected in single" "renal cancer: 0.6" "Region enhanced" "Detected in some" "hippocampal formation: 3.6" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044174 Enhanced NA NA "Cluster 7: Kidney - Transmembrane transport" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "HPA044174: AB_10963058" "unprognostic (5.35e-4)" "unprognostic (4.66e-1)" "unprognostic (6.88e-3)" "unprognostic (1.72e-1)" "unprognostic (2.20e-1)" 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.7 0.7 0.0 111.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 335.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.7 0.7 3.6 0.0 0.1 0.1 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.3 1.0 0.0 0.0 0.0 0.0 9.0 0.0 0.0 1.2 0.0 0.0 5.5 0.0 0.0 0.0 0.0 7.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 347.6 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 SLC25A4 "ANT1, PEO2, PEO3, T1" ENSG00000151729 "Solute carrier family 25 member 4" P12235 4 185143266-185150382 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Antiport, Host-virus interaction, Transport" "Cardiomyopathy, Disease variant, FDA approved drug targets, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "heart muscle: 245.1;skeletal muscle: 190.8;tongue: 346.6" "Cell type enriched" "Detected in all" 4 "Cardiomyocytes: 4722.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046835, HPA071684" Approved Supported Mitochondria NA NA 380000 "Cluster 36: GdT-cells - Adaptive immune response" "Cluster 38: Heart - Muscle contraction" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 54: Cardiomyocytes - Muscle contraction" Mitochondria "HPA046835: AB_2679831, HPA071684: AB_2686431" "unprognostic (4.19e-2)" "unprognostic (1.06e-2)" "unprognostic (3.11e-1)" "unprognostic (8.85e-2)" "unprognostic (1.37e-1)" "unprognostic (2.90e-3)" "unprognostic (8.25e-2)" "unprognostic (1.26e-2)" "unprognostic (7.87e-2)" "unprognostic (1.60e-1)" "prognostic favorable (3.41e-4)" "unprognostic (2.05e-1)" "prognostic favorable (0.00e+0)" "unprognostic (1.98e-1)" "unprognostic (1.05e-1)" "unprognostic (1.73e-1)" "unprognostic (8.28e-3)" 4.7 5.7 14.0 1.6 15.3 0.4 4.6 22.6 30.6 3.4 6.8 21.0 3.0 5.9 3.5 10.1 5.8 3.9 245.1 16.7 11.8 10.4 7.3 4.5 1.5 11.6 10.7 4.9 5.2 7.8 9.5 1.7 11.8 8.9 3.9 19.9 9.0 12.6 190.8 3.3 6.8 8.1 9.4 3.1 15.7 4.7 12.5 1.4 5.2 346.6 1.2 9.8 3.6 18.2 0.7 3.1 2.5 5.1 2.7 0.3 4.6 2.6 0.8 3.1 3.0 6.8 1.7 2.3 1.8 3.1 2.4 2.5 9.8 2.7 2.0 3.9 8.4 1.6 4.7 8.1 5.5 1.4 1.5 2.0 6.6 4.7 1.3 7.2 2.3 4.0 3.8 1.7 1.9 5.0 1.6 3.1 4.1 2.2 6.6 2.5 1.3 3.2 6.9 4.8 8.1 6.2 3.1 1.3 12.5 4.5 2.4 1.1 1.7 0.2 1.4 1.5 3.4 7.3 3.5 2.9 2.2 0.3 2.8 0.0 0.0 0.0 1.7 0.0 1.3 1.5 0.5 1.4 0.0 1.0 0.4 1.2 0.1 0.3 0.0 1.3 0.5 0.6 14.0 15.3 22.6 30.6 16.7 11.8 11.6 10.7 11.8 9.4 12.5 18.2 37.5 86.6 76.4 22.9 37.9 44.1 159.0 119.9 30.1 180.6 42.9 53.5 4722.0 115.8 80.0 71.7 104.3 69.2 41.1 44.4 988.0 75.3 20.6 77.8 7.4 80.1 53.8 3.0 35.1 74.1 56.5 120.1 54.0 33.6 12.0 18.6 27.5 92.1 65.9 159.9 43.7 40.6 215.7 8.5 13.8 16.7 46.6 6.8 190.3 19.7 9.0 541.2 16.5 26.7 29.2 51.4 28.5 112.8 76.4 59.1 113.8 178.3 144.0 221.0 105.2 134.5 402.7 28.0 34.0 33.2 18.2 40.5 27.7 23.7 54.2 50.7 SLC25A5 "2F1, ANT2, T2, T3" ENSG00000005022 "Solute carrier family 25 member 5" P05141 X 119468422-119471396 "FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Antiport, Chromosome partition, Host-virus interaction, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Distal tubular cells: 2533.6;Proximal enterocytes: 2785.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046835, HPA071684" Approved Supported Mitochondria NA NA 640000 "Cluster 12: Non-specific - Basic cellular processes" "Cluster 29: Non-specific - Vesicular transport" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 45: Enterocytes - Digestion" Mitochondria "HPA046835: AB_2679831, HPA071684: AB_2686431" "unprognostic (1.25e-2)" "prognostic favorable (7.35e-4)" "prognostic favorable (7.47e-4)" "unprognostic (1.48e-1)" "unprognostic (4.58e-2)" "unprognostic (1.45e-2)" "unprognostic (2.73e-2)" "unprognostic (1.36e-1)" "unprognostic (6.52e-2)" "unprognostic (2.47e-1)" "unprognostic (1.60e-1)" "unprognostic (2.17e-1)" "prognostic favorable (8.06e-6)" "unprognostic (1.41e-1)" "unprognostic (2.65e-1)" "unprognostic (4.36e-2)" "unprognostic (3.03e-1)" 178.1 178.3 116.9 176.0 116.1 260.9 161.3 141.6 126.0 155.0 114.3 458.7 740.2 134.5 63.9 411.0 118.6 100.4 196.1 109.0 141.5 491.8 336.1 216.5 255.4 120.6 118.0 108.2 629.1 295.3 89.0 138.1 126.4 111.9 503.0 127.7 250.2 103.8 61.6 294.9 562.8 150.5 119.3 182.6 492.1 54.2 126.4 351.9 128.8 65.1 297.7 200.8 235.3 121.5 845.1 789.6 303.3 525.4 189.5 277.3 561.0 306.8 331.3 631.7 560.8 662.4 518.4 1059.3 400.9 296.1 456.1 576.9 752.1 640.5 572.5 281.1 711.2 357.5 418.7 477.0 239.8 984.0 566.1 303.7 705.2 652.2 412.6 240.1 660.4 535.0 292.5 425.9 350.1 1868.4 878.6 995.1 640.4 1147.6 1244.3 474.5 383.4 825.7 486.9 663.6 365.0 344.5 526.7 793.3 646.7 306.7 327.7 491.0 279.5 297.3 428.9 670.8 1122.2 494.6 656.3 847.4 329.5 987.7 492.2 113.4 603.4 170.2 170.7 1045.7 198.1 459.2 248.3 224.6 872.6 376.0 243.3 232.1 99.2 318.1 824.2 476.1 443.1 931.8 116.9 116.1 141.6 126.0 109.0 141.5 120.6 118.0 126.4 119.3 126.4 121.5 260.4 163.5 308.6 28.7 339.6 815.7 567.0 1615.3 398.9 109.8 406.2 413.5 131.2 301.7 609.2 187.6 60.5 1038.8 336.2 1379.0 2533.6 578.2 4.0 137.3 134.2 257.5 401.0 349.1 16.8 1056.4 463.1 214.4 543.3 157.6 192.9 306.0 146.7 333.6 881.7 26.9 25.5 856.4 1129.1 610.6 650.9 18.1 145.4 473.2 547.8 15.0 441.2 140.8 218.3 24.1 19.2 554.1 1061.8 110.6 419.9 522.3 2785.2 1622.3 239.5 199.0 131.5 163.9 506.7 11.5 119.2 1046.8 960.2 1589.1 291.2 626.6 1053.7 809.7 SLC25A6 "ANT3, ANT3Y, MGC17525" ENSG00000169100 "Solute carrier family 25 member 6" P12236 X 1386152-1392113 "FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Antiport, Apoptosis, Host-virus interaction, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA046835, HPA071684" Approved Supported Mitochondria NA NA 450000 "Cluster 39: Non-specific - mRNA processing" "Cluster 25: Pancreas - Digestion" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 32: Non-specific - Translation" Mitochondria "HPA046835: AB_2679831, HPA071684: AB_2686431" "unprognostic (1.13e-1)" "unprognostic (1.65e-2)" "unprognostic (4.79e-2)" "unprognostic (1.45e-1)" "unprognostic (2.14e-1)" "unprognostic (1.41e-1)" "unprognostic (1.01e-3)" "unprognostic (1.34e-1)" "unprognostic (8.07e-2)" "unprognostic (1.48e-1)" "unprognostic (1.37e-3)" "unprognostic (2.51e-1)" "unprognostic (3.96e-2)" "unprognostic (2.73e-1)" "unprognostic (1.69e-1)" "unprognostic (2.85e-1)" "unprognostic (4.57e-3)" 356.6 410.1 227.8 223.3 241.4 441.5 307.3 210.8 296.7 253.7 351.6 350.9 466.0 277.9 80.6 344.8 243.4 127.2 201.5 227.9 216.1 386.8 130.0 239.4 275.0 222.6 222.8 460.8 626.9 323.5 275.8 147.1 228.0 264.1 141.5 108.3 697.7 178.8 115.5 331.3 387.7 129.4 208.3 263.7 413.9 62.2 227.4 232.7 321.5 89.2 159.3 292.0 244.6 219.2 290.4 596.8 393.8 422.6 267.5 527.4 466.2 396.8 386.1 296.8 289.2 796.7 330.6 1023.0 334.1 264.9 445.6 179.2 269.5 482.0 89.8 260.3 886.0 545.0 396.0 899.7 642.2 398.1 649.8 870.1 882.2 235.8 335.9 367.5 441.6 315.7 407.2 233.8 284.5 575.4 791.1 733.3 516.0 105.5 802.2 378.8 333.8 828.3 351.4 693.6 682.9 1096.5 271.1 817.7 1239.7 224.1 466.1 832.5 505.5 305.1 169.6 596.5 422.1 606.7 110.5 705.9 48.7 389.9 170.3 34.2 739.8 47.2 319.5 808.7 466.9 671.4 431.3 377.9 985.9 532.5 396.1 399.7 34.4 359.9 832.3 461.2 447.6 1120.7 227.8 241.4 210.8 296.7 227.9 216.1 222.6 222.8 228.0 208.3 227.4 219.2 194.2 147.4 244.3 13.7 724.4 1151.2 1447.6 1800.6 421.8 286.1 981.3 710.8 106.0 371.8 704.7 316.3 98.0 1581.2 448.5 690.4 1659.2 752.6 11.4 164.4 388.1 473.0 928.4 471.3 15.1 1473.5 1229.8 507.8 374.1 245.3 343.6 698.0 529.4 149.7 1264.7 242.3 20.4 1208.1 819.9 1553.5 1299.4 45.8 667.9 764.0 754.2 17.8 1450.5 184.6 531.4 8.0 13.7 789.8 1127.8 366.3 604.9 1452.4 1564.9 1320.8 180.3 280.0 341.8 631.7 665.6 13.3 80.7 796.7 1321.5 1744.1 494.7 847.8 1524.3 1723.2 SLC38A1 "ATA1, NAT2, SAT1" ENSG00000111371 "Solute carrier family 38 member 1" Q9H2H9 12 46183063-46270017 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Ion transport, Sodium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Bipolar cells: 443.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "U-698: 386.1" "Low region specificity" "Detected in all" "HPA039460, HPA052272" Uncertain Supported NA NA "Cluster 40: NK-cells - Unknown function" "Cluster 52: Non-specific - Ribosome" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 56: Bipolar cells - Visual perception" "HPA039460: , HPA052272: AB_2681781" "unprognostic (8.92e-3)" "unprognostic (3.23e-2)" "unprognostic (9.47e-2)" "prognostic unfavorable (4.76e-6)" "unprognostic (1.00e-1)" "unprognostic (3.74e-1)" "prognostic unfavorable (6.95e-8)" "unprognostic (2.01e-3)" "unprognostic (1.38e-1)" "unprognostic (4.19e-3)" "unprognostic (2.44e-2)" "unprognostic (3.99e-2)" "unprognostic (1.19e-2)" "unprognostic (1.17e-1)" "unprognostic (2.56e-1)" "unprognostic (3.00e-1)" "unprognostic (5.55e-2)" 8.2 5.3 20.0 38.5 18.6 26.0 81.8 48.2 18.9 13.6 0.6 39.3 16.7 16.4 8.7 26.6 15.5 16.6 44.6 15.3 42.3 20.3 6.4 13.2 64.4 44.1 25.4 9.9 23.8 78.7 19.3 22.5 34.6 29.5 38.5 79.0 20.5 35.6 90.7 30.5 22.9 27.8 48.4 31.9 21.3 1.1 26.8 59.5 42.5 82.4 54.4 23.4 11.2 59.7 77.6 79.2 28.2 104.9 12.4 4.5 142.8 60.6 98.2 27.3 42.7 136.6 74.9 176.3 113.0 74.7 83.6 116.5 94.8 124.5 50.4 109.6 49.8 12.3 127.4 51.2 108.3 126.1 4.5 21.7 186.7 8.2 325.1 67.5 61.6 112.0 65.2 144.2 86.5 96.5 112.7 22.0 104.1 0.1 122.7 99.8 6.9 124.6 105.4 109.8 111.6 77.2 126.2 152.9 71.7 108.0 88.9 91.1 129.8 21.2 19.7 0.6 62.7 136.2 126.5 386.1 67.9 242.2 18.6 1.0 0.8 26.3 51.8 0.2 71.0 50.4 54.1 61.0 34.9 57.8 62.6 57.1 2.4 68.3 0.4 44.3 63.5 46.4 20.0 18.6 48.2 18.9 15.3 42.3 44.1 25.4 34.6 48.4 26.8 59.7 10.3 35.3 44.7 75.4 150.0 97.8 73.8 103.8 30.1 443.5 136.5 64.8 207.5 38.6 61.8 213.3 141.8 106.9 216.3 99.3 3.9 56.3 0.2 78.1 9.8 26.7 40.6 25.6 104.7 46.4 79.3 14.6 19.4 123.7 3.8 30.9 5.7 6.1 12.2 8.4 157.8 73.6 79.3 12.9 76.1 0.3 2.1 23.3 26.6 30.9 13.6 51.4 107.1 94.5 59.7 53.5 52.8 0.7 138.8 66.5 23.6 1.1 29.7 54.2 0.0 62.9 34.5 0.1 0.4 70.3 122.7 185.7 167.9 1.6 93.6 75.4 SLC38A2 "ATA2, KIAA1382, SAT2, SNAT2" ENSG00000134294 "Solute carrier family 38 member 2" Q96QD8 12 46358188-46372773 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Ion transport, Sodium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Basal keratinocytes: 1118.3;Suprabasal keratinocytes: 1078.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "hTERT-HME1: 1198.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035180, HPA069672" Approved Supported "Plasma membrane" NA NA "Cluster 39: Non-specific - mRNA processing" "Cluster 85: Liver - Metabolism" "Cluster 30: Epithelial cell lines - Translation" "Cluster 7: Non-specific - Mitochondria" "Plasma membrane" "HPA035180: AB_10669901, HPA069672: " "unprognostic (6.61e-3)" "unprognostic (2.87e-2)" "unprognostic (4.88e-2)" "unprognostic (2.51e-2)" "unprognostic (2.96e-1)" "unprognostic (1.00e-2)" "unprognostic (7.78e-2)" "unprognostic (5.50e-3)" "unprognostic (1.20e-1)" "unprognostic (3.79e-1)" "unprognostic (9.24e-3)" "unprognostic (1.75e-1)" "unprognostic (1.47e-1)" "unprognostic (5.08e-2)" "unprognostic (3.80e-1)" "unprognostic (1.83e-1)" "unprognostic (8.68e-2)" 112.8 113.0 36.1 71.6 48.5 95.4 88.5 53.9 50.2 91.7 25.8 58.3 33.6 92.9 38.6 108.1 83.6 131.3 60.7 32.4 46.1 64.8 307.3 117.0 67.1 52.2 42.7 130.1 74.7 91.5 27.9 162.1 53.5 52.8 49.7 27.0 77.2 43.1 108.5 204.4 54.4 115.8 44.2 75.3 63.0 25.4 44.2 100.4 63.1 174.7 78.1 98.9 88.0 73.0 83.7 179.9 157.6 444.1 356.7 347.7 118.1 382.8 921.2 313.0 254.0 108.2 151.2 0.1 504.2 627.9 215.3 271.1 107.9 335.1 299.1 67.0 61.0 105.8 208.7 339.9 548.8 88.0 108.7 357.2 718.4 199.5 1198.9 778.5 265.7 116.3 103.8 163.1 560.4 100.0 110.3 122.8 138.2 0.1 185.1 97.5 115.5 200.9 191.6 173.4 103.9 89.8 263.5 68.5 233.7 171.0 140.5 193.8 467.3 156.7 121.8 67.8 62.2 187.8 194.3 100.6 148.0 304.5 76.8 41.1 24.9 18.9 22.7 13.1 17.4 19.2 19.0 23.0 35.2 17.8 23.5 24.8 17.5 51.6 18.4 40.6 23.7 27.6 36.1 48.5 53.9 50.2 32.4 46.1 52.2 42.7 53.5 44.2 44.2 73.0 237.7 83.3 77.4 31.3 187.7 1118.3 134.1 262.8 653.9 40.5 315.7 252.2 153.6 108.7 123.9 57.0 70.9 53.8 292.3 114.6 5.9 41.2 5.5 228.5 245.0 234.7 76.7 109.0 54.6 51.1 49.3 219.1 328.2 464.0 81.6 138.3 227.7 265.9 54.0 53.8 58.9 175.0 130.2 143.3 303.6 12.4 263.2 193.8 250.8 59.0 52.6 74.3 70.0 42.3 136.2 79.4 83.5 85.0 322.2 181.7 67.4 24.4 50.3 68.7 282.7 184.8 339.5 6.7 15.5 532.6 1078.3 38.4 252.4 84.0 110.7 150.8 SLC38A3 "G17, SN1" ENSG00000188338 "Solute carrier family 38 member 3" Q99624 3 50205246-50221486 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Antiport, Ion transport, Sodium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "liver: 331.6;retina: 172.9" "Group enriched" "Detected in many" 6 "Bipolar cells: 88.3;Cone photoreceptor cells: 187.7;Hepatocytes: 114.6;Muller glia cells: 80.1;Rod photoreceptor cells: 124.0" "Cancer enriched" "Detected in many" 9 "liver cancer: 140.0" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in single" "basophil: 2.9" "Lineage enriched" "Detected in single" 7 "granulocytes: 2.9" "Group enriched" "Detected in some" 5 "Hep G2: 49.8;SCLC-21H: 15.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA031871 Approved Microtubules,Cytosol NA NA "Cluster 34: Basophils - Unknown function" "Cluster 15: Liver - Metabolism" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 9: Photoreceptor cells - Phototransduction" Cytosol Microtubules "HPA031871: AB_2674080" "unprognostic (2.14e-1)" "unprognostic (2.10e-1)" "unprognostic (8.60e-2)" "unprognostic (6.19e-4)" "unprognostic (7.37e-2)" "unprognostic (9.61e-2)" "unprognostic (2.34e-2)" "unprognostic (2.30e-2)" "unprognostic (4.68e-3)" "unprognostic (1.46e-1)" "unprognostic (2.06e-1)" "unprognostic (5.71e-2)" "unprognostic (1.23e-3)" "unprognostic (1.90e-1)" "unprognostic (2.37e-1)" "unprognostic (1.52e-1)" "unprognostic (1.96e-1)" 1.4 0.1 30.8 0.1 33.8 1.0 1.4 38.7 42.1 0.5 27.4 0.2 1.3 0.3 0.4 1.1 0.6 0.4 5.6 29.8 30.8 5.1 331.6 0.2 0.5 35.8 40.5 6.3 37.2 7.9 4.6 1.2 34.9 0.5 0.1 172.9 1.8 0.1 35.8 0.8 0.6 0.2 32.4 0.2 1.9 1.9 36.4 0.0 1.3 35.8 0.3 0.1 0.4 35.0 0.0 0.0 1.2 7.0 0.1 0.0 1.7 0.0 0.0 1.3 0.6 4.1 0.0 0.1 1.1 0.0 0.3 0.0 1.9 0.0 0.9 0.1 0.6 0.0 1.0 49.8 0.1 0.5 0.0 0.1 0.0 0.1 0.0 5.6 0.0 0.3 0.1 0.3 0.0 0.0 0.0 0.6 0.7 0.0 0.0 0.5 0.5 0.0 0.2 0.2 15.4 1.3 0.7 0.2 0.0 2.1 2.0 0.3 0.0 0.2 1.2 0.0 1.0 0.3 0.0 0.1 0.2 0.3 0.1 2.9 0.2 0.3 0.2 0.0 0.1 0.3 0.1 0.1 0.0 0.2 0.2 0.2 0.8 0.4 0.0 0.2 0.1 0.1 30.8 33.8 38.7 42.1 29.8 30.8 35.8 40.5 34.9 32.4 36.4 35.0 0.3 0.0 0.0 17.6 0.4 0.0 0.1 0.0 0.6 88.3 3.2 1.7 3.3 17.2 0.0 0.0 187.7 0.2 0.0 0.0 0.0 1.8 0.3 0.4 0.0 3.9 3.5 2.7 0.2 2.2 0.1 0.2 0.0 0.5 0.0 0.1 2.2 114.6 0.1 8.4 0.6 0.2 0.0 2.6 0.0 0.0 2.1 0.1 0.0 7.5 0.6 80.1 0.0 4.5 3.7 0.6 0.0 0.4 0.0 0.0 0.0 4.2 0.0 124.0 0.0 0.6 0.3 2.9 3.3 0.9 0.0 1.4 0.2 0.0 0.2 0.0 SLC38A4 "ATA3, NAT3, PAAT" ENSG00000139209 "Solute carrier family 38 member 4" Q969I6 12 46764761-46832408 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Ion transport, Sodium transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 60 "liver: 609.9" "Cell type enriched" "Detected in some" 25 "Hepatocytes: 289.5" "Cancer enriched" "Detected in many" 14 "liver cancer: 61.0" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC diff: 17.7;LHCN-M2: 43.2;RH-30: 14.6;RT4: 86.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" NA NA "Cluster 15: NK-cells - Transcription" "Cluster 62: Liver - Hemostasis" "Cluster 15: RT4 - Unknown function" "Cluster 2: Hepatocytes - Metabolism" "unprognostic (3.81e-2)" "unprognostic (7.46e-3)" "unprognostic (5.22e-3)" "unprognostic (1.75e-2)" "unprognostic (3.12e-1)" "unprognostic (1.11e-1)" "prognostic favorable (5.37e-4)" "unprognostic (3.06e-2)" "unprognostic (2.57e-3)" "unprognostic (1.75e-2)" "unprognostic (1.95e-1)" "unprognostic (6.06e-2)" "unprognostic (2.84e-2)" "unprognostic (1.89e-2)" "unprognostic (8.28e-2)" "unprognostic (6.31e-3)" "unprognostic (2.21e-2)" 0.8 1.1 0.2 0.3 0.2 0.0 1.2 0.1 0.4 0.5 0.5 5.1 0.4 2.2 0.2 1.7 0.9 0.3 0.3 0.1 0.6 4.4 609.9 0.3 0.2 0.2 0.3 0.2 6.6 0.2 0.1 2.2 0.1 1.3 1.3 0.1 0.8 0.5 10.2 2.6 0.5 5.4 0.2 1.2 0.2 0.3 0.7 1.4 0.3 2.6 0.8 2.0 0.2 0.3 0.0 0.0 0.1 0.0 17.7 2.2 3.4 2.3 5.6 2.0 1.8 1.1 4.3 0.0 3.5 7.8 0.0 1.0 0.0 0.6 1.7 0.0 0.0 0.1 0.0 0.2 0.7 0.5 0.0 4.2 0.1 0.1 1.4 0.1 0.0 0.0 0.2 0.0 43.2 0.0 0.1 0.0 1.3 0.0 0.0 0.0 14.6 0.0 0.0 86.0 0.3 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.2 0.0 0.2 0.5 0.3 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.4 0.1 0.6 0.2 0.3 0.1 0.2 0.7 0.3 0.1 0.0 0.0 2.6 0.5 0.8 0.0 2.2 3.4 0.0 0.1 0.0 1.5 11.5 0.2 1.8 0.0 2.5 0.0 1.9 0.0 0.0 0.2 0.4 0.2 1.2 0.0 5.3 0.6 0.0 0.7 1.2 0.0 0.2 0.0 1.6 3.9 289.5 0.5 0.0 2.2 0.4 2.0 6.7 0.0 0.8 0.3 0.0 0.0 0.0 0.0 0.0 0.0 4.0 0.0 0.2 1.2 0.0 0.0 0.7 0.3 0.4 0.2 0.0 0.0 0.3 0.2 0.0 0.1 2.8 0.6 0.8 0.4 2.7 1.3 0.1 SLC52A2 "D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2" ENSG00000185803 "Solute carrier family 52 member 2" Q9HAB3 8 144333957-144361286 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" Transport "Host cell receptor for virus entry, Receptor" "Deafness, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 149.0;PC-3: 167.6" "Low region specificity" "Detected in all" HPA063036 Approved NA NA "Cluster 52: Eosinophils - Transcription" "Cluster 18: Non-specific - Mitochondria" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 53: Intestinal epithelial cells - Unknown function" "HPA063036: AB_2684928" "unprognostic (7.80e-3)" "prognostic unfavorable (7.55e-4)" "unprognostic (2.15e-1)" "unprognostic (2.94e-1)" "unprognostic (3.09e-2)" "unprognostic (3.94e-2)" "prognostic unfavorable (2.04e-6)" "unprognostic (7.74e-3)" "unprognostic (9.20e-2)" "unprognostic (2.24e-2)" "unprognostic (4.85e-2)" "unprognostic (3.99e-2)" "prognostic unfavorable (1.23e-4)" "unprognostic (3.12e-2)" "unprognostic (1.73e-1)" "unprognostic (1.51e-1)" "unprognostic (1.07e-1)" 29.7 31.6 13.7 5.4 13.4 5.6 27.8 15.3 18.5 21.7 14.5 35.7 9.4 23.0 8.0 33.3 17.3 3.2 26.4 13.5 14.5 29.2 16.9 24.6 5.6 15.0 14.9 15.6 41.6 5.3 24.5 7.7 14.6 22.2 5.7 1.3 29.8 6.3 13.5 30.4 29.6 4.3 14.0 34.8 31.4 31.5 15.1 4.0 21.7 2.7 4.1 24.9 21.2 14.1 38.7 65.0 7.5 17.9 19.3 12.3 37.3 28.1 18.9 26.5 24.6 57.9 42.3 16.3 42.3 27.5 20.7 42.6 18.4 25.3 9.8 18.3 34.5 26.3 31.3 50.1 51.7 9.4 29.4 14.8 34.7 27.4 24.4 19.2 15.8 16.2 40.9 23.7 18.7 149.0 15.6 38.0 17.9 51.5 167.6 29.8 8.9 44.9 30.6 34.4 25.9 29.4 31.1 44.1 35.7 9.9 27.8 18.7 20.2 20.9 46.9 48.2 37.9 9.4 13.8 12.4 37.8 26.6 25.7 0.5 4.2 9.2 5.6 5.9 3.8 3.3 3.9 5.6 4.5 9.8 3.6 2.6 1.1 5.2 7.5 7.6 5.7 1.5 13.7 13.4 15.3 18.5 13.5 14.5 15.0 14.9 14.6 14.0 15.1 14.1 31.9 6.4 8.7 5.5 24.3 31.2 27.0 41.5 12.0 11.1 30.6 17.0 3.1 12.8 34.4 12.9 2.1 85.0 36.3 81.8 0.0 62.3 3.3 11.6 16.6 24.3 17.4 7.8 3.2 66.9 92.1 22.2 42.3 21.5 10.2 16.6 18.9 5.5 52.4 11.8 3.7 56.3 36.7 13.5 27.8 5.8 12.8 21.4 30.2 2.8 40.7 14.3 19.6 7.1 2.4 85.1 46.7 19.9 43.3 54.7 52.4 14.5 11.7 10.8 19.7 12.1 31.1 34.0 40.2 20.2 36.1 52.5 24.8 23.4 65.6 36.7 SLC5A2 SGLT2 ENSG00000140675 "Solute carrier family 5 member 2" P31639 16 31483002-31490860 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Sugar transport, Symport, Transport" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Tissue enriched" "Detected in some" 18 "kidney: 54.2" "Cell type enhanced" "Detected in some" "Early spermatids: 59.7;Late spermatids: 145.7;Proximal tubular cells: 142.9;Spermatocytes: 31.7" "Not detected" "Not detected" "Region enhanced" "Detected in single" "cerebellum: 1.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA041603 Enhanced NA NA "Cluster 4: T-regs - Cell cycle regulation" "Cluster 7: Kidney - Transmembrane transport" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "HPA041603: AB_10960540" "unprognostic (1.61e-1)" "unprognostic (2.95e-1)" "unprognostic (2.84e-1)" "unprognostic (3.00e-2)" "unprognostic (8.04e-2)" "unprognostic (8.23e-3)" "unprognostic (1.49e-1)" "unprognostic (2.25e-3)" "unprognostic (2.57e-1)" "unprognostic (1.12e-2)" "unprognostic (6.43e-2)" "unprognostic (2.47e-1)" "unprognostic (1.42e-3)" "unprognostic (5.88e-2)" "unprognostic (2.14e-1)" "unprognostic (4.18e-2)" "unprognostic (3.22e-1)" 0.1 0.0 0.1 0.0 0.1 0.0 0.0 1.0 0.3 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 54.2 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.1 2.9 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.1 0.1 1.0 0.3 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.0 3.7 0.3 0.2 0.3 0.1 0.2 0.0 0.5 0.2 0.4 0.5 1.5 0.1 9.2 0.0 0.2 0.1 0.1 7.9 0.6 59.7 0.6 0.5 0.2 0.0 0.0 0.1 0.5 0.1 0.4 1.5 0.2 0.0 0.1 0.0 0.1 0.2 0.0 0.3 0.5 2.0 0.0 0.5 145.7 2.1 0.9 0.0 0.0 0.0 0.0 0.0 0.5 0.1 1.0 0.1 1.5 0.0 0.1 4.7 142.9 1.7 0.2 0.0 0.1 0.2 31.7 1.1 0.0 0.3 0.1 1.4 0.1 0.6 0.0 SLC5A5 NIS ENSG00000105641 "Solute carrier family 5 member 5" Q92911 19 17871945-17895174 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Congenital hypothyroidism, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "choroid plexus: 163.3;salivary gland: 64.4;stomach 1: 58.8" "Cell type enriched" "Detected in some" 40 "Gastric mucus-secreting cells: 244.7" "Cancer enhanced" "Detected in many" "thyroid cancer: 3.7" "Group enriched" "Detected in many" 5 "cerebellum: 5.6;hippocampal formation: 10.6;thalamus: 3.3" "Low immune cell specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in some" 4 "BEWO: 11.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB022364, HPA049055" Enhanced NA NA "Cluster 32: T-cells - Unknown function" "Cluster 88: Choroid plexus - Transmembrane transport" "Cluster 28: BEWO - Transcription regulation" "Cluster 16: Pancreatic endocrine cells - Mixed function" "CAB022364: , HPA049055: AB_2680614" "unprognostic (2.72e-2)" "unprognostic (8.94e-2)" "unprognostic (1.50e-1)" "unprognostic (1.85e-1)" "unprognostic (1.81e-1)" "unprognostic (4.02e-2)" "unprognostic (2.57e-1)" "unprognostic (1.94e-2)" "unprognostic (3.07e-1)" "unprognostic (2.01e-2)" "unprognostic (3.03e-1)" "unprognostic (3.93e-2)" "unprognostic (5.51e-8)" "unprognostic (1.07e-2)" "unprognostic (1.69e-1)" "unprognostic (1.54e-2)" "unprognostic (3.23e-1)" 0.0 0.0 0.3 0.2 0.1 0.3 0.1 5.6 1.4 5.6 163.3 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 10.6 0.1 0.0 0.0 0.1 0.3 0.2 0.7 0.0 0.0 0.0 0.3 0.0 0.4 0.1 0.0 0.1 64.4 0.0 0.4 0.2 0.2 0.0 0.1 0.2 58.8 0.4 3.3 0.0 12.0 0.0 0.1 0.2 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 11.1 0.0 0.0 0.0 0.0 0.1 0.3 0.2 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.1 0.0 0.3 0.0 0.1 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.0 0.3 0.0 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 2.6 0.0 1.1 0.1 0.1 0.3 0.4 0.4 0.3 0.9 0.1 0.2 0.3 1.2 0.9 0.6 0.2 0.1 0.1 0.6 0.3 0.3 0.1 5.6 1.4 10.6 0.1 0.2 0.7 0.4 0.1 3.3 0.3 0.0 0.0 0.6 0.3 1.1 0.4 0.0 0.0 0.0 0.0 1.7 0.0 0.8 0.0 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.2 0.2 0.0 0.0 0.5 0.6 1.3 0.1 244.7 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.3 0.6 0.2 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.0 0.0 0.9 0.1 0.0 0.0 2.9 0.0 0.0 1.2 0.2 0.1 6.1 0.2 0.3 0.0 0.9 0.0 0.0 0.2 SLC6A1 "GABATHG, GABATR, GAT1" ENSG00000157103 "Solute carrier family 6 member 1" P30531 3 10992186-11039247 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease variant, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 71.3;liver: 87.3;retina: 37.0" "Group enriched" "Detected in some" 4 "Astrocytes: 221.0;Inhibitory neurons: 332.3;Microglial cells: 108.7;Oligodendrocyte precursor cells: 130.2;Oligodendrocytes: 107.9" "Group enriched" "Detected in some" 16 "glioma: 16.1;liver cancer: 24.4" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HeLa: 1.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA013341, CAB022293" Enhanced NA NA "Cluster 15: Liver - Metabolism" "Cluster 20: HeLa - Mitochondria" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "CAB022293: , HPA013341: AB_1849509" "unprognostic (1.66e-3)" "unprognostic (1.30e-3)" "unprognostic (4.12e-3)" "unprognostic (1.70e-1)" "unprognostic (2.53e-1)" "unprognostic (2.53e-1)" "prognostic favorable (3.20e-4)" "unprognostic (1.05e-1)" "unprognostic (4.27e-2)" "unprognostic (8.26e-2)" "unprognostic (2.90e-1)" "unprognostic (2.69e-1)" "prognostic unfavorable (5.05e-6)" "unprognostic (7.32e-3)" "unprognostic (2.36e-1)" "unprognostic (1.35e-1)" "unprognostic (5.34e-2)" 1.9 0.8 51.5 0.4 56.0 2.2 1.0 45.4 67.1 3.3 0.0 1.1 0.4 1.2 2.9 9.1 1.2 1.2 4.1 35.8 53.6 2.9 87.3 2.0 0.5 39.4 63.5 2.1 0.3 15.9 3.6 0.8 34.8 2.4 0.5 37.0 0.4 4.0 2.7 1.7 0.9 0.5 43.0 0.7 0.5 4.1 71.3 17.6 0.7 0.8 0.4 0.9 2.6 39.4 0.2 0.2 0.5 0.3 0.4 0.1 0.3 0.2 0.0 0.2 0.3 0.4 0.3 0.4 0.1 0.1 0.5 0.4 0.6 0.2 0.2 0.0 0.5 0.4 1.6 0.8 0.2 0.6 0.6 0.3 0.0 0.0 0.3 0.1 0.1 0.5 0.3 1.0 0.0 0.3 0.2 0.5 0.2 0.3 0.4 0.3 0.0 0.0 0.1 0.5 0.2 0.0 0.2 0.2 0.0 0.3 0.3 0.3 0.1 0.2 0.1 0.2 0.2 0.3 0.1 0.3 0.2 0.5 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 51.5 56.0 45.4 67.1 35.8 53.6 39.4 63.5 34.8 43.0 71.3 39.4 0.3 0.0 0.5 221.0 0.0 0.3 0.0 0.0 6.2 26.6 0.1 0.0 2.1 14.3 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.1 0.0 0.1 2.6 0.0 0.0 3.7 0.0 0.0 1.4 0.0 0.0 2.5 0.2 0.0 25.2 0.0 0.0 332.3 0.0 0.0 0.8 0.0 1.6 5.6 0.2 0.0 108.7 0.0 36.6 0.0 130.2 107.9 0.0 0.0 10.1 0.0 0.0 0.0 0.2 0.0 3.7 13.1 9.4 6.8 3.8 0.1 4.9 0.0 0.0 0.0 0.0 0.0 0.0 SLC6A2 "NAT1, NET, NET1, SLC6A5" ENSG00000103546 "Solute carrier family 6 member 2" P23975 16 55655604-55706192 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 7 "brain: 149.4" "Group enriched" "Detected in some" 4 "Early spermatids: 4.3;Extravillous trophoblasts: 10.6;Late spermatids: 4.4;Spermatocytes: 11.5;Syncytiotrophoblasts: 5.6" "Cancer enhanced" "Detected in some" "liver cancer: 1.9" "Region enriched" "Detected in some" 10 "pons: 149.4" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 29 "SH-SY5Y: 489.1" "Region enriched" "Detected in some" 4 "pons and medulla: 7.8" "Region enriched" "Detected in single" 19 "pons: 13.8" "HPA004057, HPA076311, CAB078195" Enhanced Supported Approved Mitochondria,Cytosol NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 66: Spermatocytes - Spermatogenesis" Cytosol Mitochondria "CAB078195: AB_2665806, HPA004057: AB_1080012, HPA076311: AB_2732307" "unprognostic (9.58e-3)" "unprognostic (5.48e-2)" "unprognostic (1.26e-4)" "unprognostic (4.07e-1)" "unprognostic (4.16e-1)" "unprognostic (8.38e-2)" "unprognostic (2.97e-2)" "unprognostic (3.29e-1)" "unprognostic (2.31e-1)" "unprognostic (3.27e-1)" "unprognostic (2.12e-2)" "unprognostic (2.95e-2)" "unprognostic (1.72e-1)" "unprognostic (6.02e-2)" "unprognostic (8.48e-2)" "unprognostic (1.43e-2)" 0.9 21.7 0.1 0.0 0.1 0.0 0.8 0.0 0.2 2.4 0.0 0.2 0.1 5.4 0.2 0.2 0.5 0.1 0.0 0.1 0.0 0.4 0.4 0.1 0.0 3.8 14.6 0.1 0.0 0.5 0.0 12.6 149.4 0.2 0.3 0.0 1.9 0.6 0.0 13.3 0.2 0.8 0.1 0.0 0.1 6.2 0.0 0.1 0.0 0.0 0.1 0.2 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.4 0.0 0.0 0.0 0.0 0.0 0.0 5.2 3.7 489.1 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.2 0.1 0.0 3.8 14.6 149.4 0.1 0.0 0.5 1.8 0.0 0.0 0.0 0.0 1.5 0.2 0.4 0.0 0.0 0.3 0.1 0.8 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 4.3 0.1 0.0 0.3 0.0 0.0 0.0 0.0 10.6 0.4 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 0.0 0.0 0.5 4.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 11.5 0.3 0.0 0.4 5.6 0.0 0.0 0.0 0.1 SLC6A3 "DAT, DAT1" ENSG00000142319 "Solute carrier family 6 member 3" Q01959 5 1392794-1445440 "Disease related genes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease variant, Dystonia, FDA approved drug targets, Neurodegeneration, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 73 "brain: 60.6" "Cell type enhanced" "Detected in some" "Alveolar cells type 2: 2.3;Cardiomyocytes: 1.2;Smooth muscle cells: 1.4" "Cancer enriched" "Detected in some" 18 "renal cancer: 25.7" "Region enriched" "Detected in some" 26 "midbrain: 60.6" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 8 "midbrain: 80.6;thalamus: 29.0" "Region enriched" "Detected in some" 152 "midbrain: 302.6" "HPA012763, HPA013602, CAB016249, CAB078172" Enhanced Supported Approved Vesicles NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 43: Cardiomyocytes - Nuclear processes" Vesicles "CAB016249: AB_627402, CAB078172: AB_2665810, HPA012763: AB_2732405, HPA013602: AB_1847484" "unprognostic (2.25e-4)" "unprognostic (2.22e-1)" "unprognostic (8.45e-2)" "unprognostic (5.24e-2)" "unprognostic (7.75e-2)" "unprognostic (1.41e-2)" "unprognostic (4.64e-5)" "unprognostic (9.31e-2)" "unprognostic (7.89e-2)" "unprognostic (4.81e-2)" "unprognostic (1.30e-1)" "unprognostic (2.12e-2)" "prognostic unfavorable (3.40e-7)" "unprognostic (6.98e-2)" "unprognostic (1.64e-1)" "unprognostic (2.22e-2)" "unprognostic (4.74e-2)" 0.4 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.3 0.0 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.5 0.0 0.3 0.0 0.0 60.6 0.4 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.3 2.3 0.1 0.8 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.4 0.0 60.6 0.3 0.0 2.3 0.0 0.0 0.0 2.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.1 0.5 0.0 0.0 0.0 0.1 0.1 0.0 0.0 SLC6A4 "5-HTT, HTT, OCD1, SERT1" ENSG00000108576 "Solute carrier family 6 member 4" P31645 17 30194319-30236002 "FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 232.0" "Group enriched" "Detected in many" 6 "Cytotrophoblasts: 125.4;Proximal enterocytes: 100.9;Syncytiotrophoblasts: 106.4" "Cancer enhanced" "Detected in some" "breast cancer: 2.3" "Group enriched" "Detected in some" 11 "midbrain: 232.0;pons: 86.1" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BEWO: 1.9;CACO-2: 3.9;Hep G2: 10.4" "Region enriched" "Detected in some" 4 "midbrain: 58.4" "Group enriched" "Detected in some" 7 "midbrain: 38.9;pons: 29.1" "HPA054723, HPA071354, HPA074728" Supported Supported Supported "Golgi apparatus,Vesicles" NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 47: Cytotrophoblasts - Unknown function" "Golgi apparatus, Vesicles" "HPA054723: , HPA071354: , HPA074728: AB_2686708" "unprognostic (7.45e-2)" "unprognostic (7.13e-2)" "unprognostic (2.26e-1)" "unprognostic (3.72e-4)" "unprognostic (2.07e-1)" "unprognostic (8.42e-3)" "unprognostic (2.73e-2)" "unprognostic (3.39e-2)" "unprognostic (3.37e-3)" "unprognostic (1.17e-3)" "unprognostic (2.70e-3)" "unprognostic (1.16e-1)" "unprognostic (8.78e-2)" "unprognostic (4.98e-2)" "unprognostic (1.76e-1)" "unprognostic (4.05e-2)" "unprognostic (7.18e-2)" 0.1 0.1 0.1 0.0 0.0 0.2 0.2 0.3 0.2 0.2 0.0 0.5 10.3 0.0 0.0 2.8 1.7 0.0 0.9 0.1 0.2 0.2 0.0 28.8 0.1 14.8 232.0 0.1 1.4 0.2 0.0 18.4 86.1 0.1 0.1 0.1 0.7 0.2 0.1 0.5 40.3 0.0 0.0 0.1 0.9 0.3 0.2 0.0 0.5 0.0 0.2 0.1 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 3.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 10.4 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.7 0.0 0.4 0.5 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.3 0.2 0.1 0.2 14.8 232.0 86.1 0.0 0.2 0.2 1.1 16.0 5.0 0.3 0.0 0.1 0.4 0.1 17.1 1.2 0.1 0.0 1.0 0.0 1.9 1.8 0.0 125.4 1.5 0.2 0.0 0.0 2.8 0.2 0.6 3.2 0.0 0.0 0.9 0.0 8.6 1.3 0.0 0.5 2.5 0.2 2.2 0.3 9.5 0.0 0.6 2.3 0.0 1.0 1.2 2.2 0.3 5.9 0.0 0.0 0.1 0.5 2.1 0.5 0.5 0.4 0.0 0.4 0.1 0.3 100.9 0.4 0.7 0.8 0.0 1.3 0.5 0.5 0.9 4.8 0.3 106.4 0.5 0.2 4.1 0.3 SLC6A8 "CRTR, CT1" ENSG00000130821 "Solute carrier family 6 member 8" P48029 X 153687926-153696588 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Ion transport, Sodium transport, Symport, Transport" "Disease variant, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Bipolar cells: 142.0;Distal enterocytes: 382.0;Proximal enterocytes: 235.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "A-431: 155.8;AN3-CA: 151.3;SK-BR-3: 156.8" "Low region specificity" "Detected in all" NA NA "Cluster 1: Neutrophils - Mixed function" "Cluster 39: Non-specific - Mitochondria" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 53: Intestinal epithelial cells - Unknown function" "unprognostic (5.80e-2)" "unprognostic (1.24e-1)" "unprognostic (2.39e-2)" "unprognostic (9.98e-2)" "unprognostic (1.47e-1)" "unprognostic (7.16e-2)" "unprognostic (1.59e-2)" "unprognostic (1.59e-2)" "unprognostic (2.08e-1)" "unprognostic (2.10e-1)" "unprognostic (1.21e-1)" "unprognostic (1.43e-1)" "prognostic unfavorable (1.53e-4)" "unprognostic (1.41e-1)" "unprognostic (1.06e-1)" "prognostic unfavorable (7.39e-4)" "unprognostic (2.87e-1)" 31.6 66.6 77.2 9.0 99.4 34.5 23.9 77.8 80.0 17.5 39.9 73.5 51.3 32.4 13.0 54.6 17.3 31.3 130.4 76.8 82.1 81.4 4.5 9.2 1.9 89.0 90.5 12.4 20.0 45.6 21.4 36.2 76.9 31.3 30.5 34.7 52.3 35.9 166.6 45.9 75.9 20.7 71.3 13.1 30.8 38.5 87.6 11.9 8.2 75.5 3.0 41.2 36.5 116.6 155.8 6.7 39.5 151.3 14.7 9.9 10.2 22.2 37.7 28.7 35.5 20.1 2.1 0.2 17.0 27.9 33.6 54.3 85.3 78.0 17.0 2.7 83.3 0.6 50.6 59.7 50.0 1.2 10.1 20.9 16.5 27.3 103.3 50.7 14.9 0.9 37.3 2.4 15.7 9.3 0.8 3.6 47.0 30.9 67.0 7.6 5.2 2.1 30.8 29.5 56.0 64.2 33.8 156.8 107.9 9.8 30.9 23.9 14.1 45.2 73.1 58.2 66.5 5.2 3.0 1.8 105.5 4.5 47.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 77.2 99.4 77.8 80.0 76.8 82.1 89.0 90.5 76.9 71.3 87.6 116.6 5.9 0.0 1.9 14.0 2.7 23.2 14.3 91.1 13.1 142.0 19.6 18.4 106.9 21.5 55.6 5.5 110.5 15.3 2.8 382.0 3.9 4.6 1.5 21.4 38.9 6.5 25.9 23.4 8.2 22.2 37.7 8.8 6.1 16.1 4.5 14.4 3.9 0.9 4.9 119.5 9.9 44.2 38.7 1.9 5.7 3.7 9.0 4.1 24.9 2.8 3.2 19.0 0.0 9.0 23.7 47.5 101.1 8.2 0.8 28.3 235.8 53.3 31.3 49.3 32.9 15.6 19.0 2.9 3.9 16.9 15.6 90.8 2.9 1.5 20.7 18.6 SLC7A11 xCT ENSG00000151012 "Solute carrier family 7 member 11" Q9UPY5 4 138164097-138242349 "FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 26.5" "Cell type enhanced" "Detected in many" "Astrocytes: 368.6;Microglial cells: 148.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in all" "hTCEpi: 84.2;TIME: 95.2;WM-115: 138.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA064215 Approved Vesicles NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 17: WM-115 - Nervous system development" "Cluster 64: Astrocytes - Nervous system maintenance" Vesicles "HPA064215: AB_2685213" "unprognostic (3.55e-3)" "unprognostic (4.64e-3)" "unprognostic (2.43e-2)" "unprognostic (7.18e-3)" "unprognostic (2.59e-1)" "unprognostic (8.80e-3)" "unprognostic (2.07e-8)" "unprognostic (1.98e-2)" "unprognostic (1.09e-2)" "prognostic favorable (1.77e-4)" "unprognostic (1.90e-2)" "unprognostic (4.07e-2)" "unprognostic (2.22e-8)" "unprognostic (3.81e-2)" "unprognostic (3.76e-2)" "unprognostic (2.29e-2)" "unprognostic (1.54e-2)" 0.2 0.1 18.8 2.2 17.5 1.0 0.4 16.5 16.5 0.9 7.2 0.7 0.4 0.3 6.7 2.6 4.5 1.6 1.7 16.2 26.5 0.1 0.2 1.7 0.4 24.3 22.8 0.5 2.7 0.3 0.8 0.7 19.0 0.6 1.0 4.2 0.7 0.1 0.0 0.6 0.4 0.1 19.8 0.4 4.9 0.8 20.1 0.3 4.6 0.0 0.8 2.7 0.5 20.1 5.2 42.1 18.4 14.5 3.9 5.0 5.1 23.2 15.9 5.2 11.8 4.7 17.7 9.7 29.5 80.8 27.6 6.7 10.0 19.8 21.7 18.5 2.1 6.9 37.7 10.7 59.6 18.1 6.3 11.9 84.2 14.6 64.6 7.6 65.1 9.6 9.5 24.4 27.3 3.7 2.5 1.7 3.6 25.1 11.9 2.8 6.1 11.5 3.1 20.1 7.6 1.5 10.1 2.9 35.4 3.9 4.4 38.1 95.2 6.7 18.8 10.2 18.3 20.5 10.3 9.7 11.4 9.7 138.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.9 0.0 0.0 18.8 17.5 16.5 16.5 16.2 26.5 24.3 22.8 19.0 19.8 20.1 20.1 0.5 0.0 8.4 368.6 2.5 4.6 7.5 8.8 1.8 7.3 2.2 1.3 5.4 1.5 8.1 0.0 2.1 3.6 28.5 7.9 0.0 4.4 3.2 3.2 2.3 27.8 27.0 0.8 12.5 25.1 0.7 5.7 65.2 18.3 4.5 1.0 2.9 0.4 0.6 1.7 7.3 19.8 22.4 0.3 63.5 0.8 2.5 18.3 5.4 148.9 51.7 47.9 0.0 12.1 8.6 30.4 1.5 2.2 4.1 58.5 0.4 0.1 7.3 2.0 0.0 2.1 4.0 1.1 0.7 1.9 3.1 1.1 0.9 7.0 4.2 37.6 SLC7A3 "ATRC3, CAT-3, FLJ14541" ENSG00000165349 "Solute carrier family 7 member 3" Q8WY07 X 70925579-70931125 "FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 19.8" "Cell type enhanced" "Detected in some" "Breast myoepithelial cells: 1.5;Early spermatids: 6.9;Granulosa cells: 1.5;Inhibitory neurons: 1.6;Late spermatids: 2.3" "Cancer enriched" "Detected in some" 12 "testis cancer: 43.0" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "HAP1: 64.2;NTERA-2: 130.9;SuSa: 154.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" NA NA "Cluster 63: T-cells - Adaptive immune response" "Cluster 5: NTERA-2 - Transcription" "Cluster 23: Spermatids - Flagellum & Golgi organization" "unprognostic (1.42e-4)" "unprognostic (4.30e-4)" "unprognostic (3.59e-3)" "unprognostic (1.81e-2)" "unprognostic (6.45e-2)" "unprognostic (1.45e-2)" "unprognostic (3.66e-1)" "unprognostic (9.18e-3)" "unprognostic (1.89e-1)" "unprognostic (7.99e-5)" "unprognostic (1.31e-2)" "unprognostic (5.42e-4)" "unprognostic (3.57e-2)" 0.0 0.0 4.2 0.1 0.7 0.9 0.7 0.0 1.1 1.7 0.1 0.1 0.1 5.3 1.3 0.4 1.6 0.1 0.0 0.9 3.5 0.0 0.0 0.0 0.3 0.9 2.0 1.0 0.0 0.0 0.3 0.0 2.2 5.8 0.0 0.1 0.2 5.4 0.0 0.0 0.2 2.7 0.4 0.0 3.1 0.8 5.5 19.8 0.0 0.0 0.3 1.0 0.8 0.5 0.0 0.0 4.3 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 23.7 0.5 0.0 0.2 0.0 64.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 26.4 0.0 130.9 0.0 0.0 28.4 9.6 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 154.2 0.0 0.0 0.0 0.1 1.1 0.0 0.0 0.2 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 4.2 0.7 0.0 1.1 0.9 3.5 0.9 2.0 2.2 0.4 5.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 1.5 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 6.9 0.0 0.3 0.1 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 2.3 0.6 0.0 0.0 1.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.5 0.0 0.0 0.0 0.0 0.3 0.0 0.1 SLC7A7 "LPI, y+LAT-1" ENSG00000155465 "Solute carrier family 7 member 7" Q9UM01 14 22773222-22829820 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Amino-acid transport, Transport" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 131.6;kidney: 300.6" "Group enriched" "Detected in many" 4 "Hofbauer cells: 216.5;Kupffer cells: 410.6;Macrophages: 146.2;monocytes: 164.0;Proximal enterocytes: 423.1;Proximal tubular cells: 327.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "classical monocyte: 299.9;intermediate monocyte: 410.0;non-classical monocyte: 457.1" "Lineage enriched" "Detected in many" 5 "monocytes: 457.1" "Group enriched" "Detected in many" 4 "BEWO: 217.2;CACO-2: 385.7;OE19: 329.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA036227 Enhanced NA NA "Cluster 51: Monocytes - Innate immune response" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 21: OE19 - Mitochondria" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "HPA036227: AB_10696653" "unprognostic (1.34e-1)" "unprognostic (7.65e-2)" "unprognostic (4.25e-2)" "unprognostic (2.52e-1)" "unprognostic (6.12e-2)" "unprognostic (3.69e-2)" "unprognostic (7.84e-3)" "unprognostic (1.47e-1)" "unprognostic (2.88e-2)" "unprognostic (1.73e-2)" "unprognostic (2.60e-3)" "unprognostic (7.15e-2)" "prognostic unfavorable (6.28e-6)" "unprognostic (2.68e-3)" "unprognostic (1.86e-2)" "unprognostic (2.61e-1)" "unprognostic (1.12e-1)" 15.1 9.0 3.1 37.4 3.2 19.7 6.8 3.8 7.5 7.3 4.3 13.8 107.0 5.3 2.0 3.7 7.8 17.0 5.1 2.8 3.8 300.6 16.4 54.1 29.1 6.9 4.7 2.1 5.2 78.4 1.4 18.2 6.4 3.5 15.0 1.0 5.4 2.8 2.0 3.2 131.6 15.6 5.1 56.8 8.6 32.8 7.1 9.6 4.6 2.8 25.2 14.7 4.1 8.1 0.2 11.2 1.2 0.5 1.9 3.7 217.2 2.2 16.3 0.4 1.4 385.7 34.4 17.0 72.2 1.4 1.2 13.3 0.1 0.0 0.6 0.6 0.2 0.9 0.4 3.7 9.1 1.9 1.6 7.1 1.0 1.0 0.5 1.8 25.3 1.5 0.1 12.8 2.9 0.6 0.4 1.7 3.6 329.0 0.1 2.9 35.5 9.8 0.8 1.3 0.4 0.8 0.6 0.5 2.5 9.4 0.4 8.3 1.3 0.8 1.7 0.6 0.5 2.7 0.9 8.9 0.9 0.8 0.2 0.2 299.9 1.1 0.5 410.0 0.4 19.1 0.2 0.2 99.5 13.8 0.7 0.4 36.5 0.3 457.1 3.4 0.9 155.1 3.1 3.2 3.8 7.5 2.8 3.8 6.9 4.7 6.4 5.1 7.1 8.1 5.3 12.8 7.1 2.0 14.3 1.0 0.2 6.7 1.8 0.2 0.5 1.7 0.9 67.2 5.6 3.7 0.0 1.2 5.7 3.0 11.7 8.2 61.1 1.7 1.2 5.0 1.2 0.0 0.6 6.4 5.2 4.4 2.6 0.4 1.3 0.7 16.1 3.0 216.5 0.0 1.4 7.2 2.0 410.6 16.8 11.8 3.7 146.2 5.4 20.6 164.0 0.4 4.1 0.0 0.8 8.9 12.5 0.0 20.1 0.1 423.1 327.6 9.2 1.3 6.6 0.8 1.4 17.8 2.2 0.4 0.4 1.8 2.7 38.8 6.4 0.1 SLC8A1 NCX1 ENSG00000183023 "Solute carrier family 8 member A1" P32418 2 40097270-40611053 "FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Antiport, Calcium transport, Ion transport, Sodium transport, Transport" Calmodulin-binding "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "heart muscle: 117.5" "Group enriched" "Detected in many" 8 "Cardiomyocytes: 743.1;Excitatory neurons: 1267.5;Inhibitory neurons: 631.3;Microglial cells: 574.3;Oligodendrocyte precursor cells: 753.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in some" "neutrophil: 44.2" "Group enriched" "Detected in many" 6 "granulocytes: 44.2;monocytes: 11.5" "Cell line enhanced" "Detected in many" "BJ: 28.9;fHDF/TERT166: 70.4;hTERT-HME1: 19.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB022694, HPA070007" Uncertain Supported "Nucleoplasm,Plasma membrane" "Intracellular and membrane" NA NA "Cluster 1: Neutrophils - Mixed function" "Cluster 44: Heart - Cardiac muscle contraction" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" "Nucleoplasm, Plasma membrane" "CAB022694: , HPA070007: AB_2686227" "unprognostic (2.46e-1)" "unprognostic (1.33e-2)" "unprognostic (1.42e-2)" "unprognostic (7.57e-6)" "unprognostic (1.56e-1)" "unprognostic (3.94e-1)" "unprognostic (2.28e-2)" "unprognostic (4.60e-2)" "unprognostic (1.31e-1)" "unprognostic (7.71e-2)" "unprognostic (1.21e-2)" "unprognostic (1.07e-1)" "unprognostic (3.66e-2)" "unprognostic (7.04e-3)" "unprognostic (3.93e-2)" "unprognostic (5.46e-2)" "unprognostic (6.77e-2)" 6.1 4.0 25.7 7.2 25.8 2.0 1.6 0.0 28.0 4.7 0.0 9.6 5.0 19.7 5.6 5.9 5.6 6.5 117.5 30.6 11.0 17.5 3.1 5.8 3.3 1.5 19.8 2.5 1.8 0.7 0.8 11.2 0.7 18.8 4.8 5.9 1.0 27.1 0.3 1.5 5.5 23.4 2.7 7.3 3.5 0.7 19.5 2.0 0.8 0.9 1.5 8.9 2.5 24.1 3.0 2.2 2.1 0.2 3.1 6.4 0.0 28.9 11.1 9.4 6.1 0.0 4.7 0.1 2.2 70.4 10.1 1.1 0.5 4.8 9.5 0.0 3.9 0.0 0.0 0.0 0.1 0.0 0.5 3.7 0.0 10.8 19.8 4.3 0.7 0.0 0.0 0.4 12.1 0.0 0.9 0.1 1.4 0.3 4.0 7.8 14.8 0.0 3.3 0.4 3.2 0.6 0.0 0.0 0.0 9.7 0.1 0.6 9.8 8.8 0.3 0.0 3.1 1.6 0.0 0.0 1.4 1.7 1.4 0.0 8.3 0.0 0.0 9.1 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 44.2 0.0 11.5 0.3 0.0 1.1 25.7 25.8 0.0 28.0 30.6 11.0 1.5 19.8 0.7 2.7 19.5 24.1 10.3 3.2 2.8 39.5 3.6 1.3 0.0 0.2 1.2 79.1 0.5 5.8 743.1 2.8 0.6 35.0 4.2 0.5 0.3 0.0 0.0 0.0 1.1 2.3 52.8 15.1 0.0 3.0 1267.5 0.0 1.6 26.6 1.5 3.0 0.0 0.2 12.1 0.3 29.3 0.0 631.3 2.5 0.0 78.0 26.7 1.4 0.0 88.8 1.8 574.3 42.7 32.0 1.0 753.0 20.5 0.1 3.8 8.2 0.7 0.2 24.7 0.5 0.0 7.2 13.1 1.4 46.6 0.2 1.2 0.5 3.1 1.1 1.2 0.7 2.5 0.1 SLC9A3 NHE3 ENSG00000066230 "Solute carrier family 9 member A3" P48764 5 470456-524449 "Disease related genes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Antiport, Ion transport, Sodium transport, Transport" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 45.4;intestine: 94.3;kidney: 62.5;stomach 1: 50.1" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 16.0;Collecting duct cells: 16.5;Proximal tubular cells: 40.7" "Cancer enhanced" "Detected in many" "stomach cancer: 14.7" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "HDLM-2: 37.8" "Region enriched" "Detected in single" 14 "cerebellum: 4.1" "Low region specificity" "Detected in many" "HPA036493, HPA036669" Enhanced Supported "Plasma membrane" NA NA "Cluster 32: T-cells - Unknown function" "Cluster 87: Intestine & Kidney - Transmembrane transport" "Cluster 44: HDLM-2 - Immune response" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "Plasma membrane" "HPA036493: AB_10673353, HPA036669: AB_10670843" "unprognostic (1.27e-1)" "unprognostic (4.88e-1)" "unprognostic (9.35e-3)" "unprognostic (1.11e-1)" "unprognostic (2.37e-1)" "unprognostic (3.35e-1)" "unprognostic (2.51e-1)" "unprognostic (9.40e-2)" "prognostic unfavorable (8.49e-4)" "unprognostic (5.18e-2)" "unprognostic (1.29e-1)" "unprognostic (3.69e-2)" "unprognostic (3.84e-1)" "unprognostic (1.30e-1)" "unprognostic (1.04e-1)" "unprognostic (1.24e-2)" "unprognostic (1.32e-1)" 2.9 4.4 3.0 10.4 2.5 1.9 3.1 6.1 5.0 3.8 1.7 94.3 46.0 2.9 4.0 8.7 4.9 45.4 3.2 4.7 2.5 62.5 2.4 2.8 3.8 3.8 2.3 4.3 6.7 6.2 0.7 2.1 3.7 7.3 10.8 1.7 9.9 3.8 6.2 19.0 68.1 3.3 1.3 3.7 50.1 5.8 3.4 3.5 4.9 3.9 3.4 2.5 2.5 2.6 6.7 5.1 10.4 10.5 2.5 3.0 7.8 5.3 3.9 8.0 5.0 11.0 7.4 14.0 7.5 3.0 5.5 10.0 6.1 4.0 3.9 37.8 10.7 6.7 23.4 5.4 3.9 5.5 8.2 4.2 8.1 3.5 5.4 3.9 2.4 6.3 9.6 7.5 2.9 9.0 6.0 24.3 4.0 17.8 8.3 8.6 9.3 8.3 2.8 4.8 11.5 5.0 19.0 5.3 4.2 4.5 12.3 4.2 2.9 8.0 7.2 5.3 3.9 12.4 5.8 8.5 5.2 21.2 5.6 0.0 0.7 0.1 2.6 0.3 2.2 0.9 3.3 2.4 0.9 1.0 3.9 3.1 0.1 2.4 0.2 1.2 2.7 1.8 3.0 2.5 6.1 5.0 4.7 2.5 3.8 2.3 3.7 1.3 3.4 2.6 3.8 16.0 5.8 0.0 1.5 0.0 0.0 0.0 0.0 0.0 7.3 8.9 0.7 0.0 5.6 16.5 0.0 0.0 3.4 0.7 5.9 9.0 0.0 3.8 3.6 2.3 0.0 0.0 0.3 8.8 0.0 2.2 0.0 2.6 2.5 5.3 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 4.6 0.0 0.0 0.0 0.1 7.7 0.0 0.0 0.7 0.0 1.1 40.7 2.9 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 2.3 5.4 0.0 0.0 SMO "FZD11, SMOH" ENSG00000128602 "Smoothened, frizzled class receptor" Q99835 7 129188633-129213545 "Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Plasma proteins, Predicted membrane proteins, Transporters" "Developmental protein, G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Astrocytes: 27.4;Granulosa cells: 13.0;Leydig cells: 20.8;Muller glia cells: 16.6;Peritubular cells: 21.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "AF22: 45.3;AN3-CA: 84.9;NTERA-2: 64.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB011446 Approved NA NA "Cluster 15: Liver - Metabolism" "Cluster 23: AN3-CA - Transcription regulation" "Cluster 36: Stromal cells - Cell proliferation" "CAB011446: " "unprognostic (2.48e-2)" "unprognostic (2.69e-2)" "unprognostic (7.09e-2)" "unprognostic (1.10e-1)" "unprognostic (8.16e-2)" "unprognostic (2.02e-1)" "unprognostic (3.63e-1)" "unprognostic (5.89e-2)" "unprognostic (5.38e-3)" "unprognostic (1.59e-1)" "unprognostic (1.17e-2)" "unprognostic (8.74e-3)" "unprognostic (1.62e-1)" "unprognostic (5.15e-3)" "unprognostic (2.09e-1)" "unprognostic (2.25e-1)" "unprognostic (2.61e-2)" 5.2 6.0 9.4 2.6 10.8 0.4 5.5 9.9 9.6 27.4 18.4 9.6 2.5 19.2 18.6 12.0 14.5 8.4 8.0 8.9 10.0 19.0 23.9 3.6 2.2 12.4 12.4 28.3 6.3 16.1 19.2 2.6 9.9 20.0 2.1 2.0 11.5 12.3 3.7 17.1 5.7 8.1 11.8 2.8 6.3 5.6 11.4 4.4 9.1 3.7 2.0 9.0 16.7 9.7 1.6 18.2 45.3 84.9 1.1 0.2 14.3 5.2 6.7 10.1 5.8 13.8 0.1 0.0 13.9 10.4 22.8 28.3 27.4 1.5 3.9 0.0 23.0 9.4 0.0 22.5 5.5 0.4 0.0 16.2 11.0 3.3 0.0 19.9 5.8 24.9 1.5 0.0 3.1 0.0 24.4 0.1 64.2 0.0 5.3 35.1 19.7 0.0 5.2 0.0 1.3 30.2 0.0 0.0 12.3 16.8 11.1 5.8 0.0 0.7 14.1 17.6 10.1 0.6 0.0 0.0 0.0 0.0 16.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.4 10.8 9.9 9.6 8.9 10.0 12.4 12.4 9.9 11.8 11.4 9.7 0.4 0.0 0.0 27.4 0.2 1.9 2.3 3.9 2.8 0.7 3.3 5.2 1.4 2.8 3.8 11.0 0.0 0.3 0.4 0.0 1.9 3.4 0.4 1.0 8.6 0.6 0.0 0.0 1.4 1.1 0.3 7.6 0.0 1.3 0.0 13.0 1.4 8.4 4.2 0.0 0.8 0.1 2.0 1.6 1.8 1.3 20.8 1.0 0.0 3.7 0.6 16.6 0.0 4.5 0.5 1.3 0.1 21.8 0.0 2.7 0.0 3.9 0.7 0.4 6.6 3.5 3.9 0.0 2.0 3.3 2.8 0.5 0.1 6.9 0.6 0.7 SOAT1 "ACAT, SOAT, STAT" ENSG00000057252 "Sterol O-acyltransferase 1" P35610 1 179293714-179358680 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins" "Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism" "Acyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in all" 4 "adrenal gland: 165.3" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009533, HPA047171" Enhanced Enhanced "Endoplasmic reticulum" NA NA "Cluster 25: Monocytes - Inflammatory response" "Cluster 17: Adrenal gland - Steroid metabolism" "Cluster 28: BEWO - Transcription regulation" "Cluster 4: Macrophages - Innate immune response" "Endoplasmic reticulum" "CAB009533: AB_633499, HPA047171: AB_2679967" "unprognostic (3.29e-2)" "unprognostic (7.60e-2)" "unprognostic (1.11e-1)" "unprognostic (3.21e-2)" "unprognostic (2.83e-1)" "unprognostic (1.81e-3)" "unprognostic (7.81e-3)" "unprognostic (3.29e-1)" "unprognostic (9.00e-2)" "unprognostic (9.84e-2)" "unprognostic (1.06e-1)" "unprognostic (5.45e-3)" "unprognostic (7.02e-3)" "unprognostic (4.67e-3)" "unprognostic (9.64e-2)" "unprognostic (4.67e-2)" "unprognostic (1.82e-1)" 14.6 165.3 4.2 18.1 5.7 17.5 8.2 5.5 6.6 13.7 9.0 13.0 12.2 11.7 6.6 4.8 17.9 20.5 5.4 3.3 6.8 12.7 14.1 20.9 15.1 10.1 6.1 10.7 27.0 13.4 6.3 19.1 8.0 27.7 14.8 10.3 39.4 9.3 4.0 5.7 12.7 16.5 8.0 15.1 16.3 11.0 6.7 8.1 9.2 3.7 13.1 11.7 4.5 12.8 74.6 34.1 27.7 41.0 104.7 56.6 147.3 35.1 61.7 76.2 88.3 35.2 82.6 42.0 53.9 64.4 92.6 26.8 88.6 20.9 81.8 48.0 18.2 19.5 26.7 36.9 42.9 33.5 7.5 45.4 13.3 89.2 75.8 32.1 33.3 50.5 42.7 21.0 120.0 15.9 35.9 10.8 13.4 11.8 11.2 44.4 35.8 24.4 66.1 45.9 8.4 21.5 54.3 22.9 20.1 32.3 24.0 22.8 31.9 89.8 43.1 99.5 78.2 29.4 115.3 35.5 35.7 17.9 170.6 55.4 53.4 1.6 26.4 34.2 25.0 12.9 24.0 24.8 48.9 10.4 23.0 23.3 39.3 37.9 23.7 8.8 33.2 32.5 4.2 5.7 5.5 6.6 3.3 6.8 10.1 6.1 8.0 8.0 6.7 12.8 14.9 22.4 33.4 11.4 16.0 9.9 10.1 11.3 8.0 7.3 7.2 4.6 8.5 30.0 14.5 20.2 14.6 17.6 21.2 16.0 1.9 42.5 29.5 34.9 32.8 16.0 59.9 9.0 12.1 25.0 51.6 21.3 18.3 34.5 14.0 9.2 15.4 24.2 70.3 6.7 15.0 25.5 22.4 77.4 41.9 14.5 32.6 74.9 23.2 29.0 55.4 7.6 19.6 10.6 7.3 20.3 13.3 25.9 17.7 26.7 8.7 14.9 46.2 14.5 26.3 9.2 13.5 6.8 9.7 5.0 5.3 8.8 24.8 44.3 15.5 8.5 SQLE ENSG00000104549 "Squalene epoxidase" Q14534 8 124998497-125022283 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA018038, HPA020762" Enhanced Uncertain Vesicles,Cytosol NA NA "Cluster 23: Antigen presenting cells - Antigen presentation" "Cluster 37: Intestine - Unknown function" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 26: Respiratory epithelial cells - Mucosal defense" "Vesicles, Cytosol" "HPA018038: AB_2669753, HPA020762: AB_2670512" "unprognostic (1.37e-2)" "unprognostic (6.26e-3)" "unprognostic (5.12e-2)" "unprognostic (9.51e-3)" "unprognostic (4.63e-1)" "prognostic unfavorable (7.42e-4)" "unprognostic (4.76e-3)" "prognostic unfavorable (4.67e-4)" "unprognostic (3.45e-2)" "unprognostic (7.21e-2)" "prognostic unfavorable (2.73e-4)" "unprognostic (7.51e-2)" "prognostic unfavorable (5.70e-4)" "unprognostic (9.71e-2)" "unprognostic (4.62e-2)" "unprognostic (1.19e-3)" "unprognostic (7.74e-3)" 8.6 31.1 17.5 19.6 27.0 23.0 22.1 26.8 24.0 30.7 25.4 21.6 31.0 16.4 9.1 78.7 18.6 10.7 7.2 18.6 24.4 17.1 72.3 30.9 17.7 47.3 27.7 14.3 10.7 22.7 16.5 47.5 35.1 25.0 18.6 17.8 19.1 7.6 1.4 49.4 14.0 12.3 27.6 9.7 21.8 59.4 21.8 14.2 10.5 1.6 29.4 14.7 46.2 34.6 135.5 51.5 301.6 87.2 91.7 154.1 30.5 34.9 106.3 46.5 84.7 70.6 192.3 92.7 49.2 43.2 186.0 101.0 127.3 192.4 53.6 77.1 268.3 265.2 32.6 181.1 134.6 31.5 74.6 106.1 201.4 138.8 113.3 29.8 51.5 64.2 153.8 174.8 38.1 223.7 109.6 39.3 125.2 92.6 35.2 47.5 55.4 126.6 329.3 153.3 93.9 47.6 71.6 226.3 74.1 96.5 60.7 81.3 50.8 19.2 66.0 22.9 31.6 31.6 69.6 126.6 32.0 93.7 33.8 1.5 6.3 0.7 10.6 10.8 5.0 16.6 6.0 9.5 15.2 17.1 8.2 8.6 0.2 12.6 12.7 10.8 7.1 7.7 17.5 27.0 26.8 24.0 18.6 24.4 47.3 27.7 35.1 27.6 21.8 34.6 13.2 60.9 97.9 21.5 34.7 22.9 64.0 199.9 16.5 41.8 35.6 27.3 6.1 31.5 129.6 53.3 50.1 99.7 20.6 81.6 7.9 60.3 21.0 95.9 23.3 39.7 31.7 22.3 14.3 83.6 133.7 35.3 51.0 80.5 41.3 77.1 9.7 127.9 61.1 148.0 18.8 58.0 126.1 10.9 30.1 13.2 23.9 22.2 21.4 13.1 91.0 24.3 8.2 20.1 77.9 98.6 38.4 10.9 30.6 118.0 17.3 3.7 123.0 61.1 26.3 12.5 42.0 179.5 128.6 69.5 89.1 217.1 21.1 171.8 35.0 114.8 SRC "ASV, c-src, SRC1" ENSG00000197122 "SRC proto-oncogene, non-receptor tyrosine kinase" P12931 20 37344685-37406050 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Transporters" "Cell adhesion, Cell cycle, Host-virus interaction, Immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Distal enterocytes: 42.0;Gastric mucus-secreting cells: 43.8;Langerhans cells: 46.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in some" "intermediate monocyte: 2.4;non-classical monocyte: 2.3" "Group enriched" "Detected in many" 6 "dendritic cells: 1.4;monocytes: 2.4" "Cell line enhanced" "Detected in many" "A549: 110.8;HBEC3-KT: 102.6;RT4: 106.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004023, HPA030875" Approved Supported "Nucleoplasm,Plasma membrane,Cell Junctions,Cytosol" NA NA 3200000 "Cluster 51: Monocytes - Innate immune response" "Cluster 71: Testis - DNA repair" "Cluster 15: RT4 - Unknown function" "Cluster 27: Mucus-secreting cells - Mucin production" "Plasma membrane, Cell Junctions" "Nucleoplasm, Cytosol" "CAB004023: AB_2106059, HPA030875: AB_2673640" "unprognostic (5.58e-2)" "unprognostic (9.83e-2)" "unprognostic (3.56e-1)" "unprognostic (4.54e-3)" "unprognostic (1.52e-1)" "unprognostic (1.54e-2)" "prognostic unfavorable (4.90e-5)" "unprognostic (3.89e-2)" "unprognostic (7.04e-2)" "unprognostic (8.13e-2)" "unprognostic (1.54e-2)" "prognostic unfavorable (1.63e-4)" "prognostic unfavorable (1.22e-4)" "unprognostic (2.33e-2)" "unprognostic (4.72e-2)" "unprognostic (3.65e-2)" "prognostic favorable (5.22e-5)" 9.7 25.3 5.7 13.3 5.2 8.4 10.1 0.4 6.2 25.1 1.5 30.3 39.8 31.9 3.2 26.1 23.8 27.9 8.8 6.4 5.5 21.4 4.3 16.1 6.3 2.6 3.4 23.6 30.8 11.1 15.9 8.1 2.2 30.8 17.1 5.5 11.8 27.4 2.4 13.0 38.8 17.2 1.7 14.2 39.9 25.2 5.0 6.1 9.8 1.5 8.1 35.6 24.6 3.0 24.6 110.8 24.9 22.6 9.3 14.7 51.6 22.0 18.9 26.3 16.6 41.9 21.5 0.7 13.4 40.2 29.9 43.5 15.1 102.6 10.3 0.1 13.7 6.2 3.9 65.9 22.0 0.3 9.3 15.7 34.2 17.3 22.8 29.4 24.3 14.2 0.6 0.2 4.4 16.7 6.0 0.8 11.7 67.3 98.8 26.5 6.6 0.7 11.0 106.3 23.1 83.6 25.0 34.5 27.2 19.1 31.1 9.0 35.8 31.4 20.9 11.7 20.1 0.3 0.8 0.3 22.1 0.1 24.0 0.0 1.6 0.0 0.0 2.4 0.0 0.1 0.0 0.0 0.5 0.1 0.0 0.0 0.0 0.3 2.3 1.4 0.0 1.0 5.7 5.2 0.4 6.2 6.4 5.5 2.6 3.4 2.2 1.7 5.0 3.0 1.0 3.2 1.7 3.3 4.1 8.2 12.5 9.5 10.8 6.5 6.2 7.5 2.2 18.6 4.7 12.9 2.1 2.3 4.9 42.0 1.9 12.2 1.8 6.4 10.7 1.4 16.8 0.4 9.5 18.7 8.3 7.2 43.8 12.4 0.0 14.8 1.1 1.6 5.7 3.3 9.1 29.2 8.2 9.4 46.3 3.3 10.8 22.8 1.8 9.4 9.7 4.4 1.0 9.0 0.6 39.1 19.2 17.3 4.3 18.0 36.7 9.3 5.6 5.2 13.1 1.8 6.7 0.3 1.1 11.2 9.1 2.3 1.0 2.9 16.9 36.6 SRD5A1 ENSG00000145545 "Steroid 5 alpha-reductase 1" P18405 5 6633427-6674386 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins" "Differentiation, Sexual differentiation" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 29.0" "Cell type enhanced" "Detected in many" "Basal squamous epithelial cells: 67.2;Hepatocytes: 103.4;Ionocytes: 52.9;Squamous epithelial cells: 139.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "basophil: 3.5" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA051402 Approved NA NA "Cluster 38: Basophils - Unknown function" "Cluster 15: Liver - Metabolism" "Cluster 20: HeLa - Mitochondria" "Cluster 61: Squamous epithelial cells - Keratinization" "HPA051402: AB_2681470" "unprognostic (1.40e-2)" "unprognostic (1.33e-2)" "unprognostic (2.30e-3)" "prognostic unfavorable (8.73e-6)" "unprognostic (9.38e-3)" "unprognostic (8.90e-2)" "unprognostic (3.78e-2)" "unprognostic (5.90e-2)" "unprognostic (3.83e-1)" "unprognostic (1.42e-1)" "unprognostic (7.70e-3)" "unprognostic (1.54e-1)" "unprognostic (1.56e-3)" "unprognostic (3.01e-1)" "unprognostic (2.24e-1)" "unprognostic (1.59e-1)" "unprognostic (5.47e-2)" 1.5 2.0 4.7 1.9 5.3 2.2 11.0 7.4 8.8 3.9 0.1 2.4 4.1 1.7 3.0 11.0 1.7 1.7 1.0 5.5 3.2 4.6 29.0 1.9 2.3 6.0 3.3 2.5 2.3 1.4 1.1 1.0 6.3 1.5 2.3 3.8 2.7 1.1 1.3 13.6 4.1 1.6 1.8 1.4 2.5 1.5 6.9 1.6 1.3 0.7 4.1 1.1 6.6 8.3 5.2 6.1 8.0 6.7 7.6 7.3 3.5 5.7 4.5 5.7 3.5 6.0 5.3 7.1 8.1 8.7 9.1 9.8 6.6 4.0 6.0 4.3 2.6 2.2 15.3 3.7 3.4 3.3 1.8 5.4 11.3 4.1 3.2 4.2 2.9 2.7 3.7 6.2 7.5 7.1 1.4 3.6 4.5 4.1 4.7 5.1 5.8 2.0 7.6 5.4 14.0 6.4 18.2 7.6 5.8 6.1 2.6 0.9 5.8 8.6 3.4 14.2 7.6 2.3 3.6 2.6 7.2 3.6 8.0 3.5 1.3 0.5 0.3 1.0 0.2 0.5 0.3 0.5 1.6 0.6 0.2 0.3 0.7 0.5 1.1 0.7 0.4 0.5 4.7 5.3 7.4 8.8 5.5 3.2 6.0 3.3 6.3 1.8 6.9 8.3 3.7 3.2 2.7 7.8 11.9 18.5 6.7 19.0 67.2 5.0 14.5 9.1 2.6 11.5 12.8 5.5 4.2 0.9 5.0 8.3 7.9 9.8 8.1 2.6 4.3 3.2 2.4 4.4 15.5 4.7 7.4 4.7 16.3 3.2 1.3 6.0 4.6 103.4 13.0 6.7 14.9 7.2 52.9 19.4 11.6 2.6 3.4 11.6 7.2 6.5 50.7 5.1 10.3 9.0 7.6 6.7 10.4 7.9 7.2 9.4 24.9 23.4 10.4 3.8 0.0 3.7 6.1 3.4 4.4 139.2 30.4 0.8 5.9 5.2 12.0 10.2 SRD5A2 ENSG00000277893 "Steroid 5 alpha-reductase 2" P31213 2 31522480-31580938 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters" "Differentiation, Sexual differentiation" Oxidoreductase "Cancer-related genes, Disease variant, FDA approved drug targets, Pseudohermaphroditism" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 15 "epididymis: 23.5;fallopian tube: 20.4;liver: 60.8;prostate: 16.8;seminal vesicle: 18.0" "Group enriched" "Detected in some" 5 "Early spermatids: 71.7;Endometrial ciliated cells: 29.6;Hepatocytes: 20.0;Late spermatids: 59.9" "Group enriched" "Detected in some" 6 "endometrial cancer: 1.1;liver cancer: 4.2;prostate cancer: 3.2" "Region enriched" "Detected in single" 11 "midbrain: 1.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in single" "RT4: 1.5" "Not detected" "Not detected" "Not detected" "Not detected" NA NA "Cluster 85: Liver - Metabolism" "Cluster 15: RT4 - Unknown function" "Cluster 34: Spermatids - Unknown function" "unprognostic (6.75e-3)" "unprognostic (2.00e-2)" "unprognostic (1.66e-1)" "unprognostic (1.08e-3)" "unprognostic (5.92e-3)" "unprognostic (3.37e-2)" "unprognostic (2.79e-3)" "unprognostic (6.56e-2)" "unprognostic (9.10e-2)" "unprognostic (1.39e-2)" "unprognostic (3.06e-2)" "unprognostic (9.79e-3)" "unprognostic (6.61e-6)" "unprognostic (4.37e-2)" "unprognostic (2.04e-1)" "unprognostic (3.85e-1)" "unprognostic (3.48e-3)" 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 23.5 0.0 20.4 0.0 0.0 0.0 0.0 0.3 60.8 0.7 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 16.8 0.0 0.1 0.0 18.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 1.4 0.0 0.2 0.0 0.0 0.0 1.6 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.1 0.0 6.2 0.0 0.0 0.0 0.0 0.0 0.6 2.8 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 71.7 29.6 0.2 0.2 0.0 0.0 0.9 0.0 0.0 1.9 0.0 0.5 0.0 0.0 0.4 20.0 0.0 0.0 1.0 0.0 0.0 0.3 0.0 59.9 0.6 0.1 0.0 3.7 0.0 0.0 0.0 0.5 0.9 0.1 0.0 1.2 0.0 0.7 0.0 0.3 7.3 0.0 0.0 0.0 0.2 1.2 0.8 0.0 0.0 0.0 0.1 0.0 0.0 8.6 SSTR1 ENSG00000139874 "Somatostatin receptor 1" P30872 14 38207904-38213067 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 10.0;intestine: 13.8;stomach 1: 21.7" "Cell type enhanced" "Detected in some" "Enteroendocrine cells: 18.1;Gastric mucus-secreting cells: 16.8;Hepatic stellate cells: 27.1;Oligodendrocyte precursor cells: 24.1;Paneth cells: 10.7;Proximal enterocytes: 11.8" "Cancer enhanced" "Detected in many" "prostate cancer: 5.3" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "BJ: 118.9;BJ hTERT+: 32.5;BJ hTERT+ SV40 Large T+: 21.4;fHDF/TERT166: 70.7;HeLa: 26.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA003207, HPA031506" Approved Uncertain Vesicles NA NA "Cluster 10: Brain - Neuronal signaling" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 17: Intestinal endocrine cells - Hormone signaling" Vesicles "HPA003207: , HPA031506: AB_2673913" "unprognostic (1.40e-1)" "unprognostic (1.37e-1)" "unprognostic (3.36e-1)" "unprognostic (2.50e-3)" "unprognostic (4.34e-2)" "unprognostic (9.90e-2)" "unprognostic (3.66e-3)" "unprognostic (1.91e-1)" "unprognostic (6.16e-3)" "unprognostic (3.20e-2)" "unprognostic (1.72e-2)" "unprognostic (9.19e-2)" "prognostic favorable (4.28e-4)" "unprognostic (2.17e-1)" "unprognostic (1.67e-1)" "unprognostic (4.71e-2)" "unprognostic (3.28e-2)" 1.0 0.3 3.9 0.3 8.8 0.0 0.9 0.5 8.7 0.8 0.0 3.5 13.8 1.0 0.4 0.3 0.9 0.4 1.0 10.0 10.0 2.0 6.8 5.2 0.0 4.7 7.0 0.8 3.6 0.0 0.9 2.6 5.6 1.0 2.3 0.3 0.3 0.4 0.7 0.3 8.2 0.5 1.4 0.6 21.7 0.1 6.1 0.0 0.3 0.9 0.0 1.8 0.7 1.7 0.0 0.0 0.0 0.0 0.3 0.2 0.0 118.9 32.5 21.4 1.8 1.2 0.0 0.0 0.0 70.7 0.0 0.2 0.0 0.0 15.4 0.0 0.0 0.0 26.7 0.1 6.3 0.0 0.0 0.2 0.0 0.0 0.3 0.4 1.5 0.0 0.0 0.0 13.9 0.0 0.0 0.0 0.1 9.6 0.2 0.0 0.0 0.1 4.7 0.0 3.4 0.0 1.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 8.8 0.5 8.7 10.0 10.0 4.7 7.0 5.6 1.4 6.1 1.7 1.7 0.0 0.0 0.3 0.0 0.3 0.0 0.0 0.0 1.5 0.2 0.0 0.8 2.8 0.0 1.8 0.0 0.0 0.0 7.8 0.0 0.0 0.0 0.0 0.0 2.4 18.1 0.0 3.9 0.8 0.0 1.0 16.8 0.0 0.0 0.0 27.1 7.2 0.0 0.0 5.5 6.9 0.0 0.0 0.0 0.2 0.0 0.0 0.0 2.8 0.0 0.0 0.0 24.1 0.3 0.2 10.7 0.0 0.1 0.1 11.8 1.9 0.0 0.1 0.0 1.0 0.6 0.0 0.1 0.1 0.1 0.1 0.0 0.2 6.2 0.0 SSTR2 ENSG00000180616 "Somatostatin receptor 2" P30874 17 73165010-73176633 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 9.0" "Cell type enhanced" "Detected in many" "Bipolar cells: 59.1;Enteroendocrine cells: 35.7;Sertoli cells: 32.9;Smooth muscle cells: 56.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in some" "basophil: 1.4" "Lineage enriched" "Detected in single" 4 "granulocytes: 1.4" "Cell line enriched" "Detected in some" 8 "SCLC-21H: 12.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA007264 Uncertain Supported Cytosol NA NA "Cluster 17: Basophils - Unknown function" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 7: SCLC-21H - Neuronal signaling" "Cluster 48: Smooth muscle cells - ECM organization" Cytosol "HPA007264: AB_1080053" "unprognostic (2.13e-3)" "unprognostic (2.61e-3)" "unprognostic (7.43e-2)" "unprognostic (9.37e-3)" "unprognostic (6.25e-2)" "unprognostic (1.52e-1)" "unprognostic (2.29e-3)" "unprognostic (7.46e-2)" "unprognostic (2.96e-1)" "unprognostic (6.55e-2)" "prognostic favorable (6.63e-4)" "unprognostic (1.07e-1)" "prognostic unfavorable (9.04e-7)" "unprognostic (1.35e-1)" "unprognostic (1.00e-1)" "unprognostic (3.71e-3)" "unprognostic (2.95e-2)" 2.5 3.6 8.4 0.9 8.9 0.9 1.7 7.2 8.7 0.5 0.3 0.8 1.4 0.7 1.6 0.4 1.1 0.6 0.8 9.0 4.3 5.3 1.4 0.4 1.1 2.2 5.1 0.3 0.7 0.3 2.9 0.1 8.6 1.4 1.1 2.2 0.7 1.4 0.7 0.6 0.9 0.8 2.6 6.1 3.1 0.3 4.8 0.5 1.1 0.2 1.3 0.9 0.7 6.8 0.2 0.3 0.3 0.7 0.1 0.1 0.4 0.1 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.1 0.9 0.3 0.0 0.1 0.1 0.4 0.6 0.3 0.8 0.3 0.0 0.2 1.5 0.1 0.0 0.1 0.0 0.2 0.0 0.4 0.2 0.7 0.0 0.3 0.2 0.8 1.0 0.1 0.4 0.4 0.4 0.3 0.2 0.3 12.5 0.9 0.2 0.2 0.1 0.5 1.5 0.2 0.1 0.2 1.4 0.4 0.2 0.5 0.2 1.0 0.2 0.3 0.2 1.4 0.2 0.3 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.3 0.2 0.2 1.2 0.2 0.2 0.2 0.1 0.1 8.4 8.9 7.2 8.7 9.0 4.3 2.2 5.1 8.6 2.6 4.8 6.8 4.9 6.4 2.7 1.6 0.5 1.1 3.2 0.0 0.0 59.1 3.7 2.5 3.6 1.5 1.3 1.8 4.2 0.7 0.9 0.1 0.0 0.2 7.0 2.1 1.7 11.3 35.7 0.0 17.1 0.0 0.7 14.3 3.1 4.9 2.5 3.0 3.9 1.0 1.0 6.7 8.4 8.2 0.0 2.4 3.0 5.7 0.9 2.4 5.4 1.9 1.7 2.4 1.0 2.0 0.7 0.4 0.1 0.7 5.8 5.4 0.6 18.0 0.7 4.8 32.9 10.0 56.0 0.9 1.9 0.3 1.1 1.0 1.4 0.6 0.5 3.3 SSTR3 ENSG00000278195 "Somatostatin receptor 3" P32745 22 37204237-37212477 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 7.6;lymphoid tissue: 11.1;testis: 7.8" "Cell type enhanced" "Detected in some" "Excitatory neurons: 2.3;Late spermatids: 2.0;Microglial cells: 1.9" "Cancer enhanced" "Detected in some" "pancreatic cancer: 1.9" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in single" "naive CD4 T-cell: 1.1" "Lineage enriched" "Detected in single" 10 "T-cells: 1.1" "Group enriched" "Detected in some" 11 "RPMI-8226: 23.3;SCLC-21H: 8.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB022647 Approved NA NA "Cluster 32: T-cells - Unknown function" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 25: RPMI-8226 - Immune response" "Cluster 63: NK-cells & T-cells - Immune response" "CAB022647: " "unprognostic (1.63e-2)" "unprognostic (5.58e-3)" "unprognostic (1.32e-2)" "unprognostic (3.18e-2)" "unprognostic (7.03e-2)" "unprognostic (6.26e-5)" "unprognostic (1.11e-1)" "unprognostic (1.72e-2)" "unprognostic (1.90e-2)" "unprognostic (8.95e-2)" "unprognostic (3.88e-3)" "unprognostic (2.93e-1)" "unprognostic (1.51e-7)" "unprognostic (1.55e-1)" "unprognostic (1.24e-2)" "unprognostic (5.61e-3)" "unprognostic (1.06e-2)" 0.1 0.3 2.2 1.0 2.2 0.4 0.0 1.2 6.4 0.0 0.0 0.2 1.3 1.1 0.0 0.0 0.1 0.0 0.0 1.9 2.2 0.1 0.0 0.0 1.8 6.8 3.5 3.3 1.8 0.0 2.6 0.0 6.7 0.0 0.2 0.3 0.2 0.0 0.0 0.0 0.5 1.0 1.2 0.6 0.2 7.8 7.6 11.1 0.0 0.0 0.9 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 23.3 0.0 0.0 8.3 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 1.1 0.9 0.0 0.0 0.0 0.0 0.1 0.2 2.2 2.2 1.2 6.4 1.9 2.2 6.8 3.5 6.7 1.2 7.6 2.3 0.0 0.0 0.0 0.3 0.7 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.6 0.4 0.0 0.0 SSTR4 ENSG00000132671 "Somatostatin receptor 4" P31391 20 23035312-23039237 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in single" 9 "brain: 1.0" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in single" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA064252 Uncertain NA NA "Cluster 10: Brain - Neuronal signaling" "HPA064252: AB_2685227" 0.0 0.0 0.6 0.0 0.6 0.0 0.0 0.5 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.6 0.5 0.8 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SSTR5 ENSG00000162009 "Somatostatin receptor 5" P35346 16 1078781-1080142 "FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "heart muscle: 6.9;kidney: 2.9;pituitary gland: 7.3" "Not detected" "Not detected" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in single" "hypothalamus: 1.5" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 16 "Hep G2: 15.4;PC-3: 54.7" "Group enriched" "Detected in some" 5 "basal ganglia: 4.1;hypothalamus: 2.3" "Low region specificity" "Detected in many" HPA066503 Supported "Plasma membrane" NA NA "Cluster 44: Heart - Cardiac muscle contraction" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 43: Cardiomyocytes - Nuclear processes" "Plasma membrane" "HPA066503: AB_2685679" "unprognostic (2.16e-2)" "unprognostic (7.31e-2)" "unprognostic (3.69e-2)" "unprognostic (2.39e-2)" "unprognostic (2.14e-1)" "unprognostic (9.89e-3)" "unprognostic (1.72e-2)" "unprognostic (1.72e-2)" "unprognostic (2.06e-1)" "unprognostic (2.05e-1)" "unprognostic (4.09e-2)" 0.0 2.5 0.1 0.0 0.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 6.9 0.3 1.5 2.9 0.0 0.0 0.0 0.2 0.3 0.0 0.3 0.0 7.3 0.0 0.1 0.7 0.0 0.2 1.0 0.1 0.2 0.0 0.2 0.0 0.1 0.0 0.3 0.1 0.1 0.0 0.0 0.4 0.0 0.2 0.2 0.2 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 2.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 15.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 54.7 0.0 2.1 0.6 0.0 2.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.4 0.3 1.5 0.2 0.3 0.1 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 SV2A "KIAA0736, SV2" ENSG00000159164 "Synaptic vesicle glycoprotein 2A" Q7L0J3 1 149903318-149917844 "FDA approved drug targets, Predicted membrane proteins" "Neurotransmitter transport, Transport" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 128.2;parathyroid gland: 48.4" "Cell type enhanced" "Detected in many" "Bipolar cells: 111.9;Excitatory neurons: 63.4;Horizontal cells: 95.9;Inhibitory neurons: 107.2" "Cancer enriched" "Detected in many" 6 "glioma: 27.8" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "NTERA-2: 66.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002226, HPA007863" Enhanced Approved Cytosol NA NA "Cluster 35: T-regs - Unknown function" "Cluster 10: Brain - Neuronal signaling" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 62: Horizontal cells - Visual perception" Cytosol "CAB002226: AB_564144, HPA007863: AB_1080135" "unprognostic (8.05e-3)" "unprognostic (3.86e-3)" "unprognostic (2.24e-1)" "unprognostic (5.39e-2)" "unprognostic (2.66e-1)" "unprognostic (2.02e-1)" "unprognostic (6.24e-2)" "unprognostic (2.69e-1)" "unprognostic (1.40e-1)" "unprognostic (2.06e-1)" "unprognostic (9.00e-3)" "unprognostic (1.00e-1)" "prognostic unfavorable (3.22e-4)" "unprognostic (1.44e-2)" "unprognostic (9.86e-2)" "unprognostic (1.95e-2)" "unprognostic (4.81e-3)" 1.5 8.9 59.2 2.9 64.7 6.0 1.6 30.2 128.2 6.9 0.0 4.5 1.5 8.4 23.4 1.6 4.8 3.3 1.5 65.1 61.6 1.7 0.5 2.0 2.1 68.2 40.2 3.5 1.4 48.4 22.9 1.4 61.2 4.2 1.8 38.6 1.3 3.7 0.5 0.9 3.0 8.0 14.1 1.6 2.5 1.1 48.9 3.8 4.4 0.5 1.7 3.1 3.9 67.5 0.3 0.0 26.0 0.1 2.6 7.4 2.8 11.2 38.8 32.6 46.7 0.8 1.2 0.3 9.9 16.9 34.3 0.6 0.3 2.4 27.9 0.1 6.2 35.2 2.0 2.0 24.5 0.3 0.5 16.7 0.2 52.3 3.9 36.2 2.9 31.7 0.4 35.8 21.8 0.3 34.8 1.7 66.3 0.0 0.2 12.0 16.4 0.7 0.2 0.9 54.2 43.8 0.1 0.4 25.6 24.6 0.4 21.4 0.2 30.1 29.9 1.2 41.3 0.2 0.5 0.2 53.0 0.3 12.3 0.4 0.1 0.0 0.3 0.0 0.3 0.1 0.3 0.2 0.0 0.2 0.1 0.4 0.3 0.3 0.0 0.1 0.6 0.1 59.2 64.7 30.2 128.2 65.1 61.6 68.2 40.2 61.2 14.1 48.9 67.5 0.8 0.0 1.1 12.4 0.3 0.1 1.9 0.7 4.6 111.9 0.7 4.2 0.8 1.5 0.1 0.0 4.2 0.3 0.7 0.3 0.0 0.1 0.6 0.4 4.6 2.4 4.2 2.1 63.4 0.4 0.6 3.3 1.5 1.3 0.0 10.9 7.5 0.1 0.3 95.9 107.2 0.4 0.0 0.0 0.9 0.2 0.0 0.3 0.0 7.5 0.0 22.9 0.0 28.1 15.7 0.2 0.1 5.7 0.5 0.9 0.1 0.1 0.9 16.1 0.0 2.7 4.9 1.3 0.9 0.4 0.4 0.4 2.7 3.0 0.5 0.7 SYK ENSG00000165025 "Spleen associated tyrosine kinase" P43405 9 90801787-90898549 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Adaptive immunity, Angiogenesis, Host-virus interaction, Immunity, Innate immunity" "Kinase, Transferase, Tyrosine-protein kinase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 73.8;parathyroid gland: 87.6" "Cell type enhanced" "Detected in many" "B-cells: 91.3;Hofbauer cells: 73.1;Kupffer cells: 96.7;Macrophages: 95.2;Microglial cells: 114.3;monocytes: 92.5;Plasma cells: 83.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 13 "classical monocyte: 77.3;eosinophil: 83.5;intermediate monocyte: 64.0;memory B-cell: 74.5;myeloid DC: 85.1;naive B-cell: 58.4;neutrophil: 112.1;NK-cell: 30.0;non-classical monocyte: 60.2;plasmacytoid DC: 63.2" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in many" "Daudi: 125.8;HEL: 72.8;HL-60: 101.6;HMC-1: 64.1;REH: 84.4;THP-1: 76.8;U-698: 58.8;U-937: 70.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA001384, CAB007773" Enhanced Approved "Vesicles,Plasma membrane,Cytosol" No NA 290000 "Cluster 5: Granulocytes - Unknown function" "Cluster 34: Non-specific - Transcription" "Cluster 3: HMC-1 - Innate immune response" "Cluster 57: B-cells - Immune response" "Plasma membrane, Cytosol" Vesicles "CAB007773: AB_562232, HPA001384: AB_1080144" "unprognostic (1.01e-1)" "unprognostic (5.45e-2)" "unprognostic (2.10e-1)" "unprognostic (2.69e-2)" "unprognostic (2.31e-1)" "unprognostic (7.92e-2)" "unprognostic (1.06e-1)" "unprognostic (1.34e-1)" "unprognostic (6.41e-2)" "unprognostic (1.78e-2)" "unprognostic (7.20e-2)" "unprognostic (9.93e-2)" "unprognostic (2.55e-3)" "unprognostic (8.77e-2)" "unprognostic (5.36e-3)" "unprognostic (3.41e-2)" "unprognostic (1.06e-2)" 7.4 4.6 4.1 42.5 4.1 50.9 6.8 4.5 4.9 7.7 4.2 20.1 30.8 4.1 16.1 17.5 17.0 12.9 2.9 3.8 5.0 11.2 4.5 20.6 61.8 7.1 5.8 1.7 9.1 87.6 2.4 12.0 7.0 3.8 20.5 0.7 8.4 4.2 1.0 9.9 36.3 9.3 6.6 40.3 19.1 6.9 7.1 49.7 25.6 2.4 73.8 17.5 8.3 9.8 22.7 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 14.3 125.8 3.5 0.0 4.2 19.1 2.7 10.2 0.0 0.0 17.0 72.8 0.0 0.0 0.0 101.6 64.1 0.0 14.0 0.0 1.4 0.0 0.0 15.5 2.0 9.9 0.0 15.4 0.1 44.4 0.7 47.0 0.0 84.4 0.1 34.6 2.6 18.6 6.4 5.7 0.1 8.7 0.1 0.3 7.9 76.8 0.2 0.0 0.4 0.1 0.1 0.2 0.0 58.8 0.0 70.3 0.0 5.3 77.3 83.5 0.3 64.0 0.3 74.5 0.2 0.2 85.1 58.4 0.2 0.1 112.1 30.0 60.2 63.2 0.1 44.6 4.1 4.1 4.5 4.9 3.8 5.0 7.1 5.8 7.0 6.6 7.1 9.8 0.5 12.8 20.2 0.0 91.3 3.4 3.7 8.7 12.0 1.4 6.3 2.8 1.6 14.3 12.8 14.7 0.0 1.3 70.4 16.5 15.6 15.0 7.1 10.7 1.0 2.1 10.3 37.9 0.4 12.5 2.6 2.1 22.4 12.6 43.6 0.0 3.3 1.0 73.1 0.0 0.7 24.4 0.0 96.7 28.8 6.2 0.6 95.2 12.4 114.3 92.5 0.0 62.8 1.5 0.5 18.2 25.1 0.0 83.1 2.5 31.4 0.4 10.4 0.2 6.6 0.7 2.3 0.8 0.7 30.4 5.7 1.4 8.3 0.0 31.1 8.0 TAAR1 "TA1, TAR1, TRAR1" ENSG00000146399 "Trace amine associated receptor 1" Q96RJ0 6 132644898-132646051 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enriched" "Detected in some" 5 "stomach 1: 6.2" "Not detected" "Not detected" "Cancer enhanced" "Detected in single" "cervical cancer: 1.1" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA055614 Approved NA NA "Cluster 4: Stomach - Digestion" "HPA055614: AB_2682862" "unprognostic (2.19e-2)" "unprognostic (1.87e-1)" "unprognostic (1.47e-1)" "unprognostic (2.68e-2)" 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.2 0.1 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 6.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 TACR1 "NK1R, NKIR, SPR, TAC1R" ENSG00000115353 "Tachykinin receptor 1" P25103 2 75046463-75199520 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 10.0" "Cell type enriched" "Detected in some" 7 "Inhibitory neurons: 83.2" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in single" 23 "basophil: 2.2" "Lineage enriched" "Detected in single" 23 "granulocytes: 2.2" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA074573 Enhanced NA NA "Cluster 34: Basophils - Unknown function" "Cluster 57: Non-specific - Angiogenesis" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA074573: AB_2686701" "unprognostic (5.74e-4)" "unprognostic (2.41e-3)" "unprognostic (1.46e-2)" "unprognostic (1.08e-1)" "unprognostic (1.24e-1)" "unprognostic (8.62e-3)" "unprognostic (1.10e-1)" "unprognostic (3.33e-2)" "unprognostic (4.38e-2)" "unprognostic (1.46e-1)" "unprognostic (2.14e-3)" "unprognostic (1.63e-2)" "unprognostic (5.91e-4)" "unprognostic (1.03e-2)" "unprognostic (2.75e-1)" "unprognostic (1.06e-1)" "unprognostic (2.76e-2)" 6.2 0.3 1.7 0.7 3.6 0.0 5.0 0.0 7.2 4.9 0.0 1.0 0.2 3.0 0.7 1.2 2.9 1.1 0.1 0.6 3.7 0.7 0.0 0.8 1.3 2.2 4.3 0.6 0.1 0.2 0.1 0.5 10.0 1.5 0.5 1.0 1.5 1.0 0.3 4.0 0.7 2.7 0.8 0.0 0.5 0.0 2.5 1.1 0.5 0.3 1.3 2.0 2.7 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.1 0.6 0.5 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 3.6 0.0 7.2 0.6 3.7 2.2 4.3 10.0 0.8 2.5 0.9 7.6 0.0 0.0 1.0 0.0 2.5 0.0 0.0 0.0 1.0 0.3 0.3 1.4 0.0 0.0 0.0 2.1 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 11.8 0.0 0.0 4.5 0.0 0.2 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 83.2 0.2 0.0 0.0 2.6 0.9 0.0 0.0 7.2 2.8 0.0 0.4 0.0 3.5 4.2 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 3.3 0.0 0.2 0.2 0.0 0.0 0.1 1.8 0.1 0.1 0.0 0.0 0.2 TEK "CD202b, TIE-2, TIE2, VMCM, VMCM1" ENSG00000120156 "TEK receptor tyrosine kinase" Q02763 9 27109141-27230174 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins" Angiogenesis "Kinase, Receptor, Transferase, Tyrosine-protein kinase" "Cancer-related genes, Disease variant, FDA approved drug targets, Glaucoma" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 46.3" "Group enriched" "Detected in many" 10 "Adipocytes: 70.8;Endothelial cells: 73.9;Hepatic stellate cells: 122.0;Microglial cells: 38.4;Oligodendrocyte precursor cells: 137.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "HUVEC TERT2: 90.9;NTERA-2: 45.2;TIME: 99.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010359, HPA073265" Approved Supported "Plasma membrane,Centriolar satellite" "Secreted to blood" NA NA 7750000 13000000 "Cluster 9: Neutrophils - Innate immune response" "Cluster 82: Adipose tissue - ECM organization" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "Plasma membrane" "Centriolar satellite" "CAB010359: AB_2203226, HPA073265: AB_2686592" "unprognostic (2.24e-1)" "unprognostic (1.74e-1)" "unprognostic (5.55e-2)" "unprognostic (1.83e-2)" "unprognostic (1.68e-1)" "unprognostic (1.26e-3)" "prognostic favorable (2.31e-5)" "unprognostic (7.48e-2)" "unprognostic (1.72e-2)" "unprognostic (1.41e-1)" "unprognostic (5.58e-2)" "unprognostic (2.72e-1)" "prognostic favorable (7.81e-4)" "unprognostic (7.50e-3)" "unprognostic (6.87e-3)" "unprognostic (1.83e-1)" "unprognostic (5.24e-3)" 20.1 9.1 8.1 5.8 7.0 0.2 14.0 6.1 8.4 9.3 4.3 5.0 3.7 12.4 2.3 5.3 6.7 11.2 16.8 7.1 6.8 23.0 10.5 28.8 3.7 7.2 6.6 3.5 3.5 4.4 3.0 46.3 7.6 3.8 5.4 0.7 3.1 6.2 10.5 2.8 5.5 12.7 6.8 28.8 4.0 1.4 9.4 1.8 9.1 22.9 2.8 6.9 3.9 6.8 0.3 0.0 3.5 0.0 0.4 5.6 0.1 3.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.0 2.4 0.0 1.6 0.0 0.0 1.8 0.0 2.2 0.8 0.1 90.9 0.0 0.0 0.0 0.7 0.0 0.0 0.0 45.2 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 18.3 0.0 0.0 99.1 0.0 0.5 9.1 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 8.1 7.0 6.1 8.4 7.1 6.8 7.2 6.6 7.6 6.8 9.4 6.8 70.8 3.2 1.3 1.3 0.4 1.5 0.0 0.0 0.0 0.0 0.3 0.5 8.6 0.0 0.6 1.8 0.0 0.4 0.4 0.0 0.0 0.0 0.6 0.6 0.8 73.9 0.0 2.7 4.3 0.0 2.8 4.2 0.0 0.7 0.0 0.3 122.0 1.3 0.3 0.0 5.0 0.0 0.0 6.7 2.2 0.9 0.6 0.4 0.0 38.4 0.0 0.1 0.0 137.7 2.1 1.3 0.0 0.4 0.0 0.2 0.0 0.1 0.0 0.2 0.0 1.6 1.9 0.1 0.4 0.3 1.3 1.4 0.5 1.8 0.0 0.0 TFPI "EPI, LACI, TFI, TFPI1" ENSG00000003436 "Tissue factor pathway inhibitor" P10646 2 187464230-187565760 "Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins" "Blood coagulation, Hemostasis" "Protease inhibitor, Serine protease inhibitor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 272.3;placenta: 191.2" "Cell type enhanced" "Detected in many" "Extravillous trophoblasts: 2284.2;Hepatic stellate cells: 872.4;Syncytiotrophoblasts: 879.2" "Cancer enhanced" "Detected in all" "liver cancer: 22.0" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 4 "basophil: 3.3;neutrophil: 1.3;plasmacytoid DC: 2.7" "Group enriched" "Detected in many" 6 "dendritic cells: 2.7;granulocytes: 3.3" "Cell line enhanced" "Detected in many" "HHSteC: 386.2;HUVEC TERT2: 742.5;LHCN-M2: 459.9;TIME: 451.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "HPA005575, CAB020842" Supported "Secreted to blood" NA NA 58100000 87000000 "Cluster 11: Basophils - Unknown function" "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 38: Extravillous trophoblasts - Unknown function" "CAB020842: , HPA005575: AB_1080290" "unprognostic (8.75e-2)" "prognostic unfavorable (2.02e-4)" "unprognostic (7.95e-2)" "unprognostic (4.99e-2)" "unprognostic (2.32e-2)" "unprognostic (1.48e-1)" "unprognostic (3.05e-1)" "unprognostic (5.63e-2)" "unprognostic (3.86e-3)" "unprognostic (9.22e-2)" "unprognostic (2.43e-2)" "unprognostic (2.72e-2)" "unprognostic (7.05e-2)" "unprognostic (3.39e-3)" "unprognostic (4.05e-2)" "unprognostic (4.49e-2)" "unprognostic (5.81e-2)" 67.5 12.6 2.6 20.5 3.4 8.2 52.3 4.9 5.8 41.5 7.4 23.3 52.5 25.7 18.5 33.3 35.6 57.6 38.5 4.1 2.2 56.3 272.3 126.7 33.3 6.8 2.5 26.5 25.0 7.1 6.1 191.2 3.9 15.7 27.4 4.5 15.0 12.8 26.8 19.8 41.8 30.7 3.7 20.7 19.2 6.9 3.6 11.1 36.2 42.8 17.7 52.9 29.8 3.2 38.9 24.7 29.3 0.8 224.3 267.7 0.7 66.0 156.3 42.7 65.1 22.6 192.6 0.7 27.3 52.7 74.7 2.1 15.9 3.6 110.3 1.9 7.6 12.3 73.8 197.3 386.2 0.9 0.4 123.1 5.1 232.8 61.9 93.4 742.5 0.7 31.2 0.7 459.9 35.4 4.6 0.7 22.9 0.8 68.8 0.3 40.2 0.3 72.9 1.4 0.3 0.5 56.7 2.1 3.5 95.8 0.7 0.2 451.4 30.6 29.0 61.4 13.5 1.1 1.7 0.4 239.4 0.6 35.4 3.3 0.2 0.2 0.2 0.1 0.1 0.4 0.1 0.0 0.2 0.5 0.2 0.2 1.3 0.5 0.1 2.7 0.1 2.3 2.6 3.4 4.9 5.8 4.1 2.2 6.8 2.5 3.9 3.7 3.6 3.2 99.2 35.3 335.5 1.3 4.4 20.8 2.9 33.5 4.6 0.6 16.1 9.1 7.0 173.0 102.5 38.6 0.0 59.5 4.8 0.5 13.7 140.0 41.5 7.3 74.2 287.1 105.0 43.1 0.7 273.1 2284.2 283.0 12.2 5.3 13.9 1.5 872.4 382.1 50.2 1.7 0.2 11.3 158.7 63.7 41.3 15.2 171.8 21.9 26.6 13.1 33.7 33.1 1.0 0.0 0.1 157.6 34.1 70.0 9.5 8.0 36.6 109.4 45.2 1.1 216.9 141.2 127.8 2.7 0.5 10.2 18.5 879.2 8.1 30.6 18.5 16.7 TFR2 "HFE3, TFRC2" ENSG00000106327 "Transferrin receptor 2" Q9UP52 7 100620416-100642779 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Transporters" Receptor "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 15 "liver: 346.1" "Group enriched" "Detected in some" 13 "Erythroid cells: 152.8;Hepatocytes: 455.7" "Cancer enriched" "Detected in many" 70 "liver cancer: 136.2" "Not detected" "Not detected" "Group enriched" "Detected in some" 22 "basophil: 2.5;eosinophil: 1.9" "Lineage enriched" "Detected in single" 25 "granulocytes: 2.5" "Group enriched" "Detected in some" 11 "HEL: 69.7;HMC-1: 92.7;K-562: 65.8" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB016255, HPA017171, HPA073125" Enhanced Approved "Golgi apparatus" NA NA 410000 "Cluster 46: Basophils - DNA binding" "Cluster 60: Liver - Hemostasis & Lipid metabolism" "Cluster 1: K-562 - Erythropoiesis" "Cluster 15: Hepatocytes - Hemostasis" "Golgi apparatus" "CAB016255: AB_628395, HPA017171: , HPA073125: " "unprognostic (4.18e-2)" "unprognostic (1.97e-2)" "unprognostic (2.74e-1)" "unprognostic (1.04e-1)" "unprognostic (1.26e-2)" "unprognostic (4.13e-2)" "prognostic favorable (2.48e-4)" "unprognostic (2.29e-2)" "unprognostic (4.49e-2)" "unprognostic (9.26e-2)" "unprognostic (1.93e-1)" "unprognostic (2.90e-1)" "unprognostic (1.18e-9)" "unprognostic (6.51e-2)" "unprognostic (1.68e-1)" "unprognostic (3.28e-1)" "unprognostic (8.18e-2)" 0.0 0.1 0.0 0.0 0.0 22.5 0.0 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.1 0.0 0.0 346.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 6.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 69.7 0.0 7.2 0.0 1.6 92.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 65.8 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.8 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 2.5 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.3 2.1 0.3 0.9 0.4 0.0 8.5 0.3 0.6 1.2 10.0 0.8 0.0 8.4 0.1 1.7 0.1 0.0 0.4 5.8 0.1 0.6 1.2 0.0 152.8 5.4 0.2 1.1 0.5 1.5 0.2 0.0 0.2 7.1 455.7 0.3 21.9 5.4 0.3 0.0 8.6 1.7 8.4 0.0 0.4 0.0 1.0 0.2 0.4 6.2 1.5 0.7 0.1 0.1 0.0 0.4 0.6 0.1 0.1 0.3 1.9 0.0 0.4 0.7 0.7 2.9 0.2 0.6 0.1 2.6 0.1 0.6 0.5 TFRC "CD71, p90, TFR1" ENSG00000072274 "Transferrin receptor" P02786 3 196027183-196082096 "Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters" "Endocytosis, Host-virus interaction" "Host cell receptor for virus entry, Receptor, Transducer" "Cancer-related genes, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 254.5" "Cell type enhanced" "Detected in many" "Erythroid cells: 556.4;Syncytiotrophoblasts: 502.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "HDLM-2: 860.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000153, HPA028598" Enhanced Supported Endosomes,Lysosomes "Secreted to blood" NA NA 1310000000 38000000 "Cluster 27: Non-specific - Gene expression" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 36: HEL - Hemostasis" "Cluster 6: Erythroid cells - Oxygen transport" "Endosomes, Lysosomes" "CAB000153: AB_2533029, HPA028598: AB_10601599" "unprognostic (2.95e-2)" "prognostic unfavorable (3.67e-4)" "unprognostic (2.55e-1)" "unprognostic (1.48e-2)" "unprognostic (6.75e-2)" "unprognostic (7.88e-3)" "prognostic unfavorable (1.15e-4)" "unprognostic (6.92e-2)" "unprognostic (3.30e-3)" "unprognostic (4.35e-2)" "unprognostic (1.34e-2)" "unprognostic (1.14e-2)" "unprognostic (3.63e-3)" "unprognostic (3.65e-2)" "unprognostic (1.19e-2)" "prognostic unfavorable (2.96e-4)" "unprognostic (2.62e-2)" 44.6 28.7 21.6 63.4 18.3 254.5 20.2 18.5 32.3 31.3 15.7 77.2 35.9 23.8 11.1 36.0 25.9 24.9 31.0 21.9 19.0 26.4 27.8 78.0 23.0 24.2 19.9 93.9 15.9 44.8 13.1 103.2 26.3 13.2 55.6 47.3 15.7 13.4 76.2 21.8 32.1 31.5 20.8 15.5 21.4 21.6 25.3 22.0 20.1 68.7 28.1 68.5 17.4 20.7 175.3 155.0 69.8 142.1 151.7 87.3 438.7 242.5 183.7 168.1 276.3 384.6 156.6 178.5 446.3 91.0 363.5 261.8 243.3 81.1 204.2 860.4 82.4 677.4 120.2 179.2 119.4 561.8 130.4 99.1 78.6 144.5 129.0 47.8 56.9 95.6 287.3 164.1 132.8 161.7 185.8 116.8 214.9 228.6 314.0 97.3 103.9 214.1 148.3 435.3 159.3 65.9 234.4 613.9 55.2 115.9 595.0 115.8 72.5 198.4 159.7 175.3 369.7 46.3 387.8 276.7 232.3 149.2 122.3 0.0 1.6 2.2 2.2 7.3 1.4 5.1 2.4 1.5 3.5 3.1 2.1 1.7 0.2 1.9 13.2 7.1 6.4 2.1 21.6 18.3 18.5 32.3 21.9 19.0 24.2 19.9 26.3 20.8 25.3 20.7 25.4 44.8 32.1 43.1 46.6 60.3 37.2 33.6 21.1 53.1 37.1 34.9 103.0 41.5 38.8 20.2 148.0 122.5 53.2 156.6 0.0 49.4 3.5 35.3 20.3 23.6 56.1 556.4 24.7 41.8 25.3 32.4 77.5 56.1 23.4 40.2 8.6 93.2 73.4 13.5 28.3 67.8 22.4 37.1 77.6 5.3 11.5 161.7 17.8 44.0 49.4 22.0 9.2 11.6 8.2 52.0 50.8 8.6 42.1 25.6 48.3 13.1 32.1 44.4 26.3 36.3 29.3 23.8 18.2 51.3 35.8 502.7 42.6 16.6 103.5 23.7 TH DYT5b ENSG00000180176 "Tyrosine hydroxylase" P07101 11 2163929-2171815 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Catecholamine biosynthesis, Neurotransmitter biosynthesis" "Monooxygenase, Oxidoreductase" "Disease variant, Dystonia, FDA approved drug targets, Parkinson disease, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 69 "adrenal gland: 196.6;brain: 270.9" "Cell type enhanced" "Detected in some" "Endometrial stromal cells: 9.0;Extravillous trophoblasts: 12.4;Leydig cells: 3.4;Syncytiotrophoblasts: 2.2" "Cancer enriched" "Detected in some" 5 "urothelial cancer: 4.0" "Group enriched" "Detected in many" 5 "midbrain: 192.4;pons: 270.9" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 30 "PC-3: 60.8;SK-BR-3: 21.0" "Region enhanced" "Detected in many" "olfactory bulb: 178.8" "Region enriched" "Detected in many" 20 "midbrain: 594.4" "CAB002522, HPA013768, HPA014010, HPA061003, CAB072340" Enhanced Supported Approved Cytosol NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 19: HEK293 & PC-3 - Transcription regulation" "Cluster 38: Extravillous trophoblasts - Unknown function" Cytosol "CAB002522: AB_564047, CAB072340: , HPA013768: , HPA014010: , HPA061003: AB_2630374" "unprognostic (1.31e-1)" "unprognostic (1.30e-1)" "unprognostic (9.08e-2)" "unprognostic (1.75e-4)" "unprognostic (8.82e-3)" "unprognostic (5.88e-2)" "unprognostic (1.93e-1)" "unprognostic (1.74e-3)" "unprognostic (3.83e-2)" "unprognostic (4.39e-4)" "unprognostic (4.97e-1)" "unprognostic (3.61e-2)" "unprognostic (1.92e-1)" "unprognostic (1.60e-1)" "unprognostic (2.43e-1)" "unprognostic (2.70e-2)" "unprognostic (2.18e-2)" 3.3 196.6 1.9 0.1 3.0 0.0 0.0 0.2 1.3 0.6 0.2 0.1 0.0 0.5 0.1 0.7 0.2 0.4 0.1 1.3 46.5 0.4 0.4 0.0 0.0 13.9 192.4 0.7 0.2 0.0 1.7 0.1 270.9 0.3 0.0 0.1 0.1 0.0 0.0 0.8 0.5 0.0 0.8 0.2 0.3 0.5 14.6 0.0 0.0 0.0 0.0 1.4 1.5 1.6 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.6 60.8 0.0 0.0 0.0 0.1 0.1 1.1 0.2 0.0 21.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 3.0 0.2 1.3 1.3 46.5 13.9 192.4 270.9 0.8 14.6 1.6 0.3 0.0 0.0 0.0 0.5 0.1 0.1 0.2 0.0 0.0 0.0 0.1 0.9 0.0 0.2 1.8 0.0 0.2 0.0 0.1 0.0 0.1 0.1 0.4 9.0 0.4 0.0 0.0 0.1 0.0 12.4 0.4 0.0 0.3 0.0 0.0 1.1 0.2 0.5 0.0 0.3 0.1 0.0 0.0 0.3 0.2 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.7 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 1.6 0.0 0.0 2.2 0.1 0.3 0.2 0.2 THRA "AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3" ENSG00000126351 "Thyroid hormone receptor alpha" P10827 17 40058290-40093867 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Congenital hypothyroidism, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 236.7" "Cell type enhanced" "Detected in many" "Muller glia cells: 95.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009654, CAB023349" Approved Supported Cytosol NA NA "Cluster 15: NK-cells - Transcription" "Cluster 57: Non-specific - Angiogenesis" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 50: Fibroblasts - ECM organization" Cytosol "CAB023349: AB_619577, HPA009654: AB_1854603" "unprognostic (2.75e-2)" "unprognostic (2.20e-1)" "unprognostic (6.64e-2)" "unprognostic (4.22e-2)" "unprognostic (8.78e-2)" "unprognostic (1.64e-1)" "unprognostic (3.41e-3)" "prognostic favorable (1.84e-4)" "unprognostic (1.47e-1)" "unprognostic (5.47e-2)" "unprognostic (7.85e-2)" "unprognostic (2.65e-2)" "prognostic favorable (6.05e-8)" "unprognostic (3.05e-1)" "unprognostic (1.35e-1)" "unprognostic (4.21e-1)" "unprognostic (1.88e-3)" 40.7 43.7 199.1 12.0 236.7 23.0 38.9 159.3 218.3 67.5 108.5 67.2 31.1 49.9 22.0 19.1 57.7 25.8 63.8 189.7 181.8 34.1 10.2 32.2 9.7 162.4 172.1 90.7 31.3 29.9 50.0 17.1 149.4 34.5 18.8 35.4 27.3 35.5 90.7 50.2 36.2 34.6 166.5 13.9 48.0 18.7 183.6 12.8 32.6 52.8 6.3 45.0 45.9 179.9 4.9 37.6 11.5 28.9 77.4 28.2 4.2 19.3 23.0 19.6 18.2 31.5 27.2 5.6 31.3 37.6 8.7 11.4 22.6 11.7 10.6 2.1 21.6 10.4 44.5 13.4 26.0 16.9 11.2 45.1 9.5 18.4 7.1 45.4 26.6 16.7 21.2 5.2 16.5 7.1 22.8 27.4 10.6 24.6 11.8 32.1 22.7 27.6 6.4 3.3 19.5 17.7 14.8 23.3 33.7 17.5 27.3 19.5 18.7 19.4 18.9 17.7 5.9 11.9 9.0 3.4 12.0 19.1 10.6 0.2 0.3 1.9 2.0 0.1 0.8 0.2 0.8 1.2 0.3 0.4 1.4 1.7 1.1 2.1 0.3 0.6 1.0 0.7 199.1 236.7 159.3 218.3 189.7 181.8 162.4 172.1 149.4 166.5 183.6 179.9 32.2 19.2 7.3 27.1 6.2 10.6 28.1 3.3 31.3 76.4 19.6 21.2 45.4 38.6 2.7 33.1 20.9 0.8 16.5 37.9 50.9 12.3 1.1 20.5 29.5 20.8 25.1 17.9 19.1 14.8 1.4 36.8 29.0 12.1 14.0 23.1 24.7 13.8 11.6 62.2 24.2 22.6 6.1 10.6 5.1 2.7 51.6 8.6 19.6 8.4 5.1 95.2 37.0 15.6 26.5 6.9 14.6 49.7 3.9 17.2 58.8 29.9 7.5 22.5 19.7 84.7 44.4 0.3 27.3 14.6 10.4 0.3 18.1 16.3 39.9 13.8 THRB "ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2" ENSG00000151090 "Thyroid hormone receptor beta" P10828 3 24117153-24495756 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Deafness, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Astrocytes: 199.2;Cone photoreceptor cells: 164.7;Excitatory neurons: 688.0;Inhibitory neurons: 631.3;Oligodendrocyte precursor cells: 329.2" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in many" 6 "amygdala: 7.7;basal ganglia: 15.1;cerebral cortex: 17.6;hippocampal formation: 18.5;white matter: 6.7" "Group enriched" "Detected in some" 5 "basophil: 7.2;naive B-cell: 2.2" "Group enriched" "Detected in many" 15 "B-cells: 2.2;granulocytes: 7.2" "Cell line enhanced" "Detected in many" "K-562: 45.6;RT4: 32.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002008, CAB002009, HPA061035" Approved Supported "Nuclear bodies" NA NA "Cluster 34: Basophils - Unknown function" "Cluster 8: Non-specific - Mitochondria" "Cluster 1: K-562 - Erythropoiesis" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "Nuclear bodies" "CAB002008: , CAB002009: , HPA061035: AB_2684422" "unprognostic (1.82e-1)" "unprognostic (4.22e-1)" "unprognostic (2.83e-1)" "unprognostic (2.20e-6)" "unprognostic (3.37e-1)" "unprognostic (2.66e-2)" "unprognostic (1.93e-2)" "unprognostic (1.73e-1)" "unprognostic (5.78e-3)" "unprognostic (2.95e-2)" "unprognostic (4.43e-1)" "unprognostic (2.01e-2)" "prognostic favorable (9.46e-8)" "unprognostic (1.32e-3)" "unprognostic (6.75e-2)" "unprognostic (2.73e-2)" "unprognostic (3.34e-2)" 11.1 4.9 7.7 1.7 15.1 1.0 10.0 0.0 17.6 2.8 0.0 11.7 2.5 7.0 1.8 6.4 3.8 2.2 7.7 18.5 2.0 12.1 20.1 5.0 1.5 0.0 0.0 2.3 9.0 7.3 15.7 4.4 0.0 7.5 8.4 20.1 6.2 7.7 23.6 6.8 3.9 7.0 0.0 5.7 8.3 0.7 1.4 3.6 4.4 27.0 1.4 8.9 4.2 6.7 10.3 3.1 0.6 0.1 17.4 8.8 6.7 0.5 2.1 1.5 3.2 6.7 9.7 0.1 2.5 6.8 1.1 15.4 10.8 3.9 1.0 0.0 6.4 0.0 2.5 8.9 0.5 0.0 0.0 16.0 7.3 0.2 1.2 3.5 0.0 0.0 45.6 0.0 1.5 0.6 0.0 0.0 6.5 0.6 3.4 0.0 0.0 0.0 10.0 32.7 1.7 0.6 16.5 8.9 0.2 4.6 9.7 0.0 0.9 3.9 3.0 0.0 1.9 0.1 0.5 0.0 2.7 0.1 0.3 7.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 2.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 2.2 7.7 15.1 0.0 17.6 18.5 2.0 0.0 0.0 0.0 0.0 1.4 6.7 3.0 3.2 11.4 199.2 3.3 9.9 29.5 13.2 1.8 17.9 24.5 18.7 11.6 8.6 14.1 23.9 164.7 12.4 0.0 39.9 1.9 2.4 2.3 3.4 0.5 6.0 25.2 3.8 688.0 12.5 23.2 13.7 16.3 5.7 0.0 0.3 7.5 37.7 1.7 0.0 631.3 8.1 10.2 11.3 11.7 2.4 0.6 4.6 1.8 97.4 0.2 11.7 0.0 329.2 32.4 10.3 17.5 2.2 0.1 40.1 4.8 8.1 10.3 21.8 6.6 12.0 7.5 0.3 0.7 5.1 23.9 5.5 1.0 0.4 9.8 81.3 TK2 SCA31 ENSG00000166548 "Thymidine kinase 2" O00142 16 66508003-66552544 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "DNA synthesis" "Kinase, Transferase" "Disease variant, FDA approved drug targets, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA041162 Uncertain NA NA "Cluster 25: Monocytes - Inflammatory response" "Cluster 68: Epididymis - Unknown function" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 50: Fibroblasts - ECM organization" "HPA041162: AB_10961178" "unprognostic (1.12e-1)" "unprognostic (2.11e-1)" "unprognostic (1.12e-1)" "unprognostic (6.27e-3)" "unprognostic (3.94e-1)" "unprognostic (2.93e-1)" "unprognostic (1.10e-1)" "unprognostic (4.83e-2)" "unprognostic (3.35e-2)" "unprognostic (3.45e-1)" "unprognostic (3.59e-2)" "unprognostic (2.85e-1)" "prognostic favorable (2.18e-6)" "unprognostic (3.05e-2)" "unprognostic (1.74e-1)" "unprognostic (2.71e-1)" "unprognostic (7.05e-2)" 48.1 30.2 24.2 11.8 27.6 8.5 25.6 24.7 25.7 20.0 19.7 15.0 10.9 16.2 29.3 12.3 19.0 21.1 19.2 24.1 25.6 25.1 37.3 18.7 11.7 26.5 27.8 26.8 24.4 38.0 22.4 15.1 27.6 19.2 12.7 11.7 22.6 19.9 11.5 12.7 13.5 18.9 27.5 23.0 15.7 33.9 25.8 13.0 25.6 14.6 9.9 17.8 15.4 28.3 13.3 26.5 12.1 14.5 64.3 52.2 0.7 22.0 22.3 15.1 16.8 6.5 26.4 0.1 23.8 63.9 19.0 11.8 5.3 17.7 10.4 8.5 6.2 4.1 17.2 12.9 45.1 5.6 9.2 39.4 15.3 18.5 26.1 62.5 19.9 13.1 6.8 28.1 37.9 4.1 5.5 14.9 5.9 5.1 15.4 7.0 21.0 28.1 44.1 12.5 4.4 8.9 63.2 6.1 26.9 6.6 9.6 16.3 29.7 30.8 15.9 26.3 7.6 30.3 12.2 11.6 38.9 5.7 18.4 5.6 9.4 6.0 1.8 5.1 1.2 0.1 1.3 1.0 8.7 1.7 0.6 0.9 8.5 2.7 4.3 1.8 1.2 2.5 24.2 27.6 24.7 25.7 24.1 25.6 26.5 27.8 27.6 27.5 25.8 28.3 25.0 22.4 9.3 19.6 7.3 5.7 5.1 5.8 12.5 15.5 15.4 11.4 8.0 17.2 7.5 22.0 22.9 10.0 7.6 6.0 9.8 15.7 25.2 15.2 23.2 14.4 9.6 10.3 10.1 22.4 6.0 19.9 11.7 13.0 24.8 20.6 31.1 48.9 21.7 21.9 12.0 6.5 2.0 55.6 10.1 40.5 23.3 23.6 10.6 10.3 22.6 18.4 12.3 14.6 19.4 28.9 3.3 19.2 12.4 4.3 14.4 45.9 9.0 20.5 0.0 14.4 10.6 48.9 11.1 9.6 3.8 2.9 8.6 22.2 7.6 4.2 TLR2 "CD282, TIL4" ENSG00000137462 "Toll like receptor 2" O60603 4 153684070-153706260 "CD markers, Enzymes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Immunity, Inflammatory response, Innate immunity" "Hydrolase, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 69.9;lymphoid tissue: 51.7" "Cell type enhanced" "Detected in many" "Alveolar cells type 2: 77.3;Kupffer cells: 117.2;Langerhans cells: 35.7;Macrophages: 101.8;Microglial cells: 33.7;monocytes: 68.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "classical monocyte: 199.6;intermediate monocyte: 178.9;myeloid DC: 121.3;neutrophil: 457.8;non-classical monocyte: 121.5" "Group enriched" "Detected in all" 49 "dendritic cells: 121.3;granulocytes: 457.8;monocytes: 199.6" "Cell line enhanced" "Detected in some" "HL-60: 11.6;HSkMC: 12.5;hTCEpi: 12.7;NB-4: 11.4;RPTEC TERT1: 13.3;RT4: 16.3;THP-1: 62.0;U-937: 11.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA060231, HPA071546" Supported Nucleoplasm,Mitochondria No NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 43: THP-1 - Innate immune response" "Cluster 41: Macrophages - Immune response" "Nucleoplasm, Mitochondria" "HPA060231: , HPA071546: " "unprognostic (4.15e-1)" "unprognostic (3.29e-2)" "unprognostic (5.32e-2)" "unprognostic (1.52e-2)" "unprognostic (3.46e-2)" "unprognostic (4.88e-2)" "unprognostic (1.39e-2)" "unprognostic (4.24e-2)" "unprognostic (2.48e-1)" "unprognostic (2.02e-2)" "unprognostic (2.04e-1)" "unprognostic (1.33e-1)" "prognostic unfavorable (1.11e-4)" "unprognostic (7.87e-2)" "unprognostic (3.80e-3)" "unprognostic (1.42e-1)" "unprognostic (5.93e-3)" 26.8 11.8 4.3 51.7 4.4 69.9 12.5 4.6 7.5 7.9 7.6 4.6 3.9 3.3 11.8 5.4 8.2 16.3 6.1 4.0 5.3 5.1 11.3 39.9 8.8 9.5 5.9 2.5 8.8 3.4 4.0 11.4 7.9 4.7 3.3 1.5 17.2 12.3 1.7 3.5 4.9 11.7 7.1 35.9 5.2 1.9 7.4 3.6 3.4 3.7 15.4 23.6 4.0 10.1 7.1 0.1 0.3 0.0 1.0 2.9 0.0 0.0 0.5 0.5 0.8 3.3 0.4 0.0 0.8 0.0 0.0 6.4 0.6 0.4 0.3 0.1 0.1 0.2 0.0 0.8 0.1 11.6 0.9 12.5 12.7 0.0 0.1 0.8 0.0 0.0 0.0 0.1 0.1 0.1 0.0 11.4 0.7 0.0 2.7 0.3 0.0 0.0 13.3 16.3 0.0 0.3 0.7 0.1 3.3 0.4 0.0 62.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.7 11.3 1.7 48.4 199.6 1.8 0.3 178.9 0.5 0.4 1.1 0.3 121.3 1.2 1.3 0.2 457.8 5.3 121.5 1.1 0.2 76.2 4.3 4.4 4.6 7.5 4.0 5.3 9.5 5.9 7.9 7.1 7.4 10.1 1.7 6.4 77.3 0.7 1.1 1.1 1.2 18.4 1.2 0.0 9.7 2.2 1.3 2.8 19.5 3.7 0.0 0.2 0.6 0.2 0.0 5.0 0.3 1.6 0.5 2.6 0.0 3.6 0.1 3.8 0.2 1.9 2.6 4.9 3.8 0.5 1.4 1.8 17.4 0.0 0.5 0.3 0.0 117.2 35.7 1.3 0.6 101.8 1.8 33.7 68.4 0.4 1.0 1.0 0.1 3.1 0.0 0.4 1.4 3.4 1.5 1.0 7.5 0.3 13.1 0.6 5.1 0.2 1.0 1.9 1.1 0.1 2.3 0.5 0.5 2.0 TLR4 "ARMD10, CD284, hToll, TLR-4" ENSG00000136869 "Toll like receptor 4" O00206 9 117704175-117724735 "CD markers, Enzymes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Immunity, Inflammatory response, Innate immunity" "Hydrolase, Receptor" "Age-related macular degeneration, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Adipocytes: 38.6;Astrocytes: 50.9;Hepatic stellate cells: 62.8;Hofbauer cells: 38.2;Kupffer cells: 106.0;Macrophages: 64.5;monocytes: 54.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "neutrophil: 86.8" "Group enriched" "Detected in many" 33 "dendritic cells: 22.4;granulocytes: 86.8;monocytes: 65.6" "Cell line enhanced" "Detected in many" "Karpas-707: 60.0;TIME: 43.5" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "CAB004025, HPA049174" Approved Supported "Golgi apparatus,Plasma membrane" "Intracellular and membrane" NA NA "Cluster 14: Monocytes - Unknown function" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 2: Karpas-707 - Immune response" "Cluster 19: Monocytes & Neutrophils - Innate immune response" "Plasma membrane" "Golgi apparatus" "CAB004025: , HPA049174: AB_2680662" "unprognostic (1.60e-1)" "unprognostic (8.34e-2)" "unprognostic (7.22e-2)" "prognostic favorable (6.29e-4)" "unprognostic (3.39e-1)" "unprognostic (7.48e-2)" "unprognostic (8.68e-2)" "unprognostic (1.80e-1)" "unprognostic (3.38e-1)" "unprognostic (5.18e-2)" "unprognostic (8.00e-2)" "unprognostic (9.42e-2)" "unprognostic (4.08e-2)" "unprognostic (8.63e-2)" "prognostic unfavorable (3.79e-4)" "unprognostic (1.09e-2)" "unprognostic (1.96e-2)" 31.1 11.0 12.4 25.7 15.7 22.3 12.0 11.7 8.3 6.5 1.7 6.7 4.3 5.6 1.2 4.8 4.8 10.8 8.4 10.3 17.8 6.8 16.7 16.2 13.1 12.3 14.0 6.0 2.6 2.5 2.1 23.9 12.4 4.6 7.3 2.9 6.0 3.2 3.1 3.5 5.8 10.8 14.9 32.6 4.4 1.5 14.2 3.5 5.5 12.0 7.7 13.3 2.7 10.1 0.0 0.0 25.5 0.0 11.1 23.0 0.1 10.2 17.9 2.5 1.5 0.0 2.6 3.6 0.5 26.7 7.5 0.1 0.0 2.2 3.7 0.0 0.0 5.7 5.1 0.4 8.1 19.1 0.1 14.2 0.0 5.4 0.7 22.5 31.4 0.0 0.0 60.0 29.2 0.0 0.0 2.9 3.1 2.4 1.2 0.0 28.0 19.8 0.9 28.9 0.0 0.1 6.4 0.0 1.0 2.2 0.0 10.4 43.5 1.4 18.4 0.1 4.8 0.0 0.0 0.0 0.9 19.1 15.2 64.0 64.9 21.5 0.1 57.5 0.0 1.7 0.1 0.0 22.4 0.5 0.0 0.0 86.8 0.1 65.6 0.9 0.0 25.5 12.4 15.7 11.7 8.3 10.3 17.8 12.3 14.0 12.4 14.9 14.2 10.1 38.6 0.0 5.0 50.9 2.3 0.8 0.3 0.1 0.6 0.2 3.5 1.0 2.9 2.8 2.9 0.0 0.0 0.3 0.1 1.6 0.0 0.1 0.1 3.5 29.2 31.6 0.0 1.3 0.2 0.2 0.2 11.5 1.5 6.8 15.8 1.2 62.8 1.9 38.2 0.0 0.2 2.0 0.0 106.0 8.6 0.4 0.0 64.5 1.8 26.2 54.0 8.8 2.1 7.5 0.3 0.5 6.1 0.0 0.1 0.1 0.0 0.4 3.7 1.3 6.6 5.5 4.5 0.1 0.3 0.3 0.0 0.8 0.9 3.1 1.2 3.3 TLR7 ENSG00000196664 "Toll like receptor 7" Q9NYK1 X 12867072-12890361 "FDA approved drug targets, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "placenta: 6.4" "Cell type enhanced" "Detected in some" "B-cells: 10.1;dendritic cells: 24.1;Hofbauer cells: 24.6;Macrophages: 20.2;Microglial cells: 14.0;monocytes: 11.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "plasmacytoid DC: 20.7" "Low lineage specificity" "Detected in many" "Group enriched" "Detected in some" 5 "Daudi: 16.3;U-266/70: 16.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA059613 Supported NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "HPA059613: AB_2684083" "unprognostic (1.22e-1)" "unprognostic (1.09e-2)" "unprognostic (2.36e-3)" "unprognostic (9.29e-2)" "unprognostic (2.06e-1)" "unprognostic (1.06e-2)" "unprognostic (8.27e-2)" "unprognostic (6.20e-3)" "unprognostic (3.75e-1)" "unprognostic (6.91e-2)" "unprognostic (3.55e-1)" "unprognostic (8.47e-2)" "unprognostic (2.54e-1)" "unprognostic (4.17e-3)" "unprognostic (1.19e-3)" "unprognostic (1.53e-3)" "unprognostic (1.34e-1)" 1.1 1.6 1.3 4.3 1.2 0.6 4.1 1.6 1.3 1.3 1.0 1.9 1.8 0.9 0.5 0.6 0.8 2.9 0.7 1.1 1.5 0.6 0.6 4.6 4.3 3.5 2.5 0.7 0.3 0.9 0.2 6.4 3.5 0.8 2.3 0.1 1.4 1.0 0.1 0.1 1.8 2.0 3.4 3.8 1.7 0.5 2.7 3.8 0.4 0.3 5.6 2.5 0.1 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 16.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 16.3 0.0 3.1 0.0 0.3 0.0 0.4 10.0 4.5 0.0 11.6 0.0 8.7 0.0 0.0 4.9 7.2 0.0 0.0 0.5 0.1 9.7 20.7 0.0 3.3 1.3 1.2 1.6 1.3 1.1 1.5 3.5 2.5 3.5 3.4 2.7 6.1 0.2 0.0 3.9 0.0 10.1 1.3 1.3 0.0 0.0 0.0 0.2 0.6 0.5 0.0 0.6 0.0 2.1 0.3 24.1 0.0 0.0 0.0 0.0 0.3 0.2 1.3 0.0 0.0 0.1 0.0 0.3 0.9 0.0 0.5 1.3 0.0 0.7 0.2 24.6 0.0 0.1 0.0 0.0 6.2 8.1 0.7 0.6 20.2 1.8 14.0 11.2 0.0 1.0 0.0 0.1 0.0 0.0 0.0 5.7 0.9 0.0 0.0 2.2 0.7 0.0 4.5 0.5 0.0 0.1 0.1 1.0 0.3 2.5 0.1 0.0 1.6 TLR9 CD289 ENSG00000239732 "Toll like receptor 9" Q9NR96 3 52221080-52225645 "CD markers, FDA approved drug targets, Human disease related genes, Predicted membrane proteins" "Immunity, Inflammatory response, Innate immunity" Receptor "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 6.1;lymphoid tissue: 6.0" "Group enriched" "Detected in some" 5 "B-cells: 3.3;Microglial cells: 1.0;Paneth cells: 1.1;Plasma cells: 1.6" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Immune cell enriched" "Detected in some" 7 "plasmacytoid DC: 166.9" "Lineage enriched" "Detected in many" 7 "dendritic cells: 166.9" "Group enriched" "Detected in some" 8 "Daudi: 53.5;RPMI-8226: 52.4;U-698: 27.6" NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 32: Brain & Lymphoid tissue - Unknown function" "Cluster 27: U-698-M & Daudi - Adaptive immune response" "Cluster 57: B-cells - Immune response" "unprognostic (6.03e-2)" "unprognostic (5.08e-2)" "unprognostic (3.58e-3)" "unprognostic (6.69e-7)" "unprognostic (1.16e-1)" "unprognostic (1.89e-2)" "unprognostic (2.69e-1)" "unprognostic (1.58e-1)" "unprognostic (7.02e-2)" "unprognostic (1.89e-1)" "unprognostic (4.40e-2)" "unprognostic (7.60e-2)" "unprognostic (2.65e-3)" "unprognostic (2.44e-2)" "unprognostic (3.70e-1)" "unprognostic (2.27e-1)" "unprognostic (7.91e-3)" 0.5 0.2 0.9 2.6 1.0 1.3 0.4 2.2 6.1 1.2 0.7 0.9 0.4 0.7 0.0 0.3 0.9 0.6 0.3 1.1 0.8 0.3 0.3 0.6 6.0 1.1 1.0 1.5 0.1 0.0 0.3 0.2 1.7 0.7 0.1 0.0 0.7 0.2 1.2 0.3 1.3 0.1 0.9 3.0 0.5 0.4 0.9 1.5 0.6 0.4 4.1 0.7 0.8 1.2 0.0 0.0 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.1 53.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.2 0.7 0.2 0.5 0.3 0.0 0.0 0.0 0.0 0.9 0.0 0.2 0.0 0.0 5.4 1.1 0.0 0.0 0.0 1.0 0.0 52.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.2 0.0 0.1 0.0 0.0 3.6 1.7 27.6 0.0 2.5 0.0 0.0 0.0 0.0 0.2 0.2 2.7 23.5 0.9 0.6 0.3 12.8 0.2 0.2 0.5 0.0 0.0 166.9 2.5 1.8 0.9 1.0 2.2 6.1 1.1 0.8 1.1 1.0 1.7 0.9 0.9 1.2 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.2 0.0 1.1 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 TNF "DIF, TNF-alpha, TNFA, TNFSF2" ENSG00000232810 "Tumor necrosis factor" P01375 6 31575565-31578336 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Cytokine "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "bone marrow: 12.7;lymphoid tissue: 6.5" "Cell type enhanced" "Detected in many" "B-cells: 90.7;dendritic cells: 60.8;Langerhans cells: 72.7;Macrophages: 108.3;T-cells: 100.0" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Immune cell enhanced" "Detected in many" "non-classical monocyte: 68.0" "Group enriched" "Detected in all" 5 "granulocytes: 20.8;monocytes: 68.0;T-cells: 36.6" "Group enriched" "Detected in some" 8 "HDLM-2: 103.7;NB-4: 214.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" CAB078469 Supported "Secreted to blood" NA NA 10100 "Cluster 51: Monocytes - Innate immune response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 24: NB-4 - Immune response" "Cluster 57: B-cells - Immune response" "CAB078469: AB_908070" "unprognostic (1.93e-1)" "unprognostic (1.07e-2)" "unprognostic (3.85e-2)" "unprognostic (1.05e-1)" "unprognostic (1.92e-1)" "unprognostic (2.19e-2)" "unprognostic (1.67e-1)" "unprognostic (3.46e-1)" "unprognostic (1.19e-2)" "unprognostic (1.94e-1)" "unprognostic (3.07e-2)" "unprognostic (1.38e-1)" "unprognostic (1.46e-2)" "unprognostic (1.82e-1)" "unprognostic (9.85e-3)" "unprognostic (1.09e-1)" "unprognostic (2.04e-1)" 1.4 0.5 0.0 3.3 0.0 12.7 0.5 0.0 0.1 0.1 0.0 0.9 0.0 1.5 0.0 0.7 0.3 0.6 2.6 0.1 0.0 1.2 0.6 3.6 1.6 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.3 0.0 0.1 1.5 2.4 0.2 0.1 6.5 0.6 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.0 0.8 0.0 0.0 0.0 0.0 103.7 0.0 19.4 0.0 0.0 0.0 0.2 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 214.4 0.0 0.0 0.0 9.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.2 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 3.3 0.0 0.0 10.1 0.0 23.2 39.5 36.6 7.2 17.2 13.9 7.6 7.0 5.0 5.2 20.8 2.0 68.0 4.3 13.6 14.7 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 6.4 0.0 3.0 0.0 90.7 8.4 1.2 12.1 4.6 0.2 17.4 20.4 2.0 2.8 4.0 0.0 2.1 0.9 60.8 0.5 0.0 7.4 0.1 15.5 5.9 10.7 0.0 0.0 0.0 3.3 1.7 2.0 1.5 30.5 12.6 0.0 1.8 0.1 36.5 0.0 0.0 0.4 10.2 14.1 72.7 0.0 0.3 108.3 5.4 1.9 3.4 0.1 2.1 0.0 0.1 14.3 0.0 0.0 10.4 1.7 0.0 0.1 3.0 0.2 0.0 0.6 4.0 0.0 0.0 1.3 4.1 1.1 100.0 0.0 0.4 0.3 TNFSF11 "CD254, ODF, OPGL, RANKL, TRANCE" ENSG00000120659 "TNF superfamily member 11" O14788 13 42562736-42608013 "Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins" Differentiation "Cytokine, Developmental protein, Receptor" "Cancer-related genes, Disease variant, FDA approved drug targets, Osteopetrosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "breast: 4.5;liver: 5.2;lymphoid tissue: 15.2" "Cell type enhanced" "Detected in some" "Breast glandular cells: 10.8;Breast myoepithelial cells: 5.1;Ductal cells: 6.2;Early spermatids: 8.0;Late spermatids: 15.3" "Cancer enhanced" "Detected in many" "pancreatic cancer: 2.6" "Not detected" "Not detected" "Immune cell enriched" "Detected in some" 7 "NK-cell: 13.6" "Lineage enriched" "Detected in many" 7 "NK-cells: 13.6" "Cell line enhanced" "Detected in some" "HSkMC: 2.1;NTERA-2: 3.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "CAB009193, HPA045142" Enhanced "Secreted to blood" NA NA 17200 "Cluster 15: NK-cells - Transcription" "Cluster 16: Immune cells - Immune response" "Cluster 5: NTERA-2 - Transcription" "Cluster 35: Glandular cells - Unknown function" "CAB009193: , HPA045142: AB_2679231" "unprognostic (3.97e-4)" "unprognostic (1.40e-1)" "unprognostic (9.01e-3)" "unprognostic (3.81e-3)" "unprognostic (1.12e-1)" "unprognostic (1.09e-1)" "unprognostic (7.09e-2)" "unprognostic (7.70e-2)" "unprognostic (2.29e-1)" "unprognostic (1.25e-3)" "unprognostic (1.00e-1)" "unprognostic (1.50e-1)" "unprognostic (3.94e-5)" "unprognostic (1.87e-1)" "unprognostic (9.67e-2)" "unprognostic (5.46e-2)" "unprognostic (7.74e-2)" 0.2 0.0 0.0 4.8 0.0 0.2 4.5 0.0 0.1 0.8 0.2 0.9 0.4 0.1 0.0 0.1 0.0 1.4 0.1 0.0 0.1 0.1 5.2 0.1 15.2 0.5 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 2.1 0.0 0.4 1.1 0.0 0.1 1.9 0.0 0.0 0.6 0.5 1.3 0.1 1.5 0.0 0.1 5.0 1.4 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 2.1 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 13.6 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.5 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.3 0.4 0.1 0.0 0.3 0.0 0.0 10.8 5.1 0.4 1.5 0.2 0.0 0.0 0.0 2.3 0.0 0.0 6.2 8.0 0.5 0.1 0.1 1.2 0.0 0.2 0.2 0.0 0.2 0.0 0.7 0.0 0.3 0.0 1.0 0.0 0.0 0.7 0.9 0.0 0.0 0.4 15.3 0.0 0.3 0.0 0.0 0.0 0.0 2.1 0.0 0.1 3.0 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.8 0.0 0.3 0.0 1.8 0.0 0.0 0.0 TNNC1 TNNC ENSG00000114854 "Troponin C1, slow skeletal and cardiac type" P63316 3 52451100-52454041 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Muscle protein" "Cardiomyopathy, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 36 "heart muscle: 8734.3;skeletal muscle: 21081.1;tongue: 12403.9" "Cell type enriched" "Detected in many" 10 "Cardiomyocytes: 3550.1" "Cancer enhanced" "Detected in many" "head and neck cancer: 27.1" "Low region specificity" "Detected in many" "Immune cell enhanced" "Detected in single" "MAIT T-cell: 1.2" "Lineage enriched" "Detected in single" 6 "T-cells: 1.2" "Cell line enhanced" "Detected in many" "CACO-2: 68.2;CAPAN-2: 33.5;EFO-21: 65.2;HeLa: 49.1;Hep G2: 46.1;HSkMC: 67.2;U-2 OS: 97.7" "Region enriched" "Detected in all" 4 "cerebral cortex: 87.0" "Group enriched" "Detected in some" 6 "midbrain: 7.6;spinal cord: 7.1" "CAB002450, HPA044848, HPA056897" Enhanced Approved "Nucleoplasm,Actin filaments,Mitochondria" NA NA 990000 "Cluster 13: T-cells - Unknown function" "Cluster 13: Striated muscle - Muscle contraction" "Cluster 9: U-2 OS - Unknown function" "Cluster 54: Cardiomyocytes - Muscle contraction" "Nucleoplasm, Actin filaments, Mitochondria" "CAB002450: AB_564152, HPA044848: AB_2679110, HPA056897: AB_2683269" "unprognostic (2.18e-2)" "unprognostic (1.70e-1)" "unprognostic (8.66e-2)" "unprognostic (3.43e-1)" "unprognostic (4.00e-2)" "unprognostic (1.88e-2)" "unprognostic (1.11e-1)" "unprognostic (1.43e-1)" "unprognostic (1.53e-1)" "unprognostic (3.92e-1)" "unprognostic (1.03e-1)" "unprognostic (1.07e-1)" "unprognostic (2.15e-2)" "unprognostic (4.95e-2)" "unprognostic (2.31e-1)" "unprognostic (4.15e-2)" "unprognostic (4.86e-1)" 8.4 10.9 0.7 0.8 0.8 0.7 19.1 2.7 1.1 7.7 7.3 4.0 1.1 2.8 41.7 387.3 2.8 3.3 8734.3 1.2 0.7 19.2 4.0 78.5 3.9 0.8 0.9 2.4 6.8 1.6 17.6 5.2 1.0 170.1 4.1 0.4 120.8 2.2 21081.1 18.9 3.3 0.8 0.8 2.8 5.7 10.6 0.8 4.3 14.4 12403.9 1.6 5.3 5.4 0.7 0.7 5.2 3.6 0.6 0.2 0.5 8.0 0.4 0.3 0.3 0.4 68.2 33.5 0.5 65.2 9.9 0.1 0.4 0.1 0.3 0.0 1.2 1.6 0.5 49.1 46.1 0.3 0.3 0.1 67.2 1.2 0.0 0.7 0.6 0.0 2.0 0.2 5.1 2.0 0.1 0.2 0.8 0.5 15.1 0.7 0.1 2.9 2.3 3.3 13.0 0.2 0.0 0.5 6.7 0.1 3.9 26.7 0.5 0.0 0.1 97.7 0.8 0.2 2.8 1.3 0.9 0.3 0.7 0.1 0.0 0.0 0.0 0.2 0.0 1.2 0.0 0.2 0.1 0.0 0.0 0.4 0.1 0.0 0.0 0.0 0.1 0.8 0.1 0.7 0.8 2.7 1.1 1.2 0.7 0.8 0.9 1.0 0.8 0.8 0.7 0.2 125.0 12.6 0.0 0.3 1.5 1.7 4.0 0.6 0.2 0.5 0.3 3550.1 5.7 7.9 3.7 2.1 59.0 0.1 1.6 27.4 11.8 0.7 66.4 6.7 39.8 330.7 0.4 0.0 13.0 5.1 52.7 0.5 98.8 0.0 0.8 0.7 0.7 4.9 0.0 0.0 1.7 2.0 0.0 1.4 5.8 22.4 2.6 5.4 0.0 0.1 1.2 0.0 0.0 0.0 6.5 0.3 177.6 0.1 0.8 0.5 1.3 2.8 0.1 0.0 241.8 36.0 2.1 1.0 0.1 0.9 31.1 2.8 1.3 2.0 6.8 TOP1 ENSG00000198900 "DNA topoisomerase I" P11387 20 41028822-41124487 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins" "Biological rhythms, Host-virus interaction" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Syncytiotrophoblasts: 801.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009058, HPA019039" Supported Enhanced "Nucleoplasm,Nucleoli fibrillar center" No Yes 7600 "Cluster 31: Non-specific - Inflammatory response" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 36: HEL - Hemostasis" "Cluster 41: Macrophages - Immune response" Nucleoplasm "Nucleoli fibrillar center" "CAB009058: AB_2303554, HPA019039: AB_1858187" "unprognostic (1.46e-1)" "unprognostic (8.65e-2)" "unprognostic (1.33e-2)" "unprognostic (1.92e-3)" "unprognostic (5.05e-2)" "unprognostic (1.49e-3)" "prognostic unfavorable (6.42e-4)" "unprognostic (5.86e-2)" "unprognostic (1.51e-1)" "unprognostic (4.60e-2)" "unprognostic (3.74e-3)" "unprognostic (6.51e-2)" "unprognostic (8.65e-2)" "unprognostic (4.70e-2)" "unprognostic (5.14e-1)" "unprognostic (3.64e-1)" "unprognostic (1.29e-1)" 37.9 36.7 17.4 49.9 18.6 74.9 27.9 21.8 25.1 26.9 25.3 36.9 42.6 27.9 34.4 36.7 22.4 37.2 19.1 18.0 18.9 39.0 47.5 40.0 59.9 18.5 18.4 24.3 28.6 26.7 22.4 50.2 18.1 31.8 37.3 25.5 26.7 24.2 21.3 26.5 42.6 23.9 18.7 38.5 36.5 18.9 18.8 58.9 37.6 20.2 60.6 42.7 28.8 19.2 105.2 71.7 131.4 108.2 52.2 61.8 129.8 92.6 81.0 105.0 94.8 190.5 127.6 296.4 96.4 48.5 112.3 98.9 159.1 147.2 153.0 64.9 81.6 378.6 54.9 139.0 135.4 165.1 124.0 69.8 76.4 102.4 166.8 94.0 111.5 98.1 167.8 98.7 120.9 233.2 235.3 119.7 106.3 104.1 131.6 197.7 123.1 157.7 121.4 95.2 108.6 75.4 145.4 88.3 95.0 94.2 98.6 146.4 109.9 84.7 71.3 78.8 100.9 62.7 75.6 338.3 113.7 91.1 82.0 12.6 9.9 16.8 6.6 10.3 8.3 10.5 7.3 7.0 9.5 10.1 7.7 6.9 19.1 6.3 13.2 18.8 9.0 5.4 17.4 18.6 21.8 25.1 18.0 18.9 18.5 18.4 18.1 18.7 18.8 19.2 116.9 118.6 201.5 66.0 117.6 245.9 338.0 90.3 153.7 98.2 90.5 75.7 49.7 78.6 170.3 99.3 60.5 192.1 137.1 194.1 74.3 94.4 10.0 151.3 167.4 115.1 91.8 486.5 86.9 65.8 175.4 121.4 84.1 259.2 78.6 119.1 67.1 131.7 99.2 72.3 77.4 126.9 69.2 101.2 109.1 12.8 59.7 151.6 72.9 74.9 95.4 88.0 78.2 87.4 90.7 119.2 169.8 69.6 234.1 162.3 94.1 136.2 68.3 87.0 85.5 135.5 130.8 116.8 54.6 129.4 214.2 801.5 111.5 123.7 117.8 237.7 TOP1MT ENSG00000184428 "DNA topoisomerase I mitochondrial" Q969P6 8 143304384-143359979 "Enzymes, FDA approved drug targets, Predicted intracellular proteins" "DNA-binding, Isomerase, Topoisomerase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "MOLT-4: 197.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA001915, HPA021542" Approved Supported Mitochondria NA NA "Cluster 23: Antigen presenting cells - Antigen presentation" "Cluster 75: Bone marrow - mRNA splicing & Cell cycle" "Cluster 22: JURKAT & MOLT-4 - Adaptive immune response" "Cluster 32: Non-specific - Translation" Mitochondria "HPA001915: AB_1080331, HPA021542: AB_1858186" "unprognostic (5.02e-3)" "unprognostic (3.79e-2)" "unprognostic (6.57e-2)" "unprognostic (6.92e-3)" "unprognostic (2.32e-2)" "unprognostic (1.04e-2)" "unprognostic (3.05e-3)" "unprognostic (1.44e-1)" "unprognostic (1.44e-1)" "unprognostic (1.13e-1)" "unprognostic (1.50e-2)" "unprognostic (4.42e-2)" "prognostic unfavorable (1.52e-7)" "unprognostic (3.66e-2)" "unprognostic (3.62e-2)" "unprognostic (8.55e-3)" "unprognostic (5.66e-3)" 14.0 17.4 7.3 9.4 6.1 48.2 13.7 2.5 7.8 23.2 4.0 12.6 7.6 11.7 4.8 18.4 13.4 9.2 7.6 8.5 5.8 14.4 30.3 10.5 12.0 7.0 4.7 32.1 18.9 10.1 9.2 7.4 7.1 13.2 9.7 2.0 14.2 8.1 7.3 22.6 11.6 7.8 2.9 12.6 12.9 23.4 5.4 21.4 21.9 3.4 11.4 17.8 19.1 6.4 25.5 38.3 15.8 59.4 22.0 24.5 28.1 11.6 14.8 20.5 21.1 48.4 35.8 74.2 42.6 16.2 14.7 26.8 33.8 21.3 17.6 29.5 52.4 65.6 21.5 49.5 24.8 44.4 68.4 25.1 22.3 17.4 24.8 17.7 25.0 21.1 80.5 28.2 18.3 106.3 197.8 87.9 27.6 54.9 65.4 24.7 20.7 112.2 15.3 40.4 28.1 34.1 33.2 29.3 61.7 19.3 19.3 72.5 16.5 14.3 57.7 16.4 30.2 15.2 17.0 38.0 24.1 64.9 17.4 31.4 10.5 0.5 6.2 6.3 6.3 28.9 11.3 8.6 35.3 14.4 24.2 18.8 0.7 0.4 1.2 30.9 3.2 9.2 7.3 6.1 2.5 7.8 8.5 5.8 7.0 4.7 7.1 2.9 5.4 6.4 11.4 6.4 8.6 3.3 11.9 23.7 32.3 13.1 14.2 1.2 15.3 11.6 3.3 10.0 10.5 9.2 0.0 11.7 7.3 6.7 7.9 11.4 29.3 3.9 10.9 7.7 4.9 41.3 2.5 9.3 23.6 8.9 5.6 5.8 7.0 24.7 6.4 12.1 11.1 3.3 3.5 11.3 2.0 8.8 24.9 11.1 8.7 9.4 21.4 0.0 9.3 1.4 2.1 1.5 2.9 7.1 11.2 4.5 6.1 29.7 2.8 15.8 3.1 0.2 6.6 13.5 10.0 31.3 36.4 17.8 23.9 10.1 8.6 21.4 20.8 22.8 TOP2A TOP2 ENSG00000131747 "DNA topoisomerase II alpha" P11388 17 40388525-40417896 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Biological rhythms" "DNA-binding, Isomerase, Topoisomerase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 127.8;testis: 65.7" "Cell type enhanced" "Detected in many" "Erythroid cells: 216.8;Granulosa cells: 117.5;Spermatocytes: 621.2;Spermatogonia: 269.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Immune cell enhanced" "Detected in some" "T-reg: 2.4" "Low lineage specificity" "Detected in many" "Low cell line specificity" "Detected in all" "Group enriched" "Detected in many" 4 "basal ganglia: 4.2;white matter: 8.0" "Low region specificity" "Detected in some" "CAB002448, HPA006458, HPA026773" Enhanced Approved Supported Nucleoplasm,Nucleoli Yes Yes "Cluster 4: T-regs - Cell cycle regulation" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" Nucleoplasm Nucleoli "CAB002448: AB_564035, HPA006458: AB_1858189, HPA026773: AB_1858190" "unprognostic (2.09e-1)" "unprognostic (1.24e-1)" "unprognostic (2.28e-3)" "unprognostic (9.42e-3)" "unprognostic (1.80e-1)" "unprognostic (1.52e-1)" "prognostic unfavorable (5.92e-6)" "prognostic unfavorable (4.99e-4)" "unprognostic (6.21e-3)" "unprognostic (2.09e-1)" "prognostic unfavorable (3.83e-5)" "unprognostic (5.03e-2)" "prognostic unfavorable (0.00e+0)" "unprognostic (7.46e-2)" "unprognostic (1.07e-1)" "unprognostic (2.18e-1)" "unprognostic (2.29e-1)" 2.2 2.5 0.2 20.0 0.2 42.0 5.4 0.1 0.7 5.0 1.1 17.8 18.1 3.9 0.3 29.0 1.5 2.6 1.2 0.2 0.2 1.2 2.8 4.1 40.3 0.2 0.8 1.0 0.9 0.3 0.3 15.9 0.5 1.4 19.8 0.1 4.3 0.5 0.3 15.3 17.0 7.6 0.2 9.9 8.9 65.7 1.1 127.8 1.9 0.2 42.5 6.0 9.6 0.4 212.6 275.6 343.1 158.0 16.8 33.9 76.3 283.3 151.5 255.0 224.2 130.5 157.6 339.4 140.1 96.7 152.7 326.5 266.8 113.5 339.5 182.7 177.8 224.8 167.9 216.7 1.6 318.4 228.6 7.4 9.2 179.8 181.4 55.1 136.3 216.5 247.5 225.8 279.2 72.6 372.3 209.6 143.0 152.4 108.3 310.7 531.9 141.3 61.6 133.3 201.6 144.6 229.3 281.4 89.4 198.2 236.9 143.2 90.3 167.0 233.2 195.5 276.7 128.4 154.9 290.7 94.3 214.9 285.0 0.2 0.0 0.0 0.2 0.0 0.0 0.6 0.3 0.3 0.1 0.1 0.0 0.0 0.1 1.4 0.1 0.0 2.4 0.4 0.2 0.2 0.1 0.7 0.2 0.2 0.2 0.8 0.5 0.2 1.1 0.4 1.0 0.0 2.0 0.3 17.4 11.7 3.7 15.0 2.2 0.0 18.7 17.1 1.3 2.8 5.8 0.0 0.0 72.9 6.1 19.8 0.0 0.8 20.3 12.7 15.8 9.3 0.0 216.8 0.2 0.0 92.4 23.3 23.0 10.0 0.0 117.5 20.7 5.4 83.5 0.0 0.1 34.2 18.3 33.9 13.2 19.1 4.7 14.1 1.8 0.0 2.6 0.0 3.1 0.0 0.1 0.3 3.5 1.9 31.3 3.1 3.4 0.1 1.8 0.0 72.3 0.5 19.5 621.2 269.6 45.1 6.1 8.9 14.8 4.3 61.0 6.9 TOP2B ENSG00000077097 "DNA topoisomerase II beta" Q02880 3 25597905-25664907 "Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "DNA-binding, Isomerase, Topoisomerase" "Autism spectrum disorder, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "REH: 569.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004601, HPA024120, HPA050441" Supported Enhanced Nucleoplasm NA NA "Cluster 44: Non-specific - Transcription" "Cluster 34: Non-specific - Transcription" "Cluster 14: REH - Unknown function" "Cluster 13: Spermatocytes & Spermatogonia - Spermatogenesis" Nucleoplasm "CAB004601: AB_628384, HPA024120: AB_1858191, HPA050441: AB_2681127" "unprognostic (2.90e-2)" "unprognostic (5.17e-2)" "unprognostic (7.21e-3)" "unprognostic (2.42e-1)" "unprognostic (1.60e-1)" "unprognostic (1.43e-2)" "prognostic unfavorable (1.86e-7)" "unprognostic (7.86e-2)" "unprognostic (1.89e-1)" "unprognostic (2.84e-1)" "unprognostic (7.14e-2)" "unprognostic (1.08e-1)" "prognostic favorable (2.43e-4)" "unprognostic (1.01e-1)" "unprognostic (1.59e-1)" "unprognostic (1.49e-1)" "unprognostic (7.93e-2)" 27.1 25.5 15.3 38.9 17.6 49.1 34.7 25.2 16.5 36.2 12.0 30.1 28.8 42.9 25.5 34.1 29.7 26.2 38.5 15.3 16.0 32.1 27.7 28.0 50.4 13.5 16.2 40.6 28.8 53.2 11.7 34.4 15.1 38.7 33.3 112.3 27.1 34.2 29.9 32.4 28.6 34.2 16.4 36.4 32.1 19.5 14.6 82.5 45.8 36.7 46.6 43.7 18.5 25.3 57.6 58.6 125.9 155.3 41.1 51.7 50.1 54.4 69.6 49.4 53.9 30.1 44.6 176.9 37.1 79.2 30.5 47.7 105.6 60.5 82.5 85.5 56.7 268.5 71.2 50.6 28.9 212.8 137.4 37.1 29.7 55.3 48.2 49.8 81.7 118.6 92.0 84.3 64.4 64.0 138.5 52.5 95.9 38.5 44.1 569.9 71.0 82.6 43.9 199.5 63.2 109.7 81.1 57.4 49.9 72.2 59.7 187.1 78.7 68.3 52.6 55.2 58.9 129.6 78.6 185.1 44.9 155.6 46.5 3.2 1.4 2.8 3.0 1.7 3.3 2.0 2.9 3.1 2.2 2.5 3.3 3.0 1.0 3.9 2.6 2.8 2.3 1.1 15.3 17.6 25.2 16.5 15.3 16.0 13.5 16.2 15.1 16.4 14.6 25.3 36.4 64.1 62.7 65.3 47.3 39.1 47.9 30.9 31.3 62.4 44.4 31.9 121.5 34.3 36.1 25.8 56.3 47.8 65.8 29.9 13.7 34.3 3.6 48.0 58.8 36.6 59.3 65.6 77.8 33.4 24.5 40.2 28.5 45.1 34.1 71.4 25.0 35.1 26.2 60.6 89.8 32.3 20.3 40.7 50.1 6.0 39.1 45.3 23.2 43.1 49.8 51.3 68.0 76.4 113.0 35.5 22.2 33.4 46.0 56.2 20.6 25.6 39.2 95.7 32.9 56.5 51.0 94.9 44.0 57.9 37.6 46.7 53.7 48.4 39.2 64.3 TPH1 "TPH, TPRH" ENSG00000129167 "Tryptophan hydroxylase 1" P17752 11 18017564-18042426 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins" "Serotonin biosynthesis" "Monooxygenase, Oxidoreductase" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 9.0;intestine: 19.3;stomach 1: 15.0" "Cell type enriched" "Detected in many" 30 "Enteroendocrine cells: 1466.7" "Cancer enhanced" "Detected in some" "endometrial cancer: 2.4" "Group enriched" "Detected in some" 5 "hypothalamus: 3.4;midbrain: 9.0" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HL-60: 1.5" "Low region specificity" "Detected in some" "CAB010767, HPA022483" Uncertain Uncertain Cytosol NA NA "Cluster 9: Intestine - Unknown function" "Cluster 37: Hep G2 - Hepatocyte cell processes" "Cluster 17: Intestinal endocrine cells - Hormone signaling" Cytosol "CAB010767: AB_261587, HPA022483: AB_1858378" "unprognostic (2.14e-4)" "unprognostic (9.97e-2)" "unprognostic (6.92e-2)" "unprognostic (6.78e-2)" "unprognostic (1.55e-1)" "unprognostic (6.26e-5)" "unprognostic (1.73e-1)" "unprognostic (5.33e-2)" "unprognostic (1.60e-1)" "unprognostic (2.12e-2)" "unprognostic (1.19e-4)" "unprognostic (6.72e-2)" "unprognostic (5.40e-8)" "unprognostic (3.76e-2)" "unprognostic (7.42e-2)" "unprognostic (3.10e-1)" "unprognostic (2.46e-5)" 0.6 0.1 0.2 1.2 0.3 1.1 1.3 0.3 0.3 0.6 4.7 9.0 10.2 0.9 0.9 0.2 0.9 0.1 0.3 0.4 3.4 0.5 0.2 0.8 0.5 0.2 9.0 0.7 0.5 0.1 3.0 0.2 1.1 1.4 19.3 1.8 0.5 0.1 0.4 1.4 11.2 0.2 0.2 0.7 15.0 0.9 0.4 0.3 0.5 0.1 0.7 0.4 0.4 0.3 0.1 0.0 0.5 0.4 0.0 0.0 0.2 0.1 0.1 0.0 0.3 0.6 0.0 0.4 0.1 0.0 0.0 0.2 0.1 0.5 0.2 0.4 1.0 0.7 0.3 1.1 0.0 1.5 0.3 0.0 0.6 0.0 0.2 0.1 0.2 0.8 0.3 0.2 0.0 0.1 0.3 0.2 0.1 0.0 0.1 0.5 0.0 0.0 0.0 0.3 0.4 0.3 0.0 0.1 0.2 0.0 0.0 0.9 0.0 0.1 0.4 0.1 0.5 0.0 0.1 0.3 0.0 0.3 0.4 0.3 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.2 0.3 0.3 0.3 0.4 3.4 0.2 9.0 1.1 0.2 0.4 0.3 1.4 0.0 0.0 1.0 1.1 0.4 0.4 0.5 0.0 14.9 1.9 1.0 0.8 0.0 0.1 5.5 2.1 0.2 0.6 1.7 0.0 0.2 0.8 0.1 0.6 0.7 1466.7 0.4 0.5 0.6 0.0 1.2 2.0 0.2 0.0 5.6 0.4 0.2 0.2 1.7 0.4 48.2 0.0 0.3 1.4 0.8 0.9 0.5 0.0 0.0 0.1 1.4 1.0 0.0 0.6 0.4 13.4 1.2 0.3 2.3 1.5 0.3 0.9 5.6 6.6 1.3 1.3 2.8 3.7 0.0 1.4 0.0 1.2 0.0 2.7 0.4 TPH2 "FLJ37295, NTPH" ENSG00000139287 "Tryptophan hydroxylase 2" Q8IWU9 12 71938845-72186618 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Serotonin biosynthesis" "Monooxygenase, Oxidoreductase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 716 "brain: 325.8" "Group enriched" "Detected in some" 5 "Early spermatids: 8.0;Inhibitory neurons: 3.2;Late spermatids: 7.4;Spermatogonia: 3.7" "Not detected" "Not detected" "Group enriched" "Detected in many" 5 "midbrain: 325.8;pons: 141.5" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 31 "midbrain: 106.7;pons and medulla: 34.9" "Group enriched" "Detected in some" 5 "midbrain: 49.9;pons: 49.6" CAB078198 Enhanced NA NA "Cluster 73: Brain - Neuropeptide signaling" "Cluster 34: Spermatids - Unknown function" "CAB078198: AB_2665804" "unprognostic (1.19e-1)" "unprognostic (6.01e-1)" "unprognostic (3.46e-2)" "unprognostic (2.31e-1)" "unprognostic (5.91e-2)" "unprognostic (2.02e-1)" "unprognostic (5.01e-2)" "unprognostic (7.32e-2)" "unprognostic (1.34e-1)" 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.4 0.0 0.0 0.0 0.0 45.3 325.8 0.0 0.2 0.0 0.4 0.0 141.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.3 1.0 0.4 45.3 325.8 141.5 0.1 0.4 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.2 0.1 0.1 0.0 0.0 1.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.7 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 TPK1 "HTPK1, PP20" ENSG00000196511 "Thiamin pyrophosphokinase 1" Q9H3S4 7 144451941-144836395 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Kinase, Transferase" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "intestine: 14.3" "Cell type enhanced" "Detected in many" "Early spermatids: 83.0;Excitatory neurons: 82.6;Inhibitory neurons: 76.3;Late spermatids: 95.8;Microglial cells: 110.5" "Cancer enhanced" "Detected in many" "renal cancer: 3.4" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "AN3-CA: 70.6;CACO-2: 17.2;EFO-21: 21.2;TIME: 16.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA021545, HPA021849" Approved Approved Vesicles NA NA 210000 "Cluster 28: Myeloid DCs - Unknown function" "Cluster 14: B-cells - Humoral immune response" "Cluster 23: AN3-CA - Transcription regulation" "Cluster 21: Neurons & Oligodendrocytes - Neuronal signaling" Vesicles "HPA021545: AB_1858209, HPA021849: AB_1858210" "unprognostic (4.05e-2)" "unprognostic (3.28e-2)" "unprognostic (2.38e-2)" "unprognostic (3.32e-2)" "unprognostic (2.42e-1)" "unprognostic (1.63e-1)" "unprognostic (7.62e-2)" "unprognostic (6.08e-2)" "unprognostic (2.37e-1)" "unprognostic (1.68e-1)" "unprognostic (3.76e-2)" "unprognostic (6.06e-2)" "unprognostic (1.45e-3)" "unprognostic (3.15e-1)" "unprognostic (2.87e-1)" "unprognostic (1.59e-1)" "unprognostic (9.22e-3)" 4.3 3.4 2.9 5.9 3.2 2.7 4.2 2.1 4.1 2.7 3.3 6.4 14.3 2.2 1.5 1.9 2.0 3.6 3.4 2.8 5.2 3.9 4.5 5.2 5.8 3.1 3.0 2.3 2.0 1.8 1.5 5.2 3.0 1.8 6.1 2.4 3.6 2.6 1.6 1.4 7.5 3.6 2.9 8.1 2.2 3.4 4.3 2.8 3.1 2.9 5.0 4.1 1.6 3.9 0.7 0.7 0.7 70.6 0.5 0.7 5.8 0.3 0.3 0.2 0.2 17.2 2.8 1.3 21.2 1.2 1.4 0.0 1.4 0.8 0.6 4.3 1.0 0.3 0.2 0.3 1.8 5.5 1.7 1.4 1.4 0.8 1.0 2.0 13.6 2.8 1.5 3.2 0.3 2.1 1.6 8.2 1.8 2.1 5.9 0.7 1.6 2.5 10.9 6.3 0.7 0.2 1.1 0.2 1.3 1.3 1.0 10.4 16.3 0.7 1.8 1.3 0.9 1.6 4.2 1.7 2.5 13.8 0.7 0.4 10.2 0.3 5.0 7.4 5.2 6.7 5.5 4.6 13.2 7.2 6.5 5.4 4.7 5.8 10.8 3.1 7.7 5.6 2.9 3.2 2.1 4.1 2.8 5.2 3.1 3.0 3.0 2.9 4.3 3.9 8.5 9.6 2.8 43.1 23.8 2.3 2.6 3.0 0.6 3.9 4.4 2.9 5.9 8.6 1.3 3.7 8.4 41.2 8.3 20.1 19.6 4.3 83.0 5.3 2.3 8.9 1.2 2.1 82.6 6.7 14.3 6.3 7.1 8.6 7.6 6.5 6.1 5.2 17.0 1.7 76.3 5.0 0.0 18.9 19.2 95.8 5.0 17.9 8.8 110.5 15.7 3.4 17.5 55.8 38.4 9.8 15.9 1.2 9.9 1.8 20.4 8.6 3.2 5.4 0.0 3.6 2.9 14.9 10.5 2.1 1.7 32.0 12.1 4.0 8.1 4.1 TPMT ENSG00000137364 "Thiopurine S-methyltransferase" P51580 6 18128311-18155077 "Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins" "Methyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "kidney: 76.4;liver: 68.8;thyroid gland: 76.9" "Cell type enhanced" "Detected in many" "Distal enterocytes: 144.6;Proximal tubular cells: 307.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA019851, HPA062364" Enhanced NA NA 39000 "Cluster 7: Monocytes - Unknown function" "Cluster 7: Kidney - Transmembrane transport" "Cluster 17: WM-115 - Nervous system development" "Cluster 67: Proximal tubular cells - Tubular reabsorption" "HPA019851: AB_1858213, HPA062364: " "unprognostic (6.24e-2)" "unprognostic (3.16e-2)" "unprognostic (5.46e-3)" "prognostic unfavorable (8.45e-5)" "unprognostic (4.98e-2)" "unprognostic (2.25e-1)" "unprognostic (8.16e-2)" "unprognostic (4.36e-3)" "unprognostic (9.62e-2)" "prognostic favorable (1.41e-4)" "unprognostic (4.49e-2)" "unprognostic (3.40e-2)" "prognostic favorable (1.10e-4)" "unprognostic (7.56e-2)" "unprognostic (1.31e-1)" "unprognostic (1.07e-1)" "unprognostic (8.39e-3)" 5.8 16.4 9.2 12.9 12.2 10.0 10.0 10.5 12.2 7.7 9.6 34.5 34.5 6.9 17.5 10.3 7.0 10.4 12.2 10.4 9.7 76.4 68.8 9.3 10.0 9.8 9.7 4.5 11.6 18.0 7.5 5.6 9.9 10.8 35.1 13.1 12.1 6.6 13.2 10.3 28.9 10.5 9.3 11.0 12.2 6.7 9.9 9.2 76.9 11.7 10.1 15.9 7.4 9.8 24.5 7.3 7.9 19.9 12.9 24.9 19.5 27.7 30.8 23.3 36.2 17.1 5.9 3.1 20.3 37.0 18.0 12.0 11.3 20.0 38.6 16.2 16.2 20.0 12.0 25.2 14.1 9.3 17.4 14.5 21.2 26.0 16.5 15.1 32.9 13.5 40.6 5.6 17.2 11.1 9.6 12.7 13.2 33.9 20.7 11.9 19.6 13.8 27.2 24.8 13.0 10.0 18.3 31.9 36.9 19.9 22.9 9.0 14.0 53.1 10.3 28.0 40.0 8.1 38.9 8.0 19.0 12.3 54.5 8.7 22.1 7.2 11.6 46.7 14.9 2.7 9.2 11.1 32.3 2.6 8.1 11.2 2.2 10.4 40.7 6.5 16.2 17.2 9.2 12.2 10.5 12.2 10.4 9.7 9.8 9.7 9.9 9.3 9.9 9.8 13.9 16.0 15.5 4.6 12.6 42.7 41.3 23.0 13.6 15.3 20.9 15.0 22.9 25.8 15.8 35.0 22.9 20.7 20.5 144.6 115.4 52.7 1.2 38.4 15.3 14.3 24.0 18.1 18.7 37.4 25.3 11.3 14.8 39.4 22.9 4.3 17.5 86.5 44.9 6.7 13.2 34.8 22.4 48.5 60.9 2.8 4.1 41.1 24.9 9.4 32.6 33.5 29.9 11.1 10.2 76.8 106.6 10.1 9.7 38.8 80.8 307.6 12.2 19.5 0.0 9.3 13.9 0.7 7.7 19.5 34.5 17.5 21.1 9.5 50.7 78.9 TPO TPX ENSG00000115705 "Thyroid peroxidase" P07202 2 1374066-1543711 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" "Hydrogen peroxide, Thyroid hormones biosynthesis" "Oxidoreductase, Peroxidase" "Congenital hypothyroidism, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 70 "thyroid gland: 1588.2" "Cell type enhanced" "Detected in some" "Adipocytes: 24.5;Early spermatids: 4.2;Endothelial cells: 12.6;Late spermatids: 7.5;Peritubular cells: 3.8" "Cancer enriched" "Detected in some" 364 "thyroid cancer: 188.3" "Not detected" "Not detected" "Group enriched" "Detected in some" 12 "memory CD4 T-cell: 2.0;T-reg: 1.2" "Lineage enriched" "Detected in single" 20 "T-cells: 2.0" "Group enriched" "Detected in some" 5 "Karpas-707: 9.9;RPMI-8226: 3.9" "Not detected" "Not detected" "Not detected" "Not detected" "HPA007987, CAB009587" Enhanced "Intracellular and membrane" NA NA "Cluster 4: T-regs - Cell cycle regulation" "Cluster 1: Thyroid gland - Transcription" "Cluster 2: Karpas-707 - Immune response" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "CAB009587: , HPA007987: AB_1080270" "unprognostic (1.55e-1)" "unprognostic (1.04e-1)" "unprognostic (2.88e-1)" "unprognostic (1.77e-2)" "unprognostic (3.56e-2)" "unprognostic (9.11e-2)" "unprognostic (2.24e-2)" "unprognostic (1.85e-1)" "unprognostic (1.32e-1)" "unprognostic (1.19e-4)" "unprognostic (2.61e-2)" "unprognostic (3.29e-1)" "unprognostic (5.44e-4)" "unprognostic (1.21e-1)" "unprognostic (3.73e-2)" "unprognostic (4.98e-3)" "unprognostic (7.10e-3)" 13.1 0.3 0.1 0.4 0.0 0.1 11.0 0.0 0.6 0.1 0.0 4.6 0.6 0.6 0.0 2.0 0.7 3.0 11.5 0.1 0.2 0.2 0.6 0.8 1.4 0.2 0.1 0.3 2.3 0.3 0.6 0.0 0.1 0.6 0.9 0.2 3.4 0.0 6.0 1.8 3.8 0.6 0.1 22.8 2.8 1.2 0.2 0.0 1588.2 5.6 0.4 2.1 1.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 9.9 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 3.9 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.8 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.2 0.2 0.1 0.0 0.0 0.6 0.1 0.2 0.2 0.1 0.1 0.1 0.2 0.4 24.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 4.2 0.0 0.2 12.6 0.0 0.0 2.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 7.5 0.6 0.4 0.0 0.0 0.0 0.0 0.0 1.0 0.3 0.0 1.1 3.8 0.0 0.0 0.0 0.0 0.1 0.0 0.0 1.4 0.8 0.3 0.5 0.1 0.0 0.0 0.2 0.1 0.0 0.1 TRHR ENSG00000174417 "Thyrotropin releasing hormone receptor" P34981 8 109086585-109121565 "Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Congenital hypothyroidism, Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 8 "brain: 5.2" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA055162 Approved NA NA "Cluster 65: Brain - Ion transport" "Cluster 8: Neurons & Oligodendrocytes - Synaptic function" "HPA055162: AB_2732592" "unprognostic (1.92e-2)" "unprognostic (8.58e-2)" "unprognostic (1.17e-1)" 0.0 0.0 3.2 0.0 0.8 0.0 0.0 0.0 5.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 1.4 0.0 0.0 0.0 0.0 0.9 1.2 0.0 0.0 0.0 0.6 0.0 1.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.8 0.0 5.2 3.4 1.4 0.9 1.2 1.2 1.7 0.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 TRPA1 ANKTM1 ENSG00000104321 "Transient receptor potential cation channel subfamily A member 1" O75762 8 72019917-72075584 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sensory transduction, Transport" "Ion channel" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 9.2;stomach 1: 10.3;urinary bladder: 27.7" "Cell type enhanced" "Detected in some" "Early spermatids: 10.9;Excitatory neurons: 5.0;Fibroblasts: 8.1;Intestinal goblet cells: 17.2;Skeletal myocytes: 4.5" "Cancer enhanced" "Detected in many" "breast cancer: 2.7" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in some" 5 "HHSteC: 25.9" "Not detected" "Not detected" "Low region specificity" "Detected in some" NA NA "Cluster 27: Non-specific - Gene expression" "Cluster 37: Intestine - Unknown function" "Cluster 30: Epithelial cell lines - Translation" "Cluster 27: Mucus-secreting cells - Mucin production" "unprognostic (2.14e-2)" "unprognostic (2.50e-2)" "prognostic favorable (6.57e-4)" "unprognostic (1.28e-2)" "unprognostic (2.34e-1)" "unprognostic (1.95e-1)" "unprognostic (1.37e-2)" "unprognostic (8.11e-3)" "unprognostic (4.22e-2)" "unprognostic (2.47e-1)" "unprognostic (2.78e-3)" "unprognostic (1.49e-1)" "unprognostic (2.16e-4)" "unprognostic (2.37e-1)" "unprognostic (9.67e-2)" "unprognostic (1.57e-1)" "unprognostic (2.90e-1)" 0.3 0.4 0.1 3.8 0.0 0.0 0.0 0.0 0.7 0.1 0.0 7.9 6.3 0.3 0.0 1.0 0.2 7.0 0.8 0.8 0.0 0.1 0.0 0.2 0.8 0.3 0.0 0.8 0.1 0.0 0.0 0.7 0.0 0.1 9.2 0.0 0.2 0.0 0.1 0.1 7.4 0.3 0.0 0.5 10.3 0.5 0.0 0.2 0.1 0.0 0.2 27.7 0.3 0.2 0.0 2.8 0.8 0.0 0.0 0.1 0.0 0.3 2.5 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 2.0 0.4 1.5 0.1 0.0 0.5 0.0 25.9 0.0 0.2 1.7 0.0 1.2 0.2 5.5 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.1 0.6 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.1 0.1 0.5 0.0 2.6 0.2 0.0 0.4 0.0 0.1 4.0 1.2 0.0 0.3 0.3 0.0 1.9 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.2 0.0 0.1 0.0 0.0 0.7 0.8 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 10.9 0.0 0.1 0.0 0.0 0.0 5.0 0.0 0.0 8.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 17.2 0.0 0.0 0.0 0.8 0.3 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.1 0.0 1.1 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 4.5 0.8 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.5 0.0 TRPM8 ENSG00000144481 "Transient receptor potential cation channel subfamily M member 8" Q7Z2W7 2 233917373-234019522 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Sensory transduction, Transport" "Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 57 "liver: 31.5;prostate: 80.2" "Group enriched" "Detected in some" 5 "Hepatocytes: 45.2;Prostatic glandular cells: 16.3" "Cancer enriched" "Detected in some" 27 "prostate cancer: 72.4" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "GAMG: 3.4;Karpas-707: 5.5;RPTEC TERT1: 8.1;SK-MEL-30: 8.9;WM-115: 5.0" "Not detected" "Not detected" "Low region specificity" "Detected in many" NA NA "Cluster 40: NK-cells - Unknown function" "Cluster 85: Liver - Metabolism" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 2: Hepatocytes - Metabolism" "unprognostic (4.41e-3)" "unprognostic (7.91e-2)" "unprognostic (1.11e-1)" "unprognostic (5.49e-3)" "unprognostic (1.05e-1)" "unprognostic (4.60e-3)" "prognostic favorable (7.15e-4)" "unprognostic (3.28e-2)" "unprognostic (3.71e-1)" "unprognostic (9.88e-3)" "unprognostic (7.10e-3)" "unprognostic (4.69e-2)" "unprognostic (3.36e-5)" "unprognostic (1.11e-1)" "unprognostic (1.65e-1)" "unprognostic (1.18e-1)" "unprognostic (5.53e-2)" 0.0 0.2 0.2 0.2 0.3 0.1 0.0 0.3 0.3 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.3 0.3 0.1 31.5 0.0 0.1 0.1 0.9 0.0 0.0 0.1 0.5 0.0 0.3 80.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.9 0.2 0.4 0.0 0.0 0.1 0.0 0.0 0.6 0.0 0.5 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.9 0.1 0.0 0.0 0.0 0.4 0.6 8.1 0.0 0.5 0.3 0.0 0.1 8.9 0.0 0.3 0.5 0.0 0.0 0.0 0.2 0.0 1.2 2.0 0.0 0.7 0.0 5.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.0 0.0 0.0 0.0 0.2 0.3 0.3 0.3 0.3 0.3 0.1 0.9 0.3 0.0 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.4 5.5 0.1 0.0 0.7 0.2 0.0 1.1 2.8 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.4 2.3 1.2 0.6 0.5 0.0 2.7 0.3 1.7 0.0 0.3 0.0 4.4 0.0 0.1 0.7 45.2 0.3 0.0 0.9 0.0 0.0 0.6 0.8 3.9 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.1 16.3 0.0 0.0 0.0 0.2 0.0 0.4 0.2 1.3 0.6 0.0 0.1 0.0 0.5 0.0 0.0 4.1 TRPV1 VR1 ENSG00000196689 "Transient receptor potential cation channel subfamily V member 1" Q8NER1 17 3565444-3609411 "FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Ion channel" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 24.6" "Cell type enhanced" "Detected in many" "Astrocytes: 20.2;Cone photoreceptor cells: 16.7;Oligodendrocytes: 18.8;Rod photoreceptor cells: 26.0" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "HaCaT: 9.8" "Not detected" "Not detected" "Not detected" "Not detected" NA NA "Cluster 2: Granulocytes - Unknown function" "Cluster 15: Liver - Metabolism" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 46: Photoreceptor cells - Phototransduction" "unprognostic (3.96e-2)" "unprognostic (1.63e-1)" "unprognostic (1.18e-1)" "unprognostic (1.33e-2)" "unprognostic (6.83e-2)" "unprognostic (3.21e-4)" "unprognostic (9.90e-2)" "unprognostic (2.95e-1)" "unprognostic (2.03e-1)" "unprognostic (2.56e-2)" "unprognostic (3.43e-3)" "unprognostic (6.17e-3)" "unprognostic (6.97e-4)" "unprognostic (4.25e-1)" "unprognostic (4.78e-1)" "unprognostic (3.81e-2)" "unprognostic (5.12e-3)" 5.9 4.9 6.6 1.6 7.8 1.0 6.0 7.6 8.4 9.9 5.1 5.7 7.3 4.7 2.2 3.3 6.8 1.8 7.6 6.6 6.5 8.1 24.6 3.2 2.4 7.2 8.0 10.2 7.8 1.2 5.8 2.0 7.2 6.0 2.4 12.9 4.3 1.6 6.6 5.5 8.6 1.6 6.3 4.3 5.9 5.0 7.3 2.0 4.7 1.7 1.7 5.0 6.9 10.5 2.3 4.1 3.1 3.7 3.5 3.4 2.9 1.1 1.8 2.0 1.8 0.8 1.1 0.9 1.6 1.4 1.3 9.8 2.0 0.5 1.3 5.6 4.7 0.5 2.1 4.3 1.6 0.3 3.8 4.2 2.0 2.7 1.2 1.8 0.4 2.1 0.3 1.6 1.2 2.2 1.6 0.7 2.3 0.4 2.1 4.6 2.1 0.7 1.6 1.6 1.4 3.0 1.7 3.2 1.7 2.3 6.0 1.6 1.3 0.7 1.8 2.8 1.6 1.3 0.8 0.3 1.2 1.6 1.5 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.3 0.2 0.0 0.0 0.2 0.0 0.0 6.6 7.8 7.6 8.4 6.6 6.5 7.2 8.0 7.2 6.3 7.3 10.5 1.8 0.0 2.6 20.2 0.7 0.0 0.5 0.0 2.8 9.5 3.2 2.3 0.3 4.3 1.3 5.5 16.7 1.2 0.6 2.3 0.0 0.5 2.5 3.3 1.7 1.3 1.2 0.4 10.5 0.7 0.3 1.7 11.2 2.9 0.0 5.4 2.5 7.9 0.8 6.7 10.3 1.9 0.0 0.6 0.0 0.5 4.7 1.4 0.0 4.7 0.9 2.3 4.1 8.5 18.8 0.5 0.5 3.8 0.5 0.6 6.6 2.2 2.2 26.0 0.0 5.9 1.9 0.8 1.2 1.8 0.0 0.8 0.6 9.5 2.1 0.4 TRPV3 VRL3 ENSG00000167723 "Transient receptor potential cation channel subfamily V member 3" Q8NET8 17 3510502-3557812 "Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel" "Disease variant, FDA approved drug targets, Palmoplantar keratoderma" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 5.2;skin 1: 4.8" "Cell type enhanced" "Detected in many" "Basal keratinocytes: 18.7;Plasma cells: 15.9;Proximal enterocytes: 26.1;Suprabasal keratinocytes: 24.6" "Cancer enhanced" "Detected in some" "head and neck cancer: 1.6" "Low region specificity" "Detected in many" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A-431: 3.3;BEWO: 5.0;CACO-2: 3.1;RH-30: 11.9;T-47d: 5.2;U-266/70: 3.1;U-266/84: 2.7" "Not detected" "Not detected" "Low region specificity" "Detected in many" HPA069550 Approved "Plasma membrane,Centrosome,Cytosol" NA NA "Cluster 31: Skin - Epidermis development" "Cluster 31: RH-30 & LHCN-M2 - Muscle contraction" "Cluster 45: Enterocytes - Digestion" "Plasma membrane" "Centrosome, Cytosol" "HPA069550: AB_2686149" "unprognostic (1.84e-4)" "unprognostic (2.25e-1)" "unprognostic (5.22e-2)" "unprognostic (3.92e-4)" "unprognostic (4.87e-3)" "unprognostic (2.96e-2)" "unprognostic (6.66e-2)" "unprognostic (4.88e-2)" "unprognostic (7.02e-2)" "unprognostic (2.68e-1)" "unprognostic (4.88e-2)" "unprognostic (3.69e-2)" "unprognostic (0.00e+0)" "unprognostic (1.12e-1)" "unprognostic (1.77e-1)" "unprognostic (8.64e-2)" "unprognostic (2.93e-2)" 0.1 0.0 1.1 0.5 1.1 0.5 0.2 0.1 1.1 0.3 0.0 0.9 2.0 0.0 0.1 0.2 0.0 0.1 0.0 0.6 0.3 0.0 0.6 0.1 0.3 0.4 0.3 0.2 0.0 0.1 0.3 0.2 0.4 0.1 1.7 0.2 0.1 0.0 1.5 4.8 5.2 0.1 0.1 0.2 0.9 0.4 0.9 0.0 0.0 0.5 0.5 0.2 0.3 1.8 3.3 0.0 0.3 0.0 0.2 0.3 5.0 0.1 0.0 0.0 0.0 3.1 0.8 0.1 1.0 0.1 0.1 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.4 0.0 0.1 0.5 0.2 0.0 0.6 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.1 0.1 0.2 0.4 0.1 11.9 0.1 0.0 0.1 0.0 0.0 0.1 0.5 0.0 0.0 5.2 0.1 0.0 0.0 0.1 0.1 0.0 3.1 2.7 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 1.1 1.1 0.1 1.1 0.6 0.3 0.4 0.3 0.4 0.1 0.9 1.8 0.2 0.0 2.5 2.9 5.8 18.7 3.9 0.2 10.2 1.2 0.9 0.5 3.5 1.5 0.2 0.0 0.0 0.3 2.6 8.9 1.9 0.0 0.3 0.7 0.9 1.6 0.0 0.0 1.6 0.0 0.9 3.7 6.1 0.9 0.0 1.1 0.0 0.3 0.3 5.0 0.6 2.7 0.0 0.0 3.8 0.4 3.1 0.8 7.2 0.0 0.1 2.2 3.1 0.5 2.3 1.2 2.5 3.4 15.9 5.9 26.1 2.3 0.2 1.0 0.0 6.9 1.8 0.0 1.5 2.9 24.6 0.5 1.8 2.8 0.9 3.7 TSPO "BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS" ENSG00000100300 "Translocator protein" "B1AH88, P30536" 22 43151547-43163242 "Cancer-related genes, FDA approved drug targets, Predicted membrane proteins" "Lipid transport, Transport" Receptor "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 690.1" "Cell type enhanced" "Detected in many" "Basal respiratory cells: 1429.2;Pancreatic endocrine cells: 1442.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "RPMI-8226: 516.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB011232, HPA046260, HPA072304" Uncertain Supported Vesicles,Mitochondria,Cytosol NA NA "Cluster 25: Monocytes - Inflammatory response" "Cluster 11: Squamous epithelial cells - Epithelial cell function" "Cluster 25: RPMI-8226 - Immune response" "Cluster 16: Pancreatic endocrine cells - Mixed function" Mitochondria "Vesicles, Cytosol" "CAB011232: , HPA046260: , HPA072304: " "unprognostic (5.29e-3)" "unprognostic (1.41e-1)" "unprognostic (3.31e-1)" "unprognostic (4.02e-3)" "unprognostic (3.95e-1)" "unprognostic (1.46e-2)" "prognostic unfavorable (1.61e-4)" "unprognostic (2.16e-1)" "unprognostic (1.17e-1)" "unprognostic (3.75e-2)" "unprognostic (1.07e-2)" "unprognostic (1.33e-1)" "unprognostic (1.69e-1)" "unprognostic (1.53e-2)" "unprognostic (3.03e-1)" "unprognostic (1.04e-1)" "unprognostic (2.34e-3)" 249.3 164.5 42.3 65.3 46.3 488.7 204.3 50.9 61.1 217.3 45.8 189.7 73.6 91.8 8.7 690.1 108.5 39.4 174.7 39.9 51.0 120.5 81.9 181.5 44.3 61.9 48.8 72.3 93.4 22.4 50.8 30.5 57.4 126.6 33.9 4.2 244.9 28.9 84.0 388.0 116.9 26.6 58.0 206.9 216.9 21.4 59.5 22.2 77.4 27.5 39.9 135.7 355.5 69.0 300.0 143.3 10.2 134.4 54.7 175.3 10.8 216.6 107.0 109.4 115.7 28.8 222.4 0.3 147.8 175.7 52.2 242.2 27.9 171.7 13.9 49.5 111.4 28.9 150.4 10.1 193.4 66.4 145.0 137.5 276.4 65.9 58.2 125.8 262.9 0.2 24.0 53.6 114.2 244.5 1.1 188.5 11.6 154.0 355.7 67.0 0.0 516.2 139.3 173.8 14.0 65.4 103.9 200.4 263.5 0.1 76.3 256.6 269.7 132.6 96.9 135.5 92.9 21.7 4.1 2.7 170.0 218.3 171.4 656.8 1678.5 931.0 314.7 1051.6 247.7 199.2 429.9 309.2 1170.2 266.9 325.9 264.3 1052.3 365.0 713.1 209.0 539.5 1585.6 42.3 46.3 50.9 61.1 39.9 51.0 61.9 48.8 57.4 58.0 59.5 69.0 225.5 160.3 140.0 3.6 88.9 366.8 392.3 1429.2 554.3 2.8 269.3 360.2 92.1 323.1 555.7 206.0 2.1 10.0 140.3 680.7 369.8 578.5 2.4 170.8 143.6 220.4 194.9 239.9 0.3 586.4 284.9 205.1 440.9 309.5 268.6 124.3 187.1 110.5 758.5 3.3 0.8 636.8 478.1 644.7 524.7 11.7 82.6 611.6 723.9 10.3 776.9 180.5 207.0 6.0 20.1 1442.1 705.9 157.6 76.3 526.2 471.9 180.7 283.2 19.4 105.2 108.2 197.8 2.8 4.5 1067.4 536.0 20.0 180.0 30.5 664.1 786.1 TTR "CTS, CTS1, HsT2651, PALB" ENSG00000118271 Transthyretin P02766 18 31557009-31598833 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Transport "Hormone, Thyroid hormone" "Amyloidosis, Cancer-related genes, Disease variant, FDA approved drug targets, Neuropathy" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 7 "choroid plexus: 142023.1" "Cell type enriched" "Detected in many" 30 "Hepatocytes: 23659.3" "Group enriched" "Detected in many" 28 "liver cancer: 928.2;pancreatic cancer: 666.0" "Group enriched" "Detected in all" 7 "cerebellum: 621.7;hippocampal formation: 1730.9;thalamus: 688.2" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "CACO-2: 160.1;EFO-21: 39.6;Hep G2: 249.0;U-2 OS: 57.0" "Group enriched" "Detected in all" 5 "basal ganglia: 1538.3;hippocampal formation: 4891.0;pons and medulla: 5758.5;thalamus: 3400.4" "Region enhanced" "Detected in all" "medulla oblongata: 1381.8" "CAB002517, HPA002550, CAB062567, CAB073406" Supported Approved "Golgi apparatus" "Secreted to blood" NA NA 345000000000 99000000000 "Cluster 1: Neutrophils - Mixed function" "Cluster 88: Choroid plexus - Transmembrane transport" "Cluster 39: CACO-2 - Unknown function" "Cluster 2: Hepatocytes - Metabolism" "Golgi apparatus" "CAB002517: AB_563965, CAB062567: AB_2665620, CAB073406: , HPA002550: AB_1080419" "unprognostic (6.79e-3)" "unprognostic (3.38e-2)" "unprognostic (4.10e-1)" "unprognostic (1.74e-1)" "unprognostic (1.84e-2)" "unprognostic (8.15e-2)" "unprognostic (3.74e-2)" "unprognostic (9.66e-3)" "unprognostic (8.72e-2)" "unprognostic (1.23e-2)" "unprognostic (8.35e-3)" "unprognostic (5.26e-1)" "unprognostic (3.52e-2)" 4.2 0.6 148.5 0.5 56.7 9.6 0.4 621.7 83.7 2.0 142023.1 6.0 14.9 1.3 0.9 2.2 0.8 51.2 2.9 1730.9 37.3 18.4 21288.1 0.8 2.4 106.5 86.0 1.1 1785.1 186.8 6.0 2.7 27.1 1.6 4.5 80.1 1.8 0.4 1.1 15.6 6.8 0.3 12.3 3.8 49.8 2.3 688.2 1.1 1.3 0.0 0.1 2.3 0.6 133.9 1.6 0.4 0.6 0.5 0.8 0.1 1.0 0.8 0.3 0.0 0.0 160.1 0.0 2.9 39.6 0.5 0.6 0.4 0.0 0.3 0.0 5.9 0.8 5.2 1.8 249.0 0.4 11.2 1.0 0.1 0.1 0.1 0.0 0.7 0.0 0.3 2.8 0.4 0.0 0.5 0.4 0.7 0.6 4.5 0.3 0.3 7.4 0.2 0.3 1.6 0.9 1.1 5.8 0.0 0.2 1.7 0.6 0.2 1.7 2.4 57.0 0.5 4.3 1.0 2.6 17.6 0.7 4.3 0.2 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.3 0.0 0.1 0.4 0.1 0.0 0.1 0.0 0.0 148.5 56.7 621.7 83.7 1730.9 37.3 106.5 86.0 27.1 12.3 688.2 133.9 0.0 0.0 0.0 0.0 15.1 0.5 0.0 0.0 0.0 144.8 0.0 0.0 1.8 779.2 0.0 5.5 162.6 0.3 0.0 1.5 5.9 3.1 6.8 0.5 0.5 14.1 356.2 192.5 0.0 2.0 3.6 0.7 13.3 0.0 0.0 0.2 192.4 23659.3 2.4 26.9 0.1 19.6 0.0 313.7 0.0 8.7 0.3 1.2 0.0 0.0 0.0 24.9 0.0 0.0 0.0 130.5 5.2 0.0 0.0 0.2 1.3 26.9 0.0 56.0 0.0 0.0 0.3 3.3 1.1 0.0 0.1 4.0 10.9 0.0 1.7 0.0 TUBA1A "B-ALPHA-1, FLJ25113, TUBA3" ENSG00000167552 "Tubulin alpha 1a" Q71U36 12 49184686-49189080 "Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins" "Cancer-related genes, Disease variant, FDA approved drug targets, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 1313.3" "Cell type enhanced" "Detected in all" "Ductal cells: 1162.0;Respiratory ciliated cells: 1173.3;Smooth muscle cells: 1005.3" "Cancer enriched" "Detected in all" 9 "glioma: 942.8" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in all" "neutrophil: 1660.9" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "AF22: 3100.7;SCLC-21H: 1983.9" "Low region specificity" "Detected in all" "CAB008686, HPA039247, HPA043684, HPA063394" Enhanced Enhanced Microtubules NA NA "Cluster 8: Neutrophils - Inflammatory response" "Cluster 57: Non-specific - Angiogenesis" "Cluster 12: NES - Nervous system development" "Cluster 10: Non-specific - Unknown function" Microtubules "CAB008686: AB_1624202, HPA039247: AB_2676410, HPA043684: AB_2678617, HPA063394: AB_2685003" "unprognostic (3.11e-1)" "unprognostic (1.61e-1)" "unprognostic (3.77e-1)" "unprognostic (1.14e-1)" "unprognostic (4.73e-1)" "unprognostic (1.15e-2)" "unprognostic (2.56e-2)" "unprognostic (2.12e-1)" "unprognostic (3.49e-2)" "unprognostic (3.80e-1)" "unprognostic (1.11e-3)" "unprognostic (9.79e-2)" "prognostic unfavorable (2.90e-4)" "unprognostic (1.07e-2)" "unprognostic (4.27e-2)" "unprognostic (1.12e-2)" "unprognostic (1.27e-3)" 150.3 133.5 803.3 166.9 990.4 152.0 179.7 1083.4 882.6 185.8 692.7 466.4 54.4 406.3 166.6 140.0 342.0 193.1 156.5 784.4 1066.9 64.9 21.1 214.3 71.7 1209.8 1002.4 172.8 53.5 79.1 163.4 123.9 1136.6 173.4 126.5 259.7 104.7 267.3 37.4 107.9 125.9 865.4 1083.5 84.7 135.6 69.0 987.8 162.7 39.7 94.1 55.9 210.1 117.1 1313.3 3.2 154.4 3100.7 419.3 263.1 613.9 10.5 286.4 325.6 163.2 390.4 9.4 54.8 120.7 322.4 824.7 304.0 6.4 388.0 97.3 120.3 97.0 138.1 41.5 27.6 34.4 54.1 70.2 3.2 359.5 33.8 325.0 31.8 627.1 945.9 237.2 45.0 124.5 888.7 70.3 276.5 59.2 335.0 3.6 112.5 225.4 232.3 14.1 718.9 13.8 1983.9 1150.3 79.1 4.5 106.0 449.9 210.4 97.3 929.1 178.6 108.5 21.2 80.5 41.5 126.9 234.2 93.8 117.2 191.6 503.5 260.5 824.7 159.0 554.9 118.1 158.2 140.0 146.7 314.0 166.9 134.2 125.2 1660.9 89.9 812.8 101.1 172.8 495.5 803.3 990.4 1083.4 882.6 784.4 1066.9 1209.8 1002.4 1136.6 1083.5 987.8 1313.3 296.9 230.8 181.5 49.9 220.8 87.2 250.6 179.3 59.7 233.0 140.0 291.6 187.9 25.8 148.1 64.4 77.2 10.5 202.9 4.5 25.4 1162.0 10.0 414.9 413.6 334.2 785.8 48.0 78.2 16.2 12.8 391.5 63.2 102.4 547.9 695.0 165.6 2.8 452.0 249.0 60.6 15.5 329.6 80.7 277.6 20.7 193.6 204.2 183.2 37.5 616.6 788.9 77.2 73.4 432.6 333.3 12.8 142.6 32.5 60.4 1.5 73.3 1173.3 349.6 164.3 542.7 1005.3 15.4 31.2 20.9 99.3 15.9 266.5 40.6 12.4 95.7 TUBA4A "FLJ30169, H2-ALPHA, TUBA1" ENSG00000127824 "Tubulin alpha 4a" P68366 2 219249710-219278170 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Amyotrophic lateral sclerosis, FDA approved drug targets, Neurodegeneration" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 360.2;tongue: 210.3" "Cell type enhanced" "Detected in many" "Early spermatids: 423.0;Late spermatids: 823.0;Pancreatic endocrine cells: 613.5;Smooth muscle cells: 408.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HaCaT: 265.9;HBEC3-KT: 439.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004621, CAB005887, HPA039247, HPA043684, HPA063394" Approved Enhanced Microtubules NA NA 130000000 "Cluster 5: Granulocytes - Unknown function" "Cluster 59: Non-specific - Translation" "Cluster 42: Epithelial cell lines - Epithelial cell function" "Cluster 10: Non-specific - Unknown function" Microtubules "CAB004621: AB_628411, CAB005887: AB_2288001, HPA039247: AB_2676410, HPA043684: AB_2678617, HPA063394: AB_2685003" "unprognostic (8.08e-2)" "unprognostic (2.31e-1)" "unprognostic (4.03e-2)" "unprognostic (2.56e-2)" "unprognostic (5.18e-3)" "unprognostic (3.99e-2)" "prognostic unfavorable (4.54e-6)" "unprognostic (1.52e-3)" "unprognostic (4.47e-1)" "unprognostic (8.85e-2)" "unprognostic (1.49e-2)" "unprognostic (5.27e-2)" "unprognostic (1.94e-1)" "unprognostic (2.70e-1)" "unprognostic (2.36e-1)" "unprognostic (7.38e-3)" "unprognostic (9.32e-2)" 14.3 41.4 33.6 34.1 47.5 107.1 16.4 22.3 133.1 27.7 8.1 32.9 18.6 9.8 10.1 84.8 12.6 13.5 97.7 42.6 32.3 31.9 29.5 26.7 56.7 46.3 27.3 12.9 18.2 34.6 23.1 5.0 31.4 19.7 27.8 39.2 46.9 22.4 360.2 161.4 35.5 12.8 3.9 56.8 30.6 32.4 14.9 16.9 12.3 210.3 63.4 22.6 57.3 54.0 106.0 90.0 0.0 0.3 9.1 6.9 0.3 16.2 49.7 2.8 1.9 20.4 106.7 144.2 172.2 11.7 172.7 265.9 49.3 439.9 3.9 81.7 0.7 184.2 154.5 15.4 7.3 60.9 60.8 6.7 158.0 23.7 49.2 27.4 17.3 2.4 20.5 91.3 100.6 4.3 0.3 107.9 32.3 83.2 107.4 6.5 139.0 84.5 129.7 7.5 85.8 1.5 213.2 18.7 0.7 1.8 8.0 50.9 12.3 49.8 27.4 58.4 56.7 38.0 48.8 171.4 183.3 116.4 2.5 141.7 63.3 170.2 107.1 45.7 110.1 124.9 150.3 142.8 20.9 95.5 140.2 138.4 331.2 82.0 71.9 3.8 143.8 270.9 33.6 47.5 22.3 133.1 42.6 32.3 46.3 27.3 31.4 3.9 14.9 54.0 55.3 44.8 47.1 16.3 160.6 181.8 201.2 235.3 68.9 123.3 42.3 51.6 60.9 28.6 62.0 49.7 77.2 0.7 311.6 87.3 140.8 199.3 423.0 9.8 3.3 36.5 107.9 56.2 34.8 205.6 0.5 11.5 40.8 26.1 15.8 0.1 36.0 33.0 6.0 67.3 22.5 141.9 48.8 15.3 54.9 823.0 16.8 159.5 78.2 9.4 27.8 38.6 50.4 10.6 10.6 613.5 51.2 7.5 202.3 46.7 87.5 137.5 11.1 72.9 0.0 21.1 408.5 5.7 5.0 130.6 244.5 2.5 290.1 1.4 58.9 113.0 TUBB "M40, MGC16435, OK/SW-cl.56, Tubb5" ENSG00000196230 "Tubulin beta class I" P07437 6 30717435-30725538 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Extravillous trophoblasts: 2296.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005417, CAB012406, HPA043640, HPA046280" Enhanced Supported "Microtubules,Cytokinetic bridge,Mitotic spindle" Yes Yes 170000000 "Cluster 39: Non-specific - mRNA processing" "Cluster 66: Lymphoid tissue - Immune response regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 10: Non-specific - Unknown function" Microtubules "Cytokinetic bridge, Mitotic spindle" "CAB005417: AB_2241191, CAB012406: AB_2210370, HPA043640: AB_2678594, HPA046280: AB_2679612" "unprognostic (1.01e-1)" "unprognostic (2.33e-1)" "unprognostic (2.17e-3)" "unprognostic (1.92e-2)" "unprognostic (1.56e-1)" "unprognostic (2.16e-2)" "prognostic unfavorable (5.97e-4)" "unprognostic (2.57e-2)" "unprognostic (2.52e-1)" "unprognostic (2.18e-3)" "unprognostic (1.27e-2)" "unprognostic (2.47e-1)" "prognostic unfavorable (2.62e-8)" "unprognostic (8.63e-2)" "unprognostic (1.47e-1)" "unprognostic (2.49e-1)" "unprognostic (2.50e-1)" 229.5 164.8 74.6 243.5 81.8 541.0 186.9 46.2 367.7 228.7 87.0 250.3 87.6 333.0 174.5 246.3 227.0 158.5 245.3 73.5 119.7 137.8 236.6 205.3 369.2 80.5 74.8 467.5 138.1 74.4 97.0 194.4 99.2 145.2 194.4 82.4 160.2 194.6 185.7 211.9 159.4 371.0 57.5 195.0 172.8 77.8 94.0 620.4 142.4 98.6 487.6 222.3 213.8 63.5 2281.7 1027.3 2650.0 1458.4 733.2 1265.2 568.2 396.9 469.5 943.3 863.5 1329.2 703.9 1494.1 1105.1 1408.1 1877.8 805.3 2160.6 1968.0 160.3 892.5 1321.1 461.4 207.3 1306.7 345.8 2550.0 1223.9 943.6 455.9 416.0 443.6 967.1 1493.3 2058.1 1270.4 294.1 1844.8 1398.2 2719.0 249.3 377.3 604.1 948.6 102.6 708.5 911.6 1564.5 1071.4 940.8 1516.7 969.0 911.2 354.7 1625.5 1148.3 422.4 880.6 2712.0 1526.0 614.5 917.7 835.3 1735.4 2101.3 538.8 2494.6 3548.7 119.8 115.6 122.8 187.3 182.5 218.8 166.1 152.3 188.8 111.7 113.0 143.2 163.3 46.8 165.1 222.4 227.7 180.8 342.5 74.6 81.8 46.2 367.7 73.5 119.7 80.5 74.8 99.2 57.5 94.0 63.5 215.8 131.4 47.3 21.5 214.9 576.2 358.4 698.6 434.2 72.7 234.2 312.8 114.9 244.5 238.7 171.0 39.6 811.9 198.7 133.4 311.0 1091.0 9.1 69.1 261.6 370.8 163.6 1322.1 28.2 1061.1 2296.1 471.5 95.3 140.2 207.3 643.6 298.4 267.8 955.2 109.4 25.0 185.3 376.4 454.5 689.6 24.4 402.6 295.8 321.9 30.9 774.0 192.6 246.1 20.1 23.0 1087.0 90.7 237.3 304.6 199.5 117.9 245.9 66.6 65.4 118.3 124.0 838.6 58.0 126.5 447.0 430.6 220.4 244.0 224.9 253.2 229.0 TUBB1 dJ543J19.4 ENSG00000101162 "Tubulin beta 1 class VI" Q9H4B7 20 59019429-59026654 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "bone marrow: 8.5;lymphoid tissue: 4.3" "Cell type enriched" "Detected in some" 10 "Macrophages: 191.2" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in many" 17 "basophil: 63.5;neutrophil: 26.0" "Lineage enriched" "Detected in many" 24 "granulocytes: 63.5" "Cell line enriched" "Detected in some" 19 "HEL: 29.5" "Not detected" "Not detected" "Not detected" "Not detected" "CAB004286, HPA043640, HPA046280" Approved Supported "Microtubules,Cytokinetic bridge,Mitotic spindle" Yes NA 87000000 "Cluster 34: Basophils - Unknown function" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 36: HEL - Hemostasis" "Cluster 51: Myeloid cells - Hemostasis" Microtubules "Cytokinetic bridge, Mitotic spindle" "CAB004286: AB_2288090, HPA043640: AB_2678594, HPA046280: AB_2679612" "unprognostic (3.76e-1)" "unprognostic (2.69e-1)" "unprognostic (6.10e-4)" "unprognostic (1.02e-1)" "unprognostic (5.00e-2)" "unprognostic (2.02e-1)" "unprognostic (5.86e-2)" "unprognostic (7.51e-4)" "unprognostic (1.90e-2)" "unprognostic (2.63e-1)" "unprognostic (6.80e-5)" "unprognostic (3.46e-1)" "unprognostic (1.16e-1)" "unprognostic (2.55e-1)" "unprognostic (1.40e-1)" "unprognostic (2.31e-1)" "unprognostic (1.00e-1)" 0.2 0.2 0.2 0.3 0.2 8.5 0.1 0.5 0.5 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.1 0.1 0.2 0.1 0.3 2.4 0.2 0.3 0.2 0.1 0.1 0.0 0.3 1.1 0.2 0.0 0.0 0.2 0.1 0.0 0.4 0.1 0.2 0.0 0.1 4.3 0.1 0.9 0.2 0.0 0.2 1.5 0.0 0.0 0.0 0.3 0.1 0.3 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.7 0.2 0.4 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.2 29.5 0.8 1.5 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.3 1.4 0.0 0.0 0.1 0.3 0.3 0.0 0.1 0.4 0.2 0.1 0.3 0.0 0.3 0.3 0.2 0.2 0.6 0.1 0.1 0.1 0.2 0.0 0.2 0.2 0.3 0.1 0.2 0.3 0.2 0.1 0.2 0.4 63.5 2.4 1.9 0.5 0.6 0.4 0.9 0.2 0.0 1.1 0.5 0.4 0.0 26.0 0.2 0.3 2.6 0.5 281.6 0.2 0.2 0.5 0.5 0.1 0.2 0.3 0.2 0.2 0.1 0.2 0.3 0.1 0.0 1.1 0.3 1.4 0.0 0.0 0.0 0.0 1.7 0.1 0.1 0.1 0.0 0.6 0.0 4.2 0.0 3.1 0.0 0.0 0.0 16.0 0.3 0.2 1.5 0.0 19.0 0.2 0.0 0.1 0.1 0.0 0.7 1.3 0.0 3.6 0.2 0.3 0.0 0.2 0.0 0.0 2.8 0.0 5.9 0.3 191.2 0.0 0.0 13.8 0.2 13.4 0.0 0.1 0.0 0.0 0.4 0.4 0.0 0.0 0.1 0.0 1.9 0.0 0.2 0.1 0.1 0.1 0.0 0.0 0.1 1.0 0.1 0.1 0.1 TUBB3 "beta-4, CFEOM3, CFEOM3A, FEOM3" ENSG00000258947 "Tubulin beta 3 class III" Q13509 16 89921392-89938761 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 313.3" "Cell type enhanced" "Detected in some" "Astrocytes: 20.2;Ductal cells: 28.7;Excitatory neurons: 37.9;Exocrine glandular cells: 21.4;Gastric mucus-secreting cells: 27.0;Inhibitory neurons: 45.1;Pancreatic endocrine cells: 49.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in single" 8 "naive B-cell: 2.5" "Lineage enriched" "Detected in single" 9 "B-cells: 2.5" "Cell line enhanced" "Detected in many" "A549: 421.3;SCLC-21H: 424.9;SH-SY5Y: 433.8" "Low region specificity" "Detected in all" "HPA043640, HPA046280" Approved Approved "Microtubules,Cytokinetic bridge,Mitotic spindle" Yes NA 89000000 "Cluster 24: B-cells - Unknown function" "Cluster 73: Brain - Neuropeptide signaling" "Cluster 13: SH-SY5Y - Nervous system development" "Cluster 1: Pancreatic cells - Digestion" Microtubules "Cytokinetic bridge, Mitotic spindle" "HPA043640: AB_2678594, HPA046280: AB_2679612" "unprognostic (7.08e-2)" "unprognostic (3.37e-4)" "unprognostic (1.05e-1)" "unprognostic (1.06e-1)" "unprognostic (8.01e-2)" "unprognostic (3.12e-2)" "unprognostic (4.04e-3)" "unprognostic (1.12e-3)" "unprognostic (1.22e-2)" "unprognostic (6.06e-2)" "unprognostic (1.99e-2)" "unprognostic (1.38e-2)" "unprognostic (7.57e-2)" "unprognostic (1.27e-3)" "unprognostic (3.70e-2)" "unprognostic (3.05e-1)" "unprognostic (1.91e-2)" 5.7 24.8 99.4 12.1 93.3 3.4 2.1 100.5 127.6 3.3 0.0 18.4 3.7 9.7 0.2 3.6 2.3 8.8 5.5 88.6 313.3 13.3 0.9 4.1 7.1 208.8 132.7 3.9 3.2 0.4 55.1 1.8 266.2 3.0 2.6 24.8 10.6 0.4 0.6 5.2 8.0 12.7 74.2 1.3 7.2 38.0 183.4 1.0 2.5 0.3 5.2 7.3 5.3 82.5 30.1 421.3 152.6 173.9 17.9 170.8 6.8 181.0 31.0 105.8 48.2 57.2 53.5 89.6 93.6 136.8 74.3 112.1 148.9 26.7 26.3 22.7 15.5 0.7 32.5 383.7 6.0 0.0 67.6 98.4 7.9 161.9 14.0 136.8 88.4 5.9 9.2 2.5 122.3 288.6 1.2 31.5 274.3 11.2 237.3 0.1 54.1 9.5 131.8 8.1 424.9 433.8 251.2 4.4 137.1 27.5 15.0 1.9 110.9 142.8 156.9 197.3 185.3 1.4 19.6 35.2 150.2 11.5 260.8 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 99.4 93.3 100.5 127.6 88.6 313.3 208.8 132.7 266.2 74.2 183.4 82.5 0.4 0.0 0.0 20.2 0.0 0.0 0.0 0.0 3.4 1.8 0.2 0.1 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.1 0.0 28.7 8.2 0.5 2.6 3.8 4.9 0.0 37.9 21.4 0.7 6.1 27.0 0.7 0.0 0.0 0.0 0.0 0.2 5.0 45.1 0.1 0.0 0.0 0.0 16.8 0.3 0.2 0.0 9.4 0.0 0.3 0.0 16.1 9.2 49.2 0.0 0.4 0.4 0.0 0.0 0.1 0.0 1.4 0.0 0.0 5.1 0.2 0.4 3.0 0.0 1.0 0.1 0.0 0.2 0.0 TUBB4B "Beta2, TUBB2C" ENSG00000188229 "Tubulin beta 4B class IVb" P68371 9 137241287-137243707 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Deafness, Disease variant, FDA approved drug targets, Leber congenital amaurosis" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Early spermatids: 2190.0;Late spermatids: 2907.1;Spermatocytes: 1717.5" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010880, HPA043640, HPA046280" Enhanced Supported "Microtubules,Cytokinetic bridge,Mitotic spindle" Yes Yes "Cluster 38: Basophils - Unknown function" "Cluster 42: Ciliated cells - Cilium & Cell projection" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 7: Non-specific - Mitochondria" Microtubules "Cytokinetic bridge, Mitotic spindle" "CAB010880: AB_609915, HPA043640: AB_2678594, HPA046280: AB_2679612" "unprognostic (2.24e-1)" "unprognostic (1.77e-3)" "unprognostic (1.50e-1)" "prognostic favorable (4.91e-4)" "unprognostic (1.29e-2)" "unprognostic (8.93e-2)" "prognostic unfavorable (9.98e-4)" "unprognostic (9.92e-3)" "unprognostic (2.90e-1)" "unprognostic (3.63e-1)" "unprognostic (2.34e-1)" "unprognostic (4.09e-2)" "unprognostic (2.47e-3)" "unprognostic (6.37e-2)" "unprognostic (1.36e-2)" "prognostic favorable (6.36e-6)" "unprognostic (1.69e-1)" 134.5 112.6 162.0 97.2 163.4 423.9 94.4 149.4 182.7 88.1 482.7 198.3 142.0 107.7 209.1 343.3 507.2 106.0 435.8 174.0 185.2 122.5 140.1 130.5 95.5 184.1 233.6 72.9 123.8 87.8 118.0 86.3 213.9 120.2 111.9 261.8 177.9 121.5 202.5 240.0 166.4 119.8 162.9 85.6 161.4 765.7 192.6 162.9 115.7 96.6 119.7 188.3 139.4 133.9 706.2 1032.5 431.7 314.2 213.2 223.6 600.5 643.7 536.0 872.4 598.6 1101.0 840.2 429.0 480.2 631.2 848.2 1305.1 539.5 1039.2 330.2 307.9 458.5 311.2 789.6 877.8 134.5 370.0 331.5 145.0 291.5 667.5 183.1 215.7 631.7 300.6 443.0 239.7 731.2 1936.4 337.4 504.2 457.8 1234.8 1778.1 423.5 822.2 394.2 666.8 647.8 301.5 323.6 853.9 485.8 173.2 244.2 699.0 397.6 495.6 618.1 685.0 710.0 863.6 92.4 274.9 475.1 503.6 286.9 549.8 95.7 30.0 43.2 40.5 30.1 38.2 32.6 31.3 34.4 34.9 30.8 19.7 26.7 56.4 24.4 30.5 36.3 44.7 32.6 162.0 163.4 149.4 182.7 174.0 185.2 184.1 233.6 213.9 162.9 192.6 133.9 478.5 221.2 146.3 21.5 315.8 326.2 945.7 458.7 327.2 508.1 286.9 389.5 91.9 143.0 284.1 143.5 300.3 346.6 640.9 744.1 221.1 348.6 2190.0 1191.6 224.8 203.9 391.5 419.9 30.1 446.8 545.5 247.8 274.7 415.0 189.2 200.9 142.5 139.2 265.9 244.0 24.3 503.6 323.5 59.9 214.9 2907.1 254.2 299.3 138.7 22.5 224.0 299.3 49.4 15.6 19.7 477.4 697.2 153.1 264.0 475.1 540.7 345.5 1558.7 763.3 111.7 261.8 416.0 1717.5 740.9 419.1 297.6 321.1 362.9 89.8 487.3 592.7 TUBD1 "FLJ12709, TUBD" ENSG00000108423 "Tubulin delta 1" Q9UJT1 17 59859479-59892945 "FDA approved drug targets, Predicted intracellular proteins" "Cilium biogenesis/degradation" "Developmental protein" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 83.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004609, HPA023980, HPA027090" Approved Approved Nucleoplasm,Cytosol NA Yes "Cluster 13: T-cells - Unknown function" "Cluster 35: Non-specific - Unknown function" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 11: Alveolar cells - Smell perception" "Nucleoplasm, Cytosol" "CAB004609: AB_628416, HPA023980: AB_1858456, HPA027090: AB_1858457" "unprognostic (1.92e-1)" "unprognostic (5.95e-2)" "prognostic favorable (2.04e-4)" "unprognostic (1.39e-1)" "unprognostic (1.32e-2)" "unprognostic (5.64e-2)" "prognostic unfavorable (1.00e-5)" "unprognostic (2.86e-2)" "unprognostic (8.87e-3)" "unprognostic (1.02e-1)" "unprognostic (1.77e-3)" "unprognostic (2.59e-1)" "prognostic unfavorable (6.06e-4)" "unprognostic (4.97e-2)" "unprognostic (1.63e-1)" "unprognostic (1.36e-1)" "unprognostic (8.83e-2)" 4.4 4.4 5.8 4.9 6.9 3.9 7.0 9.2 7.4 7.5 5.0 7.5 3.8 5.5 9.1 10.6 6.5 4.6 6.0 5.9 6.3 6.2 5.9 5.1 6.7 6.7 6.9 9.0 7.8 5.9 6.9 4.2 7.0 7.8 4.7 5.6 7.0 6.2 6.5 6.8 4.8 4.3 6.3 5.8 6.4 5.5 6.2 8.2 7.3 7.7 8.3 6.4 8.3 8.9 11.7 15.8 12.2 12.8 6.8 4.9 9.7 9.1 5.3 11.7 9.5 17.0 7.5 10.5 15.0 2.1 7.9 9.7 17.4 5.4 11.1 6.1 21.2 12.6 12.4 20.4 3.6 7.6 6.4 2.7 8.3 10.1 3.5 4.0 9.4 10.3 27.5 7.1 4.0 83.1 15.6 8.5 10.8 13.0 6.9 16.1 17.9 16.2 5.0 4.8 11.3 6.8 6.4 4.9 6.5 14.5 11.8 7.2 3.0 8.4 18.3 5.9 9.8 8.3 13.7 16.2 4.0 8.3 7.5 6.5 8.4 16.3 11.4 5.8 13.2 11.7 14.0 12.1 5.9 8.9 18.1 14.8 8.8 10.1 6.5 9.9 16.7 7.1 5.8 6.9 9.2 7.4 5.9 6.3 6.7 6.9 7.0 6.3 6.2 8.9 8.3 12.8 36.1 10.7 16.9 15.7 14.4 9.1 10.8 7.6 10.9 11.3 5.3 5.7 17.6 3.7 6.2 6.3 9.4 3.2 11.7 5.7 1.7 9.2 8.5 9.4 10.3 13.9 9.2 4.8 7.4 9.6 4.1 16.3 11.4 9.9 8.9 3.8 4.0 3.3 9.5 5.5 8.2 4.7 7.1 0.8 5.6 6.9 7.2 9.4 6.0 10.3 13.4 8.5 18.4 3.7 7.5 8.2 10.9 12.5 3.6 3.6 9.4 8.6 6.6 13.3 9.6 14.7 24.2 10.6 16.9 4.0 16.2 2.6 4.9 6.8 TUBE1 "dJ142L7.2, FLJ22589, TUBE" ENSG00000074935 "Tubulin epsilon 1" Q9UJT0 6 112070663-112087529 "FDA approved drug targets, Predicted intracellular proteins" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in all" "Early spermatids: 199.6;Spermatocytes: 97.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Cell line enhanced" "Detected in all" "U-2197: 48.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA032073, HPA032074" Approved NA NA "Cluster 16: MAIT-cells - Unknown function" "Cluster 15: Liver - Metabolism" "Cluster 18: U-2197 - ECM organization" "Cluster 23: Spermatids - Flagellum & Golgi organization" "HPA032073: AB_10601773, HPA032074: AB_10601216" "unprognostic (4.79e-2)" "unprognostic (1.61e-1)" "unprognostic (3.76e-2)" "unprognostic (1.29e-1)" "unprognostic (2.22e-2)" "unprognostic (7.36e-2)" "unprognostic (1.22e-1)" "unprognostic (8.36e-3)" "unprognostic (2.18e-1)" "unprognostic (1.04e-1)" "unprognostic (4.99e-3)" "unprognostic (1.70e-1)" "unprognostic (5.15e-3)" "unprognostic (1.64e-1)" "unprognostic (7.68e-2)" "unprognostic (2.50e-1)" "unprognostic (1.59e-3)" 12.3 9.0 9.8 5.0 10.1 4.1 11.0 11.7 16.8 15.6 9.9 11.8 5.0 17.0 8.3 6.8 16.4 8.8 17.5 9.7 10.0 12.3 40.1 7.9 7.3 10.4 10.2 15.2 10.9 7.5 14.4 9.1 10.4 11.0 6.2 10.1 6.7 8.4 5.8 11.3 7.6 10.3 10.2 6.9 11.7 27.1 10.1 4.8 10.6 4.8 5.4 12.6 10.4 11.4 2.1 2.8 7.6 24.0 17.5 9.2 6.3 8.6 13.7 5.9 11.6 4.2 4.2 8.0 5.4 3.6 9.2 6.4 8.7 3.8 12.2 4.1 7.8 2.8 2.0 6.1 25.0 15.4 10.1 10.0 25.1 8.1 20.9 8.5 7.4 22.8 15.6 10.8 4.8 1.7 8.8 20.5 7.6 12.1 5.2 10.3 4.7 5.2 9.0 2.0 11.5 10.1 7.0 6.0 26.4 6.6 4.8 36.5 4.3 5.3 4.9 48.2 9.2 3.2 1.1 8.7 7.7 18.2 13.8 0.0 0.4 1.1 1.1 0.5 3.3 1.5 2.4 1.5 0.8 1.1 3.2 2.7 0.3 1.8 0.8 0.6 2.5 0.9 9.8 10.1 11.7 16.8 9.7 10.0 10.4 10.2 10.4 10.2 10.1 11.4 27.6 6.4 16.7 25.8 13.4 24.6 17.8 12.3 15.4 23.0 15.0 13.3 17.5 11.5 13.5 22.0 35.5 4.1 9.8 6.8 15.6 12.5 199.6 12.1 12.0 16.7 6.1 19.1 58.2 18.0 12.3 18.8 7.7 7.7 16.5 11.5 18.5 71.9 7.2 13.5 68.3 11.4 4.1 6.7 10.2 49.8 15.5 6.2 7.2 21.5 4.6 11.8 9.2 31.7 82.0 12.6 9.0 19.9 10.9 13.2 12.7 25.6 14.6 28.0 19.7 13.3 13.4 97.0 27.0 12.7 12.5 3.3 14.8 35.0 8.0 14.8 TUBG1 "TUBG, TUBGCP1" ENSG00000131462 "Tubulin gamma 1" P23258 17 42609641-42615238 "Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Disease variant, FDA approved drug targets, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "testis: 173.8" "Cell type enhanced" "Detected in all" "Early spermatids: 670.6;Erythroid cells: 286.9;Late spermatids: 560.5;Spermatocytes: 347.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB004608 Enhanced NA Yes "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 23: Testis - Cell cycle regulation" "Cluster 40: Non-specific - Basic cellular processes" "Cluster 34: Spermatids - Unknown function" "CAB004608: AB_628417" "unprognostic (1.00e-1)" "unprognostic (5.57e-2)" "unprognostic (1.79e-2)" "prognostic favorable (8.99e-4)" "unprognostic (2.86e-2)" "unprognostic (2.01e-1)" "prognostic unfavorable (1.08e-8)" "unprognostic (2.62e-3)" "unprognostic (5.67e-2)" "unprognostic (1.83e-1)" "unprognostic (3.79e-1)" "unprognostic (2.16e-1)" "prognostic unfavorable (6.48e-5)" "unprognostic (2.64e-1)" "unprognostic (3.52e-1)" "unprognostic (2.61e-3)" "unprognostic (1.97e-2)" 23.0 30.4 17.7 20.4 18.4 51.7 19.0 17.8 25.4 17.6 21.1 24.0 16.6 20.7 13.4 35.6 16.3 10.1 43.6 18.5 19.8 24.8 27.1 19.1 18.0 20.3 18.0 12.5 48.7 29.9 20.2 21.0 20.0 19.7 14.9 10.5 19.1 18.3 60.7 29.0 18.1 27.2 15.9 19.3 29.8 173.8 21.4 27.6 14.8 36.3 20.6 21.7 19.9 19.7 117.8 288.8 112.1 124.0 70.5 47.8 97.7 133.4 87.2 205.6 158.8 177.4 76.9 80.2 92.8 105.9 178.5 171.9 124.2 178.0 149.7 225.9 142.6 64.1 168.5 299.3 34.6 73.8 87.6 38.1 54.0 251.1 75.8 50.6 131.9 119.0 119.7 77.2 155.9 326.7 176.3 66.2 59.3 176.7 139.1 81.8 164.2 130.5 91.7 136.6 158.9 74.5 78.0 76.9 63.6 113.9 233.6 70.2 88.5 197.9 131.0 169.2 207.0 111.2 169.0 126.2 108.6 70.6 144.2 1.7 13.1 3.1 10.6 25.1 11.6 14.9 9.8 11.4 15.7 15.0 10.4 10.5 0.4 12.7 27.4 44.1 13.5 10.4 17.7 18.4 17.8 25.4 18.5 19.8 20.3 18.0 20.0 15.9 21.4 19.7 14.9 16.0 4.2 3.9 12.8 17.6 16.3 49.4 12.0 14.1 14.6 16.5 18.8 14.3 24.1 7.3 4.2 45.8 7.0 10.2 39.2 35.2 670.6 15.1 13.7 20.1 9.6 286.9 7.2 54.4 78.6 15.7 15.8 10.7 2.5 16.9 15.7 15.9 40.2 20.2 6.4 13.7 38.7 6.3 10.8 560.5 22.7 9.7 17.8 8.4 26.4 17.7 10.3 4.0 3.8 42.3 6.2 21.8 41.5 15.2 15.1 76.6 18.1 10.9 59.2 7.1 43.5 347.8 128.0 27.3 28.6 20.1 8.5 15.0 14.0 15.6 TXNRD1 "GRIM-12, Trxr1, TXNR" ENSG00000198431 "Thioredoxin reductase 1" Q16881 12 104215779-104350307 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Electron transport, Transport" Oxidoreductase "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Basal prostatic cells: 459.7;Prostatic glandular cells: 557.4;Urothelial cells: 488.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "fHDF/TERT166: 1452.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA001395, CAB004607, CAB015834, HPA043871" Approved Supported Nucleoplasm NA NA 6100000 "Cluster 46: Basophils - DNA binding" "Cluster 12: Smooth muscle tissue - Mixed function" "Cluster 10: BJ & FHDF - ECM organization" "Cluster 22: Epithelial cell types - Mixed function" Nucleoplasm "CAB004607: AB_628405, CAB015834: , HPA001395: AB_1858377, HPA043871: AB_2678709" "unprognostic (2.52e-2)" "unprognostic (1.16e-1)" "unprognostic (5.48e-2)" "unprognostic (1.01e-1)" "unprognostic (3.15e-1)" "unprognostic (1.94e-2)" "prognostic unfavorable (1.12e-5)" "unprognostic (5.55e-2)" "unprognostic (1.18e-1)" "unprognostic (1.08e-1)" "unprognostic (6.42e-2)" "unprognostic (2.21e-1)" "prognostic unfavorable (1.20e-5)" "unprognostic (2.13e-1)" "unprognostic (1.27e-1)" "unprognostic (1.18e-2)" "unprognostic (8.80e-2)" 47.1 148.1 22.5 40.6 21.1 64.7 28.0 20.9 22.6 28.0 37.3 50.9 58.4 47.9 21.0 30.7 39.0 55.9 65.8 21.1 29.8 37.9 46.5 63.0 34.4 55.2 26.7 34.1 19.0 33.8 21.2 39.1 33.3 41.0 45.6 20.1 20.8 60.6 67.8 12.4 39.4 51.6 22.9 27.8 52.1 37.8 24.6 42.8 30.4 64.0 34.1 141.6 30.1 25.7 228.4 1032.6 118.1 111.3 553.5 308.0 409.8 412.4 259.3 182.7 186.8 110.5 329.4 169.3 187.0 1452.6 682.1 77.7 235.7 158.6 214.1 82.7 101.8 143.1 765.8 468.0 885.7 226.3 149.9 176.9 159.8 403.7 128.1 557.1 634.0 227.9 200.5 77.5 276.8 109.1 233.4 102.7 114.4 453.0 1053.1 227.3 82.1 146.5 211.2 123.1 182.6 110.6 333.3 519.1 325.2 222.6 123.2 131.4 854.5 89.3 183.7 201.3 341.2 84.8 179.9 254.5 186.8 122.5 538.0 109.4 29.9 69.7 23.6 39.0 26.9 21.3 21.6 23.9 39.5 14.5 19.1 16.7 102.6 24.4 48.4 25.2 19.8 27.6 22.5 21.1 20.9 22.6 21.1 29.8 55.2 26.7 33.3 22.9 24.6 25.7 26.0 64.1 67.5 50.3 27.6 104.0 459.7 41.3 40.9 28.1 19.4 16.3 66.2 32.9 79.3 16.5 22.9 26.1 40.4 93.4 41.1 79.6 45.0 100.9 36.8 116.2 20.4 46.3 48.2 80.7 34.3 90.1 69.8 119.6 53.2 35.2 49.2 68.2 42.0 28.6 56.7 18.8 44.7 43.5 100.5 19.1 68.0 62.2 19.6 49.6 51.9 24.8 26.8 29.1 55.3 197.7 40.5 29.3 28.4 557.4 24.6 37.5 105.5 20.9 0.0 43.4 84.0 14.4 33.8 24.3 72.9 51.3 28.5 98.4 33.0 488.0 TYMP "ECGF1, MNGIE" ENSG00000025708 "Thymidine phosphorylase" P19971 22 50525752-50530032 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Angiogenesis, Chemotaxis, Differentiation" "Developmental protein, Glycosyltransferase, Growth factor, Transferase" "Cancer-related genes, Disease variant, FDA approved drug targets, Neuropathy, Primary mitochondrial disease, Progressive external ophthalmoplegia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" "Exocrine glandular cells: 643.9;Hofbauer cells: 477.4;Macrophages: 561.7;monocytes: 2174.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in all" 5 "classical monocyte: 135.8;eosinophil: 74.9;intermediate monocyte: 98.4;myeloid DC: 39.5;neutrophil: 114.1;non-classical monocyte: 77.1" "Group enriched" "Detected in all" 10 "dendritic cells: 39.5;granulocytes: 114.1;monocytes: 135.8" "Cell line enhanced" "Detected in many" "CAPAN-2: 40.0;HHSteC: 95.2;Karpas-707: 68.6;U-266/70: 68.6" "Not detected" "Not detected" "HPA000530, HPA001072, CAB002518" Enhanced Approved "Nuclear bodies,Golgi apparatus,Cytosol" NA NA 11000000 "Cluster 52: Eosinophils - Transcription" "Cluster 64: Macrophages - Immune response" "Cluster 29: U-266 - Adaptive immune response" "Cluster 3: Monocytes - Immune response regulation" "Nuclear bodies, Golgi apparatus" Cytosol "CAB002518: AB_563953, HPA000530: AB_2666017, HPA001072: AB_1080274" "unprognostic (7.02e-3)" "unprognostic (1.00e-1)" "unprognostic (3.61e-1)" "prognostic favorable (4.34e-5)" "unprognostic (7.60e-2)" "unprognostic (1.16e-2)" "unprognostic (2.40e-1)" "unprognostic (7.17e-2)" "unprognostic (4.64e-2)" "unprognostic (1.33e-1)" "unprognostic (3.31e-2)" "unprognostic (2.17e-1)" "prognostic unfavorable (3.50e-8)" "unprognostic (1.32e-1)" "unprognostic (4.02e-2)" "unprognostic (1.52e-2)" "unprognostic (4.60e-2)" 46.8 19.5 6.1 77.7 6.0 22.0 37.9 7.1 7.9 32.2 12.7 20.4 26.1 7.8 0.5 58.5 30.0 7.2 26.7 6.4 8.6 38.2 82.0 63.4 31.5 22.1 18.3 4.0 13.8 4.5 8.8 15.4 15.9 21.0 3.6 0.0 40.0 5.6 10.7 24.5 32.5 9.1 10.9 86.1 31.2 3.0 18.0 15.6 25.4 1.6 15.3 22.9 27.0 12.2 27.0 2.5 0.4 0.8 1.8 2.2 5.1 3.7 0.5 6.1 17.4 0.1 40.0 1.8 4.1 5.8 1.3 21.0 0.2 1.0 0.0 9.0 16.5 1.8 3.9 3.5 95.2 1.3 26.9 4.7 4.6 5.4 0.0 0.1 0.1 0.5 2.8 68.6 0.9 1.9 1.5 9.9 0.6 1.9 9.1 5.7 0.4 35.1 0.3 1.2 0.7 5.6 22.9 17.3 6.5 0.2 4.2 13.8 6.7 0.8 4.7 1.5 1.5 68.6 15.9 5.7 1.9 1.5 1.6 19.5 135.8 74.9 2.0 98.4 1.2 6.7 2.9 1.2 39.5 6.9 1.6 1.3 114.1 9.5 77.1 9.3 3.1 10.1 6.1 6.0 7.1 7.9 6.4 8.6 22.1 18.3 15.9 10.9 18.0 12.2 122.6 12.8 29.0 0.3 122.9 58.5 57.4 169.9 53.5 3.4 101.5 90.8 3.2 50.1 88.6 33.1 4.2 17.2 65.8 154.8 29.4 340.2 2.2 55.7 56.0 55.7 16.8 19.6 0.3 643.9 300.8 81.9 38.7 59.2 53.4 3.0 38.2 93.0 477.4 0.0 0.4 50.2 24.4 371.8 409.4 8.7 5.0 561.7 113.8 4.7 2174.6 2.9 71.1 0.5 0.2 364.0 86.4 1.9 102.1 109.8 214.5 105.1 78.0 6.6 26.3 93.3 62.4 1.5 8.0 71.7 56.7 33.5 62.5 3.7 51.1 76.0 TYMS "HsT422, TMS, TS, Tsase" ENSG00000176890 "Thymidylate synthetase" P04818 18 657653-673578 "Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Nucleotide biosynthesis" "Methyltransferase, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "bone marrow: 88.5;lymphoid tissue: 113.6" "Cell type enhanced" "Detected in many" "Cytotrophoblasts: 105.8;Erythroid cells: 189.3;Extravillous trophoblasts: 115.3;Plasma cells: 112.7;Spermatocytes: 180.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enhanced" "Detected in many" "T-reg: 14.1" "Group enriched" "Detected in many" 6 "NK-cells: 6.7;T-cells: 14.1" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in many" "Low region specificity" "Detected in some" "CAB002784, HPA074922" Enhanced NA Yes "Cluster 4: T-regs - Cell cycle regulation" "Cluster 53: Non-specific - Cell cycle regulation" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 12: Non-specific - Cell cycle regulation" "CAB002784: , HPA074922: " "unprognostic (7.58e-2)" "unprognostic (2.06e-3)" "unprognostic (9.31e-2)" "unprognostic (2.34e-2)" "unprognostic (7.35e-2)" "unprognostic (1.05e-1)" "prognostic unfavorable (5.10e-6)" "unprognostic (1.62e-3)" "unprognostic (1.68e-2)" "unprognostic (9.82e-2)" "unprognostic (1.07e-3)" "unprognostic (3.28e-2)" "unprognostic (1.23e-2)" "unprognostic (6.34e-2)" "unprognostic (1.66e-1)" "unprognostic (5.65e-3)" "unprognostic (2.47e-1)" 4.5 3.1 4.3 24.2 7.5 88.5 6.7 4.1 6.5 4.8 2.7 22.9 10.5 5.1 1.3 14.8 5.6 3.8 2.2 5.0 4.9 6.5 11.8 4.9 36.1 4.9 5.2 2.1 3.6 1.8 1.6 22.3 4.4 3.1 27.1 4.2 3.9 2.0 0.4 6.2 14.8 12.7 4.8 10.6 8.8 34.3 6.1 113.6 2.1 0.4 44.5 8.4 5.5 10.3 102.7 156.6 320.4 154.9 35.1 57.9 159.9 238.9 141.1 251.7 299.9 132.8 80.1 160.0 91.5 129.9 143.2 45.1 225.3 89.7 216.1 152.3 244.9 273.1 135.8 229.4 8.2 564.8 286.5 51.5 20.7 159.6 49.6 48.4 214.4 334.0 222.0 249.6 321.8 118.1 687.7 311.4 114.7 124.3 114.0 446.8 287.0 191.3 95.6 88.9 106.0 175.7 201.4 91.6 61.1 197.3 63.5 253.5 85.0 289.7 569.5 267.3 474.2 305.9 405.2 367.3 75.2 240.6 339.2 0.0 0.0 1.3 1.1 0.1 0.0 1.1 2.8 2.2 1.8 0.0 0.0 0.6 0.7 6.7 0.1 0.3 14.1 2.9 4.3 7.5 4.1 6.5 5.0 4.9 4.9 5.2 4.4 4.8 6.1 10.3 2.1 0.0 2.3 1.6 15.7 14.4 15.9 13.0 27.9 0.5 7.8 11.7 3.6 2.8 6.7 0.0 0.0 105.8 14.5 15.5 1.9 2.3 34.4 5.6 8.4 12.5 1.2 189.3 0.4 0.8 115.3 28.3 14.3 7.4 7.0 76.2 6.8 4.3 71.4 0.0 0.6 20.9 10.2 15.6 19.4 31.9 6.2 10.7 10.6 1.0 3.9 45.0 5.2 0.5 15.6 1.5 8.9 3.8 112.7 5.0 13.8 36.6 1.0 2.4 13.1 1.3 32.6 180.8 30.7 48.0 7.2 27.0 21.3 10.5 54.9 18.7 TYR "OCA1, OCA1A, OCAIA" ENSG00000077498 Tyrosinase P14679 11 89177875-89295759 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins" "Melanin biosynthesis" "Monooxygenase, Oxidoreductase, Tumor antigen" "Albinism, Deafness, Disease variant, FDA approved drug targets, Waardenburg syndrome" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in single" 37 "skin 1: 31.6" "Cell type enriched" "Detected in some" 5 "Melanocytes: 184.9" "Cancer enriched" "Detected in single" 1755 "melanoma: 351.3" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enriched" "Detected in single" 995 "SK-MEL-30: 426.0" "Not detected" "Not detected" "Not detected" "Not detected" "CAB000079, HPA043241, HPA050889, HPA064583" Enhanced Enhanced Vesicles NA NA "Cluster 61: Skin - Cornification" "Cluster 33: SK-MEL-30 - Melanocyte processes" "Cluster 23: Spermatids - Flagellum & Golgi organization" Vesicles "CAB000079: AB_564045, HPA043241: AB_2678383, HPA050889: AB_2681264, HPA064583: " "unprognostic (1.16e-1)" "unprognostic (1.01e-1)" "unprognostic (1.85e-3)" "unprognostic (9.75e-3)" 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 31.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 426.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.9 0.3 0.0 0.1 0.0 0.0 2.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 2.5 5.2 0.3 0.0 184.9 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 2.0 0.0 0.1 0.0 0.0 0.0 UGCG GCS ENSG00000148154 "UDP-glucose ceramide glucosyltransferase" Q16739 9 111896814-111935369 "Enzymes, FDA approved drug targets, Metabolic proteins, Predicted membrane proteins, Transporters" "Lipid biosynthesis, Lipid metabolism, Sphingolipid metabolism" "Glycosyltransferase, Transferase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "bone marrow: 112.9" "Cell type enhanced" "Detected in all" "Glandular and luminal cells: 294.5;Urothelial cells: 534.7" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 21 "plasmacytoid DC: 109.7" "Lineage enriched" "Detected in all" 21 "dendritic cells: 109.7" "Cell line enhanced" "Detected in all" "LHCN-M2: 195.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA024124 Approved NA NA "Cluster 3: Plasmacytoid DCs - Unknown function" "Cluster 40: Neutrophils - Inflammatory response" "Cluster 4: Mesenchymal cell lines - Antiviral immune response" "Cluster 22: Epithelial cell types - Mixed function" "HPA024124: AB_1858595" "unprognostic (1.22e-2)" "prognostic favorable (6.62e-4)" "unprognostic (5.39e-2)" "prognostic favorable (4.44e-5)" "unprognostic (1.53e-2)" "unprognostic (9.70e-2)" "unprognostic (3.20e-2)" "unprognostic (2.04e-1)" "unprognostic (3.40e-1)" "unprognostic (1.31e-1)" "unprognostic (1.95e-2)" "unprognostic (3.22e-1)" "unprognostic (9.84e-3)" "unprognostic (2.24e-2)" "unprognostic (4.92e-2)" "unprognostic (1.99e-1)" "unprognostic (3.77e-2)" 39.1 65.6 9.5 34.6 9.6 112.9 25.2 11.1 10.9 23.1 10.4 20.5 23.8 16.3 7.3 40.8 15.7 42.6 14.4 9.7 13.1 29.7 32.5 33.7 41.8 11.0 12.4 12.0 16.6 5.5 12.5 27.6 10.3 13.8 17.8 12.2 14.1 7.7 9.0 32.8 31.7 21.4 10.2 35.5 47.9 7.9 11.6 20.5 9.9 7.7 46.8 72.3 28.5 13.7 93.4 9.8 15.7 10.5 33.2 39.7 8.3 57.0 59.7 65.3 87.9 19.8 70.0 21.9 44.1 38.0 142.9 46.6 18.4 24.7 69.6 8.9 10.7 8.9 14.3 9.8 23.7 9.8 13.8 39.6 18.9 62.4 89.1 151.0 20.3 10.8 49.4 41.5 195.7 15.9 10.7 10.9 17.9 31.4 10.1 12.4 111.5 7.1 151.0 35.2 7.6 12.0 25.3 21.1 66.1 92.2 113.6 10.1 96.6 30.0 15.2 84.8 41.1 7.7 30.3 10.2 37.0 6.1 41.6 0.1 0.3 0.2 1.2 0.7 2.0 4.2 2.2 1.6 1.9 5.3 2.0 2.0 1.2 1.4 1.0 109.7 3.6 1.4 9.5 9.6 11.1 10.9 9.7 13.1 11.0 12.4 10.3 10.2 11.6 13.7 128.0 41.7 51.1 17.6 66.6 75.7 151.6 90.6 76.8 29.8 71.8 37.8 11.8 47.1 130.7 29.5 62.6 7.3 262.4 69.8 17.6 108.2 20.6 125.0 83.4 116.1 18.5 26.5 40.4 50.6 12.8 64.6 121.8 294.5 10.8 18.3 90.7 20.6 21.4 18.5 41.9 55.1 36.7 34.0 109.2 5.9 49.0 49.1 58.7 24.4 44.4 8.4 9.2 25.1 12.8 72.2 65.1 38.4 33.3 216.6 42.6 77.2 143.9 16.5 13.1 153.2 74.9 1.8 8.7 99.7 122.2 3.4 41.4 30.5 22.1 534.7 VDR "NR1I1, PPP1R163" ENSG00000111424 "Vitamin D receptor" P11473 12 47841537-47943048 "Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "parathyroid gland: 235.9" "Cell type enhanced" "Detected in many" "Distal enterocytes: 141.7;Proximal enterocytes: 88.7;Undifferentiated cells: 72.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in single" "Group enriched" "Detected in many" 7 "classical monocyte: 3.5;eosinophil: 1.9;intermediate monocyte: 6.5;myeloid DC: 5.1;neutrophil: 6.5;non-classical monocyte: 6.7" "Group enriched" "Detected in many" 8 "dendritic cells: 5.1;granulocytes: 6.5;monocytes: 6.7" "Cell line enhanced" "Detected in many" "HBEC3-KT: 55.5;HDLM-2: 80.0;U-937: 85.3" "Region enhanced" "Detected in single" "olfactory bulb: 2.1" "Region enhanced" "Detected in some" "spinal cord: 4.3" "CAB004617, HPA047740, HPA072102" Supported "Nucleoplasm,Intermediate filaments,Cytosol" NA NA "Cluster 7: Monocytes - Unknown function" "Cluster 48: Parathyroid gland - membrane proteins" "Cluster 44: HDLM-2 - Immune response" "Cluster 53: Intestinal epithelial cells - Unknown function" Nucleoplasm "Intermediate filaments, Cytosol" "CAB004617: AB_628040, HPA047740: AB_2680142, HPA072102: " "unprognostic (1.11e-2)" "unprognostic (5.49e-2)" "unprognostic (1.01e-1)" "unprognostic (7.59e-3)" "unprognostic (3.33e-3)" "unprognostic (2.74e-2)" "unprognostic (4.78e-2)" "unprognostic (1.69e-1)" "unprognostic (1.40e-1)" "unprognostic (1.62e-1)" "unprognostic (5.53e-3)" "unprognostic (6.72e-2)" "prognostic favorable (4.89e-6)" "unprognostic (1.46e-1)" "unprognostic (8.76e-2)" "unprognostic (3.28e-1)" "unprognostic (3.82e-2)" 3.6 13.7 0.2 13.3 0.2 8.2 11.3 0.2 0.4 5.0 0.9 40.4 56.0 1.6 0.4 13.6 1.8 8.5 1.2 0.2 0.7 21.0 1.1 7.7 5.3 0.7 0.4 0.5 2.1 235.9 11.1 2.9 0.6 1.9 35.3 0.2 6.1 1.8 2.8 22.1 55.0 3.8 0.1 2.6 7.4 1.0 1.4 1.5 2.2 0.6 7.2 10.4 7.6 0.3 15.0 2.6 0.1 0.1 12.0 16.4 0.2 17.7 8.6 15.0 12.9 10.6 12.1 3.5 17.4 13.6 10.7 27.1 0.5 55.5 6.4 80.0 4.0 6.3 3.1 0.9 8.1 12.2 20.3 23.6 30.5 16.4 26.0 22.3 1.2 1.3 1.8 3.9 7.0 9.2 0.3 6.0 0.2 34.8 19.1 0.3 0.0 9.9 13.3 13.5 6.2 0.2 14.7 42.6 5.9 0.1 47.6 6.7 1.0 28.8 7.3 8.2 10.2 2.2 0.1 3.0 8.6 85.3 7.7 0.1 3.5 1.9 0.0 6.5 0.1 0.5 0.3 0.0 5.1 0.0 0.1 0.0 6.5 0.2 6.7 0.4 0.7 1.5 0.2 0.2 0.2 0.4 0.2 0.7 0.7 0.4 0.6 0.1 1.4 0.3 0.4 12.8 20.1 0.3 1.4 36.1 9.0 8.5 24.5 0.5 21.2 13.7 1.7 0.0 9.2 7.3 0.0 0.2 0.9 141.7 7.9 3.5 0.2 11.9 0.5 1.3 21.7 0.0 0.4 10.9 0.1 5.3 14.3 4.7 7.0 0.2 0.0 0.3 3.4 0.0 0.3 32.8 2.0 7.3 43.4 0.0 0.0 21.2 8.8 1.0 10.4 0.2 0.0 0.5 0.1 22.4 43.3 0.4 10.9 8.3 88.7 32.0 9.0 0.2 0.0 1.1 2.2 0.7 0.3 23.4 40.6 0.3 2.8 0.0 72.4 11.6 VEGFA "VEGF, VEGF-A, VPF" ENSG00000112715 "Vascular endothelial growth factor A" P15692 6 43770184-43786487 "Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell type enhanced" "Detected in many" "Alveolar cells type 1: 349.4;Muller glia cells: 265.8" "Cancer enhanced" "Detected in all" "renal cancer: 79.5" "Low region specificity" "Detected in all" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in all" "hTERT-RPE1: 398.9;U-87 MG: 628.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB005429, CAB039240, HPA069116, CAB069907" Supported "Secreted to blood" NA NA 562000 57000 "Cluster 45: Eosinophils - Innate immune response" "Cluster 8: Non-specific - Mitochondria" "Cluster 11: RPE1 & U-87MG - Synaptic function" "Cluster 41: Macrophages - Immune response" "CAB005429: AB_2212984, CAB039240: , CAB069907: AB_10001947, HPA069116: AB_2686089" "unprognostic (1.12e-1)" "prognostic unfavorable (4.50e-4)" "unprognostic (2.42e-2)" "prognostic unfavorable (2.10e-4)" "unprognostic (4.35e-2)" "unprognostic (1.49e-1)" "prognostic unfavorable (2.34e-5)" "unprognostic (5.10e-2)" "unprognostic (5.27e-3)" "unprognostic (2.30e-2)" "unprognostic (1.40e-1)" "unprognostic (1.00e-2)" "prognostic unfavorable (1.76e-5)" "unprognostic (2.20e-1)" "unprognostic (1.80e-1)" "unprognostic (1.43e-1)" "prognostic favorable (2.73e-4)" 155.8 52.7 17.6 36.5 20.3 45.5 92.4 34.2 28.2 45.2 46.8 32.6 50.9 104.0 10.5 61.3 40.9 80.1 208.3 22.8 25.1 116.9 217.3 94.1 9.3 27.0 38.5 25.0 68.1 105.0 22.3 46.2 26.8 120.3 21.4 229.1 32.1 17.8 221.2 44.2 44.6 57.1 19.6 70.1 63.9 5.3 32.0 5.6 270.9 150.9 9.5 122.3 61.7 24.9 76.5 13.4 12.5 71.8 21.0 32.9 84.2 45.6 81.1 29.7 58.4 43.1 9.9 24.9 35.5 27.7 305.4 30.6 34.0 92.0 52.0 27.4 10.4 19.0 17.8 29.2 220.3 20.8 40.4 58.0 178.6 290.6 286.2 398.9 7.7 21.0 35.7 121.7 109.4 31.3 2.3 28.3 7.9 221.2 19.2 2.3 12.0 60.5 114.8 62.9 22.3 46.8 65.6 44.4 162.0 16.1 17.3 75.1 10.4 122.6 32.9 179.2 76.1 68.8 43.6 49.1 628.6 47.9 43.8 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.6 20.3 34.2 28.2 22.8 25.1 27.0 38.5 26.8 19.6 32.0 24.9 63.6 349.4 84.7 121.5 9.8 70.5 51.2 76.8 60.3 37.8 67.0 57.1 164.7 77.2 85.7 22.0 31.3 1.3 11.6 92.9 1.9 54.7 0.0 38.4 59.1 29.0 27.4 21.3 12.1 40.8 6.3 69.7 124.4 121.2 112.0 111.7 17.5 116.0 13.9 180.0 17.0 71.8 12.2 16.2 199.0 0.3 1.8 144.1 28.4 10.3 11.3 265.8 0.0 124.1 1.8 86.0 47.1 3.4 15.9 119.4 61.9 20.5 11.4 43.9 0.0 42.1 79.1 1.1 1.9 82.0 78.3 7.9 11.4 17.4 51.0 137.5 VKORC1 VKCFD2 ENSG00000167397 "Vitamin K epoxide reductase complex subunit 1" Q9BQB6 16 31090842-31095980 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins" Oxidoreductase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "liver: 454.9" "Cell type enhanced" "Detected in all" "Hepatocytes: 749.9" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in all" "ASC diff: 638.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042720 Approved Supported "Endoplasmic reticulum" "Intracellular and membrane" NA NA "Cluster 12: Non-specific - Basic cellular processes" "Cluster 85: Liver - Metabolism" "Cluster 34: Mesenchymal cell lines - ECM organization" "Cluster 2: Hepatocytes - Metabolism" "Endoplasmic reticulum" "HPA042720: AB_10961864" "unprognostic (5.99e-2)" "unprognostic (2.98e-1)" "unprognostic (7.11e-3)" "unprognostic (7.68e-3)" "unprognostic (5.49e-2)" "unprognostic (3.23e-3)" "unprognostic (3.02e-2)" "unprognostic (2.32e-2)" "unprognostic (2.42e-1)" "unprognostic (2.66e-1)" "unprognostic (1.04e-1)" "unprognostic (1.19e-1)" "prognostic unfavorable (2.09e-10)" "unprognostic (1.11e-2)" "unprognostic (6.65e-2)" "unprognostic (3.12e-2)" "unprognostic (9.66e-2)" 99.4 107.6 56.0 38.4 60.4 55.2 87.0 60.3 73.5 111.0 64.9 97.0 44.2 109.9 87.2 51.8 90.8 58.9 99.1 57.4 59.3 122.7 454.9 77.4 35.8 64.4 59.5 115.1 168.0 51.3 115.7 45.6 63.8 76.3 41.1 23.0 92.4 69.8 34.4 81.1 82.3 84.7 59.9 62.2 88.1 55.6 68.5 35.0 76.3 32.2 32.6 100.6 88.0 64.8 73.6 187.7 57.2 165.4 638.0 389.6 68.2 269.0 229.3 128.9 218.5 79.0 83.3 54.9 141.6 331.6 87.2 66.2 79.4 103.5 139.5 81.9 204.8 52.5 239.9 378.2 103.1 104.1 74.1 225.0 54.2 173.4 146.6 336.8 141.0 78.2 70.3 130.6 253.6 271.1 74.4 205.9 106.8 98.0 175.9 132.7 160.3 286.8 127.7 61.8 119.5 146.9 118.7 84.2 137.8 91.2 138.3 123.9 126.8 171.1 61.5 159.6 101.9 76.1 80.2 50.7 445.8 174.5 90.8 77.0 127.5 196.2 118.1 94.7 116.8 91.7 116.7 119.4 127.6 102.6 102.9 101.4 104.0 84.2 98.2 157.4 143.1 112.8 56.0 60.4 60.3 73.5 57.4 59.3 64.4 59.5 63.8 59.9 68.5 64.8 95.1 57.7 51.0 5.9 30.6 84.6 68.0 157.0 10.8 12.3 93.3 117.3 20.9 141.5 64.3 108.5 8.4 85.7 48.1 34.3 62.6 204.2 6.1 25.8 83.7 89.5 67.1 32.4 8.8 129.4 293.6 132.8 10.7 48.8 55.3 60.3 118.9 749.9 184.1 10.1 7.5 44.2 46.8 80.1 94.3 13.9 158.1 66.9 115.6 5.6 107.4 68.8 51.5 6.6 17.6 103.8 28.2 172.3 29.5 59.5 152.9 204.6 33.4 19.3 59.2 78.4 99.8 30.6 34.2 10.7 112.0 39.5 39.7 82.4 49.0 55.2 VKORC1L1 ENSG00000196715 "Vitamin K epoxide reductase complex subunit 1 like 1" Q8N0U8 7 65873074-65959563 "Enzymes, FDA approved drug targets, Predicted membrane proteins" Oxidoreductase "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA053954 Approved Supported "Endoplasmic reticulum" NA NA "Cluster 47: Plasmacytoid DCs - Protein folding" "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 44: Endometrium - Transcription" "Endoplasmic reticulum" "HPA053954: AB_2682319" "unprognostic (3.01e-1)" "unprognostic (1.76e-3)" "unprognostic (4.64e-2)" "unprognostic (4.65e-2)" "unprognostic (3.00e-3)" "unprognostic (7.15e-3)" "unprognostic (1.30e-3)" "unprognostic (8.84e-3)" "unprognostic (5.12e-2)" "unprognostic (5.59e-2)" "unprognostic (9.23e-3)" "unprognostic (1.07e-1)" "unprognostic (1.59e-2)" "unprognostic (1.17e-1)" "unprognostic (7.03e-3)" "unprognostic (4.30e-1)" "unprognostic (5.06e-2)" 54.0 11.1 8.1 11.2 9.0 4.3 23.7 8.3 12.1 12.0 3.7 12.4 11.1 12.3 10.6 12.5 10.0 10.0 12.1 10.1 9.2 10.0 22.9 18.4 8.7 18.1 10.5 17.3 9.7 33.6 6.7 12.0 10.5 12.0 12.5 11.5 10.9 12.4 21.6 12.8 11.6 11.6 8.9 7.4 12.8 9.1 8.5 9.7 13.9 15.3 8.7 11.9 9.6 9.6 46.8 29.5 23.4 29.5 72.6 28.6 42.3 49.5 31.8 29.0 29.1 28.7 44.9 40.4 39.0 35.7 43.9 31.2 33.6 20.1 47.9 25.5 33.1 27.6 25.4 24.7 35.4 38.7 20.3 23.2 25.3 29.5 40.7 22.5 29.2 22.6 59.0 30.0 34.9 18.3 31.8 44.8 56.1 43.8 22.0 34.5 34.0 50.5 28.0 18.5 28.0 39.8 38.3 68.5 21.8 32.8 34.5 29.5 33.3 46.6 32.0 29.5 51.0 26.9 47.1 46.1 28.6 43.0 41.6 2.0 1.1 2.7 1.2 1.1 1.0 1.3 1.5 1.4 1.3 1.1 0.9 0.9 1.3 2.9 2.2 3.5 1.5 0.7 8.1 9.0 8.3 12.1 10.1 9.2 18.1 10.5 10.5 8.9 8.5 9.6 19.5 73.7 41.7 16.6 5.5 24.9 18.6 16.2 9.6 21.8 18.6 15.9 21.5 27.1 24.2 16.5 12.5 12.5 10.0 27.1 5.9 18.1 39.0 13.7 23.8 17.1 13.8 26.1 42.7 24.8 21.2 22.6 19.4 25.3 5.1 24.1 10.8 46.9 16.0 30.3 36.6 26.4 20.3 6.6 10.2 9.1 17.7 12.9 7.2 28.1 10.0 11.6 7.2 26.7 34.6 31.6 8.2 18.4 15.6 36.3 14.4 11.4 11.7 20.2 6.6 24.9 26.4 18.5 7.2 17.9 32.0 8.8 6.6 10.8 20.3 22.6 XDH "XO, XOR" ENSG00000158125 "Xanthine dehydrogenase" P47989 2 31334321-31414742 "Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" Oxidoreductase "Disease variant, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "breast: 42.2;intestine: 49.5;liver: 68.5" "Cell type enhanced" "Detected in many" "Breast glandular cells: 262.1;Distal enterocytes: 143.5;Hepatocytes: 46.9;Paneth cells: 48.8;Proximal enterocytes: 96.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Not detected in immune cells" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in many" "BJ: 8.2;HBEC3-KT: 20.0;hTERT-HME1: 31.0;U-251 MG: 8.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in single" "HPA062641, HPA069323" Supported Uncertain Nucleoplasm,Nucleoli "Intracellular and membrane" No No 77000 "Cluster 41: Intestine & Liver - Lipid metabolism" "Cluster 30: Epithelial cell lines - Translation" "Cluster 30: Mammary glandular cells - Lactation" Nucleoplasm Nucleoli "HPA062641: AB_2684816, HPA069323: AB_2686121" "unprognostic (8.58e-2)" "unprognostic (4.07e-2)" "unprognostic (1.34e-2)" "unprognostic (1.79e-1)" "unprognostic (2.08e-2)" "unprognostic (7.06e-2)" "unprognostic (4.38e-3)" "unprognostic (7.48e-3)" "unprognostic (3.55e-1)" "unprognostic (3.60e-2)" "unprognostic (3.95e-3)" "unprognostic (3.51e-2)" "unprognostic (1.24e-6)" "unprognostic (2.25e-1)" "unprognostic (5.25e-2)" "unprognostic (2.54e-1)" "prognostic favorable (8.73e-6)" 0.2 0.0 0.0 4.8 0.0 0.1 42.2 0.3 0.0 0.3 0.4 11.1 44.9 0.9 2.3 9.8 0.1 4.5 0.0 0.0 0.0 0.2 68.5 0.3 0.0 0.0 0.0 0.0 0.4 0.0 1.5 0.1 0.1 1.3 9.5 0.1 3.6 0.1 0.5 1.1 49.5 0.7 0.0 0.0 3.2 0.1 0.0 0.2 0.3 0.0 2.3 2.7 2.0 0.1 2.0 0.4 0.0 0.0 0.0 0.1 0.1 8.2 4.7 1.0 1.4 0.3 2.3 0.1 1.6 0.3 0.8 4.2 0.0 20.0 1.0 1.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.1 1.8 1.1 31.0 0.4 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.2 0.4 1.2 0.2 0.0 1.4 4.5 5.7 5.2 0.0 0.1 0.1 0.3 0.0 1.7 0.0 0.0 0.0 3.8 2.4 0.2 8.9 2.5 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 1.6 0.0 2.4 0.0 0.2 0.5 6.0 5.5 2.8 0.3 262.1 6.5 0.4 2.8 3.6 0.0 0.0 0.3 1.1 143.5 0.0 3.9 0.3 7.9 2.8 0.3 11.9 0.0 0.2 8.2 0.6 0.2 2.0 37.0 0.0 0.0 1.4 46.9 0.0 0.0 0.2 8.4 2.0 1.9 0.7 0.0 0.0 0.7 0.0 0.0 0.0 0.1 0.0 0.0 0.0 10.7 48.8 0.0 0.0 2.2 96.8 0.0 1.0 0.7 0.0 0.3 0.7 0.0 0.2 1.2 0.1 0.4 0.7 0.2 22.2 16.9 XIAP "API3, BIRC4, hILP, ILP-1" ENSG00000101966 "X-linked inhibitor of apoptosis" P98170 X 123859724-123913976 "Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins" "Apoptosis, Ubl conjugation pathway, Wnt signaling pathway" "Protease inhibitor, Thiol protease inhibitor, Transferase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009203, HPA042428" Approved Supported "Nucleoplasm,Plasma membrane,Cytosol" NA NA "Cluster 38: Basophils - Unknown function" "Cluster 8: Non-specific - Mitochondria" "Cluster 18: U-2197 - ECM organization" "Cluster 53: Intestinal epithelial cells - Unknown function" "Nucleoplasm, Cytosol" "Plasma membrane" "CAB009203: AB_2257167, HPA042428: AB_2677993" "prognostic unfavorable (9.21e-4)" "unprognostic (8.43e-2)" "unprognostic (1.50e-2)" "unprognostic (2.14e-1)" "unprognostic (1.40e-1)" "unprognostic (9.41e-2)" "unprognostic (1.95e-2)" "unprognostic (8.51e-2)" "unprognostic (9.17e-2)" "unprognostic (3.90e-2)" "unprognostic (7.50e-2)" "unprognostic (4.41e-2)" "unprognostic (3.15e-3)" "unprognostic (8.21e-3)" "unprognostic (2.26e-1)" "unprognostic (4.99e-2)" "unprognostic (4.65e-2)" 9.2 7.7 6.5 9.2 7.5 8.3 9.7 6.8 7.0 9.6 12.9 12.4 10.1 8.4 10.0 11.5 7.4 8.6 7.8 5.8 8.2 11.8 12.1 8.5 10.4 7.6 8.1 7.5 8.3 18.4 6.3 8.6 7.3 8.5 10.1 21.4 8.6 7.4 10.3 8.8 10.1 7.4 8.5 10.4 10.2 4.2 8.1 8.9 14.9 11.9 8.6 9.6 6.1 10.3 15.8 13.2 10.2 8.8 11.8 15.0 13.3 16.9 12.4 8.9 7.7 5.9 17.9 14.7 24.3 14.4 17.1 5.6 15.3 10.5 16.3 15.5 8.3 9.9 11.1 9.2 14.9 18.1 19.7 10.4 16.0 14.9 19.0 10.2 12.7 10.8 15.9 16.4 17.6 16.5 10.2 8.8 8.4 15.6 10.3 10.8 11.9 15.6 13.4 22.6 6.8 10.0 22.9 13.0 13.5 9.0 8.0 8.7 15.7 0.5 6.0 27.0 18.9 13.8 14.9 15.8 18.3 12.7 11.5 9.3 1.8 2.6 3.3 1.5 3.0 3.1 2.4 3.6 1.0 4.0 2.7 1.9 5.6 2.4 2.9 2.9 1.8 1.5 6.5 7.5 6.8 7.0 5.8 8.2 7.6 8.1 7.3 8.5 8.1 10.3 50.0 80.1 91.6 26.4 42.1 26.6 36.3 35.0 28.5 72.1 29.7 19.9 44.5 44.3 55.2 53.3 95.9 17.9 41.7 122.9 27.4 36.0 2.7 38.4 44.9 55.0 47.4 23.5 30.0 54.0 30.0 38.4 39.8 50.4 60.7 30.9 64.2 85.8 29.0 75.7 34.9 62.2 26.4 43.6 33.0 4.1 42.6 44.2 8.8 29.0 45.8 45.8 55.6 32.6 41.9 65.4 53.5 51.6 39.5 53.0 59.2 59.8 50.6 133.7 65.7 43.6 34.9 15.2 21.0 30.8 35.5 38.0 40.8 30.0 48.0 68.1 XPO1 "CRM-1, CRM1, emb" ENSG00000082898 "Exportin 1" O14980 2 61476032-61538741 "Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters" "Host-virus interaction, mRNA transport, Protein transport, Transport" RNA-binding "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low immune cell specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB010184, HPA042933" Supported Enhanced "Nucleoplasm,Nuclear membrane,Vesicles,Cytosol" NA NA 410000 "Cluster 27: Non-specific - Gene expression" "Cluster 34: Non-specific - Transcription" "Cluster 26: Non-specific - Cell cycle regulation" "Cluster 36: Stromal cells - Cell proliferation" "Nucleoplasm, Nuclear membrane" "Vesicles, Cytosol" "CAB010184: AB_2215817, HPA042933: AB_2678229" "unprognostic (7.34e-2)" "unprognostic (7.04e-2)" "unprognostic (6.37e-2)" "unprognostic (1.67e-2)" "unprognostic (5.61e-2)" "unprognostic (1.28e-1)" "prognostic unfavorable (1.84e-5)" "unprognostic (1.84e-1)" "unprognostic (1.99e-3)" "unprognostic (4.43e-1)" "unprognostic (3.53e-3)" "unprognostic (4.90e-2)" "prognostic unfavorable (3.74e-4)" "unprognostic (5.69e-2)" "unprognostic (2.08e-1)" "unprognostic (2.43e-1)" "unprognostic (5.55e-2)" 33.2 29.8 30.1 48.7 31.4 25.8 39.2 35.7 44.3 37.9 31.6 34.9 24.7 52.5 37.0 35.1 45.9 32.0 36.0 27.9 33.7 30.8 41.7 31.9 65.3 28.9 30.5 58.9 26.2 38.5 22.0 52.1 30.4 34.2 42.0 52.0 19.9 34.9 37.5 34.2 33.2 48.6 30.9 43.4 31.9 54.5 32.8 73.6 38.8 47.2 60.9 38.6 22.4 38.9 169.1 152.9 194.1 135.8 91.4 107.9 145.5 166.6 109.2 192.9 151.8 217.3 114.7 256.0 117.4 127.1 186.3 125.0 307.9 126.5 268.6 151.6 110.7 242.8 136.2 148.4 55.4 234.6 145.4 62.9 103.8 149.4 145.9 126.0 149.5 108.7 285.5 127.7 164.9 97.8 212.6 100.4 213.1 189.9 111.5 175.6 208.0 148.1 103.0 124.9 152.8 77.5 174.2 142.8 87.1 185.6 108.6 110.8 98.9 153.7 178.7 137.2 175.0 102.8 203.2 347.0 96.8 214.0 151.0 3.3 1.4 2.2 1.8 2.2 1.9 1.1 1.0 1.8 2.1 0.7 1.0 1.0 0.6 2.7 1.2 1.6 1.2 1.2 30.1 31.4 35.7 44.3 27.9 33.7 28.9 30.5 30.4 30.9 32.8 38.9 42.0 41.7 43.2 114.3 55.3 52.1 32.1 45.5 78.6 67.5 40.2 38.6 64.5 38.6 38.7 31.3 95.9 54.1 56.6 27.3 13.7 29.7 4.2 58.6 79.7 47.7 45.1 73.2 87.9 26.1 49.3 49.9 42.3 68.6 41.8 100.4 41.4 55.8 57.2 72.3 101.3 34.2 40.7 55.3 58.4 11.9 33.5 63.9 37.4 68.4 64.2 33.4 61.8 83.4 102.5 32.3 20.9 30.9 57.2 55.6 21.0 22.2 56.9 101.7 19.7 50.5 55.7 65.9 91.6 83.3 56.8 30.1 54.5 54.4 46.2 47.7 YES1 "c-yes, HsT441, Yes" ENSG00000176105 "YES proto-oncogene 1, Src family tyrosine kinase" P07947 18 721588-812546 "Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins" "Kinase, Transferase, Tyrosine-protein kinase" "FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Immune cell enriched" "Detected in many" 9 "basophil: 20.2" "Lineage enriched" "Detected in many" 9 "granulocytes: 20.2" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004370, HPA026480" Approved Supported "Plasma membrane,Cytosol" NA NA "Cluster 38: Basophils - Unknown function" "Cluster 86: Liver & Placenta - Transport via ER" "Cluster 41: TIME & HUVEC/TERT2 - Endothelial cell function" "Cluster 14: Adipocytes & Endothelial cells - Angiogenesis" "Plasma membrane, Cytosol" "CAB004370: AB_627370, HPA026480: AB_1858921" "unprognostic (3.28e-1)" "unprognostic (1.62e-2)" "unprognostic (5.87e-2)" "unprognostic (2.47e-2)" "unprognostic (6.24e-2)" "unprognostic (4.24e-2)" "unprognostic (6.01e-2)" "unprognostic (1.03e-2)" "unprognostic (1.95e-2)" "unprognostic (1.85e-3)" "prognostic unfavorable (2.46e-4)" "unprognostic (2.14e-1)" "unprognostic (8.12e-2)" "unprognostic (4.65e-2)" "unprognostic (1.81e-1)" "unprognostic (4.79e-2)" "unprognostic (4.11e-1)" 25.2 13.5 11.9 10.5 12.7 4.1 21.8 12.7 14.3 17.4 11.5 21.8 24.8 16.0 17.9 22.7 13.9 18.9 13.1 11.7 13.7 27.9 50.6 17.2 6.2 13.9 13.2 12.4 26.5 20.0 6.1 41.7 13.5 15.0 22.7 8.3 21.0 11.9 8.3 16.7 23.7 15.9 14.2 27.4 21.3 19.0 14.3 10.5 22.0 14.6 8.8 20.3 11.5 14.1 42.7 20.8 64.3 50.6 37.8 46.5 75.6 27.9 56.2 32.0 43.7 49.9 30.7 0.1 28.8 47.3 41.0 24.3 60.8 49.1 62.3 0.2 20.7 12.6 19.4 35.1 30.6 9.9 21.7 35.7 51.7 48.5 53.6 39.8 109.8 7.0 56.1 18.4 46.1 29.3 6.0 13.0 40.9 26.0 26.4 7.4 50.6 3.6 46.8 49.6 13.1 15.3 57.5 42.9 37.1 42.3 29.7 20.5 95.6 78.4 86.2 59.9 75.8 15.7 8.3 2.6 29.7 13.8 47.6 20.2 0.0 1.0 2.2 0.0 1.5 0.1 0.4 1.2 0.0 0.0 1.0 1.7 0.0 1.1 0.0 0.0 0.1 0.6 11.9 12.7 12.7 14.3 11.7 13.7 13.9 13.2 13.5 14.2 14.3 14.1 120.3 25.6 36.8 18.9 3.3 60.2 46.8 21.4 50.1 6.0 38.1 26.7 18.2 24.3 31.3 29.5 6.2 37.1 52.9 40.3 3.9 29.6 29.4 32.8 35.0 91.0 22.8 12.0 0.4 39.2 26.6 35.4 57.6 43.6 13.9 35.9 39.7 44.9 4.9 3.3 10.3 37.2 14.2 5.4 14.7 11.7 18.3 5.0 24.9 46.9 2.0 16.8 16.5 31.7 30.2 51.0 28.8 12.8 28.9 65.4 33.1 45.6 29.0 8.6 19.7 35.9 23.8 20.3 13.6 53.1 49.7 45.6 27.5 42.4 36.7 66.6